drugbank-id,description,name,parent_key
DB00267,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmenoxime.,Cefmenoxime,DB00054
DB00274,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmetazole.,Cefmetazole,DB00054
DB00430,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpiramide.,Cefpiramide,DB00054
DB00438,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftazidime.,Ceftazidime,DB00054
DB00447,The therapeutic efficacy of Abciximab can be decreased when used in combination with Loracarbef.,Loracarbef,DB00054
DB00456,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefalotin.,Cefalotin,DB00054
DB00493,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotaxime.,Cefotaxime,DB00054
DB00535,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefdinir.,Cefdinir,DB00054
DB00567,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephalexin.,Cephalexin,DB00054
DB00671,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefixime.,Cefixime,DB00054
DB00689,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephaloglycin.,Cephaloglycin,DB00054
DB00833,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaclor.,Cefaclor,DB00054
DB00923,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceforanide.,Ceforanide,DB00054
DB01066,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefditoren.,Cefditoren,DB00054
DB01112,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefuroxime.,Cefuroxime,DB00054
DB01139,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefapirin.,Cefapirin,DB00054
DB01140,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefadroxil.,Cefadroxil,DB00054
DB01150,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefprozil.,Cefprozil,DB00054
DB01212,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftriaxone.,Ceftriaxone,DB00054
DB01326,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole.,Cefamandole,DB00054
DB01327,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazolin.,Cefazolin,DB00054
DB01328,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefonicid.,Cefonicid,DB00054
DB01329,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoperazone.,Cefoperazone,DB00054
DB01330,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotetan.,Cefotetan,DB00054
DB01331,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoxitin.,Cefoxitin,DB00054
DB01332,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftizoxime.,Ceftizoxime,DB00054
DB01333,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefradine.,Cefradine,DB00054
DB01413,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefepime.,Cefepime,DB00054
DB01414,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefacetrile.,Cefacetrile,DB00054
DB01415,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftibuten.,Ceftibuten,DB00054
DB01416,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpodoxime.,Cefpodoxime,DB00054
DB04570,The therapeutic efficacy of Abciximab can be decreased when used in combination with Latamoxef.,Latamoxef,DB00054
DB04918,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftobiprole.,Ceftobiprole,DB00054
DB06590,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil,DB00054
DB09008,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaloridine.,Cefaloridine,DB00054
DB09050,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftolozane.,Ceftolozane,DB00054
DB09062,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefminox.,Cefminox,DB00054
DB11367,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefroxadine.,Cefroxadine,DB00054
DB11935,The therapeutic efficacy of Abciximab can be decreased when used in combination with Flomoxef.,Flomoxef,DB00054
DB13266,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefatrizine.,Cefatrizine,DB00054
DB13461,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefcapene.,Cefcapene,DB00054
DB13470,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefodizime.,Cefodizime,DB00054
DB13499,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefsulodin.,Cefsulodin,DB00054
DB13504,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefetamet.,Cefetamet,DB00054
DB13638,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefbuperazone.,Cefbuperazone,DB00054
DB13667,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefozopran.,Cefozopran,DB00054
DB13682,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpirome.,Cefpirome,DB00054
DB13778,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazedone.,Cefazedone,DB00054
DB13821,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftezole.,Ceftezole,DB00054
DB14725,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate,DB00054
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Abciximab.,Doxycycline,DB00054
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Abciximab.,Azithromycin,DB00054
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.,Omega-3-acid ethyl esters,DB00054
DB00945,Acetylsalicylic acid may increase the antiplatelet activities of Abciximab.,Acetylsalicylic acid,DB00054
DB01050,The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab.,Ibuprofen,DB00054
DB09213,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Abciximab.,Dexibuprofen,DB00054
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Abciximab.,Tazobactam,DB00054
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Abciximab.,Erythromycin,DB00054
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Abciximab.,Trazodone,DB00054
DB00620,The therapeutic efficacy of Abciximab can be decreased when used in combination with Triamcinolone.,Triamcinolone,DB00054
DB09079,The risk or severity of bleeding can be increased when Abciximab is combined with Nintedanib.,Nintedanib,DB00054
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Abciximab.,Escitalopram,DB00054
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Abciximab.,Sertraline,DB00054
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Abciximab.","Ebola Zaire vaccine (live, attenuated)",DB00054
DB00232,The therapeutic efficacy of Abciximab can be decreased when used in combination with Methyclothiazide.,Methyclothiazide,DB00054
DB00436,The therapeutic efficacy of Abciximab can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide,DB00054
DB00562,The therapeutic efficacy of Abciximab can be decreased when used in combination with Benzthiazide.,Benzthiazide,DB00054
DB00606,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclothiazide.,Cyclothiazide,DB00054
DB00774,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide,DB00054
DB00880,The therapeutic efficacy of Abciximab can be decreased when used in combination with Chlorothiazide.,Chlorothiazide,DB00054
DB00999,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide,DB00054
DB01021,The therapeutic efficacy of Abciximab can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide,DB00054
DB01324,The therapeutic efficacy of Abciximab can be decreased when used in combination with Polythiazide.,Polythiazide,DB00054
DB13430,The therapeutic efficacy of Abciximab can be decreased when used in combination with Mebutizide.,Mebutizide,DB00054
DB13532,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide,DB00054
DB06605,Apixaban may increase the anticoagulant activities of Drotrecogin alfa.,Apixaban,DB00055
DB06695,Dabigatran etexilate may increase the anticoagulant activities of Drotrecogin alfa.,Dabigatran etexilate,DB00055
DB01254,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.,Dasatinib,DB00055
DB01609,The risk or severity of gastrointestinal bleeding can be increased when Drotrecogin alfa is combined with Deferasirox.,Deferasirox,DB00055
DB01586,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid,DB00055
DB02123,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid,DB00055
DB02659,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Cholic Acid.,Cholic Acid,DB00055
DB02691,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycocholic acid.,Glycocholic acid,DB00055
DB03619,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Deoxycholic acid.,Deoxycholic acid,DB00055
DB04348,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurocholic acid.,Taurocholic acid,DB00055
DB05990,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Obeticholic acid.,Obeticholic acid,DB00055
DB06777,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid,DB00055
DB08833,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid,DB00055
DB08834,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid,DB00055
DB08857,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Bamet-UD2.,Bamet-UD2,DB00055
DB11622,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Dehydrocholic acid.,Dehydrocholic acid,DB00055
DB11789,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid,DB00055
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Drotrecogin alfa.,Edoxaban,DB00055
DB09053,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa.,Ibrutinib,DB00055
DB08935,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Obinutuzumab.,Obinutuzumab,DB00055
DB06228,Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban,DB00055
DB06206,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Sugammadex.,Sugammadex,DB00055
DB09070,Tibolone may increase the anticoagulant activities of Drotrecogin alfa.,Tibolone,DB00055
DB00932,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.,Tipranavir,DB00055
DB00013,Urokinase may increase the anticoagulant activities of Drotrecogin alfa.,Urokinase,DB00055
DB00163,Vitamin E may increase the anticoagulant activities of Drotrecogin alfa.,Vitamin E,DB00055
DB09030,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Drotrecogin alfa.,Vorapaxar,DB00055
DB06692,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.,Aprotinin,DB00055
DB01381,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Ginkgo biloba.,Ginkgo biloba,DB00055
DB01181,The risk or severity of bleeding can be increased when Ifosfamide is combined with Drotrecogin alfa.,Ifosfamide,DB00055
DB00468,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinine.,Quinine,DB00055
DB00908,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinidine.,Quinidine,DB00055
DB00675,The risk or severity of bleeding can be increased when Tamoxifen is combined with Drotrecogin alfa.,Tamoxifen,DB00055
DB00539,The risk or severity of bleeding can be increased when Toremifene is combined with Drotrecogin alfa.,Toremifene,DB00055
DB00806,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Pentoxifylline.,Pentoxifylline,DB00055
DB00686,Pentosan polysulfate may increase the anticoagulant activities of Drotrecogin alfa.,Pentosan polysulfate,DB00055
DB00583,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Levocarnitine.,Levocarnitine,DB00055
DB00255,Diethylstilbestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Diethylstilbestrol,DB00055
DB00269,Chlorotrianisene may decrease the anticoagulant activities of Drotrecogin alfa.,Chlorotrianisene,DB00055
DB00286,Conjugated estrogens may decrease the anticoagulant activities of Drotrecogin alfa.,Conjugated estrogens,DB00055
DB00783,Estradiol may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol,DB00055
DB00977,Ethinylestradiol may decrease the anticoagulant activities of Drotrecogin alfa.,Ethinylestradiol,DB00055
DB01357,Mestranol may decrease the anticoagulant activities of Drotrecogin alfa.,Mestranol,DB00055
DB04573,Estriol may decrease the anticoagulant activities of Drotrecogin alfa.,Estriol,DB00055
DB04574,Estrone sulfate may decrease the anticoagulant activities of Drotrecogin alfa.,Estrone sulfate,DB00055
DB04575,Quinestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Quinestrol,DB00055
DB07931,Hexestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Hexestrol,DB00055
DB09317,"Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Drotrecogin alfa.","Synthetic Conjugated Estrogens, A",DB00055
DB09318,"Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Drotrecogin alfa.","Synthetic Conjugated Estrogens, B",DB00055
DB09369,Polyestradiol phosphate may decrease the anticoagulant activities of Drotrecogin alfa.,Polyestradiol phosphate,DB00055
DB09381,Esterified estrogens may decrease the anticoagulant activities of Drotrecogin alfa.,Esterified estrogens,DB00055
DB11478,Zeranol may decrease the anticoagulant activities of Drotrecogin alfa.,Zeranol,DB00055
DB11674,Equol may decrease the anticoagulant activities of Drotrecogin alfa.,Equol,DB00055
DB12487,Promestriene may decrease the anticoagulant activities of Drotrecogin alfa.,Promestriene,DB00055
DB13143,Methallenestril may decrease the anticoagulant activities of Drotrecogin alfa.,Methallenestril,DB00055
DB13386,Epimestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Epimestrol,DB00055
DB13418,Moxestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Moxestrol,DB00055
DB13952,Estradiol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol acetate,DB00055
DB13953,Estradiol benzoate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol benzoate,DB00055
DB13954,Estradiol cypionate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol cypionate,DB00055
DB13956,Estradiol valerate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol valerate,DB00055
DB15334,Biochanin A may decrease the anticoagulant activities of Drotrecogin alfa.,Biochanin A,DB00055
DB15335,Formononetin may decrease the anticoagulant activities of Drotrecogin alfa.,Formononetin,DB00055
DB00159,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Drotrecogin alfa.,Icosapent,DB00055
DB00244,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Drotrecogin alfa.,Mesalazine,DB00055
DB00328,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Drotrecogin alfa.,Indomethacin,DB00055
DB00461,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Drotrecogin alfa.,Nabumetone,DB00055
DB00465,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Drotrecogin alfa.,Ketorolac,DB00055
DB00469,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Drotrecogin alfa.,Tenoxicam,DB00055
DB00482,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Drotrecogin alfa.,Celecoxib,DB00055
DB00500,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Drotrecogin alfa.,Tolmetin,DB00055
DB00533,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Drotrecogin alfa.,Rofecoxib,DB00055
DB00554,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Drotrecogin alfa.,Piroxicam,DB00055
DB00573,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Drotrecogin alfa.,Fenoprofen,DB00055
DB00580,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Drotrecogin alfa.,Valdecoxib,DB00055
DB00586,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Drotrecogin alfa.,Diclofenac,DB00055
DB00605,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Drotrecogin alfa.,Sulindac,DB00055
DB00712,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Drotrecogin alfa.,Flurbiprofen,DB00055
DB00749,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Drotrecogin alfa.,Etodolac,DB00055
DB00784,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Drotrecogin alfa.,Mefenamic acid,DB00055
DB00788,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Drotrecogin alfa.,Naproxen,DB00055
DB00795,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Drotrecogin alfa.,Sulfasalazine,DB00055
DB00812,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Drotrecogin alfa.,Phenylbutazone,DB00055
DB00814,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Drotrecogin alfa.,Meloxicam,DB00055
DB00821,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Drotrecogin alfa.,Carprofen,DB00055
DB00861,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Drotrecogin alfa.,Diflunisal,DB00055
DB00936,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Drotrecogin alfa.,Salicylic acid,DB00055
DB00939,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Drotrecogin alfa.,Meclofenamic acid,DB00055
DB00991,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Drotrecogin alfa.,Oxaprozin,DB00055
DB01009,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Drotrecogin alfa.,Ketoprofen,DB00055
DB01014,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Drotrecogin alfa.,Balsalazide,DB00055
DB01250,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Drotrecogin alfa.,Olsalazine,DB00055
DB01283,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Drotrecogin alfa.,Lumiracoxib,DB00055
DB01397,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Drotrecogin alfa.,Magnesium salicylate,DB00055
DB01399,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Drotrecogin alfa.,Salsalate,DB00055
DB01401,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Drotrecogin alfa.,Choline magnesium trisalicylate,DB00055
DB01419,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Drotrecogin alfa.,Antrafenine,DB00055
DB01424,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Drotrecogin alfa.,Aminophenazone,DB00055
DB01435,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Drotrecogin alfa.,Antipyrine,DB00055
DB01600,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Drotrecogin alfa.,Tiaprofenic acid,DB00055
DB01628,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Drotrecogin alfa.,Etoricoxib,DB00055
DB02224,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Drotrecogin alfa.,Taxifolin,DB00055
DB03585,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Drotrecogin alfa.,Oxyphenbutazone,DB00055
DB04552,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Drotrecogin alfa.,Niflumic acid,DB00055
DB04725,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Drotrecogin alfa.,Licofelone,DB00055
DB04812,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Drotrecogin alfa.,Benoxaprofen,DB00055
DB04817,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Drotrecogin alfa.,Metamizole,DB00055
DB04828,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Drotrecogin alfa.,Zomepirac,DB00055
DB05095,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Drotrecogin alfa.,Cimicoxib,DB00055
DB06725,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Drotrecogin alfa.,Lornoxicam,DB00055
DB06736,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Drotrecogin alfa.,Aceclofenac,DB00055
DB06737,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Drotrecogin alfa.,Zaltoprofen,DB00055
DB07402,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Drotrecogin alfa.,Azapropazone,DB00055
DB07477,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Drotrecogin alfa.,Felbinac,DB00055
DB08439,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Drotrecogin alfa.,Parecoxib,DB00055
DB08797,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Drotrecogin alfa.,Salicylamide,DB00055
DB08940,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Drotrecogin alfa.,Kebuzone,DB00055
DB08942,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Drotrecogin alfa.,Isoxicam,DB00055
DB08951,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Drotrecogin alfa.,Indoprofen,DB00055
DB08955,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Drotrecogin alfa.,Ibuproxam,DB00055
DB08976,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Drotrecogin alfa.,Floctafenine,DB00055
DB08981,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Drotrecogin alfa.,Fenbufen,DB00055
DB08984,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Drotrecogin alfa.,Etofenamate,DB00055
DB08991,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Drotrecogin alfa.,Epirizole,DB00055
DB09084,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Drotrecogin alfa.,Benzydamine,DB00055
DB09212,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Drotrecogin alfa.,Loxoprofen,DB00055
DB09214,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Drotrecogin alfa.,Dexketoprofen,DB00055
DB09215,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Drotrecogin alfa.,Droxicam,DB00055
DB09216,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Drotrecogin alfa.,Tolfenamic acid,DB00055
DB09217,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Drotrecogin alfa.,Firocoxib,DB00055
DB09218,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Drotrecogin alfa.,Clonixin,DB00055
DB09285,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Drotrecogin alfa.,Morniflumate,DB00055
DB09288,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Drotrecogin alfa.,Propacetamol,DB00055
DB09295,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Drotrecogin alfa.,Talniflumate,DB00055
DB11455,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Drotrecogin alfa.,Robenacoxib,DB00055
DB11466,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Drotrecogin alfa.,Tepoxalin,DB00055
DB11518,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Drotrecogin alfa.,Flunixin,DB00055
DB12399,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Drotrecogin alfa.,Polmacoxib,DB00055
DB12480,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Drotrecogin alfa.,Betulinic Acid,DB00055
DB12610,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Drotrecogin alfa.,Ebselen,DB00055
DB13001,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Drotrecogin alfa.,Tinoridine,DB00055
DB13167,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Drotrecogin alfa.,Alclofenac,DB00055
DB13217,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Drotrecogin alfa.,Fentiazac,DB00055
DB13232,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Drotrecogin alfa.,Suxibuzone,DB00055
DB13286,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Drotrecogin alfa.,Bumadizone,DB00055
DB13314,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Drotrecogin alfa.,Alminoprofen,DB00055
DB13317,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Drotrecogin alfa.,Flunoxaprofen,DB00055
DB13364,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Drotrecogin alfa.,Feprazone,DB00055
DB13371,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Drotrecogin alfa.,Difenpiramide,DB00055
DB13407,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Drotrecogin alfa.,Nifenazone,DB00055
DB13432,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Drotrecogin alfa.,Lonazolac,DB00055
DB13481,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Drotrecogin alfa.,Tenidap,DB00055
DB13501,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Drotrecogin alfa.,Bendazac,DB00055
DB13514,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Drotrecogin alfa.,Pranoprofen,DB00055
DB13524,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Drotrecogin alfa.,Propyphenazone,DB00055
DB13527,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Drotrecogin alfa.,Proglumetacin,DB00055
DB13538,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Drotrecogin alfa.,Guacetisal,DB00055
DB13544,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Drotrecogin alfa.,Ethenzamide,DB00055
DB13612,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Drotrecogin alfa.,Carbaspirin calcium,DB00055
DB13629,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Drotrecogin alfa.,Mofebutazone,DB00055
DB13649,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Drotrecogin alfa.,Proquazone,DB00055
DB13657,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Drotrecogin alfa.,Benorilate,DB00055
DB13722,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Drotrecogin alfa.,Pirprofen,DB00055
DB13860,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Drotrecogin alfa.,Imidazole salicylate,DB00055
DB14059,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Drotrecogin alfa.,SC-236,DB00055
DB14060,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Drotrecogin alfa.,NS-398,DB00055
DB14938,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Drotrecogin alfa.,Flurbiprofen axetil,DB00055
DB04865,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Omacetaxine mepesuccinate.,Omacetaxine mepesuccinate,DB00055
DB11133,Omega-3 fatty acids may increase the anticoagulant activities of Drotrecogin alfa.,Omega-3 fatty acids,DB00055
DB00081,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.,Tositumomab,DB00055
DB09211,The risk or severity of adverse effects can be increased when Limaprost is combined with Drotrecogin alfa.,Limaprost,DB00055
DB00048,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Collagenase clostridium histolyticum.,Collagenase clostridium histolyticum,DB00055
DB00389,Carbimazole may increase the anticoagulant activities of Drotrecogin alfa.,Carbimazole,DB00055
DB00550,Propylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Propylthiouracil,DB00055
DB00763,Methimazole may increase the anticoagulant activities of Drotrecogin alfa.,Methimazole,DB00055
DB03374,"3,5-Diiodotyrosine may increase the anticoagulant activities of Drotrecogin alfa.","3,5-Diiodotyrosine",DB00055
DB06715,Potassium Iodide may increase the anticoagulant activities of Drotrecogin alfa.,Potassium Iodide,DB00055
DB07637,Dibromotyrosine may increase the anticoagulant activities of Drotrecogin alfa.,Dibromotyrosine,DB00055
DB09418,Potassium perchlorate may increase the anticoagulant activities of Drotrecogin alfa.,Potassium perchlorate,DB00055
DB13644,Methylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Methylthiouracil,DB00055
DB13804,Benzylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Benzylthiouracil,DB00055
DB00834,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mifepristone.,Mifepristone,DB00055
DB04066,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with p-Coumaric acid.,p-Coumaric acid,DB00055
DB04682,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Octylphenoxy polyethoxyethanol.,Octylphenoxy polyethoxyethanol,DB00055
DB05830,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trestolone.,Trestolone,DB00055
DB06266,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Lonidamine.,Lonidamine,DB00055
DB08867,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ulipristal.,Ulipristal,DB00055
DB09401,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Isosorbide.,Isosorbide,DB00055
DB11507,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cloprostenol.,Cloprostenol,DB00055
DB12025,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triptolide.,Triptolide,DB00055
DB13044,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Gossypol.,Gossypol,DB00055
DB13310,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ormeloxifene.,Ormeloxifene,DB00055
DB00294,Etonogestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Etonogestrel,DB00055
DB00304,Desogestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Desogestrel,DB00055
DB00351,Megestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Megestrol acetate,DB00055
DB00367,Levonorgestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Levonorgestrel,DB00055
DB00378,Dydrogesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Dydrogesterone,DB00055
DB00396,Progesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Progesterone,DB00055
DB00603,Medroxyprogesterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Medroxyprogesterone acetate,DB00055
DB00717,Norethisterone may decrease the anticoagulant activities of Drotrecogin alfa.,Norethisterone,DB00055
DB00823,Ethynodiol diacetate may decrease the anticoagulant activities of Drotrecogin alfa.,Ethynodiol diacetate,DB00055
DB00957,Norgestimate may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestimate,DB00055
DB01395,Drospirenone may decrease the anticoagulant activities of Drotrecogin alfa.,Drospirenone,DB00055
DB01431,Allylestrenol may decrease the anticoagulant activities of Drotrecogin alfa.,Allylestrenol,DB00055
DB04839,Cyproterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Cyproterone acetate,DB00055
DB06713,Norelgestromin may decrease the anticoagulant activities of Drotrecogin alfa.,Norelgestromin,DB00055
DB06730,Gestodene may decrease the anticoagulant activities of Drotrecogin alfa.,Gestodene,DB00055
DB06789,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Drotrecogin alfa.,Hydroxyprogesterone caproate,DB00055
DB09123,Dienogest may decrease the anticoagulant activities of Drotrecogin alfa.,Dienogest,DB00055
DB09124,Medrogestone may decrease the anticoagulant activities of Drotrecogin alfa.,Medrogestone,DB00055
DB09371,Norethynodrel may decrease the anticoagulant activities of Drotrecogin alfa.,Norethynodrel,DB00055
DB09389,Norgestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestrel,DB00055
DB11372,Altrenogest may decrease the anticoagulant activities of Drotrecogin alfa.,Altrenogest,DB00055
DB11619,Gestrinone may decrease the anticoagulant activities of Drotrecogin alfa.,Gestrinone,DB00055
DB11636,Nomegestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Nomegestrol,DB00055
DB12474,Lynestrenol may decrease the anticoagulant activities of Drotrecogin alfa.,Lynestrenol,DB00055
DB13230,Gestonorone may decrease the anticoagulant activities of Drotrecogin alfa.,Gestonorone,DB00055
DB13528,Chlormadinone may decrease the anticoagulant activities of Drotrecogin alfa.,Chlormadinone,DB00055
DB13533,Methylestrenolone may decrease the anticoagulant activities of Drotrecogin alfa.,Methylestrenolone,DB00055
DB13563,Norgestrienone may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestrienone,DB00055
DB13602,Promegestone may decrease the anticoagulant activities of Drotrecogin alfa.,Promegestone,DB00055
DB13685,Quingestanol may decrease the anticoagulant activities of Drotrecogin alfa.,Quingestanol,DB00055
DB13857,Demegestone may decrease the anticoagulant activities of Drotrecogin alfa.,Demegestone,DB00055
DB13866,Etynodiol may decrease the anticoagulant activities of Drotrecogin alfa.,Etynodiol,DB00055
DB13981,Nomegestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Nomegestrol acetate,DB00055
DB14570,Hydroxyprogesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Hydroxyprogesterone,DB00055
DB14678,Norethindrone enanthate may decrease the anticoagulant activities of Drotrecogin alfa.,Norethindrone enanthate,DB00055
DB14679,Quingestanol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Quingestanol acetate,DB00055
DB00233,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.,Aminosalicylic acid,DB00055
DB01294,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Drotrecogin alfa.,Bismuth subsalicylate,DB00055
DB06251,The risk or severity of bleeding can be increased when Dersalazine is combined with Drotrecogin alfa.,Dersalazine,DB00055
DB06807,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Drotrecogin alfa.,Phenyl aminosalicylate,DB00055
DB09543,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Drotrecogin alfa.,Methyl salicylate,DB00055
DB11079,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Drotrecogin alfa.,Trolamine salicylate,DB00055
DB13509,The risk or severity of bleeding can be increased when Aloxiprin is combined with Drotrecogin alfa.,Aloxiprin,DB00055
DB14006,The risk or severity of bleeding can be increased when Choline salicylate is combined with Drotrecogin alfa.,Choline salicylate,DB00055
DB14026,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Drotrecogin alfa.,Thiosalicylic acid,DB00055
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Drotrecogin alfa.,Abciximab,DB00055
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.,Eptifibatide,DB00055
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Drotrecogin alfa.,Ticlopidine,DB00055
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Drotrecogin alfa.,Anagrelide,DB00055
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Drotrecogin alfa.,Clopidogrel,DB00055
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Drotrecogin alfa.,Tirofiban,DB00055
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Drotrecogin alfa.,Dipyridamole,DB00055
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Drotrecogin alfa.,Iloprost,DB00055
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Drotrecogin alfa.,Sulfinpyrazone,DB00055
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Drotrecogin alfa.,Cilostazol,DB00055
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Drotrecogin alfa.,Ridogrel,DB00055
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Drotrecogin alfa.,Sevoflurane,DB00055
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Drotrecogin alfa.,Epoprostenol,DB00055
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Drotrecogin alfa.,Resveratrol,DB00055
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Drotrecogin alfa.,Nimesulide,DB00055
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Drotrecogin alfa.,Tesmilifene,DB00055
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Drotrecogin alfa.,Defibrotide,DB00055
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Drotrecogin alfa.,Beraprost,DB00055
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Drotrecogin alfa.,Ibudilast,DB00055
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Drotrecogin alfa.,Andrographolide,DB00055
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Drotrecogin alfa.,Caplacizumab,DB00055
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Drotrecogin alfa.,Prasugrel,DB00055
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Drotrecogin alfa.,Cangrelor,DB00055
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Drotrecogin alfa.,Tranilast,DB00055
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Drotrecogin alfa.,Triflusal,DB00055
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Drotrecogin alfa.,Ticagrelor,DB00055
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Drotrecogin alfa.,Icosapent ethyl,DB00055
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Drotrecogin alfa.,Trapidil,DB00055
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Drotrecogin alfa.,Naftopidil,DB00055
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Drotrecogin alfa.,Sarpogrelate,DB00055
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Drotrecogin alfa.,Ifetroban,DB00055
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Drotrecogin alfa.,Nitroaspirin,DB00055
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Drotrecogin alfa.,Ketanserin,DB00055
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Drotrecogin alfa.,Indobufen,DB00055
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Drotrecogin alfa.,Butylphthalide,DB00055
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Drotrecogin alfa.,Hydroxytyrosol,DB00055
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Drotrecogin alfa.,Ramatroban,DB00055
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Drotrecogin alfa.,Picotamide,DB00055
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Drotrecogin alfa.,Cloricromen,DB00055
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Drotrecogin alfa.,Linsidomine,DB00055
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Drotrecogin alfa.,Buflomedil,DB00055
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Drotrecogin alfa.,Relcovaptan,DB00055
DB00374,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.,Treprostinil,DB00055
DB03404,Hemin may increase the anticoagulant activities of Drotrecogin alfa.,Hemin,DB00055
DB13783,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Drotrecogin alfa.,Acemetacin,DB00055
DB00624,Testosterone may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone,DB00055
DB01420,Testosterone propionate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone propionate,DB00055
DB01481,1-Testosterone may increase the anticoagulant activities of Drotrecogin alfa.,1-Testosterone,DB00055
DB01485,4-Hydroxytestosterone may increase the anticoagulant activities of Drotrecogin alfa.,4-Hydroxytestosterone,DB00055
DB01510,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Drotrecogin alfa.,Dehydrochloromethyltestosterone,DB00055
DB01541,Boldenone may increase the anticoagulant activities of Drotrecogin alfa.,Boldenone,DB00055
DB01543,18-methyl-19-nortestosterone may increase the anticoagulant activities of Drotrecogin alfa.,18-methyl-19-nortestosterone,DB00055
DB01564,Calusterone may increase the anticoagulant activities of Drotrecogin alfa.,Calusterone,DB00055
DB01569,Formebolone may increase the anticoagulant activities of Drotrecogin alfa.,Formebolone,DB00055
DB01572,Methyl-1-testosterone may increase the anticoagulant activities of Drotrecogin alfa.,Methyl-1-testosterone,DB00055
DB02901,Stanolone may increase the anticoagulant activities of Drotrecogin alfa.,Stanolone,DB00055
DB07447,5beta-dihydrotestosterone may increase the anticoagulant activities of Drotrecogin alfa.,5beta-dihydrotestosterone,DB00055
DB08619,Testosterone succinate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone succinate,DB00055
DB11429,Mibolerone may increase the anticoagulant activities of Drotrecogin alfa.,Mibolerone,DB00055
DB13943,Testosterone cypionate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone cypionate,DB00055
DB13944,Testosterone enanthate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone enanthate,DB00055
DB13946,Testosterone undecanoate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone undecanoate,DB00055
DB13947,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone enantate benzilic acid hydrazone,DB00055
DB13951,Stanolone acetate may increase the anticoagulant activities of Drotrecogin alfa.,Stanolone acetate,DB00055
DB13958,Trestolone acetate may increase the anticoagulant activities of Drotrecogin alfa.,Trestolone acetate,DB00055
DB14093,"(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Drotrecogin alfa.","(1,2,6,7-3H)Testosterone",DB00055
DB14655,Drostanolone propionate may increase the anticoagulant activities of Drotrecogin alfa.,Drostanolone propionate,DB00055
DB11051,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Azficel-T.,Azficel-T,DB00055
DB09568,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Omega-3-carboxylic acids.,Omega-3-carboxylic acids,DB00055
DB00258,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Drotrecogin alfa.,Calcium acetate,DB00055
DB01164,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Drotrecogin alfa.,Calcium chloride,DB00055
DB01373,The therapeutic efficacy of Calcium can be decreased when used in combination with Drotrecogin alfa.,Calcium,DB00055
DB11126,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Drotrecogin alfa.,Calcium gluconate,DB00055
DB11608,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Eftrenonacog alfa,DB00055
DB13884,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Albutrepenonacog alfa,DB00055
DB13923,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Drotrecogin alfa.,Emicizumab,DB00055
DB14738,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.,Turoctocog alfa pegol,DB00055
DB00025,"The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Drotrecogin alfa.","Antihemophilic factor, human recombinant",DB00055
DB00036,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor VIIa Recombinant Human,DB00055
DB00100,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.,Coagulation Factor IX (Recombinant),DB00055
DB01783,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Drotrecogin alfa.,Pantothenic acid,DB00055
DB01942,The therapeutic efficacy of Formic acid can be decreased when used in combination with Drotrecogin alfa.,Formic acid,DB00055
DB02261,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Drotrecogin alfa.,Platelet Activating Factor,DB00055
DB06724,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Drotrecogin alfa.,Calcium carbonate,DB00055
DB09109,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Turoctocog alfa,DB00055
DB09222,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Drotrecogin alfa.,Fibrinogen human,DB00055
DB09310,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Drotrecogin alfa.,Catridecacog,DB00055
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Drotrecogin alfa.","Antihemophilic Factor (Recombinant), PEGylated",DB00055
DB11093,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Drotrecogin alfa.,Calcium citrate,DB00055
DB11168,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Drotrecogin alfa.,Calcium threonate,DB00055
DB11311,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Drotrecogin alfa.,Prothrombin,DB00055
DB11330,The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Drotrecogin alfa.,Factor IX Complex (Human),DB00055
DB11348,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Drotrecogin alfa.,Calcium Phosphate,DB00055
DB11606,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Susoctocog alfa,DB00055
DB11668,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Drotrecogin alfa.,Rusalatide acetate,DB00055
DB12409,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Drotrecogin alfa.,Vatreptacog alfa,DB00055
DB12909,The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Drotrecogin alfa.,Factor XIII (human),DB00055
DB13133,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Drotrecogin alfa.,Von Willebrand Factor Human,DB00055
DB13148,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor X human,DB00055
DB13150,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor VII human,DB00055
DB13151,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Drotrecogin alfa.,Anti-inhibitor coagulant complex,DB00055
DB13152,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Drotrecogin alfa.,Coagulation Factor IX Human,DB00055
DB13192,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Drotrecogin alfa.,Antihemophilic factor human,DB00055
DB13197,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Drotrecogin alfa.,Kallidinogenase,DB00055
DB13201,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Trenonacog alfa,DB00055
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Drotrecogin alfa.,Nonacog beta pegol,DB00055
DB13999,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Moroctocog alfa,DB00055
DB14473,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Beroctocog alfa,DB00055
DB14562,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Drotrecogin alfa.,Andexanet alfa,DB00055
DB14577,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Drotrecogin alfa.,Calcium cation,DB00055
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.,Damoctocog alfa pegol,DB00055
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Drotrecogin alfa.,Fluvoxamine,DB00055
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Drotrecogin alfa.,Citalopram,DB00055
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Drotrecogin alfa.,Fluoxetine,DB00055
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Drotrecogin alfa.,Paroxetine,DB00055
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Drotrecogin alfa.,Nefazodone,DB00055
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Drotrecogin alfa.,Zimelidine,DB00055
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Drotrecogin alfa.,Dapoxetine,DB00055
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Drotrecogin alfa.,Seproxetine,DB00055
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Drotrecogin alfa.,Indalpine,DB00055
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Drotrecogin alfa.,Ritanserin,DB00055
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Drotrecogin alfa.,Alaproclate,DB00055
DB00476,The risk or severity of hemorrhage can be increased when Duloxetine is combined with Drotrecogin alfa.,Duloxetine,DB00055
DB01105,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Drotrecogin alfa.,Sibutramine,DB00055
DB04896,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Drotrecogin alfa.,Milnacipran,DB00055
DB06700,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Drotrecogin alfa.,Desvenlafaxine,DB00055
DB08918,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Drotrecogin alfa.,Levomilnacipran,DB00055
DB00285,Venlafaxine may increase the antiplatelet activities of Drotrecogin alfa.,Venlafaxine,DB00055
DB00182,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Drotrecogin alfa.,Amphetamine,DB00055
DB00601,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Drotrecogin alfa.,Linezolid,DB00055
DB00614,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Drotrecogin alfa.,Furazolidone,DB00055
DB00721,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Drotrecogin alfa.,Procaine,DB00055
DB00752,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Drotrecogin alfa.,Tranylcypromine,DB00055
DB00780,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Drotrecogin alfa.,Phenelzine,DB00055
DB00805,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Drotrecogin alfa.,Minaprine,DB00055
DB01037,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Drotrecogin alfa.,Selegiline,DB00055
DB01168,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Drotrecogin alfa.,Procarbazine,DB00055
DB01171,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Drotrecogin alfa.,Moclobemide,DB00055
DB01247,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Drotrecogin alfa.,Isocarboxazid,DB00055
DB01367,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Drotrecogin alfa.,Rasagiline,DB00055
DB01626,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Drotrecogin alfa.,Pargyline,DB00055
DB04017,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Drotrecogin alfa.,Clorgiline,DB00055
DB04818,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Drotrecogin alfa.,Iproniazid,DB00055
DB04820,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Drotrecogin alfa.,Nialamide,DB00055
DB06654,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Drotrecogin alfa.,Safinamide,DB00055
DB08550,"The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Drotrecogin alfa.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",DB00055
DB09241,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Drotrecogin alfa.,Methylene blue,DB00055
DB09243,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Drotrecogin alfa.,Hydracarbazine,DB00055
DB09244,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Drotrecogin alfa.,Pirlindole,DB00055
DB09245,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Drotrecogin alfa.,Toloxatone,DB00055
DB09246,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Drotrecogin alfa.,Benmoxin,DB00055
DB09248,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Drotrecogin alfa.,Mebanazine,DB00055
DB09249,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Drotrecogin alfa.,Octamoxin,DB00055
DB09250,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Drotrecogin alfa.,Pheniprazine,DB00055
DB09251,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Drotrecogin alfa.,Phenoxypropazine,DB00055
DB09252,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Drotrecogin alfa.,Pivhydrazine,DB00055
DB09253,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Drotrecogin alfa.,Safrazine,DB00055
DB09254,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Drotrecogin alfa.,Caroxazone,DB00055
DB13875,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Drotrecogin alfa.,Harmaline,DB00055
DB13876,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Drotrecogin alfa.,Brofaromine,DB00055
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Drotrecogin alfa.,Bivalirudin,DB00055
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Drotrecogin alfa.,Dicoumarol,DB00055
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Drotrecogin alfa.,Argatroban,DB00055
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Drotrecogin alfa.,Ardeparin,DB00055
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Drotrecogin alfa.,Phenindione,DB00055
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Drotrecogin alfa.,Fondaparinux,DB00055
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Drotrecogin alfa.,Warfarin,DB00055
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Drotrecogin alfa.,Phenprocoumon,DB00055
DB00974,The risk or severity of bleeding can be increased when Edetic acid is combined with Drotrecogin alfa.,Edetic acid,DB00055
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Drotrecogin alfa.,Heparin,DB00055
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Drotrecogin alfa.,Enoxaparin,DB00055
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Drotrecogin alfa.,Acenocoumarol,DB00055
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Drotrecogin alfa.,Ximelagatran,DB00055
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Drotrecogin alfa.,Ancrod,DB00055
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Drotrecogin alfa.,Sulodexide,DB00055
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Drotrecogin alfa.,Idraparinux,DB00055
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Drotrecogin alfa.,Otamixaban,DB00055
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Drotrecogin alfa.,Danaparoid,DB00055
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Drotrecogin alfa.,Dalteparin,DB00055
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Drotrecogin alfa.,Ferulic acid,DB00055
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Drotrecogin alfa.,Ethyl biscoumacetate,DB00055
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Drotrecogin alfa.,Nadroparin,DB00055
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Drotrecogin alfa.,Dextran,DB00055
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Drotrecogin alfa.,Reviparin,DB00055
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Drotrecogin alfa.,Certoparin,DB00055
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Drotrecogin alfa.,Desirudin,DB00055
DB11268,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Drotrecogin alfa.,Protocatechualdehyde,DB00055
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Drotrecogin alfa.,Protein C,DB00055
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Drotrecogin alfa.,Antithrombin III human,DB00055
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Drotrecogin alfa.,Letaxaban,DB00055
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Drotrecogin alfa.,Darexaban,DB00055
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Drotrecogin alfa.,Nafamostat,DB00055
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Drotrecogin alfa.,Gabexate,DB00055
DB13124,The risk or severity of bleeding can be increased when Troxerutin is combined with Drotrecogin alfa.,Troxerutin,DB00055
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Drotrecogin alfa.,Fluindione,DB00055
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Drotrecogin alfa.,Protein S human,DB00055
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Drotrecogin alfa.,Melagatran,DB00055
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Drotrecogin alfa.,Potassium citrate,DB00055
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Drotrecogin alfa.,Sodium citrate,DB00055
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Drotrecogin alfa.,Tenecteplase,DB00055
DB06822,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tinzaparin.,Tinzaparin,DB00055
DB13199,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Brinase.,Brinase,DB00055
DB13646,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Saruplase.,Saruplase,DB00055
DB00086,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.,Streptokinase,DB00055
DB04925,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Desmoteplase.,Desmoteplase,DB00055
DB05254,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fibrinolysin.,Fibrinolysin,DB00055
DB06543,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Astaxanthin.,Astaxanthin,DB00055
DB08994,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ditazole.,Ditazole,DB00055
DB09258,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bemiparin.,Bemiparin,DB00055
DB09260,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Parnaparin.,Parnaparin,DB00055
DB13275,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clorindione.,Clorindione,DB00055
DB13347,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Diphenadione.,Diphenadione,DB00055
DB13451,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioclomarol.,Tioclomarol,DB00055
DB00001,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.,Lepirudin,DB00055
DB00009,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alteplase.,Alteplase,DB00055
DB00015,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.,Reteplase,DB00055
DB00029,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Anistreplase.,Anistreplase,DB00055
DB14094,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tocopherylquinone.,Tocopherylquinone,DB00055
DB06679,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amediplase.,Amediplase,DB00055
DB03410,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with 4-hydroxycoumarin.,4-hydroxycoumarin,DB00055
DB08496,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (R)-warfarin.,(R)-warfarin,DB00055
DB14055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (S)-Warfarin.,(S)-Warfarin,DB00055
DB12364,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Betrixaban.,Betrixaban,DB00055
DB14598,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous,DB00055
DB11154,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zinc citrate.,Zinc citrate,DB00055
DB11166,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Antithrombin Alfa.,Antithrombin Alfa,DB00055
DB04665,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Coumarin.,Coumarin,DB00055
DB14726,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dabigatran.,Dabigatran,DB00055
DB06294,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Semuloparin.,Semuloparin,DB00055
DB12726,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Monteplase.,Monteplase,DB00055
DB00203,The risk or severity of hemorrhage can be increased when Drotrecogin alfa is combined with Sildenafil.,Sildenafil,DB00055
DB00008,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00055
DB00011,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n1.,Interferon alfa-n1,DB00055
DB00018,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n3.,Interferon alfa-n3,DB00055
DB00022,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00055
DB00033,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon gamma-1b.,Interferon gamma-1b,DB00055
DB00034,"The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant",DB00055
DB00041,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Aldesleukin.,Aldesleukin,DB00055
DB00056,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin,DB00055
DB00068,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.,Interferon beta-1b,DB00055
DB00069,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00055
DB00073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.,Rituximab,DB00055
DB00078,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00055
DB00087,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.,Alemtuzumab,DB00055
DB00105,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00055
DB00120,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Phenylalanine.,Phenylalanine,DB00055
DB00188,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bortezomib.,Bortezomib,DB00055
DB00242,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cladribine.,Cladribine,DB00055
DB00262,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carmustine.,Carmustine,DB00055
DB00276,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amsacrine.,Amsacrine,DB00055
DB00291,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chlorambucil.,Chlorambucil,DB00055
DB00293,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Raltitrexed.,Raltitrexed,DB00055
DB00305,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitomycin.,Mitomycin,DB00055
DB00307,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bexarotene.,Bexarotene,DB00055
DB00309,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vindesine.,Vindesine,DB00055
DB00322,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Floxuridine.,Floxuridine,DB00055
DB00352,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioguanine.,Tioguanine,DB00055
DB00361,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinorelbine.,Vinorelbine,DB00055
DB00380,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane.,Dexrazoxane,DB00055
DB00398,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sorafenib.,Sorafenib,DB00055
DB00428,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptozocin.,Streptozocin,DB00055
DB00441,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemcitabine.,Gemcitabine,DB00055
DB00444,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Teniposide.,Teniposide,DB00055
DB00445,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Epirubicin.,Epirubicin,DB00055
DB00446,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chloramphenicol.,Chloramphenicol,DB00055
DB00480,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lenalidomide.,Lenalidomide,DB00055
DB00488,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Altretamine.,Altretamine,DB00055
DB00495,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zidovudine.,Zidovudine,DB00055
DB00515,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin.,Cisplatin,DB00055
DB00526,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin.,Oxaliplatin,DB00055
DB00531,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cyclophosphamide.,Cyclophosphamide,DB00055
DB00544,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fluorouracil.,Fluorouracil,DB00055
DB00552,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pentostatin.,Pentostatin,DB00055
DB00563,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Methotrexate.,Methotrexate,DB00055
DB00564,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carbamazepine.,Carbamazepine,DB00055
DB00570,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinblastine.,Vinblastine,DB00055
DB00619,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Imatinib.,Imatinib,DB00055
DB00631,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clofarabine.,Clofarabine,DB00055
DB00642,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pemetrexed.,Pemetrexed,DB00055
DB00694,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.,Daunorubicin,DB00055
DB00762,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Irinotecan.,Irinotecan,DB00055
DB00773,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Etoposide.,Etoposide,DB00055
DB00851,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dacarbazine.,Dacarbazine,DB00055
DB00853,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temozolomide.,Temozolomide,DB00055
DB00859,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Penicillamine.,Penicillamine,DB00055
DB00864,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tacrolimus.,Tacrolimus,DB00055
DB00877,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sirolimus.,Sirolimus,DB00055
DB00888,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mechlorethamine.,Mechlorethamine,DB00055
DB00928,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Azacitidine.,Azacitidine,DB00055
DB00958,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carboplatin.,Carboplatin,DB00055
DB00970,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dactinomycin.,Dactinomycin,DB00055
DB00987,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.,Cytarabine,DB00055
DB00997,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Doxorubicin.,Doxorubicin,DB00055
DB01005,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Hydroxyurea.,Hydroxyurea,DB00055
DB01008,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Busulfan.,Busulfan,DB00055
DB01030,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Topotecan.,Topotecan,DB00055
DB01033,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mercaptopurine.,Mercaptopurine,DB00055
DB01041,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thalidomide.,Thalidomide,DB00055
DB01042,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Melphalan.,Melphalan,DB00055
DB01073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fludarabine.,Fludarabine,DB00055
DB01099,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Flucytosine.,Flucytosine,DB00055
DB01101,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Capecitabine.,Capecitabine,DB00055
DB01169,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Arsenic trioxide.,Arsenic trioxide,DB00055
DB01177,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Idarubicin.,Idarubicin,DB00055
DB01204,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitoxantrone.,Mitoxantrone,DB00055
DB01206,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lomustine.,Lomustine,DB00055
DB01229,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Paclitaxel.,Paclitaxel,DB00055
DB01248,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Docetaxel.,Docetaxel,DB00055
DB01262,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Decitabine.,Decitabine,DB00055
DB01280,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nelarabine.,Nelarabine,DB00055
DB01590,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Everolimus.,Everolimus,DB00055
DB02546,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vorinostat.,Vorinostat,DB00055
DB04572,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thiotepa.,Thiotepa,DB00055
DB04845,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ixabepilone.,Ixabepilone,DB00055
DB04868,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nilotinib.,Nilotinib,DB00055
DB05015,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Belinostat.,Belinostat,DB00055
DB05109,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trabectedin.,Trabectedin,DB00055
DB05258,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa.,Interferon alfa,DB00055
DB05472,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with omega interferon.,omega interferon,DB00055
DB05773,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00055
DB06287,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temsirolimus.,Temsirolimus,DB00055
DB06616,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bosutinib.,Bosutinib,DB00055
DB06769,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bendamustine.,Bendamustine,DB00055
DB06772,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cabazitaxel.,Cabazitaxel,DB00055
DB08871,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Eribulin.,Eribulin,DB00055
DB08877,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ruxolitinib.,Ruxolitinib,DB00055
DB08889,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carfilzomib.,Carfilzomib,DB00055
DB08895,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tofacitinib.,Tofacitinib,DB00055
DB08901,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ponatinib.,Ponatinib,DB00055
DB08910,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pomalidomide.,Pomalidomide,DB00055
DB09042,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00055
DB09052,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Blinatumomab.,Blinatumomab,DB00055
DB09073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Palbociclib.,Palbociclib,DB00055
DB09074,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Olaparib.,Olaparib,DB00055
DB09077,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dinutuximab.,Dinutuximab,DB00055
DB09122,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00055
DB12814,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00055
DB00229,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotiam.,Cefotiam,DB00055
DB00267,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmenoxime.,Cefmenoxime,DB00055
DB00274,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmetazole.,Cefmetazole,DB00055
DB00430,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpiramide.,Cefpiramide,DB00055
DB00438,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftazidime.,Ceftazidime,DB00055
DB00447,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Loracarbef.,Loracarbef,DB00055
DB00456,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefalotin.,Cefalotin,DB00055
DB00493,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotaxime.,Cefotaxime,DB00055
DB00535,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefdinir.,Cefdinir,DB00055
DB00567,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephalexin.,Cephalexin,DB00055
DB00671,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefixime.,Cefixime,DB00055
DB00689,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephaloglycin.,Cephaloglycin,DB00055
DB00833,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaclor.,Cefaclor,DB00055
DB00923,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceforanide.,Ceforanide,DB00055
DB01066,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefditoren.,Cefditoren,DB00055
DB01112,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefuroxime.,Cefuroxime,DB00055
DB01139,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefapirin.,Cefapirin,DB00055
DB01140,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefadroxil.,Cefadroxil,DB00055
DB01150,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefprozil.,Cefprozil,DB00055
DB01212,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftriaxone.,Ceftriaxone,DB00055
DB01326,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole.,Cefamandole,DB00055
DB01327,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazolin.,Cefazolin,DB00055
DB01328,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefonicid.,Cefonicid,DB00055
DB01329,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoperazone.,Cefoperazone,DB00055
DB01330,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotetan.,Cefotetan,DB00055
DB01331,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoxitin.,Cefoxitin,DB00055
DB01332,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftizoxime.,Ceftizoxime,DB00055
DB01333,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefradine.,Cefradine,DB00055
DB01413,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefepime.,Cefepime,DB00055
DB01414,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefacetrile.,Cefacetrile,DB00055
DB01415,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftibuten.,Ceftibuten,DB00055
DB01416,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpodoxime.,Cefpodoxime,DB00055
DB04570,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Latamoxef.,Latamoxef,DB00055
DB04918,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftobiprole.,Ceftobiprole,DB00055
DB06590,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil,DB00055
DB09008,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaloridine.,Cefaloridine,DB00055
DB09050,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftolozane.,Ceftolozane,DB00055
DB09062,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefminox.,Cefminox,DB00055
DB11367,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefroxadine.,Cefroxadine,DB00055
DB11935,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Flomoxef.,Flomoxef,DB00055
DB13266,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefatrizine.,Cefatrizine,DB00055
DB13461,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefcapene.,Cefcapene,DB00055
DB13470,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefodizime.,Cefodizime,DB00055
DB13499,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefsulodin.,Cefsulodin,DB00055
DB13504,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefetamet.,Cefetamet,DB00055
DB13638,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefbuperazone.,Cefbuperazone,DB00055
DB13667,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefozopran.,Cefozopran,DB00055
DB13682,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpirome.,Cefpirome,DB00055
DB13778,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazedone.,Cefazedone,DB00055
DB13821,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftezole.,Ceftezole,DB00055
DB14725,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate,DB00055
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Drotrecogin alfa.,Doxycycline,DB00055
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Drotrecogin alfa.,Azithromycin,DB00055
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Drotrecogin alfa.,Omega-3-acid ethyl esters,DB00055
DB00945,Acetylsalicylic acid may increase the anticoagulant activities of Drotrecogin alfa.,Acetylsalicylic acid,DB00055
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Drotrecogin alfa.,Tazobactam,DB00055
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Drotrecogin alfa.,Erythromycin,DB00055
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Drotrecogin alfa.,Trazodone,DB00055
DB00620,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triamcinolone.,Triamcinolone,DB00055
DB09079,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nintedanib.,Nintedanib,DB00055
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Drotrecogin alfa.,Escitalopram,DB00055
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Drotrecogin alfa.,Sertraline,DB00055
DB00232,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Methyclothiazide.,Methyclothiazide,DB00055
DB00436,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide,DB00055
DB00562,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Benzthiazide.,Benzthiazide,DB00055
DB00606,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclothiazide.,Cyclothiazide,DB00055
DB00774,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide,DB00055
DB00880,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Chlorothiazide.,Chlorothiazide,DB00055
DB00999,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide,DB00055
DB01021,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide,DB00055
DB01324,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Polythiazide.,Polythiazide,DB00055
DB13430,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mebutizide.,Mebutizide,DB00055
DB13532,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide,DB00055
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.,Denosumab,DB00056
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.,Etanercept,DB00056
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.,Peginterferon alfa-2a,DB00056
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.,Interferon alfa-n1,DB00056
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin.,Interferon alfa-n3,DB00056
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.,Peginterferon alfa-2b,DB00056
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.,Anakinra,DB00056
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin.,Interferon gamma-1b,DB00056
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gemtuzumab ozogamicin.","Interferon alfa-2a, Recombinant",DB00056
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.,Aldesleukin,DB00056
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin.,Adalimumab,DB00056
DB00059,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.,Pegaspargase,DB00056
DB00065,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.,Infliximab,DB00056
DB00068,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.,Interferon beta-1b,DB00056
DB00069,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00056
DB00073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.,Rituximab,DB00056
DB00074,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.,Basiliximab,DB00056
DB00075,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.,Muromonab,DB00056
DB00078,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00056
DB00081,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.,Tositumomab,DB00056
DB00087,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.,Alemtuzumab,DB00056
DB00092,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.,Alefacept,DB00056
DB00095,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.,Efalizumab,DB00056
DB00098,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00056
DB00105,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00056
DB00111,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.,Daclizumab,DB00056
DB00112,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.,Bevacizumab,DB00056
DB00120,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.,Phenylalanine,DB00056
DB00180,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide.,Flunisolide,DB00056
DB00188,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib.,Bortezomib,DB00056
DB00242,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine.,Cladribine,DB00056
DB00262,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine.,Carmustine,DB00056
DB00276,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine.,Amsacrine,DB00056
DB00290,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin.,Bleomycin,DB00056
DB00291,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil.,Chlorambucil,DB00056
DB00293,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raltitrexed.,Raltitrexed,DB00056
DB00305,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin.,Mitomycin,DB00056
DB00307,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene.,Bexarotene,DB00056
DB00309,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine.,Vindesine,DB00056
DB00322,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine.,Floxuridine,DB00056
DB00328,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin.,Indomethacin,DB00056
DB00352,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine.,Tioguanine,DB00056
DB00361,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine.,Vinorelbine,DB00056
DB00380,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane.,Dexrazoxane,DB00056
DB00394,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00056
DB00398,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib.,Sorafenib,DB00056
DB00428,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin.,Streptozocin,DB00056
DB00432,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine.,Trifluridine,DB00056
DB00441,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine.,Gemcitabine,DB00056
DB00443,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone.,Betamethasone,DB00056
DB00444,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide.,Teniposide,DB00056
DB00445,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin.,Epirubicin,DB00056
DB00446,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol.,Chloramphenicol,DB00056
DB00480,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide.,Lenalidomide,DB00056
DB00488,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine.,Altretamine,DB00056
DB00495,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine.,Zidovudine,DB00056
DB00515,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.,Cisplatin,DB00056
DB00526,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.,Oxaliplatin,DB00056
DB00531,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.,Cyclophosphamide,DB00056
DB00541,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine.,Vincristine,DB00056
DB00544,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil.,Fluorouracil,DB00056
DB00550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.,Propylthiouracil,DB00056
DB00552,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin.,Pentostatin,DB00056
DB00563,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate.,Methotrexate,DB00056
DB00564,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine.,Carbamazepine,DB00056
DB00570,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine.,Vinblastine,DB00056
DB00588,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate.,Fluticasone propionate,DB00056
DB00591,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00056
DB00601,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid.,Linezolid,DB00056
DB00619,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib.,Imatinib,DB00056
DB00620,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone.,Triamcinolone,DB00056
DB00631,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine.,Clofarabine,DB00056
DB00635,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone.,Prednisone,DB00056
DB00642,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed.,Pemetrexed,DB00056
DB00687,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone.,Fludrocortisone,DB00056
DB00688,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00056
DB00694,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.,Daunorubicin,DB00056
DB00755,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin.,Tretinoin,DB00056
DB00762,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.,Irinotecan,DB00056
DB00763,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole.,Methimazole,DB00056
DB00764,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone.,Mometasone,DB00056
DB00773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide.,Etoposide,DB00056
DB00795,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine.,Sulfasalazine,DB00056
DB00851,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.,Dacarbazine,DB00056
DB00853,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide.,Temozolomide,DB00056
DB00859,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine.,Penicillamine,DB00056
DB00860,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone.,Prednisolone,DB00056
DB00877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus.,Sirolimus,DB00056
DB00888,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine.,Mechlorethamine,DB00056
DB00928,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine.,Azacitidine,DB00056
DB00958,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.,Carboplatin,DB00056
DB00959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone.,Methylprednisolone,DB00056
DB00970,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin.,Dactinomycin,DB00056
DB00987,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.,Cytarabine,DB00056
DB00993,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine.,Azathioprine,DB00056
DB00997,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin.,Doxorubicin,DB00056
DB01005,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea.,Hydroxyurea,DB00056
DB01008,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan.,Busulfan,DB00056
DB01024,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid.,Mycophenolic acid,DB00056
DB01030,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.,Topotecan,DB00056
DB01033,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine.,Mercaptopurine,DB00056
DB01041,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide.,Thalidomide,DB00056
DB01042,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan.,Melphalan,DB00056
DB01073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine.,Fludarabine,DB00056
DB01099,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine.,Flucytosine,DB00056
DB01101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine.,Capecitabine,DB00056
DB01108,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane.,Trilostane,DB00056
DB01168,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine.,Procarbazine,DB00056
DB01169,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide.,Arsenic trioxide,DB00056
DB01177,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin.,Idarubicin,DB00056
DB01181,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide.,Ifosfamide,DB00056
DB01196,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.,Estramustine,DB00056
DB01204,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.,Mitoxantrone,DB00056
DB01206,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine.,Lomustine,DB00056
DB01222,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide.,Budesonide,DB00056
DB01229,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel.,Paclitaxel,DB00056
DB01234,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.,Dexamethasone,DB00056
DB01248,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel.,Docetaxel,DB00056
DB01254,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.,Dasatinib,DB00056
DB01257,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab.,Eculizumab,DB00056
DB01262,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine.,Decitabine,DB00056
DB01268,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib.,Sunitinib,DB00056
DB01280,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine.,Nelarabine,DB00056
DB01281,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept.,Abatacept,DB00056
DB01285,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin.,Corticotropin,DB00056
DB01380,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate.,Cortisone acetate,DB00056
DB01384,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paramethasone.,Paramethasone,DB00056
DB01394,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Colchicine.,Colchicine,DB00056
DB01410,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.,Ciclesonide,DB00056
DB01423,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Stepronin.,Stepronin,DB00056
DB01590,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus.,Everolimus,DB00056
DB01611,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00056
DB01816,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Castanospermine.,Castanospermine,DB00056
DB02546,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat.,Vorinostat,DB00056
DB02806,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00056
DB03523,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brequinar.,Brequinar,DB00056
DB04572,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa.,Thiotepa,DB00056
DB04630,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aldosterone.,Aldosterone,DB00056
DB04845,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone.,Ixabepilone,DB00056
DB04868,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib.,Nilotinib,DB00056
DB04951,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone.,Pirfenidone,DB00056
DB04956,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Afelimomab.,Afelimomab,DB00056
DB05015,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat.,Belinostat,DB00056
DB05109,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin.,Trabectedin,DB00056
DB05258,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa.,Interferon alfa,DB00056
DB05259,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer.,Glatiramer,DB00056
DB05260,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate.,Gallium nitrate,DB00056
DB05459,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Briakinumab.,Briakinumab,DB00056
DB05472,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with omega interferon.,omega interferon,DB00056
DB05676,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast.,Apremilast,DB00056
DB05773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00056
DB06168,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab.,Canakinumab,DB00056
DB06273,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab.,Tocilizumab,DB00056
DB06287,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus.,Temsirolimus,DB00056
DB06372,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept.,Rilonacept,DB00056
DB06589,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib.,Pazopanib,DB00056
DB06603,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat.,Panobinostat,DB00056
DB06612,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab.,Mepolizumab,DB00056
DB06616,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib.,Bosutinib,DB00056
DB06662,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abetimus.,Abetimus,DB00056
DB06674,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab.,Golimumab,DB00056
DB06681,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept.,Belatacept,DB00056
DB06769,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine.,Bendamustine,DB00056
DB06772,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel.,Cabazitaxel,DB00056
DB06813,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate.,Pralatrexate,DB00056
DB08059,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Wortmannin.,Wortmannin,DB00056
DB08870,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00056
DB08871,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin.,Eribulin,DB00056
DB08877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.,Ruxolitinib,DB00056
DB08879,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab.,Belimumab,DB00056
DB08880,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide.,Teriflunomide,DB00056
DB08889,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib.,Carfilzomib,DB00056
DB08901,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib.,Ponatinib,DB00056
DB08904,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol.,Certolizumab pegol,DB00056
DB08906,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate.,Fluticasone furoate,DB00056
DB08908,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00056
DB08910,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.,Pomalidomide,DB00056
DB08935,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab.,Obinutuzumab,DB00056
DB08970,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednidene.,Fluprednidene,DB00056
DB08971,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone.,Fluocortolone,DB00056
DB09029,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.,Secukinumab,DB00056
DB09033,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab.,Vedolizumab,DB00056
DB09036,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab.,Siltuximab,DB00056
DB09052,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab.,Blinatumomab,DB00056
DB09053,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib.,Ibrutinib,DB00056
DB09054,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib.,Idelalisib,DB00056
DB09073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib.,Palbociclib,DB00056
DB09074,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.,Olaparib,DB00056
DB09077,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab.,Dinutuximab,DB00056
DB09082,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol.,Vilanterol,DB00056
DB09091,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol.,Tixocortol,DB00056
DB09122,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00056
DB09312,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00056
DB09378,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone.,Fluprednisolone,DB00056
DB09383,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone.,Meprednisone,DB00056
DB11466,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tepoxalin.,Tepoxalin,DB00056
DB11487,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00056
DB11529,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melengestrol.,Melengestrol,DB00056
DB11569,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab.,Ixekizumab,DB00056
DB11580,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab.,Ravulizumab,DB00056
DB11616,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirarubicin.,Pirarubicin,DB00056
DB11693,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin.,Voclosporin,DB00056
DB11708,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peficitinib.,Peficitinib,DB00056
DB11750,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol.,Clobetasol,DB00056
DB11767,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab.,Sarilumab,DB00056
DB11776,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab.,Brodalumab,DB00056
DB11803,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirukumab.,Sirukumab,DB00056
DB11817,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib.,Baricitinib,DB00056
DB11834,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.,Guselkumab,DB00056
DB11921,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort.,Deflazacort,DB00056
DB12025,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triptolide.,Triptolide,DB00056
DB12371,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod.,Siponimod,DB00056
DB12612,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod.,Ozanimod,DB00056
DB12617,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mizoribine.,Mizoribine,DB00056
DB12692,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gusperimus.,Gusperimus,DB00056
DB12814,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00056
DB12902,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trofosfamide.,Trofosfamide,DB00056
DB12947,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxifluridine.,Doxifluridine,DB00056
DB12991,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deoxyspergualin.,Deoxyspergualin,DB00056
DB12996,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Acteoside.,Acteoside,DB00056
DB13003,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortivazol.,Cortivazol,DB00056
DB13014,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hypericin.,Hypericin,DB00056
DB13068,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00056
DB13208,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednylidene.,Prednylidene,DB00056
DB13223,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortin.,Fluocortin,DB00056
DB13241,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Begelomab.,Begelomab,DB00056
DB13491,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluperolone.,Fluperolone,DB00056
DB13664,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Formocortal.,Formocortal,DB00056
DB13728,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Halometasone.,Halometasone,DB00056
DB13843,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cloprednol.,Cloprednol,DB00056
DB13856,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluclorolone.,Fluclorolone,DB00056
DB13867,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone.,Fluticasone,DB00056
DB14066,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetrandrine.,Tetrandrine,DB00056
DB14219,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00056
DB14512,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate.,Mometasone furoate,DB00056
DB14538,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00056
DB14539,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00056
DB14545,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00056
DB14724,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab.,Emapalumab,DB00056
DB14762,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab.,Risankizumab,DB00056
DB14919,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozanolixizumab.,Rozanolixizumab,DB00056
DB15253,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleselumab.,Bleselumab,DB00056
DB00108,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.,Natalizumab,DB00056
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.,Pimecrolimus,DB00056
DB01656,Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Roflumilast,DB00056
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.,Sipuleucel-T,DB00056
DB00363,The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine.,Clozapine,DB00056
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.,Darbepoetin alfa,DB00056
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin.,Erythropoietin,DB00056
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin.,Peginesatide,DB00056
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.,Methoxy polyethylene glycol-epoetin beta,DB00056
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin.,Sulfamethoxazole,DB00056
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Diethylstilbestrol,DB00056
DB00269,Chlorotrianisene may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Chlorotrianisene,DB00056
DB00286,Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Conjugated estrogens,DB00056
DB00655,Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estrone,DB00056
DB00783,Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol,DB00056
DB00890,Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Dienestrol,DB00056
DB00977,Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Ethinylestradiol,DB00056
DB01357,Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Mestranol,DB00056
DB04573,Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estriol,DB00056
DB04574,Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estrone sulfate,DB00056
DB04575,Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Quinestrol,DB00056
DB07931,Hexestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Hexestrol,DB00056
DB09070,Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Tibolone,DB00056
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin.","Synthetic Conjugated Estrogens, A",DB00056
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin.","Synthetic Conjugated Estrogens, B",DB00056
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Polyestradiol phosphate,DB00056
DB09381,Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Esterified estrogens,DB00056
DB11478,Zeranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Zeranol,DB00056
DB11674,Equol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Equol,DB00056
DB12487,Promestriene may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Promestriene,DB00056
DB13143,Methallenestril may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Methallenestril,DB00056
DB13386,Epimestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Epimestrol,DB00056
DB13418,Moxestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Moxestrol,DB00056
DB13952,Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol acetate,DB00056
DB13953,Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol benzoate,DB00056
DB13954,Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol cypionate,DB00056
DB13956,Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol valerate,DB00056
DB15334,Biochanin A may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Biochanin A,DB00056
DB15335,Formononetin may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Formononetin,DB00056
DB01097,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.,Leflunomide,DB00056
DB08895,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00056
DB00072,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.,Trastuzumab,DB00056
DB08868,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00056
DB00864,Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Tacrolimus,DB00056
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Gemtuzumab ozogamicin.,G17DT,DB00056
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Gemtuzumab ozogamicin.,PEV3A,DB00056
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemtuzumab ozogamicin.,INGN 225,DB00056
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gemtuzumab ozogamicin.,Rindopepimut,DB00056
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Gemtuzumab ozogamicin.,SRP 299,DB00056
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemtuzumab ozogamicin.,GI-5005,DB00056
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Gemtuzumab ozogamicin.,Vitespen,DB00056
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Gemtuzumab ozogamicin.,TG4010,DB00056
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin.,Anthrax immune globulin human,DB00056
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Gemtuzumab ozogamicin.","Rabies virus inactivated antigen, B",DB00056
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00056
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Rotavirus vaccine,DB00056
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemtuzumab ozogamicin.","Rabies virus inactivated antigen, A",DB00056
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00056
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00056
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00056
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00056
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00056
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00056
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Typhoid Vi polysaccharide vaccine,DB00056
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Hepatitis A Vaccine,DB00056
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00056
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00056
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00056
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00056
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00056
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemtuzumab ozogamicin.,Human rabies virus immune globulin,DB00056
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.,Hepatitis B Vaccine (Recombinant),DB00056
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Gemtuzumab ozogamicin.,Tecemotide,DB00056
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Typhoid vaccine,DB00056
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00056
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00056
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00056
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00056
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00056
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00056
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00056
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Vaccinia virus strain new york city board of health live antigen,DB00056
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Pertussis vaccine,DB00056
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00056
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.,Varicella Zoster Vaccine (Recombinant),DB00056
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin.,Modified vaccinia ankara,DB00056
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.,Eptifibatide,DB00056
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin.,Ticlopidine,DB00056
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin.,Anagrelide,DB00056
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin.,Clopidogrel,DB00056
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin.,Tirofiban,DB00056
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin.,Pentoxifylline,DB00056
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin.,Acetylsalicylic acid,DB00056
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin.,Dipyridamole,DB00056
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin.,Iloprost,DB00056
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin.,Sulfinpyrazone,DB00056
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin.,Cilostazol,DB00056
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Gemtuzumab ozogamicin.,Ridogrel,DB00056
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Gemtuzumab ozogamicin.,Sevoflurane,DB00056
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin.,Epoprostenol,DB00056
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Gemtuzumab ozogamicin.,Resveratrol,DB00056
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin.,Nimesulide,DB00056
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Gemtuzumab ozogamicin.,Tesmilifene,DB00056
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin.,Defibrotide,DB00056
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Gemtuzumab ozogamicin.,Beraprost,DB00056
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Gemtuzumab ozogamicin.,Ibudilast,DB00056
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Gemtuzumab ozogamicin.,Andrographolide,DB00056
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin.,Prasugrel,DB00056
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin.,Cangrelor,DB00056
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Gemtuzumab ozogamicin.,Tranilast,DB00056
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin.,Triflusal,DB00056
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin.,Ticagrelor,DB00056
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin.,Icosapent ethyl,DB00056
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin.,Vorapaxar,DB00056
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Gemtuzumab ozogamicin.,Trapidil,DB00056
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Gemtuzumab ozogamicin.,Naftopidil,DB00056
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Gemtuzumab ozogamicin.,Sarpogrelate,DB00056
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Gemtuzumab ozogamicin.,Ifetroban,DB00056
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Gemtuzumab ozogamicin.,Nitroaspirin,DB00056
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Gemtuzumab ozogamicin.,Ketanserin,DB00056
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Gemtuzumab ozogamicin.,Indobufen,DB00056
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Gemtuzumab ozogamicin.,Butylphthalide,DB00056
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Gemtuzumab ozogamicin.,Hydroxytyrosol,DB00056
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Gemtuzumab ozogamicin.,Ramatroban,DB00056
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Gemtuzumab ozogamicin.,Picotamide,DB00056
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Gemtuzumab ozogamicin.,Cloricromen,DB00056
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Gemtuzumab ozogamicin.,Linsidomine,DB00056
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Gemtuzumab ozogamicin.,Buflomedil,DB00056
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Gemtuzumab ozogamicin.,Relcovaptan,DB00056
DB11988,Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Ocrelizumab,DB00056
DB13200,Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00056
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin.,Rubella virus vaccine,DB00056
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Gemtuzumab ozogamicin.,Varicella Zoster Vaccine (Live/attenuated),DB00056
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain tice live antigen,DB00056
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain connaught live antigen,DB00056
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Gemtuzumab ozogamicin.,Yellow Fever Vaccine,DB00056
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin.,Anthrax vaccine,DB00056
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin.,Typhoid Vaccine Live,DB00056
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00056
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin.,BCG vaccine,DB00056
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00056
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Gemtuzumab ozogamicin.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00056
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin.,Adenovirus type 7 vaccine live,DB00056
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.,Cetuximab,DB00056
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.,Human immunoglobulin G,DB00056
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin.,Omalizumab,DB00056
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Gemtuzumab ozogamicin.,Abciximab,DB00056
DB00057,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.,Indium In-111 satumomab pendetide,DB00056
DB00076,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00056
DB00089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.,Capromab pendetide,DB00056
DB00110,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.,Palivizumab,DB00056
DB00113,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00056
DB01269,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab.,Panitumumab,DB00056
DB01270,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab.,Ranibizumab,DB00056
DB04901,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galiximab.,Galiximab,DB00056
DB04949,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pexelizumab.,Pexelizumab,DB00056
DB04958,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epratuzumab.,Epratuzumab,DB00056
DB04962,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bectumomab.,Bectumomab,DB00056
DB04964,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oregovomab.,Oregovomab,DB00056
DB04988,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IGN311.,IGN311,DB00056
DB05006,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Adecatumumab.,Adecatumumab,DB00056
DB05097,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab.,Labetuzumab,DB00056
DB05101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Matuzumab.,Matuzumab,DB00056
DB05111,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fontolizumab.,Fontolizumab,DB00056
DB05136,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bavituximab.,Bavituximab,DB00056
DB05139,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CR002.,CR002,DB00056
DB05209,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozrolimupab.,Rozrolimupab,DB00056
DB05304,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Girentuximab.,Girentuximab,DB00056
DB05336,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab.,Obiltoxaximab,DB00056
DB05405,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XTL-001.,XTL-001,DB00056
DB05437,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with NAV 1800.,NAV 1800,DB00056
DB05496,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Otelixizumab.,Otelixizumab,DB00056
DB05545,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AMG 108.,AMG 108,DB00056
DB05550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Iratumumab.,Iratumumab,DB00056
DB05555,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Enokizumab.,Enokizumab,DB00056
DB05578,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab.,Ramucirumab,DB00056
DB05595,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Farletuzumab.,Farletuzumab,DB00056
DB05656,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Veltuzumab.,Veltuzumab,DB00056
DB05793,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with PRO-542.,PRO-542,DB00056
DB05797,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TNX-901.,TNX-901,DB00056
DB05889,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00056
DB05892,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with RI 624.,RI 624,DB00056
DB05915,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with MYO-029.,MYO-029,DB00056
DB05916,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CT-011.,CT-011,DB00056
DB05941,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leronlimab.,Leronlimab,DB00056
DB05996,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00056
DB06043,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab.,Olaratumab,DB00056
DB06049,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IPH 2101.,IPH 2101,DB00056
DB06050,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TB-402.,TB-402,DB00056
DB06081,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Caplacizumab.,Caplacizumab,DB00056
DB06101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IMC-1C11.,IMC-1C11,DB00056
DB06116,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eldelumab.,Eldelumab,DB00056
DB06162,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumiliximab.,Lumiliximab,DB00056
DB06186,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab.,Ipilimumab,DB00056
DB06192,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nimotuzumab.,Nimotuzumab,DB00056
DB06241,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clenoliximab.,Clenoliximab,DB00056
DB06304,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with BIIB015.,BIIB015,DB00056
DB06305,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sonepcizumab.,Sonepcizumab,DB00056
DB06310,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Motavizumab.,Motavizumab,DB00056
DB06317,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab.,Elotuzumab,DB00056
DB06318,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AVE9633.,AVE9633,DB00056
DB06322,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carotuximab.,Carotuximab,DB00056
DB06324,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XmAb 2513.,XmAb 2513,DB00056
DB06342,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00056
DB06343,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab.,Teprotumumab,DB00056
DB06360,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lucatumumab.,Lucatumumab,DB00056
DB06366,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab.,Pertuzumab,DB00056
DB06371,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siplizumab.,Siplizumab,DB00056
DB06467,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apolizumab.,Apolizumab,DB00056
DB06474,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sibrotuzumab.,Sibrotuzumab,DB00056
DB06550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bivatuzumab.,Bivatuzumab,DB00056
DB06557,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lerdelimumab.,Lerdelimumab,DB00056
DB06599,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lexatumumab.,Lexatumumab,DB00056
DB06602,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab.,Reslizumab,DB00056
DB06606,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab.,Teplizumab,DB00056
DB06607,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab.,Catumaxomab,DB00056
DB06647,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Volociximab.,Volociximab,DB00056
DB06650,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab.,Ofatumumab,DB00056
DB08902,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab.,Raxibacumab,DB00056
DB09035,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab.,Nivolumab,DB00056
DB09037,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab.,Pembrolizumab,DB00056
DB09045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide.,Dulaglutide,DB00056
DB09105,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa.,Asfotase alfa,DB00056
DB09264,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab.,Idarucizumab,DB00056
DB09302,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab.,Alirocumab,DB00056
DB09303,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab.,Evolocumab,DB00056
DB09331,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab.,Daratumumab,DB00056
DB09559,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab.,Necitumumab,DB00056
DB11595,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab.,Atezolizumab,DB00056
DB11604,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00056
DB11608,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00056
DB11621,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00056
DB11646,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Conatumumab.,Conatumumab,DB00056
DB11657,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tabalumab.,Tabalumab,DB00056
DB11680,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ficlatuzumab.,Ficlatuzumab,DB00056
DB11685,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Figitumumab.,Figitumumab,DB00056
DB11714,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab.,Durvalumab,DB00056
DB11715,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bapineuzumab.,Bapineuzumab,DB00056
DB11731,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00056
DB11746,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Onartuzumab.,Onartuzumab,DB00056
DB11756,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Solanezumab.,Solanezumab,DB00056
DB11771,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab.,Tremelimumab,DB00056
DB11826,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lampalizumab.,Lampalizumab,DB00056
DB11840,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalotuzumab.,Dalotuzumab,DB00056
DB11849,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emibetuzumab.,Emibetuzumab,DB00056
DB11850,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ublituximab.,Ublituximab,DB00056
DB11856,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ligelizumab.,Ligelizumab,DB00056
DB11857,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Seribantumab.,Seribantumab,DB00056
DB11862,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Landogrozumab.,Landogrozumab,DB00056
DB11866,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab.,Romosozumab,DB00056
DB11884,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00056
DB11914,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lebrikizumab.,Lebrikizumab,DB00056
DB11930,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Varlilumab.,Varlilumab,DB00056
DB11945,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab.,Avelumab,DB00056
DB11959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crenezumab.,Crenezumab,DB00056
DB11972,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilotumumab.,Rilotumumab,DB00056
DB11976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab.,Anifrolumab,DB00056
DB12023,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab.,Benralizumab,DB00056
DB12034,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gantenerumab.,Gantenerumab,DB00056
DB12053,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Visilizumab.,Visilizumab,DB00056
DB12077,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Urelumab.,Urelumab,DB00056
DB12089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00056
DB12090,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Patritumab.,Patritumab,DB00056
DB12102,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fulranumab.,Fulranumab,DB00056
DB12104,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tarextumab.,Tarextumab,DB00056
DB12118,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotatercept.,Sotatercept,DB00056
DB12119,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gevokizumab.,Gevokizumab,DB00056
DB12142,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Duligotuzumab.,Duligotuzumab,DB00056
DB12152,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Simtuzumab.,Simtuzumab,DB00056
DB12157,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fasinumab.,Fasinumab,DB00056
DB12159,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.,Dupilumab,DB00056
DB12169,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab.,Tralokinumab,DB00056
DB12189,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etrolizumab.,Etrolizumab,DB00056
DB12202,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zalutumumab.,Zalutumumab,DB00056
DB12205,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ganitumab.,Ganitumab,DB00056
DB12213,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etaracizumab.,Etaracizumab,DB00056
DB12240,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00056
DB12246,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inclacumab.,Inclacumab,DB00056
DB12250,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cixutumumab.,Cixutumumab,DB00056
DB12261,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ascrinvacumab.,Ascrinvacumab,DB00056
DB12274,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab.,Aducanumab,DB00056
DB12281,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Luspatercept.,Luspatercept,DB00056
DB12296,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GS-5745.,GS-5745,DB00056
DB12317,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vanucizumab.,Vanucizumab,DB00056
DB12331,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00056
DB12335,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tanezumab.,Tanezumab,DB00056
DB12342,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ensituximab.,Ensituximab,DB00056
DB12344,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fezakinumab.,Fezakinumab,DB00056
DB12363,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dusigitumab.,Dusigitumab,DB00056
DB12396,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fresolimumab.,Fresolimumab,DB00056
DB12413,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00056
DB12456,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bococizumab.,Bococizumab,DB00056
DB12489,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00056
DB12498,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab.,Mogamulizumab,DB00056
DB12520,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Plozalizumab.,Plozalizumab,DB00056
DB12534,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mavrilimumab.,Mavrilimumab,DB00056
DB12560,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blosozumab.,Blosozumab,DB00056
DB12584,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimagrumab.,Bimagrumab,DB00056
DB12589,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacetuzumab.,Dacetuzumab,DB00056
DB12609,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tovetumab.,Tovetumab,DB00056
DB12683,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumretuzumab.,Lumretuzumab,DB00056
DB12698,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab.,Ibalizumab,DB00056
DB12701,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Intetumumab.,Intetumumab,DB00056
DB12718,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carlumab.,Carlumab,DB00056
DB12734,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Demcizumab.,Demcizumab,DB00056
DB12773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sifalimumab.,Sifalimumab,DB00056
DB12775,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abituzumab.,Abituzumab,DB00056
DB12797,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ecromeximab.,Ecromeximab,DB00056
DB12807,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00056
DB12815,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crotedumab.,Crotedumab,DB00056
DB12820,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Concizumab.,Concizumab,DB00056
DB12826,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab.,Depatuxizumab,DB00056
DB12844,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rontalizumab.,Rontalizumab,DB00056
DB12845,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amatuximab.,Amatuximab,DB00056
DB12849,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clazakizumab.,Clazakizumab,DB00056
DB12891,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanezumab.,Ozanezumab,DB00056
DB12893,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00056
DB12917,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab.,Bimekizumab,DB00056
DB12943,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Milatuzumab.,Milatuzumab,DB00056
DB12976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Robatumumab.,Robatumumab,DB00056
DB13017,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00056
DB13037,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Namilumab.,Namilumab,DB00056
DB13045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Racotumomab.,Racotumomab,DB00056
DB13073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tregalizumab.,Tregalizumab,DB00056
DB13127,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olokizumab.,Olokizumab,DB00056
DB13140,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab.,Bezlotoxumab,DB00056
DB13375,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Edrecolomab.,Edrecolomab,DB00056
DB13535,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nebacumab.,Nebacumab,DB00056
DB13886,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00056
DB13923,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab.,Emicizumab,DB00056
DB13976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab.,Sulesomab,DB00056
DB13979,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab.,Besilesomab,DB00056
DB14012,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab.,Burosumab,DB00056
DB14039,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.,Erenumab,DB00056
DB14040,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.,Eptinezumab,DB00056
DB14041,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab.,Fremanezumab,DB00056
DB14042,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.,Galcanezumab,DB00056
DB14211,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab.,Fanolesomab,DB00056
DB14580,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lecanemab.,Lecanemab,DB00056
DB14597,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab.,Lanadelumab,DB00056
DB14707,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab.,Cemiplimab,DB00056
DB14776,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Camrelizumab.,Camrelizumab,DB00056
DB14778,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Setrusumab.,Setrusumab,DB00056
DB14784,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gancotamab.,Gancotamab,DB00056
DB14809,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00056
DB14811,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab.,Isatuximab,DB00056
DB14824,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Icrucumab.,Icrucumab,DB00056
DB14843,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Codrituzumab.,Codrituzumab,DB00056
DB14864,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab.,Brolucizumab,DB00056
DB14871,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Xentuzumab.,Xentuzumab,DB00056
DB14877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lintuzumab.,Lintuzumab,DB00056
DB14891,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vobarilizumab.,Vobarilizumab,DB00056
DB14897,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Parsatuzumab.,Parsatuzumab,DB00056
DB14905,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emactuzumab.,Emactuzumab,DB00056
DB14907,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00056
DB14908,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Refanezumab.,Refanezumab,DB00056
DB14947,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bermekimab.,Bermekimab,DB00056
DB14952,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pamrevlumab.,Pamrevlumab,DB00056
DB14959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Opicinumab.,Opicinumab,DB00056
DB14962,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00056
DB14967,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab.,Margetuximab,DB00056
DB14988,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalantercept.,Dalantercept,DB00056
DB14997,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pateclizumab.,Pateclizumab,DB00056
DB15014,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gremubamab.,Gremubamab,DB00056
DB15022,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apomab.,Apomab,DB00056
DB15044,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab.,Tafasitamab,DB00056
DB15045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipafricept.,Ipafricept,DB00056
DB15076,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abrilumab.,Abrilumab,DB00056
DB15089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Frovocimab.,Frovocimab,DB00056
DB15090,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab.,Tezepelumab,DB00056
DB15101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tigatuzumab.,Tigatuzumab,DB00056
DB15104,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00056
DB15113,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Utomilumab.,Utomilumab,DB00056
DB15118,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zolbetuximab.,Zolbetuximab,DB00056
DB15135,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponezumab.,Ponezumab,DB00056
DB15160,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asunercept.,Asunercept,DB00056
DB15172,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Suvratoxumab.,Suvratoxumab,DB00056
DB15225,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitazalimab.,Mitazalimab,DB00056
DB15252,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nemolizumab.,Nemolizumab,DB00056
DB15277,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gedivumab.,Gedivumab,DB00056
DB15336,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Valanafusp alfa.,Valanafusp alfa,DB00056
DB15349,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00056
DB15354,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evinacumab.,Evinacumab,DB00056
DB15363,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Istiratumab.,Istiratumab,DB00056
DB15383,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pidilizumab.,Pidilizumab,DB00056
DB15397,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GMA-161.,GMA-161,DB00056
DB15409,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00056
DB15415,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tomaralimab.,Tomaralimab,DB00056
DB15428,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vesencumab.,Vesencumab,DB00056
DB15432,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00056
DB15441,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lulizumab pegol.,Lulizumab pegol,DB00056
DB15443,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00056
DB15453,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00056
DB14004,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab.,Tildrakizumab,DB00056
DB05679,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab.,Ustekinumab,DB00056
DB15559,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zenocutuzumab.,Zenocutuzumab,DB00056
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.,Palifermin,DB00056
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.,Lepirudin,DB00056
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin.,Bivalirudin,DB00056
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin.,Alteplase,DB00056
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin.,Urokinase,DB00056
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.,Reteplase,DB00056
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin.,Anistreplase,DB00056
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin.,Tenecteplase,DB00056
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.,Drotrecogin alfa,DB00056
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.,Streptokinase,DB00056
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin.,Dicoumarol,DB00056
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin.,Argatroban,DB00056
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin.,Ardeparin,DB00056
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin.,Phenindione,DB00056
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin.,Fondaparinux,DB00056
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin.,Warfarin,DB00056
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin.,Pentosan polysulfate,DB00056
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin.,Phenprocoumon,DB00056
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin.,Heparin,DB00056
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin.,Enoxaparin,DB00056
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin.,Acenocoumarol,DB00056
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Gemtuzumab ozogamicin.,4-hydroxycoumarin,DB00056
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Gemtuzumab ozogamicin.,Coumarin,DB00056
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin.,Ximelagatran,DB00056
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Gemtuzumab ozogamicin.,Desmoteplase,DB00056
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin.,Ancrod,DB00056
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Gemtuzumab ozogamicin.,Fibrinolysin,DB00056
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin.,Rivaroxaban,DB00056
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin.,Sulodexide,DB00056
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Gemtuzumab ozogamicin.,Semuloparin,DB00056
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Gemtuzumab ozogamicin.,Idraparinux,DB00056
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Gemtuzumab ozogamicin.,Astaxanthin,DB00056
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin.,Apixaban,DB00056
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Gemtuzumab ozogamicin.,Otamixaban,DB00056
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Gemtuzumab ozogamicin.,Amediplase,DB00056
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin.,Dabigatran etexilate,DB00056
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin.,Danaparoid,DB00056
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin.,Dalteparin,DB00056
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin.,Tinzaparin,DB00056
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Gemtuzumab ozogamicin.,Ferulic acid,DB00056
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Gemtuzumab ozogamicin.,(R)-warfarin,DB00056
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Gemtuzumab ozogamicin.,Ethyl biscoumacetate,DB00056
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin.,Nadroparin,DB00056
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Gemtuzumab ozogamicin.,Ditazole,DB00056
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin.,Edoxaban,DB00056
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Gemtuzumab ozogamicin.,Potassium citrate,DB00056
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin.,Sodium citrate,DB00056
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin.,Dextran,DB00056
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin.,Bemiparin,DB00056
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin.,Reviparin,DB00056
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin.,Parnaparin,DB00056
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Gemtuzumab ozogamicin.,Certoparin,DB00056
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin.,Desirudin,DB00056
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Gemtuzumab ozogamicin.,Zinc citrate,DB00056
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin.,Antithrombin Alfa,DB00056
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin.,Protein C,DB00056
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin.,Antithrombin III human,DB00056
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Gemtuzumab ozogamicin.,Letaxaban,DB00056
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Gemtuzumab ozogamicin.,Darexaban,DB00056
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin.,Betrixaban,DB00056
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Gemtuzumab ozogamicin.,Nafamostat,DB00056
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Gemtuzumab ozogamicin.,Monteplase,DB00056
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Gemtuzumab ozogamicin.,Gabexate,DB00056
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin.,Fluindione,DB00056
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin.,Protein S human,DB00056
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Gemtuzumab ozogamicin.,Brinase,DB00056
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Gemtuzumab ozogamicin.,Clorindione,DB00056
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Gemtuzumab ozogamicin.,Diphenadione,DB00056
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Gemtuzumab ozogamicin.,Tioclomarol,DB00056
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Gemtuzumab ozogamicin.,Melagatran,DB00056
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Gemtuzumab ozogamicin.,Saruplase,DB00056
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Gemtuzumab ozogamicin.,(S)-Warfarin,DB00056
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Gemtuzumab ozogamicin.,Tocopherylquinone,DB00056
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Gemtuzumab ozogamicin.,Edetate calcium disodium anhydrous,DB00056
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin.,Dabigatran,DB00056
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Gemtuzumab ozogamicin.,Methyclothiazide,DB00056
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin.,Bendroflumethiazide,DB00056
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin.,Benzthiazide,DB00056
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin.,Cyclothiazide,DB00056
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin.,Hydroflumethiazide,DB00056
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin.,Chlorothiazide,DB00056
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin.,Hydrochlorothiazide,DB00056
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin.,Trichlormethiazide,DB00056
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin.,Polythiazide,DB00056
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Gemtuzumab ozogamicin.,Mebutizide,DB00056
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin.,Cyclopenthiazide,DB00056
DB09042,The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00056
DB00091,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00056
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.,Cyanocobalamin,DB00056
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin.,Allopurinol,DB00056
DB12978,Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib.,Pexidartinib,DB00056
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin.","Ebola Zaire vaccine (live, attenuated)",DB00056
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin.,Magnesium,DB00056
DB01601,The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir.,Lopinavir,DB00056
DB12530,The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab.,Inebilizumab,DB00056
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Diethylstilbestrol,DB00057
DB00269,Chlorotrianisene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Chlorotrianisene,DB00057
DB00286,Conjugated estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Conjugated estrogens,DB00057
DB00655,Estrone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estrone,DB00057
DB00783,Estradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol,DB00057
DB00890,Dienestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Dienestrol,DB00057
DB00977,Ethinylestradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Ethinylestradiol,DB00057
DB01357,Mestranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Mestranol,DB00057
DB04573,Estriol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estriol,DB00057
DB04574,Estrone sulfate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estrone sulfate,DB00057
DB04575,Quinestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Quinestrol,DB00057
DB07931,Hexestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Hexestrol,DB00057
DB09070,Tibolone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Tibolone,DB00057
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indium In-111 satumomab pendetide.","Synthetic Conjugated Estrogens, A",DB00057
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide.","Synthetic Conjugated Estrogens, B",DB00057
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Polyestradiol phosphate,DB00057
DB09381,Esterified estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Esterified estrogens,DB00057
DB11478,Zeranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Zeranol,DB00057
DB11674,Equol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Equol,DB00057
DB12487,Promestriene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Promestriene,DB00057
DB13143,Methallenestril may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Methallenestril,DB00057
DB13386,Epimestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Epimestrol,DB00057
DB13418,Moxestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Moxestrol,DB00057
DB13952,Estradiol acetate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol acetate,DB00057
DB13953,Estradiol benzoate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol benzoate,DB00057
DB13954,Estradiol cypionate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol cypionate,DB00057
DB13956,Estradiol valerate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol valerate,DB00057
DB15334,Biochanin A may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Biochanin A,DB00057
DB15335,Formononetin may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Formononetin,DB00057
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.,Cetuximab,DB00057
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.,Human immunoglobulin G,DB00057
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Indium In-111 satumomab pendetide.,Omalizumab,DB00057
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Indium In-111 satumomab pendetide.,Adalimumab,DB00057
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Indium In-111 satumomab pendetide.,Abciximab,DB00057
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.,Gemtuzumab ozogamicin,DB00057
DB00065,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.,Infliximab,DB00057
DB00072,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.,Trastuzumab,DB00057
DB00073,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.,Rituximab,DB00057
DB00074,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.,Basiliximab,DB00057
DB00075,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.,Muromonab,DB00057
DB00076,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00057
DB00078,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00057
DB00081,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.,Tositumomab,DB00057
DB00087,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.,Alemtuzumab,DB00057
DB00089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.,Capromab pendetide,DB00057
DB00095,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.,Efalizumab,DB00057
DB00098,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00057
DB00108,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.,Natalizumab,DB00057
DB00110,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.,Palivizumab,DB00057
DB00111,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.,Daclizumab,DB00057
DB00112,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.,Bevacizumab,DB00057
DB00113,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00057
DB01257,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eculizumab.,Eculizumab,DB00057
DB01269,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Panitumumab.,Panitumumab,DB00057
DB01270,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ranibizumab.,Ranibizumab,DB00057
DB04901,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galiximab.,Galiximab,DB00057
DB04949,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pexelizumab.,Pexelizumab,DB00057
DB04956,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Afelimomab.,Afelimomab,DB00057
DB04958,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Epratuzumab.,Epratuzumab,DB00057
DB04962,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bectumomab.,Bectumomab,DB00057
DB04964,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab.,Oregovomab,DB00057
DB04988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IGN311.,IGN311,DB00057
DB05006,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Adecatumumab.,Adecatumumab,DB00057
DB05097,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab.,Labetuzumab,DB00057
DB05101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Matuzumab.,Matuzumab,DB00057
DB05111,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fontolizumab.,Fontolizumab,DB00057
DB05136,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bavituximab.,Bavituximab,DB00057
DB05139,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CR002.,CR002,DB00057
DB05209,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozrolimupab.,Rozrolimupab,DB00057
DB05304,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Girentuximab.,Girentuximab,DB00057
DB05336,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obiltoxaximab.,Obiltoxaximab,DB00057
DB05405,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XTL-001.,XTL-001,DB00057
DB05437,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with NAV 1800.,NAV 1800,DB00057
DB05459,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Briakinumab.,Briakinumab,DB00057
DB05496,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Otelixizumab.,Otelixizumab,DB00057
DB05545,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AMG 108.,AMG 108,DB00057
DB05550,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Iratumumab.,Iratumumab,DB00057
DB05555,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Enokizumab.,Enokizumab,DB00057
DB05578,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ramucirumab.,Ramucirumab,DB00057
DB05595,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Farletuzumab.,Farletuzumab,DB00057
DB05656,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Veltuzumab.,Veltuzumab,DB00057
DB05679,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ustekinumab.,Ustekinumab,DB00057
DB05773,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00057
DB05793,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with PRO-542.,PRO-542,DB00057
DB05797,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TNX-901.,TNX-901,DB00057
DB05889,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00057
DB05892,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with RI 624.,RI 624,DB00057
DB05915,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with MYO-029.,MYO-029,DB00057
DB05916,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CT-011.,CT-011,DB00057
DB05941,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Leronlimab.,Leronlimab,DB00057
DB05996,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00057
DB06043,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olaratumab.,Olaratumab,DB00057
DB06049,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IPH 2101.,IPH 2101,DB00057
DB06050,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TB-402.,TB-402,DB00057
DB06081,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Caplacizumab.,Caplacizumab,DB00057
DB06101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IMC-1C11.,IMC-1C11,DB00057
DB06116,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eldelumab.,Eldelumab,DB00057
DB06162,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumiliximab.,Lumiliximab,DB00057
DB06168,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Canakinumab.,Canakinumab,DB00057
DB06186,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipilimumab.,Ipilimumab,DB00057
DB06192,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nimotuzumab.,Nimotuzumab,DB00057
DB06241,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clenoliximab.,Clenoliximab,DB00057
DB06273,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tocilizumab.,Tocilizumab,DB00057
DB06304,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with BIIB015.,BIIB015,DB00057
DB06305,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sonepcizumab.,Sonepcizumab,DB00057
DB06310,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Motavizumab.,Motavizumab,DB00057
DB06317,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Elotuzumab.,Elotuzumab,DB00057
DB06318,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AVE9633.,AVE9633,DB00057
DB06322,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carotuximab.,Carotuximab,DB00057
DB06324,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XmAb 2513.,XmAb 2513,DB00057
DB06342,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00057
DB06343,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teprotumumab.,Teprotumumab,DB00057
DB06360,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lucatumumab.,Lucatumumab,DB00057
DB06366,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pertuzumab.,Pertuzumab,DB00057
DB06371,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siplizumab.,Siplizumab,DB00057
DB06467,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apolizumab.,Apolizumab,DB00057
DB06474,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sibrotuzumab.,Sibrotuzumab,DB00057
DB06550,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bivatuzumab.,Bivatuzumab,DB00057
DB06557,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lerdelimumab.,Lerdelimumab,DB00057
DB06599,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lexatumumab.,Lexatumumab,DB00057
DB06602,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Reslizumab.,Reslizumab,DB00057
DB06606,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teplizumab.,Teplizumab,DB00057
DB06607,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Catumaxomab.,Catumaxomab,DB00057
DB06612,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mepolizumab.,Mepolizumab,DB00057
DB06643,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Denosumab.,Denosumab,DB00057
DB06647,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Volociximab.,Volociximab,DB00057
DB06650,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ofatumumab.,Ofatumumab,DB00057
DB06674,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Golimumab.,Golimumab,DB00057
DB08870,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00057
DB08879,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Belimumab.,Belimumab,DB00057
DB08902,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Raxibacumab.,Raxibacumab,DB00057
DB08904,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Certolizumab pegol.,Certolizumab pegol,DB00057
DB08935,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obinutuzumab.,Obinutuzumab,DB00057
DB09029,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Secukinumab.,Secukinumab,DB00057
DB09033,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vedolizumab.,Vedolizumab,DB00057
DB09035,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nivolumab.,Nivolumab,DB00057
DB09036,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siltuximab.,Siltuximab,DB00057
DB09037,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pembrolizumab.,Pembrolizumab,DB00057
DB09045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dulaglutide.,Dulaglutide,DB00057
DB09052,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blinatumomab.,Blinatumomab,DB00057
DB09057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anthrax immune globulin human.,Anthrax immune globulin human,DB00057
DB09077,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dinutuximab.,Dinutuximab,DB00057
DB09105,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asfotase alfa.,Asfotase alfa,DB00057
DB09264,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Idarucizumab.,Idarucizumab,DB00057
DB09302,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alirocumab.,Alirocumab,DB00057
DB09303,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evolocumab.,Evolocumab,DB00057
DB09312,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00057
DB09331,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daratumumab.,Daratumumab,DB00057
DB09559,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Necitumumab.,Necitumumab,DB00057
DB11569,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ixekizumab.,Ixekizumab,DB00057
DB11580,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ravulizumab.,Ravulizumab,DB00057
DB11595,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Atezolizumab.,Atezolizumab,DB00057
DB11604,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00057
DB11608,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00057
DB11621,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00057
DB11646,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Conatumumab.,Conatumumab,DB00057
DB11657,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tabalumab.,Tabalumab,DB00057
DB11680,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ficlatuzumab.,Ficlatuzumab,DB00057
DB11685,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Figitumumab.,Figitumumab,DB00057
DB11714,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Durvalumab.,Durvalumab,DB00057
DB11715,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bapineuzumab.,Bapineuzumab,DB00057
DB11731,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00057
DB11746,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Onartuzumab.,Onartuzumab,DB00057
DB11756,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Solanezumab.,Solanezumab,DB00057
DB11767,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sarilumab.,Sarilumab,DB00057
DB11771,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tremelimumab.,Tremelimumab,DB00057
DB11776,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brodalumab.,Brodalumab,DB00057
DB11803,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sirukumab.,Sirukumab,DB00057
DB11826,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lampalizumab.,Lampalizumab,DB00057
DB11834,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Guselkumab.,Guselkumab,DB00057
DB11840,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalotuzumab.,Dalotuzumab,DB00057
DB11849,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emibetuzumab.,Emibetuzumab,DB00057
DB11850,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ublituximab.,Ublituximab,DB00057
DB11856,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ligelizumab.,Ligelizumab,DB00057
DB11857,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Seribantumab.,Seribantumab,DB00057
DB11862,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Landogrozumab.,Landogrozumab,DB00057
DB11866,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Romosozumab.,Romosozumab,DB00057
DB11884,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00057
DB11914,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lebrikizumab.,Lebrikizumab,DB00057
DB11930,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Varlilumab.,Varlilumab,DB00057
DB11945,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Avelumab.,Avelumab,DB00057
DB11959,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crenezumab.,Crenezumab,DB00057
DB11972,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rilotumumab.,Rilotumumab,DB00057
DB11976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anifrolumab.,Anifrolumab,DB00057
DB11988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ocrelizumab.,Ocrelizumab,DB00057
DB12023,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Benralizumab.,Benralizumab,DB00057
DB12034,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gantenerumab.,Gantenerumab,DB00057
DB12053,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Visilizumab.,Visilizumab,DB00057
DB12077,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Urelumab.,Urelumab,DB00057
DB12089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00057
DB12090,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Patritumab.,Patritumab,DB00057
DB12102,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fulranumab.,Fulranumab,DB00057
DB12104,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tarextumab.,Tarextumab,DB00057
DB12118,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sotatercept.,Sotatercept,DB00057
DB12119,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gevokizumab.,Gevokizumab,DB00057
DB12142,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Duligotuzumab.,Duligotuzumab,DB00057
DB12152,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Simtuzumab.,Simtuzumab,DB00057
DB12157,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fasinumab.,Fasinumab,DB00057
DB12159,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dupilumab.,Dupilumab,DB00057
DB12169,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tralokinumab.,Tralokinumab,DB00057
DB12189,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etrolizumab.,Etrolizumab,DB00057
DB12202,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zalutumumab.,Zalutumumab,DB00057
DB12205,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ganitumab.,Ganitumab,DB00057
DB12213,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etaracizumab.,Etaracizumab,DB00057
DB12240,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00057
DB12246,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inclacumab.,Inclacumab,DB00057
DB12250,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cixutumumab.,Cixutumumab,DB00057
DB12261,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ascrinvacumab.,Ascrinvacumab,DB00057
DB12274,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Aducanumab.,Aducanumab,DB00057
DB12281,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Luspatercept.,Luspatercept,DB00057
DB12296,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GS-5745.,GS-5745,DB00057
DB12317,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vanucizumab.,Vanucizumab,DB00057
DB12331,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00057
DB12335,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tanezumab.,Tanezumab,DB00057
DB12342,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ensituximab.,Ensituximab,DB00057
DB12344,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fezakinumab.,Fezakinumab,DB00057
DB12363,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dusigitumab.,Dusigitumab,DB00057
DB12396,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fresolimumab.,Fresolimumab,DB00057
DB12413,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00057
DB12456,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bococizumab.,Bococizumab,DB00057
DB12489,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00057
DB12498,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mogamulizumab.,Mogamulizumab,DB00057
DB12520,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Plozalizumab.,Plozalizumab,DB00057
DB12530,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inebilizumab.,Inebilizumab,DB00057
DB12534,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mavrilimumab.,Mavrilimumab,DB00057
DB12560,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blosozumab.,Blosozumab,DB00057
DB12584,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimagrumab.,Bimagrumab,DB00057
DB12589,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dacetuzumab.,Dacetuzumab,DB00057
DB12609,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tovetumab.,Tovetumab,DB00057
DB12683,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumretuzumab.,Lumretuzumab,DB00057
DB12698,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibalizumab.,Ibalizumab,DB00057
DB12701,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Intetumumab.,Intetumumab,DB00057
DB12718,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carlumab.,Carlumab,DB00057
DB12734,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Demcizumab.,Demcizumab,DB00057
DB12773,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sifalimumab.,Sifalimumab,DB00057
DB12775,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abituzumab.,Abituzumab,DB00057
DB12797,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ecromeximab.,Ecromeximab,DB00057
DB12807,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00057
DB12815,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crotedumab.,Crotedumab,DB00057
DB12820,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Concizumab.,Concizumab,DB00057
DB12826,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab.,Depatuxizumab,DB00057
DB12844,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rontalizumab.,Rontalizumab,DB00057
DB12845,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Amatuximab.,Amatuximab,DB00057
DB12849,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clazakizumab.,Clazakizumab,DB00057
DB12891,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ozanezumab.,Ozanezumab,DB00057
DB12893,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00057
DB12917,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimekizumab.,Bimekizumab,DB00057
DB12943,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Milatuzumab.,Milatuzumab,DB00057
DB12976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Robatumumab.,Robatumumab,DB00057
DB13017,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00057
DB13037,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Namilumab.,Namilumab,DB00057
DB13045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Racotumomab.,Racotumomab,DB00057
DB13073,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tregalizumab.,Tregalizumab,DB00057
DB13127,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olokizumab.,Olokizumab,DB00057
DB13140,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bezlotoxumab.,Bezlotoxumab,DB00057
DB13375,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Edrecolomab.,Edrecolomab,DB00057
DB13535,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nebacumab.,Nebacumab,DB00057
DB13886,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00057
DB13923,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emicizumab.,Emicizumab,DB00057
DB13976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sulesomab.,Sulesomab,DB00057
DB13979,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Besilesomab.,Besilesomab,DB00057
DB14004,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tildrakizumab.,Tildrakizumab,DB00057
DB14012,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Burosumab.,Burosumab,DB00057
DB14039,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Erenumab.,Erenumab,DB00057
DB14040,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eptinezumab.,Eptinezumab,DB00057
DB14041,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fremanezumab.,Fremanezumab,DB00057
DB14042,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galcanezumab.,Galcanezumab,DB00057
DB14211,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fanolesomab.,Fanolesomab,DB00057
DB14580,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lecanemab.,Lecanemab,DB00057
DB14597,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lanadelumab.,Lanadelumab,DB00057
DB14707,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cemiplimab.,Cemiplimab,DB00057
DB14724,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emapalumab.,Emapalumab,DB00057
DB14762,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Risankizumab.,Risankizumab,DB00057
DB14776,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Camrelizumab.,Camrelizumab,DB00057
DB14778,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Setrusumab.,Setrusumab,DB00057
DB14784,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gancotamab.,Gancotamab,DB00057
DB14809,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00057
DB14811,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Isatuximab.,Isatuximab,DB00057
DB14824,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Icrucumab.,Icrucumab,DB00057
DB14843,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Codrituzumab.,Codrituzumab,DB00057
DB14864,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brolucizumab.,Brolucizumab,DB00057
DB14871,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Xentuzumab.,Xentuzumab,DB00057
DB14877,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lintuzumab.,Lintuzumab,DB00057
DB14891,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vobarilizumab.,Vobarilizumab,DB00057
DB14897,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Parsatuzumab.,Parsatuzumab,DB00057
DB14905,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emactuzumab.,Emactuzumab,DB00057
DB14907,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00057
DB14908,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Refanezumab.,Refanezumab,DB00057
DB14919,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozanolixizumab.,Rozanolixizumab,DB00057
DB14947,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bermekimab.,Bermekimab,DB00057
DB14952,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pamrevlumab.,Pamrevlumab,DB00057
DB14959,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Opicinumab.,Opicinumab,DB00057
DB14962,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00057
DB14967,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Margetuximab.,Margetuximab,DB00057
DB14988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalantercept.,Dalantercept,DB00057
DB14997,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pateclizumab.,Pateclizumab,DB00057
DB15014,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gremubamab.,Gremubamab,DB00057
DB15022,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apomab.,Apomab,DB00057
DB15044,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tafasitamab.,Tafasitamab,DB00057
DB15045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipafricept.,Ipafricept,DB00057
DB15076,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abrilumab.,Abrilumab,DB00057
DB15089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Frovocimab.,Frovocimab,DB00057
DB15090,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tezepelumab.,Tezepelumab,DB00057
DB15101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tigatuzumab.,Tigatuzumab,DB00057
DB15104,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00057
DB15113,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Utomilumab.,Utomilumab,DB00057
DB15118,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zolbetuximab.,Zolbetuximab,DB00057
DB15135,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ponezumab.,Ponezumab,DB00057
DB15160,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asunercept.,Asunercept,DB00057
DB15172,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Suvratoxumab.,Suvratoxumab,DB00057
DB15225,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mitazalimab.,Mitazalimab,DB00057
DB15252,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nemolizumab.,Nemolizumab,DB00057
DB15253,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bleselumab.,Bleselumab,DB00057
DB15277,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gedivumab.,Gedivumab,DB00057
DB15336,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Valanafusp alfa.,Valanafusp alfa,DB00057
DB15349,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00057
DB15354,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evinacumab.,Evinacumab,DB00057
DB15363,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Istiratumab.,Istiratumab,DB00057
DB15383,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pidilizumab.,Pidilizumab,DB00057
DB15397,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GMA-161.,GMA-161,DB00057
DB15409,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00057
DB15415,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tomaralimab.,Tomaralimab,DB00057
DB15428,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vesencumab.,Vesencumab,DB00057
DB15432,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00057
DB15441,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lulizumab pegol.,Lulizumab pegol,DB00057
DB15443,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00057
DB15453,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00057
DB15559,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zenocutuzumab.,Zenocutuzumab,DB00057
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Indium In-111 satumomab pendetide.","Ebola Zaire vaccine (live, attenuated)",DB00057
DB00170,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione.,Menadione,DB00058
DB00302,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.,Tranexamic acid,DB00058
DB00513,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid.,Aminocaproic acid,DB00058
DB06692,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.,Aprotinin,DB00058
DB11091,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide.,Hydrogen peroxide,DB00058
DB13244,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid.,Aminomethylbenzoic acid,DB00058
DB13729,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Camostat.,Camostat,DB00058
DB09222,The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.,Fibrinogen human,DB00058
DB00755,The risk or severity of Thrombosis can be increased when Tretinoin is combined with Alpha-1-proteinase inhibitor.,Tretinoin,DB00058
DB00025,"Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant.","Antihemophilic factor, human recombinant",DB00058
DB00036,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.,Coagulation factor VIIa Recombinant Human,DB00058
DB00100,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Coagulation Factor IX (Recombinant),DB00058
DB00258,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium acetate.,Calcium acetate,DB00058
DB01164,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium chloride.,Calcium chloride,DB00058
DB01373,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium.,Calcium,DB00058
DB01783,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Pantothenic acid.,Pantothenic acid,DB00058
DB01942,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Formic acid.,Formic acid,DB00058
DB02261,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Platelet Activating Factor.,Platelet Activating Factor,DB00058
DB06724,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium carbonate.,Calcium carbonate,DB00058
DB09109,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa.,Turoctocog alfa,DB00058
DB09310,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog.,Catridecacog,DB00058
DB09329,"Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated.","Antihemophilic Factor (Recombinant), PEGylated",DB00058
DB11093,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium citrate.,Calcium citrate,DB00058
DB11126,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium gluconate.,Calcium gluconate,DB00058
DB11168,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium threonate.,Calcium threonate,DB00058
DB11311,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Prothrombin.,Prothrombin,DB00058
DB11330,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).,Factor IX Complex (Human),DB00058
DB11348,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium Phosphate.,Calcium Phosphate,DB00058
DB11606,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.,Susoctocog alfa,DB00058
DB11608,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Eftrenonacog alfa.,Eftrenonacog alfa,DB00058
DB11668,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Rusalatide acetate.,Rusalatide acetate,DB00058
DB12409,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Vatreptacog alfa.,Vatreptacog alfa,DB00058
DB12909,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).,Factor XIII (human),DB00058
DB13133,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand Factor Human.,Von Willebrand Factor Human,DB00058
DB13148,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human.,Coagulation factor X human,DB00058
DB13150,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VII human.,Coagulation factor VII human,DB00058
DB13151,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Anti-inhibitor coagulant complex.,Anti-inhibitor coagulant complex,DB00058
DB13152,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX Human.,Coagulation Factor IX Human,DB00058
DB13192,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human.,Antihemophilic factor human,DB00058
DB13197,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase.,Kallidinogenase,DB00058
DB13201,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Trenonacog alfa.,Trenonacog alfa,DB00058
DB13884,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Albutrepenonacog alfa.,Albutrepenonacog alfa,DB00058
DB13923,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab.,Emicizumab,DB00058
DB13933,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Nonacog beta pegol.,Nonacog beta pegol,DB00058
DB13999,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Moroctocog alfa.,Moroctocog alfa,DB00058
DB14473,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Beroctocog alfa.,Beroctocog alfa,DB00058
DB14562,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa.,Andexanet alfa,DB00058
DB14577,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium cation.,Calcium cation,DB00058
DB14700,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Damoctocog alfa pegol.,Damoctocog alfa pegol,DB00058
DB14738,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa pegol.,Turoctocog alfa pegol,DB00058
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.,Denosumab,DB00059
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Pegaspargase.,Etanercept,DB00059
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase.,Peginterferon alfa-2a,DB00059
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pegaspargase.,Interferon alfa-n1,DB00059
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pegaspargase.,Interferon alfa-n3,DB00059
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegaspargase.,Peginterferon alfa-2b,DB00059
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Pegaspargase.,Anakinra,DB00059
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pegaspargase.,Interferon gamma-1b,DB00059
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pegaspargase.","Interferon alfa-2a, Recombinant",DB00059
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegaspargase.,Aldesleukin,DB00059
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Pegaspargase.,Adalimumab,DB00059
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.,Gemtuzumab ozogamicin,DB00059
DB00065,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.,Infliximab,DB00059
DB00068,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.,Interferon beta-1b,DB00059
DB00069,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00059
DB00073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.,Rituximab,DB00059
DB00074,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.,Basiliximab,DB00059
DB00075,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.,Muromonab,DB00059
DB00078,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00059
DB00081,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.,Tositumomab,DB00059
DB00087,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.,Alemtuzumab,DB00059
DB00092,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.,Alefacept,DB00059
DB00095,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.,Efalizumab,DB00059
DB00098,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00059
DB00105,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00059
DB00111,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.,Daclizumab,DB00059
DB00112,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.,Bevacizumab,DB00059
DB00120,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.,Phenylalanine,DB00059
DB00180,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flunisolide.,Flunisolide,DB00059
DB00188,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bortezomib.,Bortezomib,DB00059
DB00242,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cladribine.,Cladribine,DB00059
DB00262,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine.,Carmustine,DB00059
DB00276,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Amsacrine.,Amsacrine,DB00059
DB00290,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleomycin.,Bleomycin,DB00059
DB00291,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chlorambucil.,Chlorambucil,DB00059
DB00293,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Raltitrexed.,Raltitrexed,DB00059
DB00305,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitomycin.,Mitomycin,DB00059
DB00307,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene.,Bexarotene,DB00059
DB00309,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vindesine.,Vindesine,DB00059
DB00322,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Floxuridine.,Floxuridine,DB00059
DB00328,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Indomethacin.,Indomethacin,DB00059
DB00352,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tioguanine.,Tioguanine,DB00059
DB00361,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinorelbine.,Vinorelbine,DB00059
DB00380,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane.,Dexrazoxane,DB00059
DB00394,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00059
DB00398,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sorafenib.,Sorafenib,DB00059
DB00428,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Streptozocin.,Streptozocin,DB00059
DB00432,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trifluridine.,Trifluridine,DB00059
DB00441,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gemcitabine.,Gemcitabine,DB00059
DB00443,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Betamethasone.,Betamethasone,DB00059
DB00444,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teniposide.,Teniposide,DB00059
DB00445,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Epirubicin.,Epirubicin,DB00059
DB00446,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chloramphenicol.,Chloramphenicol,DB00059
DB00480,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lenalidomide.,Lenalidomide,DB00059
DB00488,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Altretamine.,Altretamine,DB00059
DB00495,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Zidovudine.,Zidovudine,DB00059
DB00515,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cisplatin.,Cisplatin,DB00059
DB00526,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin.,Oxaliplatin,DB00059
DB00531,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cyclophosphamide.,Cyclophosphamide,DB00059
DB00541,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine.,Vincristine,DB00059
DB00544,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluorouracil.,Fluorouracil,DB00059
DB00550,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil.,Propylthiouracil,DB00059
DB00552,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pentostatin.,Pentostatin,DB00059
DB00564,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carbamazepine.,Carbamazepine,DB00059
DB00570,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinblastine.,Vinblastine,DB00059
DB00588,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone propionate.,Fluticasone propionate,DB00059
DB00591,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00059
DB00601,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Linezolid.,Linezolid,DB00059
DB00620,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triamcinolone.,Triamcinolone,DB00059
DB00631,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clofarabine.,Clofarabine,DB00059
DB00635,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisone.,Prednisone,DB00059
DB00642,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pemetrexed.,Pemetrexed,DB00059
DB00687,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludrocortisone.,Fludrocortisone,DB00059
DB00688,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00059
DB00694,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.,Daunorubicin,DB00059
DB00755,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tretinoin.,Tretinoin,DB00059
DB00762,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Irinotecan.,Irinotecan,DB00059
DB00763,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methimazole.,Methimazole,DB00059
DB00764,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone.,Mometasone,DB00059
DB00773,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Etoposide.,Etoposide,DB00059
DB00795,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sulfasalazine.,Sulfasalazine,DB00059
DB00851,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dacarbazine.,Dacarbazine,DB00059
DB00853,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temozolomide.,Temozolomide,DB00059
DB00859,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Penicillamine.,Penicillamine,DB00059
DB00860,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisolone.,Prednisolone,DB00059
DB00877,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirolimus.,Sirolimus,DB00059
DB00888,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mechlorethamine.,Mechlorethamine,DB00059
DB00928,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azacitidine.,Azacitidine,DB00059
DB00958,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin.,Carboplatin,DB00059
DB00959,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methylprednisolone.,Methylprednisolone,DB00059
DB00970,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dactinomycin.,Dactinomycin,DB00059
DB00987,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.,Cytarabine,DB00059
DB00993,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azathioprine.,Azathioprine,DB00059
DB00997,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxorubicin.,Doxorubicin,DB00059
DB01005,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxyurea.,Hydroxyurea,DB00059
DB01008,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Busulfan.,Busulfan,DB00059
DB01024,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolic acid.,Mycophenolic acid,DB00059
DB01030,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Topotecan.,Topotecan,DB00059
DB01033,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mercaptopurine.,Mercaptopurine,DB00059
DB01041,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thalidomide.,Thalidomide,DB00059
DB01042,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melphalan.,Melphalan,DB00059
DB01073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludarabine.,Fludarabine,DB00059
DB01099,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flucytosine.,Flucytosine,DB00059
DB01101,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Capecitabine.,Capecitabine,DB00059
DB01108,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trilostane.,Trilostane,DB00059
DB01168,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine.,Procarbazine,DB00059
DB01169,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Arsenic trioxide.,Arsenic trioxide,DB00059
DB01177,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idarubicin.,Idarubicin,DB00059
DB01181,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ifosfamide.,Ifosfamide,DB00059
DB01196,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Estramustine.,Estramustine,DB00059
DB01204,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitoxantrone.,Mitoxantrone,DB00059
DB01206,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lomustine.,Lomustine,DB00059
DB01222,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Budesonide.,Budesonide,DB00059
DB01229,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paclitaxel.,Paclitaxel,DB00059
DB01248,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Docetaxel.,Docetaxel,DB00059
DB01254,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dasatinib.,Dasatinib,DB00059
DB01257,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eculizumab.,Eculizumab,DB00059
DB01262,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Decitabine.,Decitabine,DB00059
DB01268,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sunitinib.,Sunitinib,DB00059
DB01280,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nelarabine.,Nelarabine,DB00059
DB01281,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abatacept.,Abatacept,DB00059
DB01285,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Corticotropin.,Corticotropin,DB00059
DB01380,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortisone acetate.,Cortisone acetate,DB00059
DB01384,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paramethasone.,Paramethasone,DB00059
DB01394,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Colchicine.,Colchicine,DB00059
DB01410,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ciclesonide.,Ciclesonide,DB00059
DB01423,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Stepronin.,Stepronin,DB00059
DB01590,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Everolimus.,Everolimus,DB00059
DB01611,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00059
DB01816,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Castanospermine.,Castanospermine,DB00059
DB02546,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vorinostat.,Vorinostat,DB00059
DB02806,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00059
DB03523,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brequinar.,Brequinar,DB00059
DB04572,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thiotepa.,Thiotepa,DB00059
DB04630,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Aldosterone.,Aldosterone,DB00059
DB04845,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixabepilone.,Ixabepilone,DB00059
DB04868,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nilotinib.,Nilotinib,DB00059
DB04951,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirfenidone.,Pirfenidone,DB00059
DB04956,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Afelimomab.,Afelimomab,DB00059
DB05015,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belinostat.,Belinostat,DB00059
DB05109,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trabectedin.,Trabectedin,DB00059
DB05258,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa.,Interferon alfa,DB00059
DB05259,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Glatiramer.,Glatiramer,DB00059
DB05260,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gallium nitrate.,Gallium nitrate,DB00059
DB05459,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Briakinumab.,Briakinumab,DB00059
DB05472,The risk or severity of adverse effects can be increased when Pegaspargase is combined with omega interferon.,omega interferon,DB00059
DB05676,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Apremilast.,Apremilast,DB00059
DB05773,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00059
DB06168,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Canakinumab.,Canakinumab,DB00059
DB06273,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tocilizumab.,Tocilizumab,DB00059
DB06287,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temsirolimus.,Temsirolimus,DB00059
DB06372,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rilonacept.,Rilonacept,DB00059
DB06589,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pazopanib.,Pazopanib,DB00059
DB06603,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Panobinostat.,Panobinostat,DB00059
DB06612,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mepolizumab.,Mepolizumab,DB00059
DB06616,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bosutinib.,Bosutinib,DB00059
DB06662,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abetimus.,Abetimus,DB00059
DB06674,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Golimumab.,Golimumab,DB00059
DB06681,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belatacept.,Belatacept,DB00059
DB06769,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bendamustine.,Bendamustine,DB00059
DB06772,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cabazitaxel.,Cabazitaxel,DB00059
DB06813,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pralatrexate.,Pralatrexate,DB00059
DB08059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Wortmannin.,Wortmannin,DB00059
DB08870,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00059
DB08871,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eribulin.,Eribulin,DB00059
DB08877,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.,Ruxolitinib,DB00059
DB08879,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belimumab.,Belimumab,DB00059
DB08880,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teriflunomide.,Teriflunomide,DB00059
DB08889,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carfilzomib.,Carfilzomib,DB00059
DB08901,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ponatinib.,Ponatinib,DB00059
DB08904,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Certolizumab pegol.,Certolizumab pegol,DB00059
DB08906,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone furoate.,Fluticasone furoate,DB00059
DB08908,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00059
DB08910,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.,Pomalidomide,DB00059
DB08935,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Obinutuzumab.,Obinutuzumab,DB00059
DB08970,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednidene.,Fluprednidene,DB00059
DB08971,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortolone.,Fluocortolone,DB00059
DB09029,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Secukinumab.,Secukinumab,DB00059
DB09033,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vedolizumab.,Vedolizumab,DB00059
DB09036,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siltuximab.,Siltuximab,DB00059
DB09052,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Blinatumomab.,Blinatumomab,DB00059
DB09053,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibrutinib.,Ibrutinib,DB00059
DB09054,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib.,Idelalisib,DB00059
DB09073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Palbociclib.,Palbociclib,DB00059
DB09074,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Olaparib.,Olaparib,DB00059
DB09077,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dinutuximab.,Dinutuximab,DB00059
DB09082,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vilanterol.,Vilanterol,DB00059
DB09091,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tixocortol.,Tixocortol,DB00059
DB09122,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00059
DB09312,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00059
DB09378,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednisolone.,Fluprednisolone,DB00059
DB09383,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Meprednisone.,Meprednisone,DB00059
DB11466,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tepoxalin.,Tepoxalin,DB00059
DB11487,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00059
DB11529,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melengestrol.,Melengestrol,DB00059
DB11569,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixekizumab.,Ixekizumab,DB00059
DB11580,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ravulizumab.,Ravulizumab,DB00059
DB11616,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirarubicin.,Pirarubicin,DB00059
DB11693,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Voclosporin.,Voclosporin,DB00059
DB11708,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peficitinib.,Peficitinib,DB00059
DB11750,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clobetasol.,Clobetasol,DB00059
DB11767,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sarilumab.,Sarilumab,DB00059
DB11776,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brodalumab.,Brodalumab,DB00059
DB11803,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirukumab.,Sirukumab,DB00059
DB11817,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Baricitinib.,Baricitinib,DB00059
DB11834,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Guselkumab.,Guselkumab,DB00059
DB11921,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deflazacort.,Deflazacort,DB00059
DB12025,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triptolide.,Triptolide,DB00059
DB12371,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siponimod.,Siponimod,DB00059
DB12612,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ozanimod.,Ozanimod,DB00059
DB12617,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mizoribine.,Mizoribine,DB00059
DB12692,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gusperimus.,Gusperimus,DB00059
DB12814,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00059
DB12902,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trofosfamide.,Trofosfamide,DB00059
DB12947,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxifluridine.,Doxifluridine,DB00059
DB12991,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deoxyspergualin.,Deoxyspergualin,DB00059
DB12996,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Acteoside.,Acteoside,DB00059
DB13003,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortivazol.,Cortivazol,DB00059
DB13014,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hypericin.,Hypericin,DB00059
DB13068,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00059
DB13208,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednylidene.,Prednylidene,DB00059
DB13223,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortin.,Fluocortin,DB00059
DB13241,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Begelomab.,Begelomab,DB00059
DB13491,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluperolone.,Fluperolone,DB00059
DB13664,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Formocortal.,Formocortal,DB00059
DB13728,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Halometasone.,Halometasone,DB00059
DB13843,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cloprednol.,Cloprednol,DB00059
DB13856,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluclorolone.,Fluclorolone,DB00059
DB13867,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone.,Fluticasone,DB00059
DB14066,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tetrandrine.,Tetrandrine,DB00059
DB14219,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00059
DB14512,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone furoate.,Mometasone furoate,DB00059
DB14538,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00059
DB14539,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00059
DB14545,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00059
DB14724,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Emapalumab.,Emapalumab,DB00059
DB14762,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Risankizumab.,Risankizumab,DB00059
DB14919,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rozanolixizumab.,Rozanolixizumab,DB00059
DB15253,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleselumab.,Bleselumab,DB00059
DB00108,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.,Natalizumab,DB00059
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.,Pimecrolimus,DB00059
DB01656,Roflumilast may increase the immunosuppressive activities of Pegaspargase.,Roflumilast,DB00059
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.,Sipuleucel-T,DB00059
DB08894,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Peginesatide.,Peginesatide,DB00059
DB09107,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Methoxy polyethylene glycol-epoetin beta.,Methoxy polyethylene glycol-epoetin beta,DB00059
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pegaspargase.,Darbepoetin alfa,DB00059
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pegaspargase.,Erythropoietin,DB00059
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegaspargase.,Sulfamethoxazole,DB00059
DB01097,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.,Leflunomide,DB00059
DB08895,Pegaspargase may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00059
DB00072,Trastuzumab may increase the neutropenic activities of Pegaspargase.,Trastuzumab,DB00059
DB00019,The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim,DB00059
DB00061,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.,Pegademase,DB00059
DB00082,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.,Pegvisomant,DB00059
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegaspargase.,Propylene glycol,DB00059
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegaspargase.,Heptaethylene glycol,DB00059
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegaspargase.,Pegaptanib,DB00059
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegaspargase.,Egaptivon pegol,DB00059
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaspargase.,PEG-uricase,DB00059
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegaspargase.,Peginterferon alfacon-1,DB00059
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegaspargase.,GlycoPEG-GCSF,DB00059
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegaspargase.,Pegnivacogin,DB00059
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegaspargase.,Pegpleranib,DB00059
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegaspargase.,Pegsunercept,DB00059
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase.,Polidocanol,DB00059
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegaspargase.,Pegloticase,DB00059
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaspargase.,Polyethylene glycol,DB00059
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegaspargase.","Antihemophilic Factor (Recombinant), PEGylated",DB00059
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegaspargase.,Polyethylene glycol 400,DB00059
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegaspargase.,Insulin peglispro,DB00059
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegaspargase.,Eptacog alfa pegol (activated),DB00059
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegaspargase.,Olaptesed Pegol,DB00059
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaspargase.,Abicipar Pegol,DB00059
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegaspargase.,Lexaptepid Pegol,DB00059
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegaspargase.,Pegvaliase,DB00059
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegaspargase.,Pegamotecan,DB00059
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegaspargase.,Lipegfilgrastim,DB00059
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegaspargase.,Nonacog beta pegol,DB00059
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegaspargase.,Damoctocog alfa pegol,DB00059
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegaspargase.,Elapegademase,DB00059
DB08868,Pegaspargase may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00059
DB00864,Tacrolimus may increase the immunosuppressive activities of Pegaspargase.,Tacrolimus,DB00059
DB01234,The serum concentration of Dexamethasone can be increased when it is combined with Pegaspargase.,Dexamethasone,DB00059
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Pegaspargase.,G17DT,DB00059
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Pegaspargase.,PEV3A,DB00059
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pegaspargase.,INGN 225,DB00059
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pegaspargase.,Rindopepimut,DB00059
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pegaspargase.,SRP 299,DB00059
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pegaspargase.,GI-5005,DB00059
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Pegaspargase.,Vitespen,DB00059
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Pegaspargase.,TG4010,DB00059
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pegaspargase.,Anthrax immune globulin human,DB00059
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pegaspargase.","Rabies virus inactivated antigen, B",DB00059
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00059
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pegaspargase.,Rotavirus vaccine,DB00059
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegaspargase.","Rabies virus inactivated antigen, A",DB00059
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00059
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00059
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00059
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00059
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00059
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00059
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pegaspargase.,Typhoid Vi polysaccharide vaccine,DB00059
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.,Hepatitis A Vaccine,DB00059
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00059
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00059
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00059
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00059
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00059
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pegaspargase.,Human rabies virus immune globulin,DB00059
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.,Hepatitis B Vaccine (Recombinant),DB00059
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Pegaspargase.,Tecemotide,DB00059
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pegaspargase.,Typhoid vaccine,DB00059
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00059
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00059
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00059
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00059
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00059
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00059
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00059
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Pegaspargase.,Vaccinia virus strain new york city board of health live antigen,DB00059
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pegaspargase.,Pertussis vaccine,DB00059
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00059
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.,Varicella Zoster Vaccine (Recombinant),DB00059
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pegaspargase.,Modified vaccinia ankara,DB00059
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pegaspargase.","Ebola Zaire vaccine (live, attenuated)",DB00059
DB11988,Ocrelizumab may increase the immunosuppressive activities of Pegaspargase.,Ocrelizumab,DB00059
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pegaspargase.,Rubella virus vaccine,DB00059
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Pegaspargase.,Varicella Zoster Vaccine (Live/attenuated),DB00059
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain tice live antigen,DB00059
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain connaught live antigen,DB00059
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Pegaspargase.,Yellow Fever Vaccine,DB00059
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Pegaspargase.,Anthrax vaccine,DB00059
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pegaspargase.,Typhoid Vaccine Live,DB00059
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00059
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Pegaspargase.,BCG vaccine,DB00059
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pegaspargase.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00059
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Pegaspargase.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00059
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pegaspargase.,Adenovirus type 7 vaccine live,DB00059
DB00563,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Pegaspargase.,Methotrexate,DB00059
DB00619,The risk or severity of liver damage can be increased when Pegaspargase is combined with Imatinib.,Imatinib,DB00059
DB00091,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00059
DB00252,The therapeutic efficacy of Phenytoin can be increased when used in combination with Pegaspargase.,Phenytoin,DB00059
DB00279,The therapeutic efficacy of Liothyronine can be increased when used in combination with Pegaspargase.,Liothyronine,DB00059
DB00451,The therapeutic efficacy of Levothyroxine can be increased when used in combination with Pegaspargase.,Levothyroxine,DB00059
DB00532,The therapeutic efficacy of Mephenytoin can be increased when used in combination with Pegaspargase.,Mephenytoin,DB00059
DB00695,The therapeutic efficacy of Furosemide can be increased when used in combination with Pegaspargase.,Furosemide,DB00059
DB00698,The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Pegaspargase.,Nitrofurantoin,DB00059
DB00754,The therapeutic efficacy of Ethotoin can be increased when used in combination with Pegaspargase.,Ethotoin,DB00059
DB00939,The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Pegaspargase.,Meclofenamic acid,DB00059
DB01109,The therapeutic efficacy of Heparin can be increased when used in combination with Pegaspargase.,Heparin,DB00059
DB01219,The therapeutic efficacy of Dantrolene can be increased when used in combination with Pegaspargase.,Dantrolene,DB00059
DB01320,The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Pegaspargase.,Fosphenytoin,DB00059
DB01583,The therapeutic efficacy of Liotrix can be increased when used in combination with Pegaspargase.,Liotrix,DB00059
DB08899,The therapeutic efficacy of Enzalutamide can be increased when used in combination with Pegaspargase.,Enzalutamide,DB00059
DB08984,The therapeutic efficacy of Etofenamate can be increased when used in combination with Pegaspargase.,Etofenamate,DB00059
DB12425,The therapeutic efficacy of Liothyronine I-131 can be increased when used in combination with Pegaspargase.,Liothyronine I-131,DB00059
DB13396,The therapeutic efficacy of Neocitrullamon can be increased when used in combination with Pegaspargase.,Neocitrullamon,DB00059
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Pegaspargase.,Magnesium,DB00059
DB01601,The serum concentration of Pegaspargase can be increased when it is combined with Lopinavir.,Lopinavir,DB00059
DB12530,The risk or severity of infection can be increased when Pegaspargase is combined with Inebilizumab.,Inebilizumab,DB00059
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1a.,Zolmitriptan,DB00060
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon beta-1a.,Caffeine,DB00060
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.,Dyphylline,DB00060
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1a.,Pentoxifylline,DB00060
DB01033,The metabolism of Mercaptopurine can be decreased when combined with Interferon beta-1a.,Mercaptopurine,DB00060
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1a.,Oxtriphylline,DB00060
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon beta-1a.,Theobromine,DB00060
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1a.,Fenethylline,DB00060
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1a.,8-azaguanine,DB00060
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1a.","7,9-Dimethylguanine",DB00060
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon beta-1a.,Xanthine,DB00060
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1a.,7-Deazaguanine,DB00060
DB02377,The metabolism of Guanine can be decreased when combined with Interferon beta-1a.,Guanine,DB00060
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1a.,9-Methylguanine,DB00060
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon beta-1a.,Peldesine,DB00060
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1a.,Hypoxanthine,DB00060
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1a.,9-Deazaguanine,DB00060
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1a.,Propentofylline,DB00060
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1a.,Valomaciclovir,DB00060
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1a.,3-isobutyl-1-methyl-7H-xanthine,DB00060
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon beta-1a.,Uric acid,DB00060
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1a.,Doxofylline,DB00060
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1a.,6-O-benzylguanine,DB00060
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1a.,Lisofylline,DB00060
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1a.,Lobucavir,DB00060
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1a.,Cafedrine,DB00060
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1a.,Theodrenaline,DB00060
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1a.,Bamifylline,DB00060
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1a.,Proxyphylline,DB00060
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon beta-1a.,Acefylline,DB00060
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1a.,Etamiphylline,DB00060
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1a.,Pentifylline,DB00060
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon beta-1a.,Bufylline,DB00060
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1a.,Bromotheophylline,DB00060
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon beta-1a.,Furafylline,DB00060
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1a.,8-chlorotheophylline,DB00060
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1a.,PCS-499,DB00060
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1a.,Fluvoxamine,DB00060
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon beta-1a.,Nicotine,DB00060
DB00188,The metabolism of Bortezomib can be decreased when combined with Interferon beta-1a.,Bortezomib,DB00060
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1a.,Betaxolol,DB00060
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1a.,Anagrelide,DB00060
DB00262,The metabolism of Carmustine can be decreased when combined with Interferon beta-1a.,Carmustine,DB00060
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.,Disopyramide,DB00060
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1a.,Lidocaine,DB00060
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1a.,Conjugated estrogens,DB00060
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1a.,Ropivacaine,DB00060
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1a.,Acetaminophen,DB00060
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1a.,Olanzapine,DB00060
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1a.,Chlorzoxazone,DB00060
DB00363,The metabolism of Clozapine can be decreased when combined with Interferon beta-1a.,Clozapine,DB00060
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1a.,Grepafloxacin,DB00060
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1a.,Mirtazapine,DB00060
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1a.,Mexiletine,DB00060
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon beta-1a.,Tacrine,DB00060
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon beta-1a.,Triamterene,DB00060
DB00420,The metabolism of Promazine can be decreased when combined with Interferon beta-1a.,Promazine,DB00060
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1a.,Zolpidem,DB00060
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon beta-1a.,Entecavir,DB00060
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1a.,Nabumetone,DB00060
DB00468,The metabolism of Quinine can be decreased when combined with Interferon beta-1a.,Quinine,DB00060
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1a.,Fluoxetine,DB00060
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1a.,Duloxetine,DB00060
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1a.,Chlorpromazine,DB00060
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon beta-1a.,Flutamide,DB00060
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.,Haloperidol,DB00060
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon beta-1a.,Albendazole,DB00060
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1a.,Rofecoxib,DB00060
DB00544,The metabolism of Fluorouracil can be decreased when combined with Interferon beta-1a.,Fluorouracil,DB00060
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1a.,Cinnarizine,DB00060
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon beta-1a.,Propranolol,DB00060
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1a.,Diclofenac,DB00060
DB00619,The metabolism of Imatinib can be decreased when combined with Interferon beta-1a.,Imatinib,DB00060
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1a.,Guanabenz,DB00060
DB00642,The metabolism of Pemetrexed can be decreased when combined with Interferon beta-1a.,Pemetrexed,DB00060
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon beta-1a.,Verapamil,DB00060
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1a.,Paroxetine,DB00060
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1a.,Thiabendazole,DB00060
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon beta-1a.,Riluzole,DB00060
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon beta-1a.,Zileuton,DB00060
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1a.,Clopidogrel,DB00060
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon beta-1a.,Estradiol,DB00060
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1a.,Acyclovir,DB00060
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon beta-1a.,Naproxen,DB00060
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1a.,Trifluoperazine,DB00060
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1a.,Perphenazine,DB00060
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1a.,Terbinafine,DB00060
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1a.,Ranitidine,DB00060
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon beta-1a.,Ethanol,DB00060
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1a.,Maprotiline,DB00060
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon beta-1a.,Alosetron,DB00060
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1a.,Lomefloxacin,DB00060
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1a.,Ramelteon,DB00060
DB00993,The metabolism of Azathioprine can be decreased when combined with Interferon beta-1a.,Azathioprine,DB00060
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1a.,Frovatriptan,DB00060
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1a.,Levobupivacaine,DB00060
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1a.,Cinacalcet,DB00060
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon beta-1a.,Selegiline,DB00060
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon beta-1a.,Tocainide,DB00060
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1a.,Praziquantel,DB00060
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon beta-1a.,Melatonin,DB00060
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon beta-1a.,Primaquine,DB00060
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1a.,Hesperetin,DB00060
DB01097,The metabolism of Leflunomide can be decreased when combined with Interferon beta-1a.,Leflunomide,DB00060
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1a.,Nifedipine,DB00060
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1a.,Carvedilol,DB00060
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1a.,Cilostazol,DB00060
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon beta-1a.,Propafenone,DB00060
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon beta-1a.,Domperidone,DB00060
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1a.,Dexfenfluramine,DB00060
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1a.,Rasagiline,DB00060
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1a.,Temafloxacin,DB00060
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1a.,Aminophenazone,DB00060
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1a.,Antipyrine,DB00060
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1a.,Bromazepam,DB00060
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1a.,Thiothixene,DB00060
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1a.,Etoricoxib,DB00060
DB01645,The metabolism of Genistein can be decreased when combined with Interferon beta-1a.,Genistein,DB00060
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1a.,Resveratrol,DB00060
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1a.,Phenacetin,DB00060
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1a.,Estrone sulfate,DB00060
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1a.,Flunarizine,DB00060
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1a.,Lorcaserin,DB00060
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1a.,Lofexidine,DB00060
DB04951,The metabolism of Pirfenidone can be decreased when combined with Interferon beta-1a.,Pirfenidone,DB00060
DB05676,The metabolism of Apremilast can be decreased when combined with Interferon beta-1a.,Apremilast,DB00060
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon beta-1a.,Mianserin,DB00060
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1a.,Eltrombopag,DB00060
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon beta-1a.,Asenapine,DB00060
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1a.,Vadimezan,DB00060
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1a.,Dapagliflozin,DB00060
DB06589,The metabolism of Pazopanib can be decreased when combined with Interferon beta-1a.,Pazopanib,DB00060
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1a.,Agomelatine,DB00060
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon beta-1a.,Axitinib,DB00060
DB06769,The metabolism of Bendamustine can be decreased when combined with Interferon beta-1a.,Bendamustine,DB00060
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1a.,Benzyl alcohol,DB00060
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1a.,Capsaicin,DB00060
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1a.,(R)-warfarin,DB00060
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon beta-1a.,Perampanel,DB00060
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1a.,Tasimelteon,DB00060
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1a.,Stiripentol,DB00060
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon beta-1a.,Zotepine,DB00060
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1a.,Propacetamol,DB00060
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1a.,Ramosetron,DB00060
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1a.,Binimetinib,DB00060
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1a.,Voxilaprevir,DB00060
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1a.,Triclabendazole,DB00060
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1a.,Rucaparib,DB00060
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1a.,Dihydralazine,DB00060
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1a.,Estradiol acetate,DB00060
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1a.,Estradiol benzoate,DB00060
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1a.,Estradiol cypionate,DB00060
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1a.,Estradiol dienanthate,DB00060
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1a.,Estradiol valerate,DB00060
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1a.,Istradefylline,DB00060
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon beta-1a.,Azelastine,DB00060
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1a.,Efavirenz,DB00060
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1a.,Metoclopramide,DB00060
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1a.,Bicifadine,DB00060
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1a.,GTS-21,DB00060
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon beta-1a.,Flecainide,DB00060
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1a.,Ethinylestradiol,DB00060
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1a.,Amitriptyline,DB00060
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon beta-1a.,Imipramine,DB00060
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon beta-1a.,Doxepin,DB00060
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1a.,Mephenytoin,DB00060
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1a.,Nortriptyline,DB00060
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon beta-1a.,Clonidine,DB00060
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1a.,Cyclobenzaprine,DB00060
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon beta-1a.,Desipramine,DB00060
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1a.,Clomipramine,DB00060
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1a.,Selumetinib,DB00060
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon beta-1a.,Theophylline,DB00060
DB00564,The metabolism of Carbamazepine can be decreased when combined with Interferon beta-1a.,Carbamazepine,DB00060
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon beta-1a.,Warfarin,DB00060
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1a.,Tizanidine,DB00060
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon beta-1a.,Pimozide,DB00060
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.,Aminophylline,DB00060
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1a.,Acenocoumarol,DB00060
DB00398,The metabolism of Sorafenib can be decreased when combined with Interferon beta-1a.,Sorafenib,DB00060
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1a.,Erlotinib,DB00060
DB00773,The metabolism of Etoposide can be decreased when combined with Interferon beta-1a.,Etoposide,DB00060
DB00851,The metabolism of Dacarbazine can be decreased when combined with Interferon beta-1a.,Dacarbazine,DB00060
DB01254,The metabolism of Dasatinib can be decreased when combined with Interferon beta-1a.,Dasatinib,DB00060
DB08910,The metabolism of Pomalidomide can be decreased when combined with Interferon beta-1a.,Pomalidomide,DB00060
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon beta-1a.,Tegafur,DB00060
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1a.,Enasidenib,DB00060
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1a.,Tamoxifen,DB00060
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Interferon beta-1a.,Rubella virus vaccine,DB00060
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain tice live antigen,DB00060
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain connaught live antigen,DB00060
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Interferon beta-1a.,Yellow Fever Vaccine,DB00060
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Interferon beta-1a.,Anthrax vaccine,DB00060
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Interferon beta-1a.,Typhoid Vaccine Live,DB00060
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00060
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Interferon beta-1a.,BCG vaccine,DB00060
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Interferon beta-1a.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00060
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon beta-1a.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00060
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Interferon beta-1a.,Adenovirus type 7 vaccine live,DB00060
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Interferon beta-1a.,Varicella Zoster Vaccine (Live/attenuated),DB00060
DB00268,The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Ropinirole.,Ropinirole,DB00060
DB00552,The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase.,Pentostatin,DB00061
DB00008,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00061
DB00019,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim,DB00061
DB00022,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00061
DB00059,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.,Pegaspargase,DB00061
DB00082,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.,Pegvisomant,DB00061
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegademase.,Propylene glycol,DB00061
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase.,Heptaethylene glycol,DB00061
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegademase.,Pegaptanib,DB00061
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegademase.,Egaptivon pegol,DB00061
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.,PEG-uricase,DB00061
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegademase.,Peginterferon alfacon-1,DB00061
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegademase.,GlycoPEG-GCSF,DB00061
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegademase.,Pegnivacogin,DB00061
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegademase.,Pegpleranib,DB00061
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegademase.,Pegsunercept,DB00061
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.,Polidocanol,DB00061
DB08894,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegademase.,Peginesatide,DB00061
DB08904,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegademase.,Certolizumab pegol,DB00061
DB09107,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.,Methoxy polyethylene glycol-epoetin beta,DB00061
DB09122,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegademase.,Peginterferon beta-1a,DB00061
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegademase.,Pegloticase,DB00061
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.,Polyethylene glycol,DB00061
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegademase.","Antihemophilic Factor (Recombinant), PEGylated",DB00061
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegademase.,Polyethylene glycol 400,DB00061
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegademase.,Insulin peglispro,DB00061
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegademase.,Eptacog alfa pegol (activated),DB00061
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegademase.,Olaptesed Pegol,DB00061
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegademase.,Abicipar Pegol,DB00061
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegademase.,Lexaptepid Pegol,DB00061
DB12814,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegademase.,Cepeginterferon alfa-2B,DB00061
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegademase.,Pegvaliase,DB00061
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegademase.,Pegamotecan,DB00061
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegademase.,Lipegfilgrastim,DB00061
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegademase.,Nonacog beta pegol,DB00061
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegademase.,Damoctocog alfa pegol,DB00061
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegademase.,Elapegademase,DB00061
DB06605,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.,Apixaban,DB00063
DB01254,Dasatinib may increase the anticoagulant activities of Eptifibatide.,Dasatinib,DB00063
DB01586,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid,DB00063
DB02123,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid,DB00063
DB02659,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Cholic Acid.,Cholic Acid,DB00063
DB02691,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycocholic acid.,Glycocholic acid,DB00063
DB03619,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic acid.,Deoxycholic acid,DB00063
DB04348,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurocholic acid.,Taurocholic acid,DB00063
DB05990,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obeticholic acid.,Obeticholic acid,DB00063
DB06777,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid,DB00063
DB08833,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid,DB00063
DB08834,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid,DB00063
DB08857,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Bamet-UD2.,Bamet-UD2,DB00063
DB11622,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Dehydrocholic acid.,Dehydrocholic acid,DB00063
DB11789,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid,DB00063
DB01296,Glucosamine may increase the antiplatelet activities of Eptifibatide.,Glucosamine,DB00063
DB00078,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00063
DB09053,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.,Ibrutinib,DB00063
DB08935,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.,Obinutuzumab,DB00063
DB00806,Pentoxifylline may increase the antiplatelet activities of Eptifibatide.,Pentoxifylline,DB00063
DB06228,Eptifibatide may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban,DB00063
DB00932,Tipranavir may increase the antiplatelet activities of Eptifibatide.,Tipranavir,DB00063
DB00013,Eptifibatide may increase the anticoagulant activities of Urokinase.,Urokinase,DB00063
DB00163,Vitamin E may increase the antiplatelet activities of Eptifibatide.,Vitamin E,DB00063
DB00686,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Eptifibatide.,Pentosan polysulfate,DB00063
DB09211,Limaprost may increase the antiplatelet activities of Eptifibatide.,Limaprost,DB00063
DB11133,Omega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.,Omega-3 fatty acids,DB00063
DB00081,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.,Tositumomab,DB00063
DB00001,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.,Lepirudin,DB00063
DB00006,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bivalirudin.,Bivalirudin,DB00063
DB00009,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alteplase.,Alteplase,DB00063
DB00015,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.,Reteplase,DB00063
DB00029,The risk or severity of bleeding can be increased when Eptifibatide is combined with Anistreplase.,Anistreplase,DB00063
DB00031,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tenecteplase.,Tenecteplase,DB00063
DB00054,The risk or severity of bleeding can be increased when Eptifibatide is combined with Abciximab.,Abciximab,DB00063
DB00055,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.,Drotrecogin alfa,DB00063
DB00086,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.,Streptokinase,DB00063
DB00266,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dicoumarol.,Dicoumarol,DB00063
DB00278,The risk or severity of bleeding can be increased when Eptifibatide is combined with Argatroban.,Argatroban,DB00063
DB00407,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ardeparin.,Ardeparin,DB00063
DB00498,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenindione.,Phenindione,DB00063
DB00569,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fondaparinux.,Fondaparinux,DB00063
DB00682,The risk or severity of bleeding can be increased when Eptifibatide is combined with Warfarin.,Warfarin,DB00063
DB00946,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenprocoumon.,Phenprocoumon,DB00063
DB00975,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dipyridamole.,Dipyridamole,DB00063
DB01088,The risk or severity of bleeding can be increased when Eptifibatide is combined with Iloprost.,Iloprost,DB00063
DB01109,The risk or severity of bleeding can be increased when Eptifibatide is combined with Heparin.,Heparin,DB00063
DB01225,The risk or severity of bleeding can be increased when Eptifibatide is combined with Enoxaparin.,Enoxaparin,DB00063
DB01240,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epoprostenol.,Epoprostenol,DB00063
DB01418,The risk or severity of bleeding can be increased when Eptifibatide is combined with Acenocoumarol.,Acenocoumarol,DB00063
DB03410,The risk or severity of bleeding can be increased when Eptifibatide is combined with 4-hydroxycoumarin.,4-hydroxycoumarin,DB00063
DB04665,The risk or severity of bleeding can be increased when Eptifibatide is combined with Coumarin.,Coumarin,DB00063
DB04898,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ximelagatran.,Ximelagatran,DB00063
DB04925,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desmoteplase.,Desmoteplase,DB00063
DB04932,The risk or severity of bleeding can be increased when Eptifibatide is combined with Defibrotide.,Defibrotide,DB00063
DB05099,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ancrod.,Ancrod,DB00063
DB05229,The risk or severity of bleeding can be increased when Eptifibatide is combined with Beraprost.,Beraprost,DB00063
DB05254,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fibrinolysin.,Fibrinolysin,DB00063
DB06209,The risk or severity of bleeding can be increased when Eptifibatide is combined with Prasugrel.,Prasugrel,DB00063
DB06271,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sulodexide.,Sulodexide,DB00063
DB06294,The risk or severity of bleeding can be increased when Eptifibatide is combined with Semuloparin.,Semuloparin,DB00063
DB06406,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idraparinux.,Idraparinux,DB00063
DB06441,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cangrelor.,Cangrelor,DB00063
DB06543,The risk or severity of bleeding can be increased when Eptifibatide is combined with Astaxanthin.,Astaxanthin,DB00063
DB06635,The risk or severity of bleeding can be increased when Eptifibatide is combined with Otamixaban.,Otamixaban,DB00063
DB06679,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amediplase.,Amediplase,DB00063
DB06754,The risk or severity of bleeding can be increased when Eptifibatide is combined with Danaparoid.,Danaparoid,DB00063
DB06779,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dalteparin.,Dalteparin,DB00063
DB06822,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tinzaparin.,Tinzaparin,DB00063
DB07767,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ferulic acid.,Ferulic acid,DB00063
DB08496,The risk or severity of bleeding can be increased when Eptifibatide is combined with (R)-warfarin.,(R)-warfarin,DB00063
DB08794,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ethyl biscoumacetate.,Ethyl biscoumacetate,DB00063
DB08813,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nadroparin.,Nadroparin,DB00063
DB08814,The risk or severity of bleeding can be increased when Eptifibatide is combined with Triflusal.,Triflusal,DB00063
DB08816,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ticagrelor.,Ticagrelor,DB00063
DB08994,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ditazole.,Ditazole,DB00063
DB09030,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorapaxar.,Vorapaxar,DB00063
DB09075,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edoxaban.,Edoxaban,DB00063
DB09125,The risk or severity of bleeding can be increased when Eptifibatide is combined with Potassium citrate.,Potassium citrate,DB00063
DB09154,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sodium citrate.,Sodium citrate,DB00063
DB09255,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dextran.,Dextran,DB00063
DB09258,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bemiparin.,Bemiparin,DB00063
DB09259,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reviparin.,Reviparin,DB00063
DB09260,The risk or severity of bleeding can be increased when Eptifibatide is combined with Parnaparin.,Parnaparin,DB00063
DB09261,The risk or severity of bleeding can be increased when Eptifibatide is combined with Certoparin.,Certoparin,DB00063
DB11095,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desirudin.,Desirudin,DB00063
DB11154,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zinc citrate.,Zinc citrate,DB00063
DB11166,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin Alfa.,Antithrombin Alfa,DB00063
DB11312,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein C.,Protein C,DB00063
DB11598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin III human.,Antithrombin III human,DB00063
DB11984,The risk or severity of bleeding can be increased when Eptifibatide is combined with Letaxaban.,Letaxaban,DB00063
DB12289,The risk or severity of bleeding can be increased when Eptifibatide is combined with Darexaban.,Darexaban,DB00063
DB12364,The risk or severity of bleeding can be increased when Eptifibatide is combined with Betrixaban.,Betrixaban,DB00063
DB12598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nafamostat.,Nafamostat,DB00063
DB12726,The risk or severity of bleeding can be increased when Eptifibatide is combined with Monteplase.,Monteplase,DB00063
DB12831,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gabexate.,Gabexate,DB00063
DB13136,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluindione.,Fluindione,DB00063
DB13149,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein S human.,Protein S human,DB00063
DB13199,The risk or severity of bleeding can be increased when Eptifibatide is combined with Brinase.,Brinase,DB00063
DB13275,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clorindione.,Clorindione,DB00063
DB13347,The risk or severity of bleeding can be increased when Eptifibatide is combined with Diphenadione.,Diphenadione,DB00063
DB13451,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioclomarol.,Tioclomarol,DB00063
DB13616,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melagatran.,Melagatran,DB00063
DB13646,The risk or severity of bleeding can be increased when Eptifibatide is combined with Saruplase.,Saruplase,DB00063
DB14055,The risk or severity of bleeding can be increased when Eptifibatide is combined with (S)-Warfarin.,(S)-Warfarin,DB00063
DB14094,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tocopherylquinone.,Tocopherylquinone,DB00063
DB14598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous,DB00063
DB14726,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dabigatran.,Dabigatran,DB00063
DB00374,Treprostinil may increase the antiplatelet activities of Eptifibatide.,Treprostinil,DB00063
DB00208,Eptifibatide may increase the antiplatelet activities of Ticlopidine.,Ticlopidine,DB00063
DB00758,Eptifibatide may increase the antiplatelet activities of Clopidogrel.,Clopidogrel,DB00063
DB00775,Eptifibatide may increase the antiplatelet activities of Tirofiban.,Tirofiban,DB00063
DB01138,Eptifibatide may increase the antiplatelet activities of Sulfinpyrazone.,Sulfinpyrazone,DB00063
DB01166,Eptifibatide may increase the antiplatelet activities of Cilostazol.,Cilostazol,DB00063
DB01207,Eptifibatide may increase the antiplatelet activities of Ridogrel.,Ridogrel,DB00063
DB01236,Eptifibatide may increase the antiplatelet activities of Sevoflurane.,Sevoflurane,DB00063
DB02709,Eptifibatide may increase the antiplatelet activities of Resveratrol.,Resveratrol,DB00063
DB04905,Eptifibatide may increase the antiplatelet activities of Tesmilifene.,Tesmilifene,DB00063
DB05266,Eptifibatide may increase the antiplatelet activities of Ibudilast.,Ibudilast,DB00063
DB05767,Eptifibatide may increase the antiplatelet activities of Andrographolide.,Andrographolide,DB00063
DB06081,Eptifibatide may increase the antiplatelet activities of Caplacizumab.,Caplacizumab,DB00063
DB07615,Eptifibatide may increase the antiplatelet activities of Tranilast.,Tranilast,DB00063
DB08887,Eptifibatide may increase the antiplatelet activities of Icosapent ethyl.,Icosapent ethyl,DB00063
DB09283,Eptifibatide may increase the antiplatelet activities of Trapidil.,Trapidil,DB00063
DB12092,Eptifibatide may increase the antiplatelet activities of Naftopidil.,Naftopidil,DB00063
DB12163,Eptifibatide may increase the antiplatelet activities of Sarpogrelate.,Sarpogrelate,DB00063
DB12321,Eptifibatide may increase the antiplatelet activities of Ifetroban.,Ifetroban,DB00063
DB12465,Eptifibatide may increase the antiplatelet activities of Ketanserin.,Ketanserin,DB00063
DB12749,Eptifibatide may increase the antiplatelet activities of Butylphthalide.,Butylphthalide,DB00063
DB12771,Eptifibatide may increase the antiplatelet activities of Hydroxytyrosol.,Hydroxytyrosol,DB00063
DB13036,Eptifibatide may increase the antiplatelet activities of Ramatroban.,Ramatroban,DB00063
DB13327,Eptifibatide may increase the antiplatelet activities of Picotamide.,Picotamide,DB00063
DB13367,Eptifibatide may increase the antiplatelet activities of Cloricromen.,Cloricromen,DB00063
DB13400,Eptifibatide may increase the antiplatelet activities of Linsidomine.,Linsidomine,DB00063
DB13510,Eptifibatide may increase the antiplatelet activities of Buflomedil.,Buflomedil,DB00063
DB13929,Eptifibatide may increase the antiplatelet activities of Relcovaptan.,Relcovaptan,DB00063
DB00261,Eptifibatide may increase the antiplatelet activities of Anagrelide.,Anagrelide,DB00063
DB00233,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aminosalicylic acid.,Aminosalicylic acid,DB00063
DB01294,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bismuth subsalicylate.,Bismuth subsalicylate,DB00063
DB06251,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dersalazine.,Dersalazine,DB00063
DB06807,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenyl aminosalicylate.,Phenyl aminosalicylate,DB00063
DB09543,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methyl salicylate.,Methyl salicylate,DB00063
DB13509,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aloxiprin.,Aloxiprin,DB00063
DB14006,The risk or severity of bleeding can be increased when Eptifibatide is combined with Choline salicylate.,Choline salicylate,DB00063
DB14026,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiosalicylic acid.,Thiosalicylic acid,DB00063
DB06695,Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.,Dabigatran etexilate,DB00063
DB00008,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00063
DB00011,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n1.,Interferon alfa-n1,DB00063
DB00018,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n3.,Interferon alfa-n3,DB00063
DB00022,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00063
DB00033,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon gamma-1b.,Interferon gamma-1b,DB00063
DB00034,"The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant",DB00063
DB00041,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.,Aldesleukin,DB00063
DB00056,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin,DB00063
DB00068,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.,Interferon beta-1b,DB00063
DB00069,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00063
DB00073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.,Rituximab,DB00063
DB00087,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.,Alemtuzumab,DB00063
DB00105,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00063
DB00120,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenylalanine.,Phenylalanine,DB00063
DB00188,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bortezomib.,Bortezomib,DB00063
DB00242,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cladribine.,Cladribine,DB00063
DB00262,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carmustine.,Carmustine,DB00063
DB00276,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amsacrine.,Amsacrine,DB00063
DB00291,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chlorambucil.,Chlorambucil,DB00063
DB00293,The risk or severity of bleeding can be increased when Eptifibatide is combined with Raltitrexed.,Raltitrexed,DB00063
DB00305,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitomycin.,Mitomycin,DB00063
DB00307,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bexarotene.,Bexarotene,DB00063
DB00309,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vindesine.,Vindesine,DB00063
DB00322,The risk or severity of bleeding can be increased when Eptifibatide is combined with Floxuridine.,Floxuridine,DB00063
DB00352,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioguanine.,Tioguanine,DB00063
DB00361,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinorelbine.,Vinorelbine,DB00063
DB00380,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane.,Dexrazoxane,DB00063
DB00398,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sorafenib.,Sorafenib,DB00063
DB00428,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptozocin.,Streptozocin,DB00063
DB00441,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemcitabine.,Gemcitabine,DB00063
DB00444,The risk or severity of bleeding can be increased when Eptifibatide is combined with Teniposide.,Teniposide,DB00063
DB00445,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epirubicin.,Epirubicin,DB00063
DB00446,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chloramphenicol.,Chloramphenicol,DB00063
DB00480,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lenalidomide.,Lenalidomide,DB00063
DB00488,The risk or severity of bleeding can be increased when Eptifibatide is combined with Altretamine.,Altretamine,DB00063
DB00495,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zidovudine.,Zidovudine,DB00063
DB00515,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin.,Cisplatin,DB00063
DB00526,The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin.,Oxaliplatin,DB00063
DB00531,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cyclophosphamide.,Cyclophosphamide,DB00063
DB00544,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluorouracil.,Fluorouracil,DB00063
DB00550,The risk or severity of bleeding can be increased when Eptifibatide is combined with Propylthiouracil.,Propylthiouracil,DB00063
DB00552,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pentostatin.,Pentostatin,DB00063
DB00563,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methotrexate.,Methotrexate,DB00063
DB00564,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carbamazepine.,Carbamazepine,DB00063
DB00570,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinblastine.,Vinblastine,DB00063
DB00619,The risk or severity of bleeding can be increased when Eptifibatide is combined with Imatinib.,Imatinib,DB00063
DB00631,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clofarabine.,Clofarabine,DB00063
DB00642,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pemetrexed.,Pemetrexed,DB00063
DB00694,The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.,Daunorubicin,DB00063
DB00762,The risk or severity of bleeding can be increased when Eptifibatide is combined with Irinotecan.,Irinotecan,DB00063
DB00763,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methimazole.,Methimazole,DB00063
DB00773,The risk or severity of bleeding can be increased when Eptifibatide is combined with Etoposide.,Etoposide,DB00063
DB00851,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dacarbazine.,Dacarbazine,DB00063
DB00853,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temozolomide.,Temozolomide,DB00063
DB00859,The risk or severity of bleeding can be increased when Eptifibatide is combined with Penicillamine.,Penicillamine,DB00063
DB00864,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tacrolimus.,Tacrolimus,DB00063
DB00877,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sirolimus.,Sirolimus,DB00063
DB00888,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mechlorethamine.,Mechlorethamine,DB00063
DB00928,The risk or severity of bleeding can be increased when Eptifibatide is combined with Azacitidine.,Azacitidine,DB00063
DB00958,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carboplatin.,Carboplatin,DB00063
DB00970,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dactinomycin.,Dactinomycin,DB00063
DB00987,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.,Cytarabine,DB00063
DB00997,The risk or severity of bleeding can be increased when Eptifibatide is combined with Doxorubicin.,Doxorubicin,DB00063
DB01005,The risk or severity of bleeding can be increased when Eptifibatide is combined with Hydroxyurea.,Hydroxyurea,DB00063
DB01008,The risk or severity of bleeding can be increased when Eptifibatide is combined with Busulfan.,Busulfan,DB00063
DB01030,The risk or severity of bleeding can be increased when Eptifibatide is combined with Topotecan.,Topotecan,DB00063
DB01033,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mercaptopurine.,Mercaptopurine,DB00063
DB01041,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thalidomide.,Thalidomide,DB00063
DB01042,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melphalan.,Melphalan,DB00063
DB01073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fludarabine.,Fludarabine,DB00063
DB01099,The risk or severity of bleeding can be increased when Eptifibatide is combined with Flucytosine.,Flucytosine,DB00063
DB01101,The risk or severity of bleeding can be increased when Eptifibatide is combined with Capecitabine.,Capecitabine,DB00063
DB01169,The risk or severity of bleeding can be increased when Eptifibatide is combined with Arsenic trioxide.,Arsenic trioxide,DB00063
DB01177,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idarubicin.,Idarubicin,DB00063
DB01181,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ifosfamide.,Ifosfamide,DB00063
DB01204,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitoxantrone.,Mitoxantrone,DB00063
DB01206,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lomustine.,Lomustine,DB00063
DB01229,The risk or severity of bleeding can be increased when Eptifibatide is combined with Paclitaxel.,Paclitaxel,DB00063
DB01248,The risk or severity of bleeding can be increased when Eptifibatide is combined with Docetaxel.,Docetaxel,DB00063
DB01262,The risk or severity of bleeding can be increased when Eptifibatide is combined with Decitabine.,Decitabine,DB00063
DB01280,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nelarabine.,Nelarabine,DB00063
DB01590,The risk or severity of bleeding can be increased when Eptifibatide is combined with Everolimus.,Everolimus,DB00063
DB02546,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorinostat.,Vorinostat,DB00063
DB04572,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiotepa.,Thiotepa,DB00063
DB04845,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ixabepilone.,Ixabepilone,DB00063
DB04868,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nilotinib.,Nilotinib,DB00063
DB05015,The risk or severity of bleeding can be increased when Eptifibatide is combined with Belinostat.,Belinostat,DB00063
DB05109,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trabectedin.,Trabectedin,DB00063
DB05258,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa.,Interferon alfa,DB00063
DB05472,The risk or severity of bleeding can be increased when Eptifibatide is combined with omega interferon.,omega interferon,DB00063
DB05773,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00063
DB06287,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temsirolimus.,Temsirolimus,DB00063
DB06616,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bosutinib.,Bosutinib,DB00063
DB06769,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bendamustine.,Bendamustine,DB00063
DB06772,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cabazitaxel.,Cabazitaxel,DB00063
DB08871,The risk or severity of bleeding can be increased when Eptifibatide is combined with Eribulin.,Eribulin,DB00063
DB08877,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.,Ruxolitinib,DB00063
DB08889,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carfilzomib.,Carfilzomib,DB00063
DB08895,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tofacitinib.,Tofacitinib,DB00063
DB08901,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ponatinib.,Ponatinib,DB00063
DB08910,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pomalidomide.,Pomalidomide,DB00063
DB09042,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00063
DB09052,The risk or severity of bleeding can be increased when Eptifibatide is combined with Blinatumomab.,Blinatumomab,DB00063
DB09073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Palbociclib.,Palbociclib,DB00063
DB09074,The risk or severity of bleeding can be increased when Eptifibatide is combined with Olaparib.,Olaparib,DB00063
DB09077,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dinutuximab.,Dinutuximab,DB00063
DB09122,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00063
DB12814,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00063
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Eptifibatide.,Fluvoxamine,DB00063
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Eptifibatide.,Citalopram,DB00063
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Eptifibatide.,Fluoxetine,DB00063
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Eptifibatide.,Paroxetine,DB00063
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Eptifibatide.,Nefazodone,DB00063
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Eptifibatide.,Zimelidine,DB00063
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Eptifibatide.,Dapoxetine,DB00063
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Eptifibatide.,Seproxetine,DB00063
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Eptifibatide.,Indalpine,DB00063
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Eptifibatide.,Ritanserin,DB00063
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Eptifibatide.,Alaproclate,DB00063
DB00285,Venlafaxine may increase the antiplatelet activities of Eptifibatide.,Venlafaxine,DB00063
DB00476,Duloxetine may increase the antiplatelet activities of Eptifibatide.,Duloxetine,DB00063
DB01105,Sibutramine may increase the antiplatelet activities of Eptifibatide.,Sibutramine,DB00063
DB04896,Milnacipran may increase the antiplatelet activities of Eptifibatide.,Milnacipran,DB00063
DB06700,Desvenlafaxine may increase the antiplatelet activities of Eptifibatide.,Desvenlafaxine,DB00063
DB08918,Levomilnacipran may increase the antiplatelet activities of Eptifibatide.,Levomilnacipran,DB00063
DB00182,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Eptifibatide.,Amphetamine,DB00063
DB00601,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Eptifibatide.,Linezolid,DB00063
DB00614,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Eptifibatide.,Furazolidone,DB00063
DB00721,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Eptifibatide.,Procaine,DB00063
DB00752,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Eptifibatide.,Tranylcypromine,DB00063
DB00780,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Eptifibatide.,Phenelzine,DB00063
DB00805,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Eptifibatide.,Minaprine,DB00063
DB01037,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Eptifibatide.,Selegiline,DB00063
DB01168,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Eptifibatide.,Procarbazine,DB00063
DB01171,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Eptifibatide.,Moclobemide,DB00063
DB01247,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Eptifibatide.,Isocarboxazid,DB00063
DB01367,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Eptifibatide.,Rasagiline,DB00063
DB01626,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Eptifibatide.,Pargyline,DB00063
DB04017,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Eptifibatide.,Clorgiline,DB00063
DB04818,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Eptifibatide.,Iproniazid,DB00063
DB04820,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Eptifibatide.,Nialamide,DB00063
DB06654,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Eptifibatide.,Safinamide,DB00063
DB08550,"The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Eptifibatide.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",DB00063
DB09241,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Eptifibatide.,Methylene blue,DB00063
DB09243,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Eptifibatide.,Hydracarbazine,DB00063
DB09244,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Eptifibatide.,Pirlindole,DB00063
DB09245,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Eptifibatide.,Toloxatone,DB00063
DB09246,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Eptifibatide.,Benmoxin,DB00063
DB09248,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Eptifibatide.,Mebanazine,DB00063
DB09249,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Eptifibatide.,Octamoxin,DB00063
DB09250,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Eptifibatide.,Pheniprazine,DB00063
DB09251,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Eptifibatide.,Phenoxypropazine,DB00063
DB09252,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Eptifibatide.,Pivhydrazine,DB00063
DB09253,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Eptifibatide.,Safrazine,DB00063
DB09254,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Eptifibatide.,Caroxazone,DB00063
DB13875,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Eptifibatide.,Harmaline,DB00063
DB13876,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Eptifibatide.,Brofaromine,DB00063
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Eptifibatide.,Omega-3-acid ethyl esters,DB00063
DB00945,Acetylsalicylic acid may increase the antiplatelet activities of Eptifibatide.,Acetylsalicylic acid,DB00063
DB00159,The risk or severity of bleeding can be increased when Icosapent is combined with Eptifibatide.,Icosapent,DB00063
DB00244,The risk or severity of bleeding can be increased when Mesalazine is combined with Eptifibatide.,Mesalazine,DB00063
DB00328,The risk or severity of bleeding can be increased when Indomethacin is combined with Eptifibatide.,Indomethacin,DB00063
DB00461,The risk or severity of bleeding can be increased when Nabumetone is combined with Eptifibatide.,Nabumetone,DB00063
DB00465,The risk or severity of bleeding can be increased when Ketorolac is combined with Eptifibatide.,Ketorolac,DB00063
DB00469,The risk or severity of bleeding can be increased when Tenoxicam is combined with Eptifibatide.,Tenoxicam,DB00063
DB00482,The risk or severity of bleeding can be increased when Celecoxib is combined with Eptifibatide.,Celecoxib,DB00063
DB00500,The risk or severity of bleeding can be increased when Tolmetin is combined with Eptifibatide.,Tolmetin,DB00063
DB00533,The risk or severity of bleeding can be increased when Rofecoxib is combined with Eptifibatide.,Rofecoxib,DB00063
DB00554,The risk or severity of bleeding can be increased when Piroxicam is combined with Eptifibatide.,Piroxicam,DB00063
DB00573,The risk or severity of bleeding can be increased when Fenoprofen is combined with Eptifibatide.,Fenoprofen,DB00063
DB00580,The risk or severity of bleeding can be increased when Valdecoxib is combined with Eptifibatide.,Valdecoxib,DB00063
DB00586,The risk or severity of bleeding can be increased when Diclofenac is combined with Eptifibatide.,Diclofenac,DB00063
DB00605,The risk or severity of bleeding can be increased when Sulindac is combined with Eptifibatide.,Sulindac,DB00063
DB00712,The risk or severity of bleeding can be increased when Flurbiprofen is combined with Eptifibatide.,Flurbiprofen,DB00063
DB00749,The risk or severity of bleeding can be increased when Etodolac is combined with Eptifibatide.,Etodolac,DB00063
DB00784,The risk or severity of bleeding can be increased when Mefenamic acid is combined with Eptifibatide.,Mefenamic acid,DB00063
DB00788,The risk or severity of bleeding can be increased when Naproxen is combined with Eptifibatide.,Naproxen,DB00063
DB00795,The risk or severity of bleeding can be increased when Sulfasalazine is combined with Eptifibatide.,Sulfasalazine,DB00063
DB00812,The risk or severity of bleeding can be increased when Phenylbutazone is combined with Eptifibatide.,Phenylbutazone,DB00063
DB00814,The risk or severity of bleeding can be increased when Meloxicam is combined with Eptifibatide.,Meloxicam,DB00063
DB00821,The risk or severity of bleeding can be increased when Carprofen is combined with Eptifibatide.,Carprofen,DB00063
DB00861,The risk or severity of bleeding can be increased when Diflunisal is combined with Eptifibatide.,Diflunisal,DB00063
DB00936,The risk or severity of bleeding can be increased when Salicylic acid is combined with Eptifibatide.,Salicylic acid,DB00063
DB00939,The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Eptifibatide.,Meclofenamic acid,DB00063
DB00991,The risk or severity of bleeding can be increased when Oxaprozin is combined with Eptifibatide.,Oxaprozin,DB00063
DB01009,The risk or severity of bleeding can be increased when Ketoprofen is combined with Eptifibatide.,Ketoprofen,DB00063
DB01014,The risk or severity of bleeding can be increased when Balsalazide is combined with Eptifibatide.,Balsalazide,DB00063
DB01050,The risk or severity of bleeding can be increased when Ibuprofen is combined with Eptifibatide.,Ibuprofen,DB00063
DB01250,The risk or severity of bleeding can be increased when Olsalazine is combined with Eptifibatide.,Olsalazine,DB00063
DB01283,The risk or severity of bleeding can be increased when Lumiracoxib is combined with Eptifibatide.,Lumiracoxib,DB00063
DB01397,The risk or severity of bleeding can be increased when Magnesium salicylate is combined with Eptifibatide.,Magnesium salicylate,DB00063
DB01399,The risk or severity of bleeding can be increased when Salsalate is combined with Eptifibatide.,Salsalate,DB00063
DB01401,The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Eptifibatide.,Choline magnesium trisalicylate,DB00063
DB01419,The risk or severity of bleeding can be increased when Antrafenine is combined with Eptifibatide.,Antrafenine,DB00063
DB01424,The risk or severity of bleeding can be increased when Aminophenazone is combined with Eptifibatide.,Aminophenazone,DB00063
DB01435,The risk or severity of bleeding can be increased when Antipyrine is combined with Eptifibatide.,Antipyrine,DB00063
DB01600,The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Eptifibatide.,Tiaprofenic acid,DB00063
DB01628,The risk or severity of bleeding can be increased when Etoricoxib is combined with Eptifibatide.,Etoricoxib,DB00063
DB02224,The risk or severity of bleeding can be increased when Taxifolin is combined with Eptifibatide.,Taxifolin,DB00063
DB03585,The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Eptifibatide.,Oxyphenbutazone,DB00063
DB04552,The risk or severity of bleeding can be increased when Niflumic acid is combined with Eptifibatide.,Niflumic acid,DB00063
DB04725,The risk or severity of bleeding can be increased when Licofelone is combined with Eptifibatide.,Licofelone,DB00063
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Eptifibatide.,Nimesulide,DB00063
DB04812,The risk or severity of bleeding can be increased when Benoxaprofen is combined with Eptifibatide.,Benoxaprofen,DB00063
DB04817,The risk or severity of bleeding can be increased when Metamizole is combined with Eptifibatide.,Metamizole,DB00063
DB04828,The risk or severity of bleeding can be increased when Zomepirac is combined with Eptifibatide.,Zomepirac,DB00063
DB05095,The risk or severity of bleeding can be increased when Cimicoxib is combined with Eptifibatide.,Cimicoxib,DB00063
DB06725,The risk or severity of bleeding can be increased when Lornoxicam is combined with Eptifibatide.,Lornoxicam,DB00063
DB06736,The risk or severity of bleeding can be increased when Aceclofenac is combined with Eptifibatide.,Aceclofenac,DB00063
DB06737,The risk or severity of bleeding can be increased when Zaltoprofen is combined with Eptifibatide.,Zaltoprofen,DB00063
DB07402,The risk or severity of bleeding can be increased when Azapropazone is combined with Eptifibatide.,Azapropazone,DB00063
DB07477,The risk or severity of bleeding can be increased when Felbinac is combined with Eptifibatide.,Felbinac,DB00063
DB08439,The risk or severity of bleeding can be increased when Parecoxib is combined with Eptifibatide.,Parecoxib,DB00063
DB08797,The risk or severity of bleeding can be increased when Salicylamide is combined with Eptifibatide.,Salicylamide,DB00063
DB08940,The risk or severity of bleeding can be increased when Kebuzone is combined with Eptifibatide.,Kebuzone,DB00063
DB08942,The risk or severity of bleeding can be increased when Isoxicam is combined with Eptifibatide.,Isoxicam,DB00063
DB08951,The risk or severity of bleeding can be increased when Indoprofen is combined with Eptifibatide.,Indoprofen,DB00063
DB08955,The risk or severity of bleeding can be increased when Ibuproxam is combined with Eptifibatide.,Ibuproxam,DB00063
DB08976,The risk or severity of bleeding can be increased when Floctafenine is combined with Eptifibatide.,Floctafenine,DB00063
DB08981,The risk or severity of bleeding can be increased when Fenbufen is combined with Eptifibatide.,Fenbufen,DB00063
DB08984,The risk or severity of bleeding can be increased when Etofenamate is combined with Eptifibatide.,Etofenamate,DB00063
DB08991,The risk or severity of bleeding can be increased when Epirizole is combined with Eptifibatide.,Epirizole,DB00063
DB09084,The risk or severity of bleeding can be increased when Benzydamine is combined with Eptifibatide.,Benzydamine,DB00063
DB09212,The risk or severity of bleeding can be increased when Loxoprofen is combined with Eptifibatide.,Loxoprofen,DB00063
DB09213,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Eptifibatide.,Dexibuprofen,DB00063
DB09214,The risk or severity of bleeding can be increased when Dexketoprofen is combined with Eptifibatide.,Dexketoprofen,DB00063
DB09215,The risk or severity of bleeding can be increased when Droxicam is combined with Eptifibatide.,Droxicam,DB00063
DB09216,The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Eptifibatide.,Tolfenamic acid,DB00063
DB09217,The risk or severity of bleeding can be increased when Firocoxib is combined with Eptifibatide.,Firocoxib,DB00063
DB09218,The risk or severity of bleeding can be increased when Clonixin is combined with Eptifibatide.,Clonixin,DB00063
DB09285,The risk or severity of bleeding can be increased when Morniflumate is combined with Eptifibatide.,Morniflumate,DB00063
DB09288,The risk or severity of bleeding can be increased when Propacetamol is combined with Eptifibatide.,Propacetamol,DB00063
DB09295,The risk or severity of bleeding can be increased when Talniflumate is combined with Eptifibatide.,Talniflumate,DB00063
DB11455,The risk or severity of bleeding can be increased when Robenacoxib is combined with Eptifibatide.,Robenacoxib,DB00063
DB11466,The risk or severity of bleeding can be increased when Tepoxalin is combined with Eptifibatide.,Tepoxalin,DB00063
DB11518,The risk or severity of bleeding can be increased when Flunixin is combined with Eptifibatide.,Flunixin,DB00063
DB12399,The risk or severity of bleeding can be increased when Polmacoxib is combined with Eptifibatide.,Polmacoxib,DB00063
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Eptifibatide.,Nitroaspirin,DB00063
DB12480,The risk or severity of bleeding can be increased when Betulinic Acid is combined with Eptifibatide.,Betulinic Acid,DB00063
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Eptifibatide.,Indobufen,DB00063
DB12610,The risk or severity of bleeding can be increased when Ebselen is combined with Eptifibatide.,Ebselen,DB00063
DB13001,The risk or severity of bleeding can be increased when Tinoridine is combined with Eptifibatide.,Tinoridine,DB00063
DB13167,The risk or severity of bleeding can be increased when Alclofenac is combined with Eptifibatide.,Alclofenac,DB00063
DB13217,The risk or severity of bleeding can be increased when Fentiazac is combined with Eptifibatide.,Fentiazac,DB00063
DB13232,The risk or severity of bleeding can be increased when Suxibuzone is combined with Eptifibatide.,Suxibuzone,DB00063
DB13286,The risk or severity of bleeding can be increased when Bumadizone is combined with Eptifibatide.,Bumadizone,DB00063
DB13314,The risk or severity of bleeding can be increased when Alminoprofen is combined with Eptifibatide.,Alminoprofen,DB00063
DB13317,The risk or severity of bleeding can be increased when Flunoxaprofen is combined with Eptifibatide.,Flunoxaprofen,DB00063
DB13364,The risk or severity of bleeding can be increased when Feprazone is combined with Eptifibatide.,Feprazone,DB00063
DB13371,The risk or severity of bleeding can be increased when Difenpiramide is combined with Eptifibatide.,Difenpiramide,DB00063
DB13407,The risk or severity of bleeding can be increased when Nifenazone is combined with Eptifibatide.,Nifenazone,DB00063
DB13432,The risk or severity of bleeding can be increased when Lonazolac is combined with Eptifibatide.,Lonazolac,DB00063
DB13481,The risk or severity of bleeding can be increased when Tenidap is combined with Eptifibatide.,Tenidap,DB00063
DB13501,The risk or severity of bleeding can be increased when Bendazac is combined with Eptifibatide.,Bendazac,DB00063
DB13514,The risk or severity of bleeding can be increased when Pranoprofen is combined with Eptifibatide.,Pranoprofen,DB00063
DB13524,The risk or severity of bleeding can be increased when Propyphenazone is combined with Eptifibatide.,Propyphenazone,DB00063
DB13527,The risk or severity of bleeding can be increased when Proglumetacin is combined with Eptifibatide.,Proglumetacin,DB00063
DB13538,The risk or severity of bleeding can be increased when Guacetisal is combined with Eptifibatide.,Guacetisal,DB00063
DB13544,The risk or severity of bleeding can be increased when Ethenzamide is combined with Eptifibatide.,Ethenzamide,DB00063
DB13612,The risk or severity of bleeding can be increased when Carbaspirin calcium is combined with Eptifibatide.,Carbaspirin calcium,DB00063
DB13629,The risk or severity of bleeding can be increased when Mofebutazone is combined with Eptifibatide.,Mofebutazone,DB00063
DB13649,The risk or severity of bleeding can be increased when Proquazone is combined with Eptifibatide.,Proquazone,DB00063
DB13657,The risk or severity of bleeding can be increased when Benorilate is combined with Eptifibatide.,Benorilate,DB00063
DB13722,The risk or severity of bleeding can be increased when Pirprofen is combined with Eptifibatide.,Pirprofen,DB00063
DB13783,The risk or severity of bleeding can be increased when Acemetacin is combined with Eptifibatide.,Acemetacin,DB00063
DB13860,The risk or severity of bleeding can be increased when Imidazole salicylate is combined with Eptifibatide.,Imidazole salicylate,DB00063
DB14059,The risk or severity of bleeding can be increased when SC-236 is combined with Eptifibatide.,SC-236,DB00063
DB14060,The risk or severity of bleeding can be increased when NS-398 is combined with Eptifibatide.,NS-398,DB00063
DB14938,The risk or severity of bleeding can be increased when Flurbiprofen axetil is combined with Eptifibatide.,Flurbiprofen axetil,DB00063
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Eptifibatide.,Trazodone,DB00063
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Eptifibatide.,Escitalopram,DB00063
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Eptifibatide.,Sertraline,DB00063
DB01281,The risk or severity of infection can be increased when Infliximab is combined with Abatacept.,Abatacept,DB00065
DB00026,The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.,Anakinra,DB00065
DB06168,The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.,Canakinumab,DB00065
DB08904,The risk or severity of infection can be increased when Infliximab is combined with Certolizumab pegol.,Certolizumab pegol,DB00065
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.,Denosumab,DB00065
DB00005,Etanercept may increase the immunosuppressive activities of Infliximab.,Etanercept,DB00065
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab.,Peginterferon alfa-2a,DB00065
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Infliximab.,Interferon alfa-n1,DB00065
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Infliximab.,Interferon alfa-n3,DB00065
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Infliximab.,Peginterferon alfa-2b,DB00065
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Infliximab.,Interferon gamma-1b,DB00065
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Infliximab.","Interferon alfa-2a, Recombinant",DB00065
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Infliximab.,Aldesleukin,DB00065
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.,Gemtuzumab ozogamicin,DB00065
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.,Pegaspargase,DB00065
DB00068,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.,Interferon beta-1b,DB00065
DB00069,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00065
DB00073,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.,Rituximab,DB00065
DB00074,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.,Basiliximab,DB00065
DB00075,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.,Muromonab,DB00065
DB00078,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00065
DB00081,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.,Tositumomab,DB00065
DB00087,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.,Alemtuzumab,DB00065
DB00092,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.,Alefacept,DB00065
DB00095,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.,Efalizumab,DB00065
DB00098,The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00065
DB00105,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00065
DB00111,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.,Daclizumab,DB00065
DB00112,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.,Bevacizumab,DB00065
DB00120,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.,Phenylalanine,DB00065
DB00242,The risk or severity of adverse effects can be increased when Infliximab is combined with Cladribine.,Cladribine,DB00065
DB00276,The risk or severity of adverse effects can be increased when Infliximab is combined with Amsacrine.,Amsacrine,DB00065
DB00290,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleomycin.,Bleomycin,DB00065
DB00291,The risk or severity of adverse effects can be increased when Infliximab is combined with Chlorambucil.,Chlorambucil,DB00065
DB00293,The risk or severity of adverse effects can be increased when Infliximab is combined with Raltitrexed.,Raltitrexed,DB00065
DB00305,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitomycin.,Mitomycin,DB00065
DB00322,The risk or severity of adverse effects can be increased when Infliximab is combined with Floxuridine.,Floxuridine,DB00065
DB00352,The risk or severity of adverse effects can be increased when Infliximab is combined with Tioguanine.,Tioguanine,DB00065
DB00380,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane.,Dexrazoxane,DB00065
DB00428,The risk or severity of adverse effects can be increased when Infliximab is combined with Streptozocin.,Streptozocin,DB00065
DB00432,The risk or severity of adverse effects can be increased when Infliximab is combined with Trifluridine.,Trifluridine,DB00065
DB00441,The risk or severity of adverse effects can be increased when Infliximab is combined with Gemcitabine.,Gemcitabine,DB00065
DB00445,The risk or severity of adverse effects can be increased when Infliximab is combined with Epirubicin.,Epirubicin,DB00065
DB00446,The risk or severity of adverse effects can be increased when Infliximab is combined with Chloramphenicol.,Chloramphenicol,DB00065
DB00480,The risk or severity of adverse effects can be increased when Infliximab is combined with Lenalidomide.,Lenalidomide,DB00065
DB00488,The risk or severity of adverse effects can be increased when Infliximab is combined with Altretamine.,Altretamine,DB00065
DB00515,The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.,Cisplatin,DB00065
DB00526,The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin.,Oxaliplatin,DB00065
DB00550,The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil.,Propylthiouracil,DB00065
DB00552,The risk or severity of adverse effects can be increased when Infliximab is combined with Pentostatin.,Pentostatin,DB00065
DB00601,The risk or severity of adverse effects can be increased when Infliximab is combined with Linezolid.,Linezolid,DB00065
DB00631,The risk or severity of adverse effects can be increased when Infliximab is combined with Clofarabine.,Clofarabine,DB00065
DB00763,The risk or severity of adverse effects can be increased when Infliximab is combined with Methimazole.,Methimazole,DB00065
DB00795,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulfasalazine.,Sulfasalazine,DB00065
DB00853,The risk or severity of adverse effects can be increased when Infliximab is combined with Temozolomide.,Temozolomide,DB00065
DB00859,The risk or severity of adverse effects can be increased when Infliximab is combined with Penicillamine.,Penicillamine,DB00065
DB00888,The risk or severity of adverse effects can be increased when Infliximab is combined with Mechlorethamine.,Mechlorethamine,DB00065
DB00928,The risk or severity of adverse effects can be increased when Infliximab is combined with Azacitidine.,Azacitidine,DB00065
DB00958,The risk or severity of adverse effects can be increased when Infliximab is combined with Carboplatin.,Carboplatin,DB00065
DB00970,The risk or severity of adverse effects can be increased when Infliximab is combined with Dactinomycin.,Dactinomycin,DB00065
DB01005,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxyurea.,Hydroxyurea,DB00065
DB01024,The risk or severity of adverse effects can be increased when Infliximab is combined with Mycophenolic acid.,Mycophenolic acid,DB00065
DB01030,The risk or severity of adverse effects can be increased when Infliximab is combined with Topotecan.,Topotecan,DB00065
DB01033,The risk or severity of adverse effects can be increased when Infliximab is combined with Mercaptopurine.,Mercaptopurine,DB00065
DB01042,The risk or severity of adverse effects can be increased when Infliximab is combined with Melphalan.,Melphalan,DB00065
DB01073,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludarabine.,Fludarabine,DB00065
DB01099,The risk or severity of adverse effects can be increased when Infliximab is combined with Flucytosine.,Flucytosine,DB00065
DB01168,The risk or severity of adverse effects can be increased when Infliximab is combined with Procarbazine.,Procarbazine,DB00065
DB01169,The risk or severity of adverse effects can be increased when Infliximab is combined with Arsenic trioxide.,Arsenic trioxide,DB00065
DB01204,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitoxantrone.,Mitoxantrone,DB00065
DB01206,The risk or severity of adverse effects can be increased when Infliximab is combined with Lomustine.,Lomustine,DB00065
DB01257,The risk or severity of adverse effects can be increased when Infliximab is combined with Eculizumab.,Eculizumab,DB00065
DB01262,The risk or severity of adverse effects can be increased when Infliximab is combined with Decitabine.,Decitabine,DB00065
DB01280,The risk or severity of adverse effects can be increased when Infliximab is combined with Nelarabine.,Nelarabine,DB00065
DB01423,The risk or severity of adverse effects can be increased when Infliximab is combined with Stepronin.,Stepronin,DB00065
DB01816,The risk or severity of adverse effects can be increased when Infliximab is combined with Castanospermine.,Castanospermine,DB00065
DB02546,The risk or severity of adverse effects can be increased when Infliximab is combined with Vorinostat.,Vorinostat,DB00065
DB02806,The risk or severity of adverse effects can be increased when Infliximab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00065
DB03523,The risk or severity of adverse effects can be increased when Infliximab is combined with Brequinar.,Brequinar,DB00065
DB04956,The risk or severity of adverse effects can be increased when Infliximab is combined with Afelimomab.,Afelimomab,DB00065
DB05258,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa.,Interferon alfa,DB00065
DB05259,The risk or severity of adverse effects can be increased when Infliximab is combined with Glatiramer.,Glatiramer,DB00065
DB05260,The risk or severity of adverse effects can be increased when Infliximab is combined with Gallium nitrate.,Gallium nitrate,DB00065
DB05459,The risk or severity of adverse effects can be increased when Infliximab is combined with Briakinumab.,Briakinumab,DB00065
DB05472,The risk or severity of adverse effects can be increased when Infliximab is combined with omega interferon.,omega interferon,DB00065
DB06612,The risk or severity of adverse effects can be increased when Infliximab is combined with Mepolizumab.,Mepolizumab,DB00065
DB06662,The risk or severity of adverse effects can be increased when Infliximab is combined with Abetimus.,Abetimus,DB00065
DB06674,The risk or severity of adverse effects can be increased when Infliximab is combined with Golimumab.,Golimumab,DB00065
DB06681,The risk or severity of adverse effects can be increased when Infliximab is combined with Belatacept.,Belatacept,DB00065
DB06813,The risk or severity of adverse effects can be increased when Infliximab is combined with Pralatrexate.,Pralatrexate,DB00065
DB08059,The risk or severity of adverse effects can be increased when Infliximab is combined with Wortmannin.,Wortmannin,DB00065
DB08871,The risk or severity of adverse effects can be increased when Infliximab is combined with Eribulin.,Eribulin,DB00065
DB08879,The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.,Belimumab,DB00065
DB08880,The risk or severity of adverse effects can be increased when Infliximab is combined with Teriflunomide.,Teriflunomide,DB00065
DB08889,The risk or severity of adverse effects can be increased when Infliximab is combined with Carfilzomib.,Carfilzomib,DB00065
DB08908,The risk or severity of adverse effects can be increased when Infliximab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00065
DB08935,The risk or severity of adverse effects can be increased when Infliximab is combined with Obinutuzumab.,Obinutuzumab,DB00065
DB09029,The risk or severity of adverse effects can be increased when Infliximab is combined with Secukinumab.,Secukinumab,DB00065
DB09036,The risk or severity of adverse effects can be increased when Infliximab is combined with Siltuximab.,Siltuximab,DB00065
DB09052,The risk or severity of adverse effects can be increased when Infliximab is combined with Blinatumomab.,Blinatumomab,DB00065
DB09077,The risk or severity of adverse effects can be increased when Infliximab is combined with Dinutuximab.,Dinutuximab,DB00065
DB09091,The risk or severity of adverse effects can be increased when Infliximab is combined with Tixocortol.,Tixocortol,DB00065
DB09122,The risk or severity of adverse effects can be increased when Infliximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00065
DB09312,The risk or severity of adverse effects can be increased when Infliximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00065
DB11466,The risk or severity of adverse effects can be increased when Infliximab is combined with Tepoxalin.,Tepoxalin,DB00065
DB11569,The risk or severity of adverse effects can be increased when Infliximab is combined with Ixekizumab.,Ixekizumab,DB00065
DB11580,The risk or severity of adverse effects can be increased when Infliximab is combined with Ravulizumab.,Ravulizumab,DB00065
DB11616,The risk or severity of adverse effects can be increased when Infliximab is combined with Pirarubicin.,Pirarubicin,DB00065
DB11693,The risk or severity of adverse effects can be increased when Infliximab is combined with Voclosporin.,Voclosporin,DB00065
DB11708,The risk or severity of adverse effects can be increased when Infliximab is combined with Peficitinib.,Peficitinib,DB00065
DB11767,The risk or severity of adverse effects can be increased when Infliximab is combined with Sarilumab.,Sarilumab,DB00065
DB11776,The risk or severity of adverse effects can be increased when Infliximab is combined with Brodalumab.,Brodalumab,DB00065
DB11803,The risk or severity of adverse effects can be increased when Infliximab is combined with Sirukumab.,Sirukumab,DB00065
DB11834,The risk or severity of adverse effects can be increased when Infliximab is combined with Guselkumab.,Guselkumab,DB00065
DB12025,The risk or severity of adverse effects can be increased when Infliximab is combined with Triptolide.,Triptolide,DB00065
DB12612,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanimod.,Ozanimod,DB00065
DB12617,The risk or severity of adverse effects can be increased when Infliximab is combined with Mizoribine.,Mizoribine,DB00065
DB12692,The risk or severity of adverse effects can be increased when Infliximab is combined with Gusperimus.,Gusperimus,DB00065
DB12814,The risk or severity of adverse effects can be increased when Infliximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00065
DB12902,The risk or severity of adverse effects can be increased when Infliximab is combined with Trofosfamide.,Trofosfamide,DB00065
DB12947,The risk or severity of adverse effects can be increased when Infliximab is combined with Doxifluridine.,Doxifluridine,DB00065
DB12991,The risk or severity of adverse effects can be increased when Infliximab is combined with Deoxyspergualin.,Deoxyspergualin,DB00065
DB12996,The risk or severity of adverse effects can be increased when Infliximab is combined with Acteoside.,Acteoside,DB00065
DB13003,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortivazol.,Cortivazol,DB00065
DB13014,The risk or severity of adverse effects can be increased when Infliximab is combined with Hypericin.,Hypericin,DB00065
DB13068,The risk or severity of adverse effects can be increased when Infliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00065
DB13223,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortin.,Fluocortin,DB00065
DB13241,The risk or severity of adverse effects can be increased when Infliximab is combined with Begelomab.,Begelomab,DB00065
DB13491,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluperolone.,Fluperolone,DB00065
DB13664,The risk or severity of adverse effects can be increased when Infliximab is combined with Formocortal.,Formocortal,DB00065
DB13728,The risk or severity of adverse effects can be increased when Infliximab is combined with Halometasone.,Halometasone,DB00065
DB13843,The risk or severity of adverse effects can be increased when Infliximab is combined with Cloprednol.,Cloprednol,DB00065
DB13856,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluclorolone.,Fluclorolone,DB00065
DB14219,The risk or severity of adverse effects can be increased when Infliximab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00065
DB14724,The risk or severity of adverse effects can be increased when Infliximab is combined with Emapalumab.,Emapalumab,DB00065
DB14762,The risk or severity of adverse effects can be increased when Infliximab is combined with Risankizumab.,Risankizumab,DB00065
DB14919,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozanolixizumab.,Rozanolixizumab,DB00065
DB15253,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleselumab.,Bleselumab,DB00065
DB00180,The risk or severity of adverse effects can be increased when Infliximab is combined with Flunisolide.,Flunisolide,DB00065
DB00394,The risk or severity of adverse effects can be increased when Infliximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00065
DB00443,The risk or severity of adverse effects can be increased when Infliximab is combined with Betamethasone.,Betamethasone,DB00065
DB00591,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00065
DB00635,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisone.,Prednisone,DB00065
DB00687,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludrocortisone.,Fludrocortisone,DB00065
DB00764,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone.,Mometasone,DB00065
DB00860,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisolone.,Prednisolone,DB00065
DB00959,The risk or severity of adverse effects can be increased when Infliximab is combined with Methylprednisolone.,Methylprednisolone,DB00065
DB01196,The risk or severity of adverse effects can be increased when Infliximab is combined with Estramustine.,Estramustine,DB00065
DB01285,The risk or severity of adverse effects can be increased when Infliximab is combined with Corticotropin.,Corticotropin,DB00065
DB01380,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortisone acetate.,Cortisone acetate,DB00065
DB01384,The risk or severity of adverse effects can be increased when Infliximab is combined with Paramethasone.,Paramethasone,DB00065
DB01611,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00065
DB04630,The risk or severity of adverse effects can be increased when Infliximab is combined with Aldosterone.,Aldosterone,DB00065
DB08970,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednidene.,Fluprednidene,DB00065
DB08971,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortolone.,Fluocortolone,DB00065
DB09082,The risk or severity of adverse effects can be increased when Infliximab is combined with Vilanterol.,Vilanterol,DB00065
DB09378,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednisolone.,Fluprednisolone,DB00065
DB09383,The risk or severity of adverse effects can be increased when Infliximab is combined with Meprednisone.,Meprednisone,DB00065
DB11487,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00065
DB11529,The risk or severity of adverse effects can be increased when Infliximab is combined with Melengestrol.,Melengestrol,DB00065
DB11750,The risk or severity of adverse effects can be increased when Infliximab is combined with Clobetasol.,Clobetasol,DB00065
DB11817,The risk or severity of adverse effects can be increased when Infliximab is combined with Baricitinib.,Baricitinib,DB00065
DB11921,The risk or severity of adverse effects can be increased when Infliximab is combined with Deflazacort.,Deflazacort,DB00065
DB13208,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednylidene.,Prednylidene,DB00065
DB14066,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetrandrine.,Tetrandrine,DB00065
DB14512,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone furoate.,Mometasone furoate,DB00065
DB14545,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00065
DB01222,The risk or severity of adverse effects can be increased when Infliximab is combined with Budesonide.,Budesonide,DB00065
DB01394,The risk or severity of adverse effects can be increased when Infliximab is combined with Colchicine.,Colchicine,DB00065
DB00108,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.,Natalizumab,DB00065
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.,Pimecrolimus,DB00065
DB06372,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.,Rilonacept,DB00065
DB01656,Infliximab may increase the immunosuppressive activities of Roflumilast.,Roflumilast,DB00065
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.,Sipuleucel-T,DB00065
DB06273,Tocilizumab may increase the immunosuppressive activities of Infliximab.,Tocilizumab,DB00065
DB08895,The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.,Tofacitinib,DB00065
DB09033,The risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.,Vedolizumab,DB00065
DB00051,Adalimumab may increase the immunosuppressive activities of Infliximab.,Adalimumab,DB00065
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Infliximab.,Sulfamethoxazole,DB00065
DB00269,Chlorotrianisene may increase the thrombogenic activities of Infliximab.,Chlorotrianisene,DB00065
DB00655,Estrone may increase the thrombogenic activities of Infliximab.,Estrone,DB00065
DB00890,Dienestrol may increase the thrombogenic activities of Infliximab.,Dienestrol,DB00065
DB04573,Estriol may increase the thrombogenic activities of Infliximab.,Estriol,DB00065
DB04575,Quinestrol may increase the thrombogenic activities of Infliximab.,Quinestrol,DB00065
DB07931,Hexestrol may increase the thrombogenic activities of Infliximab.,Hexestrol,DB00065
DB09070,Tibolone may increase the thrombogenic activities of Infliximab.,Tibolone,DB00065
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Infliximab.,Polyestradiol phosphate,DB00065
DB11478,Zeranol may increase the thrombogenic activities of Infliximab.,Zeranol,DB00065
DB11674,Equol may increase the thrombogenic activities of Infliximab.,Equol,DB00065
DB12487,Promestriene may increase the thrombogenic activities of Infliximab.,Promestriene,DB00065
DB13143,Methallenestril may increase the thrombogenic activities of Infliximab.,Methallenestril,DB00065
DB13386,Epimestrol may increase the thrombogenic activities of Infliximab.,Epimestrol,DB00065
DB13418,Moxestrol may increase the thrombogenic activities of Infliximab.,Moxestrol,DB00065
DB15334,Biochanin A may increase the thrombogenic activities of Infliximab.,Biochanin A,DB00065
DB15335,Formononetin may increase the thrombogenic activities of Infliximab.,Formononetin,DB00065
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Infliximab.","Synthetic Conjugated Estrogens, A",DB00065
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Infliximab.","Synthetic Conjugated Estrogens, B",DB00065
DB09381,Esterified estrogens may increase the thrombogenic activities of Infliximab.,Esterified estrogens,DB00065
DB01097,The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.,Leflunomide,DB00065
DB00072,Trastuzumab may increase the neutropenic activities of Infliximab.,Trastuzumab,DB00065
DB08868,Infliximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00065
DB00864,Tacrolimus may increase the immunosuppressive activities of Infliximab.,Tacrolimus,DB00065
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Infliximab.,G17DT,DB00065
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Infliximab.,PEV3A,DB00065
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.,INGN 225,DB00065
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Infliximab.,Rindopepimut,DB00065
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Infliximab.,SRP 299,DB00065
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab.,GI-5005,DB00065
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Infliximab.,Vitespen,DB00065
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Infliximab.,TG4010,DB00065
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Infliximab.,Anthrax immune globulin human,DB00065
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Infliximab.","Rabies virus inactivated antigen, B",DB00065
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00065
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Infliximab.,Rotavirus vaccine,DB00065
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab.","Rabies virus inactivated antigen, A",DB00065
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00065
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00065
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00065
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00065
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00065
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00065
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Infliximab.,Typhoid Vi polysaccharide vaccine,DB00065
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.,Hepatitis A Vaccine,DB00065
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00065
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00065
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00065
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00065
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00065
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Infliximab.,Human rabies virus immune globulin,DB00065
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.,Hepatitis B Vaccine (Recombinant),DB00065
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Infliximab.,Tecemotide,DB00065
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Infliximab.,Typhoid vaccine,DB00065
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00065
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00065
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00065
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00065
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Infliximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00065
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00065
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00065
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Infliximab.,Vaccinia virus strain new york city board of health live antigen,DB00065
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Infliximab.,Pertussis vaccine,DB00065
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00065
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Infliximab.,Varicella Zoster Vaccine (Recombinant),DB00065
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Infliximab.,Modified vaccinia ankara,DB00065
DB11988,Ocrelizumab may increase the immunosuppressive activities of Infliximab.,Ocrelizumab,DB00065
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Infliximab.,Rubella virus vaccine,DB00065
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Infliximab.,Varicella Zoster Vaccine (Live/attenuated),DB00065
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain tice live antigen,DB00065
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain connaught live antigen,DB00065
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Infliximab.,Yellow Fever Vaccine,DB00065
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Infliximab.,Anthrax vaccine,DB00065
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Infliximab.,Typhoid Vaccine Live,DB00065
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00065
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Infliximab.,BCG vaccine,DB00065
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Infliximab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00065
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Infliximab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00065
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Infliximab.,Adenovirus type 7 vaccine live,DB00065
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.,Cetuximab,DB00065
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.,Human immunoglobulin G,DB00065
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Infliximab.,Omalizumab,DB00065
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Infliximab.,Abciximab,DB00065
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.,Indium In-111 satumomab pendetide,DB00065
DB00076,The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00065
DB00089,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.,Capromab pendetide,DB00065
DB00110,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.,Palivizumab,DB00065
DB00113,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00065
DB01269,The risk or severity of adverse effects can be increased when Infliximab is combined with Panitumumab.,Panitumumab,DB00065
DB01270,The risk or severity of adverse effects can be increased when Infliximab is combined with Ranibizumab.,Ranibizumab,DB00065
DB04901,The risk or severity of adverse effects can be increased when Infliximab is combined with Galiximab.,Galiximab,DB00065
DB04949,The risk or severity of adverse effects can be increased when Infliximab is combined with Pexelizumab.,Pexelizumab,DB00065
DB04958,The risk or severity of adverse effects can be increased when Infliximab is combined with Epratuzumab.,Epratuzumab,DB00065
DB04962,The risk or severity of adverse effects can be increased when Infliximab is combined with Bectumomab.,Bectumomab,DB00065
DB04964,The risk or severity of adverse effects can be increased when Infliximab is combined with Oregovomab.,Oregovomab,DB00065
DB04988,The risk or severity of adverse effects can be increased when Infliximab is combined with IGN311.,IGN311,DB00065
DB05006,The risk or severity of adverse effects can be increased when Infliximab is combined with Adecatumumab.,Adecatumumab,DB00065
DB05097,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab.,Labetuzumab,DB00065
DB05101,The risk or severity of adverse effects can be increased when Infliximab is combined with Matuzumab.,Matuzumab,DB00065
DB05111,The risk or severity of adverse effects can be increased when Infliximab is combined with Fontolizumab.,Fontolizumab,DB00065
DB05136,The risk or severity of adverse effects can be increased when Infliximab is combined with Bavituximab.,Bavituximab,DB00065
DB05139,The risk or severity of adverse effects can be increased when Infliximab is combined with CR002.,CR002,DB00065
DB05209,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozrolimupab.,Rozrolimupab,DB00065
DB05304,The risk or severity of adverse effects can be increased when Infliximab is combined with Girentuximab.,Girentuximab,DB00065
DB05336,The risk or severity of adverse effects can be increased when Infliximab is combined with Obiltoxaximab.,Obiltoxaximab,DB00065
DB05405,The risk or severity of adverse effects can be increased when Infliximab is combined with XTL-001.,XTL-001,DB00065
DB05437,The risk or severity of adverse effects can be increased when Infliximab is combined with NAV 1800.,NAV 1800,DB00065
DB05496,The risk or severity of adverse effects can be increased when Infliximab is combined with Otelixizumab.,Otelixizumab,DB00065
DB05545,The risk or severity of adverse effects can be increased when Infliximab is combined with AMG 108.,AMG 108,DB00065
DB05550,The risk or severity of adverse effects can be increased when Infliximab is combined with Iratumumab.,Iratumumab,DB00065
DB05555,The risk or severity of adverse effects can be increased when Infliximab is combined with Enokizumab.,Enokizumab,DB00065
DB05578,The risk or severity of adverse effects can be increased when Infliximab is combined with Ramucirumab.,Ramucirumab,DB00065
DB05595,The risk or severity of adverse effects can be increased when Infliximab is combined with Farletuzumab.,Farletuzumab,DB00065
DB05656,The risk or severity of adverse effects can be increased when Infliximab is combined with Veltuzumab.,Veltuzumab,DB00065
DB05793,The risk or severity of adverse effects can be increased when Infliximab is combined with PRO-542.,PRO-542,DB00065
DB05797,The risk or severity of adverse effects can be increased when Infliximab is combined with TNX-901.,TNX-901,DB00065
DB05889,The risk or severity of adverse effects can be increased when Infliximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00065
DB05892,The risk or severity of adverse effects can be increased when Infliximab is combined with RI 624.,RI 624,DB00065
DB05915,The risk or severity of adverse effects can be increased when Infliximab is combined with MYO-029.,MYO-029,DB00065
DB05916,The risk or severity of adverse effects can be increased when Infliximab is combined with CT-011.,CT-011,DB00065
DB05941,The risk or severity of adverse effects can be increased when Infliximab is combined with Leronlimab.,Leronlimab,DB00065
DB05996,The risk or severity of adverse effects can be increased when Infliximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00065
DB06043,The risk or severity of adverse effects can be increased when Infliximab is combined with Olaratumab.,Olaratumab,DB00065
DB06049,The risk or severity of adverse effects can be increased when Infliximab is combined with IPH 2101.,IPH 2101,DB00065
DB06050,The risk or severity of adverse effects can be increased when Infliximab is combined with TB-402.,TB-402,DB00065
DB06081,The risk or severity of adverse effects can be increased when Infliximab is combined with Caplacizumab.,Caplacizumab,DB00065
DB06101,The risk or severity of adverse effects can be increased when Infliximab is combined with IMC-1C11.,IMC-1C11,DB00065
DB06116,The risk or severity of adverse effects can be increased when Infliximab is combined with Eldelumab.,Eldelumab,DB00065
DB06162,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumiliximab.,Lumiliximab,DB00065
DB06186,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipilimumab.,Ipilimumab,DB00065
DB06192,The risk or severity of adverse effects can be increased when Infliximab is combined with Nimotuzumab.,Nimotuzumab,DB00065
DB06241,The risk or severity of adverse effects can be increased when Infliximab is combined with Clenoliximab.,Clenoliximab,DB00065
DB06304,The risk or severity of adverse effects can be increased when Infliximab is combined with BIIB015.,BIIB015,DB00065
DB06305,The risk or severity of adverse effects can be increased when Infliximab is combined with Sonepcizumab.,Sonepcizumab,DB00065
DB06310,The risk or severity of adverse effects can be increased when Infliximab is combined with Motavizumab.,Motavizumab,DB00065
DB06317,The risk or severity of adverse effects can be increased when Infliximab is combined with Elotuzumab.,Elotuzumab,DB00065
DB06318,The risk or severity of adverse effects can be increased when Infliximab is combined with AVE9633.,AVE9633,DB00065
DB06322,The risk or severity of adverse effects can be increased when Infliximab is combined with Carotuximab.,Carotuximab,DB00065
DB06324,The risk or severity of adverse effects can be increased when Infliximab is combined with XmAb 2513.,XmAb 2513,DB00065
DB06342,The risk or severity of adverse effects can be increased when Infliximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00065
DB06343,The risk or severity of adverse effects can be increased when Infliximab is combined with Teprotumumab.,Teprotumumab,DB00065
DB06360,The risk or severity of adverse effects can be increased when Infliximab is combined with Lucatumumab.,Lucatumumab,DB00065
DB06366,The risk or severity of adverse effects can be increased when Infliximab is combined with Pertuzumab.,Pertuzumab,DB00065
DB06371,The risk or severity of adverse effects can be increased when Infliximab is combined with Siplizumab.,Siplizumab,DB00065
DB06467,The risk or severity of adverse effects can be increased when Infliximab is combined with Apolizumab.,Apolizumab,DB00065
DB06474,The risk or severity of adverse effects can be increased when Infliximab is combined with Sibrotuzumab.,Sibrotuzumab,DB00065
DB06550,The risk or severity of adverse effects can be increased when Infliximab is combined with Bivatuzumab.,Bivatuzumab,DB00065
DB06557,The risk or severity of adverse effects can be increased when Infliximab is combined with Lerdelimumab.,Lerdelimumab,DB00065
DB06599,The risk or severity of adverse effects can be increased when Infliximab is combined with Lexatumumab.,Lexatumumab,DB00065
DB06602,The risk or severity of adverse effects can be increased when Infliximab is combined with Reslizumab.,Reslizumab,DB00065
DB06606,The risk or severity of adverse effects can be increased when Infliximab is combined with Teplizumab.,Teplizumab,DB00065
DB06607,The risk or severity of adverse effects can be increased when Infliximab is combined with Catumaxomab.,Catumaxomab,DB00065
DB06647,The risk or severity of adverse effects can be increased when Infliximab is combined with Volociximab.,Volociximab,DB00065
DB06650,The risk or severity of adverse effects can be increased when Infliximab is combined with Ofatumumab.,Ofatumumab,DB00065
DB08902,The risk or severity of adverse effects can be increased when Infliximab is combined with Raxibacumab.,Raxibacumab,DB00065
DB09035,The risk or severity of adverse effects can be increased when Infliximab is combined with Nivolumab.,Nivolumab,DB00065
DB09037,The risk or severity of adverse effects can be increased when Infliximab is combined with Pembrolizumab.,Pembrolizumab,DB00065
DB09045,The risk or severity of adverse effects can be increased when Infliximab is combined with Dulaglutide.,Dulaglutide,DB00065
DB09105,The risk or severity of adverse effects can be increased when Infliximab is combined with Asfotase alfa.,Asfotase alfa,DB00065
DB09264,The risk or severity of adverse effects can be increased when Infliximab is combined with Idarucizumab.,Idarucizumab,DB00065
DB09302,The risk or severity of adverse effects can be increased when Infliximab is combined with Alirocumab.,Alirocumab,DB00065
DB09303,The risk or severity of adverse effects can be increased when Infliximab is combined with Evolocumab.,Evolocumab,DB00065
DB09331,The risk or severity of adverse effects can be increased when Infliximab is combined with Daratumumab.,Daratumumab,DB00065
DB09559,The risk or severity of adverse effects can be increased when Infliximab is combined with Necitumumab.,Necitumumab,DB00065
DB11595,The risk or severity of adverse effects can be increased when Infliximab is combined with Atezolizumab.,Atezolizumab,DB00065
DB11604,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00065
DB11608,The risk or severity of adverse effects can be increased when Infliximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00065
DB11621,The risk or severity of adverse effects can be increased when Infliximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00065
DB11646,The risk or severity of adverse effects can be increased when Infliximab is combined with Conatumumab.,Conatumumab,DB00065
DB11657,The risk or severity of adverse effects can be increased when Infliximab is combined with Tabalumab.,Tabalumab,DB00065
DB11680,The risk or severity of adverse effects can be increased when Infliximab is combined with Ficlatuzumab.,Ficlatuzumab,DB00065
DB11685,The risk or severity of adverse effects can be increased when Infliximab is combined with Figitumumab.,Figitumumab,DB00065
DB11714,The risk or severity of adverse effects can be increased when Infliximab is combined with Durvalumab.,Durvalumab,DB00065
DB11715,The risk or severity of adverse effects can be increased when Infliximab is combined with Bapineuzumab.,Bapineuzumab,DB00065
DB11731,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00065
DB11746,The risk or severity of adverse effects can be increased when Infliximab is combined with Onartuzumab.,Onartuzumab,DB00065
DB11756,The risk or severity of adverse effects can be increased when Infliximab is combined with Solanezumab.,Solanezumab,DB00065
DB11771,The risk or severity of adverse effects can be increased when Infliximab is combined with Tremelimumab.,Tremelimumab,DB00065
DB11826,The risk or severity of adverse effects can be increased when Infliximab is combined with Lampalizumab.,Lampalizumab,DB00065
DB11840,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalotuzumab.,Dalotuzumab,DB00065
DB11849,The risk or severity of adverse effects can be increased when Infliximab is combined with Emibetuzumab.,Emibetuzumab,DB00065
DB11850,The risk or severity of adverse effects can be increased when Infliximab is combined with Ublituximab.,Ublituximab,DB00065
DB11856,The risk or severity of adverse effects can be increased when Infliximab is combined with Ligelizumab.,Ligelizumab,DB00065
DB11857,The risk or severity of adverse effects can be increased when Infliximab is combined with Seribantumab.,Seribantumab,DB00065
DB11862,The risk or severity of adverse effects can be increased when Infliximab is combined with Landogrozumab.,Landogrozumab,DB00065
DB11866,The risk or severity of adverse effects can be increased when Infliximab is combined with Romosozumab.,Romosozumab,DB00065
DB11884,The risk or severity of adverse effects can be increased when Infliximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00065
DB11914,The risk or severity of adverse effects can be increased when Infliximab is combined with Lebrikizumab.,Lebrikizumab,DB00065
DB11930,The risk or severity of adverse effects can be increased when Infliximab is combined with Varlilumab.,Varlilumab,DB00065
DB11945,The risk or severity of adverse effects can be increased when Infliximab is combined with Avelumab.,Avelumab,DB00065
DB11959,The risk or severity of adverse effects can be increased when Infliximab is combined with Crenezumab.,Crenezumab,DB00065
DB11972,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilotumumab.,Rilotumumab,DB00065
DB11976,The risk or severity of adverse effects can be increased when Infliximab is combined with Anifrolumab.,Anifrolumab,DB00065
DB12023,The risk or severity of adverse effects can be increased when Infliximab is combined with Benralizumab.,Benralizumab,DB00065
DB12034,The risk or severity of adverse effects can be increased when Infliximab is combined with Gantenerumab.,Gantenerumab,DB00065
DB12053,The risk or severity of adverse effects can be increased when Infliximab is combined with Visilizumab.,Visilizumab,DB00065
DB12077,The risk or severity of adverse effects can be increased when Infliximab is combined with Urelumab.,Urelumab,DB00065
DB12089,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00065
DB12090,The risk or severity of adverse effects can be increased when Infliximab is combined with Patritumab.,Patritumab,DB00065
DB12102,The risk or severity of adverse effects can be increased when Infliximab is combined with Fulranumab.,Fulranumab,DB00065
DB12104,The risk or severity of adverse effects can be increased when Infliximab is combined with Tarextumab.,Tarextumab,DB00065
DB12118,The risk or severity of adverse effects can be increased when Infliximab is combined with Sotatercept.,Sotatercept,DB00065
DB12119,The risk or severity of adverse effects can be increased when Infliximab is combined with Gevokizumab.,Gevokizumab,DB00065
DB12142,The risk or severity of adverse effects can be increased when Infliximab is combined with Duligotuzumab.,Duligotuzumab,DB00065
DB12152,The risk or severity of adverse effects can be increased when Infliximab is combined with Simtuzumab.,Simtuzumab,DB00065
DB12157,The risk or severity of adverse effects can be increased when Infliximab is combined with Fasinumab.,Fasinumab,DB00065
DB12159,The risk or severity of adverse effects can be increased when Infliximab is combined with Dupilumab.,Dupilumab,DB00065
DB12169,The risk or severity of adverse effects can be increased when Infliximab is combined with Tralokinumab.,Tralokinumab,DB00065
DB12189,The risk or severity of adverse effects can be increased when Infliximab is combined with Etrolizumab.,Etrolizumab,DB00065
DB12202,The risk or severity of adverse effects can be increased when Infliximab is combined with Zalutumumab.,Zalutumumab,DB00065
DB12205,The risk or severity of adverse effects can be increased when Infliximab is combined with Ganitumab.,Ganitumab,DB00065
DB12213,The risk or severity of adverse effects can be increased when Infliximab is combined with Etaracizumab.,Etaracizumab,DB00065
DB12246,The risk or severity of adverse effects can be increased when Infliximab is combined with Inclacumab.,Inclacumab,DB00065
DB12250,The risk or severity of adverse effects can be increased when Infliximab is combined with Cixutumumab.,Cixutumumab,DB00065
DB12261,The risk or severity of adverse effects can be increased when Infliximab is combined with Ascrinvacumab.,Ascrinvacumab,DB00065
DB12274,The risk or severity of adverse effects can be increased when Infliximab is combined with Aducanumab.,Aducanumab,DB00065
DB12281,The risk or severity of adverse effects can be increased when Infliximab is combined with Luspatercept.,Luspatercept,DB00065
DB12296,The risk or severity of adverse effects can be increased when Infliximab is combined with GS-5745.,GS-5745,DB00065
DB12317,The risk or severity of adverse effects can be increased when Infliximab is combined with Vanucizumab.,Vanucizumab,DB00065
DB12331,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00065
DB12335,The risk or severity of adverse effects can be increased when Infliximab is combined with Tanezumab.,Tanezumab,DB00065
DB12342,The risk or severity of adverse effects can be increased when Infliximab is combined with Ensituximab.,Ensituximab,DB00065
DB12344,The risk or severity of adverse effects can be increased when Infliximab is combined with Fezakinumab.,Fezakinumab,DB00065
DB12363,The risk or severity of adverse effects can be increased when Infliximab is combined with Dusigitumab.,Dusigitumab,DB00065
DB12396,The risk or severity of adverse effects can be increased when Infliximab is combined with Fresolimumab.,Fresolimumab,DB00065
DB12413,The risk or severity of adverse effects can be increased when Infliximab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00065
DB12456,The risk or severity of adverse effects can be increased when Infliximab is combined with Bococizumab.,Bococizumab,DB00065
DB12489,The risk or severity of adverse effects can be increased when Infliximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00065
DB12498,The risk or severity of adverse effects can be increased when Infliximab is combined with Mogamulizumab.,Mogamulizumab,DB00065
DB12520,The risk or severity of adverse effects can be increased when Infliximab is combined with Plozalizumab.,Plozalizumab,DB00065
DB12534,The risk or severity of adverse effects can be increased when Infliximab is combined with Mavrilimumab.,Mavrilimumab,DB00065
DB12560,The risk or severity of adverse effects can be increased when Infliximab is combined with Blosozumab.,Blosozumab,DB00065
DB12584,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimagrumab.,Bimagrumab,DB00065
DB12589,The risk or severity of adverse effects can be increased when Infliximab is combined with Dacetuzumab.,Dacetuzumab,DB00065
DB12609,The risk or severity of adverse effects can be increased when Infliximab is combined with Tovetumab.,Tovetumab,DB00065
DB12683,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumretuzumab.,Lumretuzumab,DB00065
DB12698,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibalizumab.,Ibalizumab,DB00065
DB12701,The risk or severity of adverse effects can be increased when Infliximab is combined with Intetumumab.,Intetumumab,DB00065
DB12718,The risk or severity of adverse effects can be increased when Infliximab is combined with Carlumab.,Carlumab,DB00065
DB12734,The risk or severity of adverse effects can be increased when Infliximab is combined with Demcizumab.,Demcizumab,DB00065
DB12773,The risk or severity of adverse effects can be increased when Infliximab is combined with Sifalimumab.,Sifalimumab,DB00065
DB12775,The risk or severity of adverse effects can be increased when Infliximab is combined with Abituzumab.,Abituzumab,DB00065
DB12797,The risk or severity of adverse effects can be increased when Infliximab is combined with Ecromeximab.,Ecromeximab,DB00065
DB12807,The risk or severity of adverse effects can be increased when Infliximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00065
DB12815,The risk or severity of adverse effects can be increased when Infliximab is combined with Crotedumab.,Crotedumab,DB00065
DB12820,The risk or severity of adverse effects can be increased when Infliximab is combined with Concizumab.,Concizumab,DB00065
DB12826,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab.,Depatuxizumab,DB00065
DB12844,The risk or severity of adverse effects can be increased when Infliximab is combined with Rontalizumab.,Rontalizumab,DB00065
DB12845,The risk or severity of adverse effects can be increased when Infliximab is combined with Amatuximab.,Amatuximab,DB00065
DB12849,The risk or severity of adverse effects can be increased when Infliximab is combined with Clazakizumab.,Clazakizumab,DB00065
DB12891,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanezumab.,Ozanezumab,DB00065
DB12893,The risk or severity of adverse effects can be increased when Infliximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00065
DB12917,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimekizumab.,Bimekizumab,DB00065
DB12943,The risk or severity of adverse effects can be increased when Infliximab is combined with Milatuzumab.,Milatuzumab,DB00065
DB12976,The risk or severity of adverse effects can be increased when Infliximab is combined with Robatumumab.,Robatumumab,DB00065
DB13017,The risk or severity of adverse effects can be increased when Infliximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00065
DB13037,The risk or severity of adverse effects can be increased when Infliximab is combined with Namilumab.,Namilumab,DB00065
DB13045,The risk or severity of adverse effects can be increased when Infliximab is combined with Racotumomab.,Racotumomab,DB00065
DB13073,The risk or severity of adverse effects can be increased when Infliximab is combined with Tregalizumab.,Tregalizumab,DB00065
DB13127,The risk or severity of adverse effects can be increased when Infliximab is combined with Olokizumab.,Olokizumab,DB00065
DB13140,The risk or severity of adverse effects can be increased when Infliximab is combined with Bezlotoxumab.,Bezlotoxumab,DB00065
DB13375,The risk or severity of adverse effects can be increased when Infliximab is combined with Edrecolomab.,Edrecolomab,DB00065
DB13535,The risk or severity of adverse effects can be increased when Infliximab is combined with Nebacumab.,Nebacumab,DB00065
DB13886,The risk or severity of adverse effects can be increased when Infliximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00065
DB13923,The risk or severity of adverse effects can be increased when Infliximab is combined with Emicizumab.,Emicizumab,DB00065
DB13976,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulesomab.,Sulesomab,DB00065
DB13979,The risk or severity of adverse effects can be increased when Infliximab is combined with Besilesomab.,Besilesomab,DB00065
DB14012,The risk or severity of adverse effects can be increased when Infliximab is combined with Burosumab.,Burosumab,DB00065
DB14039,The risk or severity of adverse effects can be increased when Infliximab is combined with Erenumab.,Erenumab,DB00065
DB14040,The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.,Eptinezumab,DB00065
DB14041,The risk or severity of adverse effects can be increased when Infliximab is combined with Fremanezumab.,Fremanezumab,DB00065
DB14042,The risk or severity of adverse effects can be increased when Infliximab is combined with Galcanezumab.,Galcanezumab,DB00065
DB14211,The risk or severity of adverse effects can be increased when Infliximab is combined with Fanolesomab.,Fanolesomab,DB00065
DB14580,The risk or severity of adverse effects can be increased when Infliximab is combined with Lecanemab.,Lecanemab,DB00065
DB14597,The risk or severity of adverse effects can be increased when Infliximab is combined with Lanadelumab.,Lanadelumab,DB00065
DB14707,The risk or severity of adverse effects can be increased when Infliximab is combined with Cemiplimab.,Cemiplimab,DB00065
DB14776,The risk or severity of adverse effects can be increased when Infliximab is combined with Camrelizumab.,Camrelizumab,DB00065
DB14778,The risk or severity of adverse effects can be increased when Infliximab is combined with Setrusumab.,Setrusumab,DB00065
DB14784,The risk or severity of adverse effects can be increased when Infliximab is combined with Gancotamab.,Gancotamab,DB00065
DB14809,The risk or severity of adverse effects can be increased when Infliximab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00065
DB14811,The risk or severity of adverse effects can be increased when Infliximab is combined with Isatuximab.,Isatuximab,DB00065
DB14824,The risk or severity of adverse effects can be increased when Infliximab is combined with Icrucumab.,Icrucumab,DB00065
DB14843,The risk or severity of adverse effects can be increased when Infliximab is combined with Codrituzumab.,Codrituzumab,DB00065
DB14864,The risk or severity of adverse effects can be increased when Infliximab is combined with Brolucizumab.,Brolucizumab,DB00065
DB14871,The risk or severity of adverse effects can be increased when Infliximab is combined with Xentuzumab.,Xentuzumab,DB00065
DB14877,The risk or severity of adverse effects can be increased when Infliximab is combined with Lintuzumab.,Lintuzumab,DB00065
DB14891,The risk or severity of adverse effects can be increased when Infliximab is combined with Vobarilizumab.,Vobarilizumab,DB00065
DB14897,The risk or severity of adverse effects can be increased when Infliximab is combined with Parsatuzumab.,Parsatuzumab,DB00065
DB14905,The risk or severity of adverse effects can be increased when Infliximab is combined with Emactuzumab.,Emactuzumab,DB00065
DB14907,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00065
DB14908,The risk or severity of adverse effects can be increased when Infliximab is combined with Refanezumab.,Refanezumab,DB00065
DB14947,The risk or severity of adverse effects can be increased when Infliximab is combined with Bermekimab.,Bermekimab,DB00065
DB14952,The risk or severity of adverse effects can be increased when Infliximab is combined with Pamrevlumab.,Pamrevlumab,DB00065
DB14959,The risk or severity of adverse effects can be increased when Infliximab is combined with Opicinumab.,Opicinumab,DB00065
DB14962,The risk or severity of adverse effects can be increased when Infliximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00065
DB14967,The risk or severity of adverse effects can be increased when Infliximab is combined with Margetuximab.,Margetuximab,DB00065
DB14988,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalantercept.,Dalantercept,DB00065
DB14997,The risk or severity of adverse effects can be increased when Infliximab is combined with Pateclizumab.,Pateclizumab,DB00065
DB15014,The risk or severity of adverse effects can be increased when Infliximab is combined with Gremubamab.,Gremubamab,DB00065
DB15022,The risk or severity of adverse effects can be increased when Infliximab is combined with Apomab.,Apomab,DB00065
DB15044,The risk or severity of adverse effects can be increased when Infliximab is combined with Tafasitamab.,Tafasitamab,DB00065
DB15045,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipafricept.,Ipafricept,DB00065
DB15076,The risk or severity of adverse effects can be increased when Infliximab is combined with Abrilumab.,Abrilumab,DB00065
DB15089,The risk or severity of adverse effects can be increased when Infliximab is combined with Frovocimab.,Frovocimab,DB00065
DB15090,The risk or severity of adverse effects can be increased when Infliximab is combined with Tezepelumab.,Tezepelumab,DB00065
DB15101,The risk or severity of adverse effects can be increased when Infliximab is combined with Tigatuzumab.,Tigatuzumab,DB00065
DB15104,The risk or severity of adverse effects can be increased when Infliximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00065
DB15113,The risk or severity of adverse effects can be increased when Infliximab is combined with Utomilumab.,Utomilumab,DB00065
DB15118,The risk or severity of adverse effects can be increased when Infliximab is combined with Zolbetuximab.,Zolbetuximab,DB00065
DB15135,The risk or severity of adverse effects can be increased when Infliximab is combined with Ponezumab.,Ponezumab,DB00065
DB15160,The risk or severity of adverse effects can be increased when Infliximab is combined with Asunercept.,Asunercept,DB00065
DB15172,The risk or severity of adverse effects can be increased when Infliximab is combined with Suvratoxumab.,Suvratoxumab,DB00065
DB15225,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitazalimab.,Mitazalimab,DB00065
DB15252,The risk or severity of adverse effects can be increased when Infliximab is combined with Nemolizumab.,Nemolizumab,DB00065
DB15277,The risk or severity of adverse effects can be increased when Infliximab is combined with Gedivumab.,Gedivumab,DB00065
DB15336,The risk or severity of adverse effects can be increased when Infliximab is combined with Valanafusp alfa.,Valanafusp alfa,DB00065
DB15349,The risk or severity of adverse effects can be increased when Infliximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00065
DB15354,The risk or severity of adverse effects can be increased when Infliximab is combined with Evinacumab.,Evinacumab,DB00065
DB15363,The risk or severity of adverse effects can be increased when Infliximab is combined with Istiratumab.,Istiratumab,DB00065
DB15383,The risk or severity of adverse effects can be increased when Infliximab is combined with Pidilizumab.,Pidilizumab,DB00065
DB15397,The risk or severity of adverse effects can be increased when Infliximab is combined with GMA-161.,GMA-161,DB00065
DB15409,The risk or severity of adverse effects can be increased when Infliximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00065
DB15415,The risk or severity of adverse effects can be increased when Infliximab is combined with Tomaralimab.,Tomaralimab,DB00065
DB15428,The risk or severity of adverse effects can be increased when Infliximab is combined with Vesencumab.,Vesencumab,DB00065
DB15432,The risk or severity of adverse effects can be increased when Infliximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00065
DB15441,The risk or severity of adverse effects can be increased when Infliximab is combined with Lulizumab pegol.,Lulizumab pegol,DB00065
DB15443,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00065
DB15453,The risk or severity of adverse effects can be increased when Infliximab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00065
DB14004,The risk or severity of adverse effects can be increased when Infliximab is combined with Tildrakizumab.,Tildrakizumab,DB00065
DB05679,The risk or severity of adverse effects can be increased when Infliximab is combined with Ustekinumab.,Ustekinumab,DB00065
DB12240,The risk or severity of adverse effects can be increased when Infliximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00065
DB15559,The risk or severity of adverse effects can be increased when Infliximab is combined with Zenocutuzumab.,Zenocutuzumab,DB00065
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Infliximab.",Somatotropin,DB00065
DB00080,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin.",Daptomycin,DB00065
DB00175,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pravastatin.",Pravastatin,DB00065
DB00181,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Baclofen.",Baclofen,DB00065
DB00282,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pamidronic acid.",Pamidronic acid,DB00065
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Carbimazole.",Carbimazole,DB00065
DB00537,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofloxacin.",Ciprofloxacin,DB00065
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nizatidine.",Nizatidine,DB00065
DB00627,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Niacin.",Niacin,DB00065
DB00630,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid.",Alendronic acid,DB00065
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Stavudine.",Stavudine,DB00065
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nafarelin.",Nafarelin,DB00065
DB00681,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Amphotericin B.",Amphotericin B,DB00065
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Naltrexone.",Naltrexone,DB00065
DB00709,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Lamivudine.",Lamivudine,DB00065
DB00710,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ibandronate.",Ibandronate,DB00065
DB00876,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Eprosartan.",Eprosartan,DB00065
DB00884,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Risedronic acid.",Risedronic acid,DB00065
DB00887,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bumetanide.",Bumetanide,DB00065
DB00951,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isoniazid.",Isoniazid,DB00065
DB00968,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Methyldopa.",Methyldopa,DB00065
DB01004,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ganciclovir.",Ganciclovir,DB00065
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Minocycline.",Minocycline,DB00065
DB01059,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Norfloxacin.",Norfloxacin,DB00065
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Iloprost.",Iloprost,DB00065
DB01165,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ofloxacin.",Ofloxacin,DB00065
DB06693,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mevastatin.",Mevastatin,DB00065
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Raltegravir.",Raltegravir,DB00065
DB08983,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Etofibrate.",Etofibrate,DB00065
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Acipimox.",Acipimox,DB00065
DB09064,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofibrate.",Ciprofibrate,DB00065
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ubidecarenone.",Ubidecarenone,DB00065
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mebeverine.",Mebeverine,DB00065
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Emetine.",Emetine,DB00065
DB13433,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Simfibrate.",Simfibrate,DB00065
DB13460,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ronifibrate.",Ronifibrate,DB00065
DB13780,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Aluminium clofibrate.",Aluminium clofibrate,DB00065
DB13849,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibride.",Clofibride,DB00065
DB13873,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Fenofibric acid.",Fenofibric acid,DB00065
DB00007,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab.",Leuprolide,DB00065
DB00358,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mefloquine.",Mefloquine,DB00065
DB00501,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Cimetidine.",Cimetidine,DB00065
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Enalapril.",Enalapril,DB00065
DB00602,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ivermectin.",Ivermectin,DB00065
DB00636,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibrate.",Clofibrate,DB00065
DB00982,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isotretinoin.",Isotretinoin,DB00065
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Captopril.",Captopril,DB00065
DB01241,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Gemfibrozil.",Gemfibrozil,DB00065
DB01393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bezafibrate.",Bezafibrate,DB00065
DB00201,The metabolism of Caffeine can be increased when combined with Infliximab.,Caffeine,DB00065
DB00176,The metabolism of Fluvoxamine can be increased when combined with Infliximab.,Fluvoxamine,DB00065
DB00195,The metabolism of Betaxolol can be increased when combined with Infliximab.,Betaxolol,DB00065
DB00261,The metabolism of Anagrelide can be increased when combined with Infliximab.,Anagrelide,DB00065
DB00262,The metabolism of Carmustine can be increased when combined with Infliximab.,Carmustine,DB00065
DB00268,The metabolism of Ropinirole can be increased when combined with Infliximab.,Ropinirole,DB00065
DB00280,The metabolism of Disopyramide can be increased when combined with Infliximab.,Disopyramide,DB00065
DB00286,The metabolism of Conjugated estrogens can be increased when combined with Infliximab.,Conjugated estrogens,DB00065
DB00296,The metabolism of Ropivacaine can be increased when combined with Infliximab.,Ropivacaine,DB00065
DB00315,The metabolism of Zolmitriptan can be increased when combined with Infliximab.,Zolmitriptan,DB00065
DB00316,The metabolism of Acetaminophen can be increased when combined with Infliximab.,Acetaminophen,DB00065
DB00334,The metabolism of Olanzapine can be increased when combined with Infliximab.,Olanzapine,DB00065
DB00356,The metabolism of Chlorzoxazone can be increased when combined with Infliximab.,Chlorzoxazone,DB00065
DB00365,The metabolism of Grepafloxacin can be increased when combined with Infliximab.,Grepafloxacin,DB00065
DB00370,The metabolism of Mirtazapine can be increased when combined with Infliximab.,Mirtazapine,DB00065
DB00379,The metabolism of Mexiletine can be increased when combined with Infliximab.,Mexiletine,DB00065
DB00382,The metabolism of Tacrine can be increased when combined with Infliximab.,Tacrine,DB00065
DB00384,The metabolism of Triamterene can be increased when combined with Infliximab.,Triamterene,DB00065
DB00442,The metabolism of Entecavir can be increased when combined with Infliximab.,Entecavir,DB00065
DB00477,The metabolism of Chlorpromazine can be increased when combined with Infliximab.,Chlorpromazine,DB00065
DB00518,The metabolism of Albendazole can be increased when combined with Infliximab.,Albendazole,DB00065
DB00544,The metabolism of Fluorouracil can be increased when combined with Infliximab.,Fluorouracil,DB00065
DB00629,The metabolism of Guanabenz can be increased when combined with Infliximab.,Guanabenz,DB00065
DB00642,The metabolism of Pemetrexed can be increased when combined with Infliximab.,Pemetrexed,DB00065
DB00730,The metabolism of Thiabendazole can be increased when combined with Infliximab.,Thiabendazole,DB00065
DB00740,The metabolism of Riluzole can be increased when combined with Infliximab.,Riluzole,DB00065
DB00787,The metabolism of Acyclovir can be increased when combined with Infliximab.,Acyclovir,DB00065
DB00806,The metabolism of Pentoxifylline can be increased when combined with Infliximab.,Pentoxifylline,DB00065
DB00831,The metabolism of Trifluoperazine can be increased when combined with Infliximab.,Trifluoperazine,DB00065
DB00863,The metabolism of Ranitidine can be increased when combined with Infliximab.,Ranitidine,DB00065
DB00898,The metabolism of Ethanol can be increased when combined with Infliximab.,Ethanol,DB00065
DB00934,The metabolism of Maprotiline can be increased when combined with Infliximab.,Maprotiline,DB00065
DB00978,The metabolism of Lomefloxacin can be increased when combined with Infliximab.,Lomefloxacin,DB00065
DB00993,The metabolism of Azathioprine can be increased when combined with Infliximab.,Azathioprine,DB00065
DB00998,The metabolism of Frovatriptan can be increased when combined with Infliximab.,Frovatriptan,DB00065
DB01002,The metabolism of Levobupivacaine can be increased when combined with Infliximab.,Levobupivacaine,DB00065
DB01012,The metabolism of Cinacalcet can be increased when combined with Infliximab.,Cinacalcet,DB00065
DB01056,The metabolism of Tocainide can be increased when combined with Infliximab.,Tocainide,DB00065
DB01087,The metabolism of Primaquine can be increased when combined with Infliximab.,Primaquine,DB00065
DB01094,The metabolism of Hesperetin can be increased when combined with Infliximab.,Hesperetin,DB00065
DB01182,The metabolism of Propafenone can be increased when combined with Infliximab.,Propafenone,DB00065
DB01191,The metabolism of Dexfenfluramine can be increased when combined with Infliximab.,Dexfenfluramine,DB00065
DB01303,The metabolism of Oxtriphylline can be increased when combined with Infliximab.,Oxtriphylline,DB00065
DB01367,The metabolism of Rasagiline can be increased when combined with Infliximab.,Rasagiline,DB00065
DB01405,The metabolism of Temafloxacin can be increased when combined with Infliximab.,Temafloxacin,DB00065
DB01412,The metabolism of Theobromine can be increased when combined with Infliximab.,Theobromine,DB00065
DB01482,The metabolism of Fenethylline can be increased when combined with Infliximab.,Fenethylline,DB00065
DB01558,The metabolism of Bromazepam can be increased when combined with Infliximab.,Bromazepam,DB00065
DB01623,The metabolism of Thiothixene can be increased when combined with Infliximab.,Thiothixene,DB00065
DB01645,The metabolism of Genistein can be increased when combined with Infliximab.,Genistein,DB00065
DB01667,The metabolism of 8-azaguanine can be increased when combined with Infliximab.,8-azaguanine,DB00065
DB02134,The metabolism of Xanthine can be increased when combined with Infliximab.,Xanthine,DB00065
DB02489,The metabolism of 9-Methylguanine can be increased when combined with Infliximab.,9-Methylguanine,DB00065
DB02568,The metabolism of Peldesine can be increased when combined with Infliximab.,Peldesine,DB00065
DB02709,The metabolism of Resveratrol can be increased when combined with Infliximab.,Resveratrol,DB00065
DB04076,The metabolism of Hypoxanthine can be increased when combined with Infliximab.,Hypoxanthine,DB00065
DB04356,The metabolism of 9-Deazaguanine can be increased when combined with Infliximab.,9-Deazaguanine,DB00065
DB04871,The metabolism of Lorcaserin can be increased when combined with Infliximab.,Lorcaserin,DB00065
DB04948,The metabolism of Lofexidine can be increased when combined with Infliximab.,Lofexidine,DB00065
DB04951,The metabolism of Pirfenidone can be increased when combined with Infliximab.,Pirfenidone,DB00065
DB06148,The metabolism of Mianserin can be increased when combined with Infliximab.,Mianserin,DB00065
DB06210,The metabolism of Eltrombopag can be increased when combined with Infliximab.,Eltrombopag,DB00065
DB06216,The metabolism of Asenapine can be increased when combined with Infliximab.,Asenapine,DB00065
DB06235,The metabolism of Vadimezan can be increased when combined with Infliximab.,Vadimezan,DB00065
DB06479,The metabolism of Propentofylline can be increased when combined with Infliximab.,Propentofylline,DB00065
DB06594,The metabolism of Agomelatine can be increased when combined with Infliximab.,Agomelatine,DB00065
DB06769,The metabolism of Bendamustine can be increased when combined with Infliximab.,Bendamustine,DB00065
DB06770,The metabolism of Benzyl alcohol can be increased when combined with Infliximab.,Benzyl alcohol,DB00065
DB06774,The metabolism of Capsaicin can be increased when combined with Infliximab.,Capsaicin,DB00065
DB08496,The metabolism of (R)-warfarin can be increased when combined with Infliximab.,(R)-warfarin,DB00065
DB09071,The metabolism of Tasimelteon can be increased when combined with Infliximab.,Tasimelteon,DB00065
DB09118,The metabolism of Stiripentol can be increased when combined with Infliximab.,Stiripentol,DB00065
DB09225,The metabolism of Zotepine can be increased when combined with Infliximab.,Zotepine,DB00065
DB09273,The metabolism of Doxofylline can be increased when combined with Infliximab.,Doxofylline,DB00065
DB09290,The metabolism of Ramosetron can be increased when combined with Infliximab.,Ramosetron,DB00065
DB11919,The metabolism of 6-O-benzylguanine can be increased when combined with Infliximab.,6-O-benzylguanine,DB00065
DB11967,The metabolism of Binimetinib can be increased when combined with Infliximab.,Binimetinib,DB00065
DB12026,The metabolism of Voxilaprevir can be increased when combined with Infliximab.,Voxilaprevir,DB00065
DB12245,The metabolism of Triclabendazole can be increased when combined with Infliximab.,Triclabendazole,DB00065
DB12332,The metabolism of Rucaparib can be increased when combined with Infliximab.,Rucaparib,DB00065
DB12406,The metabolism of Lisofylline can be increased when combined with Infliximab.,Lisofylline,DB00065
DB12531,The metabolism of Lobucavir can be increased when combined with Infliximab.,Lobucavir,DB00065
DB12926,The metabolism of Cafedrine can be increased when combined with Infliximab.,Cafedrine,DB00065
DB12927,The metabolism of Theodrenaline can be increased when combined with Infliximab.,Theodrenaline,DB00065
DB12945,The metabolism of Dihydralazine can be increased when combined with Infliximab.,Dihydralazine,DB00065
DB13203,The metabolism of Bamifylline can be increased when combined with Infliximab.,Bamifylline,DB00065
DB13449,The metabolism of Proxyphylline can be increased when combined with Infliximab.,Proxyphylline,DB00065
DB13573,The metabolism of Acefylline can be increased when combined with Infliximab.,Acefylline,DB00065
DB13592,The metabolism of Etamiphylline can be increased when combined with Infliximab.,Etamiphylline,DB00065
DB13634,The metabolism of Pentifylline can be increased when combined with Infliximab.,Pentifylline,DB00065
DB13812,The metabolism of Bufylline can be increased when combined with Infliximab.,Bufylline,DB00065
DB14018,The metabolism of Bromotheophylline can be increased when combined with Infliximab.,Bromotheophylline,DB00065
DB14132,The metabolism of 8-chlorotheophylline can be increased when combined with Infliximab.,8-chlorotheophylline,DB00065
DB11757,The metabolism of Istradefylline can be increased when combined with Infliximab.,Istradefylline,DB00065
DB04889,The metabolism of Bicifadine can be increased when combined with Infliximab.,Bicifadine,DB00065
DB05708,The metabolism of GTS-21 can be increased when combined with Infliximab.,GTS-21,DB00065
DB00977,The metabolism of Infliximab can be increased when combined with Ethinylestradiol.,Ethinylestradiol,DB00065
DB00425,The metabolism of Zolpidem can be increased when combined with Infliximab.,Zolpidem,DB00065
DB00458,The metabolism of Imipramine can be increased when combined with Infliximab.,Imipramine,DB00065
DB00532,The metabolism of Mephenytoin can be increased when combined with Infliximab.,Mephenytoin,DB00065
DB00540,The metabolism of Nortriptyline can be increased when combined with Infliximab.,Nortriptyline,DB00065
DB00575,The metabolism of Clonidine can be increased when combined with Infliximab.,Clonidine,DB00065
DB00924,The metabolism of Cyclobenzaprine can be increased when combined with Infliximab.,Cyclobenzaprine,DB00065
DB01242,The metabolism of Clomipramine can be increased when combined with Infliximab.,Clomipramine,DB00065
DB11689,The metabolism of Selumetinib can be increased when combined with Infliximab.,Selumetinib,DB00065
DB00277,The metabolism of Theophylline can be increased when combined with Infliximab.,Theophylline,DB00065
DB00564,The metabolism of Carbamazepine can be increased when combined with Infliximab.,Carbamazepine,DB00065
DB00682,The metabolism of Warfarin can be increased when combined with Infliximab.,Warfarin,DB00065
DB00697,The metabolism of Tizanidine can be increased when combined with Infliximab.,Tizanidine,DB00065
DB01100,The metabolism of Pimozide can be increased when combined with Infliximab.,Pimozide,DB00065
DB01223,The metabolism of Aminophylline can be increased when combined with Infliximab.,Aminophylline,DB00065
DB01418,The metabolism of Acenocoumarol can be increased when combined with Infliximab.,Acenocoumarol,DB00065
DB09256,The metabolism of Tegafur can be increased when combined with Infliximab.,Tegafur,DB00065
DB00851,The metabolism of Dacarbazine can be increased when combined with Infliximab.,Dacarbazine,DB00065
DB08910,The metabolism of Pomalidomide can be increased when combined with Infliximab.,Pomalidomide,DB00065
DB00238,The metabolism of Nevirapine can be increased when combined with Infliximab.,Nevirapine,DB00065
DB00690,The metabolism of Flurazepam can be increased when combined with Infliximab.,Flurazepam,DB00065
DB00916,The metabolism of Metronidazole can be increased when combined with Infliximab.,Metronidazole,DB00065
DB00983,The metabolism of Formoterol can be increased when combined with Infliximab.,Formoterol,DB00065
DB01006,The metabolism of Letrozole can be increased when combined with Infliximab.,Letrozole,DB00065
DB01028,The metabolism of Methoxyflurane can be increased when combined with Infliximab.,Methoxyflurane,DB00065
DB01159,The metabolism of Halothane can be increased when combined with Infliximab.,Halothane,DB00065
DB01236,The metabolism of Sevoflurane can be increased when combined with Infliximab.,Sevoflurane,DB00065
DB01274,The metabolism of Arformoterol can be increased when combined with Infliximab.,Arformoterol,DB00065
DB01544,The metabolism of Flunitrazepam can be increased when combined with Infliximab.,Flunitrazepam,DB00065
DB06292,The metabolism of Dapagliflozin can be increased when combined with Infliximab.,Dapagliflozin,DB00065
DB06470,The metabolism of Clomethiazole can be increased when combined with Infliximab.,Clomethiazole,DB00065
DB09068,The metabolism of Vortioxetine can be increased when combined with Infliximab.,Vortioxetine,DB00065
DB09327,The metabolism of Tegafur-uracil can be increased when combined with Infliximab.,Tegafur-uracil,DB00065
DB11586,The metabolism of Asunaprevir can be increased when combined with Infliximab.,Asunaprevir,DB00065
DB04977,The metabolism of Plitidepsin can be increased when combined with Infliximab.,Plitidepsin,DB00065
DB06119,The metabolism of Cenobamate can be increased when combined with Infliximab.,Cenobamate,DB00065
DB00193,The metabolism of Tramadol can be increased when combined with Infliximab.,Tramadol,DB00065
DB00333,The metabolism of Methadone can be increased when combined with Infliximab.,Methadone,DB00065
DB00349,The metabolism of Clobazam can be increased when combined with Infliximab.,Clobazam,DB00065
DB00625,The metabolism of Efavirenz can be increased when combined with Infliximab.,Efavirenz,DB00065
DB00753,The metabolism of Isoflurane can be increased when combined with Infliximab.,Isoflurane,DB00065
DB00835,The metabolism of Brompheniramine can be increased when combined with Infliximab.,Brompheniramine,DB00065
DB00836,The metabolism of Loperamide can be increased when combined with Infliximab.,Loperamide,DB00065
DB00849,The metabolism of Methylphenobarbital can be increased when combined with Infliximab.,Methylphenobarbital,DB00065
DB00865,The metabolism of Benzphetamine can be increased when combined with Infliximab.,Benzphetamine,DB00065
DB01069,The metabolism of Promethazine can be increased when combined with Infliximab.,Promethazine,DB00065
DB01074,The metabolism of Perhexiline can be increased when combined with Infliximab.,Perhexiline,DB00065
DB01221,The metabolism of Ketamine can be increased when combined with Infliximab.,Ketamine,DB00065
DB01466,The metabolism of Ethylmorphine can be increased when combined with Infliximab.,Ethylmorphine,DB00065
DB01559,The metabolism of Clotiazepam can be increased when combined with Infliximab.,Clotiazepam,DB00065
DB04938,The metabolism of Ospemifene can be increased when combined with Infliximab.,Ospemifene,DB00065
DB04975,The metabolism of Banoxantrone can be increased when combined with Infliximab.,Banoxantrone,DB00065
DB05541,The metabolism of Brivaracetam can be increased when combined with Infliximab.,Brivaracetam,DB00065
DB06176,The metabolism of Romidepsin can be increased when combined with Infliximab.,Romidepsin,DB00065
DB06209,The metabolism of Prasugrel can be increased when combined with Infliximab.,Prasugrel,DB00065
DB06697,The metabolism of Artemether can be increased when combined with Infliximab.,Artemether,DB00065
DB06710,The metabolism of Methyltestosterone can be increased when combined with Infliximab.,Methyltestosterone,DB00065
DB06738,The metabolism of Ketobemidone can be increased when combined with Infliximab.,Ketobemidone,DB00065
DB06739,The metabolism of Seratrodast can be increased when combined with Infliximab.,Seratrodast,DB00065
DB11613,The metabolism of Velpatasvir can be increased when combined with Infliximab.,Velpatasvir,DB00065
DB13132,The metabolism of Artemisinin can be increased when combined with Infliximab.,Artemisinin,DB00065
DB13943,The metabolism of Testosterone cypionate can be increased when combined with Infliximab.,Testosterone cypionate,DB00065
DB13944,The metabolism of Testosterone enanthate can be increased when combined with Infliximab.,Testosterone enanthate,DB00065
DB13946,The metabolism of Testosterone undecanoate can be increased when combined with Infliximab.,Testosterone undecanoate,DB00065
DB01156,The metabolism of Bupropion can be increased when combined with Infliximab.,Bupropion,DB00065
DB00956,The metabolism of Hydrocodone can be increased when combined with Infliximab.,Hydrocodone,DB00065
DB14975,The metabolism of Voxelotor can be increased when combined with Infliximab.,Voxelotor,DB00065
DB11837,The metabolism of Osilodrostat can be increased when combined with Infliximab.,Osilodrostat,DB00065
DB13384,The metabolism of Melitracen can be increased when combined with Infliximab.,Melitracen,DB00065
DB13411,The metabolism of Lofepramine can be increased when combined with Infliximab.,Lofepramine,DB00065
DB00714,The metabolism of Apomorphine can be increased when combined with Infliximab.,Apomorphine,DB00065
DB09167,The metabolism of Dosulepin can be increased when combined with Infliximab.,Dosulepin,DB00065
DB00213,The metabolism of Pantoprazole can be increased when combined with Infliximab.,Pantoprazole,DB00065
DB00215,The metabolism of Citalopram can be increased when combined with Infliximab.,Citalopram,DB00065
DB00312,The metabolism of Pentobarbital can be increased when combined with Infliximab.,Pentobarbital,DB00065
DB00338,The metabolism of Omeprazole can be increased when combined with Infliximab.,Omeprazole,DB00065
DB00347,The metabolism of Trimethadione can be increased when combined with Infliximab.,Trimethadione,DB00065
DB00395,The metabolism of Carisoprodol can be increased when combined with Infliximab.,Carisoprodol,DB00065
DB00448,The metabolism of Lansoprazole can be increased when combined with Infliximab.,Lansoprazole,DB00065
DB00474,The metabolism of Methohexital can be increased when combined with Infliximab.,Methohexital,DB00065
DB00582,The metabolism of Voriconazole can be increased when combined with Infliximab.,Voriconazole,DB00065
DB00679,The metabolism of Thioridazine can be increased when combined with Infliximab.,Thioridazine,DB00065
DB00736,The metabolism of Esomeprazole can be increased when combined with Infliximab.,Esomeprazole,DB00065
DB00794,The metabolism of Primidone can be increased when combined with Infliximab.,Primidone,DB00065
DB00909,The metabolism of Zonisamide can be increased when combined with Infliximab.,Zonisamide,DB00065
DB01129,The metabolism of Rabeprazole can be increased when combined with Infliximab.,Rabeprazole,DB00065
DB01131,The metabolism of Proguanil can be increased when combined with Infliximab.,Proguanil,DB00065
DB01175,The metabolism of Escitalopram can be increased when combined with Infliximab.,Escitalopram,DB00065
DB01259,The metabolism of Lapatinib can be increased when combined with Infliximab.,Lapatinib,DB00065
DB01323,The metabolism of St. John's Wort can be increased when combined with Infliximab.,St. John's Wort,DB00065
DB01355,The metabolism of Hexobarbital can be increased when combined with Infliximab.,Hexobarbital,DB00065
DB01483,The metabolism of Barbital can be increased when combined with Infliximab.,Barbital,DB00065
DB05246,The metabolism of Methsuximide can be increased when combined with Infliximab.,Methsuximide,DB00065
DB05351,The metabolism of Dexlansoprazole can be increased when combined with Infliximab.,Dexlansoprazole,DB00065
DB06218,The metabolism of Lacosamide can be increased when combined with Infliximab.,Lacosamide,DB00065
DB06414,The metabolism of Etravirine can be increased when combined with Infliximab.,Etravirine,DB00065
DB06605,The metabolism of Apixaban can be increased when combined with Infliximab.,Apixaban,DB00065
DB09166,The metabolism of Etizolam can be increased when combined with Infliximab.,Etizolam,DB00065
DB12130,The metabolism of Lorlatinib can be increased when combined with Infliximab.,Lorlatinib,DB00065
DB12474,The metabolism of Lynestrenol can be increased when combined with Infliximab.,Lynestrenol,DB00065
DB13762,The metabolism of Dexrabeprazole can be increased when combined with Infliximab.,Dexrabeprazole,DB00065
DB14055,The metabolism of (S)-Warfarin can be increased when combined with Infliximab.,(S)-Warfarin,DB00065
DB00715,The metabolism of Paroxetine can be increased when combined with Infliximab.,Paroxetine,DB00065
DB12500,The metabolism of Fedratinib can be increased when combined with Infliximab.,Fedratinib,DB00065
DB04861,The metabolism of Nebivolol can be increased when combined with Infliximab.,Nebivolol,DB00065
DB06684,The metabolism of Vilazodone can be increased when combined with Infliximab.,Vilazodone,DB00065
DB01104,The metabolism of Sertraline can be increased when combined with Infliximab.,Sertraline,DB00065
DB11823,The metabolism of Esketamine can be increased when combined with Infliximab.,Esketamine,DB00065
DB00252,The metabolism of Phenytoin can be increased when combined with Infliximab.,Phenytoin,DB00065
DB00599,The metabolism of Thiopental can be increased when combined with Infliximab.,Thiopental,DB00065
DB01174,The metabolism of Phenobarbital can be increased when combined with Infliximab.,Phenobarbital,DB00065
DB01320,The metabolism of Fosphenytoin can be increased when combined with Infliximab.,Fosphenytoin,DB00065
DB00613,The metabolism of Amodiaquine can be increased when combined with Infliximab.,Amodiaquine,DB00065
DB00799,The metabolism of Tazarotene can be increased when combined with Infliximab.,Tazarotene,DB00065
DB05229,The metabolism of Beraprost can be increased when combined with Infliximab.,Beraprost,DB00065
DB06510,The metabolism of Muraglitazar can be increased when combined with Infliximab.,Muraglitazar,DB00065
DB09296,The metabolism of Ombitasvir can be increased when combined with Infliximab.,Ombitasvir,DB00065
DB01217,The metabolism of Anastrozole can be increased when combined with Infliximab.,Anastrozole,DB00065
DB00255,The metabolism of Infliximab can be increased when combined with Diethylstilbestrol.,Diethylstilbestrol,DB00065
DB00295,The metabolism of Morphine can be increased when combined with Infliximab.,Morphine,DB00065
DB00359,The metabolism of Sulfadiazine can be increased when combined with Infliximab.,Sulfadiazine,DB00065
DB00402,The metabolism of Eszopiclone can be increased when combined with Infliximab.,Eszopiclone,DB00065
DB00622,The metabolism of Nicardipine can be increased when combined with Infliximab.,Nicardipine,DB00065
DB00912,The metabolism of Repaglinide can be increased when combined with Infliximab.,Repaglinide,DB00065
DB01261,The metabolism of Sitagliptin can be increased when combined with Infliximab.,Sitagliptin,DB00065
DB06670,The metabolism of Odanacatib can be increased when combined with Infliximab.,Odanacatib,DB00065
DB08502,The metabolism of Capravirine can be increased when combined with Infliximab.,Capravirine,DB00065
DB08931,The metabolism of Riociguat can be increased when combined with Infliximab.,Riociguat,DB00065
DB09198,The metabolism of Lobeglitazone can be increased when combined with Infliximab.,Lobeglitazone,DB00065
DB09199,The metabolism of Netoglitazone can be increased when combined with Infliximab.,Netoglitazone,DB00065
DB09200,The metabolism of Rivoglitazone can be increased when combined with Infliximab.,Rivoglitazone,DB00065
DB09201,The metabolism of Ciglitazone can be increased when combined with Infliximab.,Ciglitazone,DB00065
DB11362,The metabolism of Selexipag can be increased when combined with Infliximab.,Selexipag,DB00065
DB11901,The metabolism of Apalutamide can be increased when combined with Infliximab.,Apalutamide,DB00065
DB11978,The metabolism of Glasdegib can be increased when combined with Infliximab.,Glasdegib,DB00065
DB12781,The metabolism of Balaglitazone can be increased when combined with Infliximab.,Balaglitazone,DB00065
DB01132,The metabolism of Pioglitazone can be increased when combined with Infliximab.,Pioglitazone,DB00065
DB11652,The metabolism of Tucatinib can be increased when combined with Infliximab.,Tucatinib,DB00065
DB00946,The metabolism of Phenprocoumon can be increased when combined with Infliximab.,Phenprocoumon,DB00065
DB01229,The metabolism of Paclitaxel can be increased when combined with Infliximab.,Paclitaxel,DB00065
DB00177,The metabolism of Valsartan can be increased when combined with Infliximab.,Valsartan,DB00065
DB00184,The metabolism of Nicotine can be increased when combined with Infliximab.,Nicotine,DB00065
DB00197,The metabolism of Troglitazone can be increased when combined with Infliximab.,Troglitazone,DB00065
DB00214,The metabolism of Torasemide can be increased when combined with Infliximab.,Torasemide,DB00065
DB00222,The metabolism of Glimepiride can be increased when combined with Infliximab.,Glimepiride,DB00065
DB00285,The metabolism of Venlafaxine can be increased when combined with Infliximab.,Venlafaxine,DB00065
DB00304,The metabolism of Desogestrel can be increased when combined with Infliximab.,Desogestrel,DB00065
DB00307,The metabolism of Bexarotene can be increased when combined with Infliximab.,Bexarotene,DB00065
DB00327,The metabolism of Hydromorphone can be increased when combined with Infliximab.,Hydromorphone,DB00065
DB00328,The metabolism of Indomethacin can be increased when combined with Infliximab.,Indomethacin,DB00065
DB00343,The metabolism of Diltiazem can be increased when combined with Infliximab.,Diltiazem,DB00065
DB00374,The metabolism of Treprostinil can be increased when combined with Infliximab.,Treprostinil,DB00065
DB00412,The metabolism of Rosiglitazone can be increased when combined with Infliximab.,Rosiglitazone,DB00065
DB00414,The metabolism of Acetohexamide can be increased when combined with Infliximab.,Acetohexamide,DB00065
DB00420,The metabolism of Promazine can be increased when combined with Infliximab.,Promazine,DB00065
DB00440,The metabolism of Trimethoprim can be increased when combined with Infliximab.,Trimethoprim,DB00065
DB00461,The metabolism of Nabumetone can be increased when combined with Infliximab.,Nabumetone,DB00065
DB00468,The metabolism of Quinine can be increased when combined with Infliximab.,Quinine,DB00065
DB00469,The metabolism of Tenoxicam can be increased when combined with Infliximab.,Tenoxicam,DB00065
DB00471,The metabolism of Montelukast can be increased when combined with Infliximab.,Montelukast,DB00065
DB00472,The metabolism of Fluoxetine can be increased when combined with Infliximab.,Fluoxetine,DB00065
DB00476,The metabolism of Duloxetine can be increased when combined with Infliximab.,Duloxetine,DB00065
DB00482,The metabolism of Celecoxib can be increased when combined with Infliximab.,Celecoxib,DB00065
DB00495,The metabolism of Zidovudine can be increased when combined with Infliximab.,Zidovudine,DB00065
DB00502,The metabolism of Haloperidol can be increased when combined with Infliximab.,Haloperidol,DB00065
DB00531,The metabolism of Cyclophosphamide can be increased when combined with Infliximab.,Cyclophosphamide,DB00065
DB00533,The metabolism of Rofecoxib can be increased when combined with Infliximab.,Rofecoxib,DB00065
DB00549,The metabolism of Zafirlukast can be increased when combined with Infliximab.,Zafirlukast,DB00065
DB00554,The metabolism of Piroxicam can be increased when combined with Infliximab.,Piroxicam,DB00065
DB00559,The metabolism of Bosentan can be increased when combined with Infliximab.,Bosentan,DB00065
DB00568,The metabolism of Cinnarizine can be increased when combined with Infliximab.,Cinnarizine,DB00065
DB00580,The metabolism of Valdecoxib can be increased when combined with Infliximab.,Valdecoxib,DB00065
DB00586,The metabolism of Diclofenac can be increased when combined with Infliximab.,Diclofenac,DB00065
DB00617,The metabolism of Paramethadione can be increased when combined with Infliximab.,Paramethadione,DB00065
DB00661,The metabolism of Verapamil can be increased when combined with Infliximab.,Verapamil,DB00065
DB00672,The metabolism of Chlorpropamide can be increased when combined with Infliximab.,Chlorpropamide,DB00065
DB00678,The metabolism of Losartan can be increased when combined with Infliximab.,Losartan,DB00065
DB00701,The metabolism of Amprenavir can be increased when combined with Infliximab.,Amprenavir,DB00065
DB00712,The metabolism of Flurbiprofen can be increased when combined with Infliximab.,Flurbiprofen,DB00065
DB00731,The metabolism of Nateglinide can be increased when combined with Infliximab.,Nateglinide,DB00065
DB00744,The metabolism of Zileuton can be increased when combined with Infliximab.,Zileuton,DB00065
DB00749,The metabolism of Etodolac can be increased when combined with Infliximab.,Etodolac,DB00065
DB00755,The metabolism of Tretinoin can be increased when combined with Infliximab.,Tretinoin,DB00065
DB00758,The metabolism of Clopidogrel can be increased when combined with Infliximab.,Clopidogrel,DB00065
DB00783,The metabolism of Estradiol can be increased when combined with Infliximab.,Estradiol,DB00065
DB00784,The metabolism of Mefenamic acid can be increased when combined with Infliximab.,Mefenamic acid,DB00065
DB00788,The metabolism of Naproxen can be increased when combined with Infliximab.,Naproxen,DB00065
DB00796,The metabolism of Candesartan cilexetil can be increased when combined with Infliximab.,Candesartan cilexetil,DB00065
DB00812,The metabolism of Phenylbutazone can be increased when combined with Infliximab.,Phenylbutazone,DB00065
DB00814,The metabolism of Meloxicam can be increased when combined with Infliximab.,Meloxicam,DB00065
DB00818,The metabolism of Propofol can be increased when combined with Infliximab.,Propofol,DB00065
DB00839,The metabolism of Tolazamide can be increased when combined with Infliximab.,Tolazamide,DB00065
DB00843,The metabolism of Donepezil can be increased when combined with Infliximab.,Donepezil,DB00065
DB00857,The metabolism of Terbinafine can be increased when combined with Infliximab.,Terbinafine,DB00065
DB00904,The metabolism of Ondansetron can be increased when combined with Infliximab.,Ondansetron,DB00065
DB00921,The metabolism of Buprenorphine can be increased when combined with Infliximab.,Buprenorphine,DB00065
DB00936,The metabolism of Salicylic acid can be increased when combined with Infliximab.,Salicylic acid,DB00065
DB00945,The metabolism of Acetylsalicylic acid can be increased when combined with Infliximab.,Acetylsalicylic acid,DB00065
DB00969,The metabolism of Alosetron can be increased when combined with Infliximab.,Alosetron,DB00065
DB00972,The metabolism of Azelastine can be increased when combined with Infliximab.,Azelastine,DB00065
DB00980,The metabolism of Ramelteon can be increased when combined with Infliximab.,Ramelteon,DB00065
DB01016,The metabolism of Glyburide can be increased when combined with Infliximab.,Glyburide,DB00065
DB01029,The metabolism of Irbesartan can be increased when combined with Infliximab.,Irbesartan,DB00065
DB01036,The metabolism of Tolterodine can be increased when combined with Infliximab.,Tolterodine,DB00065
DB01037,The metabolism of Selegiline can be increased when combined with Infliximab.,Selegiline,DB00065
DB01041,The metabolism of Thalidomide can be increased when combined with Infliximab.,Thalidomide,DB00065
DB01050,The metabolism of Ibuprofen can be increased when combined with Infliximab.,Ibuprofen,DB00065
DB01065,The metabolism of Melatonin can be increased when combined with Infliximab.,Melatonin,DB00065
DB01067,The metabolism of Glipizide can be increased when combined with Infliximab.,Glipizide,DB00065
DB01072,The metabolism of Atazanavir can be increased when combined with Infliximab.,Atazanavir,DB00065
DB01075,The metabolism of Diphenhydramine can be increased when combined with Infliximab.,Diphenhydramine,DB00065
DB01095,The metabolism of Fluvastatin can be increased when combined with Infliximab.,Fluvastatin,DB00065
DB01098,The metabolism of Rosuvastatin can be increased when combined with Infliximab.,Rosuvastatin,DB00065
DB01120,The metabolism of Gliclazide can be increased when combined with Infliximab.,Gliclazide,DB00065
DB01124,The metabolism of Tolbutamide can be increased when combined with Infliximab.,Tolbutamide,DB00065
DB01136,The metabolism of Carvedilol can be increased when combined with Infliximab.,Carvedilol,DB00065
DB01154,The metabolism of Thiamylal can be increased when combined with Infliximab.,Thiamylal,DB00065
DB01171,The metabolism of Moclobemide can be increased when combined with Infliximab.,Moclobemide,DB00065
DB01177,The metabolism of Idarubicin can be increased when combined with Infliximab.,Idarubicin,DB00065
DB01198,The metabolism of Zopiclone can be increased when combined with Infliximab.,Zopiclone,DB00065
DB01251,The metabolism of Gliquidone can be increased when combined with Infliximab.,Gliquidone,DB00065
DB01283,The metabolism of Lumiracoxib can be increased when combined with Infliximab.,Lumiracoxib,DB00065
DB01289,The metabolism of Glisoxepide can be increased when combined with Infliximab.,Glisoxepide,DB00065
DB01357,The metabolism of Mestranol can be increased when combined with Infliximab.,Mestranol,DB00065
DB01424,The metabolism of Aminophenazone can be increased when combined with Infliximab.,Aminophenazone,DB00065
DB01435,The metabolism of Antipyrine can be increased when combined with Infliximab.,Antipyrine,DB00065
DB01589,The metabolism of Quazepam can be increased when combined with Infliximab.,Quazepam,DB00065
DB01628,The metabolism of Etoricoxib can be increased when combined with Infliximab.,Etoricoxib,DB00065
DB03756,The metabolism of Doconexent can be increased when combined with Infliximab.,Doconexent,DB00065
DB03783,The metabolism of Phenacetin can be increased when combined with Infliximab.,Phenacetin,DB00065
DB04557,The metabolism of Arachidonic Acid can be increased when combined with Infliximab.,Arachidonic Acid,DB00065
DB04574,The metabolism of Estrone sulfate can be increased when combined with Infliximab.,Estrone sulfate,DB00065
DB04665,The metabolism of Coumarin can be increased when combined with Infliximab.,Coumarin,DB00065
DB04725,The metabolism of Licofelone can be increased when combined with Infliximab.,Licofelone,DB00065
DB04841,The metabolism of Flunarizine can be increased when combined with Infliximab.,Flunarizine,DB00065
DB04898,The metabolism of Ximelagatran can be increased when combined with Infliximab.,Ximelagatran,DB00065
DB06204,The metabolism of Tapentadol can be increased when combined with Infliximab.,Tapentadol,DB00065
DB06268,The metabolism of Sitaxentan can be increased when combined with Infliximab.,Sitaxentan,DB00065
DB06370,The metabolism of Indisulam can be increased when combined with Infliximab.,Indisulam,DB00065
DB06652,The metabolism of Vicriviroc can be increased when combined with Infliximab.,Vicriviroc,DB00065
DB06725,The metabolism of Lornoxicam can be increased when combined with Infliximab.,Lornoxicam,DB00065
DB06737,The metabolism of Zaltoprofen can be increased when combined with Infliximab.,Zaltoprofen,DB00065
DB06803,The metabolism of Niclosamide can be increased when combined with Infliximab.,Niclosamide,DB00065
DB07615,The metabolism of Tranilast can be increased when combined with Infliximab.,Tranilast,DB00065
DB08439,The metabolism of Parecoxib can be increased when combined with Infliximab.,Parecoxib,DB00065
DB08828,The metabolism of Vismodegib can be increased when combined with Infliximab.,Vismodegib,DB00065
DB08860,The metabolism of Pitavastatin can be increased when combined with Infliximab.,Pitavastatin,DB00065
DB08875,The metabolism of Cabozantinib can be increased when combined with Infliximab.,Cabozantinib,DB00065
DB08899,The metabolism of Enzalutamide can be increased when combined with Infliximab.,Enzalutamide,DB00065
DB08962,The metabolism of Glibornuride can be increased when combined with Infliximab.,Glibornuride,DB00065
DB09048,The metabolism of Netupitant can be increased when combined with Infliximab.,Netupitant,DB00065
DB09061,The metabolism of Cannabidiol can be increased when combined with Infliximab.,Cannabidiol,DB00065
DB09080,The metabolism of Olodaterol can be increased when combined with Infliximab.,Olodaterol,DB00065
DB09288,The metabolism of Propacetamol can be increased when combined with Infliximab.,Propacetamol,DB00065
DB11560,The metabolism of Lesinurad can be increased when combined with Infliximab.,Lesinurad,DB00065
DB11614,The metabolism of Rupatadine can be increased when combined with Infliximab.,Rupatadine,DB00065
DB13406,The metabolism of Carbutamide can be increased when combined with Infliximab.,Carbutamide,DB00065
DB13675,The metabolism of Metahexamide can be increased when combined with Infliximab.,Metahexamide,DB00065
DB13919,The metabolism of Candesartan can be increased when combined with Infliximab.,Candesartan,DB00065
DB13941,The metabolism of Piperaquine can be increased when combined with Infliximab.,Piperaquine,DB00065
DB13952,The metabolism of Estradiol acetate can be increased when combined with Infliximab.,Estradiol acetate,DB00065
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Infliximab.,Estradiol benzoate,DB00065
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Infliximab.,Estradiol cypionate,DB00065
DB13955,The metabolism of Estradiol dienanthate can be increased when combined with Infliximab.,Estradiol dienanthate,DB00065
DB13956,The metabolism of Estradiol valerate can be increased when combined with Infliximab.,Estradiol valerate,DB00065
DB14009,The metabolism of Medical Cannabis can be increased when combined with Infliximab.,Medical Cannabis,DB00065
DB14011,The metabolism of Nabiximols can be increased when combined with Infliximab.,Nabiximols,DB00065
DB00829,The metabolism of Diazepam can be increased when combined with Infliximab.,Diazepam,DB00065
DB00514,The metabolism of Dextromethorphan can be increased when combined with Infliximab.,Dextromethorphan,DB00065
DB00470,The metabolism of Dronabinol can be increased when combined with Infliximab.,Dronabinol,DB00065
DB09213,The metabolism of Dexibuprofen can be increased when combined with Infliximab.,Dexibuprofen,DB00065
DB00465,The metabolism of Ketorolac can be increased when combined with Infliximab.,Ketorolac,DB00065
DB15233,The metabolism of Avapritinib can be increased when combined with Infliximab.,Avapritinib,DB00065
DB00321,The metabolism of Amitriptyline can be increased when combined with Infliximab.,Amitriptyline,DB00065
DB01142,The metabolism of Doxepin can be increased when combined with Infliximab.,Doxepin,DB00065
DB00216,The metabolism of Eletriptan can be increased when combined with Infliximab.,Eletriptan,DB00065
DB00404,The metabolism of Alprazolam can be increased when combined with Infliximab.,Alprazolam,DB00065
DB00726,The metabolism of Trimipramine can be increased when combined with Infliximab.,Trimipramine,DB00065
DB01101,The metabolism of Capecitabine can be increased when combined with Infliximab.,Capecitabine,DB00065
DB00266,The metabolism of Dicoumarol can be increased when combined with Infliximab.,Dicoumarol,DB00065
DB00313,The metabolism of Valproic acid can be increased when combined with Infliximab.,Valproic acid,DB00065
DB00908,The metabolism of Quinidine can be increased when combined with Infliximab.,Quinidine,DB00065
DB13136,The metabolism of Fluindione can be increased when combined with Infliximab.,Fluindione,DB00065
DB01224,The metabolism of Quetiapine can be increased when combined with Infliximab.,Quetiapine,DB00065
DB00182,The metabolism of Amphetamine can be increased when combined with Infliximab.,Amphetamine,DB00065
DB00187,The metabolism of Esmolol can be increased when combined with Infliximab.,Esmolol,DB00065
DB00245,The metabolism of Benzatropine can be increased when combined with Infliximab.,Benzatropine,DB00065
DB00289,The metabolism of Atomoxetine can be increased when combined with Infliximab.,Atomoxetine,DB00065
DB00335,The metabolism of Atenolol can be increased when combined with Infliximab.,Atenolol,DB00065
DB00373,The metabolism of Timolol can be increased when combined with Infliximab.,Timolol,DB00065
DB00409,The metabolism of Remoxipride can be increased when combined with Infliximab.,Remoxipride,DB00065
DB00592,The metabolism of Piperazine can be increased when combined with Infliximab.,Piperazine,DB00065
DB00699,The metabolism of Nicergoline can be increased when combined with Infliximab.,Nicergoline,DB00065
DB00737,The metabolism of Meclizine can be increased when combined with Infliximab.,Meclizine,DB00065
DB00805,The metabolism of Minaprine can be increased when combined with Infliximab.,Minaprine,DB00065
DB00866,The metabolism of Alprenolol can be increased when combined with Infliximab.,Alprenolol,DB00065
DB00914,The metabolism of Phenformin can be increased when combined with Infliximab.,Phenformin,DB00065
DB00933,The metabolism of Mesoridazine can be increased when combined with Infliximab.,Mesoridazine,DB00065
DB00960,The metabolism of Pindolol can be increased when combined with Infliximab.,Pindolol,DB00065
DB01071,The metabolism of Mequitazine can be increased when combined with Infliximab.,Mequitazine,DB00065
DB01079,The metabolism of Tegaserod can be increased when combined with Infliximab.,Tegaserod,DB00065
DB01193,The metabolism of Acebutolol can be increased when combined with Infliximab.,Acebutolol,DB00065
DB01203,The metabolism of Nadolol can be increased when combined with Infliximab.,Nadolol,DB00065
DB01228,The metabolism of Encainide can be increased when combined with Infliximab.,Encainide,DB00065
DB01233,The metabolism of Metoclopramide can be increased when combined with Infliximab.,Metoclopramide,DB00065
DB01255,The metabolism of Lisdexamfetamine can be increased when combined with Infliximab.,Lisdexamfetamine,DB00065
DB01295,The metabolism of Bevantolol can be increased when combined with Infliximab.,Bevantolol,DB00065
DB01297,The metabolism of Practolol can be increased when combined with Infliximab.,Practolol,DB00065
DB01359,The metabolism of Penbutolol can be increased when combined with Infliximab.,Penbutolol,DB00065
DB01403,The metabolism of Methotrimeprazine can be increased when combined with Infliximab.,Methotrimeprazine,DB00065
DB01429,The metabolism of Aprindine can be increased when combined with Infliximab.,Aprindine,DB00065
DB01454,The metabolism of Midomafetamine can be increased when combined with Infliximab.,Midomafetamine,DB00065
DB01472,The metabolism of 4-Methoxyamphetamine can be increased when combined with Infliximab.,4-Methoxyamphetamine,DB00065
DB01576,The metabolism of Dextroamphetamine can be increased when combined with Infliximab.,Dextroamphetamine,DB00065
DB01577,The metabolism of Metamfetamine can be increased when combined with Infliximab.,Metamfetamine,DB00065
DB01580,The metabolism of Oxprenolol can be increased when combined with Infliximab.,Oxprenolol,DB00065
DB04840,The metabolism of Debrisoquine can be increased when combined with Infliximab.,Debrisoquine,DB00065
DB04844,The metabolism of Tetrabenazine can be increased when combined with Infliximab.,Tetrabenazine,DB00065
DB04846,The metabolism of Celiprolol can be increased when combined with Infliximab.,Celiprolol,DB00065
DB06217,The metabolism of Vernakalant can be increased when combined with Infliximab.,Vernakalant,DB00065
DB06506,The metabolism of Repinotan can be increased when combined with Infliximab.,Repinotan,DB00065
DB06608,The metabolism of Tafenoquine can be increased when combined with Infliximab.,Tafenoquine,DB00065
DB06678,The metabolism of Esmirtazapine can be increased when combined with Infliximab.,Esmirtazapine,DB00065
DB06726,The metabolism of Bufuralol can be increased when combined with Infliximab.,Bufuralol,DB00065
DB06727,The metabolism of Sparteine can be increased when combined with Infliximab.,Sparteine,DB00065
DB06735,The metabolism of Enclomiphene can be increased when combined with Infliximab.,Enclomiphene,DB00065
DB08807,The metabolism of Bopindolol can be increased when combined with Infliximab.,Bopindolol,DB00065
DB08808,The metabolism of Bupranolol can be increased when combined with Infliximab.,Bupranolol,DB00065
DB08952,The metabolism of Indenolol can be increased when combined with Infliximab.,Indenolol,DB00065
DB09013,The metabolism of Befunolol can be increased when combined with Infliximab.,Befunolol,DB00065
DB09076,The metabolism of Umeclidinium can be increased when combined with Infliximab.,Umeclidinium,DB00065
DB09204,The metabolism of Arotinolol can be increased when combined with Infliximab.,Arotinolol,DB00065
DB09351,The metabolism of Levobetaxolol can be increased when combined with Infliximab.,Levobetaxolol,DB00065
DB11770,The metabolism of Talinolol can be increased when combined with Infliximab.,Talinolol,DB00065
DB11785,The metabolism of Anisodamine can be increased when combined with Infliximab.,Anisodamine,DB00065
DB11855,The metabolism of Revefenacin can be increased when combined with Infliximab.,Revefenacin,DB00065
DB11979,The metabolism of Elagolix can be increased when combined with Infliximab.,Elagolix,DB00065
DB12070,The metabolism of Letermovir can be increased when combined with Infliximab.,Letermovir,DB00065
DB12212,The metabolism of Landiolol can be increased when combined with Infliximab.,Landiolol,DB00065
DB12752,The metabolism of Bucindolol can be increased when combined with Infliximab.,Bucindolol,DB00065
DB13443,The metabolism of Esatenolol can be increased when combined with Infliximab.,Esatenolol,DB00065
DB13508,The metabolism of Cloranolol can be increased when combined with Infliximab.,Cloranolol,DB00065
DB13530,The metabolism of Mepindolol can be increased when combined with Infliximab.,Mepindolol,DB00065
DB13679,The metabolism of Dexchlorpheniramine can be increased when combined with Infliximab.,Dexchlorpheniramine,DB00065
DB13757,The metabolism of Epanolol can be increased when combined with Infliximab.,Epanolol,DB00065
DB13775,The metabolism of Tertatolol can be increased when combined with Infliximab.,Tertatolol,DB00065
DB00850,The metabolism of Perphenazine can be increased when combined with Infliximab.,Perphenazine,DB00065
DB09173,The metabolism of Butyrfentanyl can be increased when combined with Infliximab.,Butyrfentanyl,DB00065
DB00281,The metabolism of Lidocaine can be increased when combined with Infliximab.,Lidocaine,DB00065
DB00598,The metabolism of Labetalol can be increased when combined with Infliximab.,Labetalol,DB00065
DB14010,"The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Infliximab.","5-methoxy-N,N-dimethyltryptamine",DB00065
DB01410,The metabolism of Ciclesonide can be increased when combined with Infliximab.,Ciclesonide,DB00065
DB00918,The metabolism of Almotriptan can be increased when combined with Infliximab.,Almotriptan,DB00065
DB08918,The metabolism of Levomilnacipran can be increased when combined with Infliximab.,Levomilnacipran,DB00065
DB08922,The metabolism of Perospirone can be increased when combined with Infliximab.,Perospirone,DB00065
DB09183,The metabolism of Dasabuvir can be increased when combined with Infliximab.,Dasabuvir,DB00065
DB02703,The metabolism of Fusidic acid can be increased when combined with Infliximab.,Fusidic acid,DB00065
DB13293,The metabolism of Ipecac can be increased when combined with Infliximab.,Ipecac,DB00065
DB00185,The metabolism of Cevimeline can be increased when combined with Infliximab.,Cevimeline,DB00065
DB00243,The metabolism of Ranolazine can be increased when combined with Infliximab.,Ranolazine,DB00065
DB00297,The metabolism of Bupivacaine can be increased when combined with Infliximab.,Bupivacaine,DB00065
DB00318,The metabolism of Codeine can be increased when combined with Infliximab.,Codeine,DB00065
DB00377,The metabolism of Palonosetron can be increased when combined with Infliximab.,Palonosetron,DB00065
DB00589,The metabolism of Lisuride can be increased when combined with Infliximab.,Lisuride,DB00065
DB00647,The metabolism of Dextropropoxyphene can be increased when combined with Infliximab.,Dextropropoxyphene,DB00065
DB00674,The metabolism of Galantamine can be increased when combined with Infliximab.,Galantamine,DB00065
DB00705,The metabolism of Delavirdine can be increased when combined with Infliximab.,Delavirdine,DB00065
DB00706,The metabolism of Tamsulosin can be increased when combined with Infliximab.,Tamsulosin,DB00065
DB00757,The metabolism of Dolasetron can be increased when combined with Infliximab.,Dolasetron,DB00065
DB01149,The metabolism of Nefazodone can be increased when combined with Infliximab.,Nefazodone,DB00065
DB01192,The metabolism of Oxymorphone can be increased when combined with Infliximab.,Oxymorphone,DB00065
DB01244,The metabolism of Bepridil can be increased when combined with Infliximab.,Bepridil,DB00065
DB01392,The metabolism of Yohimbine can be increased when combined with Infliximab.,Yohimbine,DB00065
DB01409,The metabolism of Tiotropium can be increased when combined with Infliximab.,Tiotropium,DB00065
DB01551,The metabolism of Dihydrocodeine can be increased when combined with Infliximab.,Dihydrocodeine,DB00065
DB01591,The metabolism of Solifenacin can be increased when combined with Infliximab.,Solifenacin,DB00065
DB01621,The metabolism of Pipotiazine can be increased when combined with Infliximab.,Pipotiazine,DB00065
DB04829,The metabolism of Lysergic acid diethylamide can be increased when combined with Infliximab.,Lysergic acid diethylamide,DB00065
DB04884,The metabolism of Dapoxetine can be increased when combined with Infliximab.,Dapoxetine,DB00065
DB04905,The metabolism of Tesmilifene can be increased when combined with Infliximab.,Tesmilifene,DB00065
DB04920,The metabolism of Clevidipine can be increased when combined with Infliximab.,Clevidipine,DB00065
DB05271,The metabolism of Rotigotine can be increased when combined with Infliximab.,Rotigotine,DB00065
DB06016,The metabolism of Cariprazine can be increased when combined with Infliximab.,Cariprazine,DB00065
DB06144,The metabolism of Sertindole can be increased when combined with Infliximab.,Sertindole,DB00065
DB06203,The metabolism of Alogliptin can be increased when combined with Infliximab.,Alogliptin,DB00065
DB06702,The metabolism of Fesoterodine can be increased when combined with Infliximab.,Fesoterodine,DB00065
DB08893,The metabolism of Mirabegron can be increased when combined with Infliximab.,Mirabegron,DB00065
DB09128,The metabolism of Brexpiprazole can be increased when combined with Infliximab.,Brexpiprazole,DB00065
DB09195,The metabolism of Lorpiprazole can be increased when combined with Infliximab.,Lorpiprazole,DB00065
DB09555,The metabolism of Dexchlorpheniramine maleate can be increased when combined with Infliximab.,Dexchlorpheniramine maleate,DB00065
DB11130,The metabolism of Opium can be increased when combined with Infliximab.,Opium,DB00065
DB11642,The metabolism of Pitolisant can be increased when combined with Infliximab.,Pitolisant,DB00065
DB00344,The metabolism of Protriptyline can be increased when combined with Infliximab.,Protriptyline,DB00065
DB00496,The metabolism of Darifenacin can be increased when combined with Infliximab.,Darifenacin,DB00065
DB00543,The metabolism of Amoxapine can be increased when combined with Infliximab.,Amoxapine,DB00065
DB00932,The metabolism of Tipranavir can be increased when combined with Infliximab.,Tipranavir,DB00065
DB09039,The metabolism of Eliglustat can be increased when combined with Infliximab.,Eliglustat,DB00065
DB12930,The metabolism of Opipramol can be increased when combined with Infliximab.,Opipramol,DB00065
DB00489,The metabolism of Sotalol can be increased when combined with Infliximab.,Sotalol,DB00065
DB01035,The metabolism of Procainamide can be increased when combined with Infliximab.,Procainamide,DB00065
DB01195,The metabolism of Flecainide can be increased when combined with Infliximab.,Flecainide,DB00065
DB00228,The metabolism of Enflurane can be increased when combined with Infliximab.,Enflurane,DB00065
DB06712,The metabolism of Nilvadipine can be increased when combined with Infliximab.,Nilvadipine,DB00065
DB06728,The metabolism of Aniline can be increased when combined with Infliximab.,Aniline,DB00065
DB00949,The metabolism of Felbamate can be increased when combined with Infliximab.,Felbamate,DB00065
DB00593,The metabolism of Ethosuximide can be increased when combined with Infliximab.,Ethosuximide,DB00065
DB00186,The metabolism of Lorazepam can be increased when combined with Infliximab.,Lorazepam,DB00065
DB00191,The metabolism of Phentermine can be increased when combined with Infliximab.,Phentermine,DB00065
DB00207,The metabolism of Azithromycin can be increased when combined with Infliximab.,Azithromycin,DB00065
DB00208,The metabolism of Ticlopidine can be increased when combined with Infliximab.,Ticlopidine,DB00065
DB00264,The metabolism of Metoprolol can be increased when combined with Infliximab.,Metoprolol,DB00065
DB00426,The metabolism of Famciclovir can be increased when combined with Infliximab.,Famciclovir,DB00065
DB00433,The metabolism of Prochlorperazine can be increased when combined with Infliximab.,Prochlorperazine,DB00065
DB00567,The metabolism of Cephalexin can be increased when combined with Infliximab.,Cephalexin,DB00065
DB00590,The metabolism of Doxazosin can be increased when combined with Infliximab.,Doxazosin,DB00065
DB01039,The metabolism of Fenofibrate can be increased when combined with Infliximab.,Fenofibrate,DB00065
DB01395,The metabolism of Drospirenone can be increased when combined with Infliximab.,Drospirenone,DB00065
DB01411,The metabolism of Pranlukast can be increased when combined with Infliximab.,Pranlukast,DB00065
DB01431,The metabolism of Allylestrenol can be increased when combined with Infliximab.,Allylestrenol,DB00065
DB01624,The metabolism of Zuclopenthixol can be increased when combined with Infliximab.,Zuclopenthixol,DB00065
DB06201,The metabolism of Rufinamide can be increased when combined with Infliximab.,Rufinamide,DB00065
DB06480,The metabolism of Prucalopride can be increased when combined with Infliximab.,Prucalopride,DB00065
DB08882,The metabolism of Linagliptin can be increased when combined with Infliximab.,Linagliptin,DB00065
DB09030,The metabolism of Vorapaxar can be increased when combined with Infliximab.,Vorapaxar,DB00065
DB09034,The metabolism of Suvorexant can be increased when combined with Infliximab.,Suvorexant,DB00065
DB09079,The metabolism of Nintedanib can be increased when combined with Infliximab.,Nintedanib,DB00065
DB09299,The metabolism of Tenofovir alafenamide can be increased when combined with Infliximab.,Tenofovir alafenamide,DB00065
DB09330,The metabolism of Osimertinib can be increased when combined with Infliximab.,Osimertinib,DB00065
DB11094,The metabolism of Vitamin D can be increased when combined with Infliximab.,Vitamin D,DB00065
DB11273,The metabolism of Dihydroergocornine can be increased when combined with Infliximab.,Dihydroergocornine,DB00065
DB11730,The metabolism of Ribociclib can be increased when combined with Infliximab.,Ribociclib,DB00065
DB11952,The metabolism of Duvelisib can be increased when combined with Infliximab.,Duvelisib,DB00065
DB12141,The metabolism of Gilteritinib can be increased when combined with Infliximab.,Gilteritinib,DB00065
DB12515,The metabolism of 9-aminocamptothecin can be increased when combined with Infliximab.,9-aminocamptothecin,DB00065
DB12952,The metabolism of Methylprednisone can be increased when combined with Infliximab.,Methylprednisone,DB00065
DB13345,The metabolism of Dihydroergocristine can be increased when combined with Infliximab.,Dihydroergocristine,DB00065
DB13385,The metabolism of Dihydroergocryptine can be increased when combined with Infliximab.,Dihydroergocryptine,DB00065
DB14126,The metabolism of Tenofovir can be increased when combined with Infliximab.,Tenofovir,DB00065
DB15444,The metabolism of Elexacaftor can be increased when combined with Infliximab.,Elexacaftor,DB00065
DB06717,The metabolism of Fosaprepitant can be increased when combined with Infliximab.,Fosaprepitant,DB00065
DB12825,The metabolism of Lefamulin can be increased when combined with Infliximab.,Lefamulin,DB00065
DB12887,The metabolism of Tazemetostat can be increased when combined with Infliximab.,Tazemetostat,DB00065
DB00454,The metabolism of Meperidine can be increased when combined with Infliximab.,Meperidine,DB00065
DB01151,The metabolism of Desipramine can be increased when combined with Infliximab.,Desipramine,DB00065
DB12371,The metabolism of Siponimod can be increased when combined with Infliximab.,Siponimod,DB00065
DB00247,The metabolism of Methysergide can be increased when combined with Infliximab.,Methysergide,DB00065
DB08827,The metabolism of Lomitapide can be increased when combined with Infliximab.,Lomitapide,DB00065
DB11742,The metabolism of Ebastine can be increased when combined with Infliximab.,Ebastine,DB00065
DB05015,The metabolism of Belinostat can be increased when combined with Infliximab.,Belinostat,DB00065
DB01118,The metabolism of Amiodarone can be increased when combined with Infliximab.,Amiodarone,DB00065
DB00675,The metabolism of Tamoxifen can be increased when combined with Infliximab.,Tamoxifen,DB00065
DB00204,The metabolism of Dofetilide can be increased when combined with Infliximab.,Dofetilide,DB00065
DB00342,The metabolism of Terfenadine can be increased when combined with Infliximab.,Terfenadine,DB00065
DB00451,The metabolism of Levothyroxine can be increased when combined with Infliximab.,Levothyroxine,DB00065
DB00604,The metabolism of Cisapride can be increased when combined with Infliximab.,Cisapride,DB00065
DB00877,The metabolism of Sirolimus can be increased when combined with Infliximab.,Sirolimus,DB00065
DB01008,The metabolism of Busulfan can be increased when combined with Infliximab.,Busulfan,DB00065
DB01254,The metabolism of Dasatinib can be increased when combined with Infliximab.,Dasatinib,DB00065
DB01396,The metabolism of Digitoxin can be increased when combined with Infliximab.,Digitoxin,DB00065
DB01590,The metabolism of Everolimus can be increased when combined with Infliximab.,Everolimus,DB00065
DB03410,The metabolism of 4-hydroxycoumarin can be increased when combined with Infliximab.,4-hydroxycoumarin,DB00065
DB04855,The metabolism of Dronedarone can be increased when combined with Infliximab.,Dronedarone,DB00065
DB06287,The metabolism of Temsirolimus can be increased when combined with Infliximab.,Temsirolimus,DB00065
DB09053,The metabolism of Ibrutinib can be increased when combined with Infliximab.,Ibrutinib,DB00065
DB09289,The metabolism of Tianeptine can be increased when combined with Infliximab.,Tianeptine,DB00065
DB11633,The metabolism of Isavuconazole can be increased when combined with Infliximab.,Isavuconazole,DB00065
DB13275,The metabolism of Clorindione can be increased when combined with Infliximab.,Clorindione,DB00065
DB00398,The metabolism of Sorafenib can be increased when combined with Infliximab.,Sorafenib,DB00065
DB00444,The metabolism of Teniposide can be increased when combined with Infliximab.,Teniposide,DB00065
DB00530,The metabolism of Erlotinib can be increased when combined with Infliximab.,Erlotinib,DB00065
DB00541,The metabolism of Vincristine can be increased when combined with Infliximab.,Vincristine,DB00065
DB00619,The metabolism of Imatinib can be increased when combined with Infliximab.,Imatinib,DB00065
DB00773,The metabolism of Etoposide can be increased when combined with Infliximab.,Etoposide,DB00065
DB01248,The metabolism of Docetaxel can be increased when combined with Infliximab.,Docetaxel,DB00065
DB01268,The metabolism of Sunitinib can be increased when combined with Infliximab.,Sunitinib,DB00065
DB06626,The metabolism of Axitinib can be increased when combined with Infliximab.,Axitinib,DB00065
DB08865,The metabolism of Crizotinib can be increased when combined with Infliximab.,Crizotinib,DB00065
DB08901,The metabolism of Ponatinib can be increased when combined with Infliximab.,Ponatinib,DB00065
DB12483,The metabolism of Copanlisib can be increased when combined with Infliximab.,Copanlisib,DB00065
DB00188,The metabolism of Bortezomib can be increased when combined with Infliximab.,Bortezomib,DB00065
DB00363,The metabolism of Clozapine can be increased when combined with Infliximab.,Clozapine,DB00065
DB01181,The metabolism of Ifosfamide can be increased when combined with Infliximab.,Ifosfamide,DB00065
DB05109,The metabolism of Trabectedin can be increased when combined with Infliximab.,Trabectedin,DB00065
DB12147,The metabolism of Erdafitinib can be increased when combined with Infliximab.,Erdafitinib,DB00065
DB13874,The metabolism of Enasidenib can be increased when combined with Infliximab.,Enasidenib,DB00065
DB06589,The metabolism of Pazopanib can be increased when combined with Infliximab.,Pazopanib,DB00065
DB05239,The metabolism of Cobimetinib can be increased when combined with Infliximab.,Cobimetinib,DB00065
DB09063,The metabolism of Ceritinib can be increased when combined with Infliximab.,Ceritinib,DB00065
DB11963,The metabolism of Dacomitinib can be increased when combined with Infliximab.,Dacomitinib,DB00065
DB12015,The metabolism of Alpelisib can be increased when combined with Infliximab.,Alpelisib,DB00065
DB00309,The metabolism of Vindesine can be increased when combined with Infliximab.,Vindesine,DB00065
DB00361,The metabolism of Vinorelbine can be increased when combined with Infliximab.,Vinorelbine,DB00065
DB00570,The metabolism of Vinblastine can be increased when combined with Infliximab.,Vinblastine,DB00065
DB00694,The metabolism of Daunorubicin can be increased when combined with Infliximab.,Daunorubicin,DB00065
DB00987,The metabolism of Cytarabine can be increased when combined with Infliximab.,Cytarabine,DB00065
DB00997,The metabolism of Doxorubicin can be increased when combined with Infliximab.,Doxorubicin,DB00065
DB01108,The metabolism of Trilostane can be increased when combined with Infliximab.,Trilostane,DB00065
DB04572,The metabolism of Thiotepa can be increased when combined with Infliximab.,Thiotepa,DB00065
DB04845,The metabolism of Ixabepilone can be increased when combined with Infliximab.,Ixabepilone,DB00065
DB04868,The metabolism of Nilotinib can be increased when combined with Infliximab.,Nilotinib,DB00065
DB06603,The metabolism of Panobinostat can be increased when combined with Infliximab.,Panobinostat,DB00065
DB06616,The metabolism of Bosutinib can be increased when combined with Infliximab.,Bosutinib,DB00065
DB08870,The metabolism of Brentuximab vedotin can be increased when combined with Infliximab.,Brentuximab vedotin,DB00065
DB08877,The metabolism of Ruxolitinib can be increased when combined with Infliximab.,Ruxolitinib,DB00065
DB09073,The metabolism of Palbociclib can be increased when combined with Infliximab.,Palbociclib,DB00065
DB08912,The metabolism of Dabrafenib can be increased when combined with Infliximab.,Dabrafenib,DB00065
DB12267,The metabolism of Brigatinib can be increased when combined with Infliximab.,Brigatinib,DB00065
DB11718,The metabolism of Encorafenib can be increased when combined with Infliximab.,Encorafenib,DB00065
DB00563,The metabolism of Methotrexate can be increased when combined with Infliximab.,Methotrexate,DB00065
DB05294,The metabolism of Vandetanib can be increased when combined with Infliximab.,Vandetanib,DB00065
DB05812,The metabolism of Abiraterone can be increased when combined with Infliximab.,Abiraterone,DB00065
DB08881,The metabolism of Vemurafenib can be increased when combined with Infliximab.,Vemurafenib,DB00065
DB11363,The metabolism of Alectinib can be increased when combined with Infliximab.,Alectinib,DB00065
DB11581,The metabolism of Venetoclax can be increased when combined with Infliximab.,Venetoclax,DB00065
DB11641,The metabolism of Vinflunine can be increased when combined with Infliximab.,Vinflunine,DB00065
DB11703,The metabolism of Acalabrutinib can be increased when combined with Infliximab.,Acalabrutinib,DB00065
DB15035,The metabolism of Zanubrutinib can be increased when combined with Infliximab.,Zanubrutinib,DB00065
DB00248,The metabolism of Cabergoline can be increased when combined with Infliximab.,Cabergoline,DB00065
DB06595,The metabolism of Midostaurin can be increased when combined with Infliximab.,Midostaurin,DB00065
DB09143,The metabolism of Sonidegib can be increased when combined with Infliximab.,Sonidegib,DB00065
DB11828,The metabolism of Neratinib can be increased when combined with Infliximab.,Neratinib,DB00065
DB11986,The metabolism of Entrectinib can be increased when combined with Infliximab.,Entrectinib,DB00065
DB12978,The metabolism of Pexidartinib can be increased when combined with Infliximab.,Pexidartinib,DB00065
DB14568,The metabolism of Ivosidenib can be increased when combined with Infliximab.,Ivosidenib,DB00065
DB09054,The metabolism of Idelalisib can be increased when combined with Infliximab.,Idelalisib,DB00065
DB09570,The metabolism of Ixazomib can be increased when combined with Infliximab.,Ixazomib,DB00065
DB00199,The metabolism of Erythromycin can be increased when combined with Infliximab.,Erythromycin,DB00065
DB00246,The metabolism of Ziprasidone can be increased when combined with Infliximab.,Ziprasidone,DB00065
DB00439,The metabolism of Cerivastatin can be increased when combined with Infliximab.,Cerivastatin,DB00065
DB00499,The metabolism of Flutamide can be increased when combined with Infliximab.,Flutamide,DB00065
DB00503,The metabolism of Ritonavir can be increased when combined with Infliximab.,Ritonavir,DB00065
DB00528,The metabolism of Lercanidipine can be increased when combined with Infliximab.,Lercanidipine,DB00065
DB00571,The metabolism of Propranolol can be increased when combined with Infliximab.,Propranolol,DB00065
DB00588,The metabolism of Fluticasone propionate can be increased when combined with Infliximab.,Fluticasone propionate,DB00065
DB00608,The metabolism of Chloroquine can be increased when combined with Infliximab.,Chloroquine,DB00065
DB00688,The metabolism of Mycophenolate mofetil can be increased when combined with Infliximab.,Mycophenolate mofetil,DB00065
DB00717,The metabolism of Norethisterone can be increased when combined with Infliximab.,Norethisterone,DB00065
DB00738,The metabolism of Pentamidine can be increased when combined with Infliximab.,Pentamidine,DB00065
DB00741,The metabolism of Hydrocortisone can be increased when combined with Infliximab.,Hydrocortisone,DB00065
DB00762,The metabolism of Irinotecan can be increased when combined with Infliximab.,Irinotecan,DB00065
DB00822,The metabolism of Disulfiram can be increased when combined with Infliximab.,Disulfiram,DB00065
DB00834,The metabolism of Mifepristone can be increased when combined with Infliximab.,Mifepristone,DB00065
DB00938,The metabolism of Salmeterol can be increased when combined with Infliximab.,Salmeterol,DB00065
DB00962,The metabolism of Zaleplon can be increased when combined with Infliximab.,Zaleplon,DB00065
DB00976,The metabolism of Telithromycin can be increased when combined with Infliximab.,Telithromycin,DB00065
DB01054,The metabolism of Nitrendipine can be increased when combined with Infliximab.,Nitrendipine,DB00065
DB01058,The metabolism of Praziquantel can be increased when combined with Infliximab.,Praziquantel,DB00065
DB01062,The metabolism of Oxybutynin can be increased when combined with Infliximab.,Oxybutynin,DB00065
DB01076,The metabolism of Atorvastatin can be increased when combined with Infliximab.,Atorvastatin,DB00065
DB01103,The metabolism of Quinacrine can be increased when combined with Infliximab.,Quinacrine,DB00065
DB01115,The metabolism of Nifedipine can be increased when combined with Infliximab.,Nifedipine,DB00065
DB01126,The metabolism of Dutasteride can be increased when combined with Infliximab.,Dutasteride,DB00065
DB01166,The metabolism of Cilostazol can be increased when combined with Infliximab.,Cilostazol,DB00065
DB01184,The metabolism of Domperidone can be increased when combined with Infliximab.,Domperidone,DB00065
DB01211,The metabolism of Clarithromycin can be increased when combined with Infliximab.,Clarithromycin,DB00065
DB01216,The metabolism of Finasteride can be increased when combined with Infliximab.,Finasteride,DB00065
DB01218,The metabolism of Halofantrine can be increased when combined with Infliximab.,Halofantrine,DB00065
DB05521,The metabolism of Telaprevir can be increased when combined with Infliximab.,Telaprevir,DB00065
DB05773,The metabolism of Trastuzumab emtansine can be increased when combined with Infliximab.,Trastuzumab emtansine,DB00065
DB06267,The metabolism of Udenafil can be increased when combined with Infliximab.,Udenafil,DB00065
DB06335,The metabolism of Saxagliptin can be increased when combined with Infliximab.,Saxagliptin,DB00065
DB06403,The metabolism of Ambrisentan can be increased when combined with Infliximab.,Ambrisentan,DB00065
DB06419,The metabolism of Cethromycin can be increased when combined with Infliximab.,Cethromycin,DB00065
DB06772,The metabolism of Cabazitaxel can be increased when combined with Infliximab.,Cabazitaxel,DB00065
DB06789,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Infliximab.,Hydroxyprogesterone caproate,DB00065
DB08820,The metabolism of Ivacaftor can be increased when combined with Infliximab.,Ivacaftor,DB00065
DB08873,The metabolism of Boceprevir can be increased when combined with Infliximab.,Boceprevir,DB00065
DB08883,The metabolism of Perampanel can be increased when combined with Infliximab.,Perampanel,DB00065
DB08906,The metabolism of Fluticasone furoate can be increased when combined with Infliximab.,Fluticasone furoate,DB00065
DB09065,The metabolism of Cobicistat can be increased when combined with Infliximab.,Cobicistat,DB00065
DB09074,The metabolism of Olaparib can be increased when combined with Infliximab.,Olaparib,DB00065
DB09102,The metabolism of Daclatasvir can be increased when combined with Infliximab.,Daclatasvir,DB00065
DB09231,The metabolism of Benidipine can be increased when combined with Infliximab.,Benidipine,DB00065
DB09297,The metabolism of Paritaprevir can be increased when combined with Infliximab.,Paritaprevir,DB00065
DB11574,The metabolism of Elbasvir can be increased when combined with Infliximab.,Elbasvir,DB00065
DB11712,The metabolism of Tezacaftor can be increased when combined with Infliximab.,Tezacaftor,DB00065
DB11737,The metabolism of Icotinib can be increased when combined with Infliximab.,Icotinib,DB00065
DB12301,The metabolism of Doravirine can be increased when combined with Infliximab.,Doravirine,DB00065
DB13867,The metabolism of Fluticasone can be increased when combined with Infliximab.,Fluticasone,DB00065
DB14538,The metabolism of Hydrocortisone aceponate can be increased when combined with Infliximab.,Hydrocortisone aceponate,DB00065
DB14539,The metabolism of Hydrocortisone acetate can be increased when combined with Infliximab.,Hydrocortisone acetate,DB00065
DB14541,The metabolism of Hydrocortisone cypionate can be increased when combined with Infliximab.,Hydrocortisone cypionate,DB00065
DB14542,The metabolism of Hydrocortisone phosphate can be increased when combined with Infliximab.,Hydrocortisone phosphate,DB00065
DB00396,The metabolism of Progesterone can be increased when combined with Infliximab.,Progesterone,DB00065
DB04856,The metabolism of Dexloxiglumide can be increased when combined with Infliximab.,Dexloxiglumide,DB00065
DB04957,The metabolism of Azimilide can be increased when combined with Infliximab.,Azimilide,DB00065
DB00250,The metabolism of Dapsone can be increased when combined with Infliximab.,Dapsone,DB00065
DB00317,The metabolism of Gefitinib can be increased when combined with Infliximab.,Gefitinib,DB00065
DB00367,The metabolism of Levonorgestrel can be increased when combined with Infliximab.,Levonorgestrel,DB00065
DB00497,The metabolism of Oxycodone can be increased when combined with Infliximab.,Oxycodone,DB00065
DB00620,The metabolism of Triamcinolone can be increased when combined with Infliximab.,Triamcinolone,DB00065
DB00624,The metabolism of Testosterone can be increased when combined with Infliximab.,Testosterone,DB00065
DB00656,The metabolism of Trazodone can be increased when combined with Infliximab.,Trazodone,DB00065
DB00734,The metabolism of Risperidone can be increased when combined with Infliximab.,Risperidone,DB00065
DB01114,The metabolism of Chlorpheniramine can be increased when combined with Infliximab.,Chlorpheniramine,DB00065
DB01238,The metabolism of Aripiprazole can be increased when combined with Infliximab.,Aripiprazole,DB00065
DB01267,The metabolism of Paliperidone can be increased when combined with Infliximab.,Paliperidone,DB00065
DB04946,The metabolism of Iloperidone can be increased when combined with Infliximab.,Iloperidone,DB00065
DB11915,The metabolism of Valbenazine can be increased when combined with Infliximab.,Valbenazine,DB00065
DB12161,The metabolism of Deutetrabenazine can be increased when combined with Infliximab.,Deutetrabenazine,DB00065
DB14185,The metabolism of Aripiprazole lauroxil can be increased when combined with Infliximab.,Aripiprazole lauroxil,DB00065
DB01234,The metabolism of Dexamethasone can be increased when combined with Infliximab.,Dexamethasone,DB00065
DB09237,The metabolism of Levamlodipine can be increased when combined with Infliximab.,Levamlodipine,DB00065
DB11951,The metabolism of Lemborexant can be increased when combined with Infliximab.,Lemborexant,DB00065
DB00557,The metabolism of Hydroxyzine can be increased when combined with Infliximab.,Hydroxyzine,DB00065
DB00203,The metabolism of Sildenafil can be increased when combined with Infliximab.,Sildenafil,DB00065
DB00227,The metabolism of Lovastatin can be increased when combined with Infliximab.,Lovastatin,DB00065
DB00490,The metabolism of Buspirone can be increased when combined with Infliximab.,Buspirone,DB00065
DB00641,The metabolism of Simvastatin can be increased when combined with Infliximab.,Simvastatin,DB00065
DB00673,The metabolism of Aprepitant can be increased when combined with Infliximab.,Aprepitant,DB00065
DB00820,The metabolism of Tadalafil can be increased when combined with Infliximab.,Tadalafil,DB00065
DB00862,The metabolism of Vardenafil can be increased when combined with Infliximab.,Vardenafil,DB00065
DB01190,The metabolism of Clindamycin can be increased when combined with Infliximab.,Clindamycin,DB00065
DB00224,The metabolism of Indinavir can be increased when combined with Infliximab.,Indinavir,DB00065
DB00401,The metabolism of Nisoldipine can be increased when combined with Infliximab.,Nisoldipine,DB00065
DB00637,The metabolism of Astemizole can be increased when combined with Infliximab.,Astemizole,DB00065
DB00683,The metabolism of Midazolam can be increased when combined with Infliximab.,Midazolam,DB00065
DB00700,The metabolism of Eplerenone can be increased when combined with Infliximab.,Eplerenone,DB00065
DB00802,The metabolism of Alfentanil can be increased when combined with Infliximab.,Alfentanil,DB00065
DB00813,The metabolism of Fentanyl can be increased when combined with Infliximab.,Fentanyl,DB00065
DB00897,The metabolism of Triazolam can be increased when combined with Infliximab.,Triazolam,DB00065
DB01023,The metabolism of Felodipine can be increased when combined with Infliximab.,Felodipine,DB00065
DB01227,The metabolism of Levacetylmethadol can be increased when combined with Infliximab.,Levacetylmethadol,DB00065
DB01232,The metabolism of Saquinavir can be increased when combined with Infliximab.,Saquinavir,DB00065
DB06228,The metabolism of Rivaroxaban can be increased when combined with Infliximab.,Rivaroxaban,DB00065
DB05804,The metabolism of Prasterone sulfate can be increased when combined with Infliximab.,Prasterone sulfate,DB00065
DB00091,Infliximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00065
DB05676,The therapeutic efficacy of Apremilast can be decreased when used in combination with Infliximab.,Apremilast,DB00065
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Infliximab.","Ebola Zaire vaccine (live, attenuated)",DB00065
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Infliximab.,Magnesium,DB00065
DB01601,The serum concentration of Infliximab can be increased when it is combined with Lopinavir.,Lopinavir,DB00065
DB12530,The risk or severity of infection can be increased when Infliximab is combined with Inebilizumab.,Inebilizumab,DB00065
DB00176,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluvoxamine.,Fluvoxamine,DB00066
DB00215,The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram.,Citalopram,DB00066
DB00472,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.,Fluoxetine,DB00066
DB00476,The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.,Duloxetine,DB00066
DB00656,The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.,Trazodone,DB00066
DB00715,The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.,Paroxetine,DB00066
DB01104,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sertraline.,Sertraline,DB00066
DB01105,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.,Sibutramine,DB00066
DB01149,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nefazodone.,Nefazodone,DB00066
DB01175,The therapeutic efficacy of Follitropin can be decreased when used in combination with Escitalopram.,Escitalopram,DB00066
DB04832,The therapeutic efficacy of Follitropin can be decreased when used in combination with Zimelidine.,Zimelidine,DB00066
DB04884,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dapoxetine.,Dapoxetine,DB00066
DB04896,The therapeutic efficacy of Follitropin can be decreased when used in combination with Milnacipran.,Milnacipran,DB00066
DB06700,The therapeutic efficacy of Follitropin can be decreased when used in combination with Desvenlafaxine.,Desvenlafaxine,DB00066
DB06731,The therapeutic efficacy of Follitropin can be decreased when used in combination with Seproxetine.,Seproxetine,DB00066
DB08918,The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.,Levomilnacipran,DB00066
DB08953,The therapeutic efficacy of Follitropin can be decreased when used in combination with Indalpine.,Indalpine,DB00066
DB12693,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ritanserin.,Ritanserin,DB00066
DB13233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alaproclate.,Alaproclate,DB00066
DB00182,The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.,Amphetamine,DB00066
DB00191,The risk or severity of adverse effects can be increased when Phentermine is combined with Follitropin.,Phentermine,DB00066
DB00211,The risk or severity of adverse effects can be increased when Midodrine is combined with Follitropin.,Midodrine,DB00066
DB00368,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.,Norepinephrine,DB00066
DB00388,The risk or severity of adverse effects can be increased when Phenylephrine is combined with Follitropin.,Phenylephrine,DB00066
DB00397,The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Follitropin.,Phenylpropanolamine,DB00066
DB00610,The risk or severity of adverse effects can be increased when Metaraminol is combined with Follitropin.,Metaraminol,DB00066
DB00668,The risk or severity of adverse effects can be increased when Epinephrine is combined with Follitropin.,Epinephrine,DB00066
DB00723,The risk or severity of adverse effects can be increased when Methoxamine is combined with Follitropin.,Methoxamine,DB00066
DB00816,The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.,Orciprenaline,DB00066
DB00830,The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Follitropin.,Phenmetrazine,DB00066
DB00841,The risk or severity of adverse effects can be increased when Dobutamine is combined with Follitropin.,Dobutamine,DB00066
DB00852,The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin.,Pseudoephedrine,DB00066
DB00865,The risk or severity of adverse effects can be increased when Benzphetamine is combined with Follitropin.,Benzphetamine,DB00066
DB00867,The risk or severity of adverse effects can be increased when Ritodrine is combined with Follitropin.,Ritodrine,DB00066
DB00871,The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.,Terbutaline,DB00066
DB00935,The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin.,Oxymetazoline,DB00066
DB00937,The risk or severity of adverse effects can be increased when Diethylpropion is combined with Follitropin.,Diethylpropion,DB00066
DB00988,The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.,Dopamine,DB00066
DB01064,The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin.,Isoprenaline,DB00066
DB01255,The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.,Lisdexamfetamine,DB00066
DB01288,The risk or severity of adverse effects can be increased when Fenoterol is combined with Follitropin.,Fenoterol,DB00066
DB01364,The risk or severity of adverse effects can be increased when Ephedrine is combined with Follitropin.,Ephedrine,DB00066
DB01365,The risk or severity of adverse effects can be increased when Mephentermine is combined with Follitropin.,Mephentermine,DB00066
DB01366,The risk or severity of adverse effects can be increased when Procaterol is combined with Follitropin.,Procaterol,DB00066
DB01407,The risk or severity of adverse effects can be increased when Clenbuterol is combined with Follitropin.,Clenbuterol,DB00066
DB01442,The risk or severity of adverse effects can be increased when MMDA is combined with Follitropin.,MMDA,DB00066
DB01454,The risk or severity of adverse effects can be increased when Midomafetamine is combined with Follitropin.,Midomafetamine,DB00066
DB01467,"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Follitropin.","2,5-Dimethoxy-4-ethylamphetamine",DB00066
DB01484,"The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Follitropin.","4-Bromo-2,5-dimethoxyamphetamine",DB00066
DB01509,The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Follitropin.,Tenamfetamine,DB00066
DB01556,The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Follitropin.,Chlorphentermine,DB00066
DB01566,The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Follitropin.,Methylenedioxyethamphetamine,DB00066
DB01576,The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Follitropin.,Dextroamphetamine,DB00066
DB01577,The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin.,Metamfetamine,DB00066
DB06152,The risk or severity of adverse effects can be increased when Nylidrin is combined with Follitropin.,Nylidrin,DB00066
DB06764,The risk or severity of adverse effects can be increased when Tetryzoline is combined with Follitropin.,Tetryzoline,DB00066
DB08841,The risk or severity of adverse effects can be increased when Tyramine is combined with Follitropin.,Tyramine,DB00066
DB08941,The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Follitropin.,Isoxsuprine,DB00066
DB08985,The risk or severity of adverse effects can be increased when Etilefrine is combined with Follitropin.,Etilefrine,DB00066
DB09203,The risk or severity of adverse effects can be increased when Synephrine is combined with Follitropin.,Synephrine,DB00066
DB09480,The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Follitropin.,Iofetamine I-123,DB00066
DB11124,The risk or severity of adverse effects can be increased when Racepinephrine is combined with Follitropin.,Racepinephrine,DB00066
DB12080,The risk or severity of adverse effects can be increased when Ritobegron is combined with Follitropin.,Ritobegron,DB00066
DB13064,The risk or severity of adverse effects can be increased when Tramazoline is combined with Follitropin.,Tramazoline,DB00066
DB13108,The risk or severity of adverse effects can be increased when Mephedrone is combined with Follitropin.,Mephedrone,DB00066
DB13341,The risk or severity of adverse effects can be increased when Fenozolone is combined with Follitropin.,Fenozolone,DB00066
DB13624,The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Follitropin.,Methoxyphenamine,DB00066
DB13692,The risk or severity of adverse effects can be increased when Tretoquinol is combined with Follitropin.,Tretoquinol,DB00066
DB13703,The risk or severity of adverse effects can be increased when Gepefrine is combined with Follitropin.,Gepefrine,DB00066
DB13777,The risk or severity of adverse effects can be increased when Prenalterol is combined with Follitropin.,Prenalterol,DB00066
DB13852,The risk or severity of adverse effects can be increased when Mefenorex is combined with Follitropin.,Mefenorex,DB00066
DB13940,"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Follitropin.","2,5-Dimethoxy-4-ethylthioamphetamine",DB00066
DB00598,The risk or severity of adverse effects can be increased when Labetalol is combined with Follitropin.,Labetalol,DB00066
DB01193,The risk or severity of adverse effects can be increased when Acebutolol is combined with Follitropin.,Acebutolol,DB00066
DB04846,The risk or severity of adverse effects can be increased when Celiprolol is combined with Follitropin.,Celiprolol,DB00066
DB12752,The risk or severity of adverse effects can be increased when Bucindolol is combined with Follitropin.,Bucindolol,DB00066
DB13757,The risk or severity of adverse effects can be increased when Epanolol is combined with Follitropin.,Epanolol,DB00066
DB00317,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib.,Gefitinib,DB00066
DB00398,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sorafenib.,Sorafenib,DB00066
DB00530,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib.,Erlotinib,DB00066
DB00619,The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.,Imatinib,DB00066
DB01254,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.,Dasatinib,DB00066
DB01259,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lapatinib.,Lapatinib,DB00066
DB01268,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.,Sunitinib,DB00066
DB01645,The therapeutic efficacy of Follitropin can be decreased when used in combination with Genistein.,Genistein,DB00066
DB02058,The therapeutic efficacy of Follitropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.,3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone,DB00066
DB02424,The therapeutic efficacy of Follitropin can be decreased when used in combination with Geldanamycin.,Geldanamycin,DB00066
DB02567,The therapeutic efficacy of Follitropin can be decreased when used in combination with PD173955.,PD173955,DB00066
DB03758,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radicicol.,Radicicol,DB00066
DB04849,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cediranib.,Cediranib,DB00066
DB04868,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nilotinib.,Nilotinib,DB00066
DB04879,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.,Vatalanib,DB00066
DB05294,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vandetanib.,Vandetanib,DB00066
DB05424,The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib.,Canertinib,DB00066
DB05465,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tandutinib.,Tandutinib,DB00066
DB05575,The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.,Motesanib,DB00066
DB05928,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dovitinib.,Dovitinib,DB00066
DB06302,The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.,Glesatinib,DB00066
DB06469,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lestaurtinib.,Lestaurtinib,DB00066
DB06589,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pazopanib.,Pazopanib,DB00066
DB06595,The therapeutic efficacy of Follitropin can be decreased when used in combination with Midostaurin.,Midostaurin,DB00066
DB06616,The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib.,Bosutinib,DB00066
DB06626,The therapeutic efficacy of Follitropin can be decreased when used in combination with Axitinib.,Axitinib,DB00066
DB08399,The therapeutic efficacy of Follitropin can be decreased when used in combination with Piceatannol.,Piceatannol,DB00066
DB08865,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crizotinib.,Crizotinib,DB00066
DB08875,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cabozantinib.,Cabozantinib,DB00066
DB08877,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.,Ruxolitinib,DB00066
DB08881,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vemurafenib.,Vemurafenib,DB00066
DB08896,The therapeutic efficacy of Follitropin can be decreased when used in combination with Regorafenib.,Regorafenib,DB00066
DB08901,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ponatinib.,Ponatinib,DB00066
DB08916,The therapeutic efficacy of Follitropin can be decreased when used in combination with Afatinib.,Afatinib,DB00066
DB09053,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.,Ibrutinib,DB00066
DB09063,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib.,Ceritinib,DB00066
DB09078,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.,Lenvatinib,DB00066
DB09079,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nintedanib.,Nintedanib,DB00066
DB09330,The therapeutic efficacy of Follitropin can be decreased when used in combination with Osimertinib.,Osimertinib,DB00066
DB11363,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alectinib.,Alectinib,DB00066
DB11689,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selumetinib.,Selumetinib,DB00066
DB11697,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pacritinib.,Pacritinib,DB00066
DB11703,The therapeutic efficacy of Follitropin can be decreased when used in combination with Acalabrutinib.,Acalabrutinib,DB00066
DB11737,The therapeutic efficacy of Follitropin can be decreased when used in combination with Icotinib.,Icotinib,DB00066
DB11805,The therapeutic efficacy of Follitropin can be decreased when used in combination with Saracatinib.,Saracatinib,DB00066
DB11828,The therapeutic efficacy of Follitropin can be decreased when used in combination with Neratinib.,Neratinib,DB00066
DB11832,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crenolanib.,Crenolanib,DB00066
DB11904,The therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib.,Flumatinib,DB00066
DB11963,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dacomitinib.,Dacomitinib,DB00066
DB11973,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib.,Tesevatinib,DB00066
DB11986,The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.,Entrectinib,DB00066
DB12010,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fostamatinib.,Fostamatinib,DB00066
DB12048,The therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.,Savolitinib,DB00066
DB12141,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib.,Gilteritinib,DB00066
DB12147,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erdafitinib.,Erdafitinib,DB00066
DB12267,The therapeutic efficacy of Follitropin can be decreased when used in combination with Brigatinib.,Brigatinib,DB00066
DB12307,The therapeutic efficacy of Follitropin can be decreased when used in combination with Foretinib.,Foretinib,DB00066
DB12323,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radotinib.,Radotinib,DB00066
DB14723,The therapeutic efficacy of Follitropin can be decreased when used in combination with Larotrectinib.,Larotrectinib,DB00066
DB12978,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pexidartinib.,Pexidartinib,DB00066
DB12500,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib.,Fedratinib,DB00066
DB11652,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tucatinib.,Tucatinib,DB00066
DB11791,The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib.,Capmatinib,DB00066
DB15685,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selpercatinib.,Selpercatinib,DB00066
DB05258,The therapeutic efficacy of Follitropin can be decreased when used in combination with Interferon alfa.,Interferon alfa,DB00066
DB00041,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aldesleukin.,Aldesleukin,DB00066
DB00227,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lovastatin.,Lovastatin,DB00066
DB00609,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ethionamide.,Ethionamide,DB00066
DB00829,The therapeutic efficacy of Follitropin can be decreased when used in combination with Diazepam.,Diazepam,DB00066
DB00850,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.,Perphenazine,DB00066
DB01233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.,Metoclopramide,DB00066
DB14651,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.,Perphenazine enanthate,DB00066
DB00233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.,Aminosalicylic acid,DB00066
DB11085,The therapeutic efficacy of Follitropin can be decreased when used in combination with Resorcinol.,Resorcinol,DB00066
DB00222,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Follitropin.,Glimepiride,DB00066
DB00414,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Follitropin.,Acetohexamide,DB00066
DB00672,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Follitropin.,Chlorpropamide,DB00066
DB00839,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Follitropin.,Tolazamide,DB00066
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Follitropin.,Glyburide,DB00066
DB01067,The therapeutic efficacy of Glipizide can be decreased when used in combination with Follitropin.,Glipizide,DB00066
DB01120,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Follitropin.,Gliclazide,DB00066
DB01124,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Follitropin.,Tolbutamide,DB00066
DB01251,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Follitropin.,Gliquidone,DB00066
DB01289,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Follitropin.,Glisoxepide,DB00066
DB08962,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Follitropin.,Glibornuride,DB00066
DB13406,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Follitropin.,Carbutamide,DB00066
DB13675,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Follitropin.,Metahexamide,DB00066
DB00540,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Nortriptyline.,Nortriptyline,DB00066
DB00321,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptyline.,Amitriptyline,DB00066
DB00344,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Protriptyline.,Protriptyline,DB00066
DB00458,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine.,Imipramine,DB00066
DB00543,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amoxapine.,Amoxapine,DB00066
DB00726,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Trimipramine.,Trimipramine,DB00066
DB01142,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.,Doxepin,DB00066
DB01151,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Desipramine.,Desipramine,DB00066
DB01242,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Clomipramine.,Clomipramine,DB00066
DB04836,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amineptine.,Amineptine,DB00066
DB08996,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dimetacrine.,Dimetacrine,DB00066
DB09016,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Butriptyline.,Butriptyline,DB00066
DB09167,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dosulepin.,Dosulepin,DB00066
DB09289,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Tianeptine.,Tianeptine,DB00066
DB09307,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Oxaprotiline.,Oxaprotiline,DB00066
DB12930,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Opipramol.,Opipramol,DB00066
DB13114,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptylinoxide.,Amitriptylinoxide,DB00066
DB13225,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dibenzepin.,Dibenzepin,DB00066
DB13246,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Quinupramine.,Quinupramine,DB00066
DB13384,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Melitracen.,Melitracen,DB00066
DB13411,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Lofepramine.,Lofepramine,DB00066
DB13496,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Iprindole.,Iprindole,DB00066
DB13782,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine oxide.,Imipramine oxide,DB00066
DB13967,The risk or severity of hypotension can be increased when Patent Blue is combined with Vasopressin.,Patent Blue,DB00067
DB00564,The risk or severity of water intoxication can be increased when Carbamazepine is combined with Vasopressin.,Carbamazepine,DB00067
DB00368,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Vasopressin.,Norepinephrine,DB00067
DB01356,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium cation.,Lithium cation,DB00067
DB14507,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium citrate.,Lithium citrate,DB00067
DB14509,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium carbonate.,Lithium carbonate,DB00067
DB14506,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium hydroxide.,Lithium hydroxide,DB00067
DB00407,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin.,Ardeparin,DB00067
DB01109,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Heparin.,Heparin,DB00067
DB01225,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Enoxaparin.,Enoxaparin,DB00067
DB06271,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Sulodexide.,Sulodexide,DB00067
DB06294,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Semuloparin.,Semuloparin,DB00067
DB06754,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Danaparoid.,Danaparoid,DB00067
DB06779,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Dalteparin.,Dalteparin,DB00067
DB06822,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Tinzaparin.,Tinzaparin,DB00067
DB08813,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Nadroparin.,Nadroparin,DB00067
DB09258,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin.,Bemiparin,DB00067
DB09259,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Reviparin.,Reviparin,DB00067
DB09260,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Parnaparin.,Parnaparin,DB00067
DB09261,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Certoparin.,Certoparin,DB00067
DB00024,Thyrotropin alfa may increase the vasoconstricting activities of Vasopressin.,Thyrotropin alfa,DB00067
DB00279,Liothyronine may increase the vasoconstricting activities of Vasopressin.,Liothyronine,DB00067
DB00451,Levothyroxine may increase the vasoconstricting activities of Vasopressin.,Levothyroxine,DB00067
DB01583,Liotrix may increase the vasoconstricting activities of Vasopressin.,Liotrix,DB00067
DB03604,Tiratricol may increase the vasoconstricting activities of Vasopressin.,Tiratricol,DB00067
DB09100,"Thyroid, porcine may increase the vasoconstricting activities of Vasopressin.","Thyroid, porcine",DB00067
DB00281,The risk or severity of hypertension can be increased when Vasopressin is combined with Lidocaine.,Lidocaine,DB00067
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon beta-1b.,Denosumab,DB00068
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.,Etanercept,DB00068
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.,Peginterferon alfa-2a,DB00068
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.,Interferon alfa-n1,DB00068
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon beta-1b.,Interferon alfa-n3,DB00068
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.,Peginterferon alfa-2b,DB00068
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.,Anakinra,DB00068
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon beta-1b.,Interferon gamma-1b,DB00068
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon beta-1b.","Interferon alfa-2a, Recombinant",DB00068
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.,Aldesleukin,DB00068
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon beta-1b.,Adalimumab,DB00068
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.,Gemtuzumab ozogamicin,DB00068
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.,Pegaspargase,DB00068
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.,Infliximab,DB00068
DB00069,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00068
DB00073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.,Rituximab,DB00068
DB00074,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.,Basiliximab,DB00068
DB00075,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.,Muromonab,DB00068
DB00078,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00068
DB00081,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.,Tositumomab,DB00068
DB00087,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.,Alemtuzumab,DB00068
DB00092,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.,Alefacept,DB00068
DB00095,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.,Efalizumab,DB00068
DB00098,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00068
DB00105,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00068
DB00111,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.,Daclizumab,DB00068
DB00112,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.,Bevacizumab,DB00068
DB00120,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.,Phenylalanine,DB00068
DB00180,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flunisolide.,Flunisolide,DB00068
DB00188,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bortezomib.,Bortezomib,DB00068
DB00242,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cladribine.,Cladribine,DB00068
DB00262,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carmustine.,Carmustine,DB00068
DB00276,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Amsacrine.,Amsacrine,DB00068
DB00290,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleomycin.,Bleomycin,DB00068
DB00291,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chlorambucil.,Chlorambucil,DB00068
DB00293,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Raltitrexed.,Raltitrexed,DB00068
DB00305,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitomycin.,Mitomycin,DB00068
DB00307,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bexarotene.,Bexarotene,DB00068
DB00309,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vindesine.,Vindesine,DB00068
DB00322,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Floxuridine.,Floxuridine,DB00068
DB00328,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Indomethacin.,Indomethacin,DB00068
DB00352,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tioguanine.,Tioguanine,DB00068
DB00361,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinorelbine.,Vinorelbine,DB00068
DB00380,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexrazoxane.,Dexrazoxane,DB00068
DB00394,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00068
DB00398,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sorafenib.,Sorafenib,DB00068
DB00428,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Streptozocin.,Streptozocin,DB00068
DB00432,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trifluridine.,Trifluridine,DB00068
DB00441,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gemcitabine.,Gemcitabine,DB00068
DB00443,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Betamethasone.,Betamethasone,DB00068
DB00444,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teniposide.,Teniposide,DB00068
DB00445,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Epirubicin.,Epirubicin,DB00068
DB00446,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chloramphenicol.,Chloramphenicol,DB00068
DB00480,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lenalidomide.,Lenalidomide,DB00068
DB00488,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Altretamine.,Altretamine,DB00068
DB00495,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.,Zidovudine,DB00068
DB00515,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.,Cisplatin,DB00068
DB00526,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.,Oxaliplatin,DB00068
DB00531,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.,Cyclophosphamide,DB00068
DB00541,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine.,Vincristine,DB00068
DB00544,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil.,Fluorouracil,DB00068
DB00550,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.,Propylthiouracil,DB00068
DB00552,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pentostatin.,Pentostatin,DB00068
DB00563,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methotrexate.,Methotrexate,DB00068
DB00564,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carbamazepine.,Carbamazepine,DB00068
DB00570,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinblastine.,Vinblastine,DB00068
DB00588,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone propionate.,Fluticasone propionate,DB00068
DB00591,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00068
DB00601,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Linezolid.,Linezolid,DB00068
DB00619,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Imatinib.,Imatinib,DB00068
DB00620,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triamcinolone.,Triamcinolone,DB00068
DB00631,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clofarabine.,Clofarabine,DB00068
DB00635,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisone.,Prednisone,DB00068
DB00642,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pemetrexed.,Pemetrexed,DB00068
DB00687,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludrocortisone.,Fludrocortisone,DB00068
DB00688,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00068
DB00694,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.,Daunorubicin,DB00068
DB00755,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tretinoin.,Tretinoin,DB00068
DB00762,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Irinotecan.,Irinotecan,DB00068
DB00763,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methimazole.,Methimazole,DB00068
DB00764,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone.,Mometasone,DB00068
DB00773,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Etoposide.,Etoposide,DB00068
DB00795,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sulfasalazine.,Sulfasalazine,DB00068
DB00851,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dacarbazine.,Dacarbazine,DB00068
DB00853,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temozolomide.,Temozolomide,DB00068
DB00859,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Penicillamine.,Penicillamine,DB00068
DB00860,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisolone.,Prednisolone,DB00068
DB00877,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirolimus.,Sirolimus,DB00068
DB00888,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mechlorethamine.,Mechlorethamine,DB00068
DB00928,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azacitidine.,Azacitidine,DB00068
DB00958,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.,Carboplatin,DB00068
DB00959,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone.,Methylprednisolone,DB00068
DB00970,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dactinomycin.,Dactinomycin,DB00068
DB00987,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.,Cytarabine,DB00068
DB00993,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azathioprine.,Azathioprine,DB00068
DB00997,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxorubicin.,Doxorubicin,DB00068
DB01005,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxyurea.,Hydroxyurea,DB00068
DB01008,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Busulfan.,Busulfan,DB00068
DB01024,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolic acid.,Mycophenolic acid,DB00068
DB01030,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.,Topotecan,DB00068
DB01033,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mercaptopurine.,Mercaptopurine,DB00068
DB01041,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thalidomide.,Thalidomide,DB00068
DB01042,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melphalan.,Melphalan,DB00068
DB01073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludarabine.,Fludarabine,DB00068
DB01099,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flucytosine.,Flucytosine,DB00068
DB01101,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Capecitabine.,Capecitabine,DB00068
DB01108,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trilostane.,Trilostane,DB00068
DB01168,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Procarbazine.,Procarbazine,DB00068
DB01169,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Arsenic trioxide.,Arsenic trioxide,DB00068
DB01177,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idarubicin.,Idarubicin,DB00068
DB01181,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ifosfamide.,Ifosfamide,DB00068
DB01196,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Estramustine.,Estramustine,DB00068
DB01204,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitoxantrone.,Mitoxantrone,DB00068
DB01206,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lomustine.,Lomustine,DB00068
DB01222,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Budesonide.,Budesonide,DB00068
DB01229,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paclitaxel.,Paclitaxel,DB00068
DB01234,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone.,Dexamethasone,DB00068
DB01248,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Docetaxel.,Docetaxel,DB00068
DB01254,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dasatinib.,Dasatinib,DB00068
DB01257,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eculizumab.,Eculizumab,DB00068
DB01262,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Decitabine.,Decitabine,DB00068
DB01268,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sunitinib.,Sunitinib,DB00068
DB01280,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nelarabine.,Nelarabine,DB00068
DB01281,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abatacept.,Abatacept,DB00068
DB01285,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Corticotropin.,Corticotropin,DB00068
DB01380,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortisone acetate.,Cortisone acetate,DB00068
DB01384,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paramethasone.,Paramethasone,DB00068
DB01394,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Colchicine.,Colchicine,DB00068
DB01410,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ciclesonide.,Ciclesonide,DB00068
DB01423,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Stepronin.,Stepronin,DB00068
DB01590,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Everolimus.,Everolimus,DB00068
DB01611,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00068
DB01816,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Castanospermine.,Castanospermine,DB00068
DB02546,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vorinostat.,Vorinostat,DB00068
DB02806,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00068
DB03523,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brequinar.,Brequinar,DB00068
DB04572,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thiotepa.,Thiotepa,DB00068
DB04630,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Aldosterone.,Aldosterone,DB00068
DB04845,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixabepilone.,Ixabepilone,DB00068
DB04868,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nilotinib.,Nilotinib,DB00068
DB04951,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirfenidone.,Pirfenidone,DB00068
DB04956,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Afelimomab.,Afelimomab,DB00068
DB05015,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belinostat.,Belinostat,DB00068
DB05109,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trabectedin.,Trabectedin,DB00068
DB05258,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa.,Interferon alfa,DB00068
DB05259,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Glatiramer.,Glatiramer,DB00068
DB05260,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gallium nitrate.,Gallium nitrate,DB00068
DB05459,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Briakinumab.,Briakinumab,DB00068
DB05472,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with omega interferon.,omega interferon,DB00068
DB05676,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Apremilast.,Apremilast,DB00068
DB05773,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00068
DB06168,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Canakinumab.,Canakinumab,DB00068
DB06273,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tocilizumab.,Tocilizumab,DB00068
DB06287,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temsirolimus.,Temsirolimus,DB00068
DB06372,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rilonacept.,Rilonacept,DB00068
DB06589,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pazopanib.,Pazopanib,DB00068
DB06603,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Panobinostat.,Panobinostat,DB00068
DB06612,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mepolizumab.,Mepolizumab,DB00068
DB06616,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bosutinib.,Bosutinib,DB00068
DB06662,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abetimus.,Abetimus,DB00068
DB06674,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Golimumab.,Golimumab,DB00068
DB06681,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belatacept.,Belatacept,DB00068
DB06769,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bendamustine.,Bendamustine,DB00068
DB06772,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cabazitaxel.,Cabazitaxel,DB00068
DB06813,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pralatrexate.,Pralatrexate,DB00068
DB08059,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Wortmannin.,Wortmannin,DB00068
DB08870,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00068
DB08871,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eribulin.,Eribulin,DB00068
DB08877,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.,Ruxolitinib,DB00068
DB08879,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belimumab.,Belimumab,DB00068
DB08880,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teriflunomide.,Teriflunomide,DB00068
DB08889,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carfilzomib.,Carfilzomib,DB00068
DB08901,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ponatinib.,Ponatinib,DB00068
DB08904,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Certolizumab pegol.,Certolizumab pegol,DB00068
DB08906,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone furoate.,Fluticasone furoate,DB00068
DB08908,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00068
DB08910,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.,Pomalidomide,DB00068
DB08935,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Obinutuzumab.,Obinutuzumab,DB00068
DB08970,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednidene.,Fluprednidene,DB00068
DB08971,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortolone.,Fluocortolone,DB00068
DB09029,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Secukinumab.,Secukinumab,DB00068
DB09033,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vedolizumab.,Vedolizumab,DB00068
DB09036,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siltuximab.,Siltuximab,DB00068
DB09052,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Blinatumomab.,Blinatumomab,DB00068
DB09053,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibrutinib.,Ibrutinib,DB00068
DB09054,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idelalisib.,Idelalisib,DB00068
DB09073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Palbociclib.,Palbociclib,DB00068
DB09074,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Olaparib.,Olaparib,DB00068
DB09077,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dinutuximab.,Dinutuximab,DB00068
DB09082,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vilanterol.,Vilanterol,DB00068
DB09091,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tixocortol.,Tixocortol,DB00068
DB09122,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00068
DB09312,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00068
DB09378,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednisolone.,Fluprednisolone,DB00068
DB09383,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Meprednisone.,Meprednisone,DB00068
DB11466,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tepoxalin.,Tepoxalin,DB00068
DB11487,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00068
DB11529,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melengestrol.,Melengestrol,DB00068
DB11569,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixekizumab.,Ixekizumab,DB00068
DB11580,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ravulizumab.,Ravulizumab,DB00068
DB11616,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirarubicin.,Pirarubicin,DB00068
DB11693,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Voclosporin.,Voclosporin,DB00068
DB11708,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peficitinib.,Peficitinib,DB00068
DB11750,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clobetasol.,Clobetasol,DB00068
DB11767,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sarilumab.,Sarilumab,DB00068
DB11776,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brodalumab.,Brodalumab,DB00068
DB11803,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirukumab.,Sirukumab,DB00068
DB11817,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Baricitinib.,Baricitinib,DB00068
DB11834,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Guselkumab.,Guselkumab,DB00068
DB11921,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deflazacort.,Deflazacort,DB00068
DB11988,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ocrelizumab.,Ocrelizumab,DB00068
DB12025,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triptolide.,Triptolide,DB00068
DB12371,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siponimod.,Siponimod,DB00068
DB12612,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ozanimod.,Ozanimod,DB00068
DB12617,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mizoribine.,Mizoribine,DB00068
DB12692,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gusperimus.,Gusperimus,DB00068
DB12814,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00068
DB12902,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trofosfamide.,Trofosfamide,DB00068
DB12947,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxifluridine.,Doxifluridine,DB00068
DB12991,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deoxyspergualin.,Deoxyspergualin,DB00068
DB12996,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Acteoside.,Acteoside,DB00068
DB13003,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortivazol.,Cortivazol,DB00068
DB13014,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hypericin.,Hypericin,DB00068
DB13068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00068
DB13208,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednylidene.,Prednylidene,DB00068
DB13223,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortin.,Fluocortin,DB00068
DB13241,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Begelomab.,Begelomab,DB00068
DB13491,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluperolone.,Fluperolone,DB00068
DB13664,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Formocortal.,Formocortal,DB00068
DB13728,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Halometasone.,Halometasone,DB00068
DB13843,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cloprednol.,Cloprednol,DB00068
DB13856,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluclorolone.,Fluclorolone,DB00068
DB13867,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone.,Fluticasone,DB00068
DB14066,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tetrandrine.,Tetrandrine,DB00068
DB14219,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00068
DB14512,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone furoate.,Mometasone furoate,DB00068
DB14538,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00068
DB14539,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00068
DB14545,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00068
DB14724,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Emapalumab.,Emapalumab,DB00068
DB14762,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Risankizumab.,Risankizumab,DB00068
DB14919,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rozanolixizumab.,Rozanolixizumab,DB00068
DB15253,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleselumab.,Bleselumab,DB00068
DB00108,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.,Natalizumab,DB00068
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon beta-1b.,Pimecrolimus,DB00068
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon beta-1b.,Roflumilast,DB00068
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon beta-1b.,Sipuleucel-T,DB00068
DB00363,The risk or severity of neutropenia can be increased when Interferon beta-1b is combined with Clozapine.,Clozapine,DB00068
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1b.,Zolmitriptan,DB00068
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon beta-1b.,Sulfamethoxazole,DB00068
DB01097,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Leflunomide.,Leflunomide,DB00068
DB08895,Interferon beta-1b may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00068
DB00072,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.,Trastuzumab,DB00068
DB08868,Interferon beta-1b may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00068
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon beta-1b.,Tacrolimus,DB00068
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon beta-1b.,Caffeine,DB00068
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.,Dyphylline,DB00068
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1b.,Pentoxifylline,DB00068
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1b.,Oxtriphylline,DB00068
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon beta-1b.,Theobromine,DB00068
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1b.,Fenethylline,DB00068
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1b.,8-azaguanine,DB00068
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1b.","7,9-Dimethylguanine",DB00068
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon beta-1b.,Xanthine,DB00068
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1b.,7-Deazaguanine,DB00068
DB02377,The metabolism of Guanine can be decreased when combined with Interferon beta-1b.,Guanine,DB00068
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1b.,9-Methylguanine,DB00068
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon beta-1b.,Peldesine,DB00068
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1b.,Hypoxanthine,DB00068
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1b.,9-Deazaguanine,DB00068
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1b.,Propentofylline,DB00068
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1b.,Valomaciclovir,DB00068
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1b.,3-isobutyl-1-methyl-7H-xanthine,DB00068
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon beta-1b.,Uric acid,DB00068
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1b.,Doxofylline,DB00068
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1b.,6-O-benzylguanine,DB00068
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1b.,Lisofylline,DB00068
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1b.,Lobucavir,DB00068
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1b.,Cafedrine,DB00068
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1b.,Theodrenaline,DB00068
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1b.,Bamifylline,DB00068
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1b.,Proxyphylline,DB00068
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon beta-1b.,Acefylline,DB00068
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1b.,Etamiphylline,DB00068
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1b.,Pentifylline,DB00068
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon beta-1b.,Bufylline,DB00068
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1b.,Bromotheophylline,DB00068
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon beta-1b.,Furafylline,DB00068
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1b.,8-chlorotheophylline,DB00068
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1b.,PCS-499,DB00068
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon beta-1b.,G17DT,DB00068
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon beta-1b.,PEV3A,DB00068
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon beta-1b.,INGN 225,DB00068
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon beta-1b.,Rindopepimut,DB00068
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon beta-1b.,SRP 299,DB00068
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon beta-1b.,GI-5005,DB00068
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon beta-1b.,Vitespen,DB00068
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon beta-1b.,TG4010,DB00068
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon beta-1b.,Anthrax immune globulin human,DB00068
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon beta-1b.","Rabies virus inactivated antigen, B",DB00068
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00068
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon beta-1b.,Rotavirus vaccine,DB00068
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon beta-1b.","Rabies virus inactivated antigen, A",DB00068
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00068
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00068
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00068
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00068
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00068
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00068
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon beta-1b.,Typhoid Vi polysaccharide vaccine,DB00068
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon beta-1b.,Hepatitis A Vaccine,DB00068
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00068
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00068
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00068
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00068
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00068
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon beta-1b.,Human rabies virus immune globulin,DB00068
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.,Hepatitis B Vaccine (Recombinant),DB00068
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon beta-1b.,Tecemotide,DB00068
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon beta-1b.,Typhoid vaccine,DB00068
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00068
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00068
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00068
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00068
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00068
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00068
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00068
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon beta-1b.,Vaccinia virus strain new york city board of health live antigen,DB00068
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon beta-1b.,Pertussis vaccine,DB00068
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00068
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.,Varicella Zoster Vaccine (Recombinant),DB00068
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon beta-1b.,Modified vaccinia ankara,DB00068
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon beta-1b.","Ebola Zaire vaccine (live, attenuated)",DB00068
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon beta-1b.,Abciximab,DB00068
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.,Eptifibatide,DB00068
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon beta-1b.,Ticlopidine,DB00068
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon beta-1b.,Tirofiban,DB00068
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon beta-1b.,Acetylsalicylic acid,DB00068
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon beta-1b.,Dipyridamole,DB00068
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon beta-1b.,Iloprost,DB00068
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon beta-1b.,Sulfinpyrazone,DB00068
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon beta-1b.,Ridogrel,DB00068
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon beta-1b.,Sevoflurane,DB00068
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon beta-1b.,Epoprostenol,DB00068
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon beta-1b.,Nimesulide,DB00068
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon beta-1b.,Tesmilifene,DB00068
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon beta-1b.,Defibrotide,DB00068
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon beta-1b.,Beraprost,DB00068
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon beta-1b.,Ibudilast,DB00068
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon beta-1b.,Andrographolide,DB00068
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon beta-1b.,Caplacizumab,DB00068
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon beta-1b.,Prasugrel,DB00068
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon beta-1b.,Cangrelor,DB00068
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon beta-1b.,Tranilast,DB00068
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon beta-1b.,Triflusal,DB00068
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon beta-1b.,Ticagrelor,DB00068
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon beta-1b.,Icosapent ethyl,DB00068
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon beta-1b.,Vorapaxar,DB00068
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon beta-1b.,Trapidil,DB00068
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon beta-1b.,Naftopidil,DB00068
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon beta-1b.,Sarpogrelate,DB00068
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon beta-1b.,Ifetroban,DB00068
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon beta-1b.,Nitroaspirin,DB00068
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon beta-1b.,Ketanserin,DB00068
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon beta-1b.,Indobufen,DB00068
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon beta-1b.,Butylphthalide,DB00068
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon beta-1b.,Hydroxytyrosol,DB00068
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon beta-1b.,Ramatroban,DB00068
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon beta-1b.,Picotamide,DB00068
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon beta-1b.,Cloricromen,DB00068
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon beta-1b.,Linsidomine,DB00068
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon beta-1b.,Buflomedil,DB00068
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon beta-1b.,Relcovaptan,DB00068
DB13200,Interferon beta-1b may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00068
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon beta-1b.,Rubella virus vaccine,DB00068
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon beta-1b.,Varicella Zoster Vaccine (Live/attenuated),DB00068
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain tice live antigen,DB00068
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain connaught live antigen,DB00068
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon beta-1b.,Yellow Fever Vaccine,DB00068
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon beta-1b.,Anthrax vaccine,DB00068
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon beta-1b.,Typhoid Vaccine Live,DB00068
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00068
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon beta-1b.,BCG vaccine,DB00068
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon beta-1b.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00068
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon beta-1b.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00068
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon beta-1b.,Adenovirus type 7 vaccine live,DB00068
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon beta-1b.,Palifermin,DB00068
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1b.,Fluvoxamine,DB00068
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon beta-1b.,Nicotine,DB00068
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1b.,Betaxolol,DB00068
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1b.,Anagrelide,DB00068
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.,Disopyramide,DB00068
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1b.,Lidocaine,DB00068
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1b.,Conjugated estrogens,DB00068
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1b.,Ropivacaine,DB00068
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1b.,Acetaminophen,DB00068
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1b.,Olanzapine,DB00068
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1b.,Chlorzoxazone,DB00068
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1b.,Grepafloxacin,DB00068
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1b.,Mirtazapine,DB00068
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1b.,Mexiletine,DB00068
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon beta-1b.,Tacrine,DB00068
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon beta-1b.,Triamterene,DB00068
DB00420,The metabolism of Promazine can be decreased when combined with Interferon beta-1b.,Promazine,DB00068
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1b.,Zolpidem,DB00068
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon beta-1b.,Entecavir,DB00068
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1b.,Nabumetone,DB00068
DB00468,The metabolism of Quinine can be decreased when combined with Interferon beta-1b.,Quinine,DB00068
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1b.,Fluoxetine,DB00068
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1b.,Duloxetine,DB00068
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1b.,Chlorpromazine,DB00068
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon beta-1b.,Flutamide,DB00068
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.,Haloperidol,DB00068
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon beta-1b.,Albendazole,DB00068
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1b.,Rofecoxib,DB00068
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1b.,Cinnarizine,DB00068
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon beta-1b.,Propranolol,DB00068
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1b.,Diclofenac,DB00068
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1b.,Guanabenz,DB00068
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon beta-1b.,Verapamil,DB00068
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1b.,Paroxetine,DB00068
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1b.,Thiabendazole,DB00068
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon beta-1b.,Riluzole,DB00068
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon beta-1b.,Zileuton,DB00068
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1b.,Clopidogrel,DB00068
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon beta-1b.,Estradiol,DB00068
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1b.,Acyclovir,DB00068
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon beta-1b.,Naproxen,DB00068
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1b.,Trifluoperazine,DB00068
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1b.,Perphenazine,DB00068
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1b.,Terbinafine,DB00068
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1b.,Ranitidine,DB00068
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon beta-1b.,Ethanol,DB00068
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1b.,Maprotiline,DB00068
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon beta-1b.,Alosetron,DB00068
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1b.,Lomefloxacin,DB00068
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1b.,Ramelteon,DB00068
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1b.,Frovatriptan,DB00068
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1b.,Levobupivacaine,DB00068
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1b.,Cinacalcet,DB00068
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon beta-1b.,Selegiline,DB00068
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon beta-1b.,Tocainide,DB00068
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1b.,Praziquantel,DB00068
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon beta-1b.,Melatonin,DB00068
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon beta-1b.,Primaquine,DB00068
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1b.,Hesperetin,DB00068
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1b.,Nifedipine,DB00068
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1b.,Carvedilol,DB00068
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1b.,Cilostazol,DB00068
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon beta-1b.,Propafenone,DB00068
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon beta-1b.,Domperidone,DB00068
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1b.,Dexfenfluramine,DB00068
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1b.,Rasagiline,DB00068
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1b.,Temafloxacin,DB00068
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1b.,Aminophenazone,DB00068
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1b.,Antipyrine,DB00068
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1b.,Bromazepam,DB00068
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1b.,Thiothixene,DB00068
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1b.,Etoricoxib,DB00068
DB01645,The metabolism of Genistein can be decreased when combined with Interferon beta-1b.,Genistein,DB00068
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1b.,Resveratrol,DB00068
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1b.,Phenacetin,DB00068
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1b.,Estrone sulfate,DB00068
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1b.,Flunarizine,DB00068
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1b.,Lorcaserin,DB00068
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1b.,Lofexidine,DB00068
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon beta-1b.,Mianserin,DB00068
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1b.,Eltrombopag,DB00068
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon beta-1b.,Asenapine,DB00068
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1b.,Vadimezan,DB00068
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1b.,Dapagliflozin,DB00068
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1b.,Agomelatine,DB00068
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon beta-1b.,Axitinib,DB00068
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1b.,Benzyl alcohol,DB00068
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1b.,Capsaicin,DB00068
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1b.,(R)-warfarin,DB00068
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon beta-1b.,Perampanel,DB00068
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1b.,Tasimelteon,DB00068
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1b.,Stiripentol,DB00068
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon beta-1b.,Zotepine,DB00068
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1b.,Propacetamol,DB00068
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1b.,Ramosetron,DB00068
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1b.,Binimetinib,DB00068
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1b.,Voxilaprevir,DB00068
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1b.,Triclabendazole,DB00068
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1b.,Rucaparib,DB00068
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1b.,Dihydralazine,DB00068
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1b.,Estradiol acetate,DB00068
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1b.,Estradiol benzoate,DB00068
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1b.,Estradiol cypionate,DB00068
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1b.,Estradiol dienanthate,DB00068
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1b.,Estradiol valerate,DB00068
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1b.,Istradefylline,DB00068
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon beta-1b.,Azelastine,DB00068
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1b.,Efavirenz,DB00068
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1b.,Metoclopramide,DB00068
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1b.,Bicifadine,DB00068
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1b.,GTS-21,DB00068
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon beta-1b.,Flecainide,DB00068
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1b.,Ethinylestradiol,DB00068
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1b.,Amitriptyline,DB00068
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon beta-1b.,Imipramine,DB00068
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon beta-1b.,Doxepin,DB00068
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1b.,Mephenytoin,DB00068
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1b.,Nortriptyline,DB00068
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon beta-1b.,Clonidine,DB00068
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1b.,Cyclobenzaprine,DB00068
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon beta-1b.,Desipramine,DB00068
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1b.,Clomipramine,DB00068
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1b.,Selumetinib,DB00068
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon beta-1b.,Theophylline,DB00068
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon beta-1b.,Warfarin,DB00068
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1b.,Tizanidine,DB00068
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon beta-1b.,Pimozide,DB00068
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b.,Aminophylline,DB00068
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1b.,Acenocoumarol,DB00068
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1b.,Erlotinib,DB00068
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon beta-1b.,Tegafur,DB00068
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1b.,Enasidenib,DB00068
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1b.,Tamoxifen,DB00068
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.,Lepirudin,DB00068
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon beta-1b.,Bivalirudin,DB00068
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon beta-1b.,Alteplase,DB00068
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon beta-1b.,Urokinase,DB00068
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.,Reteplase,DB00068
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon beta-1b.,Anistreplase,DB00068
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon beta-1b.,Tenecteplase,DB00068
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.,Drotrecogin alfa,DB00068
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.,Streptokinase,DB00068
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon beta-1b.,Dicoumarol,DB00068
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon beta-1b.,Argatroban,DB00068
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon beta-1b.,Ardeparin,DB00068
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon beta-1b.,Phenindione,DB00068
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon beta-1b.,Fondaparinux,DB00068
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon beta-1b.,Pentosan polysulfate,DB00068
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon beta-1b.,Phenprocoumon,DB00068
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon beta-1b.,Heparin,DB00068
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon beta-1b.,Enoxaparin,DB00068
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon beta-1b.,4-hydroxycoumarin,DB00068
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon beta-1b.,Coumarin,DB00068
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon beta-1b.,Ximelagatran,DB00068
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon beta-1b.,Desmoteplase,DB00068
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon beta-1b.,Ancrod,DB00068
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon beta-1b.,Fibrinolysin,DB00068
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon beta-1b.,Rivaroxaban,DB00068
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon beta-1b.,Sulodexide,DB00068
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon beta-1b.,Semuloparin,DB00068
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon beta-1b.,Idraparinux,DB00068
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon beta-1b.,Astaxanthin,DB00068
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon beta-1b.,Apixaban,DB00068
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon beta-1b.,Otamixaban,DB00068
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon beta-1b.,Amediplase,DB00068
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon beta-1b.,Dabigatran etexilate,DB00068
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon beta-1b.,Danaparoid,DB00068
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon beta-1b.,Dalteparin,DB00068
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon beta-1b.,Tinzaparin,DB00068
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon beta-1b.,Ferulic acid,DB00068
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon beta-1b.,Ethyl biscoumacetate,DB00068
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon beta-1b.,Nadroparin,DB00068
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon beta-1b.,Ditazole,DB00068
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon beta-1b.,Edoxaban,DB00068
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon beta-1b.,Potassium citrate,DB00068
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon beta-1b.,Sodium citrate,DB00068
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon beta-1b.,Dextran,DB00068
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon beta-1b.,Bemiparin,DB00068
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon beta-1b.,Reviparin,DB00068
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon beta-1b.,Parnaparin,DB00068
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon beta-1b.,Certoparin,DB00068
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon beta-1b.,Desirudin,DB00068
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon beta-1b.,Zinc citrate,DB00068
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon beta-1b.,Antithrombin Alfa,DB00068
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon beta-1b.,Protein C,DB00068
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon beta-1b.,Antithrombin III human,DB00068
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon beta-1b.,Letaxaban,DB00068
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon beta-1b.,Darexaban,DB00068
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon beta-1b.,Betrixaban,DB00068
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon beta-1b.,Nafamostat,DB00068
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon beta-1b.,Monteplase,DB00068
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon beta-1b.,Gabexate,DB00068
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon beta-1b.,Fluindione,DB00068
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon beta-1b.,Protein S human,DB00068
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon beta-1b.,Brinase,DB00068
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon beta-1b.,Clorindione,DB00068
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon beta-1b.,Diphenadione,DB00068
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon beta-1b.,Tioclomarol,DB00068
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon beta-1b.,Melagatran,DB00068
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon beta-1b.,Saruplase,DB00068
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon beta-1b.,(S)-Warfarin,DB00068
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon beta-1b.,Tocopherylquinone,DB00068
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon beta-1b.,Edetate calcium disodium anhydrous,DB00068
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon beta-1b.,Dabigatran,DB00068
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon beta-1b.,Methyclothiazide,DB00068
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon beta-1b.,Bendroflumethiazide,DB00068
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon beta-1b.,Benzthiazide,DB00068
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon beta-1b.,Cyclothiazide,DB00068
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon beta-1b.,Hydroflumethiazide,DB00068
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon beta-1b.,Chlorothiazide,DB00068
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon beta-1b.,Hydrochlorothiazide,DB00068
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon beta-1b.,Trichlormethiazide,DB00068
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon beta-1b.,Polythiazide,DB00068
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon beta-1b.,Mebutizide,DB00068
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon beta-1b.,Cyclopenthiazide,DB00068
DB09042,The risk or severity of myelosuppression can be increased when Interferon beta-1b is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00068
DB00091,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00068
DB00268,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ropinirole.,Ropinirole,DB00068
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.,Cyanocobalamin,DB00068
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon beta-1b.,Allopurinol,DB00068
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon beta-1b.,Magnesium,DB00068
DB01601,The serum concentration of Interferon beta-1b can be increased when it is combined with Lopinavir.,Lopinavir,DB00068
DB12530,The risk or severity of infection can be increased when Interferon beta-1b is combined with Inebilizumab.,Inebilizumab,DB00068
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfacon-1.,Denosumab,DB00069
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1.,Etanercept,DB00069
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfacon-1.,Peginterferon alfa-2a,DB00069
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1.,Interferon alfa-n1,DB00069
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfacon-1.,Interferon alfa-n3,DB00069
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1.,Peginterferon alfa-2b,DB00069
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1.,Anakinra,DB00069
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfacon-1.,Interferon gamma-1b,DB00069
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfacon-1.","Interferon alfa-2a, Recombinant",DB00069
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfacon-1.,Adalimumab,DB00069
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.,Gemtuzumab ozogamicin,DB00069
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.,Pegaspargase,DB00069
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.,Infliximab,DB00069
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.,Interferon beta-1b,DB00069
DB00073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.,Rituximab,DB00069
DB00074,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.,Basiliximab,DB00069
DB00075,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.,Muromonab,DB00069
DB00078,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00069
DB00081,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.,Tositumomab,DB00069
DB00087,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.,Alemtuzumab,DB00069
DB00092,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.,Alefacept,DB00069
DB00095,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.,Efalizumab,DB00069
DB00098,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00069
DB00105,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00069
DB00111,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.,Daclizumab,DB00069
DB00112,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.,Bevacizumab,DB00069
DB00120,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.,Phenylalanine,DB00069
DB00180,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flunisolide.,Flunisolide,DB00069
DB00188,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bortezomib.,Bortezomib,DB00069
DB00242,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cladribine.,Cladribine,DB00069
DB00262,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carmustine.,Carmustine,DB00069
DB00276,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Amsacrine.,Amsacrine,DB00069
DB00290,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleomycin.,Bleomycin,DB00069
DB00291,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chlorambucil.,Chlorambucil,DB00069
DB00293,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Raltitrexed.,Raltitrexed,DB00069
DB00305,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitomycin.,Mitomycin,DB00069
DB00307,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bexarotene.,Bexarotene,DB00069
DB00309,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vindesine.,Vindesine,DB00069
DB00322,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Floxuridine.,Floxuridine,DB00069
DB00328,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Indomethacin.,Indomethacin,DB00069
DB00352,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tioguanine.,Tioguanine,DB00069
DB00361,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinorelbine.,Vinorelbine,DB00069
DB00380,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexrazoxane.,Dexrazoxane,DB00069
DB00394,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00069
DB00398,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sorafenib.,Sorafenib,DB00069
DB00428,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Streptozocin.,Streptozocin,DB00069
DB00432,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trifluridine.,Trifluridine,DB00069
DB00441,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gemcitabine.,Gemcitabine,DB00069
DB00443,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Betamethasone.,Betamethasone,DB00069
DB00444,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teniposide.,Teniposide,DB00069
DB00445,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Epirubicin.,Epirubicin,DB00069
DB00446,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chloramphenicol.,Chloramphenicol,DB00069
DB00480,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lenalidomide.,Lenalidomide,DB00069
DB00488,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Altretamine.,Altretamine,DB00069
DB00495,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.,Zidovudine,DB00069
DB00515,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin.,Cisplatin,DB00069
DB00526,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin.,Oxaliplatin,DB00069
DB00531,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide.,Cyclophosphamide,DB00069
DB00541,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine.,Vincristine,DB00069
DB00544,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil.,Fluorouracil,DB00069
DB00550,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil.,Propylthiouracil,DB00069
DB00552,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pentostatin.,Pentostatin,DB00069
DB00563,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methotrexate.,Methotrexate,DB00069
DB00564,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carbamazepine.,Carbamazepine,DB00069
DB00570,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinblastine.,Vinblastine,DB00069
DB00588,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone propionate.,Fluticasone propionate,DB00069
DB00591,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00069
DB00601,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Linezolid.,Linezolid,DB00069
DB00619,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Imatinib.,Imatinib,DB00069
DB00620,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triamcinolone.,Triamcinolone,DB00069
DB00631,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clofarabine.,Clofarabine,DB00069
DB00635,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisone.,Prednisone,DB00069
DB00642,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pemetrexed.,Pemetrexed,DB00069
DB00687,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludrocortisone.,Fludrocortisone,DB00069
DB00688,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00069
DB00694,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.,Daunorubicin,DB00069
DB00755,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tretinoin.,Tretinoin,DB00069
DB00762,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Irinotecan.,Irinotecan,DB00069
DB00763,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methimazole.,Methimazole,DB00069
DB00764,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone.,Mometasone,DB00069
DB00773,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Etoposide.,Etoposide,DB00069
DB00795,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sulfasalazine.,Sulfasalazine,DB00069
DB00851,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dacarbazine.,Dacarbazine,DB00069
DB00853,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temozolomide.,Temozolomide,DB00069
DB00859,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Penicillamine.,Penicillamine,DB00069
DB00860,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisolone.,Prednisolone,DB00069
DB00877,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirolimus.,Sirolimus,DB00069
DB00888,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mechlorethamine.,Mechlorethamine,DB00069
DB00928,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azacitidine.,Azacitidine,DB00069
DB00958,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin.,Carboplatin,DB00069
DB00959,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone.,Methylprednisolone,DB00069
DB00970,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dactinomycin.,Dactinomycin,DB00069
DB00987,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.,Cytarabine,DB00069
DB00993,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azathioprine.,Azathioprine,DB00069
DB00997,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxorubicin.,Doxorubicin,DB00069
DB01005,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxyurea.,Hydroxyurea,DB00069
DB01008,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Busulfan.,Busulfan,DB00069
DB01024,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolic acid.,Mycophenolic acid,DB00069
DB01030,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan.,Topotecan,DB00069
DB01033,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mercaptopurine.,Mercaptopurine,DB00069
DB01041,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thalidomide.,Thalidomide,DB00069
DB01042,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melphalan.,Melphalan,DB00069
DB01073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludarabine.,Fludarabine,DB00069
DB01099,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flucytosine.,Flucytosine,DB00069
DB01101,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Capecitabine.,Capecitabine,DB00069
DB01108,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trilostane.,Trilostane,DB00069
DB01168,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Procarbazine.,Procarbazine,DB00069
DB01169,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Arsenic trioxide.,Arsenic trioxide,DB00069
DB01177,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idarubicin.,Idarubicin,DB00069
DB01181,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ifosfamide.,Ifosfamide,DB00069
DB01196,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Estramustine.,Estramustine,DB00069
DB01204,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitoxantrone.,Mitoxantrone,DB00069
DB01206,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lomustine.,Lomustine,DB00069
DB01222,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Budesonide.,Budesonide,DB00069
DB01229,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paclitaxel.,Paclitaxel,DB00069
DB01234,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone.,Dexamethasone,DB00069
DB01248,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Docetaxel.,Docetaxel,DB00069
DB01254,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dasatinib.,Dasatinib,DB00069
DB01257,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eculizumab.,Eculizumab,DB00069
DB01262,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Decitabine.,Decitabine,DB00069
DB01268,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sunitinib.,Sunitinib,DB00069
DB01280,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nelarabine.,Nelarabine,DB00069
DB01281,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abatacept.,Abatacept,DB00069
DB01285,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Corticotropin.,Corticotropin,DB00069
DB01380,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortisone acetate.,Cortisone acetate,DB00069
DB01384,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paramethasone.,Paramethasone,DB00069
DB01394,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Colchicine.,Colchicine,DB00069
DB01410,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ciclesonide.,Ciclesonide,DB00069
DB01423,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Stepronin.,Stepronin,DB00069
DB01590,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Everolimus.,Everolimus,DB00069
DB01611,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00069
DB01816,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Castanospermine.,Castanospermine,DB00069
DB02546,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vorinostat.,Vorinostat,DB00069
DB02806,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00069
DB03523,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brequinar.,Brequinar,DB00069
DB04572,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thiotepa.,Thiotepa,DB00069
DB04630,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldosterone.,Aldosterone,DB00069
DB04845,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixabepilone.,Ixabepilone,DB00069
DB04868,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nilotinib.,Nilotinib,DB00069
DB04951,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirfenidone.,Pirfenidone,DB00069
DB04956,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Afelimomab.,Afelimomab,DB00069
DB05015,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belinostat.,Belinostat,DB00069
DB05109,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trabectedin.,Trabectedin,DB00069
DB05258,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa.,Interferon alfa,DB00069
DB05259,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Glatiramer.,Glatiramer,DB00069
DB05260,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gallium nitrate.,Gallium nitrate,DB00069
DB05459,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Briakinumab.,Briakinumab,DB00069
DB05472,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with omega interferon.,omega interferon,DB00069
DB05676,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Apremilast.,Apremilast,DB00069
DB05773,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00069
DB06168,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Canakinumab.,Canakinumab,DB00069
DB06273,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tocilizumab.,Tocilizumab,DB00069
DB06287,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temsirolimus.,Temsirolimus,DB00069
DB06372,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rilonacept.,Rilonacept,DB00069
DB06589,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pazopanib.,Pazopanib,DB00069
DB06603,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Panobinostat.,Panobinostat,DB00069
DB06612,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mepolizumab.,Mepolizumab,DB00069
DB06616,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bosutinib.,Bosutinib,DB00069
DB06662,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abetimus.,Abetimus,DB00069
DB06674,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Golimumab.,Golimumab,DB00069
DB06681,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belatacept.,Belatacept,DB00069
DB06769,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bendamustine.,Bendamustine,DB00069
DB06772,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cabazitaxel.,Cabazitaxel,DB00069
DB06813,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pralatrexate.,Pralatrexate,DB00069
DB08059,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Wortmannin.,Wortmannin,DB00069
DB08870,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00069
DB08871,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eribulin.,Eribulin,DB00069
DB08877,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ruxolitinib.,Ruxolitinib,DB00069
DB08879,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belimumab.,Belimumab,DB00069
DB08880,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teriflunomide.,Teriflunomide,DB00069
DB08889,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carfilzomib.,Carfilzomib,DB00069
DB08901,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ponatinib.,Ponatinib,DB00069
DB08904,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Certolizumab pegol.,Certolizumab pegol,DB00069
DB08906,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone furoate.,Fluticasone furoate,DB00069
DB08908,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00069
DB08910,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pomalidomide.,Pomalidomide,DB00069
DB08935,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Obinutuzumab.,Obinutuzumab,DB00069
DB08970,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednidene.,Fluprednidene,DB00069
DB08971,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortolone.,Fluocortolone,DB00069
DB09029,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Secukinumab.,Secukinumab,DB00069
DB09033,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vedolizumab.,Vedolizumab,DB00069
DB09036,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siltuximab.,Siltuximab,DB00069
DB09052,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Blinatumomab.,Blinatumomab,DB00069
DB09053,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibrutinib.,Ibrutinib,DB00069
DB09054,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idelalisib.,Idelalisib,DB00069
DB09073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Palbociclib.,Palbociclib,DB00069
DB09074,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Olaparib.,Olaparib,DB00069
DB09077,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dinutuximab.,Dinutuximab,DB00069
DB09082,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vilanterol.,Vilanterol,DB00069
DB09091,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tixocortol.,Tixocortol,DB00069
DB09122,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00069
DB09312,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00069
DB09378,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednisolone.,Fluprednisolone,DB00069
DB09383,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Meprednisone.,Meprednisone,DB00069
DB11466,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tepoxalin.,Tepoxalin,DB00069
DB11487,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00069
DB11529,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melengestrol.,Melengestrol,DB00069
DB11569,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixekizumab.,Ixekizumab,DB00069
DB11580,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ravulizumab.,Ravulizumab,DB00069
DB11616,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirarubicin.,Pirarubicin,DB00069
DB11693,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Voclosporin.,Voclosporin,DB00069
DB11708,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peficitinib.,Peficitinib,DB00069
DB11750,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clobetasol.,Clobetasol,DB00069
DB11767,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sarilumab.,Sarilumab,DB00069
DB11776,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brodalumab.,Brodalumab,DB00069
DB11803,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirukumab.,Sirukumab,DB00069
DB11817,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Baricitinib.,Baricitinib,DB00069
DB11834,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Guselkumab.,Guselkumab,DB00069
DB11921,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deflazacort.,Deflazacort,DB00069
DB11988,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ocrelizumab.,Ocrelizumab,DB00069
DB12025,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triptolide.,Triptolide,DB00069
DB12371,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siponimod.,Siponimod,DB00069
DB12612,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ozanimod.,Ozanimod,DB00069
DB12617,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mizoribine.,Mizoribine,DB00069
DB12692,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gusperimus.,Gusperimus,DB00069
DB12814,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00069
DB12902,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trofosfamide.,Trofosfamide,DB00069
DB12947,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxifluridine.,Doxifluridine,DB00069
DB12991,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deoxyspergualin.,Deoxyspergualin,DB00069
DB12996,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Acteoside.,Acteoside,DB00069
DB13003,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortivazol.,Cortivazol,DB00069
DB13014,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hypericin.,Hypericin,DB00069
DB13068,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00069
DB13208,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednylidene.,Prednylidene,DB00069
DB13223,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortin.,Fluocortin,DB00069
DB13241,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Begelomab.,Begelomab,DB00069
DB13491,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluperolone.,Fluperolone,DB00069
DB13664,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Formocortal.,Formocortal,DB00069
DB13728,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Halometasone.,Halometasone,DB00069
DB13843,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cloprednol.,Cloprednol,DB00069
DB13856,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluclorolone.,Fluclorolone,DB00069
DB13867,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone.,Fluticasone,DB00069
DB14066,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tetrandrine.,Tetrandrine,DB00069
DB14219,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00069
DB14512,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone furoate.,Mometasone furoate,DB00069
DB14538,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00069
DB14539,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00069
DB14545,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00069
DB14724,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Emapalumab.,Emapalumab,DB00069
DB14762,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Risankizumab.,Risankizumab,DB00069
DB14919,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rozanolixizumab.,Rozanolixizumab,DB00069
DB15253,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleselumab.,Bleselumab,DB00069
DB00108,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.,Natalizumab,DB00069
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfacon-1.,Pimecrolimus,DB00069
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon alfacon-1.,Roflumilast,DB00069
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfacon-1.,Sipuleucel-T,DB00069
DB00041,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.,Aldesleukin,DB00069
DB00363,The risk or severity of neutropenia can be increased when Interferon alfacon-1 is combined with Clozapine.,Clozapine,DB00069
DB00333,The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.,Methadone,DB00069
DB00811,The risk or severity of anemia can be increased when Interferon alfacon-1 is combined with Ribavirin.,Ribavirin,DB00069
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfacon-1.,Zolmitriptan,DB00069
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfacon-1.,Sulfamethoxazole,DB00069
DB01265,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Telbivudine.,Telbivudine,DB00069
DB01097,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Leflunomide.,Leflunomide,DB00069
DB08895,Interferon alfacon-1 may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00069
DB00072,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.,Trastuzumab,DB00069
DB08868,Interferon alfacon-1 may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00069
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon alfacon-1.,Tacrolimus,DB00069
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon alfacon-1.,Caffeine,DB00069
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.,Dyphylline,DB00069
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfacon-1.,Pentoxifylline,DB00069
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfacon-1.,Oxtriphylline,DB00069
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon alfacon-1.,Theobromine,DB00069
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon alfacon-1.,Fenethylline,DB00069
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfacon-1.,8-azaguanine,DB00069
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfacon-1.","7,9-Dimethylguanine",DB00069
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon alfacon-1.,Xanthine,DB00069
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfacon-1.,7-Deazaguanine,DB00069
DB02377,The metabolism of Guanine can be decreased when combined with Interferon alfacon-1.,Guanine,DB00069
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfacon-1.,9-Methylguanine,DB00069
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon alfacon-1.,Peldesine,DB00069
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfacon-1.,Hypoxanthine,DB00069
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfacon-1.,9-Deazaguanine,DB00069
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon alfacon-1.,Propentofylline,DB00069
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfacon-1.,Valomaciclovir,DB00069
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfacon-1.,3-isobutyl-1-methyl-7H-xanthine,DB00069
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon alfacon-1.,Uric acid,DB00069
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon alfacon-1.,Doxofylline,DB00069
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfacon-1.,6-O-benzylguanine,DB00069
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon alfacon-1.,Lisofylline,DB00069
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon alfacon-1.,Lobucavir,DB00069
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon alfacon-1.,Cafedrine,DB00069
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon alfacon-1.,Theodrenaline,DB00069
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon alfacon-1.,Bamifylline,DB00069
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon alfacon-1.,Proxyphylline,DB00069
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon alfacon-1.,Acefylline,DB00069
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon alfacon-1.,Etamiphylline,DB00069
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon alfacon-1.,Pentifylline,DB00069
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon alfacon-1.,Bufylline,DB00069
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfacon-1.,Bromotheophylline,DB00069
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon alfacon-1.,Furafylline,DB00069
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfacon-1.,8-chlorotheophylline,DB00069
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon alfacon-1.,PCS-499,DB00069
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfacon-1.,G17DT,DB00069
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfacon-1.,PEV3A,DB00069
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfacon-1.,INGN 225,DB00069
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfacon-1.,Rindopepimut,DB00069
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfacon-1.,SRP 299,DB00069
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfacon-1.,GI-5005,DB00069
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfacon-1.,Vitespen,DB00069
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfacon-1.,TG4010,DB00069
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfacon-1.,Anthrax immune globulin human,DB00069
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfacon-1.","Rabies virus inactivated antigen, B",DB00069
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00069
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfacon-1.,Rotavirus vaccine,DB00069
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfacon-1.","Rabies virus inactivated antigen, A",DB00069
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00069
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00069
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00069
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00069
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00069
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00069
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfacon-1.,Typhoid Vi polysaccharide vaccine,DB00069
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfacon-1.,Hepatitis A Vaccine,DB00069
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00069
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00069
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00069
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00069
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00069
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfacon-1.,Human rabies virus immune globulin,DB00069
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.,Hepatitis B Vaccine (Recombinant),DB00069
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfacon-1.,Tecemotide,DB00069
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfacon-1.,Typhoid vaccine,DB00069
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00069
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00069
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00069
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00069
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00069
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00069
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00069
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfacon-1.,Vaccinia virus strain new york city board of health live antigen,DB00069
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfacon-1.,Pertussis vaccine,DB00069
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00069
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.,Varicella Zoster Vaccine (Recombinant),DB00069
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfacon-1.,Modified vaccinia ankara,DB00069
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfacon-1.","Ebola Zaire vaccine (live, attenuated)",DB00069
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfacon-1.,Abciximab,DB00069
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.,Eptifibatide,DB00069
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfacon-1.,Ticlopidine,DB00069
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfacon-1.,Tirofiban,DB00069
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfacon-1.,Acetylsalicylic acid,DB00069
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfacon-1.,Dipyridamole,DB00069
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfacon-1.,Iloprost,DB00069
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfacon-1.,Sulfinpyrazone,DB00069
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfacon-1.,Ridogrel,DB00069
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfacon-1.,Sevoflurane,DB00069
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfacon-1.,Epoprostenol,DB00069
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfacon-1.,Nimesulide,DB00069
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfacon-1.,Tesmilifene,DB00069
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfacon-1.,Defibrotide,DB00069
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfacon-1.,Beraprost,DB00069
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfacon-1.,Ibudilast,DB00069
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfacon-1.,Andrographolide,DB00069
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfacon-1.,Caplacizumab,DB00069
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfacon-1.,Prasugrel,DB00069
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfacon-1.,Cangrelor,DB00069
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfacon-1.,Tranilast,DB00069
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfacon-1.,Triflusal,DB00069
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfacon-1.,Ticagrelor,DB00069
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfacon-1.,Icosapent ethyl,DB00069
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfacon-1.,Vorapaxar,DB00069
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfacon-1.,Trapidil,DB00069
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfacon-1.,Naftopidil,DB00069
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfacon-1.,Sarpogrelate,DB00069
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfacon-1.,Ifetroban,DB00069
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfacon-1.,Nitroaspirin,DB00069
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfacon-1.,Ketanserin,DB00069
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfacon-1.,Indobufen,DB00069
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfacon-1.,Butylphthalide,DB00069
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfacon-1.,Hydroxytyrosol,DB00069
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfacon-1.,Ramatroban,DB00069
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfacon-1.,Picotamide,DB00069
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfacon-1.,Cloricromen,DB00069
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfacon-1.,Linsidomine,DB00069
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfacon-1.,Buflomedil,DB00069
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfacon-1.,Relcovaptan,DB00069
DB13200,Interferon alfacon-1 may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00069
DB10318,The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Varicella Zoster Vaccine (Live/attenuated).,Varicella Zoster Vaccine (Live/attenuated),DB00069
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfacon-1.,Rubella virus vaccine,DB00069
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain tice live antigen,DB00069
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain connaught live antigen,DB00069
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfacon-1.,Yellow Fever Vaccine,DB00069
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfacon-1.,Anthrax vaccine,DB00069
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfacon-1.,Typhoid Vaccine Live,DB00069
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00069
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfacon-1.,BCG vaccine,DB00069
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfacon-1.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00069
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfacon-1.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00069
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfacon-1.,Adenovirus type 7 vaccine live,DB00069
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfacon-1.,Palifermin,DB00069
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfacon-1.,Fluvoxamine,DB00069
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon alfacon-1.,Nicotine,DB00069
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon alfacon-1.,Betaxolol,DB00069
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon alfacon-1.,Anagrelide,DB00069
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon alfacon-1.,Disopyramide,DB00069
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon alfacon-1.,Lidocaine,DB00069
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfacon-1.,Conjugated estrogens,DB00069
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon alfacon-1.,Ropivacaine,DB00069
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon alfacon-1.,Acetaminophen,DB00069
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon alfacon-1.,Olanzapine,DB00069
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfacon-1.,Chlorzoxazone,DB00069
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfacon-1.,Grepafloxacin,DB00069
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon alfacon-1.,Mirtazapine,DB00069
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon alfacon-1.,Mexiletine,DB00069
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon alfacon-1.,Tacrine,DB00069
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon alfacon-1.,Triamterene,DB00069
DB00420,The metabolism of Promazine can be decreased when combined with Interferon alfacon-1.,Promazine,DB00069
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon alfacon-1.,Zolpidem,DB00069
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon alfacon-1.,Entecavir,DB00069
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon alfacon-1.,Nabumetone,DB00069
DB00468,The metabolism of Quinine can be decreased when combined with Interferon alfacon-1.,Quinine,DB00069
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon alfacon-1.,Fluoxetine,DB00069
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon alfacon-1.,Duloxetine,DB00069
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfacon-1.,Chlorpromazine,DB00069
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon alfacon-1.,Flutamide,DB00069
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon alfacon-1.,Haloperidol,DB00069
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon alfacon-1.,Albendazole,DB00069
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon alfacon-1.,Rofecoxib,DB00069
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon alfacon-1.,Cinnarizine,DB00069
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon alfacon-1.,Propranolol,DB00069
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon alfacon-1.,Diclofenac,DB00069
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon alfacon-1.,Guanabenz,DB00069
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon alfacon-1.,Verapamil,DB00069
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon alfacon-1.,Paroxetine,DB00069
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon alfacon-1.,Thiabendazole,DB00069
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon alfacon-1.,Riluzole,DB00069
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon alfacon-1.,Zileuton,DB00069
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon alfacon-1.,Clopidogrel,DB00069
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon alfacon-1.,Estradiol,DB00069
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon alfacon-1.,Acyclovir,DB00069
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon alfacon-1.,Naproxen,DB00069
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfacon-1.,Trifluoperazine,DB00069
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon alfacon-1.,Perphenazine,DB00069
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon alfacon-1.,Terbinafine,DB00069
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon alfacon-1.,Ranitidine,DB00069
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon alfacon-1.,Ethanol,DB00069
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon alfacon-1.,Maprotiline,DB00069
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon alfacon-1.,Alosetron,DB00069
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfacon-1.,Lomefloxacin,DB00069
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon alfacon-1.,Ramelteon,DB00069
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon alfacon-1.,Frovatriptan,DB00069
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfacon-1.,Levobupivacaine,DB00069
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon alfacon-1.,Cinacalcet,DB00069
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon alfacon-1.,Selegiline,DB00069
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon alfacon-1.,Tocainide,DB00069
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon alfacon-1.,Praziquantel,DB00069
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon alfacon-1.,Melatonin,DB00069
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon alfacon-1.,Primaquine,DB00069
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon alfacon-1.,Hesperetin,DB00069
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon alfacon-1.,Nifedipine,DB00069
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon alfacon-1.,Carvedilol,DB00069
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon alfacon-1.,Cilostazol,DB00069
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon alfacon-1.,Propafenone,DB00069
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon alfacon-1.,Domperidone,DB00069
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfacon-1.,Dexfenfluramine,DB00069
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon alfacon-1.,Rasagiline,DB00069
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon alfacon-1.,Temafloxacin,DB00069
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon alfacon-1.,Aminophenazone,DB00069
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon alfacon-1.,Antipyrine,DB00069
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon alfacon-1.,Bromazepam,DB00069
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon alfacon-1.,Thiothixene,DB00069
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon alfacon-1.,Etoricoxib,DB00069
DB01645,The metabolism of Genistein can be decreased when combined with Interferon alfacon-1.,Genistein,DB00069
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon alfacon-1.,Resveratrol,DB00069
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon alfacon-1.,Phenacetin,DB00069
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfacon-1.,Estrone sulfate,DB00069
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon alfacon-1.,Flunarizine,DB00069
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon alfacon-1.,Lorcaserin,DB00069
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon alfacon-1.,Lofexidine,DB00069
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon alfacon-1.,Mianserin,DB00069
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon alfacon-1.,Eltrombopag,DB00069
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon alfacon-1.,Asenapine,DB00069
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon alfacon-1.,Vadimezan,DB00069
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfacon-1.,Dapagliflozin,DB00069
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon alfacon-1.,Agomelatine,DB00069
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon alfacon-1.,Axitinib,DB00069
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfacon-1.,Benzyl alcohol,DB00069
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon alfacon-1.,Capsaicin,DB00069
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfacon-1.,(R)-warfarin,DB00069
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon alfacon-1.,Perampanel,DB00069
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon alfacon-1.,Tasimelteon,DB00069
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon alfacon-1.,Stiripentol,DB00069
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon alfacon-1.,Zotepine,DB00069
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon alfacon-1.,Propacetamol,DB00069
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon alfacon-1.,Ramosetron,DB00069
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon alfacon-1.,Binimetinib,DB00069
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfacon-1.,Voxilaprevir,DB00069
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon alfacon-1.,Triclabendazole,DB00069
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon alfacon-1.,Rucaparib,DB00069
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon alfacon-1.,Dihydralazine,DB00069
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfacon-1.,Estradiol acetate,DB00069
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfacon-1.,Estradiol benzoate,DB00069
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfacon-1.,Estradiol cypionate,DB00069
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfacon-1.,Estradiol dienanthate,DB00069
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfacon-1.,Estradiol valerate,DB00069
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon alfacon-1.,Istradefylline,DB00069
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon alfacon-1.,Azelastine,DB00069
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon alfacon-1.,Efavirenz,DB00069
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon alfacon-1.,Metoclopramide,DB00069
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon alfacon-1.,Bicifadine,DB00069
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon alfacon-1.,GTS-21,DB00069
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon alfacon-1.,Flecainide,DB00069
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfacon-1.,Ethinylestradiol,DB00069
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon alfacon-1.,Amitriptyline,DB00069
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon alfacon-1.,Imipramine,DB00069
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon alfacon-1.,Doxepin,DB00069
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon alfacon-1.,Mephenytoin,DB00069
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon alfacon-1.,Nortriptyline,DB00069
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon alfacon-1.,Clonidine,DB00069
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfacon-1.,Cyclobenzaprine,DB00069
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon alfacon-1.,Desipramine,DB00069
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon alfacon-1.,Clomipramine,DB00069
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon alfacon-1.,Selumetinib,DB00069
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.,Theophylline,DB00069
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon alfacon-1.,Warfarin,DB00069
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon alfacon-1.,Tizanidine,DB00069
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon alfacon-1.,Pimozide,DB00069
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1.,Aminophylline,DB00069
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfacon-1.,Acenocoumarol,DB00069
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon alfacon-1.,Erlotinib,DB00069
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon alfacon-1.,Tegafur,DB00069
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon alfacon-1.,Enasidenib,DB00069
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon alfacon-1.,Tamoxifen,DB00069
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.,Lepirudin,DB00069
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfacon-1.,Bivalirudin,DB00069
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfacon-1.,Alteplase,DB00069
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfacon-1.,Urokinase,DB00069
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.,Reteplase,DB00069
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfacon-1.,Anistreplase,DB00069
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfacon-1.,Tenecteplase,DB00069
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.,Drotrecogin alfa,DB00069
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.,Streptokinase,DB00069
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfacon-1.,Dicoumarol,DB00069
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfacon-1.,Argatroban,DB00069
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfacon-1.,Ardeparin,DB00069
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfacon-1.,Phenindione,DB00069
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfacon-1.,Fondaparinux,DB00069
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfacon-1.,Pentosan polysulfate,DB00069
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfacon-1.,Phenprocoumon,DB00069
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfacon-1.,Heparin,DB00069
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfacon-1.,Enoxaparin,DB00069
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfacon-1.,4-hydroxycoumarin,DB00069
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfacon-1.,Coumarin,DB00069
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfacon-1.,Ximelagatran,DB00069
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfacon-1.,Desmoteplase,DB00069
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfacon-1.,Ancrod,DB00069
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfacon-1.,Fibrinolysin,DB00069
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfacon-1.,Rivaroxaban,DB00069
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfacon-1.,Sulodexide,DB00069
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfacon-1.,Semuloparin,DB00069
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfacon-1.,Idraparinux,DB00069
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfacon-1.,Astaxanthin,DB00069
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfacon-1.,Apixaban,DB00069
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfacon-1.,Otamixaban,DB00069
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfacon-1.,Amediplase,DB00069
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfacon-1.,Dabigatran etexilate,DB00069
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfacon-1.,Danaparoid,DB00069
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfacon-1.,Dalteparin,DB00069
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfacon-1.,Tinzaparin,DB00069
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfacon-1.,Ferulic acid,DB00069
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfacon-1.,Ethyl biscoumacetate,DB00069
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfacon-1.,Nadroparin,DB00069
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfacon-1.,Ditazole,DB00069
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfacon-1.,Edoxaban,DB00069
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfacon-1.,Potassium citrate,DB00069
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfacon-1.,Sodium citrate,DB00069
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfacon-1.,Dextran,DB00069
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfacon-1.,Bemiparin,DB00069
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfacon-1.,Reviparin,DB00069
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfacon-1.,Parnaparin,DB00069
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfacon-1.,Certoparin,DB00069
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfacon-1.,Desirudin,DB00069
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfacon-1.,Zinc citrate,DB00069
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfacon-1.,Antithrombin Alfa,DB00069
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfacon-1.,Protein C,DB00069
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfacon-1.,Antithrombin III human,DB00069
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfacon-1.,Letaxaban,DB00069
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfacon-1.,Darexaban,DB00069
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfacon-1.,Betrixaban,DB00069
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfacon-1.,Nafamostat,DB00069
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfacon-1.,Monteplase,DB00069
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfacon-1.,Gabexate,DB00069
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfacon-1.,Fluindione,DB00069
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfacon-1.,Protein S human,DB00069
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfacon-1.,Brinase,DB00069
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfacon-1.,Clorindione,DB00069
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfacon-1.,Diphenadione,DB00069
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfacon-1.,Tioclomarol,DB00069
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfacon-1.,Melagatran,DB00069
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfacon-1.,Saruplase,DB00069
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfacon-1.,(S)-Warfarin,DB00069
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfacon-1.,Tocopherylquinone,DB00069
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfacon-1.,Edetate calcium disodium anhydrous,DB00069
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfacon-1.,Dabigatran,DB00069
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfacon-1.,Methyclothiazide,DB00069
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfacon-1.,Bendroflumethiazide,DB00069
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfacon-1.,Benzthiazide,DB00069
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfacon-1.,Cyclothiazide,DB00069
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfacon-1.,Hydroflumethiazide,DB00069
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfacon-1.,Chlorothiazide,DB00069
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfacon-1.,Hydrochlorothiazide,DB00069
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfacon-1.,Trichlormethiazide,DB00069
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfacon-1.,Polythiazide,DB00069
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfacon-1.,Mebutizide,DB00069
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfacon-1.,Cyclopenthiazide,DB00069
DB09042,The risk or severity of myelosuppression can be increased when Interferon alfacon-1 is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00069
DB00091,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00069
DB00268,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ropinirole.,Ropinirole,DB00069
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.,Cyanocobalamin,DB00069
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfacon-1.,Allopurinol,DB00069
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfacon-1.,Magnesium,DB00069
DB01601,The serum concentration of Interferon alfacon-1 can be increased when it is combined with Lopinavir.,Lopinavir,DB00069
DB12530,The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Inebilizumab.,Inebilizumab,DB00069
DB00988,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dopamine.,Dopamine,DB00070
DB00443,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone.,Betamethasone,DB00070
DB00591,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocinolone acetonide.,Fluocinolone acetonide,DB00070
DB00620,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Triamcinolone.,Triamcinolone,DB00070
DB00741,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone.,Hydrocortisone,DB00070
DB00959,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone.,Methylprednisolone,DB00070
DB01108,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Trilostane.,Trilostane,DB00070
DB01234,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone.,Dexamethasone,DB00070
DB01285,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Corticotropin.,Corticotropin,DB00070
DB01380,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone acetate.,Cortisone acetate,DB00070
DB01384,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Paramethasone.,Paramethasone,DB00070
DB04630,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aldosterone.,Aldosterone,DB00070
DB08970,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene.,Fluprednidene,DB00070
DB08971,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortolone.,Fluocortolone,DB00070
DB09378,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednisolone.,Fluprednisolone,DB00070
DB09383,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Meprednisone.,Meprednisone,DB00070
DB11487,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00070
DB11529,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol.,Melengestrol,DB00070
DB11750,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clobetasol.,Clobetasol,DB00070
DB13003,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortivazol.,Cortivazol,DB00070
DB13208,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednylidene.,Prednylidene,DB00070
DB13223,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortin.,Fluocortin,DB00070
DB13491,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluperolone.,Fluperolone,DB00070
DB13664,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formocortal.,Formocortal,DB00070
DB13728,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Halometasone.,Halometasone,DB00070
DB13843,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cloprednol.,Cloprednol,DB00070
DB13856,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluclorolone.,Fluclorolone,DB00070
DB13867,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluticasone.,Fluticasone,DB00070
DB14538,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00070
DB14545,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone succinate.,Hydrocortisone succinate,DB00070
DB00873,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Loteprednol.,Loteprednol,DB00070
DB14633,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisolone hemisuccinate.,Prednisolone hemisuccinate,DB00070
DB14634,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene acetate.,Fluprednidene acetate,DB00070
DB14643,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone aceponate.,Methylprednisolone aceponate,DB00070
DB14644,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone hemisuccinate.,Methylprednisolone hemisuccinate,DB00070
DB14646,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisone acetate.,Prednisone acetate,DB00070
DB14652,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clocortolone acetate.,Clocortolone acetate,DB00070
DB14659,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol acetate.,Melengestrol acetate,DB00070
DB14669,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone phosphate.,Betamethasone phosphate,DB00070
DB14681,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone.,Cortisone,DB00070
DB00764,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mometasone.,Mometasone,DB00070
DB00936,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Salicylic acid.,Salicylic acid,DB00070
DB06251,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dersalazine.,Dersalazine,DB00070
DB06807,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenyl aminosalicylate.,Phenyl aminosalicylate,DB00070
DB12445,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Nitroaspirin.,Nitroaspirin,DB00070
DB13509,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aloxiprin.,Aloxiprin,DB00070
DB13538,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Guacetisal.,Guacetisal,DB00070
DB13612,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Carbaspirin calcium.,Carbaspirin calcium,DB00070
DB14026,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Thiosalicylic acid.,Thiosalicylic acid,DB00070
DB00281,Hyaluronidase (ovine) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Lidocaine,DB00070
DB00297,Hyaluronidase (ovine) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Bupivacaine,DB00070
DB00527,Hyaluronidase (ovine) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Cinchocaine,DB00070
DB00645,Hyaluronidase (ovine) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Dyclonine,DB00070
DB00750,Hyaluronidase (ovine) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Prilocaine,DB00070
DB00807,Hyaluronidase (ovine) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Proparacaine,DB00070
DB00892,Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Oxybuprocaine,DB00070
DB00961,Hyaluronidase (ovine) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Mepivacaine,DB00070
DB01002,Hyaluronidase (ovine) can cause an increase in the absorption of Levobupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Levobupivacaine,DB00070
DB01086,Hyaluronidase (ovine) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Benzocaine,DB00070
DB05232,Hyaluronidase (ovine) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.,Tetrodotoxin,DB00070
DB06770,Hyaluronidase (ovine) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.,Benzyl alcohol,DB00070
DB08987,Hyaluronidase (ovine) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Etidocaine,DB00070
DB09009,Hyaluronidase (ovine) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Articaine,DB00070
DB09085,Hyaluronidase (ovine) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Tetracaine,DB00070
DB09342,Hyaluronidase (ovine) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Propoxycaine,DB00070
DB11148,Hyaluronidase (ovine) can cause an increase in the absorption of Butamben resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butamben,DB00070
DB11502,Hyaluronidase (ovine) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butacaine,DB00070
DB13328,Hyaluronidase (ovine) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butanilicaine,DB00070
DB13578,Hyaluronidase (ovine) can cause an increase in the absorption of Metabutethamine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Metabutethamine,DB00070
DB13683,Hyaluronidase (ovine) can cause an increase in the absorption of Quinisocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Quinisocaine,DB00070
DB00245,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzatropine.,Benzatropine,DB00070
DB00246,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ziprasidone.,Ziprasidone,DB00070
DB00341,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cetirizine.,Cetirizine,DB00070
DB00354,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Buclizine.,Buclizine,DB00070
DB00420,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promazine.,Promazine,DB00070
DB00458,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Imipramine.,Imipramine,DB00070
DB00477,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpromazine.,Chlorpromazine,DB00070
DB00501,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cimetidine.,Cimetidine,DB00070
DB00557,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydroxyzine.,Hydroxyzine,DB00070
DB00568,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cinnarizine.,Cinnarizine,DB00070
DB00734,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Risperidone.,Risperidone,DB00070
DB00767,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzquinamide.,Benzquinamide,DB00070
DB00777,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Propiomazine.,Propiomazine,DB00070
DB00835,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Brompheniramine.,Brompheniramine,DB00070
DB00863,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ranitidine.,Ranitidine,DB00070
DB00902,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methdilazine.,Methdilazine,DB00070
DB00927,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Famotidine.,Famotidine,DB00070
DB00940,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methantheline.,Methantheline,DB00070
DB00972,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Azelastine.,Azelastine,DB00070
DB00985,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimenhydrinate.,Dimenhydrinate,DB00070
DB01069,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promethazine.,Promethazine,DB00070
DB01071,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mequitazine.,Mequitazine,DB00070
DB01075,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diphenhydramine.,Diphenhydramine,DB00070
DB01114,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpheniramine.,Chlorpheniramine,DB00070
DB01173,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Orphenadrine.,Orphenadrine,DB00070
DB01176,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cyclizine.,Cyclizine,DB00070
DB01238,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.,Aripiprazole,DB00070
DB01239,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorprothixene.,Chlorprothixene,DB00070
DB01403,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methotrimeprazine.,Methotrimeprazine,DB00070
DB01615,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aceprometazine.,Aceprometazine,DB00070
DB01619,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenindamine.,Phenindamine,DB00070
DB01624,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zuclopenthixol.,Zuclopenthixol,DB00070
DB03255,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenol.,Phenol,DB00070
DB04819,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methapyrilene.,Methapyrilene,DB00070
DB06148,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mianserin.,Mianserin,DB00070
DB06678,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esmirtazapine.,Esmirtazapine,DB00070
DB08800,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chloropyramine.,Chloropyramine,DB00070
DB08801,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetindene.,Dimetindene,DB00070
DB08802,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Isothipendyl.,Isothipendyl,DB00070
DB08805,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Metiamide.,Metiamide,DB00070
DB08806,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Roxatidine acetate.,Roxatidine acetate,DB00070
DB08967,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetotiazine.,Dimetotiazine,DB00070
DB09007,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorphenoxamine.,Chlorphenoxamine,DB00070
DB09016,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Butriptyline.,Butriptyline,DB00070
DB09167,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dosulepin.,Dosulepin,DB00070
DB11742,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ebastine.,Ebastine,DB00070
DB12523,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mizolastine.,Mizolastine,DB00070
DB12770,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lafutidine.,Lafutidine,DB00070
DB12806,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-1004723.,GSK-1004723,DB00070
DB12877,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Oxatomide.,Oxatomide,DB00070
DB12884,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lavoltidine.,Lavoltidine,DB00070
DB13466,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Deptropine.,Deptropine,DB00070
DB13489,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Bamipine.,Bamipine,DB00070
DB13711,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tritoqualine.,Tritoqualine,DB00070
DB13713,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quifenadine.,Quifenadine,DB00070
DB13760,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Niperotidine.,Niperotidine,DB00070
DB14185,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole lauroxil.,Aripiprazole lauroxil,DB00070
DB15120,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-239512.,GSK-239512,DB00070
DB15192,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with ABT-288.,ABT-288,DB00070
DB00334,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Olanzapine.,Olanzapine,DB00070
DB00217,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Bethanidine.,Bethanidine,DB00070
DB00292,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etomidate.,Etomidate,DB00070
DB00368,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norepinephrine.,Norepinephrine,DB00070
DB00388,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Phenylephrine.,Phenylephrine,DB00070
DB00575,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Clonidine.,Clonidine,DB00070
DB00610,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Metaraminol.,Metaraminol,DB00070
DB00633,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dexmedetomidine.,Dexmedetomidine,DB00070
DB00668,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Epinephrine.,Epinephrine,DB00070
DB00723,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methoxamine.,Methoxamine,DB00070
DB00841,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dobutamine.,Dobutamine,DB00070
DB00968,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methyldopa.,Methyldopa,DB00070
DB01253,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ergometrine.,Ergometrine,DB00070
DB01364,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ephedrine.,Ephedrine,DB00070
DB01365,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Mephentermine.,Mephentermine,DB00070
DB01472,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Methoxyamphetamine.,4-Methoxyamphetamine,DB00070
DB01537,"The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Bromo-2,5-dimethoxyphenethylamine.","4-Bromo-2,5-dimethoxyphenethylamine",DB00070
DB06764,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Tetryzoline.,Tetryzoline,DB00070
DB08925,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Adrafinil.,Adrafinil,DB00070
DB08985,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etilefrine.,Etilefrine,DB00070
DB09202,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Cirazoline.,Cirazoline,DB00070
DB09203,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Synephrine.,Synephrine,DB00070
DB09242,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Moxonidine.,Moxonidine,DB00070
DB11373,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Amitraz.,Amitraz,DB00070
DB11428,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Medetomidine.,Medetomidine,DB00070
DB11477,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Xylazine.,Xylazine,DB00070
DB11543,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Romifidine.,Romifidine,DB00070
DB11556,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Detomidine.,Detomidine,DB00070
DB11738,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Rilmenidine.,Rilmenidine,DB00070
DB13251,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Octopamine.,Octopamine,DB00070
DB13378,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norfenefrine.,Norfenefrine,DB00070
DB00255,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diethylstilbestrol.,Diethylstilbestrol,DB00070
DB00269,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorotrianisene.,Chlorotrianisene,DB00070
DB00286,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Conjugated estrogens.,Conjugated estrogens,DB00070
DB00783,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol.,Estradiol,DB00070
DB00977,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ethinylestradiol.,Ethinylestradiol,DB00070
DB01357,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mestranol.,Mestranol,DB00070
DB04573,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estriol.,Estriol,DB00070
DB04574,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estrone sulfate.,Estrone sulfate,DB00070
DB04575,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quinestrol.,Quinestrol,DB00070
DB07931,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hexestrol.,Hexestrol,DB00070
DB09070,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tibolone.,Tibolone,DB00070
DB09317,"The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, A.","Synthetic Conjugated Estrogens, A",DB00070
DB09318,"The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, B.","Synthetic Conjugated Estrogens, B",DB00070
DB09369,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Polyestradiol phosphate.,Polyestradiol phosphate,DB00070
DB09381,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esterified estrogens.,Esterified estrogens,DB00070
DB11478,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zeranol.,Zeranol,DB00070
DB11674,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Equol.,Equol,DB00070
DB12487,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promestriene.,Promestriene,DB00070
DB13143,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methallenestril.,Methallenestril,DB00070
DB13386,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epimestrol.,Epimestrol,DB00070
DB13418,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Moxestrol.,Moxestrol,DB00070
DB13952,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol acetate.,Estradiol acetate,DB00070
DB13953,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol benzoate.,Estradiol benzoate,DB00070
DB13954,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol cypionate.,Estradiol cypionate,DB00070
DB13956,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol valerate.,Estradiol valerate,DB00070
DB15334,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Biochanin A.,Biochanin A,DB00070
DB15335,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formononetin.,Formononetin,DB00070
DB00186,The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (ovine).,Lorazepam,DB00070
DB00546,The therapeutic efficacy of Adinazolam can be decreased when used in combination with Hyaluronidase (ovine).,Adinazolam,DB00070
DB00683,The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase (ovine).,Midazolam,DB00070
DB00801,The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase (ovine).,Halazepam,DB00070
DB00829,The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase (ovine).,Diazepam,DB00070
DB01489,The therapeutic efficacy of Camazepam can be decreased when used in combination with Hyaluronidase (ovine).,Camazepam,DB00070
DB01511,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Hyaluronidase (ovine).,Delorazepam,DB00070
DB01544,The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Hyaluronidase (ovine).,Flunitrazepam,DB00070
DB01545,The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase (ovine).,Ethyl loflazepate,DB00070
DB01553,The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Hyaluronidase (ovine).,Cloxazolam,DB00070
DB01559,The therapeutic efficacy of Clotiazepam can be decreased when used in combination with Hyaluronidase (ovine).,Clotiazepam,DB00070
DB01567,The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase (ovine).,Fludiazepam,DB00070
DB01588,The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase (ovine).,Prazepam,DB00070
DB01594,The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Hyaluronidase (ovine).,Cinolazepam,DB00070
DB09017,The therapeutic efficacy of Brotizolam can be decreased when used in combination with Hyaluronidase (ovine).,Brotizolam,DB00070
DB09166,The therapeutic efficacy of Etizolam can be decreased when used in combination with Hyaluronidase (ovine).,Etizolam,DB00070
DB12537,The therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Hyaluronidase (ovine).,Benzodiazepine,DB00070
DB13335,The therapeutic efficacy of Pinazepam can be decreased when used in combination with Hyaluronidase (ovine).,Pinazepam,DB00070
DB13437,The therapeutic efficacy of Medazepam can be decreased when used in combination with Hyaluronidase (ovine).,Medazepam,DB00070
DB13643,The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase (ovine).,Loprazolam,DB00070
DB13837,The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Hyaluronidase (ovine).,Doxefazepam,DB00070
DB13872,The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hyaluronidase (ovine).,Lormetazepam,DB00070
DB14028,The therapeutic efficacy of Nordazepam can be decreased when used in combination with Hyaluronidase (ovine).,Nordazepam,DB00070
DB14672,The therapeutic efficacy of Oxazepam acetate can be decreased when used in combination with Hyaluronidase (ovine).,Oxazepam acetate,DB00070
DB14715,The therapeutic efficacy of Cinazepam can be decreased when used in combination with Hyaluronidase (ovine).,Cinazepam,DB00070
DB14719,The therapeutic efficacy of Bentazepam can be decreased when used in combination with Hyaluronidase (ovine).,Bentazepam,DB00070
DB00695,The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase (ovine).,Furosemide,DB00070
DB00252,The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase (ovine).,Phenytoin,DB00070
DB01320,The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase (ovine).,Fosphenytoin,DB00070
DB06655,Liraglutide may increase the hypoglycemic activities of Insulin pork.,Liraglutide,DB00071
DB09046,Metreleptin may increase the hypoglycemic activities of Insulin pork.,Metreleptin,DB00071
DB00082,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.,Pegvisomant,DB00071
DB01132,The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin pork.,Pioglitazone,DB00071
DB01278,Pramlintide may increase the hypoglycemic activities of Insulin pork.,Pramlintide,DB00071
DB00412,The risk or severity of congestive heart failure can be increased when Insulin pork is combined with Rosiglitazone.,Rosiglitazone,DB00071
DB00166,The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin pork.,Lipoic acid,DB00071
DB00974,Edetic acid may increase the hypoglycemic activities of Insulin pork.,Edetic acid,DB00071
DB00187,Esmolol may increase the hypoglycemic activities of Insulin pork.,Esmolol,DB00071
DB00218,The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.,Moxifloxacin,DB00071
DB00365,The therapeutic efficacy of Insulin pork can be increased when used in combination with Grepafloxacin.,Grepafloxacin,DB00071
DB00467,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enoxacin.,Enoxacin,DB00071
DB00487,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pefloxacin.,Pefloxacin,DB00071
DB00537,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ciprofloxacin.,Ciprofloxacin,DB00071
DB00685,The therapeutic efficacy of Insulin pork can be increased when used in combination with Trovafloxacin.,Trovafloxacin,DB00071
DB00779,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nalidixic acid.,Nalidixic acid,DB00071
DB00817,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosoxacin.,Rosoxacin,DB00071
DB00827,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cinoxacin.,Cinoxacin,DB00071
DB00978,The therapeutic efficacy of Insulin pork can be increased when used in combination with Lomefloxacin.,Lomefloxacin,DB00071
DB01044,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gatifloxacin.,Gatifloxacin,DB00071
DB01059,The therapeutic efficacy of Insulin pork can be increased when used in combination with Norfloxacin.,Norfloxacin,DB00071
DB01137,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.,Levofloxacin,DB00071
DB01155,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gemifloxacin.,Gemifloxacin,DB00071
DB01165,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ofloxacin.,Ofloxacin,DB00071
DB01208,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sparfloxacin.,Sparfloxacin,DB00071
DB01405,The therapeutic efficacy of Insulin pork can be increased when used in combination with Temafloxacin.,Temafloxacin,DB00071
DB04576,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fleroxacin.,Fleroxacin,DB00071
DB05488,The therapeutic efficacy of Insulin pork can be increased when used in combination with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin,DB00071
DB06160,The therapeutic efficacy of Insulin pork can be increased when used in combination with Garenoxacin.,Garenoxacin,DB00071
DB06600,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nemonoxacin.,Nemonoxacin,DB00071
DB08972,The therapeutic efficacy of Insulin pork can be increased when used in combination with Flumequine.,Flumequine,DB00071
DB11404,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enrofloxacin.,Enrofloxacin,DB00071
DB11443,The therapeutic efficacy of Insulin pork can be increased when used in combination with Orbifloxacin.,Orbifloxacin,DB00071
DB11491,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sarafloxacin.,Sarafloxacin,DB00071
DB11511,The therapeutic efficacy of Insulin pork can be increased when used in combination with Difloxacin.,Difloxacin,DB00071
DB11774,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pazufloxacin.,Pazufloxacin,DB00071
DB11892,The therapeutic efficacy of Insulin pork can be increased when used in combination with Prulifloxacin.,Prulifloxacin,DB00071
DB11943,The therapeutic efficacy of Insulin pork can be increased when used in combination with Delafloxacin.,Delafloxacin,DB00071
DB13261,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sitafloxacin.,Sitafloxacin,DB00071
DB13627,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxolinic acid.,Oxolinic acid,DB00071
DB13772,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rufloxacin.,Rufloxacin,DB00071
DB13823,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pipemidic acid.,Pipemidic acid,DB00071
DB00232,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methyclothiazide.,Methyclothiazide,DB00071
DB00310,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorthalidone.,Chlorthalidone,DB00071
DB00436,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide,DB00071
DB00524,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Metolazone.,Metolazone,DB00071
DB00562,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Benzthiazide.,Benzthiazide,DB00071
DB00774,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide,DB00071
DB00808,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indapamide.,Indapamide,DB00071
DB00880,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorothiazide.,Chlorothiazide,DB00071
DB00999,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide,DB00071
DB01021,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide,DB00071
DB01324,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Polythiazide.,Polythiazide,DB00071
DB01325,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quinethazone.,Quinethazone,DB00071
DB13532,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide,DB00071
DB13989,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epitizide.,Epitizide,DB00071
DB00344,Protriptyline may decrease the hypoglycemic activities of Insulin pork.,Protriptyline,DB00071
DB00543,Amoxapine may decrease the hypoglycemic activities of Insulin pork.,Amoxapine,DB00071
DB00726,Trimipramine may decrease the hypoglycemic activities of Insulin pork.,Trimipramine,DB00071
DB04836,Amineptine may decrease the hypoglycemic activities of Insulin pork.,Amineptine,DB00071
DB08996,Dimetacrine may decrease the hypoglycemic activities of Insulin pork.,Dimetacrine,DB00071
DB09016,Butriptyline may decrease the hypoglycemic activities of Insulin pork.,Butriptyline,DB00071
DB09167,Dosulepin may decrease the hypoglycemic activities of Insulin pork.,Dosulepin,DB00071
DB09289,Tianeptine may decrease the hypoglycemic activities of Insulin pork.,Tianeptine,DB00071
DB09307,Oxaprotiline may decrease the hypoglycemic activities of Insulin pork.,Oxaprotiline,DB00071
DB12930,Opipramol may decrease the hypoglycemic activities of Insulin pork.,Opipramol,DB00071
DB13114,Amitriptylinoxide may decrease the hypoglycemic activities of Insulin pork.,Amitriptylinoxide,DB00071
DB13225,Dibenzepin may decrease the hypoglycemic activities of Insulin pork.,Dibenzepin,DB00071
DB13246,Quinupramine may decrease the hypoglycemic activities of Insulin pork.,Quinupramine,DB00071
DB13384,Melitracen may decrease the hypoglycemic activities of Insulin pork.,Melitracen,DB00071
DB13411,Lofepramine may decrease the hypoglycemic activities of Insulin pork.,Lofepramine,DB00071
DB13496,Iprindole may decrease the hypoglycemic activities of Insulin pork.,Iprindole,DB00071
DB13782,Imipramine oxide may decrease the hypoglycemic activities of Insulin pork.,Imipramine oxide,DB00071
DB06292,Dapagliflozin may increase the hypoglycemic activities of Insulin pork.,Dapagliflozin,DB00071
DB08907,Canagliflozin may increase the hypoglycemic activities of Insulin pork.,Canagliflozin,DB00071
DB00007,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.,Leuprolide,DB00071
DB00014,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.,Goserelin,DB00071
DB00104,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.,Octreotide,DB00071
DB00220,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nelfinavir.,Nelfinavir,DB00071
DB00224,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indinavir.,Indinavir,DB00071
DB00246,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ziprasidone.,Ziprasidone,DB00071
DB00294,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etonogestrel.,Etonogestrel,DB00071
DB00304,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Desogestrel.,Desogestrel,DB00071
DB00334,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Olanzapine.,Olanzapine,DB00071
DB00351,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Megestrol acetate.,Megestrol acetate,DB00071
DB00363,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Clozapine.,Clozapine,DB00071
DB00367,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levonorgestrel.,Levonorgestrel,DB00071
DB00396,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Progesterone.,Progesterone,DB00071
DB00477,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorpromazine.,Chlorpromazine,DB00071
DB00502,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Haloperidol.,Haloperidol,DB00071
DB00503,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ritonavir.,Ritonavir,DB00071
DB00592,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Piperazine.,Piperazine,DB00071
DB00603,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Medroxyprogesterone acetate.,Medroxyprogesterone acetate,DB00071
DB00627,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Niacin.,Niacin,DB00071
DB00668,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epinephrine.,Epinephrine,DB00071
DB00717,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norethisterone.,Norethisterone,DB00071
DB00734,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Risperidone.,Risperidone,DB00071
DB00738,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pentamidine.,Pentamidine,DB00071
DB00823,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethynodiol diacetate.,Ethynodiol diacetate,DB00071
DB00852,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pseudoephedrine.,Pseudoephedrine,DB00071
DB00864,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.,Tacrolimus,DB00071
DB00877,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Sirolimus.,Sirolimus,DB00071
DB00903,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.,Etacrynic acid,DB00071
DB00932,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tipranavir.,Tipranavir,DB00071
DB00957,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norgestimate.,Norgestimate,DB00071
DB00977,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.,Ethinylestradiol,DB00071
DB01072,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Atazanavir.,Atazanavir,DB00071
DB01169,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Arsenic trioxide.,Arsenic trioxide,DB00071
DB01224,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quetiapine.,Quetiapine,DB00071
DB01232,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Saquinavir.,Saquinavir,DB00071
DB01238,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Aripiprazole.,Aripiprazole,DB00071
DB01267,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Paliperidone.,Paliperidone,DB00071
DB01319,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Fosamprenavir.,Fosamprenavir,DB00071
DB01323,The therapeutic efficacy of Insulin pork can be decreased when used in combination with St. John's Wort.,St. John's Wort,DB00071
DB01357,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Mestranol.,Mestranol,DB00071
DB01363,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ephedra sinica root.,Ephedra sinica root,DB00071
DB01395,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Drospirenone.,Drospirenone,DB00071
DB01403,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methotrimeprazine.,Methotrimeprazine,DB00071
DB01406,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Danazol.,Danazol,DB00071
DB01590,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Everolimus.,Everolimus,DB00071
DB01601,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lopinavir.,Lopinavir,DB00071
DB01621,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pipotiazine.,Pipotiazine,DB00071
DB02546,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Vorinostat.,Vorinostat,DB00071
DB04574,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Estrone sulfate.,Estrone sulfate,DB00071
DB04839,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyproterone acetate.,Cyproterone acetate,DB00071
DB04868,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nilotinib.,Nilotinib,DB00071
DB04946,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Iloperidone.,Iloperidone,DB00071
DB06216,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Asenapine.,Asenapine,DB00071
DB06287,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Temsirolimus.,Temsirolimus,DB00071
DB06663,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pasireotide.,Pasireotide,DB00071
DB06719,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Buserelin.,Buserelin,DB00071
DB06788,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Histrelin.,Histrelin,DB00071
DB06789,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroxyprogesterone caproate.,Hydroxyprogesterone caproate,DB00071
DB06791,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lanreotide.,Lanreotide,DB00071
DB06825,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.,Triptorelin,DB00071
DB08815,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lurasidone.,Lurasidone,DB00071
DB08912,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib.,Dabrafenib,DB00071
DB09009,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Articaine.,Articaine,DB00071
DB09063,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib.,Ceritinib,DB00071
DB09123,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dienogest.,Dienogest,DB00071
DB09128,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Brexpiprazole.,Brexpiprazole,DB00071
DB06343,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Teprotumumab.,Teprotumumab,DB00071
DB00621,Oxandrolone may increase the hypoglycemic activities of Insulin pork.,Oxandrolone,DB00071
DB00624,Testosterone may increase the hypoglycemic activities of Insulin pork.,Testosterone,DB00071
DB00984,Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin pork.,Nandrolone phenpropionate,DB00071
DB01185,Fluoxymesterone may increase the hypoglycemic activities of Insulin pork.,Fluoxymesterone,DB00071
DB01420,Testosterone propionate may increase the hypoglycemic activities of Insulin pork.,Testosterone propionate,DB00071
DB02901,Stanolone may increase the hypoglycemic activities of Insulin pork.,Stanolone,DB00071
DB06412,Oxymetholone may increase the hypoglycemic activities of Insulin pork.,Oxymetholone,DB00071
DB06710,Methyltestosterone may increase the hypoglycemic activities of Insulin pork.,Methyltestosterone,DB00071
DB06718,Stanozolol may increase the hypoglycemic activities of Insulin pork.,Stanozolol,DB00071
DB08804,Nandrolone decanoate may increase the hypoglycemic activities of Insulin pork.,Nandrolone decanoate,DB00071
DB12461,GLPG-0492 may increase the hypoglycemic activities of Insulin pork.,GLPG-0492,DB00071
DB13169,Nandrolone may increase the hypoglycemic activities of Insulin pork.,Nandrolone,DB00071
DB13587,Mesterolone may increase the hypoglycemic activities of Insulin pork.,Mesterolone,DB00071
DB13943,Testosterone cypionate may increase the hypoglycemic activities of Insulin pork.,Testosterone cypionate,DB00071
DB13944,Testosterone enanthate may increase the hypoglycemic activities of Insulin pork.,Testosterone enanthate,DB00071
DB00215,The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin pork.,Citalopram,DB00071
DB00230,The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin pork.,Pregabalin,DB00071
DB00285,The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin pork.,Venlafaxine,DB00071
DB00328,The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin pork.,Indomethacin,DB00071
DB01104,The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin pork.,Sertraline,DB00071
DB01149,The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin pork.,Nefazodone,DB00071
DB01175,The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin pork.,Escitalopram,DB00071
DB04832,The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Insulin pork.,Zimelidine,DB00071
DB04884,The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Insulin pork.,Dapoxetine,DB00071
DB04896,The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin pork.,Milnacipran,DB00071
DB06700,The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin pork.,Desvenlafaxine,DB00071
DB08918,The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin pork.,Levomilnacipran,DB00071
DB08953,The risk or severity of hypoglycemia can be increased when Indalpine is combined with Insulin pork.,Indalpine,DB00071
DB09270,The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.,Ubidecarenone,DB00071
DB12693,The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Insulin pork.,Ritanserin,DB00071
DB13233,The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Insulin pork.,Alaproclate,DB00071
DB13358,The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Insulin pork.,Cibenzoline,DB00071
DB14025,The risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Insulin pork.,Clinafloxacin,DB00071
DB00233,Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.,Aminosalicylic acid,DB00071
DB00244,Mesalazine may increase the hypoglycemic activities of Insulin pork.,Mesalazine,DB00071
DB00795,Sulfasalazine may increase the hypoglycemic activities of Insulin pork.,Sulfasalazine,DB00071
DB00861,Diflunisal may increase the hypoglycemic activities of Insulin pork.,Diflunisal,DB00071
DB00936,Salicylic acid may increase the hypoglycemic activities of Insulin pork.,Salicylic acid,DB00071
DB01014,Balsalazide may increase the hypoglycemic activities of Insulin pork.,Balsalazide,DB00071
DB01250,Olsalazine may increase the hypoglycemic activities of Insulin pork.,Olsalazine,DB00071
DB01294,Bismuth subsalicylate may increase the hypoglycemic activities of Insulin pork.,Bismuth subsalicylate,DB00071
DB06251,Dersalazine may increase the hypoglycemic activities of Insulin pork.,Dersalazine,DB00071
DB06807,Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin pork.,Phenyl aminosalicylate,DB00071
DB09543,Methyl salicylate may increase the hypoglycemic activities of Insulin pork.,Methyl salicylate,DB00071
DB11079,Trolamine salicylate may increase the hypoglycemic activities of Insulin pork.,Trolamine salicylate,DB00071
DB12445,Nitroaspirin may increase the hypoglycemic activities of Insulin pork.,Nitroaspirin,DB00071
DB13509,Aloxiprin may increase the hypoglycemic activities of Insulin pork.,Aloxiprin,DB00071
DB13538,Guacetisal may increase the hypoglycemic activities of Insulin pork.,Guacetisal,DB00071
DB13612,Carbaspirin calcium may increase the hypoglycemic activities of Insulin pork.,Carbaspirin calcium,DB00071
DB14006,Choline salicylate may increase the hypoglycemic activities of Insulin pork.,Choline salicylate,DB00071
DB14026,Thiosalicylic acid may increase the hypoglycemic activities of Insulin pork.,Thiosalicylic acid,DB00071
DB01261,Sitagliptin may increase the hypoglycemic activities of Insulin pork.,Sitagliptin,DB00071
DB04876,Vildagliptin may increase the hypoglycemic activities of Insulin pork.,Vildagliptin,DB00071
DB06011,AMG-222 may increase the hypoglycemic activities of Insulin pork.,AMG-222,DB00071
DB06127,Bisegliptin may increase the hypoglycemic activities of Insulin pork.,Bisegliptin,DB00071
DB06203,Alogliptin may increase the hypoglycemic activities of Insulin pork.,Alogliptin,DB00071
DB06335,Saxagliptin may increase the hypoglycemic activities of Insulin pork.,Saxagliptin,DB00071
DB08382,Gosogliptin may increase the hypoglycemic activities of Insulin pork.,Gosogliptin,DB00071
DB08882,Linagliptin may increase the hypoglycemic activities of Insulin pork.,Linagliptin,DB00071
DB11723,Dutogliptin may increase the hypoglycemic activities of Insulin pork.,Dutogliptin,DB00071
DB11950,Teneligliptin may increase the hypoglycemic activities of Insulin pork.,Teneligliptin,DB00071
DB11992,Omarigliptin may increase the hypoglycemic activities of Insulin pork.,Omarigliptin,DB00071
DB12268,Carmegliptin may increase the hypoglycemic activities of Insulin pork.,Carmegliptin,DB00071
DB12412,Gemigliptin may increase the hypoglycemic activities of Insulin pork.,Gemigliptin,DB00071
DB12417,Anagliptin may increase the hypoglycemic activities of Insulin pork.,Anagliptin,DB00071
DB12625,Evogliptin may increase the hypoglycemic activities of Insulin pork.,Evogliptin,DB00071
DB01276,Exenatide may increase the hypoglycemic activities of Insulin pork.,Exenatide,DB00071
DB09043,Albiglutide may increase the hypoglycemic activities of Insulin pork.,Albiglutide,DB00071
DB09045,Dulaglutide may increase the hypoglycemic activities of Insulin pork.,Dulaglutide,DB00071
DB09265,Lixisenatide may increase the hypoglycemic activities of Insulin pork.,Lixisenatide,DB00071
DB13928,Semaglutide may increase the hypoglycemic activities of Insulin pork.,Semaglutide,DB00071
DB14027,Taspoglutide may increase the hypoglycemic activities of Insulin pork.,Taspoglutide,DB00071
DB00752,Tranylcypromine may increase the hypoglycemic activities of Insulin pork.,Tranylcypromine,DB00071
DB00780,Phenelzine may increase the hypoglycemic activities of Insulin pork.,Phenelzine,DB00071
DB01171,Moclobemide may increase the hypoglycemic activities of Insulin pork.,Moclobemide,DB00071
DB01247,Isocarboxazid may increase the hypoglycemic activities of Insulin pork.,Isocarboxazid,DB00071
DB01626,Pargyline may increase the hypoglycemic activities of Insulin pork.,Pargyline,DB00071
DB00805,Minaprine may increase the hypoglycemic activities of Insulin pork.,Minaprine,DB00071
DB04818,Iproniazid may increase the hypoglycemic activities of Insulin pork.,Iproniazid,DB00071
DB04820,Nialamide may increase the hypoglycemic activities of Insulin pork.,Nialamide,DB00071
DB09244,Pirlindole may increase the hypoglycemic activities of Insulin pork.,Pirlindole,DB00071
DB09245,Toloxatone may increase the hypoglycemic activities of Insulin pork.,Toloxatone,DB00071
DB09243,Hydracarbazine may increase the hypoglycemic activities of Insulin pork.,Hydracarbazine,DB00071
DB09241,Methylene blue may increase the hypoglycemic activities of Insulin pork.,Methylene blue,DB00071
DB09246,Benmoxin may increase the hypoglycemic activities of Insulin pork.,Benmoxin,DB00071
DB09248,Mebanazine may increase the hypoglycemic activities of Insulin pork.,Mebanazine,DB00071
DB09249,Octamoxin may increase the hypoglycemic activities of Insulin pork.,Octamoxin,DB00071
DB09250,Pheniprazine may increase the hypoglycemic activities of Insulin pork.,Pheniprazine,DB00071
DB09251,Phenoxypropazine may increase the hypoglycemic activities of Insulin pork.,Phenoxypropazine,DB00071
DB09252,Pivhydrazine may increase the hypoglycemic activities of Insulin pork.,Pivhydrazine,DB00071
DB09253,Safrazine may increase the hypoglycemic activities of Insulin pork.,Safrazine,DB00071
DB09254,Caroxazone may increase the hypoglycemic activities of Insulin pork.,Caroxazone,DB00071
DB00614,Furazolidone may increase the hypoglycemic activities of Insulin pork.,Furazolidone,DB00071
DB08550,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin pork.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",DB00071
DB13875,Harmaline may increase the hypoglycemic activities of Insulin pork.,Harmaline,DB00071
DB13876,Brofaromine may increase the hypoglycemic activities of Insulin pork.,Brofaromine,DB00071
DB00721,Procaine may increase the hypoglycemic activities of Insulin pork.,Procaine,DB00071
DB00182,Amphetamine may increase the hypoglycemic activities of Insulin pork.,Amphetamine,DB00071
DB01168,Procarbazine may increase the hypoglycemic activities of Insulin pork.,Procarbazine,DB00071
DB00601,Linezolid may increase the hypoglycemic activities of Insulin pork.,Linezolid,DB00071
DB06654,Safinamide may increase the hypoglycemic activities of Insulin pork.,Safinamide,DB00071
DB04017,Clorgiline may increase the hypoglycemic activities of Insulin pork.,Clorgiline,DB00071
DB11827,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ertugliflozin.,Ertugliflozin,DB00071
DB00203,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sildenafil.,Sildenafil,DB00071
DB00214,The therapeutic efficacy of Insulin pork can be increased when used in combination with Torasemide.,Torasemide,DB00071
DB00263,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfisoxazole.,Sulfisoxazole,DB00071
DB00311,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ethoxzolamide.,Ethoxzolamide,DB00071
DB00359,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadiazine.,Sulfadiazine,DB00071
DB00482,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celecoxib.,Celecoxib,DB00071
DB00559,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bosentan.,Bosentan,DB00071
DB00576,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethizole.,Sulfamethizole,DB00071
DB00606,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cyclothiazide.,Cyclothiazide,DB00071
DB00664,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametopyrazine.,Sulfametopyrazine,DB00071
DB00669,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sumatriptan.,Sumatriptan,DB00071
DB00695,The therapeutic efficacy of Insulin pork can be increased when used in combination with Furosemide.,Furosemide,DB00071
DB00706,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tamsulosin.,Tamsulosin,DB00071
DB00819,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetazolamide.,Acetazolamide,DB00071
DB00887,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bumetanide.,Bumetanide,DB00071
DB00891,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfapyridine.,Sulfapyridine,DB00071
DB00909,The therapeutic efficacy of Insulin pork can be increased when used in combination with Zonisamide.,Zonisamide,DB00071
DB01015,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxazole.,Sulfamethoxazole,DB00071
DB01032,The therapeutic efficacy of Insulin pork can be increased when used in combination with Probenecid.,Probenecid,DB00071
DB01098,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosuvastatin.,Rosuvastatin,DB00071
DB01119,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diazoxide.,Diazoxide,DB00071
DB01144,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diclofenamide.,Diclofenamide,DB00071
DB01264,The therapeutic efficacy of Insulin pork can be increased when used in combination with Darunavir.,Darunavir,DB00071
DB01298,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfacytine.,Sulfacytine,DB00071
DB01299,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadoxine.,Sulfadoxine,DB00071
DB01382,The therapeutic efficacy of Insulin pork can be increased when used in combination with Glymidine.,Glymidine,DB00071
DB01581,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamerazine.,Sulfamerazine,DB00071
DB01582,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethazine.,Sulfamethazine,DB00071
DB02925,The therapeutic efficacy of Insulin pork can be increased when used in combination with Piretanide.,Piretanide,DB00071
DB04707,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxyfasudil.,Hydroxyfasudil,DB00071
DB06150,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadimethoxine.,Sulfadimethoxine,DB00071
DB06290,The therapeutic efficacy of Insulin pork can be increased when used in combination with Simeprevir.,Simeprevir,DB00071
DB06729,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaphenazole.,Sulfaphenazole,DB00071
DB06821,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfameter.,Sulfameter,DB00071
DB07996,The therapeutic efficacy of Insulin pork can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.,5-(2-methylpiperazine-1-sulfonyl)isoquinoline,DB00071
DB08162,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fasudil.,Fasudil,DB00071
DB08798,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamoxole.,Sulfamoxole,DB00071
DB08881,The therapeutic efficacy of Insulin pork can be increased when used in combination with Vemurafenib.,Vemurafenib,DB00071
DB08961,The therapeutic efficacy of Insulin pork can be increased when used in combination with Azosemide.,Azosemide,DB00071
DB11389,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorsulon.,Clorsulon,DB00071
DB11461,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfachlorpyridazine.,Sulfachlorpyridazine,DB00071
DB11462,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaethoxypyridazine.,Sulfaethoxypyridazine,DB00071
DB11463,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfanitran.,Sulfanitran,DB00071
DB11464,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaquinoxaline.,Sulfaquinoxaline,DB00071
DB12051,The therapeutic efficacy of Insulin pork can be increased when used in combination with Setrobuvir.,Setrobuvir,DB00071
DB12921,The therapeutic efficacy of Insulin pork can be increased when used in combination with Chlorsulfaquinoxaline.,Chlorsulfaquinoxaline,DB00071
DB13214,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadicramide.,Sulfadicramide,DB00071
DB13248,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phthalylsulfathiazole.,Phthalylsulfathiazole,DB00071
DB13283,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaisodimidine.,Sulfaisodimidine,DB00071
DB13284,The therapeutic efficacy of Insulin pork can be increased when used in combination with Meticrane.,Meticrane,DB00071
DB13320,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaperin.,Sulfaperin,DB00071
DB13405,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mefruside.,Mefruside,DB00071
DB13430,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mebutizide.,Mebutizide,DB00071
DB13485,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametomidine.,Sulfametomidine,DB00071
DB13547,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfatolamide.,Sulfatolamide,DB00071
DB13556,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamazone.,Sulfamazone,DB00071
DB13580,The therapeutic efficacy of Insulin pork can be increased when used in combination with Succinylsulfathiazole.,Succinylsulfathiazole,DB00071
DB13617,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorexolone.,Clorexolone,DB00071
DB13663,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clofenamide.,Clofenamide,DB00071
DB13699,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfathiourea.,Sulfathiourea,DB00071
DB13708,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fenquizone.,Fenquizone,DB00071
DB13726,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaguanidine.,Sulfaguanidine,DB00071
DB13773,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxypyridazine.,Sulfamethoxypyridazine,DB00071
DB13792,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clopamide.,Clopamide,DB00071
DB13803,The therapeutic efficacy of Insulin pork can be increased when used in combination with Xipamide.,Xipamide,DB00071
DB14033,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetyl sulfisoxazole.,Acetyl sulfisoxazole,DB00071
DB14708,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tosylchloramide.,Tosylchloramide,DB00071
DB00703,The therapeutic efficacy of Insulin pork can be increased when used in combination with Methazolamide.,Methazolamide,DB00071
DB06370,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indisulam.,Indisulam,DB00071
DB00176,The metabolism of Fluvoxamine can be increased when combined with Insulin pork.,Fluvoxamine,DB00071
DB00184,The metabolism of Nicotine can be increased when combined with Insulin pork.,Nicotine,DB00071
DB00188,The metabolism of Bortezomib can be increased when combined with Insulin pork.,Bortezomib,DB00071
DB00201,The metabolism of Caffeine can be increased when combined with Insulin pork.,Caffeine,DB00071
DB00261,The metabolism of Anagrelide can be increased when combined with Insulin pork.,Anagrelide,DB00071
DB00262,The metabolism of Carmustine can be increased when combined with Insulin pork.,Carmustine,DB00071
DB00281,The metabolism of Lidocaine can be increased when combined with Insulin pork.,Lidocaine,DB00071
DB00286,The metabolism of Conjugated estrogens can be increased when combined with Insulin pork.,Conjugated estrogens,DB00071
DB00296,The metabolism of Ropivacaine can be increased when combined with Insulin pork.,Ropivacaine,DB00071
DB00315,The metabolism of Zolmitriptan can be increased when combined with Insulin pork.,Zolmitriptan,DB00071
DB00316,The metabolism of Acetaminophen can be increased when combined with Insulin pork.,Acetaminophen,DB00071
DB00356,The metabolism of Chlorzoxazone can be increased when combined with Insulin pork.,Chlorzoxazone,DB00071
DB00370,The metabolism of Mirtazapine can be increased when combined with Insulin pork.,Mirtazapine,DB00071
DB00379,The metabolism of Mexiletine can be increased when combined with Insulin pork.,Mexiletine,DB00071
DB00382,The metabolism of Tacrine can be increased when combined with Insulin pork.,Tacrine,DB00071
DB00384,The metabolism of Triamterene can be increased when combined with Insulin pork.,Triamterene,DB00071
DB00420,The metabolism of Promazine can be increased when combined with Insulin pork.,Promazine,DB00071
DB00425,The metabolism of Zolpidem can be increased when combined with Insulin pork.,Zolpidem,DB00071
DB00442,The metabolism of Entecavir can be increased when combined with Insulin pork.,Entecavir,DB00071
DB00461,The metabolism of Nabumetone can be increased when combined with Insulin pork.,Nabumetone,DB00071
DB00472,The metabolism of Fluoxetine can be increased when combined with Insulin pork.,Fluoxetine,DB00071
DB00476,The metabolism of Duloxetine can be increased when combined with Insulin pork.,Duloxetine,DB00071
DB00499,The metabolism of Flutamide can be increased when combined with Insulin pork.,Flutamide,DB00071
DB00518,The metabolism of Albendazole can be increased when combined with Insulin pork.,Albendazole,DB00071
DB00533,The metabolism of Rofecoxib can be increased when combined with Insulin pork.,Rofecoxib,DB00071
DB00544,The metabolism of Fluorouracil can be increased when combined with Insulin pork.,Fluorouracil,DB00071
DB00568,The metabolism of Cinnarizine can be increased when combined with Insulin pork.,Cinnarizine,DB00071
DB00586,The metabolism of Diclofenac can be increased when combined with Insulin pork.,Diclofenac,DB00071
DB00619,The metabolism of Imatinib can be increased when combined with Insulin pork.,Imatinib,DB00071
DB00629,The metabolism of Guanabenz can be increased when combined with Insulin pork.,Guanabenz,DB00071
DB00642,The metabolism of Pemetrexed can be increased when combined with Insulin pork.,Pemetrexed,DB00071
DB00661,The metabolism of Verapamil can be increased when combined with Insulin pork.,Verapamil,DB00071
DB00715,The metabolism of Paroxetine can be increased when combined with Insulin pork.,Paroxetine,DB00071
DB00730,The metabolism of Thiabendazole can be increased when combined with Insulin pork.,Thiabendazole,DB00071
DB00740,The metabolism of Riluzole can be increased when combined with Insulin pork.,Riluzole,DB00071
DB00744,The metabolism of Zileuton can be increased when combined with Insulin pork.,Zileuton,DB00071
DB00758,The metabolism of Clopidogrel can be increased when combined with Insulin pork.,Clopidogrel,DB00071
DB00787,The metabolism of Acyclovir can be increased when combined with Insulin pork.,Acyclovir,DB00071
DB00788,The metabolism of Naproxen can be increased when combined with Insulin pork.,Naproxen,DB00071
DB00806,The metabolism of Pentoxifylline can be increased when combined with Insulin pork.,Pentoxifylline,DB00071
DB00831,The metabolism of Trifluoperazine can be increased when combined with Insulin pork.,Trifluoperazine,DB00071
DB00850,The metabolism of Perphenazine can be increased when combined with Insulin pork.,Perphenazine,DB00071
DB00857,The metabolism of Terbinafine can be increased when combined with Insulin pork.,Terbinafine,DB00071
DB00863,The metabolism of Ranitidine can be increased when combined with Insulin pork.,Ranitidine,DB00071
DB00898,The metabolism of Ethanol can be increased when combined with Insulin pork.,Ethanol,DB00071
DB00934,The metabolism of Maprotiline can be increased when combined with Insulin pork.,Maprotiline,DB00071
DB00969,The metabolism of Alosetron can be increased when combined with Insulin pork.,Alosetron,DB00071
DB00980,The metabolism of Ramelteon can be increased when combined with Insulin pork.,Ramelteon,DB00071
DB00993,The metabolism of Azathioprine can be increased when combined with Insulin pork.,Azathioprine,DB00071
DB00998,The metabolism of Frovatriptan can be increased when combined with Insulin pork.,Frovatriptan,DB00071
DB01002,The metabolism of Levobupivacaine can be increased when combined with Insulin pork.,Levobupivacaine,DB00071
DB01012,The metabolism of Cinacalcet can be increased when combined with Insulin pork.,Cinacalcet,DB00071
DB01037,The metabolism of Selegiline can be increased when combined with Insulin pork.,Selegiline,DB00071
DB01056,The metabolism of Tocainide can be increased when combined with Insulin pork.,Tocainide,DB00071
DB01058,The metabolism of Praziquantel can be increased when combined with Insulin pork.,Praziquantel,DB00071
DB01065,The metabolism of Melatonin can be increased when combined with Insulin pork.,Melatonin,DB00071
DB01087,The metabolism of Primaquine can be increased when combined with Insulin pork.,Primaquine,DB00071
DB01094,The metabolism of Hesperetin can be increased when combined with Insulin pork.,Hesperetin,DB00071
DB01097,The metabolism of Leflunomide can be increased when combined with Insulin pork.,Leflunomide,DB00071
DB01166,The metabolism of Cilostazol can be increased when combined with Insulin pork.,Cilostazol,DB00071
DB01184,The metabolism of Domperidone can be increased when combined with Insulin pork.,Domperidone,DB00071
DB01191,The metabolism of Dexfenfluramine can be increased when combined with Insulin pork.,Dexfenfluramine,DB00071
DB01303,The metabolism of Oxtriphylline can be increased when combined with Insulin pork.,Oxtriphylline,DB00071
DB01367,The metabolism of Rasagiline can be increased when combined with Insulin pork.,Rasagiline,DB00071
DB01412,The metabolism of Theobromine can be increased when combined with Insulin pork.,Theobromine,DB00071
DB01424,The metabolism of Aminophenazone can be increased when combined with Insulin pork.,Aminophenazone,DB00071
DB01435,The metabolism of Antipyrine can be increased when combined with Insulin pork.,Antipyrine,DB00071
DB01482,The metabolism of Fenethylline can be increased when combined with Insulin pork.,Fenethylline,DB00071
DB01558,The metabolism of Bromazepam can be increased when combined with Insulin pork.,Bromazepam,DB00071
DB01623,The metabolism of Thiothixene can be increased when combined with Insulin pork.,Thiothixene,DB00071
DB01628,The metabolism of Etoricoxib can be increased when combined with Insulin pork.,Etoricoxib,DB00071
DB01645,The metabolism of Genistein can be increased when combined with Insulin pork.,Genistein,DB00071
DB01667,The metabolism of 8-azaguanine can be increased when combined with Insulin pork.,8-azaguanine,DB00071
DB02134,The metabolism of Xanthine can be increased when combined with Insulin pork.,Xanthine,DB00071
DB02489,The metabolism of 9-Methylguanine can be increased when combined with Insulin pork.,9-Methylguanine,DB00071
DB02568,The metabolism of Peldesine can be increased when combined with Insulin pork.,Peldesine,DB00071
DB02709,The metabolism of Resveratrol can be increased when combined with Insulin pork.,Resveratrol,DB00071
DB03783,The metabolism of Phenacetin can be increased when combined with Insulin pork.,Phenacetin,DB00071
DB04076,The metabolism of Hypoxanthine can be increased when combined with Insulin pork.,Hypoxanthine,DB00071
DB04356,The metabolism of 9-Deazaguanine can be increased when combined with Insulin pork.,9-Deazaguanine,DB00071
DB04841,The metabolism of Flunarizine can be increased when combined with Insulin pork.,Flunarizine,DB00071
DB04871,The metabolism of Lorcaserin can be increased when combined with Insulin pork.,Lorcaserin,DB00071
DB04948,The metabolism of Lofexidine can be increased when combined with Insulin pork.,Lofexidine,DB00071
DB04951,The metabolism of Pirfenidone can be increased when combined with Insulin pork.,Pirfenidone,DB00071
DB05676,The metabolism of Apremilast can be increased when combined with Insulin pork.,Apremilast,DB00071
DB06148,The metabolism of Mianserin can be increased when combined with Insulin pork.,Mianserin,DB00071
DB06210,The metabolism of Eltrombopag can be increased when combined with Insulin pork.,Eltrombopag,DB00071
DB06235,The metabolism of Vadimezan can be increased when combined with Insulin pork.,Vadimezan,DB00071
DB06479,The metabolism of Propentofylline can be increased when combined with Insulin pork.,Propentofylline,DB00071
DB06589,The metabolism of Pazopanib can be increased when combined with Insulin pork.,Pazopanib,DB00071
DB06594,The metabolism of Agomelatine can be increased when combined with Insulin pork.,Agomelatine,DB00071
DB06626,The metabolism of Axitinib can be increased when combined with Insulin pork.,Axitinib,DB00071
DB06769,The metabolism of Bendamustine can be increased when combined with Insulin pork.,Bendamustine,DB00071
DB06770,The metabolism of Benzyl alcohol can be increased when combined with Insulin pork.,Benzyl alcohol,DB00071
DB06774,The metabolism of Capsaicin can be increased when combined with Insulin pork.,Capsaicin,DB00071
DB08496,The metabolism of (R)-warfarin can be increased when combined with Insulin pork.,(R)-warfarin,DB00071
DB08883,The metabolism of Perampanel can be increased when combined with Insulin pork.,Perampanel,DB00071
DB09071,The metabolism of Tasimelteon can be increased when combined with Insulin pork.,Tasimelteon,DB00071
DB09118,The metabolism of Stiripentol can be increased when combined with Insulin pork.,Stiripentol,DB00071
DB09225,The metabolism of Zotepine can be increased when combined with Insulin pork.,Zotepine,DB00071
DB09273,The metabolism of Doxofylline can be increased when combined with Insulin pork.,Doxofylline,DB00071
DB09288,The metabolism of Propacetamol can be increased when combined with Insulin pork.,Propacetamol,DB00071
DB09290,The metabolism of Ramosetron can be increased when combined with Insulin pork.,Ramosetron,DB00071
DB11919,The metabolism of 6-O-benzylguanine can be increased when combined with Insulin pork.,6-O-benzylguanine,DB00071
DB11967,The metabolism of Binimetinib can be increased when combined with Insulin pork.,Binimetinib,DB00071
DB12026,The metabolism of Voxilaprevir can be increased when combined with Insulin pork.,Voxilaprevir,DB00071
DB12245,The metabolism of Triclabendazole can be increased when combined with Insulin pork.,Triclabendazole,DB00071
DB12332,The metabolism of Rucaparib can be increased when combined with Insulin pork.,Rucaparib,DB00071
DB12406,The metabolism of Lisofylline can be increased when combined with Insulin pork.,Lisofylline,DB00071
DB12531,The metabolism of Lobucavir can be increased when combined with Insulin pork.,Lobucavir,DB00071
DB12926,The metabolism of Cafedrine can be increased when combined with Insulin pork.,Cafedrine,DB00071
DB12927,The metabolism of Theodrenaline can be increased when combined with Insulin pork.,Theodrenaline,DB00071
DB12945,The metabolism of Dihydralazine can be increased when combined with Insulin pork.,Dihydralazine,DB00071
DB13203,The metabolism of Bamifylline can be increased when combined with Insulin pork.,Bamifylline,DB00071
DB13449,The metabolism of Proxyphylline can be increased when combined with Insulin pork.,Proxyphylline,DB00071
DB13573,The metabolism of Acefylline can be increased when combined with Insulin pork.,Acefylline,DB00071
DB13592,The metabolism of Etamiphylline can be increased when combined with Insulin pork.,Etamiphylline,DB00071
DB13634,The metabolism of Pentifylline can be increased when combined with Insulin pork.,Pentifylline,DB00071
DB13812,The metabolism of Bufylline can be increased when combined with Insulin pork.,Bufylline,DB00071
DB13952,The metabolism of Estradiol acetate can be increased when combined with Insulin pork.,Estradiol acetate,DB00071
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Insulin pork.,Estradiol benzoate,DB00071
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Insulin pork.,Estradiol cypionate,DB00071
DB13955,The metabolism of Estradiol dienanthate can be increased when combined with Insulin pork.,Estradiol dienanthate,DB00071
DB13956,The metabolism of Estradiol valerate can be increased when combined with Insulin pork.,Estradiol valerate,DB00071
DB14018,The metabolism of Bromotheophylline can be increased when combined with Insulin pork.,Bromotheophylline,DB00071
DB14132,The metabolism of 8-chlorotheophylline can be increased when combined with Insulin pork.,8-chlorotheophylline,DB00071
DB01115,The metabolism of Nifedipine can be increased when combined with Insulin pork.,Nifedipine,DB00071
DB11757,The metabolism of Istradefylline can be increased when combined with Insulin pork.,Istradefylline,DB00071
DB00972,The metabolism of Azelastine can be increased when combined with Insulin pork.,Azelastine,DB00071
DB00625,The metabolism of Efavirenz can be increased when combined with Insulin pork.,Efavirenz,DB00071
DB04889,The metabolism of Bicifadine can be increased when combined with Insulin pork.,Bicifadine,DB00071
DB05708,The metabolism of GTS-21 can be increased when combined with Insulin pork.,GTS-21,DB00071
DB01195,The metabolism of Flecainide can be increased when combined with Insulin pork.,Flecainide,DB00071
DB00783,The metabolism of Estradiol can be increased when combined with Insulin pork.,Estradiol,DB00071
DB00321,The metabolism of Amitriptyline can be increased when combined with Insulin pork.,Amitriptyline,DB00071
DB00458,The metabolism of Imipramine can be increased when combined with Insulin pork.,Imipramine,DB00071
DB01142,The metabolism of Doxepin can be increased when combined with Insulin pork.,Doxepin,DB00071
DB00532,The metabolism of Mephenytoin can be increased when combined with Insulin pork.,Mephenytoin,DB00071
DB00540,The metabolism of Nortriptyline can be increased when combined with Insulin pork.,Nortriptyline,DB00071
DB00575,The metabolism of Clonidine can be increased when combined with Insulin pork.,Clonidine,DB00071
DB00924,The metabolism of Cyclobenzaprine can be increased when combined with Insulin pork.,Cyclobenzaprine,DB00071
DB01151,The metabolism of Desipramine can be increased when combined with Insulin pork.,Desipramine,DB00071
DB01242,The metabolism of Clomipramine can be increased when combined with Insulin pork.,Clomipramine,DB00071
DB11689,The metabolism of Selumetinib can be increased when combined with Insulin pork.,Selumetinib,DB00071
DB00277,The metabolism of Theophylline can be increased when combined with Insulin pork.,Theophylline,DB00071
DB00398,The metabolism of Sorafenib can be increased when combined with Insulin pork.,Sorafenib,DB00071
DB00530,The metabolism of Erlotinib can be increased when combined with Insulin pork.,Erlotinib,DB00071
DB00564,The metabolism of Carbamazepine can be increased when combined with Insulin pork.,Carbamazepine,DB00071
DB00682,The metabolism of Warfarin can be increased when combined with Insulin pork.,Warfarin,DB00071
DB00697,The metabolism of Tizanidine can be increased when combined with Insulin pork.,Tizanidine,DB00071
DB00773,The metabolism of Etoposide can be increased when combined with Insulin pork.,Etoposide,DB00071
DB00851,The metabolism of Dacarbazine can be increased when combined with Insulin pork.,Dacarbazine,DB00071
DB01100,The metabolism of Pimozide can be increased when combined with Insulin pork.,Pimozide,DB00071
DB01223,The metabolism of Aminophylline can be increased when combined with Insulin pork.,Aminophylline,DB00071
DB01254,The metabolism of Dasatinib can be increased when combined with Insulin pork.,Dasatinib,DB00071
DB01418,The metabolism of Acenocoumarol can be increased when combined with Insulin pork.,Acenocoumarol,DB00071
DB08910,The metabolism of Pomalidomide can be increased when combined with Insulin pork.,Pomalidomide,DB00071
DB09256,The metabolism of Tegafur can be increased when combined with Insulin pork.,Tegafur,DB00071
DB13874,The metabolism of Enasidenib can be increased when combined with Insulin pork.,Enasidenib,DB00071
DB00675,The metabolism of Tamoxifen can be increased when combined with Insulin pork.,Tamoxifen,DB00071
DB00030,The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.,Insulin human,DB00071
DB00046,The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin pork.,Insulin lispro,DB00071
DB00047,The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin pork.,Insulin glargine,DB00071
DB00197,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Troglitazone.,Troglitazone,DB00071
DB00222,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glimepiride.,Glimepiride,DB00071
DB00280,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Disopyramide.,Disopyramide,DB00071
DB00284,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acarbose.,Acarbose,DB00071
DB00414,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acetohexamide.,Acetohexamide,DB00071
DB00468,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Quinine.,Quinine,DB00071
DB00491,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Miglitol.,Miglitol,DB00071
DB00672,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Chlorpropamide.,Chlorpropamide,DB00071
DB00731,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Nateglinide.,Nateglinide,DB00071
DB00834,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mifepristone.,Mifepristone,DB00071
DB00839,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolazamide.,Tolazamide,DB00071
DB00912,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Repaglinide.,Repaglinide,DB00071
DB00914,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Phenformin.,Phenformin,DB00071
DB01016,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glyburide.,Glyburide,DB00071
DB01067,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glipizide.,Glipizide,DB00071
DB01120,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliclazide.,Gliclazide,DB00071
DB01124,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolbutamide.,Tolbutamide,DB00071
DB01200,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Bromocriptine.,Bromocriptine,DB00071
DB01251,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliquidone.,Gliquidone,DB00071
DB01252,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mitiglinide.,Mitiglinide,DB00071
DB01268,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sunitinib.,Sunitinib,DB00071
DB01277,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mecasermin.,Mecasermin,DB00071
DB01289,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glisoxepide.,Glisoxepide,DB00071
DB01306,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin aspart.,Insulin aspart,DB00071
DB01307,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin detemir.,Insulin detemir,DB00071
DB01309,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin glulisine.,Insulin glulisine,DB00071
DB01700,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with AICA ribonucleotide.,AICA ribonucleotide,DB00071
DB04830,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Buformin.,Buformin,DB00071
DB04878,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Voglibose.,Voglibose,DB00071
DB05115,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NN344.,NN344,DB00071
DB05819,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NBI-6024.,NBI-6024,DB00071
DB08962,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glibornuride.,Glibornuride,DB00071
DB09022,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Benfluorex.,Benfluorex,DB00071
DB09198,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Lobeglitazone.,Lobeglitazone,DB00071
DB09199,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Netoglitazone.,Netoglitazone,DB00071
DB09200,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Rivoglitazone.,Rivoglitazone,DB00071
DB09201,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ciglitazone.,Ciglitazone,DB00071
DB09456,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin beef.,Insulin beef,DB00071
DB09564,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin degludec.,Insulin degludec,DB00071
DB11567,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin peglispro.,Insulin peglispro,DB00071
DB11568,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin tregopil.,Insulin tregopil,DB00071
DB11698,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ipragliflozin.,Ipragliflozin,DB00071
DB11780,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Allicin.,Allicin,DB00071
DB11824,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tofogliflozin.,Tofogliflozin,DB00071
DB11898,"The risk or severity of hypoglycemia can be increased when Insulin pork is combined with 2,4-thiazolidinedione.","2,4-thiazolidinedione",DB00071
DB12713,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sotagliflozin.,Sotagliflozin,DB00071
DB12781,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Balaglitazone.,Balaglitazone,DB00071
DB12935,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Remogliflozin etabonate.,Remogliflozin etabonate,DB00071
DB13406,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Carbutamide.,Carbutamide,DB00071
DB13446,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Guar gum.,Guar gum,DB00071
DB13675,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Metahexamide.,Metahexamide,DB00071
DB14035,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Englitazone.,Englitazone,DB00071
DB15171,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tirzepatide.,Tirzepatide,DB00071
DB15217,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gastric inhibitory polypeptide.,Gastric inhibitory polypeptide,DB00071
DB09038,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Empagliflozin.,Empagliflozin,DB00071
DB00270,The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin pork.,Isradipine,DB00071
DB00343,The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin pork.,Diltiazem,DB00071
DB00347,The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin pork.,Trimethadione,DB00071
DB00381,The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin pork.,Amlodipine,DB00071
DB00393,The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin pork.,Nimodipine,DB00071
DB00401,The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin pork.,Nisoldipine,DB00071
DB00528,The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin pork.,Lercanidipine,DB00071
DB00555,The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin pork.,Lamotrigine,DB00071
DB00593,The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin pork.,Ethosuximide,DB00071
DB00622,The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin pork.,Nicardipine,DB00071
DB00653,The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin pork.,Magnesium sulfate,DB00071
DB00836,The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin pork.,Loperamide,DB00071
DB01054,The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin pork.,Nitrendipine,DB00071
DB01074,The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin pork.,Perhexiline,DB00071
DB01244,The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin pork.,Bepridil,DB00071
DB01388,The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin pork.,Mibefradil,DB00071
DB04743,The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin pork.,Nimesulide,DB00071
DB04825,The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin pork.,Prenylamine,DB00071
DB04838,The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin pork.,Cyclandelate,DB00071
DB04842,The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin pork.,Fluspirilene,DB00071
DB04920,The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.,Clevidipine,DB00071
DB05246,The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin pork.,Methsuximide,DB00071
DB05885,The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin pork.,Seletracetam,DB00071
DB06152,The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin pork.,Nylidrin,DB00071
DB06283,The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin pork.,Ziconotide,DB00071
DB06446,The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin pork.,Dotarizine,DB00071
DB06694,The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin pork.,Xylometazoline,DB00071
DB06712,The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin pork.,Nilvadipine,DB00071
DB07615,The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin pork.,Tranilast,DB00071
DB08838,The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin pork.,Agmatine,DB00071
DB08980,The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin pork.,Fendiline,DB00071
DB08992,The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin pork.,Eperisone,DB00071
DB09089,The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin pork.,Trimebutine,DB00071
DB09090,The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin pork.,Pinaverium,DB00071
DB09216,The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin pork.,Tolfenamic acid,DB00071
DB09227,The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin pork.,Barnidipine,DB00071
DB09229,The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin pork.,Aranidipine,DB00071
DB09230,The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin pork.,Azelnidipine,DB00071
DB09231,The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin pork.,Benidipine,DB00071
DB09232,The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin pork.,Cilnidipine,DB00071
DB09234,The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin pork.,Darodipine,DB00071
DB09235,The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin pork.,Efonidipine,DB00071
DB09236,The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin pork.,Lacidipine,DB00071
DB09238,The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin pork.,Manidipine,DB00071
DB09239,The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin pork.,Niguldipine,DB00071
DB09240,The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin pork.,Niludipine,DB00071
DB11960,The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin pork.,Carboxyamidotriazole,DB00071
DB12092,The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin pork.,Naftopidil,DB00071
DB12093,The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin pork.,Tetrahydropalmatine,DB00071
DB12131,The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin pork.,Vinpocetine,DB00071
DB12923,The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin pork.,Gallopamil,DB00071
DB13488,The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin pork.,Bencyclane,DB00071
DB13500,The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin pork.,Otilonium,DB00071
DB13725,The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin pork.,Terodiline,DB00071
DB13766,The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin pork.,Lidoflazine,DB00071
DB13791,The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin pork.,Penfluridol,DB00071
DB13835,The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin pork.,Caroverine,DB00071
DB13950,The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin pork.,WIN 55212-2,DB00071
DB13961,The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin pork.,Fish oil,DB00071
DB14063,The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin pork.,Dexverapamil,DB00071
DB14064,The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin pork.,Emopamil,DB00071
DB14065,The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin pork.,Lomerizine,DB00071
DB14066,The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin pork.,Tetrandrine,DB00071
DB14068,The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin pork.,Dexniguldipine,DB00071
DB01023,The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin pork.,Felodipine,DB00071
DB01118,The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin pork.,Amiodarone,DB00071
DB00191,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phentermine.,Phentermine,DB00071
DB00268,The metabolism of Ropinirole can be increased when combined with Insulin pork.,Ropinirole,DB00071
DB13074,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin pork.,Macimorelin,DB00071
DB00279,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Liothyronine.,Liothyronine,DB00071
DB00331,The risk or severity of adverse effects can be increased when Insulin pork is combined with Metformin.,Metformin,DB00071
DB00542,The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin pork.,Benazepril,DB00071
DB13946,The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin pork.,Testosterone undecanoate,DB00071
DB00945,The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin pork.,Acetylsalicylic acid,DB00071
DB00181,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Baclofen.,Baclofen,DB00071
DB00489,The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin pork.,Sotalol,DB00071
DB00196,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Fluconazole.,Fluconazole,DB00071
DB00040,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Glucagon.,Glucagon,DB00071
DB00264,The therapeutic efficacy of Insulin pork can be increased when used in combination with Metoprolol.,Metoprolol,DB00071
DB00335,The therapeutic efficacy of Insulin pork can be increased when used in combination with Atenolol.,Atenolol,DB00071
DB00373,The therapeutic efficacy of Insulin pork can be increased when used in combination with Timolol.,Timolol,DB00071
DB00598,The therapeutic efficacy of Insulin pork can be increased when used in combination with Labetalol.,Labetalol,DB00071
DB00612,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bisoprolol.,Bisoprolol,DB00071
DB00866,The therapeutic efficacy of Insulin pork can be increased when used in combination with Alprenolol.,Alprenolol,DB00071
DB00960,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pindolol.,Pindolol,DB00071
DB01193,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acebutolol.,Acebutolol,DB00071
DB01203,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nadolol.,Nadolol,DB00071
DB01295,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bevantolol.,Bevantolol,DB00071
DB01297,The therapeutic efficacy of Insulin pork can be increased when used in combination with Practolol.,Practolol,DB00071
DB01359,The therapeutic efficacy of Insulin pork can be increased when used in combination with Penbutolol.,Penbutolol,DB00071
DB01580,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxprenolol.,Oxprenolol,DB00071
DB03322,The therapeutic efficacy of Insulin pork can be increased when used in combination with Dexpropranolol.,Dexpropranolol,DB00071
DB04846,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celiprolol.,Celiprolol,DB00071
DB04861,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nebivolol.,Nebivolol,DB00071
DB06726,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bufuralol.,Bufuralol,DB00071
DB08807,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bopindolol.,Bopindolol,DB00071
DB08808,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bupranolol.,Bupranolol,DB00071
DB08952,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indenolol.,Indenolol,DB00071
DB09013,The therapeutic efficacy of Insulin pork can be increased when used in combination with Befunolol.,Befunolol,DB00071
DB09204,The therapeutic efficacy of Insulin pork can be increased when used in combination with Arotinolol.,Arotinolol,DB00071
DB09351,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levobetaxolol.,Levobetaxolol,DB00071
DB11770,The therapeutic efficacy of Insulin pork can be increased when used in combination with Talinolol.,Talinolol,DB00071
DB11785,The therapeutic efficacy of Insulin pork can be increased when used in combination with Anisodamine.,Anisodamine,DB00071
DB12212,The therapeutic efficacy of Insulin pork can be increased when used in combination with Landiolol.,Landiolol,DB00071
DB12752,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bucindolol.,Bucindolol,DB00071
DB13443,The therapeutic efficacy of Insulin pork can be increased when used in combination with Esatenolol.,Esatenolol,DB00071
DB13508,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cloranolol.,Cloranolol,DB00071
DB13530,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mepindolol.,Mepindolol,DB00071
DB13757,The therapeutic efficacy of Insulin pork can be increased when used in combination with Epanolol.,Epanolol,DB00071
DB13775,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tertatolol.,Tertatolol,DB00071
DB00195,The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin pork.,Betaxolol,DB00071
DB00571,The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin pork.,Propranolol,DB00071
DB01136,The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin pork.,Carvedilol,DB00071
DB01182,The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin pork.,Propafenone,DB00071
DB01611,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxychloroquine.,Hydroxychloroquine,DB00071
DB01233,The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin pork.,Metoclopramide,DB00071
DB00394,The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin pork.,Beclomethasone dipropionate,DB00071
DB00443,The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin pork.,Betamethasone,DB00071
DB00620,The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin pork.,Triamcinolone,DB00071
DB00635,The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin pork.,Prednisone,DB00071
DB00687,The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin pork.,Fludrocortisone,DB00071
DB00741,The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin pork.,Hydrocortisone,DB00071
DB00764,The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin pork.,Mometasone,DB00071
DB00860,The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin pork.,Prednisolone,DB00071
DB00959,The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin pork.,Methylprednisolone,DB00071
DB01234,The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin pork.,Dexamethasone,DB00071
DB01285,The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin pork.,Corticotropin,DB00071
DB01380,The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin pork.,Cortisone acetate,DB00071
DB01384,The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin pork.,Paramethasone,DB00071
DB01410,The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin pork.,Ciclesonide,DB00071
DB08906,The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin pork.,Fluticasone furoate,DB00071
DB08970,The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin pork.,Fluprednidene,DB00071
DB08971,The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin pork.,Fluocortolone,DB00071
DB09383,The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin pork.,Meprednisone,DB00071
DB11487,The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin pork.,Dexamethasone isonicotinate,DB00071
DB11750,The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin pork.,Clobetasol,DB00071
DB11921,The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin pork.,Deflazacort,DB00071
DB13003,The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin pork.,Cortivazol,DB00071
DB13208,The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin pork.,Prednylidene,DB00071
DB13843,The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin pork.,Cloprednol,DB00071
DB13867,The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin pork.,Fluticasone,DB00071
DB14512,The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin pork.,Mometasone furoate,DB00071
DB00180,The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin pork.,Flunisolide,DB00071
DB01108,The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin pork.,Trilostane,DB00071
DB01222,The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin pork.,Budesonide,DB00071
DB04630,The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin pork.,Aldosterone,DB00071
DB09378,The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin pork.,Fluprednisolone,DB00071
DB11529,The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin pork.,Melengestrol,DB00071
DB14681,The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin pork.,Cortisone,DB00071
DB00223,The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin pork.,Diflorasone,DB00071
DB00240,The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin pork.,Alclometasone,DB00071
DB00253,The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin pork.,Medrysone,DB00071
DB00288,The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin pork.,Amcinonide,DB00071
DB00324,The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin pork.,Fluorometholone,DB00071
DB00547,The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin pork.,Desoximetasone,DB00071
DB00588,The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin pork.,Fluticasone propionate,DB00071
DB00591,The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin pork.,Fluocinolone acetonide,DB00071
DB00596,The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin pork.,Ulobetasol,DB00071
DB00663,The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin pork.,Flumethasone,DB00071
DB00838,The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin pork.,Clocortolone,DB00071
DB00846,The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin pork.,Flurandrenolide,DB00071
DB14596,The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin pork.,Loteprednol etabonate,DB00071
DB00896,The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin pork.,Rimexolone,DB00071
DB01013,The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin pork.,Clobetasol propionate,DB00071
DB01047,The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin pork.,Fluocinonide,DB00071
DB01130,The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin pork.,Prednicarbate,DB00071
DB01260,The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin pork.,Desonide,DB00071
DB06781,The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin pork.,Difluprednate,DB00071
DB06786,The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin pork.,Halcinonide,DB00071
DB09091,The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin pork.,Tixocortol,DB00071
DB09095,The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin pork.,Difluocortolone,DB00071
DB13158,The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin pork.,Clobetasone,DB00071
DB13223,The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin pork.,Fluocortin,DB00071
DB13491,The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin pork.,Fluperolone,DB00071
DB13664,The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin pork.,Formocortal,DB00071
DB13728,The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin pork.,Halometasone,DB00071
DB13856,The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin pork.,Fluclorolone,DB00071
DB14538,The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin pork.,Hydrocortisone aceponate,DB00071
DB14539,The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin pork.,Hydrocortisone acetate,DB00071
DB14540,The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin pork.,Hydrocortisone butyrate,DB00071
DB14541,The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin pork.,Hydrocortisone cypionate,DB00071
DB14543,The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin pork.,Hydrocortisone probutate,DB00071
DB14544,The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin pork.,Hydrocortisone valerate,DB00071
DB14545,The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin pork.,Hydrocortisone succinate,DB00071
DB00873,The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin pork.,Loteprednol,DB00071
DB14631,The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin pork.,Prednisolone phosphate,DB00071
DB14633,The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin pork.,Prednisolone hemisuccinate,DB00071
DB14634,The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin pork.,Fluprednidene acetate,DB00071
DB14643,The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin pork.,Methylprednisolone aceponate,DB00071
DB14644,The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin pork.,Methylprednisolone hemisuccinate,DB00071
DB14646,The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin pork.,Prednisone acetate,DB00071
DB14652,The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin pork.,Clocortolone acetate,DB00071
DB14659,The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin pork.,Melengestrol acetate,DB00071
DB14669,The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin pork.,Betamethasone phosphate,DB00071
DB15566,The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin pork.,Prednisolone acetate,DB00071
DB00451,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levothyroxine.,Levothyroxine,DB00071
DB00024,Thyrotropin alfa may decrease the hypoglycemic activities of Insulin pork.,Thyrotropin alfa,DB00071
DB01583,Liotrix may decrease the hypoglycemic activities of Insulin pork.,Liotrix,DB00071
DB03604,Tiratricol may decrease the hypoglycemic activities of Insulin pork.,Tiratricol,DB00071
DB09100,"Thyroid, porcine may decrease the hypoglycemic activities of Insulin pork.","Thyroid, porcine",DB00071
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab.,Denosumab,DB00072
DB00108,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.,Natalizumab,DB00072
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab.,Pimecrolimus,DB00072
DB01656,Roflumilast may increase the immunosuppressive activities of Trastuzumab.,Roflumilast,DB00072
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trastuzumab.,Sipuleucel-T,DB00072
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab.,Darbepoetin alfa,DB00072
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trastuzumab.,Erythropoietin,DB00072
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Trastuzumab.,Peginesatide,DB00072
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab.,Methoxy polyethylene glycol-epoetin beta,DB00072
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trastuzumab.,Sulfamethoxazole,DB00072
DB01229,The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.,Paclitaxel,DB00072
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Trastuzumab.,Diethylstilbestrol,DB00072
DB00269,Chlorotrianisene may increase the thrombogenic activities of Trastuzumab.,Chlorotrianisene,DB00072
DB00286,Conjugated estrogens may increase the thrombogenic activities of Trastuzumab.,Conjugated estrogens,DB00072
DB00655,Estrone may increase the thrombogenic activities of Trastuzumab.,Estrone,DB00072
DB00783,Estradiol may increase the thrombogenic activities of Trastuzumab.,Estradiol,DB00072
DB00890,Dienestrol may increase the thrombogenic activities of Trastuzumab.,Dienestrol,DB00072
DB00977,Ethinylestradiol may increase the thrombogenic activities of Trastuzumab.,Ethinylestradiol,DB00072
DB01357,Mestranol may increase the thrombogenic activities of Trastuzumab.,Mestranol,DB00072
DB04573,Estriol may increase the thrombogenic activities of Trastuzumab.,Estriol,DB00072
DB04574,Estrone sulfate may increase the thrombogenic activities of Trastuzumab.,Estrone sulfate,DB00072
DB04575,Quinestrol may increase the thrombogenic activities of Trastuzumab.,Quinestrol,DB00072
DB07931,Hexestrol may increase the thrombogenic activities of Trastuzumab.,Hexestrol,DB00072
DB09070,Tibolone may increase the thrombogenic activities of Trastuzumab.,Tibolone,DB00072
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Trastuzumab.","Synthetic Conjugated Estrogens, A",DB00072
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Trastuzumab.","Synthetic Conjugated Estrogens, B",DB00072
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Trastuzumab.,Polyestradiol phosphate,DB00072
DB09381,Esterified estrogens may increase the thrombogenic activities of Trastuzumab.,Esterified estrogens,DB00072
DB11478,Zeranol may increase the thrombogenic activities of Trastuzumab.,Zeranol,DB00072
DB11674,Equol may increase the thrombogenic activities of Trastuzumab.,Equol,DB00072
DB12487,Promestriene may increase the thrombogenic activities of Trastuzumab.,Promestriene,DB00072
DB13143,Methallenestril may increase the thrombogenic activities of Trastuzumab.,Methallenestril,DB00072
DB13386,Epimestrol may increase the thrombogenic activities of Trastuzumab.,Epimestrol,DB00072
DB13418,Moxestrol may increase the thrombogenic activities of Trastuzumab.,Moxestrol,DB00072
DB13952,Estradiol acetate may increase the thrombogenic activities of Trastuzumab.,Estradiol acetate,DB00072
DB13953,Estradiol benzoate may increase the thrombogenic activities of Trastuzumab.,Estradiol benzoate,DB00072
DB13954,Estradiol cypionate may increase the thrombogenic activities of Trastuzumab.,Estradiol cypionate,DB00072
DB13956,Estradiol valerate may increase the thrombogenic activities of Trastuzumab.,Estradiol valerate,DB00072
DB15334,Biochanin A may increase the thrombogenic activities of Trastuzumab.,Biochanin A,DB00072
DB15335,Formononetin may increase the thrombogenic activities of Trastuzumab.,Formononetin,DB00072
DB01097,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leflunomide.,Leflunomide,DB00072
DB08895,Trastuzumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00072
DB00005,Trastuzumab may increase the neutropenic activities of Etanercept.,Etanercept,DB00072
DB00074,Trastuzumab may increase the neutropenic activities of Basiliximab.,Basiliximab,DB00072
DB00075,Trastuzumab may increase the neutropenic activities of Muromonab.,Muromonab,DB00072
DB00111,Trastuzumab may increase the neutropenic activities of Daclizumab.,Daclizumab,DB00072
DB00242,Trastuzumab may increase the neutropenic activities of Cladribine.,Cladribine,DB00072
DB00688,Trastuzumab may increase the neutropenic activities of Mycophenolate mofetil.,Mycophenolate mofetil,DB00072
DB00877,Trastuzumab may increase the neutropenic activities of Sirolimus.,Sirolimus,DB00072
DB00993,Trastuzumab may increase the neutropenic activities of Azathioprine.,Azathioprine,DB00072
DB01024,Trastuzumab may increase the neutropenic activities of Mycophenolic acid.,Mycophenolic acid,DB00072
DB01041,Trastuzumab may increase the neutropenic activities of Thalidomide.,Thalidomide,DB00072
DB01281,Trastuzumab may increase the neutropenic activities of Abatacept.,Abatacept,DB00072
DB01590,Trastuzumab may increase the neutropenic activities of Everolimus.,Everolimus,DB00072
DB06681,Trastuzumab may increase the neutropenic activities of Belatacept.,Belatacept,DB00072
DB08879,Trastuzumab may increase the neutropenic activities of Belimumab.,Belimumab,DB00072
DB08880,Trastuzumab may increase the neutropenic activities of Teriflunomide.,Teriflunomide,DB00072
DB08904,Trastuzumab may increase the neutropenic activities of Certolizumab pegol.,Certolizumab pegol,DB00072
DB06168,Trastuzumab may increase the neutropenic activities of Canakinumab.,Canakinumab,DB00072
DB09033,Trastuzumab may increase the neutropenic activities of Vedolizumab.,Vedolizumab,DB00072
DB09036,Trastuzumab may increase the neutropenic activities of Siltuximab.,Siltuximab,DB00072
DB12692,Trastuzumab may increase the neutropenic activities of Gusperimus.,Gusperimus,DB00072
DB11693,Trastuzumab may increase the neutropenic activities of Voclosporin.,Voclosporin,DB00072
DB09312,Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00072
DB06612,Trastuzumab may increase the neutropenic activities of Mepolizumab.,Mepolizumab,DB00072
DB00441,Trastuzumab may increase the neutropenic activities of Gemcitabine.,Gemcitabine,DB00072
DB00531,Trastuzumab may increase the neutropenic activities of Cyclophosphamide.,Cyclophosphamide,DB00072
DB00544,Trastuzumab may increase the neutropenic activities of Fluorouracil.,Fluorouracil,DB00072
DB00563,Trastuzumab may increase the neutropenic activities of Methotrexate.,Methotrexate,DB00072
DB00620,Trastuzumab may increase the neutropenic activities of Triamcinolone.,Triamcinolone,DB00072
DB00987,Trastuzumab may increase the neutropenic activities of Cytarabine.,Cytarabine,DB00072
DB01008,Trastuzumab may increase the neutropenic activities of Busulfan.,Busulfan,DB00072
DB01033,Trastuzumab may increase the neutropenic activities of Mercaptopurine.,Mercaptopurine,DB00072
DB01042,Trastuzumab may increase the neutropenic activities of Melphalan.,Melphalan,DB00072
DB01073,Trastuzumab may increase the neutropenic activities of Fludarabine.,Fludarabine,DB00072
DB04572,Trastuzumab may increase the neutropenic activities of Thiotepa.,Thiotepa,DB00072
DB05259,Trastuzumab may increase the neutropenic activities of Glatiramer.,Glatiramer,DB00072
DB00026,Trastuzumab may increase the neutropenic activities of Anakinra.,Anakinra,DB00072
DB00051,Trastuzumab may increase the neutropenic activities of Adalimumab.,Adalimumab,DB00072
DB00065,Trastuzumab may increase the neutropenic activities of Infliximab.,Infliximab,DB00072
DB00087,Trastuzumab may increase the neutropenic activities of Alemtuzumab.,Alemtuzumab,DB00072
DB00098,Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00072
DB00480,Trastuzumab may increase the neutropenic activities of Lenalidomide.,Lenalidomide,DB00072
DB01257,Trastuzumab may increase the neutropenic activities of Eculizumab.,Eculizumab,DB00072
DB06273,Trastuzumab may increase the neutropenic activities of Tocilizumab.,Tocilizumab,DB00072
DB06372,Trastuzumab may increase the neutropenic activities of Rilonacept.,Rilonacept,DB00072
DB06674,Trastuzumab may increase the neutropenic activities of Golimumab.,Golimumab,DB00072
DB08910,Trastuzumab may increase the neutropenic activities of Pomalidomide.,Pomalidomide,DB00072
DB09029,Trastuzumab may increase the neutropenic activities of Secukinumab.,Secukinumab,DB00072
DB00056,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin,DB00072
DB00059,Trastuzumab may increase the neutropenic activities of Pegaspargase.,Pegaspargase,DB00072
DB00073,Trastuzumab may increase the neutropenic activities of Rituximab.,Rituximab,DB00072
DB00078,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00072
DB00081,Trastuzumab may increase the neutropenic activities of Tositumomab.,Tositumomab,DB00072
DB00120,Trastuzumab may increase the neutropenic activities of Phenylalanine.,Phenylalanine,DB00072
DB00262,Trastuzumab may increase the neutropenic activities of Carmustine.,Carmustine,DB00072
DB00276,Trastuzumab may increase the neutropenic activities of Amsacrine.,Amsacrine,DB00072
DB00290,Trastuzumab may increase the neutropenic activities of Bleomycin.,Bleomycin,DB00072
DB00291,Trastuzumab may increase the neutropenic activities of Chlorambucil.,Chlorambucil,DB00072
DB00305,Trastuzumab may increase the neutropenic activities of Mitomycin.,Mitomycin,DB00072
DB00309,Trastuzumab may increase the neutropenic activities of Vindesine.,Vindesine,DB00072
DB00322,Trastuzumab may increase the neutropenic activities of Floxuridine.,Floxuridine,DB00072
DB00352,Trastuzumab may increase the neutropenic activities of Tioguanine.,Tioguanine,DB00072
DB00361,Trastuzumab may increase the neutropenic activities of Vinorelbine.,Vinorelbine,DB00072
DB00398,Trastuzumab may increase the neutropenic activities of Sorafenib.,Sorafenib,DB00072
DB00428,Trastuzumab may increase the neutropenic activities of Streptozocin.,Streptozocin,DB00072
DB00443,Trastuzumab may increase the neutropenic activities of Betamethasone.,Betamethasone,DB00072
DB00444,Trastuzumab may increase the neutropenic activities of Teniposide.,Teniposide,DB00072
DB00488,Trastuzumab may increase the neutropenic activities of Altretamine.,Altretamine,DB00072
DB00515,Trastuzumab may increase the neutropenic activities of Cisplatin.,Cisplatin,DB00072
DB00526,Trastuzumab may increase the neutropenic activities of Oxaliplatin.,Oxaliplatin,DB00072
DB00541,Trastuzumab may increase the neutropenic activities of Vincristine.,Vincristine,DB00072
DB00552,Trastuzumab may increase the neutropenic activities of Pentostatin.,Pentostatin,DB00072
DB00570,Trastuzumab may increase the neutropenic activities of Vinblastine.,Vinblastine,DB00072
DB00619,Trastuzumab may increase the neutropenic activities of Imatinib.,Imatinib,DB00072
DB00631,Trastuzumab may increase the neutropenic activities of Clofarabine.,Clofarabine,DB00072
DB00635,Trastuzumab may increase the neutropenic activities of Prednisone.,Prednisone,DB00072
DB00642,Trastuzumab may increase the neutropenic activities of Pemetrexed.,Pemetrexed,DB00072
DB00687,Trastuzumab may increase the neutropenic activities of Fludrocortisone.,Fludrocortisone,DB00072
DB00724,Trastuzumab may increase the neutropenic activities of Imiquimod.,Imiquimod,DB00072
DB00741,Trastuzumab may increase the neutropenic activities of Hydrocortisone.,Hydrocortisone,DB00072
DB00755,Trastuzumab may increase the neutropenic activities of Tretinoin.,Tretinoin,DB00072
DB00762,Trastuzumab may increase the neutropenic activities of Irinotecan.,Irinotecan,DB00072
DB00773,Trastuzumab may increase the neutropenic activities of Etoposide.,Etoposide,DB00072
DB00851,Trastuzumab may increase the neutropenic activities of Dacarbazine.,Dacarbazine,DB00072
DB00853,Trastuzumab may increase the neutropenic activities of Temozolomide.,Temozolomide,DB00072
DB00860,Trastuzumab may increase the neutropenic activities of Prednisolone.,Prednisolone,DB00072
DB00888,Trastuzumab may increase the neutropenic activities of Mechlorethamine.,Mechlorethamine,DB00072
DB00928,Trastuzumab may increase the neutropenic activities of Azacitidine.,Azacitidine,DB00072
DB00958,Trastuzumab may increase the neutropenic activities of Carboplatin.,Carboplatin,DB00072
DB00959,Trastuzumab may increase the neutropenic activities of Methylprednisolone.,Methylprednisolone,DB00072
DB00970,Trastuzumab may increase the neutropenic activities of Dactinomycin.,Dactinomycin,DB00072
DB01005,Trastuzumab may increase the neutropenic activities of Hydroxyurea.,Hydroxyurea,DB00072
DB01030,Trastuzumab may increase the neutropenic activities of Topotecan.,Topotecan,DB00072
DB01101,Trastuzumab may increase the neutropenic activities of Capecitabine.,Capecitabine,DB00072
DB01168,Trastuzumab may increase the neutropenic activities of Procarbazine.,Procarbazine,DB00072
DB01181,Trastuzumab may increase the neutropenic activities of Ifosfamide.,Ifosfamide,DB00072
DB01196,Trastuzumab may increase the neutropenic activities of Estramustine.,Estramustine,DB00072
DB01204,Trastuzumab may increase the neutropenic activities of Mitoxantrone.,Mitoxantrone,DB00072
DB01206,Trastuzumab may increase the neutropenic activities of Lomustine.,Lomustine,DB00072
DB01222,Trastuzumab may increase the neutropenic activities of Budesonide.,Budesonide,DB00072
DB01234,Trastuzumab may increase the neutropenic activities of Dexamethasone.,Dexamethasone,DB00072
DB01248,Trastuzumab may increase the neutropenic activities of Docetaxel.,Docetaxel,DB00072
DB01254,Trastuzumab may increase the neutropenic activities of Dasatinib.,Dasatinib,DB00072
DB01268,Trastuzumab may increase the neutropenic activities of Sunitinib.,Sunitinib,DB00072
DB01280,Trastuzumab may increase the neutropenic activities of Nelarabine.,Nelarabine,DB00072
DB01285,Trastuzumab may increase the neutropenic activities of Corticotropin.,Corticotropin,DB00072
DB01380,Trastuzumab may increase the neutropenic activities of Cortisone acetate.,Cortisone acetate,DB00072
DB04868,Trastuzumab may increase the neutropenic activities of Nilotinib.,Nilotinib,DB00072
DB05109,Trastuzumab may increase the neutropenic activities of Trabectedin.,Trabectedin,DB00072
DB05773,Trastuzumab may increase the neutropenic activities of Trastuzumab emtansine.,Trastuzumab emtansine,DB00072
DB06287,Trastuzumab may increase the neutropenic activities of Temsirolimus.,Temsirolimus,DB00072
DB06589,Trastuzumab may increase the neutropenic activities of Pazopanib.,Pazopanib,DB00072
DB06603,Trastuzumab may increase the neutropenic activities of Panobinostat.,Panobinostat,DB00072
DB06772,Trastuzumab may increase the neutropenic activities of Cabazitaxel.,Cabazitaxel,DB00072
DB06813,Trastuzumab may increase the neutropenic activities of Pralatrexate.,Pralatrexate,DB00072
DB08870,Trastuzumab may increase the neutropenic activities of Brentuximab vedotin.,Brentuximab vedotin,DB00072
DB08877,Trastuzumab may increase the neutropenic activities of Ruxolitinib.,Ruxolitinib,DB00072
DB08935,Trastuzumab may increase the neutropenic activities of Obinutuzumab.,Obinutuzumab,DB00072
DB09052,Trastuzumab may increase the neutropenic activities of Blinatumomab.,Blinatumomab,DB00072
DB09053,Trastuzumab may increase the neutropenic activities of Ibrutinib.,Ibrutinib,DB00072
DB09054,Trastuzumab may increase the neutropenic activities of Idelalisib.,Idelalisib,DB00072
DB09073,Trastuzumab may increase the neutropenic activities of Palbociclib.,Palbociclib,DB00072
DB09077,Trastuzumab may increase the neutropenic activities of Dinutuximab.,Dinutuximab,DB00072
DB09082,Trastuzumab may increase the neutropenic activities of Vilanterol.,Vilanterol,DB00072
DB01423,Trastuzumab may increase the neutropenic activities of Stepronin.,Stepronin,DB00072
DB01816,Trastuzumab may increase the neutropenic activities of Castanospermine.,Castanospermine,DB00072
DB02806,Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.,2-Methoxyethanol,DB00072
DB05260,Trastuzumab may increase the neutropenic activities of Gallium nitrate.,Gallium nitrate,DB00072
DB08908,Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.,Dimethyl fumarate,DB00072
DB11921,Trastuzumab may increase the neutropenic activities of Deflazacort.,Deflazacort,DB00072
DB12025,Trastuzumab may increase the neutropenic activities of Triptolide.,Triptolide,DB00072
DB12617,Trastuzumab may increase the neutropenic activities of Mizoribine.,Mizoribine,DB00072
DB12902,Trastuzumab may increase the neutropenic activities of Trofosfamide.,Trofosfamide,DB00072
DB12947,Trastuzumab may increase the neutropenic activities of Doxifluridine.,Doxifluridine,DB00072
DB12991,Trastuzumab may increase the neutropenic activities of Deoxyspergualin.,Deoxyspergualin,DB00072
DB12996,Trastuzumab may increase the neutropenic activities of Acteoside.,Acteoside,DB00072
DB13014,Trastuzumab may increase the neutropenic activities of Hypericin.,Hypericin,DB00072
DB00092,Trastuzumab may increase the neutropenic activities of Alefacept.,Alefacept,DB00072
DB00095,Trastuzumab may increase the neutropenic activities of Efalizumab.,Efalizumab,DB00072
DB04951,Trastuzumab may increase the neutropenic activities of Pirfenidone.,Pirfenidone,DB00072
DB04956,Trastuzumab may increase the neutropenic activities of Afelimomab.,Afelimomab,DB00072
DB05676,Trastuzumab may increase the neutropenic activities of Apremilast.,Apremilast,DB00072
DB06662,Trastuzumab may increase the neutropenic activities of Abetimus.,Abetimus,DB00072
DB11776,Trastuzumab may increase the neutropenic activities of Brodalumab.,Brodalumab,DB00072
DB13241,Trastuzumab may increase the neutropenic activities of Begelomab.,Begelomab,DB00072
DB08059,Trastuzumab may increase the neutropenic activities of Wortmannin.,Wortmannin,DB00072
DB13068,Trastuzumab may increase the neutropenic activities of 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00072
DB00008,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00072
DB00018,Trastuzumab may increase the neutropenic activities of Interferon alfa-n3.,Interferon alfa-n3,DB00072
DB00022,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00072
DB00041,Trastuzumab may increase the neutropenic activities of Aldesleukin.,Aldesleukin,DB00072
DB00069,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.,Interferon alfacon-1,DB00072
DB00112,Trastuzumab may increase the neutropenic activities of Bevacizumab.,Bevacizumab,DB00072
DB00188,Trastuzumab may increase the neutropenic activities of Bortezomib.,Bortezomib,DB00072
DB00293,Trastuzumab may increase the neutropenic activities of Raltitrexed.,Raltitrexed,DB00072
DB00307,Trastuzumab may increase the neutropenic activities of Bexarotene.,Bexarotene,DB00072
DB00380,Trastuzumab may increase the neutropenic activities of Dexrazoxane.,Dexrazoxane,DB00072
DB00446,Trastuzumab may increase the neutropenic activities of Chloramphenicol.,Chloramphenicol,DB00072
DB00495,Trastuzumab may increase the neutropenic activities of Zidovudine.,Zidovudine,DB00072
DB00550,Trastuzumab may increase the neutropenic activities of Propylthiouracil.,Propylthiouracil,DB00072
DB00564,Trastuzumab may increase the neutropenic activities of Carbamazepine.,Carbamazepine,DB00072
DB00601,Trastuzumab may increase the neutropenic activities of Linezolid.,Linezolid,DB00072
DB00763,Trastuzumab may increase the neutropenic activities of Methimazole.,Methimazole,DB00072
DB01099,Trastuzumab may increase the neutropenic activities of Flucytosine.,Flucytosine,DB00072
DB01169,Trastuzumab may increase the neutropenic activities of Arsenic trioxide.,Arsenic trioxide,DB00072
DB01262,Trastuzumab may increase the neutropenic activities of Decitabine.,Decitabine,DB00072
DB02546,Trastuzumab may increase the neutropenic activities of Vorinostat.,Vorinostat,DB00072
DB04845,Trastuzumab may increase the neutropenic activities of Ixabepilone.,Ixabepilone,DB00072
DB05015,Trastuzumab may increase the neutropenic activities of Belinostat.,Belinostat,DB00072
DB06616,Trastuzumab may increase the neutropenic activities of Bosutinib.,Bosutinib,DB00072
DB06769,Trastuzumab may increase the neutropenic activities of Bendamustine.,Bendamustine,DB00072
DB08871,Trastuzumab may increase the neutropenic activities of Eribulin.,Eribulin,DB00072
DB08889,Trastuzumab may increase the neutropenic activities of Carfilzomib.,Carfilzomib,DB00072
DB08901,Trastuzumab may increase the neutropenic activities of Ponatinib.,Ponatinib,DB00072
DB09074,Trastuzumab may increase the neutropenic activities of Olaparib.,Olaparib,DB00072
DB11767,Trastuzumab may increase the neutropenic activities of Sarilumab.,Sarilumab,DB00072
DB05459,Trastuzumab may increase the neutropenic activities of Briakinumab.,Briakinumab,DB00072
DB11466,Trastuzumab may increase the neutropenic activities of Tepoxalin.,Tepoxalin,DB00072
DB14066,Trastuzumab may increase the neutropenic activities of Tetrandrine.,Tetrandrine,DB00072
DB00795,Trastuzumab may increase the neutropenic activities of Sulfasalazine.,Sulfasalazine,DB00072
DB01611,Trastuzumab may increase the neutropenic activities of Hydroxychloroquine.,Hydroxychloroquine,DB00072
DB00432,Trastuzumab may increase the neutropenic activities of Trifluridine.,Trifluridine,DB00072
DB04630,Trastuzumab may increase the neutropenic activities of Aldosterone.,Aldosterone,DB00072
DB01108,Trastuzumab may increase the neutropenic activities of Trilostane.,Trilostane,DB00072
DB13208,Trastuzumab may increase the neutropenic activities of Prednylidene.,Prednylidene,DB00072
DB01384,Trastuzumab may increase the neutropenic activities of Paramethasone.,Paramethasone,DB00072
DB09383,Trastuzumab may increase the neutropenic activities of Meprednisone.,Meprednisone,DB00072
DB11529,Trastuzumab may increase the neutropenic activities of Melengestrol.,Melengestrol,DB00072
DB09378,Trastuzumab may increase the neutropenic activities of Fluprednisolone.,Fluprednisolone,DB00072
DB00180,Trastuzumab may increase the neutropenic activities of Flunisolide.,Flunisolide,DB00072
DB13003,Trastuzumab may increase the neutropenic activities of Cortivazol.,Cortivazol,DB00072
DB13843,Trastuzumab may increase the neutropenic activities of Cloprednol.,Cloprednol,DB00072
DB00240,Trastuzumab may increase the neutropenic activities of Alclometasone.,Alclometasone,DB00072
DB00288,Trastuzumab may increase the neutropenic activities of Amcinonide.,Amcinonide,DB00072
DB01410,Trastuzumab may increase the neutropenic activities of Ciclesonide.,Ciclesonide,DB00072
DB11750,Trastuzumab may increase the neutropenic activities of Clobetasol.,Clobetasol,DB00072
DB01013,Trastuzumab may increase the neutropenic activities of Clobetasol propionate.,Clobetasol propionate,DB00072
DB13158,Trastuzumab may increase the neutropenic activities of Clobetasone.,Clobetasone,DB00072
DB00838,Trastuzumab may increase the neutropenic activities of Clocortolone.,Clocortolone,DB00072
DB01260,Trastuzumab may increase the neutropenic activities of Desonide.,Desonide,DB00072
DB00547,Trastuzumab may increase the neutropenic activities of Desoximetasone.,Desoximetasone,DB00072
DB11487,Trastuzumab may increase the neutropenic activities of Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00072
DB00223,Trastuzumab may increase the neutropenic activities of Diflorasone.,Diflorasone,DB00072
DB09095,Trastuzumab may increase the neutropenic activities of Difluocortolone.,Difluocortolone,DB00072
DB06781,Trastuzumab may increase the neutropenic activities of Difluprednate.,Difluprednate,DB00072
DB13856,Trastuzumab may increase the neutropenic activities of Fluclorolone.,Fluclorolone,DB00072
DB00663,Trastuzumab may increase the neutropenic activities of Flumethasone.,Flumethasone,DB00072
DB00591,Trastuzumab may increase the neutropenic activities of Fluocinolone acetonide.,Fluocinolone acetonide,DB00072
DB01047,Trastuzumab may increase the neutropenic activities of Fluocinonide.,Fluocinonide,DB00072
DB13223,Trastuzumab may increase the neutropenic activities of Fluocortin.,Fluocortin,DB00072
DB08971,Trastuzumab may increase the neutropenic activities of Fluocortolone.,Fluocortolone,DB00072
DB00324,Trastuzumab may increase the neutropenic activities of Fluorometholone.,Fluorometholone,DB00072
DB13491,Trastuzumab may increase the neutropenic activities of Fluperolone.,Fluperolone,DB00072
DB08970,Trastuzumab may increase the neutropenic activities of Fluprednidene.,Fluprednidene,DB00072
DB00846,Trastuzumab may increase the neutropenic activities of Flurandrenolide.,Flurandrenolide,DB00072
DB13867,Trastuzumab may increase the neutropenic activities of Fluticasone.,Fluticasone,DB00072
DB08906,Trastuzumab may increase the neutropenic activities of Fluticasone furoate.,Fluticasone furoate,DB00072
DB00588,Trastuzumab may increase the neutropenic activities of Fluticasone propionate.,Fluticasone propionate,DB00072
DB13664,Trastuzumab may increase the neutropenic activities of Formocortal.,Formocortal,DB00072
DB06786,Trastuzumab may increase the neutropenic activities of Halcinonide.,Halcinonide,DB00072
DB13728,Trastuzumab may increase the neutropenic activities of Halometasone.,Halometasone,DB00072
DB14538,Trastuzumab may increase the neutropenic activities of Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00072
DB14539,Trastuzumab may increase the neutropenic activities of Hydrocortisone acetate.,Hydrocortisone acetate,DB00072
DB14543,Trastuzumab may increase the neutropenic activities of Hydrocortisone probutate.,Hydrocortisone probutate,DB00072
DB14540,Trastuzumab may increase the neutropenic activities of Hydrocortisone butyrate.,Hydrocortisone butyrate,DB00072
DB14545,Trastuzumab may increase the neutropenic activities of Hydrocortisone succinate.,Hydrocortisone succinate,DB00072
DB14544,Trastuzumab may increase the neutropenic activities of Hydrocortisone valerate.,Hydrocortisone valerate,DB00072
DB14596,Trastuzumab may increase the neutropenic activities of Loteprednol etabonate.,Loteprednol etabonate,DB00072
DB00253,Trastuzumab may increase the neutropenic activities of Medrysone.,Medrysone,DB00072
DB00764,Trastuzumab may increase the neutropenic activities of Mometasone.,Mometasone,DB00072
DB14512,Trastuzumab may increase the neutropenic activities of Mometasone furoate.,Mometasone furoate,DB00072
DB01130,Trastuzumab may increase the neutropenic activities of Prednicarbate.,Prednicarbate,DB00072
DB00896,Trastuzumab may increase the neutropenic activities of Rimexolone.,Rimexolone,DB00072
DB09091,Trastuzumab may increase the neutropenic activities of Tixocortol.,Tixocortol,DB00072
DB00596,Trastuzumab may increase the neutropenic activities of Ulobetasol.,Ulobetasol,DB00072
DB01394,Trastuzumab may increase the neutropenic activities of Colchicine.,Colchicine,DB00072
DB14219,Trastuzumab may increase the neutropenic activities of Monomethyl fumarate.,Monomethyl fumarate,DB00072
DB00859,Trastuzumab may increase the neutropenic activities of Penicillamine.,Penicillamine,DB00072
DB00328,Trastuzumab may increase the neutropenic activities of Indomethacin.,Indomethacin,DB00072
DB03523,Trastuzumab may increase the neutropenic activities of Brequinar.,Brequinar,DB00072
DB00033,Trastuzumab may increase the neutropenic activities of Interferon gamma-1b.,Interferon gamma-1b,DB00072
DB05472,Trastuzumab may increase the neutropenic activities of omega interferon.,omega interferon,DB00072
DB00011,Trastuzumab may increase the neutropenic activities of Interferon alfa-n1.,Interferon alfa-n1,DB00072
DB09122,Trastuzumab may increase the neutropenic activities of Peginterferon beta-1a.,Peginterferon beta-1a,DB00072
DB12814,Trastuzumab may increase the neutropenic activities of Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00072
DB00068,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.,Interferon beta-1b,DB00072
DB00034,"Trastuzumab may increase the neutropenic activities of Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant",DB00072
DB05258,Trastuzumab may increase the neutropenic activities of Interferon alfa.,Interferon alfa,DB00072
DB00105,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.,Interferon alfa-2b,DB00072
DB11569,Trastuzumab may increase the neutropenic activities of Ixekizumab.,Ixekizumab,DB00072
DB11803,Trastuzumab may increase the neutropenic activities of Sirukumab.,Sirukumab,DB00072
DB11817,Trastuzumab may increase the neutropenic activities of Baricitinib.,Baricitinib,DB00072
DB11834,Trastuzumab may increase the neutropenic activities of Guselkumab.,Guselkumab,DB00072
DB12612,Trastuzumab may increase the neutropenic activities of Ozanimod.,Ozanimod,DB00072
DB14724,Trastuzumab may increase the neutropenic activities of Emapalumab.,Emapalumab,DB00072
DB12371,Trastuzumab may increase the neutropenic activities of Siponimod.,Siponimod,DB00072
DB14762,Trastuzumab may increase the neutropenic activities of Risankizumab.,Risankizumab,DB00072
DB15253,Trastuzumab may increase the neutropenic activities of Bleselumab.,Bleselumab,DB00072
DB00394,Trastuzumab may increase the neutropenic activities of Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00072
DB11580,Trastuzumab may increase the neutropenic activities of Ravulizumab.,Ravulizumab,DB00072
DB11708,Trastuzumab may increase the neutropenic activities of Peficitinib.,Peficitinib,DB00072
DB14919,Trastuzumab may increase the neutropenic activities of Rozanolixizumab.,Rozanolixizumab,DB00072
DB08868,Trastuzumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00072
DB00864,Tacrolimus may increase the immunosuppressive activities of Trastuzumab.,Tacrolimus,DB00072
DB00390,Digoxin may decrease the cardiotoxic activities of Trastuzumab.,Digoxin,DB00072
DB00511,Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.,Acetyldigitoxin,DB00072
DB01078,Deslanoside may decrease the cardiotoxic activities of Trastuzumab.,Deslanoside,DB00072
DB01092,Ouabain may decrease the cardiotoxic activities of Trastuzumab.,Ouabain,DB00072
DB01396,Digitoxin may decrease the cardiotoxic activities of Trastuzumab.,Digitoxin,DB00072
DB12843,Oleandrin may decrease the cardiotoxic activities of Trastuzumab.,Oleandrin,DB00072
DB13240,Cymarin may decrease the cardiotoxic activities of Trastuzumab.,Cymarin,DB00072
DB13307,Proscillaridin may decrease the cardiotoxic activities of Trastuzumab.,Proscillaridin,DB00072
DB13401,Metildigoxin may decrease the cardiotoxic activities of Trastuzumab.,Metildigoxin,DB00072
DB13467,Lanatoside C may decrease the cardiotoxic activities of Trastuzumab.,Lanatoside C,DB00072
DB13537,Gitoformate may decrease the cardiotoxic activities of Trastuzumab.,Gitoformate,DB00072
DB13691,Acetyldigoxin may decrease the cardiotoxic activities of Trastuzumab.,Acetyldigoxin,DB00072
DB13756,Peruvoside may decrease the cardiotoxic activities of Trastuzumab.,Peruvoside,DB00072
DB00675,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Tamoxifen.,Tamoxifen,DB00072
DB01217,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Anastrozole.,Anastrozole,DB00072
DB06171,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel trevatide.,Paclitaxel trevatide,DB00072
DB13809,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel poliglumex.,Paclitaxel poliglumex,DB00072
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Trastuzumab.,G17DT,DB00072
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Trastuzumab.,PEV3A,DB00072
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab.,INGN 225,DB00072
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trastuzumab.,Rindopepimut,DB00072
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Trastuzumab.,SRP 299,DB00072
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trastuzumab.,GI-5005,DB00072
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Trastuzumab.,Vitespen,DB00072
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Trastuzumab.,TG4010,DB00072
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab.,Anthrax immune globulin human,DB00072
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Trastuzumab.","Rabies virus inactivated antigen, B",DB00072
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00072
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Trastuzumab.,Rotavirus vaccine,DB00072
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab.","Rabies virus inactivated antigen, A",DB00072
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00072
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00072
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00072
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00072
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00072
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00072
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Trastuzumab.,Typhoid Vi polysaccharide vaccine,DB00072
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.,Hepatitis A Vaccine,DB00072
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00072
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00072
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00072
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00072
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00072
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab.,Human rabies virus immune globulin,DB00072
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.,Hepatitis B Vaccine (Recombinant),DB00072
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Trastuzumab.,Tecemotide,DB00072
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Trastuzumab.,Typhoid vaccine,DB00072
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00072
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00072
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00072
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00072
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00072
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00072
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00072
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Trastuzumab.,Vaccinia virus strain new york city board of health live antigen,DB00072
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Trastuzumab.,Pertussis vaccine,DB00072
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00072
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.,Varicella Zoster Vaccine (Recombinant),DB00072
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Trastuzumab.,Modified vaccinia ankara,DB00072
DB11988,Ocrelizumab may increase the immunosuppressive activities of Trastuzumab.,Ocrelizumab,DB00072
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trastuzumab.,Rubella virus vaccine,DB00072
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Trastuzumab.,Varicella Zoster Vaccine (Live/attenuated),DB00072
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain tice live antigen,DB00072
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00072
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Trastuzumab.,Yellow Fever Vaccine,DB00072
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Trastuzumab.,Anthrax vaccine,DB00072
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Trastuzumab.,Typhoid Vaccine Live,DB00072
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00072
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Trastuzumab.,BCG vaccine,DB00072
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Trastuzumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00072
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Trastuzumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00072
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trastuzumab.,Adenovirus type 7 vaccine live,DB00072
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.,Cetuximab,DB00072
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.,Human immunoglobulin G,DB00072
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab.,Omalizumab,DB00072
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab.,Abciximab,DB00072
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.,Indium In-111 satumomab pendetide,DB00072
DB00076,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00072
DB00089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.,Capromab pendetide,DB00072
DB00110,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.,Palivizumab,DB00072
DB00113,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00072
DB01269,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Panitumumab.,Panitumumab,DB00072
DB01270,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ranibizumab.,Ranibizumab,DB00072
DB04901,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galiximab.,Galiximab,DB00072
DB04949,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pexelizumab.,Pexelizumab,DB00072
DB04958,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Epratuzumab.,Epratuzumab,DB00072
DB04962,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bectumomab.,Bectumomab,DB00072
DB04964,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Oregovomab.,Oregovomab,DB00072
DB04988,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IGN311.,IGN311,DB00072
DB05006,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Adecatumumab.,Adecatumumab,DB00072
DB05097,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab.,Labetuzumab,DB00072
DB05101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Matuzumab.,Matuzumab,DB00072
DB05111,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fontolizumab.,Fontolizumab,DB00072
DB05136,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bavituximab.,Bavituximab,DB00072
DB05139,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CR002.,CR002,DB00072
DB05209,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rozrolimupab.,Rozrolimupab,DB00072
DB05304,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Girentuximab.,Girentuximab,DB00072
DB05336,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00072
DB05405,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XTL-001.,XTL-001,DB00072
DB05437,The risk or severity of adverse effects can be increased when Trastuzumab is combined with NAV 1800.,NAV 1800,DB00072
DB05496,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Otelixizumab.,Otelixizumab,DB00072
DB05545,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AMG 108.,AMG 108,DB00072
DB05550,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Iratumumab.,Iratumumab,DB00072
DB05555,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Enokizumab.,Enokizumab,DB00072
DB05578,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ramucirumab.,Ramucirumab,DB00072
DB05595,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Farletuzumab.,Farletuzumab,DB00072
DB05656,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Veltuzumab.,Veltuzumab,DB00072
DB05793,The risk or severity of adverse effects can be increased when Trastuzumab is combined with PRO-542.,PRO-542,DB00072
DB05797,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TNX-901.,TNX-901,DB00072
DB05889,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00072
DB05892,The risk or severity of adverse effects can be increased when Trastuzumab is combined with RI 624.,RI 624,DB00072
DB05915,The risk or severity of adverse effects can be increased when Trastuzumab is combined with MYO-029.,MYO-029,DB00072
DB05916,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CT-011.,CT-011,DB00072
DB05941,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leronlimab.,Leronlimab,DB00072
DB05996,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00072
DB06043,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olaratumab.,Olaratumab,DB00072
DB06049,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IPH 2101.,IPH 2101,DB00072
DB06050,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TB-402.,TB-402,DB00072
DB06081,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Caplacizumab.,Caplacizumab,DB00072
DB06101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IMC-1C11.,IMC-1C11,DB00072
DB06116,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eldelumab.,Eldelumab,DB00072
DB06162,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumiliximab.,Lumiliximab,DB00072
DB06186,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipilimumab.,Ipilimumab,DB00072
DB06192,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nimotuzumab.,Nimotuzumab,DB00072
DB06241,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clenoliximab.,Clenoliximab,DB00072
DB06304,The risk or severity of adverse effects can be increased when Trastuzumab is combined with BIIB015.,BIIB015,DB00072
DB06305,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sonepcizumab.,Sonepcizumab,DB00072
DB06310,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Motavizumab.,Motavizumab,DB00072
DB06317,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Elotuzumab.,Elotuzumab,DB00072
DB06318,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AVE9633.,AVE9633,DB00072
DB06322,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carotuximab.,Carotuximab,DB00072
DB06324,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XmAb 2513.,XmAb 2513,DB00072
DB06342,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00072
DB06343,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teprotumumab.,Teprotumumab,DB00072
DB06360,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lucatumumab.,Lucatumumab,DB00072
DB06366,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pertuzumab.,Pertuzumab,DB00072
DB06371,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Siplizumab.,Siplizumab,DB00072
DB06467,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apolizumab.,Apolizumab,DB00072
DB06474,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00072
DB06550,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bivatuzumab.,Bivatuzumab,DB00072
DB06557,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lerdelimumab.,Lerdelimumab,DB00072
DB06599,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lexatumumab.,Lexatumumab,DB00072
DB06602,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Reslizumab.,Reslizumab,DB00072
DB06606,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teplizumab.,Teplizumab,DB00072
DB06607,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Catumaxomab.,Catumaxomab,DB00072
DB06647,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Volociximab.,Volociximab,DB00072
DB06650,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ofatumumab.,Ofatumumab,DB00072
DB08902,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Raxibacumab.,Raxibacumab,DB00072
DB09035,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nivolumab.,Nivolumab,DB00072
DB09037,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pembrolizumab.,Pembrolizumab,DB00072
DB09045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dulaglutide.,Dulaglutide,DB00072
DB09105,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asfotase alfa.,Asfotase alfa,DB00072
DB09264,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Idarucizumab.,Idarucizumab,DB00072
DB09302,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Alirocumab.,Alirocumab,DB00072
DB09303,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evolocumab.,Evolocumab,DB00072
DB09331,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Daratumumab.,Daratumumab,DB00072
DB09559,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Necitumumab.,Necitumumab,DB00072
DB11595,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Atezolizumab.,Atezolizumab,DB00072
DB11604,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00072
DB11608,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00072
DB11621,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00072
DB11646,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Conatumumab.,Conatumumab,DB00072
DB11657,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tabalumab.,Tabalumab,DB00072
DB11680,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00072
DB11685,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Figitumumab.,Figitumumab,DB00072
DB11714,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Durvalumab.,Durvalumab,DB00072
DB11715,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bapineuzumab.,Bapineuzumab,DB00072
DB11731,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00072
DB11746,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Onartuzumab.,Onartuzumab,DB00072
DB11756,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Solanezumab.,Solanezumab,DB00072
DB11771,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tremelimumab.,Tremelimumab,DB00072
DB11826,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lampalizumab.,Lampalizumab,DB00072
DB11840,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalotuzumab.,Dalotuzumab,DB00072
DB11849,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emibetuzumab.,Emibetuzumab,DB00072
DB11850,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ublituximab.,Ublituximab,DB00072
DB11856,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ligelizumab.,Ligelizumab,DB00072
DB11857,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Seribantumab.,Seribantumab,DB00072
DB11862,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Landogrozumab.,Landogrozumab,DB00072
DB11866,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Romosozumab.,Romosozumab,DB00072
DB11884,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00072
DB11914,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lebrikizumab.,Lebrikizumab,DB00072
DB11930,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Varlilumab.,Varlilumab,DB00072
DB11945,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Avelumab.,Avelumab,DB00072
DB11959,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crenezumab.,Crenezumab,DB00072
DB11972,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rilotumumab.,Rilotumumab,DB00072
DB11976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anifrolumab.,Anifrolumab,DB00072
DB12023,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Benralizumab.,Benralizumab,DB00072
DB12034,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gantenerumab.,Gantenerumab,DB00072
DB12053,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Visilizumab.,Visilizumab,DB00072
DB12077,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Urelumab.,Urelumab,DB00072
DB12089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00072
DB12090,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Patritumab.,Patritumab,DB00072
DB12102,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fulranumab.,Fulranumab,DB00072
DB12104,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tarextumab.,Tarextumab,DB00072
DB12118,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sotatercept.,Sotatercept,DB00072
DB12119,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gevokizumab.,Gevokizumab,DB00072
DB12142,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Duligotuzumab.,Duligotuzumab,DB00072
DB12152,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Simtuzumab.,Simtuzumab,DB00072
DB12157,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fasinumab.,Fasinumab,DB00072
DB12159,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dupilumab.,Dupilumab,DB00072
DB12169,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tralokinumab.,Tralokinumab,DB00072
DB12189,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etrolizumab.,Etrolizumab,DB00072
DB12202,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zalutumumab.,Zalutumumab,DB00072
DB12205,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ganitumab.,Ganitumab,DB00072
DB12213,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etaracizumab.,Etaracizumab,DB00072
DB12240,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00072
DB12246,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inclacumab.,Inclacumab,DB00072
DB12250,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cixutumumab.,Cixutumumab,DB00072
DB12261,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00072
DB12274,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Aducanumab.,Aducanumab,DB00072
DB12281,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Luspatercept.,Luspatercept,DB00072
DB12296,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GS-5745.,GS-5745,DB00072
DB12317,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vanucizumab.,Vanucizumab,DB00072
DB12331,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00072
DB12335,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tanezumab.,Tanezumab,DB00072
DB12342,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ensituximab.,Ensituximab,DB00072
DB12344,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fezakinumab.,Fezakinumab,DB00072
DB12363,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dusigitumab.,Dusigitumab,DB00072
DB12396,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fresolimumab.,Fresolimumab,DB00072
DB12413,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00072
DB12456,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bococizumab.,Bococizumab,DB00072
DB12489,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00072
DB12498,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mogamulizumab.,Mogamulizumab,DB00072
DB12520,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Plozalizumab.,Plozalizumab,DB00072
DB12534,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mavrilimumab.,Mavrilimumab,DB00072
DB12560,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Blosozumab.,Blosozumab,DB00072
DB12584,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimagrumab.,Bimagrumab,DB00072
DB12589,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dacetuzumab.,Dacetuzumab,DB00072
DB12609,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tovetumab.,Tovetumab,DB00072
DB12683,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumretuzumab.,Lumretuzumab,DB00072
DB12698,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ibalizumab.,Ibalizumab,DB00072
DB12701,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Intetumumab.,Intetumumab,DB00072
DB12718,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carlumab.,Carlumab,DB00072
DB12734,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Demcizumab.,Demcizumab,DB00072
DB12773,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sifalimumab.,Sifalimumab,DB00072
DB12775,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abituzumab.,Abituzumab,DB00072
DB12797,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ecromeximab.,Ecromeximab,DB00072
DB12807,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00072
DB12815,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crotedumab.,Crotedumab,DB00072
DB12820,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Concizumab.,Concizumab,DB00072
DB12826,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab.,Depatuxizumab,DB00072
DB12844,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rontalizumab.,Rontalizumab,DB00072
DB12845,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Amatuximab.,Amatuximab,DB00072
DB12849,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clazakizumab.,Clazakizumab,DB00072
DB12891,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ozanezumab.,Ozanezumab,DB00072
DB12893,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00072
DB12917,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimekizumab.,Bimekizumab,DB00072
DB12943,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Milatuzumab.,Milatuzumab,DB00072
DB12976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Robatumumab.,Robatumumab,DB00072
DB13017,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00072
DB13037,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Namilumab.,Namilumab,DB00072
DB13045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Racotumomab.,Racotumomab,DB00072
DB13073,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tregalizumab.,Tregalizumab,DB00072
DB13127,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olokizumab.,Olokizumab,DB00072
DB13140,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00072
DB13375,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Edrecolomab.,Edrecolomab,DB00072
DB13535,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nebacumab.,Nebacumab,DB00072
DB13886,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00072
DB13923,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emicizumab.,Emicizumab,DB00072
DB13976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sulesomab.,Sulesomab,DB00072
DB13979,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Besilesomab.,Besilesomab,DB00072
DB14012,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Burosumab.,Burosumab,DB00072
DB14039,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Erenumab.,Erenumab,DB00072
DB14040,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.,Eptinezumab,DB00072
DB14041,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fremanezumab.,Fremanezumab,DB00072
DB14042,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galcanezumab.,Galcanezumab,DB00072
DB14211,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fanolesomab.,Fanolesomab,DB00072
DB14580,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lecanemab.,Lecanemab,DB00072
DB14597,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lanadelumab.,Lanadelumab,DB00072
DB14707,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cemiplimab.,Cemiplimab,DB00072
DB14776,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Camrelizumab.,Camrelizumab,DB00072
DB14778,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Setrusumab.,Setrusumab,DB00072
DB14809,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00072
DB14811,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Isatuximab.,Isatuximab,DB00072
DB14824,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Icrucumab.,Icrucumab,DB00072
DB14843,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Codrituzumab.,Codrituzumab,DB00072
DB14864,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Brolucizumab.,Brolucizumab,DB00072
DB14871,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Xentuzumab.,Xentuzumab,DB00072
DB14877,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lintuzumab.,Lintuzumab,DB00072
DB14891,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vobarilizumab.,Vobarilizumab,DB00072
DB14897,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Parsatuzumab.,Parsatuzumab,DB00072
DB14905,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emactuzumab.,Emactuzumab,DB00072
DB14907,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00072
DB14908,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Refanezumab.,Refanezumab,DB00072
DB14947,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bermekimab.,Bermekimab,DB00072
DB14952,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pamrevlumab.,Pamrevlumab,DB00072
DB14959,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Opicinumab.,Opicinumab,DB00072
DB14962,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00072
DB14967,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Margetuximab.,Margetuximab,DB00072
DB14988,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalantercept.,Dalantercept,DB00072
DB14997,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pateclizumab.,Pateclizumab,DB00072
DB15014,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gremubamab.,Gremubamab,DB00072
DB15022,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apomab.,Apomab,DB00072
DB15044,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tafasitamab.,Tafasitamab,DB00072
DB15045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipafricept.,Ipafricept,DB00072
DB15076,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abrilumab.,Abrilumab,DB00072
DB15089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Frovocimab.,Frovocimab,DB00072
DB15090,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tezepelumab.,Tezepelumab,DB00072
DB15101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tigatuzumab.,Tigatuzumab,DB00072
DB15104,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00072
DB15113,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Utomilumab.,Utomilumab,DB00072
DB15118,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zolbetuximab.,Zolbetuximab,DB00072
DB15135,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ponezumab.,Ponezumab,DB00072
DB15160,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asunercept.,Asunercept,DB00072
DB15172,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Suvratoxumab.,Suvratoxumab,DB00072
DB15225,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mitazalimab.,Mitazalimab,DB00072
DB15252,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nemolizumab.,Nemolizumab,DB00072
DB15277,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gedivumab.,Gedivumab,DB00072
DB15336,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00072
DB15349,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00072
DB15354,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evinacumab.,Evinacumab,DB00072
DB15363,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Istiratumab.,Istiratumab,DB00072
DB15383,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pidilizumab.,Pidilizumab,DB00072
DB15397,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GMA-161.,GMA-161,DB00072
DB15409,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00072
DB15415,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tomaralimab.,Tomaralimab,DB00072
DB15428,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vesencumab.,Vesencumab,DB00072
DB15432,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00072
DB15441,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00072
DB15443,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00072
DB15453,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00072
DB14004,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tildrakizumab.,Tildrakizumab,DB00072
DB05679,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ustekinumab.,Ustekinumab,DB00072
DB15559,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00072
DB00091,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00072
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Trastuzumab.","Ebola Zaire vaccine (live, attenuated)",DB00072
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Trastuzumab.,Magnesium,DB00072
DB01601,The serum concentration of Trastuzumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00072
DB00445,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Epirubicin.,Epirubicin,DB00072
DB00694,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.,Daunorubicin,DB00072
DB00997,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Doxorubicin.,Doxorubicin,DB00072
DB01177,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Idarubicin.,Idarubicin,DB00072
DB11616,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Pirarubicin.,Pirarubicin,DB00072
DB06013,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aldoxorubicin.,Aldoxorubicin,DB00072
DB14784,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Gancotamab.,Gancotamab,DB00072
DB00385,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Valrubicin.,Valrubicin,DB00072
DB04978,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with SP1049C.,SP1049C,DB00072
DB06071,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with DTS-201.,DTS-201,DB00072
DB06420,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Annamycin.,Annamycin,DB00072
DB06810,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Plicamycin.,Plicamycin,DB00072
DB11617,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aclarubicin.,Aclarubicin,DB00072
DB11618,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zorubicin.,Zorubicin,DB00072
DB12410,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Sabarubicin.,Sabarubicin,DB00072
DB12755,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zoptarelin doxorubicin.,Zoptarelin doxorubicin,DB00072
DB13103,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with GPX-150.,GPX-150,DB00072
DB12530,The risk or severity of infection can be increased when Trastuzumab is combined with Inebilizumab.,Inebilizumab,DB00072
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.,Denosumab,DB00073
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.,Etanercept,DB00073
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab.,Peginterferon alfa-2a,DB00073
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rituximab.,Interferon alfa-n1,DB00073
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rituximab.,Interferon alfa-n3,DB00073
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rituximab.,Peginterferon alfa-2b,DB00073
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.,Anakinra,DB00073
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rituximab.,Interferon gamma-1b,DB00073
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rituximab.","Interferon alfa-2a, Recombinant",DB00073
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab.,Aldesleukin,DB00073
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.,Adalimumab,DB00073
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.,Gemtuzumab ozogamicin,DB00073
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.,Pegaspargase,DB00073
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.,Infliximab,DB00073
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.,Interferon beta-1b,DB00073
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.,Interferon alfacon-1,DB00073
DB00074,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.,Basiliximab,DB00073
DB00075,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.,Muromonab,DB00073
DB00078,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00073
DB00081,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.,Tositumomab,DB00073
DB00087,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.,Alemtuzumab,DB00073
DB00092,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.,Alefacept,DB00073
DB00095,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.,Efalizumab,DB00073
DB00098,The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00073
DB00105,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00073
DB00111,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.,Daclizumab,DB00073
DB00112,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.,Bevacizumab,DB00073
DB00120,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.,Phenylalanine,DB00073
DB00180,The risk or severity of adverse effects can be increased when Rituximab is combined with Flunisolide.,Flunisolide,DB00073
DB00188,The risk or severity of adverse effects can be increased when Rituximab is combined with Bortezomib.,Bortezomib,DB00073
DB00242,The risk or severity of adverse effects can be increased when Rituximab is combined with Cladribine.,Cladribine,DB00073
DB00262,The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine.,Carmustine,DB00073
DB00276,The risk or severity of adverse effects can be increased when Rituximab is combined with Amsacrine.,Amsacrine,DB00073
DB00290,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleomycin.,Bleomycin,DB00073
DB00291,The risk or severity of adverse effects can be increased when Rituximab is combined with Chlorambucil.,Chlorambucil,DB00073
DB00293,The risk or severity of adverse effects can be increased when Rituximab is combined with Raltitrexed.,Raltitrexed,DB00073
DB00305,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitomycin.,Mitomycin,DB00073
DB00307,The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene.,Bexarotene,DB00073
DB00309,The risk or severity of adverse effects can be increased when Rituximab is combined with Vindesine.,Vindesine,DB00073
DB00322,The risk or severity of adverse effects can be increased when Rituximab is combined with Floxuridine.,Floxuridine,DB00073
DB00328,The risk or severity of adverse effects can be increased when Rituximab is combined with Indomethacin.,Indomethacin,DB00073
DB00352,The risk or severity of adverse effects can be increased when Rituximab is combined with Tioguanine.,Tioguanine,DB00073
DB00361,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinorelbine.,Vinorelbine,DB00073
DB00380,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane.,Dexrazoxane,DB00073
DB00394,The risk or severity of adverse effects can be increased when Rituximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00073
DB00398,The risk or severity of adverse effects can be increased when Rituximab is combined with Sorafenib.,Sorafenib,DB00073
DB00428,The risk or severity of adverse effects can be increased when Rituximab is combined with Streptozocin.,Streptozocin,DB00073
DB00432,The risk or severity of adverse effects can be increased when Rituximab is combined with Trifluridine.,Trifluridine,DB00073
DB00441,The risk or severity of adverse effects can be increased when Rituximab is combined with Gemcitabine.,Gemcitabine,DB00073
DB00443,The risk or severity of adverse effects can be increased when Rituximab is combined with Betamethasone.,Betamethasone,DB00073
DB00444,The risk or severity of adverse effects can be increased when Rituximab is combined with Teniposide.,Teniposide,DB00073
DB00445,The risk or severity of adverse effects can be increased when Rituximab is combined with Epirubicin.,Epirubicin,DB00073
DB00446,The risk or severity of adverse effects can be increased when Rituximab is combined with Chloramphenicol.,Chloramphenicol,DB00073
DB00480,The risk or severity of adverse effects can be increased when Rituximab is combined with Lenalidomide.,Lenalidomide,DB00073
DB00488,The risk or severity of adverse effects can be increased when Rituximab is combined with Altretamine.,Altretamine,DB00073
DB00495,The risk or severity of adverse effects can be increased when Rituximab is combined with Zidovudine.,Zidovudine,DB00073
DB00526,The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin.,Oxaliplatin,DB00073
DB00531,The risk or severity of adverse effects can be increased when Rituximab is combined with Cyclophosphamide.,Cyclophosphamide,DB00073
DB00541,The risk or severity of adverse effects can be increased when Rituximab is combined with Vincristine.,Vincristine,DB00073
DB00544,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil.,Fluorouracil,DB00073
DB00550,The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil.,Propylthiouracil,DB00073
DB00552,The risk or severity of adverse effects can be increased when Rituximab is combined with Pentostatin.,Pentostatin,DB00073
DB00563,The risk or severity of adverse effects can be increased when Rituximab is combined with Methotrexate.,Methotrexate,DB00073
DB00564,The risk or severity of adverse effects can be increased when Rituximab is combined with Carbamazepine.,Carbamazepine,DB00073
DB00570,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinblastine.,Vinblastine,DB00073
DB00588,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone propionate.,Fluticasone propionate,DB00073
DB00591,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00073
DB00601,The risk or severity of adverse effects can be increased when Rituximab is combined with Linezolid.,Linezolid,DB00073
DB00619,The risk or severity of adverse effects can be increased when Rituximab is combined with Imatinib.,Imatinib,DB00073
DB00620,The risk or severity of adverse effects can be increased when Rituximab is combined with Triamcinolone.,Triamcinolone,DB00073
DB00631,The risk or severity of adverse effects can be increased when Rituximab is combined with Clofarabine.,Clofarabine,DB00073
DB00635,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisone.,Prednisone,DB00073
DB00642,The risk or severity of adverse effects can be increased when Rituximab is combined with Pemetrexed.,Pemetrexed,DB00073
DB00687,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludrocortisone.,Fludrocortisone,DB00073
DB00688,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00073
DB00694,The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.,Daunorubicin,DB00073
DB00755,The risk or severity of adverse effects can be increased when Rituximab is combined with Tretinoin.,Tretinoin,DB00073
DB00762,The risk or severity of adverse effects can be increased when Rituximab is combined with Irinotecan.,Irinotecan,DB00073
DB00763,The risk or severity of adverse effects can be increased when Rituximab is combined with Methimazole.,Methimazole,DB00073
DB00764,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone.,Mometasone,DB00073
DB00773,The risk or severity of adverse effects can be increased when Rituximab is combined with Etoposide.,Etoposide,DB00073
DB00795,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulfasalazine.,Sulfasalazine,DB00073
DB00851,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacarbazine.,Dacarbazine,DB00073
DB00853,The risk or severity of adverse effects can be increased when Rituximab is combined with Temozolomide.,Temozolomide,DB00073
DB00859,The risk or severity of adverse effects can be increased when Rituximab is combined with Penicillamine.,Penicillamine,DB00073
DB00860,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisolone.,Prednisolone,DB00073
DB00877,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirolimus.,Sirolimus,DB00073
DB00888,The risk or severity of adverse effects can be increased when Rituximab is combined with Mechlorethamine.,Mechlorethamine,DB00073
DB00928,The risk or severity of adverse effects can be increased when Rituximab is combined with Azacitidine.,Azacitidine,DB00073
DB00958,The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin.,Carboplatin,DB00073
DB00959,The risk or severity of adverse effects can be increased when Rituximab is combined with Methylprednisolone.,Methylprednisolone,DB00073
DB00970,The risk or severity of adverse effects can be increased when Rituximab is combined with Dactinomycin.,Dactinomycin,DB00073
DB00987,The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.,Cytarabine,DB00073
DB00993,The risk or severity of adverse effects can be increased when Rituximab is combined with Azathioprine.,Azathioprine,DB00073
DB00997,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxorubicin.,Doxorubicin,DB00073
DB01005,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxyurea.,Hydroxyurea,DB00073
DB01008,The risk or severity of adverse effects can be increased when Rituximab is combined with Busulfan.,Busulfan,DB00073
DB01024,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolic acid.,Mycophenolic acid,DB00073
DB01030,The risk or severity of adverse effects can be increased when Rituximab is combined with Topotecan.,Topotecan,DB00073
DB01033,The risk or severity of adverse effects can be increased when Rituximab is combined with Mercaptopurine.,Mercaptopurine,DB00073
DB01041,The risk or severity of adverse effects can be increased when Rituximab is combined with Thalidomide.,Thalidomide,DB00073
DB01042,The risk or severity of adverse effects can be increased when Rituximab is combined with Melphalan.,Melphalan,DB00073
DB01073,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludarabine.,Fludarabine,DB00073
DB01099,The risk or severity of adverse effects can be increased when Rituximab is combined with Flucytosine.,Flucytosine,DB00073
DB01101,The risk or severity of adverse effects can be increased when Rituximab is combined with Capecitabine.,Capecitabine,DB00073
DB01108,The risk or severity of adverse effects can be increased when Rituximab is combined with Trilostane.,Trilostane,DB00073
DB01168,The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine.,Procarbazine,DB00073
DB01169,The risk or severity of adverse effects can be increased when Rituximab is combined with Arsenic trioxide.,Arsenic trioxide,DB00073
DB01177,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarubicin.,Idarubicin,DB00073
DB01181,The risk or severity of adverse effects can be increased when Rituximab is combined with Ifosfamide.,Ifosfamide,DB00073
DB01196,The risk or severity of adverse effects can be increased when Rituximab is combined with Estramustine.,Estramustine,DB00073
DB01204,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitoxantrone.,Mitoxantrone,DB00073
DB01206,The risk or severity of adverse effects can be increased when Rituximab is combined with Lomustine.,Lomustine,DB00073
DB01222,The risk or severity of adverse effects can be increased when Rituximab is combined with Budesonide.,Budesonide,DB00073
DB01229,The risk or severity of adverse effects can be increased when Rituximab is combined with Paclitaxel.,Paclitaxel,DB00073
DB01234,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone.,Dexamethasone,DB00073
DB01248,The risk or severity of adverse effects can be increased when Rituximab is combined with Docetaxel.,Docetaxel,DB00073
DB01254,The risk or severity of adverse effects can be increased when Rituximab is combined with Dasatinib.,Dasatinib,DB00073
DB01257,The risk or severity of adverse effects can be increased when Rituximab is combined with Eculizumab.,Eculizumab,DB00073
DB01262,The risk or severity of adverse effects can be increased when Rituximab is combined with Decitabine.,Decitabine,DB00073
DB01268,The risk or severity of adverse effects can be increased when Rituximab is combined with Sunitinib.,Sunitinib,DB00073
DB01280,The risk or severity of adverse effects can be increased when Rituximab is combined with Nelarabine.,Nelarabine,DB00073
DB01285,The risk or severity of adverse effects can be increased when Rituximab is combined with Corticotropin.,Corticotropin,DB00073
DB01380,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortisone acetate.,Cortisone acetate,DB00073
DB01384,The risk or severity of adverse effects can be increased when Rituximab is combined with Paramethasone.,Paramethasone,DB00073
DB01394,The risk or severity of adverse effects can be increased when Rituximab is combined with Colchicine.,Colchicine,DB00073
DB01410,The risk or severity of adverse effects can be increased when Rituximab is combined with Ciclesonide.,Ciclesonide,DB00073
DB01423,The risk or severity of adverse effects can be increased when Rituximab is combined with Stepronin.,Stepronin,DB00073
DB01590,The risk or severity of adverse effects can be increased when Rituximab is combined with Everolimus.,Everolimus,DB00073
DB01611,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00073
DB01816,The risk or severity of adverse effects can be increased when Rituximab is combined with Castanospermine.,Castanospermine,DB00073
DB02546,The risk or severity of adverse effects can be increased when Rituximab is combined with Vorinostat.,Vorinostat,DB00073
DB02806,The risk or severity of adverse effects can be increased when Rituximab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00073
DB03523,The risk or severity of adverse effects can be increased when Rituximab is combined with Brequinar.,Brequinar,DB00073
DB04572,The risk or severity of adverse effects can be increased when Rituximab is combined with Thiotepa.,Thiotepa,DB00073
DB04630,The risk or severity of adverse effects can be increased when Rituximab is combined with Aldosterone.,Aldosterone,DB00073
DB04845,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixabepilone.,Ixabepilone,DB00073
DB04868,The risk or severity of adverse effects can be increased when Rituximab is combined with Nilotinib.,Nilotinib,DB00073
DB04951,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirfenidone.,Pirfenidone,DB00073
DB04956,The risk or severity of adverse effects can be increased when Rituximab is combined with Afelimomab.,Afelimomab,DB00073
DB05015,The risk or severity of adverse effects can be increased when Rituximab is combined with Belinostat.,Belinostat,DB00073
DB05109,The risk or severity of adverse effects can be increased when Rituximab is combined with Trabectedin.,Trabectedin,DB00073
DB05258,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa.,Interferon alfa,DB00073
DB05259,The risk or severity of adverse effects can be increased when Rituximab is combined with Glatiramer.,Glatiramer,DB00073
DB05260,The risk or severity of adverse effects can be increased when Rituximab is combined with Gallium nitrate.,Gallium nitrate,DB00073
DB05459,The risk or severity of adverse effects can be increased when Rituximab is combined with Briakinumab.,Briakinumab,DB00073
DB05472,The risk or severity of adverse effects can be increased when Rituximab is combined with omega interferon.,omega interferon,DB00073
DB05773,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00073
DB06168,The risk or severity of adverse effects can be increased when Rituximab is combined with Canakinumab.,Canakinumab,DB00073
DB06273,The risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.,Tocilizumab,DB00073
DB06287,The risk or severity of adverse effects can be increased when Rituximab is combined with Temsirolimus.,Temsirolimus,DB00073
DB06372,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilonacept.,Rilonacept,DB00073
DB06589,The risk or severity of adverse effects can be increased when Rituximab is combined with Pazopanib.,Pazopanib,DB00073
DB06603,The risk or severity of adverse effects can be increased when Rituximab is combined with Panobinostat.,Panobinostat,DB00073
DB06612,The risk or severity of adverse effects can be increased when Rituximab is combined with Mepolizumab.,Mepolizumab,DB00073
DB06616,The risk or severity of adverse effects can be increased when Rituximab is combined with Bosutinib.,Bosutinib,DB00073
DB06662,The risk or severity of adverse effects can be increased when Rituximab is combined with Abetimus.,Abetimus,DB00073
DB06674,The risk or severity of adverse effects can be increased when Rituximab is combined with Golimumab.,Golimumab,DB00073
DB06681,The risk or severity of adverse effects can be increased when Rituximab is combined with Belatacept.,Belatacept,DB00073
DB06769,The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine.,Bendamustine,DB00073
DB06772,The risk or severity of adverse effects can be increased when Rituximab is combined with Cabazitaxel.,Cabazitaxel,DB00073
DB06813,The risk or severity of adverse effects can be increased when Rituximab is combined with Pralatrexate.,Pralatrexate,DB00073
DB08059,The risk or severity of adverse effects can be increased when Rituximab is combined with Wortmannin.,Wortmannin,DB00073
DB08870,The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00073
DB08871,The risk or severity of adverse effects can be increased when Rituximab is combined with Eribulin.,Eribulin,DB00073
DB08877,The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.,Ruxolitinib,DB00073
DB08879,The risk or severity of adverse effects can be increased when Rituximab is combined with Belimumab.,Belimumab,DB00073
DB08880,The risk or severity of adverse effects can be increased when Rituximab is combined with Teriflunomide.,Teriflunomide,DB00073
DB08889,The risk or severity of adverse effects can be increased when Rituximab is combined with Carfilzomib.,Carfilzomib,DB00073
DB08901,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponatinib.,Ponatinib,DB00073
DB08906,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone furoate.,Fluticasone furoate,DB00073
DB08908,The risk or severity of adverse effects can be increased when Rituximab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00073
DB08910,The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.,Pomalidomide,DB00073
DB08935,The risk or severity of adverse effects can be increased when Rituximab is combined with Obinutuzumab.,Obinutuzumab,DB00073
DB08970,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednidene.,Fluprednidene,DB00073
DB08971,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortolone.,Fluocortolone,DB00073
DB09029,The risk or severity of adverse effects can be increased when Rituximab is combined with Secukinumab.,Secukinumab,DB00073
DB09033,The risk or severity of adverse effects can be increased when Rituximab is combined with Vedolizumab.,Vedolizumab,DB00073
DB09036,The risk or severity of adverse effects can be increased when Rituximab is combined with Siltuximab.,Siltuximab,DB00073
DB09052,The risk or severity of adverse effects can be increased when Rituximab is combined with Blinatumomab.,Blinatumomab,DB00073
DB09053,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibrutinib.,Ibrutinib,DB00073
DB09054,The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib.,Idelalisib,DB00073
DB09073,The risk or severity of adverse effects can be increased when Rituximab is combined with Palbociclib.,Palbociclib,DB00073
DB09074,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaparib.,Olaparib,DB00073
DB09077,The risk or severity of adverse effects can be increased when Rituximab is combined with Dinutuximab.,Dinutuximab,DB00073
DB09082,The risk or severity of adverse effects can be increased when Rituximab is combined with Vilanterol.,Vilanterol,DB00073
DB09091,The risk or severity of adverse effects can be increased when Rituximab is combined with Tixocortol.,Tixocortol,DB00073
DB09122,The risk or severity of adverse effects can be increased when Rituximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00073
DB09312,The risk or severity of adverse effects can be increased when Rituximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00073
DB09378,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednisolone.,Fluprednisolone,DB00073
DB09383,The risk or severity of adverse effects can be increased when Rituximab is combined with Meprednisone.,Meprednisone,DB00073
DB11466,The risk or severity of adverse effects can be increased when Rituximab is combined with Tepoxalin.,Tepoxalin,DB00073
DB11487,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00073
DB11529,The risk or severity of adverse effects can be increased when Rituximab is combined with Melengestrol.,Melengestrol,DB00073
DB11569,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixekizumab.,Ixekizumab,DB00073
DB11580,The risk or severity of adverse effects can be increased when Rituximab is combined with Ravulizumab.,Ravulizumab,DB00073
DB11616,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirarubicin.,Pirarubicin,DB00073
DB11693,The risk or severity of adverse effects can be increased when Rituximab is combined with Voclosporin.,Voclosporin,DB00073
DB11708,The risk or severity of adverse effects can be increased when Rituximab is combined with Peficitinib.,Peficitinib,DB00073
DB11750,The risk or severity of adverse effects can be increased when Rituximab is combined with Clobetasol.,Clobetasol,DB00073
DB11767,The risk or severity of adverse effects can be increased when Rituximab is combined with Sarilumab.,Sarilumab,DB00073
DB11776,The risk or severity of adverse effects can be increased when Rituximab is combined with Brodalumab.,Brodalumab,DB00073
DB11803,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirukumab.,Sirukumab,DB00073
DB11817,The risk or severity of adverse effects can be increased when Rituximab is combined with Baricitinib.,Baricitinib,DB00073
DB11834,The risk or severity of adverse effects can be increased when Rituximab is combined with Guselkumab.,Guselkumab,DB00073
DB11921,The risk or severity of adverse effects can be increased when Rituximab is combined with Deflazacort.,Deflazacort,DB00073
DB12025,The risk or severity of adverse effects can be increased when Rituximab is combined with Triptolide.,Triptolide,DB00073
DB12371,The risk or severity of adverse effects can be increased when Rituximab is combined with Siponimod.,Siponimod,DB00073
DB12612,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanimod.,Ozanimod,DB00073
DB12617,The risk or severity of adverse effects can be increased when Rituximab is combined with Mizoribine.,Mizoribine,DB00073
DB12692,The risk or severity of adverse effects can be increased when Rituximab is combined with Gusperimus.,Gusperimus,DB00073
DB12814,The risk or severity of adverse effects can be increased when Rituximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00073
DB12902,The risk or severity of adverse effects can be increased when Rituximab is combined with Trofosfamide.,Trofosfamide,DB00073
DB12947,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxifluridine.,Doxifluridine,DB00073
DB12991,The risk or severity of adverse effects can be increased when Rituximab is combined with Deoxyspergualin.,Deoxyspergualin,DB00073
DB12996,The risk or severity of adverse effects can be increased when Rituximab is combined with Acteoside.,Acteoside,DB00073
DB13003,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortivazol.,Cortivazol,DB00073
DB13014,The risk or severity of adverse effects can be increased when Rituximab is combined with Hypericin.,Hypericin,DB00073
DB13068,The risk or severity of adverse effects can be increased when Rituximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00073
DB13208,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednylidene.,Prednylidene,DB00073
DB13223,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortin.,Fluocortin,DB00073
DB13241,The risk or severity of adverse effects can be increased when Rituximab is combined with Begelomab.,Begelomab,DB00073
DB13491,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluperolone.,Fluperolone,DB00073
DB13664,The risk or severity of adverse effects can be increased when Rituximab is combined with Formocortal.,Formocortal,DB00073
DB13728,The risk or severity of adverse effects can be increased when Rituximab is combined with Halometasone.,Halometasone,DB00073
DB13843,The risk or severity of adverse effects can be increased when Rituximab is combined with Cloprednol.,Cloprednol,DB00073
DB13856,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluclorolone.,Fluclorolone,DB00073
DB13867,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone.,Fluticasone,DB00073
DB14066,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetrandrine.,Tetrandrine,DB00073
DB14219,The risk or severity of adverse effects can be increased when Rituximab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00073
DB14512,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone furoate.,Mometasone furoate,DB00073
DB14538,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00073
DB14539,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00073
DB14545,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00073
DB14724,The risk or severity of adverse effects can be increased when Rituximab is combined with Emapalumab.,Emapalumab,DB00073
DB14762,The risk or severity of adverse effects can be increased when Rituximab is combined with Risankizumab.,Risankizumab,DB00073
DB14919,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozanolixizumab.,Rozanolixizumab,DB00073
DB15253,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleselumab.,Bleselumab,DB00073
DB00108,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.,Natalizumab,DB00073
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.,Pimecrolimus,DB00073
DB01656,Roflumilast may increase the immunosuppressive activities of Rituximab.,Roflumilast,DB00073
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.,Sipuleucel-T,DB00073
DB00363,The risk or severity of neutropenia can be increased when Rituximab is combined with Clozapine.,Clozapine,DB00073
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rituximab.,Darbepoetin alfa,DB00073
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rituximab.,Erythropoietin,DB00073
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Rituximab.,Peginesatide,DB00073
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab.,Methoxy polyethylene glycol-epoetin beta,DB00073
DB01281,Rituximab may increase the immunosuppressive activities of Abatacept.,Abatacept,DB00073
DB08904,Rituximab may increase the immunosuppressive activities of Certolizumab pegol.,Certolizumab pegol,DB00073
DB08895,Rituximab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00073
DB00177,Valsartan may increase the hypotensive activities of Rituximab.,Valsartan,DB00073
DB00178,Ramipril may increase the hypotensive activities of Rituximab.,Ramipril,DB00073
DB00187,Esmolol may increase the hypotensive activities of Rituximab.,Esmolol,DB00073
DB00195,Betaxolol may increase the hypotensive activities of Rituximab.,Betaxolol,DB00073
DB00206,Reserpine may increase the hypotensive activities of Rituximab.,Reserpine,DB00073
DB00212,Remikiren may increase the hypotensive activities of Rituximab.,Remikiren,DB00073
DB00214,Torasemide may increase the hypotensive activities of Rituximab.,Torasemide,DB00073
DB00217,Bethanidine may increase the hypotensive activities of Rituximab.,Bethanidine,DB00073
DB00226,Guanadrel may increase the hypotensive activities of Rituximab.,Guanadrel,DB00073
DB00264,Metoprolol may increase the hypotensive activities of Rituximab.,Metoprolol,DB00073
DB00270,Isradipine may increase the hypotensive activities of Rituximab.,Isradipine,DB00073
DB00275,Olmesartan may increase the hypotensive activities of Rituximab.,Olmesartan,DB00073
DB00310,Chlorthalidone may increase the hypotensive activities of Rituximab.,Chlorthalidone,DB00073
DB00325,Nitroprusside may increase the hypotensive activities of Rituximab.,Nitroprusside,DB00073
DB00335,Atenolol may increase the hypotensive activities of Rituximab.,Atenolol,DB00073
DB00343,Diltiazem may increase the hypotensive activities of Rituximab.,Diltiazem,DB00073
DB00350,Minoxidil may increase the hypotensive activities of Rituximab.,Minoxidil,DB00073
DB00373,Timolol may increase the hypotensive activities of Rituximab.,Timolol,DB00073
DB00374,Treprostinil may increase the hypotensive activities of Rituximab.,Treprostinil,DB00073
DB00381,Amlodipine may increase the hypotensive activities of Rituximab.,Amlodipine,DB00073
DB00393,Nimodipine may increase the hypotensive activities of Rituximab.,Nimodipine,DB00073
DB00401,Nisoldipine may increase the hypotensive activities of Rituximab.,Nisoldipine,DB00073
DB00436,Bendroflumethiazide may increase the hypotensive activities of Rituximab.,Bendroflumethiazide,DB00073
DB00457,Prazosin may increase the hypotensive activities of Rituximab.,Prazosin,DB00073
DB00492,Fosinopril may increase the hypotensive activities of Rituximab.,Fosinopril,DB00073
DB00519,Trandolapril may increase the hypotensive activities of Rituximab.,Trandolapril,DB00073
DB00524,Metolazone may increase the hypotensive activities of Rituximab.,Metolazone,DB00073
DB00528,Lercanidipine may increase the hypotensive activities of Rituximab.,Lercanidipine,DB00073
DB00542,Benazepril may increase the hypotensive activities of Rituximab.,Benazepril,DB00073
DB00559,Bosentan may increase the hypotensive activities of Rituximab.,Bosentan,DB00073
DB00571,Propranolol may increase the hypotensive activities of Rituximab.,Propranolol,DB00073
DB00575,Clonidine may increase the hypotensive activities of Rituximab.,Clonidine,DB00073
DB00584,Enalapril may increase the hypotensive activities of Rituximab.,Enalapril,DB00073
DB00590,Doxazosin may increase the hypotensive activities of Rituximab.,Doxazosin,DB00073
DB00598,Labetalol may increase the hypotensive activities of Rituximab.,Labetalol,DB00073
DB00606,Cyclothiazide may increase the hypotensive activities of Rituximab.,Cyclothiazide,DB00073
DB00612,Bisoprolol may increase the hypotensive activities of Rituximab.,Bisoprolol,DB00073
DB00616,Candoxatril may increase the hypotensive activities of Rituximab.,Candoxatril,DB00073
DB00622,Nicardipine may increase the hypotensive activities of Rituximab.,Nicardipine,DB00073
DB00629,Guanabenz may increase the hypotensive activities of Rituximab.,Guanabenz,DB00073
DB00657,Mecamylamine may increase the hypotensive activities of Rituximab.,Mecamylamine,DB00073
DB00678,Losartan may increase the hypotensive activities of Rituximab.,Losartan,DB00073
DB00691,Moexipril may increase the hypotensive activities of Rituximab.,Moexipril,DB00073
DB00692,Phentolamine may increase the hypotensive activities of Rituximab.,Phentolamine,DB00073
DB00700,Eplerenone may increase the hypotensive activities of Rituximab.,Eplerenone,DB00073
DB00722,Lisinopril may increase the hypotensive activities of Rituximab.,Lisinopril,DB00073
DB00727,Nitroglycerin may increase the hypotensive activities of Rituximab.,Nitroglycerin,DB00073
DB00765,Metyrosine may increase the hypotensive activities of Rituximab.,Metyrosine,DB00073
DB00774,Hydroflumethiazide may increase the hypotensive activities of Rituximab.,Hydroflumethiazide,DB00073
DB00785,Cryptenamine may increase the hypotensive activities of Rituximab.,Cryptenamine,DB00073
DB00790,Perindopril may increase the hypotensive activities of Rituximab.,Perindopril,DB00073
DB00796,Candesartan cilexetil may increase the hypotensive activities of Rituximab.,Candesartan cilexetil,DB00073
DB00797,Tolazoline may increase the hypotensive activities of Rituximab.,Tolazoline,DB00073
DB00800,Fenoldopam may increase the hypotensive activities of Rituximab.,Fenoldopam,DB00073
DB00808,Indapamide may increase the hypotensive activities of Rituximab.,Indapamide,DB00073
DB00820,Tadalafil may increase the hypotensive activities of Rituximab.,Tadalafil,DB00073
DB00866,Alprenolol may increase the hypotensive activities of Rituximab.,Alprenolol,DB00073
DB00876,Eprosartan may increase the hypotensive activities of Rituximab.,Eprosartan,DB00073
DB00880,Chlorothiazide may increase the hypotensive activities of Rituximab.,Chlorothiazide,DB00073
DB00881,Quinapril may increase the hypotensive activities of Rituximab.,Quinapril,DB00073
DB00886,Omapatrilat may increase the hypotensive activities of Rituximab.,Omapatrilat,DB00073
DB00925,Phenoxybenzamine may increase the hypotensive activities of Rituximab.,Phenoxybenzamine,DB00073
DB00960,Pindolol may increase the hypotensive activities of Rituximab.,Pindolol,DB00073
DB00966,Telmisartan may increase the hypotensive activities of Rituximab.,Telmisartan,DB00073
DB00968,Methyldopa may increase the hypotensive activities of Rituximab.,Methyldopa,DB00073
DB00999,Hydrochlorothiazide may increase the hypotensive activities of Rituximab.,Hydrochlorothiazide,DB00073
DB01018,Guanfacine may increase the hypotensive activities of Rituximab.,Guanfacine,DB00073
DB01021,Trichlormethiazide may increase the hypotensive activities of Rituximab.,Trichlormethiazide,DB00073
DB01023,Felodipine may increase the hypotensive activities of Rituximab.,Felodipine,DB00073
DB01029,Irbesartan may increase the hypotensive activities of Rituximab.,Irbesartan,DB00073
DB01054,Nitrendipine may increase the hypotensive activities of Rituximab.,Nitrendipine,DB00073
DB01089,Deserpidine may increase the hypotensive activities of Rituximab.,Deserpidine,DB00073
DB01090,Pentolinium may increase the hypotensive activities of Rituximab.,Pentolinium,DB00073
DB01116,Trimethaphan may increase the hypotensive activities of Rituximab.,Trimethaphan,DB00073
DB01119,Diazoxide may increase the hypotensive activities of Rituximab.,Diazoxide,DB00073
DB01136,Carvedilol may increase the hypotensive activities of Rituximab.,Carvedilol,DB00073
DB01158,Bretylium may increase the hypotensive activities of Rituximab.,Bretylium,DB00073
DB01162,Terazosin may increase the hypotensive activities of Rituximab.,Terazosin,DB00073
DB01170,Guanethidine may increase the hypotensive activities of Rituximab.,Guanethidine,DB00073
DB01180,Rescinnamine may increase the hypotensive activities of Rituximab.,Rescinnamine,DB00073
DB01193,Acebutolol may increase the hypotensive activities of Rituximab.,Acebutolol,DB00073
DB01197,Captopril may increase the hypotensive activities of Rituximab.,Captopril,DB00073
DB01203,Nadolol may increase the hypotensive activities of Rituximab.,Nadolol,DB00073
DB01240,Epoprostenol may increase the hypotensive activities of Rituximab.,Epoprostenol,DB00073
DB01244,Bepridil may increase the hypotensive activities of Rituximab.,Bepridil,DB00073
DB01275,Hydralazine may increase the hypotensive activities of Rituximab.,Hydralazine,DB00073
DB01295,Bevantolol may increase the hypotensive activities of Rituximab.,Bevantolol,DB00073
DB01297,Practolol may increase the hypotensive activities of Rituximab.,Practolol,DB00073
DB01324,Polythiazide may increase the hypotensive activities of Rituximab.,Polythiazide,DB00073
DB01340,Cilazapril may increase the hypotensive activities of Rituximab.,Cilazapril,DB00073
DB01347,Saprisartan may increase the hypotensive activities of Rituximab.,Saprisartan,DB00073
DB01348,Spirapril may increase the hypotensive activities of Rituximab.,Spirapril,DB00073
DB01359,Penbutolol may increase the hypotensive activities of Rituximab.,Penbutolol,DB00073
DB01388,Mibefradil may increase the hypotensive activities of Rituximab.,Mibefradil,DB00073
DB01580,Oxprenolol may increase the hypotensive activities of Rituximab.,Oxprenolol,DB00073
DB01626,Pargyline may increase the hypotensive activities of Rituximab.,Pargyline,DB00073
DB03322,Dexpropranolol may increase the hypotensive activities of Rituximab.,Dexpropranolol,DB00073
DB04831,Tienilic acid may increase the hypotensive activities of Rituximab.,Tienilic acid,DB00073
DB04840,Debrisoquine may increase the hypotensive activities of Rituximab.,Debrisoquine,DB00073
DB04846,Celiprolol may increase the hypotensive activities of Rituximab.,Celiprolol,DB00073
DB04861,Nebivolol may increase the hypotensive activities of Rituximab.,Nebivolol,DB00073
DB04948,Lofexidine may increase the hypotensive activities of Rituximab.,Lofexidine,DB00073
DB06268,Sitaxentan may increase the hypotensive activities of Rituximab.,Sitaxentan,DB00073
DB06403,Ambrisentan may increase the hypotensive activities of Rituximab.,Ambrisentan,DB00073
DB06445,Diethylnorspermine may increase the hypotensive activities of Rituximab.,Diethylnorspermine,DB00073
DB06712,Nilvadipine may increase the hypotensive activities of Rituximab.,Nilvadipine,DB00073
DB06762,Pinacidil may increase the hypotensive activities of Rituximab.,Pinacidil,DB00073
DB07767,Ferulic acid may increase the hypotensive activities of Rituximab.,Ferulic acid,DB00073
DB08808,Bupranolol may increase the hypotensive activities of Rituximab.,Bupranolol,DB00073
DB08836,Temocapril may increase the hypotensive activities of Rituximab.,Temocapril,DB00073
DB08931,Riociguat may increase the hypotensive activities of Rituximab.,Riociguat,DB00073
DB08932,Macitentan may increase the hypotensive activities of Rituximab.,Macitentan,DB00073
DB08950,Indoramin may increase the hypotensive activities of Rituximab.,Indoramin,DB00073
DB08952,Indenolol may increase the hypotensive activities of Rituximab.,Indenolol,DB00073
DB08960,Hexamethonium may increase the hypotensive activities of Rituximab.,Hexamethonium,DB00073
DB09026,Aliskiren may increase the hypotensive activities of Rituximab.,Aliskiren,DB00073
DB09206,Trimazosin may increase the hypotensive activities of Rituximab.,Trimazosin,DB00073
DB09220,Nicorandil may increase the hypotensive activities of Rituximab.,Nicorandil,DB00073
DB09235,Efonidipine may increase the hypotensive activities of Rituximab.,Efonidipine,DB00073
DB09236,Lacidipine may increase the hypotensive activities of Rituximab.,Lacidipine,DB00073
DB09238,Manidipine may increase the hypotensive activities of Rituximab.,Manidipine,DB00073
DB09239,Niguldipine may increase the hypotensive activities of Rituximab.,Niguldipine,DB00073
DB09242,Moxonidine may increase the hypotensive activities of Rituximab.,Moxonidine,DB00073
DB09363,Rauwolfia serpentina root may increase the hypotensive activities of Rituximab.,Rauwolfia serpentina root,DB00073
DB09477,Enalaprilat may increase the hypotensive activities of Rituximab.,Enalaprilat,DB00073
DB11362,Selexipag may increase the hypotensive activities of Rituximab.,Selexipag,DB00073
DB11720,Angiotensin 1-7 may increase the hypotensive activities of Rituximab.,Angiotensin 1-7,DB00073
DB11738,Rilmenidine may increase the hypotensive activities of Rituximab.,Rilmenidine,DB00073
DB11770,Talinolol may increase the hypotensive activities of Rituximab.,Talinolol,DB00073
DB11783,Imidapril may increase the hypotensive activities of Rituximab.,Imidapril,DB00073
DB12054,BQ-123 may increase the hypotensive activities of Rituximab.,BQ-123,DB00073
DB12092,Naftopidil may increase the hypotensive activities of Rituximab.,Naftopidil,DB00073
DB12093,Tetrahydropalmatine may increase the hypotensive activities of Rituximab.,Tetrahydropalmatine,DB00073
DB12212,Landiolol may increase the hypotensive activities of Rituximab.,Landiolol,DB00073
DB12465,Ketanserin may increase the hypotensive activities of Rituximab.,Ketanserin,DB00073
DB12661,Urapidil may increase the hypotensive activities of Rituximab.,Urapidil,DB00073
DB12766,Cicletanine may increase the hypotensive activities of Rituximab.,Cicletanine,DB00073
DB12945,Dihydralazine may increase the hypotensive activities of Rituximab.,Dihydralazine,DB00073
DB13166,Zofenopril may increase the hypotensive activities of Rituximab.,Zofenopril,DB00073
DB13211,Guanoxan may increase the hypotensive activities of Rituximab.,Guanoxan,DB00073
DB13312,Delapril may increase the hypotensive activities of Rituximab.,Delapril,DB00073
DB13374,Vincamine may increase the hypotensive activities of Rituximab.,Vincamine,DB00073
DB13400,Linsidomine may increase the hypotensive activities of Rituximab.,Linsidomine,DB00073
DB13410,Guanoxabenz may increase the hypotensive activities of Rituximab.,Guanoxabenz,DB00073
DB13429,Tolonidine may increase the hypotensive activities of Rituximab.,Tolonidine,DB00073
DB13435,Endralazine may increase the hypotensive activities of Rituximab.,Endralazine,DB00073
DB13443,Esatenolol may increase the hypotensive activities of Rituximab.,Esatenolol,DB00073
DB13452,Cadralazine may increase the hypotensive activities of Rituximab.,Cadralazine,DB00073
DB13508,Cloranolol may increase the hypotensive activities of Rituximab.,Cloranolol,DB00073
DB13532,Cyclopenthiazide may increase the hypotensive activities of Rituximab.,Cyclopenthiazide,DB00073
DB13575,Bietaserpine may increase the hypotensive activities of Rituximab.,Bietaserpine,DB00073
DB13604,Guanazodine may increase the hypotensive activities of Rituximab.,Guanazodine,DB00073
DB13631,Methoserpidine may increase the hypotensive activities of Rituximab.,Methoserpidine,DB00073
DB13757,Epanolol may increase the hypotensive activities of Rituximab.,Epanolol,DB00073
DB13779,Guanoclor may increase the hypotensive activities of Rituximab.,Guanoclor,DB00073
DB13801,Muzolimine may increase the hypotensive activities of Rituximab.,Muzolimine,DB00073
DB13803,Xipamide may increase the hypotensive activities of Rituximab.,Xipamide,DB00073
DB13919,Candesartan may increase the hypotensive activities of Rituximab.,Candesartan,DB00073
DB14068,Dexniguldipine may increase the hypotensive activities of Rituximab.,Dexniguldipine,DB00073
DB14094,Tocopherylquinone may increase the hypotensive activities of Rituximab.,Tocopherylquinone,DB00073
DB14125,Benazeprilat may increase the hypotensive activities of Rituximab.,Benazeprilat,DB00073
DB14207,Fosinoprilat may increase the hypotensive activities of Rituximab.,Fosinoprilat,DB00073
DB14208,Ramiprilat may increase the hypotensive activities of Rituximab.,Ramiprilat,DB00073
DB14213,Perindoprilat may increase the hypotensive activities of Rituximab.,Perindoprilat,DB00073
DB14217,Quinaprilat may increase the hypotensive activities of Rituximab.,Quinaprilat,DB00073
DB00695,Furosemide may increase the hypotensive activities of Rituximab.,Furosemide,DB00073
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Rituximab.,Sulfamethoxazole,DB00073
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Rituximab.,Diethylstilbestrol,DB00073
DB00269,Chlorotrianisene may increase the thrombogenic activities of Rituximab.,Chlorotrianisene,DB00073
DB00286,Conjugated estrogens may increase the thrombogenic activities of Rituximab.,Conjugated estrogens,DB00073
DB00655,Estrone may increase the thrombogenic activities of Rituximab.,Estrone,DB00073
DB00783,Estradiol may increase the thrombogenic activities of Rituximab.,Estradiol,DB00073
DB00890,Dienestrol may increase the thrombogenic activities of Rituximab.,Dienestrol,DB00073
DB00977,Ethinylestradiol may increase the thrombogenic activities of Rituximab.,Ethinylestradiol,DB00073
DB01357,Mestranol may increase the thrombogenic activities of Rituximab.,Mestranol,DB00073
DB04573,Estriol may increase the thrombogenic activities of Rituximab.,Estriol,DB00073
DB04574,Estrone sulfate may increase the thrombogenic activities of Rituximab.,Estrone sulfate,DB00073
DB04575,Quinestrol may increase the thrombogenic activities of Rituximab.,Quinestrol,DB00073
DB07931,Hexestrol may increase the thrombogenic activities of Rituximab.,Hexestrol,DB00073
DB09070,Tibolone may increase the thrombogenic activities of Rituximab.,Tibolone,DB00073
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rituximab.","Synthetic Conjugated Estrogens, A",DB00073
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rituximab.","Synthetic Conjugated Estrogens, B",DB00073
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Rituximab.,Polyestradiol phosphate,DB00073
DB09381,Esterified estrogens may increase the thrombogenic activities of Rituximab.,Esterified estrogens,DB00073
DB11478,Zeranol may increase the thrombogenic activities of Rituximab.,Zeranol,DB00073
DB11674,Equol may increase the thrombogenic activities of Rituximab.,Equol,DB00073
DB12487,Promestriene may increase the thrombogenic activities of Rituximab.,Promestriene,DB00073
DB13143,Methallenestril may increase the thrombogenic activities of Rituximab.,Methallenestril,DB00073
DB13386,Epimestrol may increase the thrombogenic activities of Rituximab.,Epimestrol,DB00073
DB13418,Moxestrol may increase the thrombogenic activities of Rituximab.,Moxestrol,DB00073
DB13952,Estradiol acetate may increase the thrombogenic activities of Rituximab.,Estradiol acetate,DB00073
DB13953,Estradiol benzoate may increase the thrombogenic activities of Rituximab.,Estradiol benzoate,DB00073
DB13954,Estradiol cypionate may increase the thrombogenic activities of Rituximab.,Estradiol cypionate,DB00073
DB13956,Estradiol valerate may increase the thrombogenic activities of Rituximab.,Estradiol valerate,DB00073
DB15334,Biochanin A may increase the thrombogenic activities of Rituximab.,Biochanin A,DB00073
DB15335,Formononetin may increase the thrombogenic activities of Rituximab.,Formononetin,DB00073
DB01097,The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.,Leflunomide,DB00073
DB00072,Trastuzumab may increase the neutropenic activities of Rituximab.,Trastuzumab,DB00073
DB08868,Rituximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00073
DB00864,Tacrolimus may increase the immunosuppressive activities of Rituximab.,Tacrolimus,DB00073
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Rituximab.,G17DT,DB00073
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Rituximab.,PEV3A,DB00073
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Rituximab.,INGN 225,DB00073
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rituximab.,Rindopepimut,DB00073
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Rituximab.,SRP 299,DB00073
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Rituximab.,GI-5005,DB00073
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Rituximab.,Vitespen,DB00073
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Rituximab.,TG4010,DB00073
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rituximab.,Anthrax immune globulin human,DB00073
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Rituximab.","Rabies virus inactivated antigen, B",DB00073
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00073
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Rituximab.,Rotavirus vaccine,DB00073
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rituximab.","Rabies virus inactivated antigen, A",DB00073
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00073
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00073
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00073
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00073
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00073
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00073
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Rituximab.,Typhoid Vi polysaccharide vaccine,DB00073
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.,Hepatitis A Vaccine,DB00073
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00073
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00073
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00073
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00073
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00073
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rituximab.,Human rabies virus immune globulin,DB00073
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rituximab.,Hepatitis B Vaccine (Recombinant),DB00073
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Rituximab.,Tecemotide,DB00073
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Rituximab.,Typhoid vaccine,DB00073
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00073
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00073
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00073
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00073
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Rituximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00073
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00073
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00073
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Rituximab.,Vaccinia virus strain new york city board of health live antigen,DB00073
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Rituximab.,Pertussis vaccine,DB00073
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00073
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Rituximab.,Varicella Zoster Vaccine (Recombinant),DB00073
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Rituximab.,Modified vaccinia ankara,DB00073
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.,Eptifibatide,DB00073
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Rituximab.,Ticlopidine,DB00073
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Rituximab.,Anagrelide,DB00073
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Rituximab.,Clopidogrel,DB00073
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Rituximab.,Tirofiban,DB00073
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Rituximab.,Pentoxifylline,DB00073
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Rituximab.,Acetylsalicylic acid,DB00073
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Rituximab.,Dipyridamole,DB00073
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Rituximab.,Iloprost,DB00073
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Rituximab.,Sulfinpyrazone,DB00073
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Rituximab.,Cilostazol,DB00073
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Rituximab.,Ridogrel,DB00073
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Rituximab.,Sevoflurane,DB00073
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Rituximab.,Resveratrol,DB00073
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Rituximab.,Nimesulide,DB00073
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Rituximab.,Tesmilifene,DB00073
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Rituximab.,Defibrotide,DB00073
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Rituximab.,Beraprost,DB00073
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Rituximab.,Ibudilast,DB00073
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Rituximab.,Andrographolide,DB00073
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Rituximab.,Prasugrel,DB00073
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Rituximab.,Cangrelor,DB00073
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Rituximab.,Tranilast,DB00073
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Rituximab.,Triflusal,DB00073
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Rituximab.,Ticagrelor,DB00073
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Rituximab.,Icosapent ethyl,DB00073
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Rituximab.,Vorapaxar,DB00073
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Rituximab.,Trapidil,DB00073
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Rituximab.,Sarpogrelate,DB00073
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Rituximab.,Ifetroban,DB00073
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Rituximab.,Nitroaspirin,DB00073
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Rituximab.,Indobufen,DB00073
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Rituximab.,Butylphthalide,DB00073
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Rituximab.,Hydroxytyrosol,DB00073
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Rituximab.,Ramatroban,DB00073
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Rituximab.,Picotamide,DB00073
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Rituximab.,Cloricromen,DB00073
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Rituximab.,Buflomedil,DB00073
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Rituximab.,Relcovaptan,DB00073
DB11988,Ocrelizumab may increase the immunosuppressive activities of Rituximab.,Ocrelizumab,DB00073
DB13200,Rituximab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00073
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Rituximab.,Rubella virus vaccine,DB00073
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Rituximab.,Varicella Zoster Vaccine (Live/attenuated),DB00073
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain tice live antigen,DB00073
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain connaught live antigen,DB00073
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Rituximab.,Yellow Fever Vaccine,DB00073
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Rituximab.,Anthrax vaccine,DB00073
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Rituximab.,Typhoid Vaccine Live,DB00073
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00073
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Rituximab.,BCG vaccine,DB00073
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Rituximab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00073
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Rituximab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00073
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rituximab.,Adenovirus type 7 vaccine live,DB00073
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.,Cetuximab,DB00073
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.,Human immunoglobulin G,DB00073
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Rituximab.,Omalizumab,DB00073
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Rituximab.,Abciximab,DB00073
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.,Indium In-111 satumomab pendetide,DB00073
DB00076,The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00073
DB00089,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.,Capromab pendetide,DB00073
DB00110,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.,Palivizumab,DB00073
DB00113,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00073
DB01269,The risk or severity of adverse effects can be increased when Rituximab is combined with Panitumumab.,Panitumumab,DB00073
DB01270,The risk or severity of adverse effects can be increased when Rituximab is combined with Ranibizumab.,Ranibizumab,DB00073
DB04901,The risk or severity of adverse effects can be increased when Rituximab is combined with Galiximab.,Galiximab,DB00073
DB04949,The risk or severity of adverse effects can be increased when Rituximab is combined with Pexelizumab.,Pexelizumab,DB00073
DB04958,The risk or severity of adverse effects can be increased when Rituximab is combined with Epratuzumab.,Epratuzumab,DB00073
DB04962,The risk or severity of adverse effects can be increased when Rituximab is combined with Bectumomab.,Bectumomab,DB00073
DB04964,The risk or severity of adverse effects can be increased when Rituximab is combined with Oregovomab.,Oregovomab,DB00073
DB04988,The risk or severity of adverse effects can be increased when Rituximab is combined with IGN311.,IGN311,DB00073
DB05006,The risk or severity of adverse effects can be increased when Rituximab is combined with Adecatumumab.,Adecatumumab,DB00073
DB05097,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab.,Labetuzumab,DB00073
DB05101,The risk or severity of adverse effects can be increased when Rituximab is combined with Matuzumab.,Matuzumab,DB00073
DB05111,The risk or severity of adverse effects can be increased when Rituximab is combined with Fontolizumab.,Fontolizumab,DB00073
DB05136,The risk or severity of adverse effects can be increased when Rituximab is combined with Bavituximab.,Bavituximab,DB00073
DB05139,The risk or severity of adverse effects can be increased when Rituximab is combined with CR002.,CR002,DB00073
DB05209,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozrolimupab.,Rozrolimupab,DB00073
DB05304,The risk or severity of adverse effects can be increased when Rituximab is combined with Girentuximab.,Girentuximab,DB00073
DB05336,The risk or severity of adverse effects can be increased when Rituximab is combined with Obiltoxaximab.,Obiltoxaximab,DB00073
DB05405,The risk or severity of adverse effects can be increased when Rituximab is combined with XTL-001.,XTL-001,DB00073
DB05437,The risk or severity of adverse effects can be increased when Rituximab is combined with NAV 1800.,NAV 1800,DB00073
DB05496,The risk or severity of adverse effects can be increased when Rituximab is combined with Otelixizumab.,Otelixizumab,DB00073
DB05545,The risk or severity of adverse effects can be increased when Rituximab is combined with AMG 108.,AMG 108,DB00073
DB05550,The risk or severity of adverse effects can be increased when Rituximab is combined with Iratumumab.,Iratumumab,DB00073
DB05555,The risk or severity of adverse effects can be increased when Rituximab is combined with Enokizumab.,Enokizumab,DB00073
DB05578,The risk or severity of adverse effects can be increased when Rituximab is combined with Ramucirumab.,Ramucirumab,DB00073
DB05595,The risk or severity of adverse effects can be increased when Rituximab is combined with Farletuzumab.,Farletuzumab,DB00073
DB05656,The risk or severity of adverse effects can be increased when Rituximab is combined with Veltuzumab.,Veltuzumab,DB00073
DB05793,The risk or severity of adverse effects can be increased when Rituximab is combined with PRO-542.,PRO-542,DB00073
DB05797,The risk or severity of adverse effects can be increased when Rituximab is combined with TNX-901.,TNX-901,DB00073
DB05889,The risk or severity of adverse effects can be increased when Rituximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00073
DB05892,The risk or severity of adverse effects can be increased when Rituximab is combined with RI 624.,RI 624,DB00073
DB05915,The risk or severity of adverse effects can be increased when Rituximab is combined with MYO-029.,MYO-029,DB00073
DB05916,The risk or severity of adverse effects can be increased when Rituximab is combined with CT-011.,CT-011,DB00073
DB05941,The risk or severity of adverse effects can be increased when Rituximab is combined with Leronlimab.,Leronlimab,DB00073
DB05996,The risk or severity of adverse effects can be increased when Rituximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00073
DB06043,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaratumab.,Olaratumab,DB00073
DB06049,The risk or severity of adverse effects can be increased when Rituximab is combined with IPH 2101.,IPH 2101,DB00073
DB06050,The risk or severity of adverse effects can be increased when Rituximab is combined with TB-402.,TB-402,DB00073
DB06081,The risk or severity of adverse effects can be increased when Rituximab is combined with Caplacizumab.,Caplacizumab,DB00073
DB06101,The risk or severity of adverse effects can be increased when Rituximab is combined with IMC-1C11.,IMC-1C11,DB00073
DB06116,The risk or severity of adverse effects can be increased when Rituximab is combined with Eldelumab.,Eldelumab,DB00073
DB06162,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumiliximab.,Lumiliximab,DB00073
DB06186,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipilimumab.,Ipilimumab,DB00073
DB06192,The risk or severity of adverse effects can be increased when Rituximab is combined with Nimotuzumab.,Nimotuzumab,DB00073
DB06241,The risk or severity of adverse effects can be increased when Rituximab is combined with Clenoliximab.,Clenoliximab,DB00073
DB06304,The risk or severity of adverse effects can be increased when Rituximab is combined with BIIB015.,BIIB015,DB00073
DB06305,The risk or severity of adverse effects can be increased when Rituximab is combined with Sonepcizumab.,Sonepcizumab,DB00073
DB06310,The risk or severity of adverse effects can be increased when Rituximab is combined with Motavizumab.,Motavizumab,DB00073
DB06317,The risk or severity of adverse effects can be increased when Rituximab is combined with Elotuzumab.,Elotuzumab,DB00073
DB06318,The risk or severity of adverse effects can be increased when Rituximab is combined with AVE9633.,AVE9633,DB00073
DB06322,The risk or severity of adverse effects can be increased when Rituximab is combined with Carotuximab.,Carotuximab,DB00073
DB06324,The risk or severity of adverse effects can be increased when Rituximab is combined with XmAb 2513.,XmAb 2513,DB00073
DB06342,The risk or severity of adverse effects can be increased when Rituximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00073
DB06343,The risk or severity of adverse effects can be increased when Rituximab is combined with Teprotumumab.,Teprotumumab,DB00073
DB06360,The risk or severity of adverse effects can be increased when Rituximab is combined with Lucatumumab.,Lucatumumab,DB00073
DB06366,The risk or severity of adverse effects can be increased when Rituximab is combined with Pertuzumab.,Pertuzumab,DB00073
DB06371,The risk or severity of adverse effects can be increased when Rituximab is combined with Siplizumab.,Siplizumab,DB00073
DB06467,The risk or severity of adverse effects can be increased when Rituximab is combined with Apolizumab.,Apolizumab,DB00073
DB06474,The risk or severity of adverse effects can be increased when Rituximab is combined with Sibrotuzumab.,Sibrotuzumab,DB00073
DB06550,The risk or severity of adverse effects can be increased when Rituximab is combined with Bivatuzumab.,Bivatuzumab,DB00073
DB06557,The risk or severity of adverse effects can be increased when Rituximab is combined with Lerdelimumab.,Lerdelimumab,DB00073
DB06599,The risk or severity of adverse effects can be increased when Rituximab is combined with Lexatumumab.,Lexatumumab,DB00073
DB06602,The risk or severity of adverse effects can be increased when Rituximab is combined with Reslizumab.,Reslizumab,DB00073
DB06606,The risk or severity of adverse effects can be increased when Rituximab is combined with Teplizumab.,Teplizumab,DB00073
DB06607,The risk or severity of adverse effects can be increased when Rituximab is combined with Catumaxomab.,Catumaxomab,DB00073
DB06647,The risk or severity of adverse effects can be increased when Rituximab is combined with Volociximab.,Volociximab,DB00073
DB06650,The risk or severity of adverse effects can be increased when Rituximab is combined with Ofatumumab.,Ofatumumab,DB00073
DB08902,The risk or severity of adverse effects can be increased when Rituximab is combined with Raxibacumab.,Raxibacumab,DB00073
DB09035,The risk or severity of adverse effects can be increased when Rituximab is combined with Nivolumab.,Nivolumab,DB00073
DB09037,The risk or severity of adverse effects can be increased when Rituximab is combined with Pembrolizumab.,Pembrolizumab,DB00073
DB09045,The risk or severity of adverse effects can be increased when Rituximab is combined with Dulaglutide.,Dulaglutide,DB00073
DB09105,The risk or severity of adverse effects can be increased when Rituximab is combined with Asfotase alfa.,Asfotase alfa,DB00073
DB09264,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarucizumab.,Idarucizumab,DB00073
DB09302,The risk or severity of adverse effects can be increased when Rituximab is combined with Alirocumab.,Alirocumab,DB00073
DB09303,The risk or severity of adverse effects can be increased when Rituximab is combined with Evolocumab.,Evolocumab,DB00073
DB09331,The risk or severity of adverse effects can be increased when Rituximab is combined with Daratumumab.,Daratumumab,DB00073
DB09559,The risk or severity of adverse effects can be increased when Rituximab is combined with Necitumumab.,Necitumumab,DB00073
DB11595,The risk or severity of adverse effects can be increased when Rituximab is combined with Atezolizumab.,Atezolizumab,DB00073
DB11604,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00073
DB11608,The risk or severity of adverse effects can be increased when Rituximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00073
DB11621,The risk or severity of adverse effects can be increased when Rituximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00073
DB11646,The risk or severity of adverse effects can be increased when Rituximab is combined with Conatumumab.,Conatumumab,DB00073
DB11657,The risk or severity of adverse effects can be increased when Rituximab is combined with Tabalumab.,Tabalumab,DB00073
DB11680,The risk or severity of adverse effects can be increased when Rituximab is combined with Ficlatuzumab.,Ficlatuzumab,DB00073
DB11685,The risk or severity of adverse effects can be increased when Rituximab is combined with Figitumumab.,Figitumumab,DB00073
DB11714,The risk or severity of adverse effects can be increased when Rituximab is combined with Durvalumab.,Durvalumab,DB00073
DB11715,The risk or severity of adverse effects can be increased when Rituximab is combined with Bapineuzumab.,Bapineuzumab,DB00073
DB11731,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00073
DB11746,The risk or severity of adverse effects can be increased when Rituximab is combined with Onartuzumab.,Onartuzumab,DB00073
DB11756,The risk or severity of adverse effects can be increased when Rituximab is combined with Solanezumab.,Solanezumab,DB00073
DB11771,The risk or severity of adverse effects can be increased when Rituximab is combined with Tremelimumab.,Tremelimumab,DB00073
DB11826,The risk or severity of adverse effects can be increased when Rituximab is combined with Lampalizumab.,Lampalizumab,DB00073
DB11840,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalotuzumab.,Dalotuzumab,DB00073
DB11849,The risk or severity of adverse effects can be increased when Rituximab is combined with Emibetuzumab.,Emibetuzumab,DB00073
DB11850,The risk or severity of adverse effects can be increased when Rituximab is combined with Ublituximab.,Ublituximab,DB00073
DB11856,The risk or severity of adverse effects can be increased when Rituximab is combined with Ligelizumab.,Ligelizumab,DB00073
DB11857,The risk or severity of adverse effects can be increased when Rituximab is combined with Seribantumab.,Seribantumab,DB00073
DB11862,The risk or severity of adverse effects can be increased when Rituximab is combined with Landogrozumab.,Landogrozumab,DB00073
DB11866,The risk or severity of adverse effects can be increased when Rituximab is combined with Romosozumab.,Romosozumab,DB00073
DB11884,The risk or severity of adverse effects can be increased when Rituximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00073
DB11914,The risk or severity of adverse effects can be increased when Rituximab is combined with Lebrikizumab.,Lebrikizumab,DB00073
DB11930,The risk or severity of adverse effects can be increased when Rituximab is combined with Varlilumab.,Varlilumab,DB00073
DB11945,The risk or severity of adverse effects can be increased when Rituximab is combined with Avelumab.,Avelumab,DB00073
DB11959,The risk or severity of adverse effects can be increased when Rituximab is combined with Crenezumab.,Crenezumab,DB00073
DB11972,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilotumumab.,Rilotumumab,DB00073
DB11976,The risk or severity of adverse effects can be increased when Rituximab is combined with Anifrolumab.,Anifrolumab,DB00073
DB12023,The risk or severity of adverse effects can be increased when Rituximab is combined with Benralizumab.,Benralizumab,DB00073
DB12034,The risk or severity of adverse effects can be increased when Rituximab is combined with Gantenerumab.,Gantenerumab,DB00073
DB12053,The risk or severity of adverse effects can be increased when Rituximab is combined with Visilizumab.,Visilizumab,DB00073
DB12077,The risk or severity of adverse effects can be increased when Rituximab is combined with Urelumab.,Urelumab,DB00073
DB12089,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00073
DB12090,The risk or severity of adverse effects can be increased when Rituximab is combined with Patritumab.,Patritumab,DB00073
DB12102,The risk or severity of adverse effects can be increased when Rituximab is combined with Fulranumab.,Fulranumab,DB00073
DB12104,The risk or severity of adverse effects can be increased when Rituximab is combined with Tarextumab.,Tarextumab,DB00073
DB12118,The risk or severity of adverse effects can be increased when Rituximab is combined with Sotatercept.,Sotatercept,DB00073
DB12119,The risk or severity of adverse effects can be increased when Rituximab is combined with Gevokizumab.,Gevokizumab,DB00073
DB12142,The risk or severity of adverse effects can be increased when Rituximab is combined with Duligotuzumab.,Duligotuzumab,DB00073
DB12152,The risk or severity of adverse effects can be increased when Rituximab is combined with Simtuzumab.,Simtuzumab,DB00073
DB12157,The risk or severity of adverse effects can be increased when Rituximab is combined with Fasinumab.,Fasinumab,DB00073
DB12159,The risk or severity of adverse effects can be increased when Rituximab is combined with Dupilumab.,Dupilumab,DB00073
DB12169,The risk or severity of adverse effects can be increased when Rituximab is combined with Tralokinumab.,Tralokinumab,DB00073
DB12189,The risk or severity of adverse effects can be increased when Rituximab is combined with Etrolizumab.,Etrolizumab,DB00073
DB12202,The risk or severity of adverse effects can be increased when Rituximab is combined with Zalutumumab.,Zalutumumab,DB00073
DB12205,The risk or severity of adverse effects can be increased when Rituximab is combined with Ganitumab.,Ganitumab,DB00073
DB12213,The risk or severity of adverse effects can be increased when Rituximab is combined with Etaracizumab.,Etaracizumab,DB00073
DB12240,The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00073
DB12246,The risk or severity of adverse effects can be increased when Rituximab is combined with Inclacumab.,Inclacumab,DB00073
DB12250,The risk or severity of adverse effects can be increased when Rituximab is combined with Cixutumumab.,Cixutumumab,DB00073
DB12261,The risk or severity of adverse effects can be increased when Rituximab is combined with Ascrinvacumab.,Ascrinvacumab,DB00073
DB12274,The risk or severity of adverse effects can be increased when Rituximab is combined with Aducanumab.,Aducanumab,DB00073
DB12281,The risk or severity of adverse effects can be increased when Rituximab is combined with Luspatercept.,Luspatercept,DB00073
DB12296,The risk or severity of adverse effects can be increased when Rituximab is combined with GS-5745.,GS-5745,DB00073
DB12317,The risk or severity of adverse effects can be increased when Rituximab is combined with Vanucizumab.,Vanucizumab,DB00073
DB12331,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00073
DB12335,The risk or severity of adverse effects can be increased when Rituximab is combined with Tanezumab.,Tanezumab,DB00073
DB12342,The risk or severity of adverse effects can be increased when Rituximab is combined with Ensituximab.,Ensituximab,DB00073
DB12344,The risk or severity of adverse effects can be increased when Rituximab is combined with Fezakinumab.,Fezakinumab,DB00073
DB12363,The risk or severity of adverse effects can be increased when Rituximab is combined with Dusigitumab.,Dusigitumab,DB00073
DB12396,The risk or severity of adverse effects can be increased when Rituximab is combined with Fresolimumab.,Fresolimumab,DB00073
DB12413,The risk or severity of adverse effects can be increased when Rituximab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00073
DB12456,The risk or severity of adverse effects can be increased when Rituximab is combined with Bococizumab.,Bococizumab,DB00073
DB12489,The risk or severity of adverse effects can be increased when Rituximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00073
DB12498,The risk or severity of adverse effects can be increased when Rituximab is combined with Mogamulizumab.,Mogamulizumab,DB00073
DB12520,The risk or severity of adverse effects can be increased when Rituximab is combined with Plozalizumab.,Plozalizumab,DB00073
DB12534,The risk or severity of adverse effects can be increased when Rituximab is combined with Mavrilimumab.,Mavrilimumab,DB00073
DB12560,The risk or severity of adverse effects can be increased when Rituximab is combined with Blosozumab.,Blosozumab,DB00073
DB12584,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimagrumab.,Bimagrumab,DB00073
DB12589,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacetuzumab.,Dacetuzumab,DB00073
DB12609,The risk or severity of adverse effects can be increased when Rituximab is combined with Tovetumab.,Tovetumab,DB00073
DB12683,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumretuzumab.,Lumretuzumab,DB00073
DB12698,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibalizumab.,Ibalizumab,DB00073
DB12701,The risk or severity of adverse effects can be increased when Rituximab is combined with Intetumumab.,Intetumumab,DB00073
DB12718,The risk or severity of adverse effects can be increased when Rituximab is combined with Carlumab.,Carlumab,DB00073
DB12734,The risk or severity of adverse effects can be increased when Rituximab is combined with Demcizumab.,Demcizumab,DB00073
DB12773,The risk or severity of adverse effects can be increased when Rituximab is combined with Sifalimumab.,Sifalimumab,DB00073
DB12775,The risk or severity of adverse effects can be increased when Rituximab is combined with Abituzumab.,Abituzumab,DB00073
DB12797,The risk or severity of adverse effects can be increased when Rituximab is combined with Ecromeximab.,Ecromeximab,DB00073
DB12807,The risk or severity of adverse effects can be increased when Rituximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00073
DB12815,The risk or severity of adverse effects can be increased when Rituximab is combined with Crotedumab.,Crotedumab,DB00073
DB12820,The risk or severity of adverse effects can be increased when Rituximab is combined with Concizumab.,Concizumab,DB00073
DB12826,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab.,Depatuxizumab,DB00073
DB12844,The risk or severity of adverse effects can be increased when Rituximab is combined with Rontalizumab.,Rontalizumab,DB00073
DB12845,The risk or severity of adverse effects can be increased when Rituximab is combined with Amatuximab.,Amatuximab,DB00073
DB12849,The risk or severity of adverse effects can be increased when Rituximab is combined with Clazakizumab.,Clazakizumab,DB00073
DB12891,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanezumab.,Ozanezumab,DB00073
DB12893,The risk or severity of adverse effects can be increased when Rituximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00073
DB12917,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimekizumab.,Bimekizumab,DB00073
DB12943,The risk or severity of adverse effects can be increased when Rituximab is combined with Milatuzumab.,Milatuzumab,DB00073
DB12976,The risk or severity of adverse effects can be increased when Rituximab is combined with Robatumumab.,Robatumumab,DB00073
DB13017,The risk or severity of adverse effects can be increased when Rituximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00073
DB13037,The risk or severity of adverse effects can be increased when Rituximab is combined with Namilumab.,Namilumab,DB00073
DB13045,The risk or severity of adverse effects can be increased when Rituximab is combined with Racotumomab.,Racotumomab,DB00073
DB13073,The risk or severity of adverse effects can be increased when Rituximab is combined with Tregalizumab.,Tregalizumab,DB00073
DB13127,The risk or severity of adverse effects can be increased when Rituximab is combined with Olokizumab.,Olokizumab,DB00073
DB13140,The risk or severity of adverse effects can be increased when Rituximab is combined with Bezlotoxumab.,Bezlotoxumab,DB00073
DB13375,The risk or severity of adverse effects can be increased when Rituximab is combined with Edrecolomab.,Edrecolomab,DB00073
DB13535,The risk or severity of adverse effects can be increased when Rituximab is combined with Nebacumab.,Nebacumab,DB00073
DB13886,The risk or severity of adverse effects can be increased when Rituximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00073
DB13923,The risk or severity of adverse effects can be increased when Rituximab is combined with Emicizumab.,Emicizumab,DB00073
DB13976,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulesomab.,Sulesomab,DB00073
DB13979,The risk or severity of adverse effects can be increased when Rituximab is combined with Besilesomab.,Besilesomab,DB00073
DB14012,The risk or severity of adverse effects can be increased when Rituximab is combined with Burosumab.,Burosumab,DB00073
DB14039,The risk or severity of adverse effects can be increased when Rituximab is combined with Erenumab.,Erenumab,DB00073
DB14040,The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.,Eptinezumab,DB00073
DB14041,The risk or severity of adverse effects can be increased when Rituximab is combined with Fremanezumab.,Fremanezumab,DB00073
DB14042,The risk or severity of adverse effects can be increased when Rituximab is combined with Galcanezumab.,Galcanezumab,DB00073
DB14211,The risk or severity of adverse effects can be increased when Rituximab is combined with Fanolesomab.,Fanolesomab,DB00073
DB14580,The risk or severity of adverse effects can be increased when Rituximab is combined with Lecanemab.,Lecanemab,DB00073
DB14597,The risk or severity of adverse effects can be increased when Rituximab is combined with Lanadelumab.,Lanadelumab,DB00073
DB14707,The risk or severity of adverse effects can be increased when Rituximab is combined with Cemiplimab.,Cemiplimab,DB00073
DB14776,The risk or severity of adverse effects can be increased when Rituximab is combined with Camrelizumab.,Camrelizumab,DB00073
DB14778,The risk or severity of adverse effects can be increased when Rituximab is combined with Setrusumab.,Setrusumab,DB00073
DB14784,The risk or severity of adverse effects can be increased when Rituximab is combined with Gancotamab.,Gancotamab,DB00073
DB14809,The risk or severity of adverse effects can be increased when Rituximab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00073
DB14811,The risk or severity of adverse effects can be increased when Rituximab is combined with Isatuximab.,Isatuximab,DB00073
DB14824,The risk or severity of adverse effects can be increased when Rituximab is combined with Icrucumab.,Icrucumab,DB00073
DB14843,The risk or severity of adverse effects can be increased when Rituximab is combined with Codrituzumab.,Codrituzumab,DB00073
DB14864,The risk or severity of adverse effects can be increased when Rituximab is combined with Brolucizumab.,Brolucizumab,DB00073
DB14871,The risk or severity of adverse effects can be increased when Rituximab is combined with Xentuzumab.,Xentuzumab,DB00073
DB14877,The risk or severity of adverse effects can be increased when Rituximab is combined with Lintuzumab.,Lintuzumab,DB00073
DB14891,The risk or severity of adverse effects can be increased when Rituximab is combined with Vobarilizumab.,Vobarilizumab,DB00073
DB14897,The risk or severity of adverse effects can be increased when Rituximab is combined with Parsatuzumab.,Parsatuzumab,DB00073
DB14905,The risk or severity of adverse effects can be increased when Rituximab is combined with Emactuzumab.,Emactuzumab,DB00073
DB14907,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00073
DB14908,The risk or severity of adverse effects can be increased when Rituximab is combined with Refanezumab.,Refanezumab,DB00073
DB14947,The risk or severity of adverse effects can be increased when Rituximab is combined with Bermekimab.,Bermekimab,DB00073
DB14952,The risk or severity of adverse effects can be increased when Rituximab is combined with Pamrevlumab.,Pamrevlumab,DB00073
DB14959,The risk or severity of adverse effects can be increased when Rituximab is combined with Opicinumab.,Opicinumab,DB00073
DB14962,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00073
DB14967,The risk or severity of adverse effects can be increased when Rituximab is combined with Margetuximab.,Margetuximab,DB00073
DB14988,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalantercept.,Dalantercept,DB00073
DB14997,The risk or severity of adverse effects can be increased when Rituximab is combined with Pateclizumab.,Pateclizumab,DB00073
DB15014,The risk or severity of adverse effects can be increased when Rituximab is combined with Gremubamab.,Gremubamab,DB00073
DB15022,The risk or severity of adverse effects can be increased when Rituximab is combined with Apomab.,Apomab,DB00073
DB15044,The risk or severity of adverse effects can be increased when Rituximab is combined with Tafasitamab.,Tafasitamab,DB00073
DB15045,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipafricept.,Ipafricept,DB00073
DB15076,The risk or severity of adverse effects can be increased when Rituximab is combined with Abrilumab.,Abrilumab,DB00073
DB15089,The risk or severity of adverse effects can be increased when Rituximab is combined with Frovocimab.,Frovocimab,DB00073
DB15090,The risk or severity of adverse effects can be increased when Rituximab is combined with Tezepelumab.,Tezepelumab,DB00073
DB15101,The risk or severity of adverse effects can be increased when Rituximab is combined with Tigatuzumab.,Tigatuzumab,DB00073
DB15104,The risk or severity of adverse effects can be increased when Rituximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00073
DB15113,The risk or severity of adverse effects can be increased when Rituximab is combined with Utomilumab.,Utomilumab,DB00073
DB15118,The risk or severity of adverse effects can be increased when Rituximab is combined with Zolbetuximab.,Zolbetuximab,DB00073
DB15135,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponezumab.,Ponezumab,DB00073
DB15160,The risk or severity of adverse effects can be increased when Rituximab is combined with Asunercept.,Asunercept,DB00073
DB15172,The risk or severity of adverse effects can be increased when Rituximab is combined with Suvratoxumab.,Suvratoxumab,DB00073
DB15225,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitazalimab.,Mitazalimab,DB00073
DB15252,The risk or severity of adverse effects can be increased when Rituximab is combined with Nemolizumab.,Nemolizumab,DB00073
DB15277,The risk or severity of adverse effects can be increased when Rituximab is combined with Gedivumab.,Gedivumab,DB00073
DB15336,The risk or severity of adverse effects can be increased when Rituximab is combined with Valanafusp alfa.,Valanafusp alfa,DB00073
DB15349,The risk or severity of adverse effects can be increased when Rituximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00073
DB15354,The risk or severity of adverse effects can be increased when Rituximab is combined with Evinacumab.,Evinacumab,DB00073
DB15363,The risk or severity of adverse effects can be increased when Rituximab is combined with Istiratumab.,Istiratumab,DB00073
DB15383,The risk or severity of adverse effects can be increased when Rituximab is combined with Pidilizumab.,Pidilizumab,DB00073
DB15397,The risk or severity of adverse effects can be increased when Rituximab is combined with GMA-161.,GMA-161,DB00073
DB15409,The risk or severity of adverse effects can be increased when Rituximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00073
DB15415,The risk or severity of adverse effects can be increased when Rituximab is combined with Tomaralimab.,Tomaralimab,DB00073
DB15428,The risk or severity of adverse effects can be increased when Rituximab is combined with Vesencumab.,Vesencumab,DB00073
DB15432,The risk or severity of adverse effects can be increased when Rituximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00073
DB15441,The risk or severity of adverse effects can be increased when Rituximab is combined with Lulizumab pegol.,Lulizumab pegol,DB00073
DB15443,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00073
DB15453,The risk or severity of adverse effects can be increased when Rituximab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00073
DB14004,The risk or severity of adverse effects can be increased when Rituximab is combined with Tildrakizumab.,Tildrakizumab,DB00073
DB05679,The risk or severity of adverse effects can be increased when Rituximab is combined with Ustekinumab.,Ustekinumab,DB00073
DB15559,The risk or severity of adverse effects can be increased when Rituximab is combined with Zenocutuzumab.,Zenocutuzumab,DB00073
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Rituximab.,Palifermin,DB00073
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.,Lepirudin,DB00073
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Rituximab.,Bivalirudin,DB00073
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Rituximab.,Alteplase,DB00073
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Rituximab.,Urokinase,DB00073
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.,Reteplase,DB00073
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Rituximab.,Anistreplase,DB00073
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Rituximab.,Tenecteplase,DB00073
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.,Drotrecogin alfa,DB00073
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.,Streptokinase,DB00073
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Rituximab.,Dicoumarol,DB00073
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Rituximab.,Argatroban,DB00073
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Rituximab.,Ardeparin,DB00073
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Rituximab.,Phenindione,DB00073
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Rituximab.,Fondaparinux,DB00073
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Rituximab.,Warfarin,DB00073
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Rituximab.,Pentosan polysulfate,DB00073
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Rituximab.,Phenprocoumon,DB00073
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Rituximab.,Heparin,DB00073
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Rituximab.,Enoxaparin,DB00073
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Rituximab.,Acenocoumarol,DB00073
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Rituximab.,4-hydroxycoumarin,DB00073
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Rituximab.,Coumarin,DB00073
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Rituximab.,Ximelagatran,DB00073
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Rituximab.,Desmoteplase,DB00073
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Rituximab.,Ancrod,DB00073
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Rituximab.,Fibrinolysin,DB00073
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Rituximab.,Rivaroxaban,DB00073
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Rituximab.,Sulodexide,DB00073
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Rituximab.,Semuloparin,DB00073
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Rituximab.,Idraparinux,DB00073
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Rituximab.,Astaxanthin,DB00073
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Rituximab.,Apixaban,DB00073
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Rituximab.,Otamixaban,DB00073
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Rituximab.,Amediplase,DB00073
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Rituximab.,Dabigatran etexilate,DB00073
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Rituximab.,Danaparoid,DB00073
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Rituximab.,Dalteparin,DB00073
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Rituximab.,Tinzaparin,DB00073
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Rituximab.,(R)-warfarin,DB00073
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Rituximab.,Ethyl biscoumacetate,DB00073
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Rituximab.,Nadroparin,DB00073
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Rituximab.,Ditazole,DB00073
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Rituximab.,Edoxaban,DB00073
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Rituximab.,Potassium citrate,DB00073
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Rituximab.,Sodium citrate,DB00073
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Rituximab.,Dextran,DB00073
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Rituximab.,Bemiparin,DB00073
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Rituximab.,Reviparin,DB00073
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Rituximab.,Parnaparin,DB00073
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Rituximab.,Certoparin,DB00073
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Rituximab.,Desirudin,DB00073
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Rituximab.,Zinc citrate,DB00073
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Rituximab.,Antithrombin Alfa,DB00073
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Rituximab.,Protein C,DB00073
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Rituximab.,Antithrombin III human,DB00073
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Rituximab.,Letaxaban,DB00073
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Rituximab.,Darexaban,DB00073
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Rituximab.,Betrixaban,DB00073
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Rituximab.,Nafamostat,DB00073
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Rituximab.,Monteplase,DB00073
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Rituximab.,Gabexate,DB00073
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Rituximab.,Fluindione,DB00073
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Rituximab.,Protein S human,DB00073
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Rituximab.,Brinase,DB00073
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Rituximab.,Clorindione,DB00073
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Rituximab.,Diphenadione,DB00073
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Rituximab.,Tioclomarol,DB00073
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Rituximab.,Melagatran,DB00073
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Rituximab.,Saruplase,DB00073
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Rituximab.,(S)-Warfarin,DB00073
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Rituximab.,Edetate calcium disodium anhydrous,DB00073
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Rituximab.,Dabigatran,DB00073
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Rituximab.,Methyclothiazide,DB00073
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Rituximab.,Benzthiazide,DB00073
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Rituximab.,Mebutizide,DB00073
DB00515,Rituximab may increase the nephrotoxic activities of Cisplatin.,Cisplatin,DB00073
DB09042,The risk or severity of myelosuppression can be increased when Rituximab is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00073
DB00091,Rituximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00073
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.,Cyanocobalamin,DB00073
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Rituximab.,Allopurinol,DB00073
DB05676,The therapeutic efficacy of Apremilast can be decreased when used in combination with Rituximab.,Apremilast,DB00073
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Rituximab.","Ebola Zaire vaccine (live, attenuated)",DB00073
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Rituximab.,Magnesium,DB00073
DB01601,The serum concentration of Rituximab can be increased when it is combined with Lopinavir.,Lopinavir,DB00073
DB12530,The risk or severity of infection can be increased when Rituximab is combined with Inebilizumab.,Inebilizumab,DB00073
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.,Denosumab,DB00074
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Basiliximab.,Etanercept,DB00074
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab.,Peginterferon alfa-2a,DB00074
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Basiliximab.,Interferon alfa-n1,DB00074
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Basiliximab.,Interferon alfa-n3,DB00074
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Basiliximab.,Peginterferon alfa-2b,DB00074
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Basiliximab.,Anakinra,DB00074
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Basiliximab.,Interferon gamma-1b,DB00074
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Basiliximab.","Interferon alfa-2a, Recombinant",DB00074
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Basiliximab.,Aldesleukin,DB00074
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Basiliximab.,Adalimumab,DB00074
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.,Gemtuzumab ozogamicin,DB00074
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.,Pegaspargase,DB00074
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.,Infliximab,DB00074
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.,Interferon beta-1b,DB00074
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.,Interferon alfacon-1,DB00074
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.,Rituximab,DB00074
DB00075,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.,Muromonab,DB00074
DB00078,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00074
DB00081,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.,Tositumomab,DB00074
DB00087,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.,Alemtuzumab,DB00074
DB00092,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.,Alefacept,DB00074
DB00095,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.,Efalizumab,DB00074
DB00098,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00074
DB00105,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00074
DB00111,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.,Daclizumab,DB00074
DB00112,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.,Bevacizumab,DB00074
DB00120,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.,Phenylalanine,DB00074
DB00180,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flunisolide.,Flunisolide,DB00074
DB00188,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bortezomib.,Bortezomib,DB00074
DB00242,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cladribine.,Cladribine,DB00074
DB00262,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine.,Carmustine,DB00074
DB00276,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amsacrine.,Amsacrine,DB00074
DB00290,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleomycin.,Bleomycin,DB00074
DB00291,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chlorambucil.,Chlorambucil,DB00074
DB00293,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raltitrexed.,Raltitrexed,DB00074
DB00305,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitomycin.,Mitomycin,DB00074
DB00307,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene.,Bexarotene,DB00074
DB00309,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vindesine.,Vindesine,DB00074
DB00322,The risk or severity of adverse effects can be increased when Basiliximab is combined with Floxuridine.,Floxuridine,DB00074
DB00328,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indomethacin.,Indomethacin,DB00074
DB00352,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tioguanine.,Tioguanine,DB00074
DB00361,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinorelbine.,Vinorelbine,DB00074
DB00380,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane.,Dexrazoxane,DB00074
DB00394,The risk or severity of adverse effects can be increased when Basiliximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00074
DB00398,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sorafenib.,Sorafenib,DB00074
DB00428,The risk or severity of adverse effects can be increased when Basiliximab is combined with Streptozocin.,Streptozocin,DB00074
DB00432,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trifluridine.,Trifluridine,DB00074
DB00441,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gemcitabine.,Gemcitabine,DB00074
DB00443,The risk or severity of adverse effects can be increased when Basiliximab is combined with Betamethasone.,Betamethasone,DB00074
DB00444,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teniposide.,Teniposide,DB00074
DB00445,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epirubicin.,Epirubicin,DB00074
DB00446,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chloramphenicol.,Chloramphenicol,DB00074
DB00480,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lenalidomide.,Lenalidomide,DB00074
DB00488,The risk or severity of adverse effects can be increased when Basiliximab is combined with Altretamine.,Altretamine,DB00074
DB00495,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zidovudine.,Zidovudine,DB00074
DB00515,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cisplatin.,Cisplatin,DB00074
DB00526,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin.,Oxaliplatin,DB00074
DB00531,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclophosphamide.,Cyclophosphamide,DB00074
DB00541,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vincristine.,Vincristine,DB00074
DB00544,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluorouracil.,Fluorouracil,DB00074
DB00550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil.,Propylthiouracil,DB00074
DB00552,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pentostatin.,Pentostatin,DB00074
DB00563,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methotrexate.,Methotrexate,DB00074
DB00564,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carbamazepine.,Carbamazepine,DB00074
DB00570,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinblastine.,Vinblastine,DB00074
DB00588,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone propionate.,Fluticasone propionate,DB00074
DB00591,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00074
DB00601,The risk or severity of adverse effects can be increased when Basiliximab is combined with Linezolid.,Linezolid,DB00074
DB00619,The risk or severity of adverse effects can be increased when Basiliximab is combined with Imatinib.,Imatinib,DB00074
DB00620,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triamcinolone.,Triamcinolone,DB00074
DB00631,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clofarabine.,Clofarabine,DB00074
DB00635,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisone.,Prednisone,DB00074
DB00642,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pemetrexed.,Pemetrexed,DB00074
DB00687,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludrocortisone.,Fludrocortisone,DB00074
DB00688,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00074
DB00694,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.,Daunorubicin,DB00074
DB00755,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tretinoin.,Tretinoin,DB00074
DB00762,The risk or severity of adverse effects can be increased when Basiliximab is combined with Irinotecan.,Irinotecan,DB00074
DB00763,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methimazole.,Methimazole,DB00074
DB00764,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone.,Mometasone,DB00074
DB00773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etoposide.,Etoposide,DB00074
DB00795,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulfasalazine.,Sulfasalazine,DB00074
DB00851,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacarbazine.,Dacarbazine,DB00074
DB00853,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temozolomide.,Temozolomide,DB00074
DB00859,The risk or severity of adverse effects can be increased when Basiliximab is combined with Penicillamine.,Penicillamine,DB00074
DB00860,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisolone.,Prednisolone,DB00074
DB00877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirolimus.,Sirolimus,DB00074
DB00888,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mechlorethamine.,Mechlorethamine,DB00074
DB00928,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azacitidine.,Azacitidine,DB00074
DB00958,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin.,Carboplatin,DB00074
DB00959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methylprednisolone.,Methylprednisolone,DB00074
DB00970,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dactinomycin.,Dactinomycin,DB00074
DB00987,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.,Cytarabine,DB00074
DB00993,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azathioprine.,Azathioprine,DB00074
DB00997,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxorubicin.,Doxorubicin,DB00074
DB01005,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxyurea.,Hydroxyurea,DB00074
DB01008,The risk or severity of adverse effects can be increased when Basiliximab is combined with Busulfan.,Busulfan,DB00074
DB01024,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolic acid.,Mycophenolic acid,DB00074
DB01030,The risk or severity of adverse effects can be increased when Basiliximab is combined with Topotecan.,Topotecan,DB00074
DB01033,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mercaptopurine.,Mercaptopurine,DB00074
DB01041,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thalidomide.,Thalidomide,DB00074
DB01042,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melphalan.,Melphalan,DB00074
DB01073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludarabine.,Fludarabine,DB00074
DB01099,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flucytosine.,Flucytosine,DB00074
DB01101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capecitabine.,Capecitabine,DB00074
DB01108,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trilostane.,Trilostane,DB00074
DB01168,The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine.,Procarbazine,DB00074
DB01169,The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide.,Arsenic trioxide,DB00074
DB01177,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarubicin.,Idarubicin,DB00074
DB01181,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ifosfamide.,Ifosfamide,DB00074
DB01196,The risk or severity of adverse effects can be increased when Basiliximab is combined with Estramustine.,Estramustine,DB00074
DB01204,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitoxantrone.,Mitoxantrone,DB00074
DB01206,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lomustine.,Lomustine,DB00074
DB01222,The risk or severity of adverse effects can be increased when Basiliximab is combined with Budesonide.,Budesonide,DB00074
DB01229,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paclitaxel.,Paclitaxel,DB00074
DB01234,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone.,Dexamethasone,DB00074
DB01248,The risk or severity of adverse effects can be increased when Basiliximab is combined with Docetaxel.,Docetaxel,DB00074
DB01254,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dasatinib.,Dasatinib,DB00074
DB01257,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eculizumab.,Eculizumab,DB00074
DB01262,The risk or severity of adverse effects can be increased when Basiliximab is combined with Decitabine.,Decitabine,DB00074
DB01268,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sunitinib.,Sunitinib,DB00074
DB01280,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nelarabine.,Nelarabine,DB00074
DB01281,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abatacept.,Abatacept,DB00074
DB01285,The risk or severity of adverse effects can be increased when Basiliximab is combined with Corticotropin.,Corticotropin,DB00074
DB01380,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortisone acetate.,Cortisone acetate,DB00074
DB01384,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paramethasone.,Paramethasone,DB00074
DB01394,The risk or severity of adverse effects can be increased when Basiliximab is combined with Colchicine.,Colchicine,DB00074
DB01410,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ciclesonide.,Ciclesonide,DB00074
DB01423,The risk or severity of adverse effects can be increased when Basiliximab is combined with Stepronin.,Stepronin,DB00074
DB01590,The risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus.,Everolimus,DB00074
DB01611,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00074
DB01816,The risk or severity of adverse effects can be increased when Basiliximab is combined with Castanospermine.,Castanospermine,DB00074
DB02546,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vorinostat.,Vorinostat,DB00074
DB02806,The risk or severity of adverse effects can be increased when Basiliximab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00074
DB03523,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brequinar.,Brequinar,DB00074
DB04572,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thiotepa.,Thiotepa,DB00074
DB04630,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aldosterone.,Aldosterone,DB00074
DB04845,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixabepilone.,Ixabepilone,DB00074
DB04868,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nilotinib.,Nilotinib,DB00074
DB04951,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirfenidone.,Pirfenidone,DB00074
DB04956,The risk or severity of adverse effects can be increased when Basiliximab is combined with Afelimomab.,Afelimomab,DB00074
DB05015,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belinostat.,Belinostat,DB00074
DB05109,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trabectedin.,Trabectedin,DB00074
DB05258,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa.,Interferon alfa,DB00074
DB05259,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glatiramer.,Glatiramer,DB00074
DB05260,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gallium nitrate.,Gallium nitrate,DB00074
DB05459,The risk or severity of adverse effects can be increased when Basiliximab is combined with Briakinumab.,Briakinumab,DB00074
DB05472,The risk or severity of adverse effects can be increased when Basiliximab is combined with omega interferon.,omega interferon,DB00074
DB05676,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apremilast.,Apremilast,DB00074
DB05773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00074
DB06168,The risk or severity of adverse effects can be increased when Basiliximab is combined with Canakinumab.,Canakinumab,DB00074
DB06273,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tocilizumab.,Tocilizumab,DB00074
DB06287,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temsirolimus.,Temsirolimus,DB00074
DB06372,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilonacept.,Rilonacept,DB00074
DB06589,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pazopanib.,Pazopanib,DB00074
DB06603,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panobinostat.,Panobinostat,DB00074
DB06612,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mepolizumab.,Mepolizumab,DB00074
DB06616,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bosutinib.,Bosutinib,DB00074
DB06662,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abetimus.,Abetimus,DB00074
DB06674,The risk or severity of adverse effects can be increased when Basiliximab is combined with Golimumab.,Golimumab,DB00074
DB06681,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belatacept.,Belatacept,DB00074
DB06769,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bendamustine.,Bendamustine,DB00074
DB06772,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cabazitaxel.,Cabazitaxel,DB00074
DB06813,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pralatrexate.,Pralatrexate,DB00074
DB08059,The risk or severity of adverse effects can be increased when Basiliximab is combined with Wortmannin.,Wortmannin,DB00074
DB08870,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00074
DB08871,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eribulin.,Eribulin,DB00074
DB08877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.,Ruxolitinib,DB00074
DB08879,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belimumab.,Belimumab,DB00074
DB08880,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teriflunomide.,Teriflunomide,DB00074
DB08889,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carfilzomib.,Carfilzomib,DB00074
DB08901,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponatinib.,Ponatinib,DB00074
DB08904,The risk or severity of adverse effects can be increased when Basiliximab is combined with Certolizumab pegol.,Certolizumab pegol,DB00074
DB08906,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone furoate.,Fluticasone furoate,DB00074
DB08908,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00074
DB08910,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.,Pomalidomide,DB00074
DB08935,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obinutuzumab.,Obinutuzumab,DB00074
DB08970,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednidene.,Fluprednidene,DB00074
DB08971,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortolone.,Fluocortolone,DB00074
DB09029,The risk or severity of adverse effects can be increased when Basiliximab is combined with Secukinumab.,Secukinumab,DB00074
DB09033,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vedolizumab.,Vedolizumab,DB00074
DB09036,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siltuximab.,Siltuximab,DB00074
DB09052,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blinatumomab.,Blinatumomab,DB00074
DB09053,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibrutinib.,Ibrutinib,DB00074
DB09054,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib.,Idelalisib,DB00074
DB09073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palbociclib.,Palbociclib,DB00074
DB09074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaparib.,Olaparib,DB00074
DB09077,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dinutuximab.,Dinutuximab,DB00074
DB09082,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vilanterol.,Vilanterol,DB00074
DB09091,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tixocortol.,Tixocortol,DB00074
DB09122,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00074
DB09312,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00074
DB09378,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednisolone.,Fluprednisolone,DB00074
DB09383,The risk or severity of adverse effects can be increased when Basiliximab is combined with Meprednisone.,Meprednisone,DB00074
DB11466,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tepoxalin.,Tepoxalin,DB00074
DB11487,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00074
DB11529,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melengestrol.,Melengestrol,DB00074
DB11569,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixekizumab.,Ixekizumab,DB00074
DB11580,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ravulizumab.,Ravulizumab,DB00074
DB11616,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirarubicin.,Pirarubicin,DB00074
DB11693,The risk or severity of adverse effects can be increased when Basiliximab is combined with Voclosporin.,Voclosporin,DB00074
DB11708,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peficitinib.,Peficitinib,DB00074
DB11750,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clobetasol.,Clobetasol,DB00074
DB11767,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sarilumab.,Sarilumab,DB00074
DB11776,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brodalumab.,Brodalumab,DB00074
DB11803,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirukumab.,Sirukumab,DB00074
DB11817,The risk or severity of adverse effects can be increased when Basiliximab is combined with Baricitinib.,Baricitinib,DB00074
DB11834,The risk or severity of adverse effects can be increased when Basiliximab is combined with Guselkumab.,Guselkumab,DB00074
DB11921,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deflazacort.,Deflazacort,DB00074
DB12025,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triptolide.,Triptolide,DB00074
DB12371,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siponimod.,Siponimod,DB00074
DB12612,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanimod.,Ozanimod,DB00074
DB12617,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mizoribine.,Mizoribine,DB00074
DB12692,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gusperimus.,Gusperimus,DB00074
DB12814,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00074
DB12902,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trofosfamide.,Trofosfamide,DB00074
DB12947,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxifluridine.,Doxifluridine,DB00074
DB12991,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deoxyspergualin.,Deoxyspergualin,DB00074
DB12996,The risk or severity of adverse effects can be increased when Basiliximab is combined with Acteoside.,Acteoside,DB00074
DB13003,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortivazol.,Cortivazol,DB00074
DB13014,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hypericin.,Hypericin,DB00074
DB13068,The risk or severity of adverse effects can be increased when Basiliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00074
DB13208,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednylidene.,Prednylidene,DB00074
DB13223,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortin.,Fluocortin,DB00074
DB13241,The risk or severity of adverse effects can be increased when Basiliximab is combined with Begelomab.,Begelomab,DB00074
DB13491,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluperolone.,Fluperolone,DB00074
DB13664,The risk or severity of adverse effects can be increased when Basiliximab is combined with Formocortal.,Formocortal,DB00074
DB13728,The risk or severity of adverse effects can be increased when Basiliximab is combined with Halometasone.,Halometasone,DB00074
DB13843,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cloprednol.,Cloprednol,DB00074
DB13856,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluclorolone.,Fluclorolone,DB00074
DB13867,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone.,Fluticasone,DB00074
DB14066,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetrandrine.,Tetrandrine,DB00074
DB14219,The risk or severity of adverse effects can be increased when Basiliximab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00074
DB14512,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone furoate.,Mometasone furoate,DB00074
DB14538,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00074
DB14539,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00074
DB14545,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00074
DB14724,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emapalumab.,Emapalumab,DB00074
DB14762,The risk or severity of adverse effects can be increased when Basiliximab is combined with Risankizumab.,Risankizumab,DB00074
DB14919,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozanolixizumab.,Rozanolixizumab,DB00074
DB15253,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleselumab.,Bleselumab,DB00074
DB00108,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.,Natalizumab,DB00074
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.,Pimecrolimus,DB00074
DB01656,Roflumilast may increase the immunosuppressive activities of Basiliximab.,Roflumilast,DB00074
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.,Sipuleucel-T,DB00074
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Basiliximab.,Sulfamethoxazole,DB00074
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Basiliximab.,Diethylstilbestrol,DB00074
DB00269,Chlorotrianisene may increase the thrombogenic activities of Basiliximab.,Chlorotrianisene,DB00074
DB00286,Conjugated estrogens may increase the thrombogenic activities of Basiliximab.,Conjugated estrogens,DB00074
DB00655,Estrone may increase the thrombogenic activities of Basiliximab.,Estrone,DB00074
DB00783,Estradiol may increase the thrombogenic activities of Basiliximab.,Estradiol,DB00074
DB00890,Dienestrol may increase the thrombogenic activities of Basiliximab.,Dienestrol,DB00074
DB00977,Ethinylestradiol may increase the thrombogenic activities of Basiliximab.,Ethinylestradiol,DB00074
DB01357,Mestranol may increase the thrombogenic activities of Basiliximab.,Mestranol,DB00074
DB04573,Estriol may increase the thrombogenic activities of Basiliximab.,Estriol,DB00074
DB04574,Estrone sulfate may increase the thrombogenic activities of Basiliximab.,Estrone sulfate,DB00074
DB04575,Quinestrol may increase the thrombogenic activities of Basiliximab.,Quinestrol,DB00074
DB07931,Hexestrol may increase the thrombogenic activities of Basiliximab.,Hexestrol,DB00074
DB09070,Tibolone may increase the thrombogenic activities of Basiliximab.,Tibolone,DB00074
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Basiliximab.","Synthetic Conjugated Estrogens, A",DB00074
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Basiliximab.","Synthetic Conjugated Estrogens, B",DB00074
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Basiliximab.,Polyestradiol phosphate,DB00074
DB09381,Esterified estrogens may increase the thrombogenic activities of Basiliximab.,Esterified estrogens,DB00074
DB11478,Zeranol may increase the thrombogenic activities of Basiliximab.,Zeranol,DB00074
DB11674,Equol may increase the thrombogenic activities of Basiliximab.,Equol,DB00074
DB12487,Promestriene may increase the thrombogenic activities of Basiliximab.,Promestriene,DB00074
DB13143,Methallenestril may increase the thrombogenic activities of Basiliximab.,Methallenestril,DB00074
DB13386,Epimestrol may increase the thrombogenic activities of Basiliximab.,Epimestrol,DB00074
DB13418,Moxestrol may increase the thrombogenic activities of Basiliximab.,Moxestrol,DB00074
DB13952,Estradiol acetate may increase the thrombogenic activities of Basiliximab.,Estradiol acetate,DB00074
DB13953,Estradiol benzoate may increase the thrombogenic activities of Basiliximab.,Estradiol benzoate,DB00074
DB13954,Estradiol cypionate may increase the thrombogenic activities of Basiliximab.,Estradiol cypionate,DB00074
DB13956,Estradiol valerate may increase the thrombogenic activities of Basiliximab.,Estradiol valerate,DB00074
DB15334,Biochanin A may increase the thrombogenic activities of Basiliximab.,Biochanin A,DB00074
DB15335,Formononetin may increase the thrombogenic activities of Basiliximab.,Formononetin,DB00074
DB01097,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.,Leflunomide,DB00074
DB08895,Basiliximab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00074
DB00072,Trastuzumab may increase the neutropenic activities of Basiliximab.,Trastuzumab,DB00074
DB08868,Basiliximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00074
DB00864,Tacrolimus may increase the immunosuppressive activities of Basiliximab.,Tacrolimus,DB00074
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Basiliximab.,G17DT,DB00074
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Basiliximab.,PEV3A,DB00074
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Basiliximab.,INGN 225,DB00074
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Basiliximab.,Rindopepimut,DB00074
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Basiliximab.,SRP 299,DB00074
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Basiliximab.,GI-5005,DB00074
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Basiliximab.,Vitespen,DB00074
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Basiliximab.,TG4010,DB00074
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Basiliximab.,Anthrax immune globulin human,DB00074
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Basiliximab.","Rabies virus inactivated antigen, B",DB00074
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00074
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Basiliximab.,Rotavirus vaccine,DB00074
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Basiliximab.","Rabies virus inactivated antigen, A",DB00074
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00074
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00074
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00074
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00074
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00074
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00074
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Basiliximab.,Typhoid Vi polysaccharide vaccine,DB00074
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.,Hepatitis A Vaccine,DB00074
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00074
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00074
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00074
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00074
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00074
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Basiliximab.,Human rabies virus immune globulin,DB00074
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.,Hepatitis B Vaccine (Recombinant),DB00074
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Basiliximab.,Tecemotide,DB00074
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Basiliximab.,Typhoid vaccine,DB00074
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00074
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00074
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00074
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00074
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Basiliximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00074
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00074
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00074
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Basiliximab.,Vaccinia virus strain new york city board of health live antigen,DB00074
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Basiliximab.,Pertussis vaccine,DB00074
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00074
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.,Varicella Zoster Vaccine (Recombinant),DB00074
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Basiliximab.,Modified vaccinia ankara,DB00074
DB11988,Ocrelizumab may increase the immunosuppressive activities of Basiliximab.,Ocrelizumab,DB00074
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Basiliximab.,Rubella virus vaccine,DB00074
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Basiliximab.,Varicella Zoster Vaccine (Live/attenuated),DB00074
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain tice live antigen,DB00074
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain connaught live antigen,DB00074
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Basiliximab.,Yellow Fever Vaccine,DB00074
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Basiliximab.,Anthrax vaccine,DB00074
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Basiliximab.,Typhoid Vaccine Live,DB00074
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00074
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Basiliximab.,BCG vaccine,DB00074
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Basiliximab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00074
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Basiliximab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00074
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Basiliximab.,Adenovirus type 7 vaccine live,DB00074
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.,Cetuximab,DB00074
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.,Human immunoglobulin G,DB00074
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Basiliximab.,Omalizumab,DB00074
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Basiliximab.,Abciximab,DB00074
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.,Indium In-111 satumomab pendetide,DB00074
DB00076,The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00074
DB00089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.,Capromab pendetide,DB00074
DB00110,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.,Palivizumab,DB00074
DB00113,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00074
DB01269,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panitumumab.,Panitumumab,DB00074
DB01270,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ranibizumab.,Ranibizumab,DB00074
DB04901,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galiximab.,Galiximab,DB00074
DB04949,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pexelizumab.,Pexelizumab,DB00074
DB04958,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epratuzumab.,Epratuzumab,DB00074
DB04962,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bectumomab.,Bectumomab,DB00074
DB04964,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oregovomab.,Oregovomab,DB00074
DB04988,The risk or severity of adverse effects can be increased when Basiliximab is combined with IGN311.,IGN311,DB00074
DB05006,The risk or severity of adverse effects can be increased when Basiliximab is combined with Adecatumumab.,Adecatumumab,DB00074
DB05097,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab.,Labetuzumab,DB00074
DB05101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Matuzumab.,Matuzumab,DB00074
DB05111,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fontolizumab.,Fontolizumab,DB00074
DB05136,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bavituximab.,Bavituximab,DB00074
DB05139,The risk or severity of adverse effects can be increased when Basiliximab is combined with CR002.,CR002,DB00074
DB05209,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozrolimupab.,Rozrolimupab,DB00074
DB05304,The risk or severity of adverse effects can be increased when Basiliximab is combined with Girentuximab.,Girentuximab,DB00074
DB05336,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obiltoxaximab.,Obiltoxaximab,DB00074
DB05405,The risk or severity of adverse effects can be increased when Basiliximab is combined with XTL-001.,XTL-001,DB00074
DB05437,The risk or severity of adverse effects can be increased when Basiliximab is combined with NAV 1800.,NAV 1800,DB00074
DB05496,The risk or severity of adverse effects can be increased when Basiliximab is combined with Otelixizumab.,Otelixizumab,DB00074
DB05545,The risk or severity of adverse effects can be increased when Basiliximab is combined with AMG 108.,AMG 108,DB00074
DB05550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Iratumumab.,Iratumumab,DB00074
DB05555,The risk or severity of adverse effects can be increased when Basiliximab is combined with Enokizumab.,Enokizumab,DB00074
DB05578,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ramucirumab.,Ramucirumab,DB00074
DB05595,The risk or severity of adverse effects can be increased when Basiliximab is combined with Farletuzumab.,Farletuzumab,DB00074
DB05656,The risk or severity of adverse effects can be increased when Basiliximab is combined with Veltuzumab.,Veltuzumab,DB00074
DB05793,The risk or severity of adverse effects can be increased when Basiliximab is combined with PRO-542.,PRO-542,DB00074
DB05797,The risk or severity of adverse effects can be increased when Basiliximab is combined with TNX-901.,TNX-901,DB00074
DB05889,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00074
DB05892,The risk or severity of adverse effects can be increased when Basiliximab is combined with RI 624.,RI 624,DB00074
DB05915,The risk or severity of adverse effects can be increased when Basiliximab is combined with MYO-029.,MYO-029,DB00074
DB05916,The risk or severity of adverse effects can be increased when Basiliximab is combined with CT-011.,CT-011,DB00074
DB05941,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leronlimab.,Leronlimab,DB00074
DB05996,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00074
DB06043,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaratumab.,Olaratumab,DB00074
DB06049,The risk or severity of adverse effects can be increased when Basiliximab is combined with IPH 2101.,IPH 2101,DB00074
DB06050,The risk or severity of adverse effects can be increased when Basiliximab is combined with TB-402.,TB-402,DB00074
DB06081,The risk or severity of adverse effects can be increased when Basiliximab is combined with Caplacizumab.,Caplacizumab,DB00074
DB06101,The risk or severity of adverse effects can be increased when Basiliximab is combined with IMC-1C11.,IMC-1C11,DB00074
DB06116,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eldelumab.,Eldelumab,DB00074
DB06162,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumiliximab.,Lumiliximab,DB00074
DB06186,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipilimumab.,Ipilimumab,DB00074
DB06192,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nimotuzumab.,Nimotuzumab,DB00074
DB06241,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clenoliximab.,Clenoliximab,DB00074
DB06304,The risk or severity of adverse effects can be increased when Basiliximab is combined with BIIB015.,BIIB015,DB00074
DB06305,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sonepcizumab.,Sonepcizumab,DB00074
DB06310,The risk or severity of adverse effects can be increased when Basiliximab is combined with Motavizumab.,Motavizumab,DB00074
DB06317,The risk or severity of adverse effects can be increased when Basiliximab is combined with Elotuzumab.,Elotuzumab,DB00074
DB06318,The risk or severity of adverse effects can be increased when Basiliximab is combined with AVE9633.,AVE9633,DB00074
DB06322,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carotuximab.,Carotuximab,DB00074
DB06324,The risk or severity of adverse effects can be increased when Basiliximab is combined with XmAb 2513.,XmAb 2513,DB00074
DB06342,The risk or severity of adverse effects can be increased when Basiliximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00074
DB06343,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teprotumumab.,Teprotumumab,DB00074
DB06360,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lucatumumab.,Lucatumumab,DB00074
DB06366,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pertuzumab.,Pertuzumab,DB00074
DB06371,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siplizumab.,Siplizumab,DB00074
DB06467,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apolizumab.,Apolizumab,DB00074
DB06474,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sibrotuzumab.,Sibrotuzumab,DB00074
DB06550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bivatuzumab.,Bivatuzumab,DB00074
DB06557,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lerdelimumab.,Lerdelimumab,DB00074
DB06599,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lexatumumab.,Lexatumumab,DB00074
DB06602,The risk or severity of adverse effects can be increased when Basiliximab is combined with Reslizumab.,Reslizumab,DB00074
DB06606,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teplizumab.,Teplizumab,DB00074
DB06607,The risk or severity of adverse effects can be increased when Basiliximab is combined with Catumaxomab.,Catumaxomab,DB00074
DB06647,The risk or severity of adverse effects can be increased when Basiliximab is combined with Volociximab.,Volociximab,DB00074
DB06650,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ofatumumab.,Ofatumumab,DB00074
DB08902,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raxibacumab.,Raxibacumab,DB00074
DB09035,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nivolumab.,Nivolumab,DB00074
DB09037,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pembrolizumab.,Pembrolizumab,DB00074
DB09045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dulaglutide.,Dulaglutide,DB00074
DB09105,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asfotase alfa.,Asfotase alfa,DB00074
DB09264,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarucizumab.,Idarucizumab,DB00074
DB09302,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alirocumab.,Alirocumab,DB00074
DB09303,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evolocumab.,Evolocumab,DB00074
DB09331,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daratumumab.,Daratumumab,DB00074
DB09559,The risk or severity of adverse effects can be increased when Basiliximab is combined with Necitumumab.,Necitumumab,DB00074
DB11595,The risk or severity of adverse effects can be increased when Basiliximab is combined with Atezolizumab.,Atezolizumab,DB00074
DB11604,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00074
DB11608,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00074
DB11621,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00074
DB11646,The risk or severity of adverse effects can be increased when Basiliximab is combined with Conatumumab.,Conatumumab,DB00074
DB11657,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tabalumab.,Tabalumab,DB00074
DB11680,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ficlatuzumab.,Ficlatuzumab,DB00074
DB11685,The risk or severity of adverse effects can be increased when Basiliximab is combined with Figitumumab.,Figitumumab,DB00074
DB11714,The risk or severity of adverse effects can be increased when Basiliximab is combined with Durvalumab.,Durvalumab,DB00074
DB11715,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bapineuzumab.,Bapineuzumab,DB00074
DB11731,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00074
DB11746,The risk or severity of adverse effects can be increased when Basiliximab is combined with Onartuzumab.,Onartuzumab,DB00074
DB11756,The risk or severity of adverse effects can be increased when Basiliximab is combined with Solanezumab.,Solanezumab,DB00074
DB11771,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tremelimumab.,Tremelimumab,DB00074
DB11826,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lampalizumab.,Lampalizumab,DB00074
DB11840,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalotuzumab.,Dalotuzumab,DB00074
DB11849,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emibetuzumab.,Emibetuzumab,DB00074
DB11850,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ublituximab.,Ublituximab,DB00074
DB11856,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ligelizumab.,Ligelizumab,DB00074
DB11857,The risk or severity of adverse effects can be increased when Basiliximab is combined with Seribantumab.,Seribantumab,DB00074
DB11862,The risk or severity of adverse effects can be increased when Basiliximab is combined with Landogrozumab.,Landogrozumab,DB00074
DB11866,The risk or severity of adverse effects can be increased when Basiliximab is combined with Romosozumab.,Romosozumab,DB00074
DB11884,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00074
DB11914,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lebrikizumab.,Lebrikizumab,DB00074
DB11930,The risk or severity of adverse effects can be increased when Basiliximab is combined with Varlilumab.,Varlilumab,DB00074
DB11945,The risk or severity of adverse effects can be increased when Basiliximab is combined with Avelumab.,Avelumab,DB00074
DB11959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crenezumab.,Crenezumab,DB00074
DB11972,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilotumumab.,Rilotumumab,DB00074
DB11976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anifrolumab.,Anifrolumab,DB00074
DB12023,The risk or severity of adverse effects can be increased when Basiliximab is combined with Benralizumab.,Benralizumab,DB00074
DB12034,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gantenerumab.,Gantenerumab,DB00074
DB12053,The risk or severity of adverse effects can be increased when Basiliximab is combined with Visilizumab.,Visilizumab,DB00074
DB12077,The risk or severity of adverse effects can be increased when Basiliximab is combined with Urelumab.,Urelumab,DB00074
DB12089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00074
DB12090,The risk or severity of adverse effects can be increased when Basiliximab is combined with Patritumab.,Patritumab,DB00074
DB12102,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fulranumab.,Fulranumab,DB00074
DB12104,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tarextumab.,Tarextumab,DB00074
DB12118,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sotatercept.,Sotatercept,DB00074
DB12119,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gevokizumab.,Gevokizumab,DB00074
DB12142,The risk or severity of adverse effects can be increased when Basiliximab is combined with Duligotuzumab.,Duligotuzumab,DB00074
DB12152,The risk or severity of adverse effects can be increased when Basiliximab is combined with Simtuzumab.,Simtuzumab,DB00074
DB12157,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fasinumab.,Fasinumab,DB00074
DB12159,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dupilumab.,Dupilumab,DB00074
DB12169,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tralokinumab.,Tralokinumab,DB00074
DB12189,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etrolizumab.,Etrolizumab,DB00074
DB12202,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zalutumumab.,Zalutumumab,DB00074
DB12205,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ganitumab.,Ganitumab,DB00074
DB12213,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etaracizumab.,Etaracizumab,DB00074
DB12240,The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00074
DB12246,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inclacumab.,Inclacumab,DB00074
DB12250,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cixutumumab.,Cixutumumab,DB00074
DB12261,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ascrinvacumab.,Ascrinvacumab,DB00074
DB12274,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aducanumab.,Aducanumab,DB00074
DB12281,The risk or severity of adverse effects can be increased when Basiliximab is combined with Luspatercept.,Luspatercept,DB00074
DB12296,The risk or severity of adverse effects can be increased when Basiliximab is combined with GS-5745.,GS-5745,DB00074
DB12317,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vanucizumab.,Vanucizumab,DB00074
DB12331,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00074
DB12335,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tanezumab.,Tanezumab,DB00074
DB12342,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ensituximab.,Ensituximab,DB00074
DB12344,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fezakinumab.,Fezakinumab,DB00074
DB12363,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dusigitumab.,Dusigitumab,DB00074
DB12396,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fresolimumab.,Fresolimumab,DB00074
DB12413,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00074
DB12456,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bococizumab.,Bococizumab,DB00074
DB12489,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00074
DB12498,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mogamulizumab.,Mogamulizumab,DB00074
DB12520,The risk or severity of adverse effects can be increased when Basiliximab is combined with Plozalizumab.,Plozalizumab,DB00074
DB12534,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mavrilimumab.,Mavrilimumab,DB00074
DB12560,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blosozumab.,Blosozumab,DB00074
DB12584,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimagrumab.,Bimagrumab,DB00074
DB12589,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacetuzumab.,Dacetuzumab,DB00074
DB12609,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tovetumab.,Tovetumab,DB00074
DB12683,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumretuzumab.,Lumretuzumab,DB00074
DB12698,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibalizumab.,Ibalizumab,DB00074
DB12701,The risk or severity of adverse effects can be increased when Basiliximab is combined with Intetumumab.,Intetumumab,DB00074
DB12718,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carlumab.,Carlumab,DB00074
DB12734,The risk or severity of adverse effects can be increased when Basiliximab is combined with Demcizumab.,Demcizumab,DB00074
DB12773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sifalimumab.,Sifalimumab,DB00074
DB12775,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abituzumab.,Abituzumab,DB00074
DB12797,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ecromeximab.,Ecromeximab,DB00074
DB12807,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00074
DB12815,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crotedumab.,Crotedumab,DB00074
DB12820,The risk or severity of adverse effects can be increased when Basiliximab is combined with Concizumab.,Concizumab,DB00074
DB12826,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab.,Depatuxizumab,DB00074
DB12844,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rontalizumab.,Rontalizumab,DB00074
DB12845,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amatuximab.,Amatuximab,DB00074
DB12849,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clazakizumab.,Clazakizumab,DB00074
DB12891,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanezumab.,Ozanezumab,DB00074
DB12893,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00074
DB12917,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimekizumab.,Bimekizumab,DB00074
DB12943,The risk or severity of adverse effects can be increased when Basiliximab is combined with Milatuzumab.,Milatuzumab,DB00074
DB12976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Robatumumab.,Robatumumab,DB00074
DB13017,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00074
DB13037,The risk or severity of adverse effects can be increased when Basiliximab is combined with Namilumab.,Namilumab,DB00074
DB13045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Racotumomab.,Racotumomab,DB00074
DB13073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tregalizumab.,Tregalizumab,DB00074
DB13127,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olokizumab.,Olokizumab,DB00074
DB13140,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bezlotoxumab.,Bezlotoxumab,DB00074
DB13375,The risk or severity of adverse effects can be increased when Basiliximab is combined with Edrecolomab.,Edrecolomab,DB00074
DB13535,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nebacumab.,Nebacumab,DB00074
DB13886,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00074
DB13923,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emicizumab.,Emicizumab,DB00074
DB13976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulesomab.,Sulesomab,DB00074
DB13979,The risk or severity of adverse effects can be increased when Basiliximab is combined with Besilesomab.,Besilesomab,DB00074
DB14012,The risk or severity of adverse effects can be increased when Basiliximab is combined with Burosumab.,Burosumab,DB00074
DB14039,The risk or severity of adverse effects can be increased when Basiliximab is combined with Erenumab.,Erenumab,DB00074
DB14040,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.,Eptinezumab,DB00074
DB14041,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fremanezumab.,Fremanezumab,DB00074
DB14042,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galcanezumab.,Galcanezumab,DB00074
DB14211,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fanolesomab.,Fanolesomab,DB00074
DB14580,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lecanemab.,Lecanemab,DB00074
DB14597,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lanadelumab.,Lanadelumab,DB00074
DB14707,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cemiplimab.,Cemiplimab,DB00074
DB14776,The risk or severity of adverse effects can be increased when Basiliximab is combined with Camrelizumab.,Camrelizumab,DB00074
DB14778,The risk or severity of adverse effects can be increased when Basiliximab is combined with Setrusumab.,Setrusumab,DB00074
DB14784,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gancotamab.,Gancotamab,DB00074
DB14809,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00074
DB14811,The risk or severity of adverse effects can be increased when Basiliximab is combined with Isatuximab.,Isatuximab,DB00074
DB14824,The risk or severity of adverse effects can be increased when Basiliximab is combined with Icrucumab.,Icrucumab,DB00074
DB14843,The risk or severity of adverse effects can be increased when Basiliximab is combined with Codrituzumab.,Codrituzumab,DB00074
DB14864,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brolucizumab.,Brolucizumab,DB00074
DB14871,The risk or severity of adverse effects can be increased when Basiliximab is combined with Xentuzumab.,Xentuzumab,DB00074
DB14877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lintuzumab.,Lintuzumab,DB00074
DB14891,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vobarilizumab.,Vobarilizumab,DB00074
DB14897,The risk or severity of adverse effects can be increased when Basiliximab is combined with Parsatuzumab.,Parsatuzumab,DB00074
DB14905,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emactuzumab.,Emactuzumab,DB00074
DB14907,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00074
DB14908,The risk or severity of adverse effects can be increased when Basiliximab is combined with Refanezumab.,Refanezumab,DB00074
DB14947,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bermekimab.,Bermekimab,DB00074
DB14952,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pamrevlumab.,Pamrevlumab,DB00074
DB14959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Opicinumab.,Opicinumab,DB00074
DB14962,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00074
DB14967,The risk or severity of adverse effects can be increased when Basiliximab is combined with Margetuximab.,Margetuximab,DB00074
DB14988,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalantercept.,Dalantercept,DB00074
DB14997,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pateclizumab.,Pateclizumab,DB00074
DB15014,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gremubamab.,Gremubamab,DB00074
DB15022,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apomab.,Apomab,DB00074
DB15044,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tafasitamab.,Tafasitamab,DB00074
DB15045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipafricept.,Ipafricept,DB00074
DB15076,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abrilumab.,Abrilumab,DB00074
DB15089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Frovocimab.,Frovocimab,DB00074
DB15090,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tezepelumab.,Tezepelumab,DB00074
DB15101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tigatuzumab.,Tigatuzumab,DB00074
DB15104,The risk or severity of adverse effects can be increased when Basiliximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00074
DB15113,The risk or severity of adverse effects can be increased when Basiliximab is combined with Utomilumab.,Utomilumab,DB00074
DB15118,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zolbetuximab.,Zolbetuximab,DB00074
DB15135,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponezumab.,Ponezumab,DB00074
DB15160,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asunercept.,Asunercept,DB00074
DB15172,The risk or severity of adverse effects can be increased when Basiliximab is combined with Suvratoxumab.,Suvratoxumab,DB00074
DB15225,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitazalimab.,Mitazalimab,DB00074
DB15252,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nemolizumab.,Nemolizumab,DB00074
DB15277,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gedivumab.,Gedivumab,DB00074
DB15336,The risk or severity of adverse effects can be increased when Basiliximab is combined with Valanafusp alfa.,Valanafusp alfa,DB00074
DB15349,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00074
DB15354,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evinacumab.,Evinacumab,DB00074
DB15363,The risk or severity of adverse effects can be increased when Basiliximab is combined with Istiratumab.,Istiratumab,DB00074
DB15383,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pidilizumab.,Pidilizumab,DB00074
DB15397,The risk or severity of adverse effects can be increased when Basiliximab is combined with GMA-161.,GMA-161,DB00074
DB15409,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00074
DB15415,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tomaralimab.,Tomaralimab,DB00074
DB15428,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vesencumab.,Vesencumab,DB00074
DB15432,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00074
DB15441,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lulizumab pegol.,Lulizumab pegol,DB00074
DB15443,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00074
DB15453,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00074
DB14004,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tildrakizumab.,Tildrakizumab,DB00074
DB05679,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ustekinumab.,Ustekinumab,DB00074
DB15559,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zenocutuzumab.,Zenocutuzumab,DB00074
DB00091,Basiliximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00074
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Basiliximab.","Ebola Zaire vaccine (live, attenuated)",DB00074
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Basiliximab.,Magnesium,DB00074
DB01601,The serum concentration of Basiliximab can be increased when it is combined with Lopinavir.,Lopinavir,DB00074
DB12530,The risk or severity of infection can be increased when Basiliximab is combined with Inebilizumab.,Inebilizumab,DB00074
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.,Denosumab,DB00075
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Muromonab.,Etanercept,DB00075
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Muromonab.,Peginterferon alfa-2a,DB00075
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Muromonab.,Interferon alfa-n1,DB00075
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Muromonab.,Interferon alfa-n3,DB00075
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Muromonab.,Peginterferon alfa-2b,DB00075
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Muromonab.,Anakinra,DB00075
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Muromonab.,Interferon gamma-1b,DB00075
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Muromonab.","Interferon alfa-2a, Recombinant",DB00075
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Muromonab.,Aldesleukin,DB00075
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Muromonab.,Adalimumab,DB00075
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.,Gemtuzumab ozogamicin,DB00075
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.,Pegaspargase,DB00075
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.,Infliximab,DB00075
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.,Interferon beta-1b,DB00075
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.,Interferon alfacon-1,DB00075
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.,Rituximab,DB00075
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.,Basiliximab,DB00075
DB00078,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00075
DB00081,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.,Tositumomab,DB00075
DB00087,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.,Alemtuzumab,DB00075
DB00092,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.,Alefacept,DB00075
DB00095,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.,Efalizumab,DB00075
DB00098,The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00075
DB00105,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00075
DB00111,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.,Daclizumab,DB00075
DB00112,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.,Bevacizumab,DB00075
DB00120,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.,Phenylalanine,DB00075
DB00180,The risk or severity of adverse effects can be increased when Muromonab is combined with Flunisolide.,Flunisolide,DB00075
DB00188,The risk or severity of adverse effects can be increased when Muromonab is combined with Bortezomib.,Bortezomib,DB00075
DB00242,The risk or severity of adverse effects can be increased when Muromonab is combined with Cladribine.,Cladribine,DB00075
DB00262,The risk or severity of adverse effects can be increased when Muromonab is combined with Carmustine.,Carmustine,DB00075
DB00276,The risk or severity of adverse effects can be increased when Muromonab is combined with Amsacrine.,Amsacrine,DB00075
DB00290,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleomycin.,Bleomycin,DB00075
DB00291,The risk or severity of adverse effects can be increased when Muromonab is combined with Chlorambucil.,Chlorambucil,DB00075
DB00293,The risk or severity of adverse effects can be increased when Muromonab is combined with Raltitrexed.,Raltitrexed,DB00075
DB00305,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitomycin.,Mitomycin,DB00075
DB00307,The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene.,Bexarotene,DB00075
DB00309,The risk or severity of adverse effects can be increased when Muromonab is combined with Vindesine.,Vindesine,DB00075
DB00322,The risk or severity of adverse effects can be increased when Muromonab is combined with Floxuridine.,Floxuridine,DB00075
DB00328,The risk or severity of adverse effects can be increased when Muromonab is combined with Indomethacin.,Indomethacin,DB00075
DB00352,The risk or severity of adverse effects can be increased when Muromonab is combined with Tioguanine.,Tioguanine,DB00075
DB00361,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinorelbine.,Vinorelbine,DB00075
DB00380,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane.,Dexrazoxane,DB00075
DB00394,The risk or severity of adverse effects can be increased when Muromonab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00075
DB00398,The risk or severity of adverse effects can be increased when Muromonab is combined with Sorafenib.,Sorafenib,DB00075
DB00428,The risk or severity of adverse effects can be increased when Muromonab is combined with Streptozocin.,Streptozocin,DB00075
DB00432,The risk or severity of adverse effects can be increased when Muromonab is combined with Trifluridine.,Trifluridine,DB00075
DB00441,The risk or severity of adverse effects can be increased when Muromonab is combined with Gemcitabine.,Gemcitabine,DB00075
DB00443,The risk or severity of adverse effects can be increased when Muromonab is combined with Betamethasone.,Betamethasone,DB00075
DB00444,The risk or severity of adverse effects can be increased when Muromonab is combined with Teniposide.,Teniposide,DB00075
DB00445,The risk or severity of adverse effects can be increased when Muromonab is combined with Epirubicin.,Epirubicin,DB00075
DB00446,The risk or severity of adverse effects can be increased when Muromonab is combined with Chloramphenicol.,Chloramphenicol,DB00075
DB00480,The risk or severity of adverse effects can be increased when Muromonab is combined with Lenalidomide.,Lenalidomide,DB00075
DB00488,The risk or severity of adverse effects can be increased when Muromonab is combined with Altretamine.,Altretamine,DB00075
DB00495,The risk or severity of adverse effects can be increased when Muromonab is combined with Zidovudine.,Zidovudine,DB00075
DB00515,The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.,Cisplatin,DB00075
DB00526,The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin.,Oxaliplatin,DB00075
DB00531,The risk or severity of adverse effects can be increased when Muromonab is combined with Cyclophosphamide.,Cyclophosphamide,DB00075
DB00541,The risk or severity of adverse effects can be increased when Muromonab is combined with Vincristine.,Vincristine,DB00075
DB00544,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil.,Fluorouracil,DB00075
DB00550,The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil.,Propylthiouracil,DB00075
DB00552,The risk or severity of adverse effects can be increased when Muromonab is combined with Pentostatin.,Pentostatin,DB00075
DB00563,The risk or severity of adverse effects can be increased when Muromonab is combined with Methotrexate.,Methotrexate,DB00075
DB00564,The risk or severity of adverse effects can be increased when Muromonab is combined with Carbamazepine.,Carbamazepine,DB00075
DB00570,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinblastine.,Vinblastine,DB00075
DB00588,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone propionate.,Fluticasone propionate,DB00075
DB00591,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00075
DB00601,The risk or severity of adverse effects can be increased when Muromonab is combined with Linezolid.,Linezolid,DB00075
DB00619,The risk or severity of adverse effects can be increased when Muromonab is combined with Imatinib.,Imatinib,DB00075
DB00620,The risk or severity of adverse effects can be increased when Muromonab is combined with Triamcinolone.,Triamcinolone,DB00075
DB00631,The risk or severity of adverse effects can be increased when Muromonab is combined with Clofarabine.,Clofarabine,DB00075
DB00635,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisone.,Prednisone,DB00075
DB00642,The risk or severity of adverse effects can be increased when Muromonab is combined with Pemetrexed.,Pemetrexed,DB00075
DB00687,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludrocortisone.,Fludrocortisone,DB00075
DB00688,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00075
DB00694,The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.,Daunorubicin,DB00075
DB00755,The risk or severity of adverse effects can be increased when Muromonab is combined with Tretinoin.,Tretinoin,DB00075
DB00762,The risk or severity of adverse effects can be increased when Muromonab is combined with Irinotecan.,Irinotecan,DB00075
DB00763,The risk or severity of adverse effects can be increased when Muromonab is combined with Methimazole.,Methimazole,DB00075
DB00764,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone.,Mometasone,DB00075
DB00773,The risk or severity of adverse effects can be increased when Muromonab is combined with Etoposide.,Etoposide,DB00075
DB00795,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulfasalazine.,Sulfasalazine,DB00075
DB00851,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacarbazine.,Dacarbazine,DB00075
DB00853,The risk or severity of adverse effects can be increased when Muromonab is combined with Temozolomide.,Temozolomide,DB00075
DB00859,The risk or severity of adverse effects can be increased when Muromonab is combined with Penicillamine.,Penicillamine,DB00075
DB00860,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisolone.,Prednisolone,DB00075
DB00877,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirolimus.,Sirolimus,DB00075
DB00888,The risk or severity of adverse effects can be increased when Muromonab is combined with Mechlorethamine.,Mechlorethamine,DB00075
DB00928,The risk or severity of adverse effects can be increased when Muromonab is combined with Azacitidine.,Azacitidine,DB00075
DB00958,The risk or severity of adverse effects can be increased when Muromonab is combined with Carboplatin.,Carboplatin,DB00075
DB00959,The risk or severity of adverse effects can be increased when Muromonab is combined with Methylprednisolone.,Methylprednisolone,DB00075
DB00970,The risk or severity of adverse effects can be increased when Muromonab is combined with Dactinomycin.,Dactinomycin,DB00075
DB00987,The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.,Cytarabine,DB00075
DB00993,The risk or severity of adverse effects can be increased when Muromonab is combined with Azathioprine.,Azathioprine,DB00075
DB00997,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxorubicin.,Doxorubicin,DB00075
DB01005,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxyurea.,Hydroxyurea,DB00075
DB01008,The risk or severity of adverse effects can be increased when Muromonab is combined with Busulfan.,Busulfan,DB00075
DB01024,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolic acid.,Mycophenolic acid,DB00075
DB01030,The risk or severity of adverse effects can be increased when Muromonab is combined with Topotecan.,Topotecan,DB00075
DB01033,The risk or severity of adverse effects can be increased when Muromonab is combined with Mercaptopurine.,Mercaptopurine,DB00075
DB01041,The risk or severity of adverse effects can be increased when Muromonab is combined with Thalidomide.,Thalidomide,DB00075
DB01042,The risk or severity of adverse effects can be increased when Muromonab is combined with Melphalan.,Melphalan,DB00075
DB01073,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludarabine.,Fludarabine,DB00075
DB01099,The risk or severity of adverse effects can be increased when Muromonab is combined with Flucytosine.,Flucytosine,DB00075
DB01101,The risk or severity of adverse effects can be increased when Muromonab is combined with Capecitabine.,Capecitabine,DB00075
DB01108,The risk or severity of adverse effects can be increased when Muromonab is combined with Trilostane.,Trilostane,DB00075
DB01168,The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine.,Procarbazine,DB00075
DB01169,The risk or severity of adverse effects can be increased when Muromonab is combined with Arsenic trioxide.,Arsenic trioxide,DB00075
DB01177,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarubicin.,Idarubicin,DB00075
DB01181,The risk or severity of adverse effects can be increased when Muromonab is combined with Ifosfamide.,Ifosfamide,DB00075
DB01196,The risk or severity of adverse effects can be increased when Muromonab is combined with Estramustine.,Estramustine,DB00075
DB01204,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitoxantrone.,Mitoxantrone,DB00075
DB01206,The risk or severity of adverse effects can be increased when Muromonab is combined with Lomustine.,Lomustine,DB00075
DB01222,The risk or severity of adverse effects can be increased when Muromonab is combined with Budesonide.,Budesonide,DB00075
DB01229,The risk or severity of adverse effects can be increased when Muromonab is combined with Paclitaxel.,Paclitaxel,DB00075
DB01234,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone.,Dexamethasone,DB00075
DB01248,The risk or severity of adverse effects can be increased when Muromonab is combined with Docetaxel.,Docetaxel,DB00075
DB01254,The risk or severity of adverse effects can be increased when Muromonab is combined with Dasatinib.,Dasatinib,DB00075
DB01257,The risk or severity of adverse effects can be increased when Muromonab is combined with Eculizumab.,Eculizumab,DB00075
DB01262,The risk or severity of adverse effects can be increased when Muromonab is combined with Decitabine.,Decitabine,DB00075
DB01268,The risk or severity of adverse effects can be increased when Muromonab is combined with Sunitinib.,Sunitinib,DB00075
DB01280,The risk or severity of adverse effects can be increased when Muromonab is combined with Nelarabine.,Nelarabine,DB00075
DB01281,The risk or severity of adverse effects can be increased when Muromonab is combined with Abatacept.,Abatacept,DB00075
DB01285,The risk or severity of adverse effects can be increased when Muromonab is combined with Corticotropin.,Corticotropin,DB00075
DB01380,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortisone acetate.,Cortisone acetate,DB00075
DB01384,The risk or severity of adverse effects can be increased when Muromonab is combined with Paramethasone.,Paramethasone,DB00075
DB01394,The risk or severity of adverse effects can be increased when Muromonab is combined with Colchicine.,Colchicine,DB00075
DB01410,The risk or severity of adverse effects can be increased when Muromonab is combined with Ciclesonide.,Ciclesonide,DB00075
DB01423,The risk or severity of adverse effects can be increased when Muromonab is combined with Stepronin.,Stepronin,DB00075
DB01590,The risk or severity of adverse effects can be increased when Muromonab is combined with Everolimus.,Everolimus,DB00075
DB01611,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00075
DB01816,The risk or severity of adverse effects can be increased when Muromonab is combined with Castanospermine.,Castanospermine,DB00075
DB02546,The risk or severity of adverse effects can be increased when Muromonab is combined with Vorinostat.,Vorinostat,DB00075
DB02806,The risk or severity of adverse effects can be increased when Muromonab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00075
DB03523,The risk or severity of adverse effects can be increased when Muromonab is combined with Brequinar.,Brequinar,DB00075
DB04572,The risk or severity of adverse effects can be increased when Muromonab is combined with Thiotepa.,Thiotepa,DB00075
DB04630,The risk or severity of adverse effects can be increased when Muromonab is combined with Aldosterone.,Aldosterone,DB00075
DB04845,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixabepilone.,Ixabepilone,DB00075
DB04868,The risk or severity of adverse effects can be increased when Muromonab is combined with Nilotinib.,Nilotinib,DB00075
DB04951,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirfenidone.,Pirfenidone,DB00075
DB04956,The risk or severity of adverse effects can be increased when Muromonab is combined with Afelimomab.,Afelimomab,DB00075
DB05015,The risk or severity of adverse effects can be increased when Muromonab is combined with Belinostat.,Belinostat,DB00075
DB05109,The risk or severity of adverse effects can be increased when Muromonab is combined with Trabectedin.,Trabectedin,DB00075
DB05258,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa.,Interferon alfa,DB00075
DB05259,The risk or severity of adverse effects can be increased when Muromonab is combined with Glatiramer.,Glatiramer,DB00075
DB05260,The risk or severity of adverse effects can be increased when Muromonab is combined with Gallium nitrate.,Gallium nitrate,DB00075
DB05459,The risk or severity of adverse effects can be increased when Muromonab is combined with Briakinumab.,Briakinumab,DB00075
DB05472,The risk or severity of adverse effects can be increased when Muromonab is combined with omega interferon.,omega interferon,DB00075
DB05676,The risk or severity of adverse effects can be increased when Muromonab is combined with Apremilast.,Apremilast,DB00075
DB05773,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00075
DB06168,The risk or severity of adverse effects can be increased when Muromonab is combined with Canakinumab.,Canakinumab,DB00075
DB06273,The risk or severity of adverse effects can be increased when Muromonab is combined with Tocilizumab.,Tocilizumab,DB00075
DB06287,The risk or severity of adverse effects can be increased when Muromonab is combined with Temsirolimus.,Temsirolimus,DB00075
DB06372,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilonacept.,Rilonacept,DB00075
DB06589,The risk or severity of adverse effects can be increased when Muromonab is combined with Pazopanib.,Pazopanib,DB00075
DB06603,The risk or severity of adverse effects can be increased when Muromonab is combined with Panobinostat.,Panobinostat,DB00075
DB06612,The risk or severity of adverse effects can be increased when Muromonab is combined with Mepolizumab.,Mepolizumab,DB00075
DB06616,The risk or severity of adverse effects can be increased when Muromonab is combined with Bosutinib.,Bosutinib,DB00075
DB06662,The risk or severity of adverse effects can be increased when Muromonab is combined with Abetimus.,Abetimus,DB00075
DB06674,The risk or severity of adverse effects can be increased when Muromonab is combined with Golimumab.,Golimumab,DB00075
DB06681,The risk or severity of adverse effects can be increased when Muromonab is combined with Belatacept.,Belatacept,DB00075
DB06769,The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine.,Bendamustine,DB00075
DB06772,The risk or severity of adverse effects can be increased when Muromonab is combined with Cabazitaxel.,Cabazitaxel,DB00075
DB06813,The risk or severity of adverse effects can be increased when Muromonab is combined with Pralatrexate.,Pralatrexate,DB00075
DB08059,The risk or severity of adverse effects can be increased when Muromonab is combined with Wortmannin.,Wortmannin,DB00075
DB08870,The risk or severity of adverse effects can be increased when Muromonab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00075
DB08871,The risk or severity of adverse effects can be increased when Muromonab is combined with Eribulin.,Eribulin,DB00075
DB08877,The risk or severity of adverse effects can be increased when Muromonab is combined with Ruxolitinib.,Ruxolitinib,DB00075
DB08879,The risk or severity of adverse effects can be increased when Muromonab is combined with Belimumab.,Belimumab,DB00075
DB08880,The risk or severity of adverse effects can be increased when Muromonab is combined with Teriflunomide.,Teriflunomide,DB00075
DB08889,The risk or severity of adverse effects can be increased when Muromonab is combined with Carfilzomib.,Carfilzomib,DB00075
DB08901,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponatinib.,Ponatinib,DB00075
DB08904,The risk or severity of adverse effects can be increased when Muromonab is combined with Certolizumab pegol.,Certolizumab pegol,DB00075
DB08906,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone furoate.,Fluticasone furoate,DB00075
DB08908,The risk or severity of adverse effects can be increased when Muromonab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00075
DB08910,The risk or severity of adverse effects can be increased when Muromonab is combined with Pomalidomide.,Pomalidomide,DB00075
DB08935,The risk or severity of adverse effects can be increased when Muromonab is combined with Obinutuzumab.,Obinutuzumab,DB00075
DB08970,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednidene.,Fluprednidene,DB00075
DB08971,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortolone.,Fluocortolone,DB00075
DB09029,The risk or severity of adverse effects can be increased when Muromonab is combined with Secukinumab.,Secukinumab,DB00075
DB09033,The risk or severity of adverse effects can be increased when Muromonab is combined with Vedolizumab.,Vedolizumab,DB00075
DB09036,The risk or severity of adverse effects can be increased when Muromonab is combined with Siltuximab.,Siltuximab,DB00075
DB09052,The risk or severity of adverse effects can be increased when Muromonab is combined with Blinatumomab.,Blinatumomab,DB00075
DB09053,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibrutinib.,Ibrutinib,DB00075
DB09054,The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib.,Idelalisib,DB00075
DB09073,The risk or severity of adverse effects can be increased when Muromonab is combined with Palbociclib.,Palbociclib,DB00075
DB09074,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaparib.,Olaparib,DB00075
DB09077,The risk or severity of adverse effects can be increased when Muromonab is combined with Dinutuximab.,Dinutuximab,DB00075
DB09082,The risk or severity of adverse effects can be increased when Muromonab is combined with Vilanterol.,Vilanterol,DB00075
DB09091,The risk or severity of adverse effects can be increased when Muromonab is combined with Tixocortol.,Tixocortol,DB00075
DB09122,The risk or severity of adverse effects can be increased when Muromonab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00075
DB09312,The risk or severity of adverse effects can be increased when Muromonab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00075
DB09378,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednisolone.,Fluprednisolone,DB00075
DB09383,The risk or severity of adverse effects can be increased when Muromonab is combined with Meprednisone.,Meprednisone,DB00075
DB11466,The risk or severity of adverse effects can be increased when Muromonab is combined with Tepoxalin.,Tepoxalin,DB00075
DB11487,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00075
DB11529,The risk or severity of adverse effects can be increased when Muromonab is combined with Melengestrol.,Melengestrol,DB00075
DB11569,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixekizumab.,Ixekizumab,DB00075
DB11580,The risk or severity of adverse effects can be increased when Muromonab is combined with Ravulizumab.,Ravulizumab,DB00075
DB11616,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirarubicin.,Pirarubicin,DB00075
DB11693,The risk or severity of adverse effects can be increased when Muromonab is combined with Voclosporin.,Voclosporin,DB00075
DB11708,The risk or severity of adverse effects can be increased when Muromonab is combined with Peficitinib.,Peficitinib,DB00075
DB11750,The risk or severity of adverse effects can be increased when Muromonab is combined with Clobetasol.,Clobetasol,DB00075
DB11767,The risk or severity of adverse effects can be increased when Muromonab is combined with Sarilumab.,Sarilumab,DB00075
DB11776,The risk or severity of adverse effects can be increased when Muromonab is combined with Brodalumab.,Brodalumab,DB00075
DB11803,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirukumab.,Sirukumab,DB00075
DB11817,The risk or severity of adverse effects can be increased when Muromonab is combined with Baricitinib.,Baricitinib,DB00075
DB11834,The risk or severity of adverse effects can be increased when Muromonab is combined with Guselkumab.,Guselkumab,DB00075
DB11921,The risk or severity of adverse effects can be increased when Muromonab is combined with Deflazacort.,Deflazacort,DB00075
DB12025,The risk or severity of adverse effects can be increased when Muromonab is combined with Triptolide.,Triptolide,DB00075
DB12371,The risk or severity of adverse effects can be increased when Muromonab is combined with Siponimod.,Siponimod,DB00075
DB12612,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanimod.,Ozanimod,DB00075
DB12617,The risk or severity of adverse effects can be increased when Muromonab is combined with Mizoribine.,Mizoribine,DB00075
DB12692,The risk or severity of adverse effects can be increased when Muromonab is combined with Gusperimus.,Gusperimus,DB00075
DB12814,The risk or severity of adverse effects can be increased when Muromonab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00075
DB12902,The risk or severity of adverse effects can be increased when Muromonab is combined with Trofosfamide.,Trofosfamide,DB00075
DB12947,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxifluridine.,Doxifluridine,DB00075
DB12991,The risk or severity of adverse effects can be increased when Muromonab is combined with Deoxyspergualin.,Deoxyspergualin,DB00075
DB12996,The risk or severity of adverse effects can be increased when Muromonab is combined with Acteoside.,Acteoside,DB00075
DB13003,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortivazol.,Cortivazol,DB00075
DB13014,The risk or severity of adverse effects can be increased when Muromonab is combined with Hypericin.,Hypericin,DB00075
DB13068,The risk or severity of adverse effects can be increased when Muromonab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00075
DB13208,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednylidene.,Prednylidene,DB00075
DB13223,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortin.,Fluocortin,DB00075
DB13241,The risk or severity of adverse effects can be increased when Muromonab is combined with Begelomab.,Begelomab,DB00075
DB13491,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluperolone.,Fluperolone,DB00075
DB13664,The risk or severity of adverse effects can be increased when Muromonab is combined with Formocortal.,Formocortal,DB00075
DB13728,The risk or severity of adverse effects can be increased when Muromonab is combined with Halometasone.,Halometasone,DB00075
DB13843,The risk or severity of adverse effects can be increased when Muromonab is combined with Cloprednol.,Cloprednol,DB00075
DB13856,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluclorolone.,Fluclorolone,DB00075
DB13867,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone.,Fluticasone,DB00075
DB14066,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetrandrine.,Tetrandrine,DB00075
DB14219,The risk or severity of adverse effects can be increased when Muromonab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00075
DB14512,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone furoate.,Mometasone furoate,DB00075
DB14538,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00075
DB14539,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00075
DB14545,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00075
DB14724,The risk or severity of adverse effects can be increased when Muromonab is combined with Emapalumab.,Emapalumab,DB00075
DB14762,The risk or severity of adverse effects can be increased when Muromonab is combined with Risankizumab.,Risankizumab,DB00075
DB14919,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozanolixizumab.,Rozanolixizumab,DB00075
DB15253,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleselumab.,Bleselumab,DB00075
DB00108,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.,Natalizumab,DB00075
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.,Pimecrolimus,DB00075
DB01656,Roflumilast may increase the immunosuppressive activities of Muromonab.,Roflumilast,DB00075
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.,Sipuleucel-T,DB00075
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Muromonab.,Sulfamethoxazole,DB00075
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Muromonab.,Diethylstilbestrol,DB00075
DB00269,Chlorotrianisene may increase the thrombogenic activities of Muromonab.,Chlorotrianisene,DB00075
DB00286,Conjugated estrogens may increase the thrombogenic activities of Muromonab.,Conjugated estrogens,DB00075
DB00655,Estrone may increase the thrombogenic activities of Muromonab.,Estrone,DB00075
DB00783,Estradiol may increase the thrombogenic activities of Muromonab.,Estradiol,DB00075
DB00890,Dienestrol may increase the thrombogenic activities of Muromonab.,Dienestrol,DB00075
DB00977,Ethinylestradiol may increase the thrombogenic activities of Muromonab.,Ethinylestradiol,DB00075
DB01357,Mestranol may increase the thrombogenic activities of Muromonab.,Mestranol,DB00075
DB04573,Estriol may increase the thrombogenic activities of Muromonab.,Estriol,DB00075
DB04574,Estrone sulfate may increase the thrombogenic activities of Muromonab.,Estrone sulfate,DB00075
DB04575,Quinestrol may increase the thrombogenic activities of Muromonab.,Quinestrol,DB00075
DB07931,Hexestrol may increase the thrombogenic activities of Muromonab.,Hexestrol,DB00075
DB09070,Tibolone may increase the thrombogenic activities of Muromonab.,Tibolone,DB00075
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Muromonab.","Synthetic Conjugated Estrogens, A",DB00075
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Muromonab.","Synthetic Conjugated Estrogens, B",DB00075
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Muromonab.,Polyestradiol phosphate,DB00075
DB09381,Esterified estrogens may increase the thrombogenic activities of Muromonab.,Esterified estrogens,DB00075
DB11478,Zeranol may increase the thrombogenic activities of Muromonab.,Zeranol,DB00075
DB11674,Equol may increase the thrombogenic activities of Muromonab.,Equol,DB00075
DB12487,Promestriene may increase the thrombogenic activities of Muromonab.,Promestriene,DB00075
DB13143,Methallenestril may increase the thrombogenic activities of Muromonab.,Methallenestril,DB00075
DB13386,Epimestrol may increase the thrombogenic activities of Muromonab.,Epimestrol,DB00075
DB13418,Moxestrol may increase the thrombogenic activities of Muromonab.,Moxestrol,DB00075
DB13952,Estradiol acetate may increase the thrombogenic activities of Muromonab.,Estradiol acetate,DB00075
DB13953,Estradiol benzoate may increase the thrombogenic activities of Muromonab.,Estradiol benzoate,DB00075
DB13954,Estradiol cypionate may increase the thrombogenic activities of Muromonab.,Estradiol cypionate,DB00075
DB13956,Estradiol valerate may increase the thrombogenic activities of Muromonab.,Estradiol valerate,DB00075
DB15334,Biochanin A may increase the thrombogenic activities of Muromonab.,Biochanin A,DB00075
DB15335,Formononetin may increase the thrombogenic activities of Muromonab.,Formononetin,DB00075
DB01097,The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.,Leflunomide,DB00075
DB08895,Muromonab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00075
DB00072,Trastuzumab may increase the neutropenic activities of Muromonab.,Trastuzumab,DB00075
DB08868,Muromonab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00075
DB00864,Tacrolimus may increase the immunosuppressive activities of Muromonab.,Tacrolimus,DB00075
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Muromonab.,G17DT,DB00075
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Muromonab.,PEV3A,DB00075
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Muromonab.,INGN 225,DB00075
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Muromonab.,Rindopepimut,DB00075
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Muromonab.,SRP 299,DB00075
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Muromonab.,GI-5005,DB00075
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Muromonab.,Vitespen,DB00075
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Muromonab.,TG4010,DB00075
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Muromonab.,Anthrax immune globulin human,DB00075
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Muromonab.","Rabies virus inactivated antigen, B",DB00075
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00075
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Muromonab.,Rotavirus vaccine,DB00075
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Muromonab.","Rabies virus inactivated antigen, A",DB00075
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00075
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00075
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00075
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00075
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00075
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00075
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Muromonab.,Typhoid Vi polysaccharide vaccine,DB00075
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.,Hepatitis A Vaccine,DB00075
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00075
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00075
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00075
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00075
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00075
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Muromonab.,Human rabies virus immune globulin,DB00075
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Muromonab.,Hepatitis B Vaccine (Recombinant),DB00075
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Muromonab.,Tecemotide,DB00075
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Muromonab.,Typhoid vaccine,DB00075
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00075
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00075
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00075
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00075
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Muromonab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00075
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00075
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00075
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Muromonab.,Vaccinia virus strain new york city board of health live antigen,DB00075
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Muromonab.,Pertussis vaccine,DB00075
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00075
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Muromonab.,Varicella Zoster Vaccine (Recombinant),DB00075
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Muromonab.,Modified vaccinia ankara,DB00075
DB11988,Ocrelizumab may increase the immunosuppressive activities of Muromonab.,Ocrelizumab,DB00075
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Muromonab.,Rubella virus vaccine,DB00075
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Muromonab.,Varicella Zoster Vaccine (Live/attenuated),DB00075
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain tice live antigen,DB00075
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain connaught live antigen,DB00075
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Muromonab.,Yellow Fever Vaccine,DB00075
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Muromonab.,Anthrax vaccine,DB00075
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Muromonab.,Typhoid Vaccine Live,DB00075
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00075
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Muromonab.,BCG vaccine,DB00075
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Muromonab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00075
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Muromonab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00075
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Muromonab.,Adenovirus type 7 vaccine live,DB00075
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.,Cetuximab,DB00075
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.,Human immunoglobulin G,DB00075
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Muromonab.,Omalizumab,DB00075
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Muromonab.,Abciximab,DB00075
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.,Indium In-111 satumomab pendetide,DB00075
DB00076,The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine),DB00075
DB00089,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.,Capromab pendetide,DB00075
DB00110,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.,Palivizumab,DB00075
DB00113,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00075
DB01269,The risk or severity of adverse effects can be increased when Muromonab is combined with Panitumumab.,Panitumumab,DB00075
DB01270,The risk or severity of adverse effects can be increased when Muromonab is combined with Ranibizumab.,Ranibizumab,DB00075
DB04901,The risk or severity of adverse effects can be increased when Muromonab is combined with Galiximab.,Galiximab,DB00075
DB04949,The risk or severity of adverse effects can be increased when Muromonab is combined with Pexelizumab.,Pexelizumab,DB00075
DB04958,The risk or severity of adverse effects can be increased when Muromonab is combined with Epratuzumab.,Epratuzumab,DB00075
DB04962,The risk or severity of adverse effects can be increased when Muromonab is combined with Bectumomab.,Bectumomab,DB00075
DB04964,The risk or severity of adverse effects can be increased when Muromonab is combined with Oregovomab.,Oregovomab,DB00075
DB04988,The risk or severity of adverse effects can be increased when Muromonab is combined with IGN311.,IGN311,DB00075
DB05006,The risk or severity of adverse effects can be increased when Muromonab is combined with Adecatumumab.,Adecatumumab,DB00075
DB05097,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab.,Labetuzumab,DB00075
DB05101,The risk or severity of adverse effects can be increased when Muromonab is combined with Matuzumab.,Matuzumab,DB00075
DB05111,The risk or severity of adverse effects can be increased when Muromonab is combined with Fontolizumab.,Fontolizumab,DB00075
DB05136,The risk or severity of adverse effects can be increased when Muromonab is combined with Bavituximab.,Bavituximab,DB00075
DB05139,The risk or severity of adverse effects can be increased when Muromonab is combined with CR002.,CR002,DB00075
DB05209,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozrolimupab.,Rozrolimupab,DB00075
DB05304,The risk or severity of adverse effects can be increased when Muromonab is combined with Girentuximab.,Girentuximab,DB00075
DB05336,The risk or severity of adverse effects can be increased when Muromonab is combined with Obiltoxaximab.,Obiltoxaximab,DB00075
DB05405,The risk or severity of adverse effects can be increased when Muromonab is combined with XTL-001.,XTL-001,DB00075
DB05437,The risk or severity of adverse effects can be increased when Muromonab is combined with NAV 1800.,NAV 1800,DB00075
DB05496,The risk or severity of adverse effects can be increased when Muromonab is combined with Otelixizumab.,Otelixizumab,DB00075
DB05545,The risk or severity of adverse effects can be increased when Muromonab is combined with AMG 108.,AMG 108,DB00075
DB05550,The risk or severity of adverse effects can be increased when Muromonab is combined with Iratumumab.,Iratumumab,DB00075
DB05555,The risk or severity of adverse effects can be increased when Muromonab is combined with Enokizumab.,Enokizumab,DB00075
DB05578,The risk or severity of adverse effects can be increased when Muromonab is combined with Ramucirumab.,Ramucirumab,DB00075
DB05595,The risk or severity of adverse effects can be increased when Muromonab is combined with Farletuzumab.,Farletuzumab,DB00075
DB05656,The risk or severity of adverse effects can be increased when Muromonab is combined with Veltuzumab.,Veltuzumab,DB00075
DB05793,The risk or severity of adverse effects can be increased when Muromonab is combined with PRO-542.,PRO-542,DB00075
DB05797,The risk or severity of adverse effects can be increased when Muromonab is combined with TNX-901.,TNX-901,DB00075
DB05889,The risk or severity of adverse effects can be increased when Muromonab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00075
DB05892,The risk or severity of adverse effects can be increased when Muromonab is combined with RI 624.,RI 624,DB00075
DB05915,The risk or severity of adverse effects can be increased when Muromonab is combined with MYO-029.,MYO-029,DB00075
DB05916,The risk or severity of adverse effects can be increased when Muromonab is combined with CT-011.,CT-011,DB00075
DB05941,The risk or severity of adverse effects can be increased when Muromonab is combined with Leronlimab.,Leronlimab,DB00075
DB05996,The risk or severity of adverse effects can be increased when Muromonab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00075
DB06043,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaratumab.,Olaratumab,DB00075
DB06049,The risk or severity of adverse effects can be increased when Muromonab is combined with IPH 2101.,IPH 2101,DB00075
DB06050,The risk or severity of adverse effects can be increased when Muromonab is combined with TB-402.,TB-402,DB00075
DB06081,The risk or severity of adverse effects can be increased when Muromonab is combined with Caplacizumab.,Caplacizumab,DB00075
DB06101,The risk or severity of adverse effects can be increased when Muromonab is combined with IMC-1C11.,IMC-1C11,DB00075
DB06116,The risk or severity of adverse effects can be increased when Muromonab is combined with Eldelumab.,Eldelumab,DB00075
DB06162,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumiliximab.,Lumiliximab,DB00075
DB06186,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipilimumab.,Ipilimumab,DB00075
DB06192,The risk or severity of adverse effects can be increased when Muromonab is combined with Nimotuzumab.,Nimotuzumab,DB00075
DB06241,The risk or severity of adverse effects can be increased when Muromonab is combined with Clenoliximab.,Clenoliximab,DB00075
DB06304,The risk or severity of adverse effects can be increased when Muromonab is combined with BIIB015.,BIIB015,DB00075
DB06305,The risk or severity of adverse effects can be increased when Muromonab is combined with Sonepcizumab.,Sonepcizumab,DB00075
DB06310,The risk or severity of adverse effects can be increased when Muromonab is combined with Motavizumab.,Motavizumab,DB00075
DB06317,The risk or severity of adverse effects can be increased when Muromonab is combined with Elotuzumab.,Elotuzumab,DB00075
DB06318,The risk or severity of adverse effects can be increased when Muromonab is combined with AVE9633.,AVE9633,DB00075
DB06322,The risk or severity of adverse effects can be increased when Muromonab is combined with Carotuximab.,Carotuximab,DB00075
DB06324,The risk or severity of adverse effects can be increased when Muromonab is combined with XmAb 2513.,XmAb 2513,DB00075
DB06342,The risk or severity of adverse effects can be increased when Muromonab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00075
DB06343,The risk or severity of adverse effects can be increased when Muromonab is combined with Teprotumumab.,Teprotumumab,DB00075
DB06360,The risk or severity of adverse effects can be increased when Muromonab is combined with Lucatumumab.,Lucatumumab,DB00075
DB06366,The risk or severity of adverse effects can be increased when Muromonab is combined with Pertuzumab.,Pertuzumab,DB00075
DB06371,The risk or severity of adverse effects can be increased when Muromonab is combined with Siplizumab.,Siplizumab,DB00075
DB06467,The risk or severity of adverse effects can be increased when Muromonab is combined with Apolizumab.,Apolizumab,DB00075
DB06474,The risk or severity of adverse effects can be increased when Muromonab is combined with Sibrotuzumab.,Sibrotuzumab,DB00075
DB06550,The risk or severity of adverse effects can be increased when Muromonab is combined with Bivatuzumab.,Bivatuzumab,DB00075
DB06557,The risk or severity of adverse effects can be increased when Muromonab is combined with Lerdelimumab.,Lerdelimumab,DB00075
DB06599,The risk or severity of adverse effects can be increased when Muromonab is combined with Lexatumumab.,Lexatumumab,DB00075
DB06602,The risk or severity of adverse effects can be increased when Muromonab is combined with Reslizumab.,Reslizumab,DB00075
DB06606,The risk or severity of adverse effects can be increased when Muromonab is combined with Teplizumab.,Teplizumab,DB00075
DB06607,The risk or severity of adverse effects can be increased when Muromonab is combined with Catumaxomab.,Catumaxomab,DB00075
DB06647,The risk or severity of adverse effects can be increased when Muromonab is combined with Volociximab.,Volociximab,DB00075
DB06650,The risk or severity of adverse effects can be increased when Muromonab is combined with Ofatumumab.,Ofatumumab,DB00075
DB08902,The risk or severity of adverse effects can be increased when Muromonab is combined with Raxibacumab.,Raxibacumab,DB00075
DB09035,The risk or severity of adverse effects can be increased when Muromonab is combined with Nivolumab.,Nivolumab,DB00075
DB09037,The risk or severity of adverse effects can be increased when Muromonab is combined with Pembrolizumab.,Pembrolizumab,DB00075
DB09045,The risk or severity of adverse effects can be increased when Muromonab is combined with Dulaglutide.,Dulaglutide,DB00075
DB09105,The risk or severity of adverse effects can be increased when Muromonab is combined with Asfotase alfa.,Asfotase alfa,DB00075
DB09264,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarucizumab.,Idarucizumab,DB00075
DB09302,The risk or severity of adverse effects can be increased when Muromonab is combined with Alirocumab.,Alirocumab,DB00075
DB09303,The risk or severity of adverse effects can be increased when Muromonab is combined with Evolocumab.,Evolocumab,DB00075
DB09331,The risk or severity of adverse effects can be increased when Muromonab is combined with Daratumumab.,Daratumumab,DB00075
DB09559,The risk or severity of adverse effects can be increased when Muromonab is combined with Necitumumab.,Necitumumab,DB00075
DB11595,The risk or severity of adverse effects can be increased when Muromonab is combined with Atezolizumab.,Atezolizumab,DB00075
DB11604,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00075
DB11608,The risk or severity of adverse effects can be increased when Muromonab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00075
DB11621,The risk or severity of adverse effects can be increased when Muromonab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00075
DB11646,The risk or severity of adverse effects can be increased when Muromonab is combined with Conatumumab.,Conatumumab,DB00075
DB11657,The risk or severity of adverse effects can be increased when Muromonab is combined with Tabalumab.,Tabalumab,DB00075
DB11680,The risk or severity of adverse effects can be increased when Muromonab is combined with Ficlatuzumab.,Ficlatuzumab,DB00075
DB11685,The risk or severity of adverse effects can be increased when Muromonab is combined with Figitumumab.,Figitumumab,DB00075
DB11714,The risk or severity of adverse effects can be increased when Muromonab is combined with Durvalumab.,Durvalumab,DB00075
DB11715,The risk or severity of adverse effects can be increased when Muromonab is combined with Bapineuzumab.,Bapineuzumab,DB00075
DB11731,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00075
DB11746,The risk or severity of adverse effects can be increased when Muromonab is combined with Onartuzumab.,Onartuzumab,DB00075
DB11756,The risk or severity of adverse effects can be increased when Muromonab is combined with Solanezumab.,Solanezumab,DB00075
DB11771,The risk or severity of adverse effects can be increased when Muromonab is combined with Tremelimumab.,Tremelimumab,DB00075
DB11826,The risk or severity of adverse effects can be increased when Muromonab is combined with Lampalizumab.,Lampalizumab,DB00075
DB11840,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalotuzumab.,Dalotuzumab,DB00075
DB11849,The risk or severity of adverse effects can be increased when Muromonab is combined with Emibetuzumab.,Emibetuzumab,DB00075
DB11850,The risk or severity of adverse effects can be increased when Muromonab is combined with Ublituximab.,Ublituximab,DB00075
DB11856,The risk or severity of adverse effects can be increased when Muromonab is combined with Ligelizumab.,Ligelizumab,DB00075
DB11857,The risk or severity of adverse effects can be increased when Muromonab is combined with Seribantumab.,Seribantumab,DB00075
DB11862,The risk or severity of adverse effects can be increased when Muromonab is combined with Landogrozumab.,Landogrozumab,DB00075
DB11866,The risk or severity of adverse effects can be increased when Muromonab is combined with Romosozumab.,Romosozumab,DB00075
DB11884,The risk or severity of adverse effects can be increased when Muromonab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00075
DB11914,The risk or severity of adverse effects can be increased when Muromonab is combined with Lebrikizumab.,Lebrikizumab,DB00075
DB11930,The risk or severity of adverse effects can be increased when Muromonab is combined with Varlilumab.,Varlilumab,DB00075
DB11945,The risk or severity of adverse effects can be increased when Muromonab is combined with Avelumab.,Avelumab,DB00075
DB11959,The risk or severity of adverse effects can be increased when Muromonab is combined with Crenezumab.,Crenezumab,DB00075
DB11972,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilotumumab.,Rilotumumab,DB00075
DB11976,The risk or severity of adverse effects can be increased when Muromonab is combined with Anifrolumab.,Anifrolumab,DB00075
DB12023,The risk or severity of adverse effects can be increased when Muromonab is combined with Benralizumab.,Benralizumab,DB00075
DB12034,The risk or severity of adverse effects can be increased when Muromonab is combined with Gantenerumab.,Gantenerumab,DB00075
DB12053,The risk or severity of adverse effects can be increased when Muromonab is combined with Visilizumab.,Visilizumab,DB00075
DB12077,The risk or severity of adverse effects can be increased when Muromonab is combined with Urelumab.,Urelumab,DB00075
DB12089,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00075
DB12090,The risk or severity of adverse effects can be increased when Muromonab is combined with Patritumab.,Patritumab,DB00075
DB12102,The risk or severity of adverse effects can be increased when Muromonab is combined with Fulranumab.,Fulranumab,DB00075
DB12104,The risk or severity of adverse effects can be increased when Muromonab is combined with Tarextumab.,Tarextumab,DB00075
DB12118,The risk or severity of adverse effects can be increased when Muromonab is combined with Sotatercept.,Sotatercept,DB00075
DB12119,The risk or severity of adverse effects can be increased when Muromonab is combined with Gevokizumab.,Gevokizumab,DB00075
DB12142,The risk or severity of adverse effects can be increased when Muromonab is combined with Duligotuzumab.,Duligotuzumab,DB00075
DB12152,The risk or severity of adverse effects can be increased when Muromonab is combined with Simtuzumab.,Simtuzumab,DB00075
DB12157,The risk or severity of adverse effects can be increased when Muromonab is combined with Fasinumab.,Fasinumab,DB00075
DB12159,The risk or severity of adverse effects can be increased when Muromonab is combined with Dupilumab.,Dupilumab,DB00075
DB12169,The risk or severity of adverse effects can be increased when Muromonab is combined with Tralokinumab.,Tralokinumab,DB00075
DB12189,The risk or severity of adverse effects can be increased when Muromonab is combined with Etrolizumab.,Etrolizumab,DB00075
DB12202,The risk or severity of adverse effects can be increased when Muromonab is combined with Zalutumumab.,Zalutumumab,DB00075
DB12205,The risk or severity of adverse effects can be increased when Muromonab is combined with Ganitumab.,Ganitumab,DB00075
DB12213,The risk or severity of adverse effects can be increased when Muromonab is combined with Etaracizumab.,Etaracizumab,DB00075
DB12240,The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00075
DB12246,The risk or severity of adverse effects can be increased when Muromonab is combined with Inclacumab.,Inclacumab,DB00075
DB12250,The risk or severity of adverse effects can be increased when Muromonab is combined with Cixutumumab.,Cixutumumab,DB00075
DB12261,The risk or severity of adverse effects can be increased when Muromonab is combined with Ascrinvacumab.,Ascrinvacumab,DB00075
DB12274,The risk or severity of adverse effects can be increased when Muromonab is combined with Aducanumab.,Aducanumab,DB00075
DB12281,The risk or severity of adverse effects can be increased when Muromonab is combined with Luspatercept.,Luspatercept,DB00075
DB12296,The risk or severity of adverse effects can be increased when Muromonab is combined with GS-5745.,GS-5745,DB00075
DB12317,The risk or severity of adverse effects can be increased when Muromonab is combined with Vanucizumab.,Vanucizumab,DB00075
DB12331,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00075
DB12335,The risk or severity of adverse effects can be increased when Muromonab is combined with Tanezumab.,Tanezumab,DB00075
DB12342,The risk or severity of adverse effects can be increased when Muromonab is combined with Ensituximab.,Ensituximab,DB00075
DB12344,The risk or severity of adverse effects can be increased when Muromonab is combined with Fezakinumab.,Fezakinumab,DB00075
DB12363,The risk or severity of adverse effects can be increased when Muromonab is combined with Dusigitumab.,Dusigitumab,DB00075
DB12396,The risk or severity of adverse effects can be increased when Muromonab is combined with Fresolimumab.,Fresolimumab,DB00075
DB12413,The risk or severity of adverse effects can be increased when Muromonab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00075
DB12456,The risk or severity of adverse effects can be increased when Muromonab is combined with Bococizumab.,Bococizumab,DB00075
DB12489,The risk or severity of adverse effects can be increased when Muromonab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00075
DB12498,The risk or severity of adverse effects can be increased when Muromonab is combined with Mogamulizumab.,Mogamulizumab,DB00075
DB12520,The risk or severity of adverse effects can be increased when Muromonab is combined with Plozalizumab.,Plozalizumab,DB00075
DB12534,The risk or severity of adverse effects can be increased when Muromonab is combined with Mavrilimumab.,Mavrilimumab,DB00075
DB12560,The risk or severity of adverse effects can be increased when Muromonab is combined with Blosozumab.,Blosozumab,DB00075
DB12584,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimagrumab.,Bimagrumab,DB00075
DB12589,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacetuzumab.,Dacetuzumab,DB00075
DB12609,The risk or severity of adverse effects can be increased when Muromonab is combined with Tovetumab.,Tovetumab,DB00075
DB12683,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumretuzumab.,Lumretuzumab,DB00075
DB12698,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibalizumab.,Ibalizumab,DB00075
DB12701,The risk or severity of adverse effects can be increased when Muromonab is combined with Intetumumab.,Intetumumab,DB00075
DB12718,The risk or severity of adverse effects can be increased when Muromonab is combined with Carlumab.,Carlumab,DB00075
DB12734,The risk or severity of adverse effects can be increased when Muromonab is combined with Demcizumab.,Demcizumab,DB00075
DB12773,The risk or severity of adverse effects can be increased when Muromonab is combined with Sifalimumab.,Sifalimumab,DB00075
DB12775,The risk or severity of adverse effects can be increased when Muromonab is combined with Abituzumab.,Abituzumab,DB00075
DB12797,The risk or severity of adverse effects can be increased when Muromonab is combined with Ecromeximab.,Ecromeximab,DB00075
DB12807,The risk or severity of adverse effects can be increased when Muromonab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00075
DB12815,The risk or severity of adverse effects can be increased when Muromonab is combined with Crotedumab.,Crotedumab,DB00075
DB12820,The risk or severity of adverse effects can be increased when Muromonab is combined with Concizumab.,Concizumab,DB00075
DB12826,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab.,Depatuxizumab,DB00075
DB12844,The risk or severity of adverse effects can be increased when Muromonab is combined with Rontalizumab.,Rontalizumab,DB00075
DB12845,The risk or severity of adverse effects can be increased when Muromonab is combined with Amatuximab.,Amatuximab,DB00075
DB12849,The risk or severity of adverse effects can be increased when Muromonab is combined with Clazakizumab.,Clazakizumab,DB00075
DB12891,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanezumab.,Ozanezumab,DB00075
DB12893,The risk or severity of adverse effects can be increased when Muromonab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00075
DB12917,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimekizumab.,Bimekizumab,DB00075
DB12943,The risk or severity of adverse effects can be increased when Muromonab is combined with Milatuzumab.,Milatuzumab,DB00075
DB12976,The risk or severity of adverse effects can be increased when Muromonab is combined with Robatumumab.,Robatumumab,DB00075
DB13017,The risk or severity of adverse effects can be increased when Muromonab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00075
DB13037,The risk or severity of adverse effects can be increased when Muromonab is combined with Namilumab.,Namilumab,DB00075
DB13045,The risk or severity of adverse effects can be increased when Muromonab is combined with Racotumomab.,Racotumomab,DB00075
DB13073,The risk or severity of adverse effects can be increased when Muromonab is combined with Tregalizumab.,Tregalizumab,DB00075
DB13127,The risk or severity of adverse effects can be increased when Muromonab is combined with Olokizumab.,Olokizumab,DB00075
DB13140,The risk or severity of adverse effects can be increased when Muromonab is combined with Bezlotoxumab.,Bezlotoxumab,DB00075
DB13375,The risk or severity of adverse effects can be increased when Muromonab is combined with Edrecolomab.,Edrecolomab,DB00075
DB13535,The risk or severity of adverse effects can be increased when Muromonab is combined with Nebacumab.,Nebacumab,DB00075
DB13886,The risk or severity of adverse effects can be increased when Muromonab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00075
DB13923,The risk or severity of adverse effects can be increased when Muromonab is combined with Emicizumab.,Emicizumab,DB00075
DB13976,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulesomab.,Sulesomab,DB00075
DB13979,The risk or severity of adverse effects can be increased when Muromonab is combined with Besilesomab.,Besilesomab,DB00075
DB14012,The risk or severity of adverse effects can be increased when Muromonab is combined with Burosumab.,Burosumab,DB00075
DB14039,The risk or severity of adverse effects can be increased when Muromonab is combined with Erenumab.,Erenumab,DB00075
DB14040,The risk or severity of adverse effects can be increased when Muromonab is combined with Eptinezumab.,Eptinezumab,DB00075
DB14041,The risk or severity of adverse effects can be increased when Muromonab is combined with Fremanezumab.,Fremanezumab,DB00075
DB14042,The risk or severity of adverse effects can be increased when Muromonab is combined with Galcanezumab.,Galcanezumab,DB00075
DB14211,The risk or severity of adverse effects can be increased when Muromonab is combined with Fanolesomab.,Fanolesomab,DB00075
DB14580,The risk or severity of adverse effects can be increased when Muromonab is combined with Lecanemab.,Lecanemab,DB00075
DB14597,The risk or severity of adverse effects can be increased when Muromonab is combined with Lanadelumab.,Lanadelumab,DB00075
DB14707,The risk or severity of adverse effects can be increased when Muromonab is combined with Cemiplimab.,Cemiplimab,DB00075
DB14776,The risk or severity of adverse effects can be increased when Muromonab is combined with Camrelizumab.,Camrelizumab,DB00075
DB14778,The risk or severity of adverse effects can be increased when Muromonab is combined with Setrusumab.,Setrusumab,DB00075
DB14784,The risk or severity of adverse effects can be increased when Muromonab is combined with Gancotamab.,Gancotamab,DB00075
DB14809,The risk or severity of adverse effects can be increased when Muromonab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00075
DB14811,The risk or severity of adverse effects can be increased when Muromonab is combined with Isatuximab.,Isatuximab,DB00075
DB14824,The risk or severity of adverse effects can be increased when Muromonab is combined with Icrucumab.,Icrucumab,DB00075
DB14843,The risk or severity of adverse effects can be increased when Muromonab is combined with Codrituzumab.,Codrituzumab,DB00075
DB14864,The risk or severity of adverse effects can be increased when Muromonab is combined with Brolucizumab.,Brolucizumab,DB00075
DB14871,The risk or severity of adverse effects can be increased when Muromonab is combined with Xentuzumab.,Xentuzumab,DB00075
DB14877,The risk or severity of adverse effects can be increased when Muromonab is combined with Lintuzumab.,Lintuzumab,DB00075
DB14891,The risk or severity of adverse effects can be increased when Muromonab is combined with Vobarilizumab.,Vobarilizumab,DB00075
DB14897,The risk or severity of adverse effects can be increased when Muromonab is combined with Parsatuzumab.,Parsatuzumab,DB00075
DB14905,The risk or severity of adverse effects can be increased when Muromonab is combined with Emactuzumab.,Emactuzumab,DB00075
DB14907,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00075
DB14908,The risk or severity of adverse effects can be increased when Muromonab is combined with Refanezumab.,Refanezumab,DB00075
DB14947,The risk or severity of adverse effects can be increased when Muromonab is combined with Bermekimab.,Bermekimab,DB00075
DB14952,The risk or severity of adverse effects can be increased when Muromonab is combined with Pamrevlumab.,Pamrevlumab,DB00075
DB14959,The risk or severity of adverse effects can be increased when Muromonab is combined with Opicinumab.,Opicinumab,DB00075
DB14962,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00075
DB14967,The risk or severity of adverse effects can be increased when Muromonab is combined with Margetuximab.,Margetuximab,DB00075
DB14988,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalantercept.,Dalantercept,DB00075
DB14997,The risk or severity of adverse effects can be increased when Muromonab is combined with Pateclizumab.,Pateclizumab,DB00075
DB15014,The risk or severity of adverse effects can be increased when Muromonab is combined with Gremubamab.,Gremubamab,DB00075
DB15022,The risk or severity of adverse effects can be increased when Muromonab is combined with Apomab.,Apomab,DB00075
DB15044,The risk or severity of adverse effects can be increased when Muromonab is combined with Tafasitamab.,Tafasitamab,DB00075
DB15045,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipafricept.,Ipafricept,DB00075
DB15076,The risk or severity of adverse effects can be increased when Muromonab is combined with Abrilumab.,Abrilumab,DB00075
DB15089,The risk or severity of adverse effects can be increased when Muromonab is combined with Frovocimab.,Frovocimab,DB00075
DB15090,The risk or severity of adverse effects can be increased when Muromonab is combined with Tezepelumab.,Tezepelumab,DB00075
DB15101,The risk or severity of adverse effects can be increased when Muromonab is combined with Tigatuzumab.,Tigatuzumab,DB00075
DB15104,The risk or severity of adverse effects can be increased when Muromonab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00075
DB15113,The risk or severity of adverse effects can be increased when Muromonab is combined with Utomilumab.,Utomilumab,DB00075
DB15118,The risk or severity of adverse effects can be increased when Muromonab is combined with Zolbetuximab.,Zolbetuximab,DB00075
DB15135,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponezumab.,Ponezumab,DB00075
DB15160,The risk or severity of adverse effects can be increased when Muromonab is combined with Asunercept.,Asunercept,DB00075
DB15172,The risk or severity of adverse effects can be increased when Muromonab is combined with Suvratoxumab.,Suvratoxumab,DB00075
DB15225,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitazalimab.,Mitazalimab,DB00075
DB15252,The risk or severity of adverse effects can be increased when Muromonab is combined with Nemolizumab.,Nemolizumab,DB00075
DB15277,The risk or severity of adverse effects can be increased when Muromonab is combined with Gedivumab.,Gedivumab,DB00075
DB15336,The risk or severity of adverse effects can be increased when Muromonab is combined with Valanafusp alfa.,Valanafusp alfa,DB00075
DB15349,The risk or severity of adverse effects can be increased when Muromonab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00075
DB15354,The risk or severity of adverse effects can be increased when Muromonab is combined with Evinacumab.,Evinacumab,DB00075
DB15363,The risk or severity of adverse effects can be increased when Muromonab is combined with Istiratumab.,Istiratumab,DB00075
DB15383,The risk or severity of adverse effects can be increased when Muromonab is combined with Pidilizumab.,Pidilizumab,DB00075
DB15397,The risk or severity of adverse effects can be increased when Muromonab is combined with GMA-161.,GMA-161,DB00075
DB15409,The risk or severity of adverse effects can be increased when Muromonab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00075
DB15415,The risk or severity of adverse effects can be increased when Muromonab is combined with Tomaralimab.,Tomaralimab,DB00075
DB15428,The risk or severity of adverse effects can be increased when Muromonab is combined with Vesencumab.,Vesencumab,DB00075
DB15432,The risk or severity of adverse effects can be increased when Muromonab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00075
DB15441,The risk or severity of adverse effects can be increased when Muromonab is combined with Lulizumab pegol.,Lulizumab pegol,DB00075
DB15443,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00075
DB15453,The risk or severity of adverse effects can be increased when Muromonab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00075
DB14004,The risk or severity of adverse effects can be increased when Muromonab is combined with Tildrakizumab.,Tildrakizumab,DB00075
DB05679,The risk or severity of adverse effects can be increased when Muromonab is combined with Ustekinumab.,Ustekinumab,DB00075
DB15559,The risk or severity of adverse effects can be increased when Muromonab is combined with Zenocutuzumab.,Zenocutuzumab,DB00075
DB00091,Muromonab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00075
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Muromonab.","Ebola Zaire vaccine (live, attenuated)",DB00075
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Muromonab.,Magnesium,DB00075
DB01601,The serum concentration of Muromonab can be increased when it is combined with Lopinavir.,Lopinavir,DB00075
DB12530,The risk or severity of infection can be increased when Muromonab is combined with Inebilizumab.,Inebilizumab,DB00075
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Diethylstilbestrol,DB00076
DB00269,Chlorotrianisene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Chlorotrianisene,DB00076
DB00286,Conjugated estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Conjugated estrogens,DB00076
DB00655,Estrone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estrone,DB00076
DB00783,Estradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol,DB00076
DB00890,Dienestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Dienestrol,DB00076
DB00977,Ethinylestradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Ethinylestradiol,DB00076
DB01357,Mestranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Mestranol,DB00076
DB04573,Estriol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estriol,DB00076
DB04574,Estrone sulfate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estrone sulfate,DB00076
DB04575,Quinestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Quinestrol,DB00076
DB07931,Hexestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Hexestrol,DB00076
DB09070,Tibolone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Tibolone,DB00076
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).","Synthetic Conjugated Estrogens, A",DB00076
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).","Synthetic Conjugated Estrogens, B",DB00076
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Polyestradiol phosphate,DB00076
DB09381,Esterified estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Esterified estrogens,DB00076
DB11478,Zeranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Zeranol,DB00076
DB11674,Equol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Equol,DB00076
DB12487,Promestriene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Promestriene,DB00076
DB13143,Methallenestril may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Methallenestril,DB00076
DB13386,Epimestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Epimestrol,DB00076
DB13418,Moxestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Moxestrol,DB00076
DB13952,Estradiol acetate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol acetate,DB00076
DB13953,Estradiol benzoate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol benzoate,DB00076
DB13954,Estradiol cypionate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol cypionate,DB00076
DB13956,Estradiol valerate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol valerate,DB00076
DB15334,Biochanin A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Biochanin A,DB00076
DB15335,Formononetin may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Formononetin,DB00076
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).,Cetuximab,DB00076
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).,Human immunoglobulin G,DB00076
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Digoxin Immune Fab (Ovine).,Omalizumab,DB00076
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Digoxin Immune Fab (Ovine).,Adalimumab,DB00076
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Digoxin Immune Fab (Ovine).,Abciximab,DB00076
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).,Gemtuzumab ozogamicin,DB00076
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).,Indium In-111 satumomab pendetide,DB00076
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).,Infliximab,DB00076
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).,Trastuzumab,DB00076
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).,Rituximab,DB00076
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).,Basiliximab,DB00076
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).,Muromonab,DB00076
DB00078,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00076
DB00081,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.,Tositumomab,DB00076
DB00087,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.,Alemtuzumab,DB00076
DB00089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.,Capromab pendetide,DB00076
DB00095,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.,Efalizumab,DB00076
DB00098,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00076
DB00108,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.,Natalizumab,DB00076
DB00110,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.,Palivizumab,DB00076
DB00111,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.,Daclizumab,DB00076
DB00112,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.,Bevacizumab,DB00076
DB00113,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00076
DB01257,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eculizumab.,Eculizumab,DB00076
DB01269,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Panitumumab.,Panitumumab,DB00076
DB01270,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ranibizumab.,Ranibizumab,DB00076
DB04901,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galiximab.,Galiximab,DB00076
DB04949,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pexelizumab.,Pexelizumab,DB00076
DB04956,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Afelimomab.,Afelimomab,DB00076
DB04958,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Epratuzumab.,Epratuzumab,DB00076
DB04962,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bectumomab.,Bectumomab,DB00076
DB04964,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab.,Oregovomab,DB00076
DB04988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IGN311.,IGN311,DB00076
DB05006,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Adecatumumab.,Adecatumumab,DB00076
DB05097,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab.,Labetuzumab,DB00076
DB05101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Matuzumab.,Matuzumab,DB00076
DB05111,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fontolizumab.,Fontolizumab,DB00076
DB05136,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bavituximab.,Bavituximab,DB00076
DB05139,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CR002.,CR002,DB00076
DB05209,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozrolimupab.,Rozrolimupab,DB00076
DB05304,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Girentuximab.,Girentuximab,DB00076
DB05336,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obiltoxaximab.,Obiltoxaximab,DB00076
DB05405,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XTL-001.,XTL-001,DB00076
DB05437,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with NAV 1800.,NAV 1800,DB00076
DB05459,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Briakinumab.,Briakinumab,DB00076
DB05496,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Otelixizumab.,Otelixizumab,DB00076
DB05545,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AMG 108.,AMG 108,DB00076
DB05550,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Iratumumab.,Iratumumab,DB00076
DB05555,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Enokizumab.,Enokizumab,DB00076
DB05578,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ramucirumab.,Ramucirumab,DB00076
DB05595,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Farletuzumab.,Farletuzumab,DB00076
DB05656,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Veltuzumab.,Veltuzumab,DB00076
DB05679,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ustekinumab.,Ustekinumab,DB00076
DB05773,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00076
DB05793,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with PRO-542.,PRO-542,DB00076
DB05797,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TNX-901.,TNX-901,DB00076
DB05889,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00076
DB05892,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with RI 624.,RI 624,DB00076
DB05915,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with MYO-029.,MYO-029,DB00076
DB05916,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CT-011.,CT-011,DB00076
DB05941,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Leronlimab.,Leronlimab,DB00076
DB05996,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00076
DB06043,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olaratumab.,Olaratumab,DB00076
DB06049,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IPH 2101.,IPH 2101,DB00076
DB06050,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TB-402.,TB-402,DB00076
DB06081,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab.,Caplacizumab,DB00076
DB06101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IMC-1C11.,IMC-1C11,DB00076
DB06116,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eldelumab.,Eldelumab,DB00076
DB06162,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumiliximab.,Lumiliximab,DB00076
DB06168,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Canakinumab.,Canakinumab,DB00076
DB06186,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipilimumab.,Ipilimumab,DB00076
DB06192,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nimotuzumab.,Nimotuzumab,DB00076
DB06241,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clenoliximab.,Clenoliximab,DB00076
DB06273,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tocilizumab.,Tocilizumab,DB00076
DB06304,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with BIIB015.,BIIB015,DB00076
DB06305,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sonepcizumab.,Sonepcizumab,DB00076
DB06310,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Motavizumab.,Motavizumab,DB00076
DB06317,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Elotuzumab.,Elotuzumab,DB00076
DB06318,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AVE9633.,AVE9633,DB00076
DB06322,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carotuximab.,Carotuximab,DB00076
DB06324,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XmAb 2513.,XmAb 2513,DB00076
DB06342,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00076
DB06343,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teprotumumab.,Teprotumumab,DB00076
DB06360,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lucatumumab.,Lucatumumab,DB00076
DB06366,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pertuzumab.,Pertuzumab,DB00076
DB06371,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siplizumab.,Siplizumab,DB00076
DB06467,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apolizumab.,Apolizumab,DB00076
DB06474,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sibrotuzumab.,Sibrotuzumab,DB00076
DB06550,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bivatuzumab.,Bivatuzumab,DB00076
DB06557,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lerdelimumab.,Lerdelimumab,DB00076
DB06599,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lexatumumab.,Lexatumumab,DB00076
DB06602,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Reslizumab.,Reslizumab,DB00076
DB06606,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teplizumab.,Teplizumab,DB00076
DB06607,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Catumaxomab.,Catumaxomab,DB00076
DB06612,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mepolizumab.,Mepolizumab,DB00076
DB06643,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Denosumab.,Denosumab,DB00076
DB06647,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Volociximab.,Volociximab,DB00076
DB06650,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ofatumumab.,Ofatumumab,DB00076
DB06674,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Golimumab.,Golimumab,DB00076
DB08870,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00076
DB08879,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Belimumab.,Belimumab,DB00076
DB08902,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Raxibacumab.,Raxibacumab,DB00076
DB08904,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Certolizumab pegol.,Certolizumab pegol,DB00076
DB08935,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obinutuzumab.,Obinutuzumab,DB00076
DB09029,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Secukinumab.,Secukinumab,DB00076
DB09033,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vedolizumab.,Vedolizumab,DB00076
DB09035,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nivolumab.,Nivolumab,DB00076
DB09036,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siltuximab.,Siltuximab,DB00076
DB09037,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pembrolizumab.,Pembrolizumab,DB00076
DB09045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dulaglutide.,Dulaglutide,DB00076
DB09052,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blinatumomab.,Blinatumomab,DB00076
DB09057,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anthrax immune globulin human.,Anthrax immune globulin human,DB00076
DB09077,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dinutuximab.,Dinutuximab,DB00076
DB09105,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asfotase alfa.,Asfotase alfa,DB00076
DB09264,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Idarucizumab.,Idarucizumab,DB00076
DB09302,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alirocumab.,Alirocumab,DB00076
DB09303,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evolocumab.,Evolocumab,DB00076
DB09312,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00076
DB09331,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daratumumab.,Daratumumab,DB00076
DB09559,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Necitumumab.,Necitumumab,DB00076
DB11569,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ixekizumab.,Ixekizumab,DB00076
DB11580,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ravulizumab.,Ravulizumab,DB00076
DB11595,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Atezolizumab.,Atezolizumab,DB00076
DB11604,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00076
DB11608,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00076
DB11621,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00076
DB11646,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Conatumumab.,Conatumumab,DB00076
DB11657,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tabalumab.,Tabalumab,DB00076
DB11680,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ficlatuzumab.,Ficlatuzumab,DB00076
DB11685,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Figitumumab.,Figitumumab,DB00076
DB11714,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Durvalumab.,Durvalumab,DB00076
DB11715,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bapineuzumab.,Bapineuzumab,DB00076
DB11731,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00076
DB11746,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Onartuzumab.,Onartuzumab,DB00076
DB11756,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Solanezumab.,Solanezumab,DB00076
DB11767,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sarilumab.,Sarilumab,DB00076
DB11771,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tremelimumab.,Tremelimumab,DB00076
DB11776,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brodalumab.,Brodalumab,DB00076
DB11803,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sirukumab.,Sirukumab,DB00076
DB11826,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lampalizumab.,Lampalizumab,DB00076
DB11834,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Guselkumab.,Guselkumab,DB00076
DB11840,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalotuzumab.,Dalotuzumab,DB00076
DB11849,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emibetuzumab.,Emibetuzumab,DB00076
DB11850,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ublituximab.,Ublituximab,DB00076
DB11856,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ligelizumab.,Ligelizumab,DB00076
DB11857,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Seribantumab.,Seribantumab,DB00076
DB11862,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Landogrozumab.,Landogrozumab,DB00076
DB11866,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Romosozumab.,Romosozumab,DB00076
DB11884,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00076
DB11914,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lebrikizumab.,Lebrikizumab,DB00076
DB11930,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Varlilumab.,Varlilumab,DB00076
DB11945,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Avelumab.,Avelumab,DB00076
DB11959,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crenezumab.,Crenezumab,DB00076
DB11972,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rilotumumab.,Rilotumumab,DB00076
DB11976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anifrolumab.,Anifrolumab,DB00076
DB11988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ocrelizumab.,Ocrelizumab,DB00076
DB12023,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Benralizumab.,Benralizumab,DB00076
DB12034,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gantenerumab.,Gantenerumab,DB00076
DB12053,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Visilizumab.,Visilizumab,DB00076
DB12077,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Urelumab.,Urelumab,DB00076
DB12089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00076
DB12090,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Patritumab.,Patritumab,DB00076
DB12102,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fulranumab.,Fulranumab,DB00076
DB12104,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tarextumab.,Tarextumab,DB00076
DB12118,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sotatercept.,Sotatercept,DB00076
DB12119,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gevokizumab.,Gevokizumab,DB00076
DB12142,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Duligotuzumab.,Duligotuzumab,DB00076
DB12152,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Simtuzumab.,Simtuzumab,DB00076
DB12157,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fasinumab.,Fasinumab,DB00076
DB12159,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dupilumab.,Dupilumab,DB00076
DB12169,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tralokinumab.,Tralokinumab,DB00076
DB12189,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etrolizumab.,Etrolizumab,DB00076
DB12202,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zalutumumab.,Zalutumumab,DB00076
DB12205,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ganitumab.,Ganitumab,DB00076
DB12213,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etaracizumab.,Etaracizumab,DB00076
DB12240,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00076
DB12246,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inclacumab.,Inclacumab,DB00076
DB12250,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cixutumumab.,Cixutumumab,DB00076
DB12261,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ascrinvacumab.,Ascrinvacumab,DB00076
DB12274,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Aducanumab.,Aducanumab,DB00076
DB12281,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Luspatercept.,Luspatercept,DB00076
DB12296,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GS-5745.,GS-5745,DB00076
DB12317,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vanucizumab.,Vanucizumab,DB00076
DB12331,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00076
DB12335,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tanezumab.,Tanezumab,DB00076
DB12342,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ensituximab.,Ensituximab,DB00076
DB12344,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fezakinumab.,Fezakinumab,DB00076
DB12363,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dusigitumab.,Dusigitumab,DB00076
DB12396,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fresolimumab.,Fresolimumab,DB00076
DB12413,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00076
DB12456,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bococizumab.,Bococizumab,DB00076
DB12489,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00076
DB12498,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mogamulizumab.,Mogamulizumab,DB00076
DB12520,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Plozalizumab.,Plozalizumab,DB00076
DB12530,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inebilizumab.,Inebilizumab,DB00076
DB12534,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mavrilimumab.,Mavrilimumab,DB00076
DB12560,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blosozumab.,Blosozumab,DB00076
DB12584,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimagrumab.,Bimagrumab,DB00076
DB12589,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dacetuzumab.,Dacetuzumab,DB00076
DB12609,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tovetumab.,Tovetumab,DB00076
DB12683,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumretuzumab.,Lumretuzumab,DB00076
DB12698,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibalizumab.,Ibalizumab,DB00076
DB12701,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Intetumumab.,Intetumumab,DB00076
DB12718,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carlumab.,Carlumab,DB00076
DB12734,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Demcizumab.,Demcizumab,DB00076
DB12773,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sifalimumab.,Sifalimumab,DB00076
DB12775,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abituzumab.,Abituzumab,DB00076
DB12797,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ecromeximab.,Ecromeximab,DB00076
DB12807,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00076
DB12815,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crotedumab.,Crotedumab,DB00076
DB12820,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Concizumab.,Concizumab,DB00076
DB12826,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab.,Depatuxizumab,DB00076
DB12844,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rontalizumab.,Rontalizumab,DB00076
DB12845,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Amatuximab.,Amatuximab,DB00076
DB12849,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clazakizumab.,Clazakizumab,DB00076
DB12891,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ozanezumab.,Ozanezumab,DB00076
DB12893,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00076
DB12917,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimekizumab.,Bimekizumab,DB00076
DB12943,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Milatuzumab.,Milatuzumab,DB00076
DB12976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Robatumumab.,Robatumumab,DB00076
DB13017,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00076
DB13037,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Namilumab.,Namilumab,DB00076
DB13045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Racotumomab.,Racotumomab,DB00076
DB13073,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tregalizumab.,Tregalizumab,DB00076
DB13127,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olokizumab.,Olokizumab,DB00076
DB13140,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bezlotoxumab.,Bezlotoxumab,DB00076
DB13375,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Edrecolomab.,Edrecolomab,DB00076
DB13535,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nebacumab.,Nebacumab,DB00076
DB13886,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00076
DB13923,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emicizumab.,Emicizumab,DB00076
DB13976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sulesomab.,Sulesomab,DB00076
DB13979,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Besilesomab.,Besilesomab,DB00076
DB14004,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tildrakizumab.,Tildrakizumab,DB00076
DB14012,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Burosumab.,Burosumab,DB00076
DB14039,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Erenumab.,Erenumab,DB00076
DB14040,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.,Eptinezumab,DB00076
DB14041,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fremanezumab.,Fremanezumab,DB00076
DB14042,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galcanezumab.,Galcanezumab,DB00076
DB14211,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fanolesomab.,Fanolesomab,DB00076
DB14580,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lecanemab.,Lecanemab,DB00076
DB14597,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lanadelumab.,Lanadelumab,DB00076
DB14707,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cemiplimab.,Cemiplimab,DB00076
DB14724,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emapalumab.,Emapalumab,DB00076
DB14762,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Risankizumab.,Risankizumab,DB00076
DB14776,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Camrelizumab.,Camrelizumab,DB00076
DB14778,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Setrusumab.,Setrusumab,DB00076
DB14784,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gancotamab.,Gancotamab,DB00076
DB14809,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00076
DB14811,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Isatuximab.,Isatuximab,DB00076
DB14824,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Icrucumab.,Icrucumab,DB00076
DB14843,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Codrituzumab.,Codrituzumab,DB00076
DB14864,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brolucizumab.,Brolucizumab,DB00076
DB14871,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Xentuzumab.,Xentuzumab,DB00076
DB14877,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lintuzumab.,Lintuzumab,DB00076
DB14891,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vobarilizumab.,Vobarilizumab,DB00076
DB14897,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Parsatuzumab.,Parsatuzumab,DB00076
DB14905,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emactuzumab.,Emactuzumab,DB00076
DB14907,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00076
DB14908,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Refanezumab.,Refanezumab,DB00076
DB14919,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozanolixizumab.,Rozanolixizumab,DB00076
DB14947,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bermekimab.,Bermekimab,DB00076
DB14952,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pamrevlumab.,Pamrevlumab,DB00076
DB14959,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Opicinumab.,Opicinumab,DB00076
DB14962,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00076
DB14967,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Margetuximab.,Margetuximab,DB00076
DB14988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalantercept.,Dalantercept,DB00076
DB14997,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pateclizumab.,Pateclizumab,DB00076
DB15014,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gremubamab.,Gremubamab,DB00076
DB15022,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apomab.,Apomab,DB00076
DB15044,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tafasitamab.,Tafasitamab,DB00076
DB15045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipafricept.,Ipafricept,DB00076
DB15076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abrilumab.,Abrilumab,DB00076
DB15089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Frovocimab.,Frovocimab,DB00076
DB15090,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tezepelumab.,Tezepelumab,DB00076
DB15101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tigatuzumab.,Tigatuzumab,DB00076
DB15104,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00076
DB15113,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Utomilumab.,Utomilumab,DB00076
DB15118,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zolbetuximab.,Zolbetuximab,DB00076
DB15135,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ponezumab.,Ponezumab,DB00076
DB15160,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asunercept.,Asunercept,DB00076
DB15172,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Suvratoxumab.,Suvratoxumab,DB00076
DB15225,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mitazalimab.,Mitazalimab,DB00076
DB15252,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nemolizumab.,Nemolizumab,DB00076
DB15253,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bleselumab.,Bleselumab,DB00076
DB15277,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gedivumab.,Gedivumab,DB00076
DB15336,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Valanafusp alfa.,Valanafusp alfa,DB00076
DB15349,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00076
DB15354,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evinacumab.,Evinacumab,DB00076
DB15363,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Istiratumab.,Istiratumab,DB00076
DB15383,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pidilizumab.,Pidilizumab,DB00076
DB15397,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GMA-161.,GMA-161,DB00076
DB15409,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00076
DB15415,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tomaralimab.,Tomaralimab,DB00076
DB15428,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vesencumab.,Vesencumab,DB00076
DB15432,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00076
DB15441,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lulizumab pegol.,Lulizumab pegol,DB00076
DB15443,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00076
DB15453,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00076
DB15559,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zenocutuzumab.,Zenocutuzumab,DB00076
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Digoxin Immune Fab (Ovine).","Ebola Zaire vaccine (live, attenuated)",DB00076
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.,Denosumab,DB00078
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.,Etanercept,DB00078
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.,Peginterferon alfa-2a,DB00078
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.,Interferon alfa-n1,DB00078
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.,Interferon alfa-n3,DB00078
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.,Peginterferon alfa-2b,DB00078
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.,Anakinra,DB00078
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.,Interferon gamma-1b,DB00078
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibritumomab tiuxetan.","Interferon alfa-2a, Recombinant",DB00078
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.,Aldesleukin,DB00078
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.,Adalimumab,DB00078
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.,Gemtuzumab ozogamicin,DB00078
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.,Pegaspargase,DB00078
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.,Infliximab,DB00078
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.,Interferon beta-1b,DB00078
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.,Interferon alfacon-1,DB00078
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.,Rituximab,DB00078
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.,Basiliximab,DB00078
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.,Muromonab,DB00078
DB00081,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.,Tositumomab,DB00078
DB00087,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.,Alemtuzumab,DB00078
DB00092,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.,Alefacept,DB00078
DB00095,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.,Efalizumab,DB00078
DB00098,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00078
DB00105,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00078
DB00111,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.,Daclizumab,DB00078
DB00112,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.,Bevacizumab,DB00078
DB00120,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.,Phenylalanine,DB00078
DB00180,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide.,Flunisolide,DB00078
DB00188,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.,Bortezomib,DB00078
DB00242,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine.,Cladribine,DB00078
DB00262,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine.,Carmustine,DB00078
DB00276,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine.,Amsacrine,DB00078
DB00290,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin.,Bleomycin,DB00078
DB00291,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil.,Chlorambucil,DB00078
DB00293,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed.,Raltitrexed,DB00078
DB00305,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin.,Mitomycin,DB00078
DB00307,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene.,Bexarotene,DB00078
DB00309,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.,Vindesine,DB00078
DB00322,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine.,Floxuridine,DB00078
DB00328,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indomethacin.,Indomethacin,DB00078
DB00352,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.,Tioguanine,DB00078
DB00361,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine.,Vinorelbine,DB00078
DB00380,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.,Dexrazoxane,DB00078
DB00394,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00078
DB00398,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib.,Sorafenib,DB00078
DB00428,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.,Streptozocin,DB00078
DB00432,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine.,Trifluridine,DB00078
DB00441,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine.,Gemcitabine,DB00078
DB00443,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone.,Betamethasone,DB00078
DB00444,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide.,Teniposide,DB00078
DB00445,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.,Epirubicin,DB00078
DB00446,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol.,Chloramphenicol,DB00078
DB00480,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide.,Lenalidomide,DB00078
DB00488,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.,Altretamine,DB00078
DB00495,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.,Zidovudine,DB00078
DB00515,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.,Cisplatin,DB00078
DB00526,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.,Oxaliplatin,DB00078
DB00531,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide.,Cyclophosphamide,DB00078
DB00541,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.,Vincristine,DB00078
DB00544,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.,Fluorouracil,DB00078
DB00550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.,Propylthiouracil,DB00078
DB00552,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.,Pentostatin,DB00078
DB00563,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate.,Methotrexate,DB00078
DB00564,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine.,Carbamazepine,DB00078
DB00570,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.,Vinblastine,DB00078
DB00588,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate.,Fluticasone propionate,DB00078
DB00591,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00078
DB00601,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid.,Linezolid,DB00078
DB00619,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imatinib.,Imatinib,DB00078
DB00620,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone.,Triamcinolone,DB00078
DB00631,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine.,Clofarabine,DB00078
DB00635,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone.,Prednisone,DB00078
DB00642,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed.,Pemetrexed,DB00078
DB00687,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone.,Fludrocortisone,DB00078
DB00688,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00078
DB00694,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.,Daunorubicin,DB00078
DB00755,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin.,Tretinoin,DB00078
DB00762,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.,Irinotecan,DB00078
DB00763,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole.,Methimazole,DB00078
DB00764,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone.,Mometasone,DB00078
DB00773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide.,Etoposide,DB00078
DB00795,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.,Sulfasalazine,DB00078
DB00851,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.,Dacarbazine,DB00078
DB00853,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide.,Temozolomide,DB00078
DB00859,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine.,Penicillamine,DB00078
DB00860,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.,Prednisolone,DB00078
DB00877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus.,Sirolimus,DB00078
DB00888,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine.,Mechlorethamine,DB00078
DB00928,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine.,Azacitidine,DB00078
DB00958,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.,Carboplatin,DB00078
DB00959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone.,Methylprednisolone,DB00078
DB00970,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.,Dactinomycin,DB00078
DB00987,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.,Cytarabine,DB00078
DB00993,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine.,Azathioprine,DB00078
DB00997,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin.,Doxorubicin,DB00078
DB01005,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxyurea.,Hydroxyurea,DB00078
DB01008,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan.,Busulfan,DB00078
DB01024,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid.,Mycophenolic acid,DB00078
DB01030,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.,Topotecan,DB00078
DB01033,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine.,Mercaptopurine,DB00078
DB01041,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide.,Thalidomide,DB00078
DB01042,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan.,Melphalan,DB00078
DB01073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine.,Fludarabine,DB00078
DB01099,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.,Flucytosine,DB00078
DB01101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine.,Capecitabine,DB00078
DB01108,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane.,Trilostane,DB00078
DB01168,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine.,Procarbazine,DB00078
DB01169,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide.,Arsenic trioxide,DB00078
DB01177,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarubicin.,Idarubicin,DB00078
DB01181,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ifosfamide.,Ifosfamide,DB00078
DB01196,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine.,Estramustine,DB00078
DB01204,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone.,Mitoxantrone,DB00078
DB01206,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine.,Lomustine,DB00078
DB01222,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide.,Budesonide,DB00078
DB01229,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel.,Paclitaxel,DB00078
DB01234,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.,Dexamethasone,DB00078
DB01248,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel.,Docetaxel,DB00078
DB01254,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib.,Dasatinib,DB00078
DB01257,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab.,Eculizumab,DB00078
DB01262,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine.,Decitabine,DB00078
DB01268,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib.,Sunitinib,DB00078
DB01280,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine.,Nelarabine,DB00078
DB01281,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept.,Abatacept,DB00078
DB01285,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin.,Corticotropin,DB00078
DB01380,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate.,Cortisone acetate,DB00078
DB01384,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paramethasone.,Paramethasone,DB00078
DB01394,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Colchicine.,Colchicine,DB00078
DB01410,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.,Ciclesonide,DB00078
DB01423,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Stepronin.,Stepronin,DB00078
DB01590,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus.,Everolimus,DB00078
DB01611,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00078
DB01816,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Castanospermine.,Castanospermine,DB00078
DB02546,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat.,Vorinostat,DB00078
DB02806,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00078
DB03523,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brequinar.,Brequinar,DB00078
DB04572,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa.,Thiotepa,DB00078
DB04630,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aldosterone.,Aldosterone,DB00078
DB04845,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone.,Ixabepilone,DB00078
DB04868,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib.,Nilotinib,DB00078
DB04951,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone.,Pirfenidone,DB00078
DB04956,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Afelimomab.,Afelimomab,DB00078
DB05015,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat.,Belinostat,DB00078
DB05109,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin.,Trabectedin,DB00078
DB05258,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa.,Interferon alfa,DB00078
DB05259,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer.,Glatiramer,DB00078
DB05260,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate.,Gallium nitrate,DB00078
DB05459,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Briakinumab.,Briakinumab,DB00078
DB05472,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with omega interferon.,omega interferon,DB00078
DB05676,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast.,Apremilast,DB00078
DB05773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00078
DB06168,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab.,Canakinumab,DB00078
DB06273,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab.,Tocilizumab,DB00078
DB06287,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus.,Temsirolimus,DB00078
DB06372,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept.,Rilonacept,DB00078
DB06589,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib.,Pazopanib,DB00078
DB06603,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat.,Panobinostat,DB00078
DB06612,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab.,Mepolizumab,DB00078
DB06616,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib.,Bosutinib,DB00078
DB06662,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abetimus.,Abetimus,DB00078
DB06674,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab.,Golimumab,DB00078
DB06681,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept.,Belatacept,DB00078
DB06769,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine.,Bendamustine,DB00078
DB06772,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel.,Cabazitaxel,DB00078
DB06813,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate.,Pralatrexate,DB00078
DB08059,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Wortmannin.,Wortmannin,DB00078
DB08870,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00078
DB08871,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin.,Eribulin,DB00078
DB08877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.,Ruxolitinib,DB00078
DB08879,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab.,Belimumab,DB00078
DB08880,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide.,Teriflunomide,DB00078
DB08889,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib.,Carfilzomib,DB00078
DB08901,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib.,Ponatinib,DB00078
DB08904,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol.,Certolizumab pegol,DB00078
DB08906,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate.,Fluticasone furoate,DB00078
DB08908,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00078
DB08910,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.,Pomalidomide,DB00078
DB08935,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab.,Obinutuzumab,DB00078
DB08970,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene.,Fluprednidene,DB00078
DB08971,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone.,Fluocortolone,DB00078
DB09029,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab.,Secukinumab,DB00078
DB09033,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab.,Vedolizumab,DB00078
DB09036,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab.,Siltuximab,DB00078
DB09052,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab.,Blinatumomab,DB00078
DB09053,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibrutinib.,Ibrutinib,DB00078
DB09054,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib.,Idelalisib,DB00078
DB09073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib.,Palbociclib,DB00078
DB09074,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.,Olaparib,DB00078
DB09077,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab.,Dinutuximab,DB00078
DB09082,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol.,Vilanterol,DB00078
DB09091,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol.,Tixocortol,DB00078
DB09122,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00078
DB09312,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00078
DB09378,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone.,Fluprednisolone,DB00078
DB09383,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone.,Meprednisone,DB00078
DB11466,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tepoxalin.,Tepoxalin,DB00078
DB11487,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00078
DB11529,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melengestrol.,Melengestrol,DB00078
DB11569,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab.,Ixekizumab,DB00078
DB11580,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab.,Ravulizumab,DB00078
DB11616,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirarubicin.,Pirarubicin,DB00078
DB11693,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin.,Voclosporin,DB00078
DB11708,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peficitinib.,Peficitinib,DB00078
DB11750,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol.,Clobetasol,DB00078
DB11767,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab.,Sarilumab,DB00078
DB11776,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab.,Brodalumab,DB00078
DB11803,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirukumab.,Sirukumab,DB00078
DB11817,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib.,Baricitinib,DB00078
DB11834,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.,Guselkumab,DB00078
DB11921,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort.,Deflazacort,DB00078
DB12025,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triptolide.,Triptolide,DB00078
DB12371,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod.,Siponimod,DB00078
DB12612,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod.,Ozanimod,DB00078
DB12617,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mizoribine.,Mizoribine,DB00078
DB12692,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gusperimus.,Gusperimus,DB00078
DB12814,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00078
DB12902,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trofosfamide.,Trofosfamide,DB00078
DB12947,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxifluridine.,Doxifluridine,DB00078
DB12991,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deoxyspergualin.,Deoxyspergualin,DB00078
DB12996,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Acteoside.,Acteoside,DB00078
DB13003,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortivazol.,Cortivazol,DB00078
DB13014,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hypericin.,Hypericin,DB00078
DB13068,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00078
DB13208,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednylidene.,Prednylidene,DB00078
DB13223,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortin.,Fluocortin,DB00078
DB13241,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Begelomab.,Begelomab,DB00078
DB13491,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluperolone.,Fluperolone,DB00078
DB13664,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Formocortal.,Formocortal,DB00078
DB13728,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Halometasone.,Halometasone,DB00078
DB13843,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cloprednol.,Cloprednol,DB00078
DB13856,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluclorolone.,Fluclorolone,DB00078
DB13867,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone.,Fluticasone,DB00078
DB14066,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetrandrine.,Tetrandrine,DB00078
DB14219,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00078
DB14512,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate.,Mometasone furoate,DB00078
DB14538,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00078
DB14539,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00078
DB14545,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00078
DB14724,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab.,Emapalumab,DB00078
DB14762,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab.,Risankizumab,DB00078
DB14919,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozanolixizumab.,Rozanolixizumab,DB00078
DB15253,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleselumab.,Bleselumab,DB00078
DB00108,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.,Natalizumab,DB00078
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.,Pimecrolimus,DB00078
DB01656,Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Roflumilast,DB00078
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.,Sipuleucel-T,DB00078
DB00363,The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine.,Clozapine,DB00078
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.,Abciximab,DB00078
DB00063,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.,Eptifibatide,DB00078
DB00208,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.,Ticlopidine,DB00078
DB00261,The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.,Anagrelide,DB00078
DB00758,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.,Clopidogrel,DB00078
DB00775,The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.,Tirofiban,DB00078
DB00806,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.,Pentoxifylline,DB00078
DB00945,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.,Acetylsalicylic acid,DB00078
DB00975,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.,Dipyridamole,DB00078
DB01088,The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.,Iloprost,DB00078
DB01138,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan.,Sulfinpyrazone,DB00078
DB01166,The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.,Cilostazol,DB00078
DB01207,The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.,Ridogrel,DB00078
DB01236,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.,Sevoflurane,DB00078
DB01240,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.,Epoprostenol,DB00078
DB02709,The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.,Resveratrol,DB00078
DB04743,The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.,Nimesulide,DB00078
DB04905,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.,Tesmilifene,DB00078
DB04932,The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.,Defibrotide,DB00078
DB05229,The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.,Beraprost,DB00078
DB05266,The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.,Ibudilast,DB00078
DB05767,The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.,Andrographolide,DB00078
DB06081,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan.,Caplacizumab,DB00078
DB06209,The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.,Prasugrel,DB00078
DB06441,The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.,Cangrelor,DB00078
DB07615,The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.,Tranilast,DB00078
DB08814,The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.,Triflusal,DB00078
DB08816,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.,Ticagrelor,DB00078
DB08887,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.,Icosapent ethyl,DB00078
DB09030,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.,Vorapaxar,DB00078
DB09283,The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.,Trapidil,DB00078
DB12092,The risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.,Naftopidil,DB00078
DB12163,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.,Sarpogrelate,DB00078
DB12321,The risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.,Ifetroban,DB00078
DB12445,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.,Nitroaspirin,DB00078
DB12465,The risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.,Ketanserin,DB00078
DB12545,The risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.,Indobufen,DB00078
DB12749,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.,Butylphthalide,DB00078
DB12771,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.,Hydroxytyrosol,DB00078
DB13036,The risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.,Ramatroban,DB00078
DB13327,The risk or severity of adverse effects can be increased when Picotamide is combined with Ibritumomab tiuxetan.,Picotamide,DB00078
DB13367,The risk or severity of adverse effects can be increased when Cloricromen is combined with Ibritumomab tiuxetan.,Cloricromen,DB00078
DB13400,The risk or severity of adverse effects can be increased when Linsidomine is combined with Ibritumomab tiuxetan.,Linsidomine,DB00078
DB13510,The risk or severity of adverse effects can be increased when Buflomedil is combined with Ibritumomab tiuxetan.,Buflomedil,DB00078
DB13929,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan.,Relcovaptan,DB00078
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan.,Sulfamethoxazole,DB00078
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Diethylstilbestrol,DB00078
DB00269,Chlorotrianisene may increase the thrombogenic activities of Ibritumomab tiuxetan.,Chlorotrianisene,DB00078
DB00286,Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.,Conjugated estrogens,DB00078
DB00655,Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estrone,DB00078
DB00783,Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol,DB00078
DB00890,Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Dienestrol,DB00078
DB00977,Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Ethinylestradiol,DB00078
DB01357,Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Mestranol,DB00078
DB04573,Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estriol,DB00078
DB04574,Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estrone sulfate,DB00078
DB04575,Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Quinestrol,DB00078
DB07931,Hexestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Hexestrol,DB00078
DB09070,Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan.,Tibolone,DB00078
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan.","Synthetic Conjugated Estrogens, A",DB00078
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan.","Synthetic Conjugated Estrogens, B",DB00078
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Polyestradiol phosphate,DB00078
DB09381,Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.,Esterified estrogens,DB00078
DB11478,Zeranol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Zeranol,DB00078
DB11674,Equol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Equol,DB00078
DB12487,Promestriene may increase the thrombogenic activities of Ibritumomab tiuxetan.,Promestriene,DB00078
DB13143,Methallenestril may increase the thrombogenic activities of Ibritumomab tiuxetan.,Methallenestril,DB00078
DB13386,Epimestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Epimestrol,DB00078
DB13418,Moxestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Moxestrol,DB00078
DB13952,Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol acetate,DB00078
DB13953,Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol benzoate,DB00078
DB13954,Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol cypionate,DB00078
DB13956,Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol valerate,DB00078
DB15334,Biochanin A may increase the thrombogenic activities of Ibritumomab tiuxetan.,Biochanin A,DB00078
DB15335,Formononetin may increase the thrombogenic activities of Ibritumomab tiuxetan.,Formononetin,DB00078
DB01097,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.,Leflunomide,DB00078
DB08895,Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00078
DB00072,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.,Trastuzumab,DB00078
DB08868,Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00078
DB00864,Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Tacrolimus,DB00078
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Ibritumomab tiuxetan.,G17DT,DB00078
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Ibritumomab tiuxetan.,PEV3A,DB00078
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.,INGN 225,DB00078
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibritumomab tiuxetan.,Rindopepimut,DB00078
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibritumomab tiuxetan.,SRP 299,DB00078
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan.,GI-5005,DB00078
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Ibritumomab tiuxetan.,Vitespen,DB00078
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibritumomab tiuxetan.,TG4010,DB00078
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan.,Anthrax immune globulin human,DB00078
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan.","Rabies virus inactivated antigen, B",DB00078
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00078
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Rotavirus vaccine,DB00078
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan.","Rabies virus inactivated antigen, A",DB00078
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00078
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00078
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00078
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00078
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00078
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00078
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Typhoid Vi polysaccharide vaccine,DB00078
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Hepatitis A Vaccine,DB00078
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00078
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00078
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00078
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00078
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00078
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibritumomab tiuxetan.,Human rabies virus immune globulin,DB00078
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.,Hepatitis B Vaccine (Recombinant),DB00078
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibritumomab tiuxetan.,Tecemotide,DB00078
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Typhoid vaccine,DB00078
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00078
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00078
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00078
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00078
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00078
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00078
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00078
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Vaccinia virus strain new york city board of health live antigen,DB00078
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Pertussis vaccine,DB00078
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00078
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.,Varicella Zoster Vaccine (Recombinant),DB00078
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan.,Modified vaccinia ankara,DB00078
DB00266,The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.,Dicoumarol,DB00078
DB00407,The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.,Ardeparin,DB00078
DB00498,The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.,Phenindione,DB00078
DB00682,The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.,Warfarin,DB00078
DB00686,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan.,Pentosan polysulfate,DB00078
DB00946,The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.,Phenprocoumon,DB00078
DB01418,The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.,Acenocoumarol,DB00078
DB03410,The risk or severity of adverse effects can be increased when 4-hydroxycoumarin is combined with Ibritumomab tiuxetan.,4-hydroxycoumarin,DB00078
DB04665,The risk or severity of adverse effects can be increased when Coumarin is combined with Ibritumomab tiuxetan.,Coumarin,DB00078
DB04898,The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.,Ximelagatran,DB00078
DB04925,The risk or severity of adverse effects can be increased when Desmoteplase is combined with Ibritumomab tiuxetan.,Desmoteplase,DB00078
DB05254,The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Ibritumomab tiuxetan.,Fibrinolysin,DB00078
DB06228,The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.,Rivaroxaban,DB00078
DB06271,The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.,Sulodexide,DB00078
DB06294,The risk or severity of adverse effects can be increased when Semuloparin is combined with Ibritumomab tiuxetan.,Semuloparin,DB00078
DB06406,The risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.,Idraparinux,DB00078
DB06543,The risk or severity of adverse effects can be increased when Astaxanthin is combined with Ibritumomab tiuxetan.,Astaxanthin,DB00078
DB06605,The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.,Apixaban,DB00078
DB06635,The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.,Otamixaban,DB00078
DB06679,The risk or severity of adverse effects can be increased when Amediplase is combined with Ibritumomab tiuxetan.,Amediplase,DB00078
DB06695,The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.,Dabigatran etexilate,DB00078
DB07767,The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.,Ferulic acid,DB00078
DB08496,The risk or severity of adverse effects can be increased when (R)-warfarin is combined with Ibritumomab tiuxetan.,(R)-warfarin,DB00078
DB08794,The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.,Ethyl biscoumacetate,DB00078
DB08994,The risk or severity of adverse effects can be increased when Ditazole is combined with Ibritumomab tiuxetan.,Ditazole,DB00078
DB09075,The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.,Edoxaban,DB00078
DB09125,The risk or severity of adverse effects can be increased when Potassium citrate is combined with Ibritumomab tiuxetan.,Potassium citrate,DB00078
DB09154,The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan.,Sodium citrate,DB00078
DB09258,The risk or severity of adverse effects can be increased when Bemiparin is combined with Ibritumomab tiuxetan.,Bemiparin,DB00078
DB09259,The risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.,Reviparin,DB00078
DB09260,The risk or severity of adverse effects can be increased when Parnaparin is combined with Ibritumomab tiuxetan.,Parnaparin,DB00078
DB09261,The risk or severity of adverse effects can be increased when Certoparin is combined with Ibritumomab tiuxetan.,Certoparin,DB00078
DB11154,The risk or severity of adverse effects can be increased when Zinc citrate is combined with Ibritumomab tiuxetan.,Zinc citrate,DB00078
DB11984,The risk or severity of adverse effects can be increased when Letaxaban is combined with Ibritumomab tiuxetan.,Letaxaban,DB00078
DB12289,The risk or severity of adverse effects can be increased when Darexaban is combined with Ibritumomab tiuxetan.,Darexaban,DB00078
DB12364,The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan.,Betrixaban,DB00078
DB12598,The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.,Nafamostat,DB00078
DB12726,The risk or severity of adverse effects can be increased when Monteplase is combined with Ibritumomab tiuxetan.,Monteplase,DB00078
DB12831,The risk or severity of adverse effects can be increased when Gabexate is combined with Ibritumomab tiuxetan.,Gabexate,DB00078
DB13136,The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan.,Fluindione,DB00078
DB13199,The risk or severity of adverse effects can be increased when Brinase is combined with Ibritumomab tiuxetan.,Brinase,DB00078
DB13275,The risk or severity of adverse effects can be increased when Clorindione is combined with Ibritumomab tiuxetan.,Clorindione,DB00078
DB13347,The risk or severity of adverse effects can be increased when Diphenadione is combined with Ibritumomab tiuxetan.,Diphenadione,DB00078
DB13451,The risk or severity of adverse effects can be increased when Tioclomarol is combined with Ibritumomab tiuxetan.,Tioclomarol,DB00078
DB13616,The risk or severity of adverse effects can be increased when Melagatran is combined with Ibritumomab tiuxetan.,Melagatran,DB00078
DB13646,The risk or severity of adverse effects can be increased when Saruplase is combined with Ibritumomab tiuxetan.,Saruplase,DB00078
DB14055,The risk or severity of adverse effects can be increased when (S)-Warfarin is combined with Ibritumomab tiuxetan.,(S)-Warfarin,DB00078
DB14094,The risk or severity of adverse effects can be increased when Tocopherylquinone is combined with Ibritumomab tiuxetan.,Tocopherylquinone,DB00078
DB14726,The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan.,Dabigatran,DB00078
DB11988,Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Ocrelizumab,DB00078
DB13200,Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00078
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan.,Rubella virus vaccine,DB00078
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Ibritumomab tiuxetan.,Varicella Zoster Vaccine (Live/attenuated),DB00078
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain tice live antigen,DB00078
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain connaught live antigen,DB00078
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Ibritumomab tiuxetan.,Yellow Fever Vaccine,DB00078
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan.,Anthrax vaccine,DB00078
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan.,Typhoid Vaccine Live,DB00078
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00078
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan.,BCG vaccine,DB00078
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ibritumomab tiuxetan.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00078
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Ibritumomab tiuxetan.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00078
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan.,Adenovirus type 7 vaccine live,DB00078
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.,Cetuximab,DB00078
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.,Human immunoglobulin G,DB00078
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan.,Omalizumab,DB00078
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.,Indium In-111 satumomab pendetide,DB00078
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.,Digoxin Immune Fab (Ovine),DB00078
DB00089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.,Capromab pendetide,DB00078
DB00110,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.,Palivizumab,DB00078
DB00113,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00078
DB01269,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab.,Panitumumab,DB00078
DB01270,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab.,Ranibizumab,DB00078
DB04901,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galiximab.,Galiximab,DB00078
DB04949,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pexelizumab.,Pexelizumab,DB00078
DB04958,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epratuzumab.,Epratuzumab,DB00078
DB04962,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bectumomab.,Bectumomab,DB00078
DB04964,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.,Oregovomab,DB00078
DB04988,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IGN311.,IGN311,DB00078
DB05006,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Adecatumumab.,Adecatumumab,DB00078
DB05097,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab.,Labetuzumab,DB00078
DB05101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Matuzumab.,Matuzumab,DB00078
DB05111,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fontolizumab.,Fontolizumab,DB00078
DB05136,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bavituximab.,Bavituximab,DB00078
DB05139,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CR002.,CR002,DB00078
DB05209,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozrolimupab.,Rozrolimupab,DB00078
DB05304,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Girentuximab.,Girentuximab,DB00078
DB05336,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab.,Obiltoxaximab,DB00078
DB05405,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XTL-001.,XTL-001,DB00078
DB05437,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with NAV 1800.,NAV 1800,DB00078
DB05496,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Otelixizumab.,Otelixizumab,DB00078
DB05545,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AMG 108.,AMG 108,DB00078
DB05550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Iratumumab.,Iratumumab,DB00078
DB05555,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Enokizumab.,Enokizumab,DB00078
DB05578,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab.,Ramucirumab,DB00078
DB05595,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Farletuzumab.,Farletuzumab,DB00078
DB05656,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Veltuzumab.,Veltuzumab,DB00078
DB05793,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with PRO-542.,PRO-542,DB00078
DB05797,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TNX-901.,TNX-901,DB00078
DB05889,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00078
DB05892,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with RI 624.,RI 624,DB00078
DB05915,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with MYO-029.,MYO-029,DB00078
DB05916,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CT-011.,CT-011,DB00078
DB05941,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leronlimab.,Leronlimab,DB00078
DB05996,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00078
DB06043,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab.,Olaratumab,DB00078
DB06049,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IPH 2101.,IPH 2101,DB00078
DB06050,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TB-402.,TB-402,DB00078
DB06101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IMC-1C11.,IMC-1C11,DB00078
DB06116,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eldelumab.,Eldelumab,DB00078
DB06162,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumiliximab.,Lumiliximab,DB00078
DB06186,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab.,Ipilimumab,DB00078
DB06192,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nimotuzumab.,Nimotuzumab,DB00078
DB06241,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clenoliximab.,Clenoliximab,DB00078
DB06304,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with BIIB015.,BIIB015,DB00078
DB06305,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sonepcizumab.,Sonepcizumab,DB00078
DB06310,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Motavizumab.,Motavizumab,DB00078
DB06317,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab.,Elotuzumab,DB00078
DB06318,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AVE9633.,AVE9633,DB00078
DB06322,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carotuximab.,Carotuximab,DB00078
DB06324,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XmAb 2513.,XmAb 2513,DB00078
DB06342,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00078
DB06343,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab.,Teprotumumab,DB00078
DB06360,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lucatumumab.,Lucatumumab,DB00078
DB06366,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab.,Pertuzumab,DB00078
DB06371,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siplizumab.,Siplizumab,DB00078
DB06467,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apolizumab.,Apolizumab,DB00078
DB06474,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sibrotuzumab.,Sibrotuzumab,DB00078
DB06550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bivatuzumab.,Bivatuzumab,DB00078
DB06557,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lerdelimumab.,Lerdelimumab,DB00078
DB06599,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lexatumumab.,Lexatumumab,DB00078
DB06602,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab.,Reslizumab,DB00078
DB06606,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab.,Teplizumab,DB00078
DB06607,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab.,Catumaxomab,DB00078
DB06647,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Volociximab.,Volociximab,DB00078
DB06650,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab.,Ofatumumab,DB00078
DB08902,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab.,Raxibacumab,DB00078
DB09035,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab.,Nivolumab,DB00078
DB09037,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab.,Pembrolizumab,DB00078
DB09045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide.,Dulaglutide,DB00078
DB09105,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa.,Asfotase alfa,DB00078
DB09264,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarucizumab.,Idarucizumab,DB00078
DB09302,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab.,Alirocumab,DB00078
DB09303,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab.,Evolocumab,DB00078
DB09331,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab.,Daratumumab,DB00078
DB09559,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab.,Necitumumab,DB00078
DB11595,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab.,Atezolizumab,DB00078
DB11604,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00078
DB11608,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00078
DB11621,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00078
DB11646,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Conatumumab.,Conatumumab,DB00078
DB11657,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tabalumab.,Tabalumab,DB00078
DB11680,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ficlatuzumab.,Ficlatuzumab,DB00078
DB11685,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Figitumumab.,Figitumumab,DB00078
DB11714,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab.,Durvalumab,DB00078
DB11715,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bapineuzumab.,Bapineuzumab,DB00078
DB11731,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00078
DB11746,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Onartuzumab.,Onartuzumab,DB00078
DB11756,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Solanezumab.,Solanezumab,DB00078
DB11771,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab.,Tremelimumab,DB00078
DB11826,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lampalizumab.,Lampalizumab,DB00078
DB11840,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalotuzumab.,Dalotuzumab,DB00078
DB11849,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emibetuzumab.,Emibetuzumab,DB00078
DB11850,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ublituximab.,Ublituximab,DB00078
DB11856,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ligelizumab.,Ligelizumab,DB00078
DB11857,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Seribantumab.,Seribantumab,DB00078
DB11862,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Landogrozumab.,Landogrozumab,DB00078
DB11866,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab.,Romosozumab,DB00078
DB11884,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00078
DB11914,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lebrikizumab.,Lebrikizumab,DB00078
DB11930,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Varlilumab.,Varlilumab,DB00078
DB11945,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab.,Avelumab,DB00078
DB11959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crenezumab.,Crenezumab,DB00078
DB11972,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilotumumab.,Rilotumumab,DB00078
DB11976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab.,Anifrolumab,DB00078
DB12023,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab.,Benralizumab,DB00078
DB12034,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gantenerumab.,Gantenerumab,DB00078
DB12053,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Visilizumab.,Visilizumab,DB00078
DB12077,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Urelumab.,Urelumab,DB00078
DB12089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00078
DB12090,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Patritumab.,Patritumab,DB00078
DB12102,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fulranumab.,Fulranumab,DB00078
DB12104,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tarextumab.,Tarextumab,DB00078
DB12118,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotatercept.,Sotatercept,DB00078
DB12119,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gevokizumab.,Gevokizumab,DB00078
DB12142,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Duligotuzumab.,Duligotuzumab,DB00078
DB12152,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Simtuzumab.,Simtuzumab,DB00078
DB12157,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasinumab.,Fasinumab,DB00078
DB12159,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.,Dupilumab,DB00078
DB12169,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab.,Tralokinumab,DB00078
DB12189,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etrolizumab.,Etrolizumab,DB00078
DB12202,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zalutumumab.,Zalutumumab,DB00078
DB12205,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ganitumab.,Ganitumab,DB00078
DB12213,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etaracizumab.,Etaracizumab,DB00078
DB12240,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00078
DB12246,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inclacumab.,Inclacumab,DB00078
DB12250,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cixutumumab.,Cixutumumab,DB00078
DB12261,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ascrinvacumab.,Ascrinvacumab,DB00078
DB12274,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab.,Aducanumab,DB00078
DB12281,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Luspatercept.,Luspatercept,DB00078
DB12296,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GS-5745.,GS-5745,DB00078
DB12317,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vanucizumab.,Vanucizumab,DB00078
DB12331,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00078
DB12335,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tanezumab.,Tanezumab,DB00078
DB12342,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ensituximab.,Ensituximab,DB00078
DB12344,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fezakinumab.,Fezakinumab,DB00078
DB12363,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dusigitumab.,Dusigitumab,DB00078
DB12396,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fresolimumab.,Fresolimumab,DB00078
DB12413,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00078
DB12456,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bococizumab.,Bococizumab,DB00078
DB12489,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00078
DB12498,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab.,Mogamulizumab,DB00078
DB12520,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Plozalizumab.,Plozalizumab,DB00078
DB12534,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mavrilimumab.,Mavrilimumab,DB00078
DB12560,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blosozumab.,Blosozumab,DB00078
DB12584,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimagrumab.,Bimagrumab,DB00078
DB12589,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacetuzumab.,Dacetuzumab,DB00078
DB12609,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tovetumab.,Tovetumab,DB00078
DB12683,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumretuzumab.,Lumretuzumab,DB00078
DB12698,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibalizumab.,Ibalizumab,DB00078
DB12701,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Intetumumab.,Intetumumab,DB00078
DB12718,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carlumab.,Carlumab,DB00078
DB12734,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Demcizumab.,Demcizumab,DB00078
DB12773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sifalimumab.,Sifalimumab,DB00078
DB12775,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abituzumab.,Abituzumab,DB00078
DB12797,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ecromeximab.,Ecromeximab,DB00078
DB12807,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00078
DB12815,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crotedumab.,Crotedumab,DB00078
DB12820,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Concizumab.,Concizumab,DB00078
DB12826,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab.,Depatuxizumab,DB00078
DB12844,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rontalizumab.,Rontalizumab,DB00078
DB12845,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amatuximab.,Amatuximab,DB00078
DB12849,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clazakizumab.,Clazakizumab,DB00078
DB12891,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanezumab.,Ozanezumab,DB00078
DB12893,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00078
DB12917,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab.,Bimekizumab,DB00078
DB12943,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Milatuzumab.,Milatuzumab,DB00078
DB12976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Robatumumab.,Robatumumab,DB00078
DB13017,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00078
DB13037,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Namilumab.,Namilumab,DB00078
DB13045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Racotumomab.,Racotumomab,DB00078
DB13073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tregalizumab.,Tregalizumab,DB00078
DB13127,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olokizumab.,Olokizumab,DB00078
DB13140,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab.,Bezlotoxumab,DB00078
DB13375,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Edrecolomab.,Edrecolomab,DB00078
DB13535,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nebacumab.,Nebacumab,DB00078
DB13886,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00078
DB13923,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab.,Emicizumab,DB00078
DB13976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab.,Sulesomab,DB00078
DB13979,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab.,Besilesomab,DB00078
DB14012,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab.,Burosumab,DB00078
DB14039,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab.,Erenumab,DB00078
DB14040,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.,Eptinezumab,DB00078
DB14041,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab.,Fremanezumab,DB00078
DB14042,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.,Galcanezumab,DB00078
DB14211,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab.,Fanolesomab,DB00078
DB14580,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lecanemab.,Lecanemab,DB00078
DB14597,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab.,Lanadelumab,DB00078
DB14707,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab.,Cemiplimab,DB00078
DB14776,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Camrelizumab.,Camrelizumab,DB00078
DB14778,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Setrusumab.,Setrusumab,DB00078
DB14784,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gancotamab.,Gancotamab,DB00078
DB14809,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00078
DB14811,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab.,Isatuximab,DB00078
DB14824,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Icrucumab.,Icrucumab,DB00078
DB14843,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Codrituzumab.,Codrituzumab,DB00078
DB14864,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab.,Brolucizumab,DB00078
DB14871,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Xentuzumab.,Xentuzumab,DB00078
DB14877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lintuzumab.,Lintuzumab,DB00078
DB14891,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vobarilizumab.,Vobarilizumab,DB00078
DB14897,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Parsatuzumab.,Parsatuzumab,DB00078
DB14905,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emactuzumab.,Emactuzumab,DB00078
DB14907,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00078
DB14908,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Refanezumab.,Refanezumab,DB00078
DB14947,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bermekimab.,Bermekimab,DB00078
DB14952,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pamrevlumab.,Pamrevlumab,DB00078
DB14959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Opicinumab.,Opicinumab,DB00078
DB14962,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00078
DB14967,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab.,Margetuximab,DB00078
DB14988,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalantercept.,Dalantercept,DB00078
DB14997,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pateclizumab.,Pateclizumab,DB00078
DB15014,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gremubamab.,Gremubamab,DB00078
DB15022,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apomab.,Apomab,DB00078
DB15044,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab.,Tafasitamab,DB00078
DB15045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipafricept.,Ipafricept,DB00078
DB15076,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abrilumab.,Abrilumab,DB00078
DB15089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Frovocimab.,Frovocimab,DB00078
DB15090,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab.,Tezepelumab,DB00078
DB15101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tigatuzumab.,Tigatuzumab,DB00078
DB15104,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00078
DB15113,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Utomilumab.,Utomilumab,DB00078
DB15118,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zolbetuximab.,Zolbetuximab,DB00078
DB15135,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponezumab.,Ponezumab,DB00078
DB15160,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asunercept.,Asunercept,DB00078
DB15172,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Suvratoxumab.,Suvratoxumab,DB00078
DB15225,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitazalimab.,Mitazalimab,DB00078
DB15252,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nemolizumab.,Nemolizumab,DB00078
DB15277,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gedivumab.,Gedivumab,DB00078
DB15336,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Valanafusp alfa.,Valanafusp alfa,DB00078
DB15349,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00078
DB15354,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evinacumab.,Evinacumab,DB00078
DB15363,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Istiratumab.,Istiratumab,DB00078
DB15383,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pidilizumab.,Pidilizumab,DB00078
DB15397,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GMA-161.,GMA-161,DB00078
DB15409,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00078
DB15415,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tomaralimab.,Tomaralimab,DB00078
DB15428,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vesencumab.,Vesencumab,DB00078
DB15432,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00078
DB15441,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lulizumab pegol.,Lulizumab pegol,DB00078
DB15443,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00078
DB15453,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00078
DB14004,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab.,Tildrakizumab,DB00078
DB05679,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab.,Ustekinumab,DB00078
DB15559,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zenocutuzumab.,Zenocutuzumab,DB00078
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.,Palifermin,DB00078
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.,Lepirudin,DB00078
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.,Bivalirudin,DB00078
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan.,Alteplase,DB00078
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan.,Urokinase,DB00078
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.,Reteplase,DB00078
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan.,Anistreplase,DB00078
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan.,Tenecteplase,DB00078
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.,Drotrecogin alfa,DB00078
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.,Streptokinase,DB00078
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan.,Argatroban,DB00078
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan.,Fondaparinux,DB00078
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Ibritumomab tiuxetan.,Heparin,DB00078
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.,Enoxaparin,DB00078
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan.,Ancrod,DB00078
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Ibritumomab tiuxetan.,Danaparoid,DB00078
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan.,Dalteparin,DB00078
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan.,Tinzaparin,DB00078
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan.,Nadroparin,DB00078
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan.,Dextran,DB00078
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan.,Desirudin,DB00078
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan.,Antithrombin Alfa,DB00078
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan.,Protein C,DB00078
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.,Antithrombin III human,DB00078
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan.,Protein S human,DB00078
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Ibritumomab tiuxetan.,Edetate calcium disodium anhydrous,DB00078
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.,Methyclothiazide,DB00078
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan.,Bendroflumethiazide,DB00078
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan.,Benzthiazide,DB00078
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan.,Cyclothiazide,DB00078
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibritumomab tiuxetan.,Hydroflumethiazide,DB00078
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan.,Chlorothiazide,DB00078
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibritumomab tiuxetan.,Hydrochlorothiazide,DB00078
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan.,Trichlormethiazide,DB00078
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan.,Polythiazide,DB00078
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Ibritumomab tiuxetan.,Mebutizide,DB00078
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan.,Cyclopenthiazide,DB00078
DB09042,The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00078
DB00091,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00078
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.,Cyanocobalamin,DB00078
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan.,Allopurinol,DB00078
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan.","Ebola Zaire vaccine (live, attenuated)",DB00078
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan.,Magnesium,DB00078
DB01601,The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir.,Lopinavir,DB00078
DB12530,The risk or severity of infection can be increased when Ibritumomab tiuxetan is combined with Inebilizumab.,Inebilizumab,DB00078
DB00175,The risk or severity of myopathy can be increased when Pravastatin is combined with Daptomycin.,Pravastatin,DB00080
DB00227,The risk or severity of myopathy can be increased when Lovastatin is combined with Daptomycin.,Lovastatin,DB00080
DB00439,The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin.,Cerivastatin,DB00080
DB00641,The risk or severity of myopathy can be increased when Simvastatin is combined with Daptomycin.,Simvastatin,DB00080
DB01076,The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin.,Atorvastatin,DB00080
DB01095,The risk or severity of myopathy can be increased when Fluvastatin is combined with Daptomycin.,Fluvastatin,DB00080
DB01098,The risk or severity of myopathy can be increased when Rosuvastatin is combined with Daptomycin.,Rosuvastatin,DB00080
DB06693,The risk or severity of myopathy can be increased when Mevastatin is combined with Daptomycin.,Mevastatin,DB00080
DB08860,The risk or severity of myopathy can be increased when Pitavastatin is combined with Daptomycin.,Pitavastatin,DB00080
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.,BCG vaccine,DB00080
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daptomycin.,Typhoid vaccine,DB00080
DB00091,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cyclosporine,DB00080
DB00159,Icosapent may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Icosapent,DB00080
DB00229,Cefotiam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotiam,DB00080
DB00244,Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mesalazine,DB00080
DB00267,Cefmenoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefmenoxime,DB00080
DB00274,Cefmetazole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefmetazole,DB00080
DB00282,Pamidronic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pamidronic acid,DB00080
DB00300,Tenofovir disoproxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir disoproxil,DB00080
DB00328,Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indomethacin,DB00080
DB00369,Cidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cidofovir,DB00080
DB00384,Triamterene may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Triamterene,DB00080
DB00430,Cefpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpiramide,DB00080
DB00438,Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftazidime,DB00080
DB00447,Loracarbef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Loracarbef,DB00080
DB00456,Cefalotin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefalotin,DB00080
DB00461,Nabumetone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nabumetone,DB00080
DB00465,Ketorolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ketorolac,DB00080
DB00469,Tenoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenoxicam,DB00080
DB00482,Celecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Celecoxib,DB00080
DB00493,Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotaxime,DB00080
DB00500,Tolmetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tolmetin,DB00080
DB00529,Foscarnet may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Foscarnet,DB00080
DB00533,Rofecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Rofecoxib,DB00080
DB00554,Piroxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Piroxicam,DB00080
DB00563,Methotrexate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Methotrexate,DB00080
DB00567,Cephalexin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephalexin,DB00080
DB00573,Fenoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fenoprofen,DB00080
DB00577,Valaciclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Valaciclovir,DB00080
DB00580,Valdecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Valdecoxib,DB00080
DB00586,Diclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Diclofenac,DB00080
DB00605,Sulindac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sulindac,DB00080
DB00626,Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bacitracin,DB00080
DB00681,Amphotericin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Amphotericin B,DB00080
DB00689,Cephaloglycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephaloglycin,DB00080
DB00712,Flurbiprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flurbiprofen,DB00080
DB00718,Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Adefovir dipivoxil,DB00080
DB00738,Pentamidine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pentamidine,DB00080
DB00742,Mannitol may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mannitol,DB00080
DB00749,Etodolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etodolac,DB00080
DB00784,Mefenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mefenamic acid,DB00080
DB00787,Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acyclovir,DB00080
DB00788,Naproxen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Naproxen,DB00080
DB00795,Sulfasalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sulfasalazine,DB00080
DB00812,Phenylbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Phenylbutazone,DB00080
DB00814,Meloxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Meloxicam,DB00080
DB00821,Carprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carprofen,DB00080
DB00833,Cefaclor may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefaclor,DB00080
DB00861,Diflunisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Diflunisal,DB00080
DB00864,Tacrolimus may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tacrolimus,DB00080
DB00903,Etacrynic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etacrynic acid,DB00080
DB00923,Ceforanide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceforanide,DB00080
DB00936,Salicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salicylic acid,DB00080
DB00939,Meclofenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Meclofenamic acid,DB00080
DB00945,Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acetylsalicylic acid,DB00080
DB00958,Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carboplatin,DB00080
DB00991,Oxaprozin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Oxaprozin,DB00080
DB00999,Hydrochlorothiazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hydrochlorothiazide,DB00080
DB01009,Ketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ketoprofen,DB00080
DB01014,Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Balsalazide,DB00080
DB01050,Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ibuprofen,DB00080
DB01066,Cefditoren may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefditoren,DB00080
DB01072,Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Atazanavir,DB00080
DB01111,Colistimethate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Colistimethate,DB00080
DB01112,Cefuroxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefuroxime,DB00080
DB01139,Cefapirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefapirin,DB00080
DB01140,Cefadroxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefadroxil,DB00080
DB01150,Cefprozil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefprozil,DB00080
DB01212,Ceftriaxone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftriaxone,DB00080
DB01250,Olsalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Olsalazine,DB00080
DB01283,Lumiracoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lumiracoxib,DB00080
DB01326,Cefamandole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefamandole,DB00080
DB01327,Cefazolin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefazolin,DB00080
DB01328,Cefonicid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefonicid,DB00080
DB01329,Cefoperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefoperazone,DB00080
DB01330,Cefotetan may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotetan,DB00080
DB01331,Cefoxitin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefoxitin,DB00080
DB01332,Ceftizoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftizoxime,DB00080
DB01333,Cefradine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefradine,DB00080
DB01397,Magnesium salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Magnesium salicylate,DB00080
DB01399,Salsalate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salsalate,DB00080
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Choline magnesium trisalicylate,DB00080
DB01413,Cefepime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefepime,DB00080
DB01414,Cefacetrile may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefacetrile,DB00080
DB01415,Ceftibuten may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftibuten,DB00080
DB01416,Cefpodoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpodoxime,DB00080
DB01419,Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Antrafenine,DB00080
DB01424,Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aminophenazone,DB00080
DB01435,Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Antipyrine,DB00080
DB01600,Tiaprofenic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tiaprofenic acid,DB00080
DB01601,Lopinavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lopinavir,DB00080
DB01628,Etoricoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etoricoxib,DB00080
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hydrolyzed Cephalothin,DB00080
DB03450,Cephalothin Group may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephalothin Group,DB00080
DB03585,Oxyphenbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Oxyphenbutazone,DB00080
DB04552,Niflumic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Niflumic acid,DB00080
DB04570,Latamoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Latamoxef,DB00080
DB04743,Nimesulide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nimesulide,DB00080
DB04812,Benoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benoxaprofen,DB00080
DB04817,Metamizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Metamizole,DB00080
DB04828,Zomepirac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Zomepirac,DB00080
DB04918,Ceftobiprole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftobiprole,DB00080
DB05095,Cimicoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cimicoxib,DB00080
DB06590,Ceftaroline fosamil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftaroline fosamil,DB00080
DB06725,Lornoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lornoxicam,DB00080
DB06736,Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aceclofenac,DB00080
DB06737,Zaltoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Zaltoprofen,DB00080
DB07402,Azapropazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Azapropazone,DB00080
DB07477,Felbinac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Felbinac,DB00080
DB08439,Parecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Parecoxib,DB00080
DB08797,Salicylamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salicylamide,DB00080
DB08940,Kebuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Kebuzone,DB00080
DB08942,Isoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Isoxicam,DB00080
DB08951,Indoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indoprofen,DB00080
DB08955,Ibuproxam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ibuproxam,DB00080
DB08976,Floctafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Floctafenine,DB00080
DB08981,Fenbufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fenbufen,DB00080
DB08984,Etofenamate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etofenamate,DB00080
DB08991,Epirizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Epirizole,DB00080
DB09008,Cefaloridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefaloridine,DB00080
DB09062,Cefminox may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefminox,DB00080
DB09084,Benzydamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benzydamine,DB00080
DB09212,Loxoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Loxoprofen,DB00080
DB09213,Dexibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dexibuprofen,DB00080
DB09214,Dexketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dexketoprofen,DB00080
DB09215,Droxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Droxicam,DB00080
DB09216,Tolfenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tolfenamic acid,DB00080
DB09217,Firocoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Firocoxib,DB00080
DB09218,Clonixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Clonixin,DB00080
DB09285,Morniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Morniflumate,DB00080
DB09288,Propacetamol may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Propacetamol,DB00080
DB09295,Talniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Talniflumate,DB00080
DB09299,Tenofovir alafenamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir alafenamide,DB00080
DB11367,Cefroxadine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefroxadine,DB00080
DB11455,Robenacoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Robenacoxib,DB00080
DB11466,Tepoxalin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tepoxalin,DB00080
DB11518,Flunixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flunixin,DB00080
DB11935,Flomoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flomoxef,DB00080
DB12151,Brincidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Brincidofovir,DB00080
DB12445,Nitroaspirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nitroaspirin,DB00080
DB12545,Indobufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indobufen,DB00080
DB13001,Tinoridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tinoridine,DB00080
DB13167,Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Alclofenac,DB00080
DB13217,Fentiazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fentiazac,DB00080
DB13232,Suxibuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Suxibuzone,DB00080
DB13266,Cefatrizine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefatrizine,DB00080
DB13286,Bumadizone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bumadizone,DB00080
DB13314,Alminoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Alminoprofen,DB00080
DB13317,Flunoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flunoxaprofen,DB00080
DB13364,Feprazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Feprazone,DB00080
DB13371,Difenpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Difenpiramide,DB00080
DB13407,Nifenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nifenazone,DB00080
DB13432,Lonazolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lonazolac,DB00080
DB13461,Cefcapene may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefcapene,DB00080
DB13470,Cefodizime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefodizime,DB00080
DB13481,Tenidap may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenidap,DB00080
DB13499,Cefsulodin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefsulodin,DB00080
DB13501,Bendazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bendazac,DB00080
DB13504,Cefetamet may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefetamet,DB00080
DB13514,Pranoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pranoprofen,DB00080
DB13524,Propyphenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Propyphenazone,DB00080
DB13527,Proglumetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Proglumetacin,DB00080
DB13538,Guacetisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Guacetisal,DB00080
DB13544,Ethenzamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ethenzamide,DB00080
DB13612,Carbaspirin calcium may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carbaspirin calcium,DB00080
DB13629,Mofebutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mofebutazone,DB00080
DB13638,Cefbuperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefbuperazone,DB00080
DB13649,Proquazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Proquazone,DB00080
DB13657,Benorilate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benorilate,DB00080
DB13667,Cefozopran may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefozopran,DB00080
DB13682,Cefpirome may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpirome,DB00080
DB13722,Pirprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pirprofen,DB00080
DB13778,Cefazedone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefazedone,DB00080
DB13783,Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acemetacin,DB00080
DB13821,Ceftezole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftezole,DB00080
DB13860,Imidazole salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Imidazole salicylate,DB00080
DB13868,Adefovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Adefovir,DB00080
DB14059,SC-236 may decrease the excretion rate of Daptomycin which could result in a higher serum level.,SC-236,DB00080
DB14060,NS-398 may decrease the excretion rate of Daptomycin which could result in a higher serum level.,NS-398,DB00080
DB14126,Tenofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir,DB00080
DB14713,Inotersen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Inotersen,DB00080
DB01438,Phenazopyridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Phenazopyridine,DB00080
DB15066,Givosiran may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Givosiran,DB00080
DB01356,Lithium cation may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lithium cation,DB00080
DB14507,Lithium citrate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lithium citrate,DB00080
DB00014,Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Goserelin,DB00080
DB00017,Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salmon calcitonin,DB00080
DB00035,Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Desmopressin,DB00080
DB00041,Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aldesleukin,DB00080
DB00081,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tositumomab,DB00080
DB00115,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyanocobalamin,DB00080
DB00158,Daptomycin may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid,DB00080
DB00165,Daptomycin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine,DB00080
DB00176,Daptomycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine,DB00080
DB00182,Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine,DB00080
DB00185,Daptomycin may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline,DB00080
DB00186,Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam,DB00080
DB00190,Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa,DB00080
DB00193,Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol,DB00080
DB00196,Daptomycin may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole,DB00080
DB00198,Daptomycin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir,DB00080
DB00200,Daptomycin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin,DB00080
DB00206,Daptomycin may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine,DB00080
DB00208,Daptomycin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.,Ticlopidine,DB00080
DB00213,Daptomycin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole,DB00080
DB00225,Daptomycin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide,DB00080
DB00230,Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin,DB00080
DB00231,Daptomycin may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam,DB00080
DB00235,Daptomycin may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone,DB00080
DB00237,Daptomycin may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital,DB00080
DB00243,Daptomycin may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine,DB00080
DB00245,Daptomycin may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine,DB00080
DB00254,Daptomycin may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline,DB00080
DB00262,Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.,Carmustine,DB00080
DB00264,Daptomycin may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol,DB00080
DB00270,Daptomycin may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine,DB00080
DB00271,Daptomycin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate,DB00080
DB00273,Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate,DB00080
DB00279,Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine,DB00080
DB00280,Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide,DB00080
DB00284,Daptomycin may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose,DB00080
DB00285,Daptomycin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine,DB00080
DB00286,Daptomycin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens,DB00080
DB00289,Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine,DB00080
DB00290,Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.,Bleomycin,DB00080
DB00292,Daptomycin may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate,DB00080
DB00294,Daptomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel,DB00080
DB00296,Daptomycin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine,DB00080
DB00303,Daptomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem,DB00080
DB00308,Daptomycin may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide,DB00080
DB00312,Daptomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital,DB00080
DB00316,Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen,DB00080
DB00319,Daptomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin,DB00080
DB00322,Daptomycin may decrease the excretion rate of Floxuridine which could result in a higher serum level.,Floxuridine,DB00080
DB00323,Daptomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone,DB00080
DB00325,Daptomycin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside,DB00080
DB00327,Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone,DB00080
DB00330,Daptomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol,DB00080
DB00331,Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin,DB00080
DB00333,Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone,DB00080
DB00339,Daptomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide,DB00080
DB00341,Daptomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine,DB00080
DB00349,Daptomycin may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam,DB00080
DB00351,Daptomycin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate,DB00080
DB00355,Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam,DB00080
DB00356,Daptomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone,DB00080
DB00359,Daptomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine,DB00080
DB00363,Daptomycin may decrease the excretion rate of Clozapine which could result in a higher serum level.,Clozapine,DB00080
DB00364,Daptomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate,DB00080
DB00372,Daptomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine,DB00080
DB00373,Daptomycin may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol,DB00080
DB00377,Daptomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron,DB00080
DB00380,Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.,Dexrazoxane,DB00080
DB00398,Daptomycin may decrease the excretion rate of Sorafenib which could result in a higher serum level.,Sorafenib,DB00080
DB00401,Daptomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine,DB00080
DB00402,Daptomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone,DB00080
DB00404,Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam,DB00080
DB00412,Daptomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone,DB00080
DB00413,Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole,DB00080
DB00415,Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin,DB00080
DB00418,Daptomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital,DB00080
DB00422,Daptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate,DB00080
DB00432,Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level.,Trifluridine,DB00080
DB00435,Daptomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide,DB00080
DB00437,Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.,Allopurinol,DB00080
DB00441,Daptomycin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.,Gemcitabine,DB00080
DB00476,Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine,DB00080
DB00477,Daptomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine,DB00080
DB00480,Daptomycin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.,Lenalidomide,DB00080
DB00490,Daptomycin may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone,DB00080
DB00492,Daptomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril,DB00080
DB00499,Daptomycin may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide,DB00080
DB00502,Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol,DB00080
DB00535,Daptomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir,DB00080
DB00548,Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid,DB00080
DB00553,Daptomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen,DB00080
DB00555,Daptomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine,DB00080
DB00558,Daptomycin may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir,DB00080
DB00569,Daptomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux,DB00080
DB00571,Daptomycin may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol,DB00080
DB00583,Daptomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine,DB00080
DB00591,Daptomycin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.,Fluocinolone acetonide,DB00080
DB00597,Daptomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol,DB00080
DB00598,Daptomycin may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol,DB00080
DB00603,Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate,DB00080
DB00612,Daptomycin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol,DB00080
DB00624,Daptomycin may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone,DB00080
DB00628,Daptomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid,DB00080
DB00631,Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level.,Clofarabine,DB00080
DB00633,Daptomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine,DB00080
DB00635,Daptomycin may decrease the excretion rate of Prednisone which could result in a higher serum level.,Prednisone,DB00080
DB00651,Daptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline,DB00080
DB00657,Daptomycin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine,DB00080
DB00660,Daptomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone,DB00080
DB00661,Daptomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil,DB00080
DB00665,Daptomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide,DB00080
DB00669,Daptomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan,DB00080
DB00672,Daptomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide,DB00080
DB00683,Daptomycin may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam,DB00080
DB00690,Daptomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam,DB00080
DB00692,Daptomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine,DB00080
DB00698,Daptomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin,DB00080
DB00706,Daptomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin,DB00080
DB00713,Daptomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin,DB00080
DB00716,Daptomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil,DB00080
DB00722,Daptomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril,DB00080
DB00730,Daptomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole,DB00080
DB00731,Daptomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide,DB00080
DB00733,Daptomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime,DB00080
DB00743,Daptomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid,DB00080
DB00759,Daptomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline,DB00080
DB00760,Daptomycin may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem,DB00080
DB00761,Daptomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride,DB00080
DB00763,Daptomycin may decrease the excretion rate of Methimazole which could result in a higher serum level.,Methimazole,DB00080
DB00775,Daptomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban,DB00080
DB00780,Daptomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine,DB00080
DB00782,Daptomycin may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline,DB00080
DB00783,Daptomycin may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol,DB00080
DB00789,Daptomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid,DB00080
DB00790,Daptomycin may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril,DB00080
DB00800,Daptomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam,DB00080
DB00804,Daptomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine,DB00080
DB00806,Daptomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline,DB00080
DB00811,Daptomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin,DB00080
DB00820,Daptomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil,DB00080
DB00828,Daptomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin,DB00080
DB00829,Daptomycin may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam,DB00080
DB00839,Daptomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide,DB00080
DB00841,Daptomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine,DB00080
DB00842,Daptomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam,DB00080
DB00851,Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.,Dacarbazine,DB00080
DB00853,Daptomycin may decrease the excretion rate of Temozolomide which could result in a higher serum level.,Temozolomide,DB00080
DB00871,Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline,DB00080
DB00894,Daptomycin may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone,DB00080
DB00900,Daptomycin may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine,DB00080
DB00911,Daptomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole,DB00080
DB00915,Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine,DB00080
DB00918,Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan,DB00080
DB00928,Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level.,Azacitidine,DB00080
DB00934,Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline,DB00080
DB00953,Daptomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan,DB00080
DB00960,Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol,DB00080
DB00961,Daptomycin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine,DB00080
DB00962,Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon,DB00080
DB00980,Daptomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon,DB00080
DB00988,Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine,DB00080
DB00993,Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level.,Azathioprine,DB00080
DB00995,Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin,DB00080
DB01001,Daptomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol,DB00080
DB01002,Daptomycin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine,DB00080
DB01010,Daptomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium,DB00080
DB01011,Daptomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone,DB00080
DB01018,Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine,DB00080
DB01020,Daptomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate,DB00080
DB01022,Daptomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone,DB00080
DB01024,Daptomycin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.,Mycophenolic acid,DB00080
DB01030,Daptomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.,Topotecan,DB00080
DB01032,Daptomycin may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid,DB00080
DB01036,Daptomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine,DB00080
DB01043,Daptomycin may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine,DB00080
DB01046,Daptomycin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone,DB00080
DB01048,Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir,DB00080
DB01060,Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin,DB00080
DB01067,Daptomycin may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide,DB00080
DB01068,Daptomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam,DB00080
DB01069,Daptomycin may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine,DB00080
DB01093,Daptomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide,DB00080
DB01099,Daptomycin may decrease the excretion rate of Flucytosine which could result in a higher serum level.,Flucytosine,DB00080
DB01101,Daptomycin may decrease the excretion rate of Capecitabine which could result in a higher serum level.,Capecitabine,DB00080
DB01105,Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine,DB00080
DB01115,Daptomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine,DB00080
DB01124,Daptomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide,DB00080
DB01129,Daptomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole,DB00080
DB01133,Daptomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid,DB00080
DB01135,Daptomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium,DB00080
DB01137,Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin,DB00080
DB01148,Daptomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate,DB00080
DB01149,Daptomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone,DB00080
DB01156,Daptomycin may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion,DB00080
DB01157,Daptomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate,DB00080
DB01166,Daptomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level.,Cilostazol,DB00080
DB01169,Daptomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.,Arsenic trioxide,DB00080
DB01170,Daptomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine,DB00080
DB01181,Daptomycin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.,Ifosfamide,DB00080
DB01183,Daptomycin may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone,DB00080
DB01203,Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol,DB00080
DB01205,Daptomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil,DB00080
DB01213,Daptomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole,DB00080
DB01215,Daptomycin may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam,DB00080
DB01221,Daptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine,DB00080
DB01222,Daptomycin may decrease the excretion rate of Budesonide which could result in a higher serum level.,Budesonide,DB00080
DB01224,Daptomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine,DB00080
DB01240,Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol,DB00080
DB01249,Daptomycin may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol,DB00080
DB01261,Daptomycin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin,DB00080
DB01267,Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone,DB00080
DB01273,Daptomycin may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline,DB00080
DB01274,Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol,DB00080
DB01275,Daptomycin may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine,DB00080
DB01359,Daptomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol,DB00080
DB01367,Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline,DB00080
DB01409,Daptomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium,DB00080
DB01420,Daptomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate,DB00080
DB01427,Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone,DB00080
DB01428,Daptomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone,DB00080
DB01431,Daptomycin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol,DB00080
DB01550,Daptomycin may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex,DB00080
DB01558,Daptomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam,DB00080
DB01563,Daptomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate,DB00080
DB01577,Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine,DB00080
DB01587,Daptomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam,DB00080
DB01610,Daptomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir,DB00080
DB01638,Daptomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol,DB00080
DB01656,Daptomycin may decrease the excretion rate of Roflumilast which could result in a higher serum level.,Roflumilast,DB00080
DB01685,Daptomycin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat,DB00080
DB04574,Daptomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate,DB00080
DB04871,Daptomycin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin,DB00080
DB04895,Daptomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib,DB00080
DB04896,Daptomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran,DB00080
DB04920,Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine,DB00080
DB04948,Daptomycin may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine,DB00080
DB04953,Daptomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine,DB00080
DB05018,Daptomycin may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat,DB00080
DB05541,Daptomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam,DB00080
DB05676,Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level.,Apremilast,DB00080
DB06154,Daptomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate,DB00080
DB06186,Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab,DB00080
DB06196,Daptomycin may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant,DB00080
DB06203,Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin,DB00080
DB06209,Daptomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel,DB00080
DB06211,Daptomycin may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem,DB00080
DB06228,Daptomycin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.,Rivaroxaban,DB00080
DB06230,Daptomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene,DB00080
DB06262,Daptomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa,DB00080
DB06282,Daptomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine,DB00080
DB06335,Daptomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin,DB00080
DB06402,Daptomycin may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin,DB00080
DB06480,Daptomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride,DB00080
DB06623,Daptomycin may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine,DB00080
DB06637,Daptomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine,DB00080
DB06695,Daptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.,Dabigatran etexilate,DB00080
DB06700,Daptomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine,DB00080
DB06702,Daptomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine,DB00080
DB06705,Daptomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium,DB00080
DB06710,Daptomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone,DB00080
DB06767,Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride,DB00080
DB06782,Daptomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol,DB00080
DB06796,Daptomycin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir,DB00080
DB06800,Daptomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone,DB00080
DB06809,Daptomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor,DB00080
DB06813,Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.,Pralatrexate,DB00080
DB06823,Daptomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin,DB00080
DB06824,Daptomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine,DB00080
DB08824,Daptomycin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123,DB00080
DB08826,Daptomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone,DB00080
DB08840,Daptomycin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide,DB00080
DB08872,Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil,DB00080
DB08877,Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.,Ruxolitinib,DB00080
DB08893,Daptomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron,DB00080
DB08894,Daptomycin may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide,DB00080
DB08897,Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium,DB00080
DB08899,Daptomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide,DB00080
DB08900,Daptomycin may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide,DB00080
DB08904,Daptomycin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.,Certolizumab pegol,DB00080
DB08905,Daptomycin may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane,DB00080
DB08909,Daptomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate,DB00080
DB08910,Daptomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.,Pomalidomide,DB00080
DB08911,Daptomycin may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib,DB00080
DB08918,Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran,DB00080
DB08932,Daptomycin may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan,DB00080
DB08934,Daptomycin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir,DB00080
DB08964,Daptomycin may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost,DB00080
DB09027,Daptomycin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir,DB00080
DB09050,Daptomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane,DB00080
DB09066,Daptomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa,DB00080
DB09068,Daptomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine,DB00080
DB09071,Daptomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon,DB00080
DB09075,Daptomycin may decrease the excretion rate of Edoxaban which could result in a higher serum level.,Edoxaban,DB00080
DB09081,Daptomycin may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone,DB00080
DB09082,Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.,Vilanterol,DB00080
DB09089,Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine,DB00080
DB09091,Daptomycin may decrease the excretion rate of Tixocortol which could result in a higher serum level.,Tixocortol,DB00080
DB09103,Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim,DB00080
DB09104,Daptomycin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide,DB00080
DB09106,Daptomycin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch,DB00080
DB09111,Daptomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch,DB00080
DB09118,Daptomycin may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol,DB00080
DB09121,Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose,DB00080
DB09123,Daptomycin may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest,DB00080
DB09129,Daptomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride,DB00080
DB09132,Daptomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid,DB00080
DB09133,Daptomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid,DB00080
DB09134,Daptomycin may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol,DB00080
DB09135,Daptomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan,DB00080
DB09136,Daptomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue,DB00080
DB09137,Daptomycin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin,DB00080
DB09139,Daptomycin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate,DB00080
DB09148,Daptomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F),DB00080
DB09149,Daptomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F),DB00080
DB09156,Daptomycin may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide,DB00080
DB09163,Daptomycin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime,DB00080
DB09165,Daptomycin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate,DB00080
DB09185,Daptomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine,DB00080
DB09194,Daptomycin may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone,DB00080
DB09195,Daptomycin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole,DB00080
DB09204,Daptomycin may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol,DB00080
DB09205,Daptomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte,DB00080
DB09209,Daptomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine,DB00080
DB09210,Daptomycin may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam,DB00080
DB09219,Daptomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin,DB00080
DB09220,Daptomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil,DB00080
DB09223,Daptomycin may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin,DB00080
DB09224,Daptomycin may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone,DB00080
DB09241,Daptomycin may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue,DB00080
DB09244,Daptomycin may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole,DB00080
DB09245,Daptomycin may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone,DB00080
DB09255,Daptomycin may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran,DB00080
DB09256,Daptomycin may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur,DB00080
DB09257,Daptomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil,DB00080
DB09262,Daptomycin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin,DB00080
DB09264,Daptomycin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab,DB00080
DB09265,Daptomycin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide,DB00080
DB09268,Daptomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid,DB00080
DB09276,Daptomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate,DB00080
DB09277,Daptomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11,DB00080
DB09281,Daptomycin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate,DB00080
DB09292,Daptomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril,DB00080
DB09301,Daptomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate,DB00080
DB09317,"Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A",DB00080
DB09318,"Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B",DB00080
DB09320,Daptomycin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin,DB00080
DB09324,Daptomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam,DB00080
DB09325,Daptomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride,DB00080
DB09329,"Daptomycin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated",DB00080
DB09344,Daptomycin may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar,DB00080
DB09357,Daptomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol,DB00080
DB09394,Daptomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid,DB00080
DB09395,Daptomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate,DB00080
DB09407,Daptomycin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride,DB00080
DB09418,Daptomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate,DB00080
DB09472,Daptomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate,DB00080
DB09477,Daptomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat,DB00080
DB09481,Daptomycin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate,DB00080
DB09488,Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine,DB00080
DB09496,Daptomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate,DB00080
DB09502,Daptomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F),DB00080
DB09546,Daptomycin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123,DB00080
DB09570,Daptomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib,DB00080
DB11077,Daptomycin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400,DB00080
DB11090,Daptomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate,DB00080
DB11098,Daptomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate,DB00080
DB11102,Daptomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine,DB00080
DB11114,Daptomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil,DB00080
DB11127,Daptomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid,DB00080
DB11130,Daptomycin may decrease the excretion rate of Opium which could result in a higher serum level.,Opium,DB00080
DB11135,Daptomycin may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium,DB00080
DB11136,Daptomycin may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium,DB00080
DB11145,Daptomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline,DB00080
DB11156,Daptomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel,DB00080
DB11164,Daptomycin may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate,DB00080
DB11251,Daptomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol,DB00080
DB11278,Daptomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine,DB00080
DB11328,Daptomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester),DB00080
DB11338,Daptomycin may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil,DB00080
DB11358,Daptomycin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil,DB00080
DB11364,Daptomycin may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod,DB00080
DB11560,Daptomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad,DB00080
DB11577,Daptomycin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid,DB00080
DB11587,Daptomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine,DB00080
DB11598,Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human,DB00080
DB11642,Daptomycin may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant,DB00080
DB11691,Daptomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine,DB00080
DB11699,Daptomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron,DB00080
DB11817,Daptomycin may decrease the excretion rate of Baricitinib which could result in a higher serum level.,Baricitinib,DB00080
DB11901,Daptomycin may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide,DB00080
DB11915,Daptomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine,DB00080
DB11943,Daptomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin,DB00080
DB11989,Daptomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole,DB00080
DB12007,Daptomycin may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone,DB00080
DB12107,Daptomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam,DB00080
DB12161,Daptomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine,DB00080
DB12278,Daptomycin may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine,DB00080
DB12783,Daptomycin may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide,DB00080
DB13025,Daptomycin may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride,DB00080
DB13139,Daptomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol,DB00080
DB13156,Daptomycin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex,DB00080
DB13178,Daptomycin may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol,DB00080
DB13185,Daptomycin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate,DB00080
DB13191,Daptomycin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine,DB00080
DB13269,Daptomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol,DB00080
DB13595,Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate,DB00080
DB13884,Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa,DB00080
DB13909,Daptomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate,DB00080
DB13943,Daptomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate,DB00080
DB13944,Daptomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate,DB00080
DB13946,Daptomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate,DB00080
DB13952,Daptomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate,DB00080
DB13954,Daptomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate,DB00080
DB13955,Daptomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate,DB00080
DB13956,Daptomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate,DB00080
DB13967,Daptomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue,DB00080
DB14006,Daptomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate,DB00080
DB14007,Daptomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid,DB00080
DB14498,Daptomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate,DB00080
DB14499,Daptomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate,DB00080
DB14526,Daptomycin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate,DB00080
DB14527,Daptomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate,DB00080
DB14528,Daptomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate,DB00080
DB14529,Daptomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate,DB00080
DB14530,Daptomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate,DB00080
DB14754,Daptomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol,DB00080
DB06815,Daptomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione,DB00080
DB11121,Daptomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol,DB00080
DB11085,Daptomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol,DB00080
DB15593,Daptomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen,DB00080
DB00321,Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline,DB00080
DB00458,Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine,DB00080
DB01142,Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin,DB00080
DB00318,Daptomycin may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine,DB00080
DB00454,Daptomycin may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine,DB00080
DB00813,Daptomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl,DB00080
DB00879,Daptomycin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine,DB00080
DB01151,Daptomycin may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine,DB00080
DB01242,Daptomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine,DB00080
DB08996,Daptomycin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine,DB00080
DB14506,Daptomycin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide,DB00080
DB00452,Framycetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Framycetin,DB00080
DB00479,Amikacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Amikacin,DB00080
DB00684,Tobramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tobramycin,DB00080
DB00798,Gentamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Gentamicin,DB00080
DB00955,Netilmicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Netilmicin,DB00080
DB00994,Neomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Neomycin,DB00080
DB01082,Streptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Streptomycin,DB00080
DB01172,Kanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Kanamycin,DB00080
DB01421,Paromomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Paromomycin,DB00080
DB03615,Ribostamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ribostamycin,DB00080
DB04263,Geneticin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Geneticin,DB00080
DB04626,Apramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Apramycin,DB00080
DB04729,Gentamicin C1a may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Gentamicin C1a,DB00080
DB04808,Neamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Neamine,DB00080
DB06696,Arbekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Arbekacin,DB00080
DB08437,Puromycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Puromycin,DB00080
DB11512,Dihydrostreptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dihydrostreptomycin,DB00080
DB11520,Hygromycin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hygromycin B,DB00080
DB12604,Sisomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sisomicin,DB00080
DB13270,Dibekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dibekacin,DB00080
DB13274,Micronomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Micronomicin,DB00080
DB13540,Isepamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Isepamicin,DB00080
DB13673,Bekanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bekanamycin,DB00080
DB00552,Daptomycin may decrease the excretion rate of Pentostatin which could result in a higher serum level.,Pentostatin,DB00080
DB13145,Daptomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin,DB00080
DB00314,Daptomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin,DB00080
DB00390,Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin,DB00080
DB00512,Daptomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin,DB00080
DB00515,Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.,Cisplatin,DB00080
DB00564,Daptomycin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.,Carbamazepine,DB00080
DB00642,Daptomycin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.,Pemetrexed,DB00080
DB00682,Daptomycin may decrease the excretion rate of Warfarin which could result in a higher serum level.,Warfarin,DB00080
DB00908,Daptomycin may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine,DB00080
DB00982,Daptomycin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin,DB00080
DB01035,Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide,DB00080
DB12615,Daptomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin,DB00080
DB14509,Daptomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate,DB00080
DB00524,Daptomycin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone,DB00080
DB00695,Daptomycin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide,DB00080
DB00808,Daptomycin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide,DB00080
DB00909,Daptomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide,DB00080
DB08907,Daptomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin,DB00080
DB09338,Daptomycin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl,DB00080
DB00214,Torasemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide,DB00080
DB00232,Methyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide,DB00080
DB00310,Chlorthalidone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone,DB00080
DB00311,Ethoxzolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide,DB00080
DB00421,Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone,DB00080
DB00436,Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide,DB00080
DB00562,Benzthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide,DB00080
DB00594,Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride,DB00080
DB00606,Cyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide,DB00080
DB00700,Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone,DB00080
DB00703,Methazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide,DB00080
DB00774,Hydroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide,DB00080
DB00819,Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide,DB00080
DB00872,Conivaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan,DB00080
DB00880,Chlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide,DB00080
DB01021,Trichlormethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide,DB00080
DB01119,Diazoxide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide,DB00080
DB01144,Diclofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide,DB00080
DB01324,Polythiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide,DB00080
DB01325,Quinethazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone,DB00080
DB01395,Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone,DB00080
DB01412,Theobromine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine,DB00080
DB02925,Piretanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide,DB00080
DB04831,Tienilic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid,DB00080
DB05034,Ularitide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide,DB00080
DB06212,Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan,DB00080
DB06292,Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin,DB00080
DB06370,Indisulam may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam,DB00080
DB08961,Azosemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide,DB00080
DB09015,Canrenoic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid,DB00080
DB09125,Potassium citrate may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium citrate,DB00080
DB09235,Efonidipine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine,DB00080
DB09401,Isosorbide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide,DB00080
DB11827,Ertugliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin,DB00080
DB12221,Canrenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone,DB00080
DB12670,Rolofylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline,DB00080
DB12704,Spiradoline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline,DB00080
DB12766,Cicletanine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine,DB00080
DB13284,Meticrane may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane,DB00080
DB13316,Ibopamine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine,DB00080
DB13405,Mefruside may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside,DB00080
DB13430,Mebutizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide,DB00080
DB13532,Cyclopenthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide,DB00080
DB13617,Clorexolone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone,DB00080
DB13663,Clofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide,DB00080
DB13708,Fenquizone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone,DB00080
DB13792,Clopamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide,DB00080
DB13801,Muzolimine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine,DB00080
DB13803,Xipamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide,DB00080
DB13989,Epitizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide,DB00080
DB14018,Bromotheophylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline,DB00080
DB14500,Potassium may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium,DB00080
DB00266,The risk or severity of bleeding can be increased when Daptomycin is combined with Dicoumarol.,Dicoumarol,DB00080
DB00498,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenindione.,Phenindione,DB00080
DB00946,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenprocoumon.,Phenprocoumon,DB00080
DB01418,The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.,Acenocoumarol,DB00080
DB03410,The risk or severity of bleeding can be increased when Daptomycin is combined with 4-hydroxycoumarin.,4-hydroxycoumarin,DB00080
DB04665,The risk or severity of bleeding can be increased when Daptomycin is combined with Coumarin.,Coumarin,DB00080
DB08496,The risk or severity of bleeding can be increased when Daptomycin is combined with (R)-warfarin.,(R)-warfarin,DB00080
DB08794,The risk or severity of bleeding can be increased when Daptomycin is combined with Ethyl biscoumacetate.,Ethyl biscoumacetate,DB00080
DB13136,The risk or severity of bleeding can be increased when Daptomycin is combined with Fluindione.,Fluindione,DB00080
DB13275,The risk or severity of bleeding can be increased when Daptomycin is combined with Clorindione.,Clorindione,DB00080
DB13347,The risk or severity of bleeding can be increased when Daptomycin is combined with Diphenadione.,Diphenadione,DB00080
DB13451,The risk or severity of bleeding can be increased when Daptomycin is combined with Tioclomarol.,Tioclomarol,DB00080
DB14055,The risk or severity of bleeding can be increased when Daptomycin is combined with (S)-Warfarin.,(S)-Warfarin,DB00080
DB00007,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.",Leuprolide,DB00080
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Daptomycin.",Somatotropin,DB00080
DB00065,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin.",Infliximab,DB00080
DB00181,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen.",Baclofen,DB00080
DB00203,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sildenafil.",Sildenafil,DB00080
DB00224,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Indinavir.",Indinavir,DB00080
DB00242,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine.",Cladribine,DB00080
DB00252,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Phenytoin.",Phenytoin,DB00080
DB00358,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mefloquine.",Mefloquine,DB00080
DB00382,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tacrine.",Tacrine,DB00080
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Carbimazole.",Carbimazole,DB00080
DB00440,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim.",Trimethoprim,DB00080
DB00443,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Betamethasone.",Betamethasone,DB00080
DB00471,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Montelukast.",Montelukast,DB00080
DB00495,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Zidovudine.",Zidovudine,DB00080
DB00501,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cimetidine.",Cimetidine,DB00080
DB00503,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ritonavir.",Ritonavir,DB00080
DB00528,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lercanidipine.",Lercanidipine,DB00080
DB00537,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin.",Ciprofloxacin,DB00080
DB00541,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine.",Vincristine,DB00080
DB00550,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil.",Propylthiouracil,DB00080
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Enalapril.",Enalapril,DB00080
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nizatidine.",Nizatidine,DB00080
DB00602,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ivermectin.",Ivermectin,DB00080
DB00608,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Chloroquine.",Chloroquine,DB00080
DB00620,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triamcinolone.",Triamcinolone,DB00080
DB00627,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Niacin.",Niacin,DB00080
DB00630,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.",Alendronic acid,DB00080
DB00636,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibrate.",Clofibrate,DB00080
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Stavudine.",Stavudine,DB00080
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nafarelin.",Nafarelin,DB00080
DB00688,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mycophenolate mofetil.",Mycophenolate mofetil,DB00080
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone.",Naltrexone,DB00080
DB00709,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lamivudine.",Lamivudine,DB00080
DB00710,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate.",Ibandronate,DB00080
DB00818,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol.",Propofol,DB00080
DB00857,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Terbinafine.",Terbinafine,DB00080
DB00859,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Penicillamine.",Penicillamine,DB00080
DB00863,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ranitidine.",Ranitidine,DB00080
DB00876,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Eprosartan.",Eprosartan,DB00080
DB00884,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Risedronic acid.",Risedronic acid,DB00080
DB00887,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bumetanide.",Bumetanide,DB00080
DB00897,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triazolam.",Triazolam,DB00080
DB00898,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ethanol.",Ethanol,DB00080
DB00938,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol.",Salmeterol,DB00080
DB00951,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isoniazid.",Isoniazid,DB00080
DB00968,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methyldopa.",Methyldopa,DB00080
DB00987,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.",Cytarabine,DB00080
DB01004,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ganciclovir.",Ganciclovir,DB00080
DB01006,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Letrozole.",Letrozole,DB00080
DB01015,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole.",Sulfamethoxazole,DB00080
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline.",Minocycline,DB00080
DB01039,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate.",Fenofibrate,DB00080
DB01059,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Norfloxacin.",Norfloxacin,DB00080
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Iloprost.",Iloprost,DB00080
DB01097,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide.",Leflunomide,DB00080
DB01118,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amiodarone.",Amiodarone,DB00080
DB01165,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ofloxacin.",Ofloxacin,DB00080
DB01168,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine.",Procarbazine,DB00080
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Captopril.",Captopril,DB00080
DB01229,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel.",Paclitaxel,DB00080
DB01232,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Saquinavir.",Saquinavir,DB00080
DB01233,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide.",Metoclopramide,DB00080
DB01234,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone.",Dexamethasone,DB00080
DB01241,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Gemfibrozil.",Gemfibrozil,DB00080
DB01248,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Docetaxel.",Docetaxel,DB00080
DB01393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bezafibrate.",Bezafibrate,DB00080
DB01394,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Colchicine.",Colchicine,DB00080
DB02703,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fusidic acid.",Fusidic acid,DB00080
DB05109,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trabectedin.",Trabectedin,DB00080
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir.",Raltegravir,DB00080
DB08983,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Etofibrate.",Etofibrate,DB00080
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox.",Acipimox,DB00080
DB09064,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofibrate.",Ciprofibrate,DB00080
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ubidecarenone.",Ubidecarenone,DB00080
DB09289,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tianeptine.",Tianeptine,DB00080
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mebeverine.",Mebeverine,DB00080
DB13293,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ipecac.",Ipecac,DB00080
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Emetine.",Emetine,DB00080
DB13433,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Simfibrate.",Simfibrate,DB00080
DB13460,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ronifibrate.",Ronifibrate,DB00080
DB13780,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Aluminium clofibrate.",Aluminium clofibrate,DB00080
DB13849,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibride.",Clofibride,DB00080
DB13873,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibric acid.",Fenofibric acid,DB00080
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daptomycin.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00080
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.,Denosumab,DB00081
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Tositumomab.,Etanercept,DB00081
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tositumomab.,Peginterferon alfa-2a,DB00081
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tositumomab.,Interferon alfa-n1,DB00081
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tositumomab.,Interferon alfa-n3,DB00081
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tositumomab.,Peginterferon alfa-2b,DB00081
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Tositumomab.,Anakinra,DB00081
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tositumomab.,Interferon gamma-1b,DB00081
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tositumomab.","Interferon alfa-2a, Recombinant",DB00081
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tositumomab.,Aldesleukin,DB00081
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Tositumomab.,Adalimumab,DB00081
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.,Gemtuzumab ozogamicin,DB00081
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.,Pegaspargase,DB00081
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.,Infliximab,DB00081
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.,Interferon beta-1b,DB00081
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.,Interferon alfacon-1,DB00081
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.,Rituximab,DB00081
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.,Basiliximab,DB00081
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.,Muromonab,DB00081
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.,Ibritumomab tiuxetan,DB00081
DB00087,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.,Alemtuzumab,DB00081
DB00092,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.,Alefacept,DB00081
DB00095,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.,Efalizumab,DB00081
DB00098,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00081
DB00105,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00081
DB00111,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.,Daclizumab,DB00081
DB00112,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.,Bevacizumab,DB00081
DB00120,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.,Phenylalanine,DB00081
DB00180,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flunisolide.,Flunisolide,DB00081
DB00188,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bortezomib.,Bortezomib,DB00081
DB00242,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cladribine.,Cladribine,DB00081
DB00262,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carmustine.,Carmustine,DB00081
DB00276,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amsacrine.,Amsacrine,DB00081
DB00290,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleomycin.,Bleomycin,DB00081
DB00291,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chlorambucil.,Chlorambucil,DB00081
DB00293,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raltitrexed.,Raltitrexed,DB00081
DB00305,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitomycin.,Mitomycin,DB00081
DB00307,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene.,Bexarotene,DB00081
DB00309,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vindesine.,Vindesine,DB00081
DB00322,The risk or severity of adverse effects can be increased when Tositumomab is combined with Floxuridine.,Floxuridine,DB00081
DB00328,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indomethacin.,Indomethacin,DB00081
DB00352,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tioguanine.,Tioguanine,DB00081
DB00361,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinorelbine.,Vinorelbine,DB00081
DB00380,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane.,Dexrazoxane,DB00081
DB00394,The risk or severity of adverse effects can be increased when Tositumomab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00081
DB00398,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sorafenib.,Sorafenib,DB00081
DB00428,The risk or severity of adverse effects can be increased when Tositumomab is combined with Streptozocin.,Streptozocin,DB00081
DB00432,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trifluridine.,Trifluridine,DB00081
DB00441,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gemcitabine.,Gemcitabine,DB00081
DB00443,The risk or severity of adverse effects can be increased when Tositumomab is combined with Betamethasone.,Betamethasone,DB00081
DB00444,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teniposide.,Teniposide,DB00081
DB00445,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epirubicin.,Epirubicin,DB00081
DB00446,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chloramphenicol.,Chloramphenicol,DB00081
DB00480,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lenalidomide.,Lenalidomide,DB00081
DB00488,The risk or severity of adverse effects can be increased when Tositumomab is combined with Altretamine.,Altretamine,DB00081
DB00495,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zidovudine.,Zidovudine,DB00081
DB00515,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin.,Cisplatin,DB00081
DB00526,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oxaliplatin.,Oxaliplatin,DB00081
DB00531,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cyclophosphamide.,Cyclophosphamide,DB00081
DB00541,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vincristine.,Vincristine,DB00081
DB00544,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil.,Fluorouracil,DB00081
DB00550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Propylthiouracil.,Propylthiouracil,DB00081
DB00552,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pentostatin.,Pentostatin,DB00081
DB00563,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methotrexate.,Methotrexate,DB00081
DB00564,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carbamazepine.,Carbamazepine,DB00081
DB00570,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinblastine.,Vinblastine,DB00081
DB00588,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone propionate.,Fluticasone propionate,DB00081
DB00591,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00081
DB00601,The risk or severity of adverse effects can be increased when Tositumomab is combined with Linezolid.,Linezolid,DB00081
DB00619,The risk or severity of adverse effects can be increased when Tositumomab is combined with Imatinib.,Imatinib,DB00081
DB00620,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triamcinolone.,Triamcinolone,DB00081
DB00631,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clofarabine.,Clofarabine,DB00081
DB00635,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisone.,Prednisone,DB00081
DB00642,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pemetrexed.,Pemetrexed,DB00081
DB00687,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludrocortisone.,Fludrocortisone,DB00081
DB00688,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00081
DB00694,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin.,Daunorubicin,DB00081
DB00755,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tretinoin.,Tretinoin,DB00081
DB00762,The risk or severity of adverse effects can be increased when Tositumomab is combined with Irinotecan.,Irinotecan,DB00081
DB00763,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methimazole.,Methimazole,DB00081
DB00764,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone.,Mometasone,DB00081
DB00773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etoposide.,Etoposide,DB00081
DB00795,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulfasalazine.,Sulfasalazine,DB00081
DB00851,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacarbazine.,Dacarbazine,DB00081
DB00853,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temozolomide.,Temozolomide,DB00081
DB00859,The risk or severity of adverse effects can be increased when Tositumomab is combined with Penicillamine.,Penicillamine,DB00081
DB00860,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisolone.,Prednisolone,DB00081
DB00877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirolimus.,Sirolimus,DB00081
DB00888,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mechlorethamine.,Mechlorethamine,DB00081
DB00928,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azacitidine.,Azacitidine,DB00081
DB00958,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carboplatin.,Carboplatin,DB00081
DB00959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methylprednisolone.,Methylprednisolone,DB00081
DB00970,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dactinomycin.,Dactinomycin,DB00081
DB00987,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cytarabine.,Cytarabine,DB00081
DB00993,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azathioprine.,Azathioprine,DB00081
DB00997,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxorubicin.,Doxorubicin,DB00081
DB01005,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxyurea.,Hydroxyurea,DB00081
DB01008,The risk or severity of adverse effects can be increased when Tositumomab is combined with Busulfan.,Busulfan,DB00081
DB01024,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolic acid.,Mycophenolic acid,DB00081
DB01030,The risk or severity of adverse effects can be increased when Tositumomab is combined with Topotecan.,Topotecan,DB00081
DB01033,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mercaptopurine.,Mercaptopurine,DB00081
DB01041,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thalidomide.,Thalidomide,DB00081
DB01042,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melphalan.,Melphalan,DB00081
DB01073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludarabine.,Fludarabine,DB00081
DB01099,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flucytosine.,Flucytosine,DB00081
DB01101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capecitabine.,Capecitabine,DB00081
DB01108,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trilostane.,Trilostane,DB00081
DB01168,The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine.,Procarbazine,DB00081
DB01169,The risk or severity of adverse effects can be increased when Tositumomab is combined with Arsenic trioxide.,Arsenic trioxide,DB00081
DB01177,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idarubicin.,Idarubicin,DB00081
DB01181,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ifosfamide.,Ifosfamide,DB00081
DB01196,The risk or severity of adverse effects can be increased when Tositumomab is combined with Estramustine.,Estramustine,DB00081
DB01204,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitoxantrone.,Mitoxantrone,DB00081
DB01206,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lomustine.,Lomustine,DB00081
DB01222,The risk or severity of adverse effects can be increased when Tositumomab is combined with Budesonide.,Budesonide,DB00081
DB01229,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paclitaxel.,Paclitaxel,DB00081
DB01234,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone.,Dexamethasone,DB00081
DB01248,The risk or severity of adverse effects can be increased when Tositumomab is combined with Docetaxel.,Docetaxel,DB00081
DB01254,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dasatinib.,Dasatinib,DB00081
DB01257,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eculizumab.,Eculizumab,DB00081
DB01262,The risk or severity of adverse effects can be increased when Tositumomab is combined with Decitabine.,Decitabine,DB00081
DB01268,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sunitinib.,Sunitinib,DB00081
DB01280,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nelarabine.,Nelarabine,DB00081
DB01281,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abatacept.,Abatacept,DB00081
DB01285,The risk or severity of adverse effects can be increased when Tositumomab is combined with Corticotropin.,Corticotropin,DB00081
DB01380,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortisone acetate.,Cortisone acetate,DB00081
DB01384,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paramethasone.,Paramethasone,DB00081
DB01394,The risk or severity of adverse effects can be increased when Tositumomab is combined with Colchicine.,Colchicine,DB00081
DB01410,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ciclesonide.,Ciclesonide,DB00081
DB01423,The risk or severity of adverse effects can be increased when Tositumomab is combined with Stepronin.,Stepronin,DB00081
DB01590,The risk or severity of adverse effects can be increased when Tositumomab is combined with Everolimus.,Everolimus,DB00081
DB01611,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00081
DB01816,The risk or severity of adverse effects can be increased when Tositumomab is combined with Castanospermine.,Castanospermine,DB00081
DB02546,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vorinostat.,Vorinostat,DB00081
DB02806,The risk or severity of adverse effects can be increased when Tositumomab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00081
DB03523,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brequinar.,Brequinar,DB00081
DB04572,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thiotepa.,Thiotepa,DB00081
DB04630,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aldosterone.,Aldosterone,DB00081
DB04845,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixabepilone.,Ixabepilone,DB00081
DB04868,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nilotinib.,Nilotinib,DB00081
DB04951,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirfenidone.,Pirfenidone,DB00081
DB04956,The risk or severity of adverse effects can be increased when Tositumomab is combined with Afelimomab.,Afelimomab,DB00081
DB05015,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belinostat.,Belinostat,DB00081
DB05109,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trabectedin.,Trabectedin,DB00081
DB05258,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa.,Interferon alfa,DB00081
DB05259,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glatiramer.,Glatiramer,DB00081
DB05260,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gallium nitrate.,Gallium nitrate,DB00081
DB05459,The risk or severity of adverse effects can be increased when Tositumomab is combined with Briakinumab.,Briakinumab,DB00081
DB05472,The risk or severity of adverse effects can be increased when Tositumomab is combined with omega interferon.,omega interferon,DB00081
DB05676,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apremilast.,Apremilast,DB00081
DB05773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00081
DB06168,The risk or severity of adverse effects can be increased when Tositumomab is combined with Canakinumab.,Canakinumab,DB00081
DB06273,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tocilizumab.,Tocilizumab,DB00081
DB06287,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temsirolimus.,Temsirolimus,DB00081
DB06372,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilonacept.,Rilonacept,DB00081
DB06589,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pazopanib.,Pazopanib,DB00081
DB06603,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panobinostat.,Panobinostat,DB00081
DB06612,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mepolizumab.,Mepolizumab,DB00081
DB06616,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bosutinib.,Bosutinib,DB00081
DB06662,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abetimus.,Abetimus,DB00081
DB06674,The risk or severity of adverse effects can be increased when Tositumomab is combined with Golimumab.,Golimumab,DB00081
DB06681,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belatacept.,Belatacept,DB00081
DB06769,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bendamustine.,Bendamustine,DB00081
DB06772,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cabazitaxel.,Cabazitaxel,DB00081
DB06813,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pralatrexate.,Pralatrexate,DB00081
DB08059,The risk or severity of adverse effects can be increased when Tositumomab is combined with Wortmannin.,Wortmannin,DB00081
DB08870,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00081
DB08871,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eribulin.,Eribulin,DB00081
DB08877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ruxolitinib.,Ruxolitinib,DB00081
DB08879,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belimumab.,Belimumab,DB00081
DB08880,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teriflunomide.,Teriflunomide,DB00081
DB08889,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carfilzomib.,Carfilzomib,DB00081
DB08901,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponatinib.,Ponatinib,DB00081
DB08904,The risk or severity of adverse effects can be increased when Tositumomab is combined with Certolizumab pegol.,Certolizumab pegol,DB00081
DB08906,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone furoate.,Fluticasone furoate,DB00081
DB08908,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00081
DB08910,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pomalidomide.,Pomalidomide,DB00081
DB08935,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obinutuzumab.,Obinutuzumab,DB00081
DB08970,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednidene.,Fluprednidene,DB00081
DB08971,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortolone.,Fluocortolone,DB00081
DB09029,The risk or severity of adverse effects can be increased when Tositumomab is combined with Secukinumab.,Secukinumab,DB00081
DB09033,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vedolizumab.,Vedolizumab,DB00081
DB09036,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siltuximab.,Siltuximab,DB00081
DB09052,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blinatumomab.,Blinatumomab,DB00081
DB09053,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibrutinib.,Ibrutinib,DB00081
DB09054,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib.,Idelalisib,DB00081
DB09073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palbociclib.,Palbociclib,DB00081
DB09074,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaparib.,Olaparib,DB00081
DB09077,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dinutuximab.,Dinutuximab,DB00081
DB09082,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vilanterol.,Vilanterol,DB00081
DB09091,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tixocortol.,Tixocortol,DB00081
DB09122,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00081
DB09312,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00081
DB09378,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednisolone.,Fluprednisolone,DB00081
DB09383,The risk or severity of adverse effects can be increased when Tositumomab is combined with Meprednisone.,Meprednisone,DB00081
DB11466,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tepoxalin.,Tepoxalin,DB00081
DB11487,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00081
DB11529,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melengestrol.,Melengestrol,DB00081
DB11569,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixekizumab.,Ixekizumab,DB00081
DB11580,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ravulizumab.,Ravulizumab,DB00081
DB11616,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirarubicin.,Pirarubicin,DB00081
DB11693,The risk or severity of adverse effects can be increased when Tositumomab is combined with Voclosporin.,Voclosporin,DB00081
DB11708,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peficitinib.,Peficitinib,DB00081
DB11750,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clobetasol.,Clobetasol,DB00081
DB11767,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sarilumab.,Sarilumab,DB00081
DB11776,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brodalumab.,Brodalumab,DB00081
DB11803,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirukumab.,Sirukumab,DB00081
DB11817,The risk or severity of adverse effects can be increased when Tositumomab is combined with Baricitinib.,Baricitinib,DB00081
DB11834,The risk or severity of adverse effects can be increased when Tositumomab is combined with Guselkumab.,Guselkumab,DB00081
DB11921,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deflazacort.,Deflazacort,DB00081
DB12025,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triptolide.,Triptolide,DB00081
DB12371,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siponimod.,Siponimod,DB00081
DB12612,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanimod.,Ozanimod,DB00081
DB12617,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mizoribine.,Mizoribine,DB00081
DB12692,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gusperimus.,Gusperimus,DB00081
DB12814,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00081
DB12902,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trofosfamide.,Trofosfamide,DB00081
DB12947,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxifluridine.,Doxifluridine,DB00081
DB12991,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deoxyspergualin.,Deoxyspergualin,DB00081
DB12996,The risk or severity of adverse effects can be increased when Tositumomab is combined with Acteoside.,Acteoside,DB00081
DB13003,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortivazol.,Cortivazol,DB00081
DB13014,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hypericin.,Hypericin,DB00081
DB13068,The risk or severity of adverse effects can be increased when Tositumomab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00081
DB13208,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednylidene.,Prednylidene,DB00081
DB13223,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortin.,Fluocortin,DB00081
DB13241,The risk or severity of adverse effects can be increased when Tositumomab is combined with Begelomab.,Begelomab,DB00081
DB13491,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluperolone.,Fluperolone,DB00081
DB13664,The risk or severity of adverse effects can be increased when Tositumomab is combined with Formocortal.,Formocortal,DB00081
DB13728,The risk or severity of adverse effects can be increased when Tositumomab is combined with Halometasone.,Halometasone,DB00081
DB13843,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cloprednol.,Cloprednol,DB00081
DB13856,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluclorolone.,Fluclorolone,DB00081
DB13867,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone.,Fluticasone,DB00081
DB14066,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetrandrine.,Tetrandrine,DB00081
DB14219,The risk or severity of adverse effects can be increased when Tositumomab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00081
DB14512,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone furoate.,Mometasone furoate,DB00081
DB14538,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00081
DB14539,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00081
DB14545,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00081
DB14724,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emapalumab.,Emapalumab,DB00081
DB14762,The risk or severity of adverse effects can be increased when Tositumomab is combined with Risankizumab.,Risankizumab,DB00081
DB14919,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozanolixizumab.,Rozanolixizumab,DB00081
DB15253,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleselumab.,Bleselumab,DB00081
DB00108,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.,Natalizumab,DB00081
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.,Pimecrolimus,DB00081
DB01656,Roflumilast may increase the immunosuppressive activities of Tositumomab.,Roflumilast,DB00081
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.,Sipuleucel-T,DB00081
DB00363,The risk or severity of neutropenia can be increased when Tositumomab is combined with Clozapine.,Clozapine,DB00081
DB08894,The risk or severity of Thrombosis can be increased when Tositumomab is combined with Peginesatide.,Peginesatide,DB00081
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tositumomab.,Darbepoetin alfa,DB00081
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tositumomab.,Erythropoietin,DB00081
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tositumomab.,Methoxy polyethylene glycol-epoetin beta,DB00081
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tositumomab.,Sulfamethoxazole,DB00081
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Tositumomab.,Diethylstilbestrol,DB00081
DB00269,Chlorotrianisene may increase the thrombogenic activities of Tositumomab.,Chlorotrianisene,DB00081
DB00655,Estrone may increase the thrombogenic activities of Tositumomab.,Estrone,DB00081
DB00890,Dienestrol may increase the thrombogenic activities of Tositumomab.,Dienestrol,DB00081
DB00977,Ethinylestradiol may increase the thrombogenic activities of Tositumomab.,Ethinylestradiol,DB00081
DB01357,Mestranol may increase the thrombogenic activities of Tositumomab.,Mestranol,DB00081
DB04573,Estriol may increase the thrombogenic activities of Tositumomab.,Estriol,DB00081
DB04575,Quinestrol may increase the thrombogenic activities of Tositumomab.,Quinestrol,DB00081
DB07931,Hexestrol may increase the thrombogenic activities of Tositumomab.,Hexestrol,DB00081
DB09070,Tibolone may increase the thrombogenic activities of Tositumomab.,Tibolone,DB00081
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Tositumomab.,Polyestradiol phosphate,DB00081
DB09381,Esterified estrogens may increase the thrombogenic activities of Tositumomab.,Esterified estrogens,DB00081
DB11478,Zeranol may increase the thrombogenic activities of Tositumomab.,Zeranol,DB00081
DB11674,Equol may increase the thrombogenic activities of Tositumomab.,Equol,DB00081
DB12487,Promestriene may increase the thrombogenic activities of Tositumomab.,Promestriene,DB00081
DB13143,Methallenestril may increase the thrombogenic activities of Tositumomab.,Methallenestril,DB00081
DB13386,Epimestrol may increase the thrombogenic activities of Tositumomab.,Epimestrol,DB00081
DB13418,Moxestrol may increase the thrombogenic activities of Tositumomab.,Moxestrol,DB00081
DB13953,Estradiol benzoate may increase the thrombogenic activities of Tositumomab.,Estradiol benzoate,DB00081
DB15334,Biochanin A may increase the thrombogenic activities of Tositumomab.,Biochanin A,DB00081
DB15335,Formononetin may increase the thrombogenic activities of Tositumomab.,Formononetin,DB00081
DB01097,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.,Leflunomide,DB00081
DB08895,Tositumomab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00081
DB00072,Trastuzumab may increase the neutropenic activities of Tositumomab.,Trastuzumab,DB00081
DB08868,Tositumomab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00081
DB00864,Tacrolimus may increase the immunosuppressive activities of Tositumomab.,Tacrolimus,DB00081
DB00001,The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.,Lepirudin,DB00081
DB00006,The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Tositumomab.,Bivalirudin,DB00081
DB00009,The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Tositumomab.,Alteplase,DB00081
DB00013,The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Tositumomab.,Urokinase,DB00081
DB00015,The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.,Reteplase,DB00081
DB00029,The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Tositumomab.,Anistreplase,DB00081
DB00031,The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Tositumomab.,Tenecteplase,DB00081
DB00055,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.,Drotrecogin alfa,DB00081
DB00086,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.,Streptokinase,DB00081
DB00266,The risk or severity of bleeding and hemorrhage can be increased when Dicoumarol is combined with Tositumomab.,Dicoumarol,DB00081
DB00278,The risk or severity of bleeding and hemorrhage can be increased when Argatroban is combined with Tositumomab.,Argatroban,DB00081
DB00407,The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Tositumomab.,Ardeparin,DB00081
DB00498,The risk or severity of bleeding and hemorrhage can be increased when Phenindione is combined with Tositumomab.,Phenindione,DB00081
DB00569,The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Tositumomab.,Fondaparinux,DB00081
DB00682,The risk or severity of bleeding and hemorrhage can be increased when Warfarin is combined with Tositumomab.,Warfarin,DB00081
DB00686,The risk or severity of bleeding and hemorrhage can be increased when Pentosan polysulfate is combined with Tositumomab.,Pentosan polysulfate,DB00081
DB00946,The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Tositumomab.,Phenprocoumon,DB00081
DB01109,The risk or severity of bleeding and hemorrhage can be increased when Heparin is combined with Tositumomab.,Heparin,DB00081
DB01225,The risk or severity of bleeding and hemorrhage can be increased when Enoxaparin is combined with Tositumomab.,Enoxaparin,DB00081
DB01418,The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Tositumomab.,Acenocoumarol,DB00081
DB03410,The risk or severity of bleeding and hemorrhage can be increased when 4-hydroxycoumarin is combined with Tositumomab.,4-hydroxycoumarin,DB00081
DB04665,The risk or severity of bleeding and hemorrhage can be increased when Coumarin is combined with Tositumomab.,Coumarin,DB00081
DB04898,The risk or severity of bleeding and hemorrhage can be increased when Ximelagatran is combined with Tositumomab.,Ximelagatran,DB00081
DB04925,The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Tositumomab.,Desmoteplase,DB00081
DB05099,The risk or severity of bleeding and hemorrhage can be increased when Ancrod is combined with Tositumomab.,Ancrod,DB00081
DB05254,The risk or severity of bleeding and hemorrhage can be increased when Fibrinolysin is combined with Tositumomab.,Fibrinolysin,DB00081
DB06228,The risk or severity of bleeding and hemorrhage can be increased when Rivaroxaban is combined with Tositumomab.,Rivaroxaban,DB00081
DB06271,The risk or severity of bleeding and hemorrhage can be increased when Sulodexide is combined with Tositumomab.,Sulodexide,DB00081
DB06294,The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Tositumomab.,Semuloparin,DB00081
DB06406,The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Tositumomab.,Idraparinux,DB00081
DB06543,The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Tositumomab.,Astaxanthin,DB00081
DB06605,The risk or severity of bleeding and hemorrhage can be increased when Apixaban is combined with Tositumomab.,Apixaban,DB00081
DB06635,The risk or severity of bleeding and hemorrhage can be increased when Otamixaban is combined with Tositumomab.,Otamixaban,DB00081
DB06679,The risk or severity of bleeding and hemorrhage can be increased when Amediplase is combined with Tositumomab.,Amediplase,DB00081
DB06695,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Tositumomab.,Dabigatran etexilate,DB00081
DB06754,The risk or severity of bleeding and hemorrhage can be increased when Danaparoid is combined with Tositumomab.,Danaparoid,DB00081
DB06779,The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Tositumomab.,Dalteparin,DB00081
DB06822,The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Tositumomab.,Tinzaparin,DB00081
DB07767,The risk or severity of bleeding and hemorrhage can be increased when Ferulic acid is combined with Tositumomab.,Ferulic acid,DB00081
DB08496,The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Tositumomab.,(R)-warfarin,DB00081
DB08794,The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Tositumomab.,Ethyl biscoumacetate,DB00081
DB08813,The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Tositumomab.,Nadroparin,DB00081
DB08994,The risk or severity of bleeding and hemorrhage can be increased when Ditazole is combined with Tositumomab.,Ditazole,DB00081
DB09075,The risk or severity of bleeding and hemorrhage can be increased when Edoxaban is combined with Tositumomab.,Edoxaban,DB00081
DB09125,The risk or severity of bleeding and hemorrhage can be increased when Potassium citrate is combined with Tositumomab.,Potassium citrate,DB00081
DB09154,The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Tositumomab.,Sodium citrate,DB00081
DB09255,The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Tositumomab.,Dextran,DB00081
DB09258,The risk or severity of bleeding and hemorrhage can be increased when Bemiparin is combined with Tositumomab.,Bemiparin,DB00081
DB09259,The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Tositumomab.,Reviparin,DB00081
DB09260,The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Tositumomab.,Parnaparin,DB00081
DB09261,The risk or severity of bleeding and hemorrhage can be increased when Certoparin is combined with Tositumomab.,Certoparin,DB00081
DB11095,The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Tositumomab.,Desirudin,DB00081
DB11154,The risk or severity of bleeding and hemorrhage can be increased when Zinc citrate is combined with Tositumomab.,Zinc citrate,DB00081
DB11166,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Tositumomab.,Antithrombin Alfa,DB00081
DB11312,The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Tositumomab.,Protein C,DB00081
DB11598,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Tositumomab.,Antithrombin III human,DB00081
DB11984,The risk or severity of bleeding and hemorrhage can be increased when Letaxaban is combined with Tositumomab.,Letaxaban,DB00081
DB12289,The risk or severity of bleeding and hemorrhage can be increased when Darexaban is combined with Tositumomab.,Darexaban,DB00081
DB12364,The risk or severity of bleeding and hemorrhage can be increased when Betrixaban is combined with Tositumomab.,Betrixaban,DB00081
DB12598,The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Tositumomab.,Nafamostat,DB00081
DB12726,The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Tositumomab.,Monteplase,DB00081
DB12831,The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Tositumomab.,Gabexate,DB00081
DB13136,The risk or severity of bleeding and hemorrhage can be increased when Fluindione is combined with Tositumomab.,Fluindione,DB00081
DB13149,The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Tositumomab.,Protein S human,DB00081
DB13199,The risk or severity of bleeding and hemorrhage can be increased when Brinase is combined with Tositumomab.,Brinase,DB00081
DB13275,The risk or severity of bleeding and hemorrhage can be increased when Clorindione is combined with Tositumomab.,Clorindione,DB00081
DB13347,The risk or severity of bleeding and hemorrhage can be increased when Diphenadione is combined with Tositumomab.,Diphenadione,DB00081
DB13451,The risk or severity of bleeding and hemorrhage can be increased when Tioclomarol is combined with Tositumomab.,Tioclomarol,DB00081
DB13616,The risk or severity of bleeding and hemorrhage can be increased when Melagatran is combined with Tositumomab.,Melagatran,DB00081
DB13646,The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Tositumomab.,Saruplase,DB00081
DB14055,The risk or severity of bleeding and hemorrhage can be increased when (S)-Warfarin is combined with Tositumomab.,(S)-Warfarin,DB00081
DB14094,The risk or severity of bleeding and hemorrhage can be increased when Tocopherylquinone is combined with Tositumomab.,Tocopherylquinone,DB00081
DB14598,The risk or severity of bleeding and hemorrhage can be increased when Edetate calcium disodium anhydrous is combined with Tositumomab.,Edetate calcium disodium anhydrous,DB00081
DB14726,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Tositumomab.,Dabigatran,DB00081
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.,Abciximab,DB00081
DB00063,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.,Eptifibatide,DB00081
DB00208,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.,Ticlopidine,DB00081
DB00261,The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.,Anagrelide,DB00081
DB00758,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.,Clopidogrel,DB00081
DB00775,The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.,Tirofiban,DB00081
DB00806,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.,Pentoxifylline,DB00081
DB00945,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.,Acetylsalicylic acid,DB00081
DB00975,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.,Dipyridamole,DB00081
DB01088,The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.,Iloprost,DB00081
DB01138,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tositumomab.,Sulfinpyrazone,DB00081
DB01166,The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.,Cilostazol,DB00081
DB01207,The risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.,Ridogrel,DB00081
DB01236,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.,Sevoflurane,DB00081
DB01240,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.,Epoprostenol,DB00081
DB02709,The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.,Resveratrol,DB00081
DB04743,The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.,Nimesulide,DB00081
DB04905,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.,Tesmilifene,DB00081
DB04932,The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.,Defibrotide,DB00081
DB05229,The risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.,Beraprost,DB00081
DB05266,The risk or severity of adverse effects can be increased when Ibudilast is combined with Tositumomab.,Ibudilast,DB00081
DB05767,The risk or severity of adverse effects can be increased when Andrographolide is combined with Tositumomab.,Andrographolide,DB00081
DB06081,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tositumomab.,Caplacizumab,DB00081
DB06209,The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.,Prasugrel,DB00081
DB06441,The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.,Cangrelor,DB00081
DB07615,The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.,Tranilast,DB00081
DB08814,The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.,Triflusal,DB00081
DB08816,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.,Ticagrelor,DB00081
DB08887,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.,Icosapent ethyl,DB00081
DB09030,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.,Vorapaxar,DB00081
DB09283,The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.,Trapidil,DB00081
DB12092,The risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.,Naftopidil,DB00081
DB12163,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.,Sarpogrelate,DB00081
DB12321,The risk or severity of adverse effects can be increased when Ifetroban is combined with Tositumomab.,Ifetroban,DB00081
DB12445,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tositumomab.,Nitroaspirin,DB00081
DB12465,The risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.,Ketanserin,DB00081
DB12545,The risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.,Indobufen,DB00081
DB12749,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.,Butylphthalide,DB00081
DB12771,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.,Hydroxytyrosol,DB00081
DB13036,The risk or severity of adverse effects can be increased when Ramatroban is combined with Tositumomab.,Ramatroban,DB00081
DB13327,The risk or severity of adverse effects can be increased when Picotamide is combined with Tositumomab.,Picotamide,DB00081
DB13367,The risk or severity of adverse effects can be increased when Cloricromen is combined with Tositumomab.,Cloricromen,DB00081
DB13400,The risk or severity of adverse effects can be increased when Linsidomine is combined with Tositumomab.,Linsidomine,DB00081
DB13510,The risk or severity of adverse effects can be increased when Buflomedil is combined with Tositumomab.,Buflomedil,DB00081
DB13929,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tositumomab.,Relcovaptan,DB00081
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Tositumomab.,G17DT,DB00081
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Tositumomab.,PEV3A,DB00081
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tositumomab.,INGN 225,DB00081
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tositumomab.,Rindopepimut,DB00081
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tositumomab.,SRP 299,DB00081
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tositumomab.,GI-5005,DB00081
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Tositumomab.,Vitespen,DB00081
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Tositumomab.,TG4010,DB00081
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tositumomab.,Anthrax immune globulin human,DB00081
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Tositumomab.","Rabies virus inactivated antigen, B",DB00081
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00081
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Tositumomab.,Rotavirus vaccine,DB00081
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tositumomab.","Rabies virus inactivated antigen, A",DB00081
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00081
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00081
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00081
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00081
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00081
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00081
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Tositumomab.,Typhoid Vi polysaccharide vaccine,DB00081
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.,Hepatitis A Vaccine,DB00081
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00081
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00081
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00081
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00081
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00081
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tositumomab.,Human rabies virus immune globulin,DB00081
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.,Hepatitis B Vaccine (Recombinant),DB00081
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Tositumomab.,Tecemotide,DB00081
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Tositumomab.,Typhoid vaccine,DB00081
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00081
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00081
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00081
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00081
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Tositumomab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00081
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00081
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00081
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Tositumomab.,Vaccinia virus strain new york city board of health live antigen,DB00081
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tositumomab.,Pertussis vaccine,DB00081
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00081
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.,Varicella Zoster Vaccine (Recombinant),DB00081
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Tositumomab.,Modified vaccinia ankara,DB00081
DB11988,Ocrelizumab may increase the immunosuppressive activities of Tositumomab.,Ocrelizumab,DB00081
DB13200,Tositumomab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00081
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Tositumomab.,Rubella virus vaccine,DB00081
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Tositumomab.,Varicella Zoster Vaccine (Live/attenuated),DB00081
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain tice live antigen,DB00081
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain connaught live antigen,DB00081
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Tositumomab.,Yellow Fever Vaccine,DB00081
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Tositumomab.,Anthrax vaccine,DB00081
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Tositumomab.,Typhoid Vaccine Live,DB00081
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00081
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Tositumomab.,BCG vaccine,DB00081
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Tositumomab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00081
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Tositumomab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00081
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Tositumomab.,Adenovirus type 7 vaccine live,DB00081
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.,Cetuximab,DB00081
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.,Human immunoglobulin G,DB00081
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Tositumomab.,Omalizumab,DB00081
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.,Indium In-111 satumomab pendetide,DB00081
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.,Digoxin Immune Fab (Ovine),DB00081
DB00089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.,Capromab pendetide,DB00081
DB00110,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.,Palivizumab,DB00081
DB00113,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00081
DB01269,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panitumumab.,Panitumumab,DB00081
DB01270,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ranibizumab.,Ranibizumab,DB00081
DB04901,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galiximab.,Galiximab,DB00081
DB04949,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pexelizumab.,Pexelizumab,DB00081
DB04958,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epratuzumab.,Epratuzumab,DB00081
DB04962,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bectumomab.,Bectumomab,DB00081
DB04964,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oregovomab.,Oregovomab,DB00081
DB04988,The risk or severity of adverse effects can be increased when Tositumomab is combined with IGN311.,IGN311,DB00081
DB05006,The risk or severity of adverse effects can be increased when Tositumomab is combined with Adecatumumab.,Adecatumumab,DB00081
DB05097,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab.,Labetuzumab,DB00081
DB05101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Matuzumab.,Matuzumab,DB00081
DB05111,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fontolizumab.,Fontolizumab,DB00081
DB05136,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bavituximab.,Bavituximab,DB00081
DB05139,The risk or severity of adverse effects can be increased when Tositumomab is combined with CR002.,CR002,DB00081
DB05209,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozrolimupab.,Rozrolimupab,DB00081
DB05304,The risk or severity of adverse effects can be increased when Tositumomab is combined with Girentuximab.,Girentuximab,DB00081
DB05336,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obiltoxaximab.,Obiltoxaximab,DB00081
DB05405,The risk or severity of adverse effects can be increased when Tositumomab is combined with XTL-001.,XTL-001,DB00081
DB05437,The risk or severity of adverse effects can be increased when Tositumomab is combined with NAV 1800.,NAV 1800,DB00081
DB05496,The risk or severity of adverse effects can be increased when Tositumomab is combined with Otelixizumab.,Otelixizumab,DB00081
DB05545,The risk or severity of adverse effects can be increased when Tositumomab is combined with AMG 108.,AMG 108,DB00081
DB05550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Iratumumab.,Iratumumab,DB00081
DB05555,The risk or severity of adverse effects can be increased when Tositumomab is combined with Enokizumab.,Enokizumab,DB00081
DB05578,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ramucirumab.,Ramucirumab,DB00081
DB05595,The risk or severity of adverse effects can be increased when Tositumomab is combined with Farletuzumab.,Farletuzumab,DB00081
DB05656,The risk or severity of adverse effects can be increased when Tositumomab is combined with Veltuzumab.,Veltuzumab,DB00081
DB05793,The risk or severity of adverse effects can be increased when Tositumomab is combined with PRO-542.,PRO-542,DB00081
DB05797,The risk or severity of adverse effects can be increased when Tositumomab is combined with TNX-901.,TNX-901,DB00081
DB05889,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00081
DB05892,The risk or severity of adverse effects can be increased when Tositumomab is combined with RI 624.,RI 624,DB00081
DB05915,The risk or severity of adverse effects can be increased when Tositumomab is combined with MYO-029.,MYO-029,DB00081
DB05916,The risk or severity of adverse effects can be increased when Tositumomab is combined with CT-011.,CT-011,DB00081
DB05941,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leronlimab.,Leronlimab,DB00081
DB05996,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00081
DB06043,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaratumab.,Olaratumab,DB00081
DB06049,The risk or severity of adverse effects can be increased when Tositumomab is combined with IPH 2101.,IPH 2101,DB00081
DB06050,The risk or severity of adverse effects can be increased when Tositumomab is combined with TB-402.,TB-402,DB00081
DB06101,The risk or severity of adverse effects can be increased when Tositumomab is combined with IMC-1C11.,IMC-1C11,DB00081
DB06116,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eldelumab.,Eldelumab,DB00081
DB06162,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumiliximab.,Lumiliximab,DB00081
DB06192,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nimotuzumab.,Nimotuzumab,DB00081
DB06241,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clenoliximab.,Clenoliximab,DB00081
DB06304,The risk or severity of adverse effects can be increased when Tositumomab is combined with BIIB015.,BIIB015,DB00081
DB06305,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sonepcizumab.,Sonepcizumab,DB00081
DB06310,The risk or severity of adverse effects can be increased when Tositumomab is combined with Motavizumab.,Motavizumab,DB00081
DB06317,The risk or severity of adverse effects can be increased when Tositumomab is combined with Elotuzumab.,Elotuzumab,DB00081
DB06318,The risk or severity of adverse effects can be increased when Tositumomab is combined with AVE9633.,AVE9633,DB00081
DB06322,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carotuximab.,Carotuximab,DB00081
DB06324,The risk or severity of adverse effects can be increased when Tositumomab is combined with XmAb 2513.,XmAb 2513,DB00081
DB06342,The risk or severity of adverse effects can be increased when Tositumomab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00081
DB06343,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teprotumumab.,Teprotumumab,DB00081
DB06360,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lucatumumab.,Lucatumumab,DB00081
DB06366,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pertuzumab.,Pertuzumab,DB00081
DB06371,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siplizumab.,Siplizumab,DB00081
DB06467,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apolizumab.,Apolizumab,DB00081
DB06474,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sibrotuzumab.,Sibrotuzumab,DB00081
DB06550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bivatuzumab.,Bivatuzumab,DB00081
DB06557,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lerdelimumab.,Lerdelimumab,DB00081
DB06599,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lexatumumab.,Lexatumumab,DB00081
DB06602,The risk or severity of adverse effects can be increased when Tositumomab is combined with Reslizumab.,Reslizumab,DB00081
DB06606,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teplizumab.,Teplizumab,DB00081
DB06607,The risk or severity of adverse effects can be increased when Tositumomab is combined with Catumaxomab.,Catumaxomab,DB00081
DB06647,The risk or severity of adverse effects can be increased when Tositumomab is combined with Volociximab.,Volociximab,DB00081
DB06650,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ofatumumab.,Ofatumumab,DB00081
DB08902,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raxibacumab.,Raxibacumab,DB00081
DB09035,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nivolumab.,Nivolumab,DB00081
DB09037,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pembrolizumab.,Pembrolizumab,DB00081
DB09045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dulaglutide.,Dulaglutide,DB00081
DB09105,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asfotase alfa.,Asfotase alfa,DB00081
DB09302,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alirocumab.,Alirocumab,DB00081
DB09303,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evolocumab.,Evolocumab,DB00081
DB09331,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daratumumab.,Daratumumab,DB00081
DB09559,The risk or severity of adverse effects can be increased when Tositumomab is combined with Necitumumab.,Necitumumab,DB00081
DB11595,The risk or severity of adverse effects can be increased when Tositumomab is combined with Atezolizumab.,Atezolizumab,DB00081
DB11604,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00081
DB11608,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00081
DB11621,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00081
DB11646,The risk or severity of adverse effects can be increased when Tositumomab is combined with Conatumumab.,Conatumumab,DB00081
DB11657,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tabalumab.,Tabalumab,DB00081
DB11680,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ficlatuzumab.,Ficlatuzumab,DB00081
DB11685,The risk or severity of adverse effects can be increased when Tositumomab is combined with Figitumumab.,Figitumumab,DB00081
DB11714,The risk or severity of adverse effects can be increased when Tositumomab is combined with Durvalumab.,Durvalumab,DB00081
DB11715,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bapineuzumab.,Bapineuzumab,DB00081
DB11731,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00081
DB11746,The risk or severity of adverse effects can be increased when Tositumomab is combined with Onartuzumab.,Onartuzumab,DB00081
DB11756,The risk or severity of adverse effects can be increased when Tositumomab is combined with Solanezumab.,Solanezumab,DB00081
DB11771,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tremelimumab.,Tremelimumab,DB00081
DB11826,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lampalizumab.,Lampalizumab,DB00081
DB11840,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalotuzumab.,Dalotuzumab,DB00081
DB11849,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emibetuzumab.,Emibetuzumab,DB00081
DB11850,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ublituximab.,Ublituximab,DB00081
DB11856,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ligelizumab.,Ligelizumab,DB00081
DB11857,The risk or severity of adverse effects can be increased when Tositumomab is combined with Seribantumab.,Seribantumab,DB00081
DB11862,The risk or severity of adverse effects can be increased when Tositumomab is combined with Landogrozumab.,Landogrozumab,DB00081
DB11866,The risk or severity of adverse effects can be increased when Tositumomab is combined with Romosozumab.,Romosozumab,DB00081
DB11884,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00081
DB11914,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lebrikizumab.,Lebrikizumab,DB00081
DB11930,The risk or severity of adverse effects can be increased when Tositumomab is combined with Varlilumab.,Varlilumab,DB00081
DB11945,The risk or severity of adverse effects can be increased when Tositumomab is combined with Avelumab.,Avelumab,DB00081
DB11959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crenezumab.,Crenezumab,DB00081
DB11972,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilotumumab.,Rilotumumab,DB00081
DB11976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anifrolumab.,Anifrolumab,DB00081
DB12023,The risk or severity of adverse effects can be increased when Tositumomab is combined with Benralizumab.,Benralizumab,DB00081
DB12034,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gantenerumab.,Gantenerumab,DB00081
DB12053,The risk or severity of adverse effects can be increased when Tositumomab is combined with Visilizumab.,Visilizumab,DB00081
DB12077,The risk or severity of adverse effects can be increased when Tositumomab is combined with Urelumab.,Urelumab,DB00081
DB12089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00081
DB12090,The risk or severity of adverse effects can be increased when Tositumomab is combined with Patritumab.,Patritumab,DB00081
DB12102,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fulranumab.,Fulranumab,DB00081
DB12104,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tarextumab.,Tarextumab,DB00081
DB12118,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sotatercept.,Sotatercept,DB00081
DB12119,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gevokizumab.,Gevokizumab,DB00081
DB12142,The risk or severity of adverse effects can be increased when Tositumomab is combined with Duligotuzumab.,Duligotuzumab,DB00081
DB12152,The risk or severity of adverse effects can be increased when Tositumomab is combined with Simtuzumab.,Simtuzumab,DB00081
DB12157,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fasinumab.,Fasinumab,DB00081
DB12159,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dupilumab.,Dupilumab,DB00081
DB12169,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tralokinumab.,Tralokinumab,DB00081
DB12189,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etrolizumab.,Etrolizumab,DB00081
DB12202,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zalutumumab.,Zalutumumab,DB00081
DB12205,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ganitumab.,Ganitumab,DB00081
DB12213,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etaracizumab.,Etaracizumab,DB00081
DB12240,The risk or severity of adverse effects can be increased when Tositumomab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00081
DB12246,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inclacumab.,Inclacumab,DB00081
DB12250,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cixutumumab.,Cixutumumab,DB00081
DB12261,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ascrinvacumab.,Ascrinvacumab,DB00081
DB12274,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aducanumab.,Aducanumab,DB00081
DB12281,The risk or severity of adverse effects can be increased when Tositumomab is combined with Luspatercept.,Luspatercept,DB00081
DB12296,The risk or severity of adverse effects can be increased when Tositumomab is combined with GS-5745.,GS-5745,DB00081
DB12317,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vanucizumab.,Vanucizumab,DB00081
DB12331,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00081
DB12335,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tanezumab.,Tanezumab,DB00081
DB12342,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ensituximab.,Ensituximab,DB00081
DB12344,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fezakinumab.,Fezakinumab,DB00081
DB12363,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dusigitumab.,Dusigitumab,DB00081
DB12396,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fresolimumab.,Fresolimumab,DB00081
DB12413,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00081
DB12456,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bococizumab.,Bococizumab,DB00081
DB12489,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00081
DB12498,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mogamulizumab.,Mogamulizumab,DB00081
DB12520,The risk or severity of adverse effects can be increased when Tositumomab is combined with Plozalizumab.,Plozalizumab,DB00081
DB12534,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mavrilimumab.,Mavrilimumab,DB00081
DB12560,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blosozumab.,Blosozumab,DB00081
DB12584,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimagrumab.,Bimagrumab,DB00081
DB12589,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacetuzumab.,Dacetuzumab,DB00081
DB12609,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tovetumab.,Tovetumab,DB00081
DB12683,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumretuzumab.,Lumretuzumab,DB00081
DB12698,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibalizumab.,Ibalizumab,DB00081
DB12701,The risk or severity of adverse effects can be increased when Tositumomab is combined with Intetumumab.,Intetumumab,DB00081
DB12718,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carlumab.,Carlumab,DB00081
DB12734,The risk or severity of adverse effects can be increased when Tositumomab is combined with Demcizumab.,Demcizumab,DB00081
DB12773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sifalimumab.,Sifalimumab,DB00081
DB12775,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abituzumab.,Abituzumab,DB00081
DB12797,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ecromeximab.,Ecromeximab,DB00081
DB12807,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00081
DB12815,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crotedumab.,Crotedumab,DB00081
DB12820,The risk or severity of adverse effects can be increased when Tositumomab is combined with Concizumab.,Concizumab,DB00081
DB12826,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab.,Depatuxizumab,DB00081
DB12844,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rontalizumab.,Rontalizumab,DB00081
DB12845,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amatuximab.,Amatuximab,DB00081
DB12849,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clazakizumab.,Clazakizumab,DB00081
DB12891,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanezumab.,Ozanezumab,DB00081
DB12893,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00081
DB12917,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimekizumab.,Bimekizumab,DB00081
DB12943,The risk or severity of adverse effects can be increased when Tositumomab is combined with Milatuzumab.,Milatuzumab,DB00081
DB12976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Robatumumab.,Robatumumab,DB00081
DB13017,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00081
DB13037,The risk or severity of adverse effects can be increased when Tositumomab is combined with Namilumab.,Namilumab,DB00081
DB13045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Racotumomab.,Racotumomab,DB00081
DB13073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tregalizumab.,Tregalizumab,DB00081
DB13127,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olokizumab.,Olokizumab,DB00081
DB13140,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bezlotoxumab.,Bezlotoxumab,DB00081
DB13375,The risk or severity of adverse effects can be increased when Tositumomab is combined with Edrecolomab.,Edrecolomab,DB00081
DB13535,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nebacumab.,Nebacumab,DB00081
DB13886,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00081
DB13923,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emicizumab.,Emicizumab,DB00081
DB13976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulesomab.,Sulesomab,DB00081
DB13979,The risk or severity of adverse effects can be increased when Tositumomab is combined with Besilesomab.,Besilesomab,DB00081
DB14012,The risk or severity of adverse effects can be increased when Tositumomab is combined with Burosumab.,Burosumab,DB00081
DB14039,The risk or severity of adverse effects can be increased when Tositumomab is combined with Erenumab.,Erenumab,DB00081
DB14040,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eptinezumab.,Eptinezumab,DB00081
DB14041,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fremanezumab.,Fremanezumab,DB00081
DB14042,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galcanezumab.,Galcanezumab,DB00081
DB14211,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fanolesomab.,Fanolesomab,DB00081
DB14580,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lecanemab.,Lecanemab,DB00081
DB14597,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lanadelumab.,Lanadelumab,DB00081
DB14707,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cemiplimab.,Cemiplimab,DB00081
DB14776,The risk or severity of adverse effects can be increased when Tositumomab is combined with Camrelizumab.,Camrelizumab,DB00081
DB14778,The risk or severity of adverse effects can be increased when Tositumomab is combined with Setrusumab.,Setrusumab,DB00081
DB14784,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gancotamab.,Gancotamab,DB00081
DB14809,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00081
DB14811,The risk or severity of adverse effects can be increased when Tositumomab is combined with Isatuximab.,Isatuximab,DB00081
DB14824,The risk or severity of adverse effects can be increased when Tositumomab is combined with Icrucumab.,Icrucumab,DB00081
DB14843,The risk or severity of adverse effects can be increased when Tositumomab is combined with Codrituzumab.,Codrituzumab,DB00081
DB14864,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brolucizumab.,Brolucizumab,DB00081
DB14871,The risk or severity of adverse effects can be increased when Tositumomab is combined with Xentuzumab.,Xentuzumab,DB00081
DB14877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lintuzumab.,Lintuzumab,DB00081
DB14891,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vobarilizumab.,Vobarilizumab,DB00081
DB14897,The risk or severity of adverse effects can be increased when Tositumomab is combined with Parsatuzumab.,Parsatuzumab,DB00081
DB14905,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emactuzumab.,Emactuzumab,DB00081
DB14907,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00081
DB14908,The risk or severity of adverse effects can be increased when Tositumomab is combined with Refanezumab.,Refanezumab,DB00081
DB14947,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bermekimab.,Bermekimab,DB00081
DB14952,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pamrevlumab.,Pamrevlumab,DB00081
DB14959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Opicinumab.,Opicinumab,DB00081
DB14962,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00081
DB14967,The risk or severity of adverse effects can be increased when Tositumomab is combined with Margetuximab.,Margetuximab,DB00081
DB14988,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalantercept.,Dalantercept,DB00081
DB14997,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pateclizumab.,Pateclizumab,DB00081
DB15014,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gremubamab.,Gremubamab,DB00081
DB15022,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apomab.,Apomab,DB00081
DB15044,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tafasitamab.,Tafasitamab,DB00081
DB15045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ipafricept.,Ipafricept,DB00081
DB15076,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abrilumab.,Abrilumab,DB00081
DB15089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Frovocimab.,Frovocimab,DB00081
DB15090,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tezepelumab.,Tezepelumab,DB00081
DB15101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tigatuzumab.,Tigatuzumab,DB00081
DB15104,The risk or severity of adverse effects can be increased when Tositumomab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00081
DB15113,The risk or severity of adverse effects can be increased when Tositumomab is combined with Utomilumab.,Utomilumab,DB00081
DB15118,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zolbetuximab.,Zolbetuximab,DB00081
DB15135,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponezumab.,Ponezumab,DB00081
DB15160,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asunercept.,Asunercept,DB00081
DB15172,The risk or severity of adverse effects can be increased when Tositumomab is combined with Suvratoxumab.,Suvratoxumab,DB00081
DB15225,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitazalimab.,Mitazalimab,DB00081
DB15252,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nemolizumab.,Nemolizumab,DB00081
DB15277,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gedivumab.,Gedivumab,DB00081
DB15336,The risk or severity of adverse effects can be increased when Tositumomab is combined with Valanafusp alfa.,Valanafusp alfa,DB00081
DB15349,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00081
DB15354,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evinacumab.,Evinacumab,DB00081
DB15363,The risk or severity of adverse effects can be increased when Tositumomab is combined with Istiratumab.,Istiratumab,DB00081
DB15383,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pidilizumab.,Pidilizumab,DB00081
DB15397,The risk or severity of adverse effects can be increased when Tositumomab is combined with GMA-161.,GMA-161,DB00081
DB15409,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00081
DB15415,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tomaralimab.,Tomaralimab,DB00081
DB15428,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vesencumab.,Vesencumab,DB00081
DB15432,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00081
DB15441,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lulizumab pegol.,Lulizumab pegol,DB00081
DB15443,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00081
DB15453,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00081
DB14004,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tildrakizumab.,Tildrakizumab,DB00081
DB05679,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ustekinumab.,Ustekinumab,DB00081
DB15559,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zenocutuzumab.,Zenocutuzumab,DB00081
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Tositumomab.,Palifermin,DB00081
DB00159,Icosapent may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Icosapent,DB00081
DB00229,Cefotiam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotiam,DB00081
DB00244,Mesalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mesalazine,DB00081
DB00267,Cefmenoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefmenoxime,DB00081
DB00274,Cefmetazole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefmetazole,DB00081
DB00282,Pamidronic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pamidronic acid,DB00081
DB00300,Tenofovir disoproxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir disoproxil,DB00081
DB00369,Cidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cidofovir,DB00081
DB00384,Triamterene may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Triamterene,DB00081
DB00430,Cefpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpiramide,DB00081
DB00438,Ceftazidime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftazidime,DB00081
DB00447,Loracarbef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Loracarbef,DB00081
DB00456,Cefalotin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefalotin,DB00081
DB00461,Nabumetone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Nabumetone,DB00081
DB00465,Ketorolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ketorolac,DB00081
DB00469,Tenoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenoxicam,DB00081
DB00482,Celecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Celecoxib,DB00081
DB00493,Cefotaxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotaxime,DB00081
DB00500,Tolmetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tolmetin,DB00081
DB00529,Foscarnet may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Foscarnet,DB00081
DB00533,Rofecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Rofecoxib,DB00081
DB00554,Piroxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Piroxicam,DB00081
DB00567,Cephalexin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephalexin,DB00081
DB00573,Fenoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fenoprofen,DB00081
DB00577,Valaciclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Valaciclovir,DB00081
DB00580,Valdecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Valdecoxib,DB00081
DB00586,Diclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Diclofenac,DB00081
DB00605,Sulindac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Sulindac,DB00081
DB00626,Bacitracin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bacitracin,DB00081
DB00681,Amphotericin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Amphotericin B,DB00081
DB00689,Cephaloglycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephaloglycin,DB00081
DB00712,Flurbiprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flurbiprofen,DB00081
DB00718,Adefovir dipivoxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Adefovir dipivoxil,DB00081
DB00738,Pentamidine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pentamidine,DB00081
DB00742,Mannitol may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mannitol,DB00081
DB00749,Etodolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etodolac,DB00081
DB00784,Mefenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mefenamic acid,DB00081
DB00787,Acyclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Acyclovir,DB00081
DB00788,Naproxen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Naproxen,DB00081
DB00812,Phenylbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Phenylbutazone,DB00081
DB00814,Meloxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Meloxicam,DB00081
DB00821,Carprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Carprofen,DB00081
DB00833,Cefaclor may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefaclor,DB00081
DB00861,Diflunisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Diflunisal,DB00081
DB00903,Etacrynic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etacrynic acid,DB00081
DB00923,Ceforanide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceforanide,DB00081
DB00936,Salicylic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salicylic acid,DB00081
DB00939,Meclofenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Meclofenamic acid,DB00081
DB00991,Oxaprozin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Oxaprozin,DB00081
DB00999,Hydrochlorothiazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hydrochlorothiazide,DB00081
DB01009,Ketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ketoprofen,DB00081
DB01014,Balsalazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Balsalazide,DB00081
DB01050,Ibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ibuprofen,DB00081
DB01066,Cefditoren may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefditoren,DB00081
DB01072,Atazanavir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Atazanavir,DB00081
DB01111,Colistimethate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Colistimethate,DB00081
DB01112,Cefuroxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefuroxime,DB00081
DB01139,Cefapirin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefapirin,DB00081
DB01140,Cefadroxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefadroxil,DB00081
DB01150,Cefprozil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefprozil,DB00081
DB01212,Ceftriaxone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftriaxone,DB00081
DB01250,Olsalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Olsalazine,DB00081
DB01283,Lumiracoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lumiracoxib,DB00081
DB01326,Cefamandole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefamandole,DB00081
DB01327,Cefazolin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefazolin,DB00081
DB01328,Cefonicid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefonicid,DB00081
DB01329,Cefoperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefoperazone,DB00081
DB01330,Cefotetan may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotetan,DB00081
DB01331,Cefoxitin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefoxitin,DB00081
DB01332,Ceftizoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftizoxime,DB00081
DB01333,Cefradine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefradine,DB00081
DB01397,Magnesium salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Magnesium salicylate,DB00081
DB01399,Salsalate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salsalate,DB00081
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Choline magnesium trisalicylate,DB00081
DB01413,Cefepime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefepime,DB00081
DB01414,Cefacetrile may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefacetrile,DB00081
DB01415,Ceftibuten may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftibuten,DB00081
DB01416,Cefpodoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpodoxime,DB00081
DB01419,Antrafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Antrafenine,DB00081
DB01424,Aminophenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Aminophenazone,DB00081
DB01435,Antipyrine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Antipyrine,DB00081
DB01600,Tiaprofenic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tiaprofenic acid,DB00081
DB01628,Etoricoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etoricoxib,DB00081
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hydrolyzed Cephalothin,DB00081
DB03450,Cephalothin Group may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephalothin Group,DB00081
DB03585,Oxyphenbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Oxyphenbutazone,DB00081
DB04552,Niflumic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Niflumic acid,DB00081
DB04570,Latamoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Latamoxef,DB00081
DB04812,Benoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benoxaprofen,DB00081
DB04817,Metamizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Metamizole,DB00081
DB04828,Zomepirac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Zomepirac,DB00081
DB04918,Ceftobiprole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftobiprole,DB00081
DB05095,Cimicoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cimicoxib,DB00081
DB06590,Ceftaroline fosamil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftaroline fosamil,DB00081
DB06725,Lornoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lornoxicam,DB00081
DB06736,Aceclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Aceclofenac,DB00081
DB06737,Zaltoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Zaltoprofen,DB00081
DB07402,Azapropazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Azapropazone,DB00081
DB07477,Felbinac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Felbinac,DB00081
DB08439,Parecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Parecoxib,DB00081
DB08797,Salicylamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salicylamide,DB00081
DB08940,Kebuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Kebuzone,DB00081
DB08942,Isoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Isoxicam,DB00081
DB08951,Indoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Indoprofen,DB00081
DB08955,Ibuproxam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ibuproxam,DB00081
DB08976,Floctafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Floctafenine,DB00081
DB08981,Fenbufen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fenbufen,DB00081
DB08984,Etofenamate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etofenamate,DB00081
DB08991,Epirizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Epirizole,DB00081
DB09008,Cefaloridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefaloridine,DB00081
DB09062,Cefminox may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefminox,DB00081
DB09084,Benzydamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benzydamine,DB00081
DB09212,Loxoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Loxoprofen,DB00081
DB09213,Dexibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dexibuprofen,DB00081
DB09214,Dexketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dexketoprofen,DB00081
DB09215,Droxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Droxicam,DB00081
DB09216,Tolfenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tolfenamic acid,DB00081
DB09217,Firocoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Firocoxib,DB00081
DB09218,Clonixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Clonixin,DB00081
DB09285,Morniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Morniflumate,DB00081
DB09288,Propacetamol may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Propacetamol,DB00081
DB09295,Talniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Talniflumate,DB00081
DB09299,Tenofovir alafenamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir alafenamide,DB00081
DB11367,Cefroxadine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefroxadine,DB00081
DB11455,Robenacoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Robenacoxib,DB00081
DB11518,Flunixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flunixin,DB00081
DB11935,Flomoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flomoxef,DB00081
DB12151,Brincidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Brincidofovir,DB00081
DB13001,Tinoridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tinoridine,DB00081
DB13167,Alclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Alclofenac,DB00081
DB13217,Fentiazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fentiazac,DB00081
DB13232,Suxibuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Suxibuzone,DB00081
DB13266,Cefatrizine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefatrizine,DB00081
DB13286,Bumadizone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bumadizone,DB00081
DB13314,Alminoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Alminoprofen,DB00081
DB13317,Flunoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flunoxaprofen,DB00081
DB13364,Feprazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Feprazone,DB00081
DB13371,Difenpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Difenpiramide,DB00081
DB13407,Nifenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Nifenazone,DB00081
DB13432,Lonazolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lonazolac,DB00081
DB13461,Cefcapene may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefcapene,DB00081
DB13470,Cefodizime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefodizime,DB00081
DB13481,Tenidap may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenidap,DB00081
DB13499,Cefsulodin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefsulodin,DB00081
DB13501,Bendazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bendazac,DB00081
DB13504,Cefetamet may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefetamet,DB00081
DB13514,Pranoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pranoprofen,DB00081
DB13524,Propyphenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Propyphenazone,DB00081
DB13527,Proglumetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Proglumetacin,DB00081
DB13538,Guacetisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Guacetisal,DB00081
DB13544,Ethenzamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ethenzamide,DB00081
DB13612,Carbaspirin calcium may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Carbaspirin calcium,DB00081
DB13629,Mofebutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mofebutazone,DB00081
DB13638,Cefbuperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefbuperazone,DB00081
DB13649,Proquazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Proquazone,DB00081
DB13657,Benorilate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benorilate,DB00081
DB13667,Cefozopran may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefozopran,DB00081
DB13682,Cefpirome may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpirome,DB00081
DB13722,Pirprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pirprofen,DB00081
DB13778,Cefazedone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefazedone,DB00081
DB13783,Acemetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Acemetacin,DB00081
DB13821,Ceftezole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftezole,DB00081
DB13860,Imidazole salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Imidazole salicylate,DB00081
DB13868,Adefovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Adefovir,DB00081
DB14059,SC-236 may decrease the excretion rate of Tositumomab which could result in a higher serum level.,SC-236,DB00081
DB14060,NS-398 may decrease the excretion rate of Tositumomab which could result in a higher serum level.,NS-398,DB00081
DB14126,Tenofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir,DB00081
DB14713,Inotersen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Inotersen,DB00081
DB01438,Phenazopyridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Phenazopyridine,DB00081
DB15066,Givosiran may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Givosiran,DB00081
DB01356,Lithium cation may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lithium cation,DB00081
DB14507,Lithium citrate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lithium citrate,DB00081
DB00007,Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Leuprolide,DB00081
DB00014,Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Goserelin,DB00081
DB00017,Salmon calcitonin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salmon calcitonin,DB00081
DB00035,Desmopressin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Desmopressin,DB00081
DB00080,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Daptomycin,DB00081
DB00158,Tositumomab may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid,DB00081
DB00165,Tositumomab may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine,DB00081
DB00176,Tositumomab may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine,DB00081
DB00181,Tositumomab may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen,DB00081
DB00182,Tositumomab may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine,DB00081
DB00185,Tositumomab may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline,DB00081
DB00186,Tositumomab may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam,DB00081
DB00190,Tositumomab may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa,DB00081
DB00193,Tositumomab may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol,DB00081
DB00196,Tositumomab may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole,DB00081
DB00198,Tositumomab may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir,DB00081
DB00200,Tositumomab may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin,DB00081
DB00206,Tositumomab may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine,DB00081
DB00213,Tositumomab may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole,DB00081
DB00225,Tositumomab may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide,DB00081
DB00230,Tositumomab may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin,DB00081
DB00231,Tositumomab may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam,DB00081
DB00235,Tositumomab may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone,DB00081
DB00237,Tositumomab may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital,DB00081
DB00243,Tositumomab may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine,DB00081
DB00245,Tositumomab may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine,DB00081
DB00254,Tositumomab may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline,DB00081
DB00264,Tositumomab may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol,DB00081
DB00270,Tositumomab may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine,DB00081
DB00271,Tositumomab may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate,DB00081
DB00273,Tositumomab may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate,DB00081
DB00279,Tositumomab may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine,DB00081
DB00280,Tositumomab may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide,DB00081
DB00284,Tositumomab may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose,DB00081
DB00285,Tositumomab may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine,DB00081
DB00286,Tositumomab may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens,DB00081
DB00289,Tositumomab may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine,DB00081
DB00292,Tositumomab may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate,DB00081
DB00294,Tositumomab may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel,DB00081
DB00296,Tositumomab may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine,DB00081
DB00303,Tositumomab may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem,DB00081
DB00308,Tositumomab may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide,DB00081
DB00312,Tositumomab may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital,DB00081
DB00316,Tositumomab may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen,DB00081
DB00319,Tositumomab may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin,DB00081
DB00323,Tositumomab may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone,DB00081
DB00325,Tositumomab may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside,DB00081
DB00327,Tositumomab may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone,DB00081
DB00330,Tositumomab may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol,DB00081
DB00331,Tositumomab may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin,DB00081
DB00333,Tositumomab may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone,DB00081
DB00339,Tositumomab may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide,DB00081
DB00341,Tositumomab may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine,DB00081
DB00349,Tositumomab may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam,DB00081
DB00351,Tositumomab may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate,DB00081
DB00355,Tositumomab may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam,DB00081
DB00356,Tositumomab may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone,DB00081
DB00359,Tositumomab may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine,DB00081
DB00364,Tositumomab may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate,DB00081
DB00372,Tositumomab may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine,DB00081
DB00373,Tositumomab may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol,DB00081
DB00377,Tositumomab may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron,DB00081
DB00401,Tositumomab may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine,DB00081
DB00402,Tositumomab may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone,DB00081
DB00404,Tositumomab may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam,DB00081
DB00412,Tositumomab may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone,DB00081
DB00413,Tositumomab may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole,DB00081
DB00415,Tositumomab may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin,DB00081
DB00418,Tositumomab may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital,DB00081
DB00422,Tositumomab may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate,DB00081
DB00435,Tositumomab may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide,DB00081
DB00440,Tositumomab may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim,DB00081
DB00476,Tositumomab may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine,DB00081
DB00477,Tositumomab may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine,DB00081
DB00490,Tositumomab may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone,DB00081
DB00492,Tositumomab may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril,DB00081
DB00499,Tositumomab may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide,DB00081
DB00502,Tositumomab may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol,DB00081
DB00535,Tositumomab may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir,DB00081
DB00537,Tositumomab may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.,Ciprofloxacin,DB00081
DB00548,Tositumomab may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid,DB00081
DB00553,Tositumomab may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen,DB00081
DB00555,Tositumomab may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine,DB00081
DB00558,Tositumomab may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir,DB00081
DB00571,Tositumomab may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol,DB00081
DB00583,Tositumomab may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine,DB00081
DB00597,Tositumomab may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol,DB00081
DB00598,Tositumomab may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol,DB00081
DB00603,Tositumomab may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate,DB00081
DB00608,Tositumomab may decrease the excretion rate of Chloroquine which could result in a higher serum level.,Chloroquine,DB00081
DB00612,Tositumomab may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol,DB00081
DB00624,Tositumomab may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone,DB00081
DB00628,Tositumomab may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid,DB00081
DB00633,Tositumomab may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine,DB00081
DB00651,Tositumomab may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline,DB00081
DB00657,Tositumomab may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine,DB00081
DB00660,Tositumomab may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone,DB00081
DB00661,Tositumomab may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil,DB00081
DB00665,Tositumomab may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide,DB00081
DB00669,Tositumomab may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan,DB00081
DB00672,Tositumomab may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide,DB00081
DB00683,Tositumomab may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam,DB00081
DB00690,Tositumomab may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam,DB00081
DB00692,Tositumomab may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine,DB00081
DB00698,Tositumomab may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin,DB00081
DB00706,Tositumomab may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin,DB00081
DB00709,Tositumomab may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine,DB00081
DB00713,Tositumomab may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin,DB00081
DB00716,Tositumomab may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil,DB00081
DB00722,Tositumomab may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril,DB00081
DB00730,Tositumomab may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole,DB00081
DB00731,Tositumomab may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide,DB00081
DB00733,Tositumomab may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime,DB00081
DB00743,Tositumomab may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid,DB00081
DB00759,Tositumomab may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline,DB00081
DB00760,Tositumomab may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem,DB00081
DB00761,Tositumomab may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride,DB00081
DB00780,Tositumomab may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine,DB00081
DB00782,Tositumomab may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline,DB00081
DB00783,Tositumomab may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol,DB00081
DB00789,Tositumomab may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid,DB00081
DB00790,Tositumomab may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril,DB00081
DB00800,Tositumomab may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam,DB00081
DB00804,Tositumomab may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine,DB00081
DB00811,Tositumomab may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin,DB00081
DB00820,Tositumomab may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil,DB00081
DB00828,Tositumomab may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin,DB00081
DB00829,Tositumomab may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam,DB00081
DB00839,Tositumomab may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide,DB00081
DB00841,Tositumomab may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine,DB00081
DB00842,Tositumomab may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam,DB00081
DB00863,Tositumomab may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine,DB00081
DB00871,Tositumomab may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline,DB00081
DB00894,Tositumomab may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone,DB00081
DB00897,Tositumomab may decrease the excretion rate of Triazolam which could result in a higher serum level.,Triazolam,DB00081
DB00900,Tositumomab may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine,DB00081
DB00911,Tositumomab may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole,DB00081
DB00915,Tositumomab may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine,DB00081
DB00918,Tositumomab may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan,DB00081
DB00934,Tositumomab may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline,DB00081
DB00951,Tositumomab may decrease the excretion rate of Isoniazid which could result in a higher serum level.,Isoniazid,DB00081
DB00953,Tositumomab may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan,DB00081
DB00960,Tositumomab may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol,DB00081
DB00961,Tositumomab may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine,DB00081
DB00962,Tositumomab may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon,DB00081
DB00968,Tositumomab may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa,DB00081
DB00980,Tositumomab may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon,DB00081
DB00988,Tositumomab may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine,DB00081
DB00995,Tositumomab may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin,DB00081
DB01001,Tositumomab may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol,DB00081
DB01002,Tositumomab may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine,DB00081
DB01004,Tositumomab may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir,DB00081
DB01010,Tositumomab may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium,DB00081
DB01011,Tositumomab may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone,DB00081
DB01018,Tositumomab may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine,DB00081
DB01020,Tositumomab may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate,DB00081
DB01022,Tositumomab may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone,DB00081
DB01032,Tositumomab may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid,DB00081
DB01036,Tositumomab may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine,DB00081
DB01039,Tositumomab may decrease the excretion rate of Fenofibrate which could result in a higher serum level.,Fenofibrate,DB00081
DB01043,Tositumomab may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine,DB00081
DB01046,Tositumomab may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone,DB00081
DB01048,Tositumomab may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir,DB00081
DB01060,Tositumomab may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin,DB00081
DB01067,Tositumomab may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide,DB00081
DB01068,Tositumomab may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam,DB00081
DB01069,Tositumomab may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine,DB00081
DB01093,Tositumomab may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide,DB00081
DB01105,Tositumomab may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine,DB00081
DB01115,Tositumomab may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine,DB00081
DB01124,Tositumomab may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide,DB00081
DB01129,Tositumomab may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole,DB00081
DB01133,Tositumomab may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid,DB00081
DB01135,Tositumomab may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium,DB00081
DB01137,Tositumomab may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin,DB00081
DB01148,Tositumomab may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate,DB00081
DB01149,Tositumomab may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone,DB00081
DB01156,Tositumomab may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion,DB00081
DB01157,Tositumomab may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate,DB00081
DB01170,Tositumomab may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine,DB00081
DB01183,Tositumomab may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone,DB00081
DB01203,Tositumomab may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol,DB00081
DB01205,Tositumomab may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil,DB00081
DB01213,Tositumomab may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole,DB00081
DB01215,Tositumomab may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam,DB00081
DB01221,Tositumomab may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine,DB00081
DB01224,Tositumomab may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine,DB00081
DB01233,Tositumomab may decrease the excretion rate of Metoclopramide which could result in a higher serum level.,Metoclopramide,DB00081
DB01241,Tositumomab may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.,Gemfibrozil,DB00081
DB01249,Tositumomab may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol,DB00081
DB01261,Tositumomab may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin,DB00081
DB01267,Tositumomab may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone,DB00081
DB01273,Tositumomab may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline,DB00081
DB01274,Tositumomab may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol,DB00081
DB01275,Tositumomab may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine,DB00081
DB01359,Tositumomab may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol,DB00081
DB01367,Tositumomab may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline,DB00081
DB01409,Tositumomab may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium,DB00081
DB01420,Tositumomab may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate,DB00081
DB01427,Tositumomab may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone,DB00081
DB01428,Tositumomab may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone,DB00081
DB01431,Tositumomab may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol,DB00081
DB01550,Tositumomab may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex,DB00081
DB01558,Tositumomab may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam,DB00081
DB01563,Tositumomab may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate,DB00081
DB01577,Tositumomab may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine,DB00081
DB01587,Tositumomab may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam,DB00081
DB01610,Tositumomab may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir,DB00081
DB01638,Tositumomab may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol,DB00081
DB01685,Tositumomab may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat,DB00081
DB04574,Tositumomab may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate,DB00081
DB04871,Tositumomab may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin,DB00081
DB04895,Tositumomab may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib,DB00081
DB04896,Tositumomab may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran,DB00081
DB04920,Tositumomab may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine,DB00081
DB04948,Tositumomab may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine,DB00081
DB04953,Tositumomab may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine,DB00081
DB05018,Tositumomab may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat,DB00081
DB05541,Tositumomab may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam,DB00081
DB06154,Tositumomab may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate,DB00081
DB06186,Tositumomab may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab,DB00081
DB06196,Tositumomab may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant,DB00081
DB06203,Tositumomab may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin,DB00081
DB06211,Tositumomab may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem,DB00081
DB06230,Tositumomab may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene,DB00081
DB06262,Tositumomab may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa,DB00081
DB06282,Tositumomab may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine,DB00081
DB06335,Tositumomab may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin,DB00081
DB06402,Tositumomab may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin,DB00081
DB06480,Tositumomab may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride,DB00081
DB06623,Tositumomab may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine,DB00081
DB06637,Tositumomab may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine,DB00081
DB06700,Tositumomab may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine,DB00081
DB06702,Tositumomab may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine,DB00081
DB06705,Tositumomab may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium,DB00081
DB06710,Tositumomab may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone,DB00081
DB06767,Tositumomab may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride,DB00081
DB06782,Tositumomab may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol,DB00081
DB06796,Tositumomab may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir,DB00081
DB06800,Tositumomab may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone,DB00081
DB06809,Tositumomab may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor,DB00081
DB06823,Tositumomab may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin,DB00081
DB06824,Tositumomab may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine,DB00081
DB08824,Tositumomab may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123,DB00081
DB08826,Tositumomab may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone,DB00081
DB08840,Tositumomab may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide,DB00081
DB08872,Tositumomab may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil,DB00081
DB08893,Tositumomab may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron,DB00081
DB08897,Tositumomab may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium,DB00081
DB08899,Tositumomab may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide,DB00081
DB08900,Tositumomab may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide,DB00081
DB08905,Tositumomab may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane,DB00081
DB08909,Tositumomab may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate,DB00081
DB08911,Tositumomab may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib,DB00081
DB08918,Tositumomab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran,DB00081
DB08932,Tositumomab may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan,DB00081
DB08934,Tositumomab may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir,DB00081
DB08964,Tositumomab may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost,DB00081
DB09027,Tositumomab may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir,DB00081
DB09050,Tositumomab may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane,DB00081
DB09066,Tositumomab may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa,DB00081
DB09068,Tositumomab may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine,DB00081
DB09071,Tositumomab may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon,DB00081
DB09081,Tositumomab may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone,DB00081
DB09089,Tositumomab may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine,DB00081
DB09103,Tositumomab may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim,DB00081
DB09104,Tositumomab may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide,DB00081
DB09106,Tositumomab may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch,DB00081
DB09111,Tositumomab may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch,DB00081
DB09118,Tositumomab may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol,DB00081
DB09121,Tositumomab may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose,DB00081
DB09123,Tositumomab may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest,DB00081
DB09129,Tositumomab may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride,DB00081
DB09132,Tositumomab may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid,DB00081
DB09133,Tositumomab may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid,DB00081
DB09134,Tositumomab may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol,DB00081
DB09135,Tositumomab may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan,DB00081
DB09136,Tositumomab may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue,DB00081
DB09137,Tositumomab may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin,DB00081
DB09139,Tositumomab may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate,DB00081
DB09148,Tositumomab may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F),DB00081
DB09149,Tositumomab may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F),DB00081
DB09156,Tositumomab may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide,DB00081
DB09163,Tositumomab may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime,DB00081
DB09165,Tositumomab may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate,DB00081
DB09185,Tositumomab may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine,DB00081
DB09194,Tositumomab may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone,DB00081
DB09195,Tositumomab may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole,DB00081
DB09204,Tositumomab may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol,DB00081
DB09205,Tositumomab may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte,DB00081
DB09209,Tositumomab may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine,DB00081
DB09210,Tositumomab may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam,DB00081
DB09219,Tositumomab may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin,DB00081
DB09220,Tositumomab may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil,DB00081
DB09223,Tositumomab may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin,DB00081
DB09224,Tositumomab may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone,DB00081
DB09241,Tositumomab may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue,DB00081
DB09244,Tositumomab may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole,DB00081
DB09245,Tositumomab may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone,DB00081
DB09256,Tositumomab may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur,DB00081
DB09257,Tositumomab may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil,DB00081
DB09262,Tositumomab may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin,DB00081
DB09264,Tositumomab may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab,DB00081
DB09265,Tositumomab may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide,DB00081
DB09268,Tositumomab may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid,DB00081
DB09276,Tositumomab may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate,DB00081
DB09277,Tositumomab may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11,DB00081
DB09281,Tositumomab may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate,DB00081
DB09292,Tositumomab may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril,DB00081
DB09301,Tositumomab may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate,DB00081
DB09317,"Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A",DB00081
DB09318,"Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B",DB00081
DB09320,Tositumomab may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin,DB00081
DB09324,Tositumomab may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam,DB00081
DB09325,Tositumomab may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride,DB00081
DB09329,"Tositumomab may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated",DB00081
DB09344,Tositumomab may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar,DB00081
DB09357,Tositumomab may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol,DB00081
DB09394,Tositumomab may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid,DB00081
DB09395,Tositumomab may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate,DB00081
DB09407,Tositumomab may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride,DB00081
DB09418,Tositumomab may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate,DB00081
DB09472,Tositumomab may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate,DB00081
DB09477,Tositumomab may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat,DB00081
DB09481,Tositumomab may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate,DB00081
DB09488,Tositumomab may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine,DB00081
DB09496,Tositumomab may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate,DB00081
DB09502,Tositumomab may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F),DB00081
DB09546,Tositumomab may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123,DB00081
DB09570,Tositumomab may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib,DB00081
DB11077,Tositumomab may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400,DB00081
DB11090,Tositumomab may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate,DB00081
DB11098,Tositumomab may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate,DB00081
DB11102,Tositumomab may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine,DB00081
DB11114,Tositumomab may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil,DB00081
DB11127,Tositumomab may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid,DB00081
DB11130,Tositumomab may decrease the excretion rate of Opium which could result in a higher serum level.,Opium,DB00081
DB11135,Tositumomab may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium,DB00081
DB11136,Tositumomab may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium,DB00081
DB11145,Tositumomab may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline,DB00081
DB11156,Tositumomab may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel,DB00081
DB11164,Tositumomab may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate,DB00081
DB11251,Tositumomab may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol,DB00081
DB11278,Tositumomab may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine,DB00081
DB11328,Tositumomab may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester),DB00081
DB11338,Tositumomab may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil,DB00081
DB11358,Tositumomab may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil,DB00081
DB11364,Tositumomab may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod,DB00081
DB11560,Tositumomab may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad,DB00081
DB11577,Tositumomab may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid,DB00081
DB11587,Tositumomab may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine,DB00081
DB11642,Tositumomab may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant,DB00081
DB11691,Tositumomab may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine,DB00081
DB11699,Tositumomab may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron,DB00081
DB11901,Tositumomab may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide,DB00081
DB11915,Tositumomab may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine,DB00081
DB11943,Tositumomab may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin,DB00081
DB11989,Tositumomab may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole,DB00081
DB12007,Tositumomab may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone,DB00081
DB12107,Tositumomab may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam,DB00081
DB12161,Tositumomab may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine,DB00081
DB12278,Tositumomab may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine,DB00081
DB12783,Tositumomab may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide,DB00081
DB13025,Tositumomab may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride,DB00081
DB13139,Tositumomab may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol,DB00081
DB13156,Tositumomab may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex,DB00081
DB13178,Tositumomab may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol,DB00081
DB13185,Tositumomab may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate,DB00081
DB13191,Tositumomab may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine,DB00081
DB13269,Tositumomab may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol,DB00081
DB13293,Tositumomab may decrease the excretion rate of Ipecac which could result in a higher serum level.,Ipecac,DB00081
DB13595,Tositumomab may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate,DB00081
DB13873,Tositumomab may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.,Fenofibric acid,DB00081
DB13884,Tositumomab may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa,DB00081
DB13909,Tositumomab may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate,DB00081
DB13943,Tositumomab may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate,DB00081
DB13944,Tositumomab may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate,DB00081
DB13946,Tositumomab may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate,DB00081
DB13952,Tositumomab may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate,DB00081
DB13954,Tositumomab may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate,DB00081
DB13955,Tositumomab may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate,DB00081
DB13956,Tositumomab may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate,DB00081
DB13967,Tositumomab may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue,DB00081
DB14006,Tositumomab may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate,DB00081
DB14007,Tositumomab may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid,DB00081
DB14498,Tositumomab may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate,DB00081
DB14499,Tositumomab may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate,DB00081
DB14526,Tositumomab may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate,DB00081
DB14527,Tositumomab may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate,DB00081
DB14528,Tositumomab may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate,DB00081
DB14529,Tositumomab may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate,DB00081
DB14530,Tositumomab may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate,DB00081
DB14754,Tositumomab may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol,DB00081
DB06815,Tositumomab may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione,DB00081
DB11121,Tositumomab may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol,DB00081
DB11085,Tositumomab may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol,DB00081
DB00501,Tositumomab may decrease the excretion rate of Cimetidine which could result in a higher serum level.,Cimetidine,DB00081
DB15593,Tositumomab may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen,DB00081
DB00321,Tositumomab may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline,DB00081
DB00458,Tositumomab may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine,DB00081
DB01142,Tositumomab may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin,DB00081
DB00318,Tositumomab may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine,DB00081
DB00454,Tositumomab may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine,DB00081
DB00813,Tositumomab may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl,DB00081
DB00879,Tositumomab may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine,DB00081
DB01151,Tositumomab may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine,DB00081
DB01242,Tositumomab may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine,DB00081
DB08996,Tositumomab may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine,DB00081
DB14506,Tositumomab may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide,DB00081
DB00452,Framycetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Framycetin,DB00081
DB00479,Amikacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Amikacin,DB00081
DB00684,Tobramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tobramycin,DB00081
DB00798,Gentamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Gentamicin,DB00081
DB00955,Netilmicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Netilmicin,DB00081
DB00994,Neomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Neomycin,DB00081
DB01082,Streptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Streptomycin,DB00081
DB01172,Kanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Kanamycin,DB00081
DB01421,Paromomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Paromomycin,DB00081
DB03615,Ribostamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ribostamycin,DB00081
DB04263,Geneticin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Geneticin,DB00081
DB04626,Apramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Apramycin,DB00081
DB04729,Gentamicin C1a may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Gentamicin C1a,DB00081
DB04808,Neamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Neamine,DB00081
DB06696,Arbekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Arbekacin,DB00081
DB08437,Puromycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Puromycin,DB00081
DB11512,Dihydrostreptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dihydrostreptomycin,DB00081
DB11520,Hygromycin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hygromycin B,DB00081
DB12604,Sisomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Sisomicin,DB00081
DB13270,Dibekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dibekacin,DB00081
DB13274,Micronomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Micronomicin,DB00081
DB13540,Isepamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Isepamicin,DB00081
DB13673,Bekanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bekanamycin,DB00081
DB13145,Tositumomab may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin,DB00081
DB00314,Tositumomab may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin,DB00081
DB00390,Tositumomab may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin,DB00081
DB00512,Tositumomab may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin,DB00081
DB00908,Tositumomab may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine,DB00081
DB00982,Tositumomab may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin,DB00081
DB01035,Tositumomab may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide,DB00081
DB12615,Tositumomab may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin,DB00081
DB14509,Tositumomab may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate,DB00081
DB00232,Methyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide,DB00081
DB00436,Bendroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide,DB00081
DB00562,Benzthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide,DB00081
DB00606,Cyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide,DB00081
DB00774,Hydroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide,DB00081
DB00880,Chlorothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide,DB00081
DB01021,Trichlormethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide,DB00081
DB01119,Diazoxide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide,DB00081
DB01324,Polythiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide,DB00081
DB13430,Mebutizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide,DB00081
DB13532,Cyclopenthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide,DB00081
DB00524,Tositumomab may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone,DB00081
DB00695,Tositumomab may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide,DB00081
DB00808,Tositumomab may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide,DB00081
DB00887,Tositumomab may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.,Bumetanide,DB00081
DB00909,Tositumomab may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide,DB00081
DB08907,Tositumomab may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin,DB00081
DB09338,Tositumomab may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl,DB00081
DB00214,Torasemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide,DB00081
DB00310,Chlorthalidone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone,DB00081
DB00311,Ethoxzolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide,DB00081
DB00421,Spironolactone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone,DB00081
DB00594,Amiloride may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride,DB00081
DB00700,Eplerenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone,DB00081
DB00703,Methazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide,DB00081
DB00819,Acetazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide,DB00081
DB00872,Conivaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan,DB00081
DB01144,Diclofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide,DB00081
DB01325,Quinethazone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone,DB00081
DB01395,Drospirenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone,DB00081
DB01412,Theobromine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine,DB00081
DB02925,Piretanide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide,DB00081
DB04831,Tienilic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid,DB00081
DB05034,Ularitide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide,DB00081
DB06212,Tolvaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan,DB00081
DB06292,Dapagliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin,DB00081
DB06370,Indisulam may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam,DB00081
DB08961,Azosemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide,DB00081
DB09015,Canrenoic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid,DB00081
DB09235,Efonidipine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine,DB00081
DB09401,Isosorbide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide,DB00081
DB11827,Ertugliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin,DB00081
DB12221,Canrenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone,DB00081
DB12670,Rolofylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline,DB00081
DB12704,Spiradoline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline,DB00081
DB12766,Cicletanine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine,DB00081
DB13284,Meticrane may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane,DB00081
DB13316,Ibopamine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine,DB00081
DB13405,Mefruside may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside,DB00081
DB13617,Clorexolone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone,DB00081
DB13663,Clofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide,DB00081
DB13708,Fenquizone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone,DB00081
DB13792,Clopamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide,DB00081
DB13801,Muzolimine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine,DB00081
DB13803,Xipamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide,DB00081
DB13989,Epitizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide,DB00081
DB14018,Bromotheophylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline,DB00081
DB14500,Potassium may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Potassium,DB00081
DB09042,The risk or severity of myelosuppression can be increased when Tositumomab is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00081
DB00091,Tositumomab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00081
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.,Cyanocobalamin,DB00081
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Tositumomab.,Allopurinol,DB00081
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tositumomab.","Ebola Zaire vaccine (live, attenuated)",DB00081
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Tositumomab.,Magnesium,DB00081
DB01601,The serum concentration of Tositumomab can be increased when it is combined with Lopinavir.,Lopinavir,DB00081
DB12530,The risk or severity of infection can be increased when Tositumomab is combined with Inebilizumab.,Inebilizumab,DB00081
DB00030,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.,Insulin human,DB00082
DB00046,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.,Insulin lispro,DB00082
DB00047,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.,Insulin glargine,DB00082
DB00071,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.,Insulin pork,DB00082
DB00197,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Troglitazone.,Troglitazone,DB00082
DB00222,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glimepiride.,Glimepiride,DB00082
DB00263,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfisoxazole.,Sulfisoxazole,DB00082
DB00280,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.,Disopyramide,DB00082
DB00284,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acarbose.,Acarbose,DB00082
DB00331,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.,Metformin,DB00082
DB00359,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfadiazine.,Sulfadiazine,DB00082
DB00412,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rosiglitazone.,Rosiglitazone,DB00082
DB00414,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acetohexamide.,Acetohexamide,DB00082
DB00468,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.,Quinine,DB00082
DB00491,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Miglitol.,Miglitol,DB00082
DB00672,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Chlorpropamide.,Chlorpropamide,DB00082
DB00731,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nateglinide.,Nateglinide,DB00082
DB00738,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pentamidine.,Pentamidine,DB00082
DB00834,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mifepristone.,Mifepristone,DB00082
DB00839,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.,Tolazamide,DB00082
DB00912,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.,Repaglinide,DB00082
DB00914,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Phenformin.,Phenformin,DB00082
DB01015,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.,Sulfamethoxazole,DB00082
DB01016,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.,Glyburide,DB00082
DB01067,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glipizide.,Glipizide,DB00082
DB01120,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliclazide.,Gliclazide,DB00082
DB01124,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolbutamide.,Tolbutamide,DB00082
DB01132,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.,Pioglitazone,DB00082
DB01200,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.,Bromocriptine,DB00082
DB01251,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliquidone.,Gliquidone,DB00082
DB01252,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mitiglinide.,Mitiglinide,DB00082
DB01261,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sitagliptin.,Sitagliptin,DB00082
DB01268,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.,Sunitinib,DB00082
DB01276,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Exenatide.,Exenatide,DB00082
DB01277,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mecasermin.,Mecasermin,DB00082
DB01278,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.,Pramlintide,DB00082
DB01289,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glisoxepide.,Glisoxepide,DB00082
DB01306,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin aspart.,Insulin aspart,DB00082
DB01307,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir.,Insulin detemir,DB00082
DB01309,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glulisine.,Insulin glulisine,DB00082
DB01382,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glymidine.,Glymidine,DB00082
DB01700,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AICA ribonucleotide.,AICA ribonucleotide,DB00082
DB04830,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Buformin.,Buformin,DB00082
DB04876,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Vildagliptin.,Vildagliptin,DB00082
DB04878,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Voglibose.,Voglibose,DB00082
DB05115,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NN344.,NN344,DB00082
DB05819,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NBI-6024.,NBI-6024,DB00082
DB06011,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AMG-222.,AMG-222,DB00082
DB06127,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bisegliptin.,Bisegliptin,DB00082
DB06203,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.,Alogliptin,DB00082
DB06292,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.,Dapagliflozin,DB00082
DB06335,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Saxagliptin.,Saxagliptin,DB00082
DB06655,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Liraglutide.,Liraglutide,DB00082
DB08382,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gosogliptin.,Gosogliptin,DB00082
DB08882,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.,Linagliptin,DB00082
DB08907,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.,Canagliflozin,DB00082
DB08962,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glibornuride.,Glibornuride,DB00082
DB09022,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Benfluorex.,Benfluorex,DB00082
DB09038,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.,Empagliflozin,DB00082
DB09043,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.,Albiglutide,DB00082
DB09045,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.,Dulaglutide,DB00082
DB09198,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lobeglitazone.,Lobeglitazone,DB00082
DB09199,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Netoglitazone.,Netoglitazone,DB00082
DB09200,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rivoglitazone.,Rivoglitazone,DB00082
DB09201,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.,Ciglitazone,DB00082
DB09265,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide.,Lixisenatide,DB00082
DB09456,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin beef.,Insulin beef,DB00082
DB09564,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin degludec.,Insulin degludec,DB00082
DB11567,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin peglispro.,Insulin peglispro,DB00082
DB11568,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin tregopil.,Insulin tregopil,DB00082
DB11698,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ipragliflozin.,Ipragliflozin,DB00082
DB11723,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dutogliptin.,Dutogliptin,DB00082
DB11780,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Allicin.,Allicin,DB00082
DB11824,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tofogliflozin.,Tofogliflozin,DB00082
DB11827,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ertugliflozin.,Ertugliflozin,DB00082
DB11898,"The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with 2,4-thiazolidinedione.","2,4-thiazolidinedione",DB00082
DB11950,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Teneligliptin.,Teneligliptin,DB00082
DB11992,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Omarigliptin.,Omarigliptin,DB00082
DB12268,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carmegliptin.,Carmegliptin,DB00082
DB12412,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gemigliptin.,Gemigliptin,DB00082
DB12417,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Anagliptin.,Anagliptin,DB00082
DB12625,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Evogliptin.,Evogliptin,DB00082
DB12713,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sotagliflozin.,Sotagliflozin,DB00082
DB12781,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Balaglitazone.,Balaglitazone,DB00082
DB12935,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Remogliflozin etabonate.,Remogliflozin etabonate,DB00082
DB13406,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carbutamide.,Carbutamide,DB00082
DB13446,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Guar gum.,Guar gum,DB00082
DB13675,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metahexamide.,Metahexamide,DB00082
DB13928,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Semaglutide.,Semaglutide,DB00082
DB14027,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Taspoglutide.,Taspoglutide,DB00082
DB14035,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Englitazone.,Englitazone,DB00082
DB15171,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tirzepatide.,Tirzepatide,DB00082
DB15217,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gastric inhibitory polypeptide.,Gastric inhibitory polypeptide,DB00082
DB00104,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.,Octreotide,DB00082
DB04894,The risk or severity of increased transaminases can be increased when Vapreotide is combined with Pegvisomant.,Vapreotide,DB00082
DB06663,The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant.,Pasireotide,DB00082
DB06791,The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.,Lanreotide,DB00082
DB09099,The risk or severity of increased transaminases can be increased when Somatostatin is combined with Pegvisomant.,Somatostatin,DB00082
DB01238,The metabolism of Aripiprazole can be increased when combined with Pegvisomant.,Aripiprazole,DB00082
DB14185,The metabolism of Aripiprazole lauroxil can be increased when combined with Pegvisomant.,Aripiprazole lauroxil,DB00082
DB00295,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.,Morphine,DB00082
DB00318,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.,Codeine,DB00082
DB00327,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.,Hydromorphone,DB00082
DB00333,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.,Methadone,DB00082
DB00454,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meperidine.,Meperidine,DB00082
DB00497,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.,Oxycodone,DB00082
DB00611,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.,Butorphanol,DB00082
DB00647,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.,Dextropropoxyphene,DB00082
DB00652,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.,Pentazocine,DB00082
DB00704,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.,Naltrexone,DB00082
DB00708,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.,Sufentanil,DB00082
DB00802,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.,Alfentanil,DB00082
DB00813,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.,Fentanyl,DB00082
DB00844,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.,Nalbuphine,DB00082
DB00854,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.,Levorphanol,DB00082
DB00899,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.,Remifentanil,DB00082
DB00921,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.,Buprenorphine,DB00082
DB01081,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.,Diphenoxylate,DB00082
DB01192,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.,Oxymorphone,DB00082
DB01209,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.,Dezocine,DB00082
DB01227,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levacetylmethadol.,Levacetylmethadol,DB00082
DB01433,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl acetate.,Methadyl acetate,DB00082
DB01450,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.,Dihydroetorphine,DB00082
DB01452,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diamorphine.,Diamorphine,DB00082
DB01459,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.,Bezitramide,DB00082
DB01466,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.,Ethylmorphine,DB00082
DB01497,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.,Etorphine,DB00082
DB01529,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.,Dextromoramide,DB00082
DB01531,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Desomorphine.,Desomorphine,DB00082
DB01535,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil.,Carfentanil,DB00082
DB01551,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.,Dihydrocodeine,DB00082
DB01555,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphacetylmethadol.,Alphacetylmethadol,DB00082
DB01565,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.,Dihydromorphine,DB00082
DB06204,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.,Tapentadol,DB00082
DB06738,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.,Ketobemidone,DB00082
DB08861,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.,DPDPE,DB00082
DB09174,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Lofentanil.,Lofentanil,DB00082
DB09272,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Eluxadoline.,Eluxadoline,DB00082
DB11130,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.,Opium,DB00082
DB11609,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.,Normethadone,DB00082
DB12492,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.,Piritramide,DB00082
DB13160,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine.,Alphaprodine,DB00082
DB13454,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nicomorphine.,Nicomorphine,DB00082
DB13478,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.,Meptazinol,DB00082
DB13605,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenoperidine.,Phenoperidine,DB00082
DB13606,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenazocine.,Phenazocine,DB00082
DB13787,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tilidine.,Tilidine,DB00082
DB15360,"The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil, C-11.","Carfentanil, C-11",DB00082
DB15465,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Benzhydrocodone.,Benzhydrocodone,DB00082
DB00956,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.,Hydrocodone,DB00082
DB00975,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.,Dipyridamole,DB00082
DB01364,Pegvisomant may increase the neuromuscular blocking activities of Ephedrine.,Ephedrine,DB00082
DB01408,Pegvisomant may increase the neuromuscular blocking activities of Bambuterol.,Bambuterol,DB00082
DB05875,"Pegvisomant may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.","Sar9, Met (O2)11-Substance P",DB00082
DB09205,Pegvisomant may increase the neuromuscular blocking activities of Moxisylyte.,Moxisylyte,DB00082
DB00721,Pegvisomant may increase the neuromuscular blocking activities of Procaine.,Procaine,DB00082
DB00907,Pegvisomant may increase the neuromuscular blocking activities of Cocaine.,Cocaine,DB00082
DB01116,Pegvisomant may increase the neuromuscular blocking activities of Trimethaphan.,Trimethaphan,DB00082
DB01135,Pegvisomant may increase the neuromuscular blocking activities of Doxacurium.,Doxacurium,DB00082
DB01161,Pegvisomant may increase the neuromuscular blocking activities of Chloroprocaine.,Chloroprocaine,DB00082
DB01199,Pegvisomant may increase the neuromuscular blocking activities of Tubocurarine.,Tubocurarine,DB00082
DB08897,Pegvisomant may increase the neuromuscular blocking activities of Aclidinium.,Aclidinium,DB00082
DB09288,Pegvisomant may increase the neuromuscular blocking activities of Propacetamol.,Propacetamol,DB00082
DB04250,Pegvisomant may increase the neuromuscular blocking activities of Butyrylthiocholine.,Butyrylthiocholine,DB00082
DB00762,Pegvisomant may increase the neuromuscular blocking activities of Irinotecan.,Irinotecan,DB00082
DB04920,Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.,Clevidipine,DB00082
DB08893,Pegvisomant may increase the neuromuscular blocking activities of Mirabegron.,Mirabegron,DB00082
DB01181,The metabolism of Ifosfamide can be increased when combined with Pegvisomant.,Ifosfamide,DB00082
DB08883,The metabolism of Perampanel can be increased when combined with Pegvisomant.,Perampanel,DB00082
DB00682,The metabolism of Warfarin can be increased when combined with Pegvisomant.,Warfarin,DB00082
DB01418,The metabolism of Acenocoumarol can be increased when combined with Pegvisomant.,Acenocoumarol,DB00082
DB08496,The metabolism of (R)-warfarin can be increased when combined with Pegvisomant.,(R)-warfarin,DB00082
DB08735,"The metabolism of R,S-Warfarin alcohol can be increased when combined with Pegvisomant.","R,S-Warfarin alcohol",DB00082
DB08736,"The metabolism of S,R-Warfarin alcohol can be increased when combined with Pegvisomant.","S,R-Warfarin alcohol",DB00082
DB14055,The metabolism of (S)-Warfarin can be increased when combined with Pegvisomant.,(S)-Warfarin,DB00082
DB00202,The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.,Succinylcholine,DB00082
DB00008,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00082
DB00019,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim,DB00082
DB00022,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00082
DB00059,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.,Pegaspargase,DB00082
DB00061,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.,Pegademase,DB00082
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegvisomant.,Propylene glycol,DB00082
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegvisomant.,Heptaethylene glycol,DB00082
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegvisomant.,Pegaptanib,DB00082
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegvisomant.,Egaptivon pegol,DB00082
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegvisomant.,PEG-uricase,DB00082
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegvisomant.,Peginterferon alfacon-1,DB00082
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegvisomant.,GlycoPEG-GCSF,DB00082
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegvisomant.,Pegnivacogin,DB00082
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegvisomant.,Pegpleranib,DB00082
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegvisomant.,Pegsunercept,DB00082
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant.,Polidocanol,DB00082
DB08894,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegvisomant.,Peginesatide,DB00082
DB08904,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegvisomant.,Certolizumab pegol,DB00082
DB09107,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.,Methoxy polyethylene glycol-epoetin beta,DB00082
DB09122,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegvisomant.,Peginterferon beta-1a,DB00082
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegvisomant.,Pegloticase,DB00082
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.,Polyethylene glycol,DB00082
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegvisomant.","Antihemophilic Factor (Recombinant), PEGylated",DB00082
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegvisomant.,Polyethylene glycol 400,DB00082
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegvisomant.,Eptacog alfa pegol (activated),DB00082
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegvisomant.,Olaptesed Pegol,DB00082
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegvisomant.,Abicipar Pegol,DB00082
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegvisomant.,Lexaptepid Pegol,DB00082
DB12814,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegvisomant.,Cepeginterferon alfa-2B,DB00082
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegvisomant.,Pegvaliase,DB00082
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegvisomant.,Pegamotecan,DB00082
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegvisomant.,Lipegfilgrastim,DB00082
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegvisomant.,Nonacog beta pegol,DB00082
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegvisomant.,Damoctocog alfa pegol,DB00082
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvisomant.,Elapegademase,DB00082
DB00530,The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant.,Erlotinib,DB00082
DB00209,The therapeutic efficacy of Trospium can be decreased when used in combination with Pegvisomant.,Trospium,DB00082
DB00219,The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Pegvisomant.,Oxyphenonium,DB00082
DB00237,The therapeutic efficacy of Butabarbital can be decreased when used in combination with Pegvisomant.,Butabarbital,DB00082
DB00241,The therapeutic efficacy of Butalbital can be decreased when used in combination with Pegvisomant.,Butalbital,DB00082
DB00245,The therapeutic efficacy of Benzatropine can be decreased when used in combination with Pegvisomant.,Benzatropine,DB00082
DB00306,The therapeutic efficacy of Talbutal can be decreased when used in combination with Pegvisomant.,Talbutal,DB00082
DB00312,The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Pegvisomant.,Pentobarbital,DB00082
DB00332,The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.,Ipratropium,DB00082
DB00334,The therapeutic efficacy of Olanzapine can be decreased when used in combination with Pegvisomant.,Olanzapine,DB00082
DB00340,The therapeutic efficacy of Metixene can be decreased when used in combination with Pegvisomant.,Metixene,DB00082
DB00354,The therapeutic efficacy of Buclizine can be decreased when used in combination with Pegvisomant.,Buclizine,DB00082
DB00366,The therapeutic efficacy of Doxylamine can be decreased when used in combination with Pegvisomant.,Doxylamine,DB00082
DB00376,The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pegvisomant.,Trihexyphenidyl,DB00082
DB00383,The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Pegvisomant.,Oxyphencyclimine,DB00082
DB00387,The therapeutic efficacy of Procyclidine can be decreased when used in combination with Pegvisomant.,Procyclidine,DB00082
DB00392,The therapeutic efficacy of Profenamine can be decreased when used in combination with Pegvisomant.,Profenamine,DB00082
DB00418,The therapeutic efficacy of Secobarbital can be decreased when used in combination with Pegvisomant.,Secobarbital,DB00082
DB00420,The therapeutic efficacy of Promazine can be decreased when used in combination with Pegvisomant.,Promazine,DB00082
DB00424,The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pegvisomant.,Hyoscyamine,DB00082
DB00434,The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Pegvisomant.,Cyproheptadine,DB00082
DB00462,The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Pegvisomant.,Methscopolamine bromide,DB00082
DB00463,The therapeutic efficacy of Metharbital can be decreased when used in combination with Pegvisomant.,Metharbital,DB00082
DB00472,The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pegvisomant.,Fluoxetine,DB00082
DB00505,The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Pegvisomant.,Tridihexethyl,DB00082
DB00508,The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Pegvisomant.,Triflupromazine,DB00082
DB00514,The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Pegvisomant.,Dextromethorphan,DB00082
DB00517,The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Pegvisomant.,Anisotropine methylbromide,DB00082
DB00543,The therapeutic efficacy of Amoxapine can be decreased when used in combination with Pegvisomant.,Amoxapine,DB00082
DB00555,The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pegvisomant.,Lamotrigine,DB00082
DB00572,The therapeutic efficacy of Atropine can be decreased when used in combination with Pegvisomant.,Atropine,DB00082
DB00599,The therapeutic efficacy of Thiopental can be decreased when used in combination with Pegvisomant.,Thiopental,DB00082
DB00622,The therapeutic efficacy of Nicardipine can be decreased when used in combination with Pegvisomant.,Nicardipine,DB00082
DB00657,The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pegvisomant.,Mecamylamine,DB00082
DB00670,The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pegvisomant.,Pirenzepine,DB00082
DB00715,The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pegvisomant.,Paroxetine,DB00082
DB00725,The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Pegvisomant.,Homatropine methylbromide,DB00082
DB00747,The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.,Scopolamine,DB00082
DB00753,The therapeutic efficacy of Isoflurane can be decreased when used in combination with Pegvisomant.,Isoflurane,DB00082
DB00767,The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Pegvisomant.,Benzquinamide,DB00082
DB00771,The therapeutic efficacy of Clidinium can be decreased when used in combination with Pegvisomant.,Clidinium,DB00082
DB00777,The therapeutic efficacy of Propiomazine can be decreased when used in combination with Pegvisomant.,Propiomazine,DB00082
DB00782,The therapeutic efficacy of Propantheline can be decreased when used in combination with Pegvisomant.,Propantheline,DB00082
DB00794,The therapeutic efficacy of Primidone can be decreased when used in combination with Pegvisomant.,Primidone,DB00082
DB00804,The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pegvisomant.,Dicyclomine,DB00082
DB00810,The therapeutic efficacy of Biperiden can be decreased when used in combination with Pegvisomant.,Biperiden,DB00082
DB00835,The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Pegvisomant.,Brompheniramine,DB00082
DB00849,The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Pegvisomant.,Methylphenobarbital,DB00082
DB00875,The therapeutic efficacy of Flupentixol can be decreased when used in combination with Pegvisomant.,Flupentixol,DB00082
DB00915,The therapeutic efficacy of Amantadine can be decreased when used in combination with Pegvisomant.,Amantadine,DB00082
DB00934,The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pegvisomant.,Maprotiline,DB00082
DB00940,The therapeutic efficacy of Methantheline can be decreased when used in combination with Pegvisomant.,Methantheline,DB00082
DB00941,The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Pegvisomant.,Hexafluronium,DB00082
DB00942,The therapeutic efficacy of Cycrimine can be decreased when used in combination with Pegvisomant.,Cycrimine,DB00082
DB00967,The therapeutic efficacy of Desloratadine can be decreased when used in combination with Pegvisomant.,Desloratadine,DB00082
DB00986,The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Pegvisomant.,Glycopyrronium,DB00082
DB01036,The therapeutic efficacy of Tolterodine can be decreased when used in combination with Pegvisomant.,Tolterodine,DB00082
DB01062,The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pegvisomant.,Oxybutynin,DB00082
DB01069,The therapeutic efficacy of Promethazine can be decreased when used in combination with Pegvisomant.,Promethazine,DB00082
DB01075,The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Pegvisomant.,Diphenhydramine,DB00082
DB01090,The therapeutic efficacy of Pentolinium can be decreased when used in combination with Pegvisomant.,Pentolinium,DB00082
DB01148,The therapeutic efficacy of Flavoxate can be decreased when used in combination with Pegvisomant.,Flavoxate,DB00082
DB01173,The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Pegvisomant.,Orphenadrine,DB00082
DB01175,The therapeutic efficacy of Escitalopram can be decreased when used in combination with Pegvisomant.,Escitalopram,DB00082
DB01231,The therapeutic efficacy of Diphenidol can be decreased when used in combination with Pegvisomant.,Diphenidol,DB00082
DB01239,The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Pegvisomant.,Chlorprothixene,DB00082
DB01288,The therapeutic efficacy of Fenoterol can be decreased when used in combination with Pegvisomant.,Fenoterol,DB00082
DB01351,The therapeutic efficacy of Amobarbital can be decreased when used in combination with Pegvisomant.,Amobarbital,DB00082
DB01352,The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Pegvisomant.,Aprobarbital,DB00082
DB01353,The therapeutic efficacy of Butobarbital can be decreased when used in combination with Pegvisomant.,Butobarbital,DB00082
DB01354,The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Pegvisomant.,Heptabarbital,DB00082
DB01355,The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Pegvisomant.,Hexobarbital,DB00082
DB01403,The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pegvisomant.,Methotrimeprazine,DB00082
DB01409,The therapeutic efficacy of Tiotropium can be decreased when used in combination with Pegvisomant.,Tiotropium,DB00082
DB01483,The therapeutic efficacy of Barbital can be decreased when used in combination with Pegvisomant.,Barbital,DB00082
DB01496,"The therapeutic efficacy of Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione can be decreased when used in combination with Pegvisomant.","Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione",DB00082
DB01591,The therapeutic efficacy of Solifenacin can be decreased when used in combination with Pegvisomant.,Solifenacin,DB00082
DB01625,The therapeutic efficacy of Isopropamide can be decreased when used in combination with Pegvisomant.,Isopropamide,DB00082
DB04843,The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Pegvisomant.,Mepenzolate,DB00082
DB05710,The therapeutic efficacy of Gantacurium can be decreased when used in combination with Pegvisomant.,Gantacurium,DB00082
DB06153,The therapeutic efficacy of Pizotifen can be decreased when used in combination with Pegvisomant.,Pizotifen,DB00082
DB06702,The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pegvisomant.,Fesoterodine,DB00082
DB06787,The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Pegvisomant.,Hexocyclium,DB00082
DB08801,The therapeutic efficacy of Dimetindene can be decreased when used in combination with Pegvisomant.,Dimetindene,DB00082
DB08838,The therapeutic efficacy of Agmatine can be decreased when used in combination with Pegvisomant.,Agmatine,DB00082
DB08960,The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Pegvisomant.,Hexamethonium,DB00082
DB08997,The therapeutic efficacy of Dexetimide can be decreased when used in combination with Pegvisomant.,Dexetimide,DB00082
DB09007,The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Pegvisomant.,Chlorphenoxamine,DB00082
DB09023,The therapeutic efficacy of Benactyzine can be decreased when used in combination with Pegvisomant.,Benactyzine,DB00082
DB09076,The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Pegvisomant.,Umeclidinium,DB00082
DB09089,The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pegvisomant.,Trimebutine,DB00082
DB09167,The therapeutic efficacy of Dosulepin can be decreased when used in combination with Pegvisomant.,Dosulepin,DB00082
DB09262,The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Pegvisomant.,Imidafenacin,DB00082
DB09300,The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Pegvisomant.,Butylscopolamine,DB00082
DB11235,The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Pegvisomant.,Thonzylamine,DB00082
DB11315,The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Pegvisomant.,Methscopolamine,DB00082
DB11855,The therapeutic efficacy of Revefenacin can be decreased when used in combination with Pegvisomant.,Revefenacin,DB00082
DB12086,The therapeutic efficacy of Oxitropium can be decreased when used in combination with Pegvisomant.,Oxitropium,DB00082
DB12278,The therapeutic efficacy of Propiverine can be decreased when used in combination with Pegvisomant.,Propiverine,DB00082
DB12526,The therapeutic efficacy of Batefenterol can be decreased when used in combination with Pegvisomant.,Batefenterol,DB00082
DB12554,The therapeutic efficacy of Mebeverine can be decreased when used in combination with Pegvisomant.,Mebeverine,DB00082
DB13252,The therapeutic efficacy of Tropatepine can be decreased when used in combination with Pegvisomant.,Tropatepine,DB00082
DB13254,The therapeutic efficacy of Prifinium can be decreased when used in combination with Pegvisomant.,Prifinium,DB00082
DB13351,The therapeutic efficacy of Piperidolate can be decreased when used in combination with Pegvisomant.,Piperidolate,DB00082
DB13369,The therapeutic efficacy of Benzilone can be decreased when used in combination with Pegvisomant.,Benzilone,DB00082
DB13380,The therapeutic efficacy of Difemerine can be decreased when used in combination with Pegvisomant.,Difemerine,DB00082
DB13413,The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Pegvisomant.,Phenglutarimide,DB00082
DB13448,The therapeutic efficacy of Mazaticol can be decreased when used in combination with Pegvisomant.,Mazaticol,DB00082
DB13468,The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Pegvisomant.,Etybenzatropine,DB00082
DB13500,The therapeutic efficacy of Otilonium can be decreased when used in combination with Pegvisomant.,Otilonium,DB00082
DB13505,The therapeutic efficacy of Emepronium can be decreased when used in combination with Pegvisomant.,Emepronium,DB00082
DB13507,The therapeutic efficacy of Poldine can be decreased when used in combination with Pegvisomant.,Poldine,DB00082
DB13542,The therapeutic efficacy of Bevonium can be decreased when used in combination with Pegvisomant.,Bevonium,DB00082
DB13581,The therapeutic efficacy of Rociverine can be decreased when used in combination with Pegvisomant.,Rociverine,DB00082
DB13619,The therapeutic efficacy of Bornaprine can be decreased when used in combination with Pegvisomant.,Bornaprine,DB00082
DB13636,The therapeutic efficacy of Etanautine can be decreased when used in combination with Pegvisomant.,Etanautine,DB00082
DB13666,The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Pegvisomant.,Tiemonium iodide,DB00082
DB13678,The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Pegvisomant.,Dihexyverine,DB00082
DB13695,The therapeutic efficacy of Penthienate can be decreased when used in combination with Pegvisomant.,Penthienate,DB00082
DB13720,The therapeutic efficacy of Diphemanil can be decreased when used in combination with Pegvisomant.,Diphemanil,DB00082
DB13738,The therapeutic efficacy of Camylofin can be decreased when used in combination with Pegvisomant.,Camylofin,DB00082
DB13759,The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Pegvisomant.,Fenpiverinium,DB00082
DB13769,The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Pegvisomant.,Emetonium iodide,DB00082
DB13844,The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Pegvisomant.,Pipenzolate,DB00082
DB13850,The therapeutic efficacy of Timepidium can be decreased when used in combination with Pegvisomant.,Timepidium,DB00082
DB01224,The therapeutic efficacy of Quetiapine can be decreased when used in combination with Pegvisomant.,Quetiapine,DB00082
DB00321,The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Pegvisomant.,Amitriptyline,DB00082
DB01142,The therapeutic efficacy of Doxepin can be decreased when used in combination with Pegvisomant.,Doxepin,DB00082
DB00496,The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pegvisomant.,Darifenacin,DB00082
DB00540,The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Pegvisomant.,Nortriptyline,DB00082
DB00187,Pegvisomant may increase the bradycardic activities of Esmolol.,Esmolol,DB00082
DB00195,Pegvisomant may increase the bradycardic activities of Betaxolol.,Betaxolol,DB00082
DB00335,Pegvisomant may increase the bradycardic activities of Atenolol.,Atenolol,DB00082
DB00373,Pegvisomant may increase the bradycardic activities of Timolol.,Timolol,DB00082
DB00489,Pegvisomant may increase the bradycardic activities of Sotalol.,Sotalol,DB00082
DB00598,Pegvisomant may increase the bradycardic activities of Labetalol.,Labetalol,DB00082
DB00866,Pegvisomant may increase the bradycardic activities of Alprenolol.,Alprenolol,DB00082
DB00960,Pegvisomant may increase the bradycardic activities of Pindolol.,Pindolol,DB00082
DB01193,Pegvisomant may increase the bradycardic activities of Acebutolol.,Acebutolol,DB00082
DB01203,Pegvisomant may increase the bradycardic activities of Nadolol.,Nadolol,DB00082
DB01295,Pegvisomant may increase the bradycardic activities of Bevantolol.,Bevantolol,DB00082
DB01297,Pegvisomant may increase the bradycardic activities of Practolol.,Practolol,DB00082
DB01359,Pegvisomant may increase the bradycardic activities of Penbutolol.,Penbutolol,DB00082
DB01580,Pegvisomant may increase the bradycardic activities of Oxprenolol.,Oxprenolol,DB00082
DB03322,Pegvisomant may increase the bradycardic activities of Dexpropranolol.,Dexpropranolol,DB00082
DB04846,Pegvisomant may increase the bradycardic activities of Celiprolol.,Celiprolol,DB00082
DB06726,Pegvisomant may increase the bradycardic activities of Bufuralol.,Bufuralol,DB00082
DB08807,Pegvisomant may increase the bradycardic activities of Bopindolol.,Bopindolol,DB00082
DB08808,Pegvisomant may increase the bradycardic activities of Bupranolol.,Bupranolol,DB00082
DB08952,Pegvisomant may increase the bradycardic activities of Indenolol.,Indenolol,DB00082
DB09013,Pegvisomant may increase the bradycardic activities of Befunolol.,Befunolol,DB00082
DB09204,Pegvisomant may increase the bradycardic activities of Arotinolol.,Arotinolol,DB00082
DB09351,Pegvisomant may increase the bradycardic activities of Levobetaxolol.,Levobetaxolol,DB00082
DB11770,Pegvisomant may increase the bradycardic activities of Talinolol.,Talinolol,DB00082
DB11785,Pegvisomant may increase the bradycardic activities of Anisodamine.,Anisodamine,DB00082
DB12212,Pegvisomant may increase the bradycardic activities of Landiolol.,Landiolol,DB00082
DB12752,Pegvisomant may increase the bradycardic activities of Bucindolol.,Bucindolol,DB00082
DB13443,Pegvisomant may increase the bradycardic activities of Esatenolol.,Esatenolol,DB00082
DB13508,Pegvisomant may increase the bradycardic activities of Cloranolol.,Cloranolol,DB00082
DB13530,Pegvisomant may increase the bradycardic activities of Mepindolol.,Mepindolol,DB00082
DB13757,Pegvisomant may increase the bradycardic activities of Epanolol.,Epanolol,DB00082
DB13775,Pegvisomant may increase the bradycardic activities of Tertatolol.,Tertatolol,DB00082
DB00571,Pegvisomant may increase the bradycardic activities of Propranolol.,Propranolol,DB00082
DB00612,Pegvisomant may increase the bradycardic activities of Bisoprolol.,Bisoprolol,DB00082
DB01136,Pegvisomant may increase the bradycardic activities of Carvedilol.,Carvedilol,DB00082
DB01182,Pegvisomant may increase the bradycardic activities of Propafenone.,Propafenone,DB00082
DB04861,Pegvisomant may increase the bradycardic activities of Nebivolol.,Nebivolol,DB00082
DB00411,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.,Carbamoylcholine,DB00082
DB01019,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Bethanechol.,Bethanechol,DB00082
DB01085,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Pilocarpine.,Pilocarpine,DB00082
DB01273,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Varenicline.,Varenicline,DB00082
DB03128,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Acetylcholine.,Acetylcholine,DB00082
DB04365,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Arecoline.,Arecoline,DB00082
DB05137,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Lobeline.,Lobeline,DB00082
DB05152,The risk or severity of adverse effects can be increased when Pegvisomant is combined with NGX267.,NGX267,DB00082
DB05708,The risk or severity of adverse effects can be increased when Pegvisomant is combined with GTS-21.,GTS-21,DB00082
DB06709,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Methacholine.,Methacholine,DB00082
DB07720,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Epibatidine.,Epibatidine,DB00082
DB15357,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Xanomeline.,Xanomeline,DB00082
DB00184,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Nicotine.,Nicotine,DB00082
DB00185,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Cevimeline.,Cevimeline,DB00082
DB00166,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lipoic acid.,Lipoic acid,DB00082
DB00328,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indomethacin.,Indomethacin,DB00082
DB01044,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gatifloxacin.,Gatifloxacin,DB00082
DB04832,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Zimelidine.,Zimelidine,DB00082
DB09270,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ubidecarenone.,Ubidecarenone,DB00082
DB12693,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ritanserin.,Ritanserin,DB00082
DB13233,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alaproclate.,Alaproclate,DB00082
DB13358,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Cibenzoline.,Cibenzoline,DB00082
DB14025,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Clinafloxacin.,Clinafloxacin,DB00082
DB00176,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Fluvoxamine.,Fluvoxamine,DB00082
DB00215,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Citalopram.,Citalopram,DB00082
DB00230,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pregabalin.,Pregabalin,DB00082
DB00285,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Venlafaxine.,Venlafaxine,DB00082
DB01104,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sertraline.,Sertraline,DB00082
DB01149,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nefazodone.,Nefazodone,DB00082
DB04884,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapoxetine.,Dapoxetine,DB00082
DB06700,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Desvenlafaxine.,Desvenlafaxine,DB00082
DB08953,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indalpine.,Indalpine,DB00082
DB09091,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tixocortol.,Tixocortol,DB00082
DB13003,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortivazol.,Cortivazol,DB00082
DB13223,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortin.,Fluocortin,DB00082
DB13491,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluperolone.,Fluperolone,DB00082
DB13664,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Formocortal.,Formocortal,DB00082
DB13728,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Halometasone.,Halometasone,DB00082
DB13843,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cloprednol.,Cloprednol,DB00082
DB13856,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluclorolone.,Fluclorolone,DB00082
DB00873,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Loteprednol.,Loteprednol,DB00082
DB14631,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone phosphate.,Prednisolone phosphate,DB00082
DB14633,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone hemisuccinate.,Prednisolone hemisuccinate,DB00082
DB14634,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene acetate.,Fluprednidene acetate,DB00082
DB14643,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone aceponate.,Methylprednisolone aceponate,DB00082
DB14644,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone hemisuccinate.,Methylprednisolone hemisuccinate,DB00082
DB14646,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone acetate.,Prednisone acetate,DB00082
DB14652,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clocortolone acetate.,Clocortolone acetate,DB00082
DB14659,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol acetate.,Melengestrol acetate,DB00082
DB14669,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone phosphate.,Betamethasone phosphate,DB00082
DB14681,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone.,Cortisone,DB00082
DB00180,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Flunisolide.,Flunisolide,DB00082
DB00394,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00082
DB00443,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone.,Betamethasone,DB00082
DB00588,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone propionate.,Fluticasone propionate,DB00082
DB00591,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocinolone acetonide.,Fluocinolone acetonide,DB00082
DB00620,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Triamcinolone.,Triamcinolone,DB00082
DB00635,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone.,Prednisone,DB00082
DB00687,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fludrocortisone.,Fludrocortisone,DB00082
DB00741,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone.,Hydrocortisone,DB00082
DB00764,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone.,Mometasone,DB00082
DB00860,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone.,Prednisolone,DB00082
DB00959,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone.,Methylprednisolone,DB00082
DB01108,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Trilostane.,Trilostane,DB00082
DB01234,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone.,Dexamethasone,DB00082
DB01285,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Corticotropin.,Corticotropin,DB00082
DB01380,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone acetate.,Cortisone acetate,DB00082
DB01384,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Paramethasone.,Paramethasone,DB00082
DB01410,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ciclesonide.,Ciclesonide,DB00082
DB04630,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Aldosterone.,Aldosterone,DB00082
DB08906,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone furoate.,Fluticasone furoate,DB00082
DB08970,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene.,Fluprednidene,DB00082
DB08971,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortolone.,Fluocortolone,DB00082
DB09378,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednisolone.,Fluprednisolone,DB00082
DB09383,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meprednisone.,Meprednisone,DB00082
DB11487,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00082
DB11529,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol.,Melengestrol,DB00082
DB11750,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clobetasol.,Clobetasol,DB00082
DB11921,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Deflazacort.,Deflazacort,DB00082
DB13208,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednylidene.,Prednylidene,DB00082
DB13867,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone.,Fluticasone,DB00082
DB14512,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone furoate.,Mometasone furoate,DB00082
DB14538,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00082
DB14539,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone acetate.,Hydrocortisone acetate,DB00082
DB14541,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone cypionate.,Hydrocortisone cypionate,DB00082
DB14545,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone succinate.,Hydrocortisone succinate,DB00082
DB01222,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Budesonide.,Budesonide,DB00082
DB00416,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine iodide.,Metocurine iodide,DB00082
DB00483,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine triethiodide.,Gallamine triethiodide,DB00082
DB00565,Pegvisomant may decrease the neuromuscular blocking activities of Cisatracurium.,Cisatracurium,DB00082
DB00728,Pegvisomant may decrease the neuromuscular blocking activities of Rocuronium.,Rocuronium,DB00082
DB00732,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium besylate.,Atracurium besylate,DB00082
DB01226,Pegvisomant may decrease the neuromuscular blocking activities of Mivacurium.,Mivacurium,DB00082
DB01336,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine.,Metocurine,DB00082
DB01337,Pegvisomant may decrease the neuromuscular blocking activities of Pancuronium.,Pancuronium,DB00082
DB01338,Pegvisomant may decrease the neuromuscular blocking activities of Pipecuronium.,Pipecuronium,DB00082
DB01339,Pegvisomant may decrease the neuromuscular blocking activities of Vecuronium.,Vecuronium,DB00082
DB04834,Pegvisomant may decrease the neuromuscular blocking activities of Rapacuronium.,Rapacuronium,DB00082
DB13295,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium.,Atracurium,DB00082
DB13584,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine.,Gallamine,DB00082
DB13648,Pegvisomant may decrease the neuromuscular blocking activities of Alcuronium.,Alcuronium,DB00082
DB14583,The metabolism of Segesterone acetate can be increased when combined with Pegvisomant.,Segesterone acetate,DB00082
DB00255,The metabolism of Diethylstilbestrol can be increased when combined with Pegvisomant.,Diethylstilbestrol,DB00082
DB00294,The metabolism of Etonogestrel can be increased when combined with Pegvisomant.,Etonogestrel,DB00082
DB00304,The metabolism of Desogestrel can be increased when combined with Pegvisomant.,Desogestrel,DB00082
DB00351,The metabolism of Megestrol acetate can be increased when combined with Pegvisomant.,Megestrol acetate,DB00082
DB00367,The metabolism of Levonorgestrel can be increased when combined with Pegvisomant.,Levonorgestrel,DB00082
DB00396,The metabolism of Progesterone can be increased when combined with Pegvisomant.,Progesterone,DB00082
DB00603,The metabolism of Medroxyprogesterone acetate can be increased when combined with Pegvisomant.,Medroxyprogesterone acetate,DB00082
DB00717,The metabolism of Norethisterone can be increased when combined with Pegvisomant.,Norethisterone,DB00082
DB00783,The metabolism of Estradiol can be increased when combined with Pegvisomant.,Estradiol,DB00082
DB00823,The metabolism of Ethynodiol diacetate can be increased when combined with Pegvisomant.,Ethynodiol diacetate,DB00082
DB00957,The metabolism of Norgestimate can be increased when combined with Pegvisomant.,Norgestimate,DB00082
DB00977,The metabolism of Ethinylestradiol can be increased when combined with Pegvisomant.,Ethinylestradiol,DB00082
DB01357,The metabolism of Mestranol can be increased when combined with Pegvisomant.,Mestranol,DB00082
DB01395,The metabolism of Drospirenone can be increased when combined with Pegvisomant.,Drospirenone,DB00082
DB04066,The metabolism of p-Coumaric acid can be increased when combined with Pegvisomant.,p-Coumaric acid,DB00082
DB04574,The metabolism of Estrone sulfate can be increased when combined with Pegvisomant.,Estrone sulfate,DB00082
DB04682,The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Pegvisomant.,Octylphenoxy polyethoxyethanol,DB00082
DB04839,The metabolism of Cyproterone acetate can be increased when combined with Pegvisomant.,Cyproterone acetate,DB00082
DB05830,The metabolism of Trestolone can be increased when combined with Pegvisomant.,Trestolone,DB00082
DB06266,The metabolism of Lonidamine can be increased when combined with Pegvisomant.,Lonidamine,DB00082
DB06713,The metabolism of Norelgestromin can be increased when combined with Pegvisomant.,Norelgestromin,DB00082
DB06730,The metabolism of Gestodene can be increased when combined with Pegvisomant.,Gestodene,DB00082
DB06789,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Pegvisomant.,Hydroxyprogesterone caproate,DB00082
DB09123,The metabolism of Dienogest can be increased when combined with Pegvisomant.,Dienogest,DB00082
DB09371,The metabolism of Norethynodrel can be increased when combined with Pegvisomant.,Norethynodrel,DB00082
DB09389,The metabolism of Norgestrel can be increased when combined with Pegvisomant.,Norgestrel,DB00082
DB09401,The metabolism of Isosorbide can be increased when combined with Pegvisomant.,Isosorbide,DB00082
DB11507,The metabolism of Cloprostenol can be increased when combined with Pegvisomant.,Cloprostenol,DB00082
DB11619,The metabolism of Gestrinone can be increased when combined with Pegvisomant.,Gestrinone,DB00082
DB11636,The metabolism of Nomegestrol can be increased when combined with Pegvisomant.,Nomegestrol,DB00082
DB12025,The metabolism of Triptolide can be increased when combined with Pegvisomant.,Triptolide,DB00082
DB12474,The metabolism of Lynestrenol can be increased when combined with Pegvisomant.,Lynestrenol,DB00082
DB13044,The metabolism of Gossypol can be increased when combined with Pegvisomant.,Gossypol,DB00082
DB13310,The metabolism of Ormeloxifene can be increased when combined with Pegvisomant.,Ormeloxifene,DB00082
DB13528,The metabolism of Chlormadinone can be increased when combined with Pegvisomant.,Chlormadinone,DB00082
DB13563,The metabolism of Norgestrienone can be increased when combined with Pegvisomant.,Norgestrienone,DB00082
DB13685,The metabolism of Quingestanol can be increased when combined with Pegvisomant.,Quingestanol,DB00082
DB13857,The metabolism of Demegestone can be increased when combined with Pegvisomant.,Demegestone,DB00082
DB13866,The metabolism of Etynodiol can be increased when combined with Pegvisomant.,Etynodiol,DB00082
DB13944,The metabolism of Testosterone enanthate can be increased when combined with Pegvisomant.,Testosterone enanthate,DB00082
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Pegvisomant.,Estradiol benzoate,DB00082
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Pegvisomant.,Estradiol cypionate,DB00082
DB13956,The metabolism of Estradiol valerate can be increased when combined with Pegvisomant.,Estradiol valerate,DB00082
DB13981,The metabolism of Nomegestrol acetate can be increased when combined with Pegvisomant.,Nomegestrol acetate,DB00082
DB14678,The metabolism of Norethindrone enanthate can be increased when combined with Pegvisomant.,Norethindrone enanthate,DB00082
DB08867,The metabolism of Ulipristal can be increased when combined with Pegvisomant.,Ulipristal,DB00082
DB00246,The metabolism of Ziprasidone can be increased when combined with Pegvisomant.,Ziprasidone,DB00082
DB00477,The metabolism of Chlorpromazine can be increased when combined with Pegvisomant.,Chlorpromazine,DB00082
DB01151,The metabolism of Desipramine can be increased when combined with Pegvisomant.,Desipramine,DB00082
DB00186,The metabolism of Lorazepam can be increased when combined with Pegvisomant.,Lorazepam,DB00082
DB00191,The metabolism of Phentermine can be increased when combined with Pegvisomant.,Phentermine,DB00082
DB00207,The metabolism of Azithromycin can be increased when combined with Pegvisomant.,Azithromycin,DB00082
DB00208,The metabolism of Ticlopidine can be increased when combined with Pegvisomant.,Ticlopidine,DB00082
DB00264,The metabolism of Metoprolol can be increased when combined with Pegvisomant.,Metoprolol,DB00082
DB00426,The metabolism of Famciclovir can be increased when combined with Pegvisomant.,Famciclovir,DB00082
DB00433,The metabolism of Prochlorperazine can be increased when combined with Pegvisomant.,Prochlorperazine,DB00082
DB00476,The metabolism of Duloxetine can be increased when combined with Pegvisomant.,Duloxetine,DB00082
DB00518,The metabolism of Albendazole can be increased when combined with Pegvisomant.,Albendazole,DB00082
DB00567,The metabolism of Cephalexin can be increased when combined with Pegvisomant.,Cephalexin,DB00082
DB00590,The metabolism of Doxazosin can be increased when combined with Pegvisomant.,Doxazosin,DB00082
DB01039,The metabolism of Fenofibrate can be increased when combined with Pegvisomant.,Fenofibrate,DB00082
DB01072,The metabolism of Atazanavir can be increased when combined with Pegvisomant.,Atazanavir,DB00082
DB01323,The metabolism of St. John's Wort can be increased when combined with Pegvisomant.,St. John's Wort,DB00082
DB01411,The metabolism of Pranlukast can be increased when combined with Pegvisomant.,Pranlukast,DB00082
DB01431,The metabolism of Allylestrenol can be increased when combined with Pegvisomant.,Allylestrenol,DB00082
DB01624,The metabolism of Zuclopenthixol can be increased when combined with Pegvisomant.,Zuclopenthixol,DB00082
DB01656,The metabolism of Roflumilast can be increased when combined with Pegvisomant.,Roflumilast,DB00082
DB06201,The metabolism of Rufinamide can be increased when combined with Pegvisomant.,Rufinamide,DB00082
DB06218,The metabolism of Lacosamide can be increased when combined with Pegvisomant.,Lacosamide,DB00082
DB06480,The metabolism of Prucalopride can be increased when combined with Pegvisomant.,Prucalopride,DB00082
DB09030,The metabolism of Vorapaxar can be increased when combined with Pegvisomant.,Vorapaxar,DB00082
DB09034,The metabolism of Suvorexant can be increased when combined with Pegvisomant.,Suvorexant,DB00082
DB09048,The metabolism of Netupitant can be increased when combined with Pegvisomant.,Netupitant,DB00082
DB09071,The metabolism of Tasimelteon can be increased when combined with Pegvisomant.,Tasimelteon,DB00082
DB09079,The metabolism of Nintedanib can be increased when combined with Pegvisomant.,Nintedanib,DB00082
DB09299,The metabolism of Tenofovir alafenamide can be increased when combined with Pegvisomant.,Tenofovir alafenamide,DB00082
DB09330,The metabolism of Osimertinib can be increased when combined with Pegvisomant.,Osimertinib,DB00082
DB11094,The metabolism of Vitamin D can be increased when combined with Pegvisomant.,Vitamin D,DB00082
DB11273,The metabolism of Dihydroergocornine can be increased when combined with Pegvisomant.,Dihydroergocornine,DB00082
DB11730,The metabolism of Ribociclib can be increased when combined with Pegvisomant.,Ribociclib,DB00082
DB11952,The metabolism of Duvelisib can be increased when combined with Pegvisomant.,Duvelisib,DB00082
DB12141,The metabolism of Gilteritinib can be increased when combined with Pegvisomant.,Gilteritinib,DB00082
DB12515,The metabolism of 9-aminocamptothecin can be increased when combined with Pegvisomant.,9-aminocamptothecin,DB00082
DB12952,The metabolism of Methylprednisone can be increased when combined with Pegvisomant.,Methylprednisone,DB00082
DB13345,The metabolism of Dihydroergocristine can be increased when combined with Pegvisomant.,Dihydroergocristine,DB00082
DB13385,The metabolism of Dihydroergocryptine can be increased when combined with Pegvisomant.,Dihydroergocryptine,DB00082
DB14009,The metabolism of Medical Cannabis can be increased when combined with Pegvisomant.,Medical Cannabis,DB00082
DB14126,The metabolism of Tenofovir can be increased when combined with Pegvisomant.,Tenofovir,DB00082
DB01098,The metabolism of Rosuvastatin can be increased when combined with Pegvisomant.,Rosuvastatin,DB00082
DB00549,The metabolism of Zafirlukast can be increased when combined with Pegvisomant.,Zafirlukast,DB00082
DB15444,The metabolism of Elexacaftor can be increased when combined with Pegvisomant.,Elexacaftor,DB00082
DB12887,The metabolism of Tazemetostat can be increased when combined with Pegvisomant.,Tazemetostat,DB00082
DB06717,The metabolism of Fosaprepitant can be increased when combined with Pegvisomant.,Fosaprepitant,DB00082
DB12825,The metabolism of Lefamulin can be increased when combined with Pegvisomant.,Lefamulin,DB00082
DB00247,The metabolism of Methysergide can be increased when combined with Pegvisomant.,Methysergide,DB00082
DB00637,The metabolism of Astemizole can be increased when combined with Pegvisomant.,Astemizole,DB00082
DB08827,The metabolism of Lomitapide can be increased when combined with Pegvisomant.,Lomitapide,DB00082
DB11742,The metabolism of Ebastine can be increased when combined with Pegvisomant.,Ebastine,DB00082
DB12371,The metabolism of Siponimod can be increased when combined with Pegvisomant.,Siponimod,DB00082
DB00363,The metabolism of Clozapine can be increased when combined with Pegvisomant.,Clozapine,DB00082
DB00091,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.,Cyclosporine,DB00082
DB00204,The metabolism of Dofetilide can be increased when combined with Pegvisomant.,Dofetilide,DB00082
DB00277,The metabolism of Theophylline can be increased when combined with Pegvisomant.,Theophylline,DB00082
DB00342,The metabolism of Terfenadine can be increased when combined with Pegvisomant.,Terfenadine,DB00082
DB00451,The metabolism of Levothyroxine can be increased when combined with Pegvisomant.,Levothyroxine,DB00082
DB00564,The metabolism of Carbamazepine can be increased when combined with Pegvisomant.,Carbamazepine,DB00082
DB00604,The metabolism of Cisapride can be increased when combined with Pegvisomant.,Cisapride,DB00082
DB00864,The metabolism of Tacrolimus can be increased when combined with Pegvisomant.,Tacrolimus,DB00082
DB00877,The metabolism of Sirolimus can be increased when combined with Pegvisomant.,Sirolimus,DB00082
DB00908,The metabolism of Quinidine can be increased when combined with Pegvisomant.,Quinidine,DB00082
DB00946,The metabolism of Phenprocoumon can be increased when combined with Pegvisomant.,Phenprocoumon,DB00082
DB01008,The metabolism of Busulfan can be increased when combined with Pegvisomant.,Busulfan,DB00082
DB01100,The metabolism of Pimozide can be increased when combined with Pegvisomant.,Pimozide,DB00082
DB01118,The metabolism of Amiodarone can be increased when combined with Pegvisomant.,Amiodarone,DB00082
DB01223,The metabolism of Aminophylline can be increased when combined with Pegvisomant.,Aminophylline,DB00082
DB01229,The metabolism of Paclitaxel can be increased when combined with Pegvisomant.,Paclitaxel,DB00082
DB01254,The metabolism of Dasatinib can be increased when combined with Pegvisomant.,Dasatinib,DB00082
DB01320,The metabolism of Fosphenytoin can be increased when combined with Pegvisomant.,Fosphenytoin,DB00082
DB01396,The metabolism of Digitoxin can be increased when combined with Pegvisomant.,Digitoxin,DB00082
DB01590,The metabolism of Everolimus can be increased when combined with Pegvisomant.,Everolimus,DB00082
DB03410,The metabolism of 4-hydroxycoumarin can be increased when combined with Pegvisomant.,4-hydroxycoumarin,DB00082
DB04855,The metabolism of Dronedarone can be increased when combined with Pegvisomant.,Dronedarone,DB00082
DB06287,The metabolism of Temsirolimus can be increased when combined with Pegvisomant.,Temsirolimus,DB00082
DB09053,The metabolism of Ibrutinib can be increased when combined with Pegvisomant.,Ibrutinib,DB00082
DB09289,The metabolism of Tianeptine can be increased when combined with Pegvisomant.,Tianeptine,DB00082
DB11633,The metabolism of Isavuconazole can be increased when combined with Pegvisomant.,Isavuconazole,DB00082
DB13136,The metabolism of Fluindione can be increased when combined with Pegvisomant.,Fluindione,DB00082
DB13275,The metabolism of Clorindione can be increased when combined with Pegvisomant.,Clorindione,DB00082
DB05239,The metabolism of Cobimetinib can be increased when combined with Pegvisomant.,Cobimetinib,DB00082
DB09054,The metabolism of Idelalisib can be increased when combined with Pegvisomant.,Idelalisib,DB00082
DB09063,The metabolism of Ceritinib can be increased when combined with Pegvisomant.,Ceritinib,DB00082
DB11963,The metabolism of Dacomitinib can be increased when combined with Pegvisomant.,Dacomitinib,DB00082
DB12015,The metabolism of Alpelisib can be increased when combined with Pegvisomant.,Alpelisib,DB00082
DB00563,The metabolism of Methotrexate can be increased when combined with Pegvisomant.,Methotrexate,DB00082
DB00361,The metabolism of Vinorelbine can be increased when combined with Pegvisomant.,Vinorelbine,DB00082
DB00541,The metabolism of Vincristine can be increased when combined with Pegvisomant.,Vincristine,DB00082
DB00570,The metabolism of Vinblastine can be increased when combined with Pegvisomant.,Vinblastine,DB00082
DB00694,The metabolism of Daunorubicin can be increased when combined with Pegvisomant.,Daunorubicin,DB00082
DB00987,The metabolism of Cytarabine can be increased when combined with Pegvisomant.,Cytarabine,DB00082
DB00997,The metabolism of Doxorubicin can be increased when combined with Pegvisomant.,Doxorubicin,DB00082
DB01248,The metabolism of Docetaxel can be increased when combined with Pegvisomant.,Docetaxel,DB00082
DB04572,The metabolism of Thiotepa can be increased when combined with Pegvisomant.,Thiotepa,DB00082
DB05109,The metabolism of Trabectedin can be increased when combined with Pegvisomant.,Trabectedin,DB00082
DB05294,The metabolism of Vandetanib can be increased when combined with Pegvisomant.,Vandetanib,DB00082
DB05812,The metabolism of Abiraterone can be increased when combined with Pegvisomant.,Abiraterone,DB00082
DB08881,The metabolism of Vemurafenib can be increased when combined with Pegvisomant.,Vemurafenib,DB00082
DB11363,The metabolism of Alectinib can be increased when combined with Pegvisomant.,Alectinib,DB00082
DB11581,The metabolism of Venetoclax can be increased when combined with Pegvisomant.,Venetoclax,DB00082
DB11641,The metabolism of Vinflunine can be increased when combined with Pegvisomant.,Vinflunine,DB00082
DB11703,The metabolism of Acalabrutinib can be increased when combined with Pegvisomant.,Acalabrutinib,DB00082
DB13874,The metabolism of Enasidenib can be increased when combined with Pegvisomant.,Enasidenib,DB00082
DB15035,The metabolism of Zanubrutinib can be increased when combined with Pegvisomant.,Zanubrutinib,DB00082
DB00188,The metabolism of Bortezomib can be increased when combined with Pegvisomant.,Bortezomib,DB00082
DB00248,The metabolism of Cabergoline can be increased when combined with Pegvisomant.,Cabergoline,DB00082
DB00309,The metabolism of Vindesine can be increased when combined with Pegvisomant.,Vindesine,DB00082
DB00398,The metabolism of Sorafenib can be increased when combined with Pegvisomant.,Sorafenib,DB00082
DB00444,The metabolism of Teniposide can be increased when combined with Pegvisomant.,Teniposide,DB00082
DB00619,The metabolism of Imatinib can be increased when combined with Pegvisomant.,Imatinib,DB00082
DB00675,The metabolism of Tamoxifen can be increased when combined with Pegvisomant.,Tamoxifen,DB00082
DB00773,The metabolism of Etoposide can be increased when combined with Pegvisomant.,Etoposide,DB00082
DB04845,The metabolism of Ixabepilone can be increased when combined with Pegvisomant.,Ixabepilone,DB00082
DB04868,The metabolism of Nilotinib can be increased when combined with Pegvisomant.,Nilotinib,DB00082
DB05015,The metabolism of Belinostat can be increased when combined with Pegvisomant.,Belinostat,DB00082
DB06589,The metabolism of Pazopanib can be increased when combined with Pegvisomant.,Pazopanib,DB00082
DB06595,The metabolism of Midostaurin can be increased when combined with Pegvisomant.,Midostaurin,DB00082
DB06603,The metabolism of Panobinostat can be increased when combined with Pegvisomant.,Panobinostat,DB00082
DB06616,The metabolism of Bosutinib can be increased when combined with Pegvisomant.,Bosutinib,DB00082
DB06626,The metabolism of Axitinib can be increased when combined with Pegvisomant.,Axitinib,DB00082
DB08865,The metabolism of Crizotinib can be increased when combined with Pegvisomant.,Crizotinib,DB00082
DB08870,The metabolism of Brentuximab vedotin can be increased when combined with Pegvisomant.,Brentuximab vedotin,DB00082
DB08877,The metabolism of Ruxolitinib can be increased when combined with Pegvisomant.,Ruxolitinib,DB00082
DB08901,The metabolism of Ponatinib can be increased when combined with Pegvisomant.,Ponatinib,DB00082
DB08912,The metabolism of Dabrafenib can be increased when combined with Pegvisomant.,Dabrafenib,DB00082
DB09073,The metabolism of Palbociclib can be increased when combined with Pegvisomant.,Palbociclib,DB00082
DB09143,The metabolism of Sonidegib can be increased when combined with Pegvisomant.,Sonidegib,DB00082
DB09570,The metabolism of Ixazomib can be increased when combined with Pegvisomant.,Ixazomib,DB00082
DB11718,The metabolism of Encorafenib can be increased when combined with Pegvisomant.,Encorafenib,DB00082
DB11828,The metabolism of Neratinib can be increased when combined with Pegvisomant.,Neratinib,DB00082
DB12147,The metabolism of Erdafitinib can be increased when combined with Pegvisomant.,Erdafitinib,DB00082
DB12267,The metabolism of Brigatinib can be increased when combined with Pegvisomant.,Brigatinib,DB00082
DB12483,The metabolism of Copanlisib can be increased when combined with Pegvisomant.,Copanlisib,DB00082
DB12978,The metabolism of Pexidartinib can be increased when combined with Pegvisomant.,Pexidartinib,DB00082
DB14568,The metabolism of Ivosidenib can be increased when combined with Pegvisomant.,Ivosidenib,DB00082
DB04896,The metabolism of Milnacipran can be increased when combined with Pegvisomant.,Milnacipran,DB00082
DB08918,The metabolism of Levomilnacipran can be increased when combined with Pegvisomant.,Levomilnacipran,DB00082
DB01256,The metabolism of Retapamulin can be increased when combined with Pegvisomant.,Retapamulin,DB00082
DB11640,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Amifampridine.,Amifampridine,DB00082
DB00381,The metabolism of Amlodipine can be increased when combined with Pegvisomant.,Amlodipine,DB00082
DB01068,The metabolism of Clonazepam can be increased when combined with Pegvisomant.,Clonazepam,DB00082
DB00425,The metabolism of Zolpidem can be increased when combined with Pegvisomant.,Zolpidem,DB00082
DB00402,The serum concentration of Eszopiclone can be decreased when it is combined with Pegvisomant.,Eszopiclone,DB00082
DB01174,The metabolism of Phenobarbital can be decreased when combined with Pegvisomant.,Phenobarbital,DB00082
DB00818,The metabolism of Propofol can be decreased when combined with Pegvisomant.,Propofol,DB00082
DB00252,The metabolism of Phenytoin can be decreased when combined with Pegvisomant.,Phenytoin,DB00082
DB00281,The metabolism of Lidocaine can be decreased when combined with Pegvisomant.,Lidocaine,DB00082
DB00338,The metabolism of Omeprazole can be decreased when combined with Pegvisomant.,Omeprazole,DB00082
DB00349,The metabolism of Clobazam can be decreased when combined with Pegvisomant.,Clobazam,DB00082
DB00448,The metabolism of Lansoprazole can be decreased when combined with Pegvisomant.,Lansoprazole,DB00082
DB00531,The metabolism of Cyclophosphamide can be decreased when combined with Pegvisomant.,Cyclophosphamide,DB00082
DB00586,The metabolism of Diclofenac can be decreased when combined with Pegvisomant.,Diclofenac,DB00082
DB00755,The metabolism of Tretinoin can be decreased when combined with Pegvisomant.,Tretinoin,DB00082
DB01424,The metabolism of Aminophenazone can be decreased when combined with Pegvisomant.,Aminophenazone,DB00082
DB01435,The metabolism of Antipyrine can be decreased when combined with Pegvisomant.,Antipyrine,DB00082
DB01559,The metabolism of Clotiazepam can be decreased when combined with Pegvisomant.,Clotiazepam,DB00082
DB09166,The metabolism of Etizolam can be decreased when combined with Pegvisomant.,Etizolam,DB00082
DB11757,The metabolism of Istradefylline can be decreased when combined with Pegvisomant.,Istradefylline,DB00082
DB00458,The metabolism of Imipramine can be decreased when combined with Pegvisomant.,Imipramine,DB00082
DB11986,The metabolism of Entrectinib can be increased when combined with Pegvisomant.,Entrectinib,DB00082
DB11951,The serum concentration of Lemborexant can be decreased when it is combined with Pegvisomant.,Lemborexant,DB00082
DB06077,The serum concentration of Lumateperone can be decreased when it is combined with Pegvisomant.,Lumateperone,DB00082
DB00243,The metabolism of Ranolazine can be increased when combined with Pegvisomant.,Ranolazine,DB00082
DB00193,The metabolism of Pegvisomant can be increased when combined with Tramadol.,Tramadol,DB00082
DB01190,The metabolism of Clindamycin can be increased when combined with Pegvisomant.,Clindamycin,DB00082
DB12457,The metabolism of Rimegepant can be increased when combined with Pegvisomant.,Rimegepant,DB00082
DB11791,The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant.,Capmatinib,DB00082
DB15685,The serum concentration of Selpercatinib can be decreased when it is combined with Pegvisomant.,Selpercatinib,DB00082
DB00921,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.,Buprenorphine,DB00083
DB00366,Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Doxylamine,DB00083
DB00470,Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Dronabinol,DB00083
DB00450,Droperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Droperidol,DB00083
DB00956,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.,Hydrocodone,DB00083
DB00557,Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Hydroxyzine,DB00083
DB00653,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium sulfate.,Magnesium sulfate,DB00083
DB00765,Botulinum toxin type A may increase the sedative activities of Metyrosine.,Metyrosine,DB00083
DB01017,Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Minocycline,DB00083
DB00370,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.,Mirtazapine,DB00083
DB00486,Nabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Nabilone,DB00083
DB09117,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.,Paraldehyde,DB00083
DB08883,Perampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Perampanel,DB00083
DB00413,Botulinum toxin type A may increase the sedative activities of Pramipexole.,Pramipexole,DB00083
DB00268,Botulinum toxin type A may increase the sedative activities of Ropinirole.,Ropinirole,DB00083
DB05271,Botulinum toxin type A may increase the sedative activities of Rotigotine.,Rotigotine,DB00083
DB06201,The risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum toxin type A.,Rufinamide,DB00083
DB09072,Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Sodium oxybate,DB00083
DB09034,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.,Suvorexant,DB00083
DB06204,Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Tapentadol,DB00083
DB01041,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.,Thalidomide,DB00083
DB00425,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.,Zolpidem,DB00083
DB00202,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type A.,Succinylcholine,DB00083
DB01245,The therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum toxin type A.,Decamethonium,DB00083
DB11156,The therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum toxin type A.,Pyrantel,DB00083
DB12989,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum toxin type A.,Neosaxitoxin,DB00083
DB00333,The risk or severity of adverse effects can be increased when Methadone is combined with Botulinum toxin type A.,Methadone,DB00083
DB00193,The risk or severity of adverse effects can be increased when Tramadol is combined with Botulinum toxin type A.,Tramadol,DB00083
DB00209,The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type A.,Trospium,DB00083
DB00219,The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum toxin type A.,Oxyphenonium,DB00083
DB00237,The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type A.,Butabarbital,DB00083
DB00241,The risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum toxin type A.,Butalbital,DB00083
DB00245,The risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum toxin type A.,Benzatropine,DB00083
DB00246,The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.,Ziprasidone,DB00083
DB00280,The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.,Disopyramide,DB00083
DB00306,The risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum toxin type A.,Talbutal,DB00083
DB00312,The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type A.,Pentobarbital,DB00083
DB00321,The risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum toxin type A.,Amitriptyline,DB00083
DB00332,The risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum toxin type A.,Ipratropium,DB00083
DB00334,The risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum toxin type A.,Olanzapine,DB00083
DB00340,The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type A.,Metixene,DB00083
DB00342,The risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum toxin type A.,Terfenadine,DB00083
DB00354,The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type A.,Buclizine,DB00083
DB00363,The risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum toxin type A.,Clozapine,DB00083
DB00376,The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum toxin type A.,Trihexyphenidyl,DB00083
DB00383,The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum toxin type A.,Oxyphencyclimine,DB00083
DB00387,The risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum toxin type A.,Procyclidine,DB00083
DB00392,The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type A.,Profenamine,DB00083
DB00416,The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Botulinum toxin type A.,Metocurine iodide,DB00083
DB00418,The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type A.,Secobarbital,DB00083
DB00420,The risk or severity of adverse effects can be increased when Promazine is combined with Botulinum toxin type A.,Promazine,DB00083
DB00424,The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.,Hyoscyamine,DB00083
DB00434,The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum toxin type A.,Cyproheptadine,DB00083
DB00458,The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.,Imipramine,DB00083
DB00462,The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type A.,Methscopolamine bromide,DB00083
DB00463,The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type A.,Metharbital,DB00083
DB00472,The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A.,Fluoxetine,DB00083
DB00477,The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum toxin type A.,Chlorpromazine,DB00083
DB00483,The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Botulinum toxin type A.,Gallamine triethiodide,DB00083
DB00496,The risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum toxin type A.,Darifenacin,DB00083
DB00505,The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum toxin type A.,Tridihexethyl,DB00083
DB00508,The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type A.,Triflupromazine,DB00083
DB00514,The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum toxin type A.,Dextromethorphan,DB00083
DB00517,The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type A.,Anisotropine methylbromide,DB00083
DB00540,The risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum toxin type A.,Nortriptyline,DB00083
DB00543,The risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum toxin type A.,Amoxapine,DB00083
DB00555,The risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum toxin type A.,Lamotrigine,DB00083
DB00565,The risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum toxin type A.,Cisatracurium,DB00083
DB00572,The risk or severity of adverse effects can be increased when Atropine is combined with Botulinum toxin type A.,Atropine,DB00083
DB00599,The risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum toxin type A.,Thiopental,DB00083
DB00622,The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum toxin type A.,Nicardipine,DB00083
DB00657,The risk or severity of adverse effects can be increased when Mecamylamine is combined with Botulinum toxin type A.,Mecamylamine,DB00083
DB00670,The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type A.,Pirenzepine,DB00083
DB00715,The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.,Paroxetine,DB00083
DB00721,The risk or severity of adverse effects can be increased when Procaine is combined with Botulinum toxin type A.,Procaine,DB00083
DB00725,The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Botulinum toxin type A.,Homatropine methylbromide,DB00083
DB00728,The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum toxin type A.,Rocuronium,DB00083
DB00732,The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type A.,Atracurium besylate,DB00083
DB00747,The risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum toxin type A.,Scopolamine,DB00083
DB00753,The risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum toxin type A.,Isoflurane,DB00083
DB00767,The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type A.,Benzquinamide,DB00083
DB00771,The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type A.,Clidinium,DB00083
DB00777,The risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum toxin type A.,Propiomazine,DB00083
DB00782,The risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum toxin type A.,Propantheline,DB00083
DB00794,The risk or severity of adverse effects can be increased when Primidone is combined with Botulinum toxin type A.,Primidone,DB00083
DB00804,The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type A.,Dicyclomine,DB00083
DB00810,The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type A.,Biperiden,DB00083
DB00835,The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type A.,Brompheniramine,DB00083
DB00849,The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum toxin type A.,Methylphenobarbital,DB00083
DB00875,The risk or severity of adverse effects can be increased when Flupentixol is combined with Botulinum toxin type A.,Flupentixol,DB00083
DB00907,The risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum toxin type A.,Cocaine,DB00083
DB00908,The risk or severity of adverse effects can be increased when Quinidine is combined with Botulinum toxin type A.,Quinidine,DB00083
DB00915,The risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum toxin type A.,Amantadine,DB00083
DB00934,The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.,Maprotiline,DB00083
DB00940,The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type A.,Methantheline,DB00083
DB00941,The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type A.,Hexafluronium,DB00083
DB00942,The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type A.,Cycrimine,DB00083
DB00967,The risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum toxin type A.,Desloratadine,DB00083
DB00986,The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum toxin type A.,Glycopyrronium,DB00083
DB01036,The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type A.,Tolterodine,DB00083
DB01062,The risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum toxin type A.,Oxybutynin,DB00083
DB01069,The risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum toxin type A.,Promethazine,DB00083
DB01075,The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum toxin type A.,Diphenhydramine,DB00083
DB01090,The risk or severity of adverse effects can be increased when Pentolinium is combined with Botulinum toxin type A.,Pentolinium,DB00083
DB01116,The risk or severity of adverse effects can be increased when Trimethaphan is combined with Botulinum toxin type A.,Trimethaphan,DB00083
DB01135,The risk or severity of adverse effects can be increased when Doxacurium is combined with Botulinum toxin type A.,Doxacurium,DB00083
DB01142,The risk or severity of adverse effects can be increased when Doxepin is combined with Botulinum toxin type A.,Doxepin,DB00083
DB01148,The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum toxin type A.,Flavoxate,DB00083
DB01151,The risk or severity of adverse effects can be increased when Desipramine is combined with Botulinum toxin type A.,Desipramine,DB00083
DB01161,The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Botulinum toxin type A.,Chloroprocaine,DB00083
DB01173,The risk or severity of adverse effects can be increased when Orphenadrine is combined with Botulinum toxin type A.,Orphenadrine,DB00083
DB01174,The risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum toxin type A.,Phenobarbital,DB00083
DB01175,The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.,Escitalopram,DB00083
DB01199,The risk or severity of adverse effects can be increased when Tubocurarine is combined with Botulinum toxin type A.,Tubocurarine,DB00083
DB01224,The risk or severity of adverse effects can be increased when Quetiapine is combined with Botulinum toxin type A.,Quetiapine,DB00083
DB01226,The risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum toxin type A.,Mivacurium,DB00083
DB01227,The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum toxin type A.,Levacetylmethadol,DB00083
DB01231,The risk or severity of adverse effects can be increased when Diphenidol is combined with Botulinum toxin type A.,Diphenidol,DB00083
DB01238,The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum toxin type A.,Aripiprazole,DB00083
DB01239,The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum toxin type A.,Chlorprothixene,DB00083
DB01288,The risk or severity of adverse effects can be increased when Fenoterol is combined with Botulinum toxin type A.,Fenoterol,DB00083
DB01336,The risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum toxin type A.,Metocurine,DB00083
DB01337,The risk or severity of adverse effects can be increased when Pancuronium is combined with Botulinum toxin type A.,Pancuronium,DB00083
DB01338,The risk or severity of adverse effects can be increased when Pipecuronium is combined with Botulinum toxin type A.,Pipecuronium,DB00083
DB01339,The risk or severity of adverse effects can be increased when Vecuronium is combined with Botulinum toxin type A.,Vecuronium,DB00083
DB01351,The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum toxin type A.,Amobarbital,DB00083
DB01352,The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum toxin type A.,Aprobarbital,DB00083
DB01353,The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum toxin type A.,Butobarbital,DB00083
DB01354,The risk or severity of adverse effects can be increased when Heptabarbital is combined with Botulinum toxin type A.,Heptabarbital,DB00083
DB01355,The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum toxin type A.,Hexobarbital,DB00083
DB01403,The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Botulinum toxin type A.,Methotrimeprazine,DB00083
DB01409,The risk or severity of adverse effects can be increased when Tiotropium is combined with Botulinum toxin type A.,Tiotropium,DB00083
DB01483,The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum toxin type A.,Barbital,DB00083
DB01496,"The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Botulinum toxin type A.","Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione",DB00083
DB01591,The risk or severity of adverse effects can be increased when Solifenacin is combined with Botulinum toxin type A.,Solifenacin,DB00083
DB01625,The risk or severity of adverse effects can be increased when Isopropamide is combined with Botulinum toxin type A.,Isopropamide,DB00083
DB04834,The risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum toxin type A.,Rapacuronium,DB00083
DB04843,The risk or severity of adverse effects can be increased when Mepenzolate is combined with Botulinum toxin type A.,Mepenzolate,DB00083
DB05710,The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum toxin type A.,Gantacurium,DB00083
DB06153,The risk or severity of adverse effects can be increased when Pizotifen is combined with Botulinum toxin type A.,Pizotifen,DB00083
DB06702,The risk or severity of adverse effects can be increased when Fesoterodine is combined with Botulinum toxin type A.,Fesoterodine,DB00083
DB06787,The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum toxin type A.,Hexocyclium,DB00083
DB08801,The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum toxin type A.,Dimetindene,DB00083
DB08838,The risk or severity of adverse effects can be increased when Agmatine is combined with Botulinum toxin type A.,Agmatine,DB00083
DB08897,The risk or severity of adverse effects can be increased when Aclidinium is combined with Botulinum toxin type A.,Aclidinium,DB00083
DB08960,The risk or severity of adverse effects can be increased when Hexamethonium is combined with Botulinum toxin type A.,Hexamethonium,DB00083
DB08997,The risk or severity of adverse effects can be increased when Dexetimide is combined with Botulinum toxin type A.,Dexetimide,DB00083
DB09007,The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum toxin type A.,Chlorphenoxamine,DB00083
DB09023,The risk or severity of adverse effects can be increased when Benactyzine is combined with Botulinum toxin type A.,Benactyzine,DB00083
DB09076,The risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum toxin type A.,Umeclidinium,DB00083
DB09089,The risk or severity of adverse effects can be increased when Trimebutine is combined with Botulinum toxin type A.,Trimebutine,DB00083
DB09167,The risk or severity of adverse effects can be increased when Dosulepin is combined with Botulinum toxin type A.,Dosulepin,DB00083
DB09262,The risk or severity of adverse effects can be increased when Imidafenacin is combined with Botulinum toxin type A.,Imidafenacin,DB00083
DB09300,The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum toxin type A.,Butylscopolamine,DB00083
DB11235,The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum toxin type A.,Thonzylamine,DB00083
DB11315,The risk or severity of adverse effects can be increased when Methscopolamine is combined with Botulinum toxin type A.,Methscopolamine,DB00083
DB11855,The risk or severity of adverse effects can be increased when Revefenacin is combined with Botulinum toxin type A.,Revefenacin,DB00083
DB12086,The risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum toxin type A.,Oxitropium,DB00083
DB12278,The risk or severity of adverse effects can be increased when Propiverine is combined with Botulinum toxin type A.,Propiverine,DB00083
DB12526,The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum toxin type A.,Batefenterol,DB00083
DB12554,The risk or severity of adverse effects can be increased when Mebeverine is combined with Botulinum toxin type A.,Mebeverine,DB00083
DB13252,The risk or severity of adverse effects can be increased when Tropatepine is combined with Botulinum toxin type A.,Tropatepine,DB00083
DB13254,The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum toxin type A.,Prifinium,DB00083
DB13295,The risk or severity of adverse effects can be increased when Atracurium is combined with Botulinum toxin type A.,Atracurium,DB00083
DB13351,The risk or severity of adverse effects can be increased when Piperidolate is combined with Botulinum toxin type A.,Piperidolate,DB00083
DB13369,The risk or severity of adverse effects can be increased when Benzilone is combined with Botulinum toxin type A.,Benzilone,DB00083
DB13380,The risk or severity of adverse effects can be increased when Difemerine is combined with Botulinum toxin type A.,Difemerine,DB00083
DB13413,The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum toxin type A.,Phenglutarimide,DB00083
DB13448,The risk or severity of adverse effects can be increased when Mazaticol is combined with Botulinum toxin type A.,Mazaticol,DB00083
DB13468,The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Botulinum toxin type A.,Etybenzatropine,DB00083
DB13500,The risk or severity of adverse effects can be increased when Otilonium is combined with Botulinum toxin type A.,Otilonium,DB00083
DB13505,The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum toxin type A.,Emepronium,DB00083
DB13507,The risk or severity of adverse effects can be increased when Poldine is combined with Botulinum toxin type A.,Poldine,DB00083
DB13542,The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum toxin type A.,Bevonium,DB00083
DB13581,The risk or severity of adverse effects can be increased when Rociverine is combined with Botulinum toxin type A.,Rociverine,DB00083
DB13584,The risk or severity of adverse effects can be increased when Gallamine is combined with Botulinum toxin type A.,Gallamine,DB00083
DB13619,The risk or severity of adverse effects can be increased when Bornaprine is combined with Botulinum toxin type A.,Bornaprine,DB00083
DB13636,The risk or severity of adverse effects can be increased when Etanautine is combined with Botulinum toxin type A.,Etanautine,DB00083
DB13648,The risk or severity of adverse effects can be increased when Alcuronium is combined with Botulinum toxin type A.,Alcuronium,DB00083
DB13666,The risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Botulinum toxin type A.,Tiemonium iodide,DB00083
DB13678,The risk or severity of adverse effects can be increased when Dihexyverine is combined with Botulinum toxin type A.,Dihexyverine,DB00083
DB13695,The risk or severity of adverse effects can be increased when Penthienate is combined with Botulinum toxin type A.,Penthienate,DB00083
DB13720,The risk or severity of adverse effects can be increased when Diphemanil is combined with Botulinum toxin type A.,Diphemanil,DB00083
DB13738,The risk or severity of adverse effects can be increased when Camylofin is combined with Botulinum toxin type A.,Camylofin,DB00083
DB13759,The risk or severity of adverse effects can be increased when Fenpiverinium is combined with Botulinum toxin type A.,Fenpiverinium,DB00083
DB13769,The risk or severity of adverse effects can be increased when Emetonium iodide is combined with Botulinum toxin type A.,Emetonium iodide,DB00083
DB13844,The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum toxin type A.,Pipenzolate,DB00083
DB13850,The risk or severity of adverse effects can be increased when Timepidium is combined with Botulinum toxin type A.,Timepidium,DB00083
DB00898,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Ethanol.,Ethanol,DB00083
DB00972,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Azelastine.,Azelastine,DB00083
DB00484,Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Brimonidine,DB00083
DB00176,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluvoxamine.,Fluvoxamine,DB00083
DB00215,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.,Citalopram,DB00083
DB00476,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Duloxetine.,Duloxetine,DB00083
DB00656,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trazodone.,Trazodone,DB00083
DB01104,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertraline.,Sertraline,DB00083
DB01105,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sibutramine.,Sibutramine,DB00083
DB01149,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefazodone.,Nefazodone,DB00083
DB04832,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zimelidine.,Zimelidine,DB00083
DB04884,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dapoxetine.,Dapoxetine,DB00083
DB04896,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Milnacipran.,Milnacipran,DB00083
DB06700,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desvenlafaxine.,Desvenlafaxine,DB00083
DB06731,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Seproxetine.,Seproxetine,DB00083
DB08918,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.,Levomilnacipran,DB00083
DB08953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indalpine.,Indalpine,DB00083
DB12693,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ritanserin.,Ritanserin,DB00083
DB13233,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alaproclate.,Alaproclate,DB00083
DB01198,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zopiclone.,Zopiclone,DB00083
DB00150,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tryptophan.,Tryptophan,DB00083
DB00181,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Baclofen.,Baclofen,DB00083
DB00182,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amphetamine.,Amphetamine,DB00083
DB00186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorazepam.,Lorazepam,DB00083
DB00189,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethchlorvynol.,Ethchlorvynol,DB00083
DB00206,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reserpine.,Reserpine,DB00083
DB00216,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eletriptan.,Eletriptan,DB00083
DB00228,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Enflurane.,Enflurane,DB00083
DB00231,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Temazepam.,Temazepam,DB00083
DB00234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reboxetine.,Reboxetine,DB00083
DB00247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methysergide.,Methysergide,DB00083
DB00248,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.,Cabergoline,DB00083
DB00252,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenytoin.,Phenytoin,DB00083
DB00273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Topiramate.,Topiramate,DB00083
DB00283,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clemastine.,Clemastine,DB00083
DB00285,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Venlafaxine.,Venlafaxine,DB00083
DB00289,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Atomoxetine.,Atomoxetine,DB00083
DB00292,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etomidate.,Etomidate,DB00083
DB00295,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Morphine.,Morphine,DB00083
DB00313,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.,Valproic acid,DB00083
DB00315,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolmitriptan.,Zolmitriptan,DB00083
DB00318,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Codeine.,Codeine,DB00083
DB00320,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroergotamine.,Dihydroergotamine,DB00083
DB00323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolcapone.,Tolcapone,DB00083
DB00327,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydromorphone.,Hydromorphone,DB00083
DB00341,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cetirizine.,Cetirizine,DB00083
DB00344,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Protriptyline.,Protriptyline,DB00083
DB00347,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethadione.,Trimethadione,DB00083
DB00349,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clobazam.,Clobazam,DB00083
DB00356,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorzoxazone.,Chlorzoxazone,DB00083
DB00371,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meprobamate.,Meprobamate,DB00083
DB00372,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiethylperazine.,Thiethylperazine,DB00083
DB00377,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Palonosetron.,Palonosetron,DB00083
DB00391,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulpiride.,Sulpiride,DB00083
DB00404,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprazolam.,Alprazolam,DB00083
DB00405,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexbrompheniramine.,Dexbrompheniramine,DB00083
DB00408,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loxapine.,Loxapine,DB00083
DB00409,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remoxipride.,Remoxipride,DB00083
DB00423,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methocarbamol.,Methocarbamol,DB00083
DB00427,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triprolidine.,Triprolidine,DB00083
DB00433,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.,Prochlorperazine,DB00083
DB00454,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meperidine.,Meperidine,DB00083
DB00474,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methohexital.,Methohexital,DB00083
DB00475,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlordiazepoxide.,Chlordiazepoxide,DB00083
DB00494,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Entacapone.,Entacapone,DB00083
DB00497,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxycodone.,Oxycodone,DB00083
DB00532,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenytoin.,Mephenytoin,DB00083
DB00546,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adinazolam.,Adinazolam,DB00083
DB00564,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbamazepine.,Carbamazepine,DB00083
DB00574,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenfluramine.,Fenfluramine,DB00083
DB00579,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mazindol.,Mazindol,DB00083
DB00588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluticasone propionate.,Fluticasone propionate,DB00083
DB00589,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lisuride.,Lisuride,DB00083
DB00593,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.,Ethosuximide,DB00083
DB00601,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Linezolid.,Linezolid,DB00083
DB00604,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cisapride.,Cisapride,DB00083
DB00611,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butorphanol.,Butorphanol,DB00083
DB00614,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Furazolidone.,Furazolidone,DB00083
DB00617,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paramethadione.,Paramethadione,DB00083
DB00623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluphenazine.,Fluphenazine,DB00083
DB00625,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Efavirenz.,Efavirenz,DB00083
DB00628,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorazepic acid.,Clorazepic acid,DB00083
DB00633,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmedetomidine.,Dexmedetomidine,DB00083
DB00645,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dyclonine.,Dyclonine,DB00083
DB00647,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextropropoxyphene.,Dextropropoxyphene,DB00083
DB00652,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pentazocine.,Pentazocine,DB00083
DB00660,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metaxalone.,Metaxalone,DB00083
DB00662,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethobenzamide.,Trimethobenzamide,DB00083
DB00669,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sumatriptan.,Sumatriptan,DB00083
DB00679,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioridazine.,Thioridazine,DB00083
DB00680,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moricizine.,Moricizine,DB00083
DB00683,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midazolam.,Midazolam,DB00083
DB00690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flurazepam.,Flurazepam,DB00083
DB00696,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergotamine.,Ergotamine,DB00083
DB00697,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tizanidine.,Tizanidine,DB00083
DB00708,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sufentanil.,Sufentanil,DB00083
DB00714,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.,Apomorphine,DB00083
DB00726,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimipramine.,Trimipramine,DB00083
DB00734,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Risperidone.,Risperidone,DB00083
DB00737,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meclizine.,Meclizine,DB00083
DB00740,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Riluzole.,Riluzole,DB00083
DB00748,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbinoxamine.,Carbinoxamine,DB00083
DB00752,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tranylcypromine.,Tranylcypromine,DB00083
DB00754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethotoin.,Ethotoin,DB00083
DB00757,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dolasetron.,Dolasetron,DB00083
DB00776,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxcarbazepine.,Oxcarbazepine,DB00083
DB00780,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenelzine.,Phenelzine,DB00083
DB00801,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halazepam.,Halazepam,DB00083
DB00802,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfentanil.,Alfentanil,DB00083
DB00805,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Minaprine.,Minaprine,DB00083
DB00813,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fentanyl.,Fentanyl,DB00083
DB00818,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propofol.,Propofol,DB00083
DB00819,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetazolamide.,Acetazolamide,DB00083
DB00829,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diazepam.,Diazepam,DB00083
DB00831,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluoperazine.,Trifluoperazine,DB00083
DB00832,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phensuximide.,Phensuximide,DB00083
DB00837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Progabide.,Progabide,DB00083
DB00842,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam.,Oxazepam,DB00083
DB00843,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Donepezil.,Donepezil,DB00083
DB00844,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nalbuphine.,Nalbuphine,DB00083
DB00850,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine.,Perphenazine,DB00083
DB00854,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levorphanol.,Levorphanol,DB00083
DB00865,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzphetamine.,Benzphetamine,DB00083
DB00866,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprenolol.,Alprenolol,DB00083
DB00889,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.,Granisetron,DB00083
DB00897,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triazolam.,Triazolam,DB00083
DB00899,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remifentanil.,Remifentanil,DB00083
DB00904,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ondansetron.,Ondansetron,DB00083
DB00906,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiagabine.,Tiagabine,DB00083
DB00909,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.,Zonisamide,DB00083
DB00918,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Almotriptan.,Almotriptan,DB00083
DB00933,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mesoridazine.,Mesoridazine,DB00083
DB00937,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethylpropion.,Diethylpropion,DB00083
DB00949,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Felbamate.,Felbamate,DB00083
DB00952,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naratriptan.,Naratriptan,DB00083
DB00953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rizatriptan.,Rizatriptan,DB00083
DB00960,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pindolol.,Pindolol,DB00083
DB00962,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zaleplon.,Zaleplon,DB00083
DB00969,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alosetron.,Alosetron,DB00083
DB00980,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramelteon.,Ramelteon,DB00083
DB00985,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimenhydrinate.,Dimenhydrinate,DB00083
DB00996,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin.,Gabapentin,DB00083
DB00998,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Frovatriptan.,Frovatriptan,DB00083
DB01018,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Guanfacine.,Guanfacine,DB00083
DB01028,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methoxyflurane.,Methoxyflurane,DB00083
DB01037,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Selegiline.,Selegiline,DB00083
DB01049,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergoloid mesylate.,Ergoloid mesylate,DB00083
DB01063,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetophenazine.,Acetophenazine,DB00083
DB01065,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melatonin.,Melatonin,DB00083
DB01068,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clonazepam.,Clonazepam,DB00083
DB01080,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vigabatrin.,Vigabatrin,DB00083
DB01081,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diphenoxylate.,Diphenoxylate,DB00083
DB01100,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimozide.,Pimozide,DB00083
DB01107,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methyprylon.,Methyprylon,DB00083
DB01114,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorpheniramine.,Chlorpheniramine,DB00083
DB01121,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenacemide.,Phenacemide,DB00083
DB01154,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiamylal.,Thiamylal,DB00083
DB01156,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bupropion.,Bupropion,DB00083
DB01159,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halothane.,Halothane,DB00083
DB01168,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Procarbazine.,Procarbazine,DB00083
DB01171,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moclobemide.,Moclobemide,DB00083
DB01176,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclizine.,Cyclizine,DB00083
DB01178,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlormezanone.,Chlormezanone,DB00083
DB01186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pergolide.,Pergolide,DB00083
DB01189,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desflurane.,Desflurane,DB00083
DB01192,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxymorphone.,Oxymorphone,DB00083
DB01200,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.,Bromocriptine,DB00083
DB01202,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levetiracetam.,Levetiracetam,DB00083
DB01209,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dezocine.,Dezocine,DB00083
DB01215,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Estazolam.,Estazolam,DB00083
DB01221,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketamine.,Ketamine,DB00083
DB01235,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levodopa.,Levodopa,DB00083
DB01236,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sevoflurane.,Sevoflurane,DB00083
DB01242,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomipramine.,Clomipramine,DB00083
DB01246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alimemazine.,Alimemazine,DB00083
DB01247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Isocarboxazid.,Isocarboxazid,DB00083
DB01253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergometrine.,Ergometrine,DB00083
DB01267,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.,Paliperidone,DB00083
DB01320,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fosphenytoin.,Fosphenytoin,DB00083
DB01323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with St. John's Wort.,St. John's Wort,DB00083
DB01356,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium cation.,Lithium cation,DB00083
DB01359,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penbutolol.,Penbutolol,DB00083
DB01367,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rasagiline.,Rasagiline,DB00083
DB01392,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Yohimbine.,Yohimbine,DB00083
DB01433,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methadyl acetate.,Methadyl acetate,DB00083
DB01437,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Glutethimide.,Glutethimide,DB00083
DB01440,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with gamma-Hydroxybutyric acid.,gamma-Hydroxybutyric acid,DB00083
DB01442,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MMDA.,MMDA,DB00083
DB01445,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bufotenine.,Bufotenine,DB00083
DB01450,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroetorphine.,Dihydroetorphine,DB00083
DB01452,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diamorphine.,Diamorphine,DB00083
DB01454,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midomafetamine.,Midomafetamine,DB00083
DB01463,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fencamfamin.,Fencamfamin,DB00083
DB01466,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethylmorphine.,Ethylmorphine,DB00083
DB01472,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Methoxyamphetamine.,4-Methoxyamphetamine,DB00083
DB01484,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Bromo-2,5-dimethoxyamphetamine.","4-Bromo-2,5-dimethoxyamphetamine",DB00083
DB01488,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimethyltryptamine.,Dimethyltryptamine,DB00083
DB01489,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Camazepam.,Camazepam,DB00083
DB01495,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dichloralphenazone.,Dichloralphenazone,DB00083
DB01497,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etorphine.,Etorphine,DB00083
DB01501,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Difenoxin.,Difenoxin,DB00083
DB01509,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tenamfetamine.,Tenamfetamine,DB00083
DB01511,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Delorazepam.,Delorazepam,DB00083
DB01529,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextromoramide.,Dextromoramide,DB00083
DB01531,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desomorphine.,Desomorphine,DB00083
DB01534,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorhexadol.,Chlorhexadol,DB00083
DB01535,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil.,Carfentanil,DB00083
DB01544,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunitrazepam.,Flunitrazepam,DB00083
DB01545,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethyl loflazepate.,Ethyl loflazepate,DB00083
DB01547,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Drotebanol.,Drotebanol,DB00083
DB01551,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydrocodeine.,Dihydrocodeine,DB00083
DB01553,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cloxazolam.,Cloxazolam,DB00083
DB01555,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphacetylmethadol.,Alphacetylmethadol,DB00083
DB01558,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromazepam.,Bromazepam,DB00083
DB01559,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clotiazepam.,Clotiazepam,DB00083
DB01560,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cathinone.,Cathinone,DB00083
DB01563,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chloral hydrate.,Chloral hydrate,DB00083
DB01565,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydromorphine.,Dihydromorphine,DB00083
DB01567,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fludiazepam.,Fludiazepam,DB00083
DB01577,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metamfetamine.,Metamfetamine,DB00083
DB01580,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxprenolol.,Oxprenolol,DB00083
DB01587,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketazolam.,Ketazolam,DB00083
DB01588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prazepam.,Prazepam,DB00083
DB01589,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quazepam.,Quazepam,DB00083
DB01594,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinolazepam.,Cinolazepam,DB00083
DB01595,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrazepam.,Nitrazepam,DB00083
DB01608,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Periciazine.,Periciazine,DB00083
DB01614,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acepromazine.,Acepromazine,DB00083
DB01615,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aceprometazine.,Aceprometazine,DB00083
DB01616,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alverine.,Alverine,DB00083
DB01618,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Molindone.,Molindone,DB00083
DB01621,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipotiazine.,Pipotiazine,DB00083
DB01622,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioproperazine.,Thioproperazine,DB00083
DB01623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiothixene.,Thiothixene,DB00083
DB01624,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zuclopenthixol.,Zuclopenthixol,DB00083
DB01626,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pargyline.,Pargyline,DB00083
DB01954,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rolipram.,Rolipram,DB00083
DB02207,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7-Nitroindazole.,7-Nitroindazole,DB00083
DB02234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with S-Ethylisothiourea.,S-Ethylisothiourea,DB00083
DB02852,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Domoic Acid.,Domoic Acid,DB00083
DB02959,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxitriptan.,Oxitriptan,DB00083
DB03575,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phencyclidine.,Phencyclidine,DB00083
DB04017,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorgiline.,Clorgiline,DB00083
DB04165,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valpromide.,Valpromide,DB00083
DB04325,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenethylamine.,Phenethylamine,DB00083
DB04599,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aniracetam.,Aniracetam,DB00083
DB04818,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproniazid.,Iproniazid,DB00083
DB04819,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methapyrilene.,Methapyrilene,DB00083
DB04820,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nialamide.,Nialamide,DB00083
DB04821,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nomifensine.,Nomifensine,DB00083
DB04827,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urethane.,Urethane,DB00083
DB04829,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lysergic acid diethylamide.,Lysergic acid diethylamide,DB00083
DB04833,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methaqualone.,Methaqualone,DB00083
DB04836,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amineptine.,Amineptine,DB00083
DB04841,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunarizine.,Flunarizine,DB00083
DB04842,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluspirilene.,Fluspirilene,DB00083
DB04871,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorcaserin.,Lorcaserin,DB00083
DB04872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Osanetant.,Osanetant,DB00083
DB04885,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cilansetron.,Cilansetron,DB00083
DB04888,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifeprunox.,Bifeprunox,DB00083
DB04903,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pagoclone.,Pagoclone,DB00083
DB04908,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flibanserin.,Flibanserin,DB00083
DB04917,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Renzapride.,Renzapride,DB00083
DB04946,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iloperidone.,Iloperidone,DB00083
DB04953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ezogabine.,Ezogabine,DB00083
DB05227,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with APD791.,APD791,DB00083
DB05232,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrodotoxin.,Tetrodotoxin,DB00083
DB05246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.,Methsuximide,DB00083
DB05316,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimavanserin.,Pimavanserin,DB00083
DB05541,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brivaracetam.,Brivaracetam,DB00083
DB05542,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naronapride.,Naronapride,DB00083
DB05562,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naluzotan.,Naluzotan,DB00083
DB05607,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with PRX-08066.,PRX-08066,DB00083
DB05687,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with BL-1020.,BL-1020,DB00083
DB06016,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cariprazine.,Cariprazine,DB00083
DB06077,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lumateperone.,Lumateperone,DB00083
DB06109,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with YKP-1358.,YKP-1358,DB00083
DB06144,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertindole.,Sertindole,DB00083
DB06148,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mianserin.,Mianserin,DB00083
DB06216,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Asenapine.,Asenapine,DB00083
DB06218,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lacosamide.,Lacosamide,DB00083
DB06264,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolperisone.,Tolperisone,DB00083
DB06282,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levocetirizine.,Levocetirizine,DB00083
DB06283,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ziconotide.,Ziconotide,DB00083
DB06288,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amisulpride.,Amisulpride,DB00083
DB06446,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dotarizine.,Dotarizine,DB00083
DB06458,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remacemide.,Remacemide,DB00083
DB06470,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomethiazole.,Clomethiazole,DB00083
DB06512,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deramciclane.,Deramciclane,DB00083
DB06527,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tramiprosate.,Tramiprosate,DB00083
DB06529,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ocinaplon.,Ocinaplon,DB00083
DB06554,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gaboxadol.,Gaboxadol,DB00083
DB06579,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adipiplon.,Adipiplon,DB00083
DB06582,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextofisopam.,Dextofisopam,DB00083
DB06594,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Agomelatine.,Agomelatine,DB00083
DB06654,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safinamide.,Safinamide,DB00083
DB06660,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Saredutant.,Saredutant,DB00083
DB06678,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esmirtazapine.,Esmirtazapine,DB00083
DB06684,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vilazodone.,Vilazodone,DB00083
DB06690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrous oxide.,Nitrous oxide,DB00083
DB06691,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mepyramine.,Mepyramine,DB00083
DB06701,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmethylphenidate.,Dexmethylphenidate,DB00083
DB06716,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fospropofol.,Fospropofol,DB00083
DB06738,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketobemidone.,Ketobemidone,DB00083
DB06753,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triclofos.,Triclofos,DB00083
DB06770,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzyl alcohol.,Benzyl alcohol,DB00083
DB06797,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebutamate.,Mebutamate,DB00083
DB08059,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Wortmannin.,Wortmannin,DB00083
DB08329,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulthiame.,Sulthiame,DB00083
DB08550,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",DB00083
DB08810,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinitapride.,Cinitapride,DB00083
DB08811,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tofisopam.,Tofisopam,DB00083
DB08815,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.,Lurasidone,DB00083
DB08839,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Serotonin.,Serotonin,DB00083
DB08861,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with DPDPE.,DPDPE,DB00083
DB08872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin enacarbil.,Gabapentin enacarbil,DB00083
DB08892,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Arbaclofen Placarbil.,Arbaclofen Placarbil,DB00083
DB08910,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pomalidomide.,Pomalidomide,DB00083
DB08922,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perospirone.,Perospirone,DB00083
DB08927,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amperozide.,Amperozide,DB00083
DB08954,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ifenprodil.,Ifenprodil,DB00083
DB08986,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etifoxine.,Etifoxine,DB00083
DB08992,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eperisone.,Eperisone,DB00083
DB08996,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimetacrine.,Dimetacrine,DB00083
DB09000,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyamemazine.,Cyamemazine,DB00083
DB09001,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Barbexaclone.,Barbexaclone,DB00083
DB09011,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Beclamide.,Beclamide,DB00083
DB09014,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Captodiame.,Captodiame,DB00083
DB09016,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butriptyline.,Butriptyline,DB00083
DB09017,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brotizolam.,Brotizolam,DB00083
DB09021,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzoctamine.,Benzoctamine,DB00083
DB09068,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vortioxetine.,Vortioxetine,DB00083
DB09071,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tasimelteon.,Tasimelteon,DB00083
DB09118,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Stiripentol.,Stiripentol,DB00083
DB09119,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine acetate.,Eslicarbazepine acetate,DB00083
DB09128,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexpiprazole.,Brexpiprazole,DB00083
DB09166,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etizolam.,Etizolam,DB00083
DB09174,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofentanil.,Lofentanil,DB00083
DB09184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Edivoxetine.,Edivoxetine,DB00083
DB09185,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Viloxazine.,Viloxazine,DB00083
DB09186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nisoxetine.,Nisoxetine,DB00083
DB09187,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lortalamine.,Lortalamine,DB00083
DB09190,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Talopram.,Talopram,DB00083
DB09194,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etoperidone.,Etoperidone,DB00083
DB09223,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Blonanserin.,Blonanserin,DB00083
DB09224,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melperone.,Melperone,DB00083
DB09225,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zotepine.,Zotepine,DB00083
DB09226,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brilaroxazine.,Brilaroxazine,DB00083
DB09241,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylene blue.,Methylene blue,DB00083
DB09243,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydracarbazine.,Hydracarbazine,DB00083
DB09244,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pirlindole.,Pirlindole,DB00083
DB09245,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Toloxatone.,Toloxatone,DB00083
DB09246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benmoxin.,Benmoxin,DB00083
DB09247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproclozide.,Iproclozide,DB00083
DB09248,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebanazine.,Mebanazine,DB00083
DB09249,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Octamoxin.,Octamoxin,DB00083
DB09250,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheniprazine.,Pheniprazine,DB00083
DB09251,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoxypropazine.,Phenoxypropazine,DB00083
DB09252,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivhydrazine.,Pivhydrazine,DB00083
DB09253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safrazine.,Safrazine,DB00083
DB09254,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Caroxazone.,Caroxazone,DB00083
DB09286,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipamperone.,Pipamperone,DB00083
DB09289,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tianeptine.,Tianeptine,DB00083
DB09290,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramosetron.,Ramosetron,DB00083
DB09307,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaprotiline.,Oxaprotiline,DB00083
DB11130,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opium.,Opium,DB00083
DB11371,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfaxalone.,Alfaxalone,DB00083
DB11376,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Azaperone.,Azaperone,DB00083
DB11400,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doramectin.,Doramectin,DB00083
DB11428,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medetomidine.,Medetomidine,DB00083
DB11477,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Xylazine.,Xylazine,DB00083
DB11540,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propiopromazine.,Propiopromazine,DB00083
DB11543,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Romifidine.,Romifidine,DB00083
DB11549,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiletamine.,Tiletamine,DB00083
DB11552,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tricaine.,Tricaine,DB00083
DB11555,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolazepam.,Zolazepam,DB00083
DB11556,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Detomidine.,Detomidine,DB00083
DB11582,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiocolchicoside.,Thiocolchicoside,DB00083
DB11609,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Normethadone.,Normethadone,DB00083
DB11664,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Psilocybin.,Psilocybin,DB00083
DB11675,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapride.,Mosapride,DB00083
DB11686,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iferanserin.,Iferanserin,DB00083
DB11699,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tropisetron.,Tropisetron,DB00083
DB11755,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydrocannabivarin.,Tetrahydrocannabivarin,DB00083
DB11859,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexanolone.,Brexanolone,DB00083
DB11868,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etiracetam.,Etiracetam,DB00083
DB11889,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lanicemine.,Lanicemine,DB00083
DB11957,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Idalopirdine.,Idalopirdine,DB00083
DB12071,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vabicaserin.,Vabicaserin,DB00083
DB12093,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydropalmatine.,Tetrahydropalmatine,DB00083
DB12105,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imagabalin.,Imagabalin,DB00083
DB12110,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with m-Chlorophenylpiperazine.,m-Chlorophenylpiperazine,DB00083
DB12111,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MK-212.,MK-212,DB00083
DB12131,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinpocetine.,Vinpocetine,DB00083
DB12163,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sarpogrelate.,Sarpogrelate,DB00083
DB12177,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eplivanserin.,Eplivanserin,DB00083
DB12184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gepirone.,Gepirone,DB00083
DB12229,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cerlapirdine.,Cerlapirdine,DB00083
DB12273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ecopipam.,Ecopipam,DB00083
DB12308,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltanolone.,Eltanolone,DB00083
DB12327,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Salvinorin A.,Salvinorin A,DB00083
DB12338,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carisbamate.,Carisbamate,DB00083
DB12361,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piclozotan.,Piclozotan,DB00083
DB12395,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esreboxetine.,Esreboxetine,DB00083
DB12401,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromperidol.,Bromperidol,DB00083
DB12427,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Orvepitant.,Orvepitant,DB00083
DB12465,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketanserin.,Ketanserin,DB00083
DB12492,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piritramide.,Piritramide,DB00083
DB12518,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Raclopride.,Raclopride,DB00083
DB12537,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzodiazepine.,Benzodiazepine,DB00083
DB12576,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with AZD-3043.,AZD-3043,DB00083
DB12590,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indiplon.,Indiplon,DB00083
DB12661,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urapidil.,Urapidil,DB00083
DB12710,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perazine.,Perazine,DB00083
DB12725,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with TD-8954.,TD-8954,DB00083
DB12833,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tandospirone.,Tandospirone,DB00083
DB12867,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benperidol.,Benperidol,DB00083
DB12883,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltoprazine.,Eltoprazine,DB00083
DB12930,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opipramol.,Opipramol,DB00083
DB12951,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivagabine.,Pivagabine,DB00083
DB12958,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prothipendyl.,Prothipendyl,DB00083
DB13014,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hypericin.,Hypericin,DB00083
DB13025,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiapride.,Tiapride,DB00083
DB13082,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefiracetam.,Nefiracetam,DB00083
DB13099,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valnoctamide.,Valnoctamide,DB00083
DB13114,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amitriptylinoxide.,Amitriptylinoxide,DB00083
DB13160,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphaprodine.,Alphaprodine,DB00083
DB13213,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butaperazine.,Butaperazine,DB00083
DB13219,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medifoxamine.,Medifoxamine,DB00083
DB13221,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apronalide.,Apronalide,DB00083
DB13225,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dibenzepin.,Dibenzepin,DB00083
DB13234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propanidid.,Propanidid,DB00083
DB13246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quinupramine.,Quinupramine,DB00083
DB13253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Proxibarbal.,Proxibarbal,DB00083
DB13256,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clothiapine.,Clothiapine,DB00083
DB13273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sultopride.,Sultopride,DB00083
DB13303,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Febarbamate.,Febarbamate,DB00083
DB13323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trichloroethylene.,Trichloroethylene,DB00083
DB13324,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrazepam.,Tetrazepam,DB00083
DB13331,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrithyldione.,Pyrithyldione,DB00083
DB13335,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pinazepam.,Pinazepam,DB00083
DB13352,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deanol.,Deanol,DB00083
DB13354,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenprobamate.,Phenprobamate,DB00083
DB13357,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Styramate.,Styramate,DB00083
DB13362,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheneturide.,Pheneturide,DB00083
DB13370,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromisoval.,Bromisoval,DB00083
DB13377,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinbarbital.,Vinbarbital,DB00083
DB13382,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorproethazine.,Chlorproethazine,DB00083
DB13384,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melitracen.,Melitracen,DB00083
DB13396,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Neocitrullamon.,Neocitrullamon,DB00083
DB13402,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetylglycinamide chloral hydrate.,Acetylglycinamide chloral hydrate,DB00083
DB13403,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxypertine.,Oxypertine,DB00083
DB13411,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofepramine.,Lofepramine,DB00083
DB13414,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenyramidol.,Fenyramidol,DB00083
DB13420,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiazinam.,Thiazinam,DB00083
DB13437,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medazepam.,Medazepam,DB00083
DB13455,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenibut.,Phenibut,DB00083
DB13457,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaflozane.,Oxaflozane,DB00083
DB13478,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meptazinol.,Meptazinol,DB00083
DB13496,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprindole.,Iprindole,DB00083
DB13520,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metergoline.,Metergoline,DB00083
DB13522,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebicar.,Mebicar,DB00083
DB13523,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Veralipride.,Veralipride,DB00083
DB13534,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gedocarnil.,Gedocarnil,DB00083
DB13541,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprazochrome.,Iprazochrome,DB00083
DB13550,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifemelane.,Bifemelane,DB00083
DB13552,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluperidol.,Trifluperidol,DB00083
DB13554,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moperone.,Moperone,DB00083
DB13557,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiopropazate.,Thiopropazate,DB00083
DB13572,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Emylcamate.,Emylcamate,DB00083
DB13577,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Allobarbital.,Allobarbital,DB00083
DB13588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naftidrofuryl.,Naftidrofuryl,DB00083
DB13598,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethyl ether.,Diethyl ether,DB00083
DB13601,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxiracetam.,Oxiracetam,DB00083
DB13605,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoperidine.,Phenoperidine,DB00083
DB13606,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenazocine.,Phenazocine,DB00083
DB13623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fabomotizole.,Fabomotizole,DB00083
DB13642,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pridinol.,Pridinol,DB00083
DB13643,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loprazolam.,Loprazolam,DB00083
DB13662,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hexapropymate.,Hexapropymate,DB00083
DB13665,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluanisone.,Fluanisone,DB00083
DB13676,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapramine.,Mosapramine,DB00083
DB13687,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Niaprazine.,Niaprazine,DB00083
DB13690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinyl ether.,Vinyl ether,DB00083
DB13733,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylpentynol.,Methylpentynol,DB00083
DB13737,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclobarbital.,Cyclobarbital,DB00083
DB13745,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fazadinium bromide.,Fazadinium bromide,DB00083
DB13754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenoxalone.,Mephenoxalone,DB00083
DB13770,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinylbital.,Vinylbital,DB00083
DB13782,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imipramine oxide.,Imipramine oxide,DB00083
DB13784,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dixyrazine.,Dixyrazine,DB00083
DB13787,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tilidine.,Tilidine,DB00083
DB13791,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penfluridol.,Penfluridol,DB00083
DB13799,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethadione.,Ethadione,DB00083
DB13805,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reposal.,Reposal,DB00083
DB13817,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbromal.,Carbromal,DB00083
DB13837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doxefazepam.,Doxefazepam,DB00083
DB13841,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clopenthixol.,Clopenthixol,DB00083
DB13872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lormetazepam.,Lormetazepam,DB00083
DB13875,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Harmaline.,Harmaline,DB00083
DB13876,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brofaromine.,Brofaromine,DB00083
DB13940,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.","2,5-Dimethoxy-4-ethylthioamphetamine",DB00083
DB13948,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.","N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine",DB00083
DB13984,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopropane.,Cyclopropane,DB00083
DB13993,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MRK-409.,MRK-409,DB00083
DB14010,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 5-methoxy-N,N-dimethyltryptamine.","5-methoxy-N,N-dimethyltryptamine",DB00083
DB14028,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nordazepam.,Nordazepam,DB00083
DB14050,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cannabidivarin.,Cannabidivarin,DB00083
DB14185,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aripiprazole lauroxil.,Aripiprazole lauroxil,DB00083
DB14509,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium carbonate.,Lithium carbonate,DB00083
DB14575,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine.,Eslicarbazepine,DB00083
DB14651,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine enanthate.,Perphenazine enanthate,DB00083
DB14672,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam acetate.,Oxazepam acetate,DB00083
DB14715,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinazepam.,Cinazepam,DB00083
DB14718,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrazolam.,Pyrazolam,DB00083
DB14719,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bentazepam.,Bentazepam,DB00083
DB14754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Solriamfetol.,Solriamfetol,DB00083
DB15203,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with JNJ-26489112.,JNJ-26489112,DB00083
DB15360,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil, C-11.","Carfentanil, C-11",DB00083
DB11951,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lemborexant.,Lemborexant,DB00083
DB00230,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Pregabalin.,Pregabalin,DB00083
DB04948,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Lofexidine.,Lofexidine,DB00083
DB00042,The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Botulinum toxin type A.,Botulinum Toxin Type B,DB00083
DB00184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nicotine.,Nicotine,DB00083
DB08837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetraethylammonium.,Tetraethylammonium,DB00083
DB08999,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopentamine.,Cyclopentamine,DB00083
DB00091,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.,Cyclosporine,DB00083
DB00254,The risk or severity of adverse effects can be increased when Doxycycline is combined with Botulinum toxin type A.,Doxycycline,DB00083
DB00256,The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum toxin type A.,Lymecycline,DB00083
DB00314,The risk or severity of adverse effects can be increased when Capreomycin is combined with Botulinum toxin type A.,Capreomycin,DB00083
DB00319,The risk or severity of adverse effects can be increased when Piperacillin is combined with Botulinum toxin type A.,Piperacillin,DB00083
DB00452,The risk or severity of adverse effects can be increased when Framycetin is combined with Botulinum toxin type A.,Framycetin,DB00083
DB00453,The risk or severity of adverse effects can be increased when Clomocycline is combined with Botulinum toxin type A.,Clomocycline,DB00083
DB00468,The risk or severity of adverse effects can be increased when Quinine is combined with Botulinum toxin type A.,Quinine,DB00083
DB00512,The risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum toxin type A.,Vancomycin,DB00083
DB00560,The risk or severity of adverse effects can be increased when Tigecycline is combined with Botulinum toxin type A.,Tigecycline,DB00083
DB00595,The risk or severity of adverse effects can be increased when Oxytetracycline is combined with Botulinum toxin type A.,Oxytetracycline,DB00083
DB00608,The risk or severity of adverse effects can be increased when Chloroquine is combined with Botulinum toxin type A.,Chloroquine,DB00083
DB00618,The risk or severity of adverse effects can be increased when Demeclocycline is combined with Botulinum toxin type A.,Demeclocycline,DB00083
DB00684,The risk or severity of adverse effects can be increased when Tobramycin is combined with Botulinum toxin type A.,Tobramycin,DB00083
DB00759,The risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum toxin type A.,Tetracycline,DB00083
DB00798,The risk or severity of adverse effects can be increased when Gentamicin is combined with Botulinum toxin type A.,Gentamicin,DB00083
DB00903,The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Botulinum toxin type A.,Etacrynic acid,DB00083
DB00931,The risk or severity of adverse effects can be increased when Metacycline is combined with Botulinum toxin type A.,Metacycline,DB00083
DB00955,The risk or severity of adverse effects can be increased when Netilmicin is combined with Botulinum toxin type A.,Netilmicin,DB00083
DB00994,The risk or severity of adverse effects can be increased when Neomycin is combined with Botulinum toxin type A.,Neomycin,DB00083
DB01035,The risk or severity of adverse effects can be increased when Procainamide is combined with Botulinum toxin type A.,Procainamide,DB00083
DB01082,The risk or severity of adverse effects can be increased when Streptomycin is combined with Botulinum toxin type A.,Streptomycin,DB00083
DB01111,The risk or severity of adverse effects can be increased when Colistimethate is combined with Botulinum toxin type A.,Colistimethate,DB00083
DB01172,The risk or severity of adverse effects can be increased when Kanamycin is combined with Botulinum toxin type A.,Kanamycin,DB00083
DB01190,The risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum toxin type A.,Clindamycin,DB00083
DB01219,The risk or severity of adverse effects can be increased when Dantrolene is combined with Botulinum toxin type A.,Dantrolene,DB00083
DB01301,The risk or severity of adverse effects can be increased when Rolitetracycline is combined with Botulinum toxin type A.,Rolitetracycline,DB00083
DB01377,The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Botulinum toxin type A.,Magnesium oxide,DB00083
DB01378,The risk or severity of adverse effects can be increased when Magnesium cation is combined with Botulinum toxin type A.,Magnesium cation,DB00083
DB01421,The risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum toxin type A.,Paromomycin,DB00083
DB01627,The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum toxin type A.,Lincomycin,DB00083
DB03615,The risk or severity of adverse effects can be increased when Ribostamycin is combined with Botulinum toxin type A.,Ribostamycin,DB00083
DB04263,The risk or severity of adverse effects can be increased when Geneticin is combined with Botulinum toxin type A.,Geneticin,DB00083
DB04626,The risk or severity of adverse effects can be increased when Apramycin is combined with Botulinum toxin type A.,Apramycin,DB00083
DB04729,The risk or severity of adverse effects can be increased when Gentamicin C1a is combined with Botulinum toxin type A.,Gentamicin C1a,DB00083
DB04808,The risk or severity of adverse effects can be increased when Neamine is combined with Botulinum toxin type A.,Neamine,DB00083
DB06696,The risk or severity of adverse effects can be increased when Arbekacin is combined with Botulinum toxin type A.,Arbekacin,DB00083
DB06827,The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum toxin type A.,Viomycin,DB00083
DB08437,The risk or severity of adverse effects can be increased when Puromycin is combined with Botulinum toxin type A.,Puromycin,DB00083
DB09104,The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum toxin type A.,Magnesium hydroxide,DB00083
DB09281,The risk or severity of adverse effects can be increased when Magnesium trisilicate is combined with Botulinum toxin type A.,Magnesium trisilicate,DB00083
DB09407,The risk or severity of adverse effects can be increased when Magnesium chloride is combined with Botulinum toxin type A.,Magnesium chloride,DB00083
DB09409,The risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Botulinum toxin type A.,Magnesium acetate tetrahydrate,DB00083
DB09481,The risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Botulinum toxin type A.,Magnesium carbonate,DB00083
DB11110,The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Botulinum toxin type A.,Magnesium citrate,DB00083
DB11189,The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Botulinum toxin type A.,Magnesium glycinate,DB00083
DB11230,The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type A.,Magnesium Aluminum Silicate,DB00083
DB11512,The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Botulinum toxin type A.,Dihydrostreptomycin,DB00083
DB11520,The risk or severity of adverse effects can be increased when Hygromycin B is combined with Botulinum toxin type A.,Hygromycin B,DB00083
DB12604,The risk or severity of adverse effects can be increased when Sisomicin is combined with Botulinum toxin type A.,Sisomicin,DB00083
DB12615,The risk or severity of adverse effects can be increased when Plazomicin is combined with Botulinum toxin type A.,Plazomicin,DB00083
DB13249,The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Botulinum toxin type A.,Magnesium silicate,DB00083
DB13264,The risk or severity of adverse effects can be increased when Penimepicycline is combined with Botulinum toxin type A.,Penimepicycline,DB00083
DB13270,The risk or severity of adverse effects can be increased when Dibekacin is combined with Botulinum toxin type A.,Dibekacin,DB00083
DB13274,The risk or severity of adverse effects can be increased when Micronomicin is combined with Botulinum toxin type A.,Micronomicin,DB00083
DB13359,The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Botulinum toxin type A.,Magnesium aspartate,DB00083
DB13540,The risk or severity of adverse effects can be increased when Isepamicin is combined with Botulinum toxin type A.,Isepamicin,DB00083
DB13673,The risk or severity of adverse effects can be increased when Bekanamycin is combined with Botulinum toxin type A.,Bekanamycin,DB00083
DB13749,The risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Botulinum toxin type A.,Magnesium gluconate,DB00083
DB13786,The risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum toxin type A.,Magnesium orotate,DB00083
DB13862,The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type A.,Magnesium phosphate,DB00083
DB13996,The risk or severity of adverse effects can be increased when Magnesium acetate is combined with Botulinum toxin type A.,Magnesium acetate,DB00083
DB05077,The risk or severity of adverse effects can be increased when SLV319 is combined with Botulinum toxin type A.,SLV319,DB00083
DB06155,The risk or severity of adverse effects can be increased when Rimonabant is combined with Botulinum toxin type A.,Rimonabant,DB00083
DB06624,The risk or severity of adverse effects can be increased when Taranabant is combined with Botulinum toxin type A.,Taranabant,DB00083
DB09061,The risk or severity of adverse effects can be increased when Cannabidiol is combined with Botulinum toxin type A.,Cannabidiol,DB00083
DB11903,The risk or severity of adverse effects can be increased when GW842166 is combined with Botulinum toxin type A.,GW842166,DB00083
DB12193,The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Botulinum toxin type A.,Ajulemic acid,DB00083
DB12649,The risk or severity of adverse effects can be increased when Ibipinabant is combined with Botulinum toxin type A.,Ibipinabant,DB00083
DB13070,The risk or severity of adverse effects can be increased when Surinabant is combined with Botulinum toxin type A.,Surinabant,DB00083
DB13950,The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Botulinum toxin type A.,WIN 55212-2,DB00083
DB14011,The risk or severity of adverse effects can be increased when Nabiximols is combined with Botulinum toxin type A.,Nabiximols,DB00083
DB14043,The risk or severity of adverse effects can be increased when Palmidrol is combined with Botulinum toxin type A.,Palmidrol,DB00083
DB14737,The risk or severity of adverse effects can be increased when Cannabinol is combined with Botulinum toxin type A.,Cannabinol,DB00083
DB11823,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esketamine.,Esketamine,DB00083
DB00395,The risk or severity of adverse effects can be increased when Carisoprodol is combined with Botulinum toxin type A.,Carisoprodol,DB00083
DB00704,The risk or severity of respiratory depression can be increased when Naltrexone is combined with Botulinum toxin type A.,Naltrexone,DB00083
DB01459,The risk or severity of respiratory depression can be increased when Bezitramide is combined with Botulinum toxin type A.,Bezitramide,DB00083
DB09272,The risk or severity of respiratory depression can be increased when Eluxadoline is combined with Botulinum toxin type A.,Eluxadoline,DB00083
DB13454,The risk or severity of respiratory depression can be increased when Nicomorphine is combined with Botulinum toxin type A.,Nicomorphine,DB00083
DB15465,The risk or severity of respiratory depression can be increased when Benzhydrocodone is combined with Botulinum toxin type A.,Benzhydrocodone,DB00083
DB00402,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Eszopiclone.,Eszopiclone,DB00083
DB00575,The risk or severity of sedation can be increased when Clonidine is combined with Botulinum toxin type A.,Clonidine,DB00083
DB00924,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Cyclobenzaprine.,Cyclobenzaprine,DB00083
DB01233,The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.,Metoclopramide,DB00083
DB11732,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lasmiditan.,Lasmiditan,DB00083
DB14513,Magnesium can cause a decrease in the absorption of Botulinum toxin type A resulting in a reduced serum concentration and potentially a decrease in efficacy.,Magnesium,DB00083
DB00502,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.,Haloperidol,DB00083
DB00325,Pancrelipase can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.,Nitroprusside,DB00085
DB06783,Pancrelipase can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.,Prussian blue,DB00085
DB09146,Pancrelipase can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.,Iron sucrose,DB00085
DB09501,Pancrelipase can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric ammonium citrate,DB00085
DB09507,Pancrelipase can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferumoxsil,DB00085
DB09508,Pancrelipase can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferumoxides,DB00085
DB11171,Pancrelipase can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric sulfate,DB00085
DB11210,Pancrelipase can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous bisglycinate,DB00085
DB11417,Pancrelipase can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.,Gleptoferron,DB00085
DB11576,Pancrelipase can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric oxide,DB00085
DB12208,Pancrelipase can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.,Iron isomaltoside 1000,DB00085
DB12821,Pancrelipase can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.,Perflubutane,DB00085
DB13257,Pancrelipase can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous sulfate anhydrous,DB00085
DB13381,Pancrelipase can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Sodium feredetate,DB00085
DB13423,Pancrelipase can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric hydroxide,DB00085
DB13569,Pancrelipase can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous chloride,DB00085
DB13949,Pancrelipase can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric cation,DB00085
DB14488,Pancrelipase can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous gluconate,DB00085
DB14489,Pancrelipase can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous succinate,DB00085
DB14491,Pancrelipase can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous fumarate,DB00085
DB14520,Pancrelipase can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Tetraferric tricitrate decahydrate,DB00085
DB14695,Pancrelipase can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric oxyhydroxide,DB00085
DB15598,Pancrelipase can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric maltol,DB00085
DB06605,Apixaban may increase the anticoagulant activities of Streptokinase.,Apixaban,DB00086
DB06695,Dabigatran etexilate may increase the anticoagulant activities of Streptokinase.,Dabigatran etexilate,DB00086
DB01254,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase.,Dasatinib,DB00086
DB01609,The risk or severity of gastrointestinal bleeding can be increased when Streptokinase is combined with Deferasirox.,Deferasirox,DB00086
DB01586,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid,DB00086
DB02123,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid,DB00086
DB02659,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Cholic Acid.,Cholic Acid,DB00086
DB02691,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycocholic acid.,Glycocholic acid,DB00086
DB03619,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Deoxycholic acid.,Deoxycholic acid,DB00086
DB04348,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurocholic acid.,Taurocholic acid,DB00086
DB05990,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Obeticholic acid.,Obeticholic acid,DB00086
DB06777,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid,DB00086
DB08833,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid,DB00086
DB08834,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid,DB00086
DB08857,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Bamet-UD2.,Bamet-UD2,DB00086
DB11622,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Dehydrocholic acid.,Dehydrocholic acid,DB00086
DB11789,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid,DB00086
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Streptokinase.,Edoxaban,DB00086
DB09053,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase.,Ibrutinib,DB00086
DB08935,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Obinutuzumab.,Obinutuzumab,DB00086
DB06228,Streptokinase may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban,DB00086
DB06206,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Sugammadex.,Sugammadex,DB00086
DB09070,Tibolone may increase the anticoagulant activities of Streptokinase.,Tibolone,DB00086
DB00932,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase.,Tipranavir,DB00086
DB00013,Urokinase may increase the anticoagulant activities of Streptokinase.,Urokinase,DB00086
DB00163,Vitamin E may increase the anticoagulant activities of Streptokinase.,Vitamin E,DB00086
DB09030,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Streptokinase.,Vorapaxar,DB00086
DB06692,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.,Aprotinin,DB00086
DB00476,The risk or severity of orthostatic hypotension and syncope can be increased when Streptokinase is combined with Duloxetine.,Duloxetine,DB00086
DB01235,The risk or severity of hypotension and orthostatic hypotension can be increased when Streptokinase is combined with Levodopa.,Levodopa,DB00086
DB00734,Streptokinase may increase the hypotensive activities of Risperidone.,Risperidone,DB00086
DB01381,The therapeutic efficacy of Streptokinase can be increased when used in combination with Ginkgo biloba.,Ginkgo biloba,DB00086
DB01181,The risk or severity of bleeding can be increased when Ifosfamide is combined with Streptokinase.,Ifosfamide,DB00086
DB00468,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinine.,Quinine,DB00086
DB00908,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinidine.,Quinidine,DB00086
DB00675,The risk or severity of bleeding can be increased when Tamoxifen is combined with Streptokinase.,Tamoxifen,DB00086
DB00539,The risk or severity of bleeding can be increased when Toremifene is combined with Streptokinase.,Toremifene,DB00086
DB00407,Streptokinase may increase the anticoagulant activities of Ardeparin.,Ardeparin,DB00086
DB01109,Streptokinase may increase the anticoagulant activities of Heparin.,Heparin,DB00086
DB01225,Streptokinase may increase the anticoagulant activities of Enoxaparin.,Enoxaparin,DB00086
DB06271,Streptokinase may increase the anticoagulant activities of Sulodexide.,Sulodexide,DB00086
DB06294,Streptokinase may increase the anticoagulant activities of Semuloparin.,Semuloparin,DB00086
DB06754,Streptokinase may increase the anticoagulant activities of Danaparoid.,Danaparoid,DB00086
DB06779,Streptokinase may increase the anticoagulant activities of Dalteparin.,Dalteparin,DB00086
DB06822,Streptokinase may increase the anticoagulant activities of Tinzaparin.,Tinzaparin,DB00086
DB08813,Streptokinase may increase the anticoagulant activities of Nadroparin.,Nadroparin,DB00086
DB09258,Streptokinase may increase the anticoagulant activities of Bemiparin.,Bemiparin,DB00086
DB09259,Streptokinase may increase the anticoagulant activities of Reviparin.,Reviparin,DB00086
DB09260,Streptokinase may increase the anticoagulant activities of Parnaparin.,Parnaparin,DB00086
DB09261,Streptokinase may increase the anticoagulant activities of Certoparin.,Certoparin,DB00086
DB00806,The therapeutic efficacy of Streptokinase can be increased when used in combination with Pentoxifylline.,Pentoxifylline,DB00086
DB00686,Pentosan polysulfate may increase the anticoagulant activities of Streptokinase.,Pentosan polysulfate,DB00086
DB00583,The therapeutic efficacy of Streptokinase can be increased when used in combination with Levocarnitine.,Levocarnitine,DB00086
DB01238,Aripiprazole may increase the hypotensive activities of Streptokinase.,Aripiprazole,DB00086
DB14185,Aripiprazole lauroxil may increase the hypotensive activities of Streptokinase.,Aripiprazole lauroxil,DB00086
DB09220,Nicorandil may increase the hypotensive activities of Streptokinase.,Nicorandil,DB00086
DB00255,Diethylstilbestrol may decrease the anticoagulant activities of Streptokinase.,Diethylstilbestrol,DB00086
DB00269,Chlorotrianisene may decrease the anticoagulant activities of Streptokinase.,Chlorotrianisene,DB00086
DB00286,Conjugated estrogens may decrease the anticoagulant activities of Streptokinase.,Conjugated estrogens,DB00086
DB00783,Estradiol may decrease the anticoagulant activities of Streptokinase.,Estradiol,DB00086
DB00977,Ethinylestradiol may decrease the anticoagulant activities of Streptokinase.,Ethinylestradiol,DB00086
DB01357,Mestranol may decrease the anticoagulant activities of Streptokinase.,Mestranol,DB00086
DB04573,Estriol may decrease the anticoagulant activities of Streptokinase.,Estriol,DB00086
DB04574,Estrone sulfate may decrease the anticoagulant activities of Streptokinase.,Estrone sulfate,DB00086
DB04575,Quinestrol may decrease the anticoagulant activities of Streptokinase.,Quinestrol,DB00086
DB07931,Hexestrol may decrease the anticoagulant activities of Streptokinase.,Hexestrol,DB00086
DB09317,"Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Streptokinase.","Synthetic Conjugated Estrogens, A",DB00086
DB09318,"Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Streptokinase.","Synthetic Conjugated Estrogens, B",DB00086
DB09369,Polyestradiol phosphate may decrease the anticoagulant activities of Streptokinase.,Polyestradiol phosphate,DB00086
DB09381,Esterified estrogens may decrease the anticoagulant activities of Streptokinase.,Esterified estrogens,DB00086
DB11478,Zeranol may decrease the anticoagulant activities of Streptokinase.,Zeranol,DB00086
DB11674,Equol may decrease the anticoagulant activities of Streptokinase.,Equol,DB00086
DB12487,Promestriene may decrease the anticoagulant activities of Streptokinase.,Promestriene,DB00086
DB13143,Methallenestril may decrease the anticoagulant activities of Streptokinase.,Methallenestril,DB00086
DB13386,Epimestrol may decrease the anticoagulant activities of Streptokinase.,Epimestrol,DB00086
DB13418,Moxestrol may decrease the anticoagulant activities of Streptokinase.,Moxestrol,DB00086
DB13952,Estradiol acetate may decrease the anticoagulant activities of Streptokinase.,Estradiol acetate,DB00086
DB13953,Estradiol benzoate may decrease the anticoagulant activities of Streptokinase.,Estradiol benzoate,DB00086
DB13954,Estradiol cypionate may decrease the anticoagulant activities of Streptokinase.,Estradiol cypionate,DB00086
DB13956,Estradiol valerate may decrease the anticoagulant activities of Streptokinase.,Estradiol valerate,DB00086
DB15334,Biochanin A may decrease the anticoagulant activities of Streptokinase.,Biochanin A,DB00086
DB15335,Formononetin may decrease the anticoagulant activities of Streptokinase.,Formononetin,DB00086
DB00159,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Streptokinase.,Icosapent,DB00086
DB00244,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Streptokinase.,Mesalazine,DB00086
DB00328,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Streptokinase.,Indomethacin,DB00086
DB00461,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Streptokinase.,Nabumetone,DB00086
DB00465,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Streptokinase.,Ketorolac,DB00086
DB00469,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Streptokinase.,Tenoxicam,DB00086
DB00482,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Streptokinase.,Celecoxib,DB00086
DB00500,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Streptokinase.,Tolmetin,DB00086
DB00533,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Streptokinase.,Rofecoxib,DB00086
DB00554,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Streptokinase.,Piroxicam,DB00086
DB00573,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Streptokinase.,Fenoprofen,DB00086
DB00580,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Streptokinase.,Valdecoxib,DB00086
DB00586,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Streptokinase.,Diclofenac,DB00086
DB00605,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Streptokinase.,Sulindac,DB00086
DB00712,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Streptokinase.,Flurbiprofen,DB00086
DB00749,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Streptokinase.,Etodolac,DB00086
DB00784,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Streptokinase.,Mefenamic acid,DB00086
DB00788,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Streptokinase.,Naproxen,DB00086
DB00795,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Streptokinase.,Sulfasalazine,DB00086
DB00812,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Streptokinase.,Phenylbutazone,DB00086
DB00814,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Streptokinase.,Meloxicam,DB00086
DB00821,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Streptokinase.,Carprofen,DB00086
DB00861,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Streptokinase.,Diflunisal,DB00086
DB00936,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Streptokinase.,Salicylic acid,DB00086
DB00939,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Streptokinase.,Meclofenamic acid,DB00086
DB00991,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Streptokinase.,Oxaprozin,DB00086
DB01009,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Streptokinase.,Ketoprofen,DB00086
DB01014,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Streptokinase.,Balsalazide,DB00086
DB01250,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Streptokinase.,Olsalazine,DB00086
DB01283,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Streptokinase.,Lumiracoxib,DB00086
DB01397,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Streptokinase.,Magnesium salicylate,DB00086
DB01399,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Streptokinase.,Salsalate,DB00086
DB01401,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Streptokinase.,Choline magnesium trisalicylate,DB00086
DB01419,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Streptokinase.,Antrafenine,DB00086
DB01424,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Streptokinase.,Aminophenazone,DB00086
DB01435,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Streptokinase.,Antipyrine,DB00086
DB01600,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Streptokinase.,Tiaprofenic acid,DB00086
DB01628,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Streptokinase.,Etoricoxib,DB00086
DB02224,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Streptokinase.,Taxifolin,DB00086
DB03585,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Streptokinase.,Oxyphenbutazone,DB00086
DB04552,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Streptokinase.,Niflumic acid,DB00086
DB04725,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Streptokinase.,Licofelone,DB00086
DB04812,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Streptokinase.,Benoxaprofen,DB00086
DB04817,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Streptokinase.,Metamizole,DB00086
DB04828,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Streptokinase.,Zomepirac,DB00086
DB05095,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Streptokinase.,Cimicoxib,DB00086
DB06725,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Streptokinase.,Lornoxicam,DB00086
DB06736,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Streptokinase.,Aceclofenac,DB00086
DB06737,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Streptokinase.,Zaltoprofen,DB00086
DB07402,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Streptokinase.,Azapropazone,DB00086
DB07477,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Streptokinase.,Felbinac,DB00086
DB08439,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Streptokinase.,Parecoxib,DB00086
DB08797,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Streptokinase.,Salicylamide,DB00086
DB08940,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Streptokinase.,Kebuzone,DB00086
DB08942,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Streptokinase.,Isoxicam,DB00086
DB08951,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Streptokinase.,Indoprofen,DB00086
DB08955,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Streptokinase.,Ibuproxam,DB00086
DB08976,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Streptokinase.,Floctafenine,DB00086
DB08981,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Streptokinase.,Fenbufen,DB00086
DB08984,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Streptokinase.,Etofenamate,DB00086
DB08991,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Streptokinase.,Epirizole,DB00086
DB09084,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Streptokinase.,Benzydamine,DB00086
DB09212,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Streptokinase.,Loxoprofen,DB00086
DB09214,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Streptokinase.,Dexketoprofen,DB00086
DB09215,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Streptokinase.,Droxicam,DB00086
DB09216,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Streptokinase.,Tolfenamic acid,DB00086
DB09217,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Streptokinase.,Firocoxib,DB00086
DB09218,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Streptokinase.,Clonixin,DB00086
DB09285,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Streptokinase.,Morniflumate,DB00086
DB09288,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Streptokinase.,Propacetamol,DB00086
DB09295,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Streptokinase.,Talniflumate,DB00086
DB11455,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Streptokinase.,Robenacoxib,DB00086
DB11466,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Streptokinase.,Tepoxalin,DB00086
DB11518,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Streptokinase.,Flunixin,DB00086
DB12399,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Streptokinase.,Polmacoxib,DB00086
DB12480,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Streptokinase.,Betulinic Acid,DB00086
DB12610,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Streptokinase.,Ebselen,DB00086
DB13001,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Streptokinase.,Tinoridine,DB00086
DB13167,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Streptokinase.,Alclofenac,DB00086
DB13217,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Streptokinase.,Fentiazac,DB00086
DB13232,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Streptokinase.,Suxibuzone,DB00086
DB13286,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Streptokinase.,Bumadizone,DB00086
DB13314,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Streptokinase.,Alminoprofen,DB00086
DB13317,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Streptokinase.,Flunoxaprofen,DB00086
DB13364,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Streptokinase.,Feprazone,DB00086
DB13371,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Streptokinase.,Difenpiramide,DB00086
DB13407,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Streptokinase.,Nifenazone,DB00086
DB13432,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Streptokinase.,Lonazolac,DB00086
DB13481,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Streptokinase.,Tenidap,DB00086
DB13501,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Streptokinase.,Bendazac,DB00086
DB13514,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Streptokinase.,Pranoprofen,DB00086
DB13524,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Streptokinase.,Propyphenazone,DB00086
DB13527,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Streptokinase.,Proglumetacin,DB00086
DB13538,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Streptokinase.,Guacetisal,DB00086
DB13544,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Streptokinase.,Ethenzamide,DB00086
DB13612,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Streptokinase.,Carbaspirin calcium,DB00086
DB13629,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Streptokinase.,Mofebutazone,DB00086
DB13649,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Streptokinase.,Proquazone,DB00086
DB13657,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Streptokinase.,Benorilate,DB00086
DB13722,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Streptokinase.,Pirprofen,DB00086
DB13860,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Streptokinase.,Imidazole salicylate,DB00086
DB14059,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Streptokinase.,SC-236,DB00086
DB14060,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Streptokinase.,NS-398,DB00086
DB14938,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Streptokinase.,Flurbiprofen axetil,DB00086
DB04865,The risk or severity of bleeding can be increased when Streptokinase is combined with Omacetaxine mepesuccinate.,Omacetaxine mepesuccinate,DB00086
DB11133,Omega-3 fatty acids may increase the anticoagulant activities of Streptokinase.,Omega-3 fatty acids,DB00086
DB00081,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.,Tositumomab,DB00086
DB09211,The risk or severity of adverse effects can be increased when Limaprost is combined with Streptokinase.,Limaprost,DB00086
DB00048,The risk or severity of adverse effects can be increased when Streptokinase is combined with Collagenase clostridium histolyticum.,Collagenase clostridium histolyticum,DB00086
DB00389,Carbimazole may increase the anticoagulant activities of Streptokinase.,Carbimazole,DB00086
DB00550,Propylthiouracil may increase the anticoagulant activities of Streptokinase.,Propylthiouracil,DB00086
DB00763,Methimazole may increase the anticoagulant activities of Streptokinase.,Methimazole,DB00086
DB03374,"3,5-Diiodotyrosine may increase the anticoagulant activities of Streptokinase.","3,5-Diiodotyrosine",DB00086
DB06715,Potassium Iodide may increase the anticoagulant activities of Streptokinase.,Potassium Iodide,DB00086
DB07637,Dibromotyrosine may increase the anticoagulant activities of Streptokinase.,Dibromotyrosine,DB00086
DB09418,Potassium perchlorate may increase the anticoagulant activities of Streptokinase.,Potassium perchlorate,DB00086
DB13644,Methylthiouracil may increase the anticoagulant activities of Streptokinase.,Methylthiouracil,DB00086
DB13804,Benzylthiouracil may increase the anticoagulant activities of Streptokinase.,Benzylthiouracil,DB00086
DB00834,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mifepristone.,Mifepristone,DB00086
DB04066,The therapeutic efficacy of Streptokinase can be decreased when used in combination with p-Coumaric acid.,p-Coumaric acid,DB00086
DB04682,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.,Octylphenoxy polyethoxyethanol,DB00086
DB05830,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Trestolone.,Trestolone,DB00086
DB06266,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Lonidamine.,Lonidamine,DB00086
DB08867,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ulipristal.,Ulipristal,DB00086
DB09401,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Isosorbide.,Isosorbide,DB00086
DB11507,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cloprostenol.,Cloprostenol,DB00086
DB12025,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triptolide.,Triptolide,DB00086
DB13044,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Gossypol.,Gossypol,DB00086
DB13310,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ormeloxifene.,Ormeloxifene,DB00086
DB00182,Amphetamine may increase the orthostatic hypotensive activities of Streptokinase.,Amphetamine,DB00086
DB00601,Linezolid may increase the orthostatic hypotensive activities of Streptokinase.,Linezolid,DB00086
DB00614,Furazolidone may increase the orthostatic hypotensive activities of Streptokinase.,Furazolidone,DB00086
DB00721,Procaine may increase the orthostatic hypotensive activities of Streptokinase.,Procaine,DB00086
DB00752,Tranylcypromine may increase the orthostatic hypotensive activities of Streptokinase.,Tranylcypromine,DB00086
DB00780,Phenelzine may increase the orthostatic hypotensive activities of Streptokinase.,Phenelzine,DB00086
DB00805,Minaprine may increase the orthostatic hypotensive activities of Streptokinase.,Minaprine,DB00086
DB01037,Selegiline may increase the orthostatic hypotensive activities of Streptokinase.,Selegiline,DB00086
DB01168,Procarbazine may increase the orthostatic hypotensive activities of Streptokinase.,Procarbazine,DB00086
DB01171,Moclobemide may increase the orthostatic hypotensive activities of Streptokinase.,Moclobemide,DB00086
DB01247,Isocarboxazid may increase the orthostatic hypotensive activities of Streptokinase.,Isocarboxazid,DB00086
DB01367,Rasagiline may increase the orthostatic hypotensive activities of Streptokinase.,Rasagiline,DB00086
DB01626,Pargyline may increase the orthostatic hypotensive activities of Streptokinase.,Pargyline,DB00086
DB04017,Clorgiline may increase the orthostatic hypotensive activities of Streptokinase.,Clorgiline,DB00086
DB04818,Iproniazid may increase the orthostatic hypotensive activities of Streptokinase.,Iproniazid,DB00086
DB04820,Nialamide may increase the orthostatic hypotensive activities of Streptokinase.,Nialamide,DB00086
DB06654,Safinamide may increase the orthostatic hypotensive activities of Streptokinase.,Safinamide,DB00086
DB08550,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Streptokinase.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",DB00086
DB09241,Methylene blue may increase the orthostatic hypotensive activities of Streptokinase.,Methylene blue,DB00086
DB09243,Hydracarbazine may increase the orthostatic hypotensive activities of Streptokinase.,Hydracarbazine,DB00086
DB09244,Pirlindole may increase the orthostatic hypotensive activities of Streptokinase.,Pirlindole,DB00086
DB09245,Toloxatone may increase the orthostatic hypotensive activities of Streptokinase.,Toloxatone,DB00086
DB09246,Benmoxin may increase the orthostatic hypotensive activities of Streptokinase.,Benmoxin,DB00086
DB09248,Mebanazine may increase the orthostatic hypotensive activities of Streptokinase.,Mebanazine,DB00086
DB09249,Octamoxin may increase the orthostatic hypotensive activities of Streptokinase.,Octamoxin,DB00086
DB09250,Pheniprazine may increase the orthostatic hypotensive activities of Streptokinase.,Pheniprazine,DB00086
DB09251,Phenoxypropazine may increase the orthostatic hypotensive activities of Streptokinase.,Phenoxypropazine,DB00086
DB09252,Pivhydrazine may increase the orthostatic hypotensive activities of Streptokinase.,Pivhydrazine,DB00086
DB09253,Safrazine may increase the orthostatic hypotensive activities of Streptokinase.,Safrazine,DB00086
DB09254,Caroxazone may increase the orthostatic hypotensive activities of Streptokinase.,Caroxazone,DB00086
DB13875,Harmaline may increase the orthostatic hypotensive activities of Streptokinase.,Harmaline,DB00086
DB13876,Brofaromine may increase the orthostatic hypotensive activities of Streptokinase.,Brofaromine,DB00086
DB00294,Etonogestrel may decrease the anticoagulant activities of Streptokinase.,Etonogestrel,DB00086
DB00304,Desogestrel may decrease the anticoagulant activities of Streptokinase.,Desogestrel,DB00086
DB00351,Megestrol acetate may decrease the anticoagulant activities of Streptokinase.,Megestrol acetate,DB00086
DB00367,Levonorgestrel may decrease the anticoagulant activities of Streptokinase.,Levonorgestrel,DB00086
DB00378,Dydrogesterone may decrease the anticoagulant activities of Streptokinase.,Dydrogesterone,DB00086
DB00396,Progesterone may decrease the anticoagulant activities of Streptokinase.,Progesterone,DB00086
DB00603,Medroxyprogesterone acetate may decrease the anticoagulant activities of Streptokinase.,Medroxyprogesterone acetate,DB00086
DB00717,Norethisterone may decrease the anticoagulant activities of Streptokinase.,Norethisterone,DB00086
DB00823,Ethynodiol diacetate may decrease the anticoagulant activities of Streptokinase.,Ethynodiol diacetate,DB00086
DB00957,Norgestimate may decrease the anticoagulant activities of Streptokinase.,Norgestimate,DB00086
DB01395,Drospirenone may decrease the anticoagulant activities of Streptokinase.,Drospirenone,DB00086
DB01431,Allylestrenol may decrease the anticoagulant activities of Streptokinase.,Allylestrenol,DB00086
DB04839,Cyproterone acetate may decrease the anticoagulant activities of Streptokinase.,Cyproterone acetate,DB00086
DB06713,Norelgestromin may decrease the anticoagulant activities of Streptokinase.,Norelgestromin,DB00086
DB06730,Gestodene may decrease the anticoagulant activities of Streptokinase.,Gestodene,DB00086
DB06789,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Streptokinase.,Hydroxyprogesterone caproate,DB00086
DB09123,Dienogest may decrease the anticoagulant activities of Streptokinase.,Dienogest,DB00086
DB09124,Medrogestone may decrease the anticoagulant activities of Streptokinase.,Medrogestone,DB00086
DB09371,Norethynodrel may decrease the anticoagulant activities of Streptokinase.,Norethynodrel,DB00086
DB09389,Norgestrel may decrease the anticoagulant activities of Streptokinase.,Norgestrel,DB00086
DB11372,Altrenogest may decrease the anticoagulant activities of Streptokinase.,Altrenogest,DB00086
DB11619,Gestrinone may decrease the anticoagulant activities of Streptokinase.,Gestrinone,DB00086
DB11636,Nomegestrol may decrease the anticoagulant activities of Streptokinase.,Nomegestrol,DB00086
DB12474,Lynestrenol may decrease the anticoagulant activities of Streptokinase.,Lynestrenol,DB00086
DB13230,Gestonorone may decrease the anticoagulant activities of Streptokinase.,Gestonorone,DB00086
DB13528,Chlormadinone may decrease the anticoagulant activities of Streptokinase.,Chlormadinone,DB00086
DB13533,Methylestrenolone may decrease the anticoagulant activities of Streptokinase.,Methylestrenolone,DB00086
DB13563,Norgestrienone may decrease the anticoagulant activities of Streptokinase.,Norgestrienone,DB00086
DB13602,Promegestone may decrease the anticoagulant activities of Streptokinase.,Promegestone,DB00086
DB13685,Quingestanol may decrease the anticoagulant activities of Streptokinase.,Quingestanol,DB00086
DB13857,Demegestone may decrease the anticoagulant activities of Streptokinase.,Demegestone,DB00086
DB13866,Etynodiol may decrease the anticoagulant activities of Streptokinase.,Etynodiol,DB00086
DB13981,Nomegestrol acetate may decrease the anticoagulant activities of Streptokinase.,Nomegestrol acetate,DB00086
DB14570,Hydroxyprogesterone may decrease the anticoagulant activities of Streptokinase.,Hydroxyprogesterone,DB00086
DB14678,Norethindrone enanthate may decrease the anticoagulant activities of Streptokinase.,Norethindrone enanthate,DB00086
DB14679,Quingestanol acetate may decrease the anticoagulant activities of Streptokinase.,Quingestanol acetate,DB00086
DB00233,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.,Aminosalicylic acid,DB00086
DB01294,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Streptokinase.,Bismuth subsalicylate,DB00086
DB06251,The risk or severity of bleeding can be increased when Dersalazine is combined with Streptokinase.,Dersalazine,DB00086
DB06807,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Streptokinase.,Phenyl aminosalicylate,DB00086
DB09543,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Streptokinase.,Methyl salicylate,DB00086
DB11079,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Streptokinase.,Trolamine salicylate,DB00086
DB13509,The risk or severity of bleeding can be increased when Aloxiprin is combined with Streptokinase.,Aloxiprin,DB00086
DB14006,The risk or severity of bleeding can be increased when Choline salicylate is combined with Streptokinase.,Choline salicylate,DB00086
DB14026,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Streptokinase.,Thiosalicylic acid,DB00086
DB00241,Butalbital may increase the hypotensive activities of Streptokinase.,Butalbital,DB00086
DB00312,Pentobarbital may increase the hypotensive activities of Streptokinase.,Pentobarbital,DB00086
DB00418,Secobarbital may increase the hypotensive activities of Streptokinase.,Secobarbital,DB00086
DB00474,Methohexital may increase the hypotensive activities of Streptokinase.,Methohexital,DB00086
DB00599,Thiopental may increase the hypotensive activities of Streptokinase.,Thiopental,DB00086
DB00794,Primidone may increase the hypotensive activities of Streptokinase.,Primidone,DB00086
DB00849,Methylphenobarbital may increase the hypotensive activities of Streptokinase.,Methylphenobarbital,DB00086
DB01154,Thiamylal may increase the hypotensive activities of Streptokinase.,Thiamylal,DB00086
DB01174,Phenobarbital may increase the hypotensive activities of Streptokinase.,Phenobarbital,DB00086
DB01351,Amobarbital may increase the hypotensive activities of Streptokinase.,Amobarbital,DB00086
DB01355,Hexobarbital may increase the hypotensive activities of Streptokinase.,Hexobarbital,DB00086
DB01483,Barbital may increase the hypotensive activities of Streptokinase.,Barbital,DB00086
DB09001,Barbexaclone may increase the hypotensive activities of Streptokinase.,Barbexaclone,DB00086
DB00237,Butabarbital may increase the hypotensive activities of Streptokinase.,Butabarbital,DB00086
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Streptokinase.,Abciximab,DB00086
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.,Eptifibatide,DB00086
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Streptokinase.,Ticlopidine,DB00086
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Streptokinase.,Anagrelide,DB00086
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Streptokinase.,Clopidogrel,DB00086
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Streptokinase.,Tirofiban,DB00086
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Streptokinase.,Dipyridamole,DB00086
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Streptokinase.,Iloprost,DB00086
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptokinase.,Sulfinpyrazone,DB00086
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Streptokinase.,Cilostazol,DB00086
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Streptokinase.,Ridogrel,DB00086
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Streptokinase.,Sevoflurane,DB00086
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Streptokinase.,Epoprostenol,DB00086
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Streptokinase.,Resveratrol,DB00086
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Streptokinase.,Nimesulide,DB00086
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Streptokinase.,Tesmilifene,DB00086
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Streptokinase.,Defibrotide,DB00086
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Streptokinase.,Beraprost,DB00086
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Streptokinase.,Ibudilast,DB00086
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Streptokinase.,Andrographolide,DB00086
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptokinase.,Caplacizumab,DB00086
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Streptokinase.,Prasugrel,DB00086
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Streptokinase.,Cangrelor,DB00086
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Streptokinase.,Tranilast,DB00086
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Streptokinase.,Triflusal,DB00086
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Streptokinase.,Ticagrelor,DB00086
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Streptokinase.,Icosapent ethyl,DB00086
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Streptokinase.,Trapidil,DB00086
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Streptokinase.,Naftopidil,DB00086
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Streptokinase.,Sarpogrelate,DB00086
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Streptokinase.,Ifetroban,DB00086
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Streptokinase.,Nitroaspirin,DB00086
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Streptokinase.,Ketanserin,DB00086
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Streptokinase.,Indobufen,DB00086
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Streptokinase.,Butylphthalide,DB00086
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Streptokinase.,Hydroxytyrosol,DB00086
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Streptokinase.,Ramatroban,DB00086
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Streptokinase.,Picotamide,DB00086
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Streptokinase.,Cloricromen,DB00086
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Streptokinase.,Linsidomine,DB00086
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Streptokinase.,Buflomedil,DB00086
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Streptokinase.,Relcovaptan,DB00086
DB00374,The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.,Treprostinil,DB00086
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.,Aldesleukin,DB00086
DB00232,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.,Methyclothiazide,DB00086
DB00268,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropinirole.,Ropinirole,DB00086
DB00295,The risk or severity of adverse effects can be increased when Streptokinase is combined with Morphine.,Morphine,DB00086
DB00296,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropivacaine.,Ropivacaine,DB00086
DB00297,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bupivacaine.,Bupivacaine,DB00086
DB00323,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.,Tolcapone,DB00086
DB00334,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olanzapine.,Olanzapine,DB00086
DB00363,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clozapine.,Clozapine,DB00086
DB00384,The risk or severity of adverse effects can be increased when Streptokinase is combined with Triamterene.,Triamterene,DB00086
DB00413,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pramipexole.,Pramipexole,DB00086
DB00421,The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.,Spironolactone,DB00086
DB00435,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitric Oxide.,Nitric Oxide,DB00086
DB00458,The risk or severity of adverse effects can be increased when Streptokinase is combined with Imipramine.,Imipramine,DB00086
DB00477,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorpromazine.,Chlorpromazine,DB00086
DB00486,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nabilone.,Nabilone,DB00086
DB00489,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.,Sotalol,DB00086
DB00594,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiloride.,Amiloride,DB00086
DB00631,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clofarabine.,Clofarabine,DB00086
DB00633,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dexmedetomidine.,Dexmedetomidine,DB00086
DB00661,The risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.,Verapamil,DB00086
DB00679,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thioridazine.,Thioridazine,DB00086
DB00681,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amphotericin B.,Amphotericin B,DB00086
DB00695,The risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.,Furosemide,DB00086
DB00697,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.,Tizanidine,DB00086
DB00703,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methazolamide.,Methazolamide,DB00086
DB00706,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.,Tamsulosin,DB00086
DB00708,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.,Sufentanil,DB00086
DB00714,The risk or severity of adverse effects can be increased when Streptokinase is combined with Apomorphine.,Apomorphine,DB00086
DB00742,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.,Mannitol,DB00086
DB00753,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoflurane.,Isoflurane,DB00086
DB00755,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tretinoin.,Tretinoin,DB00086
DB00818,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propofol.,Propofol,DB00086
DB00872,The risk or severity of adverse effects can be increased when Streptokinase is combined with Conivaptan.,Conivaptan,DB00086
DB00883,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide dinitrate.,Isosorbide dinitrate,DB00086
DB00887,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bumetanide.,Bumetanide,DB00086
DB00899,The risk or severity of adverse effects can be increased when Streptokinase is combined with Remifentanil.,Remifentanil,DB00086
DB00903,The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.,Etacrynic acid,DB00086
DB00922,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levosimendan.,Levosimendan,DB00086
DB01002,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levobupivacaine.,Levobupivacaine,DB00086
DB01020,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide mononitrate.,Isosorbide mononitrate,DB00086
DB01041,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.,Thalidomide,DB00086
DB01113,The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.,Papaverine,DB00086
DB01118,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiodarone.,Amiodarone,DB00086
DB01143,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amifostine.,Amifostine,DB00086
DB01144,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diclofenamide.,Diclofenamide,DB00086
DB01159,The risk or severity of adverse effects can be increased when Streptokinase is combined with Halothane.,Halothane,DB00086
DB01169,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arsenic trioxide.,Arsenic trioxide,DB00086
DB01189,The risk or severity of adverse effects can be increased when Streptokinase is combined with Desflurane.,Desflurane,DB00086
DB01200,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bromocriptine.,Bromocriptine,DB00086
DB01224,The risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.,Quetiapine,DB00086
DB01229,The risk or severity of adverse effects can be increased when Streptokinase is combined with Paclitaxel.,Paclitaxel,DB00086
DB01242,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clomipramine.,Clomipramine,DB00086
DB01282,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carbetocin.,Carbetocin,DB00086
DB01612,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amyl Nitrite.,Amyl Nitrite,DB00086
DB04899,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nesiritide.,Nesiritide,DB00086
DB04920,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.,Clevidipine,DB00086
DB05271,The risk or severity of adverse effects can be increased when Streptokinase is combined with Rotigotine.,Rotigotine,DB00086
DB06292,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.,Dapagliflozin,DB00086
DB08907,The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.,Canagliflozin,DB00086
DB08941,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoxsuprine.,Isoxsuprine,DB00086
DB09038,The risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.,Empagliflozin,DB00086
DB09077,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.,Dinutuximab,DB00086
DB09112,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrous acid.,Nitrous acid,DB00086
DB09204,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arotinolol.,Arotinolol,DB00086
DB09227,The risk or severity of adverse effects can be increased when Streptokinase is combined with Barnidipine.,Barnidipine,DB00086
DB09232,The risk or severity of adverse effects can be increased when Streptokinase is combined with Cilnidipine.,Cilnidipine,DB00086
DB09279,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fimasartan.,Fimasartan,DB00086
DB09286,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pipamperone.,Pipamperone,DB00086
DB00187,The risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.,Esmolol,DB00086
DB00195,The risk or severity of adverse effects can be increased when Streptokinase is combined with Betaxolol.,Betaxolol,DB00086
DB00206,The risk or severity of adverse effects can be increased when Streptokinase is combined with Reserpine.,Reserpine,DB00086
DB00214,The risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.,Torasemide,DB00086
DB00264,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metoprolol.,Metoprolol,DB00086
DB00270,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isradipine.,Isradipine,DB00086
DB00275,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.,Olmesartan,DB00086
DB00310,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorthalidone.,Chlorthalidone,DB00086
DB00325,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroprusside.,Nitroprusside,DB00086
DB00335,The risk or severity of adverse effects can be increased when Streptokinase is combined with Atenolol.,Atenolol,DB00086
DB00343,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diltiazem.,Diltiazem,DB00086
DB00350,The risk or severity of adverse effects can be increased when Streptokinase is combined with Minoxidil.,Minoxidil,DB00086
DB00373,The risk or severity of adverse effects can be increased when Streptokinase is combined with Timolol.,Timolol,DB00086
DB00381,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.,Amlodipine,DB00086
DB00393,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nimodipine.,Nimodipine,DB00086
DB00401,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.,Nisoldipine,DB00086
DB00436,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.,Bendroflumethiazide,DB00086
DB00457,The risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.,Prazosin,DB00086
DB00524,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.,Metolazone,DB00086
DB00528,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lercanidipine.,Lercanidipine,DB00086
DB00571,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propranolol.,Propranolol,DB00086
DB00575,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine.,Clonidine,DB00086
DB00590,The risk or severity of adverse effects can be increased when Streptokinase is combined with Doxazosin.,Doxazosin,DB00086
DB00598,The risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.,Labetalol,DB00086
DB00612,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bisoprolol.,Bisoprolol,DB00086
DB00622,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nicardipine.,Nicardipine,DB00086
DB00657,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.,Mecamylamine,DB00086
DB00692,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phentolamine.,Phentolamine,DB00086
DB00700,The risk or severity of adverse effects can be increased when Streptokinase is combined with Eplerenone.,Eplerenone,DB00086
DB00727,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin.,Nitroglycerin,DB00086
DB00774,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydroflumethiazide.,Hydroflumethiazide,DB00086
DB00796,The risk or severity of adverse effects can be increased when Streptokinase is combined with Candesartan cilexetil.,Candesartan cilexetil,DB00086
DB00797,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolazoline.,Tolazoline,DB00086
DB00800,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fenoldopam.,Fenoldopam,DB00086
DB00808,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.,Indapamide,DB00086
DB00880,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide.,Chlorothiazide,DB00086
DB00925,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phenoxybenzamine.,Phenoxybenzamine,DB00086
DB00960,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.,Pindolol,DB00086
DB00968,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyldopa.,Methyldopa,DB00086
DB00999,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.,Hydrochlorothiazide,DB00086
DB01018,The risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.,Guanfacine,DB00086
DB01023,The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.,Felodipine,DB00086
DB01029,The risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.,Irbesartan,DB00086
DB01054,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrendipine.,Nitrendipine,DB00086
DB01119,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diazoxide.,Diazoxide,DB00086
DB01136,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carvedilol.,Carvedilol,DB00086
DB01158,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bretylium.,Bretylium,DB00086
DB01162,The risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.,Terazosin,DB00086
DB01193,The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.,Acebutolol,DB00086
DB01203,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.,Nadolol,DB00086
DB01244,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bepridil.,Bepridil,DB00086
DB01275,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydralazine.,Hydralazine,DB00086
DB01359,The risk or severity of adverse effects can be increased when Streptokinase is combined with Penbutolol.,Penbutolol,DB00086
DB01580,The risk or severity of adverse effects can be increased when Streptokinase is combined with Oxprenolol.,Oxprenolol,DB00086
DB04861,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.,Nebivolol,DB00086
DB04948,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lofexidine.,Lofexidine,DB00086
DB06712,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nilvadipine.,Nilvadipine,DB00086
DB08931,The risk or severity of adverse effects can be increased when Streptokinase is combined with Riociguat.,Riociguat,DB00086
DB08950,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indoramin.,Indoramin,DB00086
DB09026,The risk or severity of adverse effects can be increased when Streptokinase is combined with Aliskiren.,Aliskiren,DB00086
DB09235,The risk or severity of adverse effects can be increased when Streptokinase is combined with Efonidipine.,Efonidipine,DB00086
DB09242,The risk or severity of adverse effects can be increased when Streptokinase is combined with Moxonidine.,Moxonidine,DB00086
DB01115,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nifedipine.,Nifedipine,DB00086
DB03404,Hemin may increase the anticoagulant activities of Streptokinase.,Hemin,DB00086
DB13783,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Streptokinase.,Acemetacin,DB00086
DB09236,Streptokinase may increase the hypotensive activities of Lacidipine.,Lacidipine,DB00086
DB00898,Ethanol may increase the hypotensive activities of Streptokinase.,Ethanol,DB00086
DB00624,Testosterone may increase the anticoagulant activities of Streptokinase.,Testosterone,DB00086
DB01420,Testosterone propionate may increase the anticoagulant activities of Streptokinase.,Testosterone propionate,DB00086
DB01481,1-Testosterone may increase the anticoagulant activities of Streptokinase.,1-Testosterone,DB00086
DB01485,4-Hydroxytestosterone may increase the anticoagulant activities of Streptokinase.,4-Hydroxytestosterone,DB00086
DB01510,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Streptokinase.,Dehydrochloromethyltestosterone,DB00086
DB01541,Boldenone may increase the anticoagulant activities of Streptokinase.,Boldenone,DB00086
DB01543,18-methyl-19-nortestosterone may increase the anticoagulant activities of Streptokinase.,18-methyl-19-nortestosterone,DB00086
DB01564,Calusterone may increase the anticoagulant activities of Streptokinase.,Calusterone,DB00086
DB01569,Formebolone may increase the anticoagulant activities of Streptokinase.,Formebolone,DB00086
DB01572,Methyl-1-testosterone may increase the anticoagulant activities of Streptokinase.,Methyl-1-testosterone,DB00086
DB02901,Stanolone may increase the anticoagulant activities of Streptokinase.,Stanolone,DB00086
DB07447,5beta-dihydrotestosterone may increase the anticoagulant activities of Streptokinase.,5beta-dihydrotestosterone,DB00086
DB08619,Testosterone succinate may increase the anticoagulant activities of Streptokinase.,Testosterone succinate,DB00086
DB11429,Mibolerone may increase the anticoagulant activities of Streptokinase.,Mibolerone,DB00086
DB13943,Testosterone cypionate may increase the anticoagulant activities of Streptokinase.,Testosterone cypionate,DB00086
DB13944,Testosterone enanthate may increase the anticoagulant activities of Streptokinase.,Testosterone enanthate,DB00086
DB13946,Testosterone undecanoate may increase the anticoagulant activities of Streptokinase.,Testosterone undecanoate,DB00086
DB13947,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Streptokinase.,Testosterone enantate benzilic acid hydrazone,DB00086
DB13951,Stanolone acetate may increase the anticoagulant activities of Streptokinase.,Stanolone acetate,DB00086
DB13958,Trestolone acetate may increase the anticoagulant activities of Streptokinase.,Trestolone acetate,DB00086
DB14093,"(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Streptokinase.","(1,2,6,7-3H)Testosterone",DB00086
DB14655,Drostanolone propionate may increase the anticoagulant activities of Streptokinase.,Drostanolone propionate,DB00086
DB11051,The risk or severity of adverse effects can be increased when Streptokinase is combined with Azficel-T.,Azficel-T,DB00086
DB09568,The therapeutic efficacy of Streptokinase can be increased when used in combination with Omega-3-carboxylic acids.,Omega-3-carboxylic acids,DB00086
DB00258,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Streptokinase.,Calcium acetate,DB00086
DB01164,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Streptokinase.,Calcium chloride,DB00086
DB01373,The therapeutic efficacy of Calcium can be decreased when used in combination with Streptokinase.,Calcium,DB00086
DB11126,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Streptokinase.,Calcium gluconate,DB00086
DB11608,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Streptokinase.,Eftrenonacog alfa,DB00086
DB13884,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Streptokinase.,Albutrepenonacog alfa,DB00086
DB13923,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Streptokinase.,Emicizumab,DB00086
DB14738,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Streptokinase.,Turoctocog alfa pegol,DB00086
DB00025,"The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Streptokinase.","Antihemophilic factor, human recombinant",DB00086
DB00036,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Streptokinase.,Coagulation factor VIIa Recombinant Human,DB00086
DB00100,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.,Coagulation Factor IX (Recombinant),DB00086
DB01783,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Streptokinase.,Pantothenic acid,DB00086
DB01942,The therapeutic efficacy of Formic acid can be decreased when used in combination with Streptokinase.,Formic acid,DB00086
DB02261,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Streptokinase.,Platelet Activating Factor,DB00086
DB06724,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Streptokinase.,Calcium carbonate,DB00086
DB09109,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Streptokinase.,Turoctocog alfa,DB00086
DB09222,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Streptokinase.,Fibrinogen human,DB00086
DB09310,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Streptokinase.,Catridecacog,DB00086
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Streptokinase.","Antihemophilic Factor (Recombinant), PEGylated",DB00086
DB11093,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Streptokinase.,Calcium citrate,DB00086
DB11168,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Streptokinase.,Calcium threonate,DB00086
DB11311,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Streptokinase.,Prothrombin,DB00086
DB11330,The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Streptokinase.,Factor IX Complex (Human),DB00086
DB11348,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Streptokinase.,Calcium Phosphate,DB00086
DB11606,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Streptokinase.,Susoctocog alfa,DB00086
DB11668,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Streptokinase.,Rusalatide acetate,DB00086
DB12409,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Streptokinase.,Vatreptacog alfa,DB00086
DB12909,The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Streptokinase.,Factor XIII (human),DB00086
DB13133,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Streptokinase.,Von Willebrand Factor Human,DB00086
DB13148,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Streptokinase.,Coagulation factor X human,DB00086
DB13150,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Streptokinase.,Coagulation factor VII human,DB00086
DB13151,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Streptokinase.,Anti-inhibitor coagulant complex,DB00086
DB13152,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Streptokinase.,Coagulation Factor IX Human,DB00086
DB13192,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Streptokinase.,Antihemophilic factor human,DB00086
DB13197,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Streptokinase.,Kallidinogenase,DB00086
DB13201,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Streptokinase.,Trenonacog alfa,DB00086
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Streptokinase.,Nonacog beta pegol,DB00086
DB13999,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Streptokinase.,Moroctocog alfa,DB00086
DB14473,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Streptokinase.,Beroctocog alfa,DB00086
DB14562,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Streptokinase.,Andexanet alfa,DB00086
DB14577,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Streptokinase.,Calcium cation,DB00086
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Streptokinase.,Damoctocog alfa pegol,DB00086
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Streptokinase.,Fluvoxamine,DB00086
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Streptokinase.,Citalopram,DB00086
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Streptokinase.,Fluoxetine,DB00086
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Streptokinase.,Paroxetine,DB00086
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Streptokinase.,Nefazodone,DB00086
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Streptokinase.,Zimelidine,DB00086
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Streptokinase.,Dapoxetine,DB00086
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Streptokinase.,Seproxetine,DB00086
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Streptokinase.,Indalpine,DB00086
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Streptokinase.,Ritanserin,DB00086
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Streptokinase.,Alaproclate,DB00086
DB01105,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Streptokinase.,Sibutramine,DB00086
DB04896,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Streptokinase.,Milnacipran,DB00086
DB06700,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Streptokinase.,Desvenlafaxine,DB00086
DB08918,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Streptokinase.,Levomilnacipran,DB00086
DB00285,Venlafaxine may increase the antiplatelet activities of Streptokinase.,Venlafaxine,DB00086
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Streptokinase.,Bivalirudin,DB00086
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Streptokinase.,Dicoumarol,DB00086
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Streptokinase.,Argatroban,DB00086
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Streptokinase.,Phenindione,DB00086
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Streptokinase.,Fondaparinux,DB00086
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Streptokinase.,Warfarin,DB00086
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Streptokinase.,Phenprocoumon,DB00086
DB00974,The risk or severity of bleeding can be increased when Edetic acid is combined with Streptokinase.,Edetic acid,DB00086
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Streptokinase.,Acenocoumarol,DB00086
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Streptokinase.,Ximelagatran,DB00086
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Streptokinase.,Ancrod,DB00086
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Streptokinase.,Idraparinux,DB00086
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Streptokinase.,Otamixaban,DB00086
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Streptokinase.,Ferulic acid,DB00086
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Streptokinase.,Ethyl biscoumacetate,DB00086
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Streptokinase.,Dextran,DB00086
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Streptokinase.,Desirudin,DB00086
DB11268,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Streptokinase.,Protocatechualdehyde,DB00086
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Streptokinase.,Protein C,DB00086
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Streptokinase.,Antithrombin III human,DB00086
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Streptokinase.,Letaxaban,DB00086
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Streptokinase.,Darexaban,DB00086
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Streptokinase.,Nafamostat,DB00086
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Streptokinase.,Gabexate,DB00086
DB13124,The risk or severity of bleeding can be increased when Troxerutin is combined with Streptokinase.,Troxerutin,DB00086
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Streptokinase.,Fluindione,DB00086
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Streptokinase.,Protein S human,DB00086
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Streptokinase.,Melagatran,DB00086
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Streptokinase.,Potassium citrate,DB00086
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Streptokinase.,Sodium citrate,DB00086
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Streptokinase.,Tenecteplase,DB00086
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.,Drotrecogin alfa,DB00086
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Streptokinase.,Brinase,DB00086
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Streptokinase.,Saruplase,DB00086
DB04925,The risk or severity of bleeding can be increased when Streptokinase is combined with Desmoteplase.,Desmoteplase,DB00086
DB05254,The risk or severity of bleeding can be increased when Streptokinase is combined with Fibrinolysin.,Fibrinolysin,DB00086
DB06543,The risk or severity of bleeding can be increased when Streptokinase is combined with Astaxanthin.,Astaxanthin,DB00086
DB08994,The risk or severity of bleeding can be increased when Streptokinase is combined with Ditazole.,Ditazole,DB00086
DB13275,The risk or severity of bleeding can be increased when Streptokinase is combined with Clorindione.,Clorindione,DB00086
DB13347,The risk or severity of bleeding can be increased when Streptokinase is combined with Diphenadione.,Diphenadione,DB00086
DB13451,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioclomarol.,Tioclomarol,DB00086
DB00001,The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.,Lepirudin,DB00086
DB00009,The risk or severity of bleeding can be increased when Streptokinase is combined with Alteplase.,Alteplase,DB00086
DB00015,The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.,Reteplase,DB00086
DB00029,The risk or severity of bleeding can be increased when Streptokinase is combined with Anistreplase.,Anistreplase,DB00086
DB14094,The risk or severity of bleeding can be increased when Streptokinase is combined with Tocopherylquinone.,Tocopherylquinone,DB00086
DB06679,The risk or severity of bleeding can be increased when Streptokinase is combined with Amediplase.,Amediplase,DB00086
DB03410,The risk or severity of bleeding can be increased when Streptokinase is combined with 4-hydroxycoumarin.,4-hydroxycoumarin,DB00086
DB08496,The risk or severity of bleeding can be increased when Streptokinase is combined with (R)-warfarin.,(R)-warfarin,DB00086
DB14055,The risk or severity of bleeding can be increased when Streptokinase is combined with (S)-Warfarin.,(S)-Warfarin,DB00086
DB12364,The risk or severity of bleeding can be increased when Streptokinase is combined with Betrixaban.,Betrixaban,DB00086
DB14598,The risk or severity of bleeding can be increased when Streptokinase is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous,DB00086
DB11154,The risk or severity of bleeding can be increased when Streptokinase is combined with Zinc citrate.,Zinc citrate,DB00086
DB11166,The risk or severity of bleeding can be increased when Streptokinase is combined with Antithrombin Alfa.,Antithrombin Alfa,DB00086
DB04665,The risk or severity of bleeding can be increased when Streptokinase is combined with Coumarin.,Coumarin,DB00086
DB14726,The risk or severity of bleeding can be increased when Streptokinase is combined with Dabigatran.,Dabigatran,DB00086
DB12726,The risk or severity of bleeding can be increased when Streptokinase is combined with Monteplase.,Monteplase,DB00086
DB00177,The risk or severity of angioedema can be increased when Streptokinase is combined with Valsartan.,Valsartan,DB00086
DB00178,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramipril.,Ramipril,DB00086
DB00230,The risk or severity of angioedema can be increased when Streptokinase is combined with Pregabalin.,Pregabalin,DB00086
DB00492,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinopril.,Fosinopril,DB00086
DB00519,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolapril.,Trandolapril,DB00086
DB00542,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazepril.,Benazepril,DB00086
DB00584,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalapril.,Enalapril,DB00086
DB00678,The risk or severity of angioedema can be increased when Streptokinase is combined with Losartan.,Losartan,DB00086
DB00691,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexipril.,Moexipril,DB00086
DB00722,The risk or severity of angioedema can be increased when Streptokinase is combined with Lisinopril.,Lisinopril,DB00086
DB00790,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindopril.,Perindopril,DB00086
DB00876,The risk or severity of angioedema can be increased when Streptokinase is combined with Eprosartan.,Eprosartan,DB00086
DB00877,The risk or severity of angioedema can be increased when Streptokinase is combined with Sirolimus.,Sirolimus,DB00086
DB00881,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinapril.,Quinapril,DB00086
DB00886,The risk or severity of angioedema can be increased when Streptokinase is combined with Omapatrilat.,Omapatrilat,DB00086
DB00966,The risk or severity of angioedema can be increased when Streptokinase is combined with Telmisartan.,Telmisartan,DB00086
DB01050,The risk or severity of angioedema can be increased when Streptokinase is combined with Ibuprofen.,Ibuprofen,DB00086
DB01180,The risk or severity of angioedema can be increased when Streptokinase is combined with Rescinnamine.,Rescinnamine,DB00086
DB01197,The risk or severity of angioedema can be increased when Streptokinase is combined with Captopril.,Captopril,DB00086
DB01261,The risk or severity of angioedema can be increased when Streptokinase is combined with Sitagliptin.,Sitagliptin,DB00086
DB01340,The risk or severity of angioedema can be increased when Streptokinase is combined with Cilazapril.,Cilazapril,DB00086
DB01342,The risk or severity of angioedema can be increased when Streptokinase is combined with Forasartan.,Forasartan,DB00086
DB01347,The risk or severity of angioedema can be increased when Streptokinase is combined with Saprisartan.,Saprisartan,DB00086
DB01348,The risk or severity of angioedema can be increased when Streptokinase is combined with Spirapril.,Spirapril,DB00086
DB04876,The risk or severity of angioedema can be increased when Streptokinase is combined with Vildagliptin.,Vildagliptin,DB00086
DB06011,The risk or severity of angioedema can be increased when Streptokinase is combined with AMG-222.,AMG-222,DB00086
DB06127,The risk or severity of angioedema can be increased when Streptokinase is combined with Bisegliptin.,Bisegliptin,DB00086
DB06196,The risk or severity of angioedema can be increased when Streptokinase is combined with Icatibant.,Icatibant,DB00086
DB06203,The risk or severity of angioedema can be increased when Streptokinase is combined with Alogliptin.,Alogliptin,DB00086
DB06245,The risk or severity of angioedema can be increased when Streptokinase is combined with Lanoteplase.,Lanoteplase,DB00086
DB06287,The risk or severity of angioedema can be increased when Streptokinase is combined with Temsirolimus.,Temsirolimus,DB00086
DB06335,The risk or severity of angioedema can be increased when Streptokinase is combined with Saxagliptin.,Saxagliptin,DB00086
DB08382,The risk or severity of angioedema can be increased when Streptokinase is combined with Gosogliptin.,Gosogliptin,DB00086
DB08822,The risk or severity of angioedema can be increased when Streptokinase is combined with Azilsartan medoxomil.,Azilsartan medoxomil,DB00086
DB08836,The risk or severity of angioedema can be increased when Streptokinase is combined with Temocapril.,Temocapril,DB00086
DB08882,The risk or severity of angioedema can be increased when Streptokinase is combined with Linagliptin.,Linagliptin,DB00086
DB09292,The risk or severity of angioedema can be increased when Streptokinase is combined with Sacubitril.,Sacubitril,DB00086
DB09477,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalaprilat.,Enalaprilat,DB00086
DB11723,The risk or severity of angioedema can be increased when Streptokinase is combined with Dutogliptin.,Dutogliptin,DB00086
DB11783,The risk or severity of angioedema can be increased when Streptokinase is combined with Imidapril.,Imidapril,DB00086
DB11950,The risk or severity of angioedema can be increased when Streptokinase is combined with Teneligliptin.,Teneligliptin,DB00086
DB11992,The risk or severity of angioedema can be increased when Streptokinase is combined with Omarigliptin.,Omarigliptin,DB00086
DB12268,The risk or severity of angioedema can be increased when Streptokinase is combined with Carmegliptin.,Carmegliptin,DB00086
DB12412,The risk or severity of angioedema can be increased when Streptokinase is combined with Gemigliptin.,Gemigliptin,DB00086
DB12417,The risk or severity of angioedema can be increased when Streptokinase is combined with Anagliptin.,Anagliptin,DB00086
DB12625,The risk or severity of angioedema can be increased when Streptokinase is combined with Evogliptin.,Evogliptin,DB00086
DB13166,The risk or severity of angioedema can be increased when Streptokinase is combined with Zofenopril.,Zofenopril,DB00086
DB13312,The risk or severity of angioedema can be increased when Streptokinase is combined with Delapril.,Delapril,DB00086
DB14125,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazeprilat.,Benazeprilat,DB00086
DB14207,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinoprilat.,Fosinoprilat,DB00086
DB14208,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramiprilat.,Ramiprilat,DB00086
DB14209,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolaprilat.,Trandolaprilat,DB00086
DB14210,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexiprilat.,Moexiprilat,DB00086
DB14213,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindoprilat.,Perindoprilat,DB00086
DB14217,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinaprilat.,Quinaprilat,DB00086
DB14231,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinoline Yellow WS.,Quinoline Yellow WS,DB00086
DB00203,The risk or severity of hemorrhage can be increased when Streptokinase is combined with Sildenafil.,Sildenafil,DB00086
DB00008,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00086
DB00011,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n1.,Interferon alfa-n1,DB00086
DB00018,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n3.,Interferon alfa-n3,DB00086
DB00022,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00086
DB00033,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon gamma-1b.,Interferon gamma-1b,DB00086
DB00034,"The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant",DB00086
DB00056,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin,DB00086
DB00068,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.,Interferon beta-1b,DB00086
DB00069,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.,Interferon alfacon-1,DB00086
DB00073,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.,Rituximab,DB00086
DB00078,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00086
DB00087,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.,Alemtuzumab,DB00086
DB00105,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00086
DB00120,The risk or severity of bleeding can be increased when Streptokinase is combined with Phenylalanine.,Phenylalanine,DB00086
DB00242,The risk or severity of bleeding can be increased when Streptokinase is combined with Cladribine.,Cladribine,DB00086
DB00262,The risk or severity of bleeding can be increased when Streptokinase is combined with Carmustine.,Carmustine,DB00086
DB00276,The risk or severity of bleeding can be increased when Streptokinase is combined with Amsacrine.,Amsacrine,DB00086
DB00291,The risk or severity of bleeding can be increased when Streptokinase is combined with Chlorambucil.,Chlorambucil,DB00086
DB00293,The risk or severity of bleeding can be increased when Streptokinase is combined with Raltitrexed.,Raltitrexed,DB00086
DB00305,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitomycin.,Mitomycin,DB00086
DB00307,The risk or severity of bleeding can be increased when Streptokinase is combined with Bexarotene.,Bexarotene,DB00086
DB00309,The risk or severity of bleeding can be increased when Streptokinase is combined with Vindesine.,Vindesine,DB00086
DB00322,The risk or severity of bleeding can be increased when Streptokinase is combined with Floxuridine.,Floxuridine,DB00086
DB00352,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioguanine.,Tioguanine,DB00086
DB00361,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinorelbine.,Vinorelbine,DB00086
DB00380,The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane.,Dexrazoxane,DB00086
DB00398,The risk or severity of bleeding can be increased when Streptokinase is combined with Sorafenib.,Sorafenib,DB00086
DB00428,The risk or severity of bleeding can be increased when Streptokinase is combined with Streptozocin.,Streptozocin,DB00086
DB00441,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemcitabine.,Gemcitabine,DB00086
DB00444,The risk or severity of bleeding can be increased when Streptokinase is combined with Teniposide.,Teniposide,DB00086
DB00445,The risk or severity of bleeding can be increased when Streptokinase is combined with Epirubicin.,Epirubicin,DB00086
DB00446,The risk or severity of bleeding can be increased when Streptokinase is combined with Chloramphenicol.,Chloramphenicol,DB00086
DB00480,The risk or severity of bleeding can be increased when Streptokinase is combined with Lenalidomide.,Lenalidomide,DB00086
DB00488,The risk or severity of bleeding can be increased when Streptokinase is combined with Altretamine.,Altretamine,DB00086
DB00495,The risk or severity of bleeding can be increased when Streptokinase is combined with Zidovudine.,Zidovudine,DB00086
DB00515,The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin.,Cisplatin,DB00086
DB00526,The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin.,Oxaliplatin,DB00086
DB00531,The risk or severity of bleeding can be increased when Streptokinase is combined with Cyclophosphamide.,Cyclophosphamide,DB00086
DB00544,The risk or severity of bleeding can be increased when Streptokinase is combined with Fluorouracil.,Fluorouracil,DB00086
DB00552,The risk or severity of bleeding can be increased when Streptokinase is combined with Pentostatin.,Pentostatin,DB00086
DB00563,The risk or severity of bleeding can be increased when Streptokinase is combined with Methotrexate.,Methotrexate,DB00086
DB00564,The risk or severity of bleeding can be increased when Streptokinase is combined with Carbamazepine.,Carbamazepine,DB00086
DB00570,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinblastine.,Vinblastine,DB00086
DB00619,The risk or severity of bleeding can be increased when Streptokinase is combined with Imatinib.,Imatinib,DB00086
DB00642,The risk or severity of bleeding can be increased when Streptokinase is combined with Pemetrexed.,Pemetrexed,DB00086
DB00694,The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.,Daunorubicin,DB00086
DB00762,The risk or severity of bleeding can be increased when Streptokinase is combined with Irinotecan.,Irinotecan,DB00086
DB00773,The risk or severity of bleeding can be increased when Streptokinase is combined with Etoposide.,Etoposide,DB00086
DB00851,The risk or severity of bleeding can be increased when Streptokinase is combined with Dacarbazine.,Dacarbazine,DB00086
DB00853,The risk or severity of bleeding can be increased when Streptokinase is combined with Temozolomide.,Temozolomide,DB00086
DB00859,The risk or severity of bleeding can be increased when Streptokinase is combined with Penicillamine.,Penicillamine,DB00086
DB00864,The risk or severity of bleeding can be increased when Streptokinase is combined with Tacrolimus.,Tacrolimus,DB00086
DB00888,The risk or severity of bleeding can be increased when Streptokinase is combined with Mechlorethamine.,Mechlorethamine,DB00086
DB00928,The risk or severity of bleeding can be increased when Streptokinase is combined with Azacitidine.,Azacitidine,DB00086
DB00958,The risk or severity of bleeding can be increased when Streptokinase is combined with Carboplatin.,Carboplatin,DB00086
DB00970,The risk or severity of bleeding can be increased when Streptokinase is combined with Dactinomycin.,Dactinomycin,DB00086
DB00987,The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.,Cytarabine,DB00086
DB00997,The risk or severity of bleeding can be increased when Streptokinase is combined with Doxorubicin.,Doxorubicin,DB00086
DB01005,The risk or severity of bleeding can be increased when Streptokinase is combined with Hydroxyurea.,Hydroxyurea,DB00086
DB01008,The risk or severity of bleeding can be increased when Streptokinase is combined with Busulfan.,Busulfan,DB00086
DB01030,The risk or severity of bleeding can be increased when Streptokinase is combined with Topotecan.,Topotecan,DB00086
DB01033,The risk or severity of bleeding can be increased when Streptokinase is combined with Mercaptopurine.,Mercaptopurine,DB00086
DB01042,The risk or severity of bleeding can be increased when Streptokinase is combined with Melphalan.,Melphalan,DB00086
DB01073,The risk or severity of bleeding can be increased when Streptokinase is combined with Fludarabine.,Fludarabine,DB00086
DB01099,The risk or severity of bleeding can be increased when Streptokinase is combined with Flucytosine.,Flucytosine,DB00086
DB01101,The risk or severity of bleeding can be increased when Streptokinase is combined with Capecitabine.,Capecitabine,DB00086
DB01177,The risk or severity of bleeding can be increased when Streptokinase is combined with Idarubicin.,Idarubicin,DB00086
DB01204,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitoxantrone.,Mitoxantrone,DB00086
DB01206,The risk or severity of bleeding can be increased when Streptokinase is combined with Lomustine.,Lomustine,DB00086
DB01248,The risk or severity of bleeding can be increased when Streptokinase is combined with Docetaxel.,Docetaxel,DB00086
DB01262,The risk or severity of bleeding can be increased when Streptokinase is combined with Decitabine.,Decitabine,DB00086
DB01280,The risk or severity of bleeding can be increased when Streptokinase is combined with Nelarabine.,Nelarabine,DB00086
DB01590,The risk or severity of bleeding can be increased when Streptokinase is combined with Everolimus.,Everolimus,DB00086
DB02546,The risk or severity of bleeding can be increased when Streptokinase is combined with Vorinostat.,Vorinostat,DB00086
DB04572,The risk or severity of bleeding can be increased when Streptokinase is combined with Thiotepa.,Thiotepa,DB00086
DB04845,The risk or severity of bleeding can be increased when Streptokinase is combined with Ixabepilone.,Ixabepilone,DB00086
DB04868,The risk or severity of bleeding can be increased when Streptokinase is combined with Nilotinib.,Nilotinib,DB00086
DB05015,The risk or severity of bleeding can be increased when Streptokinase is combined with Belinostat.,Belinostat,DB00086
DB05109,The risk or severity of bleeding can be increased when Streptokinase is combined with Trabectedin.,Trabectedin,DB00086
DB05258,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa.,Interferon alfa,DB00086
DB05472,The risk or severity of bleeding can be increased when Streptokinase is combined with omega interferon.,omega interferon,DB00086
DB05773,The risk or severity of bleeding can be increased when Streptokinase is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00086
DB06616,The risk or severity of bleeding can be increased when Streptokinase is combined with Bosutinib.,Bosutinib,DB00086
DB06769,The risk or severity of bleeding can be increased when Streptokinase is combined with Bendamustine.,Bendamustine,DB00086
DB06772,The risk or severity of bleeding can be increased when Streptokinase is combined with Cabazitaxel.,Cabazitaxel,DB00086
DB08871,The risk or severity of bleeding can be increased when Streptokinase is combined with Eribulin.,Eribulin,DB00086
DB08877,The risk or severity of bleeding can be increased when Streptokinase is combined with Ruxolitinib.,Ruxolitinib,DB00086
DB08889,The risk or severity of bleeding can be increased when Streptokinase is combined with Carfilzomib.,Carfilzomib,DB00086
DB08895,The risk or severity of bleeding can be increased when Streptokinase is combined with Tofacitinib.,Tofacitinib,DB00086
DB08901,The risk or severity of bleeding can be increased when Streptokinase is combined with Ponatinib.,Ponatinib,DB00086
DB08910,The risk or severity of bleeding can be increased when Streptokinase is combined with Pomalidomide.,Pomalidomide,DB00086
DB09042,The risk or severity of bleeding can be increased when Streptokinase is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00086
DB09052,The risk or severity of bleeding can be increased when Streptokinase is combined with Blinatumomab.,Blinatumomab,DB00086
DB09073,The risk or severity of bleeding can be increased when Streptokinase is combined with Palbociclib.,Palbociclib,DB00086
DB09074,The risk or severity of bleeding can be increased when Streptokinase is combined with Olaparib.,Olaparib,DB00086
DB09122,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00086
DB12814,The risk or severity of bleeding can be increased when Streptokinase is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00086
DB00188,The risk or severity of bleeding can be increased when Streptokinase is combined with Bortezomib.,Bortezomib,DB00086
DB00229,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotiam.,Cefotiam,DB00086
DB00267,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmenoxime.,Cefmenoxime,DB00086
DB00274,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmetazole.,Cefmetazole,DB00086
DB00430,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpiramide.,Cefpiramide,DB00086
DB00438,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftazidime.,Ceftazidime,DB00086
DB00447,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Loracarbef.,Loracarbef,DB00086
DB00456,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefalotin.,Cefalotin,DB00086
DB00493,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotaxime.,Cefotaxime,DB00086
DB00535,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefdinir.,Cefdinir,DB00086
DB00567,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephalexin.,Cephalexin,DB00086
DB00671,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefixime.,Cefixime,DB00086
DB00689,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephaloglycin.,Cephaloglycin,DB00086
DB00833,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaclor.,Cefaclor,DB00086
DB00923,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceforanide.,Ceforanide,DB00086
DB01066,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefditoren.,Cefditoren,DB00086
DB01112,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefuroxime.,Cefuroxime,DB00086
DB01139,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefapirin.,Cefapirin,DB00086
DB01140,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefadroxil.,Cefadroxil,DB00086
DB01150,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefprozil.,Cefprozil,DB00086
DB01212,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftriaxone.,Ceftriaxone,DB00086
DB01326,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole.,Cefamandole,DB00086
DB01327,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazolin.,Cefazolin,DB00086
DB01328,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefonicid.,Cefonicid,DB00086
DB01329,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoperazone.,Cefoperazone,DB00086
DB01330,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotetan.,Cefotetan,DB00086
DB01331,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoxitin.,Cefoxitin,DB00086
DB01332,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftizoxime.,Ceftizoxime,DB00086
DB01333,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefradine.,Cefradine,DB00086
DB01413,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefepime.,Cefepime,DB00086
DB01414,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefacetrile.,Cefacetrile,DB00086
DB01415,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftibuten.,Ceftibuten,DB00086
DB01416,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpodoxime.,Cefpodoxime,DB00086
DB04570,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Latamoxef.,Latamoxef,DB00086
DB04918,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftobiprole.,Ceftobiprole,DB00086
DB06590,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil,DB00086
DB09008,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaloridine.,Cefaloridine,DB00086
DB09050,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftolozane.,Ceftolozane,DB00086
DB09062,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefminox.,Cefminox,DB00086
DB11367,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefroxadine.,Cefroxadine,DB00086
DB11935,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Flomoxef.,Flomoxef,DB00086
DB13266,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefatrizine.,Cefatrizine,DB00086
DB13461,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefcapene.,Cefcapene,DB00086
DB13470,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefodizime.,Cefodizime,DB00086
DB13499,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefsulodin.,Cefsulodin,DB00086
DB13504,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefetamet.,Cefetamet,DB00086
DB13638,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefbuperazone.,Cefbuperazone,DB00086
DB13667,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefozopran.,Cefozopran,DB00086
DB13682,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpirome.,Cefpirome,DB00086
DB13778,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazedone.,Cefazedone,DB00086
DB13821,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftezole.,Ceftezole,DB00086
DB14725,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate,DB00086
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Streptokinase.,Doxycycline,DB00086
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Streptokinase.,Azithromycin,DB00086
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Streptokinase.,Omega-3-acid ethyl esters,DB00086
DB00212,Streptokinase may increase the hypotensive activities of Remikiren.,Remikiren,DB00086
DB00217,Streptokinase may increase the hypotensive activities of Bethanidine.,Bethanidine,DB00086
DB00226,Streptokinase may increase the hypotensive activities of Guanadrel.,Guanadrel,DB00086
DB00559,Streptokinase may increase the hypotensive activities of Bosentan.,Bosentan,DB00086
DB00606,Streptokinase may increase the hypotensive activities of Cyclothiazide.,Cyclothiazide,DB00086
DB00616,Streptokinase may increase the hypotensive activities of Candoxatril.,Candoxatril,DB00086
DB00629,Streptokinase may increase the hypotensive activities of Guanabenz.,Guanabenz,DB00086
DB00765,Streptokinase may increase the hypotensive activities of Metyrosine.,Metyrosine,DB00086
DB00785,Streptokinase may increase the hypotensive activities of Cryptenamine.,Cryptenamine,DB00086
DB00820,Streptokinase may increase the hypotensive activities of Tadalafil.,Tadalafil,DB00086
DB00866,Streptokinase may increase the hypotensive activities of Alprenolol.,Alprenolol,DB00086
DB01021,Streptokinase may increase the hypotensive activities of Trichlormethiazide.,Trichlormethiazide,DB00086
DB01089,Streptokinase may increase the hypotensive activities of Deserpidine.,Deserpidine,DB00086
DB01090,Streptokinase may increase the hypotensive activities of Pentolinium.,Pentolinium,DB00086
DB01116,Streptokinase may increase the hypotensive activities of Trimethaphan.,Trimethaphan,DB00086
DB01170,Streptokinase may increase the hypotensive activities of Guanethidine.,Guanethidine,DB00086
DB01295,Streptokinase may increase the hypotensive activities of Bevantolol.,Bevantolol,DB00086
DB01297,Streptokinase may increase the hypotensive activities of Practolol.,Practolol,DB00086
DB01324,Streptokinase may increase the hypotensive activities of Polythiazide.,Polythiazide,DB00086
DB01388,Streptokinase may increase the hypotensive activities of Mibefradil.,Mibefradil,DB00086
DB03322,Streptokinase may increase the hypotensive activities of Dexpropranolol.,Dexpropranolol,DB00086
DB04831,Streptokinase may increase the hypotensive activities of Tienilic acid.,Tienilic acid,DB00086
DB04840,Streptokinase may increase the hypotensive activities of Debrisoquine.,Debrisoquine,DB00086
DB04846,Streptokinase may increase the hypotensive activities of Celiprolol.,Celiprolol,DB00086
DB06268,Streptokinase may increase the hypotensive activities of Sitaxentan.,Sitaxentan,DB00086
DB06403,Streptokinase may increase the hypotensive activities of Ambrisentan.,Ambrisentan,DB00086
DB06445,Streptokinase may increase the hypotensive activities of Diethylnorspermine.,Diethylnorspermine,DB00086
DB06762,Streptokinase may increase the hypotensive activities of Pinacidil.,Pinacidil,DB00086
DB08808,Streptokinase may increase the hypotensive activities of Bupranolol.,Bupranolol,DB00086
DB08932,Streptokinase may increase the hypotensive activities of Macitentan.,Macitentan,DB00086
DB08952,Streptokinase may increase the hypotensive activities of Indenolol.,Indenolol,DB00086
DB08960,Streptokinase may increase the hypotensive activities of Hexamethonium.,Hexamethonium,DB00086
DB09206,Streptokinase may increase the hypotensive activities of Trimazosin.,Trimazosin,DB00086
DB09238,Streptokinase may increase the hypotensive activities of Manidipine.,Manidipine,DB00086
DB09239,Streptokinase may increase the hypotensive activities of Niguldipine.,Niguldipine,DB00086
DB09363,Streptokinase may increase the hypotensive activities of Rauwolfia serpentina root.,Rauwolfia serpentina root,DB00086
DB11362,Streptokinase may increase the hypotensive activities of Selexipag.,Selexipag,DB00086
DB11720,Streptokinase may increase the hypotensive activities of Angiotensin 1-7.,Angiotensin 1-7,DB00086
DB11738,Streptokinase may increase the hypotensive activities of Rilmenidine.,Rilmenidine,DB00086
DB11770,Streptokinase may increase the hypotensive activities of Talinolol.,Talinolol,DB00086
DB12054,Streptokinase may increase the hypotensive activities of BQ-123.,BQ-123,DB00086
DB12093,Streptokinase may increase the hypotensive activities of Tetrahydropalmatine.,Tetrahydropalmatine,DB00086
DB12212,Streptokinase may increase the hypotensive activities of Landiolol.,Landiolol,DB00086
DB12661,Streptokinase may increase the hypotensive activities of Urapidil.,Urapidil,DB00086
DB12766,Streptokinase may increase the hypotensive activities of Cicletanine.,Cicletanine,DB00086
DB12945,Streptokinase may increase the hypotensive activities of Dihydralazine.,Dihydralazine,DB00086
DB13211,Streptokinase may increase the hypotensive activities of Guanoxan.,Guanoxan,DB00086
DB13374,Streptokinase may increase the hypotensive activities of Vincamine.,Vincamine,DB00086
DB13410,Streptokinase may increase the hypotensive activities of Guanoxabenz.,Guanoxabenz,DB00086
DB13429,Streptokinase may increase the hypotensive activities of Tolonidine.,Tolonidine,DB00086
DB13435,Streptokinase may increase the hypotensive activities of Endralazine.,Endralazine,DB00086
DB13443,Streptokinase may increase the hypotensive activities of Esatenolol.,Esatenolol,DB00086
DB13452,Streptokinase may increase the hypotensive activities of Cadralazine.,Cadralazine,DB00086
DB13508,Streptokinase may increase the hypotensive activities of Cloranolol.,Cloranolol,DB00086
DB13532,Streptokinase may increase the hypotensive activities of Cyclopenthiazide.,Cyclopenthiazide,DB00086
DB13575,Streptokinase may increase the hypotensive activities of Bietaserpine.,Bietaserpine,DB00086
DB13604,Streptokinase may increase the hypotensive activities of Guanazodine.,Guanazodine,DB00086
DB13631,Streptokinase may increase the hypotensive activities of Methoserpidine.,Methoserpidine,DB00086
DB13757,Streptokinase may increase the hypotensive activities of Epanolol.,Epanolol,DB00086
DB13779,Streptokinase may increase the hypotensive activities of Guanoclor.,Guanoclor,DB00086
DB13801,Streptokinase may increase the hypotensive activities of Muzolimine.,Muzolimine,DB00086
DB13803,Streptokinase may increase the hypotensive activities of Xipamide.,Xipamide,DB00086
DB13919,Streptokinase may increase the hypotensive activities of Candesartan.,Candesartan,DB00086
DB14068,Streptokinase may increase the hypotensive activities of Dexniguldipine.,Dexniguldipine,DB00086
DB00945,Acetylsalicylic acid may increase the anticoagulant activities of Streptokinase.,Acetylsalicylic acid,DB00086
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Streptokinase.,Tazobactam,DB00086
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Streptokinase.,Erythromycin,DB00086
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Streptokinase.,Trazodone,DB00086
DB00620,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triamcinolone.,Triamcinolone,DB00086
DB09079,The risk or severity of bleeding can be increased when Streptokinase is combined with Nintedanib.,Nintedanib,DB00086
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Streptokinase.,Escitalopram,DB00086
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Streptokinase.,Sertraline,DB00086
DB00562,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Benzthiazide.,Benzthiazide,DB00086
DB13430,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mebutizide.,Mebutizide,DB00086
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.,Denosumab,DB00087
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.,Etanercept,DB00087
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.,Peginterferon alfa-2a,DB00087
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alemtuzumab.,Interferon alfa-n1,DB00087
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alemtuzumab.,Interferon alfa-n3,DB00087
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.,Peginterferon alfa-2b,DB00087
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.,Anakinra,DB00087
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alemtuzumab.,Interferon gamma-1b,DB00087
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alemtuzumab.","Interferon alfa-2a, Recombinant",DB00087
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.,Aldesleukin,DB00087
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab.,Adalimumab,DB00087
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.,Gemtuzumab ozogamicin,DB00087
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.,Pegaspargase,DB00087
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.,Infliximab,DB00087
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.,Interferon beta-1b,DB00087
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.,Interferon alfacon-1,DB00087
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.,Rituximab,DB00087
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.,Basiliximab,DB00087
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.,Muromonab,DB00087
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.,Ibritumomab tiuxetan,DB00087
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.,Tositumomab,DB00087
DB00092,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.,Alefacept,DB00087
DB00095,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.,Efalizumab,DB00087
DB00098,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00087
DB00105,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00087
DB00111,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.,Daclizumab,DB00087
DB00112,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.,Bevacizumab,DB00087
DB00120,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.,Phenylalanine,DB00087
DB00180,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flunisolide.,Flunisolide,DB00087
DB00188,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib.,Bortezomib,DB00087
DB00242,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cladribine.,Cladribine,DB00087
DB00262,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine.,Carmustine,DB00087
DB00276,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amsacrine.,Amsacrine,DB00087
DB00290,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin.,Bleomycin,DB00087
DB00291,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chlorambucil.,Chlorambucil,DB00087
DB00293,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raltitrexed.,Raltitrexed,DB00087
DB00305,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitomycin.,Mitomycin,DB00087
DB00307,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene.,Bexarotene,DB00087
DB00309,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vindesine.,Vindesine,DB00087
DB00322,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Floxuridine.,Floxuridine,DB00087
DB00328,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indomethacin.,Indomethacin,DB00087
DB00352,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tioguanine.,Tioguanine,DB00087
DB00361,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinorelbine.,Vinorelbine,DB00087
DB00380,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane.,Dexrazoxane,DB00087
DB00394,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00087
DB00398,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sorafenib.,Sorafenib,DB00087
DB00428,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Streptozocin.,Streptozocin,DB00087
DB00432,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trifluridine.,Trifluridine,DB00087
DB00441,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gemcitabine.,Gemcitabine,DB00087
DB00443,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Betamethasone.,Betamethasone,DB00087
DB00444,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teniposide.,Teniposide,DB00087
DB00445,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epirubicin.,Epirubicin,DB00087
DB00446,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chloramphenicol.,Chloramphenicol,DB00087
DB00480,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lenalidomide.,Lenalidomide,DB00087
DB00488,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Altretamine.,Altretamine,DB00087
DB00495,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zidovudine.,Zidovudine,DB00087
DB00515,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.,Cisplatin,DB00087
DB00526,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.,Oxaliplatin,DB00087
DB00531,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.,Cyclophosphamide,DB00087
DB00541,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine.,Vincristine,DB00087
DB00544,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil.,Fluorouracil,DB00087
DB00550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.,Propylthiouracil,DB00087
DB00552,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentostatin.,Pentostatin,DB00087
DB00563,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methotrexate.,Methotrexate,DB00087
DB00564,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carbamazepine.,Carbamazepine,DB00087
DB00570,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinblastine.,Vinblastine,DB00087
DB00588,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone propionate.,Fluticasone propionate,DB00087
DB00591,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00087
DB00601,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Linezolid.,Linezolid,DB00087
DB00619,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imatinib.,Imatinib,DB00087
DB00620,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triamcinolone.,Triamcinolone,DB00087
DB00631,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine.,Clofarabine,DB00087
DB00635,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisone.,Prednisone,DB00087
DB00642,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pemetrexed.,Pemetrexed,DB00087
DB00687,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludrocortisone.,Fludrocortisone,DB00087
DB00688,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00087
DB00694,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.,Daunorubicin,DB00087
DB00755,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tretinoin.,Tretinoin,DB00087
DB00762,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.,Irinotecan,DB00087
DB00763,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methimazole.,Methimazole,DB00087
DB00764,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone.,Mometasone,DB00087
DB00773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etoposide.,Etoposide,DB00087
DB00795,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulfasalazine.,Sulfasalazine,DB00087
DB00851,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.,Dacarbazine,DB00087
DB00853,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temozolomide.,Temozolomide,DB00087
DB00859,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Penicillamine.,Penicillamine,DB00087
DB00860,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone.,Prednisolone,DB00087
DB00877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirolimus.,Sirolimus,DB00087
DB00888,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mechlorethamine.,Mechlorethamine,DB00087
DB00928,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azacitidine.,Azacitidine,DB00087
DB00958,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.,Carboplatin,DB00087
DB00959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone.,Methylprednisolone,DB00087
DB00970,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin.,Dactinomycin,DB00087
DB00987,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.,Cytarabine,DB00087
DB00993,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azathioprine.,Azathioprine,DB00087
DB00997,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxorubicin.,Doxorubicin,DB00087
DB01005,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxyurea.,Hydroxyurea,DB00087
DB01008,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Busulfan.,Busulfan,DB00087
DB01024,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolic acid.,Mycophenolic acid,DB00087
DB01030,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.,Topotecan,DB00087
DB01033,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mercaptopurine.,Mercaptopurine,DB00087
DB01041,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thalidomide.,Thalidomide,DB00087
DB01042,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melphalan.,Melphalan,DB00087
DB01073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludarabine.,Fludarabine,DB00087
DB01099,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flucytosine.,Flucytosine,DB00087
DB01101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capecitabine.,Capecitabine,DB00087
DB01108,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trilostane.,Trilostane,DB00087
DB01168,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine.,Procarbazine,DB00087
DB01169,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide.,Arsenic trioxide,DB00087
DB01177,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarubicin.,Idarubicin,DB00087
DB01181,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ifosfamide.,Ifosfamide,DB00087
DB01196,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.,Estramustine,DB00087
DB01204,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.,Mitoxantrone,DB00087
DB01206,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lomustine.,Lomustine,DB00087
DB01222,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Budesonide.,Budesonide,DB00087
DB01229,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paclitaxel.,Paclitaxel,DB00087
DB01234,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.,Dexamethasone,DB00087
DB01248,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Docetaxel.,Docetaxel,DB00087
DB01254,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.,Dasatinib,DB00087
DB01257,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eculizumab.,Eculizumab,DB00087
DB01262,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Decitabine.,Decitabine,DB00087
DB01268,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sunitinib.,Sunitinib,DB00087
DB01280,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nelarabine.,Nelarabine,DB00087
DB01281,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept.,Abatacept,DB00087
DB01285,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Corticotropin.,Corticotropin,DB00087
DB01380,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortisone acetate.,Cortisone acetate,DB00087
DB01384,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paramethasone.,Paramethasone,DB00087
DB01394,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Colchicine.,Colchicine,DB00087
DB01410,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ciclesonide.,Ciclesonide,DB00087
DB01423,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Stepronin.,Stepronin,DB00087
DB01590,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Everolimus.,Everolimus,DB00087
DB01611,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00087
DB01816,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Castanospermine.,Castanospermine,DB00087
DB02546,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vorinostat.,Vorinostat,DB00087
DB02806,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00087
DB03523,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brequinar.,Brequinar,DB00087
DB04572,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thiotepa.,Thiotepa,DB00087
DB04630,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aldosterone.,Aldosterone,DB00087
DB04845,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixabepilone.,Ixabepilone,DB00087
DB04868,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nilotinib.,Nilotinib,DB00087
DB04951,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirfenidone.,Pirfenidone,DB00087
DB04956,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Afelimomab.,Afelimomab,DB00087
DB05015,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat.,Belinostat,DB00087
DB05109,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trabectedin.,Trabectedin,DB00087
DB05258,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa.,Interferon alfa,DB00087
DB05259,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glatiramer.,Glatiramer,DB00087
DB05260,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gallium nitrate.,Gallium nitrate,DB00087
DB05459,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Briakinumab.,Briakinumab,DB00087
DB05472,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with omega interferon.,omega interferon,DB00087
DB05676,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apremilast.,Apremilast,DB00087
DB05773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00087
DB06168,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Canakinumab.,Canakinumab,DB00087
DB06273,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tocilizumab.,Tocilizumab,DB00087
DB06287,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temsirolimus.,Temsirolimus,DB00087
DB06372,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilonacept.,Rilonacept,DB00087
DB06589,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pazopanib.,Pazopanib,DB00087
DB06603,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panobinostat.,Panobinostat,DB00087
DB06612,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mepolizumab.,Mepolizumab,DB00087
DB06616,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib.,Bosutinib,DB00087
DB06662,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.,Abetimus,DB00087
DB06674,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Golimumab.,Golimumab,DB00087
DB06681,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belatacept.,Belatacept,DB00087
DB06769,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine.,Bendamustine,DB00087
DB06772,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cabazitaxel.,Cabazitaxel,DB00087
DB06813,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate.,Pralatrexate,DB00087
DB08059,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Wortmannin.,Wortmannin,DB00087
DB08870,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00087
DB08871,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin.,Eribulin,DB00087
DB08877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.,Ruxolitinib,DB00087
DB08879,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belimumab.,Belimumab,DB00087
DB08880,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide.,Teriflunomide,DB00087
DB08889,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carfilzomib.,Carfilzomib,DB00087
DB08901,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponatinib.,Ponatinib,DB00087
DB08904,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Certolizumab pegol.,Certolizumab pegol,DB00087
DB08906,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone furoate.,Fluticasone furoate,DB00087
DB08908,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00087
DB08910,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.,Pomalidomide,DB00087
DB08935,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obinutuzumab.,Obinutuzumab,DB00087
DB08970,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednidene.,Fluprednidene,DB00087
DB08971,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortolone.,Fluocortolone,DB00087
DB09029,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.,Secukinumab,DB00087
DB09033,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vedolizumab.,Vedolizumab,DB00087
DB09036,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siltuximab.,Siltuximab,DB00087
DB09052,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blinatumomab.,Blinatumomab,DB00087
DB09053,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib.,Ibrutinib,DB00087
DB09054,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib.,Idelalisib,DB00087
DB09073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palbociclib.,Palbociclib,DB00087
DB09074,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.,Olaparib,DB00087
DB09077,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dinutuximab.,Dinutuximab,DB00087
DB09082,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vilanterol.,Vilanterol,DB00087
DB09091,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tixocortol.,Tixocortol,DB00087
DB09122,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00087
DB09312,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00087
DB09378,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednisolone.,Fluprednisolone,DB00087
DB09383,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Meprednisone.,Meprednisone,DB00087
DB11466,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tepoxalin.,Tepoxalin,DB00087
DB11487,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00087
DB11529,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melengestrol.,Melengestrol,DB00087
DB11569,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab.,Ixekizumab,DB00087
DB11580,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ravulizumab.,Ravulizumab,DB00087
DB11616,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirarubicin.,Pirarubicin,DB00087
DB11693,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Voclosporin.,Voclosporin,DB00087
DB11708,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peficitinib.,Peficitinib,DB00087
DB11750,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clobetasol.,Clobetasol,DB00087
DB11767,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sarilumab.,Sarilumab,DB00087
DB11776,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab.,Brodalumab,DB00087
DB11803,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab.,Sirukumab,DB00087
DB11817,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Baricitinib.,Baricitinib,DB00087
DB11834,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.,Guselkumab,DB00087
DB11921,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deflazacort.,Deflazacort,DB00087
DB12025,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triptolide.,Triptolide,DB00087
DB12371,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siponimod.,Siponimod,DB00087
DB12612,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanimod.,Ozanimod,DB00087
DB12617,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mizoribine.,Mizoribine,DB00087
DB12692,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gusperimus.,Gusperimus,DB00087
DB12814,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00087
DB12902,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trofosfamide.,Trofosfamide,DB00087
DB12947,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxifluridine.,Doxifluridine,DB00087
DB12991,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deoxyspergualin.,Deoxyspergualin,DB00087
DB12996,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Acteoside.,Acteoside,DB00087
DB13003,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortivazol.,Cortivazol,DB00087
DB13014,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hypericin.,Hypericin,DB00087
DB13068,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00087
DB13208,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednylidene.,Prednylidene,DB00087
DB13223,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortin.,Fluocortin,DB00087
DB13241,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Begelomab.,Begelomab,DB00087
DB13491,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluperolone.,Fluperolone,DB00087
DB13664,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Formocortal.,Formocortal,DB00087
DB13728,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Halometasone.,Halometasone,DB00087
DB13843,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cloprednol.,Cloprednol,DB00087
DB13856,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluclorolone.,Fluclorolone,DB00087
DB13867,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone.,Fluticasone,DB00087
DB14066,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetrandrine.,Tetrandrine,DB00087
DB14219,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00087
DB14512,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone furoate.,Mometasone furoate,DB00087
DB14538,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00087
DB14539,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00087
DB14545,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00087
DB14724,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab.,Emapalumab,DB00087
DB14762,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Risankizumab.,Risankizumab,DB00087
DB14919,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.,Rozanolixizumab,DB00087
DB15253,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleselumab.,Bleselumab,DB00087
DB00108,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.,Natalizumab,DB00087
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.,Pimecrolimus,DB00087
DB01656,Roflumilast may increase the immunosuppressive activities of Alemtuzumab.,Roflumilast,DB00087
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.,Sipuleucel-T,DB00087
DB00363,The risk or severity of neutropenia can be increased when Alemtuzumab is combined with Clozapine.,Clozapine,DB00087
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.,Darbepoetin alfa,DB00087
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alemtuzumab.,Erythropoietin,DB00087
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alemtuzumab.,Peginesatide,DB00087
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.,Methoxy polyethylene glycol-epoetin beta,DB00087
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alemtuzumab.,Sulfamethoxazole,DB00087
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Alemtuzumab.,Diethylstilbestrol,DB00087
DB00269,Chlorotrianisene may increase the thrombogenic activities of Alemtuzumab.,Chlorotrianisene,DB00087
DB00286,Conjugated estrogens may increase the thrombogenic activities of Alemtuzumab.,Conjugated estrogens,DB00087
DB00655,Estrone may increase the thrombogenic activities of Alemtuzumab.,Estrone,DB00087
DB00783,Estradiol may increase the thrombogenic activities of Alemtuzumab.,Estradiol,DB00087
DB00890,Dienestrol may increase the thrombogenic activities of Alemtuzumab.,Dienestrol,DB00087
DB00977,Ethinylestradiol may increase the thrombogenic activities of Alemtuzumab.,Ethinylestradiol,DB00087
DB01357,Mestranol may increase the thrombogenic activities of Alemtuzumab.,Mestranol,DB00087
DB04573,Estriol may increase the thrombogenic activities of Alemtuzumab.,Estriol,DB00087
DB04574,Estrone sulfate may increase the thrombogenic activities of Alemtuzumab.,Estrone sulfate,DB00087
DB04575,Quinestrol may increase the thrombogenic activities of Alemtuzumab.,Quinestrol,DB00087
DB07931,Hexestrol may increase the thrombogenic activities of Alemtuzumab.,Hexestrol,DB00087
DB09070,Tibolone may increase the thrombogenic activities of Alemtuzumab.,Tibolone,DB00087
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Alemtuzumab.","Synthetic Conjugated Estrogens, A",DB00087
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Alemtuzumab.","Synthetic Conjugated Estrogens, B",DB00087
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Alemtuzumab.,Polyestradiol phosphate,DB00087
DB09381,Esterified estrogens may increase the thrombogenic activities of Alemtuzumab.,Esterified estrogens,DB00087
DB11478,Zeranol may increase the thrombogenic activities of Alemtuzumab.,Zeranol,DB00087
DB11674,Equol may increase the thrombogenic activities of Alemtuzumab.,Equol,DB00087
DB12487,Promestriene may increase the thrombogenic activities of Alemtuzumab.,Promestriene,DB00087
DB13143,Methallenestril may increase the thrombogenic activities of Alemtuzumab.,Methallenestril,DB00087
DB13386,Epimestrol may increase the thrombogenic activities of Alemtuzumab.,Epimestrol,DB00087
DB13418,Moxestrol may increase the thrombogenic activities of Alemtuzumab.,Moxestrol,DB00087
DB13952,Estradiol acetate may increase the thrombogenic activities of Alemtuzumab.,Estradiol acetate,DB00087
DB13953,Estradiol benzoate may increase the thrombogenic activities of Alemtuzumab.,Estradiol benzoate,DB00087
DB13954,Estradiol cypionate may increase the thrombogenic activities of Alemtuzumab.,Estradiol cypionate,DB00087
DB13956,Estradiol valerate may increase the thrombogenic activities of Alemtuzumab.,Estradiol valerate,DB00087
DB15334,Biochanin A may increase the thrombogenic activities of Alemtuzumab.,Biochanin A,DB00087
DB15335,Formononetin may increase the thrombogenic activities of Alemtuzumab.,Formononetin,DB00087
DB01097,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.,Leflunomide,DB00087
DB08895,Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00087
DB00072,Trastuzumab may increase the neutropenic activities of Alemtuzumab.,Trastuzumab,DB00087
DB08868,Alemtuzumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00087
DB00864,Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.,Tacrolimus,DB00087
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.,G17DT,DB00087
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alemtuzumab.,PEV3A,DB00087
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.,INGN 225,DB00087
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alemtuzumab.,Rindopepimut,DB00087
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alemtuzumab.,SRP 299,DB00087
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab.,GI-5005,DB00087
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab.,Vitespen,DB00087
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab.,TG4010,DB00087
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alemtuzumab.,Anthrax immune globulin human,DB00087
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab.","Rabies virus inactivated antigen, B",DB00087
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00087
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alemtuzumab.,Rotavirus vaccine,DB00087
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab.","Rabies virus inactivated antigen, A",DB00087
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00087
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00087
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00087
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00087
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00087
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00087
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab.,Typhoid Vi polysaccharide vaccine,DB00087
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.,Hepatitis A Vaccine,DB00087
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00087
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00087
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00087
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00087
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00087
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alemtuzumab.,Human rabies virus immune globulin,DB00087
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.,Hepatitis B Vaccine (Recombinant),DB00087
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab.,Tecemotide,DB00087
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alemtuzumab.,Typhoid vaccine,DB00087
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00087
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00087
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00087
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00087
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00087
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00087
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00087
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alemtuzumab.,Vaccinia virus strain new york city board of health live antigen,DB00087
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alemtuzumab.,Pertussis vaccine,DB00087
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00087
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.,Varicella Zoster Vaccine (Recombinant),DB00087
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab.,Modified vaccinia ankara,DB00087
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.,Eptifibatide,DB00087
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Alemtuzumab.,Ticlopidine,DB00087
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Alemtuzumab.,Anagrelide,DB00087
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Alemtuzumab.,Clopidogrel,DB00087
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Alemtuzumab.,Tirofiban,DB00087
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Alemtuzumab.,Pentoxifylline,DB00087
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Alemtuzumab.,Acetylsalicylic acid,DB00087
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Alemtuzumab.,Dipyridamole,DB00087
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Alemtuzumab.,Iloprost,DB00087
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alemtuzumab.,Sulfinpyrazone,DB00087
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Alemtuzumab.,Cilostazol,DB00087
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Alemtuzumab.,Ridogrel,DB00087
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Alemtuzumab.,Sevoflurane,DB00087
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Alemtuzumab.,Epoprostenol,DB00087
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Alemtuzumab.,Resveratrol,DB00087
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Alemtuzumab.,Nimesulide,DB00087
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Alemtuzumab.,Tesmilifene,DB00087
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Alemtuzumab.,Defibrotide,DB00087
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Alemtuzumab.,Beraprost,DB00087
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Alemtuzumab.,Ibudilast,DB00087
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Alemtuzumab.,Andrographolide,DB00087
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Alemtuzumab.,Prasugrel,DB00087
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Alemtuzumab.,Cangrelor,DB00087
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Alemtuzumab.,Tranilast,DB00087
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Alemtuzumab.,Triflusal,DB00087
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Alemtuzumab.,Ticagrelor,DB00087
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab.,Icosapent ethyl,DB00087
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Alemtuzumab.,Vorapaxar,DB00087
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Alemtuzumab.,Trapidil,DB00087
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Alemtuzumab.,Naftopidil,DB00087
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Alemtuzumab.,Sarpogrelate,DB00087
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Alemtuzumab.,Ifetroban,DB00087
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Alemtuzumab.,Nitroaspirin,DB00087
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Alemtuzumab.,Ketanserin,DB00087
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Alemtuzumab.,Indobufen,DB00087
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Alemtuzumab.,Butylphthalide,DB00087
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Alemtuzumab.,Hydroxytyrosol,DB00087
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Alemtuzumab.,Ramatroban,DB00087
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Alemtuzumab.,Picotamide,DB00087
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Alemtuzumab.,Cloricromen,DB00087
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Alemtuzumab.,Linsidomine,DB00087
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Alemtuzumab.,Buflomedil,DB00087
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Alemtuzumab.,Relcovaptan,DB00087
DB11988,Ocrelizumab may increase the immunosuppressive activities of Alemtuzumab.,Ocrelizumab,DB00087
DB13200,Alemtuzumab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00087
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.,Rubella virus vaccine,DB00087
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alemtuzumab.,Varicella Zoster Vaccine (Live/attenuated),DB00087
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain tice live antigen,DB00087
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00087
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alemtuzumab.,Yellow Fever Vaccine,DB00087
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab.,Anthrax vaccine,DB00087
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alemtuzumab.,Typhoid Vaccine Live,DB00087
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00087
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab.,BCG vaccine,DB00087
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alemtuzumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00087
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alemtuzumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00087
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alemtuzumab.,Adenovirus type 7 vaccine live,DB00087
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.,Cetuximab,DB00087
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.,Human immunoglobulin G,DB00087
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Alemtuzumab.,Omalizumab,DB00087
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Alemtuzumab.,Abciximab,DB00087
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.,Indium In-111 satumomab pendetide,DB00087
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.,Digoxin Immune Fab (Ovine),DB00087
DB00089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.,Capromab pendetide,DB00087
DB00110,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.,Palivizumab,DB00087
DB00113,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00087
DB01269,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panitumumab.,Panitumumab,DB00087
DB01270,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.,Ranibizumab,DB00087
DB04901,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab.,Galiximab,DB00087
DB04949,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pexelizumab.,Pexelizumab,DB00087
DB04958,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epratuzumab.,Epratuzumab,DB00087
DB04962,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bectumomab.,Bectumomab,DB00087
DB04964,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.,Oregovomab,DB00087
DB04988,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IGN311.,IGN311,DB00087
DB05006,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Adecatumumab.,Adecatumumab,DB00087
DB05097,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab.,Labetuzumab,DB00087
DB05101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Matuzumab.,Matuzumab,DB00087
DB05111,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fontolizumab.,Fontolizumab,DB00087
DB05136,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bavituximab.,Bavituximab,DB00087
DB05139,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CR002.,CR002,DB00087
DB05209,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozrolimupab.,Rozrolimupab,DB00087
DB05304,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Girentuximab.,Girentuximab,DB00087
DB05336,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00087
DB05405,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XTL-001.,XTL-001,DB00087
DB05437,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with NAV 1800.,NAV 1800,DB00087
DB05496,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Otelixizumab.,Otelixizumab,DB00087
DB05545,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AMG 108.,AMG 108,DB00087
DB05550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Iratumumab.,Iratumumab,DB00087
DB05555,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Enokizumab.,Enokizumab,DB00087
DB05578,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ramucirumab.,Ramucirumab,DB00087
DB05595,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Farletuzumab.,Farletuzumab,DB00087
DB05656,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Veltuzumab.,Veltuzumab,DB00087
DB05793,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with PRO-542.,PRO-542,DB00087
DB05797,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TNX-901.,TNX-901,DB00087
DB05889,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00087
DB05892,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with RI 624.,RI 624,DB00087
DB05915,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with MYO-029.,MYO-029,DB00087
DB05916,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CT-011.,CT-011,DB00087
DB05941,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leronlimab.,Leronlimab,DB00087
DB05996,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00087
DB06043,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaratumab.,Olaratumab,DB00087
DB06049,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IPH 2101.,IPH 2101,DB00087
DB06050,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TB-402.,TB-402,DB00087
DB06081,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.,Caplacizumab,DB00087
DB06101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IMC-1C11.,IMC-1C11,DB00087
DB06116,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab.,Eldelumab,DB00087
DB06162,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumiliximab.,Lumiliximab,DB00087
DB06186,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab.,Ipilimumab,DB00087
DB06192,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nimotuzumab.,Nimotuzumab,DB00087
DB06241,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clenoliximab.,Clenoliximab,DB00087
DB06304,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with BIIB015.,BIIB015,DB00087
DB06305,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sonepcizumab.,Sonepcizumab,DB00087
DB06310,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Motavizumab.,Motavizumab,DB00087
DB06317,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Elotuzumab.,Elotuzumab,DB00087
DB06318,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AVE9633.,AVE9633,DB00087
DB06322,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab.,Carotuximab,DB00087
DB06324,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XmAb 2513.,XmAb 2513,DB00087
DB06342,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00087
DB06343,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.,Teprotumumab,DB00087
DB06360,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.,Lucatumumab,DB00087
DB06366,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pertuzumab.,Pertuzumab,DB00087
DB06371,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab.,Siplizumab,DB00087
DB06467,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apolizumab.,Apolizumab,DB00087
DB06474,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00087
DB06550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bivatuzumab.,Bivatuzumab,DB00087
DB06557,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lerdelimumab.,Lerdelimumab,DB00087
DB06599,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lexatumumab.,Lexatumumab,DB00087
DB06602,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Reslizumab.,Reslizumab,DB00087
DB06606,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teplizumab.,Teplizumab,DB00087
DB06607,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Catumaxomab.,Catumaxomab,DB00087
DB06647,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Volociximab.,Volociximab,DB00087
DB06650,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ofatumumab.,Ofatumumab,DB00087
DB08902,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raxibacumab.,Raxibacumab,DB00087
DB09035,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nivolumab.,Nivolumab,DB00087
DB09037,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pembrolizumab.,Pembrolizumab,DB00087
DB09045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dulaglutide.,Dulaglutide,DB00087
DB09105,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asfotase alfa.,Asfotase alfa,DB00087
DB09264,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarucizumab.,Idarucizumab,DB00087
DB09302,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alirocumab.,Alirocumab,DB00087
DB09303,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evolocumab.,Evolocumab,DB00087
DB09331,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daratumumab.,Daratumumab,DB00087
DB09559,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Necitumumab.,Necitumumab,DB00087
DB11595,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atezolizumab.,Atezolizumab,DB00087
DB11604,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00087
DB11608,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00087
DB11621,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00087
DB11646,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab.,Conatumumab,DB00087
DB11657,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tabalumab.,Tabalumab,DB00087
DB11680,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00087
DB11685,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Figitumumab.,Figitumumab,DB00087
DB11714,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Durvalumab.,Durvalumab,DB00087
DB11715,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bapineuzumab.,Bapineuzumab,DB00087
DB11731,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00087
DB11746,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Onartuzumab.,Onartuzumab,DB00087
DB11756,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Solanezumab.,Solanezumab,DB00087
DB11771,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tremelimumab.,Tremelimumab,DB00087
DB11826,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lampalizumab.,Lampalizumab,DB00087
DB11840,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalotuzumab.,Dalotuzumab,DB00087
DB11849,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emibetuzumab.,Emibetuzumab,DB00087
DB11850,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ublituximab.,Ublituximab,DB00087
DB11856,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ligelizumab.,Ligelizumab,DB00087
DB11857,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Seribantumab.,Seribantumab,DB00087
DB11862,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Landogrozumab.,Landogrozumab,DB00087
DB11866,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Romosozumab.,Romosozumab,DB00087
DB11884,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00087
DB11914,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lebrikizumab.,Lebrikizumab,DB00087
DB11930,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.,Varlilumab,DB00087
DB11945,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Avelumab.,Avelumab,DB00087
DB11959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crenezumab.,Crenezumab,DB00087
DB11972,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab.,Rilotumumab,DB00087
DB11976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anifrolumab.,Anifrolumab,DB00087
DB12023,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Benralizumab.,Benralizumab,DB00087
DB12034,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gantenerumab.,Gantenerumab,DB00087
DB12053,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Visilizumab.,Visilizumab,DB00087
DB12077,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab.,Urelumab,DB00087
DB12089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00087
DB12090,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Patritumab.,Patritumab,DB00087
DB12102,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fulranumab.,Fulranumab,DB00087
DB12104,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tarextumab.,Tarextumab,DB00087
DB12118,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sotatercept.,Sotatercept,DB00087
DB12119,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gevokizumab.,Gevokizumab,DB00087
DB12142,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Duligotuzumab.,Duligotuzumab,DB00087
DB12152,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Simtuzumab.,Simtuzumab,DB00087
DB12157,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasinumab.,Fasinumab,DB00087
DB12159,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.,Dupilumab,DB00087
DB12169,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tralokinumab.,Tralokinumab,DB00087
DB12189,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etrolizumab.,Etrolizumab,DB00087
DB12202,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zalutumumab.,Zalutumumab,DB00087
DB12205,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ganitumab.,Ganitumab,DB00087
DB12213,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etaracizumab.,Etaracizumab,DB00087
DB12240,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00087
DB12246,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inclacumab.,Inclacumab,DB00087
DB12250,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cixutumumab.,Cixutumumab,DB00087
DB12261,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00087
DB12274,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab.,Aducanumab,DB00087
DB12281,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Luspatercept.,Luspatercept,DB00087
DB12296,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GS-5745.,GS-5745,DB00087
DB12317,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vanucizumab.,Vanucizumab,DB00087
DB12331,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00087
DB12335,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tanezumab.,Tanezumab,DB00087
DB12342,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ensituximab.,Ensituximab,DB00087
DB12344,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fezakinumab.,Fezakinumab,DB00087
DB12363,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dusigitumab.,Dusigitumab,DB00087
DB12396,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fresolimumab.,Fresolimumab,DB00087
DB12413,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00087
DB12456,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bococizumab.,Bococizumab,DB00087
DB12489,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00087
DB12498,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mogamulizumab.,Mogamulizumab,DB00087
DB12520,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Plozalizumab.,Plozalizumab,DB00087
DB12534,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab.,Mavrilimumab,DB00087
DB12560,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blosozumab.,Blosozumab,DB00087
DB12584,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimagrumab.,Bimagrumab,DB00087
DB12589,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab.,Dacetuzumab,DB00087
DB12609,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tovetumab.,Tovetumab,DB00087
DB12683,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumretuzumab.,Lumretuzumab,DB00087
DB12698,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibalizumab.,Ibalizumab,DB00087
DB12701,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Intetumumab.,Intetumumab,DB00087
DB12718,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carlumab.,Carlumab,DB00087
DB12734,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Demcizumab.,Demcizumab,DB00087
DB12773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sifalimumab.,Sifalimumab,DB00087
DB12775,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abituzumab.,Abituzumab,DB00087
DB12797,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ecromeximab.,Ecromeximab,DB00087
DB12807,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00087
DB12815,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crotedumab.,Crotedumab,DB00087
DB12820,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Concizumab.,Concizumab,DB00087
DB12826,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab.,Depatuxizumab,DB00087
DB12844,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rontalizumab.,Rontalizumab,DB00087
DB12845,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amatuximab.,Amatuximab,DB00087
DB12849,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clazakizumab.,Clazakizumab,DB00087
DB12891,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanezumab.,Ozanezumab,DB00087
DB12893,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00087
DB12917,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimekizumab.,Bimekizumab,DB00087
DB12943,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Milatuzumab.,Milatuzumab,DB00087
DB12976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Robatumumab.,Robatumumab,DB00087
DB13017,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00087
DB13037,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Namilumab.,Namilumab,DB00087
DB13045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Racotumomab.,Racotumomab,DB00087
DB13073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tregalizumab.,Tregalizumab,DB00087
DB13127,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olokizumab.,Olokizumab,DB00087
DB13140,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00087
DB13375,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Edrecolomab.,Edrecolomab,DB00087
DB13535,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nebacumab.,Nebacumab,DB00087
DB13886,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00087
DB13923,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emicizumab.,Emicizumab,DB00087
DB13976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulesomab.,Sulesomab,DB00087
DB13979,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Besilesomab.,Besilesomab,DB00087
DB14012,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Burosumab.,Burosumab,DB00087
DB14039,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.,Erenumab,DB00087
DB14040,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.,Eptinezumab,DB00087
DB14041,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fremanezumab.,Fremanezumab,DB00087
DB14042,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.,Galcanezumab,DB00087
DB14211,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fanolesomab.,Fanolesomab,DB00087
DB14580,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lecanemab.,Lecanemab,DB00087
DB14597,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lanadelumab.,Lanadelumab,DB00087
DB14707,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab.,Cemiplimab,DB00087
DB14776,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.,Camrelizumab,DB00087
DB14778,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Setrusumab.,Setrusumab,DB00087
DB14784,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gancotamab.,Gancotamab,DB00087
DB14809,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00087
DB14811,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Isatuximab.,Isatuximab,DB00087
DB14824,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Icrucumab.,Icrucumab,DB00087
DB14843,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Codrituzumab.,Codrituzumab,DB00087
DB14864,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab.,Brolucizumab,DB00087
DB14871,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Xentuzumab.,Xentuzumab,DB00087
DB14877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lintuzumab.,Lintuzumab,DB00087
DB14891,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vobarilizumab.,Vobarilizumab,DB00087
DB14897,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Parsatuzumab.,Parsatuzumab,DB00087
DB14905,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emactuzumab.,Emactuzumab,DB00087
DB14907,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00087
DB14908,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Refanezumab.,Refanezumab,DB00087
DB14947,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bermekimab.,Bermekimab,DB00087
DB14952,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.,Pamrevlumab,DB00087
DB14959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Opicinumab.,Opicinumab,DB00087
DB14962,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00087
DB14967,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab.,Margetuximab,DB00087
DB14988,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept.,Dalantercept,DB00087
DB14997,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pateclizumab.,Pateclizumab,DB00087
DB15014,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gremubamab.,Gremubamab,DB00087
DB15022,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apomab.,Apomab,DB00087
DB15044,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab.,Tafasitamab,DB00087
DB15045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipafricept.,Ipafricept,DB00087
DB15076,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abrilumab.,Abrilumab,DB00087
DB15089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Frovocimab.,Frovocimab,DB00087
DB15090,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tezepelumab.,Tezepelumab,DB00087
DB15101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tigatuzumab.,Tigatuzumab,DB00087
DB15104,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00087
DB15113,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.,Utomilumab,DB00087
DB15118,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zolbetuximab.,Zolbetuximab,DB00087
DB15135,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponezumab.,Ponezumab,DB00087
DB15160,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept.,Asunercept,DB00087
DB15172,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Suvratoxumab.,Suvratoxumab,DB00087
DB15225,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitazalimab.,Mitazalimab,DB00087
DB15252,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nemolizumab.,Nemolizumab,DB00087
DB15277,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gedivumab.,Gedivumab,DB00087
DB15336,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00087
DB15349,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00087
DB15354,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.,Evinacumab,DB00087
DB15363,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Istiratumab.,Istiratumab,DB00087
DB15383,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pidilizumab.,Pidilizumab,DB00087
DB15397,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GMA-161.,GMA-161,DB00087
DB15409,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00087
DB15415,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tomaralimab.,Tomaralimab,DB00087
DB15428,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vesencumab.,Vesencumab,DB00087
DB15432,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00087
DB15441,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00087
DB15443,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00087
DB15453,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00087
DB14004,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.,Tildrakizumab,DB00087
DB05679,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ustekinumab.,Ustekinumab,DB00087
DB15559,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00087
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.,Palifermin,DB00087
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.,Lepirudin,DB00087
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Alemtuzumab.,Bivalirudin,DB00087
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Alemtuzumab.,Alteplase,DB00087
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Alemtuzumab.,Urokinase,DB00087
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.,Reteplase,DB00087
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Alemtuzumab.,Anistreplase,DB00087
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Alemtuzumab.,Tenecteplase,DB00087
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.,Drotrecogin alfa,DB00087
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.,Streptokinase,DB00087
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Alemtuzumab.,Dicoumarol,DB00087
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Alemtuzumab.,Argatroban,DB00087
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Alemtuzumab.,Ardeparin,DB00087
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Alemtuzumab.,Phenindione,DB00087
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Alemtuzumab.,Fondaparinux,DB00087
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Alemtuzumab.,Warfarin,DB00087
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Alemtuzumab.,Pentosan polysulfate,DB00087
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Alemtuzumab.,Phenprocoumon,DB00087
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Alemtuzumab.,Heparin,DB00087
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Alemtuzumab.,Enoxaparin,DB00087
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Alemtuzumab.,Acenocoumarol,DB00087
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Alemtuzumab.,4-hydroxycoumarin,DB00087
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Alemtuzumab.,Coumarin,DB00087
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Alemtuzumab.,Ximelagatran,DB00087
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Alemtuzumab.,Desmoteplase,DB00087
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Alemtuzumab.,Ancrod,DB00087
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Alemtuzumab.,Fibrinolysin,DB00087
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Alemtuzumab.,Rivaroxaban,DB00087
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Alemtuzumab.,Sulodexide,DB00087
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Alemtuzumab.,Semuloparin,DB00087
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Alemtuzumab.,Idraparinux,DB00087
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Alemtuzumab.,Astaxanthin,DB00087
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Alemtuzumab.,Apixaban,DB00087
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Alemtuzumab.,Otamixaban,DB00087
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Alemtuzumab.,Amediplase,DB00087
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Alemtuzumab.,Dabigatran etexilate,DB00087
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Alemtuzumab.,Danaparoid,DB00087
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Alemtuzumab.,Dalteparin,DB00087
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Alemtuzumab.,Tinzaparin,DB00087
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Alemtuzumab.,Ferulic acid,DB00087
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Alemtuzumab.,(R)-warfarin,DB00087
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Alemtuzumab.,Ethyl biscoumacetate,DB00087
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Alemtuzumab.,Nadroparin,DB00087
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Alemtuzumab.,Ditazole,DB00087
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Alemtuzumab.,Edoxaban,DB00087
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Alemtuzumab.,Potassium citrate,DB00087
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Alemtuzumab.,Sodium citrate,DB00087
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Alemtuzumab.,Dextran,DB00087
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Alemtuzumab.,Bemiparin,DB00087
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Alemtuzumab.,Reviparin,DB00087
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Alemtuzumab.,Parnaparin,DB00087
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Alemtuzumab.,Certoparin,DB00087
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Alemtuzumab.,Desirudin,DB00087
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Alemtuzumab.,Zinc citrate,DB00087
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Alemtuzumab.,Antithrombin Alfa,DB00087
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Alemtuzumab.,Protein C,DB00087
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Alemtuzumab.,Antithrombin III human,DB00087
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Alemtuzumab.,Letaxaban,DB00087
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Alemtuzumab.,Darexaban,DB00087
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Alemtuzumab.,Betrixaban,DB00087
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Alemtuzumab.,Nafamostat,DB00087
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Alemtuzumab.,Monteplase,DB00087
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Alemtuzumab.,Gabexate,DB00087
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Alemtuzumab.,Fluindione,DB00087
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Alemtuzumab.,Protein S human,DB00087
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Alemtuzumab.,Brinase,DB00087
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Alemtuzumab.,Clorindione,DB00087
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Alemtuzumab.,Diphenadione,DB00087
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Alemtuzumab.,Tioclomarol,DB00087
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Alemtuzumab.,Melagatran,DB00087
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Alemtuzumab.,Saruplase,DB00087
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Alemtuzumab.,(S)-Warfarin,DB00087
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Alemtuzumab.,Tocopherylquinone,DB00087
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Alemtuzumab.,Edetate calcium disodium anhydrous,DB00087
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.,Dabigatran,DB00087
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.,Methyclothiazide,DB00087
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Alemtuzumab.,Bendroflumethiazide,DB00087
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Alemtuzumab.,Benzthiazide,DB00087
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Alemtuzumab.,Cyclothiazide,DB00087
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Alemtuzumab.,Hydroflumethiazide,DB00087
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Alemtuzumab.,Chlorothiazide,DB00087
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Alemtuzumab.,Hydrochlorothiazide,DB00087
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Alemtuzumab.,Trichlormethiazide,DB00087
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Alemtuzumab.,Polythiazide,DB00087
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Alemtuzumab.,Mebutizide,DB00087
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Alemtuzumab.,Cyclopenthiazide,DB00087
DB09042,The risk or severity of myelosuppression can be increased when Alemtuzumab is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00087
DB00091,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00087
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.,Cyanocobalamin,DB00087
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Alemtuzumab.,Allopurinol,DB00087
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alemtuzumab.","Ebola Zaire vaccine (live, attenuated)",DB00087
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Alemtuzumab.,Magnesium,DB00087
DB01601,The serum concentration of Alemtuzumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00087
DB12530,The risk or severity of infection can be increased when Alemtuzumab is combined with Inebilizumab.,Inebilizumab,DB00087
DB00269,Chlorotrianisene may increase the thrombogenic activities of Capromab pendetide.,Chlorotrianisene,DB00089
DB00286,Conjugated estrogens may increase the thrombogenic activities of Capromab pendetide.,Conjugated estrogens,DB00089
DB00655,Estrone may increase the thrombogenic activities of Capromab pendetide.,Estrone,DB00089
DB00890,Dienestrol may increase the thrombogenic activities of Capromab pendetide.,Dienestrol,DB00089
DB04573,Estriol may increase the thrombogenic activities of Capromab pendetide.,Estriol,DB00089
DB04575,Quinestrol may increase the thrombogenic activities of Capromab pendetide.,Quinestrol,DB00089
DB07931,Hexestrol may increase the thrombogenic activities of Capromab pendetide.,Hexestrol,DB00089
DB09070,Tibolone may increase the thrombogenic activities of Capromab pendetide.,Tibolone,DB00089
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Capromab pendetide.","Synthetic Conjugated Estrogens, A",DB00089
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide.","Synthetic Conjugated Estrogens, B",DB00089
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Capromab pendetide.,Polyestradiol phosphate,DB00089
DB09381,Esterified estrogens may increase the thrombogenic activities of Capromab pendetide.,Esterified estrogens,DB00089
DB11478,Zeranol may increase the thrombogenic activities of Capromab pendetide.,Zeranol,DB00089
DB11674,Equol may increase the thrombogenic activities of Capromab pendetide.,Equol,DB00089
DB12487,Promestriene may increase the thrombogenic activities of Capromab pendetide.,Promestriene,DB00089
DB13143,Methallenestril may increase the thrombogenic activities of Capromab pendetide.,Methallenestril,DB00089
DB13386,Epimestrol may increase the thrombogenic activities of Capromab pendetide.,Epimestrol,DB00089
DB13418,Moxestrol may increase the thrombogenic activities of Capromab pendetide.,Moxestrol,DB00089
DB13952,Estradiol acetate may increase the thrombogenic activities of Capromab pendetide.,Estradiol acetate,DB00089
DB15334,Biochanin A may increase the thrombogenic activities of Capromab pendetide.,Biochanin A,DB00089
DB15335,Formononetin may increase the thrombogenic activities of Capromab pendetide.,Formononetin,DB00089
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Capromab pendetide.,Diethylstilbestrol,DB00089
DB00783,Estradiol may increase the thrombogenic activities of Capromab pendetide.,Estradiol,DB00089
DB00977,Ethinylestradiol may increase the thrombogenic activities of Capromab pendetide.,Ethinylestradiol,DB00089
DB01357,Mestranol may increase the thrombogenic activities of Capromab pendetide.,Mestranol,DB00089
DB04574,Estrone sulfate may increase the thrombogenic activities of Capromab pendetide.,Estrone sulfate,DB00089
DB13953,Estradiol benzoate may increase the thrombogenic activities of Capromab pendetide.,Estradiol benzoate,DB00089
DB13954,Estradiol cypionate may increase the thrombogenic activities of Capromab pendetide.,Estradiol cypionate,DB00089
DB13956,Estradiol valerate may increase the thrombogenic activities of Capromab pendetide.,Estradiol valerate,DB00089
DB00007,Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Leuprolide,DB00089
DB00014,Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Goserelin,DB00089
DB00644,Gonadorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Gonadorelin,DB00089
DB00666,Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Nafarelin,DB00089
DB06719,Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Buserelin,DB00089
DB06788,Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Histrelin,DB00089
DB06825,Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Triptorelin,DB00089
DB11510,Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Deslorelin,DB00089
DB01406,Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Danazol,DB00089
DB11979,Elagolix may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Elagolix,DB00089
DB11619,Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Gestrinone,DB00089
DB00499,Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Flutamide,DB00089
DB00665,Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Nilutamide,DB00089
DB01128,Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Bicalutamide,DB00089
DB08899,Enzalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Enzalutamide,DB00089
DB11901,Apalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Apalutamide,DB00089
DB12941,Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Darolutamide,DB00089
DB04839,Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Cyproterone acetate,DB00089
DB13528,Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Chlormadinone,DB00089
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.,Cetuximab,DB00089
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.,Human immunoglobulin G,DB00089
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Capromab pendetide.,Omalizumab,DB00089
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.,Adalimumab,DB00089
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.,Abciximab,DB00089
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.,Gemtuzumab ozogamicin,DB00089
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.,Indium In-111 satumomab pendetide,DB00089
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.,Infliximab,DB00089
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.,Trastuzumab,DB00089
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.,Rituximab,DB00089
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.,Basiliximab,DB00089
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.,Muromonab,DB00089
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.,Digoxin Immune Fab (Ovine),DB00089
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.,Ibritumomab tiuxetan,DB00089
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.,Tositumomab,DB00089
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.,Alemtuzumab,DB00089
DB00095,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.,Efalizumab,DB00089
DB00098,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00089
DB00108,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.,Natalizumab,DB00089
DB00110,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.,Palivizumab,DB00089
DB00111,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.,Daclizumab,DB00089
DB00112,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.,Bevacizumab,DB00089
DB00113,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00089
DB01257,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eculizumab.,Eculizumab,DB00089
DB01269,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Panitumumab.,Panitumumab,DB00089
DB01270,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ranibizumab.,Ranibizumab,DB00089
DB04901,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galiximab.,Galiximab,DB00089
DB04949,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pexelizumab.,Pexelizumab,DB00089
DB04956,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.,Afelimomab,DB00089
DB04958,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Epratuzumab.,Epratuzumab,DB00089
DB04962,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bectumomab.,Bectumomab,DB00089
DB04964,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab.,Oregovomab,DB00089
DB04988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IGN311.,IGN311,DB00089
DB05006,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.,Adecatumumab,DB00089
DB05097,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab.,Labetuzumab,DB00089
DB05101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Matuzumab.,Matuzumab,DB00089
DB05111,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fontolizumab.,Fontolizumab,DB00089
DB05136,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bavituximab.,Bavituximab,DB00089
DB05139,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CR002.,CR002,DB00089
DB05209,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozrolimupab.,Rozrolimupab,DB00089
DB05304,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Girentuximab.,Girentuximab,DB00089
DB05336,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obiltoxaximab.,Obiltoxaximab,DB00089
DB05405,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XTL-001.,XTL-001,DB00089
DB05437,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with NAV 1800.,NAV 1800,DB00089
DB05459,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Briakinumab.,Briakinumab,DB00089
DB05496,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Otelixizumab.,Otelixizumab,DB00089
DB05545,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AMG 108.,AMG 108,DB00089
DB05550,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Iratumumab.,Iratumumab,DB00089
DB05555,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Enokizumab.,Enokizumab,DB00089
DB05578,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ramucirumab.,Ramucirumab,DB00089
DB05595,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Farletuzumab.,Farletuzumab,DB00089
DB05656,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Veltuzumab.,Veltuzumab,DB00089
DB05679,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ustekinumab.,Ustekinumab,DB00089
DB05773,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00089
DB05793,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with PRO-542.,PRO-542,DB00089
DB05797,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TNX-901.,TNX-901,DB00089
DB05889,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00089
DB05892,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with RI 624.,RI 624,DB00089
DB05915,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with MYO-029.,MYO-029,DB00089
DB05916,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CT-011.,CT-011,DB00089
DB05941,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Leronlimab.,Leronlimab,DB00089
DB05996,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00089
DB06043,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olaratumab.,Olaratumab,DB00089
DB06049,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IPH 2101.,IPH 2101,DB00089
DB06050,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TB-402.,TB-402,DB00089
DB06081,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Caplacizumab.,Caplacizumab,DB00089
DB06101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IMC-1C11.,IMC-1C11,DB00089
DB06116,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eldelumab.,Eldelumab,DB00089
DB06162,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumiliximab.,Lumiliximab,DB00089
DB06168,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Canakinumab.,Canakinumab,DB00089
DB06186,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipilimumab.,Ipilimumab,DB00089
DB06192,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nimotuzumab.,Nimotuzumab,DB00089
DB06241,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clenoliximab.,Clenoliximab,DB00089
DB06273,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tocilizumab.,Tocilizumab,DB00089
DB06304,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with BIIB015.,BIIB015,DB00089
DB06305,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sonepcizumab.,Sonepcizumab,DB00089
DB06310,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Motavizumab.,Motavizumab,DB00089
DB06317,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Elotuzumab.,Elotuzumab,DB00089
DB06318,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AVE9633.,AVE9633,DB00089
DB06322,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carotuximab.,Carotuximab,DB00089
DB06324,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XmAb 2513.,XmAb 2513,DB00089
DB06342,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00089
DB06343,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teprotumumab.,Teprotumumab,DB00089
DB06360,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lucatumumab.,Lucatumumab,DB00089
DB06366,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pertuzumab.,Pertuzumab,DB00089
DB06371,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siplizumab.,Siplizumab,DB00089
DB06467,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apolizumab.,Apolizumab,DB00089
DB06474,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sibrotuzumab.,Sibrotuzumab,DB00089
DB06550,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bivatuzumab.,Bivatuzumab,DB00089
DB06557,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lerdelimumab.,Lerdelimumab,DB00089
DB06599,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lexatumumab.,Lexatumumab,DB00089
DB06602,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Reslizumab.,Reslizumab,DB00089
DB06606,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teplizumab.,Teplizumab,DB00089
DB06607,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Catumaxomab.,Catumaxomab,DB00089
DB06612,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mepolizumab.,Mepolizumab,DB00089
DB06643,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Denosumab.,Denosumab,DB00089
DB06647,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Volociximab.,Volociximab,DB00089
DB06650,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ofatumumab.,Ofatumumab,DB00089
DB06674,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Golimumab.,Golimumab,DB00089
DB08870,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00089
DB08879,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belimumab.,Belimumab,DB00089
DB08902,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Raxibacumab.,Raxibacumab,DB00089
DB08904,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Certolizumab pegol.,Certolizumab pegol,DB00089
DB08935,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obinutuzumab.,Obinutuzumab,DB00089
DB09029,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Secukinumab.,Secukinumab,DB00089
DB09033,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vedolizumab.,Vedolizumab,DB00089
DB09035,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nivolumab.,Nivolumab,DB00089
DB09036,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siltuximab.,Siltuximab,DB00089
DB09037,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pembrolizumab.,Pembrolizumab,DB00089
DB09045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dulaglutide.,Dulaglutide,DB00089
DB09052,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blinatumomab.,Blinatumomab,DB00089
DB09057,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anthrax immune globulin human.,Anthrax immune globulin human,DB00089
DB09077,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dinutuximab.,Dinutuximab,DB00089
DB09105,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asfotase alfa.,Asfotase alfa,DB00089
DB09264,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Idarucizumab.,Idarucizumab,DB00089
DB09302,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab.,Alirocumab,DB00089
DB09303,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evolocumab.,Evolocumab,DB00089
DB09312,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00089
DB09331,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daratumumab.,Daratumumab,DB00089
DB09559,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Necitumumab.,Necitumumab,DB00089
DB11569,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ixekizumab.,Ixekizumab,DB00089
DB11580,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ravulizumab.,Ravulizumab,DB00089
DB11595,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Atezolizumab.,Atezolizumab,DB00089
DB11604,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00089
DB11608,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00089
DB11621,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00089
DB11646,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Conatumumab.,Conatumumab,DB00089
DB11657,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tabalumab.,Tabalumab,DB00089
DB11680,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ficlatuzumab.,Ficlatuzumab,DB00089
DB11685,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Figitumumab.,Figitumumab,DB00089
DB11714,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Durvalumab.,Durvalumab,DB00089
DB11715,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bapineuzumab.,Bapineuzumab,DB00089
DB11731,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00089
DB11746,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Onartuzumab.,Onartuzumab,DB00089
DB11756,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Solanezumab.,Solanezumab,DB00089
DB11767,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sarilumab.,Sarilumab,DB00089
DB11771,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tremelimumab.,Tremelimumab,DB00089
DB11776,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brodalumab.,Brodalumab,DB00089
DB11803,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sirukumab.,Sirukumab,DB00089
DB11826,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lampalizumab.,Lampalizumab,DB00089
DB11834,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Guselkumab.,Guselkumab,DB00089
DB11840,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalotuzumab.,Dalotuzumab,DB00089
DB11849,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emibetuzumab.,Emibetuzumab,DB00089
DB11850,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ublituximab.,Ublituximab,DB00089
DB11856,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ligelizumab.,Ligelizumab,DB00089
DB11857,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Seribantumab.,Seribantumab,DB00089
DB11862,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Landogrozumab.,Landogrozumab,DB00089
DB11866,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Romosozumab.,Romosozumab,DB00089
DB11884,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00089
DB11914,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lebrikizumab.,Lebrikizumab,DB00089
DB11930,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Varlilumab.,Varlilumab,DB00089
DB11945,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Avelumab.,Avelumab,DB00089
DB11959,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crenezumab.,Crenezumab,DB00089
DB11972,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rilotumumab.,Rilotumumab,DB00089
DB11976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anifrolumab.,Anifrolumab,DB00089
DB11988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ocrelizumab.,Ocrelizumab,DB00089
DB12023,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Benralizumab.,Benralizumab,DB00089
DB12034,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gantenerumab.,Gantenerumab,DB00089
DB12053,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Visilizumab.,Visilizumab,DB00089
DB12077,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Urelumab.,Urelumab,DB00089
DB12089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00089
DB12090,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Patritumab.,Patritumab,DB00089
DB12102,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fulranumab.,Fulranumab,DB00089
DB12104,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tarextumab.,Tarextumab,DB00089
DB12118,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sotatercept.,Sotatercept,DB00089
DB12119,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gevokizumab.,Gevokizumab,DB00089
DB12142,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Duligotuzumab.,Duligotuzumab,DB00089
DB12152,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Simtuzumab.,Simtuzumab,DB00089
DB12157,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fasinumab.,Fasinumab,DB00089
DB12159,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dupilumab.,Dupilumab,DB00089
DB12169,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tralokinumab.,Tralokinumab,DB00089
DB12189,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etrolizumab.,Etrolizumab,DB00089
DB12202,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zalutumumab.,Zalutumumab,DB00089
DB12205,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ganitumab.,Ganitumab,DB00089
DB12213,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etaracizumab.,Etaracizumab,DB00089
DB12240,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00089
DB12246,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inclacumab.,Inclacumab,DB00089
DB12250,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cixutumumab.,Cixutumumab,DB00089
DB12261,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ascrinvacumab.,Ascrinvacumab,DB00089
DB12274,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.,Aducanumab,DB00089
DB12281,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Luspatercept.,Luspatercept,DB00089
DB12296,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GS-5745.,GS-5745,DB00089
DB12317,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vanucizumab.,Vanucizumab,DB00089
DB12331,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00089
DB12335,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tanezumab.,Tanezumab,DB00089
DB12342,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ensituximab.,Ensituximab,DB00089
DB12344,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fezakinumab.,Fezakinumab,DB00089
DB12363,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dusigitumab.,Dusigitumab,DB00089
DB12396,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fresolimumab.,Fresolimumab,DB00089
DB12413,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00089
DB12456,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bococizumab.,Bococizumab,DB00089
DB12489,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00089
DB12498,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mogamulizumab.,Mogamulizumab,DB00089
DB12520,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Plozalizumab.,Plozalizumab,DB00089
DB12530,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inebilizumab.,Inebilizumab,DB00089
DB12534,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mavrilimumab.,Mavrilimumab,DB00089
DB12560,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blosozumab.,Blosozumab,DB00089
DB12584,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimagrumab.,Bimagrumab,DB00089
DB12589,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dacetuzumab.,Dacetuzumab,DB00089
DB12609,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tovetumab.,Tovetumab,DB00089
DB12683,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumretuzumab.,Lumretuzumab,DB00089
DB12698,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ibalizumab.,Ibalizumab,DB00089
DB12701,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Intetumumab.,Intetumumab,DB00089
DB12718,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carlumab.,Carlumab,DB00089
DB12734,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Demcizumab.,Demcizumab,DB00089
DB12773,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sifalimumab.,Sifalimumab,DB00089
DB12775,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.,Abituzumab,DB00089
DB12797,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ecromeximab.,Ecromeximab,DB00089
DB12807,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00089
DB12815,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crotedumab.,Crotedumab,DB00089
DB12820,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Concizumab.,Concizumab,DB00089
DB12826,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab.,Depatuxizumab,DB00089
DB12844,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rontalizumab.,Rontalizumab,DB00089
DB12845,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amatuximab.,Amatuximab,DB00089
DB12849,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clazakizumab.,Clazakizumab,DB00089
DB12891,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ozanezumab.,Ozanezumab,DB00089
DB12893,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00089
DB12917,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimekizumab.,Bimekizumab,DB00089
DB12943,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Milatuzumab.,Milatuzumab,DB00089
DB12976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Robatumumab.,Robatumumab,DB00089
DB13017,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00089
DB13037,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Namilumab.,Namilumab,DB00089
DB13045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Racotumomab.,Racotumomab,DB00089
DB13073,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tregalizumab.,Tregalizumab,DB00089
DB13127,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olokizumab.,Olokizumab,DB00089
DB13140,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bezlotoxumab.,Bezlotoxumab,DB00089
DB13375,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Edrecolomab.,Edrecolomab,DB00089
DB13535,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nebacumab.,Nebacumab,DB00089
DB13886,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00089
DB13923,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emicizumab.,Emicizumab,DB00089
DB13976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sulesomab.,Sulesomab,DB00089
DB13979,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Besilesomab.,Besilesomab,DB00089
DB14004,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tildrakizumab.,Tildrakizumab,DB00089
DB14012,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Burosumab.,Burosumab,DB00089
DB14039,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Erenumab.,Erenumab,DB00089
DB14040,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eptinezumab.,Eptinezumab,DB00089
DB14041,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fremanezumab.,Fremanezumab,DB00089
DB14042,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galcanezumab.,Galcanezumab,DB00089
DB14211,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fanolesomab.,Fanolesomab,DB00089
DB14580,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lecanemab.,Lecanemab,DB00089
DB14597,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lanadelumab.,Lanadelumab,DB00089
DB14707,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cemiplimab.,Cemiplimab,DB00089
DB14724,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emapalumab.,Emapalumab,DB00089
DB14762,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Risankizumab.,Risankizumab,DB00089
DB14776,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Camrelizumab.,Camrelizumab,DB00089
DB14778,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Setrusumab.,Setrusumab,DB00089
DB14784,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gancotamab.,Gancotamab,DB00089
DB14809,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00089
DB14811,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Isatuximab.,Isatuximab,DB00089
DB14824,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Icrucumab.,Icrucumab,DB00089
DB14843,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Codrituzumab.,Codrituzumab,DB00089
DB14864,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brolucizumab.,Brolucizumab,DB00089
DB14871,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Xentuzumab.,Xentuzumab,DB00089
DB14877,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lintuzumab.,Lintuzumab,DB00089
DB14891,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vobarilizumab.,Vobarilizumab,DB00089
DB14897,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Parsatuzumab.,Parsatuzumab,DB00089
DB14905,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emactuzumab.,Emactuzumab,DB00089
DB14907,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00089
DB14908,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Refanezumab.,Refanezumab,DB00089
DB14919,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozanolixizumab.,Rozanolixizumab,DB00089
DB14947,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bermekimab.,Bermekimab,DB00089
DB14952,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pamrevlumab.,Pamrevlumab,DB00089
DB14959,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Opicinumab.,Opicinumab,DB00089
DB14962,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00089
DB14967,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Margetuximab.,Margetuximab,DB00089
DB14988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalantercept.,Dalantercept,DB00089
DB14997,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pateclizumab.,Pateclizumab,DB00089
DB15014,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gremubamab.,Gremubamab,DB00089
DB15022,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apomab.,Apomab,DB00089
DB15044,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tafasitamab.,Tafasitamab,DB00089
DB15045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipafricept.,Ipafricept,DB00089
DB15076,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab.,Abrilumab,DB00089
DB15089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Frovocimab.,Frovocimab,DB00089
DB15090,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tezepelumab.,Tezepelumab,DB00089
DB15101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tigatuzumab.,Tigatuzumab,DB00089
DB15104,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00089
DB15113,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Utomilumab.,Utomilumab,DB00089
DB15118,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zolbetuximab.,Zolbetuximab,DB00089
DB15135,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ponezumab.,Ponezumab,DB00089
DB15160,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asunercept.,Asunercept,DB00089
DB15172,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Suvratoxumab.,Suvratoxumab,DB00089
DB15225,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mitazalimab.,Mitazalimab,DB00089
DB15252,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nemolizumab.,Nemolizumab,DB00089
DB15253,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bleselumab.,Bleselumab,DB00089
DB15277,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gedivumab.,Gedivumab,DB00089
DB15336,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Valanafusp alfa.,Valanafusp alfa,DB00089
DB15349,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00089
DB15354,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evinacumab.,Evinacumab,DB00089
DB15363,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Istiratumab.,Istiratumab,DB00089
DB15383,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pidilizumab.,Pidilizumab,DB00089
DB15397,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GMA-161.,GMA-161,DB00089
DB15409,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00089
DB15415,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tomaralimab.,Tomaralimab,DB00089
DB15428,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vesencumab.,Vesencumab,DB00089
DB15432,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00089
DB15441,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lulizumab pegol.,Lulizumab pegol,DB00089
DB15443,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00089
DB15453,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00089
DB15559,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zenocutuzumab.,Zenocutuzumab,DB00089
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Capromab pendetide.","Ebola Zaire vaccine (live, attenuated)",DB00089
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.,Pimecrolimus,DB00091
DB01656,Roflumilast may increase the immunosuppressive activities of Cyclosporine.,Roflumilast,DB00091
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.,Sipuleucel-T,DB00091
DB00819,The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.,Acetazolamide,DB00091
DB00051,The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.,Adalimumab,DB00091
DB08916,The serum concentration of Cyclosporine can be increased when it is combined with Afatinib.,Afatinib,DB00091
DB09026,The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.,Aliskiren,DB00091
DB06403,The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.,Ambrisentan,DB00091
DB01118,The serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.,Amiodarone,DB00091
DB00681,Amphotericin B may increase the nephrotoxic activities of Cyclosporine.,Amphotericin B,DB00091
DB01026,Ketoconazole may increase the nephrotoxic activities of Cyclosporine.,Ketoconazole,DB00091
DB01076,The excretion of Atorvastatin can be decreased when combined with Cyclosporine.,Atorvastatin,DB00091
DB08873,The serum concentration of Cyclosporine can be increased when it is combined with Boceprevir.,Boceprevir,DB00091
DB00559,The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.,Bosentan,DB00091
DB01200,The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.,Bromocriptine,DB00091
DB00564,The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.,Carbamazepine,DB00091
DB01136,The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.,Carvedilol,DB00091
DB00520,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.,Caspofungin,DB00091
DB00446,The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.,Chloramphenicol,DB00091
DB02123,Cyclosporine may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.,Glycochenodeoxycholic Acid,DB00091
DB05804,Prasterone sulfate may decrease the excretion rate of Cyclosporine which could result in a higher serum level.,Prasterone sulfate,DB00091
DB00222,Cyclosporine may decrease the excretion rate of Glimepiride which could result in a higher serum level.,Glimepiride,DB00091
DB00572,Cyclosporine may decrease the excretion rate of Atropine which could result in a higher serum level.,Atropine,DB00091
DB00693,Cyclosporine may decrease the excretion rate of Fluorescein which could result in a higher serum level.,Fluorescein,DB00091
DB00698,Cyclosporine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin,DB00091
DB00833,Cyclosporine may decrease the excretion rate of Cefaclor which could result in a higher serum level.,Cefaclor,DB00091
DB09374,Cyclosporine may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.,Indocyanine green acid form,DB00091
DB12319,Cyclosporine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.,Benzbromarone,DB00091
DB12712,Cyclosporine may decrease the excretion rate of Pilsicainide which could result in a higher serum level.,Pilsicainide,DB00091
DB13751,Cyclosporine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.,Glycyrrhizic acid,DB00091
DB00412,Cyclosporine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone,DB00091
DB02659,Cyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.,Cholic Acid,DB00091
DB04348,Cyclosporine may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.,Taurocholic acid,DB00091
DB00455,Cyclosporine may decrease the excretion rate of Loratadine which could result in a higher serum level.,Loratadine,DB00091
DB00975,Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.,Dipyridamole,DB00091
DB00930,The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.,Colesevelam,DB00091
DB08865,The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.,Crizotinib,DB00091
DB00531,The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.,Cyclophosphamide,DB00091
DB00390,The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.,Digoxin,DB00091
DB13401,The serum concentration of Metildigoxin can be increased when it is combined with Cyclosporine.,Metildigoxin,DB00091
DB13691,The serum concentration of Acetyldigoxin can be increased when it is combined with Cyclosporine.,Acetyldigoxin,DB00091
DB04855,The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.,Dronedarone,DB00091
DB09075,The serum concentration of Cyclosporine can be increased when it is combined with Edoxaban.,Edoxaban,DB00091
DB00625,The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.,Efavirenz,DB00091
DB08899,The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.,Enzalutamide,DB00091
DB00773,The serum concentration of Etoposide can be increased when it is combined with Cyclosporine.,Etoposide,DB00091
DB01590,The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.,Everolimus,DB00091
DB00973,The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.,Ezetimibe,DB00091
DB00196,The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.,Fluconazole,DB00091
DB01095,The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.,Fluvastatin,DB00091
DB00529,Foscarnet may increase the nephrotoxic activities of Cyclosporine.,Foscarnet,DB00091
DB00252,The serum concentration of Cyclosporine can be decreased when it is combined with Phenytoin.,Phenytoin,DB00091
DB01320,The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.,Fosphenytoin,DB00091
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.,Glyburide,DB00091
DB00400,The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.,Griseofulvin,DB00091
DB00619,The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.,Imatinib,DB00091
DB01598,Cyclosporine may increase the neurotoxic activities of Imipenem.,Imipenem,DB00091
DB09027,The serum concentration of Cyclosporine can be increased when it is combined with Ledipasvir.,Ledipasvir,DB00091
DB00227,The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.,Lovastatin,DB00091
DB01042,Melphalan may increase the nephrotoxic activities of Cyclosporine.,Melphalan,DB00091
DB00563,The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.,Methotrexate,DB00091
DB00959,The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.,Methylprednisolone,DB00091
DB01233,Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Metoclopramide,DB00091
DB00834,The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.,Mifepristone,DB00091
DB01204,The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.,Mitoxantrone,DB00091
DB06413,The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.,Armodafinil,DB00091
DB00745,The serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.,Modafinil,DB00091
DB00607,The metabolism of Cyclosporine can be increased when combined with Nafcillin.,Nafcillin,DB00091
DB01059,The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.,Norfloxacin,DB00091
DB00338,The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.,Omeprazole,DB00091
DB00736,The serum concentration of Cyclosporine can be increased when it is combined with Esomeprazole.,Esomeprazole,DB00091
DB01083,Orlistat can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.,Orlistat,DB00091
DB08860,The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.,Pitavastatin,DB00091
DB00175,The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.,Pravastatin,DB00091
DB06480,The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.,Prucalopride,DB00091
DB00339,The serum concentration of Cyclosporine can be decreased when it is combined with Pyrazinamide.,Pyrazinamide,DB00091
DB01369,The serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.,Quinupristin,DB00091
DB00243,The serum concentration of Cyclosporine can be increased when it is combined with Ranolazine.,Ranolazine,DB00091
DB00912,The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.,Repaglinide,DB00091
DB01220,The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.,Rifaximin,DB00091
DB00503,The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.,Ritonavir,DB00091
DB01098,The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.,Rosuvastatin,DB00091
DB00658,The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.,Sevelamer,DB00091
DB06207,The serum concentration of Cyclosporine can be increased when it is combined with Silodosin.,Silodosin,DB00091
DB06290,The serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.,Simeprevir,DB00091
DB00641,The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.,Simvastatin,DB00091
DB06268,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Sitaxentan.,Sitaxentan,DB00091
DB01138,The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.,Sulfinpyrazone,DB00091
DB05521,The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.,Telaprevir,DB00091
DB08816,The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.,Ticagrelor,DB00091
DB00163,The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.,Vitamin E,DB00091
DB00212,Cyclosporine may decrease the antihypertensive activities of Remikiren.,Remikiren,DB00091
DB00226,Cyclosporine may decrease the antihypertensive activities of Guanadrel.,Guanadrel,DB00091
DB00616,Cyclosporine may decrease the antihypertensive activities of Candoxatril.,Candoxatril,DB00091
DB00727,Cyclosporine may decrease the antihypertensive activities of Nitroglycerin.,Nitroglycerin,DB00091
DB00765,Cyclosporine may decrease the antihypertensive activities of Metyrosine.,Metyrosine,DB00091
DB00785,Cyclosporine may decrease the antihypertensive activities of Cryptenamine.,Cryptenamine,DB00091
DB01089,Cyclosporine may decrease the antihypertensive activities of Deserpidine.,Deserpidine,DB00091
DB01158,Cyclosporine may decrease the antihypertensive activities of Bretylium.,Bretylium,DB00091
DB03322,Cyclosporine may decrease the antihypertensive activities of Dexpropranolol.,Dexpropranolol,DB00091
DB04831,Cyclosporine may decrease the antihypertensive activities of Tienilic acid.,Tienilic acid,DB00091
DB06445,Cyclosporine may decrease the antihypertensive activities of Diethylnorspermine.,Diethylnorspermine,DB00091
DB07767,Cyclosporine may decrease the antihypertensive activities of Ferulic acid.,Ferulic acid,DB00091
DB09206,Cyclosporine may decrease the antihypertensive activities of Trimazosin.,Trimazosin,DB00091
DB09363,Cyclosporine may decrease the antihypertensive activities of Rauwolfia serpentina root.,Rauwolfia serpentina root,DB00091
DB11720,Cyclosporine may decrease the antihypertensive activities of Angiotensin 1-7.,Angiotensin 1-7,DB00091
DB12054,Cyclosporine may decrease the antihypertensive activities of BQ-123.,BQ-123,DB00091
DB12465,Cyclosporine may decrease the antihypertensive activities of Ketanserin.,Ketanserin,DB00091
DB12766,Cyclosporine may decrease the antihypertensive activities of Cicletanine.,Cicletanine,DB00091
DB12945,Cyclosporine may decrease the antihypertensive activities of Dihydralazine.,Dihydralazine,DB00091
DB13211,Cyclosporine may decrease the antihypertensive activities of Guanoxan.,Guanoxan,DB00091
DB13374,Cyclosporine may decrease the antihypertensive activities of Vincamine.,Vincamine,DB00091
DB13400,Cyclosporine may decrease the antihypertensive activities of Linsidomine.,Linsidomine,DB00091
DB13410,Cyclosporine may decrease the antihypertensive activities of Guanoxabenz.,Guanoxabenz,DB00091
DB13429,Cyclosporine may decrease the antihypertensive activities of Tolonidine.,Tolonidine,DB00091
DB13435,Cyclosporine may decrease the antihypertensive activities of Endralazine.,Endralazine,DB00091
DB13452,Cyclosporine may decrease the antihypertensive activities of Cadralazine.,Cadralazine,DB00091
DB13575,Cyclosporine may decrease the antihypertensive activities of Bietaserpine.,Bietaserpine,DB00091
DB13604,Cyclosporine may decrease the antihypertensive activities of Guanazodine.,Guanazodine,DB00091
DB13631,Cyclosporine may decrease the antihypertensive activities of Methoserpidine.,Methoserpidine,DB00091
DB13779,Cyclosporine may decrease the antihypertensive activities of Guanoclor.,Guanoclor,DB00091
DB13801,Cyclosporine may decrease the antihypertensive activities of Muzolimine.,Muzolimine,DB00091
DB14094,Cyclosporine may decrease the antihypertensive activities of Tocopherylquinone.,Tocopherylquinone,DB00091
DB06762,Cyclosporine may decrease the antihypertensive activities of Pinacidil.,Pinacidil,DB00091
DB00374,Cyclosporine may decrease the antihypertensive activities of Treprostinil.,Treprostinil,DB00091
DB00393,Cyclosporine may decrease the antihypertensive activities of Nimodipine.,Nimodipine,DB00091
DB01162,Cyclosporine may decrease the antihypertensive activities of Terazosin.,Terazosin,DB00091
DB01340,Cyclosporine may decrease the antihypertensive activities of Cilazapril.,Cilazapril,DB00091
DB00381,Cyclosporine may decrease the antihypertensive activities of Amlodipine.,Amlodipine,DB00091
DB09128,The metabolism of Brexpiprazole can be decreased when combined with Cyclosporine.,Brexpiprazole,DB00091
DB09039,The metabolism of Eliglustat can be decreased when combined with Cyclosporine.,Eliglustat,DB00091
DB04908,The metabolism of Cyclosporine can be decreased when combined with Flibanserin.,Flibanserin,DB00091
DB09083,The metabolism of Cyclosporine can be decreased when combined with Ivabradine.,Ivabradine,DB00091
DB08820,The metabolism of Cyclosporine can be decreased when combined with Ivacaftor.,Ivacaftor,DB00091
DB08815,The metabolism of Lurasidone can be decreased when combined with Cyclosporine.,Lurasidone,DB00091
DB09049,The metabolism of Naloxegol can be decreased when combined with Cyclosporine.,Naloxegol,DB00091
DB09143,The metabolism of Cyclosporine can be decreased when combined with Sonidegib.,Sonidegib,DB00091
DB06237,The metabolism of Avanafil can be decreased when combined with Cyclosporine.,Avanafil,DB00091
DB00202,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.,Succinylcholine,DB00091
DB00416,The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Cyclosporine.,Metocurine iodide,DB00091
DB00483,The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Cyclosporine.,Gallamine triethiodide,DB00091
DB00565,The therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.,Cisatracurium,DB00091
DB00728,The therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.,Rocuronium,DB00091
DB00732,The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine.,Atracurium besylate,DB00091
DB01135,The therapeutic efficacy of Doxacurium can be increased when used in combination with Cyclosporine.,Doxacurium,DB00091
DB01226,The therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.,Mivacurium,DB00091
DB01245,The therapeutic efficacy of Decamethonium can be increased when used in combination with Cyclosporine.,Decamethonium,DB00091
DB01336,The therapeutic efficacy of Metocurine can be increased when used in combination with Cyclosporine.,Metocurine,DB00091
DB01337,The therapeutic efficacy of Pancuronium can be increased when used in combination with Cyclosporine.,Pancuronium,DB00091
DB01338,The therapeutic efficacy of Pipecuronium can be increased when used in combination with Cyclosporine.,Pipecuronium,DB00091
DB01339,The therapeutic efficacy of Vecuronium can be increased when used in combination with Cyclosporine.,Vecuronium,DB00091
DB04834,The therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine.,Rapacuronium,DB00091
DB11156,The therapeutic efficacy of Pyrantel can be increased when used in combination with Cyclosporine.,Pyrantel,DB00091
DB12989,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Cyclosporine.,Neosaxitoxin,DB00091
DB13295,The therapeutic efficacy of Atracurium can be increased when used in combination with Cyclosporine.,Atracurium,DB00091
DB13584,The therapeutic efficacy of Gallamine can be increased when used in combination with Cyclosporine.,Gallamine,DB00091
DB13648,The therapeutic efficacy of Alcuronium can be increased when used in combination with Cyclosporine.,Alcuronium,DB00091
DB01199,The therapeutic efficacy of Tubocurarine can be increased when used in combination with Cyclosporine.,Tubocurarine,DB00091
DB00211,The risk or severity of hypertension can be increased when Cyclosporine is combined with Midodrine.,Midodrine,DB00091
DB00217,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bethanidine.,Bethanidine,DB00091
DB00221,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoetharine.,Isoetharine,DB00091
DB00315,The risk or severity of hypertension can be increased when Cyclosporine is combined with Zolmitriptan.,Zolmitriptan,DB00091
DB00368,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norepinephrine.,Norepinephrine,DB00091
DB00388,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylephrine.,Phenylephrine,DB00091
DB00397,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylpropanolamine.,Phenylpropanolamine,DB00091
DB00561,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxapram.,Doxapram,DB00091
DB00610,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metaraminol.,Metaraminol,DB00091
DB00614,The risk or severity of hypertension can be increased when Cyclosporine is combined with Furazolidone.,Furazolidone,DB00091
DB00629,The risk or severity of hypertension can be increased when Cyclosporine is combined with Guanabenz.,Guanabenz,DB00091
DB00723,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxamine.,Methoxamine,DB00091
DB00753,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoflurane.,Isoflurane,DB00091
DB00777,The risk or severity of hypertension can be increased when Cyclosporine is combined with Propiomazine.,Propiomazine,DB00091
DB00797,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tolazoline.,Tolazoline,DB00091
DB00816,The risk or severity of hypertension can be increased when Cyclosporine is combined with Orciprenaline.,Orciprenaline,DB00091
DB00830,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenmetrazine.,Phenmetrazine,DB00091
DB00852,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pseudoephedrine.,Pseudoephedrine,DB00091
DB00867,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritodrine.,Ritodrine,DB00091
DB00899,The risk or severity of hypertension can be increased when Cyclosporine is combined with Remifentanil.,Remifentanil,DB00091
DB00901,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bitolterol.,Bitolterol,DB00091
DB00925,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxybenzamine.,Phenoxybenzamine,DB00091
DB00935,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxymetazoline.,Oxymetazoline,DB00091
DB00937,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethylpropion.,Diethylpropion,DB00091
DB00952,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naratriptan.,Naratriptan,DB00091
DB00998,The risk or severity of hypertension can be increased when Cyclosporine is combined with Frovatriptan.,Frovatriptan,DB00091
DB01064,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoprenaline.,Isoprenaline,DB00091
DB01102,The risk or severity of hypertension can be increased when Cyclosporine is combined with Arbutamine.,Arbutamine,DB00091
DB01189,The risk or severity of hypertension can be increased when Cyclosporine is combined with Desflurane.,Desflurane,DB00091
DB01247,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isocarboxazid.,Isocarboxazid,DB00091
DB01288,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenoterol.,Fenoterol,DB00091
DB01291,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pirbuterol.,Pirbuterol,DB00091
DB01363,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedra sinica root.,Ephedra sinica root,DB00091
DB01364,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedrine.,Ephedrine,DB00091
DB01365,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephentermine.,Mephentermine,DB00091
DB01366,The risk or severity of hypertension can be increased when Cyclosporine is combined with Procaterol.,Procaterol,DB00091
DB01407,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clenbuterol.,Clenbuterol,DB00091
DB01408,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bambuterol.,Bambuterol,DB00091
DB01442,The risk or severity of hypertension can be increased when Cyclosporine is combined with MMDA.,MMDA,DB00091
DB01467,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylamphetamine.","2,5-Dimethoxy-4-ethylamphetamine",DB00091
DB01484,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 4-Bromo-2,5-dimethoxyamphetamine.","4-Bromo-2,5-dimethoxyamphetamine",DB00091
DB01509,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tenamfetamine.,Tenamfetamine,DB00091
DB01556,The risk or severity of hypertension can be increased when Cyclosporine is combined with Chlorphentermine.,Chlorphentermine,DB00091
DB01579,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phendimetrazine.,Phendimetrazine,DB00091
DB01626,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pargyline.,Pargyline,DB00091
DB02032,The risk or severity of hypertension can be increased when Cyclosporine is combined with Epicaptopril.,Epicaptopril,DB00091
DB04017,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clorgiline.,Clorgiline,DB00091
DB04581,The risk or severity of hypertension can be increased when Cyclosporine is combined with 1-benzylimidazole.,1-benzylimidazole,DB00091
DB04818,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iproniazid.,Iproniazid,DB00091
DB04820,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nialamide.,Nialamide,DB00091
DB05395,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amibegron.,Amibegron,DB00091
DB05562,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naluzotan.,Naluzotan,DB00091
DB06153,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pizotifen.,Pizotifen,DB00091
DB06190,The risk or severity of hypertension can be increased when Cyclosporine is combined with Solabegron.,Solabegron,DB00091
DB06690,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nitrous oxide.,Nitrous oxide,DB00091
DB06694,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylometazoline.,Xylometazoline,DB00091
DB06701,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dexmethylphenidate.,Dexmethylphenidate,DB00091
DB06706,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isometheptene.,Isometheptene,DB00091
DB06707,The risk or severity of hypertension can be increased when Cyclosporine is combined with Levonordefrin.,Levonordefrin,DB00091
DB06711,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naphazoline.,Naphazoline,DB00091
DB06764,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetryzoline.,Tetryzoline,DB00091
DB08810,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cinitapride.,Cinitapride,DB00091
DB08841,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tyramine.,Tyramine,DB00091
DB08925,The risk or severity of hypertension can be increased when Cyclosporine is combined with Adrafinil.,Adrafinil,DB00091
DB08941,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoxsuprine.,Isoxsuprine,DB00091
DB08950,The risk or severity of hypertension can be increased when Cyclosporine is combined with Indoramin.,Indoramin,DB00091
DB08957,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hexoprenaline.,Hexoprenaline,DB00091
DB08985,The risk or severity of hypertension can be increased when Cyclosporine is combined with Etilefrine.,Etilefrine,DB00091
DB09202,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cirazoline.,Cirazoline,DB00091
DB09203,The risk or severity of hypertension can be increased when Cyclosporine is combined with Synephrine.,Synephrine,DB00091
DB09242,The risk or severity of hypertension can be increased when Cyclosporine is combined with Moxonidine.,Moxonidine,DB00091
DB09243,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hydracarbazine.,Hydracarbazine,DB00091
DB09246,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benmoxin.,Benmoxin,DB00091
DB09248,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mebanazine.,Mebanazine,DB00091
DB09249,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octamoxin.,Octamoxin,DB00091
DB09250,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pheniprazine.,Pheniprazine,DB00091
DB09251,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxypropazine.,Phenoxypropazine,DB00091
DB09252,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pivhydrazine.,Pivhydrazine,DB00091
DB09253,The risk or severity of hypertension can be increased when Cyclosporine is combined with Safrazine.,Safrazine,DB00091
DB09254,The risk or severity of hypertension can be increased when Cyclosporine is combined with Caroxazone.,Caroxazone,DB00091
DB09273,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxofylline.,Doxofylline,DB00091
DB09480,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iofetamine I-123.,Iofetamine I-123,DB00091
DB11124,The risk or severity of hypertension can be increased when Cyclosporine is combined with Racepinephrine.,Racepinephrine,DB00091
DB11373,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amitraz.,Amitraz,DB00091
DB11428,The risk or severity of hypertension can be increased when Cyclosporine is combined with Medetomidine.,Medetomidine,DB00091
DB11477,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylazine.,Xylazine,DB00091
DB11481,The risk or severity of hypertension can be increased when Cyclosporine is combined with Atipamezole.,Atipamezole,DB00091
DB11541,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ractopamine.,Ractopamine,DB00091
DB11543,The risk or severity of hypertension can be increased when Cyclosporine is combined with Romifidine.,Romifidine,DB00091
DB11556,The risk or severity of hypertension can be increased when Cyclosporine is combined with Detomidine.,Detomidine,DB00091
DB11738,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rilmenidine.,Rilmenidine,DB00091
DB11755,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetrahydrocannabivarin.,Tetrahydrocannabivarin,DB00091
DB11871,The risk or severity of hypertension can be increased when Cyclosporine is combined with PF-00610355.,PF-00610355,DB00091
DB12080,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritobegron.,Ritobegron,DB00091
DB12100,The risk or severity of hypertension can be increased when Cyclosporine is combined with Abediterol.,Abediterol,DB00091
DB12248,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tulobuterol.,Tulobuterol,DB00091
DB12313,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopexamine.,Dopexamine,DB00091
DB12361,The risk or severity of hypertension can be increased when Cyclosporine is combined with Piclozotan.,Piclozotan,DB00091
DB12551,The risk or severity of hypertension can be increased when Cyclosporine is combined with Idazoxan.,Idazoxan,DB00091
DB12661,The risk or severity of hypertension can be increased when Cyclosporine is combined with Urapidil.,Urapidil,DB00091
DB12779,The risk or severity of hypertension can be increased when Cyclosporine is combined with Higenamine.,Higenamine,DB00091
DB12846,The risk or severity of hypertension can be increased when Cyclosporine is combined with Reproterol.,Reproterol,DB00091
DB12927,The risk or severity of hypertension can be increased when Cyclosporine is combined with Theodrenaline.,Theodrenaline,DB00091
DB13064,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tramazoline.,Tramazoline,DB00091
DB13108,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephedrone.,Mephedrone,DB00091
DB13251,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octopamine.,Octopamine,DB00091
DB13316,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ibopamine.,Ibopamine,DB00091
DB13323,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trichloroethylene.,Trichloroethylene,DB00091
DB13341,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenozolone.,Fenozolone,DB00091
DB13378,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norfenefrine.,Norfenefrine,DB00091
DB13398,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxyfedrine.,Oxyfedrine,DB00091
DB13453,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xenon.,Xenon,DB00091
DB13510,The risk or severity of hypertension can be increased when Cyclosporine is combined with Buflomedil.,Buflomedil,DB00091
DB13520,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metergoline.,Metergoline,DB00091
DB13559,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rimiterol.,Rimiterol,DB00091
DB13624,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxyphenamine.,Methoxyphenamine,DB00091
DB13692,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tretoquinol.,Tretoquinol,DB00091
DB13703,The risk or severity of hypertension can be increased when Cyclosporine is combined with Gepefrine.,Gepefrine,DB00091
DB13777,The risk or severity of hypertension can be increased when Cyclosporine is combined with Prenalterol.,Prenalterol,DB00091
DB13781,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xamoterol.,Xamoterol,DB00091
DB13852,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mefenorex.,Mefenorex,DB00091
DB13875,The risk or severity of hypertension can be increased when Cyclosporine is combined with Harmaline.,Harmaline,DB00091
DB13917,The risk or severity of hypertension can be increased when Cyclosporine is combined with Deoxyepinephrine.,Deoxyepinephrine,DB00091
DB13940,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.","2,5-Dimethoxy-4-ethylthioamphetamine",DB00091
DB14231,The risk or severity of hypertension can be increased when Cyclosporine is combined with Quinoline Yellow WS.,Quinoline Yellow WS,DB00091
DB00708,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sufentanil.,Sufentanil,DB00091
DB00865,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benzphetamine.,Benzphetamine,DB00091
DB01049,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergoloid mesylate.,Ergoloid mesylate,DB00091
DB01236,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sevoflurane.,Sevoflurane,DB00091
DB06216,The risk or severity of hypertension can be increased when Cyclosporine is combined with Asenapine.,Asenapine,DB00091
DB13399,The risk or severity of hypertension can be increased when Cyclosporine is combined with Terguride.,Terguride,DB00091
DB00831,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trifluoperazine.,Trifluoperazine,DB00091
DB00875,The risk or severity of hypertension can be increased when Cyclosporine is combined with Flupentixol.,Flupentixol,DB00091
DB01159,The risk or severity of hypertension can be increased when Cyclosporine is combined with Halothane.,Halothane,DB00091
DB01253,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergometrine.,Ergometrine,DB00091
DB09080,The risk or severity of hypertension can be increased when Cyclosporine is combined with Olodaterol.,Olodaterol,DB00091
DB13598,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethyl ether.,Diethyl ether,DB00091
DB01186,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pergolide.,Pergolide,DB00091
DB15685,The risk or severity of hypertension can be increased when Cyclosporine is combined with Selpercatinib.,Selpercatinib,DB00091
DB01166,The metabolism of Cilostazol can be decreased when combined with Cyclosporine.,Cilostazol,DB00091
DB00813,The metabolism of Cyclosporine can be decreased when combined with Fentanyl.,Fentanyl,DB00091
DB04946,The metabolism of Iloperidone can be decreased when combined with Cyclosporine.,Iloperidone,DB00091
DB01256,The metabolism of Retapamulin can be decreased when combined with Cyclosporine.,Retapamulin,DB00091
DB00862,The metabolism of Vardenafil can be decreased when combined with Cyclosporine.,Vardenafil,DB00091
DB00402,The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.,Eszopiclone,DB00091
DB01198,The metabolism of Zopiclone can be decreased when combined with Cyclosporine.,Zopiclone,DB00091
DB09046,The metabolism of Cyclosporine can be increased when combined with Metreleptin.,Metreleptin,DB00091
DB00346,The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.,Alfuzosin,DB00091
DB00404,The metabolism of Alprazolam can be decreased when combined with Cyclosporine.,Alprazolam,DB00091
DB00289,The metabolism of Atomoxetine can be decreased when combined with Cyclosporine.,Atomoxetine,DB00091
DB00742,The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.,Mannitol,DB00091
DB09299,Tenofovir alafenamide may increase the nephrotoxic activities of Cyclosporine.,Tenofovir alafenamide,DB00091
DB14126,Tenofovir may increase the nephrotoxic activities of Cyclosporine.,Tenofovir,DB00091
DB00300,Cyclosporine may increase the nephrotoxic activities of Tenofovir disoproxil.,Tenofovir disoproxil,DB00091
DB00682,The serum concentration of Warfarin can be increased when it is combined with Cyclosporine.,Warfarin,DB00091
DB01418,The serum concentration of Acenocoumarol can be increased when it is combined with Cyclosporine.,Acenocoumarol,DB00091
DB08496,The serum concentration of (R)-warfarin can be increased when it is combined with Cyclosporine.,(R)-warfarin,DB00091
DB08735,"The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Cyclosporine.","R,S-Warfarin alcohol",DB00091
DB08736,"The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Cyclosporine.","S,R-Warfarin alcohol",DB00091
DB14055,The serum concentration of (S)-Warfarin can be increased when it is combined with Cyclosporine.,(S)-Warfarin,DB00091
DB00683,The serum concentration of Midazolam can be increased when it is combined with Cyclosporine.,Midazolam,DB00091
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclosporine.,Sulfamethoxazole,DB00091
DB00997,The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.,Doxorubicin,DB00091
DB09272,The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.,Eluxadoline,DB00091
DB00636,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.,Clofibrate,DB00091
DB01039,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.,Fenofibrate,DB00091
DB01241,The risk or severity of renal failure can be increased when Cyclosporine is combined with Gemfibrozil.,Gemfibrozil,DB00091
DB01393,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.,Bezafibrate,DB00091
DB08983,The risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate.,Etofibrate,DB00091
DB09064,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ciprofibrate.,Ciprofibrate,DB00091
DB13433,The risk or severity of renal failure can be increased when Cyclosporine is combined with Simfibrate.,Simfibrate,DB00091
DB13460,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ronifibrate.,Ronifibrate,DB00091
DB13780,The risk or severity of renal failure can be increased when Cyclosporine is combined with Aluminium clofibrate.,Aluminium clofibrate,DB00091
DB13849,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibride.,Clofibride,DB00091
DB13873,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibric acid.,Fenofibric acid,DB00091
DB00350,The risk or severity of Hypertrichosis can be increased when Cyclosporine is combined with Minoxidil.,Minoxidil,DB00091
DB00864,Tacrolimus may increase the nephrotoxic activities of Cyclosporine.,Tacrolimus,DB00091
DB00104,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.,Octreotide,DB00091
DB04894,The serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.,Vapreotide,DB00091
DB06663,The serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.,Pasireotide,DB00091
DB06791,The serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.,Lanreotide,DB00091
DB09099,The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.,Somatostatin,DB00091
DB00126,The serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.,Ascorbic acid,DB00091
DB00177,The risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclosporine.,Valsartan,DB00091
DB00275,The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclosporine.,Olmesartan,DB00091
DB00678,The risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.,Losartan,DB00091
DB00796,The risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Cyclosporine.,Candesartan cilexetil,DB00091
DB00876,The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclosporine.,Eprosartan,DB00091
DB00966,The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.,Telmisartan,DB00091
DB01029,The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclosporine.,Irbesartan,DB00091
DB01342,The risk or severity of hyperkalemia can be increased when Forasartan is combined with Cyclosporine.,Forasartan,DB00091
DB01347,The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Cyclosporine.,Saprisartan,DB00091
DB01349,The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Cyclosporine.,Tasosartan,DB00091
DB06763,The risk or severity of hyperkalemia can be increased when Saralasin is combined with Cyclosporine.,Saralasin,DB00091
DB08822,The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Cyclosporine.,Azilsartan medoxomil,DB00091
DB09279,The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Cyclosporine.,Fimasartan,DB00091
DB13919,The risk or severity of hyperkalemia can be increased when Candesartan is combined with Cyclosporine.,Candesartan,DB00091
DB00199,The metabolism of Cyclosporine can be decreased when combined with Erythromycin.,Erythromycin,DB00091
DB00207,The metabolism of Cyclosporine can be decreased when combined with Azithromycin.,Azithromycin,DB00091
DB00954,The metabolism of Cyclosporine can be decreased when combined with Dirithromycin.,Dirithromycin,DB00091
DB00976,The metabolism of Cyclosporine can be decreased when combined with Telithromycin.,Telithromycin,DB00091
DB01152,The metabolism of Cyclosporine can be decreased when combined with Candicidin.,Candicidin,DB00091
DB01211,The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.,Clarithromycin,DB00091
DB01321,The metabolism of Cyclosporine can be decreased when combined with Josamycin.,Josamycin,DB00091
DB01873,The metabolism of Cyclosporine can be decreased when combined with Epothilone D.,Epothilone D,DB00091
DB03010,The metabolism of Cyclosporine can be decreased when combined with Patupilone.,Patupilone,DB00091
DB04070,The metabolism of Cyclosporine can be decreased when combined with 6-Deoxyerythronolide B.,6-Deoxyerythronolide B,DB00091
DB05903,The metabolism of Cyclosporine can be decreased when combined with KOS-1584.,KOS-1584,DB00091
DB06233,The metabolism of Cyclosporine can be decreased when combined with Ridaforolimus.,Ridaforolimus,DB00091
DB06318,The metabolism of Cyclosporine can be decreased when combined with AVE9633.,AVE9633,DB00091
DB06342,The metabolism of Cyclosporine can be decreased when combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00091
DB06419,The metabolism of Cyclosporine can be decreased when combined with Cethromycin.,Cethromycin,DB00091
DB06587,The metabolism of Cyclosporine can be decreased when combined with Mitemcinal.,Mitemcinal,DB00091
DB07348,The metabolism of Cyclosporine can be decreased when combined with Brefeldin A.,Brefeldin A,DB00091
DB09308,The metabolism of Cyclosporine can be decreased when combined with Solithromycin.,Solithromycin,DB00091
DB09309,The metabolism of Cyclosporine can be decreased when combined with Kitasamycin.,Kitasamycin,DB00091
DB11383,The metabolism of Cyclosporine can be decreased when combined with Carbomycin.,Carbomycin,DB00091
DB11400,The metabolism of Cyclosporine can be decreased when combined with Doramectin.,Doramectin,DB00091
DB11405,The metabolism of Cyclosporine can be decreased when combined with Eprinomectin.,Eprinomectin,DB00091
DB11442,The metabolism of Cyclosporine can be decreased when combined with Oleandomycin.,Oleandomycin,DB00091
DB11459,The metabolism of Cyclosporine can be decreased when combined with Selamectin.,Selamectin,DB00091
DB11470,The metabolism of Cyclosporine can be decreased when combined with Tildipirosin.,Tildipirosin,DB00091
DB11471,The metabolism of Cyclosporine can be decreased when combined with Tilmicosin.,Tilmicosin,DB00091
DB11475,The metabolism of Cyclosporine can be decreased when combined with Tylosin.,Tylosin,DB00091
DB11554,The metabolism of Cyclosporine can be decreased when combined with Tylvalosin.,Tylvalosin,DB00091
DB11752,The metabolism of Cyclosporine can be decreased when combined with Bryostatin 1.,Bryostatin 1,DB00091
DB12089,The metabolism of Cyclosporine can be decreased when combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00091
DB12266,The metabolism of Cyclosporine can be decreased when combined with Epofolate.,Epofolate,DB00091
DB12391,The metabolism of Cyclosporine can be decreased when combined with Sagopilone.,Sagopilone,DB00091
DB12489,The metabolism of Cyclosporine can be decreased when combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00091
DB13179,The metabolism of Cyclosporine can be decreased when combined with Troleandomycin.,Troleandomycin,DB00091
DB13287,The metabolism of Cyclosporine can be decreased when combined with Miocamycin.,Miocamycin,DB00091
DB13338,The metabolism of Cyclosporine can be decreased when combined with Flurithromycin.,Flurithromycin,DB00091
DB13409,The metabolism of Cyclosporine can be decreased when combined with Rokitamycin.,Rokitamycin,DB00091
DB13456,The metabolism of Cyclosporine can be decreased when combined with Midecamycin.,Midecamycin,DB00091
DB13633,The metabolism of Cyclosporine can be decreased when combined with Mepartricin.,Mepartricin,DB00091
DB00903,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.,Etacrynic acid,DB00091
DB00241,The metabolism of Cyclosporine can be increased when combined with Butalbital.,Butalbital,DB00091
DB00312,The metabolism of Cyclosporine can be increased when combined with Pentobarbital.,Pentobarbital,DB00091
DB00418,The metabolism of Cyclosporine can be increased when combined with Secobarbital.,Secobarbital,DB00091
DB00474,The metabolism of Cyclosporine can be increased when combined with Methohexital.,Methohexital,DB00091
DB00599,The metabolism of Cyclosporine can be increased when combined with Thiopental.,Thiopental,DB00091
DB00794,The metabolism of Cyclosporine can be increased when combined with Primidone.,Primidone,DB00091
DB00849,The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.,Methylphenobarbital,DB00091
DB01154,The metabolism of Cyclosporine can be increased when combined with Thiamylal.,Thiamylal,DB00091
DB01174,The metabolism of Cyclosporine can be increased when combined with Phenobarbital.,Phenobarbital,DB00091
DB01351,The metabolism of Cyclosporine can be increased when combined with Amobarbital.,Amobarbital,DB00091
DB01355,The metabolism of Cyclosporine can be increased when combined with Hexobarbital.,Hexobarbital,DB00091
DB01483,The metabolism of Cyclosporine can be increased when combined with Barbital.,Barbital,DB00091
DB09001,The metabolism of Cyclosporine can be increased when combined with Barbexaclone.,Barbexaclone,DB00091
DB00237,The metabolism of Butabarbital can be increased when combined with Cyclosporine.,Butabarbital,DB00091
DB09280,The serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.,Lumacaftor,DB00091
DB00214,The risk or severity of renal failure can be increased when Cyclosporine is combined with Torasemide.,Torasemide,DB00091
DB00887,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bumetanide.,Bumetanide,DB00091
DB02925,The risk or severity of renal failure can be increased when Cyclosporine is combined with Piretanide.,Piretanide,DB00091
DB08961,The risk or severity of renal failure can be increased when Cyclosporine is combined with Azosemide.,Azosemide,DB00091
DB00203,The risk or severity of renal failure can be increased when Sildenafil is combined with Cyclosporine.,Sildenafil,DB00091
DB00232,The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.,Methyclothiazide,DB00091
DB00263,The risk or severity of renal failure can be increased when Sulfisoxazole is combined with Cyclosporine.,Sulfisoxazole,DB00091
DB00310,The risk or severity of renal failure can be increased when Chlorthalidone is combined with Cyclosporine.,Chlorthalidone,DB00091
DB00311,The risk or severity of renal failure can be increased when Ethoxzolamide is combined with Cyclosporine.,Ethoxzolamide,DB00091
DB00359,The risk or severity of renal failure can be increased when Sulfadiazine is combined with Cyclosporine.,Sulfadiazine,DB00091
DB00436,The risk or severity of renal failure can be increased when Bendroflumethiazide is combined with Cyclosporine.,Bendroflumethiazide,DB00091
DB00524,The risk or severity of renal failure can be increased when Metolazone is combined with Cyclosporine.,Metolazone,DB00091
DB00562,The risk or severity of renal failure can be increased when Benzthiazide is combined with Cyclosporine.,Benzthiazide,DB00091
DB00576,The risk or severity of renal failure can be increased when Sulfamethizole is combined with Cyclosporine.,Sulfamethizole,DB00091
DB00606,The risk or severity of renal failure can be increased when Cyclothiazide is combined with Cyclosporine.,Cyclothiazide,DB00091
DB00664,The risk or severity of renal failure can be increased when Sulfametopyrazine is combined with Cyclosporine.,Sulfametopyrazine,DB00091
DB00669,The risk or severity of renal failure can be increased when Sumatriptan is combined with Cyclosporine.,Sumatriptan,DB00091
DB00706,The risk or severity of renal failure can be increased when Tamsulosin is combined with Cyclosporine.,Tamsulosin,DB00091
DB00774,The risk or severity of renal failure can be increased when Hydroflumethiazide is combined with Cyclosporine.,Hydroflumethiazide,DB00091
DB00808,The risk or severity of renal failure can be increased when Indapamide is combined with Cyclosporine.,Indapamide,DB00091
DB00880,The risk or severity of renal failure can be increased when Chlorothiazide is combined with Cyclosporine.,Chlorothiazide,DB00091
DB00891,The risk or severity of renal failure can be increased when Sulfapyridine is combined with Cyclosporine.,Sulfapyridine,DB00091
DB00909,The risk or severity of renal failure can be increased when Zonisamide is combined with Cyclosporine.,Zonisamide,DB00091
DB00999,The risk or severity of renal failure can be increased when Hydrochlorothiazide is combined with Cyclosporine.,Hydrochlorothiazide,DB00091
DB01021,The risk or severity of renal failure can be increased when Trichlormethiazide is combined with Cyclosporine.,Trichlormethiazide,DB00091
DB01032,The risk or severity of renal failure can be increased when Probenecid is combined with Cyclosporine.,Probenecid,DB00091
DB01119,The risk or severity of renal failure can be increased when Diazoxide is combined with Cyclosporine.,Diazoxide,DB00091
DB01144,The risk or severity of renal failure can be increased when Diclofenamide is combined with Cyclosporine.,Diclofenamide,DB00091
DB01298,The risk or severity of renal failure can be increased when Sulfacytine is combined with Cyclosporine.,Sulfacytine,DB00091
DB01299,The risk or severity of renal failure can be increased when Sulfadoxine is combined with Cyclosporine.,Sulfadoxine,DB00091
DB01324,The risk or severity of renal failure can be increased when Polythiazide is combined with Cyclosporine.,Polythiazide,DB00091
DB01325,The risk or severity of renal failure can be increased when Quinethazone is combined with Cyclosporine.,Quinethazone,DB00091
DB01382,The risk or severity of renal failure can be increased when Glymidine is combined with Cyclosporine.,Glymidine,DB00091
DB01581,The risk or severity of renal failure can be increased when Sulfamerazine is combined with Cyclosporine.,Sulfamerazine,DB00091
DB01582,The risk or severity of renal failure can be increased when Sulfamethazine is combined with Cyclosporine.,Sulfamethazine,DB00091
DB04707,The risk or severity of renal failure can be increased when Hydroxyfasudil is combined with Cyclosporine.,Hydroxyfasudil,DB00091
DB06150,The risk or severity of renal failure can be increased when Sulfadimethoxine is combined with Cyclosporine.,Sulfadimethoxine,DB00091
DB06729,The risk or severity of renal failure can be increased when Sulfaphenazole is combined with Cyclosporine.,Sulfaphenazole,DB00091
DB06821,The risk or severity of renal failure can be increased when Sulfameter is combined with Cyclosporine.,Sulfameter,DB00091
DB07996,The risk or severity of renal failure can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclosporine.,5-(2-methylpiperazine-1-sulfonyl)isoquinoline,DB00091
DB08162,The risk or severity of renal failure can be increased when Fasudil is combined with Cyclosporine.,Fasudil,DB00091
DB08798,The risk or severity of renal failure can be increased when Sulfamoxole is combined with Cyclosporine.,Sulfamoxole,DB00091
DB11389,The risk or severity of renal failure can be increased when Clorsulon is combined with Cyclosporine.,Clorsulon,DB00091
DB11461,The risk or severity of renal failure can be increased when Sulfachlorpyridazine is combined with Cyclosporine.,Sulfachlorpyridazine,DB00091
DB11462,The risk or severity of renal failure can be increased when Sulfaethoxypyridazine is combined with Cyclosporine.,Sulfaethoxypyridazine,DB00091
DB11463,The risk or severity of renal failure can be increased when Sulfanitran is combined with Cyclosporine.,Sulfanitran,DB00091
DB11464,The risk or severity of renal failure can be increased when Sulfaquinoxaline is combined with Cyclosporine.,Sulfaquinoxaline,DB00091
DB12051,The risk or severity of renal failure can be increased when Setrobuvir is combined with Cyclosporine.,Setrobuvir,DB00091
DB12921,The risk or severity of renal failure can be increased when Chlorsulfaquinoxaline is combined with Cyclosporine.,Chlorsulfaquinoxaline,DB00091
DB13214,The risk or severity of renal failure can be increased when Sulfadicramide is combined with Cyclosporine.,Sulfadicramide,DB00091
DB13248,The risk or severity of renal failure can be increased when Phthalylsulfathiazole is combined with Cyclosporine.,Phthalylsulfathiazole,DB00091
DB13283,The risk or severity of renal failure can be increased when Sulfaisodimidine is combined with Cyclosporine.,Sulfaisodimidine,DB00091
DB13284,The risk or severity of renal failure can be increased when Meticrane is combined with Cyclosporine.,Meticrane,DB00091
DB13320,The risk or severity of renal failure can be increased when Sulfaperin is combined with Cyclosporine.,Sulfaperin,DB00091
DB13405,The risk or severity of renal failure can be increased when Mefruside is combined with Cyclosporine.,Mefruside,DB00091
DB13430,The risk or severity of renal failure can be increased when Mebutizide is combined with Cyclosporine.,Mebutizide,DB00091
DB13485,The risk or severity of renal failure can be increased when Sulfametomidine is combined with Cyclosporine.,Sulfametomidine,DB00091
DB13532,The risk or severity of renal failure can be increased when Cyclopenthiazide is combined with Cyclosporine.,Cyclopenthiazide,DB00091
DB13547,The risk or severity of renal failure can be increased when Sulfatolamide is combined with Cyclosporine.,Sulfatolamide,DB00091
DB13556,The risk or severity of renal failure can be increased when Sulfamazone is combined with Cyclosporine.,Sulfamazone,DB00091
DB13580,The risk or severity of renal failure can be increased when Succinylsulfathiazole is combined with Cyclosporine.,Succinylsulfathiazole,DB00091
DB13617,The risk or severity of renal failure can be increased when Clorexolone is combined with Cyclosporine.,Clorexolone,DB00091
DB13663,The risk or severity of renal failure can be increased when Clofenamide is combined with Cyclosporine.,Clofenamide,DB00091
DB13699,The risk or severity of renal failure can be increased when Sulfathiourea is combined with Cyclosporine.,Sulfathiourea,DB00091
DB13708,The risk or severity of renal failure can be increased when Fenquizone is combined with Cyclosporine.,Fenquizone,DB00091
DB13726,The risk or severity of renal failure can be increased when Sulfaguanidine is combined with Cyclosporine.,Sulfaguanidine,DB00091
DB13773,The risk or severity of renal failure can be increased when Sulfamethoxypyridazine is combined with Cyclosporine.,Sulfamethoxypyridazine,DB00091
DB13792,The risk or severity of renal failure can be increased when Clopamide is combined with Cyclosporine.,Clopamide,DB00091
DB13803,The risk or severity of renal failure can be increased when Xipamide is combined with Cyclosporine.,Xipamide,DB00091
DB14033,The risk or severity of renal failure can be increased when Acetyl sulfisoxazole is combined with Cyclosporine.,Acetyl sulfisoxazole,DB00091
DB14708,The risk or severity of renal failure can be increased when Tosylchloramide is combined with Cyclosporine.,Tosylchloramide,DB00091
DB06370,The risk or severity of renal failure can be increased when Cyclosporine is combined with Indisulam.,Indisulam,DB00091
DB00703,The risk or severity of renal failure can be increased when Methazolamide is combined with Cyclosporine.,Methazolamide,DB00091
DB00384,The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.,Triamterene,DB00091
DB00421,The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.,Spironolactone,DB00091
DB00594,The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.,Amiloride,DB00091
DB00700,The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclosporine.,Eplerenone,DB00091
DB09015,The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Cyclosporine.,Canrenoic acid,DB00091
DB12221,The risk or severity of hyperkalemia can be increased when Canrenone is combined with Cyclosporine.,Canrenone,DB00091
DB00229,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotiam.,Cefotiam,DB00091
DB00267,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmenoxime.,Cefmenoxime,DB00091
DB00274,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmetazole.,Cefmetazole,DB00091
DB00430,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpiramide.,Cefpiramide,DB00091
DB00447,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.,Loracarbef,DB00091
DB00456,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefalotin.,Cefalotin,DB00091
DB00493,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.,Cefotaxime,DB00091
DB00626,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Bacitracin.,Bacitracin,DB00091
DB00689,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephaloglycin.,Cephaloglycin,DB00091
DB00718,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir dipivoxil.,Adefovir dipivoxil,DB00091
DB00923,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceforanide.,Ceforanide,DB00091
DB01066,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren.,Cefditoren,DB00091
DB01111,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Colistimethate.,Colistimethate,DB00091
DB01112,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime.,Cefuroxime,DB00091
DB01139,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefapirin.,Cefapirin,DB00091
DB01150,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefprozil.,Cefprozil,DB00091
DB01326,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefamandole.,Cefamandole,DB00091
DB01327,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazolin.,Cefazolin,DB00091
DB01328,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefonicid.,Cefonicid,DB00091
DB01331,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoxitin.,Cefoxitin,DB00091
DB01332,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftizoxime.,Ceftizoxime,DB00091
DB01413,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefepime.,Cefepime,DB00091
DB01414,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefacetrile.,Cefacetrile,DB00091
DB01416,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime.,Cefpodoxime,DB00091
DB02247,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Hydrolyzed Cephalothin.,Hydrolyzed Cephalothin,DB00091
DB03450,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalothin Group.,Cephalothin Group,DB00091
DB04570,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef.,Latamoxef,DB00091
DB04918,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftobiprole.,Ceftobiprole,DB00091
DB06590,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.,Ceftaroline fosamil,DB00091
DB09008,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefaloridine.,Cefaloridine,DB00091
DB09062,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefminox.,Cefminox,DB00091
DB11935,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Flomoxef.,Flomoxef,DB00091
DB13266,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefatrizine.,Cefatrizine,DB00091
DB13461,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefcapene.,Cefcapene,DB00091
DB13470,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefodizime.,Cefodizime,DB00091
DB13499,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefsulodin.,Cefsulodin,DB00091
DB13504,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefetamet.,Cefetamet,DB00091
DB13638,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefbuperazone.,Cefbuperazone,DB00091
DB13667,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefozopran.,Cefozopran,DB00091
DB13682,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpirome.,Cefpirome,DB00091
DB13778,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazedone.,Cefazedone,DB00091
DB13821,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftezole.,Ceftezole,DB00091
DB13868,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir.,Adefovir,DB00091
DB14713,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Inotersen.,Inotersen,DB00091
DB01438,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Phenazopyridine.,Phenazopyridine,DB00091
DB15066,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Givosiran.,Givosiran,DB00091
DB01329,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoperazone.,Cefoperazone,DB00091
DB01356,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium cation.,Lithium cation,DB00091
DB14507,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium citrate.,Lithium citrate,DB00091
DB00621,The risk or severity of liver damage can be increased when Oxandrolone is combined with Cyclosporine.,Oxandrolone,DB00091
DB00624,The risk or severity of liver damage can be increased when Testosterone is combined with Cyclosporine.,Testosterone,DB00091
DB00984,The risk or severity of liver damage can be increased when Nandrolone phenpropionate is combined with Cyclosporine.,Nandrolone phenpropionate,DB00091
DB01185,The risk or severity of liver damage can be increased when Fluoxymesterone is combined with Cyclosporine.,Fluoxymesterone,DB00091
DB01406,The risk or severity of liver damage can be increased when Danazol is combined with Cyclosporine.,Danazol,DB00091
DB01420,The risk or severity of liver damage can be increased when Testosterone propionate is combined with Cyclosporine.,Testosterone propionate,DB00091
DB02901,The risk or severity of liver damage can be increased when Stanolone is combined with Cyclosporine.,Stanolone,DB00091
DB06412,The risk or severity of liver damage can be increased when Oxymetholone is combined with Cyclosporine.,Oxymetholone,DB00091
DB06710,The risk or severity of liver damage can be increased when Methyltestosterone is combined with Cyclosporine.,Methyltestosterone,DB00091
DB06718,The risk or severity of liver damage can be increased when Stanozolol is combined with Cyclosporine.,Stanozolol,DB00091
DB08804,The risk or severity of liver damage can be increased when Nandrolone decanoate is combined with Cyclosporine.,Nandrolone decanoate,DB00091
DB12461,The risk or severity of liver damage can be increased when GLPG-0492 is combined with Cyclosporine.,GLPG-0492,DB00091
DB13169,The risk or severity of liver damage can be increased when Nandrolone is combined with Cyclosporine.,Nandrolone,DB00091
DB13587,The risk or severity of liver damage can be increased when Mesterolone is combined with Cyclosporine.,Mesterolone,DB00091
DB13943,The risk or severity of liver damage can be increased when Testosterone cypionate is combined with Cyclosporine.,Testosterone cypionate,DB00091
DB13944,The risk or severity of liver damage can be increased when Testosterone enanthate is combined with Cyclosporine.,Testosterone enanthate,DB00091
DB14010,"The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Cyclosporine.","5-methoxy-N,N-dimethyltryptamine",DB00091
DB00318,The metabolism of Codeine can be decreased when combined with Cyclosporine.,Codeine,DB00091
DB00454,The metabolism of Meperidine can be decreased when combined with Cyclosporine.,Meperidine,DB00091
DB00458,The metabolism of Imipramine can be decreased when combined with Cyclosporine.,Imipramine,DB00091
DB00908,The metabolism of Quinidine can be decreased when combined with Cyclosporine.,Quinidine,DB00091
DB01035,The metabolism of Procainamide can be decreased when combined with Cyclosporine.,Procainamide,DB00091
DB01151,The metabolism of Desipramine can be decreased when combined with Cyclosporine.,Desipramine,DB00091
DB01242,The metabolism of Clomipramine can be decreased when combined with Cyclosporine.,Clomipramine,DB00091
DB00238,The metabolism of Cyclosporine can be decreased when combined with Nevirapine.,Nevirapine,DB00091
DB11586,The metabolism of Cyclosporine can be decreased when combined with Asunaprevir.,Asunaprevir,DB00091
DB00497,The metabolism of Cyclosporine can be decreased when combined with Oxycodone.,Oxycodone,DB00091
DB00514,The metabolism of Cyclosporine can be decreased when combined with Dextromethorphan.,Dextromethorphan,DB00091
DB00731,The metabolism of Cyclosporine can be decreased when combined with Nateglinide.,Nateglinide,DB00091
DB00738,The metabolism of Cyclosporine can be decreased when combined with Pentamidine.,Pentamidine,DB00091
DB00904,The metabolism of Cyclosporine can be decreased when combined with Ondansetron.,Ondansetron,DB00091
DB01114,The metabolism of Cyclosporine can be decreased when combined with Chlorpheniramine.,Chlorpheniramine,DB00091
DB01184,The metabolism of Cyclosporine can be decreased when combined with Domperidone.,Domperidone,DB00091
DB09068,The metabolism of Cyclosporine can be decreased when combined with Vortioxetine.,Vortioxetine,DB00091
DB11915,The metabolism of Cyclosporine can be decreased when combined with Valbenazine.,Valbenazine,DB00091
DB12161,The metabolism of Cyclosporine can be decreased when combined with Deutetrabenazine.,Deutetrabenazine,DB00091
DB00176,The metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.,Fluvoxamine,DB00091
DB00281,The metabolism of Cyclosporine can be decreased when combined with Lidocaine.,Lidocaine,DB00091
DB00285,The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.,Venlafaxine,DB00091
DB00316,The metabolism of Cyclosporine can be decreased when combined with Acetaminophen.,Acetaminophen,DB00091
DB00317,The metabolism of Cyclosporine can be decreased when combined with Gefitinib.,Gefitinib,DB00091
DB00333,The metabolism of Cyclosporine can be decreased when combined with Methadone.,Methadone,DB00091
DB00342,The metabolism of Cyclosporine can be decreased when combined with Terfenadine.,Terfenadine,DB00091
DB00343,The metabolism of Cyclosporine can be decreased when combined with Diltiazem.,Diltiazem,DB00091
DB00344,The metabolism of Cyclosporine can be decreased when combined with Protriptyline.,Protriptyline,DB00091
DB00468,The metabolism of Cyclosporine can be decreased when combined with Quinine.,Quinine,DB00091
DB00472,The metabolism of Cyclosporine can be decreased when combined with Fluoxetine.,Fluoxetine,DB00091
DB00476,The metabolism of Cyclosporine can be decreased when combined with Duloxetine.,Duloxetine,DB00091
DB00477,The metabolism of Cyclosporine can be decreased when combined with Chlorpromazine.,Chlorpromazine,DB00091
DB00490,The metabolism of Cyclosporine can be decreased when combined with Buspirone.,Buspirone,DB00091
DB00543,The metabolism of Cyclosporine can be decreased when combined with Amoxapine.,Amoxapine,DB00091
DB00590,The metabolism of Cyclosporine can be decreased when combined with Doxazosin.,Doxazosin,DB00091
DB00637,The metabolism of Cyclosporine can be decreased when combined with Astemizole.,Astemizole,DB00091
DB00715,The metabolism of Cyclosporine can be decreased when combined with Paroxetine.,Paroxetine,DB00091
DB00836,The metabolism of Cyclosporine can be decreased when combined with Loperamide.,Loperamide,DB00091
DB00921,The metabolism of Cyclosporine can be decreased when combined with Buprenorphine.,Buprenorphine,DB00091
DB00932,The metabolism of Cyclosporine can be decreased when combined with Tipranavir.,Tipranavir,DB00091
DB00972,The metabolism of Cyclosporine can be decreased when combined with Azelastine.,Azelastine,DB00091
DB01037,The metabolism of Cyclosporine can be decreased when combined with Selegiline.,Selegiline,DB00091
DB01069,The metabolism of Cyclosporine can be decreased when combined with Promethazine.,Promethazine,DB00091
DB01100,The metabolism of Cyclosporine can be decreased when combined with Pimozide.,Pimozide,DB00091
DB01104,The metabolism of Cyclosporine can be decreased when combined with Sertraline.,Sertraline,DB00091
DB01182,The metabolism of Cyclosporine can be decreased when combined with Propafenone.,Propafenone,DB00091
DB01244,The metabolism of Cyclosporine can be decreased when combined with Bepridil.,Bepridil,DB00091
DB01392,The metabolism of Cyclosporine can be decreased when combined with Yohimbine.,Yohimbine,DB00091
DB06770,The metabolism of Cyclosporine can be decreased when combined with Benzyl alcohol.,Benzyl alcohol,DB00091
DB08893,The metabolism of Cyclosporine can be decreased when combined with Mirabegron.,Mirabegron,DB00091
DB09048,The metabolism of Cyclosporine can be decreased when combined with Netupitant.,Netupitant,DB00091
DB11963,The metabolism of Cyclosporine can be decreased when combined with Dacomitinib.,Dacomitinib,DB00091
DB12070,The metabolism of Cyclosporine can be decreased when combined with Letermovir.,Letermovir,DB00091
DB12332,The metabolism of Cyclosporine can be decreased when combined with Rucaparib.,Rucaparib,DB00091
DB13874,The metabolism of Cyclosporine can be decreased when combined with Enasidenib.,Enasidenib,DB00091
DB00216,The metabolism of Eletriptan can be decreased when combined with Cyclosporine.,Eletriptan,DB00091
DB00277,The metabolism of Theophylline can be decreased when combined with Cyclosporine.,Theophylline,DB00091
DB00496,The metabolism of Darifenacin can be decreased when combined with Cyclosporine.,Darifenacin,DB00091
DB00540,The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.,Nortriptyline,DB00091
DB00575,The metabolism of Clonidine can be decreased when combined with Cyclosporine.,Clonidine,DB00091
DB00726,The metabolism of Trimipramine can be decreased when combined with Cyclosporine.,Trimipramine,DB00091
DB01142,The metabolism of Doxepin can be decreased when combined with Cyclosporine.,Doxepin,DB00091
DB01224,The metabolism of Quetiapine can be decreased when combined with Cyclosporine.,Quetiapine,DB00091
DB00363,The metabolism of Cyclosporine can be decreased when combined with Clozapine.,Clozapine,DB00091
DB00396,The metabolism of Cyclosporine can be decreased when combined with Progesterone.,Progesterone,DB00091
DB00675,The metabolism of Cyclosporine can be decreased when combined with Tamoxifen.,Tamoxifen,DB00091
DB01115,The metabolism of Cyclosporine can be decreased when combined with Nifedipine.,Nifedipine,DB00091
DB04905,The metabolism of Cyclosporine can be decreased when combined with Tesmilifene.,Tesmilifene,DB00091
DB04920,The metabolism of Cyclosporine can be decreased when combined with Clevidipine.,Clevidipine,DB00091
DB01149,The metabolism of Cyclosporine can be decreased when combined with Nefazodone.,Nefazodone,DB00091
DB00705,The metabolism of Cyclosporine can be decreased when combined with Delavirdine.,Delavirdine,DB00091
DB00215,The metabolism of Citalopram can be decreased when combined with Cyclosporine.,Citalopram,DB00091
DB00335,The metabolism of Atenolol can be decreased when combined with Cyclosporine.,Atenolol,DB00091
DB01193,The metabolism of Acebutolol can be decreased when combined with Cyclosporine.,Acebutolol,DB00091
DB01203,The metabolism of Nadolol can be decreased when combined with Cyclosporine.,Nadolol,DB00091
DB04840,The metabolism of Debrisoquine can be decreased when combined with Cyclosporine.,Debrisoquine,DB00091
DB04846,The metabolism of Celiprolol can be decreased when combined with Cyclosporine.,Celiprolol,DB00091
DB09076,The metabolism of Umeclidinium can be decreased when combined with Cyclosporine.,Umeclidinium,DB00091
DB11770,The metabolism of Talinolol can be decreased when combined with Cyclosporine.,Talinolol,DB00091
DB11979,The metabolism of Elagolix can be decreased when combined with Cyclosporine.,Elagolix,DB00091
DB00182,The metabolism of Amphetamine can be decreased when combined with Cyclosporine.,Amphetamine,DB00091
DB00245,The metabolism of Benzatropine can be decreased when combined with Cyclosporine.,Benzatropine,DB00091
DB00598,The metabolism of Labetalol can be decreased when combined with Cyclosporine.,Labetalol,DB00091
DB00934,The metabolism of Maprotiline can be decreased when combined with Cyclosporine.,Maprotiline,DB00091
DB00960,The metabolism of Pindolol can be decreased when combined with Cyclosporine.,Pindolol,DB00091
DB01274,The metabolism of Arformoterol can be decreased when combined with Cyclosporine.,Arformoterol,DB00091
DB01359,The metabolism of Penbutolol can be decreased when combined with Cyclosporine.,Penbutolol,DB00091
DB01577,The metabolism of Metamfetamine can be decreased when combined with Cyclosporine.,Metamfetamine,DB00091
DB04948,The metabolism of Lofexidine can be decreased when combined with Cyclosporine.,Lofexidine,DB00091
DB09204,The metabolism of Arotinolol can be decreased when combined with Cyclosporine.,Arotinolol,DB00091
DB00532,The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.,Mephenytoin,DB00091
DB00983,The metabolism of Formoterol can be decreased when combined with Cyclosporine.,Formoterol,DB00091
DB01075,The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.,Diphenhydramine,DB00091
DB01171,The metabolism of Moclobemide can be decreased when combined with Cyclosporine.,Moclobemide,DB00091
DB06204,The metabolism of Tapentadol can be decreased when combined with Cyclosporine.,Tapentadol,DB00091
DB00530,The metabolism of Erlotinib can be decreased when combined with Cyclosporine.,Erlotinib,DB00091
DB00187,The metabolism of Esmolol can be decreased when combined with Cyclosporine.,Esmolol,DB00091
DB00195,The metabolism of Betaxolol can be decreased when combined with Cyclosporine.,Betaxolol,DB00091
DB00334,The metabolism of Olanzapine can be decreased when combined with Cyclosporine.,Olanzapine,DB00091
DB00409,The metabolism of Remoxipride can be decreased when combined with Cyclosporine.,Remoxipride,DB00091
DB00489,The metabolism of Sotalol can be decreased when combined with Cyclosporine.,Sotalol,DB00091
DB00592,The metabolism of Piperazine can be decreased when combined with Cyclosporine.,Piperazine,DB00091
DB00679,The metabolism of Thioridazine can be decreased when combined with Cyclosporine.,Thioridazine,DB00091
DB00699,The metabolism of Nicergoline can be decreased when combined with Cyclosporine.,Nicergoline,DB00091
DB00737,The metabolism of Meclizine can be decreased when combined with Cyclosporine.,Meclizine,DB00091
DB00805,The metabolism of Minaprine can be decreased when combined with Cyclosporine.,Minaprine,DB00091
DB00866,The metabolism of Alprenolol can be decreased when combined with Cyclosporine.,Alprenolol,DB00091
DB00914,The metabolism of Phenformin can be decreased when combined with Cyclosporine.,Phenformin,DB00091
DB00933,The metabolism of Mesoridazine can be decreased when combined with Cyclosporine.,Mesoridazine,DB00091
DB01071,The metabolism of Mequitazine can be decreased when combined with Cyclosporine.,Mequitazine,DB00091
DB01079,The metabolism of Tegaserod can be decreased when combined with Cyclosporine.,Tegaserod,DB00091
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Cyclosporine.,Dexfenfluramine,DB00091
DB01195,The metabolism of Flecainide can be decreased when combined with Cyclosporine.,Flecainide,DB00091
DB01228,The metabolism of Encainide can be decreased when combined with Cyclosporine.,Encainide,DB00091
DB01255,The metabolism of Lisdexamfetamine can be decreased when combined with Cyclosporine.,Lisdexamfetamine,DB00091
DB01295,The metabolism of Bevantolol can be decreased when combined with Cyclosporine.,Bevantolol,DB00091
DB01297,The metabolism of Practolol can be decreased when combined with Cyclosporine.,Practolol,DB00091
DB01403,The metabolism of Methotrimeprazine can be decreased when combined with Cyclosporine.,Methotrimeprazine,DB00091
DB01429,The metabolism of Aprindine can be decreased when combined with Cyclosporine.,Aprindine,DB00091
DB01454,The metabolism of Midomafetamine can be decreased when combined with Cyclosporine.,Midomafetamine,DB00091
DB01472,The metabolism of 4-Methoxyamphetamine can be decreased when combined with Cyclosporine.,4-Methoxyamphetamine,DB00091
DB01576,The metabolism of Dextroamphetamine can be decreased when combined with Cyclosporine.,Dextroamphetamine,DB00091
DB01580,The metabolism of Oxprenolol can be decreased when combined with Cyclosporine.,Oxprenolol,DB00091
DB04844,The metabolism of Tetrabenazine can be decreased when combined with Cyclosporine.,Tetrabenazine,DB00091
DB06217,The metabolism of Vernakalant can be decreased when combined with Cyclosporine.,Vernakalant,DB00091
DB06506,The metabolism of Repinotan can be decreased when combined with Cyclosporine.,Repinotan,DB00091
DB06608,The metabolism of Tafenoquine can be decreased when combined with Cyclosporine.,Tafenoquine,DB00091
DB06678,The metabolism of Esmirtazapine can be decreased when combined with Cyclosporine.,Esmirtazapine,DB00091
DB06726,The metabolism of Bufuralol can be decreased when combined with Cyclosporine.,Bufuralol,DB00091
DB06727,The metabolism of Sparteine can be decreased when combined with Cyclosporine.,Sparteine,DB00091
DB06735,The metabolism of Enclomiphene can be decreased when combined with Cyclosporine.,Enclomiphene,DB00091
DB08807,The metabolism of Bopindolol can be decreased when combined with Cyclosporine.,Bopindolol,DB00091
DB08808,The metabolism of Bupranolol can be decreased when combined with Cyclosporine.,Bupranolol,DB00091
DB08952,The metabolism of Indenolol can be decreased when combined with Cyclosporine.,Indenolol,DB00091
DB09013,The metabolism of Befunolol can be decreased when combined with Cyclosporine.,Befunolol,DB00091
DB09167,The metabolism of Dosulepin can be decreased when combined with Cyclosporine.,Dosulepin,DB00091
DB09351,The metabolism of Levobetaxolol can be decreased when combined with Cyclosporine.,Levobetaxolol,DB00091
DB11785,The metabolism of Anisodamine can be decreased when combined with Cyclosporine.,Anisodamine,DB00091
DB12212,The metabolism of Landiolol can be decreased when combined with Cyclosporine.,Landiolol,DB00091
DB12752,The metabolism of Bucindolol can be decreased when combined with Cyclosporine.,Bucindolol,DB00091
DB12930,The metabolism of Opipramol can be decreased when combined with Cyclosporine.,Opipramol,DB00091
DB13443,The metabolism of Esatenolol can be decreased when combined with Cyclosporine.,Esatenolol,DB00091
DB13508,The metabolism of Cloranolol can be decreased when combined with Cyclosporine.,Cloranolol,DB00091
DB13530,The metabolism of Mepindolol can be decreased when combined with Cyclosporine.,Mepindolol,DB00091
DB13679,The metabolism of Dexchlorpheniramine can be decreased when combined with Cyclosporine.,Dexchlorpheniramine,DB00091
DB13757,The metabolism of Epanolol can be decreased when combined with Cyclosporine.,Epanolol,DB00091
DB13775,The metabolism of Tertatolol can be decreased when combined with Cyclosporine.,Tertatolol,DB00091
DB08918,The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.,Levomilnacipran,DB00091
DB00184,The metabolism of Cyclosporine can be decreased when combined with Nicotine.,Nicotine,DB00091
DB00185,The metabolism of Cyclosporine can be decreased when combined with Cevimeline.,Cevimeline,DB00091
DB00208,The metabolism of Cyclosporine can be decreased when combined with Ticlopidine.,Ticlopidine,DB00091
DB00264,The metabolism of Cyclosporine can be decreased when combined with Metoprolol.,Metoprolol,DB00091
DB00297,The metabolism of Cyclosporine can be decreased when combined with Bupivacaine.,Bupivacaine,DB00091
DB00356,The metabolism of Cyclosporine can be decreased when combined with Chlorzoxazone.,Chlorzoxazone,DB00091
DB00370,The metabolism of Cyclosporine can be decreased when combined with Mirtazapine.,Mirtazapine,DB00091
DB00377,The metabolism of Cyclosporine can be decreased when combined with Palonosetron.,Palonosetron,DB00091
DB00379,The metabolism of Cyclosporine can be decreased when combined with Mexiletine.,Mexiletine,DB00091
DB00420,The metabolism of Cyclosporine can be decreased when combined with Promazine.,Promazine,DB00091
DB00433,The metabolism of Cyclosporine can be decreased when combined with Prochlorperazine.,Prochlorperazine,DB00091
DB00568,The metabolism of Cyclosporine can be decreased when combined with Cinnarizine.,Cinnarizine,DB00091
DB00589,The metabolism of Cyclosporine can be decreased when combined with Lisuride.,Lisuride,DB00091
DB00647,The metabolism of Cyclosporine can be decreased when combined with Dextropropoxyphene.,Dextropropoxyphene,DB00091
DB00656,The metabolism of Cyclosporine can be decreased when combined with Trazodone.,Trazodone,DB00091
DB00674,The metabolism of Cyclosporine can be decreased when combined with Galantamine.,Galantamine,DB00091
DB00701,The metabolism of Cyclosporine can be decreased when combined with Amprenavir.,Amprenavir,DB00091
DB00734,The metabolism of Cyclosporine can be decreased when combined with Risperidone.,Risperidone,DB00091
DB00757,The metabolism of Cyclosporine can be decreased when combined with Dolasetron.,Dolasetron,DB00091
DB00843,The metabolism of Cyclosporine can be decreased when combined with Donepezil.,Donepezil,DB00091
DB00850,The metabolism of Cyclosporine can be decreased when combined with Perphenazine.,Perphenazine,DB00091
DB00918,The metabolism of Cyclosporine can be decreased when combined with Almotriptan.,Almotriptan,DB00091
DB01028,The metabolism of Cyclosporine can be decreased when combined with Methoxyflurane.,Methoxyflurane,DB00091
DB01036,The metabolism of Cyclosporine can be decreased when combined with Tolterodine.,Tolterodine,DB00091
DB01074,The metabolism of Cyclosporine can be decreased when combined with Perhexiline.,Perhexiline,DB00091
DB01175,The metabolism of Cyclosporine can be decreased when combined with Escitalopram.,Escitalopram,DB00091
DB01192,The metabolism of Cyclosporine can be decreased when combined with Oxymorphone.,Oxymorphone,DB00091
DB01409,The metabolism of Cyclosporine can be decreased when combined with Tiotropium.,Tiotropium,DB00091
DB01466,The metabolism of Cyclosporine can be decreased when combined with Ethylmorphine.,Ethylmorphine,DB00091
DB01551,The metabolism of Cyclosporine can be decreased when combined with Dihydrocodeine.,Dihydrocodeine,DB00091
DB01591,The metabolism of Cyclosporine can be decreased when combined with Solifenacin.,Solifenacin,DB00091
DB01621,The metabolism of Cyclosporine can be decreased when combined with Pipotiazine.,Pipotiazine,DB00091
DB01624,The metabolism of Cyclosporine can be decreased when combined with Zuclopenthixol.,Zuclopenthixol,DB00091
DB02703,The metabolism of Cyclosporine can be decreased when combined with Fusidic acid.,Fusidic acid,DB00091
DB03783,The metabolism of Cyclosporine can be decreased when combined with Phenacetin.,Phenacetin,DB00091
DB04829,The metabolism of Cyclosporine can be decreased when combined with Lysergic acid diethylamide.,Lysergic acid diethylamide,DB00091
DB04841,The metabolism of Cyclosporine can be decreased when combined with Flunarizine.,Flunarizine,DB00091
DB04861,The metabolism of Cyclosporine can be decreased when combined with Nebivolol.,Nebivolol,DB00091
DB04871,The metabolism of Cyclosporine can be decreased when combined with Lorcaserin.,Lorcaserin,DB00091
DB04884,The metabolism of Cyclosporine can be decreased when combined with Dapoxetine.,Dapoxetine,DB00091
DB05271,The metabolism of Cyclosporine can be decreased when combined with Rotigotine.,Rotigotine,DB00091
DB06016,The metabolism of Cyclosporine can be decreased when combined with Cariprazine.,Cariprazine,DB00091
DB06144,The metabolism of Cyclosporine can be decreased when combined with Sertindole.,Sertindole,DB00091
DB06148,The metabolism of Cyclosporine can be decreased when combined with Mianserin.,Mianserin,DB00091
DB06203,The metabolism of Cyclosporine can be decreased when combined with Alogliptin.,Alogliptin,DB00091
DB06292,The metabolism of Cyclosporine can be decreased when combined with Dapagliflozin.,Dapagliflozin,DB00091
DB06684,The metabolism of Cyclosporine can be decreased when combined with Vilazodone.,Vilazodone,DB00091
DB06702,The metabolism of Cyclosporine can be decreased when combined with Fesoterodine.,Fesoterodine,DB00091
DB08922,The metabolism of Cyclosporine can be decreased when combined with Perospirone.,Perospirone,DB00091
DB09183,The metabolism of Cyclosporine can be decreased when combined with Dasabuvir.,Dasabuvir,DB00091
DB09195,The metabolism of Cyclosporine can be decreased when combined with Lorpiprazole.,Lorpiprazole,DB00091
DB09555,The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate,DB00091
DB11130,The metabolism of Cyclosporine can be decreased when combined with Opium.,Opium,DB00091
DB11614,The metabolism of Cyclosporine can be decreased when combined with Rupatadine.,Rupatadine,DB00091
DB11718,The metabolism of Cyclosporine can be decreased when combined with Encorafenib.,Encorafenib,DB00091
DB12245,The metabolism of Cyclosporine can be decreased when combined with Triclabendazole.,Triclabendazole,DB00091
DB13293,The metabolism of Cyclosporine can be decreased when combined with Ipecac.,Ipecac,DB00091
DB09173,The metabolism of Butyrfentanyl can be decreased when combined with Cyclosporine.,Butyrfentanyl,DB00091
DB11757,The metabolism of Istradefylline can be decreased when combined with Cyclosporine.,Istradefylline,DB00091
DB04889,The metabolism of Bicifadine can be decreased when combined with Cyclosporine.,Bicifadine,DB00091
DB01267,The metabolism of Cyclosporine can be decreased when combined with Paliperidone.,Paliperidone,DB00091
DB00571,The metabolism of Cyclosporine can be decreased when combined with Propranolol.,Propranolol,DB00091
DB00425,The metabolism of Zolpidem can be decreased when combined with Cyclosporine.,Zolpidem,DB00091
DB00956,The metabolism of Hydrocodone can be decreased when combined with Cyclosporine.,Hydrocodone,DB00091
DB00178,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramipril.,Ramipril,DB00091
DB00407,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ardeparin.,Ardeparin,DB00091
DB00519,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Trandolapril.,Trandolapril,DB00091
DB00542,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazepril.,Benazepril,DB00091
DB00691,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Moexipril.,Moexipril,DB00091
DB00881,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinapril.,Quinapril,DB00091
DB00886,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Omapatrilat.,Omapatrilat,DB00091
DB01109,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Heparin.,Heparin,DB00091
DB01180,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Rescinnamine.,Rescinnamine,DB00091
DB01225,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Enoxaparin.,Enoxaparin,DB00091
DB01348,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Spirapril.,Spirapril,DB00091
DB02968,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penicillin G Acyl-Serine.,Penicillin G Acyl-Serine,DB00091
DB06271,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Sulodexide.,Sulodexide,DB00091
DB06754,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Danaparoid.,Danaparoid,DB00091
DB06779,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dalteparin.,Dalteparin,DB00091
DB06822,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tinzaparin.,Tinzaparin,DB00091
DB08813,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nadroparin.,Nadroparin,DB00091
DB08836,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Temocapril.,Temocapril,DB00091
DB09258,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bemiparin.,Bemiparin,DB00091
DB09259,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Reviparin.,Reviparin,DB00091
DB09260,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Parnaparin.,Parnaparin,DB00091
DB09261,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Certoparin.,Certoparin,DB00091
DB11783,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Imidapril.,Imidapril,DB00091
DB12097,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Mannitol busulfan.,Mannitol busulfan,DB00091
DB13166,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Zofenopril.,Zofenopril,DB00091
DB13312,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Delapril.,Delapril,DB00091
DB14125,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazeprilat.,Benazeprilat,DB00091
DB14207,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fosinoprilat.,Fosinoprilat,DB00091
DB14208,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramiprilat.,Ramiprilat,DB00091
DB14213,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Perindoprilat.,Perindoprilat,DB00091
DB14217,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinaprilat.,Quinaprilat,DB00091
DB01219,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dantrolene.,Dantrolene,DB00091
DB09236,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lacidipine.,Lacidipine,DB00091
DB12092,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Naftopidil.,Naftopidil,DB00091
DB12093,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tetrahydropalmatine.,Tetrahydropalmatine,DB00091
DB00825,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Levomenthol.,Levomenthol,DB00091
DB04825,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Prenylamine.,Prenylamine,DB00091
DB04838,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cyclandelate.,Cyclandelate,DB00091
DB04842,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fluspirilene.,Fluspirilene,DB00091
DB05885,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Seletracetam.,Seletracetam,DB00091
DB06152,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nylidrin.,Nylidrin,DB00091
DB06446,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dotarizine.,Dotarizine,DB00091
DB08838,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Agmatine.,Agmatine,DB00091
DB08980,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fendiline.,Fendiline,DB00091
DB08992,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Eperisone.,Eperisone,DB00091
DB09090,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Pinaverium.,Pinaverium,DB00091
DB09229,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Aranidipine.,Aranidipine,DB00091
DB09230,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Azelnidipine.,Azelnidipine,DB00091
DB09232,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cilnidipine.,Cilnidipine,DB00091
DB09234,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Darodipine.,Darodipine,DB00091
DB09240,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Niludipine.,Niludipine,DB00091
DB11960,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Carboxyamidotriazole.,Carboxyamidotriazole,DB00091
DB13488,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bencyclane.,Bencyclane,DB00091
DB13500,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Otilonium.,Otilonium,DB00091
DB13725,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Terodiline.,Terodiline,DB00091
DB13766,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lidoflazine.,Lidoflazine,DB00091
DB13791,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penfluridol.,Penfluridol,DB00091
DB13835,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Caroverine.,Caroverine,DB00091
DB13961,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fish oil.,Fish oil,DB00091
DB07615,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tranilast.,Tranilast,DB00091
DB12923,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Gallopamil.,Gallopamil,DB00091
DB14063,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dexverapamil.,Dexverapamil,DB00091
DB14064,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Emopamil.,Emopamil,DB00091
DB14065,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lomerizine.,Lomerizine,DB00091
DB05239,The metabolism of Cyclosporine can be decreased when combined with Cobimetinib.,Cobimetinib,DB00091
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.,G17DT,DB00091
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Cyclosporine.,PEV3A,DB00091
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.,INGN 225,DB00091
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.,Rindopepimut,DB00091
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.,SRP 299,DB00091
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.,GI-5005,DB00091
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Cyclosporine.,Vitespen,DB00091
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.,TG4010,DB00091
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclosporine.,Anthrax immune globulin human,DB00091
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Cyclosporine.","Rabies virus inactivated antigen, B",DB00091
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00091
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cyclosporine.,Rotavirus vaccine,DB00091
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.","Rabies virus inactivated antigen, A",DB00091
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00091
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00091
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00091
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00091
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00091
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00091
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cyclosporine.,Typhoid Vi polysaccharide vaccine,DB00091
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.,Hepatitis A Vaccine,DB00091
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00091
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00091
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00091
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00091
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00091
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.,Human rabies virus immune globulin,DB00091
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.,Hepatitis B Vaccine (Recombinant),DB00091
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.,Tecemotide,DB00091
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cyclosporine.,Typhoid vaccine,DB00091
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00091
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00091
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00091
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00091
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00091
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00091
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00091
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Cyclosporine.,Vaccinia virus strain new york city board of health live antigen,DB00091
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclosporine.,Pertussis vaccine,DB00091
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00091
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.,Varicella Zoster Vaccine (Recombinant),DB00091
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Cyclosporine.,Modified vaccinia ankara,DB00091
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cyclosporine.","Ebola Zaire vaccine (live, attenuated)",DB00091
DB12364,The serum concentration of Cyclosporine can be increased when it is combined with Betrixaban.,Betrixaban,DB00091
DB08881,The serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.,Vemurafenib,DB00091
DB00159,The risk or severity of renal failure and hypertension can be increased when Icosapent is combined with Cyclosporine.,Icosapent,DB00091
DB00244,The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.,Mesalazine,DB00091
DB00461,The risk or severity of renal failure and hypertension can be increased when Nabumetone is combined with Cyclosporine.,Nabumetone,DB00091
DB00465,The risk or severity of renal failure and hypertension can be increased when Ketorolac is combined with Cyclosporine.,Ketorolac,DB00091
DB00469,The risk or severity of renal failure and hypertension can be increased when Tenoxicam is combined with Cyclosporine.,Tenoxicam,DB00091
DB00482,The risk or severity of renal failure and hypertension can be increased when Celecoxib is combined with Cyclosporine.,Celecoxib,DB00091
DB00500,The risk or severity of renal failure and hypertension can be increased when Tolmetin is combined with Cyclosporine.,Tolmetin,DB00091
DB00533,The risk or severity of renal failure and hypertension can be increased when Rofecoxib is combined with Cyclosporine.,Rofecoxib,DB00091
DB00554,The risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.,Piroxicam,DB00091
DB00573,The risk or severity of renal failure and hypertension can be increased when Fenoprofen is combined with Cyclosporine.,Fenoprofen,DB00091
DB00580,The risk or severity of renal failure and hypertension can be increased when Valdecoxib is combined with Cyclosporine.,Valdecoxib,DB00091
DB00605,The risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.,Sulindac,DB00091
DB00712,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen is combined with Cyclosporine.,Flurbiprofen,DB00091
DB00749,The risk or severity of renal failure and hypertension can be increased when Etodolac is combined with Cyclosporine.,Etodolac,DB00091
DB00784,The risk or severity of renal failure and hypertension can be increased when Mefenamic acid is combined with Cyclosporine.,Mefenamic acid,DB00091
DB00788,The risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.,Naproxen,DB00091
DB00812,The risk or severity of renal failure and hypertension can be increased when Phenylbutazone is combined with Cyclosporine.,Phenylbutazone,DB00091
DB00814,The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.,Meloxicam,DB00091
DB00821,The risk or severity of renal failure and hypertension can be increased when Carprofen is combined with Cyclosporine.,Carprofen,DB00091
DB00861,The risk or severity of renal failure and hypertension can be increased when Diflunisal is combined with Cyclosporine.,Diflunisal,DB00091
DB00936,The risk or severity of renal failure and hypertension can be increased when Salicylic acid is combined with Cyclosporine.,Salicylic acid,DB00091
DB00939,The risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine.,Meclofenamic acid,DB00091
DB00945,The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine.,Acetylsalicylic acid,DB00091
DB00991,The risk or severity of renal failure and hypertension can be increased when Oxaprozin is combined with Cyclosporine.,Oxaprozin,DB00091
DB01009,The risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine.,Ketoprofen,DB00091
DB01014,The risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.,Balsalazide,DB00091
DB01050,The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.,Ibuprofen,DB00091
DB01250,The risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine.,Olsalazine,DB00091
DB01283,The risk or severity of renal failure and hypertension can be increased when Lumiracoxib is combined with Cyclosporine.,Lumiracoxib,DB00091
DB01397,The risk or severity of renal failure and hypertension can be increased when Magnesium salicylate is combined with Cyclosporine.,Magnesium salicylate,DB00091
DB01399,The risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.,Salsalate,DB00091
DB01401,The risk or severity of renal failure and hypertension can be increased when Choline magnesium trisalicylate is combined with Cyclosporine.,Choline magnesium trisalicylate,DB00091
DB01419,The risk or severity of renal failure and hypertension can be increased when Antrafenine is combined with Cyclosporine.,Antrafenine,DB00091
DB01424,The risk or severity of renal failure and hypertension can be increased when Aminophenazone is combined with Cyclosporine.,Aminophenazone,DB00091
DB01435,The risk or severity of renal failure and hypertension can be increased when Antipyrine is combined with Cyclosporine.,Antipyrine,DB00091
DB01600,The risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.,Tiaprofenic acid,DB00091
DB01628,The risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.,Etoricoxib,DB00091
DB02224,The risk or severity of renal failure and hypertension can be increased when Taxifolin is combined with Cyclosporine.,Taxifolin,DB00091
DB03585,The risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.,Oxyphenbutazone,DB00091
DB04552,The risk or severity of renal failure and hypertension can be increased when Niflumic acid is combined with Cyclosporine.,Niflumic acid,DB00091
DB04725,The risk or severity of renal failure and hypertension can be increased when Licofelone is combined with Cyclosporine.,Licofelone,DB00091
DB04743,The risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.,Nimesulide,DB00091
DB04812,The risk or severity of renal failure and hypertension can be increased when Benoxaprofen is combined with Cyclosporine.,Benoxaprofen,DB00091
DB04817,The risk or severity of renal failure and hypertension can be increased when Metamizole is combined with Cyclosporine.,Metamizole,DB00091
DB04828,The risk or severity of renal failure and hypertension can be increased when Zomepirac is combined with Cyclosporine.,Zomepirac,DB00091
DB05095,The risk or severity of renal failure and hypertension can be increased when Cimicoxib is combined with Cyclosporine.,Cimicoxib,DB00091
DB06725,The risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.,Lornoxicam,DB00091
DB06736,The risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Cyclosporine.,Aceclofenac,DB00091
DB06737,The risk or severity of renal failure and hypertension can be increased when Zaltoprofen is combined with Cyclosporine.,Zaltoprofen,DB00091
DB07402,The risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine.,Azapropazone,DB00091
DB07477,The risk or severity of renal failure and hypertension can be increased when Felbinac is combined with Cyclosporine.,Felbinac,DB00091
DB08439,The risk or severity of renal failure and hypertension can be increased when Parecoxib is combined with Cyclosporine.,Parecoxib,DB00091
DB08797,The risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.,Salicylamide,DB00091
DB08940,The risk or severity of renal failure and hypertension can be increased when Kebuzone is combined with Cyclosporine.,Kebuzone,DB00091
DB08942,The risk or severity of renal failure and hypertension can be increased when Isoxicam is combined with Cyclosporine.,Isoxicam,DB00091
DB08951,The risk or severity of renal failure and hypertension can be increased when Indoprofen is combined with Cyclosporine.,Indoprofen,DB00091
DB08955,The risk or severity of renal failure and hypertension can be increased when Ibuproxam is combined with Cyclosporine.,Ibuproxam,DB00091
DB08976,The risk or severity of renal failure and hypertension can be increased when Floctafenine is combined with Cyclosporine.,Floctafenine,DB00091
DB08981,The risk or severity of renal failure and hypertension can be increased when Fenbufen is combined with Cyclosporine.,Fenbufen,DB00091
DB08984,The risk or severity of renal failure and hypertension can be increased when Etofenamate is combined with Cyclosporine.,Etofenamate,DB00091
DB08991,The risk or severity of renal failure and hypertension can be increased when Epirizole is combined with Cyclosporine.,Epirizole,DB00091
DB09084,The risk or severity of renal failure and hypertension can be increased when Benzydamine is combined with Cyclosporine.,Benzydamine,DB00091
DB09212,The risk or severity of renal failure and hypertension can be increased when Loxoprofen is combined with Cyclosporine.,Loxoprofen,DB00091
DB09213,The risk or severity of renal failure and hypertension can be increased when Dexibuprofen is combined with Cyclosporine.,Dexibuprofen,DB00091
DB09214,The risk or severity of renal failure and hypertension can be increased when Dexketoprofen is combined with Cyclosporine.,Dexketoprofen,DB00091
DB09215,The risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.,Droxicam,DB00091
DB09216,The risk or severity of renal failure and hypertension can be increased when Tolfenamic acid is combined with Cyclosporine.,Tolfenamic acid,DB00091
DB09217,The risk or severity of renal failure and hypertension can be increased when Firocoxib is combined with Cyclosporine.,Firocoxib,DB00091
DB09218,The risk or severity of renal failure and hypertension can be increased when Clonixin is combined with Cyclosporine.,Clonixin,DB00091
DB09285,The risk or severity of renal failure and hypertension can be increased when Morniflumate is combined with Cyclosporine.,Morniflumate,DB00091
DB09288,The risk or severity of renal failure and hypertension can be increased when Propacetamol is combined with Cyclosporine.,Propacetamol,DB00091
DB09295,The risk or severity of renal failure and hypertension can be increased when Talniflumate is combined with Cyclosporine.,Talniflumate,DB00091
DB11455,The risk or severity of renal failure and hypertension can be increased when Robenacoxib is combined with Cyclosporine.,Robenacoxib,DB00091
DB11518,The risk or severity of renal failure and hypertension can be increased when Flunixin is combined with Cyclosporine.,Flunixin,DB00091
DB12399,The risk or severity of renal failure and hypertension can be increased when Polmacoxib is combined with Cyclosporine.,Polmacoxib,DB00091
DB12445,The risk or severity of renal failure and hypertension can be increased when Nitroaspirin is combined with Cyclosporine.,Nitroaspirin,DB00091
DB12480,The risk or severity of renal failure and hypertension can be increased when Betulinic Acid is combined with Cyclosporine.,Betulinic Acid,DB00091
DB12545,The risk or severity of renal failure and hypertension can be increased when Indobufen is combined with Cyclosporine.,Indobufen,DB00091
DB12610,The risk or severity of renal failure and hypertension can be increased when Ebselen is combined with Cyclosporine.,Ebselen,DB00091
DB13001,The risk or severity of renal failure and hypertension can be increased when Tinoridine is combined with Cyclosporine.,Tinoridine,DB00091
DB13167,The risk or severity of renal failure and hypertension can be increased when Alclofenac is combined with Cyclosporine.,Alclofenac,DB00091
DB13217,The risk or severity of renal failure and hypertension can be increased when Fentiazac is combined with Cyclosporine.,Fentiazac,DB00091
DB13232,The risk or severity of renal failure and hypertension can be increased when Suxibuzone is combined with Cyclosporine.,Suxibuzone,DB00091
DB13286,The risk or severity of renal failure and hypertension can be increased when Bumadizone is combined with Cyclosporine.,Bumadizone,DB00091
DB13314,The risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.,Alminoprofen,DB00091
DB13317,The risk or severity of renal failure and hypertension can be increased when Flunoxaprofen is combined with Cyclosporine.,Flunoxaprofen,DB00091
DB13364,The risk or severity of renal failure and hypertension can be increased when Feprazone is combined with Cyclosporine.,Feprazone,DB00091
DB13371,The risk or severity of renal failure and hypertension can be increased when Difenpiramide is combined with Cyclosporine.,Difenpiramide,DB00091
DB13407,The risk or severity of renal failure and hypertension can be increased when Nifenazone is combined with Cyclosporine.,Nifenazone,DB00091
DB13432,The risk or severity of renal failure and hypertension can be increased when Lonazolac is combined with Cyclosporine.,Lonazolac,DB00091
DB13481,The risk or severity of renal failure and hypertension can be increased when Tenidap is combined with Cyclosporine.,Tenidap,DB00091
DB13501,The risk or severity of renal failure and hypertension can be increased when Bendazac is combined with Cyclosporine.,Bendazac,DB00091
DB13514,The risk or severity of renal failure and hypertension can be increased when Pranoprofen is combined with Cyclosporine.,Pranoprofen,DB00091
DB13524,The risk or severity of renal failure and hypertension can be increased when Propyphenazone is combined with Cyclosporine.,Propyphenazone,DB00091
DB13527,The risk or severity of renal failure and hypertension can be increased when Proglumetacin is combined with Cyclosporine.,Proglumetacin,DB00091
DB13538,The risk or severity of renal failure and hypertension can be increased when Guacetisal is combined with Cyclosporine.,Guacetisal,DB00091
DB13544,The risk or severity of renal failure and hypertension can be increased when Ethenzamide is combined with Cyclosporine.,Ethenzamide,DB00091
DB13612,The risk or severity of renal failure and hypertension can be increased when Carbaspirin calcium is combined with Cyclosporine.,Carbaspirin calcium,DB00091
DB13629,The risk or severity of renal failure and hypertension can be increased when Mofebutazone is combined with Cyclosporine.,Mofebutazone,DB00091
DB13649,The risk or severity of renal failure and hypertension can be increased when Proquazone is combined with Cyclosporine.,Proquazone,DB00091
DB13657,The risk or severity of renal failure and hypertension can be increased when Benorilate is combined with Cyclosporine.,Benorilate,DB00091
DB13722,The risk or severity of renal failure and hypertension can be increased when Pirprofen is combined with Cyclosporine.,Pirprofen,DB00091
DB13783,The risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Cyclosporine.,Acemetacin,DB00091
DB13860,The risk or severity of renal failure and hypertension can be increased when Imidazole salicylate is combined with Cyclosporine.,Imidazole salicylate,DB00091
DB14059,The risk or severity of renal failure and hypertension can be increased when SC-236 is combined with Cyclosporine.,SC-236,DB00091
DB14060,The risk or severity of renal failure and hypertension can be increased when NS-398 is combined with Cyclosporine.,NS-398,DB00091
DB14938,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen axetil is combined with Cyclosporine.,Flurbiprofen axetil,DB00091
DB09227,The serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.,Barnidipine,DB00091
DB13615,The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cyclosporine.,Mifamurtide,DB00091
DB11901,The serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.,Apalutamide,DB00091
DB11642,The serum concentration of Cyclosporine can be decreased when it is combined with Pitolisant.,Pitolisant,DB00091
DB11633,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazole.,Isavuconazole,DB00091
DB06636,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazonium.,Isavuconazonium,DB00091
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cyclosporine.,Rubella virus vaccine,DB00091
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Cyclosporine.,Varicella Zoster Vaccine (Live/attenuated),DB00091
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain tice live antigen,DB00091
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain connaught live antigen,DB00091
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Cyclosporine.,Yellow Fever Vaccine,DB00091
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Cyclosporine.,Anthrax vaccine,DB00091
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cyclosporine.,Typhoid Vaccine Live,DB00091
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00091
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Cyclosporine.,BCG vaccine,DB00091
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cyclosporine.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00091
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Cyclosporine.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00091
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cyclosporine.,Adenovirus type 7 vaccine live,DB00091
DB00158,Cyclosporine may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid,DB00091
DB00740,Cyclosporine may decrease the excretion rate of Riluzole which could result in a higher serum level.,Riluzole,DB00091
DB03496,Cyclosporine may decrease the excretion rate of Alvocidib which could result in a higher serum level.,Alvocidib,DB00091
DB08931,Cyclosporine may decrease the excretion rate of Riociguat which could result in a higher serum level.,Riociguat,DB00091
DB12941,Cyclosporine may decrease the excretion rate of Darolutamide which could result in a higher serum level.,Darolutamide,DB00091
DB00286,Cyclosporine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens,DB00091
DB00457,Cyclosporine may decrease the excretion rate of Prazosin which could result in a higher serum level.,Prazosin,DB00091
DB00709,Cyclosporine may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine,DB00091
DB04690,Cyclosporine may decrease the excretion rate of Camptothecin which could result in a higher serum level.,Camptothecin,DB00091
DB12001,Cyclosporine may decrease the excretion rate of Abemaciclib which could result in a higher serum level.,Abemaciclib,DB00091
DB13125,Cyclosporine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.,Lusutrombopag,DB00091
DB00612,The serum concentration of Bisoprolol can be increased when it is combined with Cyclosporine.,Bisoprolol,DB00091
DB01238,The metabolism of Aripiprazole can be decreased when combined with Cyclosporine.,Aripiprazole,DB00091
DB14185,The metabolism of Aripiprazole lauroxil can be decreased when combined with Cyclosporine.,Aripiprazole lauroxil,DB00091
DB00256,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lymecycline.,Lymecycline,DB00091
DB00453,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Clomocycline.,Clomocycline,DB00091
DB00560,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Tigecycline.,Tigecycline,DB00091
DB00595,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Oxytetracycline.,Oxytetracycline,DB00091
DB00618,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Demeclocycline.,Demeclocycline,DB00091
DB00931,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Metacycline.,Metacycline,DB00091
DB01301,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Rolitetracycline.,Rolitetracycline,DB00091
DB01377,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium oxide.,Magnesium oxide,DB00091
DB01378,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium cation.,Magnesium cation,DB00091
DB01627,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lincomycin.,Lincomycin,DB00091
DB06827,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Viomycin.,Viomycin,DB00091
DB09409,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate tetrahydrate.,Magnesium acetate tetrahydrate,DB00091
DB11110,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium citrate.,Magnesium citrate,DB00091
DB11189,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium glycinate.,Magnesium glycinate,DB00091
DB11230,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.,Magnesium Aluminum Silicate,DB00091
DB13249,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium silicate.,Magnesium silicate,DB00091
DB13264,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Penimepicycline.,Penimepicycline,DB00091
DB13359,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium aspartate.,Magnesium aspartate,DB00091
DB13749,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium gluconate.,Magnesium gluconate,DB00091
DB13786,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium orotate.,Magnesium orotate,DB00091
DB13862,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate.,Magnesium phosphate,DB00091
DB13996,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate.,Magnesium acetate,DB00091
DB00042,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type B.,Botulinum Toxin Type B,DB00091
DB00083,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.,Botulinum toxin type A,DB00091
DB00657,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mecamylamine.,Mecamylamine,DB00091
DB01090,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pentolinium.,Pentolinium,DB00091
DB01116,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Trimethaphan.,Trimethaphan,DB00091
DB08837,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetraethylammonium.,Tetraethylammonium,DB00091
DB08960,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Hexamethonium.,Hexamethonium,DB00091
DB08999,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine.,Cyclopentamine,DB00091
DB00282,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Pamidronic acid.,Pamidronic acid,DB00091
DB00399,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.,Zoledronic acid,DB00091
DB00630,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.,Alendronic acid,DB00091
DB00710,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.,Ibandronate,DB00091
DB00720,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Clodronic acid.,Clodronic acid,DB00091
DB00884,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Risedronic acid.,Risedronic acid,DB00091
DB01077,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Etidronic acid.,Etidronic acid,DB00091
DB01133,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Tiludronic acid.,Tiludronic acid,DB00091
DB06255,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Incadronic acid.,Incadronic acid,DB00091
DB06695,The serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclosporine.,Dabigatran etexilate,DB00091
DB00917,The excretion of Dinoprostone can be decreased when combined with Cyclosporine.,Dinoprostone,DB00091
DB01053,The excretion of Benzylpenicillin can be decreased when combined with Cyclosporine.,Benzylpenicillin,DB00091
DB01092,The excretion of Ouabain can be decreased when combined with Cyclosporine.,Ouabain,DB00091
DB06199,The excretion of Atrasentan can be decreased when combined with Cyclosporine.,Atrasentan,DB00091
DB06721,The excretion of Gimatecan can be decreased when combined with Cyclosporine.,Gimatecan,DB00091
DB08862,The excretion of Cholecystokinin can be decreased when combined with Cyclosporine.,Cholecystokinin,DB00091
DB08884,The excretion of Gadoxetic acid can be decreased when combined with Cyclosporine.,Gadoxetic acid,DB00091
DB01583,The excretion of Liotrix can be decreased when combined with Cyclosporine.,Liotrix,DB00091
DB01586,The risk or severity of liver damage can be increased when Cyclosporine is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid,DB00091
DB14057,The risk or severity of liver damage can be increased when Cyclosporine is combined with Valinomycin.,Valinomycin,DB00091
DB00555,Cyclosporine may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine,DB00091
DB00014,Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.,Goserelin,DB00091
DB00017,Cyclosporine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.,Salmon calcitonin,DB00091
DB00035,Cyclosporine may decrease the excretion rate of Desmopressin which could result in a higher serum level.,Desmopressin,DB00091
DB00080,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Daptomycin,DB00091
DB00115,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyanocobalamin,DB00091
DB00165,Cyclosporine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine,DB00091
DB00190,Cyclosporine may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa,DB00091
DB00198,Cyclosporine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir,DB00091
DB00200,Cyclosporine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin,DB00091
DB00225,Cyclosporine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide,DB00091
DB00235,Cyclosporine may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone,DB00091
DB00271,Cyclosporine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate,DB00091
DB00284,Cyclosporine may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose,DB00091
DB00292,Cyclosporine may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate,DB00091
DB00303,Cyclosporine may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem,DB00091
DB00308,Cyclosporine may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide,DB00091
DB00319,Cyclosporine may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin,DB00091
DB00323,Cyclosporine may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone,DB00091
DB00325,Cyclosporine may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside,DB00091
DB00330,Cyclosporine may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol,DB00091
DB00331,Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin,DB00091
DB00355,Cyclosporine may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam,DB00091
DB00364,Cyclosporine may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate,DB00091
DB00369,Cyclosporine may decrease the excretion rate of Cidofovir which could result in a higher serum level.,Cidofovir,DB00091
DB00372,Cyclosporine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine,DB00091
DB00413,Cyclosporine may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole,DB00091
DB00415,Cyclosporine may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin,DB00091
DB00422,Cyclosporine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate,DB00091
DB00438,Cyclosporine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.,Ceftazidime,DB00091
DB00492,Cyclosporine may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril,DB00091
DB00535,Cyclosporine may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir,DB00091
DB00548,Cyclosporine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid,DB00091
DB00553,Cyclosporine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen,DB00091
DB00558,Cyclosporine may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir,DB00091
DB00569,Cyclosporine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux,DB00091
DB00577,Cyclosporine may decrease the excretion rate of Valaciclovir which could result in a higher serum level.,Valaciclovir,DB00091
DB00583,Cyclosporine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine,DB00091
DB00597,Cyclosporine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol,DB00091
DB00633,Cyclosporine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine,DB00091
DB00651,Cyclosporine may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline,DB00091
DB00660,Cyclosporine may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone,DB00091
DB00665,Cyclosporine may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide,DB00091
DB00672,Cyclosporine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide,DB00091
DB00692,Cyclosporine may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine,DB00091
DB00713,Cyclosporine may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin,DB00091
DB00716,Cyclosporine may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil,DB00091
DB00722,Cyclosporine may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril,DB00091
DB00730,Cyclosporine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole,DB00091
DB00733,Cyclosporine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime,DB00091
DB00743,Cyclosporine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid,DB00091
DB00760,Cyclosporine may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem,DB00091
DB00761,Cyclosporine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride,DB00091
DB00775,Cyclosporine may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban,DB00091
DB00782,Cyclosporine may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline,DB00091
DB00787,Cyclosporine may decrease the excretion rate of Acyclovir which could result in a higher serum level.,Acyclovir,DB00091
DB00789,Cyclosporine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid,DB00091
DB00790,Cyclosporine may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril,DB00091
DB00800,Cyclosporine may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam,DB00091
DB00804,Cyclosporine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine,DB00091
DB00806,Cyclosporine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline,DB00091
DB00811,Cyclosporine may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin,DB00091
DB00828,Cyclosporine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin,DB00091
DB00839,Cyclosporine may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide,DB00091
DB00841,Cyclosporine may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine,DB00091
DB00871,Cyclosporine may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline,DB00091
DB00894,Cyclosporine may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone,DB00091
DB00900,Cyclosporine may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine,DB00091
DB00915,Cyclosporine may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine,DB00091
DB00953,Cyclosporine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan,DB00091
DB00961,Cyclosporine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine,DB00091
DB00968,Cyclosporine may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa,DB00091
DB00988,Cyclosporine may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine,DB00091
DB00995,Cyclosporine may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin,DB00091
DB01004,Cyclosporine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir,DB00091
DB01010,Cyclosporine may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium,DB00091
DB01022,Cyclosporine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone,DB00091
DB01043,Cyclosporine may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine,DB00091
DB01046,Cyclosporine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone,DB00091
DB01048,Cyclosporine may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir,DB00091
DB01060,Cyclosporine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin,DB00091
DB01124,Cyclosporine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide,DB00091
DB01140,Cyclosporine may decrease the excretion rate of Cefadroxil which could result in a higher serum level.,Cefadroxil,DB00091
DB01148,Cyclosporine may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate,DB00091
DB01157,Cyclosporine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate,DB00091
DB01205,Cyclosporine may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil,DB00091
DB01213,Cyclosporine may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole,DB00091
DB01240,Cyclosporine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol,DB00091
DB01249,Cyclosporine may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol,DB00091
DB01273,Cyclosporine may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline,DB00091
DB01330,Cyclosporine may decrease the excretion rate of Cefotetan which could result in a higher serum level.,Cefotetan,DB00091
DB01367,Cyclosporine may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline,DB00091
DB01415,Cyclosporine may decrease the excretion rate of Ceftibuten which could result in a higher serum level.,Ceftibuten,DB00091
DB01427,Cyclosporine may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone,DB00091
DB01428,Cyclosporine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone,DB00091
DB01550,Cyclosporine may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex,DB00091
DB01563,Cyclosporine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate,DB00091
DB01610,Cyclosporine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir,DB00091
DB01638,Cyclosporine may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol,DB00091
DB04895,Cyclosporine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib,DB00091
DB04953,Cyclosporine may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine,DB00091
DB05018,Cyclosporine may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat,DB00091
DB06154,Cyclosporine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate,DB00091
DB06186,Cyclosporine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab,DB00091
DB06196,Cyclosporine may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant,DB00091
DB06209,Cyclosporine may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel,DB00091
DB06211,Cyclosporine may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem,DB00091
DB06230,Cyclosporine may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene,DB00091
DB06262,Cyclosporine may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa,DB00091
DB06402,Cyclosporine may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin,DB00091
DB06623,Cyclosporine may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine,DB00091
DB06705,Cyclosporine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium,DB00091
DB06767,Cyclosporine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride,DB00091
DB06782,Cyclosporine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol,DB00091
DB06796,Cyclosporine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir,DB00091
DB06800,Cyclosporine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone,DB00091
DB06809,Cyclosporine may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor,DB00091
DB06823,Cyclosporine may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin,DB00091
DB06824,Cyclosporine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine,DB00091
DB08824,Cyclosporine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123,DB00091
DB08826,Cyclosporine may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone,DB00091
DB08840,Cyclosporine may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide,DB00091
DB08872,Cyclosporine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil,DB00091
DB08894,Cyclosporine may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide,DB00091
DB08897,Cyclosporine may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium,DB00091
DB08900,Cyclosporine may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide,DB00091
DB08964,Cyclosporine may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost,DB00091
DB09050,Cyclosporine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane,DB00091
DB09066,Cyclosporine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa,DB00091
DB09081,Cyclosporine may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone,DB00091
DB09103,Cyclosporine may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim,DB00091
DB09104,Cyclosporine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide,DB00091
DB09106,Cyclosporine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch,DB00091
DB09111,Cyclosporine may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch,DB00091
DB09121,Cyclosporine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose,DB00091
DB09129,Cyclosporine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride,DB00091
DB09132,Cyclosporine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid,DB00091
DB09133,Cyclosporine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid,DB00091
DB09134,Cyclosporine may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol,DB00091
DB09135,Cyclosporine may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan,DB00091
DB09136,Cyclosporine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue,DB00091
DB09137,Cyclosporine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin,DB00091
DB09139,Cyclosporine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate,DB00091
DB09148,Cyclosporine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F),DB00091
DB09149,Cyclosporine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F),DB00091
DB09156,Cyclosporine may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide,DB00091
DB09163,Cyclosporine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime,DB00091
DB09165,Cyclosporine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate,DB00091
DB09185,Cyclosporine may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine,DB00091
DB09194,Cyclosporine may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone,DB00091
DB09205,Cyclosporine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte,DB00091
DB09209,Cyclosporine may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine,DB00091
DB09210,Cyclosporine may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam,DB00091
DB09219,Cyclosporine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin,DB00091
DB09220,Cyclosporine may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil,DB00091
DB09224,Cyclosporine may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone,DB00091
DB09244,Cyclosporine may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole,DB00091
DB09245,Cyclosporine may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone,DB00091
DB09255,Cyclosporine may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran,DB00091
DB09257,Cyclosporine may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil,DB00091
DB09264,Cyclosporine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab,DB00091
DB09265,Cyclosporine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide,DB00091
DB09268,Cyclosporine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid,DB00091
DB09276,Cyclosporine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate,DB00091
DB09277,Cyclosporine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11,DB00091
DB09281,Cyclosporine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate,DB00091
DB09292,Cyclosporine may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril,DB00091
DB09301,Cyclosporine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate,DB00091
DB09320,Cyclosporine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin,DB00091
DB09324,Cyclosporine may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam,DB00091
DB09325,Cyclosporine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride,DB00091
DB09329,"Cyclosporine may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated",DB00091
DB09338,Cyclosporine may decrease the excretion rate of Mersalyl which could result in a higher serum level.,Mersalyl,DB00091
DB09344,Cyclosporine may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar,DB00091
DB09357,Cyclosporine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol,DB00091
DB09394,Cyclosporine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid,DB00091
DB09395,Cyclosporine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate,DB00091
DB09407,Cyclosporine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride,DB00091
DB09418,Cyclosporine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate,DB00091
DB09472,Cyclosporine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate,DB00091
DB09477,Cyclosporine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat,DB00091
DB09481,Cyclosporine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate,DB00091
DB09488,Cyclosporine may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine,DB00091
DB09496,Cyclosporine may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate,DB00091
DB09502,Cyclosporine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F),DB00091
DB09546,Cyclosporine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123,DB00091
DB11077,Cyclosporine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400,DB00091
DB11090,Cyclosporine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate,DB00091
DB11098,Cyclosporine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate,DB00091
DB11102,Cyclosporine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine,DB00091
DB11114,Cyclosporine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil,DB00091
DB11127,Cyclosporine may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid,DB00091
DB11135,Cyclosporine may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium,DB00091
DB11136,Cyclosporine may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium,DB00091
DB11145,Cyclosporine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline,DB00091
DB11164,Cyclosporine may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate,DB00091
DB11278,Cyclosporine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine,DB00091
DB11328,Cyclosporine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester),DB00091
DB11338,Cyclosporine may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil,DB00091
DB11358,Cyclosporine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil,DB00091
DB11364,Cyclosporine may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod,DB00091
DB11367,Cyclosporine may decrease the excretion rate of Cefroxadine which could result in a higher serum level.,Cefroxadine,DB00091
DB11577,Cyclosporine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid,DB00091
DB11587,Cyclosporine may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine,DB00091
DB11598,Cyclosporine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human,DB00091
DB11691,Cyclosporine may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine,DB00091
DB11699,Cyclosporine may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron,DB00091
DB11989,Cyclosporine may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole,DB00091
DB12007,Cyclosporine may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone,DB00091
DB12107,Cyclosporine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam,DB00091
DB12151,Cyclosporine may decrease the excretion rate of Brincidofovir which could result in a higher serum level.,Brincidofovir,DB00091
DB12783,Cyclosporine may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide,DB00091
DB13025,Cyclosporine may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride,DB00091
DB13156,Cyclosporine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex,DB00091
DB13178,Cyclosporine may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol,DB00091
DB13185,Cyclosporine may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate,DB00091
DB13191,Cyclosporine may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine,DB00091
DB13269,Cyclosporine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol,DB00091
DB13595,Cyclosporine may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate,DB00091
DB13884,Cyclosporine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa,DB00091
DB13909,Cyclosporine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate,DB00091
DB13967,Cyclosporine may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue,DB00091
DB14006,Cyclosporine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate,DB00091
DB14007,Cyclosporine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid,DB00091
DB14498,Cyclosporine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate,DB00091
DB14499,Cyclosporine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate,DB00091
DB14526,Cyclosporine may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate,DB00091
DB14527,Cyclosporine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate,DB00091
DB14528,Cyclosporine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate,DB00091
DB14529,Cyclosporine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate,DB00091
DB14530,Cyclosporine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate,DB00091
DB06815,Cyclosporine may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione,DB00091
DB11121,Cyclosporine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol,DB00091
DB00842,Cyclosporine may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam,DB00091
DB01020,Cyclosporine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate,DB00091
DB01067,Cyclosporine may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide,DB00091
DB01558,Cyclosporine may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam,DB00091
DB00231,Cyclosporine may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam,DB00091
DB01170,Cyclosporine may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine,DB00091
DB11085,Cyclosporine may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol,DB00091
DB13139,Cyclosporine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol,DB00091
DB01018,Cyclosporine may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine,DB00091
DB08932,Cyclosporine may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan,DB00091
DB00294,Cyclosporine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel,DB00091
DB09123,Cyclosporine may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest,DB00091
DB00007,Cyclosporine may decrease the excretion rate of Leuprolide which could result in a higher serum level.,Leuprolide,DB00091
DB00280,Cyclosporine may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide,DB00091
DB00296,Cyclosporine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine,DB00091
DB00628,Cyclosporine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid,DB00091
DB00911,Cyclosporine may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole,DB00091
DB01001,Cyclosporine may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol,DB00091
DB01002,Cyclosporine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine,DB00091
DB01105,Cyclosporine may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine,DB00091
DB01215,Cyclosporine may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam,DB00091
DB06282,Cyclosporine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine,DB00091
DB09089,Cyclosporine may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine,DB00091
DB09223,Cyclosporine may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin,DB00091
DB09262,Cyclosporine may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin,DB00091
DB09317,"Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A",DB00091
DB09318,"Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B",DB00091
DB11251,Cyclosporine may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol,DB00091
DB12278,Cyclosporine may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine,DB00091
DB15593,Cyclosporine may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen,DB00091
DB00327,Cyclosporine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone,DB00091
DB00980,Cyclosporine may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon,DB00091
DB04574,Cyclosporine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate,DB00091
DB00279,Cyclosporine may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine,DB00091
DB00863,Cyclosporine may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine,DB00091
DB00213,Cyclosporine may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole,DB00091
DB00341,Cyclosporine may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine,DB00091
DB00351,Cyclosporine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate,DB00091
DB00440,Cyclosporine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim,DB00091
DB00690,Cyclosporine may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam,DB00091
DB01212,Cyclosporine may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.,Ceftriaxone,DB00091
DB08996,Cyclosporine may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine,DB00091
DB00879,Cyclosporine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine,DB00091
DB14506,Cyclosporine may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide,DB00091
DB00452,Cyclosporine may decrease the excretion rate of Framycetin which could result in a higher serum level.,Framycetin,DB00091
DB00479,Cyclosporine may decrease the excretion rate of Amikacin which could result in a higher serum level.,Amikacin,DB00091
DB00684,Cyclosporine may decrease the excretion rate of Tobramycin which could result in a higher serum level.,Tobramycin,DB00091
DB00798,Cyclosporine may decrease the excretion rate of Gentamicin which could result in a higher serum level.,Gentamicin,DB00091
DB00955,Cyclosporine may decrease the excretion rate of Netilmicin which could result in a higher serum level.,Netilmicin,DB00091
DB01082,Cyclosporine may decrease the excretion rate of Streptomycin which could result in a higher serum level.,Streptomycin,DB00091
DB01172,Cyclosporine may decrease the excretion rate of Kanamycin which could result in a higher serum level.,Kanamycin,DB00091
DB01421,Cyclosporine may decrease the excretion rate of Paromomycin which could result in a higher serum level.,Paromomycin,DB00091
DB03615,Cyclosporine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.,Ribostamycin,DB00091
DB04263,Cyclosporine may decrease the excretion rate of Geneticin which could result in a higher serum level.,Geneticin,DB00091
DB04626,Cyclosporine may decrease the excretion rate of Apramycin which could result in a higher serum level.,Apramycin,DB00091
DB04729,Cyclosporine may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level.,Gentamicin C1a,DB00091
DB04808,Cyclosporine may decrease the excretion rate of Neamine which could result in a higher serum level.,Neamine,DB00091
DB06696,Cyclosporine may decrease the excretion rate of Arbekacin which could result in a higher serum level.,Arbekacin,DB00091
DB08437,Cyclosporine may decrease the excretion rate of Puromycin which could result in a higher serum level.,Puromycin,DB00091
DB11512,Cyclosporine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.,Dihydrostreptomycin,DB00091
DB11520,Cyclosporine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.,Hygromycin B,DB00091
DB12604,Cyclosporine may decrease the excretion rate of Sisomicin which could result in a higher serum level.,Sisomicin,DB00091
DB13270,Cyclosporine may decrease the excretion rate of Dibekacin which could result in a higher serum level.,Dibekacin,DB00091
DB13274,Cyclosporine may decrease the excretion rate of Micronomicin which could result in a higher serum level.,Micronomicin,DB00091
DB13540,Cyclosporine may decrease the excretion rate of Isepamicin which could result in a higher serum level.,Isepamicin,DB00091
DB13673,Cyclosporine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.,Bekanamycin,DB00091
DB00314,Cyclosporine may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin,DB00091
DB00512,Cyclosporine may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin,DB00091
DB00982,Cyclosporine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin,DB00091
DB12615,Cyclosporine may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin,DB00091
DB14509,Cyclosporine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate,DB00091
DB13145,Cyclosporine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin,DB00091
DB00408,The serum concentration of Cyclosporine can be increased when it is combined with Loxapine.,Loxapine,DB00091
DB00539,The serum concentration of Cyclosporine can be increased when it is combined with Toremifene.,Toremifene,DB00091
DB00872,The serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.,Conivaptan,DB00091
DB01167,The serum concentration of Cyclosporine can be increased when it is combined with Itraconazole.,Itraconazole,DB00091
DB01259,The serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.,Lapatinib,DB00091
DB01388,The serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.,Mibefradil,DB00091
DB04851,The serum concentration of Cyclosporine can be increased when it is combined with Biricodar.,Biricodar,DB00091
DB04881,The serum concentration of Cyclosporine can be increased when it is combined with Elacridar.,Elacridar,DB00091
DB05294,The serum concentration of Cyclosporine can be increased when it is combined with Vandetanib.,Vandetanib,DB00091
DB06191,The serum concentration of Cyclosporine can be increased when it is combined with Zosuquidar.,Zosuquidar,DB00091
DB06240,The serum concentration of Cyclosporine can be increased when it is combined with Tariquidar.,Tariquidar,DB00091
DB08896,The serum concentration of Cyclosporine can be increased when it is combined with Regorafenib.,Regorafenib,DB00091
DB08907,The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.,Canagliflozin,DB00091
DB09030,The serum concentration of Cyclosporine can be increased when it is combined with Vorapaxar.,Vorapaxar,DB00091
DB09034,The serum concentration of Cyclosporine can be increased when it is combined with Suvorexant.,Suvorexant,DB00091
DB09065,The serum concentration of Cyclosporine can be increased when it is combined with Cobicistat.,Cobicistat,DB00091
DB09102,The serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.,Daclatasvir,DB00091
DB09239,The serum concentration of Cyclosporine can be increased when it is combined with Niguldipine.,Niguldipine,DB00091
DB09291,The serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.,Rolapitant,DB00091
DB11581,The serum concentration of Cyclosporine can be increased when it is combined with Venetoclax.,Venetoclax,DB00091
DB11613,The serum concentration of Cyclosporine can be increased when it is combined with Velpatasvir.,Velpatasvir,DB00091
DB11828,The serum concentration of Cyclosporine can be increased when it is combined with Neratinib.,Neratinib,DB00091
DB11869,The serum concentration of Cyclosporine can be increased when it is combined with Valspodar.,Valspodar,DB00091
DB11978,The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib.,Glasdegib,DB00091
DB12026,The serum concentration of Cyclosporine can be increased when it is combined with Voxilaprevir.,Voxilaprevir,DB00091
DB12035,The serum concentration of Cyclosporine can be increased when it is combined with Sarecycline.,Sarecycline,DB00091
DB12799,The serum concentration of Cyclosporine can be increased when it is combined with Laniquidar.,Laniquidar,DB00091
DB13878,The serum concentration of Cyclosporine can be increased when it is combined with Pibrentasvir.,Pibrentasvir,DB00091
DB13879,The serum concentration of Cyclosporine can be increased when it is combined with Glecaprevir.,Glecaprevir,DB00091
DB14068,The serum concentration of Cyclosporine can be increased when it is combined with Dexniguldipine.,Dexniguldipine,DB00091
DB14069,The serum concentration of Cyclosporine can be increased when it is combined with ONT-093.,ONT-093,DB00091
DB14568,The serum concentration of Cyclosporine can be increased when it is combined with Ivosidenib.,Ivosidenib,DB00091
DB12500,The serum concentration of Fedratinib can be increased when it is combined with Cyclosporine.,Fedratinib,DB00091
DB08827,The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.,Lomitapide,DB00091
DB08882,The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.,Linagliptin,DB00091
DB11760,The serum concentration of Cyclosporine can be increased when it is combined with Talazoparib.,Talazoparib,DB00091
DB00206,The serum concentration of Cyclosporine can be increased when it is combined with Reserpine.,Reserpine,DB00091
DB12466,The serum concentration of Cyclosporine can be increased when it is combined with Favipiravir.,Favipiravir,DB00091
DB11967,The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine.,Binimetinib,DB00091
DB14840,The serum concentration of Ripretinib can be increased when it is combined with Cyclosporine.,Ripretinib,DB00091
DB09125,Cyclosporine may increase the hyperkalemic activities of Potassium citrate.,Potassium citrate,DB00091
DB06715,Potassium Iodide may increase the hyperkalemic activities of Cyclosporine.,Potassium Iodide,DB00091
DB09087,Potassium alum may increase the hyperkalemic activities of Cyclosporine.,Potassium alum,DB00091
DB09413,Monopotassium phosphate may increase the hyperkalemic activities of Cyclosporine.,Monopotassium phosphate,DB00091
DB09414,Dipotassium phosphate may increase the hyperkalemic activities of Cyclosporine.,Dipotassium phosphate,DB00091
DB09449,"Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclosporine.","Sodium phosphate, monobasic",DB00091
DB09483,Potassium lactate may increase the hyperkalemic activities of Cyclosporine.,Potassium lactate,DB00091
DB11107,Potassium bitartrate may increase the hyperkalemic activities of Cyclosporine.,Potassium bitartrate,DB00091
DB11153,Potassium hydroxide may increase the hyperkalemic activities of Cyclosporine.,Potassium hydroxide,DB00091
DB13620,Potassium gluconate may increase the hyperkalemic activities of Cyclosporine.,Potassium gluconate,DB00091
DB13735,Potassium Guaiacolsulfonate may increase the hyperkalemic activities of Cyclosporine.,Potassium Guaiacolsulfonate,DB00091
DB13831,Potassium permanganate may increase the hyperkalemic activities of Cyclosporine.,Potassium permanganate,DB00091
DB13977,Potassium carbonate may increase the hyperkalemic activities of Cyclosporine.,Potassium carbonate,DB00091
DB14492,Potassium triiodide may increase the hyperkalemic activities of Cyclosporine.,Potassium triiodide,DB00091
DB14500,Potassium may increase the hyperkalemic activities of Cyclosporine.,Potassium,DB00091
DB00155,The excretion of Citrulline can be decreased when combined with Cyclosporine.,Citrulline,DB00091
DB00345,The excretion of Aminohippuric acid can be decreased when combined with Cyclosporine.,Aminohippuric acid,DB00091
DB00770,The excretion of Alprostadil can be decreased when combined with Cyclosporine.,Alprostadil,DB00091
DB00943,The excretion of Zalcitabine can be decreased when combined with Cyclosporine.,Zalcitabine,DB00091
DB01606,The excretion of Tazobactam can be decreased when combined with Cyclosporine.,Tazobactam,DB00091
DB02527,The excretion of Cyclic adenosine monophosphate can be decreased when combined with Cyclosporine.,Cyclic adenosine monophosphate,DB00091
DB03553,The excretion of Glutaric Acid can be decreased when combined with Cyclosporine.,Glutaric Acid,DB00091
DB08846,The excretion of Ellagic acid can be decreased when combined with Cyclosporine.,Ellagic acid,DB00091
DB09298,The excretion of Silibinin can be decreased when combined with Cyclosporine.,Silibinin,DB00091
DB12243,The excretion of Edaravone can be decreased when combined with Cyclosporine.,Edaravone,DB00091
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cyclosporine.",Somatotropin,DB00091
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Carbimazole.",Carbimazole,DB00091
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Stavudine.",Stavudine,DB00091
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nafarelin.",Nafarelin,DB00091
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Naltrexone.",Naltrexone,DB00091
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Minocycline.",Minocycline,DB00091
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Iloprost.",Iloprost,DB00091
DB06693,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mevastatin.",Mevastatin,DB00091
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir.",Raltegravir,DB00091
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Acipimox.",Acipimox,DB00091
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mebeverine.",Mebeverine,DB00091
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Emetine.",Emetine,DB00091
DB01006,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Letrozole.",Letrozole,DB00091
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Enalapril.",Enalapril,DB00091
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Captopril.",Captopril,DB00091
DB00382,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Tacrine.",Tacrine,DB00091
DB00471,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Montelukast.",Montelukast,DB00091
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nizatidine.",Nizatidine,DB00091
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ubidecarenone.",Ubidecarenone,DB00091
DB01045,The metabolism of Cyclosporine can be increased when combined with Rifampicin.,Rifampicin,DB00091
DB01323,The metabolism of Cyclosporine can be increased when combined with St. John's Wort.,St. John's Wort,DB00091
DB06595,The metabolism of Cyclosporine can be increased when combined with Midostaurin.,Midostaurin,DB00091
DB11753,The metabolism of Cyclosporine can be increased when combined with Rifamycin.,Rifamycin,DB00091
DB00648,The metabolism of Cyclosporine can be increased when combined with Mitotane.,Mitotane,DB00091
DB06414,The metabolism of Cyclosporine can be increased when combined with Etravirine.,Etravirine,DB00091
DB06442,The metabolism of Cyclosporine can be increased when combined with Avasimibe.,Avasimibe,DB00091
DB08912,The metabolism of Cyclosporine can be increased when combined with Dabrafenib.,Dabrafenib,DB00091
DB14240,The metabolism of Cyclosporine can be increased when combined with Echinacea.,Echinacea,DB00091
DB00273,The metabolism of Cyclosporine can be increased when combined with Topiramate.,Topiramate,DB00091
DB00615,The metabolism of Cyclosporine can be increased when combined with Rifabutin.,Rifabutin,DB00091
DB00949,The metabolism of Cyclosporine can be increased when combined with Felbamate.,Felbamate,DB00091
DB04911,The metabolism of Cyclosporine can be increased when combined with Oritavancin.,Oritavancin,DB00091
DB06201,The metabolism of Cyclosporine can be increased when combined with Rufinamide.,Rufinamide,DB00091
DB08909,The metabolism of Cyclosporine can be increased when combined with Glycerol phenylbutyrate.,Glycerol phenylbutyrate,DB00091
DB09078,The metabolism of Cyclosporine can be increased when combined with Lenvatinib.,Lenvatinib,DB00091
DB09119,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine acetate.,Eslicarbazepine acetate,DB00091
DB11560,The metabolism of Lesinurad can be increased when combined with Cyclosporine.,Lesinurad,DB00091
DB01645,The metabolism of Cyclosporine can be increased when combined with Genistein.,Genistein,DB00091
DB00349,The metabolism of Cyclosporine can be increased when combined with Clobazam.,Clobazam,DB00091
DB00082,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.,Pegvisomant,DB00091
DB06717,The metabolism of Fosaprepitant can be increased when combined with Cyclosporine.,Fosaprepitant,DB00091
DB00136,The metabolism of Cyclosporine can be increased when combined with Calcitriol.,Calcitriol,DB00091
DB00197,The metabolism of Cyclosporine can be increased when combined with Troglitazone.,Troglitazone,DB00091
DB00301,The metabolism of Cyclosporine can be increased when combined with Flucloxacillin.,Flucloxacillin,DB00091
DB00357,The metabolism of Cyclosporine can be increased when combined with Aminoglutethimide.,Aminoglutethimide,DB00091
DB00439,The metabolism of Cyclosporine can be increased when combined with Cerivastatin.,Cerivastatin,DB00091
DB00485,The metabolism of Cyclosporine can be increased when combined with Dicloxacillin.,Dicloxacillin,DB00091
DB00603,The metabolism of Cyclosporine can be increased when combined with Medroxyprogesterone acetate.,Medroxyprogesterone acetate,DB00091
DB00754,The metabolism of Cyclosporine can be increased when combined with Ethotoin.,Ethotoin,DB00091
DB00769,The metabolism of Cyclosporine can be increased when combined with Hydrocortamate.,Hydrocortamate,DB00091
DB00857,The metabolism of Cyclosporine can be increased when combined with Terbinafine.,Terbinafine,DB00091
DB00898,The metabolism of Cyclosporine can be increased when combined with Ethanol.,Ethanol,DB00091
DB00957,The metabolism of Cyclosporine can be increased when combined with Norgestimate.,Norgestimate,DB00091
DB01011,The metabolism of Cyclosporine can be increased when combined with Metyrapone.,Metyrapone,DB00091
DB01201,The metabolism of Cyclosporine can be increased when combined with Rifapentine.,Rifapentine,DB00091
DB01221,The metabolism of Cyclosporine can be increased when combined with Ketamine.,Ketamine,DB00091
DB01333,The metabolism of Cyclosporine can be increased when combined with Cefradine.,Cefradine,DB00091
DB01352,The metabolism of Cyclosporine can be increased when combined with Aprobarbital.,Aprobarbital,DB00091
DB01609,The metabolism of Cyclosporine can be increased when combined with Deferasirox.,Deferasirox,DB00091
DB06708,The metabolism of Cyclosporine can be increased when combined with Lumefantrine.,Lumefantrine,DB00091
DB06739,The metabolism of Cyclosporine can be increased when combined with Seratrodast.,Seratrodast,DB00091
DB08905,The metabolism of Cyclosporine can be increased when combined with Formestane.,Formestane,DB00091
DB08911,The metabolism of Cyclosporine can be increased when combined with Trametinib.,Trametinib,DB00091
DB09330,The metabolism of Cyclosporine can be increased when combined with Osimertinib.,Osimertinib,DB00091
DB12267,The metabolism of Cyclosporine can be increased when combined with Brigatinib.,Brigatinib,DB00091
DB13952,The metabolism of Cyclosporine can be increased when combined with Estradiol acetate.,Estradiol acetate,DB00091
DB13953,The metabolism of Cyclosporine can be increased when combined with Estradiol benzoate.,Estradiol benzoate,DB00091
DB13954,The metabolism of Cyclosporine can be increased when combined with Estradiol cypionate.,Estradiol cypionate,DB00091
DB13955,The metabolism of Cyclosporine can be increased when combined with Estradiol dienanthate.,Estradiol dienanthate,DB00091
DB13956,The metabolism of Cyclosporine can be increased when combined with Estradiol valerate.,Estradiol valerate,DB00091
DB08883,The metabolism of Perampanel can be increased when combined with Cyclosporine.,Perampanel,DB00091
DB00776,The metabolism of Cyclosporine can be increased when combined with Oxcarbazepine.,Oxcarbazepine,DB00091
DB14575,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine.,Eslicarbazepine,DB00091
DB00448,The metabolism of Cyclosporine can be increased when combined with Lansoprazole.,Lansoprazole,DB00091
DB00602,The metabolism of Ivermectin can be increased when combined with Cyclosporine.,Ivermectin,DB00091
DB01183,The metabolism of Cyclosporine can be decreased when combined with Naloxone.,Naloxone,DB00091
DB09118,The metabolism of Cyclosporine can be decreased when combined with Stiripentol.,Stiripentol,DB00091
DB11779,The metabolism of Cyclosporine can be decreased when combined with Danoprevir.,Danoprevir,DB00091
DB11730,The metabolism of Cyclosporine can be decreased when combined with Ribociclib.,Ribociclib,DB00091
DB09101,The metabolism of Cyclosporine can be decreased when combined with Elvitegravir.,Elvitegravir,DB00091
DB00696,The metabolism of Cyclosporine can be decreased when combined with Ergotamine.,Ergotamine,DB00091
DB01263,The metabolism of Posaconazole can be decreased when combined with Cyclosporine.,Posaconazole,DB00091
DB01072,The metabolism of Atazanavir can be decreased when combined with Cyclosporine.,Atazanavir,DB00091
DB11712,The metabolism of Cyclosporine can be decreased when combined with Tezacaftor.,Tezacaftor,DB00091
DB01396,The metabolism of Digitoxin can be decreased when combined with Cyclosporine.,Digitoxin,DB00091
DB00951,The metabolism of Isoniazid can be decreased when combined with Cyclosporine.,Isoniazid,DB00091
DB00582,The metabolism of Cyclosporine can be decreased when combined with Voriconazole.,Voriconazole,DB00091
DB04896,The metabolism of Milnacipran can be decreased when combined with Cyclosporine.,Milnacipran,DB00091
DB11641,The metabolism of Cyclosporine can be decreased when combined with Vinflunine.,Vinflunine,DB00091
DB06712,The metabolism of Nilvadipine can be decreased when combined with Cyclosporine.,Nilvadipine,DB00091
DB06700,The metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.,Desvenlafaxine,DB00091
DB08953,The metabolism of Cyclosporine can be decreased when combined with Indalpine.,Indalpine,DB00091
DB14019,The metabolism of Cyclosporine can be decreased when combined with Fosnetupitant.,Fosnetupitant,DB00091
DB00204,The metabolism of Dofetilide can be decreased when combined with Cyclosporine.,Dofetilide,DB00091
DB00451,The metabolism of Levothyroxine can be decreased when combined with Cyclosporine.,Levothyroxine,DB00091
DB00946,The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.,Phenprocoumon,DB00091
DB01223,The metabolism of Aminophylline can be decreased when combined with Cyclosporine.,Aminophylline,DB00091
DB03410,The metabolism of 4-hydroxycoumarin can be decreased when combined with Cyclosporine.,4-hydroxycoumarin,DB00091
DB09289,The metabolism of Tianeptine can be decreased when combined with Cyclosporine.,Tianeptine,DB00091
DB13136,The metabolism of Fluindione can be decreased when combined with Cyclosporine.,Fluindione,DB00091
DB13275,The metabolism of Clorindione can be decreased when combined with Cyclosporine.,Clorindione,DB00091
DB00270,The metabolism of Cyclosporine can be decreased when combined with Isradipine.,Isradipine,DB00091
DB00622,The metabolism of Cyclosporine can be decreased when combined with Nicardipine.,Nicardipine,DB00091
DB01110,The metabolism of Cyclosporine can be decreased when combined with Miconazole.,Miconazole,DB00091
DB01087,The metabolism of Cyclosporine can be decreased when combined with Primaquine.,Primaquine,DB00091
DB04832,The metabolism of Cyclosporine can be decreased when combined with Zimelidine.,Zimelidine,DB00091
DB05812,The metabolism of Abiraterone can be decreased when combined with Cyclosporine.,Abiraterone,DB00091
DB11363,The metabolism of Alectinib can be decreased when combined with Cyclosporine.,Alectinib,DB00091
DB09570,The metabolism of Ixazomib can be decreased when combined with Cyclosporine.,Ixazomib,DB00091
DB12978,The metabolism of Pexidartinib can be decreased when combined with Cyclosporine.,Pexidartinib,DB00091
DB00501,The metabolism of Cyclosporine can be decreased when combined with Cimetidine.,Cimetidine,DB00091
DB01764,The metabolism of Cyclosporine can be decreased when combined with Dalfopristin.,Dalfopristin,DB00091
DB04794,The metabolism of Cyclosporine can be decreased when combined with Bifonazole.,Bifonazole,DB00091
DB09063,The metabolism of Cyclosporine can be decreased when combined with Ceritinib.,Ceritinib,DB00091
DB13941,The metabolism of Piperaquine can be decreased when combined with Cyclosporine.,Piperaquine,DB00091
DB09238,The metabolism of Manidipine can be decreased when combined with Cyclosporine.,Manidipine,DB00091
DB04839,The metabolism of Cyproterone acetate can be decreased when combined with Cyclosporine.,Cyproterone acetate,DB00091
DB00778,The metabolism of Cyclosporine can be decreased when combined with Roxithromycin.,Roxithromycin,DB00091
DB01173,The metabolism of Cyclosporine can be decreased when combined with Orphenadrine.,Orphenadrine,DB00091
DB00818,The metabolism of Cyclosporine can be decreased when combined with Propofol.,Propofol,DB00091
DB01128,The metabolism of Cyclosporine can be decreased when combined with Bicalutamide.,Bicalutamide,DB00091
DB05928,The metabolism of Cyclosporine can be decreased when combined with Dovitinib.,Dovitinib,DB00091
DB11837,The metabolism of Cyclosporine can be decreased when combined with Osilodrostat.,Osilodrostat,DB00091
DB08864,The metabolism of Cyclosporine can be decreased when combined with Rilpivirine.,Rilpivirine,DB00091
DB01395,The metabolism of Cyclosporine can be decreased when combined with Drospirenone.,Drospirenone,DB00091
DB00186,The metabolism of Cyclosporine can be decreased when combined with Lorazepam.,Lorazepam,DB00091
DB00191,The metabolism of Cyclosporine can be decreased when combined with Phentermine.,Phentermine,DB00091
DB00426,The metabolism of Cyclosporine can be decreased when combined with Famciclovir.,Famciclovir,DB00091
DB00567,The metabolism of Cyclosporine can be decreased when combined with Cephalexin.,Cephalexin,DB00091
DB01411,The metabolism of Cyclosporine can be decreased when combined with Pranlukast.,Pranlukast,DB00091
DB01431,The metabolism of Cyclosporine can be decreased when combined with Allylestrenol.,Allylestrenol,DB00091
DB06218,The metabolism of Cyclosporine can be decreased when combined with Lacosamide.,Lacosamide,DB00091
DB09071,The metabolism of Cyclosporine can be decreased when combined with Tasimelteon.,Tasimelteon,DB00091
DB09079,The metabolism of Cyclosporine can be decreased when combined with Nintedanib.,Nintedanib,DB00091
DB11094,The metabolism of Cyclosporine can be decreased when combined with Vitamin D.,Vitamin D,DB00091
DB11273,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocornine.,Dihydroergocornine,DB00091
DB11952,The metabolism of Cyclosporine can be decreased when combined with Duvelisib.,Duvelisib,DB00091
DB12141,The metabolism of Cyclosporine can be decreased when combined with Gilteritinib.,Gilteritinib,DB00091
DB12515,The metabolism of Cyclosporine can be decreased when combined with 9-aminocamptothecin.,9-aminocamptothecin,DB00091
DB12952,The metabolism of Cyclosporine can be decreased when combined with Methylprednisone.,Methylprednisone,DB00091
DB13345,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocristine.,Dihydroergocristine,DB00091
DB13385,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocryptine.,Dihydroergocryptine,DB00091
DB12887,The metabolism of Tazemetostat can be decreased when combined with Cyclosporine.,Tazemetostat,DB00091
DB00518,The metabolism of Cyclosporine can be decreased when combined with Albendazole.,Albendazole,DB00091
DB00247,The metabolism of Methysergide can be decreased when combined with Cyclosporine.,Methysergide,DB00091
DB11742,The metabolism of Ebastine can be decreased when combined with Cyclosporine.,Ebastine,DB00091
DB00220,The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.,Nelfinavir,DB00091
DB00673,The metabolism of Aprepitant can be decreased when combined with Cyclosporine.,Aprepitant,DB00091
DB01232,The metabolism of Saquinavir can be decreased when combined with Cyclosporine.,Saquinavir,DB00091
DB00780,The metabolism of Cyclosporine can be decreased when combined with Phenelzine.,Phenelzine,DB00091
DB02520,The metabolism of Cyclosporine can be decreased when combined with Ditiocarb.,Ditiocarb,DB00091
DB06731,The metabolism of Cyclosporine can be decreased when combined with Seproxetine.,Seproxetine,DB00091
DB11574,The metabolism of Cyclosporine can be decreased when combined with Elbasvir.,Elbasvir,DB00091
DB09241,The metabolism of Methylene blue can be decreased when combined with Cyclosporine.,Methylene blue,DB00091
DB06654,The metabolism of Cyclosporine can be decreased when combined with Safinamide.,Safinamide,DB00091
DB06730,The metabolism of Cyclosporine can be decreased when combined with Gestodene.,Gestodene,DB00091
DB11703,The metabolism of Cyclosporine can be decreased when combined with Acalabrutinib.,Acalabrutinib,DB00091
DB00224,The metabolism of Cyclosporine can be decreased when combined with Indinavir.,Indinavir,DB00091
DB00250,The metabolism of Cyclosporine can be decreased when combined with Dapsone.,Dapsone,DB00091
DB00499,The metabolism of Cyclosporine can be decreased when combined with Flutamide.,Flutamide,DB00091
DB00758,The metabolism of Cyclosporine can be decreased when combined with Clopidogrel.,Clopidogrel,DB00091
DB00822,The metabolism of Cyclosporine can be decreased when combined with Disulfiram.,Disulfiram,DB00091
DB00962,The metabolism of Cyclosporine can be decreased when combined with Zaleplon.,Zaleplon,DB00091
DB01058,The metabolism of Cyclosporine can be decreased when combined with Praziquantel.,Praziquantel,DB00091
DB01126,The metabolism of Cyclosporine can be decreased when combined with Dutasteride.,Dutasteride,DB00091
DB01216,The metabolism of Cyclosporine can be decreased when combined with Finasteride.,Finasteride,DB00091
DB01218,The metabolism of Cyclosporine can be decreased when combined with Halofantrine.,Halofantrine,DB00091
DB01227,The metabolism of Cyclosporine can be decreased when combined with Levacetylmethadol.,Levacetylmethadol,DB00091
DB06176,The metabolism of Cyclosporine can be decreased when combined with Romidepsin.,Romidepsin,DB00091
DB06267,The metabolism of Cyclosporine can be decreased when combined with Udenafil.,Udenafil,DB00091
DB06335,The metabolism of Cyclosporine can be decreased when combined with Saxagliptin.,Saxagliptin,DB00091
DB06605,The metabolism of Cyclosporine can be decreased when combined with Apixaban.,Apixaban,DB00091
DB06626,The metabolism of Cyclosporine can be decreased when combined with Axitinib.,Axitinib,DB00091
DB06652,The metabolism of Cyclosporine can be decreased when combined with Vicriviroc.,Vicriviroc,DB00091
DB06789,The metabolism of Cyclosporine can be decreased when combined with Hydroxyprogesterone caproate.,Hydroxyprogesterone caproate,DB00091
DB09256,The metabolism of Cyclosporine can be decreased when combined with Tegafur.,Tegafur,DB00091
DB11737,The metabolism of Cyclosporine can be decreased when combined with Icotinib.,Icotinib,DB00091
DB12130,The metabolism of Cyclosporine can be decreased when combined with Lorlatinib.,Lorlatinib,DB00091
DB12301,The metabolism of Cyclosporine can be decreased when combined with Doravirine.,Doravirine,DB00091
DB12483,The metabolism of Cyclosporine can be decreased when combined with Copanlisib.,Copanlisib,DB00091
DB14542,The metabolism of Cyclosporine can be decreased when combined with Hydrocortisone phosphate.,Hydrocortisone phosphate,DB00091
DB00604,The metabolism of Cisapride can be decreased when combined with Cyclosporine.,Cisapride,DB00091
DB00820,The metabolism of Tadalafil can be decreased when combined with Cyclosporine.,Tadalafil,DB00091
DB00897,The metabolism of Triazolam can be decreased when combined with Cyclosporine.,Triazolam,DB00091
DB06228,The metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.,Rivaroxaban,DB00091
DB00783,The metabolism of Cyclosporine can be decreased when combined with Estradiol.,Estradiol,DB00091
DB00246,The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.,Ziprasidone,DB00091
DB00717,The metabolism of Cyclosporine can be decreased when combined with Norethisterone.,Norethisterone,DB00091
DB00829,The metabolism of Cyclosporine can be decreased when combined with Diazepam.,Diazepam,DB00091
DB00977,The metabolism of Cyclosporine can be decreased when combined with Ethinylestradiol.,Ethinylestradiol,DB00091
DB01062,The metabolism of Cyclosporine can be decreased when combined with Oxybutynin.,Oxybutynin,DB00091
DB06697,The metabolism of Artemether can be decreased when combined with Cyclosporine.,Artemether,DB00091
DB04856,The metabolism of Dexloxiglumide can be decreased when combined with Cyclosporine.,Dexloxiglumide,DB00091
DB04957,The metabolism of Azimilide can be decreased when combined with Cyclosporine.,Azimilide,DB00091
DB00367,The metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.,Levonorgestrel,DB00091
DB00528,The metabolism of Lercanidipine can be decreased when combined with Cyclosporine.,Lercanidipine,DB00091
DB00938,The metabolism of Salmeterol can be decreased when combined with Cyclosporine.,Salmeterol,DB00091
DB09061,The metabolism of Cannabidiol can be decreased when combined with Cyclosporine.,Cannabidiol,DB00091
DB09231,The metabolism of Benidipine can be decreased when combined with Cyclosporine.,Benidipine,DB00091
DB14011,The metabolism of Nabiximols can be decreased when combined with Cyclosporine.,Nabiximols,DB00091
DB00557,The metabolism of Hydroxyzine can be decreased when combined with Cyclosporine.,Hydroxyzine,DB00091
DB11951,The metabolism of Lemborexant can be decreased when combined with Cyclosporine.,Lemborexant,DB00091
DB01190,The metabolism of Clindamycin can be decreased when combined with Cyclosporine.,Clindamycin,DB00091
DB01054,The metabolism of Cyclosporine can be decreased when combined with Nitrendipine.,Nitrendipine,DB00091
DB01103,The metabolism of Cyclosporine can be decreased when combined with Quinacrine.,Quinacrine,DB00091
DB09297,The metabolism of Paritaprevir can be decreased when combined with Cyclosporine.,Paritaprevir,DB00091
DB00401,The metabolism of Cyclosporine can be decreased when combined with Nisoldipine.,Nisoldipine,DB00091
DB00802,The metabolism of Cyclosporine can be decreased when combined with Alfentanil.,Alfentanil,DB00091
DB00714,The metabolism of Apomorphine can be decreased when combined with Cyclosporine.,Apomorphine,DB00091
DB00260,Cyclosporine may increase the neurotoxic activities of Cycloserine.,Cycloserine,DB00091
DB00391,Cyclosporine may increase the neurotoxic activities of Sulpiride.,Sulpiride,DB00091
DB00450,Cyclosporine may increase the neurotoxic activities of Droperidol.,Droperidol,DB00091
DB00680,Cyclosporine may increase the neurotoxic activities of Moricizine.,Moricizine,DB00091
DB01063,Cyclosporine may increase the neurotoxic activities of Acetophenazine.,Acetophenazine,DB00091
DB01294,Cyclosporine may increase the neurotoxic activities of Bismuth subsalicylate.,Bismuth subsalicylate,DB00091
DB01608,Cyclosporine may increase the neurotoxic activities of Periciazine.,Periciazine,DB00091
DB01614,Cyclosporine may increase the neurotoxic activities of Acepromazine.,Acepromazine,DB00091
DB01615,Cyclosporine may increase the neurotoxic activities of Aceprometazine.,Aceprometazine,DB00091
DB01618,Cyclosporine may increase the neurotoxic activities of Molindone.,Molindone,DB00091
DB01622,Cyclosporine may increase the neurotoxic activities of Thioproperazine.,Thioproperazine,DB00091
DB01623,Cyclosporine may increase the neurotoxic activities of Thiothixene.,Thiothixene,DB00091
DB04836,Cyclosporine may increase the neurotoxic activities of Amineptine.,Amineptine,DB00091
DB04872,Cyclosporine may increase the neurotoxic activities of Osanetant.,Osanetant,DB00091
DB04888,Cyclosporine may increase the neurotoxic activities of Bifeprunox.,Bifeprunox,DB00091
DB05316,Cyclosporine may increase the neurotoxic activities of Pimavanserin.,Pimavanserin,DB00091
DB05687,Cyclosporine may increase the neurotoxic activities of BL-1020.,BL-1020,DB00091
DB06288,Cyclosporine may increase the neurotoxic activities of Amisulpride.,Amisulpride,DB00091
DB08927,Cyclosporine may increase the neurotoxic activities of Amperozide.,Amperozide,DB00091
DB09000,Cyclosporine may increase the neurotoxic activities of Cyamemazine.,Cyamemazine,DB00091
DB09016,Cyclosporine may increase the neurotoxic activities of Butriptyline.,Butriptyline,DB00091
DB09154,Cyclosporine may increase the neurotoxic activities of Sodium citrate.,Sodium citrate,DB00091
DB09226,Cyclosporine may increase the neurotoxic activities of Brilaroxazine.,Brilaroxazine,DB00091
DB09275,Cyclosporine may increase the neurotoxic activities of Bismuth subcitrate potassium.,Bismuth subcitrate potassium,DB00091
DB09286,Cyclosporine may increase the neurotoxic activities of Pipamperone.,Pipamperone,DB00091
DB09307,Cyclosporine may increase the neurotoxic activities of Oxaprotiline.,Oxaprotiline,DB00091
DB11281,Cyclosporine may increase the neurotoxic activities of Bismuth subcarbonate.,Bismuth subcarbonate,DB00091
DB11376,Cyclosporine may increase the neurotoxic activities of Azaperone.,Azaperone,DB00091
DB11537,Cyclosporine may increase the neurotoxic activities of Pirlimycin.,Pirlimycin,DB00091
DB11540,Cyclosporine may increase the neurotoxic activities of Propiopromazine.,Propiopromazine,DB00091
DB12273,Cyclosporine may increase the neurotoxic activities of Ecopipam.,Ecopipam,DB00091
DB12518,Cyclosporine may increase the neurotoxic activities of Raclopride.,Raclopride,DB00091
DB12693,Cyclosporine may increase the neurotoxic activities of Ritanserin.,Ritanserin,DB00091
DB12710,Cyclosporine may increase the neurotoxic activities of Perazine.,Perazine,DB00091
DB12867,Cyclosporine may increase the neurotoxic activities of Benperidol.,Benperidol,DB00091
DB12958,Cyclosporine may increase the neurotoxic activities of Prothipendyl.,Prothipendyl,DB00091
DB13114,Cyclosporine may increase the neurotoxic activities of Amitriptylinoxide.,Amitriptylinoxide,DB00091
DB13209,Cyclosporine may increase the neurotoxic activities of Bismuth subnitrate.,Bismuth subnitrate,DB00091
DB13213,Cyclosporine may increase the neurotoxic activities of Butaperazine.,Butaperazine,DB00091
DB13225,Cyclosporine may increase the neurotoxic activities of Dibenzepin.,Dibenzepin,DB00091
DB13246,Cyclosporine may increase the neurotoxic activities of Quinupramine.,Quinupramine,DB00091
DB13256,Cyclosporine may increase the neurotoxic activities of Clothiapine.,Clothiapine,DB00091
DB13273,Cyclosporine may increase the neurotoxic activities of Sultopride.,Sultopride,DB00091
DB13382,Cyclosporine may increase the neurotoxic activities of Chlorproethazine.,Chlorproethazine,DB00091
DB13384,Cyclosporine may increase the neurotoxic activities of Melitracen.,Melitracen,DB00091
DB13403,Cyclosporine may increase the neurotoxic activities of Oxypertine.,Oxypertine,DB00091
DB13411,Cyclosporine may increase the neurotoxic activities of Lofepramine.,Lofepramine,DB00091
DB13420,Cyclosporine may increase the neurotoxic activities of Thiazinam.,Thiazinam,DB00091
DB13496,Cyclosporine may increase the neurotoxic activities of Iprindole.,Iprindole,DB00091
DB13523,Cyclosporine may increase the neurotoxic activities of Veralipride.,Veralipride,DB00091
DB13552,Cyclosporine may increase the neurotoxic activities of Trifluperidol.,Trifluperidol,DB00091
DB13554,Cyclosporine may increase the neurotoxic activities of Moperone.,Moperone,DB00091
DB13557,Cyclosporine may increase the neurotoxic activities of Thiopropazate.,Thiopropazate,DB00091
DB13665,Cyclosporine may increase the neurotoxic activities of Fluanisone.,Fluanisone,DB00091
DB13676,Cyclosporine may increase the neurotoxic activities of Mosapramine.,Mosapramine,DB00091
DB13782,Cyclosporine may increase the neurotoxic activities of Imipramine oxide.,Imipramine oxide,DB00091
DB13784,Cyclosporine may increase the neurotoxic activities of Dixyrazine.,Dixyrazine,DB00091
DB13841,Cyclosporine may increase the neurotoxic activities of Clopenthixol.,Clopenthixol,DB00091
DB13910,Cyclosporine may increase the neurotoxic activities of Valproate bismuth.,Valproate bismuth,DB00091
DB14651,Cyclosporine may increase the neurotoxic activities of Perphenazine enanthate.,Perphenazine enanthate,DB00091
DB01246,Cyclosporine may increase the neurotoxic activities of Alimemazine.,Alimemazine,DB00091
DB09225,Cyclosporine may increase the neurotoxic activities of Zotepine.,Zotepine,DB00091
DB00508,Cyclosporine may increase the neurotoxic activities of Triflupromazine.,Triflupromazine,DB00091
DB00623,Cyclosporine may increase the neurotoxic activities of Fluphenazine.,Fluphenazine,DB00091
DB01239,Cyclosporine may increase the neurotoxic activities of Chlorprothixene.,Chlorprothixene,DB00091
DB12401,Cyclosporine may increase the neurotoxic activities of Bromperidol.,Bromperidol,DB00091
DB00924,Cyclosporine may increase the neurotoxic activities of Cyclobenzaprine.,Cyclobenzaprine,DB00091
DB01597,The excretion of Cyclosporine can be increased when combined with Cilastatin.,Cilastatin,DB00091
DB00653,The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Cyclosporine.,Magnesium sulfate,DB00091
DB00463,The therapeutic efficacy of Metharbital can be decreased when used in combination with Cyclosporine.,Metharbital,DB00091
DB00697,The therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclosporine.,Tizanidine,DB00091
DB00832,The therapeutic efficacy of Phensuximide can be decreased when used in combination with Cyclosporine.,Phensuximide,DB00091
DB00837,The therapeutic efficacy of Progabide can be decreased when used in combination with Cyclosporine.,Progabide,DB00091
DB01080,The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cyclosporine.,Vigabatrin,DB00091
DB01121,The therapeutic efficacy of Phenacemide can be decreased when used in combination with Cyclosporine.,Phenacemide,DB00091
DB01511,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Cyclosporine.,Delorazepam,DB00091
DB02207,The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Cyclosporine.,7-Nitroindazole,DB00091
DB04165,The therapeutic efficacy of Valpromide can be decreased when used in combination with Cyclosporine.,Valpromide,DB00091
DB06512,The therapeutic efficacy of Deramciclane can be decreased when used in combination with Cyclosporine.,Deramciclane,DB00091
DB06527,The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Cyclosporine.,Tramiprosate,DB00091
DB06554,The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Cyclosporine.,Gaboxadol,DB00091
DB08329,The therapeutic efficacy of Sulthiame can be decreased when used in combination with Cyclosporine.,Sulthiame,DB00091
DB08954,The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cyclosporine.,Ifenprodil,DB00091
DB09011,The therapeutic efficacy of Beclamide can be decreased when used in combination with Cyclosporine.,Beclamide,DB00091
DB09117,The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Cyclosporine.,Paraldehyde,DB00091
DB11549,The therapeutic efficacy of Tiletamine can be decreased when used in combination with Cyclosporine.,Tiletamine,DB00091
DB11859,The therapeutic efficacy of Brexanolone can be decreased when used in combination with Cyclosporine.,Brexanolone,DB00091
DB11868,The therapeutic efficacy of Etiracetam can be decreased when used in combination with Cyclosporine.,Etiracetam,DB00091
DB12338,The therapeutic efficacy of Carisbamate can be decreased when used in combination with Cyclosporine.,Carisbamate,DB00091
DB13362,The therapeutic efficacy of Pheneturide can be decreased when used in combination with Cyclosporine.,Pheneturide,DB00091
DB13396,The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Cyclosporine.,Neocitrullamon,DB00091
DB13437,The therapeutic efficacy of Medazepam can be decreased when used in combination with Cyclosporine.,Medazepam,DB00091
DB13455,The therapeutic efficacy of Phenibut can be decreased when used in combination with Cyclosporine.,Phenibut,DB00091
DB13799,The therapeutic efficacy of Ethadione can be decreased when used in combination with Cyclosporine.,Ethadione,DB00091
DB14050,The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Cyclosporine.,Cannabidivarin,DB00091
DB15203,The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Cyclosporine.,JNJ-26489112,DB00091
DB00230,The therapeutic efficacy of Cyclosporine can be decreased when used in combination with Pregabalin.,Pregabalin,DB00091
DB01068,The therapeutic efficacy of Clonazepam can be decreased when used in combination with Cyclosporine.,Clonazepam,DB00091
DB00996,The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cyclosporine.,Gabapentin,DB00091
DB00906,The therapeutic efficacy of Tiagabine can be decreased when used in combination with Cyclosporine.,Tiagabine,DB00091
DB01595,The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Cyclosporine.,Nitrazepam,DB00091
DB06470,The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Cyclosporine.,Clomethiazole,DB00091
DB12131,The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Cyclosporine.,Vinpocetine,DB00091
DB00347,The therapeutic efficacy of Trimethadione can be decreased when used in combination with Cyclosporine.,Trimethadione,DB00091
DB00617,The therapeutic efficacy of Paramethadione can be decreased when used in combination with Cyclosporine.,Paramethadione,DB00091
DB05246,The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.,Methsuximide,DB00091
DB05541,The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Cyclosporine.,Brivaracetam,DB00091
DB01202,The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Cyclosporine.,Levetiracetam,DB00091
DB00593,The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cyclosporine.,Ethosuximide,DB00091
DB11640,The risk or severity of seizure can be increased when Cyclosporine is combined with Amifampridine.,Amifampridine,DB00091
DB09142,The excretion of Sincalide can be decreased when combined with Cyclosporine.,Sincalide,DB00091
DB11936,The excretion of Bempedoic acid can be decreased when combined with Cyclosporine.,Bempedoic acid,DB00091
DB11855,Cyclosporine may decrease the excretion rate of Revefenacin which could result in a higher serum level.,Revefenacin,DB00091
DB00218,The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.,Moxifloxacin,DB00091
DB00365,The risk or severity of nephrotoxicity can be increased when Grepafloxacin is combined with Cyclosporine.,Grepafloxacin,DB00091
DB00467,The risk or severity of nephrotoxicity can be increased when Enoxacin is combined with Cyclosporine.,Enoxacin,DB00091
DB00487,The risk or severity of nephrotoxicity can be increased when Pefloxacin is combined with Cyclosporine.,Pefloxacin,DB00091
DB00685,The risk or severity of nephrotoxicity can be increased when Trovafloxacin is combined with Cyclosporine.,Trovafloxacin,DB00091
DB00779,The risk or severity of nephrotoxicity can be increased when Nalidixic acid is combined with Cyclosporine.,Nalidixic acid,DB00091
DB00817,The risk or severity of nephrotoxicity can be increased when Rosoxacin is combined with Cyclosporine.,Rosoxacin,DB00091
DB00827,The risk or severity of nephrotoxicity can be increased when Cinoxacin is combined with Cyclosporine.,Cinoxacin,DB00091
DB00978,The risk or severity of nephrotoxicity can be increased when Lomefloxacin is combined with Cyclosporine.,Lomefloxacin,DB00091
DB01044,The risk or severity of nephrotoxicity can be increased when Gatifloxacin is combined with Cyclosporine.,Gatifloxacin,DB00091
DB01155,The risk or severity of nephrotoxicity can be increased when Gemifloxacin is combined with Cyclosporine.,Gemifloxacin,DB00091
DB01165,The risk or severity of nephrotoxicity can be increased when Ofloxacin is combined with Cyclosporine.,Ofloxacin,DB00091
DB01208,The risk or severity of nephrotoxicity can be increased when Sparfloxacin is combined with Cyclosporine.,Sparfloxacin,DB00091
DB01405,The risk or severity of nephrotoxicity can be increased when Temafloxacin is combined with Cyclosporine.,Temafloxacin,DB00091
DB04576,The risk or severity of nephrotoxicity can be increased when Fleroxacin is combined with Cyclosporine.,Fleroxacin,DB00091
DB05488,The risk or severity of nephrotoxicity can be increased when Technetium Tc-99m ciprofloxacin is combined with Cyclosporine.,Technetium Tc-99m ciprofloxacin,DB00091
DB06160,The risk or severity of nephrotoxicity can be increased when Garenoxacin is combined with Cyclosporine.,Garenoxacin,DB00091
DB06600,The risk or severity of nephrotoxicity can be increased when Nemonoxacin is combined with Cyclosporine.,Nemonoxacin,DB00091
DB08972,The risk or severity of nephrotoxicity can be increased when Flumequine is combined with Cyclosporine.,Flumequine,DB00091
DB11404,The risk or severity of nephrotoxicity can be increased when Enrofloxacin is combined with Cyclosporine.,Enrofloxacin,DB00091
DB11443,The risk or severity of nephrotoxicity can be increased when Orbifloxacin is combined with Cyclosporine.,Orbifloxacin,DB00091
DB11491,The risk or severity of nephrotoxicity can be increased when Sarafloxacin is combined with Cyclosporine.,Sarafloxacin,DB00091
DB11511,The risk or severity of nephrotoxicity can be increased when Difloxacin is combined with Cyclosporine.,Difloxacin,DB00091
DB11774,The risk or severity of nephrotoxicity can be increased when Pazufloxacin is combined with Cyclosporine.,Pazufloxacin,DB00091
DB11892,The risk or severity of nephrotoxicity can be increased when Prulifloxacin is combined with Cyclosporine.,Prulifloxacin,DB00091
DB11943,The risk or severity of nephrotoxicity can be increased when Delafloxacin is combined with Cyclosporine.,Delafloxacin,DB00091
DB13261,The risk or severity of nephrotoxicity can be increased when Sitafloxacin is combined with Cyclosporine.,Sitafloxacin,DB00091
DB13627,The risk or severity of nephrotoxicity can be increased when Oxolinic acid is combined with Cyclosporine.,Oxolinic acid,DB00091
DB13772,The risk or severity of nephrotoxicity can be increased when Rufloxacin is combined with Cyclosporine.,Rufloxacin,DB00091
DB13823,The risk or severity of nephrotoxicity can be increased when Pipemidic acid is combined with Cyclosporine.,Pipemidic acid,DB00091
DB00882,The serum concentration of Cyclosporine can be increased when it is combined with Clomifene.,Clomifene,DB00091
DB05889,The serum concentration of Cyclosporine can be increased when it is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00091
DB08930,The serum concentration of Cyclosporine can be increased when it is combined with Dolutegravir.,Dolutegravir,DB00091
DB08934,The serum concentration of Cyclosporine can be increased when it is combined with Sofosbuvir.,Sofosbuvir,DB00091
DB09161,The serum concentration of Cyclosporine can be increased when it is combined with Technetium Tc-99m sestamibi.,Technetium Tc-99m sestamibi,DB00091
DB09296,The serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.,Ombitasvir,DB00091
DB11827,The serum concentration of Cyclosporine can be increased when it is combined with Ertugliflozin.,Ertugliflozin,DB00091
DB11995,The serum concentration of Cyclosporine can be increased when it is combined with Avatrombopag.,Avatrombopag,DB00091
DB12455,The serum concentration of Cyclosporine can be increased when it is combined with Omadacycline.,Omadacycline,DB00091
DB12836,The serum concentration of Cyclosporine can be increased when it is combined with Grapiprant.,Grapiprant,DB00091
DB13007,The serum concentration of Cyclosporine can be increased when it is combined with Enfortumab vedotin.,Enfortumab vedotin,DB00091
DB06212,The serum concentration of Cyclosporine can be increased when it is combined with Tolvaptan.,Tolvaptan,DB00091
DB00950,The serum concentration of Cyclosporine can be increased when it is combined with Fexofenadine.,Fexofenadine,DB00091
DB00295,The serum concentration of Cyclosporine can be increased when it is combined with Morphine.,Morphine,DB00091
DB01261,The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.,Sitagliptin,DB00091
DB05039,The serum concentration of Cyclosporine can be increased when it is combined with Indacaterol.,Indacaterol,DB00091
DB06670,The serum concentration of Cyclosporine can be increased when it is combined with Odanacatib.,Odanacatib,DB00091
DB11362,The serum concentration of Cyclosporine can be increased when it is combined with Selexipag.,Selexipag,DB00091
DB11575,The serum concentration of Cyclosporine can be increased when it is combined with Grazoprevir.,Grazoprevir,DB00091
DB14723,The serum concentration of Cyclosporine can be increased when it is combined with Larotrectinib.,Larotrectinib,DB00091
DB00586,The serum concentration of Diclofenac can be increased when it is combined with Cyclosporine.,Diclofenac,DB00091
DB00005,Etanercept may increase the immunosuppressive activities of Cyclosporine.,Etanercept,DB00091
DB00008,Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.,Peginterferon alfa-2a,DB00091
DB00011,Interferon alfa-n1 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-n1,DB00091
DB00018,Interferon alfa-n3 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-n3,DB00091
DB00022,Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Peginterferon alfa-2b,DB00091
DB00026,Anakinra may increase the immunosuppressive activities of Cyclosporine.,Anakinra,DB00091
DB00033,Interferon gamma-1b may increase the immunosuppressive activities of Cyclosporine.,Interferon gamma-1b,DB00091
DB00034,"Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Cyclosporine.","Interferon alfa-2a, Recombinant",DB00091
DB00041,Aldesleukin may increase the immunosuppressive activities of Cyclosporine.,Aldesleukin,DB00091
DB00056,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.,Gemtuzumab ozogamicin,DB00091
DB00059,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.,Pegaspargase,DB00091
DB00065,Infliximab may increase the immunosuppressive activities of Cyclosporine.,Infliximab,DB00091
DB00068,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.,Interferon beta-1b,DB00091
DB00069,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfacon-1,DB00091
DB00072,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.,Trastuzumab,DB00091
DB00073,Rituximab may increase the immunosuppressive activities of Cyclosporine.,Rituximab,DB00091
DB00074,Basiliximab may increase the immunosuppressive activities of Cyclosporine.,Basiliximab,DB00091
DB00075,Muromonab may increase the immunosuppressive activities of Cyclosporine.,Muromonab,DB00091
DB00078,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.,Ibritumomab tiuxetan,DB00091
DB00081,Tositumomab may increase the immunosuppressive activities of Cyclosporine.,Tositumomab,DB00091
DB00087,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.,Alemtuzumab,DB00091
DB00092,Alefacept may increase the immunosuppressive activities of Cyclosporine.,Alefacept,DB00091
DB00095,Efalizumab may increase the immunosuppressive activities of Cyclosporine.,Efalizumab,DB00091
DB00098,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.,Antithymocyte immunoglobulin (rabbit),DB00091
DB00105,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-2b,DB00091
DB00108,Natalizumab may increase the immunosuppressive activities of Cyclosporine.,Natalizumab,DB00091
DB00111,Daclizumab may increase the immunosuppressive activities of Cyclosporine.,Daclizumab,DB00091
DB00112,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.,Bevacizumab,DB00091
DB00120,Phenylalanine may increase the immunosuppressive activities of Cyclosporine.,Phenylalanine,DB00091
DB00180,Flunisolide may increase the immunosuppressive activities of Cyclosporine.,Flunisolide,DB00091
DB00188,Bortezomib may increase the immunosuppressive activities of Cyclosporine.,Bortezomib,DB00091
DB00242,Cladribine may increase the immunosuppressive activities of Cyclosporine.,Cladribine,DB00091
DB00262,Carmustine may increase the immunosuppressive activities of Cyclosporine.,Carmustine,DB00091
DB00276,Amsacrine may increase the immunosuppressive activities of Cyclosporine.,Amsacrine,DB00091
DB00290,Bleomycin may increase the immunosuppressive activities of Cyclosporine.,Bleomycin,DB00091
DB00291,Chlorambucil may increase the immunosuppressive activities of Cyclosporine.,Chlorambucil,DB00091
DB00293,Raltitrexed may increase the immunosuppressive activities of Cyclosporine.,Raltitrexed,DB00091
DB00305,Mitomycin may increase the immunosuppressive activities of Cyclosporine.,Mitomycin,DB00091
DB00307,Bexarotene may increase the immunosuppressive activities of Cyclosporine.,Bexarotene,DB00091
DB00309,Vindesine may increase the immunosuppressive activities of Cyclosporine.,Vindesine,DB00091
DB00322,Floxuridine may increase the immunosuppressive activities of Cyclosporine.,Floxuridine,DB00091
DB00328,Indomethacin may increase the immunosuppressive activities of Cyclosporine.,Indomethacin,DB00091
DB00352,Tioguanine may increase the immunosuppressive activities of Cyclosporine.,Tioguanine,DB00091
DB00361,Vinorelbine may increase the immunosuppressive activities of Cyclosporine.,Vinorelbine,DB00091
DB00380,Dexrazoxane may increase the immunosuppressive activities of Cyclosporine.,Dexrazoxane,DB00091
DB00394,Beclomethasone dipropionate may increase the immunosuppressive activities of Cyclosporine.,Beclomethasone dipropionate,DB00091
DB00398,Sorafenib may increase the immunosuppressive activities of Cyclosporine.,Sorafenib,DB00091
DB00428,Streptozocin may increase the immunosuppressive activities of Cyclosporine.,Streptozocin,DB00091
DB00432,Trifluridine may increase the immunosuppressive activities of Cyclosporine.,Trifluridine,DB00091
DB00441,Gemcitabine may increase the immunosuppressive activities of Cyclosporine.,Gemcitabine,DB00091
DB00443,Betamethasone may increase the immunosuppressive activities of Cyclosporine.,Betamethasone,DB00091
DB00444,Teniposide may increase the immunosuppressive activities of Cyclosporine.,Teniposide,DB00091
DB00445,Epirubicin may increase the immunosuppressive activities of Cyclosporine.,Epirubicin,DB00091
DB00480,Lenalidomide may increase the immunosuppressive activities of Cyclosporine.,Lenalidomide,DB00091
DB00488,Altretamine may increase the immunosuppressive activities of Cyclosporine.,Altretamine,DB00091
DB00495,Zidovudine may increase the immunosuppressive activities of Cyclosporine.,Zidovudine,DB00091
DB00515,Cisplatin may increase the immunosuppressive activities of Cyclosporine.,Cisplatin,DB00091
DB00526,Oxaliplatin may increase the immunosuppressive activities of Cyclosporine.,Oxaliplatin,DB00091
DB00541,Vincristine may increase the immunosuppressive activities of Cyclosporine.,Vincristine,DB00091
DB00544,Fluorouracil may increase the immunosuppressive activities of Cyclosporine.,Fluorouracil,DB00091
DB00550,Propylthiouracil may increase the immunosuppressive activities of Cyclosporine.,Propylthiouracil,DB00091
DB00552,Pentostatin may increase the immunosuppressive activities of Cyclosporine.,Pentostatin,DB00091
DB00570,Vinblastine may increase the immunosuppressive activities of Cyclosporine.,Vinblastine,DB00091
DB00588,Fluticasone propionate may increase the immunosuppressive activities of Cyclosporine.,Fluticasone propionate,DB00091
DB00591,Fluocinolone acetonide may increase the immunosuppressive activities of Cyclosporine.,Fluocinolone acetonide,DB00091
DB00601,Linezolid may increase the immunosuppressive activities of Cyclosporine.,Linezolid,DB00091
DB00620,Triamcinolone may increase the immunosuppressive activities of Cyclosporine.,Triamcinolone,DB00091
DB00631,Clofarabine may increase the immunosuppressive activities of Cyclosporine.,Clofarabine,DB00091
DB00635,Prednisone may increase the immunosuppressive activities of Cyclosporine.,Prednisone,DB00091
DB00642,Pemetrexed may increase the immunosuppressive activities of Cyclosporine.,Pemetrexed,DB00091
DB00687,Fludrocortisone may increase the immunosuppressive activities of Cyclosporine.,Fludrocortisone,DB00091
DB00688,Mycophenolate mofetil may increase the immunosuppressive activities of Cyclosporine.,Mycophenolate mofetil,DB00091
DB00694,Daunorubicin may increase the immunosuppressive activities of Cyclosporine.,Daunorubicin,DB00091
DB00741,Hydrocortisone may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone,DB00091
DB00755,Tretinoin may increase the immunosuppressive activities of Cyclosporine.,Tretinoin,DB00091
DB00762,Irinotecan may increase the immunosuppressive activities of Cyclosporine.,Irinotecan,DB00091
DB00763,Methimazole may increase the immunosuppressive activities of Cyclosporine.,Methimazole,DB00091
DB00764,Mometasone may increase the immunosuppressive activities of Cyclosporine.,Mometasone,DB00091
DB00795,Sulfasalazine may increase the immunosuppressive activities of Cyclosporine.,Sulfasalazine,DB00091
DB00851,Dacarbazine may increase the immunosuppressive activities of Cyclosporine.,Dacarbazine,DB00091
DB00853,Temozolomide may increase the immunosuppressive activities of Cyclosporine.,Temozolomide,DB00091
DB00859,Penicillamine may increase the immunosuppressive activities of Cyclosporine.,Penicillamine,DB00091
DB00860,Prednisolone may increase the immunosuppressive activities of Cyclosporine.,Prednisolone,DB00091
DB00877,Sirolimus may increase the immunosuppressive activities of Cyclosporine.,Sirolimus,DB00091
DB00888,Mechlorethamine may increase the immunosuppressive activities of Cyclosporine.,Mechlorethamine,DB00091
DB00928,Azacitidine may increase the immunosuppressive activities of Cyclosporine.,Azacitidine,DB00091
DB00958,Carboplatin may increase the immunosuppressive activities of Cyclosporine.,Carboplatin,DB00091
DB00970,Dactinomycin may increase the immunosuppressive activities of Cyclosporine.,Dactinomycin,DB00091
DB00987,Cytarabine may increase the immunosuppressive activities of Cyclosporine.,Cytarabine,DB00091
DB00993,Azathioprine may increase the immunosuppressive activities of Cyclosporine.,Azathioprine,DB00091
DB01005,Hydroxyurea may increase the immunosuppressive activities of Cyclosporine.,Hydroxyurea,DB00091
DB01008,Busulfan may increase the immunosuppressive activities of Cyclosporine.,Busulfan,DB00091
DB01024,Mycophenolic acid may increase the immunosuppressive activities of Cyclosporine.,Mycophenolic acid,DB00091
DB01030,Topotecan may increase the immunosuppressive activities of Cyclosporine.,Topotecan,DB00091
DB01033,Mercaptopurine may increase the immunosuppressive activities of Cyclosporine.,Mercaptopurine,DB00091
DB01041,Thalidomide may increase the immunosuppressive activities of Cyclosporine.,Thalidomide,DB00091
DB01073,Fludarabine may increase the immunosuppressive activities of Cyclosporine.,Fludarabine,DB00091
DB01097,Leflunomide may increase the immunosuppressive activities of Cyclosporine.,Leflunomide,DB00091
DB01099,Flucytosine may increase the immunosuppressive activities of Cyclosporine.,Flucytosine,DB00091
DB01101,Capecitabine may increase the immunosuppressive activities of Cyclosporine.,Capecitabine,DB00091
DB01108,Trilostane may increase the immunosuppressive activities of Cyclosporine.,Trilostane,DB00091
DB01168,Procarbazine may increase the immunosuppressive activities of Cyclosporine.,Procarbazine,DB00091
DB01169,Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine.,Arsenic trioxide,DB00091
DB01177,Idarubicin may increase the immunosuppressive activities of Cyclosporine.,Idarubicin,DB00091
DB01181,Ifosfamide may increase the immunosuppressive activities of Cyclosporine.,Ifosfamide,DB00091
DB01196,Estramustine may increase the immunosuppressive activities of Cyclosporine.,Estramustine,DB00091
DB01206,Lomustine may increase the immunosuppressive activities of Cyclosporine.,Lomustine,DB00091
DB01222,Budesonide may increase the immunosuppressive activities of Cyclosporine.,Budesonide,DB00091
DB01229,Paclitaxel may increase the immunosuppressive activities of Cyclosporine.,Paclitaxel,DB00091
DB01234,Dexamethasone may increase the immunosuppressive activities of Cyclosporine.,Dexamethasone,DB00091
DB01248,Docetaxel may increase the immunosuppressive activities of Cyclosporine.,Docetaxel,DB00091
DB01254,Dasatinib may increase the immunosuppressive activities of Cyclosporine.,Dasatinib,DB00091
DB01257,Eculizumab may increase the immunosuppressive activities of Cyclosporine.,Eculizumab,DB00091
DB01262,Decitabine may increase the immunosuppressive activities of Cyclosporine.,Decitabine,DB00091
DB01268,Sunitinib may increase the immunosuppressive activities of Cyclosporine.,Sunitinib,DB00091
DB01280,Nelarabine may increase the immunosuppressive activities of Cyclosporine.,Nelarabine,DB00091
DB01281,Abatacept may increase the immunosuppressive activities of Cyclosporine.,Abatacept,DB00091
DB01285,Corticotropin may increase the immunosuppressive activities of Cyclosporine.,Corticotropin,DB00091
DB01380,Cortisone acetate may increase the immunosuppressive activities of Cyclosporine.,Cortisone acetate,DB00091
DB01384,Paramethasone may increase the immunosuppressive activities of Cyclosporine.,Paramethasone,DB00091
DB01394,Colchicine may increase the immunosuppressive activities of Cyclosporine.,Colchicine,DB00091
DB01410,Ciclesonide may increase the immunosuppressive activities of Cyclosporine.,Ciclesonide,DB00091
DB01423,Stepronin may increase the immunosuppressive activities of Cyclosporine.,Stepronin,DB00091
DB01611,Hydroxychloroquine may increase the immunosuppressive activities of Cyclosporine.,Hydroxychloroquine,DB00091
DB01816,Castanospermine may increase the immunosuppressive activities of Cyclosporine.,Castanospermine,DB00091
DB02546,Vorinostat may increase the immunosuppressive activities of Cyclosporine.,Vorinostat,DB00091
DB02806,2-Methoxyethanol may increase the immunosuppressive activities of Cyclosporine.,2-Methoxyethanol,DB00091
DB03523,Brequinar may increase the immunosuppressive activities of Cyclosporine.,Brequinar,DB00091
DB04572,Thiotepa may increase the immunosuppressive activities of Cyclosporine.,Thiotepa,DB00091
DB04630,Aldosterone may increase the immunosuppressive activities of Cyclosporine.,Aldosterone,DB00091
DB04845,Ixabepilone may increase the immunosuppressive activities of Cyclosporine.,Ixabepilone,DB00091
DB04868,Nilotinib may increase the immunosuppressive activities of Cyclosporine.,Nilotinib,DB00091
DB04951,Pirfenidone may increase the immunosuppressive activities of Cyclosporine.,Pirfenidone,DB00091
DB04956,Afelimomab may increase the immunosuppressive activities of Cyclosporine.,Afelimomab,DB00091
DB05015,Belinostat may increase the immunosuppressive activities of Cyclosporine.,Belinostat,DB00091
DB05109,Trabectedin may increase the immunosuppressive activities of Cyclosporine.,Trabectedin,DB00091
DB05258,Interferon alfa may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa,DB00091
DB05259,Glatiramer may increase the immunosuppressive activities of Cyclosporine.,Glatiramer,DB00091
DB05260,Gallium nitrate may increase the immunosuppressive activities of Cyclosporine.,Gallium nitrate,DB00091
DB05459,Briakinumab may increase the immunosuppressive activities of Cyclosporine.,Briakinumab,DB00091
DB05472,omega interferon may increase the immunosuppressive activities of Cyclosporine.,omega interferon,DB00091
DB05676,Apremilast may increase the immunosuppressive activities of Cyclosporine.,Apremilast,DB00091
DB05773,Trastuzumab emtansine may increase the immunosuppressive activities of Cyclosporine.,Trastuzumab emtansine,DB00091
DB06168,Canakinumab may increase the immunosuppressive activities of Cyclosporine.,Canakinumab,DB00091
DB06273,Tocilizumab may increase the immunosuppressive activities of Cyclosporine.,Tocilizumab,DB00091
DB06287,Temsirolimus may increase the immunosuppressive activities of Cyclosporine.,Temsirolimus,DB00091
DB06372,Rilonacept may increase the immunosuppressive activities of Cyclosporine.,Rilonacept,DB00091
DB06589,Pazopanib may increase the immunosuppressive activities of Cyclosporine.,Pazopanib,DB00091
DB06603,Panobinostat may increase the immunosuppressive activities of Cyclosporine.,Panobinostat,DB00091
DB06612,Mepolizumab may increase the immunosuppressive activities of Cyclosporine.,Mepolizumab,DB00091
DB06616,Bosutinib may increase the immunosuppressive activities of Cyclosporine.,Bosutinib,DB00091
DB06643,Denosumab may increase the immunosuppressive activities of Cyclosporine.,Denosumab,DB00091
DB06662,Abetimus may increase the immunosuppressive activities of Cyclosporine.,Abetimus,DB00091
DB06674,Golimumab may increase the immunosuppressive activities of Cyclosporine.,Golimumab,DB00091
DB06681,Belatacept may increase the immunosuppressive activities of Cyclosporine.,Belatacept,DB00091
DB06769,Bendamustine may increase the immunosuppressive activities of Cyclosporine.,Bendamustine,DB00091
DB06772,Cabazitaxel may increase the immunosuppressive activities of Cyclosporine.,Cabazitaxel,DB00091
DB06813,Pralatrexate may increase the immunosuppressive activities of Cyclosporine.,Pralatrexate,DB00091
DB08059,Wortmannin may increase the immunosuppressive activities of Cyclosporine.,Wortmannin,DB00091
DB08868,Fingolimod may increase the immunosuppressive activities of Cyclosporine.,Fingolimod,DB00091
DB08870,Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine.,Brentuximab vedotin,DB00091
DB08871,Eribulin may increase the immunosuppressive activities of Cyclosporine.,Eribulin,DB00091
DB08877,Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.,Ruxolitinib,DB00091
DB08879,Belimumab may increase the immunosuppressive activities of Cyclosporine.,Belimumab,DB00091
DB08880,Teriflunomide may increase the immunosuppressive activities of Cyclosporine.,Teriflunomide,DB00091
DB08889,Carfilzomib may increase the immunosuppressive activities of Cyclosporine.,Carfilzomib,DB00091
DB08895,Tofacitinib may increase the immunosuppressive activities of Cyclosporine.,Tofacitinib,DB00091
DB08901,Ponatinib may increase the immunosuppressive activities of Cyclosporine.,Ponatinib,DB00091
DB08904,Certolizumab pegol may increase the immunosuppressive activities of Cyclosporine.,Certolizumab pegol,DB00091
DB08906,Fluticasone furoate may increase the immunosuppressive activities of Cyclosporine.,Fluticasone furoate,DB00091
DB08908,Dimethyl fumarate may increase the immunosuppressive activities of Cyclosporine.,Dimethyl fumarate,DB00091
DB08910,Pomalidomide may increase the immunosuppressive activities of Cyclosporine.,Pomalidomide,DB00091
DB08935,Obinutuzumab may increase the immunosuppressive activities of Cyclosporine.,Obinutuzumab,DB00091
DB08970,Fluprednidene may increase the immunosuppressive activities of Cyclosporine.,Fluprednidene,DB00091
DB08971,Fluocortolone may increase the immunosuppressive activities of Cyclosporine.,Fluocortolone,DB00091
DB09029,Secukinumab may increase the immunosuppressive activities of Cyclosporine.,Secukinumab,DB00091
DB09033,Vedolizumab may increase the immunosuppressive activities of Cyclosporine.,Vedolizumab,DB00091
DB09036,Siltuximab may increase the immunosuppressive activities of Cyclosporine.,Siltuximab,DB00091
DB09052,Blinatumomab may increase the immunosuppressive activities of Cyclosporine.,Blinatumomab,DB00091
DB09053,Ibrutinib may increase the immunosuppressive activities of Cyclosporine.,Ibrutinib,DB00091
DB09054,Idelalisib may increase the immunosuppressive activities of Cyclosporine.,Idelalisib,DB00091
DB09073,Palbociclib may increase the immunosuppressive activities of Cyclosporine.,Palbociclib,DB00091
DB09074,Olaparib may increase the immunosuppressive activities of Cyclosporine.,Olaparib,DB00091
DB09077,Dinutuximab may increase the immunosuppressive activities of Cyclosporine.,Dinutuximab,DB00091
DB09082,Vilanterol may increase the immunosuppressive activities of Cyclosporine.,Vilanterol,DB00091
DB09091,Tixocortol may increase the immunosuppressive activities of Cyclosporine.,Tixocortol,DB00091
DB09122,Peginterferon beta-1a may increase the immunosuppressive activities of Cyclosporine.,Peginterferon beta-1a,DB00091
DB09312,Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Cyclosporine.,Antilymphocyte immunoglobulin (horse),DB00091
DB09378,Fluprednisolone may increase the immunosuppressive activities of Cyclosporine.,Fluprednisolone,DB00091
DB09383,Meprednisone may increase the immunosuppressive activities of Cyclosporine.,Meprednisone,DB00091
DB11466,Tepoxalin may increase the immunosuppressive activities of Cyclosporine.,Tepoxalin,DB00091
DB11487,Dexamethasone isonicotinate may increase the immunosuppressive activities of Cyclosporine.,Dexamethasone isonicotinate,DB00091
DB11529,Melengestrol may increase the immunosuppressive activities of Cyclosporine.,Melengestrol,DB00091
DB11569,Ixekizumab may increase the immunosuppressive activities of Cyclosporine.,Ixekizumab,DB00091
DB11580,Ravulizumab may increase the immunosuppressive activities of Cyclosporine.,Ravulizumab,DB00091
DB11616,Pirarubicin may increase the immunosuppressive activities of Cyclosporine.,Pirarubicin,DB00091
DB11693,Voclosporin may increase the immunosuppressive activities of Cyclosporine.,Voclosporin,DB00091
DB11708,Peficitinib may increase the immunosuppressive activities of Cyclosporine.,Peficitinib,DB00091
DB11750,Clobetasol may increase the immunosuppressive activities of Cyclosporine.,Clobetasol,DB00091
DB11767,Sarilumab may increase the immunosuppressive activities of Cyclosporine.,Sarilumab,DB00091
DB11776,Brodalumab may increase the immunosuppressive activities of Cyclosporine.,Brodalumab,DB00091
DB11803,Sirukumab may increase the immunosuppressive activities of Cyclosporine.,Sirukumab,DB00091
DB11817,Baricitinib may increase the immunosuppressive activities of Cyclosporine.,Baricitinib,DB00091
DB11834,Guselkumab may increase the immunosuppressive activities of Cyclosporine.,Guselkumab,DB00091
DB11921,Deflazacort may increase the immunosuppressive activities of Cyclosporine.,Deflazacort,DB00091
DB11988,Ocrelizumab may increase the immunosuppressive activities of Cyclosporine.,Ocrelizumab,DB00091
DB12025,Triptolide may increase the immunosuppressive activities of Cyclosporine.,Triptolide,DB00091
DB12371,Siponimod may increase the immunosuppressive activities of Cyclosporine.,Siponimod,DB00091
DB12612,Ozanimod may increase the immunosuppressive activities of Cyclosporine.,Ozanimod,DB00091
DB12617,Mizoribine may increase the immunosuppressive activities of Cyclosporine.,Mizoribine,DB00091
DB12692,Gusperimus may increase the immunosuppressive activities of Cyclosporine.,Gusperimus,DB00091
DB12814,Cepeginterferon alfa-2B may increase the immunosuppressive activities of Cyclosporine.,Cepeginterferon alfa-2B,DB00091
DB12902,Trofosfamide may increase the immunosuppressive activities of Cyclosporine.,Trofosfamide,DB00091
DB12947,Doxifluridine may increase the immunosuppressive activities of Cyclosporine.,Doxifluridine,DB00091
DB12991,Deoxyspergualin may increase the immunosuppressive activities of Cyclosporine.,Deoxyspergualin,DB00091
DB12996,Acteoside may increase the immunosuppressive activities of Cyclosporine.,Acteoside,DB00091
DB13003,Cortivazol may increase the immunosuppressive activities of Cyclosporine.,Cortivazol,DB00091
DB13014,Hypericin may increase the immunosuppressive activities of Cyclosporine.,Hypericin,DB00091
DB13068,9-(N-methyl-L-isoleucine)-cyclosporin A may increase the immunosuppressive activities of Cyclosporine.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00091
DB13208,Prednylidene may increase the immunosuppressive activities of Cyclosporine.,Prednylidene,DB00091
DB13223,Fluocortin may increase the immunosuppressive activities of Cyclosporine.,Fluocortin,DB00091
DB13241,Begelomab may increase the immunosuppressive activities of Cyclosporine.,Begelomab,DB00091
DB13491,Fluperolone may increase the immunosuppressive activities of Cyclosporine.,Fluperolone,DB00091
DB13664,Formocortal may increase the immunosuppressive activities of Cyclosporine.,Formocortal,DB00091
DB13728,Halometasone may increase the immunosuppressive activities of Cyclosporine.,Halometasone,DB00091
DB13843,Cloprednol may increase the immunosuppressive activities of Cyclosporine.,Cloprednol,DB00091
DB13856,Fluclorolone may increase the immunosuppressive activities of Cyclosporine.,Fluclorolone,DB00091
DB13867,Fluticasone may increase the immunosuppressive activities of Cyclosporine.,Fluticasone,DB00091
DB14066,Tetrandrine may increase the immunosuppressive activities of Cyclosporine.,Tetrandrine,DB00091
DB14219,Monomethyl fumarate may increase the immunosuppressive activities of Cyclosporine.,Monomethyl fumarate,DB00091
DB14512,Mometasone furoate may increase the immunosuppressive activities of Cyclosporine.,Mometasone furoate,DB00091
DB14538,Hydrocortisone aceponate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone aceponate,DB00091
DB14539,Hydrocortisone acetate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone acetate,DB00091
DB14545,Hydrocortisone succinate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone succinate,DB00091
DB14724,Emapalumab may increase the immunosuppressive activities of Cyclosporine.,Emapalumab,DB00091
DB14762,Risankizumab may increase the immunosuppressive activities of Cyclosporine.,Risankizumab,DB00091
DB14919,Rozanolixizumab may increase the immunosuppressive activities of Cyclosporine.,Rozanolixizumab,DB00091
DB15253,Bleselumab may increase the immunosuppressive activities of Cyclosporine.,Bleselumab,DB00091
DB00321,The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.,Amitriptyline,DB00091
DB11823,The risk or severity of hypertension can be increased when Esketamine is combined with Cyclosporine.,Esketamine,DB00091
DB00437,The serum concentration of Cyclosporine can be increased when it is combined with Allopurinol.,Allopurinol,DB00091
DB00781,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Polymyxin B.,Polymyxin B,DB00091
DB14754,The risk or severity of hypertension can be increased when Solriamfetol is combined with Cyclosporine.,Solriamfetol,DB00091
DB13946,Testosterone undecanoate may increase the hypertensive activities of Cyclosporine.,Testosterone undecanoate,DB00091
DB12147,The serum concentration of Cyclosporine can be increased when it is combined with Erdafitinib.,Erdafitinib,DB00091
DB00181,Cyclosporine may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen,DB00091
DB00537,Cyclosporine may increase the nephrotoxic activities of Ciprofloxacin.,Ciprofloxacin,DB00091
DB12015,The serum concentration of Alpelisib can be increased when it is combined with Cyclosporine.,Alpelisib,DB00091
DB00373,The metabolism of Timolol can be decreased when combined with Cyclosporine.,Timolol,DB00091
DB05154,The serum concentration of Pretomanid can be increased when it is combined with Cyclosporine.,Pretomanid,DB00091
DB11986,The metabolism of Entrectinib can be decreased when combined with Cyclosporine.,Entrectinib,DB00091
DB12825,The serum concentration of Lefamulin can be increased when it is combined with Cyclosporine.,Lefamulin,DB00091
DB06637,The risk or severity of seizure can be increased when Cyclosporine is combined with Dalfampridine.,Dalfampridine,DB00091
DB11732,The serum concentration of Cyclosporine can be increased when it is combined with Lasmiditan.,Lasmiditan,DB00091
DB15444,The serum concentration of Elexacaftor can be increased when it is combined with Cyclosporine.,Elexacaftor,DB00091
DB14541,The risk or severity of adverse effects can be increased when Hydrocortisone cypionate is combined with Cyclosporine.,Hydrocortisone cypionate,DB00091
DB14631,The risk or severity of adverse effects can be increased when Prednisolone phosphate is combined with Cyclosporine.,Prednisolone phosphate,DB00091
DB14633,The risk or severity of adverse effects can be increased when Prednisolone hemisuccinate is combined with Cyclosporine.,Prednisolone hemisuccinate,DB00091
DB14634,The risk or severity of adverse effects can be increased when Fluprednidene acetate is combined with Cyclosporine.,Fluprednidene acetate,DB00091
DB14644,The risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Cyclosporine.,Methylprednisolone hemisuccinate,DB00091
DB14646,The risk or severity of adverse effects can be increased when Prednisone acetate is combined with Cyclosporine.,Prednisone acetate,DB00091
DB14652,The risk or severity of adverse effects can be increased when Clocortolone acetate is combined with Cyclosporine.,Clocortolone acetate,DB00091
DB14659,The risk or severity of adverse effects can be increased when Melengestrol acetate is combined with Cyclosporine.,Melengestrol acetate,DB00091
DB14669,The risk or severity of adverse effects can be increased when Betamethasone phosphate is combined with Cyclosporine.,Betamethasone phosphate,DB00091
DB14681,The risk or severity of adverse effects can be increased when Cortisone is combined with Cyclosporine.,Cortisone,DB00091
DB00223,The risk or severity of adverse effects can be increased when Diflorasone is combined with Cyclosporine.,Diflorasone,DB00091
DB00240,The risk or severity of adverse effects can be increased when Alclometasone is combined with Cyclosporine.,Alclometasone,DB00091
DB00253,The risk or severity of adverse effects can be increased when Medrysone is combined with Cyclosporine.,Medrysone,DB00091
DB00288,The risk or severity of adverse effects can be increased when Amcinonide is combined with Cyclosporine.,Amcinonide,DB00091
DB00324,The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cyclosporine.,Fluorometholone,DB00091
DB00547,The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cyclosporine.,Desoximetasone,DB00091
DB00596,The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cyclosporine.,Ulobetasol,DB00091
DB00663,The risk or severity of adverse effects can be increased when Flumethasone is combined with Cyclosporine.,Flumethasone,DB00091
DB00838,The risk or severity of adverse effects can be increased when Clocortolone is combined with Cyclosporine.,Clocortolone,DB00091
DB00846,The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cyclosporine.,Flurandrenolide,DB00091
DB14596,The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Cyclosporine.,Loteprednol etabonate,DB00091
DB00896,The risk or severity of adverse effects can be increased when Rimexolone is combined with Cyclosporine.,Rimexolone,DB00091
DB01013,The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cyclosporine.,Clobetasol propionate,DB00091
DB01047,The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cyclosporine.,Fluocinonide,DB00091
DB01130,The risk or severity of adverse effects can be increased when Prednicarbate is combined with Cyclosporine.,Prednicarbate,DB00091
DB01260,The risk or severity of adverse effects can be increased when Desonide is combined with Cyclosporine.,Desonide,DB00091
DB06781,The risk or severity of adverse effects can be increased when Difluprednate is combined with Cyclosporine.,Difluprednate,DB00091
DB06786,The risk or severity of adverse effects can be increased when Halcinonide is combined with Cyclosporine.,Halcinonide,DB00091
DB09095,The risk or severity of adverse effects can be increased when Difluocortolone is combined with Cyclosporine.,Difluocortolone,DB00091
DB13158,The risk or severity of adverse effects can be increased when Clobetasone is combined with Cyclosporine.,Clobetasone,DB00091
DB14540,The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Cyclosporine.,Hydrocortisone butyrate,DB00091
DB14543,The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Cyclosporine.,Hydrocortisone probutate,DB00091
DB14544,The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Cyclosporine.,Hydrocortisone valerate,DB00091
DB00873,The risk or severity of adverse effects can be increased when Loteprednol is combined with Cyclosporine.,Loteprednol,DB00091
DB14643,The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Cyclosporine.,Methylprednisolone aceponate,DB00091
DB15566,The risk or severity of adverse effects can be increased when Prednisolone acetate is combined with Cyclosporine.,Prednisolone acetate,DB00091
DB15035,The metabolism of Zanubrutinib can be decreased when combined with Cyclosporine.,Zanubrutinib,DB00091
DB14975,The serum concentration of Voxelotor can be increased when it is combined with Cyclosporine.,Voxelotor,DB00091
DB01156,The risk or severity of seizure can be increased when Cyclosporine is combined with Bupropion.,Bupropion,DB00091
DB00661,The serum concentration of Cyclosporine can be increased when it is combined with Verapamil.,Verapamil,DB00091
DB06119,The serum concentration of Cenobamate can be decreased when it is combined with Cyclosporine.,Cenobamate,DB00091
DB00646,The serum concentration of Cyclosporine can be increased when it is combined with Nystatin.,Nystatin,DB00091
DB09237,The serum concentration of Cyclosporine can be increased when it is combined with Levamlodipine.,Levamlodipine,DB00091
DB06077,The serum concentration of Lumateperone can be increased when it is combined with Cyclosporine.,Lumateperone,DB00091
DB15328,The serum concentration of Ubrogepant can be increased when it is combined with Cyclosporine.,Ubrogepant,DB00091
DB00695,The risk or severity of gouty arthritis can be increased when Cyclosporine is combined with Furosemide.,Furosemide,DB00091
DB00193,The metabolism of Cyclosporine can be decreased when combined with Tramadol.,Tramadol,DB00091
DB01137,The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.,Levofloxacin,DB00091
DB12457,The serum concentration of Rimegepant can be increased when it is combined with Cyclosporine.,Rimegepant,DB00091
DB00994,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Neomycin.,Neomycin,DB00091
DB01264,The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.,Darunavir,DB00091
DB00608,The serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.,Chloroquine,DB00091
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Cyclosporine.,Magnesium,DB00091
DB01601,The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.,Lopinavir,DB00091
DB00502,The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.,Haloperidol,DB00091
DB05990,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Obeticholic acid.,Obeticholic acid,DB00091
DB11689,The serum concentration of Selumetinib can be increased when it is combined with Cyclosporine.,Selumetinib,DB00091
DB11652,Cyclosporine may decrease the excretion rate of Tucatinib which could result in a higher serum level.,Tucatinib,DB00091
DB15102,The metabolism of Pemigatinib can be decreased when combined with Cyclosporine.,Pemigatinib,DB00091
DB11791,The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib.,Capmatinib,DB00091
DB12530,The risk or severity of infection can be increased when Cyclosporine is combined with Inebilizumab.,Inebilizumab,DB00091
DB12674,The serum concentration of Lurbinectedin can be increased when it is combined with Cyclosporine.,Lurbinectedin,DB00091
DB00627,The metabolism of Cyclosporine can be decreased when combined with Niacin.,Niacin,DB00091
DB00481,The metabolism of Raloxifene can be decreased when combined with Cyclosporine.,Raloxifene,DB00091
DB00435,The metabolism of Nitric Oxide can be decreased when combined with Cyclosporine.,Nitric Oxide,DB00091
DB01275,The metabolism of Hydralazine can be decreased when combined with Cyclosporine.,Hydralazine,DB00091
DB01685,The metabolism of Topiroxostat can be decreased when combined with Cyclosporine.,Topiroxostat,DB00091
DB00313,The metabolism of Valproic acid can be decreased when combined with Cyclosporine.,Valproic acid,DB00091
DB00549,The metabolism of Zafirlukast can be decreased when combined with Cyclosporine.,Zafirlukast,DB00091
DB00668,The metabolism of Cyclosporine can be decreased when combined with Epinephrine.,Epinephrine,DB00091
DB00752,The metabolism of Cyclosporine can be decreased when combined with Tranylcypromine.,Tranylcypromine,DB00091
DB01085,The metabolism of Cyclosporine can be decreased when combined with Pilocarpine.,Pilocarpine,DB00091
DB01698,The metabolism of Cyclosporine can be decreased when combined with Rutin.,Rutin,DB00091
DB02709,The metabolism of Cyclosporine can be decreased when combined with Resveratrol.,Resveratrol,DB00091
DB05814,The metabolism of Cyclosporine can be decreased when combined with GPI-1485.,GPI-1485,DB00091
DB06174,The metabolism of Cyclosporine can be decreased when combined with Noscapine.,Noscapine,DB00091
DB06458,The metabolism of Cyclosporine can be decreased when combined with Remacemide.,Remacemide,DB00091
DB06469,The metabolism of Cyclosporine can be decreased when combined with Lestaurtinib.,Lestaurtinib,DB00091
DB06774,The metabolism of Cyclosporine can be decreased when combined with Capsaicin.,Capsaicin,DB00091
DB08811,The metabolism of Cyclosporine can be decreased when combined with Tofisopam.,Tofisopam,DB00091
DB11198,The metabolism of Cyclosporine can be decreased when combined with Peppermint oil.,Peppermint oil,DB00091
DB11805,The metabolism of Cyclosporine can be decreased when combined with Saracatinib.,Saracatinib,DB00091
DB12532,The metabolism of Cyclosporine can be decreased when combined with Oxetacaine.,Oxetacaine,DB00091
DB13975,The metabolism of Cyclosporine can be decreased when combined with Black cohosh.,Black cohosh,DB00091
DB00248,The metabolism of Cyclosporine can be decreased when combined with Cabergoline.,Cabergoline,DB00091
DB00254,The metabolism of Cyclosporine can be decreased when combined with Doxycycline.,Doxycycline,DB00091
DB00255,The metabolism of Cyclosporine can be decreased when combined with Diethylstilbestrol.,Diethylstilbestrol,DB00091
DB00353,The metabolism of Cyclosporine can be decreased when combined with Methylergometrine.,Methylergometrine,DB00091
DB00759,The metabolism of Cyclosporine can be decreased when combined with Tetracycline.,Tetracycline,DB00091
DB01129,The metabolism of Cyclosporine can be decreased when combined with Rabeprazole.,Rabeprazole,DB00091
DB01587,The metabolism of Cyclosporine can be decreased when combined with Ketazolam.,Ketazolam,DB00091
DB05482,The metabolism of Cyclosporine can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.,7-ethyl-10-hydroxycamptothecin,DB00091
DB09235,The metabolism of Cyclosporine can be decreased when combined with Efonidipine.,Efonidipine,DB00091
DB12010,The metabolism of Cyclosporine can be decreased when combined with Fostamatinib.,Fostamatinib,DB00091
DB13950,The metabolism of Cyclosporine can be decreased when combined with WIN 55212-2.,WIN 55212-2,DB00091
DB14009,The metabolism of Cyclosporine can be decreased when combined with Medical Cannabis.,Medical Cannabis,DB00091
DB01093,The metabolism of Cyclosporine can be decreased when combined with Dimethyl sulfoxide.,Dimethyl sulfoxide,DB00091
DB14635,The metabolism of Cyclosporine can be decreased when combined with Curcumin sulfate.,Curcumin sulfate,DB00091
DB00358,The metabolism of Cyclosporine can be decreased when combined with Mefloquine.,Mefloquine,DB00091
DB00845,The metabolism of Cyclosporine can be decreased when combined with Clofazimine.,Clofazimine,DB00091
DB00916,The metabolism of Cyclosporine can be decreased when combined with Metronidazole.,Metronidazole,DB00091
DB00320,The metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.,Dihydroergotamine,DB00091
DB01023,The metabolism of Cyclosporine can be decreased when combined with Felodipine.,Felodipine,DB00091
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.,Denosumab,DB00092
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Alefacept.,Etanercept,DB00092
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alefacept.,Peginterferon alfa-2a,DB00092
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alefacept.,Interferon alfa-n1,DB00092
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alefacept.,Interferon alfa-n3,DB00092
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alefacept.,Peginterferon alfa-2b,DB00092
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Alefacept.,Anakinra,DB00092
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alefacept.,Interferon gamma-1b,DB00092
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alefacept.","Interferon alfa-2a, Recombinant",DB00092
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alefacept.,Aldesleukin,DB00092
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alefacept.,Adalimumab,DB00092
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.,Gemtuzumab ozogamicin,DB00092
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.,Pegaspargase,DB00092
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.,Infliximab,DB00092
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.,Interferon beta-1b,DB00092
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.,Interferon alfacon-1,DB00092
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.,Rituximab,DB00092
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.,Basiliximab,DB00092
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.,Muromonab,DB00092
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.,Ibritumomab tiuxetan,DB00092
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.,Tositumomab,DB00092
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.,Alemtuzumab,DB00092
DB00095,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.,Efalizumab,DB00092
DB00098,The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00092
DB00105,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00092
DB00111,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.,Daclizumab,DB00092
DB00112,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.,Bevacizumab,DB00092
DB00120,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.,Phenylalanine,DB00092
DB00180,The risk or severity of adverse effects can be increased when Alefacept is combined with Flunisolide.,Flunisolide,DB00092
DB00188,The risk or severity of adverse effects can be increased when Alefacept is combined with Bortezomib.,Bortezomib,DB00092
DB00242,The risk or severity of adverse effects can be increased when Alefacept is combined with Cladribine.,Cladribine,DB00092
DB00262,The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine.,Carmustine,DB00092
DB00276,The risk or severity of adverse effects can be increased when Alefacept is combined with Amsacrine.,Amsacrine,DB00092
DB00290,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleomycin.,Bleomycin,DB00092
DB00291,The risk or severity of adverse effects can be increased when Alefacept is combined with Chlorambucil.,Chlorambucil,DB00092
DB00293,The risk or severity of adverse effects can be increased when Alefacept is combined with Raltitrexed.,Raltitrexed,DB00092
DB00305,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitomycin.,Mitomycin,DB00092
DB00307,The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene.,Bexarotene,DB00092
DB00309,The risk or severity of adverse effects can be increased when Alefacept is combined with Vindesine.,Vindesine,DB00092
DB00322,The risk or severity of adverse effects can be increased when Alefacept is combined with Floxuridine.,Floxuridine,DB00092
DB00328,The risk or severity of adverse effects can be increased when Alefacept is combined with Indomethacin.,Indomethacin,DB00092
DB00352,The risk or severity of adverse effects can be increased when Alefacept is combined with Tioguanine.,Tioguanine,DB00092
DB00361,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinorelbine.,Vinorelbine,DB00092
DB00380,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane.,Dexrazoxane,DB00092
DB00394,The risk or severity of adverse effects can be increased when Alefacept is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00092
DB00398,The risk or severity of adverse effects can be increased when Alefacept is combined with Sorafenib.,Sorafenib,DB00092
DB00428,The risk or severity of adverse effects can be increased when Alefacept is combined with Streptozocin.,Streptozocin,DB00092
DB00432,The risk or severity of adverse effects can be increased when Alefacept is combined with Trifluridine.,Trifluridine,DB00092
DB00441,The risk or severity of adverse effects can be increased when Alefacept is combined with Gemcitabine.,Gemcitabine,DB00092
DB00443,The risk or severity of adverse effects can be increased when Alefacept is combined with Betamethasone.,Betamethasone,DB00092
DB00444,The risk or severity of adverse effects can be increased when Alefacept is combined with Teniposide.,Teniposide,DB00092
DB00445,The risk or severity of adverse effects can be increased when Alefacept is combined with Epirubicin.,Epirubicin,DB00092
DB00446,The risk or severity of adverse effects can be increased when Alefacept is combined with Chloramphenicol.,Chloramphenicol,DB00092
DB00480,The risk or severity of adverse effects can be increased when Alefacept is combined with Lenalidomide.,Lenalidomide,DB00092
DB00488,The risk or severity of adverse effects can be increased when Alefacept is combined with Altretamine.,Altretamine,DB00092
DB00495,The risk or severity of adverse effects can be increased when Alefacept is combined with Zidovudine.,Zidovudine,DB00092
DB00515,The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.,Cisplatin,DB00092
DB00526,The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin.,Oxaliplatin,DB00092
DB00531,The risk or severity of adverse effects can be increased when Alefacept is combined with Cyclophosphamide.,Cyclophosphamide,DB00092
DB00541,The risk or severity of adverse effects can be increased when Alefacept is combined with Vincristine.,Vincristine,DB00092
DB00544,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil.,Fluorouracil,DB00092
DB00550,The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil.,Propylthiouracil,DB00092
DB00552,The risk or severity of adverse effects can be increased when Alefacept is combined with Pentostatin.,Pentostatin,DB00092
DB00563,The risk or severity of adverse effects can be increased when Alefacept is combined with Methotrexate.,Methotrexate,DB00092
DB00564,The risk or severity of adverse effects can be increased when Alefacept is combined with Carbamazepine.,Carbamazepine,DB00092
DB00570,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinblastine.,Vinblastine,DB00092
DB00588,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone propionate.,Fluticasone propionate,DB00092
DB00591,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00092
DB00601,The risk or severity of adverse effects can be increased when Alefacept is combined with Linezolid.,Linezolid,DB00092
DB00619,The risk or severity of adverse effects can be increased when Alefacept is combined with Imatinib.,Imatinib,DB00092
DB00620,The risk or severity of adverse effects can be increased when Alefacept is combined with Triamcinolone.,Triamcinolone,DB00092
DB00631,The risk or severity of adverse effects can be increased when Alefacept is combined with Clofarabine.,Clofarabine,DB00092
DB00635,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisone.,Prednisone,DB00092
DB00642,The risk or severity of adverse effects can be increased when Alefacept is combined with Pemetrexed.,Pemetrexed,DB00092
DB00687,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludrocortisone.,Fludrocortisone,DB00092
DB00688,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00092
DB00694,The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.,Daunorubicin,DB00092
DB00755,The risk or severity of adverse effects can be increased when Alefacept is combined with Tretinoin.,Tretinoin,DB00092
DB00762,The risk or severity of adverse effects can be increased when Alefacept is combined with Irinotecan.,Irinotecan,DB00092
DB00763,The risk or severity of adverse effects can be increased when Alefacept is combined with Methimazole.,Methimazole,DB00092
DB00764,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone.,Mometasone,DB00092
DB00773,The risk or severity of adverse effects can be increased when Alefacept is combined with Etoposide.,Etoposide,DB00092
DB00795,The risk or severity of adverse effects can be increased when Alefacept is combined with Sulfasalazine.,Sulfasalazine,DB00092
DB00851,The risk or severity of adverse effects can be increased when Alefacept is combined with Dacarbazine.,Dacarbazine,DB00092
DB00853,The risk or severity of adverse effects can be increased when Alefacept is combined with Temozolomide.,Temozolomide,DB00092
DB00859,The risk or severity of adverse effects can be increased when Alefacept is combined with Penicillamine.,Penicillamine,DB00092
DB00860,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisolone.,Prednisolone,DB00092
DB00877,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirolimus.,Sirolimus,DB00092
DB00888,The risk or severity of adverse effects can be increased when Alefacept is combined with Mechlorethamine.,Mechlorethamine,DB00092
DB00928,The risk or severity of adverse effects can be increased when Alefacept is combined with Azacitidine.,Azacitidine,DB00092
DB00958,The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin.,Carboplatin,DB00092
DB00959,The risk or severity of adverse effects can be increased when Alefacept is combined with Methylprednisolone.,Methylprednisolone,DB00092
DB00970,The risk or severity of adverse effects can be increased when Alefacept is combined with Dactinomycin.,Dactinomycin,DB00092
DB00987,The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.,Cytarabine,DB00092
DB00993,The risk or severity of adverse effects can be increased when Alefacept is combined with Azathioprine.,Azathioprine,DB00092
DB00997,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxorubicin.,Doxorubicin,DB00092
DB01005,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxyurea.,Hydroxyurea,DB00092
DB01008,The risk or severity of adverse effects can be increased when Alefacept is combined with Busulfan.,Busulfan,DB00092
DB01024,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolic acid.,Mycophenolic acid,DB00092
DB01030,The risk or severity of adverse effects can be increased when Alefacept is combined with Topotecan.,Topotecan,DB00092
DB01033,The risk or severity of adverse effects can be increased when Alefacept is combined with Mercaptopurine.,Mercaptopurine,DB00092
DB01041,The risk or severity of adverse effects can be increased when Alefacept is combined with Thalidomide.,Thalidomide,DB00092
DB01042,The risk or severity of adverse effects can be increased when Alefacept is combined with Melphalan.,Melphalan,DB00092
DB01073,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludarabine.,Fludarabine,DB00092
DB01099,The risk or severity of adverse effects can be increased when Alefacept is combined with Flucytosine.,Flucytosine,DB00092
DB01101,The risk or severity of adverse effects can be increased when Alefacept is combined with Capecitabine.,Capecitabine,DB00092
DB01108,The risk or severity of adverse effects can be increased when Alefacept is combined with Trilostane.,Trilostane,DB00092
DB01168,The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine.,Procarbazine,DB00092
DB01169,The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide.,Arsenic trioxide,DB00092
DB01177,The risk or severity of adverse effects can be increased when Alefacept is combined with Idarubicin.,Idarubicin,DB00092
DB01181,The risk or severity of adverse effects can be increased when Alefacept is combined with Ifosfamide.,Ifosfamide,DB00092
DB01196,The risk or severity of adverse effects can be increased when Alefacept is combined with Estramustine.,Estramustine,DB00092
DB01204,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitoxantrone.,Mitoxantrone,DB00092
DB01206,The risk or severity of adverse effects can be increased when Alefacept is combined with Lomustine.,Lomustine,DB00092
DB01222,The risk or severity of adverse effects can be increased when Alefacept is combined with Budesonide.,Budesonide,DB00092
DB01229,The risk or severity of adverse effects can be increased when Alefacept is combined with Paclitaxel.,Paclitaxel,DB00092
DB01234,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone.,Dexamethasone,DB00092
DB01248,The risk or severity of adverse effects can be increased when Alefacept is combined with Docetaxel.,Docetaxel,DB00092
DB01254,The risk or severity of adverse effects can be increased when Alefacept is combined with Dasatinib.,Dasatinib,DB00092
DB01257,The risk or severity of adverse effects can be increased when Alefacept is combined with Eculizumab.,Eculizumab,DB00092
DB01262,The risk or severity of adverse effects can be increased when Alefacept is combined with Decitabine.,Decitabine,DB00092
DB01268,The risk or severity of adverse effects can be increased when Alefacept is combined with Sunitinib.,Sunitinib,DB00092
DB01280,The risk or severity of adverse effects can be increased when Alefacept is combined with Nelarabine.,Nelarabine,DB00092
DB01281,The risk or severity of adverse effects can be increased when Alefacept is combined with Abatacept.,Abatacept,DB00092
DB01285,The risk or severity of adverse effects can be increased when Alefacept is combined with Corticotropin.,Corticotropin,DB00092
DB01380,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortisone acetate.,Cortisone acetate,DB00092
DB01384,The risk or severity of adverse effects can be increased when Alefacept is combined with Paramethasone.,Paramethasone,DB00092
DB01394,The risk or severity of adverse effects can be increased when Alefacept is combined with Colchicine.,Colchicine,DB00092
DB01410,The risk or severity of adverse effects can be increased when Alefacept is combined with Ciclesonide.,Ciclesonide,DB00092
DB01423,The risk or severity of adverse effects can be increased when Alefacept is combined with Stepronin.,Stepronin,DB00092
DB01590,The risk or severity of adverse effects can be increased when Alefacept is combined with Everolimus.,Everolimus,DB00092
DB01611,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00092
DB01816,The risk or severity of adverse effects can be increased when Alefacept is combined with Castanospermine.,Castanospermine,DB00092
DB02546,The risk or severity of adverse effects can be increased when Alefacept is combined with Vorinostat.,Vorinostat,DB00092
DB02806,The risk or severity of adverse effects can be increased when Alefacept is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00092
DB03523,The risk or severity of adverse effects can be increased when Alefacept is combined with Brequinar.,Brequinar,DB00092
DB04572,The risk or severity of adverse effects can be increased when Alefacept is combined with Thiotepa.,Thiotepa,DB00092
DB04630,The risk or severity of adverse effects can be increased when Alefacept is combined with Aldosterone.,Aldosterone,DB00092
DB04845,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixabepilone.,Ixabepilone,DB00092
DB04868,The risk or severity of adverse effects can be increased when Alefacept is combined with Nilotinib.,Nilotinib,DB00092
DB04951,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirfenidone.,Pirfenidone,DB00092
DB04956,The risk or severity of adverse effects can be increased when Alefacept is combined with Afelimomab.,Afelimomab,DB00092
DB05015,The risk or severity of adverse effects can be increased when Alefacept is combined with Belinostat.,Belinostat,DB00092
DB05109,The risk or severity of adverse effects can be increased when Alefacept is combined with Trabectedin.,Trabectedin,DB00092
DB05258,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa.,Interferon alfa,DB00092
DB05259,The risk or severity of adverse effects can be increased when Alefacept is combined with Glatiramer.,Glatiramer,DB00092
DB05260,The risk or severity of adverse effects can be increased when Alefacept is combined with Gallium nitrate.,Gallium nitrate,DB00092
DB05459,The risk or severity of adverse effects can be increased when Alefacept is combined with Briakinumab.,Briakinumab,DB00092
DB05472,The risk or severity of adverse effects can be increased when Alefacept is combined with omega interferon.,omega interferon,DB00092
DB05676,The risk or severity of adverse effects can be increased when Alefacept is combined with Apremilast.,Apremilast,DB00092
DB05773,The risk or severity of adverse effects can be increased when Alefacept is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00092
DB06168,The risk or severity of adverse effects can be increased when Alefacept is combined with Canakinumab.,Canakinumab,DB00092
DB06273,The risk or severity of adverse effects can be increased when Alefacept is combined with Tocilizumab.,Tocilizumab,DB00092
DB06287,The risk or severity of adverse effects can be increased when Alefacept is combined with Temsirolimus.,Temsirolimus,DB00092
DB06372,The risk or severity of adverse effects can be increased when Alefacept is combined with Rilonacept.,Rilonacept,DB00092
DB06589,The risk or severity of adverse effects can be increased when Alefacept is combined with Pazopanib.,Pazopanib,DB00092
DB06603,The risk or severity of adverse effects can be increased when Alefacept is combined with Panobinostat.,Panobinostat,DB00092
DB06612,The risk or severity of adverse effects can be increased when Alefacept is combined with Mepolizumab.,Mepolizumab,DB00092
DB06616,The risk or severity of adverse effects can be increased when Alefacept is combined with Bosutinib.,Bosutinib,DB00092
DB06662,The risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.,Abetimus,DB00092
DB06674,The risk or severity of adverse effects can be increased when Alefacept is combined with Golimumab.,Golimumab,DB00092
DB06681,The risk or severity of adverse effects can be increased when Alefacept is combined with Belatacept.,Belatacept,DB00092
DB06769,The risk or severity of adverse effects can be increased when Alefacept is combined with Bendamustine.,Bendamustine,DB00092
DB06772,The risk or severity of adverse effects can be increased when Alefacept is combined with Cabazitaxel.,Cabazitaxel,DB00092
DB06813,The risk or severity of adverse effects can be increased when Alefacept is combined with Pralatrexate.,Pralatrexate,DB00092
DB08059,The risk or severity of adverse effects can be increased when Alefacept is combined with Wortmannin.,Wortmannin,DB00092
DB08870,The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00092
DB08871,The risk or severity of adverse effects can be increased when Alefacept is combined with Eribulin.,Eribulin,DB00092
DB08877,The risk or severity of adverse effects can be increased when Alefacept is combined with Ruxolitinib.,Ruxolitinib,DB00092
DB08879,The risk or severity of adverse effects can be increased when Alefacept is combined with Belimumab.,Belimumab,DB00092
DB08880,The risk or severity of adverse effects can be increased when Alefacept is combined with Teriflunomide.,Teriflunomide,DB00092
DB08889,The risk or severity of adverse effects can be increased when Alefacept is combined with Carfilzomib.,Carfilzomib,DB00092
DB08901,The risk or severity of adverse effects can be increased when Alefacept is combined with Ponatinib.,Ponatinib,DB00092
DB08904,The risk or severity of adverse effects can be increased when Alefacept is combined with Certolizumab pegol.,Certolizumab pegol,DB00092
DB08906,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone furoate.,Fluticasone furoate,DB00092
DB08908,The risk or severity of adverse effects can be increased when Alefacept is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00092
DB08910,The risk or severity of adverse effects can be increased when Alefacept is combined with Pomalidomide.,Pomalidomide,DB00092
DB08935,The risk or severity of adverse effects can be increased when Alefacept is combined with Obinutuzumab.,Obinutuzumab,DB00092
DB08970,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednidene.,Fluprednidene,DB00092
DB08971,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortolone.,Fluocortolone,DB00092
DB09029,The risk or severity of adverse effects can be increased when Alefacept is combined with Secukinumab.,Secukinumab,DB00092
DB09033,The risk or severity of adverse effects can be increased when Alefacept is combined with Vedolizumab.,Vedolizumab,DB00092
DB09036,The risk or severity of adverse effects can be increased when Alefacept is combined with Siltuximab.,Siltuximab,DB00092
DB09052,The risk or severity of adverse effects can be increased when Alefacept is combined with Blinatumomab.,Blinatumomab,DB00092
DB09053,The risk or severity of adverse effects can be increased when Alefacept is combined with Ibrutinib.,Ibrutinib,DB00092
DB09054,The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib.,Idelalisib,DB00092
DB09073,The risk or severity of adverse effects can be increased when Alefacept is combined with Palbociclib.,Palbociclib,DB00092
DB09074,The risk or severity of adverse effects can be increased when Alefacept is combined with Olaparib.,Olaparib,DB00092
DB09077,The risk or severity of adverse effects can be increased when Alefacept is combined with Dinutuximab.,Dinutuximab,DB00092
DB09082,The risk or severity of adverse effects can be increased when Alefacept is combined with Vilanterol.,Vilanterol,DB00092
DB09091,The risk or severity of adverse effects can be increased when Alefacept is combined with Tixocortol.,Tixocortol,DB00092
DB09122,The risk or severity of adverse effects can be increased when Alefacept is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00092
DB09312,The risk or severity of adverse effects can be increased when Alefacept is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00092
DB09378,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednisolone.,Fluprednisolone,DB00092
DB09383,The risk or severity of adverse effects can be increased when Alefacept is combined with Meprednisone.,Meprednisone,DB00092
DB11466,The risk or severity of adverse effects can be increased when Alefacept is combined with Tepoxalin.,Tepoxalin,DB00092
DB11487,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00092
DB11529,The risk or severity of adverse effects can be increased when Alefacept is combined with Melengestrol.,Melengestrol,DB00092
DB11569,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixekizumab.,Ixekizumab,DB00092
DB11580,The risk or severity of adverse effects can be increased when Alefacept is combined with Ravulizumab.,Ravulizumab,DB00092
DB11616,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.,Pirarubicin,DB00092
DB11693,The risk or severity of adverse effects can be increased when Alefacept is combined with Voclosporin.,Voclosporin,DB00092
DB11708,The risk or severity of adverse effects can be increased when Alefacept is combined with Peficitinib.,Peficitinib,DB00092
DB11750,The risk or severity of adverse effects can be increased when Alefacept is combined with Clobetasol.,Clobetasol,DB00092
DB11767,The risk or severity of adverse effects can be increased when Alefacept is combined with Sarilumab.,Sarilumab,DB00092
DB11776,The risk or severity of adverse effects can be increased when Alefacept is combined with Brodalumab.,Brodalumab,DB00092
DB11803,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirukumab.,Sirukumab,DB00092
DB11817,The risk or severity of adverse effects can be increased when Alefacept is combined with Baricitinib.,Baricitinib,DB00092
DB11834,The risk or severity of adverse effects can be increased when Alefacept is combined with Guselkumab.,Guselkumab,DB00092
DB11921,The risk or severity of adverse effects can be increased when Alefacept is combined with Deflazacort.,Deflazacort,DB00092
DB11988,The risk or severity of adverse effects can be increased when Alefacept is combined with Ocrelizumab.,Ocrelizumab,DB00092
DB12025,The risk or severity of adverse effects can be increased when Alefacept is combined with Triptolide.,Triptolide,DB00092
DB12371,The risk or severity of adverse effects can be increased when Alefacept is combined with Siponimod.,Siponimod,DB00092
DB12612,The risk or severity of adverse effects can be increased when Alefacept is combined with Ozanimod.,Ozanimod,DB00092
DB12617,The risk or severity of adverse effects can be increased when Alefacept is combined with Mizoribine.,Mizoribine,DB00092
DB12692,The risk or severity of adverse effects can be increased when Alefacept is combined with Gusperimus.,Gusperimus,DB00092
DB12814,The risk or severity of adverse effects can be increased when Alefacept is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00092
DB12902,The risk or severity of adverse effects can be increased when Alefacept is combined with Trofosfamide.,Trofosfamide,DB00092
DB12947,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxifluridine.,Doxifluridine,DB00092
DB12991,The risk or severity of adverse effects can be increased when Alefacept is combined with Deoxyspergualin.,Deoxyspergualin,DB00092
DB12996,The risk or severity of adverse effects can be increased when Alefacept is combined with Acteoside.,Acteoside,DB00092
DB13003,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortivazol.,Cortivazol,DB00092
DB13014,The risk or severity of adverse effects can be increased when Alefacept is combined with Hypericin.,Hypericin,DB00092
DB13068,The risk or severity of adverse effects can be increased when Alefacept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00092
DB13208,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednylidene.,Prednylidene,DB00092
DB13223,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortin.,Fluocortin,DB00092
DB13241,The risk or severity of adverse effects can be increased when Alefacept is combined with Begelomab.,Begelomab,DB00092
DB13491,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluperolone.,Fluperolone,DB00092
DB13664,The risk or severity of adverse effects can be increased when Alefacept is combined with Formocortal.,Formocortal,DB00092
DB13728,The risk or severity of adverse effects can be increased when Alefacept is combined with Halometasone.,Halometasone,DB00092
DB13843,The risk or severity of adverse effects can be increased when Alefacept is combined with Cloprednol.,Cloprednol,DB00092
DB13856,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluclorolone.,Fluclorolone,DB00092
DB13867,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone.,Fluticasone,DB00092
DB14066,The risk or severity of adverse effects can be increased when Alefacept is combined with Tetrandrine.,Tetrandrine,DB00092
DB14219,The risk or severity of adverse effects can be increased when Alefacept is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00092
DB14512,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone furoate.,Mometasone furoate,DB00092
DB14538,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00092
DB14539,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00092
DB14545,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00092
DB14724,The risk or severity of adverse effects can be increased when Alefacept is combined with Emapalumab.,Emapalumab,DB00092
DB14762,The risk or severity of adverse effects can be increased when Alefacept is combined with Risankizumab.,Risankizumab,DB00092
DB14919,The risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.,Rozanolixizumab,DB00092
DB15253,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleselumab.,Bleselumab,DB00092
DB00108,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.,Natalizumab,DB00092
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.,Pimecrolimus,DB00092
DB01656,Roflumilast may increase the immunosuppressive activities of Alefacept.,Roflumilast,DB00092
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.,Sipuleucel-T,DB00092
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alefacept.,Sulfamethoxazole,DB00092
DB01097,The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.,Leflunomide,DB00092
DB08895,Alefacept may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00092
DB00072,Trastuzumab may increase the neutropenic activities of Alefacept.,Trastuzumab,DB00092
DB08868,Alefacept may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00092
DB00864,Tacrolimus may increase the immunosuppressive activities of Alefacept.,Tacrolimus,DB00092
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.,G17DT,DB00092
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alefacept.,PEV3A,DB00092
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.,INGN 225,DB00092
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alefacept.,Rindopepimut,DB00092
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alefacept.,SRP 299,DB00092
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.,GI-5005,DB00092
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept.,Vitespen,DB00092
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.,TG4010,DB00092
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alefacept.,Anthrax immune globulin human,DB00092
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept.","Rabies virus inactivated antigen, B",DB00092
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00092
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alefacept.,Rotavirus vaccine,DB00092
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept.","Rabies virus inactivated antigen, A",DB00092
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00092
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00092
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00092
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00092
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00092
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00092
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept.,Typhoid Vi polysaccharide vaccine,DB00092
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.,Hepatitis A Vaccine,DB00092
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00092
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00092
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00092
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00092
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00092
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alefacept.,Human rabies virus immune globulin,DB00092
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alefacept.,Hepatitis B Vaccine (Recombinant),DB00092
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept.,Tecemotide,DB00092
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alefacept.,Typhoid vaccine,DB00092
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00092
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00092
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00092
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00092
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alefacept.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00092
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00092
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00092
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alefacept.,Vaccinia virus strain new york city board of health live antigen,DB00092
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alefacept.,Pertussis vaccine,DB00092
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00092
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alefacept.,Varicella Zoster Vaccine (Recombinant),DB00092
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept.,Modified vaccinia ankara,DB00092
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alefacept.","Ebola Zaire vaccine (live, attenuated)",DB00092
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.,Rubella virus vaccine,DB00092
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alefacept.,Varicella Zoster Vaccine (Live/attenuated),DB00092
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain tice live antigen,DB00092
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain connaught live antigen,DB00092
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alefacept.,Yellow Fever Vaccine,DB00092
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept.,Anthrax vaccine,DB00092
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alefacept.,Typhoid Vaccine Live,DB00092
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00092
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Alefacept.,BCG vaccine,DB00092
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alefacept.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00092
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alefacept.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00092
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alefacept.,Adenovirus type 7 vaccine live,DB00092
DB00091,Alefacept may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00092
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Alefacept.,Magnesium,DB00092
DB01601,The serum concentration of Alefacept can be increased when it is combined with Lopinavir.,Lopinavir,DB00092
DB12530,The risk or severity of infection can be increased when Alefacept is combined with Inebilizumab.,Inebilizumab,DB00092
DB13967,The risk or severity of hypotension can be increased when Patent Blue is combined with Felypressin.,Patent Blue,DB00093
DB00024,Thyrotropin alfa may increase the vasoconstricting activities of Felypressin.,Thyrotropin alfa,DB00093
DB00279,Liothyronine may increase the vasoconstricting activities of Felypressin.,Liothyronine,DB00093
DB00451,Levothyroxine may increase the vasoconstricting activities of Felypressin.,Levothyroxine,DB00093
DB01583,Liotrix may increase the vasoconstricting activities of Felypressin.,Liotrix,DB00093
DB03604,Tiratricol may increase the vasoconstricting activities of Felypressin.,Tiratricol,DB00093
DB09100,"Thyroid, porcine may increase the vasoconstricting activities of Felypressin.","Thyroid, porcine",DB00093
DB00281,The risk or severity of hypertension can be increased when Felypressin is combined with Lidocaine.,Lidocaine,DB00093
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.,Denosumab,DB00095
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab.,Etanercept,DB00095
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efalizumab.,Peginterferon alfa-2a,DB00095
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab.,Interferon alfa-n1,DB00095
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efalizumab.,Interferon alfa-n3,DB00095
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab.,Peginterferon alfa-2b,DB00095
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab.,Anakinra,DB00095
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efalizumab.,Interferon gamma-1b,DB00095
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Efalizumab.","Interferon alfa-2a, Recombinant",DB00095
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab.,Aldesleukin,DB00095
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Efalizumab.,Adalimumab,DB00095
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.,Gemtuzumab ozogamicin,DB00095
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.,Pegaspargase,DB00095
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.,Infliximab,DB00095
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.,Interferon beta-1b,DB00095
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.,Interferon alfacon-1,DB00095
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.,Rituximab,DB00095
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.,Basiliximab,DB00095
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.,Muromonab,DB00095
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.,Ibritumomab tiuxetan,DB00095
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.,Tositumomab,DB00095
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.,Alemtuzumab,DB00095
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.,Alefacept,DB00095
DB00098,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit),DB00095
DB00105,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00095
DB00111,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.,Daclizumab,DB00095
DB00112,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.,Bevacizumab,DB00095
DB00120,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.,Phenylalanine,DB00095
DB00180,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flunisolide.,Flunisolide,DB00095
DB00188,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib.,Bortezomib,DB00095
DB00242,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cladribine.,Cladribine,DB00095
DB00262,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine.,Carmustine,DB00095
DB00276,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amsacrine.,Amsacrine,DB00095
DB00290,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin.,Bleomycin,DB00095
DB00291,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chlorambucil.,Chlorambucil,DB00095
DB00293,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raltitrexed.,Raltitrexed,DB00095
DB00305,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitomycin.,Mitomycin,DB00095
DB00307,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene.,Bexarotene,DB00095
DB00309,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vindesine.,Vindesine,DB00095
DB00322,The risk or severity of adverse effects can be increased when Efalizumab is combined with Floxuridine.,Floxuridine,DB00095
DB00328,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indomethacin.,Indomethacin,DB00095
DB00352,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tioguanine.,Tioguanine,DB00095
DB00361,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinorelbine.,Vinorelbine,DB00095
DB00380,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane.,Dexrazoxane,DB00095
DB00394,The risk or severity of adverse effects can be increased when Efalizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00095
DB00398,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sorafenib.,Sorafenib,DB00095
DB00428,The risk or severity of adverse effects can be increased when Efalizumab is combined with Streptozocin.,Streptozocin,DB00095
DB00432,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trifluridine.,Trifluridine,DB00095
DB00441,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gemcitabine.,Gemcitabine,DB00095
DB00443,The risk or severity of adverse effects can be increased when Efalizumab is combined with Betamethasone.,Betamethasone,DB00095
DB00444,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teniposide.,Teniposide,DB00095
DB00445,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epirubicin.,Epirubicin,DB00095
DB00446,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chloramphenicol.,Chloramphenicol,DB00095
DB00480,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lenalidomide.,Lenalidomide,DB00095
DB00488,The risk or severity of adverse effects can be increased when Efalizumab is combined with Altretamine.,Altretamine,DB00095
DB00495,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zidovudine.,Zidovudine,DB00095
DB00515,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.,Cisplatin,DB00095
DB00526,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin.,Oxaliplatin,DB00095
DB00531,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide.,Cyclophosphamide,DB00095
DB00541,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine.,Vincristine,DB00095
DB00544,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil.,Fluorouracil,DB00095
DB00550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil.,Propylthiouracil,DB00095
DB00552,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pentostatin.,Pentostatin,DB00095
DB00563,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methotrexate.,Methotrexate,DB00095
DB00564,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carbamazepine.,Carbamazepine,DB00095
DB00570,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinblastine.,Vinblastine,DB00095
DB00588,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone propionate.,Fluticasone propionate,DB00095
DB00591,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00095
DB00601,The risk or severity of adverse effects can be increased when Efalizumab is combined with Linezolid.,Linezolid,DB00095
DB00619,The risk or severity of adverse effects can be increased when Efalizumab is combined with Imatinib.,Imatinib,DB00095
DB00620,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triamcinolone.,Triamcinolone,DB00095
DB00631,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine.,Clofarabine,DB00095
DB00635,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisone.,Prednisone,DB00095
DB00642,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pemetrexed.,Pemetrexed,DB00095
DB00687,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludrocortisone.,Fludrocortisone,DB00095
DB00688,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00095
DB00694,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.,Daunorubicin,DB00095
DB00755,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tretinoin.,Tretinoin,DB00095
DB00762,The risk or severity of adverse effects can be increased when Efalizumab is combined with Irinotecan.,Irinotecan,DB00095
DB00763,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methimazole.,Methimazole,DB00095
DB00764,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone.,Mometasone,DB00095
DB00773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etoposide.,Etoposide,DB00095
DB00795,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulfasalazine.,Sulfasalazine,DB00095
DB00851,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine.,Dacarbazine,DB00095
DB00853,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temozolomide.,Temozolomide,DB00095
DB00859,The risk or severity of adverse effects can be increased when Efalizumab is combined with Penicillamine.,Penicillamine,DB00095
DB00860,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisolone.,Prednisolone,DB00095
DB00877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirolimus.,Sirolimus,DB00095
DB00888,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mechlorethamine.,Mechlorethamine,DB00095
DB00928,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azacitidine.,Azacitidine,DB00095
DB00958,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin.,Carboplatin,DB00095
DB00959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone.,Methylprednisolone,DB00095
DB00970,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin.,Dactinomycin,DB00095
DB00987,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.,Cytarabine,DB00095
DB00993,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azathioprine.,Azathioprine,DB00095
DB00997,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxorubicin.,Doxorubicin,DB00095
DB01005,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxyurea.,Hydroxyurea,DB00095
DB01008,The risk or severity of adverse effects can be increased when Efalizumab is combined with Busulfan.,Busulfan,DB00095
DB01024,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolic acid.,Mycophenolic acid,DB00095
DB01030,The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan.,Topotecan,DB00095
DB01033,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mercaptopurine.,Mercaptopurine,DB00095
DB01041,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thalidomide.,Thalidomide,DB00095
DB01042,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melphalan.,Melphalan,DB00095
DB01073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludarabine.,Fludarabine,DB00095
DB01099,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flucytosine.,Flucytosine,DB00095
DB01101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Capecitabine.,Capecitabine,DB00095
DB01108,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trilostane.,Trilostane,DB00095
DB01168,The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine.,Procarbazine,DB00095
DB01169,The risk or severity of adverse effects can be increased when Efalizumab is combined with Arsenic trioxide.,Arsenic trioxide,DB00095
DB01177,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarubicin.,Idarubicin,DB00095
DB01181,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ifosfamide.,Ifosfamide,DB00095
DB01196,The risk or severity of adverse effects can be increased when Efalizumab is combined with Estramustine.,Estramustine,DB00095
DB01204,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitoxantrone.,Mitoxantrone,DB00095
DB01206,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lomustine.,Lomustine,DB00095
DB01222,The risk or severity of adverse effects can be increased when Efalizumab is combined with Budesonide.,Budesonide,DB00095
DB01229,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paclitaxel.,Paclitaxel,DB00095
DB01234,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone.,Dexamethasone,DB00095
DB01248,The risk or severity of adverse effects can be increased when Efalizumab is combined with Docetaxel.,Docetaxel,DB00095
DB01254,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dasatinib.,Dasatinib,DB00095
DB01257,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eculizumab.,Eculizumab,DB00095
DB01262,The risk or severity of adverse effects can be increased when Efalizumab is combined with Decitabine.,Decitabine,DB00095
DB01268,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sunitinib.,Sunitinib,DB00095
DB01280,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nelarabine.,Nelarabine,DB00095
DB01281,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abatacept.,Abatacept,DB00095
DB01285,The risk or severity of adverse effects can be increased when Efalizumab is combined with Corticotropin.,Corticotropin,DB00095
DB01380,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortisone acetate.,Cortisone acetate,DB00095
DB01384,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paramethasone.,Paramethasone,DB00095
DB01394,The risk or severity of adverse effects can be increased when Efalizumab is combined with Colchicine.,Colchicine,DB00095
DB01410,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ciclesonide.,Ciclesonide,DB00095
DB01423,The risk or severity of adverse effects can be increased when Efalizumab is combined with Stepronin.,Stepronin,DB00095
DB01590,The risk or severity of adverse effects can be increased when Efalizumab is combined with Everolimus.,Everolimus,DB00095
DB01611,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00095
DB01816,The risk or severity of adverse effects can be increased when Efalizumab is combined with Castanospermine.,Castanospermine,DB00095
DB02546,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vorinostat.,Vorinostat,DB00095
DB02806,The risk or severity of adverse effects can be increased when Efalizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00095
DB03523,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brequinar.,Brequinar,DB00095
DB04572,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thiotepa.,Thiotepa,DB00095
DB04630,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aldosterone.,Aldosterone,DB00095
DB04845,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixabepilone.,Ixabepilone,DB00095
DB04868,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nilotinib.,Nilotinib,DB00095
DB04951,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirfenidone.,Pirfenidone,DB00095
DB04956,The risk or severity of adverse effects can be increased when Efalizumab is combined with Afelimomab.,Afelimomab,DB00095
DB05015,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belinostat.,Belinostat,DB00095
DB05109,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trabectedin.,Trabectedin,DB00095
DB05258,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa.,Interferon alfa,DB00095
DB05259,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glatiramer.,Glatiramer,DB00095
DB05260,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gallium nitrate.,Gallium nitrate,DB00095
DB05459,The risk or severity of adverse effects can be increased when Efalizumab is combined with Briakinumab.,Briakinumab,DB00095
DB05472,The risk or severity of adverse effects can be increased when Efalizumab is combined with omega interferon.,omega interferon,DB00095
DB05676,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apremilast.,Apremilast,DB00095
DB05773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00095
DB06168,The risk or severity of adverse effects can be increased when Efalizumab is combined with Canakinumab.,Canakinumab,DB00095
DB06273,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tocilizumab.,Tocilizumab,DB00095
DB06287,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temsirolimus.,Temsirolimus,DB00095
DB06372,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilonacept.,Rilonacept,DB00095
DB06589,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pazopanib.,Pazopanib,DB00095
DB06603,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panobinostat.,Panobinostat,DB00095
DB06612,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mepolizumab.,Mepolizumab,DB00095
DB06616,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bosutinib.,Bosutinib,DB00095
DB06662,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abetimus.,Abetimus,DB00095
DB06674,The risk or severity of adverse effects can be increased when Efalizumab is combined with Golimumab.,Golimumab,DB00095
DB06681,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belatacept.,Belatacept,DB00095
DB06769,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bendamustine.,Bendamustine,DB00095
DB06772,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cabazitaxel.,Cabazitaxel,DB00095
DB06813,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pralatrexate.,Pralatrexate,DB00095
DB08059,The risk or severity of adverse effects can be increased when Efalizumab is combined with Wortmannin.,Wortmannin,DB00095
DB08870,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00095
DB08871,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eribulin.,Eribulin,DB00095
DB08877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ruxolitinib.,Ruxolitinib,DB00095
DB08879,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belimumab.,Belimumab,DB00095
DB08880,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teriflunomide.,Teriflunomide,DB00095
DB08889,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carfilzomib.,Carfilzomib,DB00095
DB08901,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponatinib.,Ponatinib,DB00095
DB08904,The risk or severity of adverse effects can be increased when Efalizumab is combined with Certolizumab pegol.,Certolizumab pegol,DB00095
DB08906,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone furoate.,Fluticasone furoate,DB00095
DB08908,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00095
DB08910,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pomalidomide.,Pomalidomide,DB00095
DB08935,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obinutuzumab.,Obinutuzumab,DB00095
DB08970,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednidene.,Fluprednidene,DB00095
DB08971,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortolone.,Fluocortolone,DB00095
DB09029,The risk or severity of adverse effects can be increased when Efalizumab is combined with Secukinumab.,Secukinumab,DB00095
DB09033,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vedolizumab.,Vedolizumab,DB00095
DB09036,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siltuximab.,Siltuximab,DB00095
DB09052,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blinatumomab.,Blinatumomab,DB00095
DB09053,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibrutinib.,Ibrutinib,DB00095
DB09054,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib.,Idelalisib,DB00095
DB09073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palbociclib.,Palbociclib,DB00095
DB09074,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaparib.,Olaparib,DB00095
DB09077,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dinutuximab.,Dinutuximab,DB00095
DB09082,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vilanterol.,Vilanterol,DB00095
DB09091,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tixocortol.,Tixocortol,DB00095
DB09122,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00095
DB09312,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00095
DB09378,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednisolone.,Fluprednisolone,DB00095
DB09383,The risk or severity of adverse effects can be increased when Efalizumab is combined with Meprednisone.,Meprednisone,DB00095
DB11466,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tepoxalin.,Tepoxalin,DB00095
DB11487,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00095
DB11529,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melengestrol.,Melengestrol,DB00095
DB11569,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixekizumab.,Ixekizumab,DB00095
DB11580,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ravulizumab.,Ravulizumab,DB00095
DB11616,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirarubicin.,Pirarubicin,DB00095
DB11693,The risk or severity of adverse effects can be increased when Efalizumab is combined with Voclosporin.,Voclosporin,DB00095
DB11708,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peficitinib.,Peficitinib,DB00095
DB11750,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clobetasol.,Clobetasol,DB00095
DB11767,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sarilumab.,Sarilumab,DB00095
DB11776,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brodalumab.,Brodalumab,DB00095
DB11803,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirukumab.,Sirukumab,DB00095
DB11817,The risk or severity of adverse effects can be increased when Efalizumab is combined with Baricitinib.,Baricitinib,DB00095
DB11834,The risk or severity of adverse effects can be increased when Efalizumab is combined with Guselkumab.,Guselkumab,DB00095
DB11921,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deflazacort.,Deflazacort,DB00095
DB11988,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ocrelizumab.,Ocrelizumab,DB00095
DB12025,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triptolide.,Triptolide,DB00095
DB12371,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siponimod.,Siponimod,DB00095
DB12612,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanimod.,Ozanimod,DB00095
DB12617,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mizoribine.,Mizoribine,DB00095
DB12692,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gusperimus.,Gusperimus,DB00095
DB12814,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00095
DB12902,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trofosfamide.,Trofosfamide,DB00095
DB12947,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxifluridine.,Doxifluridine,DB00095
DB12991,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deoxyspergualin.,Deoxyspergualin,DB00095
DB12996,The risk or severity of adverse effects can be increased when Efalizumab is combined with Acteoside.,Acteoside,DB00095
DB13003,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortivazol.,Cortivazol,DB00095
DB13014,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hypericin.,Hypericin,DB00095
DB13068,The risk or severity of adverse effects can be increased when Efalizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00095
DB13208,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednylidene.,Prednylidene,DB00095
DB13223,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortin.,Fluocortin,DB00095
DB13241,The risk or severity of adverse effects can be increased when Efalizumab is combined with Begelomab.,Begelomab,DB00095
DB13491,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluperolone.,Fluperolone,DB00095
DB13664,The risk or severity of adverse effects can be increased when Efalizumab is combined with Formocortal.,Formocortal,DB00095
DB13728,The risk or severity of adverse effects can be increased when Efalizumab is combined with Halometasone.,Halometasone,DB00095
DB13843,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cloprednol.,Cloprednol,DB00095
DB13856,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluclorolone.,Fluclorolone,DB00095
DB13867,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone.,Fluticasone,DB00095
DB14066,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetrandrine.,Tetrandrine,DB00095
DB14219,The risk or severity of adverse effects can be increased when Efalizumab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00095
DB14512,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone furoate.,Mometasone furoate,DB00095
DB14538,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00095
DB14539,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00095
DB14545,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00095
DB14724,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emapalumab.,Emapalumab,DB00095
DB14762,The risk or severity of adverse effects can be increased when Efalizumab is combined with Risankizumab.,Risankizumab,DB00095
DB14919,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozanolixizumab.,Rozanolixizumab,DB00095
DB15253,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleselumab.,Bleselumab,DB00095
DB00108,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.,Natalizumab,DB00095
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.,Pimecrolimus,DB00095
DB01656,Roflumilast may increase the immunosuppressive activities of Efalizumab.,Roflumilast,DB00095
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.,Sipuleucel-T,DB00095
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Efalizumab.,Sulfamethoxazole,DB00095
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Efalizumab.,Diethylstilbestrol,DB00095
DB00269,Chlorotrianisene may increase the thrombogenic activities of Efalizumab.,Chlorotrianisene,DB00095
DB00286,Conjugated estrogens may increase the thrombogenic activities of Efalizumab.,Conjugated estrogens,DB00095
DB00655,Estrone may increase the thrombogenic activities of Efalizumab.,Estrone,DB00095
DB00783,Estradiol may increase the thrombogenic activities of Efalizumab.,Estradiol,DB00095
DB00890,Dienestrol may increase the thrombogenic activities of Efalizumab.,Dienestrol,DB00095
DB00977,Ethinylestradiol may increase the thrombogenic activities of Efalizumab.,Ethinylestradiol,DB00095
DB01357,Mestranol may increase the thrombogenic activities of Efalizumab.,Mestranol,DB00095
DB04573,Estriol may increase the thrombogenic activities of Efalizumab.,Estriol,DB00095
DB04574,Estrone sulfate may increase the thrombogenic activities of Efalizumab.,Estrone sulfate,DB00095
DB04575,Quinestrol may increase the thrombogenic activities of Efalizumab.,Quinestrol,DB00095
DB07931,Hexestrol may increase the thrombogenic activities of Efalizumab.,Hexestrol,DB00095
DB09070,Tibolone may increase the thrombogenic activities of Efalizumab.,Tibolone,DB00095
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Efalizumab.","Synthetic Conjugated Estrogens, A",DB00095
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efalizumab.","Synthetic Conjugated Estrogens, B",DB00095
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Efalizumab.,Polyestradiol phosphate,DB00095
DB09381,Esterified estrogens may increase the thrombogenic activities of Efalizumab.,Esterified estrogens,DB00095
DB11478,Zeranol may increase the thrombogenic activities of Efalizumab.,Zeranol,DB00095
DB11674,Equol may increase the thrombogenic activities of Efalizumab.,Equol,DB00095
DB12487,Promestriene may increase the thrombogenic activities of Efalizumab.,Promestriene,DB00095
DB13143,Methallenestril may increase the thrombogenic activities of Efalizumab.,Methallenestril,DB00095
DB13386,Epimestrol may increase the thrombogenic activities of Efalizumab.,Epimestrol,DB00095
DB13418,Moxestrol may increase the thrombogenic activities of Efalizumab.,Moxestrol,DB00095
DB13952,Estradiol acetate may increase the thrombogenic activities of Efalizumab.,Estradiol acetate,DB00095
DB13953,Estradiol benzoate may increase the thrombogenic activities of Efalizumab.,Estradiol benzoate,DB00095
DB13954,Estradiol cypionate may increase the thrombogenic activities of Efalizumab.,Estradiol cypionate,DB00095
DB13956,Estradiol valerate may increase the thrombogenic activities of Efalizumab.,Estradiol valerate,DB00095
DB15334,Biochanin A may increase the thrombogenic activities of Efalizumab.,Biochanin A,DB00095
DB15335,Formononetin may increase the thrombogenic activities of Efalizumab.,Formononetin,DB00095
DB01097,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.,Leflunomide,DB00095
DB08895,Efalizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00095
DB00072,Trastuzumab may increase the neutropenic activities of Efalizumab.,Trastuzumab,DB00095
DB08868,Efalizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00095
DB00864,Tacrolimus may increase the immunosuppressive activities of Efalizumab.,Tacrolimus,DB00095
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Efalizumab.,G17DT,DB00095
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Efalizumab.,PEV3A,DB00095
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Efalizumab.,INGN 225,DB00095
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Efalizumab.,Rindopepimut,DB00095
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Efalizumab.,SRP 299,DB00095
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Efalizumab.,GI-5005,DB00095
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Efalizumab.,Vitespen,DB00095
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Efalizumab.,TG4010,DB00095
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efalizumab.,Anthrax immune globulin human,DB00095
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Efalizumab.","Rabies virus inactivated antigen, B",DB00095
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00095
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Efalizumab.,Rotavirus vaccine,DB00095
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab.","Rabies virus inactivated antigen, A",DB00095
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00095
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00095
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00095
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00095
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00095
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00095
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Efalizumab.,Typhoid Vi polysaccharide vaccine,DB00095
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.,Hepatitis A Vaccine,DB00095
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00095
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00095
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00095
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00095
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00095
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Efalizumab.,Human rabies virus immune globulin,DB00095
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.,Hepatitis B Vaccine (Recombinant),DB00095
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Efalizumab.,Tecemotide,DB00095
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Efalizumab.,Typhoid vaccine,DB00095
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00095
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00095
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00095
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00095
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Efalizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00095
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00095
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00095
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Efalizumab.,Vaccinia virus strain new york city board of health live antigen,DB00095
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Efalizumab.,Pertussis vaccine,DB00095
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00095
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.,Varicella Zoster Vaccine (Recombinant),DB00095
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Efalizumab.,Modified vaccinia ankara,DB00095
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Efalizumab.,Rubella virus vaccine,DB00095
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Efalizumab.,Varicella Zoster Vaccine (Live/attenuated),DB00095
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain tice live antigen,DB00095
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00095
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Efalizumab.,Yellow Fever Vaccine,DB00095
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Efalizumab.,Anthrax vaccine,DB00095
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Efalizumab.,Typhoid Vaccine Live,DB00095
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00095
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Efalizumab.,BCG vaccine,DB00095
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Efalizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00095
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Efalizumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00095
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Efalizumab.,Adenovirus type 7 vaccine live,DB00095
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.,Cetuximab,DB00095
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.,Human immunoglobulin G,DB00095
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Efalizumab.,Omalizumab,DB00095
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Efalizumab.,Abciximab,DB00095
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.,Indium In-111 satumomab pendetide,DB00095
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.,Digoxin Immune Fab (Ovine),DB00095
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.,Capromab pendetide,DB00095
DB00110,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.,Palivizumab,DB00095
DB00113,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00095
DB01269,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panitumumab.,Panitumumab,DB00095
DB01270,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ranibizumab.,Ranibizumab,DB00095
DB04901,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galiximab.,Galiximab,DB00095
DB04949,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pexelizumab.,Pexelizumab,DB00095
DB04958,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epratuzumab.,Epratuzumab,DB00095
DB04962,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bectumomab.,Bectumomab,DB00095
DB04964,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oregovomab.,Oregovomab,DB00095
DB04988,The risk or severity of adverse effects can be increased when Efalizumab is combined with IGN311.,IGN311,DB00095
DB05006,The risk or severity of adverse effects can be increased when Efalizumab is combined with Adecatumumab.,Adecatumumab,DB00095
DB05097,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab.,Labetuzumab,DB00095
DB05101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Matuzumab.,Matuzumab,DB00095
DB05111,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fontolizumab.,Fontolizumab,DB00095
DB05136,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bavituximab.,Bavituximab,DB00095
DB05139,The risk or severity of adverse effects can be increased when Efalizumab is combined with CR002.,CR002,DB00095
DB05209,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozrolimupab.,Rozrolimupab,DB00095
DB05304,The risk or severity of adverse effects can be increased when Efalizumab is combined with Girentuximab.,Girentuximab,DB00095
DB05336,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00095
DB05405,The risk or severity of adverse effects can be increased when Efalizumab is combined with XTL-001.,XTL-001,DB00095
DB05437,The risk or severity of adverse effects can be increased when Efalizumab is combined with NAV 1800.,NAV 1800,DB00095
DB05496,The risk or severity of adverse effects can be increased when Efalizumab is combined with Otelixizumab.,Otelixizumab,DB00095
DB05545,The risk or severity of adverse effects can be increased when Efalizumab is combined with AMG 108.,AMG 108,DB00095
DB05550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Iratumumab.,Iratumumab,DB00095
DB05555,The risk or severity of adverse effects can be increased when Efalizumab is combined with Enokizumab.,Enokizumab,DB00095
DB05578,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ramucirumab.,Ramucirumab,DB00095
DB05595,The risk or severity of adverse effects can be increased when Efalizumab is combined with Farletuzumab.,Farletuzumab,DB00095
DB05656,The risk or severity of adverse effects can be increased when Efalizumab is combined with Veltuzumab.,Veltuzumab,DB00095
DB05793,The risk or severity of adverse effects can be increased when Efalizumab is combined with PRO-542.,PRO-542,DB00095
DB05797,The risk or severity of adverse effects can be increased when Efalizumab is combined with TNX-901.,TNX-901,DB00095
DB05889,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00095
DB05892,The risk or severity of adverse effects can be increased when Efalizumab is combined with RI 624.,RI 624,DB00095
DB05915,The risk or severity of adverse effects can be increased when Efalizumab is combined with MYO-029.,MYO-029,DB00095
DB05916,The risk or severity of adverse effects can be increased when Efalizumab is combined with CT-011.,CT-011,DB00095
DB05941,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leronlimab.,Leronlimab,DB00095
DB05996,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00095
DB06043,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaratumab.,Olaratumab,DB00095
DB06049,The risk or severity of adverse effects can be increased when Efalizumab is combined with IPH 2101.,IPH 2101,DB00095
DB06050,The risk or severity of adverse effects can be increased when Efalizumab is combined with TB-402.,TB-402,DB00095
DB06081,The risk or severity of adverse effects can be increased when Efalizumab is combined with Caplacizumab.,Caplacizumab,DB00095
DB06101,The risk or severity of adverse effects can be increased when Efalizumab is combined with IMC-1C11.,IMC-1C11,DB00095
DB06116,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eldelumab.,Eldelumab,DB00095
DB06162,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumiliximab.,Lumiliximab,DB00095
DB06186,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipilimumab.,Ipilimumab,DB00095
DB06192,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nimotuzumab.,Nimotuzumab,DB00095
DB06241,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clenoliximab.,Clenoliximab,DB00095
DB06304,The risk or severity of adverse effects can be increased when Efalizumab is combined with BIIB015.,BIIB015,DB00095
DB06305,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sonepcizumab.,Sonepcizumab,DB00095
DB06310,The risk or severity of adverse effects can be increased when Efalizumab is combined with Motavizumab.,Motavizumab,DB00095
DB06317,The risk or severity of adverse effects can be increased when Efalizumab is combined with Elotuzumab.,Elotuzumab,DB00095
DB06318,The risk or severity of adverse effects can be increased when Efalizumab is combined with AVE9633.,AVE9633,DB00095
DB06322,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carotuximab.,Carotuximab,DB00095
DB06324,The risk or severity of adverse effects can be increased when Efalizumab is combined with XmAb 2513.,XmAb 2513,DB00095
DB06342,The risk or severity of adverse effects can be increased when Efalizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00095
DB06343,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teprotumumab.,Teprotumumab,DB00095
DB06360,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lucatumumab.,Lucatumumab,DB00095
DB06366,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pertuzumab.,Pertuzumab,DB00095
DB06371,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siplizumab.,Siplizumab,DB00095
DB06467,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apolizumab.,Apolizumab,DB00095
DB06474,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00095
DB06550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bivatuzumab.,Bivatuzumab,DB00095
DB06557,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lerdelimumab.,Lerdelimumab,DB00095
DB06599,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lexatumumab.,Lexatumumab,DB00095
DB06602,The risk or severity of adverse effects can be increased when Efalizumab is combined with Reslizumab.,Reslizumab,DB00095
DB06606,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teplizumab.,Teplizumab,DB00095
DB06607,The risk or severity of adverse effects can be increased when Efalizumab is combined with Catumaxomab.,Catumaxomab,DB00095
DB06647,The risk or severity of adverse effects can be increased when Efalizumab is combined with Volociximab.,Volociximab,DB00095
DB06650,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ofatumumab.,Ofatumumab,DB00095
DB08902,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raxibacumab.,Raxibacumab,DB00095
DB09035,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nivolumab.,Nivolumab,DB00095
DB09037,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pembrolizumab.,Pembrolizumab,DB00095
DB09045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dulaglutide.,Dulaglutide,DB00095
DB09105,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asfotase alfa.,Asfotase alfa,DB00095
DB09264,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarucizumab.,Idarucizumab,DB00095
DB09302,The risk or severity of adverse effects can be increased when Efalizumab is combined with Alirocumab.,Alirocumab,DB00095
DB09303,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evolocumab.,Evolocumab,DB00095
DB09331,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daratumumab.,Daratumumab,DB00095
DB09559,The risk or severity of adverse effects can be increased when Efalizumab is combined with Necitumumab.,Necitumumab,DB00095
DB11595,The risk or severity of adverse effects can be increased when Efalizumab is combined with Atezolizumab.,Atezolizumab,DB00095
DB11604,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00095
DB11608,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00095
DB11621,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00095
DB11646,The risk or severity of adverse effects can be increased when Efalizumab is combined with Conatumumab.,Conatumumab,DB00095
DB11657,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tabalumab.,Tabalumab,DB00095
DB11680,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00095
DB11685,The risk or severity of adverse effects can be increased when Efalizumab is combined with Figitumumab.,Figitumumab,DB00095
DB11714,The risk or severity of adverse effects can be increased when Efalizumab is combined with Durvalumab.,Durvalumab,DB00095
DB11715,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bapineuzumab.,Bapineuzumab,DB00095
DB11731,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00095
DB11746,The risk or severity of adverse effects can be increased when Efalizumab is combined with Onartuzumab.,Onartuzumab,DB00095
DB11756,The risk or severity of adverse effects can be increased when Efalizumab is combined with Solanezumab.,Solanezumab,DB00095
DB11771,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tremelimumab.,Tremelimumab,DB00095
DB11826,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lampalizumab.,Lampalizumab,DB00095
DB11840,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalotuzumab.,Dalotuzumab,DB00095
DB11849,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emibetuzumab.,Emibetuzumab,DB00095
DB11850,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ublituximab.,Ublituximab,DB00095
DB11856,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ligelizumab.,Ligelizumab,DB00095
DB11857,The risk or severity of adverse effects can be increased when Efalizumab is combined with Seribantumab.,Seribantumab,DB00095
DB11862,The risk or severity of adverse effects can be increased when Efalizumab is combined with Landogrozumab.,Landogrozumab,DB00095
DB11866,The risk or severity of adverse effects can be increased when Efalizumab is combined with Romosozumab.,Romosozumab,DB00095
DB11884,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00095
DB11914,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lebrikizumab.,Lebrikizumab,DB00095
DB11930,The risk or severity of adverse effects can be increased when Efalizumab is combined with Varlilumab.,Varlilumab,DB00095
DB11945,The risk or severity of adverse effects can be increased when Efalizumab is combined with Avelumab.,Avelumab,DB00095
DB11959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crenezumab.,Crenezumab,DB00095
DB11972,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilotumumab.,Rilotumumab,DB00095
DB11976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anifrolumab.,Anifrolumab,DB00095
DB12023,The risk or severity of adverse effects can be increased when Efalizumab is combined with Benralizumab.,Benralizumab,DB00095
DB12034,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gantenerumab.,Gantenerumab,DB00095
DB12053,The risk or severity of adverse effects can be increased when Efalizumab is combined with Visilizumab.,Visilizumab,DB00095
DB12077,The risk or severity of adverse effects can be increased when Efalizumab is combined with Urelumab.,Urelumab,DB00095
DB12089,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00095
DB12090,The risk or severity of adverse effects can be increased when Efalizumab is combined with Patritumab.,Patritumab,DB00095
DB12102,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fulranumab.,Fulranumab,DB00095
DB12104,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tarextumab.,Tarextumab,DB00095
DB12118,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sotatercept.,Sotatercept,DB00095
DB12119,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gevokizumab.,Gevokizumab,DB00095
DB12142,The risk or severity of adverse effects can be increased when Efalizumab is combined with Duligotuzumab.,Duligotuzumab,DB00095
DB12152,The risk or severity of adverse effects can be increased when Efalizumab is combined with Simtuzumab.,Simtuzumab,DB00095
DB12157,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fasinumab.,Fasinumab,DB00095
DB12159,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dupilumab.,Dupilumab,DB00095
DB12169,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tralokinumab.,Tralokinumab,DB00095
DB12189,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etrolizumab.,Etrolizumab,DB00095
DB12202,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zalutumumab.,Zalutumumab,DB00095
DB12205,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ganitumab.,Ganitumab,DB00095
DB12213,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etaracizumab.,Etaracizumab,DB00095
DB12240,The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00095
DB12246,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inclacumab.,Inclacumab,DB00095
DB12250,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cixutumumab.,Cixutumumab,DB00095
DB12261,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00095
DB12274,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aducanumab.,Aducanumab,DB00095
DB12281,The risk or severity of adverse effects can be increased when Efalizumab is combined with Luspatercept.,Luspatercept,DB00095
DB12296,The risk or severity of adverse effects can be increased when Efalizumab is combined with GS-5745.,GS-5745,DB00095
DB12317,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vanucizumab.,Vanucizumab,DB00095
DB12331,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00095
DB12335,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tanezumab.,Tanezumab,DB00095
DB12342,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ensituximab.,Ensituximab,DB00095
DB12344,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fezakinumab.,Fezakinumab,DB00095
DB12363,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dusigitumab.,Dusigitumab,DB00095
DB12396,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fresolimumab.,Fresolimumab,DB00095
DB12413,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00095
DB12456,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bococizumab.,Bococizumab,DB00095
DB12489,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00095
DB12498,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mogamulizumab.,Mogamulizumab,DB00095
DB12520,The risk or severity of adverse effects can be increased when Efalizumab is combined with Plozalizumab.,Plozalizumab,DB00095
DB12534,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mavrilimumab.,Mavrilimumab,DB00095
DB12560,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blosozumab.,Blosozumab,DB00095
DB12584,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimagrumab.,Bimagrumab,DB00095
DB12589,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacetuzumab.,Dacetuzumab,DB00095
DB12609,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tovetumab.,Tovetumab,DB00095
DB12683,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumretuzumab.,Lumretuzumab,DB00095
DB12698,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibalizumab.,Ibalizumab,DB00095
DB12701,The risk or severity of adverse effects can be increased when Efalizumab is combined with Intetumumab.,Intetumumab,DB00095
DB12718,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carlumab.,Carlumab,DB00095
DB12734,The risk or severity of adverse effects can be increased when Efalizumab is combined with Demcizumab.,Demcizumab,DB00095
DB12773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sifalimumab.,Sifalimumab,DB00095
DB12775,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abituzumab.,Abituzumab,DB00095
DB12797,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ecromeximab.,Ecromeximab,DB00095
DB12807,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00095
DB12815,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crotedumab.,Crotedumab,DB00095
DB12820,The risk or severity of adverse effects can be increased when Efalizumab is combined with Concizumab.,Concizumab,DB00095
DB12826,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab.,Depatuxizumab,DB00095
DB12844,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rontalizumab.,Rontalizumab,DB00095
DB12845,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amatuximab.,Amatuximab,DB00095
DB12849,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clazakizumab.,Clazakizumab,DB00095
DB12891,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanezumab.,Ozanezumab,DB00095
DB12893,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00095
DB12917,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimekizumab.,Bimekizumab,DB00095
DB12943,The risk or severity of adverse effects can be increased when Efalizumab is combined with Milatuzumab.,Milatuzumab,DB00095
DB12976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Robatumumab.,Robatumumab,DB00095
DB13017,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00095
DB13037,The risk or severity of adverse effects can be increased when Efalizumab is combined with Namilumab.,Namilumab,DB00095
DB13045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Racotumomab.,Racotumomab,DB00095
DB13073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tregalizumab.,Tregalizumab,DB00095
DB13127,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olokizumab.,Olokizumab,DB00095
DB13140,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00095
DB13375,The risk or severity of adverse effects can be increased when Efalizumab is combined with Edrecolomab.,Edrecolomab,DB00095
DB13535,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nebacumab.,Nebacumab,DB00095
DB13886,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00095
DB13923,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emicizumab.,Emicizumab,DB00095
DB13976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulesomab.,Sulesomab,DB00095
DB13979,The risk or severity of adverse effects can be increased when Efalizumab is combined with Besilesomab.,Besilesomab,DB00095
DB14012,The risk or severity of adverse effects can be increased when Efalizumab is combined with Burosumab.,Burosumab,DB00095
DB14039,The risk or severity of adverse effects can be increased when Efalizumab is combined with Erenumab.,Erenumab,DB00095
DB14040,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eptinezumab.,Eptinezumab,DB00095
DB14041,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fremanezumab.,Fremanezumab,DB00095
DB14042,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galcanezumab.,Galcanezumab,DB00095
DB14211,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fanolesomab.,Fanolesomab,DB00095
DB14580,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lecanemab.,Lecanemab,DB00095
DB14597,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lanadelumab.,Lanadelumab,DB00095
DB14707,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cemiplimab.,Cemiplimab,DB00095
DB14776,The risk or severity of adverse effects can be increased when Efalizumab is combined with Camrelizumab.,Camrelizumab,DB00095
DB14778,The risk or severity of adverse effects can be increased when Efalizumab is combined with Setrusumab.,Setrusumab,DB00095
DB14784,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gancotamab.,Gancotamab,DB00095
DB14809,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00095
DB14811,The risk or severity of adverse effects can be increased when Efalizumab is combined with Isatuximab.,Isatuximab,DB00095
DB14824,The risk or severity of adverse effects can be increased when Efalizumab is combined with Icrucumab.,Icrucumab,DB00095
DB14843,The risk or severity of adverse effects can be increased when Efalizumab is combined with Codrituzumab.,Codrituzumab,DB00095
DB14864,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brolucizumab.,Brolucizumab,DB00095
DB14871,The risk or severity of adverse effects can be increased when Efalizumab is combined with Xentuzumab.,Xentuzumab,DB00095
DB14877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lintuzumab.,Lintuzumab,DB00095
DB14891,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vobarilizumab.,Vobarilizumab,DB00095
DB14897,The risk or severity of adverse effects can be increased when Efalizumab is combined with Parsatuzumab.,Parsatuzumab,DB00095
DB14905,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emactuzumab.,Emactuzumab,DB00095
DB14907,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00095
DB14908,The risk or severity of adverse effects can be increased when Efalizumab is combined with Refanezumab.,Refanezumab,DB00095
DB14947,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bermekimab.,Bermekimab,DB00095
DB14952,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pamrevlumab.,Pamrevlumab,DB00095
DB14959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Opicinumab.,Opicinumab,DB00095
DB14962,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00095
DB14967,The risk or severity of adverse effects can be increased when Efalizumab is combined with Margetuximab.,Margetuximab,DB00095
DB14988,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalantercept.,Dalantercept,DB00095
DB14997,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pateclizumab.,Pateclizumab,DB00095
DB15014,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gremubamab.,Gremubamab,DB00095
DB15022,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apomab.,Apomab,DB00095
DB15044,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tafasitamab.,Tafasitamab,DB00095
DB15045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipafricept.,Ipafricept,DB00095
DB15076,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abrilumab.,Abrilumab,DB00095
DB15089,The risk or severity of adverse effects can be increased when Efalizumab is combined with Frovocimab.,Frovocimab,DB00095
DB15090,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tezepelumab.,Tezepelumab,DB00095
DB15101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tigatuzumab.,Tigatuzumab,DB00095
DB15104,The risk or severity of adverse effects can be increased when Efalizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00095
DB15113,The risk or severity of adverse effects can be increased when Efalizumab is combined with Utomilumab.,Utomilumab,DB00095
DB15118,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zolbetuximab.,Zolbetuximab,DB00095
DB15135,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponezumab.,Ponezumab,DB00095
DB15160,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asunercept.,Asunercept,DB00095
DB15172,The risk or severity of adverse effects can be increased when Efalizumab is combined with Suvratoxumab.,Suvratoxumab,DB00095
DB15225,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitazalimab.,Mitazalimab,DB00095
DB15252,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nemolizumab.,Nemolizumab,DB00095
DB15277,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gedivumab.,Gedivumab,DB00095
DB15336,The risk or severity of adverse effects can be increased when Efalizumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00095
DB15349,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00095
DB15354,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evinacumab.,Evinacumab,DB00095
DB15363,The risk or severity of adverse effects can be increased when Efalizumab is combined with Istiratumab.,Istiratumab,DB00095
DB15383,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pidilizumab.,Pidilizumab,DB00095
DB15397,The risk or severity of adverse effects can be increased when Efalizumab is combined with GMA-161.,GMA-161,DB00095
DB15409,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00095
DB15415,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tomaralimab.,Tomaralimab,DB00095
DB15428,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vesencumab.,Vesencumab,DB00095
DB15432,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00095
DB15441,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00095
DB15443,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00095
DB15453,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00095
DB14004,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tildrakizumab.,Tildrakizumab,DB00095
DB05679,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ustekinumab.,Ustekinumab,DB00095
DB15559,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00095
DB00091,Efalizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00095
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Efalizumab.","Ebola Zaire vaccine (live, attenuated)",DB00095
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Efalizumab.,Magnesium,DB00095
DB01601,The serum concentration of Efalizumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00095
DB12530,The risk or severity of infection can be increased when Efalizumab is combined with Inebilizumab.,Inebilizumab,DB00095
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit).,Denosumab,DB00098
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit).,Etanercept,DB00098
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit).,Peginterferon alfa-2a,DB00098
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfa-n1,DB00098
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfa-n3,DB00098
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit).,Peginterferon alfa-2b,DB00098
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit).,Anakinra,DB00098
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antithymocyte immunoglobulin (rabbit).,Interferon gamma-1b,DB00098
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Antithymocyte immunoglobulin (rabbit).","Interferon alfa-2a, Recombinant",DB00098
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit).,Aldesleukin,DB00098
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit).,Adalimumab,DB00098
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).,Gemtuzumab ozogamicin,DB00098
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).,Pegaspargase,DB00098
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).,Infliximab,DB00098
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).,Interferon beta-1b,DB00098
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfacon-1,DB00098
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).,Rituximab,DB00098
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).,Basiliximab,DB00098
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).,Muromonab,DB00098
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).,Ibritumomab tiuxetan,DB00098
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).,Tositumomab,DB00098
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).,Alemtuzumab,DB00098
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).,Alefacept,DB00098
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Efalizumab,DB00098
DB00105,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.,Interferon alfa-2b,DB00098
DB00111,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.,Daclizumab,DB00098
DB00112,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.,Bevacizumab,DB00098
DB00120,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.,Phenylalanine,DB00098
DB00180,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flunisolide.,Flunisolide,DB00098
DB00188,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib.,Bortezomib,DB00098
DB00242,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cladribine.,Cladribine,DB00098
DB00262,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine.,Carmustine,DB00098
DB00276,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amsacrine.,Amsacrine,DB00098
DB00290,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin.,Bleomycin,DB00098
DB00291,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chlorambucil.,Chlorambucil,DB00098
DB00293,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raltitrexed.,Raltitrexed,DB00098
DB00305,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitomycin.,Mitomycin,DB00098
DB00307,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene.,Bexarotene,DB00098
DB00309,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vindesine.,Vindesine,DB00098
DB00322,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Floxuridine.,Floxuridine,DB00098
DB00328,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indomethacin.,Indomethacin,DB00098
DB00352,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tioguanine.,Tioguanine,DB00098
DB00361,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinorelbine.,Vinorelbine,DB00098
DB00380,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane.,Dexrazoxane,DB00098
DB00394,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00098
DB00398,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sorafenib.,Sorafenib,DB00098
DB00428,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Streptozocin.,Streptozocin,DB00098
DB00432,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trifluridine.,Trifluridine,DB00098
DB00441,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gemcitabine.,Gemcitabine,DB00098
DB00443,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Betamethasone.,Betamethasone,DB00098
DB00444,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teniposide.,Teniposide,DB00098
DB00445,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epirubicin.,Epirubicin,DB00098
DB00446,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chloramphenicol.,Chloramphenicol,DB00098
DB00480,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lenalidomide.,Lenalidomide,DB00098
DB00488,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Altretamine.,Altretamine,DB00098
DB00495,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zidovudine.,Zidovudine,DB00098
DB00515,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin.,Cisplatin,DB00098
DB00526,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin.,Oxaliplatin,DB00098
DB00531,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide.,Cyclophosphamide,DB00098
DB00541,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine.,Vincristine,DB00098
DB00544,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil.,Fluorouracil,DB00098
DB00550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil.,Propylthiouracil,DB00098
DB00552,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pentostatin.,Pentostatin,DB00098
DB00563,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methotrexate.,Methotrexate,DB00098
DB00564,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carbamazepine.,Carbamazepine,DB00098
DB00570,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinblastine.,Vinblastine,DB00098
DB00588,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone propionate.,Fluticasone propionate,DB00098
DB00591,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00098
DB00601,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Linezolid.,Linezolid,DB00098
DB00619,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imatinib.,Imatinib,DB00098
DB00620,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triamcinolone.,Triamcinolone,DB00098
DB00631,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine.,Clofarabine,DB00098
DB00635,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisone.,Prednisone,DB00098
DB00642,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pemetrexed.,Pemetrexed,DB00098
DB00687,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludrocortisone.,Fludrocortisone,DB00098
DB00688,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00098
DB00694,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.,Daunorubicin,DB00098
DB00755,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tretinoin.,Tretinoin,DB00098
DB00762,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan.,Irinotecan,DB00098
DB00763,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methimazole.,Methimazole,DB00098
DB00764,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone.,Mometasone,DB00098
DB00773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etoposide.,Etoposide,DB00098
DB00795,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulfasalazine.,Sulfasalazine,DB00098
DB00851,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine.,Dacarbazine,DB00098
DB00853,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temozolomide.,Temozolomide,DB00098
DB00859,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Penicillamine.,Penicillamine,DB00098
DB00860,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone.,Prednisolone,DB00098
DB00877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirolimus.,Sirolimus,DB00098
DB00888,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mechlorethamine.,Mechlorethamine,DB00098
DB00928,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azacitidine.,Azacitidine,DB00098
DB00958,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin.,Carboplatin,DB00098
DB00959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone.,Methylprednisolone,DB00098
DB00970,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin.,Dactinomycin,DB00098
DB00987,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.,Cytarabine,DB00098
DB00993,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azathioprine.,Azathioprine,DB00098
DB00997,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxorubicin.,Doxorubicin,DB00098
DB01005,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxyurea.,Hydroxyurea,DB00098
DB01008,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Busulfan.,Busulfan,DB00098
DB01024,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolic acid.,Mycophenolic acid,DB00098
DB01030,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan.,Topotecan,DB00098
DB01033,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mercaptopurine.,Mercaptopurine,DB00098
DB01041,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thalidomide.,Thalidomide,DB00098
DB01042,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melphalan.,Melphalan,DB00098
DB01073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludarabine.,Fludarabine,DB00098
DB01099,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flucytosine.,Flucytosine,DB00098
DB01101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Capecitabine.,Capecitabine,DB00098
DB01108,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trilostane.,Trilostane,DB00098
DB01168,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine.,Procarbazine,DB00098
DB01169,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide.,Arsenic trioxide,DB00098
DB01177,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarubicin.,Idarubicin,DB00098
DB01181,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ifosfamide.,Ifosfamide,DB00098
DB01196,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Estramustine.,Estramustine,DB00098
DB01204,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitoxantrone.,Mitoxantrone,DB00098
DB01206,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lomustine.,Lomustine,DB00098
DB01222,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Budesonide.,Budesonide,DB00098
DB01229,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paclitaxel.,Paclitaxel,DB00098
DB01234,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone.,Dexamethasone,DB00098
DB01248,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Docetaxel.,Docetaxel,DB00098
DB01254,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dasatinib.,Dasatinib,DB00098
DB01257,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eculizumab.,Eculizumab,DB00098
DB01262,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Decitabine.,Decitabine,DB00098
DB01268,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sunitinib.,Sunitinib,DB00098
DB01280,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nelarabine.,Nelarabine,DB00098
DB01281,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abatacept.,Abatacept,DB00098
DB01285,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Corticotropin.,Corticotropin,DB00098
DB01380,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortisone acetate.,Cortisone acetate,DB00098
DB01384,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paramethasone.,Paramethasone,DB00098
DB01394,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Colchicine.,Colchicine,DB00098
DB01410,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ciclesonide.,Ciclesonide,DB00098
DB01423,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Stepronin.,Stepronin,DB00098
DB01590,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Everolimus.,Everolimus,DB00098
DB01611,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00098
DB01816,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Castanospermine.,Castanospermine,DB00098
DB02546,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vorinostat.,Vorinostat,DB00098
DB02806,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00098
DB03523,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brequinar.,Brequinar,DB00098
DB04572,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thiotepa.,Thiotepa,DB00098
DB04630,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aldosterone.,Aldosterone,DB00098
DB04845,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixabepilone.,Ixabepilone,DB00098
DB04868,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nilotinib.,Nilotinib,DB00098
DB04951,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirfenidone.,Pirfenidone,DB00098
DB04956,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Afelimomab.,Afelimomab,DB00098
DB05015,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belinostat.,Belinostat,DB00098
DB05109,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trabectedin.,Trabectedin,DB00098
DB05258,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa.,Interferon alfa,DB00098
DB05259,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glatiramer.,Glatiramer,DB00098
DB05260,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gallium nitrate.,Gallium nitrate,DB00098
DB05459,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Briakinumab.,Briakinumab,DB00098
DB05472,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with omega interferon.,omega interferon,DB00098
DB05676,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apremilast.,Apremilast,DB00098
DB05773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00098
DB06168,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Canakinumab.,Canakinumab,DB00098
DB06273,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tocilizumab.,Tocilizumab,DB00098
DB06287,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temsirolimus.,Temsirolimus,DB00098
DB06372,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilonacept.,Rilonacept,DB00098
DB06589,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pazopanib.,Pazopanib,DB00098
DB06603,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panobinostat.,Panobinostat,DB00098
DB06612,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mepolizumab.,Mepolizumab,DB00098
DB06616,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bosutinib.,Bosutinib,DB00098
DB06662,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abetimus.,Abetimus,DB00098
DB06674,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Golimumab.,Golimumab,DB00098
DB06681,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belatacept.,Belatacept,DB00098
DB06769,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bendamustine.,Bendamustine,DB00098
DB06772,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cabazitaxel.,Cabazitaxel,DB00098
DB06813,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pralatrexate.,Pralatrexate,DB00098
DB08059,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Wortmannin.,Wortmannin,DB00098
DB08870,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00098
DB08871,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eribulin.,Eribulin,DB00098
DB08877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.,Ruxolitinib,DB00098
DB08879,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belimumab.,Belimumab,DB00098
DB08880,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teriflunomide.,Teriflunomide,DB00098
DB08889,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carfilzomib.,Carfilzomib,DB00098
DB08901,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponatinib.,Ponatinib,DB00098
DB08904,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Certolizumab pegol.,Certolizumab pegol,DB00098
DB08906,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone furoate.,Fluticasone furoate,DB00098
DB08908,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00098
DB08910,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.,Pomalidomide,DB00098
DB08935,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obinutuzumab.,Obinutuzumab,DB00098
DB08970,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednidene.,Fluprednidene,DB00098
DB08971,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortolone.,Fluocortolone,DB00098
DB09029,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Secukinumab.,Secukinumab,DB00098
DB09033,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vedolizumab.,Vedolizumab,DB00098
DB09036,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siltuximab.,Siltuximab,DB00098
DB09052,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blinatumomab.,Blinatumomab,DB00098
DB09053,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibrutinib.,Ibrutinib,DB00098
DB09054,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib.,Idelalisib,DB00098
DB09073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palbociclib.,Palbociclib,DB00098
DB09074,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaparib.,Olaparib,DB00098
DB09077,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dinutuximab.,Dinutuximab,DB00098
DB09082,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vilanterol.,Vilanterol,DB00098
DB09091,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tixocortol.,Tixocortol,DB00098
DB09122,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00098
DB09312,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00098
DB09378,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednisolone.,Fluprednisolone,DB00098
DB09383,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Meprednisone.,Meprednisone,DB00098
DB11466,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tepoxalin.,Tepoxalin,DB00098
DB11487,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00098
DB11529,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melengestrol.,Melengestrol,DB00098
DB11569,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixekizumab.,Ixekizumab,DB00098
DB11580,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ravulizumab.,Ravulizumab,DB00098
DB11616,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirarubicin.,Pirarubicin,DB00098
DB11693,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Voclosporin.,Voclosporin,DB00098
DB11708,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peficitinib.,Peficitinib,DB00098
DB11750,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clobetasol.,Clobetasol,DB00098
DB11767,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sarilumab.,Sarilumab,DB00098
DB11776,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brodalumab.,Brodalumab,DB00098
DB11803,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirukumab.,Sirukumab,DB00098
DB11817,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Baricitinib.,Baricitinib,DB00098
DB11834,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Guselkumab.,Guselkumab,DB00098
DB11921,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deflazacort.,Deflazacort,DB00098
DB12025,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triptolide.,Triptolide,DB00098
DB12371,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siponimod.,Siponimod,DB00098
DB12612,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanimod.,Ozanimod,DB00098
DB12617,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mizoribine.,Mizoribine,DB00098
DB12692,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gusperimus.,Gusperimus,DB00098
DB12814,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00098
DB12902,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trofosfamide.,Trofosfamide,DB00098
DB12947,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxifluridine.,Doxifluridine,DB00098
DB12991,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deoxyspergualin.,Deoxyspergualin,DB00098
DB12996,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Acteoside.,Acteoside,DB00098
DB13003,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortivazol.,Cortivazol,DB00098
DB13014,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hypericin.,Hypericin,DB00098
DB13068,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00098
DB13208,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednylidene.,Prednylidene,DB00098
DB13223,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortin.,Fluocortin,DB00098
DB13241,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Begelomab.,Begelomab,DB00098
DB13491,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluperolone.,Fluperolone,DB00098
DB13664,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Formocortal.,Formocortal,DB00098
DB13728,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Halometasone.,Halometasone,DB00098
DB13843,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cloprednol.,Cloprednol,DB00098
DB13856,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluclorolone.,Fluclorolone,DB00098
DB13867,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone.,Fluticasone,DB00098
DB14066,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetrandrine.,Tetrandrine,DB00098
DB14219,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00098
DB14512,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone furoate.,Mometasone furoate,DB00098
DB14538,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00098
DB14539,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00098
DB14545,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00098
DB14724,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emapalumab.,Emapalumab,DB00098
DB14762,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Risankizumab.,Risankizumab,DB00098
DB14919,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozanolixizumab.,Rozanolixizumab,DB00098
DB15253,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleselumab.,Bleselumab,DB00098
DB00108,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.,Natalizumab,DB00098
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).,Pimecrolimus,DB00098
DB01656,Roflumilast may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Roflumilast,DB00098
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Sipuleucel-T,DB00098
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antithymocyte immunoglobulin (rabbit).,Sulfamethoxazole,DB00098
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Diethylstilbestrol,DB00098
DB00269,Chlorotrianisene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Chlorotrianisene,DB00098
DB00286,Conjugated estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Conjugated estrogens,DB00098
DB00655,Estrone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estrone,DB00098
DB00783,Estradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol,DB00098
DB00890,Dienestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Dienestrol,DB00098
DB00977,Ethinylestradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Ethinylestradiol,DB00098
DB01357,Mestranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Mestranol,DB00098
DB04573,Estriol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estriol,DB00098
DB04574,Estrone sulfate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estrone sulfate,DB00098
DB04575,Quinestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Quinestrol,DB00098
DB07931,Hexestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Hexestrol,DB00098
DB09070,Tibolone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Tibolone,DB00098
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).","Synthetic Conjugated Estrogens, A",DB00098
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).","Synthetic Conjugated Estrogens, B",DB00098
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Polyestradiol phosphate,DB00098
DB09381,Esterified estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Esterified estrogens,DB00098
DB11478,Zeranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Zeranol,DB00098
DB11674,Equol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Equol,DB00098
DB12487,Promestriene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Promestriene,DB00098
DB13143,Methallenestril may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Methallenestril,DB00098
DB13386,Epimestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Epimestrol,DB00098
DB13418,Moxestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Moxestrol,DB00098
DB13952,Estradiol acetate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol acetate,DB00098
DB13953,Estradiol benzoate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol benzoate,DB00098
DB13954,Estradiol cypionate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol cypionate,DB00098
DB13956,Estradiol valerate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol valerate,DB00098
DB15334,Biochanin A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Biochanin A,DB00098
DB15335,Formononetin may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Formononetin,DB00098
DB01097,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leflunomide.,Leflunomide,DB00098
DB08895,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00098
DB00072,Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).,Trastuzumab,DB00098
DB08868,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00098
DB00864,Tacrolimus may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Tacrolimus,DB00098
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,G17DT,DB00098
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,PEV3A,DB00098
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,INGN 225,DB00098
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Rindopepimut,DB00098
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,SRP 299,DB00098
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,GI-5005,DB00098
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Vitespen,DB00098
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,TG4010,DB00098
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Anthrax immune globulin human,DB00098
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Rabies virus inactivated antigen, B",DB00098
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00098
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Rotavirus vaccine,DB00098
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Rabies virus inactivated antigen, A",DB00098
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00098
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00098
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00098
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00098
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00098
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00098
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Typhoid Vi polysaccharide vaccine,DB00098
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Hepatitis A Vaccine,DB00098
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00098
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00098
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00098
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00098
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00098
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Human rabies virus immune globulin,DB00098
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Hepatitis B Vaccine (Recombinant),DB00098
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Tecemotide,DB00098
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Typhoid vaccine,DB00098
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00098
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00098
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00098
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00098
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00098
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00098
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00098
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Vaccinia virus strain new york city board of health live antigen,DB00098
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Pertussis vaccine,DB00098
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00098
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Varicella Zoster Vaccine (Recombinant),DB00098
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Modified vaccinia ankara,DB00098
DB11988,Ocrelizumab may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Ocrelizumab,DB00098
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Rubella virus vaccine,DB00098
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Antithymocyte immunoglobulin (rabbit).,Varicella Zoster Vaccine (Live/attenuated),DB00098
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain tice live antigen,DB00098
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain connaught live antigen,DB00098
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Yellow Fever Vaccine,DB00098
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Anthrax vaccine,DB00098
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Antithymocyte immunoglobulin (rabbit).,Typhoid Vaccine Live,DB00098
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00098
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Antithymocyte immunoglobulin (rabbit).,BCG vaccine,DB00098
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Antithymocyte immunoglobulin (rabbit).,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00098
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Vibrio cholerae CVD 103-HgR strain live antigen,DB00098
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Antithymocyte immunoglobulin (rabbit).,Adenovirus type 7 vaccine live,DB00098
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).,Cetuximab,DB00098
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).,Human immunoglobulin G,DB00098
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Omalizumab,DB00098
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Antithymocyte immunoglobulin (rabbit).,Abciximab,DB00098
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Indium In-111 satumomab pendetide,DB00098
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).,Digoxin Immune Fab (Ovine),DB00098
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Capromab pendetide,DB00098
DB00110,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.,Palivizumab,DB00098
DB00113,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00098
DB01269,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panitumumab.,Panitumumab,DB00098
DB01270,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ranibizumab.,Ranibizumab,DB00098
DB04901,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galiximab.,Galiximab,DB00098
DB04949,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pexelizumab.,Pexelizumab,DB00098
DB04958,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epratuzumab.,Epratuzumab,DB00098
DB04962,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bectumomab.,Bectumomab,DB00098
DB04964,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.,Oregovomab,DB00098
DB04988,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IGN311.,IGN311,DB00098
DB05006,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Adecatumumab.,Adecatumumab,DB00098
DB05097,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab.,Labetuzumab,DB00098
DB05101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Matuzumab.,Matuzumab,DB00098
DB05111,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fontolizumab.,Fontolizumab,DB00098
DB05136,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bavituximab.,Bavituximab,DB00098
DB05139,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CR002.,CR002,DB00098
DB05209,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozrolimupab.,Rozrolimupab,DB00098
DB05304,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Girentuximab.,Girentuximab,DB00098
DB05336,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab.,Obiltoxaximab,DB00098
DB05405,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XTL-001.,XTL-001,DB00098
DB05437,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with NAV 1800.,NAV 1800,DB00098
DB05496,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Otelixizumab.,Otelixizumab,DB00098
DB05545,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AMG 108.,AMG 108,DB00098
DB05550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Iratumumab.,Iratumumab,DB00098
DB05555,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Enokizumab.,Enokizumab,DB00098
DB05578,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ramucirumab.,Ramucirumab,DB00098
DB05595,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Farletuzumab.,Farletuzumab,DB00098
DB05656,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Veltuzumab.,Veltuzumab,DB00098
DB05793,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with PRO-542.,PRO-542,DB00098
DB05797,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TNX-901.,TNX-901,DB00098
DB05889,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00098
DB05892,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with RI 624.,RI 624,DB00098
DB05915,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with MYO-029.,MYO-029,DB00098
DB05916,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CT-011.,CT-011,DB00098
DB05941,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leronlimab.,Leronlimab,DB00098
DB05996,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00098
DB06043,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaratumab.,Olaratumab,DB00098
DB06049,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IPH 2101.,IPH 2101,DB00098
DB06050,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TB-402.,TB-402,DB00098
DB06081,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab.,Caplacizumab,DB00098
DB06101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IMC-1C11.,IMC-1C11,DB00098
DB06116,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eldelumab.,Eldelumab,DB00098
DB06162,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumiliximab.,Lumiliximab,DB00098
DB06186,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipilimumab.,Ipilimumab,DB00098
DB06192,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nimotuzumab.,Nimotuzumab,DB00098
DB06241,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clenoliximab.,Clenoliximab,DB00098
DB06304,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with BIIB015.,BIIB015,DB00098
DB06305,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sonepcizumab.,Sonepcizumab,DB00098
DB06310,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Motavizumab.,Motavizumab,DB00098
DB06317,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Elotuzumab.,Elotuzumab,DB00098
DB06318,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AVE9633.,AVE9633,DB00098
DB06322,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carotuximab.,Carotuximab,DB00098
DB06324,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XmAb 2513.,XmAb 2513,DB00098
DB06342,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00098
DB06343,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teprotumumab.,Teprotumumab,DB00098
DB06360,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lucatumumab.,Lucatumumab,DB00098
DB06366,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pertuzumab.,Pertuzumab,DB00098
DB06371,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siplizumab.,Siplizumab,DB00098
DB06467,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apolizumab.,Apolizumab,DB00098
DB06474,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sibrotuzumab.,Sibrotuzumab,DB00098
DB06550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bivatuzumab.,Bivatuzumab,DB00098
DB06557,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lerdelimumab.,Lerdelimumab,DB00098
DB06599,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lexatumumab.,Lexatumumab,DB00098
DB06602,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Reslizumab.,Reslizumab,DB00098
DB06606,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teplizumab.,Teplizumab,DB00098
DB06607,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Catumaxomab.,Catumaxomab,DB00098
DB06647,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Volociximab.,Volociximab,DB00098
DB06650,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ofatumumab.,Ofatumumab,DB00098
DB08902,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raxibacumab.,Raxibacumab,DB00098
DB09035,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nivolumab.,Nivolumab,DB00098
DB09037,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pembrolizumab.,Pembrolizumab,DB00098
DB09045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dulaglutide.,Dulaglutide,DB00098
DB09105,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asfotase alfa.,Asfotase alfa,DB00098
DB09264,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarucizumab.,Idarucizumab,DB00098
DB09302,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Alirocumab.,Alirocumab,DB00098
DB09303,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evolocumab.,Evolocumab,DB00098
DB09331,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daratumumab.,Daratumumab,DB00098
DB09559,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Necitumumab.,Necitumumab,DB00098
DB11595,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Atezolizumab.,Atezolizumab,DB00098
DB11604,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00098
DB11608,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00098
DB11621,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00098
DB11646,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Conatumumab.,Conatumumab,DB00098
DB11657,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tabalumab.,Tabalumab,DB00098
DB11680,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ficlatuzumab.,Ficlatuzumab,DB00098
DB11685,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Figitumumab.,Figitumumab,DB00098
DB11714,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Durvalumab.,Durvalumab,DB00098
DB11715,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bapineuzumab.,Bapineuzumab,DB00098
DB11731,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00098
DB11746,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Onartuzumab.,Onartuzumab,DB00098
DB11756,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Solanezumab.,Solanezumab,DB00098
DB11771,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tremelimumab.,Tremelimumab,DB00098
DB11826,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lampalizumab.,Lampalizumab,DB00098
DB11840,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalotuzumab.,Dalotuzumab,DB00098
DB11849,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emibetuzumab.,Emibetuzumab,DB00098
DB11850,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ublituximab.,Ublituximab,DB00098
DB11856,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ligelizumab.,Ligelizumab,DB00098
DB11857,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Seribantumab.,Seribantumab,DB00098
DB11862,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Landogrozumab.,Landogrozumab,DB00098
DB11866,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Romosozumab.,Romosozumab,DB00098
DB11884,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00098
DB11914,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lebrikizumab.,Lebrikizumab,DB00098
DB11930,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Varlilumab.,Varlilumab,DB00098
DB11945,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Avelumab.,Avelumab,DB00098
DB11959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crenezumab.,Crenezumab,DB00098
DB11972,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilotumumab.,Rilotumumab,DB00098
DB11976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anifrolumab.,Anifrolumab,DB00098
DB12023,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Benralizumab.,Benralizumab,DB00098
DB12034,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gantenerumab.,Gantenerumab,DB00098
DB12053,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Visilizumab.,Visilizumab,DB00098
DB12077,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab.,Urelumab,DB00098
DB12089,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00098
DB12090,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Patritumab.,Patritumab,DB00098
DB12102,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fulranumab.,Fulranumab,DB00098
DB12104,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tarextumab.,Tarextumab,DB00098
DB12118,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sotatercept.,Sotatercept,DB00098
DB12119,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gevokizumab.,Gevokizumab,DB00098
DB12142,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Duligotuzumab.,Duligotuzumab,DB00098
DB12152,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Simtuzumab.,Simtuzumab,DB00098
DB12157,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fasinumab.,Fasinumab,DB00098
DB12159,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dupilumab.,Dupilumab,DB00098
DB12169,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tralokinumab.,Tralokinumab,DB00098
DB12189,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etrolizumab.,Etrolizumab,DB00098
DB12202,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zalutumumab.,Zalutumumab,DB00098
DB12205,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ganitumab.,Ganitumab,DB00098
DB12213,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etaracizumab.,Etaracizumab,DB00098
DB12240,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00098
DB12246,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inclacumab.,Inclacumab,DB00098
DB12250,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cixutumumab.,Cixutumumab,DB00098
DB12261,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ascrinvacumab.,Ascrinvacumab,DB00098
DB12274,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aducanumab.,Aducanumab,DB00098
DB12281,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Luspatercept.,Luspatercept,DB00098
DB12296,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GS-5745.,GS-5745,DB00098
DB12317,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vanucizumab.,Vanucizumab,DB00098
DB12331,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00098
DB12335,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tanezumab.,Tanezumab,DB00098
DB12342,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ensituximab.,Ensituximab,DB00098
DB12344,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fezakinumab.,Fezakinumab,DB00098
DB12363,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dusigitumab.,Dusigitumab,DB00098
DB12396,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fresolimumab.,Fresolimumab,DB00098
DB12413,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00098
DB12456,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bococizumab.,Bococizumab,DB00098
DB12489,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00098
DB12498,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mogamulizumab.,Mogamulizumab,DB00098
DB12520,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Plozalizumab.,Plozalizumab,DB00098
DB12534,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mavrilimumab.,Mavrilimumab,DB00098
DB12560,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blosozumab.,Blosozumab,DB00098
DB12584,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimagrumab.,Bimagrumab,DB00098
DB12589,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacetuzumab.,Dacetuzumab,DB00098
DB12609,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tovetumab.,Tovetumab,DB00098
DB12683,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumretuzumab.,Lumretuzumab,DB00098
DB12698,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibalizumab.,Ibalizumab,DB00098
DB12701,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Intetumumab.,Intetumumab,DB00098
DB12718,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carlumab.,Carlumab,DB00098
DB12734,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Demcizumab.,Demcizumab,DB00098
DB12773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sifalimumab.,Sifalimumab,DB00098
DB12775,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abituzumab.,Abituzumab,DB00098
DB12797,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ecromeximab.,Ecromeximab,DB00098
DB12807,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00098
DB12815,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crotedumab.,Crotedumab,DB00098
DB12820,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Concizumab.,Concizumab,DB00098
DB12826,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab.,Depatuxizumab,DB00098
DB12844,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rontalizumab.,Rontalizumab,DB00098
DB12845,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amatuximab.,Amatuximab,DB00098
DB12849,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clazakizumab.,Clazakizumab,DB00098
DB12891,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanezumab.,Ozanezumab,DB00098
DB12893,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00098
DB12917,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimekizumab.,Bimekizumab,DB00098
DB12943,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Milatuzumab.,Milatuzumab,DB00098
DB12976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Robatumumab.,Robatumumab,DB00098
DB13017,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00098
DB13037,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Namilumab.,Namilumab,DB00098
DB13045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Racotumomab.,Racotumomab,DB00098
DB13073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tregalizumab.,Tregalizumab,DB00098
DB13127,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olokizumab.,Olokizumab,DB00098
DB13140,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bezlotoxumab.,Bezlotoxumab,DB00098
DB13375,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Edrecolomab.,Edrecolomab,DB00098
DB13535,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nebacumab.,Nebacumab,DB00098
DB13886,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00098
DB13923,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emicizumab.,Emicizumab,DB00098
DB13976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulesomab.,Sulesomab,DB00098
DB13979,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Besilesomab.,Besilesomab,DB00098
DB14012,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Burosumab.,Burosumab,DB00098
DB14039,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Erenumab.,Erenumab,DB00098
DB14040,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.,Eptinezumab,DB00098
DB14041,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fremanezumab.,Fremanezumab,DB00098
DB14042,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.,Galcanezumab,DB00098
DB14211,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fanolesomab.,Fanolesomab,DB00098
DB14580,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lecanemab.,Lecanemab,DB00098
DB14597,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lanadelumab.,Lanadelumab,DB00098
DB14707,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cemiplimab.,Cemiplimab,DB00098
DB14776,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Camrelizumab.,Camrelizumab,DB00098
DB14778,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Setrusumab.,Setrusumab,DB00098
DB14784,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gancotamab.,Gancotamab,DB00098
DB14809,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00098
DB14811,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Isatuximab.,Isatuximab,DB00098
DB14824,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Icrucumab.,Icrucumab,DB00098
DB14843,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Codrituzumab.,Codrituzumab,DB00098
DB14864,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brolucizumab.,Brolucizumab,DB00098
DB14871,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Xentuzumab.,Xentuzumab,DB00098
DB14877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lintuzumab.,Lintuzumab,DB00098
DB14891,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vobarilizumab.,Vobarilizumab,DB00098
DB14897,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Parsatuzumab.,Parsatuzumab,DB00098
DB14905,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emactuzumab.,Emactuzumab,DB00098
DB14907,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00098
DB14908,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Refanezumab.,Refanezumab,DB00098
DB14947,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bermekimab.,Bermekimab,DB00098
DB14952,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pamrevlumab.,Pamrevlumab,DB00098
DB14959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Opicinumab.,Opicinumab,DB00098
DB14962,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00098
DB14967,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Margetuximab.,Margetuximab,DB00098
DB14988,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalantercept.,Dalantercept,DB00098
DB14997,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pateclizumab.,Pateclizumab,DB00098
DB15014,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gremubamab.,Gremubamab,DB00098
DB15022,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apomab.,Apomab,DB00098
DB15044,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tafasitamab.,Tafasitamab,DB00098
DB15045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipafricept.,Ipafricept,DB00098
DB15076,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abrilumab.,Abrilumab,DB00098
DB15089,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Frovocimab.,Frovocimab,DB00098
DB15090,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tezepelumab.,Tezepelumab,DB00098
DB15101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tigatuzumab.,Tigatuzumab,DB00098
DB15104,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00098
DB15113,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Utomilumab.,Utomilumab,DB00098
DB15118,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zolbetuximab.,Zolbetuximab,DB00098
DB15135,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponezumab.,Ponezumab,DB00098
DB15160,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept.,Asunercept,DB00098
DB15172,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Suvratoxumab.,Suvratoxumab,DB00098
DB15225,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitazalimab.,Mitazalimab,DB00098
DB15252,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nemolizumab.,Nemolizumab,DB00098
DB15277,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gedivumab.,Gedivumab,DB00098
DB15336,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Valanafusp alfa.,Valanafusp alfa,DB00098
DB15349,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00098
DB15354,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evinacumab.,Evinacumab,DB00098
DB15363,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Istiratumab.,Istiratumab,DB00098
DB15383,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pidilizumab.,Pidilizumab,DB00098
DB15397,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GMA-161.,GMA-161,DB00098
DB15409,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00098
DB15415,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tomaralimab.,Tomaralimab,DB00098
DB15428,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vesencumab.,Vesencumab,DB00098
DB15432,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00098
DB15441,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lulizumab pegol.,Lulizumab pegol,DB00098
DB15443,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00098
DB15453,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00098
DB14004,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tildrakizumab.,Tildrakizumab,DB00098
DB05679,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ustekinumab.,Ustekinumab,DB00098
DB15559,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zenocutuzumab.,Zenocutuzumab,DB00098
DB00091,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00098
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Ebola Zaire vaccine (live, attenuated)",DB00098
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Antithymocyte immunoglobulin (rabbit).,Magnesium,DB00098
DB01601,The serum concentration of Antithymocyte immunoglobulin (rabbit) can be increased when it is combined with Lopinavir.,Lopinavir,DB00098
DB12530,The risk or severity of infection can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inebilizumab.,Inebilizumab,DB00098
DB00290,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin.,Bleomycin,DB00099
DB00531,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide.,Cyclophosphamide,DB00099
DB01030,The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan.,Topotecan,DB00099
DB00309,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vindesine.,Vindesine,DB00099
DB00361,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinorelbine.,Vinorelbine,DB00099
DB00541,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine.,Vincristine,DB00099
DB00570,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine.,Vinblastine,DB00099
DB05168,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide.,Vintafolide,DB00099
DB11641,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinflunine.,Vinflunine,DB00099
DB13374,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincamine.,Vincamine,DB00099
DB00513,The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation Factor IX (Recombinant).,Aminocaproic acid,DB00100
DB00058,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Alpha-1-proteinase inhibitor,DB00100
DB00170,Menadione may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Menadione,DB00100
DB00302,Tranexamic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Tranexamic acid,DB00100
DB06692,Aprotinin may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Aprotinin,DB00100
DB11091,Hydrogen peroxide may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Hydrogen peroxide,DB00100
DB13244,Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Aminomethylbenzoic acid,DB00100
DB13729,Camostat may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Camostat,DB00100
DB12726,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Monteplase.,Monteplase,DB00100
DB00001,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.,Lepirudin,DB00100
DB00006,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bivalirudin.,Bivalirudin,DB00100
DB00009,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Alteplase.,Alteplase,DB00100
DB00013,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Urokinase.,Urokinase,DB00100
DB00015,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.,Reteplase,DB00100
DB00029,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Anistreplase.,Anistreplase,DB00100
DB00031,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tenecteplase.,Tenecteplase,DB00100
DB00054,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Abciximab.,Abciximab,DB00100
DB00055,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.,Drotrecogin alfa,DB00100
DB00086,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.,Streptokinase,DB00100
DB00266,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dicoumarol.,Dicoumarol,DB00100
DB00278,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Argatroban.,Argatroban,DB00100
DB00407,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ardeparin.,Ardeparin,DB00100
DB00498,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenindione.,Phenindione,DB00100
DB00569,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fondaparinux.,Fondaparinux,DB00100
DB00682,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Warfarin.,Warfarin,DB00100
DB00686,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Pentosan polysulfate.,Pentosan polysulfate,DB00100
DB00945,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acetylsalicylic acid.,Acetylsalicylic acid,DB00100
DB00946,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenprocoumon.,Phenprocoumon,DB00100
DB00975,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dipyridamole.,Dipyridamole,DB00100
DB01088,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Iloprost.,Iloprost,DB00100
DB01109,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Heparin.,Heparin,DB00100
DB01225,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Enoxaparin.,Enoxaparin,DB00100
DB01240,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Epoprostenol.,Epoprostenol,DB00100
DB01418,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acenocoumarol.,Acenocoumarol,DB00100
DB03410,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with 4-hydroxycoumarin.,4-hydroxycoumarin,DB00100
DB04665,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Coumarin.,Coumarin,DB00100
DB04898,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ximelagatran.,Ximelagatran,DB00100
DB04925,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desmoteplase.,Desmoteplase,DB00100
DB04932,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Defibrotide.,Defibrotide,DB00100
DB05099,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ancrod.,Ancrod,DB00100
DB05229,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Beraprost.,Beraprost,DB00100
DB05254,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fibrinolysin.,Fibrinolysin,DB00100
DB06209,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Prasugrel.,Prasugrel,DB00100
DB06228,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Rivaroxaban.,Rivaroxaban,DB00100
DB06271,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sulodexide.,Sulodexide,DB00100
DB06406,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Idraparinux.,Idraparinux,DB00100
DB06441,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Cangrelor.,Cangrelor,DB00100
DB06543,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Astaxanthin.,Astaxanthin,DB00100
DB06605,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Apixaban.,Apixaban,DB00100
DB06635,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Otamixaban.,Otamixaban,DB00100
DB06679,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Amediplase.,Amediplase,DB00100
DB06695,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran etexilate.,Dabigatran etexilate,DB00100
DB06754,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Danaparoid.,Danaparoid,DB00100
DB06779,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dalteparin.,Dalteparin,DB00100
DB06822,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tinzaparin.,Tinzaparin,DB00100
DB07767,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ferulic acid.,Ferulic acid,DB00100
DB08496,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (R)-warfarin.,(R)-warfarin,DB00100
DB08794,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ethyl biscoumacetate.,Ethyl biscoumacetate,DB00100
DB08813,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nadroparin.,Nadroparin,DB00100
DB08814,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Triflusal.,Triflusal,DB00100
DB08816,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ticagrelor.,Ticagrelor,DB00100
DB08994,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ditazole.,Ditazole,DB00100
DB09030,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Vorapaxar.,Vorapaxar,DB00100
DB09075,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edoxaban.,Edoxaban,DB00100
DB09125,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Potassium citrate.,Potassium citrate,DB00100
DB09154,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sodium citrate.,Sodium citrate,DB00100
DB09255,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dextran.,Dextran,DB00100
DB09258,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bemiparin.,Bemiparin,DB00100
DB09259,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reviparin.,Reviparin,DB00100
DB09260,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Parnaparin.,Parnaparin,DB00100
DB09261,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Certoparin.,Certoparin,DB00100
DB11095,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desirudin.,Desirudin,DB00100
DB11154,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Zinc citrate.,Zinc citrate,DB00100
DB11166,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin Alfa.,Antithrombin Alfa,DB00100
DB11312,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein C.,Protein C,DB00100
DB11598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin III human.,Antithrombin III human,DB00100
DB11984,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Letaxaban.,Letaxaban,DB00100
DB12289,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Darexaban.,Darexaban,DB00100
DB12364,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Betrixaban.,Betrixaban,DB00100
DB12598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nafamostat.,Nafamostat,DB00100
DB12831,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Gabexate.,Gabexate,DB00100
DB13136,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fluindione.,Fluindione,DB00100
DB13149,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein S human.,Protein S human,DB00100
DB13199,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Brinase.,Brinase,DB00100
DB13275,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Clorindione.,Clorindione,DB00100
DB13347,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Diphenadione.,Diphenadione,DB00100
DB13451,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tioclomarol.,Tioclomarol,DB00100
DB13616,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Melagatran.,Melagatran,DB00100
DB13646,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Saruplase.,Saruplase,DB00100
DB14055,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (S)-Warfarin.,(S)-Warfarin,DB00100
DB14094,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tocopherylquinone.,Tocopherylquinone,DB00100
DB14598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous,DB00100
DB14726,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran.,Dabigatran,DB00100
DB06294,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Semuloparin.,Semuloparin,DB00100
DB00608,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.,Chloroquine,DB00103
DB00798,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.,Gentamicin,DB00103
DB01118,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.,Amiodarone,DB00103
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.,Darbepoetin alfa,DB00104
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Octreotide.,Erythropoietin,DB00104
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Octreotide.,Peginesatide,DB00104
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.,Methoxy polyethylene glycol-epoetin beta,DB00104
DB08827,The metabolism of Octreotide can be decreased when combined with Lomitapide.,Lomitapide,DB00104
DB01200,The serum concentration of Bromocriptine can be increased when it is combined with Octreotide.,Bromocriptine,DB00104
DB09063,Octreotide may increase the bradycardic activities of Ceritinib.,Ceritinib,DB00104
DB09083,Octreotide may increase the bradycardic activities of Ivabradine.,Ivabradine,DB00104
DB00082,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.,Pegvisomant,DB00104
DB08877,Ruxolitinib may increase the bradycardic activities of Octreotide.,Ruxolitinib,DB00104
DB09039,The metabolism of Eliglustat can be decreased when combined with Octreotide.,Eliglustat,DB00104
DB09053,The metabolism of Ibrutinib can be decreased when combined with Octreotide.,Ibrutinib,DB00104
DB01166,The metabolism of Cilostazol can be decreased when combined with Octreotide.,Cilostazol,DB00104
DB01394,The metabolism of Colchicine can be decreased when combined with Octreotide.,Colchicine,DB00104
DB00813,The metabolism of Fentanyl can be decreased when combined with Octreotide.,Fentanyl,DB00104
DB04946,The metabolism of Iloperidone can be decreased when combined with Octreotide.,Iloperidone,DB00104
DB01256,The metabolism of Retapamulin can be decreased when combined with Octreotide.,Retapamulin,DB00104
DB08895,The metabolism of Tofacitinib can be decreased when combined with Octreotide.,Tofacitinib,DB00104
DB00862,The metabolism of Vardenafil can be decreased when combined with Octreotide.,Vardenafil,DB00104
DB00402,The metabolism of Eszopiclone can be decreased when combined with Octreotide.,Eszopiclone,DB00104
DB01198,The metabolism of Zopiclone can be decreased when combined with Octreotide.,Zopiclone,DB00104
DB00227,The metabolism of Lovastatin can be decreased when combined with Octreotide.,Lovastatin,DB00104
DB00346,The metabolism of Alfuzosin can be decreased when combined with Octreotide.,Alfuzosin,DB00104
DB00404,The metabolism of Alprazolam can be decreased when combined with Octreotide.,Alprazolam,DB00104
DB00682,The serum concentration of Warfarin can be increased when it is combined with Octreotide.,Warfarin,DB00104
DB01418,The serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.,Acenocoumarol,DB00104
DB08496,The serum concentration of (R)-warfarin can be increased when it is combined with Octreotide.,(R)-warfarin,DB00104
DB08735,"The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Octreotide.","R,S-Warfarin alcohol",DB00104
DB08736,"The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Octreotide.","S,R-Warfarin alcohol",DB00104
DB14055,The serum concentration of (S)-Warfarin can be increased when it is combined with Octreotide.,(S)-Warfarin,DB00104
DB00683,The serum concentration of Midazolam can be increased when it is combined with Octreotide.,Midazolam,DB00104
DB00864,The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.,Tacrolimus,DB00104
DB01076,The metabolism of Atorvastatin can be decreased when combined with Octreotide.,Atorvastatin,DB00104
DB00091,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.,Cyclosporine,DB00104
DB00030,The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.,Insulin human,DB00104
DB00046,The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Octreotide.,Insulin lispro,DB00104
DB00047,The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Octreotide.,Insulin glargine,DB00104
DB00071,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.,Insulin pork,DB00104
DB00197,The therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.,Troglitazone,DB00104
DB00222,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Octreotide.,Glimepiride,DB00104
DB00284,The therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.,Acarbose,DB00104
DB00359,The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Octreotide.,Sulfadiazine,DB00104
DB00412,The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.,Rosiglitazone,DB00104
DB00414,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.,Acetohexamide,DB00104
DB00491,The therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.,Miglitol,DB00104
DB00672,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Octreotide.,Chlorpropamide,DB00104
DB00731,The therapeutic efficacy of Nateglinide can be decreased when used in combination with Octreotide.,Nateglinide,DB00104
DB00839,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Octreotide.,Tolazamide,DB00104
DB00912,The therapeutic efficacy of Repaglinide can be decreased when used in combination with Octreotide.,Repaglinide,DB00104
DB00914,The therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.,Phenformin,DB00104
DB01015,The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Octreotide.,Sulfamethoxazole,DB00104
DB01067,The therapeutic efficacy of Glipizide can be decreased when used in combination with Octreotide.,Glipizide,DB00104
DB01120,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Octreotide.,Gliclazide,DB00104
DB01124,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Octreotide.,Tolbutamide,DB00104
DB01132,The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.,Pioglitazone,DB00104
DB01251,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.,Gliquidone,DB00104
DB01252,The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Octreotide.,Mitiglinide,DB00104
DB01261,The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.,Sitagliptin,DB00104
DB01276,The therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.,Exenatide,DB00104
DB01277,The therapeutic efficacy of Mecasermin can be decreased when used in combination with Octreotide.,Mecasermin,DB00104
DB01278,The therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.,Pramlintide,DB00104
DB01289,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Octreotide.,Glisoxepide,DB00104
DB01306,The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Octreotide.,Insulin aspart,DB00104
DB01307,The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Octreotide.,Insulin detemir,DB00104
DB01309,The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Octreotide.,Insulin glulisine,DB00104
DB01382,The therapeutic efficacy of Glymidine can be decreased when used in combination with Octreotide.,Glymidine,DB00104
DB01700,The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Octreotide.,AICA ribonucleotide,DB00104
DB04830,The therapeutic efficacy of Buformin can be decreased when used in combination with Octreotide.,Buformin,DB00104
DB04876,The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.,Vildagliptin,DB00104
DB04878,The therapeutic efficacy of Voglibose can be decreased when used in combination with Octreotide.,Voglibose,DB00104
DB05115,The therapeutic efficacy of NN344 can be decreased when used in combination with Octreotide.,NN344,DB00104
DB05819,The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Octreotide.,NBI-6024,DB00104
DB06011,The therapeutic efficacy of AMG-222 can be decreased when used in combination with Octreotide.,AMG-222,DB00104
DB06127,The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Octreotide.,Bisegliptin,DB00104
DB06203,The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.,Alogliptin,DB00104
DB06292,The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.,Dapagliflozin,DB00104
DB06335,The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.,Saxagliptin,DB00104
DB06655,The therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.,Liraglutide,DB00104
DB08382,The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Octreotide.,Gosogliptin,DB00104
DB08962,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.,Glibornuride,DB00104
DB09022,The therapeutic efficacy of Benfluorex can be decreased when used in combination with Octreotide.,Benfluorex,DB00104
DB09038,The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.,Empagliflozin,DB00104
DB09043,The therapeutic efficacy of Albiglutide can be decreased when used in combination with Octreotide.,Albiglutide,DB00104
DB09045,The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.,Dulaglutide,DB00104
DB09198,The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Octreotide.,Lobeglitazone,DB00104
DB09199,The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Octreotide.,Netoglitazone,DB00104
DB09200,The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Octreotide.,Rivoglitazone,DB00104
DB09201,The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.,Ciglitazone,DB00104
DB09265,The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Octreotide.,Lixisenatide,DB00104
DB09456,The therapeutic efficacy of Insulin beef can be decreased when used in combination with Octreotide.,Insulin beef,DB00104
DB09564,The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Octreotide.,Insulin degludec,DB00104
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Octreotide.,Insulin peglispro,DB00104
DB11568,The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Octreotide.,Insulin tregopil,DB00104
DB11698,The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Octreotide.,Ipragliflozin,DB00104
DB11723,The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Octreotide.,Dutogliptin,DB00104
DB11780,The therapeutic efficacy of Allicin can be decreased when used in combination with Octreotide.,Allicin,DB00104
DB11824,The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Octreotide.,Tofogliflozin,DB00104
DB11898,"The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Octreotide.","2,4-thiazolidinedione",DB00104
DB11950,The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Octreotide.,Teneligliptin,DB00104
DB11992,The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Octreotide.,Omarigliptin,DB00104
DB12268,The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Octreotide.,Carmegliptin,DB00104
DB12412,The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Octreotide.,Gemigliptin,DB00104
DB12417,The therapeutic efficacy of Anagliptin can be decreased when used in combination with Octreotide.,Anagliptin,DB00104
DB12625,The therapeutic efficacy of Evogliptin can be decreased when used in combination with Octreotide.,Evogliptin,DB00104
DB12713,The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Octreotide.,Sotagliflozin,DB00104
DB12781,The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Octreotide.,Balaglitazone,DB00104
DB12935,The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Octreotide.,Remogliflozin etabonate,DB00104
DB13406,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Octreotide.,Carbutamide,DB00104
DB13446,The therapeutic efficacy of Guar gum can be decreased when used in combination with Octreotide.,Guar gum,DB00104
DB13675,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Octreotide.,Metahexamide,DB00104
DB13928,The therapeutic efficacy of Semaglutide can be decreased when used in combination with Octreotide.,Semaglutide,DB00104
DB14027,The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Octreotide.,Taspoglutide,DB00104
DB14035,The therapeutic efficacy of Englitazone can be decreased when used in combination with Octreotide.,Englitazone,DB00104
DB15171,The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Octreotide.,Tirzepatide,DB00104
DB15217,The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Octreotide.,Gastric inhibitory polypeptide,DB00104
DB08882,The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.,Linagliptin,DB00104
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Octreotide.,Glyburide,DB00104
DB08907,The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.,Canagliflozin,DB00104
DB11827,The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Octreotide.,Ertugliflozin,DB00104
DB00007,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.,Leuprolide,DB00104
DB00014,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.,Goserelin,DB00104
DB00195,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Betaxolol.,Betaxolol,DB00104
DB00218,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.,Moxifloxacin,DB00104
DB00263,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulfisoxazole.,Sulfisoxazole,DB00104
DB00391,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulpiride.,Sulpiride,DB00104
DB00420,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promazine.,Promazine,DB00104
DB00433,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prochlorperazine.,Prochlorperazine,DB00104
DB00450,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Droperidol.,Droperidol,DB00104
DB00526,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.,Oxaliplatin,DB00104
DB00537,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.,Ciprofloxacin,DB00104
DB00544,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil.,Fluorouracil,DB00104
DB00556,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perflutren.,Perflutren,DB00104
DB00568,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinnarizine.,Cinnarizine,DB00104
DB00571,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propranolol.,Propranolol,DB00104
DB00572,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atropine.,Atropine,DB00104
DB00625,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efavirenz.,Efavirenz,DB00104
DB00640,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Adenosine.,Adenosine,DB00104
DB00738,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pentamidine.,Pentamidine,DB00104
DB00743,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gadobenic acid.,Gadobenic acid,DB00104
DB00748,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Carbinoxamine.,Carbinoxamine,DB00104
DB00757,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dolasetron.,Dolasetron,DB00104
DB00778,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Roxithromycin.,Roxithromycin,DB00104
DB00779,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nalidixic acid.,Nalidixic acid,DB00104
DB00827,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinoxacin.,Cinoxacin,DB00104
DB00889,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Granisetron.,Granisetron,DB00104
DB00904,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ondansetron.,Ondansetron,DB00104
DB00922,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levosimendan.,Levosimendan,DB00104
DB00933,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mesoridazine.,Mesoridazine,DB00104
DB00967,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desloratadine.,Desloratadine,DB00104
DB00976,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telithromycin.,Telithromycin,DB00104
DB00978,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lomefloxacin.,Lomefloxacin,DB00104
DB00985,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dimenhydrinate.,Dimenhydrinate,DB00104
DB01113,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.,Papaverine,DB00104
DB01114,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpheniramine.,Chlorpheniramine,DB00104
DB01115,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nifedipine.,Nifedipine,DB00104
DB01155,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gemifloxacin.,Gemifloxacin,DB00104
DB01165,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ofloxacin.,Ofloxacin,DB00104
DB01193,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acebutolol.,Acebutolol,DB00104
DB01195,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flecainide.,Flecainide,DB00104
DB01580,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxprenolol.,Oxprenolol,DB00104
DB01599,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Probucol.,Probucol,DB00104
DB01615,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aceprometazine.,Aceprometazine,DB00104
DB02638,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terlipressin.,Terlipressin,DB00104
DB04825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prenylamine.,Prenylamine,DB00104
DB04842,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluspirilene.,Fluspirilene,DB00104
DB04948,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lofexidine.,Lofexidine,DB00104
DB04957,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azimilide.,Azimilide,DB00104
DB05223,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pracinostat.,Pracinostat,DB00104
DB05488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin,DB00104
DB06160,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Garenoxacin.,Garenoxacin,DB00104
DB06200,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tedisamil.,Tedisamil,DB00104
DB06334,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tucidinostat.,Tucidinostat,DB00104
DB06402,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telavancin.,Telavancin,DB00104
DB06600,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nemonoxacin.,Nemonoxacin,DB00104
DB06712,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nilvadipine.,Nilvadipine,DB00104
DB08799,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Antazoline.,Antazoline,DB00104
DB08903,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bedaquiline.,Bedaquiline,DB00104
DB08952,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indenolol.,Indenolol,DB00104
DB08980,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fendiline.,Fendiline,DB00104
DB08992,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eperisone.,Eperisone,DB00104
DB09016,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Butriptyline.,Butriptyline,DB00104
DB09078,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lenvatinib.,Lenvatinib,DB00104
DB09224,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Melperone.,Melperone,DB00104
DB09231,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benidipine.,Benidipine,DB00104
DB09555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate,DB00104
DB11640,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amifampridine.,Amifampridine,DB00104
DB11830,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mocetinostat.,Mocetinostat,DB00104
DB11841,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entinostat.,Entinostat,DB00104
DB12141,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gilteritinib.,Gilteritinib,DB00104
DB12174,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-101.,CUDC-101,DB00104
DB12286,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Simendan.,Simendan,DB00104
DB12376,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ricolinostat.,Ricolinostat,DB00104
DB12523,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mizolastine.,Mizolastine,DB00104
DB12565,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Abexinostat.,Abexinostat,DB00104
DB12877,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxatomide.,Oxatomide,DB00104
DB13261,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sitafloxacin.,Sitafloxacin,DB00104
DB13273,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sultopride.,Sultopride,DB00104
DB13500,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Otilonium.,Otilonium,DB00104
DB13546,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nizofenone.,Nizofenone,DB00104
DB13652,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bunaftine.,Bunaftine,DB00104
DB13653,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorcainide.,Lorcainide,DB00104
DB13679,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine.,Dexchlorpheniramine,DB00104
DB13791,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Penfluridol.,Penfluridol,DB00104
DB00207,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azithromycin.,Azithromycin,DB00104
DB00477,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpromazine.,Chlorpromazine,DB00104
DB00199,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Erythromycin.,Erythromycin,DB00104
DB00243,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ranolazine.,Ranolazine,DB00104
DB00321,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amitriptyline.,Amitriptyline,DB00104
DB00333,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methadone.,Methadone,DB00104
DB00343,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diltiazem.,Diltiazem,DB00104
DB00393,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nimodipine.,Nimodipine,DB00104
DB00458,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.,Imipramine,DB00104
DB00608,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chloroquine.,Chloroquine,DB00104
DB00836,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Loperamide.,Loperamide,DB00104
DB01087,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Primaquine.,Primaquine,DB00104
DB01137,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.,Levofloxacin,DB00104
DB01182,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propafenone.,Propafenone,DB00104
DB01211,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clarithromycin.,Clarithromycin,DB00104
DB01224,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quetiapine.,Quetiapine,DB00104
DB01388,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mibefradil.,Mibefradil,DB00104
DB14063,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexverapamil.,Dexverapamil,DB00104
DB01227,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levacetylmethadol.,Levacetylmethadol,DB00104
DB01232,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Saquinavir.,Saquinavir,DB00104
DB01242,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clomipramine.,Clomipramine,DB00104
DB00166,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Lipoic acid.,Lipoic acid,DB00104
DB04884,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Dapoxetine.,Dapoxetine,DB00104
DB04896,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Milnacipran.,Milnacipran,DB00104
DB06700,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Desvenlafaxine.,Desvenlafaxine,DB00104
DB08953,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indalpine.,Indalpine,DB00104
DB12693,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ritanserin.,Ritanserin,DB00104
DB13233,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Alaproclate.,Alaproclate,DB00104
DB14025,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Clinafloxacin.,Clinafloxacin,DB00104
DB00176,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Fluvoxamine.,Fluvoxamine,DB00104
DB00328,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indomethacin.,Indomethacin,DB00104
DB00715,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.,Paroxetine,DB00104
DB01104,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Sertraline.,Sertraline,DB00104
DB01149,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Nefazodone.,Nefazodone,DB00104
DB04832,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Zimelidine.,Zimelidine,DB00104
DB08918,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.,Levomilnacipran,DB00104
DB09270,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ubidecarenone.,Ubidecarenone,DB00104
DB00211,Octreotide may increase the bradycardic activities of Midodrine.,Midodrine,DB00104
DB00335,Octreotide may increase the bradycardic activities of Atenolol.,Atenolol,DB00104
DB00436,Octreotide may increase the bradycardic activities of Bendroflumethiazide.,Bendroflumethiazide,DB00104
DB00528,Octreotide may increase the bradycardic activities of Lercanidipine.,Lercanidipine,DB00104
DB00598,Octreotide may increase the bradycardic activities of Labetalol.,Labetalol,DB00104
DB00633,Octreotide may increase the bradycardic activities of Dexmedetomidine.,Dexmedetomidine,DB00104
DB00653,Octreotide may increase the bradycardic activities of Magnesium sulfate.,Magnesium sulfate,DB00104
DB00708,Octreotide may increase the bradycardic activities of Sufentanil.,Sufentanil,DB00104
DB00866,Octreotide may increase the bradycardic activities of Alprenolol.,Alprenolol,DB00104
DB00899,Octreotide may increase the bradycardic activities of Remifentanil.,Remifentanil,DB00104
DB00960,Octreotide may increase the bradycardic activities of Pindolol.,Pindolol,DB00104
DB00968,Octreotide may increase the bradycardic activities of Methyldopa.,Methyldopa,DB00104
DB00989,Octreotide may increase the bradycardic activities of Rivastigmine.,Rivastigmine,DB00104
DB01018,Octreotide may increase the bradycardic activities of Guanfacine.,Guanfacine,DB00104
DB01295,Octreotide may increase the bradycardic activities of Bevantolol.,Bevantolol,DB00104
DB01297,Octreotide may increase the bradycardic activities of Practolol.,Practolol,DB00104
DB01359,Octreotide may increase the bradycardic activities of Penbutolol.,Penbutolol,DB00104
DB04743,Octreotide may increase the bradycardic activities of Nimesulide.,Nimesulide,DB00104
DB04838,Octreotide may increase the bradycardic activities of Cyclandelate.,Cyclandelate,DB00104
DB04841,Octreotide may increase the bradycardic activities of Flunarizine.,Flunarizine,DB00104
DB04861,Octreotide may increase the bradycardic activities of Nebivolol.,Nebivolol,DB00104
DB04897,Octreotide may increase the bradycardic activities of Lucinactant.,Lucinactant,DB00104
DB04920,Octreotide may increase the bradycardic activities of Clevidipine.,Clevidipine,DB00104
DB05885,Octreotide may increase the bradycardic activities of Seletracetam.,Seletracetam,DB00104
DB06152,Octreotide may increase the bradycardic activities of Nylidrin.,Nylidrin,DB00104
DB06218,Octreotide may increase the bradycardic activities of Lacosamide.,Lacosamide,DB00104
DB06415,Octreotide may increase the bradycardic activities of Calfactant.,Calfactant,DB00104
DB06446,Octreotide may increase the bradycardic activities of Dotarizine.,Dotarizine,DB00104
DB06726,Octreotide may increase the bradycardic activities of Bufuralol.,Bufuralol,DB00104
DB06761,Octreotide may increase the bradycardic activities of Beractant.,Beractant,DB00104
DB06791,Octreotide may increase the bradycardic activities of Lanreotide.,Lanreotide,DB00104
DB07615,Octreotide may increase the bradycardic activities of Tranilast.,Tranilast,DB00104
DB08807,Octreotide may increase the bradycardic activities of Bopindolol.,Bopindolol,DB00104
DB08838,Octreotide may increase the bradycardic activities of Agmatine.,Agmatine,DB00104
DB09013,Octreotide may increase the bradycardic activities of Befunolol.,Befunolol,DB00104
DB09113,Octreotide may increase the bradycardic activities of Poractant alfa.,Poractant alfa,DB00104
DB09204,Octreotide may increase the bradycardic activities of Arotinolol.,Arotinolol,DB00104
DB09216,Octreotide may increase the bradycardic activities of Tolfenamic acid.,Tolfenamic acid,DB00104
DB09227,Octreotide may increase the bradycardic activities of Barnidipine.,Barnidipine,DB00104
DB09230,Octreotide may increase the bradycardic activities of Azelnidipine.,Azelnidipine,DB00104
DB09232,Octreotide may increase the bradycardic activities of Cilnidipine.,Cilnidipine,DB00104
DB09234,Octreotide may increase the bradycardic activities of Darodipine.,Darodipine,DB00104
DB09238,Octreotide may increase the bradycardic activities of Manidipine.,Manidipine,DB00104
DB09240,Octreotide may increase the bradycardic activities of Niludipine.,Niludipine,DB00104
DB09351,Octreotide may increase the bradycardic activities of Levobetaxolol.,Levobetaxolol,DB00104
DB11960,Octreotide may increase the bradycardic activities of Carboxyamidotriazole.,Carboxyamidotriazole,DB00104
DB12092,Octreotide may increase the bradycardic activities of Naftopidil.,Naftopidil,DB00104
DB12131,Octreotide may increase the bradycardic activities of Vinpocetine.,Vinpocetine,DB00104
DB12212,Octreotide may increase the bradycardic activities of Landiolol.,Landiolol,DB00104
DB12752,Octreotide may increase the bradycardic activities of Bucindolol.,Bucindolol,DB00104
DB13443,Octreotide may increase the bradycardic activities of Esatenolol.,Esatenolol,DB00104
DB13508,Octreotide may increase the bradycardic activities of Cloranolol.,Cloranolol,DB00104
DB13530,Octreotide may increase the bradycardic activities of Mepindolol.,Mepindolol,DB00104
DB13757,Octreotide may increase the bradycardic activities of Epanolol.,Epanolol,DB00104
DB13775,Octreotide may increase the bradycardic activities of Tertatolol.,Tertatolol,DB00104
DB13835,Octreotide may increase the bradycardic activities of Caroverine.,Caroverine,DB00104
DB13950,Octreotide may increase the bradycardic activities of WIN 55212-2.,WIN 55212-2,DB00104
DB13961,Octreotide may increase the bradycardic activities of Fish oil.,Fish oil,DB00104
DB00381,Octreotide may increase the bradycardic activities of Amlodipine.,Amlodipine,DB00104
DB00612,Octreotide may increase the bradycardic activities of Bisoprolol.,Bisoprolol,DB00104
DB00661,Octreotide may increase the bradycardic activities of Verapamil.,Verapamil,DB00104
DB00843,Octreotide may increase the bradycardic activities of Donepezil.,Donepezil,DB00104
DB01136,Octreotide may increase the bradycardic activities of Carvedilol.,Carvedilol,DB00104
DB01203,Octreotide may increase the bradycardic activities of Nadolol.,Nadolol,DB00104
DB08868,Octreotide may increase the bradycardic activities of Fingolimod.,Fingolimod,DB00104
DB08896,Octreotide may increase the bradycardic activities of Regorafenib.,Regorafenib,DB00104
DB14064,Octreotide may increase the bradycardic activities of Emopamil.,Emopamil,DB00104
DB14065,Octreotide may increase the bradycardic activities of Lomerizine.,Lomerizine,DB00104
DB14066,Octreotide may increase the bradycardic activities of Tetrandrine.,Tetrandrine,DB00104
DB14068,Octreotide may increase the bradycardic activities of Dexniguldipine.,Dexniguldipine,DB00104
DB00401,Octreotide may increase the bradycardic activities of Nisoldipine.,Nisoldipine,DB00104
DB00575,Octreotide may increase the bradycardic activities of Clonidine.,Clonidine,DB00104
DB00802,Octreotide may increase the bradycardic activities of Alfentanil.,Alfentanil,DB00104
DB00215,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.,Citalopram,DB00104
DB00261,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anagrelide.,Anagrelide,DB00104
DB00280,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disopyramide.,Disopyramide,DB00104
DB00283,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clemastine.,Clemastine,DB00104
DB00308,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibutilide.,Ibutilide,DB00104
DB00313,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.,Valproic acid,DB00104
DB00365,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Grepafloxacin.,Grepafloxacin,DB00104
DB00468,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quinine.,Quinine,DB00104
DB00489,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sotalol.,Sotalol,DB00104
DB00539,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Toremifene.,Toremifene,DB00104
DB00679,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thioridazine.,Thioridazine,DB00104
DB00685,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trovafloxacin.,Trovafloxacin,DB00104
DB00834,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mifepristone.,Mifepristone,DB00104
DB00875,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flupentixol.,Flupentixol,DB00104
DB00907,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cocaine.,Cocaine,DB00104
DB01035,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Procainamide.,Procainamide,DB00104
DB01169,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arsenic trioxide.,Arsenic trioxide,DB00104
DB01175,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Escitalopram.,Escitalopram,DB00104
DB01184,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Domperidone.,Domperidone,DB00104
DB01208,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sparfloxacin.,Sparfloxacin,DB00104
DB01218,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Halofantrine.,Halofantrine,DB00104
DB01244,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bepridil.,Bepridil,DB00104
DB01267,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.,Paliperidone,DB00104
DB01356,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lithium cation.,Lithium cation,DB00104
DB01405,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temafloxacin.,Temafloxacin,DB00104
DB01624,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zuclopenthixol.,Zuclopenthixol,DB00104
DB04844,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrabenazine.,Tetrabenazine,DB00104
DB06176,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Romidepsin.,Romidepsin,DB00104
DB06216,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Asenapine.,Asenapine,DB00104
DB06697,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Artemether.,Artemether,DB00104
DB06708,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lumefantrine.,Lumefantrine,DB00104
DB11730,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ribociclib.,Ribociclib,DB00104
DB11978,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib.,Glasdegib,DB00104
DB12161,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Deutetrabenazine.,Deutetrabenazine,DB00104
DB13725,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terodiline.,Terodiline,DB00104
DB00637,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Astemizole.,Astemizole,DB00104
DB08881,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vemurafenib.,Vemurafenib,DB00104
DB13925,Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.,Dotatate gallium Ga-68,DB00104
DB13985,The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.,Lutetium Lu 177 dotatate,DB00104
DB11637,Octreotide may increase the QTc-prolonging activities of Delamanid.,Delamanid,DB00104
DB01238,The metabolism of Aripiprazole can be decreased when combined with Octreotide.,Aripiprazole,DB00104
DB14185,The metabolism of Aripiprazole lauroxil can be decreased when combined with Octreotide.,Aripiprazole lauroxil,DB00104
DB00230,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pregabalin.,Pregabalin,DB00104
DB06663,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pasireotide.,Pasireotide,DB00104
DB00107,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.,Oxytocin,DB00104
DB00187,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Esmolol.,Esmolol,DB00104
DB00245,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benzatropine.,Benzatropine,DB00104
DB00289,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atomoxetine.,Atomoxetine,DB00104
DB00347,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimethadione.,Trimethadione,DB00104
DB00354,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buclizine.,Buclizine,DB00104
DB00366,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxylamine.,Doxylamine,DB00104
DB00370,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirtazapine.,Mirtazapine,DB00104
DB00374,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Treprostinil.,Treprostinil,DB00104
DB00405,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.,Dexbrompheniramine,DB00104
DB00424,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hyoscyamine.,Hyoscyamine,DB00104
DB00427,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triprolidine.,Triprolidine,DB00104
DB00434,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyproheptadine.,Cyproheptadine,DB00104
DB00467,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Enoxacin.,Enoxacin,DB00104
DB00487,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pefloxacin.,Pefloxacin,DB00104
DB00529,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Foscarnet.,Foscarnet,DB00104
DB00582,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Voriconazole.,Voriconazole,DB00104
DB00674,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Galantamine.,Galantamine,DB00104
DB00680,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moricizine.,Moricizine,DB00104
DB00691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moexipril.,Moexipril,DB00104
DB00697,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tizanidine.,Tizanidine,DB00104
DB00710,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.,Ibandronate,DB00104
DB00714,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.,Apomorphine,DB00104
DB00719,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azatadine.,Azatadine,DB00104
DB00753,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isoflurane.,Isoflurane,DB00104
DB00808,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indapamide.,Indapamide,DB00104
DB00817,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rosoxacin.,Rosoxacin,DB00104
DB00822,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disulfiram.,Disulfiram,DB00104
DB00825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levomenthol.,Levomenthol,DB00104
DB00835,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Brompheniramine.,Brompheniramine,DB00104
DB00871,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.,Terbutaline,DB00104
DB00915,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amantadine.,Amantadine,DB00104
DB00920,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketotifen.,Ketotifen,DB00104
DB00927,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famotidine.,Famotidine,DB00104
DB00934,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.,Maprotiline,DB00104
DB00949,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felbamate.,Felbamate,DB00104
DB00983,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Formoterol.,Formoterol,DB00104
DB00999,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydrochlorothiazide.,Hydrochlorothiazide,DB00104
DB01001,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salbutamol.,Salbutamol,DB00104
DB01036,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tolterodine.,Tolterodine,DB00104
DB01044,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gatifloxacin.,Gatifloxacin,DB00104
DB01059,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Norfloxacin.,Norfloxacin,DB00104
DB01071,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mequitazine.,Mequitazine,DB00104
DB01074,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perhexiline.,Perhexiline,DB00104
DB01075,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diphenhydramine.,Diphenhydramine,DB00104
DB01106,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocabastine.,Levocabastine,DB00104
DB01158,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bretylium.,Bretylium,DB00104
DB01173,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orphenadrine.,Orphenadrine,DB00104
DB01176,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyclizine.,Cyclizine,DB00104
DB01189,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desflurane.,Desflurane,DB00104
DB01228,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encainide.,Encainide,DB00104
DB01236,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sevoflurane.,Sevoflurane,DB00104
DB01246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Alimemazine.,Alimemazine,DB00104
DB01274,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arformoterol.,Arformoterol,DB00104
DB01403,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methotrimeprazine.,Methotrimeprazine,DB00104
DB01426,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ajmaline.,Ajmaline,DB00104
DB01591,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Solifenacin.,Solifenacin,DB00104
DB01620,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pheniramine.,Pheniramine,DB00104
DB01623,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thiothixene.,Thiothixene,DB00104
DB02546,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vorinostat.,Vorinostat,DB00104
DB04576,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fleroxacin.,Fleroxacin,DB00104
DB04695,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl thiopyrophosphate.,Farnesyl thiopyrophosphate,DB00104
DB04953,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ezogabine.,Ezogabine,DB00104
DB05246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methsuximide.,Methsuximide,DB00104
DB05465,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tandutinib.,Tandutinib,DB00104
DB06217,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vernakalant.,Vernakalant,DB00104
DB06282,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocetirizine.,Levocetirizine,DB00104
DB06288,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amisulpride.,Amisulpride,DB00104
DB06468,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cariporide.,Cariporide,DB00104
DB06691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mepyramine.,Mepyramine,DB00104
DB06699,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix.,Degarelix,DB00104
DB06719,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buserelin.,Buserelin,DB00104
DB06788,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Histrelin.,Histrelin,DB00104
DB06825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin.,Triptorelin,DB00104
DB07780,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl diphosphate.,Farnesyl diphosphate,DB00104
DB07841,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Geranylgeranyl diphosphate.,Geranylgeranyl diphosphate,DB00104
DB08808,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bupranolol.,Bupranolol,DB00104
DB08871,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin.,Eribulin,DB00104
DB08936,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorcyclizine.,Chlorcyclizine,DB00104
DB08972,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flumequine.,Flumequine,DB00104
DB09080,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olodaterol.,Olodaterol,DB00104
DB09082,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vilanterol.,Vilanterol,DB00104
DB09089,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimebutine.,Trimebutine,DB00104
DB09090,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pinaverium.,Pinaverium,DB00104
DB09167,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dosulepin.,Dosulepin,DB00104
DB09229,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aranidipine.,Aranidipine,DB00104
DB09235,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efonidipine.,Efonidipine,DB00104
DB09236,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lacidipine.,Lacidipine,DB00104
DB09488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acrivastine.,Acrivastine,DB00104
DB11390,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Coumaphos.,Coumaphos,DB00104
DB11397,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dichlorvos.,Dichlorvos,DB00104
DB11408,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famphur.,Famphur,DB00104
DB11412,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fenthion.,Fenthion,DB00104
DB11443,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orbifloxacin.,Orbifloxacin,DB00104
DB11448,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Phosmet.,Phosmet,DB00104
DB11491,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sarafloxacin.,Sarafloxacin,DB00104
DB11511,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Difloxacin.,Difloxacin,DB00104
DB11591,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bilastine.,Bilastine,DB00104
DB11614,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rupatadine.,Rupatadine,DB00104
DB11774,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pazufloxacin.,Pazufloxacin,DB00104
DB11785,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anisodamine.,Anisodamine,DB00104
DB11891,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-907.,CUDC-907,DB00104
DB11892,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prulifloxacin.,Prulifloxacin,DB00104
DB11943,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Delafloxacin.,Delafloxacin,DB00104
DB12093,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrahydropalmatine.,Tetrahydropalmatine,DB00104
DB12231,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temefos.,Temefos,DB00104
DB12245,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triclabendazole.,Triclabendazole,DB00104
DB12645,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Givinostat.,Givinostat,DB00104
DB12712,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pilsicainide.,Pilsicainide,DB00104
DB12766,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cicletanine.,Cicletanine,DB00104
DB13358,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cibenzoline.,Cibenzoline,DB00104
DB13488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bencyclane.,Bencyclane,DB00104
DB13555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prajmaline.,Prajmaline,DB00104
DB13627,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxolinic acid.,Oxolinic acid,DB00104
DB13651,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorajmine.,Lorajmine,DB00104
DB13691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acetyldigoxin.,Acetyldigoxin,DB00104
DB13744,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Piromidic acid.,Piromidic acid,DB00104
DB13766,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lidoflazine.,Lidoflazine,DB00104
DB13772,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rufloxacin.,Rufloxacin,DB00104
DB13823,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pipemidic acid.,Pipemidic acid,DB00104
DB14713,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Inotersen.,Inotersen,DB00104
DB00938,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.,Salmeterol,DB00104
DB01072,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atazanavir.,Atazanavir,DB00104
DB01151,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desipramine.,Desipramine,DB00104
DB00196,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluconazole.,Fluconazole,DB00104
DB00220,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nelfinavir.,Nelfinavir,DB00104
DB00270,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isradipine.,Isradipine,DB00104
DB00285,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Venlafaxine.,Venlafaxine,DB00104
DB00334,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olanzapine.,Olanzapine,DB00104
DB00341,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cetirizine.,Cetirizine,DB00104
DB00344,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Protriptyline.,Protriptyline,DB00104
DB00358,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mefloquine.,Mefloquine,DB00104
DB00373,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Timolol.,Timolol,DB00104
DB00390,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Digoxin.,Digoxin,DB00104
DB00503,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ritonavir.,Ritonavir,DB00104
DB00543,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amoxapine.,Amoxapine,DB00104
DB00555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lamotrigine.,Lamotrigine,DB00104
DB00613,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amodiaquine.,Amodiaquine,DB00104
DB00622,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nicardipine.,Nicardipine,DB00104
DB00678,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Losartan.,Losartan,DB00104
DB00726,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimipramine.,Trimipramine,DB00104
DB00734,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Risperidone.,Risperidone,DB00104
DB00818,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propofol.,Propofol,DB00104
DB00909,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zonisamide.,Zonisamide,DB00104
DB00916,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metronidazole.,Metronidazole,DB00104
DB01026,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketoconazole.,Ketoconazole,DB00104
DB01054,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nitrendipine.,Nitrendipine,DB00104
DB01069,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promethazine.,Promethazine,DB00104
DB01142,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxepin.,Doxepin,DB00104
DB01167,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Itraconazole.,Itraconazole,DB00104
DB01233,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.,Metoclopramide,DB00104
DB01239,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorprothixene.,Chlorprothixene,DB00104
DB01259,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lapatinib.,Lapatinib,DB00104
DB01263,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Posaconazole.,Posaconazole,DB00104
DB01601,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lopinavir.,Lopinavir,DB00104
DB01611,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00104
DB04846,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Celiprolol.,Celiprolol,DB00104
DB05039,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indacaterol.,Indacaterol,DB00104
DB08893,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirabegron.,Mirabegron,DB00104
DB09239,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Niguldipine.,Niguldipine,DB00104
DB11770,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Talinolol.,Talinolol,DB00104
DB12923,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gallopamil.,Gallopamil,DB00104
DB00593,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ethosuximide.,Ethosuximide,DB00104
DB01023,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felodipine.,Felodipine,DB00104
DB00540,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nortriptyline.,Nortriptyline,DB00104
DB08815,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lurasidone.,Lurasidone,DB00104
DB08864,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rilpivirine.,Rilpivirine,DB00104
DB11742,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ebastine.,Ebastine,DB00104
DB00845,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clofazimine.,Clofazimine,DB00104
DB00186,The metabolism of Lorazepam can be decreased when combined with Octreotide.,Lorazepam,DB00104
DB00191,The metabolism of Phentermine can be decreased when combined with Octreotide.,Phentermine,DB00104
DB00208,The metabolism of Ticlopidine can be decreased when combined with Octreotide.,Ticlopidine,DB00104
DB00426,The metabolism of Famciclovir can be decreased when combined with Octreotide.,Famciclovir,DB00104
DB00567,The metabolism of Cephalexin can be decreased when combined with Octreotide.,Cephalexin,DB00104
DB00717,The metabolism of Norethisterone can be decreased when combined with Octreotide.,Norethisterone,DB00104
DB01323,The metabolism of St. John's Wort can be decreased when combined with Octreotide.,St. John's Wort,DB00104
DB01395,The metabolism of Drospirenone can be decreased when combined with Octreotide.,Drospirenone,DB00104
DB01411,The metabolism of Pranlukast can be decreased when combined with Octreotide.,Pranlukast,DB00104
DB01431,The metabolism of Allylestrenol can be decreased when combined with Octreotide.,Allylestrenol,DB00104
DB01656,The metabolism of Roflumilast can be decreased when combined with Octreotide.,Roflumilast,DB00104
DB06201,The metabolism of Rufinamide can be decreased when combined with Octreotide.,Rufinamide,DB00104
DB09071,The metabolism of Tasimelteon can be decreased when combined with Octreotide.,Tasimelteon,DB00104
DB11094,The metabolism of Vitamin D can be decreased when combined with Octreotide.,Vitamin D,DB00104
DB11273,The metabolism of Dihydroergocornine can be decreased when combined with Octreotide.,Dihydroergocornine,DB00104
DB12515,The metabolism of 9-aminocamptothecin can be decreased when combined with Octreotide.,9-aminocamptothecin,DB00104
DB12952,The metabolism of Methylprednisone can be decreased when combined with Octreotide.,Methylprednisone,DB00104
DB13345,The metabolism of Dihydroergocristine can be decreased when combined with Octreotide.,Dihydroergocristine,DB00104
DB13385,The metabolism of Dihydroergocryptine can be decreased when combined with Octreotide.,Dihydroergocryptine,DB00104
DB14009,The metabolism of Medical Cannabis can be decreased when combined with Octreotide.,Medical Cannabis,DB00104
DB01098,The metabolism of Rosuvastatin can be decreased when combined with Octreotide.,Rosuvastatin,DB00104
DB00549,The metabolism of Zafirlukast can be decreased when combined with Octreotide.,Zafirlukast,DB00104
DB15444,The metabolism of Elexacaftor can be decreased when combined with Octreotide.,Elexacaftor,DB00104
DB00476,The metabolism of Duloxetine can be decreased when combined with Octreotide.,Duloxetine,DB00104
DB00518,The metabolism of Albendazole can be decreased when combined with Octreotide.,Albendazole,DB00104
DB00590,The metabolism of Doxazosin can be decreased when combined with Octreotide.,Doxazosin,DB00104
DB01039,The metabolism of Fenofibrate can be decreased when combined with Octreotide.,Fenofibrate,DB00104
DB06717,The metabolism of Fosaprepitant can be decreased when combined with Octreotide.,Fosaprepitant,DB00104
DB09030,The metabolism of Vorapaxar can be decreased when combined with Octreotide.,Vorapaxar,DB00104
DB09034,The metabolism of Suvorexant can be decreased when combined with Octreotide.,Suvorexant,DB00104
DB09048,The metabolism of Netupitant can be decreased when combined with Octreotide.,Netupitant,DB00104
DB00264,The metabolism of Metoprolol can be decreased when combined with Octreotide.,Metoprolol,DB00104
DB09079,The metabolism of Nintedanib can be decreased when combined with Octreotide.,Nintedanib,DB00104
DB09299,The metabolism of Tenofovir alafenamide can be decreased when combined with Octreotide.,Tenofovir alafenamide,DB00104
DB09330,The metabolism of Osimertinib can be decreased when combined with Octreotide.,Osimertinib,DB00104
DB11952,The metabolism of Duvelisib can be decreased when combined with Octreotide.,Duvelisib,DB00104
DB12887,The metabolism of Tazemetostat can be decreased when combined with Octreotide.,Tazemetostat,DB00104
DB14126,The metabolism of Tenofovir can be decreased when combined with Octreotide.,Tenofovir,DB00104
DB00247,The metabolism of Methysergide can be decreased when combined with Octreotide.,Methysergide,DB00104
DB00454,The metabolism of Meperidine can be decreased when combined with Octreotide.,Meperidine,DB00104
DB12371,The metabolism of Siponimod can be decreased when combined with Octreotide.,Siponimod,DB00104
DB00363,The metabolism of Clozapine can be decreased when combined with Octreotide.,Clozapine,DB00104
DB06589,The metabolism of Pazopanib can be decreased when combined with Octreotide.,Pazopanib,DB00104
DB06603,The metabolism of Panobinostat can be decreased when combined with Octreotide.,Panobinostat,DB00104
DB00530,The metabolism of Erlotinib can be decreased when combined with Octreotide.,Erlotinib,DB00104
DB00619,The metabolism of Imatinib can be decreased when combined with Octreotide.,Imatinib,DB00104
DB04868,The metabolism of Nilotinib can be decreased when combined with Octreotide.,Nilotinib,DB00104
DB05294,The metabolism of Vandetanib can be decreased when combined with Octreotide.,Vandetanib,DB00104
DB00188,The metabolism of Bortezomib can be decreased when combined with Octreotide.,Bortezomib,DB00104
DB00342,The metabolism of Octreotide can be decreased when combined with Terfenadine.,Terfenadine,DB00104
DB00877,The metabolism of Octreotide can be decreased when combined with Sirolimus.,Sirolimus,DB00104
DB00908,The metabolism of Octreotide can be decreased when combined with Quinidine.,Quinidine,DB00104
DB01100,The metabolism of Octreotide can be decreased when combined with Pimozide.,Pimozide,DB00104
DB01118,The metabolism of Octreotide can be decreased when combined with Amiodarone.,Amiodarone,DB00104
DB01229,The metabolism of Octreotide can be decreased when combined with Paclitaxel.,Paclitaxel,DB00104
DB01254,The metabolism of Octreotide can be decreased when combined with Dasatinib.,Dasatinib,DB00104
DB01590,The metabolism of Octreotide can be decreased when combined with Everolimus.,Everolimus,DB00104
DB04855,The metabolism of Octreotide can be decreased when combined with Dronedarone.,Dronedarone,DB00104
DB06287,The metabolism of Octreotide can be decreased when combined with Temsirolimus.,Temsirolimus,DB00104
DB00564,The metabolism of Carbamazepine can be decreased when combined with Octreotide.,Carbamazepine,DB00104
DB01396,The metabolism of Digitoxin can be decreased when combined with Octreotide.,Digitoxin,DB00104
DB00204,The metabolism of Dofetilide can be decreased when combined with Octreotide.,Dofetilide,DB00104
DB00277,The metabolism of Theophylline can be decreased when combined with Octreotide.,Theophylline,DB00104
DB00604,The metabolism of Cisapride can be decreased when combined with Octreotide.,Cisapride,DB00104
DB00946,The metabolism of Phenprocoumon can be decreased when combined with Octreotide.,Phenprocoumon,DB00104
DB01008,The metabolism of Busulfan can be decreased when combined with Octreotide.,Busulfan,DB00104
DB01223,The metabolism of Aminophylline can be decreased when combined with Octreotide.,Aminophylline,DB00104
DB01320,The metabolism of Fosphenytoin can be decreased when combined with Octreotide.,Fosphenytoin,DB00104
DB03410,The metabolism of 4-hydroxycoumarin can be decreased when combined with Octreotide.,4-hydroxycoumarin,DB00104
DB09289,The metabolism of Tianeptine can be decreased when combined with Octreotide.,Tianeptine,DB00104
DB13136,The metabolism of Fluindione can be decreased when combined with Octreotide.,Fluindione,DB00104
DB13275,The metabolism of Clorindione can be decreased when combined with Octreotide.,Clorindione,DB00104
DB00451,The metabolism of Levothyroxine can be decreased when combined with Octreotide.,Levothyroxine,DB00104
DB09054,The metabolism of Idelalisib can be decreased when combined with Octreotide.,Idelalisib,DB00104
DB11633,The metabolism of Isavuconazole can be decreased when combined with Octreotide.,Isavuconazole,DB00104
DB11963,The metabolism of Dacomitinib can be decreased when combined with Octreotide.,Dacomitinib,DB00104
DB12015,The metabolism of Alpelisib can be decreased when combined with Octreotide.,Alpelisib,DB00104
DB05239,The metabolism of Cobimetinib can be decreased when combined with Octreotide.,Cobimetinib,DB00104
DB01268,The metabolism of Sunitinib can be decreased when combined with Octreotide.,Sunitinib,DB00104
DB08865,The metabolism of Crizotinib can be decreased when combined with Octreotide.,Crizotinib,DB00104
DB14568,The metabolism of Ivosidenib can be decreased when combined with Octreotide.,Ivosidenib,DB00104
DB00398,The metabolism of Sorafenib can be decreased when combined with Octreotide.,Sorafenib,DB00104
DB00675,The metabolism of Tamoxifen can be decreased when combined with Octreotide.,Tamoxifen,DB00104
DB08912,The metabolism of Dabrafenib can be decreased when combined with Octreotide.,Dabrafenib,DB00104
DB00563,The metabolism of Methotrexate can be decreased when combined with Octreotide.,Methotrexate,DB00104
DB00361,The metabolism of Vinorelbine can be decreased when combined with Octreotide.,Vinorelbine,DB00104
DB00541,The metabolism of Vincristine can be decreased when combined with Octreotide.,Vincristine,DB00104
DB00570,The metabolism of Vinblastine can be decreased when combined with Octreotide.,Vinblastine,DB00104
DB00694,The metabolism of Daunorubicin can be decreased when combined with Octreotide.,Daunorubicin,DB00104
DB00987,The metabolism of Cytarabine can be decreased when combined with Octreotide.,Cytarabine,DB00104
DB00997,The metabolism of Doxorubicin can be decreased when combined with Octreotide.,Doxorubicin,DB00104
DB01108,The metabolism of Trilostane can be decreased when combined with Octreotide.,Trilostane,DB00104
DB01248,The metabolism of Docetaxel can be decreased when combined with Octreotide.,Docetaxel,DB00104
DB04572,The metabolism of Thiotepa can be decreased when combined with Octreotide.,Thiotepa,DB00104
DB05109,The metabolism of Trabectedin can be decreased when combined with Octreotide.,Trabectedin,DB00104
DB05812,The metabolism of Abiraterone can be decreased when combined with Octreotide.,Abiraterone,DB00104
DB11363,The metabolism of Alectinib can be decreased when combined with Octreotide.,Alectinib,DB00104
DB11581,The metabolism of Venetoclax can be decreased when combined with Octreotide.,Venetoclax,DB00104
DB11641,The metabolism of Vinflunine can be decreased when combined with Octreotide.,Vinflunine,DB00104
DB11703,The metabolism of Acalabrutinib can be decreased when combined with Octreotide.,Acalabrutinib,DB00104
DB13874,The metabolism of Enasidenib can be decreased when combined with Octreotide.,Enasidenib,DB00104
DB15035,The metabolism of Zanubrutinib can be decreased when combined with Octreotide.,Zanubrutinib,DB00104
DB00248,The metabolism of Cabergoline can be decreased when combined with Octreotide.,Cabergoline,DB00104
DB00309,The metabolism of Vindesine can be decreased when combined with Octreotide.,Vindesine,DB00104
DB00444,The metabolism of Teniposide can be decreased when combined with Octreotide.,Teniposide,DB00104
DB00773,The metabolism of Etoposide can be decreased when combined with Octreotide.,Etoposide,DB00104
DB01181,The metabolism of Ifosfamide can be decreased when combined with Octreotide.,Ifosfamide,DB00104
DB04845,The metabolism of Ixabepilone can be decreased when combined with Octreotide.,Ixabepilone,DB00104
DB05015,The metabolism of Belinostat can be decreased when combined with Octreotide.,Belinostat,DB00104
DB06595,The metabolism of Midostaurin can be decreased when combined with Octreotide.,Midostaurin,DB00104
DB06616,The metabolism of Bosutinib can be decreased when combined with Octreotide.,Bosutinib,DB00104
DB06626,The metabolism of Axitinib can be decreased when combined with Octreotide.,Axitinib,DB00104
DB08870,The metabolism of Brentuximab vedotin can be decreased when combined with Octreotide.,Brentuximab vedotin,DB00104
DB08901,The metabolism of Ponatinib can be decreased when combined with Octreotide.,Ponatinib,DB00104
DB09073,The metabolism of Palbociclib can be decreased when combined with Octreotide.,Palbociclib,DB00104
DB09143,The metabolism of Sonidegib can be decreased when combined with Octreotide.,Sonidegib,DB00104
DB09570,The metabolism of Ixazomib can be decreased when combined with Octreotide.,Ixazomib,DB00104
DB11718,The metabolism of Encorafenib can be decreased when combined with Octreotide.,Encorafenib,DB00104
DB11828,The metabolism of Neratinib can be decreased when combined with Octreotide.,Neratinib,DB00104
DB12147,The metabolism of Erdafitinib can be decreased when combined with Octreotide.,Erdafitinib,DB00104
DB12267,The metabolism of Brigatinib can be decreased when combined with Octreotide.,Brigatinib,DB00104
DB12483,The metabolism of Copanlisib can be decreased when combined with Octreotide.,Copanlisib,DB00104
DB12978,The metabolism of Pexidartinib can be decreased when combined with Octreotide.,Pexidartinib,DB00104
DB06480,The metabolism of Prucalopride can be decreased when combined with Octreotide.,Prucalopride,DB00104
DB13074,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Octreotide.,Macimorelin,DB00104
DB00331,The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.,Metformin,DB00104
DB00656,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Octreotide.,Trazodone,DB00104
DB11986,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib.,Entrectinib,DB00104
DB11642,Pitolisant may increase the QTc-prolonging activities of Octreotide.,Pitolisant,DB00104
DB12825,Lefamulin may increase the QTc-prolonging activities of Octreotide.,Lefamulin,DB00104
DB15494,Octreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent.,Edotreotide gallium Ga-68,DB00104
DB11732,Lasmiditan may increase the bradycardic activities of Octreotide.,Lasmiditan,DB00104
DB14975,The serum concentration of Voxelotor can be increased when it is combined with Octreotide.,Voxelotor,DB00104
DB09237,The serum concentration of Levamlodipine can be increased when it is combined with Octreotide.,Levamlodipine,DB00104
DB15328,The serum concentration of Ubrogepant can be increased when it is combined with Octreotide.,Ubrogepant,DB00104
DB00557,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.,Hydroxyzine,DB00104
DB00193,The metabolism of Tramadol can be decreased when combined with Octreotide.,Tramadol,DB00104
DB00246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.,Ziprasidone,DB00104
DB00502,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.,Haloperidol,DB00104
DB00472,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluoxetine.,Fluoxetine,DB00104
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-2b.,Denosumab,DB00105
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2b.,Etanercept,DB00105
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b.,Peginterferon alfa-2a,DB00105
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2b.,Interferon alfa-n1,DB00105
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2b.,Interferon alfa-n3,DB00105
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2b.,Peginterferon alfa-2b,DB00105
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2b.,Anakinra,DB00105
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2b.,Interferon gamma-1b,DB00105
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfa-2b.","Interferon alfa-2a, Recombinant",DB00105
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfa-2b.,Adalimumab,DB00105
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.,Gemtuzumab ozogamicin,DB00105
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.,Pegaspargase,DB00105
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.,Infliximab,DB00105
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.,Interferon beta-1b,DB00105
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.,Interferon alfacon-1,DB00105
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.,Rituximab,DB00105
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.,Basiliximab,DB00105
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.,Muromonab,DB00105
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.,Ibritumomab tiuxetan,DB00105
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.,Tositumomab,DB00105
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.,Alemtuzumab,DB00105
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.,Alefacept,DB00105
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.,Efalizumab,DB00105
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.,Antithymocyte immunoglobulin (rabbit),DB00105
DB00111,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.,Daclizumab,DB00105
DB00112,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.,Bevacizumab,DB00105
DB00120,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.,Phenylalanine,DB00105
DB00180,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flunisolide.,Flunisolide,DB00105
DB00188,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bortezomib.,Bortezomib,DB00105
DB00242,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cladribine.,Cladribine,DB00105
DB00262,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carmustine.,Carmustine,DB00105
DB00276,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Amsacrine.,Amsacrine,DB00105
DB00290,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleomycin.,Bleomycin,DB00105
DB00291,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chlorambucil.,Chlorambucil,DB00105
DB00293,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Raltitrexed.,Raltitrexed,DB00105
DB00305,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitomycin.,Mitomycin,DB00105
DB00307,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bexarotene.,Bexarotene,DB00105
DB00309,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vindesine.,Vindesine,DB00105
DB00322,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Floxuridine.,Floxuridine,DB00105
DB00328,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Indomethacin.,Indomethacin,DB00105
DB00352,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tioguanine.,Tioguanine,DB00105
DB00361,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinorelbine.,Vinorelbine,DB00105
DB00380,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexrazoxane.,Dexrazoxane,DB00105
DB00394,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00105
DB00398,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sorafenib.,Sorafenib,DB00105
DB00428,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Streptozocin.,Streptozocin,DB00105
DB00432,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trifluridine.,Trifluridine,DB00105
DB00441,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gemcitabine.,Gemcitabine,DB00105
DB00443,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Betamethasone.,Betamethasone,DB00105
DB00444,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teniposide.,Teniposide,DB00105
DB00445,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Epirubicin.,Epirubicin,DB00105
DB00446,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chloramphenicol.,Chloramphenicol,DB00105
DB00480,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lenalidomide.,Lenalidomide,DB00105
DB00488,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Altretamine.,Altretamine,DB00105
DB00515,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cisplatin.,Cisplatin,DB00105
DB00526,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin.,Oxaliplatin,DB00105
DB00531,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cyclophosphamide.,Cyclophosphamide,DB00105
DB00541,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vincristine.,Vincristine,DB00105
DB00544,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluorouracil.,Fluorouracil,DB00105
DB00550,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil.,Propylthiouracil,DB00105
DB00552,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pentostatin.,Pentostatin,DB00105
DB00563,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methotrexate.,Methotrexate,DB00105
DB00570,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinblastine.,Vinblastine,DB00105
DB00588,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone propionate.,Fluticasone propionate,DB00105
DB00591,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00105
DB00601,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Linezolid.,Linezolid,DB00105
DB00619,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Imatinib.,Imatinib,DB00105
DB00620,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triamcinolone.,Triamcinolone,DB00105
DB00631,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clofarabine.,Clofarabine,DB00105
DB00635,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisone.,Prednisone,DB00105
DB00642,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pemetrexed.,Pemetrexed,DB00105
DB00687,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludrocortisone.,Fludrocortisone,DB00105
DB00688,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00105
DB00694,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.,Daunorubicin,DB00105
DB00755,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tretinoin.,Tretinoin,DB00105
DB00762,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Irinotecan.,Irinotecan,DB00105
DB00763,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methimazole.,Methimazole,DB00105
DB00764,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone.,Mometasone,DB00105
DB00773,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Etoposide.,Etoposide,DB00105
DB00795,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sulfasalazine.,Sulfasalazine,DB00105
DB00851,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dacarbazine.,Dacarbazine,DB00105
DB00853,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temozolomide.,Temozolomide,DB00105
DB00859,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Penicillamine.,Penicillamine,DB00105
DB00860,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisolone.,Prednisolone,DB00105
DB00877,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirolimus.,Sirolimus,DB00105
DB00888,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mechlorethamine.,Mechlorethamine,DB00105
DB00928,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azacitidine.,Azacitidine,DB00105
DB00958,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin.,Carboplatin,DB00105
DB00959,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methylprednisolone.,Methylprednisolone,DB00105
DB00970,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dactinomycin.,Dactinomycin,DB00105
DB00987,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.,Cytarabine,DB00105
DB00993,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azathioprine.,Azathioprine,DB00105
DB00997,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxorubicin.,Doxorubicin,DB00105
DB01005,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxyurea.,Hydroxyurea,DB00105
DB01008,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Busulfan.,Busulfan,DB00105
DB01024,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolic acid.,Mycophenolic acid,DB00105
DB01030,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Topotecan.,Topotecan,DB00105
DB01033,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mercaptopurine.,Mercaptopurine,DB00105
DB01041,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thalidomide.,Thalidomide,DB00105
DB01042,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melphalan.,Melphalan,DB00105
DB01073,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludarabine.,Fludarabine,DB00105
DB01099,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flucytosine.,Flucytosine,DB00105
DB01101,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Capecitabine.,Capecitabine,DB00105
DB01108,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trilostane.,Trilostane,DB00105
DB01168,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Procarbazine.,Procarbazine,DB00105
DB01169,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Arsenic trioxide.,Arsenic trioxide,DB00105
DB01177,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idarubicin.,Idarubicin,DB00105
DB01181,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ifosfamide.,Ifosfamide,DB00105
DB01196,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Estramustine.,Estramustine,DB00105
DB01204,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitoxantrone.,Mitoxantrone,DB00105
DB01206,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lomustine.,Lomustine,DB00105
DB01222,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Budesonide.,Budesonide,DB00105
DB01229,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paclitaxel.,Paclitaxel,DB00105
DB01234,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone.,Dexamethasone,DB00105
DB01248,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Docetaxel.,Docetaxel,DB00105
DB01254,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dasatinib.,Dasatinib,DB00105
DB01257,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eculizumab.,Eculizumab,DB00105
DB01262,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Decitabine.,Decitabine,DB00105
DB01268,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sunitinib.,Sunitinib,DB00105
DB01280,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nelarabine.,Nelarabine,DB00105
DB01281,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abatacept.,Abatacept,DB00105
DB01285,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Corticotropin.,Corticotropin,DB00105
DB01380,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortisone acetate.,Cortisone acetate,DB00105
DB01384,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paramethasone.,Paramethasone,DB00105
DB01394,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Colchicine.,Colchicine,DB00105
DB01410,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ciclesonide.,Ciclesonide,DB00105
DB01423,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Stepronin.,Stepronin,DB00105
DB01590,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Everolimus.,Everolimus,DB00105
DB01611,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00105
DB01816,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Castanospermine.,Castanospermine,DB00105
DB02546,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vorinostat.,Vorinostat,DB00105
DB02806,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00105
DB03523,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brequinar.,Brequinar,DB00105
DB04572,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thiotepa.,Thiotepa,DB00105
DB04630,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldosterone.,Aldosterone,DB00105
DB04845,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixabepilone.,Ixabepilone,DB00105
DB04868,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nilotinib.,Nilotinib,DB00105
DB04951,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirfenidone.,Pirfenidone,DB00105
DB04956,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Afelimomab.,Afelimomab,DB00105
DB05015,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belinostat.,Belinostat,DB00105
DB05109,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trabectedin.,Trabectedin,DB00105
DB05258,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Interferon alfa.,Interferon alfa,DB00105
DB05259,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Glatiramer.,Glatiramer,DB00105
DB05260,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gallium nitrate.,Gallium nitrate,DB00105
DB05459,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Briakinumab.,Briakinumab,DB00105
DB05472,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with omega interferon.,omega interferon,DB00105
DB05676,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Apremilast.,Apremilast,DB00105
DB05773,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00105
DB06168,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Canakinumab.,Canakinumab,DB00105
DB06273,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tocilizumab.,Tocilizumab,DB00105
DB06287,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temsirolimus.,Temsirolimus,DB00105
DB06372,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rilonacept.,Rilonacept,DB00105
DB06589,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pazopanib.,Pazopanib,DB00105
DB06603,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Panobinostat.,Panobinostat,DB00105
DB06612,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mepolizumab.,Mepolizumab,DB00105
DB06616,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bosutinib.,Bosutinib,DB00105
DB06662,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abetimus.,Abetimus,DB00105
DB06674,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Golimumab.,Golimumab,DB00105
DB06681,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belatacept.,Belatacept,DB00105
DB06769,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bendamustine.,Bendamustine,DB00105
DB06772,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cabazitaxel.,Cabazitaxel,DB00105
DB06813,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pralatrexate.,Pralatrexate,DB00105
DB08059,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Wortmannin.,Wortmannin,DB00105
DB08870,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00105
DB08871,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eribulin.,Eribulin,DB00105
DB08877,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.,Ruxolitinib,DB00105
DB08879,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belimumab.,Belimumab,DB00105
DB08880,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teriflunomide.,Teriflunomide,DB00105
DB08889,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carfilzomib.,Carfilzomib,DB00105
DB08901,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ponatinib.,Ponatinib,DB00105
DB08904,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Certolizumab pegol.,Certolizumab pegol,DB00105
DB08906,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone furoate.,Fluticasone furoate,DB00105
DB08908,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00105
DB08910,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.,Pomalidomide,DB00105
DB08935,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Obinutuzumab.,Obinutuzumab,DB00105
DB08970,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednidene.,Fluprednidene,DB00105
DB08971,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortolone.,Fluocortolone,DB00105
DB09029,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Secukinumab.,Secukinumab,DB00105
DB09033,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vedolizumab.,Vedolizumab,DB00105
DB09036,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siltuximab.,Siltuximab,DB00105
DB09052,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Blinatumomab.,Blinatumomab,DB00105
DB09053,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ibrutinib.,Ibrutinib,DB00105
DB09054,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idelalisib.,Idelalisib,DB00105
DB09073,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Palbociclib.,Palbociclib,DB00105
DB09074,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Olaparib.,Olaparib,DB00105
DB09077,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dinutuximab.,Dinutuximab,DB00105
DB09082,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vilanterol.,Vilanterol,DB00105
DB09091,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tixocortol.,Tixocortol,DB00105
DB09122,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00105
DB09312,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00105
DB09378,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednisolone.,Fluprednisolone,DB00105
DB09383,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Meprednisone.,Meprednisone,DB00105
DB11466,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tepoxalin.,Tepoxalin,DB00105
DB11487,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00105
DB11529,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melengestrol.,Melengestrol,DB00105
DB11569,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixekizumab.,Ixekizumab,DB00105
DB11580,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ravulizumab.,Ravulizumab,DB00105
DB11616,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirarubicin.,Pirarubicin,DB00105
DB11693,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Voclosporin.,Voclosporin,DB00105
DB11708,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peficitinib.,Peficitinib,DB00105
DB11750,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clobetasol.,Clobetasol,DB00105
DB11767,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sarilumab.,Sarilumab,DB00105
DB11776,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brodalumab.,Brodalumab,DB00105
DB11803,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirukumab.,Sirukumab,DB00105
DB11817,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Baricitinib.,Baricitinib,DB00105
DB11834,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Guselkumab.,Guselkumab,DB00105
DB11921,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deflazacort.,Deflazacort,DB00105
DB12025,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triptolide.,Triptolide,DB00105
DB12371,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siponimod.,Siponimod,DB00105
DB12612,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ozanimod.,Ozanimod,DB00105
DB12617,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mizoribine.,Mizoribine,DB00105
DB12692,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gusperimus.,Gusperimus,DB00105
DB12814,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00105
DB12902,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trofosfamide.,Trofosfamide,DB00105
DB12947,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxifluridine.,Doxifluridine,DB00105
DB12991,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deoxyspergualin.,Deoxyspergualin,DB00105
DB12996,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Acteoside.,Acteoside,DB00105
DB13003,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortivazol.,Cortivazol,DB00105
DB13014,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hypericin.,Hypericin,DB00105
DB13068,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00105
DB13208,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednylidene.,Prednylidene,DB00105
DB13223,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortin.,Fluocortin,DB00105
DB13241,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Begelomab.,Begelomab,DB00105
DB13491,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluperolone.,Fluperolone,DB00105
DB13664,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Formocortal.,Formocortal,DB00105
DB13728,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Halometasone.,Halometasone,DB00105
DB13843,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cloprednol.,Cloprednol,DB00105
DB13856,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluclorolone.,Fluclorolone,DB00105
DB13867,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone.,Fluticasone,DB00105
DB14066,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tetrandrine.,Tetrandrine,DB00105
DB14219,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00105
DB14512,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone furoate.,Mometasone furoate,DB00105
DB14538,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00105
DB14539,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00105
DB14545,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00105
DB14724,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Emapalumab.,Emapalumab,DB00105
DB14762,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Risankizumab.,Risankizumab,DB00105
DB14919,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rozanolixizumab.,Rozanolixizumab,DB00105
DB15253,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleselumab.,Bleselumab,DB00105
DB00108,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.,Natalizumab,DB00105
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2b.,Pimecrolimus,DB00105
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon alfa-2b.,Roflumilast,DB00105
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-2b.,Sipuleucel-T,DB00105
DB00041,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldesleukin.,Aldesleukin,DB00105
DB00363,The risk or severity of neutropenia can be increased when Interferon alfa-2b is combined with Clozapine.,Clozapine,DB00105
DB00333,The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2b.,Methadone,DB00105
DB00811,The risk or severity of anemia can be increased when Interferon alfa-2b is combined with Ribavirin.,Ribavirin,DB00105
DB00495,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Zidovudine.,Zidovudine,DB00105
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Interferon alfa-2b.,Darbepoetin alfa,DB00105
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Interferon alfa-2b.,Erythropoietin,DB00105
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Interferon alfa-2b.,Peginesatide,DB00105
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b.,Methoxy polyethylene glycol-epoetin beta,DB00105
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2b.,Zolmitriptan,DB00105
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2b.,Sulfamethoxazole,DB00105
DB04817,The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-2b.,Metamizole,DB00105
DB01265,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Telbivudine.,Telbivudine,DB00105
DB01097,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Leflunomide.,Leflunomide,DB00105
DB08895,Interferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00105
DB00072,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.,Trastuzumab,DB00105
DB08868,Interferon alfa-2b may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00105
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2b.,Tacrolimus,DB00105
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon alfa-2b.,Caffeine,DB00105
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon alfa-2b.,Dyphylline,DB00105
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-2b.,Pentoxifylline,DB00105
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-2b.,Oxtriphylline,DB00105
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon alfa-2b.,Theobromine,DB00105
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon alfa-2b.,Fenethylline,DB00105
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-2b.,8-azaguanine,DB00105
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-2b.","7,9-Dimethylguanine",DB00105
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon alfa-2b.,Xanthine,DB00105
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-2b.,7-Deazaguanine,DB00105
DB02377,The metabolism of Guanine can be decreased when combined with Interferon alfa-2b.,Guanine,DB00105
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-2b.,9-Methylguanine,DB00105
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon alfa-2b.,Peldesine,DB00105
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-2b.,Hypoxanthine,DB00105
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-2b.,9-Deazaguanine,DB00105
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon alfa-2b.,Propentofylline,DB00105
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-2b.,Valomaciclovir,DB00105
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-2b.,3-isobutyl-1-methyl-7H-xanthine,DB00105
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon alfa-2b.,Uric acid,DB00105
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon alfa-2b.,Doxofylline,DB00105
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-2b.,6-O-benzylguanine,DB00105
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon alfa-2b.,Lisofylline,DB00105
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon alfa-2b.,Lobucavir,DB00105
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon alfa-2b.,Cafedrine,DB00105
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-2b.,Theodrenaline,DB00105
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon alfa-2b.,Bamifylline,DB00105
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-2b.,Proxyphylline,DB00105
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon alfa-2b.,Acefylline,DB00105
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-2b.,Etamiphylline,DB00105
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon alfa-2b.,Pentifylline,DB00105
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon alfa-2b.,Bufylline,DB00105
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-2b.,Bromotheophylline,DB00105
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon alfa-2b.,Furafylline,DB00105
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-2b.,8-chlorotheophylline,DB00105
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon alfa-2b.,PCS-499,DB00105
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-2b.,G17DT,DB00105
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-2b.,PEV3A,DB00105
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-2b.,INGN 225,DB00105
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-2b.,Rindopepimut,DB00105
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-2b.,SRP 299,DB00105
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2b.,GI-5005,DB00105
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-2b.,Vitespen,DB00105
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-2b.,TG4010,DB00105
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2b.,Anthrax immune globulin human,DB00105
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-2b.","Rabies virus inactivated antigen, B",DB00105
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00105
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-2b.,Rotavirus vaccine,DB00105
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-2b.","Rabies virus inactivated antigen, A",DB00105
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00105
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00105
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00105
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00105
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00105
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00105
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-2b.,Typhoid Vi polysaccharide vaccine,DB00105
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2b.,Hepatitis A Vaccine,DB00105
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00105
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00105
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00105
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00105
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00105
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2b.,Human rabies virus immune globulin,DB00105
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.,Hepatitis B Vaccine (Recombinant),DB00105
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-2b.,Tecemotide,DB00105
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-2b.,Typhoid vaccine,DB00105
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00105
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00105
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00105
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00105
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00105
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00105
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00105
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-2b.,Vaccinia virus strain new york city board of health live antigen,DB00105
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-2b.,Pertussis vaccine,DB00105
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00105
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.,Varicella Zoster Vaccine (Recombinant),DB00105
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-2b.,Modified vaccinia ankara,DB00105
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-2b.","Ebola Zaire vaccine (live, attenuated)",DB00105
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-2b.,Abciximab,DB00105
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.,Eptifibatide,DB00105
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-2b.,Ticlopidine,DB00105
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-2b.,Tirofiban,DB00105
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2b.,Acetylsalicylic acid,DB00105
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2b.,Dipyridamole,DB00105
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-2b.,Iloprost,DB00105
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2b.,Sulfinpyrazone,DB00105
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-2b.,Ridogrel,DB00105
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-2b.,Sevoflurane,DB00105
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2b.,Epoprostenol,DB00105
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-2b.,Nimesulide,DB00105
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-2b.,Tesmilifene,DB00105
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-2b.,Defibrotide,DB00105
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-2b.,Beraprost,DB00105
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-2b.,Ibudilast,DB00105
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-2b.,Andrographolide,DB00105
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2b.,Caplacizumab,DB00105
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-2b.,Prasugrel,DB00105
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-2b.,Cangrelor,DB00105
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-2b.,Tranilast,DB00105
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-2b.,Triflusal,DB00105
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2b.,Ticagrelor,DB00105
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-2b.,Icosapent ethyl,DB00105
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-2b.,Vorapaxar,DB00105
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-2b.,Trapidil,DB00105
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-2b.,Naftopidil,DB00105
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-2b.,Sarpogrelate,DB00105
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-2b.,Ifetroban,DB00105
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-2b.,Nitroaspirin,DB00105
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-2b.,Ketanserin,DB00105
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-2b.,Indobufen,DB00105
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-2b.,Butylphthalide,DB00105
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-2b.,Hydroxytyrosol,DB00105
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-2b.,Ramatroban,DB00105
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-2b.,Picotamide,DB00105
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-2b.,Cloricromen,DB00105
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-2b.,Linsidomine,DB00105
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-2b.,Buflomedil,DB00105
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-2b.,Relcovaptan,DB00105
DB11988,Ocrelizumab may increase the immunosuppressive activities of Interferon alfa-2b.,Ocrelizumab,DB00105
DB13200,Interferon alfa-2b may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim,DB00105
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2b.,Rubella virus vaccine,DB00105
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon alfa-2b.,Varicella Zoster Vaccine (Live/attenuated),DB00105
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain tice live antigen,DB00105
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain connaught live antigen,DB00105
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-2b.,Yellow Fever Vaccine,DB00105
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-2b.,Anthrax vaccine,DB00105
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-2b.,Typhoid Vaccine Live,DB00105
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00105
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-2b.,BCG vaccine,DB00105
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-2b.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00105
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-2b.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00105
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-2b.,Adenovirus type 7 vaccine live,DB00105
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2b.,Palifermin,DB00105
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-2b.,Fluvoxamine,DB00105
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon alfa-2b.,Nicotine,DB00105
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2b.,Betaxolol,DB00105
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon alfa-2b.,Anagrelide,DB00105
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.,Disopyramide,DB00105
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon alfa-2b.,Lidocaine,DB00105
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-2b.,Conjugated estrogens,DB00105
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-2b.,Ropivacaine,DB00105
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2b.,Acetaminophen,DB00105
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon alfa-2b.,Olanzapine,DB00105
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-2b.,Chlorzoxazone,DB00105
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-2b.,Grepafloxacin,DB00105
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-2b.,Mirtazapine,DB00105
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon alfa-2b.,Mexiletine,DB00105
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon alfa-2b.,Tacrine,DB00105
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon alfa-2b.,Triamterene,DB00105
DB00420,The metabolism of Promazine can be decreased when combined with Interferon alfa-2b.,Promazine,DB00105
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon alfa-2b.,Zolpidem,DB00105
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon alfa-2b.,Entecavir,DB00105
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon alfa-2b.,Nabumetone,DB00105
DB00468,The metabolism of Quinine can be decreased when combined with Interferon alfa-2b.,Quinine,DB00105
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2b.,Fluoxetine,DB00105
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon alfa-2b.,Duloxetine,DB00105
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-2b.,Chlorpromazine,DB00105
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon alfa-2b.,Flutamide,DB00105
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.,Haloperidol,DB00105
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon alfa-2b.,Albendazole,DB00105
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-2b.,Rofecoxib,DB00105
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-2b.,Cinnarizine,DB00105
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon alfa-2b.,Propranolol,DB00105
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon alfa-2b.,Diclofenac,DB00105
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon alfa-2b.,Guanabenz,DB00105
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon alfa-2b.,Verapamil,DB00105
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2b.,Paroxetine,DB00105
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-2b.,Thiabendazole,DB00105
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon alfa-2b.,Riluzole,DB00105
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon alfa-2b.,Zileuton,DB00105
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-2b.,Clopidogrel,DB00105
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon alfa-2b.,Estradiol,DB00105
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon alfa-2b.,Acyclovir,DB00105
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon alfa-2b.,Naproxen,DB00105
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2b.,Trifluoperazine,DB00105
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2b.,Perphenazine,DB00105
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon alfa-2b.,Terbinafine,DB00105
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon alfa-2b.,Ranitidine,DB00105
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon alfa-2b.,Ethanol,DB00105
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2b.,Maprotiline,DB00105
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon alfa-2b.,Alosetron,DB00105
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-2b.,Lomefloxacin,DB00105
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon alfa-2b.,Ramelteon,DB00105
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-2b.,Frovatriptan,DB00105
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-2b.,Levobupivacaine,DB00105
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-2b.,Cinacalcet,DB00105
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon alfa-2b.,Selegiline,DB00105
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon alfa-2b.,Tocainide,DB00105
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon alfa-2b.,Praziquantel,DB00105
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon alfa-2b.,Melatonin,DB00105
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon alfa-2b.,Primaquine,DB00105
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon alfa-2b.,Hesperetin,DB00105
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon alfa-2b.,Nifedipine,DB00105
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon alfa-2b.,Carvedilol,DB00105
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon alfa-2b.,Cilostazol,DB00105
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon alfa-2b.,Propafenone,DB00105
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon alfa-2b.,Domperidone,DB00105
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-2b.,Dexfenfluramine,DB00105
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2b.,Rasagiline,DB00105
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-2b.,Temafloxacin,DB00105
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-2b.,Aminophenazone,DB00105
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon alfa-2b.,Antipyrine,DB00105
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon alfa-2b.,Bromazepam,DB00105
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2b.,Thiothixene,DB00105
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-2b.,Etoricoxib,DB00105
DB01645,The metabolism of Genistein can be decreased when combined with Interferon alfa-2b.,Genistein,DB00105
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon alfa-2b.,Resveratrol,DB00105
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon alfa-2b.,Phenacetin,DB00105
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-2b.,Estrone sulfate,DB00105
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon alfa-2b.,Flunarizine,DB00105
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-2b.,Lorcaserin,DB00105
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon alfa-2b.,Lofexidine,DB00105
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon alfa-2b.,Mianserin,DB00105
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2b.,Eltrombopag,DB00105
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon alfa-2b.,Asenapine,DB00105
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2b.,Vadimezan,DB00105
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2b.,Dapagliflozin,DB00105
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon alfa-2b.,Agomelatine,DB00105
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon alfa-2b.,Axitinib,DB00105
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-2b.,Benzyl alcohol,DB00105
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon alfa-2b.,Capsaicin,DB00105
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-2b.,(R)-warfarin,DB00105
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon alfa-2b.,Perampanel,DB00105
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-2b.,Tasimelteon,DB00105
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon alfa-2b.,Stiripentol,DB00105
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon alfa-2b.,Zotepine,DB00105
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon alfa-2b.,Propacetamol,DB00105
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon alfa-2b.,Ramosetron,DB00105
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2b.,Binimetinib,DB00105
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-2b.,Voxilaprevir,DB00105
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-2b.,Triclabendazole,DB00105
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon alfa-2b.,Rucaparib,DB00105
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-2b.,Dihydralazine,DB00105
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-2b.,Estradiol acetate,DB00105
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-2b.,Estradiol benzoate,DB00105
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-2b.,Estradiol cypionate,DB00105
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-2b.,Estradiol dienanthate,DB00105
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-2b.,Estradiol valerate,DB00105
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon alfa-2b.,Istradefylline,DB00105
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon alfa-2b.,Azelastine,DB00105
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2b.,Efavirenz,DB00105
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2b.,Metoclopramide,DB00105
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon alfa-2b.,Bicifadine,DB00105
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon alfa-2b.,GTS-21,DB00105
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon alfa-2b.,Flecainide,DB00105
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2b.,Ethinylestradiol,DB00105
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-2b.,Amitriptyline,DB00105
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b.,Imipramine,DB00105
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon alfa-2b.,Doxepin,DB00105
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-2b.,Mephenytoin,DB00105
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-2b.,Nortriptyline,DB00105
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon alfa-2b.,Clonidine,DB00105
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2b.,Cyclobenzaprine,DB00105
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon alfa-2b.,Desipramine,DB00105
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon alfa-2b.,Clomipramine,DB00105
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon alfa-2b.,Selumetinib,DB00105
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon alfa-2b.,Theophylline,DB00105
DB00564,The metabolism of Carbamazepine can be decreased when combined with Interferon alfa-2b.,Carbamazepine,DB00105
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon alfa-2b.,Warfarin,DB00105
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon alfa-2b.,Tizanidine,DB00105
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon alfa-2b.,Pimozide,DB00105
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon alfa-2b.,Aminophylline,DB00105
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2b.,Acenocoumarol,DB00105
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2b.,Erlotinib,DB00105
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon alfa-2b.,Tegafur,DB00105
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon alfa-2b.,Enasidenib,DB00105
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-2b.,Tamoxifen,DB00105
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.,Lepirudin,DB00105
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2b.,Bivalirudin,DB00105
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2b.,Alteplase,DB00105
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2b.,Urokinase,DB00105
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.,Reteplase,DB00105
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2b.,Anistreplase,DB00105
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2b.,Tenecteplase,DB00105
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.,Drotrecogin alfa,DB00105
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.,Streptokinase,DB00105
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-2b.,Dicoumarol,DB00105
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-2b.,Argatroban,DB00105
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-2b.,Ardeparin,DB00105
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-2b.,Phenindione,DB00105
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-2b.,Fondaparinux,DB00105
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-2b.,Pentosan polysulfate,DB00105
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-2b.,Phenprocoumon,DB00105
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-2b.,Heparin,DB00105
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-2b.,Enoxaparin,DB00105
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-2b.,4-hydroxycoumarin,DB00105
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-2b.,Coumarin,DB00105
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-2b.,Ximelagatran,DB00105
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-2b.,Desmoteplase,DB00105
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-2b.,Ancrod,DB00105
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-2b.,Fibrinolysin,DB00105
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-2b.,Rivaroxaban,DB00105
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-2b.,Sulodexide,DB00105
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-2b.,Semuloparin,DB00105
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-2b.,Idraparinux,DB00105
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-2b.,Astaxanthin,DB00105
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-2b.,Apixaban,DB00105
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-2b.,Otamixaban,DB00105
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-2b.,Amediplase,DB00105
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2b.,Dabigatran etexilate,DB00105
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-2b.,Danaparoid,DB00105
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-2b.,Dalteparin,DB00105
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-2b.,Tinzaparin,DB00105
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-2b.,Ferulic acid,DB00105
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-2b.,Ethyl biscoumacetate,DB00105
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-2b.,Nadroparin,DB00105
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-2b.,Ditazole,DB00105
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-2b.,Edoxaban,DB00105
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-2b.,Potassium citrate,DB00105
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2b.,Sodium citrate,DB00105
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-2b.,Dextran,DB00105
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-2b.,Bemiparin,DB00105
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-2b.,Reviparin,DB00105
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-2b.,Parnaparin,DB00105
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-2b.,Certoparin,DB00105
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-2b.,Desirudin,DB00105
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-2b.,Zinc citrate,DB00105
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2b.,Antithrombin Alfa,DB00105
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-2b.,Protein C,DB00105
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2b.,Antithrombin III human,DB00105
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-2b.,Letaxaban,DB00105
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-2b.,Darexaban,DB00105
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-2b.,Betrixaban,DB00105
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-2b.,Nafamostat,DB00105
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-2b.,Monteplase,DB00105
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-2b.,Gabexate,DB00105
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-2b.,Fluindione,DB00105
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-2b.,Protein S human,DB00105
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-2b.,Brinase,DB00105
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-2b.,Clorindione,DB00105
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-2b.,Diphenadione,DB00105
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-2b.,Tioclomarol,DB00105
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-2b.,Melagatran,DB00105
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-2b.,Saruplase,DB00105
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-2b.,(S)-Warfarin,DB00105
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-2b.,Tocopherylquinone,DB00105
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-2b.,Edetate calcium disodium anhydrous,DB00105
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2b.,Dabigatran,DB00105
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2b.,Methyclothiazide,DB00105
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2b.,Bendroflumethiazide,DB00105
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-2b.,Benzthiazide,DB00105
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-2b.,Cyclothiazide,DB00105
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-2b.,Hydroflumethiazide,DB00105
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-2b.,Chlorothiazide,DB00105
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-2b.,Hydrochlorothiazide,DB00105
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-2b.,Trichlormethiazide,DB00105
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-2b.,Polythiazide,DB00105
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-2b.,Mebutizide,DB00105
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-2b.,Cyclopenthiazide,DB00105
DB09042,The risk or severity of myelosuppression can be increased when Interferon alfa-2b is combined with Tedizolid phosphate.,Tedizolid phosphate,DB00105
DB00091,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00105
DB00268,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ropinirole.,Ropinirole,DB00105
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.,Cyanocobalamin,DB00105
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-2b.,Allopurinol,DB00105
DB12978,Interferon alfa-2b may increase the hepatotoxic activities of Pexidartinib.,Pexidartinib,DB00105
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-2b.,Magnesium,DB00105
DB01601,The serum concentration of Interferon alfa-2b can be increased when it is combined with Lopinavir.,Lopinavir,DB00105
DB12530,The risk or severity of infection can be increased when Interferon alfa-2b is combined with Inebilizumab.,Inebilizumab,DB00105
DB00429,Carboprost tromethamine may increase the uterotonic activities of Oxytocin.,Carboprost tromethamine,DB00107
DB00917,The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.,Dinoprostone,DB00107
DB00929,The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.,Misoprostol,DB00107
DB00007,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.,Leuprolide,DB00107
DB00014,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.,Goserelin,DB00107
DB00195,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Betaxolol.,Betaxolol,DB00107
DB00199,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.,Erythromycin,DB00107
DB00207,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azithromycin.,Azithromycin,DB00107
DB00218,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.,Moxifloxacin,DB00107
DB00243,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ranolazine.,Ranolazine,DB00107
DB00263,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfisoxazole.,Sulfisoxazole,DB00107
DB00321,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amitriptyline.,Amitriptyline,DB00107
DB00333,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.,Methadone,DB00107
DB00343,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diltiazem.,Diltiazem,DB00107
DB00363,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clozapine.,Clozapine,DB00107
DB00391,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulpiride.,Sulpiride,DB00107
DB00393,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nimodipine.,Nimodipine,DB00107
DB00420,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promazine.,Promazine,DB00107
DB00433,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.,Prochlorperazine,DB00107
DB00450,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Droperidol.,Droperidol,DB00107
DB00458,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.,Imipramine,DB00107
DB00477,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpromazine.,Chlorpromazine,DB00107
DB00526,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.,Oxaliplatin,DB00107
DB00537,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.,Ciprofloxacin,DB00107
DB00544,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.,Fluorouracil,DB00107
DB00556,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perflutren.,Perflutren,DB00107
DB00568,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.,Cinnarizine,DB00107
DB00571,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propranolol.,Propranolol,DB00107
DB00572,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.,Atropine,DB00107
DB00608,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chloroquine.,Chloroquine,DB00107
DB00625,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.,Efavirenz,DB00107
DB00640,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.,Adenosine,DB00107
DB00738,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pentamidine.,Pentamidine,DB00107
DB00743,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gadobenic acid.,Gadobenic acid,DB00107
DB00748,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Carbinoxamine.,Carbinoxamine,DB00107
DB00757,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.,Dolasetron,DB00107
DB00778,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Roxithromycin.,Roxithromycin,DB00107
DB00779,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nalidixic acid.,Nalidixic acid,DB00107
DB00827,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinoxacin.,Cinoxacin,DB00107
DB00836,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loperamide.,Loperamide,DB00107
DB00889,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.,Granisetron,DB00107
DB00904,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ondansetron.,Ondansetron,DB00107
DB00922,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levosimendan.,Levosimendan,DB00107
DB00933,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mesoridazine.,Mesoridazine,DB00107
DB00967,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desloratadine.,Desloratadine,DB00107
DB00976,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telithromycin.,Telithromycin,DB00107
DB00978,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lomefloxacin.,Lomefloxacin,DB00107
DB00985,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.,Dimenhydrinate,DB00107
DB01087,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Primaquine.,Primaquine,DB00107
DB01113,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.,Papaverine,DB00107
DB01114,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpheniramine.,Chlorpheniramine,DB00107
DB01115,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nifedipine.,Nifedipine,DB00107
DB01137,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.,Levofloxacin,DB00107
DB01155,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gemifloxacin.,Gemifloxacin,DB00107
DB01165,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ofloxacin.,Ofloxacin,DB00107
DB01182,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.,Propafenone,DB00107
DB01193,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acebutolol.,Acebutolol,DB00107
DB01195,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flecainide.,Flecainide,DB00107
DB01211,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clarithromycin.,Clarithromycin,DB00107
DB01227,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levacetylmethadol.,Levacetylmethadol,DB00107
DB01232,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Saquinavir.,Saquinavir,DB00107
DB01242,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clomipramine.,Clomipramine,DB00107
DB01388,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mibefradil.,Mibefradil,DB00107
DB01580,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxprenolol.,Oxprenolol,DB00107
DB01599,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Probucol.,Probucol,DB00107
DB01615,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aceprometazine.,Aceprometazine,DB00107
DB02638,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terlipressin.,Terlipressin,DB00107
DB04825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prenylamine.,Prenylamine,DB00107
DB04842,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.,Fluspirilene,DB00107
DB04948,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lofexidine.,Lofexidine,DB00107
DB04957,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azimilide.,Azimilide,DB00107
DB05223,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pracinostat.,Pracinostat,DB00107
DB05488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin,DB00107
DB06160,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Garenoxacin.,Garenoxacin,DB00107
DB06200,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tedisamil.,Tedisamil,DB00107
DB06334,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tucidinostat.,Tucidinostat,DB00107
DB06402,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telavancin.,Telavancin,DB00107
DB06589,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazopanib.,Pazopanib,DB00107
DB06600,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nemonoxacin.,Nemonoxacin,DB00107
DB06603,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Panobinostat.,Panobinostat,DB00107
DB06712,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilvadipine.,Nilvadipine,DB00107
DB08799,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Antazoline.,Antazoline,DB00107
DB08865,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Crizotinib.,Crizotinib,DB00107
DB08903,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bedaquiline.,Bedaquiline,DB00107
DB08952,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indenolol.,Indenolol,DB00107
DB08980,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.,Fendiline,DB00107
DB08992,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eperisone.,Eperisone,DB00107
DB09016,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Butriptyline.,Butriptyline,DB00107
DB09063,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib.,Ceritinib,DB00107
DB09078,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.,Lenvatinib,DB00107
DB09224,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Melperone.,Melperone,DB00107
DB09231,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benidipine.,Benidipine,DB00107
DB09555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate,DB00107
DB11640,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amifampridine.,Amifampridine,DB00107
DB11830,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mocetinostat.,Mocetinostat,DB00107
DB11841,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entinostat.,Entinostat,DB00107
DB12141,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib.,Gilteritinib,DB00107
DB12174,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-101.,CUDC-101,DB00107
DB12286,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Simendan.,Simendan,DB00107
DB12376,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ricolinostat.,Ricolinostat,DB00107
DB12523,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mizolastine.,Mizolastine,DB00107
DB12565,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Abexinostat.,Abexinostat,DB00107
DB12877,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxatomide.,Oxatomide,DB00107
DB13261,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sitafloxacin.,Sitafloxacin,DB00107
DB13273,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sultopride.,Sultopride,DB00107
DB13500,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Otilonium.,Otilonium,DB00107
DB13546,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nizofenone.,Nizofenone,DB00107
DB13652,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bunaftine.,Bunaftine,DB00107
DB13653,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorcainide.,Lorcainide,DB00107
DB13679,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine.,Dexchlorpheniramine,DB00107
DB13791,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Penfluridol.,Penfluridol,DB00107
DB14063,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexverapamil.,Dexverapamil,DB00107
DB14568,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib.,Ivosidenib,DB00107
DB01224,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quetiapine.,Quetiapine,DB00107
DB11718,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.,Encorafenib,DB00107
DB00204,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dofetilide.,Dofetilide,DB00107
DB00215,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.,Citalopram,DB00107
DB00261,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anagrelide.,Anagrelide,DB00107
DB00280,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.,Disopyramide,DB00107
DB00283,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clemastine.,Clemastine,DB00107
DB00308,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibutilide.,Ibutilide,DB00107
DB00313,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.,Valproic acid,DB00107
DB00342,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terfenadine.,Terfenadine,DB00107
DB00365,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Grepafloxacin.,Grepafloxacin,DB00107
DB00468,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinine.,Quinine,DB00107
DB00489,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sotalol.,Sotalol,DB00107
DB00530,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib.,Erlotinib,DB00107
DB00539,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Toremifene.,Toremifene,DB00107
DB00604,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cisapride.,Cisapride,DB00107
DB00619,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imatinib.,Imatinib,DB00107
DB00637,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Astemizole.,Astemizole,DB00107
DB00679,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thioridazine.,Thioridazine,DB00107
DB00685,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trovafloxacin.,Trovafloxacin,DB00107
DB00834,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mifepristone.,Mifepristone,DB00107
DB00875,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flupentixol.,Flupentixol,DB00107
DB00907,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cocaine.,Cocaine,DB00107
DB00908,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinidine.,Quinidine,DB00107
DB01035,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Procainamide.,Procainamide,DB00107
DB01100,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pimozide.,Pimozide,DB00107
DB01118,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amiodarone.,Amiodarone,DB00107
DB01169,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arsenic trioxide.,Arsenic trioxide,DB00107
DB01175,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Escitalopram.,Escitalopram,DB00107
DB01184,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Domperidone.,Domperidone,DB00107
DB01208,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sparfloxacin.,Sparfloxacin,DB00107
DB01218,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Halofantrine.,Halofantrine,DB00107
DB01244,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bepridil.,Bepridil,DB00107
DB01267,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.,Paliperidone,DB00107
DB01356,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lithium cation.,Lithium cation,DB00107
DB01405,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temafloxacin.,Temafloxacin,DB00107
DB01624,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zuclopenthixol.,Zuclopenthixol,DB00107
DB04844,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrabenazine.,Tetrabenazine,DB00107
DB04855,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dronedarone.,Dronedarone,DB00107
DB04868,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilotinib.,Nilotinib,DB00107
DB04946,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Iloperidone.,Iloperidone,DB00107
DB05294,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vandetanib.,Vandetanib,DB00107
DB06176,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin.,Romidepsin,DB00107
DB06216,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Asenapine.,Asenapine,DB00107
DB06697,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Artemether.,Artemether,DB00107
DB06708,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lumefantrine.,Lumefantrine,DB00107
DB09039,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eliglustat.,Eliglustat,DB00107
DB09083,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivabradine.,Ivabradine,DB00107
DB11730,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ribociclib.,Ribociclib,DB00107
DB11978,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib.,Glasdegib,DB00107
DB12161,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Deutetrabenazine.,Deutetrabenazine,DB00107
DB13074,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Macimorelin.,Macimorelin,DB00107
DB13725,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terodiline.,Terodiline,DB00107
DB08881,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vemurafenib.,Vemurafenib,DB00107
DB11637,Oxytocin may increase the QTc-prolonging activities of Delamanid.,Delamanid,DB00107
DB00104,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.,Octreotide,DB00107
DB00187,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Esmolol.,Esmolol,DB00107
DB00188,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib.,Bortezomib,DB00107
DB00196,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluconazole.,Fluconazole,DB00107
DB00220,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nelfinavir.,Nelfinavir,DB00107
DB00230,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pregabalin.,Pregabalin,DB00107
DB00245,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benzatropine.,Benzatropine,DB00107
DB00270,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isradipine.,Isradipine,DB00107
DB00285,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Venlafaxine.,Venlafaxine,DB00107
DB00289,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atomoxetine.,Atomoxetine,DB00107
DB00334,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olanzapine.,Olanzapine,DB00107
DB00341,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cetirizine.,Cetirizine,DB00107
DB00344,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Protriptyline.,Protriptyline,DB00107
DB00346,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.,Alfuzosin,DB00107
DB00347,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimethadione.,Trimethadione,DB00107
DB00354,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buclizine.,Buclizine,DB00107
DB00358,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mefloquine.,Mefloquine,DB00107
DB00366,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxylamine.,Doxylamine,DB00107
DB00370,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirtazapine.,Mirtazapine,DB00107
DB00373,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Timolol.,Timolol,DB00107
DB00374,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Treprostinil.,Treprostinil,DB00107
DB00390,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digoxin.,Digoxin,DB00107
DB00398,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sorafenib.,Sorafenib,DB00107
DB00405,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.,Dexbrompheniramine,DB00107
DB00424,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hyoscyamine.,Hyoscyamine,DB00107
DB00427,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triprolidine.,Triprolidine,DB00107
DB00434,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyproheptadine.,Cyproheptadine,DB00107
DB00467,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Enoxacin.,Enoxacin,DB00107
DB00487,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pefloxacin.,Pefloxacin,DB00107
DB00503,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ritonavir.,Ritonavir,DB00107
DB00529,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Foscarnet.,Foscarnet,DB00107
DB00540,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nortriptyline.,Nortriptyline,DB00107
DB00543,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amoxapine.,Amoxapine,DB00107
DB00555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lamotrigine.,Lamotrigine,DB00107
DB00582,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Voriconazole.,Voriconazole,DB00107
DB00593,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ethosuximide.,Ethosuximide,DB00107
DB00613,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amodiaquine.,Amodiaquine,DB00107
DB00622,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nicardipine.,Nicardipine,DB00107
DB00674,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Galantamine.,Galantamine,DB00107
DB00675,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tamoxifen.,Tamoxifen,DB00107
DB00678,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Losartan.,Losartan,DB00107
DB00680,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moricizine.,Moricizine,DB00107
DB00691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moexipril.,Moexipril,DB00107
DB00697,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tizanidine.,Tizanidine,DB00107
DB00710,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.,Ibandronate,DB00107
DB00714,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.,Apomorphine,DB00107
DB00719,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azatadine.,Azatadine,DB00107
DB00726,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimipramine.,Trimipramine,DB00107
DB00734,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Risperidone.,Risperidone,DB00107
DB00753,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isoflurane.,Isoflurane,DB00107
DB00808,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indapamide.,Indapamide,DB00107
DB00817,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rosoxacin.,Rosoxacin,DB00107
DB00818,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propofol.,Propofol,DB00107
DB00822,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disulfiram.,Disulfiram,DB00107
DB00825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levomenthol.,Levomenthol,DB00107
DB00835,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Brompheniramine.,Brompheniramine,DB00107
DB00862,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vardenafil.,Vardenafil,DB00107
DB00864,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.,Tacrolimus,DB00107
DB00871,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.,Terbutaline,DB00107
DB00909,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zonisamide.,Zonisamide,DB00107
DB00915,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.,Amantadine,DB00107
DB00916,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metronidazole.,Metronidazole,DB00107
DB00920,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketotifen.,Ketotifen,DB00107
DB00927,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.,Famotidine,DB00107
DB00934,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.,Maprotiline,DB00107
DB00938,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.,Salmeterol,DB00107
DB00949,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felbamate.,Felbamate,DB00107
DB00983,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Formoterol.,Formoterol,DB00107
DB00999,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydrochlorothiazide.,Hydrochlorothiazide,DB00107
DB01001,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salbutamol.,Salbutamol,DB00107
DB01015,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfamethoxazole.,Sulfamethoxazole,DB00107
DB01023,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felodipine.,Felodipine,DB00107
DB01026,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketoconazole.,Ketoconazole,DB00107
DB01036,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tolterodine.,Tolterodine,DB00107
DB01044,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gatifloxacin.,Gatifloxacin,DB00107
DB01054,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nitrendipine.,Nitrendipine,DB00107
DB01059,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Norfloxacin.,Norfloxacin,DB00107
DB01069,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promethazine.,Promethazine,DB00107
DB01071,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mequitazine.,Mequitazine,DB00107
DB01072,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atazanavir.,Atazanavir,DB00107
DB01074,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perhexiline.,Perhexiline,DB00107
DB01075,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diphenhydramine.,Diphenhydramine,DB00107
DB01106,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocabastine.,Levocabastine,DB00107
DB01142,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxepin.,Doxepin,DB00107
DB01151,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desipramine.,Desipramine,DB00107
DB01158,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bretylium.,Bretylium,DB00107
DB01166,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cilostazol.,Cilostazol,DB00107
DB01167,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Itraconazole.,Itraconazole,DB00107
DB01173,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orphenadrine.,Orphenadrine,DB00107
DB01176,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyclizine.,Cyclizine,DB00107
DB01189,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desflurane.,Desflurane,DB00107
DB01228,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encainide.,Encainide,DB00107
DB01233,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.,Metoclopramide,DB00107
DB01236,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sevoflurane.,Sevoflurane,DB00107
DB01238,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.,Aripiprazole,DB00107
DB01239,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorprothixene.,Chlorprothixene,DB00107
DB01246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alimemazine.,Alimemazine,DB00107
DB01254,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.,Dasatinib,DB00107
DB01259,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lapatinib.,Lapatinib,DB00107
DB01263,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Posaconazole.,Posaconazole,DB00107
DB01268,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sunitinib.,Sunitinib,DB00107
DB01274,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arformoterol.,Arformoterol,DB00107
DB01396,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digitoxin.,Digitoxin,DB00107
DB01403,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methotrimeprazine.,Methotrimeprazine,DB00107
DB01426,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ajmaline.,Ajmaline,DB00107
DB01591,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Solifenacin.,Solifenacin,DB00107
DB01611,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00107
DB01620,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pheniramine.,Pheniramine,DB00107
DB01623,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thiothixene.,Thiothixene,DB00107
DB02546,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vorinostat.,Vorinostat,DB00107
DB04576,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fleroxacin.,Fleroxacin,DB00107
DB04695,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl thiopyrophosphate.,Farnesyl thiopyrophosphate,DB00107
DB04846,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Celiprolol.,Celiprolol,DB00107
DB04953,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ezogabine.,Ezogabine,DB00107
DB05039,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indacaterol.,Indacaterol,DB00107
DB05246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.,Methsuximide,DB00107
DB05465,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tandutinib.,Tandutinib,DB00107
DB06217,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vernakalant.,Vernakalant,DB00107
DB06282,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocetirizine.,Levocetirizine,DB00107
DB06288,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amisulpride.,Amisulpride,DB00107
DB06468,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cariporide.,Cariporide,DB00107
DB06663,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pasireotide.,Pasireotide,DB00107
DB06691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mepyramine.,Mepyramine,DB00107
DB06699,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix.,Degarelix,DB00107
DB06719,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buserelin.,Buserelin,DB00107
DB06788,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Histrelin.,Histrelin,DB00107
DB06825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin.,Triptorelin,DB00107
DB07780,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl diphosphate.,Farnesyl diphosphate,DB00107
DB07841,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Geranylgeranyl diphosphate.,Geranylgeranyl diphosphate,DB00107
DB08808,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bupranolol.,Bupranolol,DB00107
DB08815,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lurasidone.,Lurasidone,DB00107
DB08864,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rilpivirine.,Rilpivirine,DB00107
DB08871,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin.,Eribulin,DB00107
DB08893,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirabegron.,Mirabegron,DB00107
DB08912,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib.,Dabrafenib,DB00107
DB08936,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorcyclizine.,Chlorcyclizine,DB00107
DB08972,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flumequine.,Flumequine,DB00107
DB09080,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olodaterol.,Olodaterol,DB00107
DB09082,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vilanterol.,Vilanterol,DB00107
DB09089,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimebutine.,Trimebutine,DB00107
DB09090,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pinaverium.,Pinaverium,DB00107
DB09167,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dosulepin.,Dosulepin,DB00107
DB09229,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aranidipine.,Aranidipine,DB00107
DB09235,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efonidipine.,Efonidipine,DB00107
DB09236,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lacidipine.,Lacidipine,DB00107
DB09239,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Niguldipine.,Niguldipine,DB00107
DB09488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acrivastine.,Acrivastine,DB00107
DB11390,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Coumaphos.,Coumaphos,DB00107
DB11397,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dichlorvos.,Dichlorvos,DB00107
DB11408,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famphur.,Famphur,DB00107
DB11412,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fenthion.,Fenthion,DB00107
DB11443,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orbifloxacin.,Orbifloxacin,DB00107
DB11448,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Phosmet.,Phosmet,DB00107
DB11491,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sarafloxacin.,Sarafloxacin,DB00107
DB11511,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Difloxacin.,Difloxacin,DB00107
DB11591,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bilastine.,Bilastine,DB00107
DB11614,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rupatadine.,Rupatadine,DB00107
DB11742,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ebastine.,Ebastine,DB00107
DB11770,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Talinolol.,Talinolol,DB00107
DB11774,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazufloxacin.,Pazufloxacin,DB00107
DB11785,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anisodamine.,Anisodamine,DB00107
DB11891,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-907.,CUDC-907,DB00107
DB11892,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prulifloxacin.,Prulifloxacin,DB00107
DB11943,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Delafloxacin.,Delafloxacin,DB00107
DB12093,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrahydropalmatine.,Tetrahydropalmatine,DB00107
DB12231,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temefos.,Temefos,DB00107
DB12245,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triclabendazole.,Triclabendazole,DB00107
DB12645,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Givinostat.,Givinostat,DB00107
DB12712,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pilsicainide.,Pilsicainide,DB00107
DB12766,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cicletanine.,Cicletanine,DB00107
DB12923,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gallopamil.,Gallopamil,DB00107
DB13358,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cibenzoline.,Cibenzoline,DB00107
DB13488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bencyclane.,Bencyclane,DB00107
DB13555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prajmaline.,Prajmaline,DB00107
DB13627,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxolinic acid.,Oxolinic acid,DB00107
DB13651,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorajmine.,Lorajmine,DB00107
DB13691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acetyldigoxin.,Acetyldigoxin,DB00107
DB13744,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Piromidic acid.,Piromidic acid,DB00107
DB13766,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lidoflazine.,Lidoflazine,DB00107
DB13772,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rufloxacin.,Rufloxacin,DB00107
DB13823,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pipemidic acid.,Pipemidic acid,DB00107
DB14185,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole lauroxil.,Aripiprazole lauroxil,DB00107
DB14713,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Inotersen.,Inotersen,DB00107
DB01601,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lopinavir.,Lopinavir,DB00107
DB00845,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clofazimine.,Clofazimine,DB00107
DB00656,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxytocin.,Trazodone,DB00107
DB11986,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib.,Entrectinib,DB00107
DB11642,Oxytocin may increase the QTc-prolonging activities of Pitolisant.,Pitolisant,DB00107
DB12825,Lefamulin may increase the QTc-prolonging activities of Oxytocin.,Lefamulin,DB00107
DB00388,The risk or severity of hypertension can be increased when Oxytocin is combined with Phenylephrine.,Phenylephrine,DB00107
DB00557,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxyzine.,Hydroxyzine,DB00107
DB00246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.,Ziprasidone,DB00107
DB00502,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.,Haloperidol,DB00107
DB01364,The risk or severity of hypertension can be increased when Oxytocin is combined with Ephedrine.,Ephedrine,DB00107
DB00472,The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin.,Fluoxetine,DB00107
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.,Denosumab,DB00108
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.,Etanercept,DB00108
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab.,Peginterferon alfa-2a,DB00108
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Natalizumab.,Interferon alfa-n1,DB00108
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Natalizumab.,Interferon alfa-n3,DB00108
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Natalizumab.,Peginterferon alfa-2b,DB00108
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.,Anakinra,DB00108
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Natalizumab.,Interferon gamma-1b,DB00108
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Natalizumab.","Interferon alfa-2a, Recombinant",DB00108
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Natalizumab.,Aldesleukin,DB00108
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.,Adalimumab,DB00108
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.,Gemtuzumab ozogamicin,DB00108
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.,Pegaspargase,DB00108
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.,Infliximab,DB00108
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.,Interferon beta-1b,DB00108
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.,Interferon alfacon-1,DB00108
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.,Trastuzumab,DB00108
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.,Rituximab,DB00108
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.,Basiliximab,DB00108
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.,Muromonab,DB00108
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.,Ibritumomab tiuxetan,DB00108
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.,Tositumomab,DB00108
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.,Alemtuzumab,DB00108
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.,Alefacept,DB00108
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.,Efalizumab,DB00108
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.,Antithymocyte immunoglobulin (rabbit),DB00108
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.,Interferon alfa-2b,DB00108
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.,Daclizumab,DB00108
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.,Bevacizumab,DB00108
DB00120,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Natalizumab.,Phenylalanine,DB00108
DB00180,The risk or severity of adverse effects can be increased when Flunisolide is combined with Natalizumab.,Flunisolide,DB00108
DB00188,The risk or severity of adverse effects can be increased when Bortezomib is combined with Natalizumab.,Bortezomib,DB00108
DB00242,The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.,Cladribine,DB00108
DB00262,The risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.,Carmustine,DB00108
DB00276,The risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.,Amsacrine,DB00108
DB00290,The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.,Bleomycin,DB00108
DB00291,The risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.,Chlorambucil,DB00108
DB00293,The risk or severity of adverse effects can be increased when Raltitrexed is combined with Natalizumab.,Raltitrexed,DB00108
DB00305,The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.,Mitomycin,DB00108
DB00307,The risk or severity of adverse effects can be increased when Bexarotene is combined with Natalizumab.,Bexarotene,DB00108
DB00309,The risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.,Vindesine,DB00108
DB00322,The risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.,Floxuridine,DB00108
DB00328,The risk or severity of adverse effects can be increased when Indomethacin is combined with Natalizumab.,Indomethacin,DB00108
DB00352,The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.,Tioguanine,DB00108
DB00361,The risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.,Vinorelbine,DB00108
DB00380,The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab.,Dexrazoxane,DB00108
DB00394,The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Natalizumab.,Beclomethasone dipropionate,DB00108
DB00398,The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.,Sorafenib,DB00108
DB00428,The risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.,Streptozocin,DB00108
DB00432,The risk or severity of adverse effects can be increased when Trifluridine is combined with Natalizumab.,Trifluridine,DB00108
DB00441,The risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.,Gemcitabine,DB00108
DB00443,The risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.,Betamethasone,DB00108
DB00444,The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.,Teniposide,DB00108
DB00445,The risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.,Epirubicin,DB00108
DB00446,The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Natalizumab.,Chloramphenicol,DB00108
DB00480,The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.,Lenalidomide,DB00108
DB00488,The risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.,Altretamine,DB00108
DB00495,The risk or severity of adverse effects can be increased when Zidovudine is combined with Natalizumab.,Zidovudine,DB00108
DB00515,The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.,Cisplatin,DB00108
DB00526,The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.,Oxaliplatin,DB00108
DB00531,The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.,Cyclophosphamide,DB00108
DB00541,The risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.,Vincristine,DB00108
DB00544,The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.,Fluorouracil,DB00108
DB00550,The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Natalizumab.,Propylthiouracil,DB00108
DB00552,The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.,Pentostatin,DB00108
DB00563,The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.,Methotrexate,DB00108
DB00564,The risk or severity of adverse effects can be increased when Carbamazepine is combined with Natalizumab.,Carbamazepine,DB00108
DB00570,The risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.,Vinblastine,DB00108
DB00588,The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Natalizumab.,Fluticasone propionate,DB00108
DB00591,The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Natalizumab.,Fluocinolone acetonide,DB00108
DB00601,The risk or severity of adverse effects can be increased when Linezolid is combined with Natalizumab.,Linezolid,DB00108
DB00619,The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.,Imatinib,DB00108
DB00620,The risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.,Triamcinolone,DB00108
DB00631,The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.,Clofarabine,DB00108
DB00635,The risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.,Prednisone,DB00108
DB00642,The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.,Pemetrexed,DB00108
DB00687,The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.,Fludrocortisone,DB00108
DB00688,The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.,Mycophenolate mofetil,DB00108
DB00694,The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.,Daunorubicin,DB00108
DB00741,The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.,Hydrocortisone,DB00108
DB00755,The risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.,Tretinoin,DB00108
DB00762,The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.,Irinotecan,DB00108
DB00763,The risk or severity of adverse effects can be increased when Methimazole is combined with Natalizumab.,Methimazole,DB00108
DB00764,The risk or severity of adverse effects can be increased when Mometasone is combined with Natalizumab.,Mometasone,DB00108
DB00773,The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.,Etoposide,DB00108
DB00795,The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Natalizumab.,Sulfasalazine,DB00108
DB00851,The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.,Dacarbazine,DB00108
DB00853,The risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.,Temozolomide,DB00108
DB00859,The risk or severity of adverse effects can be increased when Penicillamine is combined with Natalizumab.,Penicillamine,DB00108
DB00860,The risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.,Prednisolone,DB00108
DB00864,The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.,Tacrolimus,DB00108
DB00877,The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.,Sirolimus,DB00108
DB00888,The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.,Mechlorethamine,DB00108
DB00928,The risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.,Azacitidine,DB00108
DB00958,The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.,Carboplatin,DB00108
DB00959,The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.,Methylprednisolone,DB00108
DB00970,The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.,Dactinomycin,DB00108
DB00987,The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.,Cytarabine,DB00108
DB00993,The risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.,Azathioprine,DB00108
DB00997,The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.,Doxorubicin,DB00108
DB01005,The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.,Hydroxyurea,DB00108
DB01008,The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.,Busulfan,DB00108
DB01024,The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.,Mycophenolic acid,DB00108
DB01030,The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.,Topotecan,DB00108
DB01033,The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.,Mercaptopurine,DB00108
DB01041,The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.,Thalidomide,DB00108
DB01042,The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.,Melphalan,DB00108
DB01073,The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.,Fludarabine,DB00108
DB01097,The risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.,Leflunomide,DB00108
DB01099,The risk or severity of adverse effects can be increased when Flucytosine is combined with Natalizumab.,Flucytosine,DB00108
DB01101,The risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.,Capecitabine,DB00108
DB01108,The risk or severity of adverse effects can be increased when Trilostane is combined with Natalizumab.,Trilostane,DB00108
DB01168,The risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.,Procarbazine,DB00108
DB01169,The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Natalizumab.,Arsenic trioxide,DB00108
DB01177,The risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.,Idarubicin,DB00108
DB01181,The risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.,Ifosfamide,DB00108
DB01196,The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.,Estramustine,DB00108
DB01204,The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.,Mitoxantrone,DB00108
DB01206,The risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.,Lomustine,DB00108
DB01222,The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.,Budesonide,DB00108
DB01229,The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.,Paclitaxel,DB00108
DB01234,The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.,Dexamethasone,DB00108
DB01248,The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.,Docetaxel,DB00108
DB01254,The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.,Dasatinib,DB00108
DB01257,The risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.,Eculizumab,DB00108
DB01262,The risk or severity of adverse effects can be increased when Decitabine is combined with Natalizumab.,Decitabine,DB00108
DB01268,The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.,Sunitinib,DB00108
DB01280,The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.,Nelarabine,DB00108
DB01281,The risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.,Abatacept,DB00108
DB01285,The risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.,Corticotropin,DB00108
DB01380,The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.,Cortisone acetate,DB00108
DB01384,The risk or severity of adverse effects can be increased when Paramethasone is combined with Natalizumab.,Paramethasone,DB00108
DB01394,The risk or severity of adverse effects can be increased when Colchicine is combined with Natalizumab.,Colchicine,DB00108
DB01410,The risk or severity of adverse effects can be increased when Ciclesonide is combined with Natalizumab.,Ciclesonide,DB00108
DB01423,The risk or severity of adverse effects can be increased when Stepronin is combined with Natalizumab.,Stepronin,DB00108
DB01590,The risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.,Everolimus,DB00108
DB01611,The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Natalizumab.,Hydroxychloroquine,DB00108
DB01816,The risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.,Castanospermine,DB00108
DB02546,The risk or severity of adverse effects can be increased when Vorinostat is combined with Natalizumab.,Vorinostat,DB00108
DB02806,The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Natalizumab.,2-Methoxyethanol,DB00108
DB03523,The risk or severity of adverse effects can be increased when Brequinar is combined with Natalizumab.,Brequinar,DB00108
DB04572,The risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.,Thiotepa,DB00108
DB04630,The risk or severity of adverse effects can be increased when Aldosterone is combined with Natalizumab.,Aldosterone,DB00108
DB04845,The risk or severity of adverse effects can be increased when Ixabepilone is combined with Natalizumab.,Ixabepilone,DB00108
DB04868,The risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.,Nilotinib,DB00108
DB04951,The risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.,Pirfenidone,DB00108
DB04956,The risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.,Afelimomab,DB00108
DB05015,The risk or severity of adverse effects can be increased when Belinostat is combined with Natalizumab.,Belinostat,DB00108
DB05109,The risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.,Trabectedin,DB00108
DB05258,The risk or severity of adverse effects can be increased when Interferon alfa is combined with Natalizumab.,Interferon alfa,DB00108
DB05259,The risk or severity of adverse effects can be increased when Glatiramer is combined with Natalizumab.,Glatiramer,DB00108
DB05260,The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Natalizumab.,Gallium nitrate,DB00108
DB05459,The risk or severity of adverse effects can be increased when Briakinumab is combined with Natalizumab.,Briakinumab,DB00108
DB05472,The risk or severity of adverse effects can be increased when omega interferon is combined with Natalizumab.,omega interferon,DB00108
DB05676,The risk or severity of adverse effects can be increased when Apremilast is combined with Natalizumab.,Apremilast,DB00108
DB05773,The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Natalizumab.,Trastuzumab emtansine,DB00108
DB06168,The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.,Canakinumab,DB00108
DB06273,The risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.,Tocilizumab,DB00108
DB06287,The risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.,Temsirolimus,DB00108
DB06372,The risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.,Rilonacept,DB00108
DB06589,The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.,Pazopanib,DB00108
DB06603,The risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.,Panobinostat,DB00108
DB06612,The risk or severity of adverse effects can be increased when Mepolizumab is combined with Natalizumab.,Mepolizumab,DB00108
DB06616,The risk or severity of adverse effects can be increased when Bosutinib is combined with Natalizumab.,Bosutinib,DB00108
DB06662,The risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.,Abetimus,DB00108
DB06674,The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.,Golimumab,DB00108
DB06681,The risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.,Belatacept,DB00108
DB06769,The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab.,Bendamustine,DB00108
DB06772,The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.,Cabazitaxel,DB00108
DB06813,The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.,Pralatrexate,DB00108
DB08059,The risk or severity of adverse effects can be increased when Wortmannin is combined with Natalizumab.,Wortmannin,DB00108
DB08868,The risk or severity of adverse effects can be increased when Fingolimod is combined with Natalizumab.,Fingolimod,DB00108
DB08870,The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.,Brentuximab vedotin,DB00108
DB08871,The risk or severity of adverse effects can be increased when Eribulin is combined with Natalizumab.,Eribulin,DB00108
DB08877,The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.,Ruxolitinib,DB00108
DB08879,The risk or severity of adverse effects can be increased when Belimumab is combined with Natalizumab.,Belimumab,DB00108
DB08880,The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.,Teriflunomide,DB00108
DB08889,The risk or severity of adverse effects can be increased when Carfilzomib is combined with Natalizumab.,Carfilzomib,DB00108
DB08895,The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.,Tofacitinib,DB00108
DB08901,The risk or severity of adverse effects can be increased when Ponatinib is combined with Natalizumab.,Ponatinib,DB00108
DB08904,The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.,Certolizumab pegol,DB00108
DB08906,The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Natalizumab.,Fluticasone furoate,DB00108
DB08908,The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Natalizumab.,Dimethyl fumarate,DB00108
DB08910,The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.,Pomalidomide,DB00108
DB08935,The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.,Obinutuzumab,DB00108
DB08970,The risk or severity of adverse effects can be increased when Fluprednidene is combined with Natalizumab.,Fluprednidene,DB00108
DB08971,The risk or severity of adverse effects can be increased when Fluocortolone is combined with Natalizumab.,Fluocortolone,DB00108
DB09029,The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.,Secukinumab,DB00108
DB09036,The risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.,Siltuximab,DB00108
DB09052,The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.,Blinatumomab,DB00108
DB09053,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.,Ibrutinib,DB00108
DB09054,The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.,Idelalisib,DB00108
DB09073,The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.,Palbociclib,DB00108
DB09074,The risk or severity of adverse effects can be increased when Olaparib is combined with Natalizumab.,Olaparib,DB00108
DB09077,The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.,Dinutuximab,DB00108
DB09082,The risk or severity of adverse effects can be increased when Vilanterol is combined with Natalizumab.,Vilanterol,DB00108
DB09091,The risk or severity of adverse effects can be increased when Tixocortol is combined with Natalizumab.,Tixocortol,DB00108
DB09122,The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Natalizumab.,Peginterferon beta-1a,DB00108
DB09312,The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab.,Antilymphocyte immunoglobulin (horse),DB00108
DB09378,The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Natalizumab.,Fluprednisolone,DB00108
DB09383,The risk or severity of adverse effects can be increased when Meprednisone is combined with Natalizumab.,Meprednisone,DB00108
DB11466,The risk or severity of adverse effects can be increased when Tepoxalin is combined with Natalizumab.,Tepoxalin,DB00108
DB11487,The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Natalizumab.,Dexamethasone isonicotinate,DB00108
DB11529,The risk or severity of adverse effects can be increased when Melengestrol is combined with Natalizumab.,Melengestrol,DB00108
DB11569,The risk or severity of adverse effects can be increased when Ixekizumab is combined with Natalizumab.,Ixekizumab,DB00108
DB11580,The risk or severity of adverse effects can be increased when Ravulizumab is combined with Natalizumab.,Ravulizumab,DB00108
DB11616,The risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.,Pirarubicin,DB00108
DB11693,The risk or severity of adverse effects can be increased when Voclosporin is combined with Natalizumab.,Voclosporin,DB00108
DB11708,The risk or severity of adverse effects can be increased when Peficitinib is combined with Natalizumab.,Peficitinib,DB00108
DB11750,The risk or severity of adverse effects can be increased when Clobetasol is combined with Natalizumab.,Clobetasol,DB00108
DB11767,The risk or severity of adverse effects can be increased when Sarilumab is combined with Natalizumab.,Sarilumab,DB00108
DB11776,The risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.,Brodalumab,DB00108
DB11803,The risk or severity of adverse effects can be increased when Sirukumab is combined with Natalizumab.,Sirukumab,DB00108
DB11817,The risk or severity of adverse effects can be increased when Baricitinib is combined with Natalizumab.,Baricitinib,DB00108
DB11834,The risk or severity of adverse effects can be increased when Guselkumab is combined with Natalizumab.,Guselkumab,DB00108
DB11921,The risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.,Deflazacort,DB00108
DB12025,The risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.,Triptolide,DB00108
DB12371,The risk or severity of adverse effects can be increased when Siponimod is combined with Natalizumab.,Siponimod,DB00108
DB12612,The risk or severity of adverse effects can be increased when Ozanimod is combined with Natalizumab.,Ozanimod,DB00108
DB12617,The risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.,Mizoribine,DB00108
DB12692,The risk or severity of adverse effects can be increased when Gusperimus is combined with Natalizumab.,Gusperimus,DB00108
DB12814,The risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Natalizumab.,Cepeginterferon alfa-2B,DB00108
DB12902,The risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.,Trofosfamide,DB00108
DB12947,The risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.,Doxifluridine,DB00108
DB12991,The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Natalizumab.,Deoxyspergualin,DB00108
DB12996,The risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.,Acteoside,DB00108
DB13003,The risk or severity of adverse effects can be increased when Cortivazol is combined with Natalizumab.,Cortivazol,DB00108
DB13014,The risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.,Hypericin,DB00108
DB13068,The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Natalizumab.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00108
DB13208,The risk or severity of adverse effects can be increased when Prednylidene is combined with Natalizumab.,Prednylidene,DB00108
DB13223,The risk or severity of adverse effects can be increased when Fluocortin is combined with Natalizumab.,Fluocortin,DB00108
DB13241,The risk or severity of adverse effects can be increased when Begelomab is combined with Natalizumab.,Begelomab,DB00108
DB13491,The risk or severity of adverse effects can be increased when Fluperolone is combined with Natalizumab.,Fluperolone,DB00108
DB13664,The risk or severity of adverse effects can be increased when Formocortal is combined with Natalizumab.,Formocortal,DB00108
DB13728,The risk or severity of adverse effects can be increased when Halometasone is combined with Natalizumab.,Halometasone,DB00108
DB13843,The risk or severity of adverse effects can be increased when Cloprednol is combined with Natalizumab.,Cloprednol,DB00108
DB13856,The risk or severity of adverse effects can be increased when Fluclorolone is combined with Natalizumab.,Fluclorolone,DB00108
DB13867,The risk or severity of adverse effects can be increased when Fluticasone is combined with Natalizumab.,Fluticasone,DB00108
DB14066,The risk or severity of adverse effects can be increased when Tetrandrine is combined with Natalizumab.,Tetrandrine,DB00108
DB14219,The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Natalizumab.,Monomethyl fumarate,DB00108
DB14512,The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Natalizumab.,Mometasone furoate,DB00108
DB14538,The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Natalizumab.,Hydrocortisone aceponate,DB00108
DB14539,The risk or severity of adverse effects can be increased when Hydrocortisone acetate is combined with Natalizumab.,Hydrocortisone acetate,DB00108
DB14545,The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Natalizumab.,Hydrocortisone succinate,DB00108
DB14724,The risk or severity of adverse effects can be increased when Emapalumab is combined with Natalizumab.,Emapalumab,DB00108
DB14762,The risk or severity of adverse effects can be increased when Risankizumab is combined with Natalizumab.,Risankizumab,DB00108
DB14919,The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Natalizumab.,Rozanolixizumab,DB00108
DB15253,The risk or severity of adverse effects can be increased when Bleselumab is combined with Natalizumab.,Bleselumab,DB00108
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.,Pimecrolimus,DB00108
DB01656,Roflumilast may increase the immunosuppressive activities of Natalizumab.,Roflumilast,DB00108
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.,Sipuleucel-T,DB00108
DB09033,The risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.,Vedolizumab,DB00108
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Natalizumab.,Sulfamethoxazole,DB00108
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Natalizumab.,Diethylstilbestrol,DB00108
DB00269,Chlorotrianisene may increase the thrombogenic activities of Natalizumab.,Chlorotrianisene,DB00108
DB00286,Conjugated estrogens may increase the thrombogenic activities of Natalizumab.,Conjugated estrogens,DB00108
DB00655,Estrone may increase the thrombogenic activities of Natalizumab.,Estrone,DB00108
DB00783,Estradiol may increase the thrombogenic activities of Natalizumab.,Estradiol,DB00108
DB00890,Dienestrol may increase the thrombogenic activities of Natalizumab.,Dienestrol,DB00108
DB00977,Ethinylestradiol may increase the thrombogenic activities of Natalizumab.,Ethinylestradiol,DB00108
DB01357,Mestranol may increase the thrombogenic activities of Natalizumab.,Mestranol,DB00108
DB04573,Estriol may increase the thrombogenic activities of Natalizumab.,Estriol,DB00108
DB04574,Estrone sulfate may increase the thrombogenic activities of Natalizumab.,Estrone sulfate,DB00108
DB04575,Quinestrol may increase the thrombogenic activities of Natalizumab.,Quinestrol,DB00108
DB07931,Hexestrol may increase the thrombogenic activities of Natalizumab.,Hexestrol,DB00108
DB09070,Tibolone may increase the thrombogenic activities of Natalizumab.,Tibolone,DB00108
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Natalizumab.","Synthetic Conjugated Estrogens, A",DB00108
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Natalizumab.","Synthetic Conjugated Estrogens, B",DB00108
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Natalizumab.,Polyestradiol phosphate,DB00108
DB09381,Esterified estrogens may increase the thrombogenic activities of Natalizumab.,Esterified estrogens,DB00108
DB11478,Zeranol may increase the thrombogenic activities of Natalizumab.,Zeranol,DB00108
DB11674,Equol may increase the thrombogenic activities of Natalizumab.,Equol,DB00108
DB12487,Promestriene may increase the thrombogenic activities of Natalizumab.,Promestriene,DB00108
DB13143,Methallenestril may increase the thrombogenic activities of Natalizumab.,Methallenestril,DB00108
DB13386,Epimestrol may increase the thrombogenic activities of Natalizumab.,Epimestrol,DB00108
DB13418,Moxestrol may increase the thrombogenic activities of Natalizumab.,Moxestrol,DB00108
DB13952,Estradiol acetate may increase the thrombogenic activities of Natalizumab.,Estradiol acetate,DB00108
DB13953,Estradiol benzoate may increase the thrombogenic activities of Natalizumab.,Estradiol benzoate,DB00108
DB13954,Estradiol cypionate may increase the thrombogenic activities of Natalizumab.,Estradiol cypionate,DB00108
DB13956,Estradiol valerate may increase the thrombogenic activities of Natalizumab.,Estradiol valerate,DB00108
DB15334,Biochanin A may increase the thrombogenic activities of Natalizumab.,Biochanin A,DB00108
DB15335,Formononetin may increase the thrombogenic activities of Natalizumab.,Formononetin,DB00108
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Natalizumab.,G17DT,DB00108
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Natalizumab.,PEV3A,DB00108
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Natalizumab.,INGN 225,DB00108
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Natalizumab.,Rindopepimut,DB00108
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Natalizumab.,SRP 299,DB00108
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Natalizumab.,GI-5005,DB00108
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Natalizumab.,Vitespen,DB00108
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Natalizumab.,TG4010,DB00108
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Natalizumab.,Anthrax immune globulin human,DB00108
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Natalizumab.","Rabies virus inactivated antigen, B",DB00108
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00108
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Natalizumab.,Rotavirus vaccine,DB00108
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Natalizumab.","Rabies virus inactivated antigen, A",DB00108
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00108
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00108
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00108
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00108
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00108
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00108
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Natalizumab.,Typhoid Vi polysaccharide vaccine,DB00108
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.,Hepatitis A Vaccine,DB00108
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00108
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00108
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00108
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00108
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00108
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Natalizumab.,Human rabies virus immune globulin,DB00108
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.,Hepatitis B Vaccine (Recombinant),DB00108
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Natalizumab.,Tecemotide,DB00108
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Natalizumab.,Typhoid vaccine,DB00108
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00108
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00108
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00108
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00108
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Natalizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00108
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00108
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00108
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Natalizumab.,Vaccinia virus strain new york city board of health live antigen,DB00108
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Natalizumab.,Pertussis vaccine,DB00108
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00108
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.,Varicella Zoster Vaccine (Recombinant),DB00108
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Natalizumab.,Modified vaccinia ankara,DB00108
DB11988,Ocrelizumab may increase the immunosuppressive activities of Natalizumab.,Ocrelizumab,DB00108
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Natalizumab.,Rubella virus vaccine,DB00108
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Natalizumab.,Varicella Zoster Vaccine (Live/attenuated),DB00108
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain tice live antigen,DB00108
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00108
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Natalizumab.,Yellow Fever Vaccine,DB00108
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Natalizumab.,Anthrax vaccine,DB00108
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Natalizumab.,Typhoid Vaccine Live,DB00108
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00108
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Natalizumab.,BCG vaccine,DB00108
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Natalizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00108
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Natalizumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00108
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Natalizumab.,Adenovirus type 7 vaccine live,DB00108
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.,Cetuximab,DB00108
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.,Human immunoglobulin G,DB00108
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Natalizumab.,Omalizumab,DB00108
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Natalizumab.,Abciximab,DB00108
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.,Indium In-111 satumomab pendetide,DB00108
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.,Digoxin Immune Fab (Ovine),DB00108
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.,Capromab pendetide,DB00108
DB00110,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.,Palivizumab,DB00108
DB00113,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00108
DB01269,The risk or severity of adverse effects can be increased when Natalizumab is combined with Panitumumab.,Panitumumab,DB00108
DB01270,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ranibizumab.,Ranibizumab,DB00108
DB04901,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galiximab.,Galiximab,DB00108
DB04949,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pexelizumab.,Pexelizumab,DB00108
DB04958,The risk or severity of adverse effects can be increased when Natalizumab is combined with Epratuzumab.,Epratuzumab,DB00108
DB04962,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bectumomab.,Bectumomab,DB00108
DB04964,The risk or severity of adverse effects can be increased when Natalizumab is combined with Oregovomab.,Oregovomab,DB00108
DB04988,The risk or severity of adverse effects can be increased when Natalizumab is combined with IGN311.,IGN311,DB00108
DB05006,The risk or severity of adverse effects can be increased when Natalizumab is combined with Adecatumumab.,Adecatumumab,DB00108
DB05097,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab.,Labetuzumab,DB00108
DB05101,The risk or severity of adverse effects can be increased when Natalizumab is combined with Matuzumab.,Matuzumab,DB00108
DB05111,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fontolizumab.,Fontolizumab,DB00108
DB05136,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bavituximab.,Bavituximab,DB00108
DB05139,The risk or severity of adverse effects can be increased when Natalizumab is combined with CR002.,CR002,DB00108
DB05209,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rozrolimupab.,Rozrolimupab,DB00108
DB05304,The risk or severity of adverse effects can be increased when Natalizumab is combined with Girentuximab.,Girentuximab,DB00108
DB05336,The risk or severity of adverse effects can be increased when Natalizumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00108
DB05405,The risk or severity of adverse effects can be increased when Natalizumab is combined with XTL-001.,XTL-001,DB00108
DB05437,The risk or severity of adverse effects can be increased when Natalizumab is combined with NAV 1800.,NAV 1800,DB00108
DB05496,The risk or severity of adverse effects can be increased when Natalizumab is combined with Otelixizumab.,Otelixizumab,DB00108
DB05545,The risk or severity of adverse effects can be increased when Natalizumab is combined with AMG 108.,AMG 108,DB00108
DB05550,The risk or severity of adverse effects can be increased when Natalizumab is combined with Iratumumab.,Iratumumab,DB00108
DB05555,The risk or severity of adverse effects can be increased when Natalizumab is combined with Enokizumab.,Enokizumab,DB00108
DB05578,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ramucirumab.,Ramucirumab,DB00108
DB05595,The risk or severity of adverse effects can be increased when Natalizumab is combined with Farletuzumab.,Farletuzumab,DB00108
DB05656,The risk or severity of adverse effects can be increased when Natalizumab is combined with Veltuzumab.,Veltuzumab,DB00108
DB05793,The risk or severity of adverse effects can be increased when Natalizumab is combined with PRO-542.,PRO-542,DB00108
DB05797,The risk or severity of adverse effects can be increased when Natalizumab is combined with TNX-901.,TNX-901,DB00108
DB05889,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00108
DB05892,The risk or severity of adverse effects can be increased when Natalizumab is combined with RI 624.,RI 624,DB00108
DB05915,The risk or severity of adverse effects can be increased when Natalizumab is combined with MYO-029.,MYO-029,DB00108
DB05916,The risk or severity of adverse effects can be increased when Natalizumab is combined with CT-011.,CT-011,DB00108
DB05941,The risk or severity of adverse effects can be increased when Natalizumab is combined with Leronlimab.,Leronlimab,DB00108
DB05996,The risk or severity of adverse effects can be increased when Natalizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00108
DB06043,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olaratumab.,Olaratumab,DB00108
DB06049,The risk or severity of adverse effects can be increased when Natalizumab is combined with IPH 2101.,IPH 2101,DB00108
DB06050,The risk or severity of adverse effects can be increased when Natalizumab is combined with TB-402.,TB-402,DB00108
DB06081,The risk or severity of adverse effects can be increased when Natalizumab is combined with Caplacizumab.,Caplacizumab,DB00108
DB06101,The risk or severity of adverse effects can be increased when Natalizumab is combined with IMC-1C11.,IMC-1C11,DB00108
DB06116,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eldelumab.,Eldelumab,DB00108
DB06162,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumiliximab.,Lumiliximab,DB00108
DB06186,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipilimumab.,Ipilimumab,DB00108
DB06192,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nimotuzumab.,Nimotuzumab,DB00108
DB06241,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clenoliximab.,Clenoliximab,DB00108
DB06304,The risk or severity of adverse effects can be increased when Natalizumab is combined with BIIB015.,BIIB015,DB00108
DB06305,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sonepcizumab.,Sonepcizumab,DB00108
DB06310,The risk or severity of adverse effects can be increased when Natalizumab is combined with Motavizumab.,Motavizumab,DB00108
DB06317,The risk or severity of adverse effects can be increased when Natalizumab is combined with Elotuzumab.,Elotuzumab,DB00108
DB06318,The risk or severity of adverse effects can be increased when Natalizumab is combined with AVE9633.,AVE9633,DB00108
DB06322,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carotuximab.,Carotuximab,DB00108
DB06324,The risk or severity of adverse effects can be increased when Natalizumab is combined with XmAb 2513.,XmAb 2513,DB00108
DB06342,The risk or severity of adverse effects can be increased when Natalizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00108
DB06343,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teprotumumab.,Teprotumumab,DB00108
DB06360,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lucatumumab.,Lucatumumab,DB00108
DB06366,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pertuzumab.,Pertuzumab,DB00108
DB06371,The risk or severity of adverse effects can be increased when Natalizumab is combined with Siplizumab.,Siplizumab,DB00108
DB06467,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apolizumab.,Apolizumab,DB00108
DB06474,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00108
DB06550,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bivatuzumab.,Bivatuzumab,DB00108
DB06557,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lerdelimumab.,Lerdelimumab,DB00108
DB06599,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lexatumumab.,Lexatumumab,DB00108
DB06602,The risk or severity of adverse effects can be increased when Natalizumab is combined with Reslizumab.,Reslizumab,DB00108
DB06606,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teplizumab.,Teplizumab,DB00108
DB06607,The risk or severity of adverse effects can be increased when Natalizumab is combined with Catumaxomab.,Catumaxomab,DB00108
DB06647,The risk or severity of adverse effects can be increased when Natalizumab is combined with Volociximab.,Volociximab,DB00108
DB06650,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ofatumumab.,Ofatumumab,DB00108
DB08902,The risk or severity of adverse effects can be increased when Natalizumab is combined with Raxibacumab.,Raxibacumab,DB00108
DB09035,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nivolumab.,Nivolumab,DB00108
DB09037,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pembrolizumab.,Pembrolizumab,DB00108
DB09045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dulaglutide.,Dulaglutide,DB00108
DB09105,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asfotase alfa.,Asfotase alfa,DB00108
DB09264,The risk or severity of adverse effects can be increased when Natalizumab is combined with Idarucizumab.,Idarucizumab,DB00108
DB09302,The risk or severity of adverse effects can be increased when Natalizumab is combined with Alirocumab.,Alirocumab,DB00108
DB09303,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evolocumab.,Evolocumab,DB00108
DB09331,The risk or severity of adverse effects can be increased when Natalizumab is combined with Daratumumab.,Daratumumab,DB00108
DB09559,The risk or severity of adverse effects can be increased when Natalizumab is combined with Necitumumab.,Necitumumab,DB00108
DB11595,The risk or severity of adverse effects can be increased when Natalizumab is combined with Atezolizumab.,Atezolizumab,DB00108
DB11604,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00108
DB11608,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00108
DB11621,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00108
DB11646,The risk or severity of adverse effects can be increased when Natalizumab is combined with Conatumumab.,Conatumumab,DB00108
DB11657,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tabalumab.,Tabalumab,DB00108
DB11680,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00108
DB11685,The risk or severity of adverse effects can be increased when Natalizumab is combined with Figitumumab.,Figitumumab,DB00108
DB11714,The risk or severity of adverse effects can be increased when Natalizumab is combined with Durvalumab.,Durvalumab,DB00108
DB11715,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bapineuzumab.,Bapineuzumab,DB00108
DB11731,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00108
DB11746,The risk or severity of adverse effects can be increased when Natalizumab is combined with Onartuzumab.,Onartuzumab,DB00108
DB11756,The risk or severity of adverse effects can be increased when Natalizumab is combined with Solanezumab.,Solanezumab,DB00108
DB11771,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tremelimumab.,Tremelimumab,DB00108
DB11826,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lampalizumab.,Lampalizumab,DB00108
DB11840,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalotuzumab.,Dalotuzumab,DB00108
DB11849,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emibetuzumab.,Emibetuzumab,DB00108
DB11850,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ublituximab.,Ublituximab,DB00108
DB11856,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ligelizumab.,Ligelizumab,DB00108
DB11857,The risk or severity of adverse effects can be increased when Natalizumab is combined with Seribantumab.,Seribantumab,DB00108
DB11862,The risk or severity of adverse effects can be increased when Natalizumab is combined with Landogrozumab.,Landogrozumab,DB00108
DB11866,The risk or severity of adverse effects can be increased when Natalizumab is combined with Romosozumab.,Romosozumab,DB00108
DB11884,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00108
DB11914,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lebrikizumab.,Lebrikizumab,DB00108
DB11930,The risk or severity of adverse effects can be increased when Natalizumab is combined with Varlilumab.,Varlilumab,DB00108
DB11945,The risk or severity of adverse effects can be increased when Natalizumab is combined with Avelumab.,Avelumab,DB00108
DB11959,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crenezumab.,Crenezumab,DB00108
DB11972,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rilotumumab.,Rilotumumab,DB00108
DB11976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anifrolumab.,Anifrolumab,DB00108
DB12023,The risk or severity of adverse effects can be increased when Natalizumab is combined with Benralizumab.,Benralizumab,DB00108
DB12034,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gantenerumab.,Gantenerumab,DB00108
DB12053,The risk or severity of adverse effects can be increased when Natalizumab is combined with Visilizumab.,Visilizumab,DB00108
DB12077,The risk or severity of adverse effects can be increased when Natalizumab is combined with Urelumab.,Urelumab,DB00108
DB12089,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00108
DB12090,The risk or severity of adverse effects can be increased when Natalizumab is combined with Patritumab.,Patritumab,DB00108
DB12102,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fulranumab.,Fulranumab,DB00108
DB12104,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tarextumab.,Tarextumab,DB00108
DB12118,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sotatercept.,Sotatercept,DB00108
DB12119,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gevokizumab.,Gevokizumab,DB00108
DB12142,The risk or severity of adverse effects can be increased when Natalizumab is combined with Duligotuzumab.,Duligotuzumab,DB00108
DB12152,The risk or severity of adverse effects can be increased when Natalizumab is combined with Simtuzumab.,Simtuzumab,DB00108
DB12157,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fasinumab.,Fasinumab,DB00108
DB12159,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dupilumab.,Dupilumab,DB00108
DB12169,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tralokinumab.,Tralokinumab,DB00108
DB12189,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etrolizumab.,Etrolizumab,DB00108
DB12202,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zalutumumab.,Zalutumumab,DB00108
DB12205,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ganitumab.,Ganitumab,DB00108
DB12213,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etaracizumab.,Etaracizumab,DB00108
DB12240,The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00108
DB12246,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inclacumab.,Inclacumab,DB00108
DB12250,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cixutumumab.,Cixutumumab,DB00108
DB12261,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00108
DB12274,The risk or severity of adverse effects can be increased when Natalizumab is combined with Aducanumab.,Aducanumab,DB00108
DB12281,The risk or severity of adverse effects can be increased when Natalizumab is combined with Luspatercept.,Luspatercept,DB00108
DB12296,The risk or severity of adverse effects can be increased when Natalizumab is combined with GS-5745.,GS-5745,DB00108
DB12317,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vanucizumab.,Vanucizumab,DB00108
DB12331,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00108
DB12335,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tanezumab.,Tanezumab,DB00108
DB12342,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ensituximab.,Ensituximab,DB00108
DB12344,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fezakinumab.,Fezakinumab,DB00108
DB12363,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dusigitumab.,Dusigitumab,DB00108
DB12396,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fresolimumab.,Fresolimumab,DB00108
DB12413,The risk or severity of adverse effects can be increased when Natalizumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00108
DB12456,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bococizumab.,Bococizumab,DB00108
DB12489,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00108
DB12498,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mogamulizumab.,Mogamulizumab,DB00108
DB12520,The risk or severity of adverse effects can be increased when Natalizumab is combined with Plozalizumab.,Plozalizumab,DB00108
DB12534,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mavrilimumab.,Mavrilimumab,DB00108
DB12560,The risk or severity of adverse effects can be increased when Natalizumab is combined with Blosozumab.,Blosozumab,DB00108
DB12584,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimagrumab.,Bimagrumab,DB00108
DB12589,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dacetuzumab.,Dacetuzumab,DB00108
DB12609,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tovetumab.,Tovetumab,DB00108
DB12683,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumretuzumab.,Lumretuzumab,DB00108
DB12698,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ibalizumab.,Ibalizumab,DB00108
DB12701,The risk or severity of adverse effects can be increased when Natalizumab is combined with Intetumumab.,Intetumumab,DB00108
DB12718,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carlumab.,Carlumab,DB00108
DB12734,The risk or severity of adverse effects can be increased when Natalizumab is combined with Demcizumab.,Demcizumab,DB00108
DB12773,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sifalimumab.,Sifalimumab,DB00108
DB12775,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abituzumab.,Abituzumab,DB00108
DB12797,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ecromeximab.,Ecromeximab,DB00108
DB12807,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00108
DB12815,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crotedumab.,Crotedumab,DB00108
DB12820,The risk or severity of adverse effects can be increased when Natalizumab is combined with Concizumab.,Concizumab,DB00108
DB12826,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab.,Depatuxizumab,DB00108
DB12844,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rontalizumab.,Rontalizumab,DB00108
DB12845,The risk or severity of adverse effects can be increased when Natalizumab is combined with Amatuximab.,Amatuximab,DB00108
DB12849,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clazakizumab.,Clazakizumab,DB00108
DB12891,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ozanezumab.,Ozanezumab,DB00108
DB12893,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00108
DB12917,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimekizumab.,Bimekizumab,DB00108
DB12943,The risk or severity of adverse effects can be increased when Natalizumab is combined with Milatuzumab.,Milatuzumab,DB00108
DB12976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Robatumumab.,Robatumumab,DB00108
DB13017,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00108
DB13037,The risk or severity of adverse effects can be increased when Natalizumab is combined with Namilumab.,Namilumab,DB00108
DB13045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Racotumomab.,Racotumomab,DB00108
DB13073,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tregalizumab.,Tregalizumab,DB00108
DB13127,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olokizumab.,Olokizumab,DB00108
DB13140,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00108
DB13375,The risk or severity of adverse effects can be increased when Natalizumab is combined with Edrecolomab.,Edrecolomab,DB00108
DB13535,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nebacumab.,Nebacumab,DB00108
DB13886,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00108
DB13923,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emicizumab.,Emicizumab,DB00108
DB13976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sulesomab.,Sulesomab,DB00108
DB13979,The risk or severity of adverse effects can be increased when Natalizumab is combined with Besilesomab.,Besilesomab,DB00108
DB14012,The risk or severity of adverse effects can be increased when Natalizumab is combined with Burosumab.,Burosumab,DB00108
DB14039,The risk or severity of adverse effects can be increased when Natalizumab is combined with Erenumab.,Erenumab,DB00108
DB14040,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.,Eptinezumab,DB00108
DB14041,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fremanezumab.,Fremanezumab,DB00108
DB14042,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galcanezumab.,Galcanezumab,DB00108
DB14211,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fanolesomab.,Fanolesomab,DB00108
DB14580,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lecanemab.,Lecanemab,DB00108
DB14597,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lanadelumab.,Lanadelumab,DB00108
DB14707,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cemiplimab.,Cemiplimab,DB00108
DB14776,The risk or severity of adverse effects can be increased when Natalizumab is combined with Camrelizumab.,Camrelizumab,DB00108
DB14778,The risk or severity of adverse effects can be increased when Natalizumab is combined with Setrusumab.,Setrusumab,DB00108
DB14784,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gancotamab.,Gancotamab,DB00108
DB14809,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00108
DB14811,The risk or severity of adverse effects can be increased when Natalizumab is combined with Isatuximab.,Isatuximab,DB00108
DB14824,The risk or severity of adverse effects can be increased when Natalizumab is combined with Icrucumab.,Icrucumab,DB00108
DB14843,The risk or severity of adverse effects can be increased when Natalizumab is combined with Codrituzumab.,Codrituzumab,DB00108
DB14864,The risk or severity of adverse effects can be increased when Natalizumab is combined with Brolucizumab.,Brolucizumab,DB00108
DB14871,The risk or severity of adverse effects can be increased when Natalizumab is combined with Xentuzumab.,Xentuzumab,DB00108
DB14877,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lintuzumab.,Lintuzumab,DB00108
DB14891,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vobarilizumab.,Vobarilizumab,DB00108
DB14897,The risk or severity of adverse effects can be increased when Natalizumab is combined with Parsatuzumab.,Parsatuzumab,DB00108
DB14905,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emactuzumab.,Emactuzumab,DB00108
DB14907,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00108
DB14908,The risk or severity of adverse effects can be increased when Natalizumab is combined with Refanezumab.,Refanezumab,DB00108
DB14947,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bermekimab.,Bermekimab,DB00108
DB14952,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pamrevlumab.,Pamrevlumab,DB00108
DB14959,The risk or severity of adverse effects can be increased when Natalizumab is combined with Opicinumab.,Opicinumab,DB00108
DB14962,The risk or severity of adverse effects can be increased when Natalizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00108
DB14967,The risk or severity of adverse effects can be increased when Natalizumab is combined with Margetuximab.,Margetuximab,DB00108
DB14988,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalantercept.,Dalantercept,DB00108
DB14997,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pateclizumab.,Pateclizumab,DB00108
DB15014,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gremubamab.,Gremubamab,DB00108
DB15022,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apomab.,Apomab,DB00108
DB15044,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tafasitamab.,Tafasitamab,DB00108
DB15045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipafricept.,Ipafricept,DB00108
DB15076,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abrilumab.,Abrilumab,DB00108
DB15089,The risk or severity of adverse effects can be increased when Natalizumab is combined with Frovocimab.,Frovocimab,DB00108
DB15090,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tezepelumab.,Tezepelumab,DB00108
DB15101,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tigatuzumab.,Tigatuzumab,DB00108
DB15104,The risk or severity of adverse effects can be increased when Natalizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00108
DB15113,The risk or severity of adverse effects can be increased when Natalizumab is combined with Utomilumab.,Utomilumab,DB00108
DB15118,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zolbetuximab.,Zolbetuximab,DB00108
DB15135,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ponezumab.,Ponezumab,DB00108
DB15160,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asunercept.,Asunercept,DB00108
DB15172,The risk or severity of adverse effects can be increased when Natalizumab is combined with Suvratoxumab.,Suvratoxumab,DB00108
DB15225,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mitazalimab.,Mitazalimab,DB00108
DB15252,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nemolizumab.,Nemolizumab,DB00108
DB15277,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gedivumab.,Gedivumab,DB00108
DB15336,The risk or severity of adverse effects can be increased when Natalizumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00108
DB15349,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00108
DB15354,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evinacumab.,Evinacumab,DB00108
DB15363,The risk or severity of adverse effects can be increased when Natalizumab is combined with Istiratumab.,Istiratumab,DB00108
DB15383,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pidilizumab.,Pidilizumab,DB00108
DB15397,The risk or severity of adverse effects can be increased when Natalizumab is combined with GMA-161.,GMA-161,DB00108
DB15409,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00108
DB15415,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tomaralimab.,Tomaralimab,DB00108
DB15428,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vesencumab.,Vesencumab,DB00108
DB15432,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00108
DB15441,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00108
DB15443,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00108
DB15453,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00108
DB14004,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tildrakizumab.,Tildrakizumab,DB00108
DB05679,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ustekinumab.,Ustekinumab,DB00108
DB15559,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00108
DB00091,Natalizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00108
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Natalizumab.","Ebola Zaire vaccine (live, attenuated)",DB00108
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Natalizumab.,Magnesium,DB00108
DB01601,The serum concentration of Natalizumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00108
DB12530,The risk or severity of infection can be increased when Natalizumab is combined with Inebilizumab.,Inebilizumab,DB00108
DB00503,The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.,Ritonavir,DB00109
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Enfuvirtide.,Rubella virus vaccine,DB00109
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain tice live antigen,DB00109
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain connaught live antigen,DB00109
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Enfuvirtide.,Yellow Fever Vaccine,DB00109
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Enfuvirtide.,Anthrax vaccine,DB00109
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Enfuvirtide.,Typhoid Vaccine Live,DB00109
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00109
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enfuvirtide.,BCG vaccine,DB00109
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Enfuvirtide.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00109
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Enfuvirtide.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00109
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Enfuvirtide.,Adenovirus type 7 vaccine live,DB00109
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Enfuvirtide.,Varicella Zoster Vaccine (Live/attenuated),DB00109
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Palivizumab.,Diethylstilbestrol,DB00110
DB00269,Chlorotrianisene may increase the thrombogenic activities of Palivizumab.,Chlorotrianisene,DB00110
DB00286,Conjugated estrogens may increase the thrombogenic activities of Palivizumab.,Conjugated estrogens,DB00110
DB00655,Estrone may increase the thrombogenic activities of Palivizumab.,Estrone,DB00110
DB00783,Estradiol may increase the thrombogenic activities of Palivizumab.,Estradiol,DB00110
DB00890,Dienestrol may increase the thrombogenic activities of Palivizumab.,Dienestrol,DB00110
DB00977,Ethinylestradiol may increase the thrombogenic activities of Palivizumab.,Ethinylestradiol,DB00110
DB01357,Mestranol may increase the thrombogenic activities of Palivizumab.,Mestranol,DB00110
DB04573,Estriol may increase the thrombogenic activities of Palivizumab.,Estriol,DB00110
DB04574,Estrone sulfate may increase the thrombogenic activities of Palivizumab.,Estrone sulfate,DB00110
DB04575,Quinestrol may increase the thrombogenic activities of Palivizumab.,Quinestrol,DB00110
DB07931,Hexestrol may increase the thrombogenic activities of Palivizumab.,Hexestrol,DB00110
DB09070,Tibolone may increase the thrombogenic activities of Palivizumab.,Tibolone,DB00110
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Palivizumab.","Synthetic Conjugated Estrogens, A",DB00110
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab.","Synthetic Conjugated Estrogens, B",DB00110
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Palivizumab.,Polyestradiol phosphate,DB00110
DB09381,Esterified estrogens may increase the thrombogenic activities of Palivizumab.,Esterified estrogens,DB00110
DB11478,Zeranol may increase the thrombogenic activities of Palivizumab.,Zeranol,DB00110
DB11674,Equol may increase the thrombogenic activities of Palivizumab.,Equol,DB00110
DB12487,Promestriene may increase the thrombogenic activities of Palivizumab.,Promestriene,DB00110
DB13143,Methallenestril may increase the thrombogenic activities of Palivizumab.,Methallenestril,DB00110
DB13386,Epimestrol may increase the thrombogenic activities of Palivizumab.,Epimestrol,DB00110
DB13418,Moxestrol may increase the thrombogenic activities of Palivizumab.,Moxestrol,DB00110
DB13952,Estradiol acetate may increase the thrombogenic activities of Palivizumab.,Estradiol acetate,DB00110
DB13953,Estradiol benzoate may increase the thrombogenic activities of Palivizumab.,Estradiol benzoate,DB00110
DB13954,Estradiol cypionate may increase the thrombogenic activities of Palivizumab.,Estradiol cypionate,DB00110
DB13956,Estradiol valerate may increase the thrombogenic activities of Palivizumab.,Estradiol valerate,DB00110
DB15334,Biochanin A may increase the thrombogenic activities of Palivizumab.,Biochanin A,DB00110
DB15335,Formononetin may increase the thrombogenic activities of Palivizumab.,Formononetin,DB00110
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.,Cetuximab,DB00110
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.,Human immunoglobulin G,DB00110
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Palivizumab.,Omalizumab,DB00110
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Palivizumab.,Adalimumab,DB00110
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Palivizumab.,Abciximab,DB00110
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.,Gemtuzumab ozogamicin,DB00110
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.,Indium In-111 satumomab pendetide,DB00110
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.,Infliximab,DB00110
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.,Trastuzumab,DB00110
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.,Rituximab,DB00110
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.,Basiliximab,DB00110
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.,Muromonab,DB00110
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.,Digoxin Immune Fab (Ovine),DB00110
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.,Ibritumomab tiuxetan,DB00110
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.,Tositumomab,DB00110
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.,Alemtuzumab,DB00110
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.,Capromab pendetide,DB00110
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.,Efalizumab,DB00110
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.,Antithymocyte immunoglobulin (rabbit),DB00110
DB00108,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.,Natalizumab,DB00110
DB00111,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.,Daclizumab,DB00110
DB00112,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.,Bevacizumab,DB00110
DB00113,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00110
DB01257,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eculizumab.,Eculizumab,DB00110
DB01269,The risk or severity of adverse effects can be increased when Palivizumab is combined with Panitumumab.,Panitumumab,DB00110
DB01270,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ranibizumab.,Ranibizumab,DB00110
DB04901,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galiximab.,Galiximab,DB00110
DB04949,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pexelizumab.,Pexelizumab,DB00110
DB04956,The risk or severity of adverse effects can be increased when Palivizumab is combined with Afelimomab.,Afelimomab,DB00110
DB04958,The risk or severity of adverse effects can be increased when Palivizumab is combined with Epratuzumab.,Epratuzumab,DB00110
DB04962,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bectumomab.,Bectumomab,DB00110
DB04964,The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab.,Oregovomab,DB00110
DB04988,The risk or severity of adverse effects can be increased when Palivizumab is combined with IGN311.,IGN311,DB00110
DB05006,The risk or severity of adverse effects can be increased when Palivizumab is combined with Adecatumumab.,Adecatumumab,DB00110
DB05097,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab.,Labetuzumab,DB00110
DB05101,The risk or severity of adverse effects can be increased when Palivizumab is combined with Matuzumab.,Matuzumab,DB00110
DB05111,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fontolizumab.,Fontolizumab,DB00110
DB05136,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bavituximab.,Bavituximab,DB00110
DB05139,The risk or severity of adverse effects can be increased when Palivizumab is combined with CR002.,CR002,DB00110
DB05209,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozrolimupab.,Rozrolimupab,DB00110
DB05304,The risk or severity of adverse effects can be increased when Palivizumab is combined with Girentuximab.,Girentuximab,DB00110
DB05336,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00110
DB05405,The risk or severity of adverse effects can be increased when Palivizumab is combined with XTL-001.,XTL-001,DB00110
DB05437,The risk or severity of adverse effects can be increased when Palivizumab is combined with NAV 1800.,NAV 1800,DB00110
DB05459,The risk or severity of adverse effects can be increased when Palivizumab is combined with Briakinumab.,Briakinumab,DB00110
DB05496,The risk or severity of adverse effects can be increased when Palivizumab is combined with Otelixizumab.,Otelixizumab,DB00110
DB05545,The risk or severity of adverse effects can be increased when Palivizumab is combined with AMG 108.,AMG 108,DB00110
DB05550,The risk or severity of adverse effects can be increased when Palivizumab is combined with Iratumumab.,Iratumumab,DB00110
DB05555,The risk or severity of adverse effects can be increased when Palivizumab is combined with Enokizumab.,Enokizumab,DB00110
DB05578,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ramucirumab.,Ramucirumab,DB00110
DB05595,The risk or severity of adverse effects can be increased when Palivizumab is combined with Farletuzumab.,Farletuzumab,DB00110
DB05656,The risk or severity of adverse effects can be increased when Palivizumab is combined with Veltuzumab.,Veltuzumab,DB00110
DB05679,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ustekinumab.,Ustekinumab,DB00110
DB05773,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00110
DB05793,The risk or severity of adverse effects can be increased when Palivizumab is combined with PRO-542.,PRO-542,DB00110
DB05797,The risk or severity of adverse effects can be increased when Palivizumab is combined with TNX-901.,TNX-901,DB00110
DB05889,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00110
DB05892,The risk or severity of adverse effects can be increased when Palivizumab is combined with RI 624.,RI 624,DB00110
DB05915,The risk or severity of adverse effects can be increased when Palivizumab is combined with MYO-029.,MYO-029,DB00110
DB05916,The risk or severity of adverse effects can be increased when Palivizumab is combined with CT-011.,CT-011,DB00110
DB05941,The risk or severity of adverse effects can be increased when Palivizumab is combined with Leronlimab.,Leronlimab,DB00110
DB05996,The risk or severity of adverse effects can be increased when Palivizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00110
DB06043,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olaratumab.,Olaratumab,DB00110
DB06049,The risk or severity of adverse effects can be increased when Palivizumab is combined with IPH 2101.,IPH 2101,DB00110
DB06050,The risk or severity of adverse effects can be increased when Palivizumab is combined with TB-402.,TB-402,DB00110
DB06081,The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab.,Caplacizumab,DB00110
DB06101,The risk or severity of adverse effects can be increased when Palivizumab is combined with IMC-1C11.,IMC-1C11,DB00110
DB06116,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eldelumab.,Eldelumab,DB00110
DB06162,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumiliximab.,Lumiliximab,DB00110
DB06168,The risk or severity of adverse effects can be increased when Palivizumab is combined with Canakinumab.,Canakinumab,DB00110
DB06186,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipilimumab.,Ipilimumab,DB00110
DB06192,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nimotuzumab.,Nimotuzumab,DB00110
DB06241,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clenoliximab.,Clenoliximab,DB00110
DB06273,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tocilizumab.,Tocilizumab,DB00110
DB06304,The risk or severity of adverse effects can be increased when Palivizumab is combined with BIIB015.,BIIB015,DB00110
DB06305,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sonepcizumab.,Sonepcizumab,DB00110
DB06310,The risk or severity of adverse effects can be increased when Palivizumab is combined with Motavizumab.,Motavizumab,DB00110
DB06317,The risk or severity of adverse effects can be increased when Palivizumab is combined with Elotuzumab.,Elotuzumab,DB00110
DB06318,The risk or severity of adverse effects can be increased when Palivizumab is combined with AVE9633.,AVE9633,DB00110
DB06322,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carotuximab.,Carotuximab,DB00110
DB06324,The risk or severity of adverse effects can be increased when Palivizumab is combined with XmAb 2513.,XmAb 2513,DB00110
DB06342,The risk or severity of adverse effects can be increased when Palivizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00110
DB06343,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teprotumumab.,Teprotumumab,DB00110
DB06360,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lucatumumab.,Lucatumumab,DB00110
DB06366,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pertuzumab.,Pertuzumab,DB00110
DB06371,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siplizumab.,Siplizumab,DB00110
DB06467,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apolizumab.,Apolizumab,DB00110
DB06474,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00110
DB06550,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bivatuzumab.,Bivatuzumab,DB00110
DB06557,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lerdelimumab.,Lerdelimumab,DB00110
DB06599,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lexatumumab.,Lexatumumab,DB00110
DB06602,The risk or severity of adverse effects can be increased when Palivizumab is combined with Reslizumab.,Reslizumab,DB00110
DB06606,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teplizumab.,Teplizumab,DB00110
DB06607,The risk or severity of adverse effects can be increased when Palivizumab is combined with Catumaxomab.,Catumaxomab,DB00110
DB06612,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mepolizumab.,Mepolizumab,DB00110
DB06643,The risk or severity of adverse effects can be increased when Palivizumab is combined with Denosumab.,Denosumab,DB00110
DB06647,The risk or severity of adverse effects can be increased when Palivizumab is combined with Volociximab.,Volociximab,DB00110
DB06650,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ofatumumab.,Ofatumumab,DB00110
DB06674,The risk or severity of adverse effects can be increased when Palivizumab is combined with Golimumab.,Golimumab,DB00110
DB08870,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00110
DB08879,The risk or severity of adverse effects can be increased when Palivizumab is combined with Belimumab.,Belimumab,DB00110
DB08902,The risk or severity of adverse effects can be increased when Palivizumab is combined with Raxibacumab.,Raxibacumab,DB00110
DB08904,The risk or severity of adverse effects can be increased when Palivizumab is combined with Certolizumab pegol.,Certolizumab pegol,DB00110
DB08935,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obinutuzumab.,Obinutuzumab,DB00110
DB09029,The risk or severity of adverse effects can be increased when Palivizumab is combined with Secukinumab.,Secukinumab,DB00110
DB09033,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vedolizumab.,Vedolizumab,DB00110
DB09035,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nivolumab.,Nivolumab,DB00110
DB09036,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siltuximab.,Siltuximab,DB00110
DB09037,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pembrolizumab.,Pembrolizumab,DB00110
DB09045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dulaglutide.,Dulaglutide,DB00110
DB09052,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blinatumomab.,Blinatumomab,DB00110
DB09057,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anthrax immune globulin human.,Anthrax immune globulin human,DB00110
DB09077,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dinutuximab.,Dinutuximab,DB00110
DB09105,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asfotase alfa.,Asfotase alfa,DB00110
DB09264,The risk or severity of adverse effects can be increased when Palivizumab is combined with Idarucizumab.,Idarucizumab,DB00110
DB09302,The risk or severity of adverse effects can be increased when Palivizumab is combined with Alirocumab.,Alirocumab,DB00110
DB09303,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evolocumab.,Evolocumab,DB00110
DB09312,The risk or severity of adverse effects can be increased when Palivizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00110
DB09331,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daratumumab.,Daratumumab,DB00110
DB09559,The risk or severity of adverse effects can be increased when Palivizumab is combined with Necitumumab.,Necitumumab,DB00110
DB11569,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ixekizumab.,Ixekizumab,DB00110
DB11580,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ravulizumab.,Ravulizumab,DB00110
DB11595,The risk or severity of adverse effects can be increased when Palivizumab is combined with Atezolizumab.,Atezolizumab,DB00110
DB11604,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00110
DB11608,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00110
DB11621,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00110
DB11646,The risk or severity of adverse effects can be increased when Palivizumab is combined with Conatumumab.,Conatumumab,DB00110
DB11657,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tabalumab.,Tabalumab,DB00110
DB11680,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00110
DB11685,The risk or severity of adverse effects can be increased when Palivizumab is combined with Figitumumab.,Figitumumab,DB00110
DB11714,The risk or severity of adverse effects can be increased when Palivizumab is combined with Durvalumab.,Durvalumab,DB00110
DB11715,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bapineuzumab.,Bapineuzumab,DB00110
DB11731,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00110
DB11746,The risk or severity of adverse effects can be increased when Palivizumab is combined with Onartuzumab.,Onartuzumab,DB00110
DB11756,The risk or severity of adverse effects can be increased when Palivizumab is combined with Solanezumab.,Solanezumab,DB00110
DB11767,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sarilumab.,Sarilumab,DB00110
DB11771,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tremelimumab.,Tremelimumab,DB00110
DB11776,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brodalumab.,Brodalumab,DB00110
DB11803,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sirukumab.,Sirukumab,DB00110
DB11826,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lampalizumab.,Lampalizumab,DB00110
DB11834,The risk or severity of adverse effects can be increased when Palivizumab is combined with Guselkumab.,Guselkumab,DB00110
DB11840,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalotuzumab.,Dalotuzumab,DB00110
DB11849,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emibetuzumab.,Emibetuzumab,DB00110
DB11850,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ublituximab.,Ublituximab,DB00110
DB11856,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ligelizumab.,Ligelizumab,DB00110
DB11857,The risk or severity of adverse effects can be increased when Palivizumab is combined with Seribantumab.,Seribantumab,DB00110
DB11862,The risk or severity of adverse effects can be increased when Palivizumab is combined with Landogrozumab.,Landogrozumab,DB00110
DB11866,The risk or severity of adverse effects can be increased when Palivizumab is combined with Romosozumab.,Romosozumab,DB00110
DB11884,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00110
DB11914,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lebrikizumab.,Lebrikizumab,DB00110
DB11930,The risk or severity of adverse effects can be increased when Palivizumab is combined with Varlilumab.,Varlilumab,DB00110
DB11945,The risk or severity of adverse effects can be increased when Palivizumab is combined with Avelumab.,Avelumab,DB00110
DB11959,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crenezumab.,Crenezumab,DB00110
DB11972,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rilotumumab.,Rilotumumab,DB00110
DB11976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anifrolumab.,Anifrolumab,DB00110
DB11988,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ocrelizumab.,Ocrelizumab,DB00110
DB12023,The risk or severity of adverse effects can be increased when Palivizumab is combined with Benralizumab.,Benralizumab,DB00110
DB12034,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gantenerumab.,Gantenerumab,DB00110
DB12053,The risk or severity of adverse effects can be increased when Palivizumab is combined with Visilizumab.,Visilizumab,DB00110
DB12077,The risk or severity of adverse effects can be increased when Palivizumab is combined with Urelumab.,Urelumab,DB00110
DB12089,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00110
DB12090,The risk or severity of adverse effects can be increased when Palivizumab is combined with Patritumab.,Patritumab,DB00110
DB12102,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fulranumab.,Fulranumab,DB00110
DB12104,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tarextumab.,Tarextumab,DB00110
DB12118,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sotatercept.,Sotatercept,DB00110
DB12119,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gevokizumab.,Gevokizumab,DB00110
DB12142,The risk or severity of adverse effects can be increased when Palivizumab is combined with Duligotuzumab.,Duligotuzumab,DB00110
DB12152,The risk or severity of adverse effects can be increased when Palivizumab is combined with Simtuzumab.,Simtuzumab,DB00110
DB12157,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fasinumab.,Fasinumab,DB00110
DB12159,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dupilumab.,Dupilumab,DB00110
DB12169,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tralokinumab.,Tralokinumab,DB00110
DB12189,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etrolizumab.,Etrolizumab,DB00110
DB12202,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zalutumumab.,Zalutumumab,DB00110
DB12205,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ganitumab.,Ganitumab,DB00110
DB12213,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etaracizumab.,Etaracizumab,DB00110
DB12240,The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00110
DB12246,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inclacumab.,Inclacumab,DB00110
DB12250,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cixutumumab.,Cixutumumab,DB00110
DB12261,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00110
DB12274,The risk or severity of adverse effects can be increased when Palivizumab is combined with Aducanumab.,Aducanumab,DB00110
DB12281,The risk or severity of adverse effects can be increased when Palivizumab is combined with Luspatercept.,Luspatercept,DB00110
DB12296,The risk or severity of adverse effects can be increased when Palivizumab is combined with GS-5745.,GS-5745,DB00110
DB12317,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vanucizumab.,Vanucizumab,DB00110
DB12331,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00110
DB12335,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tanezumab.,Tanezumab,DB00110
DB12342,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ensituximab.,Ensituximab,DB00110
DB12344,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fezakinumab.,Fezakinumab,DB00110
DB12363,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dusigitumab.,Dusigitumab,DB00110
DB12396,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fresolimumab.,Fresolimumab,DB00110
DB12413,The risk or severity of adverse effects can be increased when Palivizumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00110
DB12456,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bococizumab.,Bococizumab,DB00110
DB12489,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00110
DB12498,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mogamulizumab.,Mogamulizumab,DB00110
DB12520,The risk or severity of adverse effects can be increased when Palivizumab is combined with Plozalizumab.,Plozalizumab,DB00110
DB12530,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inebilizumab.,Inebilizumab,DB00110
DB12534,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mavrilimumab.,Mavrilimumab,DB00110
DB12560,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blosozumab.,Blosozumab,DB00110
DB12584,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimagrumab.,Bimagrumab,DB00110
DB12589,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dacetuzumab.,Dacetuzumab,DB00110
DB12609,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tovetumab.,Tovetumab,DB00110
DB12683,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumretuzumab.,Lumretuzumab,DB00110
DB12698,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ibalizumab.,Ibalizumab,DB00110
DB12701,The risk or severity of adverse effects can be increased when Palivizumab is combined with Intetumumab.,Intetumumab,DB00110
DB12718,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carlumab.,Carlumab,DB00110
DB12734,The risk or severity of adverse effects can be increased when Palivizumab is combined with Demcizumab.,Demcizumab,DB00110
DB12773,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sifalimumab.,Sifalimumab,DB00110
DB12775,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abituzumab.,Abituzumab,DB00110
DB12797,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ecromeximab.,Ecromeximab,DB00110
DB12807,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00110
DB12815,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crotedumab.,Crotedumab,DB00110
DB12820,The risk or severity of adverse effects can be increased when Palivizumab is combined with Concizumab.,Concizumab,DB00110
DB12826,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab.,Depatuxizumab,DB00110
DB12844,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rontalizumab.,Rontalizumab,DB00110
DB12845,The risk or severity of adverse effects can be increased when Palivizumab is combined with Amatuximab.,Amatuximab,DB00110
DB12849,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clazakizumab.,Clazakizumab,DB00110
DB12891,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ozanezumab.,Ozanezumab,DB00110
DB12893,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00110
DB12917,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimekizumab.,Bimekizumab,DB00110
DB12943,The risk or severity of adverse effects can be increased when Palivizumab is combined with Milatuzumab.,Milatuzumab,DB00110
DB12976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Robatumumab.,Robatumumab,DB00110
DB13017,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00110
DB13037,The risk or severity of adverse effects can be increased when Palivizumab is combined with Namilumab.,Namilumab,DB00110
DB13045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Racotumomab.,Racotumomab,DB00110
DB13073,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tregalizumab.,Tregalizumab,DB00110
DB13127,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olokizumab.,Olokizumab,DB00110
DB13140,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00110
DB13375,The risk or severity of adverse effects can be increased when Palivizumab is combined with Edrecolomab.,Edrecolomab,DB00110
DB13535,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nebacumab.,Nebacumab,DB00110
DB13886,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00110
DB13923,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emicizumab.,Emicizumab,DB00110
DB13976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sulesomab.,Sulesomab,DB00110
DB13979,The risk or severity of adverse effects can be increased when Palivizumab is combined with Besilesomab.,Besilesomab,DB00110
DB14004,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tildrakizumab.,Tildrakizumab,DB00110
DB14012,The risk or severity of adverse effects can be increased when Palivizumab is combined with Burosumab.,Burosumab,DB00110
DB14039,The risk or severity of adverse effects can be increased when Palivizumab is combined with Erenumab.,Erenumab,DB00110
DB14040,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.,Eptinezumab,DB00110
DB14041,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fremanezumab.,Fremanezumab,DB00110
DB14042,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galcanezumab.,Galcanezumab,DB00110
DB14211,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fanolesomab.,Fanolesomab,DB00110
DB14580,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lecanemab.,Lecanemab,DB00110
DB14597,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lanadelumab.,Lanadelumab,DB00110
DB14707,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cemiplimab.,Cemiplimab,DB00110
DB14724,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emapalumab.,Emapalumab,DB00110
DB14762,The risk or severity of adverse effects can be increased when Palivizumab is combined with Risankizumab.,Risankizumab,DB00110
DB14776,The risk or severity of adverse effects can be increased when Palivizumab is combined with Camrelizumab.,Camrelizumab,DB00110
DB14778,The risk or severity of adverse effects can be increased when Palivizumab is combined with Setrusumab.,Setrusumab,DB00110
DB14784,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gancotamab.,Gancotamab,DB00110
DB14809,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00110
DB14811,The risk or severity of adverse effects can be increased when Palivizumab is combined with Isatuximab.,Isatuximab,DB00110
DB14824,The risk or severity of adverse effects can be increased when Palivizumab is combined with Icrucumab.,Icrucumab,DB00110
DB14843,The risk or severity of adverse effects can be increased when Palivizumab is combined with Codrituzumab.,Codrituzumab,DB00110
DB14864,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brolucizumab.,Brolucizumab,DB00110
DB14871,The risk or severity of adverse effects can be increased when Palivizumab is combined with Xentuzumab.,Xentuzumab,DB00110
DB14877,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lintuzumab.,Lintuzumab,DB00110
DB14891,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vobarilizumab.,Vobarilizumab,DB00110
DB14897,The risk or severity of adverse effects can be increased when Palivizumab is combined with Parsatuzumab.,Parsatuzumab,DB00110
DB14905,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emactuzumab.,Emactuzumab,DB00110
DB14907,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00110
DB14908,The risk or severity of adverse effects can be increased when Palivizumab is combined with Refanezumab.,Refanezumab,DB00110
DB14919,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozanolixizumab.,Rozanolixizumab,DB00110
DB14947,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bermekimab.,Bermekimab,DB00110
DB14952,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pamrevlumab.,Pamrevlumab,DB00110
DB14959,The risk or severity of adverse effects can be increased when Palivizumab is combined with Opicinumab.,Opicinumab,DB00110
DB14962,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00110
DB14967,The risk or severity of adverse effects can be increased when Palivizumab is combined with Margetuximab.,Margetuximab,DB00110
DB14988,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalantercept.,Dalantercept,DB00110
DB14997,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pateclizumab.,Pateclizumab,DB00110
DB15014,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gremubamab.,Gremubamab,DB00110
DB15022,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apomab.,Apomab,DB00110
DB15044,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tafasitamab.,Tafasitamab,DB00110
DB15045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipafricept.,Ipafricept,DB00110
DB15076,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abrilumab.,Abrilumab,DB00110
DB15089,The risk or severity of adverse effects can be increased when Palivizumab is combined with Frovocimab.,Frovocimab,DB00110
DB15090,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tezepelumab.,Tezepelumab,DB00110
DB15101,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tigatuzumab.,Tigatuzumab,DB00110
DB15104,The risk or severity of adverse effects can be increased when Palivizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00110
DB15113,The risk or severity of adverse effects can be increased when Palivizumab is combined with Utomilumab.,Utomilumab,DB00110
DB15118,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zolbetuximab.,Zolbetuximab,DB00110
DB15135,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ponezumab.,Ponezumab,DB00110
DB15160,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asunercept.,Asunercept,DB00110
DB15172,The risk or severity of adverse effects can be increased when Palivizumab is combined with Suvratoxumab.,Suvratoxumab,DB00110
DB15225,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mitazalimab.,Mitazalimab,DB00110
DB15252,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nemolizumab.,Nemolizumab,DB00110
DB15253,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bleselumab.,Bleselumab,DB00110
DB15277,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gedivumab.,Gedivumab,DB00110
DB15336,The risk or severity of adverse effects can be increased when Palivizumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00110
DB15349,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00110
DB15354,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evinacumab.,Evinacumab,DB00110
DB15363,The risk or severity of adverse effects can be increased when Palivizumab is combined with Istiratumab.,Istiratumab,DB00110
DB15383,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pidilizumab.,Pidilizumab,DB00110
DB15397,The risk or severity of adverse effects can be increased when Palivizumab is combined with GMA-161.,GMA-161,DB00110
DB15409,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00110
DB15415,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tomaralimab.,Tomaralimab,DB00110
DB15428,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vesencumab.,Vesencumab,DB00110
DB15432,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00110
DB15441,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00110
DB15443,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00110
DB15453,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00110
DB15559,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00110
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Palivizumab.,Rubella virus vaccine,DB00110
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain tice live antigen,DB00110
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00110
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Palivizumab.,Yellow Fever Vaccine,DB00110
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Palivizumab.,Anthrax vaccine,DB00110
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Palivizumab.,Typhoid Vaccine Live,DB00110
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00110
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Palivizumab.,BCG vaccine,DB00110
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Palivizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00110
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Palivizumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00110
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Palivizumab.,Adenovirus type 7 vaccine live,DB00110
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Palivizumab.,Varicella Zoster Vaccine (Live/attenuated),DB00110
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Palivizumab.","Ebola Zaire vaccine (live, attenuated)",DB00110
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.,Denosumab,DB00111
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.,Etanercept,DB00111
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab.,Peginterferon alfa-2a,DB00111
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.,Interferon alfa-n1,DB00111
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daclizumab.,Interferon alfa-n3,DB00111
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.,Peginterferon alfa-2b,DB00111
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.,Anakinra,DB00111
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daclizumab.,Interferon gamma-1b,DB00111
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Daclizumab.","Interferon alfa-2a, Recombinant",DB00111
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.,Aldesleukin,DB00111
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.,Adalimumab,DB00111
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.,Gemtuzumab ozogamicin,DB00111
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.,Pegaspargase,DB00111
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.,Infliximab,DB00111
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.,Interferon beta-1b,DB00111
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.,Interferon alfacon-1,DB00111
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.,Rituximab,DB00111
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.,Basiliximab,DB00111
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.,Muromonab,DB00111
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.,Ibritumomab tiuxetan,DB00111
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.,Tositumomab,DB00111
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.,Alemtuzumab,DB00111
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.,Alefacept,DB00111
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.,Efalizumab,DB00111
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.,Antithymocyte immunoglobulin (rabbit),DB00111
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.,Interferon alfa-2b,DB00111
DB00112,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.,Bevacizumab,DB00111
DB00120,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.,Phenylalanine,DB00111
DB00180,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flunisolide.,Flunisolide,DB00111
DB00188,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bortezomib.,Bortezomib,DB00111
DB00242,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cladribine.,Cladribine,DB00111
DB00262,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine.,Carmustine,DB00111
DB00276,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amsacrine.,Amsacrine,DB00111
DB00290,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin.,Bleomycin,DB00111
DB00291,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chlorambucil.,Chlorambucil,DB00111
DB00293,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed.,Raltitrexed,DB00111
DB00305,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin.,Mitomycin,DB00111
DB00307,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene.,Bexarotene,DB00111
DB00309,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine.,Vindesine,DB00111
DB00322,The risk or severity of adverse effects can be increased when Daclizumab is combined with Floxuridine.,Floxuridine,DB00111
DB00328,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin.,Indomethacin,DB00111
DB00352,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine.,Tioguanine,DB00111
DB00361,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinorelbine.,Vinorelbine,DB00111
DB00380,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane.,Dexrazoxane,DB00111
DB00394,The risk or severity of adverse effects can be increased when Daclizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00111
DB00398,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sorafenib.,Sorafenib,DB00111
DB00428,The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin.,Streptozocin,DB00111
DB00432,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trifluridine.,Trifluridine,DB00111
DB00441,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gemcitabine.,Gemcitabine,DB00111
DB00443,The risk or severity of adverse effects can be increased when Daclizumab is combined with Betamethasone.,Betamethasone,DB00111
DB00444,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide.,Teniposide,DB00111
DB00445,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin.,Epirubicin,DB00111
DB00446,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chloramphenicol.,Chloramphenicol,DB00111
DB00480,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lenalidomide.,Lenalidomide,DB00111
DB00488,The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.,Altretamine,DB00111
DB00495,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine.,Zidovudine,DB00111
DB00515,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.,Cisplatin,DB00111
DB00526,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin.,Oxaliplatin,DB00111
DB00531,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.,Cyclophosphamide,DB00111
DB00541,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine.,Vincristine,DB00111
DB00544,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil.,Fluorouracil,DB00111
DB00550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.,Propylthiouracil,DB00111
DB00552,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin.,Pentostatin,DB00111
DB00563,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methotrexate.,Methotrexate,DB00111
DB00564,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carbamazepine.,Carbamazepine,DB00111
DB00570,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine.,Vinblastine,DB00111
DB00588,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone propionate.,Fluticasone propionate,DB00111
DB00591,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00111
DB00601,The risk or severity of adverse effects can be increased when Daclizumab is combined with Linezolid.,Linezolid,DB00111
DB00619,The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib.,Imatinib,DB00111
DB00620,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triamcinolone.,Triamcinolone,DB00111
DB00631,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clofarabine.,Clofarabine,DB00111
DB00635,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisone.,Prednisone,DB00111
DB00642,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pemetrexed.,Pemetrexed,DB00111
DB00687,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludrocortisone.,Fludrocortisone,DB00111
DB00688,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00111
DB00694,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.,Daunorubicin,DB00111
DB00755,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tretinoin.,Tretinoin,DB00111
DB00762,The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.,Irinotecan,DB00111
DB00763,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methimazole.,Methimazole,DB00111
DB00764,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone.,Mometasone,DB00111
DB00773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etoposide.,Etoposide,DB00111
DB00795,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine.,Sulfasalazine,DB00111
DB00851,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine.,Dacarbazine,DB00111
DB00853,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temozolomide.,Temozolomide,DB00111
DB00859,The risk or severity of adverse effects can be increased when Daclizumab is combined with Penicillamine.,Penicillamine,DB00111
DB00860,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone.,Prednisolone,DB00111
DB00877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirolimus.,Sirolimus,DB00111
DB00888,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine.,Mechlorethamine,DB00111
DB00928,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azacitidine.,Azacitidine,DB00111
DB00958,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.,Carboplatin,DB00111
DB00959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone.,Methylprednisolone,DB00111
DB00970,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin.,Dactinomycin,DB00111
DB00987,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.,Cytarabine,DB00111
DB00993,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azathioprine.,Azathioprine,DB00111
DB00997,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxorubicin.,Doxorubicin,DB00111
DB01005,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxyurea.,Hydroxyurea,DB00111
DB01008,The risk or severity of adverse effects can be increased when Daclizumab is combined with Busulfan.,Busulfan,DB00111
DB01024,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolic acid.,Mycophenolic acid,DB00111
DB01030,The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.,Topotecan,DB00111
DB01033,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine.,Mercaptopurine,DB00111
DB01041,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide.,Thalidomide,DB00111
DB01042,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melphalan.,Melphalan,DB00111
DB01073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludarabine.,Fludarabine,DB00111
DB01099,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flucytosine.,Flucytosine,DB00111
DB01101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Capecitabine.,Capecitabine,DB00111
DB01108,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trilostane.,Trilostane,DB00111
DB01168,The risk or severity of adverse effects can be increased when Daclizumab is combined with Procarbazine.,Procarbazine,DB00111
DB01169,The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide.,Arsenic trioxide,DB00111
DB01177,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarubicin.,Idarubicin,DB00111
DB01181,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ifosfamide.,Ifosfamide,DB00111
DB01196,The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.,Estramustine,DB00111
DB01204,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.,Mitoxantrone,DB00111
DB01206,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lomustine.,Lomustine,DB00111
DB01222,The risk or severity of adverse effects can be increased when Daclizumab is combined with Budesonide.,Budesonide,DB00111
DB01229,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paclitaxel.,Paclitaxel,DB00111
DB01234,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.,Dexamethasone,DB00111
DB01248,The risk or severity of adverse effects can be increased when Daclizumab is combined with Docetaxel.,Docetaxel,DB00111
DB01254,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.,Dasatinib,DB00111
DB01257,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eculizumab.,Eculizumab,DB00111
DB01262,The risk or severity of adverse effects can be increased when Daclizumab is combined with Decitabine.,Decitabine,DB00111
DB01268,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sunitinib.,Sunitinib,DB00111
DB01280,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nelarabine.,Nelarabine,DB00111
DB01281,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abatacept.,Abatacept,DB00111
DB01285,The risk or severity of adverse effects can be increased when Daclizumab is combined with Corticotropin.,Corticotropin,DB00111
DB01380,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortisone acetate.,Cortisone acetate,DB00111
DB01384,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paramethasone.,Paramethasone,DB00111
DB01394,The risk or severity of adverse effects can be increased when Daclizumab is combined with Colchicine.,Colchicine,DB00111
DB01410,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.,Ciclesonide,DB00111
DB01423,The risk or severity of adverse effects can be increased when Daclizumab is combined with Stepronin.,Stepronin,DB00111
DB01590,The risk or severity of adverse effects can be increased when Daclizumab is combined with Everolimus.,Everolimus,DB00111
DB01611,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00111
DB01816,The risk or severity of adverse effects can be increased when Daclizumab is combined with Castanospermine.,Castanospermine,DB00111
DB02546,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vorinostat.,Vorinostat,DB00111
DB02806,The risk or severity of adverse effects can be increased when Daclizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00111
DB03523,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brequinar.,Brequinar,DB00111
DB04572,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thiotepa.,Thiotepa,DB00111
DB04630,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone.,Aldosterone,DB00111
DB04845,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixabepilone.,Ixabepilone,DB00111
DB04868,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nilotinib.,Nilotinib,DB00111
DB04951,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirfenidone.,Pirfenidone,DB00111
DB04956,The risk or severity of adverse effects can be increased when Daclizumab is combined with Afelimomab.,Afelimomab,DB00111
DB05015,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belinostat.,Belinostat,DB00111
DB05109,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trabectedin.,Trabectedin,DB00111
DB05258,The risk or severity of adverse effects can be increased when Daclizumab is combined with Interferon alfa.,Interferon alfa,DB00111
DB05259,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glatiramer.,Glatiramer,DB00111
DB05260,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gallium nitrate.,Gallium nitrate,DB00111
DB05459,The risk or severity of adverse effects can be increased when Daclizumab is combined with Briakinumab.,Briakinumab,DB00111
DB05472,The risk or severity of adverse effects can be increased when Daclizumab is combined with omega interferon.,omega interferon,DB00111
DB05676,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apremilast.,Apremilast,DB00111
DB05773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00111
DB06168,The risk or severity of adverse effects can be increased when Daclizumab is combined with Canakinumab.,Canakinumab,DB00111
DB06273,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tocilizumab.,Tocilizumab,DB00111
DB06287,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temsirolimus.,Temsirolimus,DB00111
DB06372,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilonacept.,Rilonacept,DB00111
DB06589,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pazopanib.,Pazopanib,DB00111
DB06603,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panobinostat.,Panobinostat,DB00111
DB06612,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mepolizumab.,Mepolizumab,DB00111
DB06616,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bosutinib.,Bosutinib,DB00111
DB06662,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abetimus.,Abetimus,DB00111
DB06674,The risk or severity of adverse effects can be increased when Daclizumab is combined with Golimumab.,Golimumab,DB00111
DB06681,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belatacept.,Belatacept,DB00111
DB06769,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bendamustine.,Bendamustine,DB00111
DB06772,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cabazitaxel.,Cabazitaxel,DB00111
DB06813,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pralatrexate.,Pralatrexate,DB00111
DB08059,The risk or severity of adverse effects can be increased when Daclizumab is combined with Wortmannin.,Wortmannin,DB00111
DB08870,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00111
DB08871,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eribulin.,Eribulin,DB00111
DB08877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ruxolitinib.,Ruxolitinib,DB00111
DB08879,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.,Belimumab,DB00111
DB08880,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide.,Teriflunomide,DB00111
DB08889,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carfilzomib.,Carfilzomib,DB00111
DB08901,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponatinib.,Ponatinib,DB00111
DB08904,The risk or severity of adverse effects can be increased when Daclizumab is combined with Certolizumab pegol.,Certolizumab pegol,DB00111
DB08906,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone furoate.,Fluticasone furoate,DB00111
DB08908,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00111
DB08910,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.,Pomalidomide,DB00111
DB08935,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obinutuzumab.,Obinutuzumab,DB00111
DB08970,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene.,Fluprednidene,DB00111
DB08971,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone.,Fluocortolone,DB00111
DB09029,The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.,Secukinumab,DB00111
DB09033,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vedolizumab.,Vedolizumab,DB00111
DB09036,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siltuximab.,Siltuximab,DB00111
DB09052,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blinatumomab.,Blinatumomab,DB00111
DB09053,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibrutinib.,Ibrutinib,DB00111
DB09054,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idelalisib.,Idelalisib,DB00111
DB09073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Palbociclib.,Palbociclib,DB00111
DB09074,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaparib.,Olaparib,DB00111
DB09077,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dinutuximab.,Dinutuximab,DB00111
DB09082,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vilanterol.,Vilanterol,DB00111
DB09091,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tixocortol.,Tixocortol,DB00111
DB09122,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00111
DB09312,The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00111
DB09378,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednisolone.,Fluprednisolone,DB00111
DB09383,The risk or severity of adverse effects can be increased when Daclizumab is combined with Meprednisone.,Meprednisone,DB00111
DB11466,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tepoxalin.,Tepoxalin,DB00111
DB11487,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00111
DB11529,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melengestrol.,Melengestrol,DB00111
DB11569,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixekizumab.,Ixekizumab,DB00111
DB11580,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ravulizumab.,Ravulizumab,DB00111
DB11616,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirarubicin.,Pirarubicin,DB00111
DB11693,The risk or severity of adverse effects can be increased when Daclizumab is combined with Voclosporin.,Voclosporin,DB00111
DB11708,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peficitinib.,Peficitinib,DB00111
DB11750,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clobetasol.,Clobetasol,DB00111
DB11767,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sarilumab.,Sarilumab,DB00111
DB11776,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brodalumab.,Brodalumab,DB00111
DB11803,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirukumab.,Sirukumab,DB00111
DB11817,The risk or severity of adverse effects can be increased when Daclizumab is combined with Baricitinib.,Baricitinib,DB00111
DB11834,The risk or severity of adverse effects can be increased when Daclizumab is combined with Guselkumab.,Guselkumab,DB00111
DB11921,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deflazacort.,Deflazacort,DB00111
DB12025,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triptolide.,Triptolide,DB00111
DB12371,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siponimod.,Siponimod,DB00111
DB12612,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanimod.,Ozanimod,DB00111
DB12617,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mizoribine.,Mizoribine,DB00111
DB12692,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gusperimus.,Gusperimus,DB00111
DB12814,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00111
DB12902,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trofosfamide.,Trofosfamide,DB00111
DB12947,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxifluridine.,Doxifluridine,DB00111
DB12991,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deoxyspergualin.,Deoxyspergualin,DB00111
DB12996,The risk or severity of adverse effects can be increased when Daclizumab is combined with Acteoside.,Acteoside,DB00111
DB13003,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortivazol.,Cortivazol,DB00111
DB13014,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hypericin.,Hypericin,DB00111
DB13068,The risk or severity of adverse effects can be increased when Daclizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00111
DB13208,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednylidene.,Prednylidene,DB00111
DB13223,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortin.,Fluocortin,DB00111
DB13241,The risk or severity of adverse effects can be increased when Daclizumab is combined with Begelomab.,Begelomab,DB00111
DB13491,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluperolone.,Fluperolone,DB00111
DB13664,The risk or severity of adverse effects can be increased when Daclizumab is combined with Formocortal.,Formocortal,DB00111
DB13728,The risk or severity of adverse effects can be increased when Daclizumab is combined with Halometasone.,Halometasone,DB00111
DB13843,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cloprednol.,Cloprednol,DB00111
DB13856,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluclorolone.,Fluclorolone,DB00111
DB13867,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone.,Fluticasone,DB00111
DB14066,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetrandrine.,Tetrandrine,DB00111
DB14219,The risk or severity of adverse effects can be increased when Daclizumab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00111
DB14512,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone furoate.,Mometasone furoate,DB00111
DB14538,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00111
DB14539,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00111
DB14545,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00111
DB14724,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emapalumab.,Emapalumab,DB00111
DB14762,The risk or severity of adverse effects can be increased when Daclizumab is combined with Risankizumab.,Risankizumab,DB00111
DB14919,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozanolixizumab.,Rozanolixizumab,DB00111
DB15253,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleselumab.,Bleselumab,DB00111
DB00108,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.,Natalizumab,DB00111
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.,Pimecrolimus,DB00111
DB01656,Roflumilast may increase the immunosuppressive activities of Daclizumab.,Roflumilast,DB00111
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.,Sipuleucel-T,DB00111
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daclizumab.,Sulfamethoxazole,DB00111
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Daclizumab.,Diethylstilbestrol,DB00111
DB00269,Chlorotrianisene may increase the thrombogenic activities of Daclizumab.,Chlorotrianisene,DB00111
DB00286,Conjugated estrogens may increase the thrombogenic activities of Daclizumab.,Conjugated estrogens,DB00111
DB00655,Estrone may increase the thrombogenic activities of Daclizumab.,Estrone,DB00111
DB00783,Estradiol may increase the thrombogenic activities of Daclizumab.,Estradiol,DB00111
DB00890,Dienestrol may increase the thrombogenic activities of Daclizumab.,Dienestrol,DB00111
DB00977,Ethinylestradiol may increase the thrombogenic activities of Daclizumab.,Ethinylestradiol,DB00111
DB01357,Mestranol may increase the thrombogenic activities of Daclizumab.,Mestranol,DB00111
DB04573,Estriol may increase the thrombogenic activities of Daclizumab.,Estriol,DB00111
DB04574,Estrone sulfate may increase the thrombogenic activities of Daclizumab.,Estrone sulfate,DB00111
DB04575,Quinestrol may increase the thrombogenic activities of Daclizumab.,Quinestrol,DB00111
DB07931,Hexestrol may increase the thrombogenic activities of Daclizumab.,Hexestrol,DB00111
DB09070,Tibolone may increase the thrombogenic activities of Daclizumab.,Tibolone,DB00111
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Daclizumab.","Synthetic Conjugated Estrogens, A",DB00111
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daclizumab.","Synthetic Conjugated Estrogens, B",DB00111
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Daclizumab.,Polyestradiol phosphate,DB00111
DB09381,Esterified estrogens may increase the thrombogenic activities of Daclizumab.,Esterified estrogens,DB00111
DB11478,Zeranol may increase the thrombogenic activities of Daclizumab.,Zeranol,DB00111
DB11674,Equol may increase the thrombogenic activities of Daclizumab.,Equol,DB00111
DB12487,Promestriene may increase the thrombogenic activities of Daclizumab.,Promestriene,DB00111
DB13143,Methallenestril may increase the thrombogenic activities of Daclizumab.,Methallenestril,DB00111
DB13386,Epimestrol may increase the thrombogenic activities of Daclizumab.,Epimestrol,DB00111
DB13418,Moxestrol may increase the thrombogenic activities of Daclizumab.,Moxestrol,DB00111
DB13952,Estradiol acetate may increase the thrombogenic activities of Daclizumab.,Estradiol acetate,DB00111
DB13953,Estradiol benzoate may increase the thrombogenic activities of Daclizumab.,Estradiol benzoate,DB00111
DB13954,Estradiol cypionate may increase the thrombogenic activities of Daclizumab.,Estradiol cypionate,DB00111
DB13956,Estradiol valerate may increase the thrombogenic activities of Daclizumab.,Estradiol valerate,DB00111
DB15334,Biochanin A may increase the thrombogenic activities of Daclizumab.,Biochanin A,DB00111
DB15335,Formononetin may increase the thrombogenic activities of Daclizumab.,Formononetin,DB00111
DB01097,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.,Leflunomide,DB00111
DB08895,Daclizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00111
DB00072,Trastuzumab may increase the neutropenic activities of Daclizumab.,Trastuzumab,DB00111
DB08868,Daclizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00111
DB00864,Tacrolimus may increase the immunosuppressive activities of Daclizumab.,Tacrolimus,DB00111
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Daclizumab.,G17DT,DB00111
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Daclizumab.,PEV3A,DB00111
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Daclizumab.,INGN 225,DB00111
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Daclizumab.,Rindopepimut,DB00111
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Daclizumab.,SRP 299,DB00111
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daclizumab.,GI-5005,DB00111
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Daclizumab.,Vitespen,DB00111
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Daclizumab.,TG4010,DB00111
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daclizumab.,Anthrax immune globulin human,DB00111
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Daclizumab.","Rabies virus inactivated antigen, B",DB00111
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00111
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Daclizumab.,Rotavirus vaccine,DB00111
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab.","Rabies virus inactivated antigen, A",DB00111
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00111
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00111
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00111
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00111
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00111
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00111
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Daclizumab.,Typhoid Vi polysaccharide vaccine,DB00111
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.,Hepatitis A Vaccine,DB00111
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00111
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00111
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00111
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00111
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00111
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daclizumab.,Human rabies virus immune globulin,DB00111
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.,Hepatitis B Vaccine (Recombinant),DB00111
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Daclizumab.,Tecemotide,DB00111
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daclizumab.,Typhoid vaccine,DB00111
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00111
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00111
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00111
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00111
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Daclizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00111
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00111
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00111
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Daclizumab.,Vaccinia virus strain new york city board of health live antigen,DB00111
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daclizumab.,Pertussis vaccine,DB00111
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00111
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.,Varicella Zoster Vaccine (Recombinant),DB00111
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Daclizumab.,Modified vaccinia ankara,DB00111
DB11988,Ocrelizumab may increase the immunosuppressive activities of Daclizumab.,Ocrelizumab,DB00111
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daclizumab.,Rubella virus vaccine,DB00111
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Daclizumab.,Varicella Zoster Vaccine (Live/attenuated),DB00111
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain tice live antigen,DB00111
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00111
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Daclizumab.,Yellow Fever Vaccine,DB00111
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Daclizumab.,Anthrax vaccine,DB00111
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Daclizumab.,Typhoid Vaccine Live,DB00111
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00111
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Daclizumab.,BCG vaccine,DB00111
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Daclizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00111
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Daclizumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00111
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daclizumab.,Adenovirus type 7 vaccine live,DB00111
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.,Cetuximab,DB00111
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.,Human immunoglobulin G,DB00111
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Daclizumab.,Omalizumab,DB00111
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Daclizumab.,Abciximab,DB00111
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.,Indium In-111 satumomab pendetide,DB00111
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.,Digoxin Immune Fab (Ovine),DB00111
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.,Capromab pendetide,DB00111
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.,Palivizumab,DB00111
DB00113,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00111
DB01269,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panitumumab.,Panitumumab,DB00111
DB01270,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ranibizumab.,Ranibizumab,DB00111
DB04901,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galiximab.,Galiximab,DB00111
DB04949,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pexelizumab.,Pexelizumab,DB00111
DB04958,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epratuzumab.,Epratuzumab,DB00111
DB04962,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bectumomab.,Bectumomab,DB00111
DB04964,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oregovomab.,Oregovomab,DB00111
DB04988,The risk or severity of adverse effects can be increased when Daclizumab is combined with IGN311.,IGN311,DB00111
DB05006,The risk or severity of adverse effects can be increased when Daclizumab is combined with Adecatumumab.,Adecatumumab,DB00111
DB05097,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab.,Labetuzumab,DB00111
DB05101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Matuzumab.,Matuzumab,DB00111
DB05111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fontolizumab.,Fontolizumab,DB00111
DB05136,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bavituximab.,Bavituximab,DB00111
DB05139,The risk or severity of adverse effects can be increased when Daclizumab is combined with CR002.,CR002,DB00111
DB05209,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozrolimupab.,Rozrolimupab,DB00111
DB05304,The risk or severity of adverse effects can be increased when Daclizumab is combined with Girentuximab.,Girentuximab,DB00111
DB05336,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00111
DB05405,The risk or severity of adverse effects can be increased when Daclizumab is combined with XTL-001.,XTL-001,DB00111
DB05437,The risk or severity of adverse effects can be increased when Daclizumab is combined with NAV 1800.,NAV 1800,DB00111
DB05496,The risk or severity of adverse effects can be increased when Daclizumab is combined with Otelixizumab.,Otelixizumab,DB00111
DB05545,The risk or severity of adverse effects can be increased when Daclizumab is combined with AMG 108.,AMG 108,DB00111
DB05550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Iratumumab.,Iratumumab,DB00111
DB05555,The risk or severity of adverse effects can be increased when Daclizumab is combined with Enokizumab.,Enokizumab,DB00111
DB05578,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ramucirumab.,Ramucirumab,DB00111
DB05595,The risk or severity of adverse effects can be increased when Daclizumab is combined with Farletuzumab.,Farletuzumab,DB00111
DB05656,The risk or severity of adverse effects can be increased when Daclizumab is combined with Veltuzumab.,Veltuzumab,DB00111
DB05793,The risk or severity of adverse effects can be increased when Daclizumab is combined with PRO-542.,PRO-542,DB00111
DB05797,The risk or severity of adverse effects can be increased when Daclizumab is combined with TNX-901.,TNX-901,DB00111
DB05889,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00111
DB05892,The risk or severity of adverse effects can be increased when Daclizumab is combined with RI 624.,RI 624,DB00111
DB05915,The risk or severity of adverse effects can be increased when Daclizumab is combined with MYO-029.,MYO-029,DB00111
DB05916,The risk or severity of adverse effects can be increased when Daclizumab is combined with CT-011.,CT-011,DB00111
DB05941,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leronlimab.,Leronlimab,DB00111
DB05996,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00111
DB06043,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaratumab.,Olaratumab,DB00111
DB06049,The risk or severity of adverse effects can be increased when Daclizumab is combined with IPH 2101.,IPH 2101,DB00111
DB06050,The risk or severity of adverse effects can be increased when Daclizumab is combined with TB-402.,TB-402,DB00111
DB06081,The risk or severity of adverse effects can be increased when Daclizumab is combined with Caplacizumab.,Caplacizumab,DB00111
DB06101,The risk or severity of adverse effects can be increased when Daclizumab is combined with IMC-1C11.,IMC-1C11,DB00111
DB06116,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eldelumab.,Eldelumab,DB00111
DB06162,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumiliximab.,Lumiliximab,DB00111
DB06186,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipilimumab.,Ipilimumab,DB00111
DB06192,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nimotuzumab.,Nimotuzumab,DB00111
DB06241,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clenoliximab.,Clenoliximab,DB00111
DB06304,The risk or severity of adverse effects can be increased when Daclizumab is combined with BIIB015.,BIIB015,DB00111
DB06305,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sonepcizumab.,Sonepcizumab,DB00111
DB06310,The risk or severity of adverse effects can be increased when Daclizumab is combined with Motavizumab.,Motavizumab,DB00111
DB06317,The risk or severity of adverse effects can be increased when Daclizumab is combined with Elotuzumab.,Elotuzumab,DB00111
DB06318,The risk or severity of adverse effects can be increased when Daclizumab is combined with AVE9633.,AVE9633,DB00111
DB06322,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carotuximab.,Carotuximab,DB00111
DB06324,The risk or severity of adverse effects can be increased when Daclizumab is combined with XmAb 2513.,XmAb 2513,DB00111
DB06342,The risk or severity of adverse effects can be increased when Daclizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00111
DB06343,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teprotumumab.,Teprotumumab,DB00111
DB06360,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lucatumumab.,Lucatumumab,DB00111
DB06366,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pertuzumab.,Pertuzumab,DB00111
DB06371,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siplizumab.,Siplizumab,DB00111
DB06467,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apolizumab.,Apolizumab,DB00111
DB06474,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00111
DB06550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bivatuzumab.,Bivatuzumab,DB00111
DB06557,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lerdelimumab.,Lerdelimumab,DB00111
DB06599,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lexatumumab.,Lexatumumab,DB00111
DB06602,The risk or severity of adverse effects can be increased when Daclizumab is combined with Reslizumab.,Reslizumab,DB00111
DB06606,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teplizumab.,Teplizumab,DB00111
DB06607,The risk or severity of adverse effects can be increased when Daclizumab is combined with Catumaxomab.,Catumaxomab,DB00111
DB06647,The risk or severity of adverse effects can be increased when Daclizumab is combined with Volociximab.,Volociximab,DB00111
DB06650,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ofatumumab.,Ofatumumab,DB00111
DB08902,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raxibacumab.,Raxibacumab,DB00111
DB09035,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nivolumab.,Nivolumab,DB00111
DB09037,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pembrolizumab.,Pembrolizumab,DB00111
DB09045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dulaglutide.,Dulaglutide,DB00111
DB09105,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asfotase alfa.,Asfotase alfa,DB00111
DB09264,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarucizumab.,Idarucizumab,DB00111
DB09302,The risk or severity of adverse effects can be increased when Daclizumab is combined with Alirocumab.,Alirocumab,DB00111
DB09303,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evolocumab.,Evolocumab,DB00111
DB09331,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daratumumab.,Daratumumab,DB00111
DB09559,The risk or severity of adverse effects can be increased when Daclizumab is combined with Necitumumab.,Necitumumab,DB00111
DB11595,The risk or severity of adverse effects can be increased when Daclizumab is combined with Atezolizumab.,Atezolizumab,DB00111
DB11604,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00111
DB11608,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00111
DB11621,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00111
DB11646,The risk or severity of adverse effects can be increased when Daclizumab is combined with Conatumumab.,Conatumumab,DB00111
DB11657,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tabalumab.,Tabalumab,DB00111
DB11680,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00111
DB11685,The risk or severity of adverse effects can be increased when Daclizumab is combined with Figitumumab.,Figitumumab,DB00111
DB11714,The risk or severity of adverse effects can be increased when Daclizumab is combined with Durvalumab.,Durvalumab,DB00111
DB11715,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bapineuzumab.,Bapineuzumab,DB00111
DB11731,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00111
DB11746,The risk or severity of adverse effects can be increased when Daclizumab is combined with Onartuzumab.,Onartuzumab,DB00111
DB11756,The risk or severity of adverse effects can be increased when Daclizumab is combined with Solanezumab.,Solanezumab,DB00111
DB11771,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tremelimumab.,Tremelimumab,DB00111
DB11826,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lampalizumab.,Lampalizumab,DB00111
DB11840,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalotuzumab.,Dalotuzumab,DB00111
DB11849,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emibetuzumab.,Emibetuzumab,DB00111
DB11850,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ublituximab.,Ublituximab,DB00111
DB11856,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ligelizumab.,Ligelizumab,DB00111
DB11857,The risk or severity of adverse effects can be increased when Daclizumab is combined with Seribantumab.,Seribantumab,DB00111
DB11862,The risk or severity of adverse effects can be increased when Daclizumab is combined with Landogrozumab.,Landogrozumab,DB00111
DB11866,The risk or severity of adverse effects can be increased when Daclizumab is combined with Romosozumab.,Romosozumab,DB00111
DB11884,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00111
DB11914,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lebrikizumab.,Lebrikizumab,DB00111
DB11930,The risk or severity of adverse effects can be increased when Daclizumab is combined with Varlilumab.,Varlilumab,DB00111
DB11945,The risk or severity of adverse effects can be increased when Daclizumab is combined with Avelumab.,Avelumab,DB00111
DB11959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crenezumab.,Crenezumab,DB00111
DB11972,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilotumumab.,Rilotumumab,DB00111
DB11976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anifrolumab.,Anifrolumab,DB00111
DB12023,The risk or severity of adverse effects can be increased when Daclizumab is combined with Benralizumab.,Benralizumab,DB00111
DB12034,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gantenerumab.,Gantenerumab,DB00111
DB12053,The risk or severity of adverse effects can be increased when Daclizumab is combined with Visilizumab.,Visilizumab,DB00111
DB12077,The risk or severity of adverse effects can be increased when Daclizumab is combined with Urelumab.,Urelumab,DB00111
DB12089,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00111
DB12090,The risk or severity of adverse effects can be increased when Daclizumab is combined with Patritumab.,Patritumab,DB00111
DB12102,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fulranumab.,Fulranumab,DB00111
DB12104,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tarextumab.,Tarextumab,DB00111
DB12118,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sotatercept.,Sotatercept,DB00111
DB12119,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gevokizumab.,Gevokizumab,DB00111
DB12142,The risk or severity of adverse effects can be increased when Daclizumab is combined with Duligotuzumab.,Duligotuzumab,DB00111
DB12152,The risk or severity of adverse effects can be increased when Daclizumab is combined with Simtuzumab.,Simtuzumab,DB00111
DB12157,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fasinumab.,Fasinumab,DB00111
DB12159,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dupilumab.,Dupilumab,DB00111
DB12169,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tralokinumab.,Tralokinumab,DB00111
DB12189,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etrolizumab.,Etrolizumab,DB00111
DB12202,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zalutumumab.,Zalutumumab,DB00111
DB12205,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ganitumab.,Ganitumab,DB00111
DB12213,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etaracizumab.,Etaracizumab,DB00111
DB12240,The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00111
DB12246,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inclacumab.,Inclacumab,DB00111
DB12250,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cixutumumab.,Cixutumumab,DB00111
DB12261,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00111
DB12274,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aducanumab.,Aducanumab,DB00111
DB12281,The risk or severity of adverse effects can be increased when Daclizumab is combined with Luspatercept.,Luspatercept,DB00111
DB12296,The risk or severity of adverse effects can be increased when Daclizumab is combined with GS-5745.,GS-5745,DB00111
DB12317,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vanucizumab.,Vanucizumab,DB00111
DB12331,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00111
DB12335,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tanezumab.,Tanezumab,DB00111
DB12342,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ensituximab.,Ensituximab,DB00111
DB12344,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fezakinumab.,Fezakinumab,DB00111
DB12363,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dusigitumab.,Dusigitumab,DB00111
DB12396,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fresolimumab.,Fresolimumab,DB00111
DB12413,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00111
DB12456,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bococizumab.,Bococizumab,DB00111
DB12489,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00111
DB12498,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mogamulizumab.,Mogamulizumab,DB00111
DB12520,The risk or severity of adverse effects can be increased when Daclizumab is combined with Plozalizumab.,Plozalizumab,DB00111
DB12534,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mavrilimumab.,Mavrilimumab,DB00111
DB12560,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blosozumab.,Blosozumab,DB00111
DB12584,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimagrumab.,Bimagrumab,DB00111
DB12589,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacetuzumab.,Dacetuzumab,DB00111
DB12609,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tovetumab.,Tovetumab,DB00111
DB12683,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumretuzumab.,Lumretuzumab,DB00111
DB12698,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibalizumab.,Ibalizumab,DB00111
DB12701,The risk or severity of adverse effects can be increased when Daclizumab is combined with Intetumumab.,Intetumumab,DB00111
DB12718,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carlumab.,Carlumab,DB00111
DB12734,The risk or severity of adverse effects can be increased when Daclizumab is combined with Demcizumab.,Demcizumab,DB00111
DB12773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sifalimumab.,Sifalimumab,DB00111
DB12775,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abituzumab.,Abituzumab,DB00111
DB12797,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ecromeximab.,Ecromeximab,DB00111
DB12807,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00111
DB12815,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crotedumab.,Crotedumab,DB00111
DB12820,The risk or severity of adverse effects can be increased when Daclizumab is combined with Concizumab.,Concizumab,DB00111
DB12826,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab.,Depatuxizumab,DB00111
DB12844,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rontalizumab.,Rontalizumab,DB00111
DB12845,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amatuximab.,Amatuximab,DB00111
DB12849,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clazakizumab.,Clazakizumab,DB00111
DB12891,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanezumab.,Ozanezumab,DB00111
DB12893,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00111
DB12917,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimekizumab.,Bimekizumab,DB00111
DB12943,The risk or severity of adverse effects can be increased when Daclizumab is combined with Milatuzumab.,Milatuzumab,DB00111
DB12976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Robatumumab.,Robatumumab,DB00111
DB13017,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00111
DB13037,The risk or severity of adverse effects can be increased when Daclizumab is combined with Namilumab.,Namilumab,DB00111
DB13045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Racotumomab.,Racotumomab,DB00111
DB13073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tregalizumab.,Tregalizumab,DB00111
DB13127,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olokizumab.,Olokizumab,DB00111
DB13140,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00111
DB13375,The risk or severity of adverse effects can be increased when Daclizumab is combined with Edrecolomab.,Edrecolomab,DB00111
DB13535,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nebacumab.,Nebacumab,DB00111
DB13886,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00111
DB13923,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emicizumab.,Emicizumab,DB00111
DB13976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulesomab.,Sulesomab,DB00111
DB13979,The risk or severity of adverse effects can be increased when Daclizumab is combined with Besilesomab.,Besilesomab,DB00111
DB14012,The risk or severity of adverse effects can be increased when Daclizumab is combined with Burosumab.,Burosumab,DB00111
DB14039,The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.,Erenumab,DB00111
DB14040,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eptinezumab.,Eptinezumab,DB00111
DB14041,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fremanezumab.,Fremanezumab,DB00111
DB14042,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galcanezumab.,Galcanezumab,DB00111
DB14211,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fanolesomab.,Fanolesomab,DB00111
DB14580,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lecanemab.,Lecanemab,DB00111
DB14597,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lanadelumab.,Lanadelumab,DB00111
DB14707,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cemiplimab.,Cemiplimab,DB00111
DB14776,The risk or severity of adverse effects can be increased when Daclizumab is combined with Camrelizumab.,Camrelizumab,DB00111
DB14778,The risk or severity of adverse effects can be increased when Daclizumab is combined with Setrusumab.,Setrusumab,DB00111
DB14784,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gancotamab.,Gancotamab,DB00111
DB14809,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00111
DB14811,The risk or severity of adverse effects can be increased when Daclizumab is combined with Isatuximab.,Isatuximab,DB00111
DB14824,The risk or severity of adverse effects can be increased when Daclizumab is combined with Icrucumab.,Icrucumab,DB00111
DB14843,The risk or severity of adverse effects can be increased when Daclizumab is combined with Codrituzumab.,Codrituzumab,DB00111
DB14864,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brolucizumab.,Brolucizumab,DB00111
DB14871,The risk or severity of adverse effects can be increased when Daclizumab is combined with Xentuzumab.,Xentuzumab,DB00111
DB14877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lintuzumab.,Lintuzumab,DB00111
DB14891,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vobarilizumab.,Vobarilizumab,DB00111
DB14897,The risk or severity of adverse effects can be increased when Daclizumab is combined with Parsatuzumab.,Parsatuzumab,DB00111
DB14905,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emactuzumab.,Emactuzumab,DB00111
DB14907,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00111
DB14908,The risk or severity of adverse effects can be increased when Daclizumab is combined with Refanezumab.,Refanezumab,DB00111
DB14947,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bermekimab.,Bermekimab,DB00111
DB14952,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pamrevlumab.,Pamrevlumab,DB00111
DB14959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Opicinumab.,Opicinumab,DB00111
DB14962,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00111
DB14967,The risk or severity of adverse effects can be increased when Daclizumab is combined with Margetuximab.,Margetuximab,DB00111
DB14988,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalantercept.,Dalantercept,DB00111
DB14997,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pateclizumab.,Pateclizumab,DB00111
DB15014,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gremubamab.,Gremubamab,DB00111
DB15022,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apomab.,Apomab,DB00111
DB15044,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tafasitamab.,Tafasitamab,DB00111
DB15045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipafricept.,Ipafricept,DB00111
DB15076,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abrilumab.,Abrilumab,DB00111
DB15089,The risk or severity of adverse effects can be increased when Daclizumab is combined with Frovocimab.,Frovocimab,DB00111
DB15090,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tezepelumab.,Tezepelumab,DB00111
DB15101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tigatuzumab.,Tigatuzumab,DB00111
DB15104,The risk or severity of adverse effects can be increased when Daclizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00111
DB15113,The risk or severity of adverse effects can be increased when Daclizumab is combined with Utomilumab.,Utomilumab,DB00111
DB15118,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zolbetuximab.,Zolbetuximab,DB00111
DB15135,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponezumab.,Ponezumab,DB00111
DB15160,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asunercept.,Asunercept,DB00111
DB15172,The risk or severity of adverse effects can be increased when Daclizumab is combined with Suvratoxumab.,Suvratoxumab,DB00111
DB15225,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitazalimab.,Mitazalimab,DB00111
DB15252,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nemolizumab.,Nemolizumab,DB00111
DB15277,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gedivumab.,Gedivumab,DB00111
DB15336,The risk or severity of adverse effects can be increased when Daclizumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00111
DB15349,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00111
DB15354,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evinacumab.,Evinacumab,DB00111
DB15363,The risk or severity of adverse effects can be increased when Daclizumab is combined with Istiratumab.,Istiratumab,DB00111
DB15383,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pidilizumab.,Pidilizumab,DB00111
DB15397,The risk or severity of adverse effects can be increased when Daclizumab is combined with GMA-161.,GMA-161,DB00111
DB15409,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00111
DB15415,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tomaralimab.,Tomaralimab,DB00111
DB15428,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vesencumab.,Vesencumab,DB00111
DB15432,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00111
DB15441,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00111
DB15443,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00111
DB15453,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00111
DB14004,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tildrakizumab.,Tildrakizumab,DB00111
DB05679,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ustekinumab.,Ustekinumab,DB00111
DB15559,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00111
DB00091,Daclizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00111
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Daclizumab.","Ebola Zaire vaccine (live, attenuated)",DB00111
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Daclizumab.,Magnesium,DB00111
DB01601,The serum concentration of Daclizumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00111
DB12530,The risk or severity of infection can be increased when Daclizumab is combined with Inebilizumab.,Inebilizumab,DB00111
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Bevacizumab.,Denosumab,DB00112
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Bevacizumab.,Etanercept,DB00112
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab.,Peginterferon alfa-2a,DB00112
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bevacizumab.,Interferon alfa-n1,DB00112
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bevacizumab.,Interferon alfa-n3,DB00112
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bevacizumab.,Peginterferon alfa-2b,DB00112
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Bevacizumab.,Anakinra,DB00112
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bevacizumab.,Interferon gamma-1b,DB00112
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bevacizumab.","Interferon alfa-2a, Recombinant",DB00112
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bevacizumab.,Aldesleukin,DB00112
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab.,Adalimumab,DB00112
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.,Gemtuzumab ozogamicin,DB00112
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.,Pegaspargase,DB00112
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.,Infliximab,DB00112
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.,Interferon beta-1b,DB00112
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.,Interferon alfacon-1,DB00112
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.,Rituximab,DB00112
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.,Basiliximab,DB00112
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.,Muromonab,DB00112
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.,Ibritumomab tiuxetan,DB00112
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.,Tositumomab,DB00112
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.,Alemtuzumab,DB00112
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.,Alefacept,DB00112
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.,Efalizumab,DB00112
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.,Antithymocyte immunoglobulin (rabbit),DB00112
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.,Interferon alfa-2b,DB00112
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.,Daclizumab,DB00112
DB00120,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.,Phenylalanine,DB00112
DB00180,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flunisolide.,Flunisolide,DB00112
DB00188,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bortezomib.,Bortezomib,DB00112
DB00242,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cladribine.,Cladribine,DB00112
DB00262,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carmustine.,Carmustine,DB00112
DB00276,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amsacrine.,Amsacrine,DB00112
DB00290,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleomycin.,Bleomycin,DB00112
DB00291,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chlorambucil.,Chlorambucil,DB00112
DB00293,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raltitrexed.,Raltitrexed,DB00112
DB00305,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitomycin.,Mitomycin,DB00112
DB00307,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bexarotene.,Bexarotene,DB00112
DB00309,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vindesine.,Vindesine,DB00112
DB00322,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Floxuridine.,Floxuridine,DB00112
DB00328,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indomethacin.,Indomethacin,DB00112
DB00352,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tioguanine.,Tioguanine,DB00112
DB00361,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinorelbine.,Vinorelbine,DB00112
DB00380,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexrazoxane.,Dexrazoxane,DB00112
DB00394,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00112
DB00428,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Streptozocin.,Streptozocin,DB00112
DB00432,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trifluridine.,Trifluridine,DB00112
DB00441,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gemcitabine.,Gemcitabine,DB00112
DB00443,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Betamethasone.,Betamethasone,DB00112
DB00444,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teniposide.,Teniposide,DB00112
DB00445,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epirubicin.,Epirubicin,DB00112
DB00446,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chloramphenicol.,Chloramphenicol,DB00112
DB00480,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lenalidomide.,Lenalidomide,DB00112
DB00488,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Altretamine.,Altretamine,DB00112
DB00495,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zidovudine.,Zidovudine,DB00112
DB00515,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cisplatin.,Cisplatin,DB00112
DB00526,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oxaliplatin.,Oxaliplatin,DB00112
DB00531,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cyclophosphamide.,Cyclophosphamide,DB00112
DB00541,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vincristine.,Vincristine,DB00112
DB00544,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluorouracil.,Fluorouracil,DB00112
DB00550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Propylthiouracil.,Propylthiouracil,DB00112
DB00552,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pentostatin.,Pentostatin,DB00112
DB00563,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methotrexate.,Methotrexate,DB00112
DB00564,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carbamazepine.,Carbamazepine,DB00112
DB00570,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinblastine.,Vinblastine,DB00112
DB00588,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone propionate.,Fluticasone propionate,DB00112
DB00591,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00112
DB00601,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Linezolid.,Linezolid,DB00112
DB00619,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Imatinib.,Imatinib,DB00112
DB00620,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triamcinolone.,Triamcinolone,DB00112
DB00631,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clofarabine.,Clofarabine,DB00112
DB00635,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisone.,Prednisone,DB00112
DB00642,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pemetrexed.,Pemetrexed,DB00112
DB00687,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludrocortisone.,Fludrocortisone,DB00112
DB00688,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00112
DB00694,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daunorubicin.,Daunorubicin,DB00112
DB00755,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tretinoin.,Tretinoin,DB00112
DB00762,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.,Irinotecan,DB00112
DB00763,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methimazole.,Methimazole,DB00112
DB00764,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone.,Mometasone,DB00112
DB00773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etoposide.,Etoposide,DB00112
DB00795,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulfasalazine.,Sulfasalazine,DB00112
DB00851,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacarbazine.,Dacarbazine,DB00112
DB00853,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temozolomide.,Temozolomide,DB00112
DB00859,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Penicillamine.,Penicillamine,DB00112
DB00860,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisolone.,Prednisolone,DB00112
DB00877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirolimus.,Sirolimus,DB00112
DB00888,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mechlorethamine.,Mechlorethamine,DB00112
DB00928,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azacitidine.,Azacitidine,DB00112
DB00958,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carboplatin.,Carboplatin,DB00112
DB00959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methylprednisolone.,Methylprednisolone,DB00112
DB00970,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dactinomycin.,Dactinomycin,DB00112
DB00987,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cytarabine.,Cytarabine,DB00112
DB00993,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azathioprine.,Azathioprine,DB00112
DB00997,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxorubicin.,Doxorubicin,DB00112
DB01005,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxyurea.,Hydroxyurea,DB00112
DB01008,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Busulfan.,Busulfan,DB00112
DB01024,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolic acid.,Mycophenolic acid,DB00112
DB01030,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Topotecan.,Topotecan,DB00112
DB01033,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mercaptopurine.,Mercaptopurine,DB00112
DB01041,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thalidomide.,Thalidomide,DB00112
DB01042,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melphalan.,Melphalan,DB00112
DB01073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludarabine.,Fludarabine,DB00112
DB01099,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flucytosine.,Flucytosine,DB00112
DB01101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Capecitabine.,Capecitabine,DB00112
DB01108,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trilostane.,Trilostane,DB00112
DB01168,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Procarbazine.,Procarbazine,DB00112
DB01169,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Arsenic trioxide.,Arsenic trioxide,DB00112
DB01177,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarubicin.,Idarubicin,DB00112
DB01181,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ifosfamide.,Ifosfamide,DB00112
DB01196,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Estramustine.,Estramustine,DB00112
DB01204,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitoxantrone.,Mitoxantrone,DB00112
DB01206,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lomustine.,Lomustine,DB00112
DB01222,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Budesonide.,Budesonide,DB00112
DB01229,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paclitaxel.,Paclitaxel,DB00112
DB01234,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone.,Dexamethasone,DB00112
DB01248,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Docetaxel.,Docetaxel,DB00112
DB01254,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dasatinib.,Dasatinib,DB00112
DB01257,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eculizumab.,Eculizumab,DB00112
DB01262,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Decitabine.,Decitabine,DB00112
DB01280,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nelarabine.,Nelarabine,DB00112
DB01281,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abatacept.,Abatacept,DB00112
DB01285,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Corticotropin.,Corticotropin,DB00112
DB01380,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortisone acetate.,Cortisone acetate,DB00112
DB01384,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paramethasone.,Paramethasone,DB00112
DB01394,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Colchicine.,Colchicine,DB00112
DB01410,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ciclesonide.,Ciclesonide,DB00112
DB01423,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Stepronin.,Stepronin,DB00112
DB01590,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Everolimus.,Everolimus,DB00112
DB01611,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00112
DB01816,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Castanospermine.,Castanospermine,DB00112
DB02546,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vorinostat.,Vorinostat,DB00112
DB02806,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00112
DB03523,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brequinar.,Brequinar,DB00112
DB04572,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thiotepa.,Thiotepa,DB00112
DB04630,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aldosterone.,Aldosterone,DB00112
DB04845,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixabepilone.,Ixabepilone,DB00112
DB04868,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nilotinib.,Nilotinib,DB00112
DB04951,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirfenidone.,Pirfenidone,DB00112
DB04956,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Afelimomab.,Afelimomab,DB00112
DB05015,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belinostat.,Belinostat,DB00112
DB05109,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trabectedin.,Trabectedin,DB00112
DB05258,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Interferon alfa.,Interferon alfa,DB00112
DB05259,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glatiramer.,Glatiramer,DB00112
DB05260,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gallium nitrate.,Gallium nitrate,DB00112
DB05459,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Briakinumab.,Briakinumab,DB00112
DB05472,The risk or severity of adverse effects can be increased when Bevacizumab is combined with omega interferon.,omega interferon,DB00112
DB05676,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apremilast.,Apremilast,DB00112
DB05773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00112
DB06168,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Canakinumab.,Canakinumab,DB00112
DB06273,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tocilizumab.,Tocilizumab,DB00112
DB06287,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temsirolimus.,Temsirolimus,DB00112
DB06372,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilonacept.,Rilonacept,DB00112
DB06589,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pazopanib.,Pazopanib,DB00112
DB06603,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panobinostat.,Panobinostat,DB00112
DB06612,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mepolizumab.,Mepolizumab,DB00112
DB06616,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bosutinib.,Bosutinib,DB00112
DB06662,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abetimus.,Abetimus,DB00112
DB06674,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Golimumab.,Golimumab,DB00112
DB06681,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belatacept.,Belatacept,DB00112
DB06769,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bendamustine.,Bendamustine,DB00112
DB06772,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cabazitaxel.,Cabazitaxel,DB00112
DB06813,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pralatrexate.,Pralatrexate,DB00112
DB08059,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Wortmannin.,Wortmannin,DB00112
DB08870,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00112
DB08871,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eribulin.,Eribulin,DB00112
DB08877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ruxolitinib.,Ruxolitinib,DB00112
DB08879,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.,Belimumab,DB00112
DB08880,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teriflunomide.,Teriflunomide,DB00112
DB08889,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carfilzomib.,Carfilzomib,DB00112
DB08901,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponatinib.,Ponatinib,DB00112
DB08904,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Certolizumab pegol.,Certolizumab pegol,DB00112
DB08906,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone furoate.,Fluticasone furoate,DB00112
DB08908,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00112
DB08910,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pomalidomide.,Pomalidomide,DB00112
DB08935,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obinutuzumab.,Obinutuzumab,DB00112
DB08970,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednidene.,Fluprednidene,DB00112
DB08971,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortolone.,Fluocortolone,DB00112
DB09029,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.,Secukinumab,DB00112
DB09033,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vedolizumab.,Vedolizumab,DB00112
DB09036,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siltuximab.,Siltuximab,DB00112
DB09052,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.,Blinatumomab,DB00112
DB09053,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibrutinib.,Ibrutinib,DB00112
DB09054,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idelalisib.,Idelalisib,DB00112
DB09073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Palbociclib.,Palbociclib,DB00112
DB09074,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaparib.,Olaparib,DB00112
DB09077,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dinutuximab.,Dinutuximab,DB00112
DB09082,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vilanterol.,Vilanterol,DB00112
DB09091,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tixocortol.,Tixocortol,DB00112
DB09122,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a,DB00112
DB09312,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00112
DB09378,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednisolone.,Fluprednisolone,DB00112
DB09383,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Meprednisone.,Meprednisone,DB00112
DB11466,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tepoxalin.,Tepoxalin,DB00112
DB11487,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate,DB00112
DB11529,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melengestrol.,Melengestrol,DB00112
DB11569,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixekizumab.,Ixekizumab,DB00112
DB11580,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ravulizumab.,Ravulizumab,DB00112
DB11616,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirarubicin.,Pirarubicin,DB00112
DB11693,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Voclosporin.,Voclosporin,DB00112
DB11708,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peficitinib.,Peficitinib,DB00112
DB11750,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clobetasol.,Clobetasol,DB00112
DB11767,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.,Sarilumab,DB00112
DB11776,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brodalumab.,Brodalumab,DB00112
DB11803,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirukumab.,Sirukumab,DB00112
DB11817,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Baricitinib.,Baricitinib,DB00112
DB11834,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.,Guselkumab,DB00112
DB11921,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deflazacort.,Deflazacort,DB00112
DB12025,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triptolide.,Triptolide,DB00112
DB12371,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siponimod.,Siponimod,DB00112
DB12612,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanimod.,Ozanimod,DB00112
DB12617,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mizoribine.,Mizoribine,DB00112
DB12692,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gusperimus.,Gusperimus,DB00112
DB12814,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00112
DB12902,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trofosfamide.,Trofosfamide,DB00112
DB12947,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxifluridine.,Doxifluridine,DB00112
DB12991,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deoxyspergualin.,Deoxyspergualin,DB00112
DB12996,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Acteoside.,Acteoside,DB00112
DB13003,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortivazol.,Cortivazol,DB00112
DB13014,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hypericin.,Hypericin,DB00112
DB13068,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A,DB00112
DB13208,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednylidene.,Prednylidene,DB00112
DB13223,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortin.,Fluocortin,DB00112
DB13241,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Begelomab.,Begelomab,DB00112
DB13491,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluperolone.,Fluperolone,DB00112
DB13664,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Formocortal.,Formocortal,DB00112
DB13728,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Halometasone.,Halometasone,DB00112
DB13843,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cloprednol.,Cloprednol,DB00112
DB13856,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluclorolone.,Fluclorolone,DB00112
DB13867,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone.,Fluticasone,DB00112
DB14066,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetrandrine.,Tetrandrine,DB00112
DB14219,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Monomethyl fumarate.,Monomethyl fumarate,DB00112
DB14512,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone furoate.,Mometasone furoate,DB00112
DB14538,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate,DB00112
DB14539,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate,DB00112
DB14545,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate,DB00112
DB14724,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab.,Emapalumab,DB00112
DB14762,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Risankizumab.,Risankizumab,DB00112
DB14919,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozanolixizumab.,Rozanolixizumab,DB00112
DB15253,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleselumab.,Bleselumab,DB00112
DB00108,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.,Natalizumab,DB00112
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bevacizumab.,Pimecrolimus,DB00112
DB01656,Roflumilast may increase the immunosuppressive activities of Bevacizumab.,Roflumilast,DB00112
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bevacizumab.,Sipuleucel-T,DB00112
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.,Darbepoetin alfa,DB00112
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bevacizumab.,Erythropoietin,DB00112
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bevacizumab.,Peginesatide,DB00112
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.,Methoxy polyethylene glycol-epoetin beta,DB00112
DB00398,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.,Sorafenib,DB00112
DB01268,The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.,Sunitinib,DB00112
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bevacizumab.,Sulfamethoxazole,DB00112
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.,Diethylstilbestrol,DB00112
DB00269,Chlorotrianisene may increase the thrombogenic activities of Bevacizumab.,Chlorotrianisene,DB00112
DB00286,Conjugated estrogens may increase the thrombogenic activities of Bevacizumab.,Conjugated estrogens,DB00112
DB00655,Estrone may increase the thrombogenic activities of Bevacizumab.,Estrone,DB00112
DB00783,Estradiol may increase the thrombogenic activities of Bevacizumab.,Estradiol,DB00112
DB00890,Dienestrol may increase the thrombogenic activities of Bevacizumab.,Dienestrol,DB00112
DB00977,Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.,Ethinylestradiol,DB00112
DB01357,Mestranol may increase the thrombogenic activities of Bevacizumab.,Mestranol,DB00112
DB04573,Estriol may increase the thrombogenic activities of Bevacizumab.,Estriol,DB00112
DB04574,Estrone sulfate may increase the thrombogenic activities of Bevacizumab.,Estrone sulfate,DB00112
DB04575,Quinestrol may increase the thrombogenic activities of Bevacizumab.,Quinestrol,DB00112
DB07931,Hexestrol may increase the thrombogenic activities of Bevacizumab.,Hexestrol,DB00112
DB09070,Tibolone may increase the thrombogenic activities of Bevacizumab.,Tibolone,DB00112
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bevacizumab.","Synthetic Conjugated Estrogens, A",DB00112
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab.","Synthetic Conjugated Estrogens, B",DB00112
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.,Polyestradiol phosphate,DB00112
DB09381,Esterified estrogens may increase the thrombogenic activities of Bevacizumab.,Esterified estrogens,DB00112
DB11478,Zeranol may increase the thrombogenic activities of Bevacizumab.,Zeranol,DB00112
DB11674,Equol may increase the thrombogenic activities of Bevacizumab.,Equol,DB00112
DB12487,Promestriene may increase the thrombogenic activities of Bevacizumab.,Promestriene,DB00112
DB13143,Methallenestril may increase the thrombogenic activities of Bevacizumab.,Methallenestril,DB00112
DB13386,Epimestrol may increase the thrombogenic activities of Bevacizumab.,Epimestrol,DB00112
DB13418,Moxestrol may increase the thrombogenic activities of Bevacizumab.,Moxestrol,DB00112
DB13952,Estradiol acetate may increase the thrombogenic activities of Bevacizumab.,Estradiol acetate,DB00112
DB13953,Estradiol benzoate may increase the thrombogenic activities of Bevacizumab.,Estradiol benzoate,DB00112
DB13954,Estradiol cypionate may increase the thrombogenic activities of Bevacizumab.,Estradiol cypionate,DB00112
DB13956,Estradiol valerate may increase the thrombogenic activities of Bevacizumab.,Estradiol valerate,DB00112
DB15334,Biochanin A may increase the thrombogenic activities of Bevacizumab.,Biochanin A,DB00112
DB15335,Formononetin may increase the thrombogenic activities of Bevacizumab.,Formononetin,DB00112
DB01097,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leflunomide.,Leflunomide,DB00112
DB08895,Bevacizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib,DB00112
DB00072,Trastuzumab may increase the neutropenic activities of Bevacizumab.,Trastuzumab,DB00112
DB08868,Bevacizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod,DB00112
DB00864,Tacrolimus may increase the immunosuppressive activities of Bevacizumab.,Tacrolimus,DB00112
DB00282,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.,Pamidronic acid,DB00112
DB00399,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.,Zoledronic acid,DB00112
DB00630,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.,Alendronic acid,DB00112
DB00710,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.,Ibandronate,DB00112
DB00720,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Clodronic acid.,Clodronic acid,DB00112
DB00884,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid.,Risedronic acid,DB00112
DB01077,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.,Etidronic acid,DB00112
DB01133,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Tiludronic acid.,Tiludronic acid,DB00112
DB06255,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Incadronic acid.,Incadronic acid,DB00112
DB00390,Digoxin may decrease the cardiotoxic activities of Bevacizumab.,Digoxin,DB00112
DB00511,Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.,Acetyldigitoxin,DB00112
DB01078,Deslanoside may decrease the cardiotoxic activities of Bevacizumab.,Deslanoside,DB00112
DB01092,Ouabain may decrease the cardiotoxic activities of Bevacizumab.,Ouabain,DB00112
DB01396,Digitoxin may decrease the cardiotoxic activities of Bevacizumab.,Digitoxin,DB00112
DB12843,Oleandrin may decrease the cardiotoxic activities of Bevacizumab.,Oleandrin,DB00112
DB13240,Cymarin may decrease the cardiotoxic activities of Bevacizumab.,Cymarin,DB00112
DB13307,Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.,Proscillaridin,DB00112
DB13401,Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.,Metildigoxin,DB00112
DB13467,Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.,Lanatoside C,DB00112
DB13537,Gitoformate may decrease the cardiotoxic activities of Bevacizumab.,Gitoformate,DB00112
DB13691,Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.,Acetyldigoxin,DB00112
DB13756,Peruvoside may decrease the cardiotoxic activities of Bevacizumab.,Peruvoside,DB00112
DB00675,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tamoxifen.,Tamoxifen,DB00112
DB01217,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Anastrozole.,Anastrozole,DB00112
DB06013,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Aldoxorubicin.,Aldoxorubicin,DB00112
DB06171,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide.,Paclitaxel trevatide,DB00112
DB13809,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.,Paclitaxel poliglumex,DB00112
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Bevacizumab.,G17DT,DB00112
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Bevacizumab.,PEV3A,DB00112
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Bevacizumab.,INGN 225,DB00112
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bevacizumab.,Rindopepimut,DB00112
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Bevacizumab.,SRP 299,DB00112
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bevacizumab.,GI-5005,DB00112
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Bevacizumab.,Vitespen,DB00112
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Bevacizumab.,TG4010,DB00112
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bevacizumab.,Anthrax immune globulin human,DB00112
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bevacizumab.","Rabies virus inactivated antigen, B",DB00112
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,DB00112
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bevacizumab.,Rotavirus vaccine,DB00112
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab.","Rabies virus inactivated antigen, A",DB00112
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen,DB00112
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated),DB00112
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated),DB00112
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated),DB00112
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated),DB00112
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated),DB00112
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bevacizumab.,Typhoid Vi polysaccharide vaccine,DB00112
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.,Hepatitis A Vaccine,DB00112
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen,DB00112
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated),DB00112
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated),DB00112
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated),DB00112
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated),DB00112
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.,Human rabies virus immune globulin,DB00112
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.,Hepatitis B Vaccine (Recombinant),DB00112
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Bevacizumab.,Tecemotide,DB00112
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bevacizumab.,Typhoid vaccine,DB00112
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated),DB00112
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated),DB00112
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen,DB00112
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated),DB00112
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen,DB00112
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated),DB00112
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated),DB00112
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Bevacizumab.,Vaccinia virus strain new york city board of health live antigen,DB00112
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bevacizumab.,Pertussis vaccine,DB00112
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated),DB00112
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.,Varicella Zoster Vaccine (Recombinant),DB00112
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bevacizumab.,Modified vaccinia ankara,DB00112
DB11988,Ocrelizumab may increase the immunosuppressive activities of Bevacizumab.,Ocrelizumab,DB00112
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bevacizumab.,Rubella virus vaccine,DB00112
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Bevacizumab.,Varicella Zoster Vaccine (Live/attenuated),DB00112
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain tice live antigen,DB00112
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain connaught live antigen,DB00112
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Bevacizumab.,Yellow Fever Vaccine,DB00112
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Bevacizumab.,Anthrax vaccine,DB00112
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bevacizumab.,Typhoid Vaccine Live,DB00112
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen,DB00112
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Bevacizumab.,BCG vaccine,DB00112
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Bevacizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen,DB00112
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Bevacizumab.,Vibrio cholerae CVD 103-HgR strain live antigen,DB00112
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bevacizumab.,Adenovirus type 7 vaccine live,DB00112
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.,Cetuximab,DB00112
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.,Human immunoglobulin G,DB00112
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.,Omalizumab,DB00112
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab.,Abciximab,DB00112
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.,Indium In-111 satumomab pendetide,DB00112
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.,Digoxin Immune Fab (Ovine),DB00112
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.,Capromab pendetide,DB00112
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.,Palivizumab,DB00112
DB00113,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab,DB00112
DB01269,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.,Panitumumab,DB00112
DB01270,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.,Ranibizumab,DB00112
DB04901,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galiximab.,Galiximab,DB00112
DB04949,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pexelizumab.,Pexelizumab,DB00112
DB04958,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epratuzumab.,Epratuzumab,DB00112
DB04962,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bectumomab.,Bectumomab,DB00112
DB04964,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oregovomab.,Oregovomab,DB00112
DB04988,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IGN311.,IGN311,DB00112
DB05006,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Adecatumumab.,Adecatumumab,DB00112
DB05097,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab.,Labetuzumab,DB00112
DB05101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Matuzumab.,Matuzumab,DB00112
DB05111,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fontolizumab.,Fontolizumab,DB00112
DB05136,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bavituximab.,Bavituximab,DB00112
DB05139,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CR002.,CR002,DB00112
DB05209,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozrolimupab.,Rozrolimupab,DB00112
DB05304,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Girentuximab.,Girentuximab,DB00112
DB05336,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.,Obiltoxaximab,DB00112
DB05405,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XTL-001.,XTL-001,DB00112
DB05437,The risk or severity of adverse effects can be increased when Bevacizumab is combined with NAV 1800.,NAV 1800,DB00112
DB05496,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Otelixizumab.,Otelixizumab,DB00112
DB05545,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AMG 108.,AMG 108,DB00112
DB05550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Iratumumab.,Iratumumab,DB00112
DB05555,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Enokizumab.,Enokizumab,DB00112
DB05578,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ramucirumab.,Ramucirumab,DB00112
DB05595,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Farletuzumab.,Farletuzumab,DB00112
DB05656,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Veltuzumab.,Veltuzumab,DB00112
DB05793,The risk or severity of adverse effects can be increased when Bevacizumab is combined with PRO-542.,PRO-542,DB00112
DB05797,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TNX-901.,TNX-901,DB00112
DB05889,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00112
DB05892,The risk or severity of adverse effects can be increased when Bevacizumab is combined with RI 624.,RI 624,DB00112
DB05915,The risk or severity of adverse effects can be increased when Bevacizumab is combined with MYO-029.,MYO-029,DB00112
DB05916,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CT-011.,CT-011,DB00112
DB05941,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leronlimab.,Leronlimab,DB00112
DB05996,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00112
DB06043,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab.,Olaratumab,DB00112
DB06049,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IPH 2101.,IPH 2101,DB00112
DB06050,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TB-402.,TB-402,DB00112
DB06081,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.,Caplacizumab,DB00112
DB06101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IMC-1C11.,IMC-1C11,DB00112
DB06116,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eldelumab.,Eldelumab,DB00112
DB06162,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumiliximab.,Lumiliximab,DB00112
DB06186,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.,Ipilimumab,DB00112
DB06192,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nimotuzumab.,Nimotuzumab,DB00112
DB06241,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clenoliximab.,Clenoliximab,DB00112
DB06304,The risk or severity of adverse effects can be increased when Bevacizumab is combined with BIIB015.,BIIB015,DB00112
DB06305,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sonepcizumab.,Sonepcizumab,DB00112
DB06310,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Motavizumab.,Motavizumab,DB00112
DB06317,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.,Elotuzumab,DB00112
DB06318,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AVE9633.,AVE9633,DB00112
DB06322,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carotuximab.,Carotuximab,DB00112
DB06324,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XmAb 2513.,XmAb 2513,DB00112
DB06342,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00112
DB06343,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teprotumumab.,Teprotumumab,DB00112
DB06360,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lucatumumab.,Lucatumumab,DB00112
DB06366,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pertuzumab.,Pertuzumab,DB00112
DB06371,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siplizumab.,Siplizumab,DB00112
DB06467,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apolizumab.,Apolizumab,DB00112
DB06474,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sibrotuzumab.,Sibrotuzumab,DB00112
DB06550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bivatuzumab.,Bivatuzumab,DB00112
DB06557,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lerdelimumab.,Lerdelimumab,DB00112
DB06599,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lexatumumab.,Lexatumumab,DB00112
DB06602,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab.,Reslizumab,DB00112
DB06606,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teplizumab.,Teplizumab,DB00112
DB06607,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Catumaxomab.,Catumaxomab,DB00112
DB06647,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Volociximab.,Volociximab,DB00112
DB06650,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab.,Ofatumumab,DB00112
DB08902,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab.,Raxibacumab,DB00112
DB09035,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.,Nivolumab,DB00112
DB09037,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pembrolizumab.,Pembrolizumab,DB00112
DB09045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.,Dulaglutide,DB00112
DB09105,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asfotase alfa.,Asfotase alfa,DB00112
DB09264,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarucizumab.,Idarucizumab,DB00112
DB09302,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Alirocumab.,Alirocumab,DB00112
DB09303,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab.,Evolocumab,DB00112
DB09331,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.,Daratumumab,DB00112
DB09559,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.,Necitumumab,DB00112
DB11595,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.,Atezolizumab,DB00112
DB11604,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00112
DB11608,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00112
DB11621,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00112
DB11646,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Conatumumab.,Conatumumab,DB00112
DB11657,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tabalumab.,Tabalumab,DB00112
DB11680,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ficlatuzumab.,Ficlatuzumab,DB00112
DB11685,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Figitumumab.,Figitumumab,DB00112
DB11714,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab.,Durvalumab,DB00112
DB11715,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bapineuzumab.,Bapineuzumab,DB00112
DB11731,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00112
DB11746,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Onartuzumab.,Onartuzumab,DB00112
DB11756,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Solanezumab.,Solanezumab,DB00112
DB11771,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tremelimumab.,Tremelimumab,DB00112
DB11826,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lampalizumab.,Lampalizumab,DB00112
DB11840,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalotuzumab.,Dalotuzumab,DB00112
DB11849,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emibetuzumab.,Emibetuzumab,DB00112
DB11850,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab.,Ublituximab,DB00112
DB11856,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ligelizumab.,Ligelizumab,DB00112
DB11857,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Seribantumab.,Seribantumab,DB00112
DB11862,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Landogrozumab.,Landogrozumab,DB00112
DB11866,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Romosozumab.,Romosozumab,DB00112
DB11884,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00112
DB11914,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lebrikizumab.,Lebrikizumab,DB00112
DB11930,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Varlilumab.,Varlilumab,DB00112
DB11945,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.,Avelumab,DB00112
DB11959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crenezumab.,Crenezumab,DB00112
DB11972,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilotumumab.,Rilotumumab,DB00112
DB11976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anifrolumab.,Anifrolumab,DB00112
DB12023,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.,Benralizumab,DB00112
DB12034,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gantenerumab.,Gantenerumab,DB00112
DB12053,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Visilizumab.,Visilizumab,DB00112
DB12077,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Urelumab.,Urelumab,DB00112
DB12089,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00112
DB12090,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Patritumab.,Patritumab,DB00112
DB12102,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fulranumab.,Fulranumab,DB00112
DB12104,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tarextumab.,Tarextumab,DB00112
DB12118,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotatercept.,Sotatercept,DB00112
DB12119,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gevokizumab.,Gevokizumab,DB00112
DB12142,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Duligotuzumab.,Duligotuzumab,DB00112
DB12152,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Simtuzumab.,Simtuzumab,DB00112
DB12157,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fasinumab.,Fasinumab,DB00112
DB12159,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.,Dupilumab,DB00112
DB12169,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.,Tralokinumab,DB00112
DB12189,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etrolizumab.,Etrolizumab,DB00112
DB12202,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zalutumumab.,Zalutumumab,DB00112
DB12205,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ganitumab.,Ganitumab,DB00112
DB12213,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etaracizumab.,Etaracizumab,DB00112
DB12240,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00112
DB12246,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inclacumab.,Inclacumab,DB00112
DB12250,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cixutumumab.,Cixutumumab,DB00112
DB12261,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ascrinvacumab.,Ascrinvacumab,DB00112
DB12274,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab.,Aducanumab,DB00112
DB12281,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Luspatercept.,Luspatercept,DB00112
DB12296,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GS-5745.,GS-5745,DB00112
DB12317,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vanucizumab.,Vanucizumab,DB00112
DB12331,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00112
DB12335,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tanezumab.,Tanezumab,DB00112
DB12342,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ensituximab.,Ensituximab,DB00112
DB12344,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fezakinumab.,Fezakinumab,DB00112
DB12363,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dusigitumab.,Dusigitumab,DB00112
DB12396,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fresolimumab.,Fresolimumab,DB00112
DB12413,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00112
DB12456,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bococizumab.,Bococizumab,DB00112
DB12489,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00112
DB12498,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab.,Mogamulizumab,DB00112
DB12520,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Plozalizumab.,Plozalizumab,DB00112
DB12534,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mavrilimumab.,Mavrilimumab,DB00112
DB12560,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blosozumab.,Blosozumab,DB00112
DB12584,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimagrumab.,Bimagrumab,DB00112
DB12589,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacetuzumab.,Dacetuzumab,DB00112
DB12609,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tovetumab.,Tovetumab,DB00112
DB12683,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumretuzumab.,Lumretuzumab,DB00112
DB12698,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.,Ibalizumab,DB00112
DB12701,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Intetumumab.,Intetumumab,DB00112
DB12718,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carlumab.,Carlumab,DB00112
DB12734,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Demcizumab.,Demcizumab,DB00112
DB12773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sifalimumab.,Sifalimumab,DB00112
DB12775,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abituzumab.,Abituzumab,DB00112
DB12797,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ecromeximab.,Ecromeximab,DB00112
DB12807,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00112
DB12815,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crotedumab.,Crotedumab,DB00112
DB12820,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Concizumab.,Concizumab,DB00112
DB12826,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab.,Depatuxizumab,DB00112
DB12844,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rontalizumab.,Rontalizumab,DB00112
DB12845,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amatuximab.,Amatuximab,DB00112
DB12849,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clazakizumab.,Clazakizumab,DB00112
DB12891,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanezumab.,Ozanezumab,DB00112
DB12893,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00112
DB12917,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab.,Bimekizumab,DB00112
DB12943,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Milatuzumab.,Milatuzumab,DB00112
DB12976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Robatumumab.,Robatumumab,DB00112
DB13017,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00112
DB13037,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Namilumab.,Namilumab,DB00112
DB13045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Racotumomab.,Racotumomab,DB00112
DB13073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tregalizumab.,Tregalizumab,DB00112
DB13127,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olokizumab.,Olokizumab,DB00112
DB13140,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bezlotoxumab.,Bezlotoxumab,DB00112
DB13375,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Edrecolomab.,Edrecolomab,DB00112
DB13535,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nebacumab.,Nebacumab,DB00112
DB13886,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00112
DB13923,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emicizumab.,Emicizumab,DB00112
DB13976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulesomab.,Sulesomab,DB00112
DB13979,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Besilesomab.,Besilesomab,DB00112
DB14012,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab.,Burosumab,DB00112
DB14039,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.,Erenumab,DB00112
DB14040,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.,Eptinezumab,DB00112
DB14041,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fremanezumab.,Fremanezumab,DB00112
DB14042,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.,Galcanezumab,DB00112
DB14211,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fanolesomab.,Fanolesomab,DB00112
DB14580,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lecanemab.,Lecanemab,DB00112
DB14597,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lanadelumab.,Lanadelumab,DB00112
DB14707,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.,Cemiplimab,DB00112
DB14776,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Camrelizumab.,Camrelizumab,DB00112
DB14778,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Setrusumab.,Setrusumab,DB00112
DB14784,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gancotamab.,Gancotamab,DB00112
DB14809,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00112
DB14811,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Isatuximab.,Isatuximab,DB00112
DB14824,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Icrucumab.,Icrucumab,DB00112
DB14843,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Codrituzumab.,Codrituzumab,DB00112
DB14864,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab.,Brolucizumab,DB00112
DB14871,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Xentuzumab.,Xentuzumab,DB00112
DB14877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lintuzumab.,Lintuzumab,DB00112
DB14891,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vobarilizumab.,Vobarilizumab,DB00112
DB14897,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Parsatuzumab.,Parsatuzumab,DB00112
DB14905,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emactuzumab.,Emactuzumab,DB00112
DB14907,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00112
DB14908,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Refanezumab.,Refanezumab,DB00112
DB14947,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bermekimab.,Bermekimab,DB00112
DB14952,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pamrevlumab.,Pamrevlumab,DB00112
DB14959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Opicinumab.,Opicinumab,DB00112
DB14962,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00112
DB14967,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab.,Margetuximab,DB00112
DB14988,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalantercept.,Dalantercept,DB00112
DB14997,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pateclizumab.,Pateclizumab,DB00112
DB15014,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gremubamab.,Gremubamab,DB00112
DB15022,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apomab.,Apomab,DB00112
DB15044,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab.,Tafasitamab,DB00112
DB15045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipafricept.,Ipafricept,DB00112
DB15076,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abrilumab.,Abrilumab,DB00112
DB15089,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Frovocimab.,Frovocimab,DB00112
DB15090,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.,Tezepelumab,DB00112
DB15101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tigatuzumab.,Tigatuzumab,DB00112
DB15104,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00112
DB15113,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Utomilumab.,Utomilumab,DB00112
DB15118,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zolbetuximab.,Zolbetuximab,DB00112
DB15135,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponezumab.,Ponezumab,DB00112
DB15160,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asunercept.,Asunercept,DB00112
DB15172,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Suvratoxumab.,Suvratoxumab,DB00112
DB15225,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitazalimab.,Mitazalimab,DB00112
DB15252,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nemolizumab.,Nemolizumab,DB00112
DB15277,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gedivumab.,Gedivumab,DB00112
DB15336,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Valanafusp alfa.,Valanafusp alfa,DB00112
DB15349,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00112
DB15354,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evinacumab.,Evinacumab,DB00112
DB15363,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Istiratumab.,Istiratumab,DB00112
DB15383,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pidilizumab.,Pidilizumab,DB00112
DB15397,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GMA-161.,GMA-161,DB00112
DB15409,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00112
DB15415,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tomaralimab.,Tomaralimab,DB00112
DB15428,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vesencumab.,Vesencumab,DB00112
DB15432,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00112
DB15441,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lulizumab pegol.,Lulizumab pegol,DB00112
DB15443,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00112
DB15453,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00112
DB14004,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.,Tildrakizumab,DB00112
DB05679,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ustekinumab.,Ustekinumab,DB00112
DB15559,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zenocutuzumab.,Zenocutuzumab,DB00112
DB00091,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine,DB00112
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bevacizumab.","Ebola Zaire vaccine (live, attenuated)",DB00112
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Bevacizumab.,Magnesium,DB00112
DB01601,The serum concentration of Bevacizumab can be increased when it is combined with Lopinavir.,Lopinavir,DB00112
DB12530,The risk or severity of infection can be increased when Bevacizumab is combined with Inebilizumab.,Inebilizumab,DB00112
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Diethylstilbestrol,DB00113
DB00269,Chlorotrianisene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Chlorotrianisene,DB00113
DB00286,Conjugated estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Conjugated estrogens,DB00113
DB00655,Estrone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estrone,DB00113
DB00783,Estradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol,DB00113
DB00890,Dienestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Dienestrol,DB00113
DB00977,Ethinylestradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Ethinylestradiol,DB00113
DB01357,Mestranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Mestranol,DB00113
DB04573,Estriol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estriol,DB00113
DB04574,Estrone sulfate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estrone sulfate,DB00113
DB04575,Quinestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Quinestrol,DB00113
DB07931,Hexestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Hexestrol,DB00113
DB09070,Tibolone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Tibolone,DB00113
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.","Synthetic Conjugated Estrogens, A",DB00113
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.","Synthetic Conjugated Estrogens, B",DB00113
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Polyestradiol phosphate,DB00113
DB09381,Esterified estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Esterified estrogens,DB00113
DB11478,Zeranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Zeranol,DB00113
DB11674,Equol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Equol,DB00113
DB12487,Promestriene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Promestriene,DB00113
DB13143,Methallenestril may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Methallenestril,DB00113
DB13386,Epimestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Epimestrol,DB00113
DB13418,Moxestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Moxestrol,DB00113
DB13952,Estradiol acetate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol acetate,DB00113
DB13953,Estradiol benzoate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol benzoate,DB00113
DB13954,Estradiol cypionate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol cypionate,DB00113
DB13956,Estradiol valerate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol valerate,DB00113
DB15334,Biochanin A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Biochanin A,DB00113
DB15335,Formononetin may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Formononetin,DB00113
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.,Cetuximab,DB00113
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.,Human immunoglobulin G,DB00113
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Technetium Tc-99m arcitumomab.,Omalizumab,DB00113
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Technetium Tc-99m arcitumomab.,Adalimumab,DB00113
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Technetium Tc-99m arcitumomab.,Abciximab,DB00113
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.,Gemtuzumab ozogamicin,DB00113
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.,Indium In-111 satumomab pendetide,DB00113
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.,Infliximab,DB00113
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.,Trastuzumab,DB00113
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.,Rituximab,DB00113
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.,Basiliximab,DB00113
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.,Muromonab,DB00113
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.,Digoxin Immune Fab (Ovine),DB00113
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.,Ibritumomab tiuxetan,DB00113
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.,Tositumomab,DB00113
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.,Alemtuzumab,DB00113
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.,Capromab pendetide,DB00113
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.,Efalizumab,DB00113
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.,Antithymocyte immunoglobulin (rabbit),DB00113
DB00108,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.,Natalizumab,DB00113
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.,Palivizumab,DB00113
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.,Daclizumab,DB00113
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.,Bevacizumab,DB00113
DB01257,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eculizumab.,Eculizumab,DB00113
DB01269,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Panitumumab.,Panitumumab,DB00113
DB01270,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ranibizumab.,Ranibizumab,DB00113
DB04901,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galiximab.,Galiximab,DB00113
DB04949,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pexelizumab.,Pexelizumab,DB00113
DB04956,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Afelimomab.,Afelimomab,DB00113
DB04958,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Epratuzumab.,Epratuzumab,DB00113
DB04962,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bectumomab.,Bectumomab,DB00113
DB04964,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab.,Oregovomab,DB00113
DB04988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IGN311.,IGN311,DB00113
DB05006,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Adecatumumab.,Adecatumumab,DB00113
DB05097,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab.,Labetuzumab,DB00113
DB05101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Matuzumab.,Matuzumab,DB00113
DB05111,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fontolizumab.,Fontolizumab,DB00113
DB05136,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bavituximab.,Bavituximab,DB00113
DB05139,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CR002.,CR002,DB00113
DB05209,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozrolimupab.,Rozrolimupab,DB00113
DB05304,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Girentuximab.,Girentuximab,DB00113
DB05336,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obiltoxaximab.,Obiltoxaximab,DB00113
DB05405,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XTL-001.,XTL-001,DB00113
DB05437,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with NAV 1800.,NAV 1800,DB00113
DB05459,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Briakinumab.,Briakinumab,DB00113
DB05496,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Otelixizumab.,Otelixizumab,DB00113
DB05545,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AMG 108.,AMG 108,DB00113
DB05550,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Iratumumab.,Iratumumab,DB00113
DB05555,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Enokizumab.,Enokizumab,DB00113
DB05578,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ramucirumab.,Ramucirumab,DB00113
DB05595,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Farletuzumab.,Farletuzumab,DB00113
DB05656,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Veltuzumab.,Veltuzumab,DB00113
DB05679,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ustekinumab.,Ustekinumab,DB00113
DB05773,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00113
DB05793,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with PRO-542.,PRO-542,DB00113
DB05797,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TNX-901.,TNX-901,DB00113
DB05889,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin,DB00113
DB05892,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with RI 624.,RI 624,DB00113
DB05915,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with MYO-029.,MYO-029,DB00113
DB05916,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CT-011.,CT-011,DB00113
DB05941,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Leronlimab.,Leronlimab,DB00113
DB05996,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glembatumumab vedotin.,Glembatumumab vedotin,DB00113
DB06043,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olaratumab.,Olaratumab,DB00113
DB06049,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IPH 2101.,IPH 2101,DB00113
DB06050,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TB-402.,TB-402,DB00113
DB06081,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Caplacizumab.,Caplacizumab,DB00113
DB06101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IMC-1C11.,IMC-1C11,DB00113
DB06116,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eldelumab.,Eldelumab,DB00113
DB06162,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumiliximab.,Lumiliximab,DB00113
DB06168,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Canakinumab.,Canakinumab,DB00113
DB06186,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipilimumab.,Ipilimumab,DB00113
DB06192,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nimotuzumab.,Nimotuzumab,DB00113
DB06241,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clenoliximab.,Clenoliximab,DB00113
DB06273,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tocilizumab.,Tocilizumab,DB00113
DB06304,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with BIIB015.,BIIB015,DB00113
DB06305,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sonepcizumab.,Sonepcizumab,DB00113
DB06310,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Motavizumab.,Motavizumab,DB00113
DB06317,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Elotuzumab.,Elotuzumab,DB00113
DB06318,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AVE9633.,AVE9633,DB00113
DB06322,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carotuximab.,Carotuximab,DB00113
DB06324,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XmAb 2513.,XmAb 2513,DB00113
DB06342,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Coltuximab ravtansine.,Coltuximab ravtansine,DB00113
DB06343,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teprotumumab.,Teprotumumab,DB00113
DB06360,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lucatumumab.,Lucatumumab,DB00113
DB06366,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pertuzumab.,Pertuzumab,DB00113
DB06371,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siplizumab.,Siplizumab,DB00113
DB06467,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apolizumab.,Apolizumab,DB00113
DB06474,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sibrotuzumab.,Sibrotuzumab,DB00113
DB06550,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bivatuzumab.,Bivatuzumab,DB00113
DB06557,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lerdelimumab.,Lerdelimumab,DB00113
DB06599,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lexatumumab.,Lexatumumab,DB00113
DB06602,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Reslizumab.,Reslizumab,DB00113
DB06606,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teplizumab.,Teplizumab,DB00113
DB06607,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Catumaxomab.,Catumaxomab,DB00113
DB06612,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mepolizumab.,Mepolizumab,DB00113
DB06643,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Denosumab.,Denosumab,DB00113
DB06647,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Volociximab.,Volociximab,DB00113
DB06650,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ofatumumab.,Ofatumumab,DB00113
DB06674,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Golimumab.,Golimumab,DB00113
DB08870,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00113
DB08879,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Belimumab.,Belimumab,DB00113
DB08902,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Raxibacumab.,Raxibacumab,DB00113
DB08904,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Certolizumab pegol.,Certolizumab pegol,DB00113
DB08935,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obinutuzumab.,Obinutuzumab,DB00113
DB09029,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Secukinumab.,Secukinumab,DB00113
DB09033,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vedolizumab.,Vedolizumab,DB00113
DB09035,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nivolumab.,Nivolumab,DB00113
DB09036,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siltuximab.,Siltuximab,DB00113
DB09037,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pembrolizumab.,Pembrolizumab,DB00113
DB09045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dulaglutide.,Dulaglutide,DB00113
DB09052,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blinatumomab.,Blinatumomab,DB00113
DB09057,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anthrax immune globulin human.,Anthrax immune globulin human,DB00113
DB09077,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dinutuximab.,Dinutuximab,DB00113
DB09105,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asfotase alfa.,Asfotase alfa,DB00113
DB09264,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Idarucizumab.,Idarucizumab,DB00113
DB09302,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Alirocumab.,Alirocumab,DB00113
DB09303,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evolocumab.,Evolocumab,DB00113
DB09312,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse),DB00113
DB09331,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Daratumumab.,Daratumumab,DB00113
DB09559,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Necitumumab.,Necitumumab,DB00113
DB11569,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ixekizumab.,Ixekizumab,DB00113
DB11580,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ravulizumab.,Ravulizumab,DB00113
DB11595,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atezolizumab.,Atezolizumab,DB00113
DB11604,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin,DB00113
DB11608,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eftrenonacog alfa.,Eftrenonacog alfa,DB00113
DB11621,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin,DB00113
DB11646,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Conatumumab.,Conatumumab,DB00113
DB11657,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tabalumab.,Tabalumab,DB00113
DB11680,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ficlatuzumab.,Ficlatuzumab,DB00113
DB11685,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Figitumumab.,Figitumumab,DB00113
DB11714,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Durvalumab.,Durvalumab,DB00113
DB11715,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bapineuzumab.,Bapineuzumab,DB00113
DB11731,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin,DB00113
DB11746,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Onartuzumab.,Onartuzumab,DB00113
DB11756,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Solanezumab.,Solanezumab,DB00113
DB11767,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sarilumab.,Sarilumab,DB00113
DB11771,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tremelimumab.,Tremelimumab,DB00113
DB11776,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brodalumab.,Brodalumab,DB00113
DB11803,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sirukumab.,Sirukumab,DB00113
DB11826,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lampalizumab.,Lampalizumab,DB00113
DB11834,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Guselkumab.,Guselkumab,DB00113
DB11840,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalotuzumab.,Dalotuzumab,DB00113
DB11849,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emibetuzumab.,Emibetuzumab,DB00113
DB11850,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ublituximab.,Ublituximab,DB00113
DB11856,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ligelizumab.,Ligelizumab,DB00113
DB11857,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Seribantumab.,Seribantumab,DB00113
DB11862,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Landogrozumab.,Landogrozumab,DB00113
DB11866,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Romosozumab.,Romosozumab,DB00113
DB11884,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vadastuximab Talirine.,Vadastuximab Talirine,DB00113
DB11914,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lebrikizumab.,Lebrikizumab,DB00113
DB11930,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Varlilumab.,Varlilumab,DB00113
DB11945,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Avelumab.,Avelumab,DB00113
DB11959,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crenezumab.,Crenezumab,DB00113
DB11972,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rilotumumab.,Rilotumumab,DB00113
DB11976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anifrolumab.,Anifrolumab,DB00113
DB11988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ocrelizumab.,Ocrelizumab,DB00113
DB12023,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Benralizumab.,Benralizumab,DB00113
DB12034,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gantenerumab.,Gantenerumab,DB00113
DB12053,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Visilizumab.,Visilizumab,DB00113
DB12077,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Urelumab.,Urelumab,DB00113
DB12089,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine,DB00113
DB12090,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Patritumab.,Patritumab,DB00113
DB12102,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fulranumab.,Fulranumab,DB00113
DB12104,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tarextumab.,Tarextumab,DB00113
DB12118,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sotatercept.,Sotatercept,DB00113
DB12119,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gevokizumab.,Gevokizumab,DB00113
DB12142,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Duligotuzumab.,Duligotuzumab,DB00113
DB12152,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Simtuzumab.,Simtuzumab,DB00113
DB12157,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fasinumab.,Fasinumab,DB00113
DB12159,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dupilumab.,Dupilumab,DB00113
DB12169,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tralokinumab.,Tralokinumab,DB00113
DB12189,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etrolizumab.,Etrolizumab,DB00113
DB12202,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zalutumumab.,Zalutumumab,DB00113
DB12205,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ganitumab.,Ganitumab,DB00113
DB12213,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etaracizumab.,Etaracizumab,DB00113
DB12240,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Polatuzumab vedotin.,Polatuzumab vedotin,DB00113
DB12246,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inclacumab.,Inclacumab,DB00113
DB12250,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cixutumumab.,Cixutumumab,DB00113
DB12261,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ascrinvacumab.,Ascrinvacumab,DB00113
DB12274,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Aducanumab.,Aducanumab,DB00113
DB12281,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Luspatercept.,Luspatercept,DB00113
DB12296,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GS-5745.,GS-5745,DB00113
DB12317,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vanucizumab.,Vanucizumab,DB00113
DB12331,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab govitecan.,Labetuzumab govitecan,DB00113
DB12335,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tanezumab.,Tanezumab,DB00113
DB12342,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ensituximab.,Ensituximab,DB00113
DB12344,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fezakinumab.,Fezakinumab,DB00113
DB12363,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dusigitumab.,Dusigitumab,DB00113
DB12396,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fresolimumab.,Fresolimumab,DB00113
DB12413,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Indusatumab vedotin.,Indusatumab vedotin,DB00113
DB12456,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bococizumab.,Bococizumab,DB00113
DB12489,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine,DB00113
DB12498,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mogamulizumab.,Mogamulizumab,DB00113
DB12520,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Plozalizumab.,Plozalizumab,DB00113
DB12530,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inebilizumab.,Inebilizumab,DB00113
DB12534,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mavrilimumab.,Mavrilimumab,DB00113
DB12560,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blosozumab.,Blosozumab,DB00113
DB12584,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimagrumab.,Bimagrumab,DB00113
DB12589,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dacetuzumab.,Dacetuzumab,DB00113
DB12609,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tovetumab.,Tovetumab,DB00113
DB12683,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumretuzumab.,Lumretuzumab,DB00113
DB12698,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ibalizumab.,Ibalizumab,DB00113
DB12701,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Intetumumab.,Intetumumab,DB00113
DB12718,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carlumab.,Carlumab,DB00113
DB12734,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Demcizumab.,Demcizumab,DB00113
DB12773,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sifalimumab.,Sifalimumab,DB00113
DB12775,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abituzumab.,Abituzumab,DB00113
DB12797,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ecromeximab.,Ecromeximab,DB00113
DB12807,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox,DB00113
DB12815,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crotedumab.,Crotedumab,DB00113
DB12820,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Concizumab.,Concizumab,DB00113
DB12826,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab.,Depatuxizumab,DB00113
DB12844,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rontalizumab.,Rontalizumab,DB00113
DB12845,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Amatuximab.,Amatuximab,DB00113
DB12849,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clazakizumab.,Clazakizumab,DB00113
DB12891,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ozanezumab.,Ozanezumab,DB00113
DB12893,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sacituzumab govitecan.,Sacituzumab govitecan,DB00113
DB12917,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimekizumab.,Bimekizumab,DB00113
DB12943,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Milatuzumab.,Milatuzumab,DB00113
DB12976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Robatumumab.,Robatumumab,DB00113
DB13017,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine,DB00113
DB13037,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Namilumab.,Namilumab,DB00113
DB13045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Racotumomab.,Racotumomab,DB00113
DB13073,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tregalizumab.,Tregalizumab,DB00113
DB13127,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olokizumab.,Olokizumab,DB00113
DB13140,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bezlotoxumab.,Bezlotoxumab,DB00113
DB13375,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Edrecolomab.,Edrecolomab,DB00113
DB13535,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nebacumab.,Nebacumab,DB00113
DB13886,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin,DB00113
DB13923,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emicizumab.,Emicizumab,DB00113
DB13976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sulesomab.,Sulesomab,DB00113
DB13979,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Besilesomab.,Besilesomab,DB00113
DB14004,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tildrakizumab.,Tildrakizumab,DB00113
DB14012,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Burosumab.,Burosumab,DB00113
DB14039,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Erenumab.,Erenumab,DB00113
DB14040,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eptinezumab.,Eptinezumab,DB00113
DB14041,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fremanezumab.,Fremanezumab,DB00113
DB14042,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galcanezumab.,Galcanezumab,DB00113
DB14211,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fanolesomab.,Fanolesomab,DB00113
DB14580,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lecanemab.,Lecanemab,DB00113
DB14597,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lanadelumab.,Lanadelumab,DB00113
DB14707,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cemiplimab.,Cemiplimab,DB00113
DB14724,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emapalumab.,Emapalumab,DB00113
DB14762,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Risankizumab.,Risankizumab,DB00113
DB14776,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Camrelizumab.,Camrelizumab,DB00113
DB14778,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Setrusumab.,Setrusumab,DB00113
DB14784,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gancotamab.,Gancotamab,DB00113
DB14809,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anetumab ravtansine.,Anetumab ravtansine,DB00113
DB14811,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Isatuximab.,Isatuximab,DB00113
DB14824,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Icrucumab.,Icrucumab,DB00113
DB14843,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Codrituzumab.,Codrituzumab,DB00113
DB14864,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brolucizumab.,Brolucizumab,DB00113
DB14871,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Xentuzumab.,Xentuzumab,DB00113
DB14877,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lintuzumab.,Lintuzumab,DB00113
DB14891,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vobarilizumab.,Vobarilizumab,DB00113
DB14897,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Parsatuzumab.,Parsatuzumab,DB00113
DB14905,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emactuzumab.,Emactuzumab,DB00113
DB14907,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89,DB00113
DB14908,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Refanezumab.,Refanezumab,DB00113
DB14919,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozanolixizumab.,Rozanolixizumab,DB00113
DB14947,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bermekimab.,Bermekimab,DB00113
DB14952,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pamrevlumab.,Pamrevlumab,DB00113
DB14959,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Opicinumab.,Opicinumab,DB00113
DB14962,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan,DB00113
DB14967,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Margetuximab.,Margetuximab,DB00113
DB14988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalantercept.,Dalantercept,DB00113
DB14997,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pateclizumab.,Pateclizumab,DB00113
DB15014,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gremubamab.,Gremubamab,DB00113
DB15022,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apomab.,Apomab,DB00113
DB15044,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tafasitamab.,Tafasitamab,DB00113
DB15045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipafricept.,Ipafricept,DB00113
DB15076,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abrilumab.,Abrilumab,DB00113
DB15089,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Frovocimab.,Frovocimab,DB00113
DB15090,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tezepelumab.,Tezepelumab,DB00113
DB15101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tigatuzumab.,Tigatuzumab,DB00113
DB15104,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin,DB00113
DB15113,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Utomilumab.,Utomilumab,DB00113
DB15118,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zolbetuximab.,Zolbetuximab,DB00113
DB15135,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ponezumab.,Ponezumab,DB00113
DB15160,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asunercept.,Asunercept,DB00113
DB15172,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Suvratoxumab.,Suvratoxumab,DB00113
DB15225,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mitazalimab.,Mitazalimab,DB00113
DB15252,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nemolizumab.,Nemolizumab,DB00113
DB15253,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bleselumab.,Bleselumab,DB00113
DB15277,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gedivumab.,Gedivumab,DB00113
DB15336,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Valanafusp alfa.,Valanafusp alfa,DB00113
DB15349,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sofituzumab vedotin.,Sofituzumab vedotin,DB00113
DB15354,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evinacumab.,Evinacumab,DB00113
DB15363,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Istiratumab.,Istiratumab,DB00113
DB15383,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pidilizumab.,Pidilizumab,DB00113
DB15397,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GMA-161.,GMA-161,DB00113
DB15409,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin,DB00113
DB15415,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tomaralimab.,Tomaralimab,DB00113
DB15428,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vesencumab.,Vesencumab,DB00113
DB15432,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin,DB00113
DB15441,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lulizumab pegol.,Lulizumab pegol,DB00113
DB15443,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorukafusp alfa.,Lorukafusp alfa,DB00113
DB15453,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naratuximab emtansine.,Naratuximab emtansine,DB00113
DB15559,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zenocutuzumab.,Zenocutuzumab,DB00113
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.","Ebola Zaire vaccine (live, attenuated)",DB00113
DB00446,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chloramphenicol.,Chloramphenicol,DB00115
DB01394,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Colchicine.,Colchicine,DB00115
DB00091,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyclosporine,DB00115
DB00229,Cefotiam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotiam,DB00115
DB00244,Mesalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mesalazine,DB00115
DB00267,Cefmenoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefmenoxime,DB00115
DB00274,Cefmetazole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefmetazole,DB00115
DB00282,Pamidronic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pamidronic acid,DB00115
DB00300,Tenofovir disoproxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir disoproxil,DB00115
DB00369,Cidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cidofovir,DB00115
DB00384,Triamterene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Triamterene,DB00115
DB00430,Cefpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpiramide,DB00115
DB00438,Ceftazidime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftazidime,DB00115
DB00447,Loracarbef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Loracarbef,DB00115
DB00456,Cefalotin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefalotin,DB00115
DB00461,Nabumetone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nabumetone,DB00115
DB00465,Ketorolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ketorolac,DB00115
DB00469,Tenoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenoxicam,DB00115
DB00482,Celecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Celecoxib,DB00115
DB00493,Cefotaxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotaxime,DB00115
DB00500,Tolmetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tolmetin,DB00115
DB00529,Foscarnet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Foscarnet,DB00115
DB00533,Rofecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Rofecoxib,DB00115
DB00554,Piroxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Piroxicam,DB00115
DB00567,Cephalexin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephalexin,DB00115
DB00573,Fenoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fenoprofen,DB00115
DB00577,Valaciclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Valaciclovir,DB00115
DB00580,Valdecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Valdecoxib,DB00115
DB00586,Diclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Diclofenac,DB00115
DB00605,Sulindac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sulindac,DB00115
DB00626,Bacitracin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bacitracin,DB00115
DB00681,Amphotericin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Amphotericin B,DB00115
DB00689,Cephaloglycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephaloglycin,DB00115
DB00712,Flurbiprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flurbiprofen,DB00115
DB00718,Adefovir dipivoxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Adefovir dipivoxil,DB00115
DB00738,Pentamidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pentamidine,DB00115
DB00742,Mannitol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mannitol,DB00115
DB00749,Etodolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etodolac,DB00115
DB00784,Mefenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mefenamic acid,DB00115
DB00787,Acyclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acyclovir,DB00115
DB00788,Naproxen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Naproxen,DB00115
DB00795,Sulfasalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sulfasalazine,DB00115
DB00812,Phenylbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Phenylbutazone,DB00115
DB00814,Meloxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Meloxicam,DB00115
DB00821,Carprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Carprofen,DB00115
DB00833,Cefaclor may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefaclor,DB00115
DB00861,Diflunisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Diflunisal,DB00115
DB00903,Etacrynic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etacrynic acid,DB00115
DB00923,Ceforanide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceforanide,DB00115
DB00936,Salicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salicylic acid,DB00115
DB00939,Meclofenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Meclofenamic acid,DB00115
DB00945,Acetylsalicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acetylsalicylic acid,DB00115
DB00991,Oxaprozin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Oxaprozin,DB00115
DB00999,Hydrochlorothiazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hydrochlorothiazide,DB00115
DB01009,Ketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ketoprofen,DB00115
DB01014,Balsalazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Balsalazide,DB00115
DB01050,Ibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ibuprofen,DB00115
DB01066,Cefditoren may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefditoren,DB00115
DB01072,Atazanavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Atazanavir,DB00115
DB01111,Colistimethate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Colistimethate,DB00115
DB01112,Cefuroxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefuroxime,DB00115
DB01139,Cefapirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefapirin,DB00115
DB01140,Cefadroxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefadroxil,DB00115
DB01150,Cefprozil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefprozil,DB00115
DB01212,Ceftriaxone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftriaxone,DB00115
DB01250,Olsalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Olsalazine,DB00115
DB01283,Lumiracoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lumiracoxib,DB00115
DB01326,Cefamandole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefamandole,DB00115
DB01327,Cefazolin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefazolin,DB00115
DB01328,Cefonicid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefonicid,DB00115
DB01329,Cefoperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefoperazone,DB00115
DB01330,Cefotetan may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotetan,DB00115
DB01331,Cefoxitin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefoxitin,DB00115
DB01332,Ceftizoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftizoxime,DB00115
DB01333,Cefradine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefradine,DB00115
DB01397,Magnesium salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Magnesium salicylate,DB00115
DB01399,Salsalate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salsalate,DB00115
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Choline magnesium trisalicylate,DB00115
DB01413,Cefepime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefepime,DB00115
DB01414,Cefacetrile may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefacetrile,DB00115
DB01415,Ceftibuten may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftibuten,DB00115
DB01416,Cefpodoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpodoxime,DB00115
DB01419,Antrafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Antrafenine,DB00115
DB01424,Aminophenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Aminophenazone,DB00115
DB01435,Antipyrine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Antipyrine,DB00115
DB01600,Tiaprofenic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tiaprofenic acid,DB00115
DB01601,Lopinavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lopinavir,DB00115
DB01628,Etoricoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etoricoxib,DB00115
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hydrolyzed Cephalothin,DB00115
DB03450,Cephalothin Group may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephalothin Group,DB00115
DB03585,Oxyphenbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Oxyphenbutazone,DB00115
DB04552,Niflumic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Niflumic acid,DB00115
DB04570,Latamoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Latamoxef,DB00115
DB04743,Nimesulide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nimesulide,DB00115
DB04812,Benoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benoxaprofen,DB00115
DB04817,Metamizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Metamizole,DB00115
DB04828,Zomepirac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Zomepirac,DB00115
DB04918,Ceftobiprole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftobiprole,DB00115
DB05095,Cimicoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cimicoxib,DB00115
DB06590,Ceftaroline fosamil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftaroline fosamil,DB00115
DB06725,Lornoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lornoxicam,DB00115
DB06736,Aceclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Aceclofenac,DB00115
DB06737,Zaltoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Zaltoprofen,DB00115
DB07402,Azapropazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Azapropazone,DB00115
DB07477,Felbinac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Felbinac,DB00115
DB08439,Parecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Parecoxib,DB00115
DB08797,Salicylamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salicylamide,DB00115
DB08940,Kebuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Kebuzone,DB00115
DB08942,Isoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Isoxicam,DB00115
DB08951,Indoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Indoprofen,DB00115
DB08955,Ibuproxam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ibuproxam,DB00115
DB08976,Floctafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Floctafenine,DB00115
DB08981,Fenbufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fenbufen,DB00115
DB08984,Etofenamate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etofenamate,DB00115
DB08991,Epirizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Epirizole,DB00115
DB09008,Cefaloridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefaloridine,DB00115
DB09062,Cefminox may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefminox,DB00115
DB09084,Benzydamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benzydamine,DB00115
DB09212,Loxoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Loxoprofen,DB00115
DB09213,Dexibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dexibuprofen,DB00115
DB09214,Dexketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dexketoprofen,DB00115
DB09215,Droxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Droxicam,DB00115
DB09216,Tolfenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tolfenamic acid,DB00115
DB09217,Firocoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Firocoxib,DB00115
DB09218,Clonixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Clonixin,DB00115
DB09285,Morniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Morniflumate,DB00115
DB09288,Propacetamol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Propacetamol,DB00115
DB09295,Talniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Talniflumate,DB00115
DB09299,Tenofovir alafenamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir alafenamide,DB00115
DB11367,Cefroxadine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefroxadine,DB00115
DB11455,Robenacoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Robenacoxib,DB00115
DB11466,Tepoxalin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tepoxalin,DB00115
DB11518,Flunixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flunixin,DB00115
DB11935,Flomoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flomoxef,DB00115
DB12151,Brincidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Brincidofovir,DB00115
DB12445,Nitroaspirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nitroaspirin,DB00115
DB12545,Indobufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Indobufen,DB00115
DB13001,Tinoridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tinoridine,DB00115
DB13167,Alclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Alclofenac,DB00115
DB13217,Fentiazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fentiazac,DB00115
DB13232,Suxibuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Suxibuzone,DB00115
DB13266,Cefatrizine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefatrizine,DB00115
DB13286,Bumadizone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bumadizone,DB00115
DB13314,Alminoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Alminoprofen,DB00115
DB13317,Flunoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flunoxaprofen,DB00115
DB13364,Feprazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Feprazone,DB00115
DB13371,Difenpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Difenpiramide,DB00115
DB13407,Nifenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nifenazone,DB00115
DB13432,Lonazolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lonazolac,DB00115
DB13461,Cefcapene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefcapene,DB00115
DB13470,Cefodizime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefodizime,DB00115
DB13481,Tenidap may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenidap,DB00115
DB13499,Cefsulodin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefsulodin,DB00115
DB13501,Bendazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bendazac,DB00115
DB13504,Cefetamet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefetamet,DB00115
DB13514,Pranoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pranoprofen,DB00115
DB13524,Propyphenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Propyphenazone,DB00115
DB13527,Proglumetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Proglumetacin,DB00115
DB13538,Guacetisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Guacetisal,DB00115
DB13544,Ethenzamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ethenzamide,DB00115
DB13612,Carbaspirin calcium may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Carbaspirin calcium,DB00115
DB13629,Mofebutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mofebutazone,DB00115
DB13638,Cefbuperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefbuperazone,DB00115
DB13649,Proquazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Proquazone,DB00115
DB13657,Benorilate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benorilate,DB00115
DB13667,Cefozopran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefozopran,DB00115
DB13682,Cefpirome may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpirome,DB00115
DB13722,Pirprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pirprofen,DB00115
DB13778,Cefazedone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefazedone,DB00115
DB13783,Acemetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acemetacin,DB00115
DB13821,Ceftezole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftezole,DB00115
DB13860,Imidazole salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Imidazole salicylate,DB00115
DB13868,Adefovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Adefovir,DB00115
DB14059,SC-236 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,SC-236,DB00115
DB14060,NS-398 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,NS-398,DB00115
DB14126,Tenofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir,DB00115
DB14713,Inotersen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Inotersen,DB00115
DB01438,Phenazopyridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Phenazopyridine,DB00115
DB15066,Givosiran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Givosiran,DB00115
DB01356,Lithium cation may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lithium cation,DB00115
DB14507,Lithium citrate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lithium citrate,DB00115
DB00501,Cimetidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cimetidine,DB00115
DB00007,Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Leuprolide,DB00115
DB00014,Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Goserelin,DB00115
DB00017,Salmon calcitonin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salmon calcitonin,DB00115
DB00035,Desmopressin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Desmopressin,DB00115
DB00080,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Daptomycin,DB00115
DB00176,Cyanocobalamin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine,DB00115
DB00181,Cyanocobalamin may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen,DB00115
DB00182,Cyanocobalamin may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine,DB00115
DB00185,Cyanocobalamin may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline,DB00115
DB00186,Cyanocobalamin may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam,DB00115
DB00190,Cyanocobalamin may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa,DB00115
DB00193,Cyanocobalamin may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol,DB00115
DB00196,Cyanocobalamin may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole,DB00115
DB00198,Cyanocobalamin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir,DB00115
DB00200,Cyanocobalamin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin,DB00115
DB00206,Cyanocobalamin may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine,DB00115
DB00208,Cyanocobalamin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.,Ticlopidine,DB00115
DB00213,Cyanocobalamin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole,DB00115
DB00225,Cyanocobalamin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide,DB00115
DB00230,Cyanocobalamin may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin,DB00115
DB00231,Cyanocobalamin may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam,DB00115
DB00235,Cyanocobalamin may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone,DB00115
DB00237,Cyanocobalamin may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital,DB00115
DB00243,Cyanocobalamin may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine,DB00115
DB00245,Cyanocobalamin may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine,DB00115
DB00254,Cyanocobalamin may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline,DB00115
DB00264,Cyanocobalamin may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol,DB00115
DB00270,Cyanocobalamin may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine,DB00115
DB00271,Cyanocobalamin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate,DB00115
DB00273,Cyanocobalamin may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate,DB00115
DB00279,Cyanocobalamin may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine,DB00115
DB00280,Cyanocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide,DB00115
DB00284,Cyanocobalamin may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose,DB00115
DB00285,Cyanocobalamin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine,DB00115
DB00286,Cyanocobalamin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens,DB00115
DB00289,Cyanocobalamin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine,DB00115
DB00290,Cyanocobalamin may decrease the excretion rate of Bleomycin which could result in a higher serum level.,Bleomycin,DB00115
DB00292,Cyanocobalamin may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate,DB00115
DB00294,Cyanocobalamin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel,DB00115
DB00296,Cyanocobalamin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine,DB00115
DB00303,Cyanocobalamin may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem,DB00115
DB00308,Cyanocobalamin may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide,DB00115
DB00312,Cyanocobalamin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital,DB00115
DB00316,Cyanocobalamin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen,DB00115
DB00319,Cyanocobalamin may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin,DB00115
DB00323,Cyanocobalamin may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone,DB00115
DB00325,Cyanocobalamin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside,DB00115
DB00327,Cyanocobalamin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone,DB00115
DB00330,Cyanocobalamin may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol,DB00115
DB00331,Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin,DB00115
DB00333,Cyanocobalamin may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone,DB00115
DB00339,Cyanocobalamin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide,DB00115
DB00341,Cyanocobalamin may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine,DB00115
DB00349,Cyanocobalamin may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam,DB00115
DB00351,Cyanocobalamin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate,DB00115
DB00355,Cyanocobalamin may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam,DB00115
DB00356,Cyanocobalamin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone,DB00115
DB00359,Cyanocobalamin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine,DB00115
DB00363,Cyanocobalamin may decrease the excretion rate of Clozapine which could result in a higher serum level.,Clozapine,DB00115
DB00364,Cyanocobalamin may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate,DB00115
DB00372,Cyanocobalamin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine,DB00115
DB00373,Cyanocobalamin may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol,DB00115
DB00377,Cyanocobalamin may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron,DB00115
DB00401,Cyanocobalamin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine,DB00115
DB00402,Cyanocobalamin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone,DB00115
DB00404,Cyanocobalamin may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam,DB00115
DB00412,Cyanocobalamin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone,DB00115
DB00413,Cyanocobalamin may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole,DB00115
DB00415,Cyanocobalamin may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin,DB00115
DB00418,Cyanocobalamin may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital,DB00115
DB00422,Cyanocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate,DB00115
DB00432,Cyanocobalamin may decrease the excretion rate of Trifluridine which could result in a higher serum level.,Trifluridine,DB00115
DB00435,Cyanocobalamin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide,DB00115
DB00437,Cyanocobalamin may decrease the excretion rate of Allopurinol which could result in a higher serum level.,Allopurinol,DB00115
DB00440,Cyanocobalamin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim,DB00115
DB00476,Cyanocobalamin may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine,DB00115
DB00477,Cyanocobalamin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine,DB00115
DB00490,Cyanocobalamin may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone,DB00115
DB00492,Cyanocobalamin may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril,DB00115
DB00499,Cyanocobalamin may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide,DB00115
DB00502,Cyanocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol,DB00115
DB00535,Cyanocobalamin may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir,DB00115
DB00537,Cyanocobalamin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.,Ciprofloxacin,DB00115
DB00548,Cyanocobalamin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid,DB00115
DB00553,Cyanocobalamin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen,DB00115
DB00555,Cyanocobalamin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine,DB00115
DB00558,Cyanocobalamin may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir,DB00115
DB00569,Cyanocobalamin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux,DB00115
DB00571,Cyanocobalamin may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol,DB00115
DB00583,Cyanocobalamin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine,DB00115
DB00591,Cyanocobalamin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.,Fluocinolone acetonide,DB00115
DB00597,Cyanocobalamin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol,DB00115
DB00598,Cyanocobalamin may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol,DB00115
DB00603,Cyanocobalamin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate,DB00115
DB00608,Cyanocobalamin may decrease the excretion rate of Chloroquine which could result in a higher serum level.,Chloroquine,DB00115
DB00612,Cyanocobalamin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol,DB00115
DB00624,Cyanocobalamin may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone,DB00115
DB00628,Cyanocobalamin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid,DB00115
DB00633,Cyanocobalamin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine,DB00115
DB00635,Cyanocobalamin may decrease the excretion rate of Prednisone which could result in a higher serum level.,Prednisone,DB00115
DB00651,Cyanocobalamin may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline,DB00115
DB00657,Cyanocobalamin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine,DB00115
DB00660,Cyanocobalamin may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone,DB00115
DB00661,Cyanocobalamin may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil,DB00115
DB00665,Cyanocobalamin may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide,DB00115
DB00669,Cyanocobalamin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan,DB00115
DB00672,Cyanocobalamin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide,DB00115
DB00683,Cyanocobalamin may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam,DB00115
DB00688,Cyanocobalamin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.,Mycophenolate mofetil,DB00115
DB00690,Cyanocobalamin may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam,DB00115
DB00692,Cyanocobalamin may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine,DB00115
DB00698,Cyanocobalamin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin,DB00115
DB00706,Cyanocobalamin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin,DB00115
DB00709,Cyanocobalamin may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine,DB00115
DB00713,Cyanocobalamin may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin,DB00115
DB00716,Cyanocobalamin may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil,DB00115
DB00722,Cyanocobalamin may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril,DB00115
DB00730,Cyanocobalamin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole,DB00115
DB00731,Cyanocobalamin may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide,DB00115
DB00733,Cyanocobalamin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime,DB00115
DB00743,Cyanocobalamin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid,DB00115
DB00759,Cyanocobalamin may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline,DB00115
DB00760,Cyanocobalamin may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem,DB00115
DB00775,Cyanocobalamin may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban,DB00115
DB00780,Cyanocobalamin may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine,DB00115
DB00782,Cyanocobalamin may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline,DB00115
DB00783,Cyanocobalamin may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol,DB00115
DB00789,Cyanocobalamin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid,DB00115
DB00790,Cyanocobalamin may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril,DB00115
DB00800,Cyanocobalamin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam,DB00115
DB00804,Cyanocobalamin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine,DB00115
DB00806,Cyanocobalamin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline,DB00115
DB00811,Cyanocobalamin may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin,DB00115
DB00820,Cyanocobalamin may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil,DB00115
DB00828,Cyanocobalamin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin,DB00115
DB00829,Cyanocobalamin may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam,DB00115
DB00839,Cyanocobalamin may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide,DB00115
DB00841,Cyanocobalamin may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine,DB00115
DB00842,Cyanocobalamin may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam,DB00115
DB00863,Cyanocobalamin may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine,DB00115
DB00871,Cyanocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline,DB00115
DB00894,Cyanocobalamin may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone,DB00115
DB00897,Cyanocobalamin may decrease the excretion rate of Triazolam which could result in a higher serum level.,Triazolam,DB00115
DB00900,Cyanocobalamin may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine,DB00115
DB00911,Cyanocobalamin may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole,DB00115
DB00915,Cyanocobalamin may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine,DB00115
DB00918,Cyanocobalamin may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan,DB00115
DB00934,Cyanocobalamin may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline,DB00115
DB00951,Cyanocobalamin may decrease the excretion rate of Isoniazid which could result in a higher serum level.,Isoniazid,DB00115
DB00953,Cyanocobalamin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan,DB00115
DB00960,Cyanocobalamin may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol,DB00115
DB00961,Cyanocobalamin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine,DB00115
DB00962,Cyanocobalamin may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon,DB00115
DB00968,Cyanocobalamin may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa,DB00115
DB00980,Cyanocobalamin may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon,DB00115
DB00988,Cyanocobalamin may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine,DB00115
DB00993,Cyanocobalamin may decrease the excretion rate of Azathioprine which could result in a higher serum level.,Azathioprine,DB00115
DB00995,Cyanocobalamin may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin,DB00115
DB01001,Cyanocobalamin may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol,DB00115
DB01002,Cyanocobalamin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine,DB00115
DB01004,Cyanocobalamin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir,DB00115
DB01010,Cyanocobalamin may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium,DB00115
DB01011,Cyanocobalamin may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone,DB00115
DB01015,Cyanocobalamin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.,Sulfamethoxazole,DB00115
DB01018,Cyanocobalamin may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine,DB00115
DB01020,Cyanocobalamin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate,DB00115
DB01024,Cyanocobalamin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.,Mycophenolic acid,DB00115
DB01032,Cyanocobalamin may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid,DB00115
DB01036,Cyanocobalamin may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine,DB00115
DB01039,Cyanocobalamin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.,Fenofibrate,DB00115
DB01043,Cyanocobalamin may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine,DB00115
DB01046,Cyanocobalamin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone,DB00115
DB01048,Cyanocobalamin may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir,DB00115
DB01060,Cyanocobalamin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin,DB00115
DB01067,Cyanocobalamin may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide,DB00115
DB01068,Cyanocobalamin may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam,DB00115
DB01069,Cyanocobalamin may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine,DB00115
DB01093,Cyanocobalamin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide,DB00115
DB01105,Cyanocobalamin may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine,DB00115
DB01115,Cyanocobalamin may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine,DB00115
DB01124,Cyanocobalamin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide,DB00115
DB01129,Cyanocobalamin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole,DB00115
DB01133,Cyanocobalamin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid,DB00115
DB01135,Cyanocobalamin may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium,DB00115
DB01137,Cyanocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin,DB00115
DB01148,Cyanocobalamin may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate,DB00115
DB01149,Cyanocobalamin may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone,DB00115
DB01156,Cyanocobalamin may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion,DB00115
DB01157,Cyanocobalamin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate,DB00115
DB01166,Cyanocobalamin may decrease the excretion rate of Cilostazol which could result in a higher serum level.,Cilostazol,DB00115
DB01170,Cyanocobalamin may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine,DB00115
DB01183,Cyanocobalamin may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone,DB00115
DB01203,Cyanocobalamin may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol,DB00115
DB01205,Cyanocobalamin may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil,DB00115
DB01213,Cyanocobalamin may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole,DB00115
DB01215,Cyanocobalamin may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam,DB00115
DB01221,Cyanocobalamin may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine,DB00115
DB01222,Cyanocobalamin may decrease the excretion rate of Budesonide which could result in a higher serum level.,Budesonide,DB00115
DB01224,Cyanocobalamin may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine,DB00115
DB01233,Cyanocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.,Metoclopramide,DB00115
DB01240,Cyanocobalamin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol,DB00115
DB01241,Cyanocobalamin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.,Gemfibrozil,DB00115
DB01249,Cyanocobalamin may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol,DB00115
DB01261,Cyanocobalamin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin,DB00115
DB01267,Cyanocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone,DB00115
DB01273,Cyanocobalamin may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline,DB00115
DB01274,Cyanocobalamin may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol,DB00115
DB01275,Cyanocobalamin may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine,DB00115
DB01359,Cyanocobalamin may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol,DB00115
DB01367,Cyanocobalamin may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline,DB00115
DB01409,Cyanocobalamin may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium,DB00115
DB01420,Cyanocobalamin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate,DB00115
DB01427,Cyanocobalamin may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone,DB00115
DB01428,Cyanocobalamin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone,DB00115
DB01431,Cyanocobalamin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol,DB00115
DB01550,Cyanocobalamin may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex,DB00115
DB01558,Cyanocobalamin may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam,DB00115
DB01563,Cyanocobalamin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate,DB00115
DB01577,Cyanocobalamin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine,DB00115
DB01587,Cyanocobalamin may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam,DB00115
DB01610,Cyanocobalamin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir,DB00115
DB01638,Cyanocobalamin may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol,DB00115
DB01656,Cyanocobalamin may decrease the excretion rate of Roflumilast which could result in a higher serum level.,Roflumilast,DB00115
DB01685,Cyanocobalamin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat,DB00115
DB04574,Cyanocobalamin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate,DB00115
DB04871,Cyanocobalamin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin,DB00115
DB04895,Cyanocobalamin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib,DB00115
DB04896,Cyanocobalamin may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran,DB00115
DB04920,Cyanocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine,DB00115
DB04948,Cyanocobalamin may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine,DB00115
DB04953,Cyanocobalamin may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine,DB00115
DB05018,Cyanocobalamin may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat,DB00115
DB05541,Cyanocobalamin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam,DB00115
DB05676,Cyanocobalamin may decrease the excretion rate of Apremilast which could result in a higher serum level.,Apremilast,DB00115
DB06154,Cyanocobalamin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate,DB00115
DB06186,Cyanocobalamin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab,DB00115
DB06196,Cyanocobalamin may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant,DB00115
DB06203,Cyanocobalamin may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin,DB00115
DB06209,Cyanocobalamin may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel,DB00115
DB06211,Cyanocobalamin may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem,DB00115
DB06228,Cyanocobalamin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.,Rivaroxaban,DB00115
DB06230,Cyanocobalamin may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene,DB00115
DB06262,Cyanocobalamin may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa,DB00115
DB06282,Cyanocobalamin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine,DB00115
DB06335,Cyanocobalamin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin,DB00115
DB06402,Cyanocobalamin may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin,DB00115
DB06480,Cyanocobalamin may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride,DB00115
DB06623,Cyanocobalamin may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine,DB00115
DB06637,Cyanocobalamin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine,DB00115
DB06695,Cyanocobalamin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.,Dabigatran etexilate,DB00115
DB06700,Cyanocobalamin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine,DB00115
DB06702,Cyanocobalamin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine,DB00115
DB06705,Cyanocobalamin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium,DB00115
DB06710,Cyanocobalamin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone,DB00115
DB06767,Cyanocobalamin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride,DB00115
DB06782,Cyanocobalamin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol,DB00115
DB06796,Cyanocobalamin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir,DB00115
DB06800,Cyanocobalamin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone,DB00115
DB06809,Cyanocobalamin may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor,DB00115
DB06813,Cyanocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.,Pralatrexate,DB00115
DB06823,Cyanocobalamin may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin,DB00115
DB06824,Cyanocobalamin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine,DB00115
DB08824,Cyanocobalamin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123,DB00115
DB08826,Cyanocobalamin may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone,DB00115
DB08840,Cyanocobalamin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide,DB00115
DB08872,Cyanocobalamin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil,DB00115
DB08893,Cyanocobalamin may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron,DB00115
DB08894,Cyanocobalamin may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide,DB00115
DB08897,Cyanocobalamin may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium,DB00115
DB08899,Cyanocobalamin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide,DB00115
DB08900,Cyanocobalamin may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide,DB00115
DB08904,Cyanocobalamin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.,Certolizumab pegol,DB00115
DB08905,Cyanocobalamin may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane,DB00115
DB08909,Cyanocobalamin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate,DB00115
DB08911,Cyanocobalamin may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib,DB00115
DB08918,Cyanocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran,DB00115
DB08932,Cyanocobalamin may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan,DB00115
DB08934,Cyanocobalamin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir,DB00115
DB08964,Cyanocobalamin may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost,DB00115
DB09027,Cyanocobalamin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir,DB00115
DB09050,Cyanocobalamin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane,DB00115
DB09066,Cyanocobalamin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa,DB00115
DB09068,Cyanocobalamin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine,DB00115
DB09071,Cyanocobalamin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon,DB00115
DB09075,Cyanocobalamin may decrease the excretion rate of Edoxaban which could result in a higher serum level.,Edoxaban,DB00115
DB09081,Cyanocobalamin may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone,DB00115
DB09082,Cyanocobalamin may decrease the excretion rate of Vilanterol which could result in a higher serum level.,Vilanterol,DB00115
DB09089,Cyanocobalamin may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine,DB00115
DB09091,Cyanocobalamin may decrease the excretion rate of Tixocortol which could result in a higher serum level.,Tixocortol,DB00115
DB09103,Cyanocobalamin may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim,DB00115
DB09104,Cyanocobalamin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide,DB00115
DB09106,Cyanocobalamin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch,DB00115
DB09111,Cyanocobalamin may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch,DB00115
DB09118,Cyanocobalamin may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol,DB00115
DB09121,Cyanocobalamin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose,DB00115
DB09123,Cyanocobalamin may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest,DB00115
DB09132,Cyanocobalamin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid,DB00115
DB09133,Cyanocobalamin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid,DB00115
DB09134,Cyanocobalamin may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol,DB00115
DB09135,Cyanocobalamin may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan,DB00115
DB09136,Cyanocobalamin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue,DB00115
DB09137,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin,DB00115
DB09139,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate,DB00115
DB09148,Cyanocobalamin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F),DB00115
DB09149,Cyanocobalamin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F),DB00115
DB09156,Cyanocobalamin may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide,DB00115
DB09163,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime,DB00115
DB09165,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate,DB00115
DB09185,Cyanocobalamin may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine,DB00115
DB09194,Cyanocobalamin may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone,DB00115
DB09195,Cyanocobalamin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole,DB00115
DB09204,Cyanocobalamin may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol,DB00115
DB09205,Cyanocobalamin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte,DB00115
DB09209,Cyanocobalamin may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine,DB00115
DB09210,Cyanocobalamin may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam,DB00115
DB09219,Cyanocobalamin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin,DB00115
DB09220,Cyanocobalamin may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil,DB00115
DB09223,Cyanocobalamin may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin,DB00115
DB09224,Cyanocobalamin may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone,DB00115
DB09241,Cyanocobalamin may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue,DB00115
DB09244,Cyanocobalamin may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole,DB00115
DB09245,Cyanocobalamin may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone,DB00115
DB09255,Cyanocobalamin may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran,DB00115
DB09256,Cyanocobalamin may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur,DB00115
DB09257,Cyanocobalamin may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil,DB00115
DB09262,Cyanocobalamin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin,DB00115
DB09264,Cyanocobalamin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab,DB00115
DB09265,Cyanocobalamin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide,DB00115
DB09268,Cyanocobalamin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid,DB00115
DB09276,Cyanocobalamin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate,DB00115
DB09277,Cyanocobalamin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11,DB00115
DB09281,Cyanocobalamin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate,DB00115
DB09292,Cyanocobalamin may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril,DB00115
DB09301,Cyanocobalamin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate,DB00115
DB09317,"Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A",DB00115
DB09318,"Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B",DB00115
DB09320,Cyanocobalamin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin,DB00115
DB09324,Cyanocobalamin may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam,DB00115
DB09329,"Cyanocobalamin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated",DB00115
DB09344,Cyanocobalamin may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar,DB00115
DB09394,Cyanocobalamin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid,DB00115
DB09395,Cyanocobalamin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate,DB00115
DB09407,Cyanocobalamin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride,DB00115
DB09418,Cyanocobalamin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate,DB00115
DB09472,Cyanocobalamin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate,DB00115
DB09477,Cyanocobalamin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat,DB00115
DB09488,Cyanocobalamin may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine,DB00115
DB09496,Cyanocobalamin may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate,DB00115
DB09502,Cyanocobalamin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F),DB00115
DB09546,Cyanocobalamin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123,DB00115
DB09570,Cyanocobalamin may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib,DB00115
DB11077,Cyanocobalamin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400,DB00115
DB11090,Cyanocobalamin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate,DB00115
DB11098,Cyanocobalamin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate,DB00115
DB11102,Cyanocobalamin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine,DB00115
DB11114,Cyanocobalamin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil,DB00115
DB11130,Cyanocobalamin may decrease the excretion rate of Opium which could result in a higher serum level.,Opium,DB00115
DB11145,Cyanocobalamin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline,DB00115
DB11156,Cyanocobalamin may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel,DB00115
DB11164,Cyanocobalamin may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate,DB00115
DB11278,Cyanocobalamin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine,DB00115
DB11328,Cyanocobalamin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester),DB00115
DB11338,Cyanocobalamin may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil,DB00115
DB11358,Cyanocobalamin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil,DB00115
DB11364,Cyanocobalamin may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod,DB00115
DB11560,Cyanocobalamin may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad,DB00115
DB11577,Cyanocobalamin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid,DB00115
DB11587,Cyanocobalamin may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine,DB00115
DB11598,Cyanocobalamin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human,DB00115
DB11642,Cyanocobalamin may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant,DB00115
DB11691,Cyanocobalamin may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine,DB00115
DB11699,Cyanocobalamin may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron,DB00115
DB11817,Cyanocobalamin may decrease the excretion rate of Baricitinib which could result in a higher serum level.,Baricitinib,DB00115
DB11901,Cyanocobalamin may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide,DB00115
DB11915,Cyanocobalamin may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine,DB00115
DB11943,Cyanocobalamin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin,DB00115
DB11989,Cyanocobalamin may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole,DB00115
DB12007,Cyanocobalamin may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone,DB00115
DB12107,Cyanocobalamin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam,DB00115
DB12161,Cyanocobalamin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine,DB00115
DB12278,Cyanocobalamin may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine,DB00115
DB12783,Cyanocobalamin may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide,DB00115
DB13025,Cyanocobalamin may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride,DB00115
DB13139,Cyanocobalamin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol,DB00115
DB13156,Cyanocobalamin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex,DB00115
DB13185,Cyanocobalamin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate,DB00115
DB13191,Cyanocobalamin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine,DB00115
DB13269,Cyanocobalamin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol,DB00115
DB13293,Cyanocobalamin may decrease the excretion rate of Ipecac which could result in a higher serum level.,Ipecac,DB00115
DB13595,Cyanocobalamin may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate,DB00115
DB13873,Cyanocobalamin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.,Fenofibric acid,DB00115
DB13884,Cyanocobalamin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa,DB00115
DB13909,Cyanocobalamin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate,DB00115
DB13943,Cyanocobalamin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate,DB00115
DB13944,Cyanocobalamin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate,DB00115
DB13946,Cyanocobalamin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate,DB00115
DB13952,Cyanocobalamin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate,DB00115
DB13954,Cyanocobalamin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate,DB00115
DB13955,Cyanocobalamin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate,DB00115
DB13956,Cyanocobalamin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate,DB00115
DB13967,Cyanocobalamin may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue,DB00115
DB14006,Cyanocobalamin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate,DB00115
DB14007,Cyanocobalamin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid,DB00115
DB14498,Cyanocobalamin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate,DB00115
DB14499,Cyanocobalamin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate,DB00115
DB14526,Cyanocobalamin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate,DB00115
DB14527,Cyanocobalamin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate,DB00115
DB14528,Cyanocobalamin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate,DB00115
DB14529,Cyanocobalamin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate,DB00115
DB14530,Cyanocobalamin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate,DB00115
DB14754,Cyanocobalamin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol,DB00115
DB06815,Cyanocobalamin may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione,DB00115
DB11121,Cyanocobalamin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol,DB00115
DB11085,Cyanocobalamin may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol,DB00115
DB15593,Cyanocobalamin may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen,DB00115
DB00321,Cyanocobalamin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline,DB00115
DB00458,Cyanocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine,DB00115
DB01142,Cyanocobalamin may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin,DB00115
DB00318,Cyanocobalamin may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine,DB00115
DB00454,Cyanocobalamin may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine,DB00115
DB00813,Cyanocobalamin may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl,DB00115
DB00879,Cyanocobalamin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine,DB00115
DB01151,Cyanocobalamin may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine,DB00115
DB01242,Cyanocobalamin may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine,DB00115
DB08996,Cyanocobalamin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine,DB00115
DB14506,Cyanocobalamin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide,DB00115
DB00452,Framycetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Framycetin,DB00115
DB00479,Amikacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Amikacin,DB00115
DB00684,Tobramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tobramycin,DB00115
DB00798,Gentamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Gentamicin,DB00115
DB00955,Netilmicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Netilmicin,DB00115
DB01082,Streptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Streptomycin,DB00115
DB01172,Kanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Kanamycin,DB00115
DB01421,Paromomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Paromomycin,DB00115
DB03615,Ribostamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ribostamycin,DB00115
DB04263,Geneticin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Geneticin,DB00115
DB04626,Apramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Apramycin,DB00115
DB04729,Gentamicin C1a may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Gentamicin C1a,DB00115
DB04808,Neamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Neamine,DB00115
DB06696,Arbekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Arbekacin,DB00115
DB08437,Puromycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Puromycin,DB00115
DB11512,Dihydrostreptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dihydrostreptomycin,DB00115
DB11520,Hygromycin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hygromycin B,DB00115
DB12604,Sisomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sisomicin,DB00115
DB13270,Dibekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dibekacin,DB00115
DB13274,Micronomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Micronomicin,DB00115
DB13540,Isepamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Isepamicin,DB00115
DB13673,Bekanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bekanamycin,DB00115
DB13145,Cyanocobalamin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin,DB00115
DB00314,Cyanocobalamin may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin,DB00115
DB00390,Cyanocobalamin may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin,DB00115
DB00512,Cyanocobalamin may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin,DB00115
DB00682,Cyanocobalamin may decrease the excretion rate of Warfarin which could result in a higher serum level.,Warfarin,DB00115
DB00908,Cyanocobalamin may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine,DB00115
DB00982,Cyanocobalamin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin,DB00115
DB01035,Cyanocobalamin may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide,DB00115
DB12615,Cyanocobalamin may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin,DB00115
DB14509,Cyanocobalamin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate,DB00115
DB00524,Cyanocobalamin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone,DB00115
DB00695,Cyanocobalamin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide,DB00115
DB00808,Cyanocobalamin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide,DB00115
DB00887,Cyanocobalamin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.,Bumetanide,DB00115
DB00909,Cyanocobalamin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide,DB00115
DB08907,Cyanocobalamin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin,DB00115
DB09338,Cyanocobalamin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl,DB00115
DB00214,Torasemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide,DB00115
DB00232,Methyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide,DB00115
DB00310,Chlorthalidone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone,DB00115
DB00311,Ethoxzolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide,DB00115
DB00421,Spironolactone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone,DB00115
DB00436,Bendroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide,DB00115
DB00562,Benzthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide,DB00115
DB00594,Amiloride may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride,DB00115
DB00606,Cyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide,DB00115
DB00700,Eplerenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone,DB00115
DB00703,Methazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide,DB00115
DB00774,Hydroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide,DB00115
DB00819,Acetazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide,DB00115
DB00872,Conivaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan,DB00115
DB00880,Chlorothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide,DB00115
DB01021,Trichlormethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide,DB00115
DB01119,Diazoxide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide,DB00115
DB01144,Diclofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide,DB00115
DB01324,Polythiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide,DB00115
DB01325,Quinethazone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone,DB00115
DB01395,Drospirenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone,DB00115
DB01412,Theobromine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine,DB00115
DB02925,Piretanide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide,DB00115
DB04831,Tienilic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid,DB00115
DB05034,Ularitide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide,DB00115
DB06212,Tolvaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan,DB00115
DB06292,Dapagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin,DB00115
DB06370,Indisulam may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam,DB00115
DB08961,Azosemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide,DB00115
DB09015,Canrenoic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid,DB00115
DB09125,Potassium citrate may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium citrate,DB00115
DB09235,Efonidipine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine,DB00115
DB09401,Isosorbide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide,DB00115
DB11827,Ertugliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin,DB00115
DB12221,Canrenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone,DB00115
DB12670,Rolofylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline,DB00115
DB12704,Spiradoline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline,DB00115
DB12766,Cicletanine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine,DB00115
DB13284,Meticrane may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane,DB00115
DB13316,Ibopamine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine,DB00115
DB13405,Mefruside may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside,DB00115
DB13430,Mebutizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide,DB00115
DB13532,Cyclopenthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide,DB00115
DB13617,Clorexolone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone,DB00115
DB13663,Clofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide,DB00115
DB13708,Fenquizone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone,DB00115
DB13792,Clopamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide,DB00115
DB13801,Muzolimine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine,DB00115
DB13803,Xipamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide,DB00115
DB13989,Epitizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide,DB00115
DB14018,Bromotheophylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline,DB00115
DB00008,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a,DB00115
DB00011,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n1.,Interferon alfa-n1,DB00115
DB00018,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n3.,Interferon alfa-n3,DB00115
DB00022,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b,DB00115
DB00033,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon gamma-1b.,Interferon gamma-1b,DB00115
DB00034,"The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant",DB00115
DB00041,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Aldesleukin.,Aldesleukin,DB00115
DB00056,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin,DB00115
DB00068,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.,Interferon beta-1b,DB00115
DB00069,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.,Interferon alfacon-1,DB00115
DB00073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.,Rituximab,DB00115
DB00078,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.,Ibritumomab tiuxetan,DB00115
DB00081,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.,Tositumomab,DB00115
DB00087,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.,Alemtuzumab,DB00115
DB00105,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.,Interferon alfa-2b,DB00115
DB00120,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Phenylalanine.,Phenylalanine,DB00115
DB00188,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bortezomib.,Bortezomib,DB00115
DB00242,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cladribine.,Cladribine,DB00115
DB00262,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carmustine.,Carmustine,DB00115
DB00276,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Amsacrine.,Amsacrine,DB00115
DB00291,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chlorambucil.,Chlorambucil,DB00115
DB00293,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Raltitrexed.,Raltitrexed,DB00115
DB00305,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitomycin.,Mitomycin,DB00115
DB00307,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bexarotene.,Bexarotene,DB00115
DB00309,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vindesine.,Vindesine,DB00115
DB00322,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Floxuridine.,Floxuridine,DB00115
DB00328,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Indomethacin.,Indomethacin,DB00115
DB00352,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tioguanine.,Tioguanine,DB00115
DB00361,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinorelbine.,Vinorelbine,DB00115
DB00380,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane.,Dexrazoxane,DB00115
DB00398,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sorafenib.,Sorafenib,DB00115
DB00428,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Streptozocin.,Streptozocin,DB00115
DB00441,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemcitabine.,Gemcitabine,DB00115
DB00444,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Teniposide.,Teniposide,DB00115
DB00445,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Epirubicin.,Epirubicin,DB00115
DB00480,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lenalidomide.,Lenalidomide,DB00115
DB00488,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Altretamine.,Altretamine,DB00115
DB00495,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Zidovudine.,Zidovudine,DB00115
DB00515,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin.,Cisplatin,DB00115
DB00526,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Oxaliplatin.,Oxaliplatin,DB00115
DB00531,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cyclophosphamide.,Cyclophosphamide,DB00115
DB00544,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fluorouracil.,Fluorouracil,DB00115
DB00550,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Propylthiouracil.,Propylthiouracil,DB00115
DB00552,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pentostatin.,Pentostatin,DB00115
DB00563,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methotrexate.,Methotrexate,DB00115
DB00564,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carbamazepine.,Carbamazepine,DB00115
DB00570,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinblastine.,Vinblastine,DB00115
DB00601,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Linezolid.,Linezolid,DB00115
DB00619,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Imatinib.,Imatinib,DB00115
DB00631,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Clofarabine.,Clofarabine,DB00115
DB00642,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pemetrexed.,Pemetrexed,DB00115
DB00694,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.,Daunorubicin,DB00115
DB00762,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Irinotecan.,Irinotecan,DB00115
DB00763,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methimazole.,Methimazole,DB00115
DB00773,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Etoposide.,Etoposide,DB00115
DB00851,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dacarbazine.,Dacarbazine,DB00115
DB00853,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temozolomide.,Temozolomide,DB00115
DB00859,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Penicillamine.,Penicillamine,DB00115
DB00864,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tacrolimus.,Tacrolimus,DB00115
DB00877,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sirolimus.,Sirolimus,DB00115
DB00888,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mechlorethamine.,Mechlorethamine,DB00115
DB00928,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Azacitidine.,Azacitidine,DB00115
DB00958,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carboplatin.,Carboplatin,DB00115
DB00970,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dactinomycin.,Dactinomycin,DB00115
DB00987,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.,Cytarabine,DB00115
DB00997,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Doxorubicin.,Doxorubicin,DB00115
DB01005,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Hydroxyurea.,Hydroxyurea,DB00115
DB01008,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Busulfan.,Busulfan,DB00115
DB01030,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Topotecan.,Topotecan,DB00115
DB01033,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mercaptopurine.,Mercaptopurine,DB00115
DB01041,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thalidomide.,Thalidomide,DB00115
DB01042,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Melphalan.,Melphalan,DB00115
DB01073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fludarabine.,Fludarabine,DB00115
DB01099,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Flucytosine.,Flucytosine,DB00115
DB01101,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Capecitabine.,Capecitabine,DB00115
DB01168,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Procarbazine.,Procarbazine,DB00115
DB01169,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Arsenic trioxide.,Arsenic trioxide,DB00115
DB01177,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Idarubicin.,Idarubicin,DB00115
DB01181,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ifosfamide.,Ifosfamide,DB00115
DB01204,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitoxantrone.,Mitoxantrone,DB00115
DB01206,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lomustine.,Lomustine,DB00115
DB01229,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Paclitaxel.,Paclitaxel,DB00115
DB01248,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Docetaxel.,Docetaxel,DB00115
DB01254,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dasatinib.,Dasatinib,DB00115
DB01262,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Decitabine.,Decitabine,DB00115
DB01280,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nelarabine.,Nelarabine,DB00115
DB01590,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Everolimus.,Everolimus,DB00115
DB02546,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vorinostat.,Vorinostat,DB00115
DB04572,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thiotepa.,Thiotepa,DB00115
DB04845,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ixabepilone.,Ixabepilone,DB00115
DB04868,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nilotinib.,Nilotinib,DB00115
DB05015,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Belinostat.,Belinostat,DB00115
DB05109,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trabectedin.,Trabectedin,DB00115
DB05258,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa.,Interferon alfa,DB00115
DB05472,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with omega interferon.,omega interferon,DB00115
DB05773,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trastuzumab emtansine.,Trastuzumab emtansine,DB00115
DB06287,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temsirolimus.,Temsirolimus,DB00115
DB06616,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bosutinib.,Bosutinib,DB00115
DB06769,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bendamustine.,Bendamustine,DB00115
DB06772,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cabazitaxel.,Cabazitaxel,DB00115
DB08871,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Eribulin.,Eribulin,DB00115
DB08877,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.,Ruxolitinib,DB00115
DB08889,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carfilzomib.,Carfilzomib,DB00115
DB08895,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tofacitinib.,Tofacitinib,DB00115
DB08901,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ponatinib.,Ponatinib,DB00115
DB08910,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pomalidomide.,Pomalidomide,DB00115
DB08935,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Obinutuzumab.,Obinutuzumab,DB00115
DB09042,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tedizolid phosphate.,Tedizolid phosphate,DB00115
DB09052,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Blinatumomab.,Blinatumomab,DB00115
DB09053,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibrutinib.,Ibrutinib,DB00115
DB09073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Palbociclib.,Palbociclib,DB00115
DB09074,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Olaparib.,Olaparib,DB00115
DB09077,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dinutuximab.,Dinutuximab,DB00115
DB09122,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon beta-1a.,Peginterferon beta-1a,DB00115
DB12814,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B,DB00115
DB00994,Neomycin can cause a decrease in the absorption of Cyanocobalamin resulting in a reduced serum concentration and potentially a decrease in efficacy.,Neomycin,DB00115
DB01320,The serum concentration of Fosphenytoin can be decreased when it is combined with Tetrahydrofolic acid.,Fosphenytoin,DB00116
DB00293,The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Tetrahydrofolic acid.,Raltitrexed,DB00116
DB00795,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine.,Sulfasalazine,DB00116
DB00252,The serum concentration of Phenytoin can be decreased when it is combined with Tetrahydrofolic acid.,Phenytoin,DB00116
DB08898,The serum concentration of the active metabolites of Tetrahydrofolic acid can be reduced when Tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.,Glucarpidase,DB00116
DB01174,The serum concentration of Phenobarbital can be decreased when it is combined with Tetrahydrofolic acid.,Phenobarbital,DB00116
DB00794,The serum concentration of Primidone can be decreased when it is combined with Tetrahydrofolic acid.,Primidone,DB00116
DB00205,The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with Tetrahydrofolic acid.,Pyrimethamine,DB00116
DB00250,The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid.,Dapsone,DB00116
DB00440,The therapeutic efficacy of Trimethoprim can be decreased when used in combination with Tetrahydrofolic acid.,Trimethoprim,DB00116
DB00563,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Tetrahydrofolic acid.,Methotrexate,DB00116
DB00642,The therapeutic efficacy of Pemetrexed can be decreased when used in combination with Tetrahydrofolic acid.,Pemetrexed,DB00116
DB01131,The therapeutic efficacy of Proguanil can be decreased when used in combination with Tetrahydrofolic acid.,Proguanil,DB00116
DB01157,The therapeutic efficacy of Trimetrexate can be decreased when used in combination with Tetrahydrofolic acid.,Trimetrexate,DB00116
DB03695,The therapeutic efficacy of Piritrexim can be decreased when used in combination with Tetrahydrofolic acid.,Piritrexim,DB00116
DB04655,The therapeutic efficacy of Metoprine can be decreased when used in combination with Tetrahydrofolic acid.,Metoprine,DB00116
DB06358,The therapeutic efficacy of Iclaprim can be decreased when used in combination with Tetrahydrofolic acid.,Iclaprim,DB00116
DB06813,The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Tetrahydrofolic acid.,Pralatrexate,DB00116
DB08878,The therapeutic efficacy of Aminopterin can be decreased when used in combination with Tetrahydrofolic acid.,Aminopterin,DB00116
DB12769,The therapeutic efficacy of Lometrexol can be decreased when used in combination with Tetrahydrofolic acid.,Lometrexol,DB00116
DB12912,The therapeutic efficacy of Nolatrexed can be decreased when used in combination with Tetrahydrofolic acid.,Nolatrexed,DB00116
DB13795,The therapeutic efficacy of Brodimoprim can be decreased when used in combination with Tetrahydrofolic acid.,Brodimoprim,DB00116
DB14763,The therapeutic efficacy of Cycloguanil can be decreased when used in combination with Tetrahydrofolic acid.,Cycloguanil,DB00116
DB00313,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Valproic acid.,Valproic acid,DB00116
DB00375,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Colestipol.,Colestipol,DB00116
DB00564,The serum concentration of Carbamazepine can be decreased when it is combined with Tetrahydrofolic acid.,Carbamazepine,DB00116
DB00544,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Fluorouracil.,Fluorouracil,DB00116
DB01099,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Flucytosine.,Flucytosine,DB00116
DB01101,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Capecitabine.,Capecitabine,DB00116
DB01629,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with 5-fluorouridine.,5-fluorouridine,DB00116
DB03419,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Uracil.,Uracil,DB00116
DB09256,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Tegafur.,Tegafur,DB00116
DB12947,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Doxifluridine.,Doxifluridine,DB00116
DB00228,The metabolism of Enflurane can be decreased when combined with Ademetionine.,Enflurane,DB00118
DB00347,The metabolism of Trimethadione can be decreased when combined with Ademetionine.,Trimethadione,DB00118
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Ademetionine.,Chlorzoxazone,DB00118
DB00753,The metabolism of Isoflurane can be decreased when combined with Ademetionine.,Isoflurane,DB00118
DB00898,The metabolism of Ethanol can be decreased when combined with Ademetionine.,Ethanol,DB00118
DB01028,The metabolism of Methoxyflurane can be decreased when combined with Ademetionine.,Methoxyflurane,DB00118
DB01159,The metabolism of Halothane can be decreased when combined with Ademetionine.,Halothane,DB00118
DB01236,The metabolism of Sevoflurane can be decreased when combined with Ademetionine.,Sevoflurane,DB00118
DB06712,The metabolism of Nilvadipine can be decreased when combined with Ademetionine.,Nilvadipine,DB00118
DB06728,The metabolism of Aniline can be decreased when combined with Ademetionine.,Aniline,DB00118
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Ademetionine.,Benzyl alcohol,DB00118
DB00949,The metabolism of Felbamate can be decreased when combined with Ademetionine.,Felbamate,DB00118
DB06119,The metabolism of Cenobamate can be decreased when combined with Ademetionine.,Cenobamate,DB00118
DB01136,The metabolism of Carvedilol can be decreased when combined with Ademetionine.,Carvedilol,DB00118
DB00252,The metabolism of Phenytoin can be decreased when combined with Ademetionine.,Phenytoin,DB00118
DB08868,The metabolism of Fingolimod can be decreased when combined with Ademetionine.,Fingolimod,DB00118
DB00593,The metabolism of Ethosuximide can be decreased when combined with Ademetionine.,Ethosuximide,DB00118
DB11689,The metabolism of Selumetinib can be decreased when combined with Ademetionine.,Selumetinib,DB00118
DB00908,The metabolism of Quinidine can be decreased when combined with Ademetionine.,Quinidine,DB00118
DB00675,The metabolism of Tamoxifen can be decreased when combined with Ademetionine.,Tamoxifen,DB00118
DB05109,The metabolism of Trabectedin can be decreased when combined with Ademetionine.,Trabectedin,DB00118
DB00316,Ademetionine may increase the hepatotoxic activities of Acetaminophen.,Acetaminophen,DB00118
DB09288,Ademetionine may increase the hepatotoxic activities of Propacetamol.,Propacetamol,DB00118
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Phenylalanine.,Denosumab,DB00120
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.,Etanercept,DB00120
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Phenylalanine.,Peginterferon alfa-2a,DB00120
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.,Interferon alfa-n1,DB00120
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Phenylalanine.,Interferon alfa-n3,DB00120
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Phenylalanine.,Peginterferon alfa-2b,DB00120
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.,Anakinra,DB00120
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Phenylalanine.,Interferon gamma-1b,DB00120
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Phenylalanine.","Interferon alfa-2a, Recombinant",DB00120
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.,Aldesleukin,DB00120
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Phenylalanine.,Adalimumab,DB00120
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.,Gemtuzumab ozogamicin,DB00120
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.,Pegaspargase,DB00120
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.,Infliximab,DB00120
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.,Interferon beta-1b,DB00120
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.,Interferon alfacon-1,DB00120
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.,Rituximab,DB00120
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.,Basiliximab,DB00120
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.,Muromonab,DB00120
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.,Ibritumomab tiuxetan,DB00120
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.,Tositumomab,DB00120
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.,Alemtuzumab,DB00120
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.,Alefacept,DB00120
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.,Efalizumab,DB00120
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.,Antithymocyte immunoglobulin (rabbit),DB00120
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.,Interferon alfa-2b,DB00120
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.,Daclizumab,DB00120
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.,Bevacizumab,DB00120
DB00180,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flunisolide.,Flunisolide,DB00120
DB00188,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib.,Bortezomib,DB00120
DB00242,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cladribine.,Cladribine,DB00120
DB00262,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine.,Carmustine,DB00120
DB00276,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Amsacrine.,Amsacrine,DB00120
DB00290,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin.,Bleomycin,DB00120
DB00291,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chlorambucil.,Chlorambucil,DB00120
DB00293,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Raltitrexed.,Raltitrexed,DB00120
DB00305,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitomycin.,Mitomycin,DB00120
DB00307,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene.,Bexarotene,DB00120
DB00309,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vindesine.,Vindesine,DB00120
DB00322,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Floxuridine.,Floxuridine,DB00120
DB00328,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Indomethacin.,Indomethacin,DB00120
DB00352,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tioguanine.,Tioguanine,DB00120
DB00361,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinorelbine.,Vinorelbine,DB00120
DB00380,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane.,Dexrazoxane,DB00120
DB00394,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate,DB00120
DB00398,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sorafenib.,Sorafenib,DB00120
DB00428,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Streptozocin.,Streptozocin,DB00120
DB00432,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trifluridine.,Trifluridine,DB00120
DB00441,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gemcitabine.,Gemcitabine,DB00120
DB00443,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Betamethasone.,Betamethasone,DB00120
DB00444,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teniposide.,Teniposide,DB00120
DB00445,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Epirubicin.,Epirubicin,DB00120
DB00446,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chloramphenicol.,Chloramphenicol,DB00120
DB00480,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lenalidomide.,Lenalidomide,DB00120
DB00488,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Altretamine.,Altretamine,DB00120
DB00495,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Zidovudine.,Zidovudine,DB00120
DB00515,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cisplatin.,Cisplatin,DB00120
DB00526,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin.,Oxaliplatin,DB00120
DB00531,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cyclophosphamide.,Cyclophosphamide,DB00120
DB00541,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine.,Vincristine,DB00120
DB00544,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil.,Fluorouracil,DB00120
DB00550,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil.,Propylthiouracil,DB00120
DB00552,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pentostatin.,Pentostatin,DB00120
DB00563,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methotrexate.,Methotrexate,DB00120
DB00564,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carbamazepine.,Carbamazepine,DB00120
DB00570,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinblastine.,Vinblastine,DB00120
DB00588,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone propionate.,Fluticasone propionate,DB00120
DB00591,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinolone acetonide.,Fluocinolone acetonide,DB00120
DB00601,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Linezolid.,Linezolid,DB00120
DB00619,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Imatinib.,Imatinib,DB00120
DB00620,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Triamcinolone.,Triamcinolone,DB00120
DB00631,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine.,Clofarabine,DB00120
DB00635,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisone.,Prednisone,DB00120
DB00642,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pemetrexed.,Pemetrexed,DB00120
DB00687,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludrocortisone.,Fludrocortisone,DB00120
DB00688,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolate mofetil.,Mycophenolate mofetil,DB00120
DB00694,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.,Daunorubicin,DB00120
DB00755,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tretinoin.,Tretinoin,DB00120
DB00762,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Irinotecan.,Irinotecan,DB00120
DB00763,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methimazole.,Methimazole,DB00120
DB00764,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mometasone.,Mometasone,DB00120
DB00773,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Etoposide.,Etoposide,DB00120
DB00795,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sulfasalazine.,Sulfasalazine,DB00120
DB00851,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dacarbazine.,Dacarbazine,DB00120
DB00853,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temozolomide.,Temozolomide,DB00120
DB00859,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Penicillamine.,Penicillamine,DB00120
DB00860,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisolone.,Prednisolone,DB00120
DB00877,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sirolimus.,Sirolimus,DB00120
DB00888,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mechlorethamine.,Mechlorethamine,DB00120
DB00928,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azacitidine.,Azacitidine,DB00120
DB00958,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin.,Carboplatin,DB00120
DB00959,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methylprednisolone.,Methylprednisolone,DB00120
DB00970,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin.,Dactinomycin,DB00120
DB00987,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.,Cytarabine,DB00120
DB00993,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azathioprine.,Azathioprine,DB00120
DB00997,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Doxorubicin.,Doxorubicin,DB00120
DB01005,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxyurea.,Hydroxyurea,DB00120
DB01008,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Busulfan.,Busulfan,DB00120
DB01024,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolic acid.,Mycophenolic acid,DB00120
DB01030,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Topotecan.,Topotecan,DB00120
DB01033,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mercaptopurine.,Mercaptopurine,DB00120
DB01041,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thalidomide.,Thalidomide,DB00120
DB01042,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Melphalan.,Melphalan,DB00120
DB01073,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludarabine.,Fludarabine,DB00120
DB01099,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flucytosine.,Flucytosine,DB00120
DB01101,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Capecitabine.,Capecitabine,DB00120
DB01108,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trilostane.,Trilostane,DB00120
DB01168,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Procarbazine.,Procarbazine,DB00120
DB01169,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Arsenic trioxide.,Arsenic trioxide,DB00120
DB01177,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idarubicin.,Idarubicin,DB00120
DB01181,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ifosfamide.,Ifosfamide,DB00120
DB01196,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Estramustine.,Estramustine,DB00120
DB01204,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitoxantrone.,Mitoxantrone,DB00120
DB01206,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lomustine.,Lomustine,DB00120
DB01222,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Budesonide.,Budesonide,DB00120
DB01229,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paclitaxel.,Paclitaxel,DB00120
DB01234,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexamethasone.,Dexamethasone,DB00120
DB01248,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Docetaxel.,Docetaxel,DB00120
DB01254,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dasatinib.,Dasatinib,DB00120
DB01257,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eculizumab.,Eculizumab,DB00120
DB01262,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Decitabine.,Decitabine,DB00120
DB01268,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sunitinib.,Sunitinib,DB00120
DB01280,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nelarabine.,Nelarabine,DB00120
DB01281,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abatacept.,Abatacept,DB00120
DB01285,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Corticotropin.,Corticotropin,DB00120
DB01380,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cortisone acetate.,Cortisone acetate,DB00120
DB01384,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paramethasone.,Paramethasone,DB00120
DB01394,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Colchicine.,Colchicine,DB00120
DB01410,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ciclesonide.,Ciclesonide,DB00120
DB01423,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Stepronin.,Stepronin,DB00120
DB01590,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Everolimus.,Everolimus,DB00120
DB01611,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxychloroquine.,Hydroxychloroquine,DB00120
DB01816,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Castanospermine.,Castanospermine,DB00120
DB02546,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vorinostat.,Vorinostat,DB00120
DB02806,The risk or severity of adverse effects can be increased when Phenylalanine is combined with 2-Methoxyethanol.,2-Methoxyethanol,DB00120
DB03523,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brequinar.,Brequinar,DB00120
DB04572,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thiotepa.,Thiotepa,DB00120
DB04630,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Aldosterone.,Aldosterone,DB00120
DB04845,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ixabepilone.,Ixabepilone,DB00120
DB04868,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nilotinib.,Nilotinib,DB00120
DB04951,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pirfenidone.,Pirfenidone,DB00120
DB04956,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Afelimomab.,Afelimomab,DB00120
DB05015,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belinostat.,Belinostat,DB00120
DB05109,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trabectedin.,Trabectedin,DB00120
DB05258,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Interferon alfa.,Interferon alfa,DB00120
DB05259,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Glatiramer.,Glatiramer,DB00120
DB05260,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gallium nitrate.,Gallium nitrate,DB00120
DB05459,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Briakinumab.,Briakinumab,DB00120
DB05472,The risk or severity of adverse effects can be increased when Phenylalanine is combined with omega interferon.,omega interferon,DB00120
DB05676,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Apremilast.,Apremilast,DB00120
DB05773,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trastuzumab emtansine.,Trastuzumab emtansine,DB00120
DB06168,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Canakinumab.,Canakinumab,DB00120
DB06273,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tocilizumab.,Tocilizumab,DB00120
DB06287,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temsirolimus.,Temsirolimus,DB00120
DB06372,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Rilonacept.,Rilonacept,DB00120
DB06589,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pazopanib.,Pazopanib,DB00120
DB06603,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Panobinostat.,Panobinostat,DB00120
DB06612,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mepolizumab.,Mepolizumab,DB00120
DB06616,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bosutinib.,Bosutinib,DB00120
DB06662,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abetimus.,Abetimus,DB00120
DB06674,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Golimumab.,Golimumab,DB00120
DB06681,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belatacept.,Belatacept,DB00120
DB06769,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bendamustine.,Bendamustine,DB00120
DB06772,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cabazitaxel.,Cabazitaxel,DB00120
DB06813,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pralatrexate.,Pralatrexate,DB00120
DB08059,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Wortmannin.,Wortmannin,DB00120
DB08870,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brentuximab vedotin.,Brentuximab vedotin,DB00120
DB08871,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eribulin.,Eribulin,DB00120
DB08877,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ruxolitinib.,Ruxolitinib,DB00120
DB08879,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belimumab.,Belimumab,DB00120
DB08880,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teriflunomide.,Teriflunomide,DB00120
DB08889,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carfilzomib.,Carfilzomib,DB00120
DB08901,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ponatinib.,Ponatinib,DB00120
DB08904,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Certolizumab pegol.,Certolizumab pegol,DB00120
DB08906,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone furoate.,Fluticasone furoate,DB00120
DB08908,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dimethyl fumarate.,Dimethyl fumarate,DB00120
DB08910,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pomalidomide.,Pomalidomide,DB00120
DB08935,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Obinutuzumab.,Obinutuzumab,DB00120
DB08970,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednidene.,Fluprednidene,DB00120
DB08971,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortolone.,Fluocortolone,DB00120
DB09029,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Secukinumab.,Secukinumab,DB00120
DB09033,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vedolizumab.,Vedolizumab,DB00120
DB09036,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Siltuximab.,Siltuximab,DB00120
DB09052,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Blinatumomab.,Blinatumomab,DB00120
